<SEC-DOCUMENT>0001193125-26-085490.txt : 20260302
<SEC-HEADER>0001193125-26-085490.hdr.sgml : 20260302
<ACCEPTANCE-DATETIME>20260302162710
ACCESSION NUMBER:		0001193125-26-085490
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		79
CONFORMED PERIOD OF REPORT:	20251231
FILED AS OF DATE:		20260302
DATE AS OF CHANGE:		20260302

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Tyra Biosciences, Inc.
		CENTRAL INDEX KEY:			0001863127
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				831476348
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40800
		FILM NUMBER:		26708107

	BUSINESS ADDRESS:	
		STREET 1:		2656 STATE STREET
		CITY:			CARLSBAD
		STATE:			CA
		ZIP:			92008
		BUSINESS PHONE:		(619) 728-4760

	MAIL ADDRESS:	
		STREET 1:		2656 STATE STREET
		CITY:			CARLSBAD
		STATE:			CA
		ZIP:			92008
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>tyra-20251231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2026-03-02T14:21:19.7631+00:00 -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:tyra="http://tyra.bio/20251231" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_781c05a3-e565-4acb-b9ef-62ffed817c1f" name="dei:EntityCentralIndexKey" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa">0001863127</ix:nonNumeric><ix:nonNumeric id="F_cd841b59-2d85-4050-a1da-37179de8e753" name="dei:DocumentFiscalPeriodFocus" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa">FY</ix:nonNumeric><ix:nonNumeric id="F_7c3df980-d0d2-4a79-80d2-cb65d24ba954" name="dei:AmendmentFlag" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric id="F_5fdff729-926c-4404-a28d-2bbd12c5440b" name="dei:CurrentFiscalYearEndDate" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa">--12-31</ix:nonNumeric><ix:nonFraction id="F_e3d03354-93a3-4909-bbcb-fa330f37e738" name="us-gaap:CommitmentsAndContingencies" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_b98141a9-56b2-47e3-96de-3efef16eed5c" name="us-gaap:CommitmentsAndContingencies" contextRef="C_75025707-e814-4796-aefb-117d79769679" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_de6e2adb-217c-46f8-87ab-7f9f75f3c64f" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_3e3448c5-6e20-4fa9-a323-78badf09db26" format="ixt-sec:durwordsen">three years</ix:nonNumeric><ix:nonNumeric id="F_1e6f4a6c-c495-424f-a078-c4745eb638bc" name="us-gaap:SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa">http://tyra.bio/20251231#ChiefOperatingDecisionMakerMember</ix:nonNumeric><ix:nonFraction id="F_1191e240-a690-465b-8ee1-430de97506c1" name="us-gaap:NumberOfReportableSegments" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" unitRef="U_Segment" decimals="0" format="ixt-sec:numwordsen">One</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="tyra-20251231.xsd"/></ix:references><ix:resources><xbrli:context id="C_80b76e96-2cd7-4fc4-8522-d847b364b8ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8160c430-5e2d-4be6-9c79-14512c0fe02b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_81cdd1a9-196d-4908-8af2-c3bceb99e972"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-02-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_81db5fa1-5ce2-4991-960b-fe8f42d5dc85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_822f9ef4-d69d-4947-92b4-eae4cf622064"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_82407490-dbff-4f2d-ab88-7b2feada5686"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_83e9b223-47dc-4d04-a739-70fa68863bb9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_859a4837-02fe-4595-8853-de8c56b1c468"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_87dc3b26-58ec-4bf3-9b29-98e651cdbe8a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">tyra:TYRA-300ACHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tyra:ChiefOperatingDecisionMakerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_885b4f15-9028-4e67-83a3-63a20100958e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_88813698-fe70-4238-9dca-06637a729f85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tyra:AccumulatedOtherComprehensiveLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_88fc6773-cb7f-4a2b-917e-b6e8a47d801c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tyra:ChiefOperatingDecisionMakerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8959a728-1257-4d40-89a1-c9a8bdd37f42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tyra:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8b56e0c7-22d7-4f97-bc7f-f3c1c34ac2a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8c23cd18-4f82-4221-821a-3472384eac40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8c64e7bc-c688-492a-99e8-86f5cb335e47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">tyra:FGFRDiscoveryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tyra:ChiefOperatingDecisionMakerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8d8b0049-b397-46d9-9515-7b644360184f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8e43d91f-24cf-4fdb-b79e-137f0345b2bb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8ffa982e-10e5-4fab-99ed-6f19493d39e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_90b314f0-e678-446e-845b-a940c76b3ed3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_91ad5ba4-1680-46a4-9791-00d5894e9338"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_93dfdc64-6b4a-406f-b392-50dedb2970c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_95f923d9-c4c3-4d2a-b6b5-83207327a686"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9622fb4d-a971-4870-b202-86d8c0745065"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">tyra:TYRA-300MUCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tyra:ChiefOperatingDecisionMakerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9631bb15-a89e-4277-b443-2488946a4125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_96648163-51bf-41fb-8618-dc87cf09bd07"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_997236c7-47c3-4ba7-822f-0fd00f5213e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9a95952b-9590-45cc-ba3c-2182f5811f96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tyra:EstimatedSharesPurchasableUnderTheEsppMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9b41307d-a228-4022-aec0-907dd0345fdf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-10-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9dc741f3-157e-4e28-9a5f-c2124c563656"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9e723f9e-f294-44a4-b7ba-1b0bfe9753cc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a11e42ed-6bba-4898-af75-300d1ef896ce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a190af4b-bf04-4d25-9ef5-ba22a9fc2494"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a2ec13b8-8e1d-47c2-8e4f-4c5969096b03"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tyra:TwoThousandTwentyFourPrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-06</xbrli:startDate><xbrli:endDate>2024-02-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a3aa4fd7-a874-4bd2-a938-6252e0593cbe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a412b29c-2a01-4356-b322-11c7037ef382"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">tyra:PersonnelCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tyra:ChiefOperatingDecisionMakerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a6c7e448-562b-41de-8bae-d10d83c24d49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">tyra:TwoThousandTwentyEightLeaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a8ff3708-7767-47f5-93fc-4c5992d13af3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tyra:TwoThousandTwentyFourPreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a968be01-32a6-49ed-80ec-d5190256e424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a9af0aa2-ccc8-48f7-89f5-e604bc391411"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ab0a8b53-9e09-43e5-aaf1-65d9f9db8341"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tyra:TwoThousandTwentyFourPrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ab4cdc5b-1496-46f9-9dd9-d01d8da9a387"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tyra:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ab4f8aaa-c4e6-4bd1-a17b-592c475ced76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">tyra:FGFRDiscoveryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tyra:ChiefOperatingDecisionMakerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ab8dd7ed-5d07-40f6-9887-243d8544fc7c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_aba7e5f4-1031-43f5-85fd-1ca0501bbfac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_aea32a63-e986-417a-9465-dd9fe57915c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_af11564f-7c3c-4fbd-944d-2526428166a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tyra:TwentyTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_afd54226-bb0b-422e-afb5-a979bf3c3fb7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tyra:AccumulatedOtherComprehensiveLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b08ce2b8-ac16-4b53-b8cb-6aa4f4c5e677"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b1df5da0-307d-4f91-b407-099a8215e1e5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b208f498-8b12-48b2-b2d8-4d1f1322980d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tyra:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b5150520-b9f3-4bdf-8a55-8f5cea1cb93e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">tyra:TYRA-300MUCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tyra:ChiefOperatingDecisionMakerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b8c32c5b-98c6-4415-8115-4d928ac1827f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b90df891-3d95-47b5-b447-6bd47c401d88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bab9baa6-70cc-470c-8e11-bb4b93099597"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bc04b846-a20d-4016-ac01-a4c1c095b08c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">tyra:AtmSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-05-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bf0901d4-ef49-48dc-b81b-94822de4c19d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c2661784-8ff1-4a9e-8a82-f75b049f70ad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c3062351-4e8a-468c-9ace-a5178560f024"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c487f789-6116-468a-b633-8abf3bf8a878"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c6068cd1-21e5-450a-9869-2d60615e13b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c857b1ec-ca11-4482-b531-9da5ac07706d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c949f769-29f9-45f2-a776-8adefcf0977e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">tyra:ExpansionLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c95fc3d9-d94a-493b-a598-ac4bb3b1b07c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tyra:TwentyTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cabc47b3-0098-4429-acc8-8b363378e0b6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cc72b396-646c-4763-93d2-cd1c738569ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tyra:TwentyTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cd230b0d-0361-47ec-8672-4de4e7ba7e85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">tyra:FacilitiesAndOtherCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tyra:ChiefOperatingDecisionMakerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cdc6cc80-baf4-45fe-8841-dff91027f8b8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d259c846-1a3b-459d-8db5-38b89ca9f52b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d412cb4d-1732-4801-8e1b-648dfb7030c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tyra:ChiefOperatingDecisionMakerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">tyra:OtherDevelopmentProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d576a493-6d1f-4530-ae76-85c14a98774c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d58f684d-19a9-4256-8716-4e0a68a997cd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d60e36b5-9479-436f-8d6e-500af75adcec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_da6d61f4-da45-4047-8849-7facd82c9bab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dbea103f-6acc-4340-83b5-1436e3999584"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">tyra:TYRA-430Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tyra:ChiefOperatingDecisionMakerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dea229cd-0197-42d7-b781-d2cf1a9090ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_deb06a64-1ca6-42a0-9e9d-5e5fc523e1b1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tyra:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_df547fe0-45f9-4a1e-9a51-de2c71f2fc5c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dfcd0690-10f5-44d8-bca0-e39e09cfb498"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dfcfe63e-d4f8-4148-85c4-ec750c1d7200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tyra:TwoThousandsAndTwentyOneIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e0df3a23-dd2e-494b-a002-48c55afa2131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e120fb96-8ac9-4670-bbd9-1db2900be3f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tyra:TwoThousandTwentyFourPrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tyra:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e15e6e13-7c17-4e72-95fd-e55ebe7fabb3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e1d47e5f-72ba-41d6-899c-26d974ae34de"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">tyra:ExpansionLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e212c6e1-9c59-4476-81a3-9bdba80a582e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e214f6fc-28de-40f3-bcc1-08bf1f39a68d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tyra:ChiefOperatingDecisionMakerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e25b71f6-c32b-4edc-aafd-1871c1261431"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e3b45be7-247c-43d2-afaf-765b16ea5709"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tyra:UnvestedCommonStockExerciseOfStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f04ad497-713a-4578-b5ab-98ae7619c3da"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-18</xbrli:startDate><xbrli:endDate>2024-10-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f0dad730-1497-4f1d-aca3-f9d1d48a1d39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f25354f8-700d-4a8d-907f-0257bf311019"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f4992ea8-42cd-4f1d-87f7-2a24c1d21969"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tyra:EstimatedSharesPurchasableUnderTheEsppMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_00649a27-87e2-4280-9938-2abad92658ac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_011705ed-dba2-4b57-a549-edfd6d1424ce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tyra:ChiefOperatingDecisionMakerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">tyra:OtherDevelopmentProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_01b9476b-1614-4aa1-8247-68243ed0c8dd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0244e69e-96e4-4497-bf2c-57c743c5abcb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">tyra:StateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_032ccc29-8b89-4307-90c0-e7071ba56b28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">tyra:TYRA-200Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tyra:ChiefOperatingDecisionMakerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_04a08b7e-86bb-4a84-910d-c8256976e1da"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_04b24ac9-453f-4621-9f44-543a1e069772"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0639343e-0151-4fb3-a3ca-f73ad2a5550b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">tyra:FirstAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0732721d-acf1-480d-a569-2b3ce25dc4c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0982e5f9-320c-4189-b4b7-e92e3372022d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tyra:UnvestedCommonStockExerciseOfStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0aaa07cf-e8dc-4ed0-ba3c-1e37ea8486c6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">tyra:FacilitiesAndOtherCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tyra:ChiefOperatingDecisionMakerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0cc2e2b1-f863-41ab-8c8e-baf6fe802ceb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">tyra:TwoThousandTwentySevenLeaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0f90cf19-a5f9-46f3-880e-0596d855590c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1113fea0-b015-450d-8260-f27bbaccdf6f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_12bd91d1-7116-4439-9d77-a7650dbde2f7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1373ea03-27b7-4611-89c2-aedca10e502b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_14e460cb-2da4-49f1-a533-de969fc89258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">tyra:PersonnelCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tyra:ChiefOperatingDecisionMakerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_15910e68-42b0-4058-8d01-7cdf352e9ab5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_18a4d379-7bc9-4fbe-85e9-2af7258397b9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">tyra:TYRA-430Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tyra:ChiefOperatingDecisionMakerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1e213811-870d-4dbf-826c-e35260a70b15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1f9dc1d4-60d0-45af-852c-cdd76bc64f9f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tyra:StockOptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1faac4fa-e650-47b7-9da8-bf595e935e95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1fbdc9f6-75dd-418c-a9c1-887b681c7dc0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">tyra:AlanFuhrmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_23d8f849-93e2-4c5e-8518-5df9a193ecf2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_25ac70f7-9ef0-442b-8bfc-d6387da53e1f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_27b488c8-414a-4614-80fa-db1682dc7f77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">tyra:AtmSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-08</xbrli:startDate><xbrli:endDate>2025-05-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_27fab6ea-d588-459f-a85f-6bc9be1ab8c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_28193a65-0be5-40f3-9592-5ab7a4f62e34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">tyra:FirstAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2a06acfa-3379-4f4d-8b99-addfb1d70ade"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tyra:AccumulatedOtherComprehensiveLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2d6333b8-aede-4396-b3d4-df2848f7e547"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">tyra:FederalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2d692ebc-a844-453a-851e-e2ddc17d2c55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2f77ccfa-5653-4673-b977-01323fe14f9a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_31142ef9-0890-41ac-a5b5-d09b26dfd124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_31bd97f3-271f-4ee8-8a62-0213b666d430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tyra:TwoThousandTwentyFourPrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-06</xbrli:startDate><xbrli:endDate>2024-02-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_31ea1ae9-69e0-48ac-9963-d48f9f1c7a0d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_356fc121-7b99-4486-a3fc-2e281fdbe579"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_35d9901f-2f43-4932-960b-edaffa307b8e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_371b11b6-fa70-4468-9e81-af92b5ec918f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3bfbb795-7b7e-4213-b6a6-ea14b283ed4f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3ddda0f3-7839-43d8-b02a-428842db25ae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">tyra:AtmSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-03</xbrli:startDate><xbrli:endDate>2022-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3df03dca-0dc7-4c5f-a85f-71adcbb157d4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tyra:TwentyTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3e3448c5-6e20-4fa9-a323-78badf09db26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3ef83027-7be9-4941-bbec-b03fb69c9691"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">srt:OfficeBuildingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">tyra:FirstAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4210f2e9-05d8-4850-ac3c-f78b3d31289e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">tyra:TYRA-300UTUCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tyra:ChiefOperatingDecisionMakerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_445d4a10-50d6-4fad-8ed4-556b6ce24ec6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4723f99d-c390-41ed-a5c5-1df9fcae7f68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">tyra:TYRA-200Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tyra:ChiefOperatingDecisionMakerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4892d6b0-f063-48f2-b508-738cf390c782"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tyra:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4952b098-3c5d-47e1-a11e-2ad51ec8c584"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4a3a2077-3bda-4557-8dc1-0b3803890cbf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4a9d47d3-2b9a-48d7-83f8-6532afecf992"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4b1febba-292b-4542-9c54-ea17a48a4fcd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4bfe509f-d4f2-43a9-a149-54a5ecae443d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">srt:OfficeBuildingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">tyra:FirstAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4f2fa7fb-50cf-4ab7-a541-88b9de8c16cd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_54f748e8-97d4-411e-9f01-5dd8ca0908ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_55243387-85c0-4527-827d-52fcc91c1646"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">srt:OfficeBuildingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">tyra:FirstAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_56b4e6c1-43af-48e2-a24b-2a315a435b15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tyra:StockOptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_57adc4c3-e413-40ba-9f2b-b0623d7e6ec7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tyra:AccumulatedOtherComprehensiveLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_58b2744f-4829-4186-a4c0-62f067475f6f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tyra:AccumulatedOtherComprehensiveLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_591792f7-6fd3-4548-a3dc-761a47696c50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">tyra:ExpansionLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5a67af1f-955f-4fed-a7a1-8ddc18ed22ab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5bd11727-b5f4-41c0-a8a8-fecf149214ac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">tyra:ToddHarrisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5e5587d3-9989-48f5-9e25-23f05bd5b860"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">tyra:TYRA-300UTUCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tyra:ChiefOperatingDecisionMakerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_66a3ee93-337d-4531-9b7b-c8623780d836"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_66a8c0d4-dc01-437f-8643-ae23ca05710c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">tyra:TYRA-300NMIBCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tyra:ChiefOperatingDecisionMakerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_68757860-b94a-4127-be6e-9246030381f8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_68fd01c3-dd3c-414b-9432-cffd7c483daf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">tyra:AlanFuhrmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_692e28c5-456f-441d-81a6-b3281646a0af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_69bde7cd-c11f-4704-8be8-b885ee6842e9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6aa70afb-c483-4af1-aab6-5e31327063dc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6b1f5ee9-14ee-4a7c-af93-d46a982aa30b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tyra:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-18</xbrli:startDate><xbrli:endDate>2024-10-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6c246792-9518-4437-a499-5e637972016a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">tyra:ToddHarrisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6cb8fd5f-1c00-421b-8722-81009515faf7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6d93fb41-00d4-4bba-9d0f-e71f27a586ce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6f8e39dd-1c81-4d46-8007-0bbb98e5748d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6fe01dec-1d26-432c-84d4-861aa02e32d6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7060b8eb-7cf2-40dd-abeb-7bbe283f0ab1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">tyra:TYRA-300NMIBCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tyra:ChiefOperatingDecisionMakerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7168fb48-4ee5-4fb1-9a24-58d8fea23470"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_718b96d9-785c-40ed-a094-d99e0b9a8377"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">tyra:AtmSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7235c0d6-d80c-4a20-a791-afd7ff2647e0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_730568c6-2cf1-41de-a80e-e6d97f16ba8c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_73360da3-36fa-405b-810f-ac396bf24bee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_75025707-e814-4796-aefb-117d79769679"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7a958c54-6cff-41ea-bb1a-33c200dccaae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7ed9a919-4011-4987-b82f-187ecd2ac2c6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">tyra:TYRA-300ACHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tyra:ChiefOperatingDecisionMakerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7f967b5d-c00a-4062-a27e-e4707a82ef23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7fed64a7-b51b-4be1-a469-9f7679712854"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001863127</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tyra:TwoThousandTwentyFourPrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tyra:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="U_Renewal"><xbrli:measure>tyra:Renewal</xbrli:measure></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>tyra:Segment</xbrli:measure></xbrli:unit><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_7f5db674-35e9-4226-a24a-70d6bb548e24" fromRefs="F_1feeacb7-f63b-4743-b9bf-d02683a62a3e F_5afad17c-078e-4959-a690-06c22068e3d4"/><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_132f20ce-f34d-4ee8-a541-6bc46878b344" fromRefs="F_95fed51a-1724-4c4a-bca1-cd4dd667f477 F_a4c73223-a8f2-45c0-b939-895fae466da5"/><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_bba94c94-ee85-4e4d-b64e-20c95d3d3e2a" fromRefs="F_2ef49d1a-2d11-4c19-9f37-954b86c4a8fb F_3f608c29-f15c-4349-8faf-2c8418f2cb3b"/><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_a2a8f412-f3ed-40a6-91bc-571db48e95e7" fromRefs="F_462c7276-b09b-4c39-9995-95a55b303357 F_54208db0-fdfa-4282-bd8a-f1b532057094"/></ix:resources></ix:header></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Washington, D.C. 20549</span></p><p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0f445a4c-9bf0-45c7-a554-f714e89fc49d" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10-K</span></ix:nonNumeric></span></p><p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Mark One)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:3%;box-sizing:content-box;"/>
     <td style="width:97%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_4271b133-44c3-4de9-ac25-12813b1e99c6" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="dei:DocumentAnnualReport" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_feef0434-2f04-43b1-875c-5510a7a6ecd4" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3d9d9b21-ab38-45cc-bdd3-018291f7829f" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2025</span></ix:nonNumeric></span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:3%;box-sizing:content-box;"/>
     <td style="width:97%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_4300de0b-3ca3-46c6-af9f-c3659a1101e4" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="dei:DocumentTransitionReport" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM                        TO</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">                     </span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commission File Number </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0212adb5-3a43-4143-9a76-b76f15b6b5a4" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">001-40800</span></ix:nonNumeric></span></p><p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:20pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7225a411-c5f0-4646-8f18-37c9f82823f0" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:20pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TYRA BIOSCIENCES, INC.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact name of Registrant as specified in its Charter)</span></p><p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:50%;box-sizing:content-box;"/>
     <td style="width:50%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_760cc7f2-3e9c-4d1a-96d4-930f1846d12c" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_a0361ea2-18f4-418e-b069-61ca4383014b" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">83-1476348</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">incorporation or organization)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(I.R.S. Employer</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Identification No.)</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span><ix:nonNumeric id="F_7b21606e-43f9-4362-b2bd-dd69e3f9142e" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2656 State Street</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_71e47d4d-617e-4b5b-862d-57f207d5de25" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Carlsbad</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_fd81a011-86e5-42b4-ae97-fc5fd8c348fc" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">California</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_6933ce35-f85a-4e81-9020-9c5f30cc0cf2" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">92008</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Zip Code)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registrant&#8217;s telephone number, including area code: (</span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c152718a-fb82-497b-b6aa-29825125e7b4" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">619</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c93075e9-93fa-412f-b29d-fc83e2af0736" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">728-4760</span></ix:nonNumeric></span></p><p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:38.384%;box-sizing:content-box;"/>
     <td style="width:1.01%;box-sizing:content-box;"/>
     <td style="width:15.152%;box-sizing:content-box;"/>
     <td style="width:1.01%;box-sizing:content-box;"/>
     <td style="width:44.444%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title of each class</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Symbol(s)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_19e9ece8-db0f-4839-8791-93a1a089f5c9" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common Stock, $0.0001 par value per share</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_4fbd6af9-ec02-4ac4-9ccd-26887e6b0808" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">TYRA</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_7067e5c3-f525-42f0-aae8-cdf9df36a2ba" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">The Nasdaq Global Select Market</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Act: </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#9744;     </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4c9d72c4-9f6f-4fc7-bc1a-b118c958313d" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="dei:EntityWellKnownSeasonedIssuer"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#9746;</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.  </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9744;     </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9a3bcf9d-40fa-4b57-9829-be0d91d86d86" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="dei:EntityVoluntaryFilers"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#9746;</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cd9e583c-4493-41e8-b66b-ad5a7dca3750" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="dei:EntityCurrentReportingStatus"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#9746;     </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#9744;</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).  </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c208c57a-9953-4d0b-96ba-03be3db541bc" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="dei:EntityInteractiveDataCurrent"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#9746;     </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#9744;</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:19.116%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:55.649%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:20.316%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.92%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Large accelerated filer</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accelerated filer</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
    </tr>
    <tr style="height:2.15pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_0b83660c-4bd3-4070-9394-88a0c0ce0f9c" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Smaller reporting company</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_c9fdc0d8-6f89-42e4-957f-cb7f807cf018" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:2.15pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Emerging growth company</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_f1466b56-7d8e-452b-a022-a0341f1941f1" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_004c5ff8-be27-4c99-b650-9d5738fe50f0" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_48a7b236-df65-405a-8fc4-c53bed9df404" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_aa28a7bd-ef55-4bf9-ab47-4a4a25b9c353" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#9744;     </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4708947a-e6fe-416a-95a1-6447c8e639ed" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate market value of registrant&#8217;s common stock held by non-affiliates of the registrant, computed by reference to the closing price as of the last business day of the registrant&#8217;s most recently completed second fiscal quarter, June 30, 2025, was approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89a2b968-a7a6-45f3-843c-9640e9c48a89" contextRef="C_aba7e5f4-1031-43f5-85fd-1ca0501bbfac" name="dei:EntityPublicFloat" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">297.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of February 25, 2026</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the registrant had </span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8369cd8b-6338-46d0-9671-214393569528" contextRef="C_81cdd1a9-196d-4908-8af2-c3bceb99e972" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">53,867,115</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock ($0.0001 par value) outstanding.</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><div style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_12181c91-2c7d-4306-8b62-23ee606d0412" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain sections of the registrant&#8217;s definitive proxy statement for the </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2025</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> annual meeting of stockholders to be filed with the Securities and Exchange Commission pursuant to Regulation 14A not later than 120 days after the end of the fiscal year covered by this Form 10-K are incorporated by reference into Part III of this Form 10-K.</span></p></ix:nonNumeric></div><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1.5pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:15%;box-sizing:content-box;"/>
     <td style="width:78%;box-sizing:content-box;"/>
     <td style="width:7%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Page</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PART I</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_business"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Business</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1A.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a_risk_factors"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Risk Factors</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1B.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1C.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1c_cybersecurity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Cybersecurity</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 2.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_properties"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Properties</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 3.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3_legal_proceedings"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Legal Proceedings</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 4.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PART II</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 5.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5_market_for_registrants_common"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 6.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_6_selected_financial_data"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">[Reserved]</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 7.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7_managements_discussion"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 7A.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7a_quantitative_and_qualitative"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">110</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 8.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_8_financial_statements"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">112</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9_changes_in_and_disagreements"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">135</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9A.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9a_controls_and_procedures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Controls and Procedures</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">135</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9B.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9b_other_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Other Information</span></a></p></td>
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">136</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9C.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9c_disclosure_regarding_foreign"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">136</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PART III</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 10.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_10_directors_executive_officers"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">136</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 11.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_11_executive_compensation"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Executive Compensation</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">137</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 12.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_12_security_ownership_of_certain"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">137</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 13.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_13_certain_relationships_and_relate"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">137</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 14.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_14_principal_accounting_fees_servic"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Principal Accounting Fees and Services</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">137</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PART IV</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 15.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_15_exhibits_financial_statement"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Exhibits and Financial Statement Schedules</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">137</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 16.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_16_form_10_k_summary"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form 10-K Summary</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">137</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:6.85pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.267%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">SIGNATURES</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#signatures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Signatures</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">140</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART I</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORWARD-LOOKING STATEMENTS AND MARKET DATA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Annual Report on Form 10-K (Annual Report) contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act). All statements other than statements of historical facts contained in this Annual Report, including statements regarding our future results of operations and financial position, business strategy, research and development plans, the anticipated timing and phase of development, costs, design and conduct of our ongoing and planned preclinical studies and clinical trials for our product candidates, the potential benefits of regulatory designations, the timing and likelihood of regulatory filings and approvals for our product candidates, the potential to develop product candidates and the safety and therapeutic benefits of our product candidates, our ability to commercialize our product candidates, if approved, the pricing and reimbursement of our product candidates, if approved, the timing and likelihood of success, plans and objectives of management for future operations, and future results of anticipated product development efforts, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. This Annual Report also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In some cases, you can identify forward-looking statements by terms such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue&#8221; &#8220;could,&#8221; &#8220;contemplate,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will&#8221; or "would" or the negative of these terms or other similar expressions. The forward-looking statements in this Annual Report are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Annual Report and are subject to a number of risks, uncertainties and assumptions, including, without limitation, the risk factors described in Part I, Item 1A, &#8220;Risk Factors.&#8221; The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Annual Report includes trademarks, tradenames and service marks that are the property of other organizations. Solely for convenience, trademarks and tradenames referred to in this Annual Report appear without the &#174; and &#153; symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights, or that the applicable owner will not assert its rights, to these trademarks and tradenames.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We maintain a website at www.tyra.bio, to which we regularly post copies of our press releases as well as additional information about us. Our filings with the Securities and Exchange Commission (SEC) are available free of charge through our website as soon as reasonably practicable after being electronically filed with or furnished to the SEC. Information contained in our website does not constitute a part of this report or our other filings with the SEC.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1_business"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">em 1. Business.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overview</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our in-house precision medicine platform, SN&#197;P, enables rapid and precise drug design through iterative molecular SN&#197;Pshots that help us design and predict which product candidates may demonstrate the highest potency, selectivity and tolerability in the clinic. Through this approach, we have built a wholly-owned pipeline of oral small molecule product candidates focused on targets that have previously been considered difficult-to-drug.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our FGFR3 Programs&#8212;oral dabogratinib (formerly TYRA-300) for Urothelial Cancers and Skeletal Dysplasia</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Alterations in the protein receptor FGFR3 are a validated driver in multiple indications with large market opportunities: urothelial cancers and skeletal dysplasia conditions. In urothelial cancer, uncontrolled activation of FGFR3 on the cell surface stimulates cellular proliferation. In skeletal dysplasia conditions, increased activity of FGFR3 expressed in growth plate chondrocytes (cartilage cells) results in excessive limitation of long bone growth.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our lead program, oral dabogratinib, was designed to be more selective for FGFR3 over FGFR1, FGFR2, and FGFR4 to minimize off-target side effects, providing potential clinical advantages over less selective first-generation compounds and potentially addressing key unmet needs across both urothelial cancers and skeletal dysplasia conditions. To date, oral dabogratinib has been administered to over 100 participants across multiple clinical studies.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We demonstrated initial clinical proof-of-concept results with oral dabogratinib in the SURF301 study, a Phase 1 proof-of-concept study in metastatic urothelial carcinoma (mUC). Oral dabogratinib demonstrated encouraging anti-tumor activity and was generally well-tolerated, with infrequent FGFR2- and FGFR1-associated toxicities. Response, safety, pharmacokinetics (PK) / pharmacodynamics (PD) and circulating tumor DNA (ctDNA) data from this study were leveraged to select doses that have the potential to achieve our target product profile for efficacy and safety in our Phase 2 trials and beyond.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are currently advancing oral dabogratinib in three Phase 2 trials for three outsized market indications: SURF303, evaluating the treatment of low-grade upper tract urothelial carcinoma (LG-UTUC); SURF302, evaluating the treatment of intermediate risk non-muscle invasive bladder cancer (IR NMIBC); and BEACH301, evaluating the treatment of achondroplasia (ACH) in children. If we are successful with these Phase 2 studies, we expect to advance oral dabogratinib toward three potential registrational trials in LG-UTUC, IR NMIBC and ACH. We are calling this approach our &#8220;dabogratinib 3x3&#8221; strategy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SURF303 for LG-UTUC: This open-label Phase 2a/b clinical trial was designed as a potential registrational trial to evaluate the efficacy and safety of oral dabogratinib at doses of 60 mg and 80 mg once daily (QD) in participants with FGFR3-altered low-grade upper tract urothelial carcinoma, where approximately 85% of tumors are driven by FGFR3. Study startup is ongoing and the first patient in this study is anticipated to be dosed in 2026.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SURF302 for IR NMIBC: This open-label Phase 2 clinical trial is evaluating the efficacy and safety of oral dabogratinib at 50 mg and 60 mg QD in participants with FGFR3-altered low-grade, IR NMIBC, where  approximately 70% of tumors are driven by FGFR3. We anticipate reporting initial three-month CR data from approximately 10-20 patients per cohort from this study by the end of the first half of 2026.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">BEACH301 for ACH: This study is an open-label, Phase 2 dose-escalation/dose-expansion trial evaluating oral dabogratinib at lower doses (0.125, 0.25, 0.375, 0.50 mg/kg), as compared to the oncology studies, in children ages 3 to 10 with ACH with open growth plates, where approximately 99% of cases are driven by FGFR3. The study is enrolling a safety sentinel cohort of 3 or more participants per dose level in children ages 5 to 10, and a natural history run-in for cohorts 1 and 2 with children ages 3 to 10. Initial results from the safety sentinel cohort, including 6-month average height velocity (AHV) results and interim safety, are on-track and expected to be reported in the second half of 2026.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our Other Programs</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TYRA-430 was designed to be biased for FGFR4 and FGFR3 over the FGFR1 and FGFR2 isoforms specifically to address the FGF19 signaling pathway, while also potentially limiting side effects due to inhibition of FGFR1 and FGFR2, as well as to address acquired resistance mutations that have limited the efficacy of previous FGFR4-specific inhibitors. TYRA-430 is currently being evaluated in SURF431, a global, Phase 1, multicenter, open-label trial, with a focus on achieving clinical proof-of-concept in a cohort of patients with FGF19+ hepatocellular carcinoma (HCC).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TYRA-200 is an FGFR1/2/3 inhibitor designed to be active against nearly all of the clinically identified acquired resistant mutations that arise during treatment with pan-FGFR inhibitors, which we believe is necessary to address the problem of disease progression due to polyclonal resistance. TYRA-200 is currently being evaluated in SURF201, a global, Phase 1, multicenter, open-label trial, with a focus on achieving clinical proof-of-concept in a cohort of FGFR2-driven intrahepatic cholangiocarcinoma (ICC) resistant to previous FGFR inhibitors.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our Pipeline</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img94995564_0.jpg" alt="img94995564_0.jpg" style="width:624px;height:310px;"/></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Strategy</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our mission is to improve outcomes for patients living with cancer and genetically defined conditions. We are executing on our mission by focusing on advancing our pipeline and building a leading company around FGFR biology. With this strategy, our goal is the discovery, development and commercialization of next-generation precision small molecules against clinically validated targets to treat a wide range of indications currently lacking adequate treatment options.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The elements of our strategy to achieve this goal are to:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Advance our lead product candidate, oral dabogratinib, toward pivotal studies and commercialization in the United States and certain other territories in urothelial cancers and skeletal dysplasia conditions;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Advance our early-stage clinical pipeline and maintain our position as a leader in our focus area of FGFR biology; and</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Harness the power of our SN&#197;P platform to expand our pipeline of next-generation precision medicines for oncology and rare disease indications within FGFR biology and potentially other target areas of interest. </span></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All of our assets have been developed in-house and we retain full development and commercialization rights for our pipeline. We intend to maximize the value of our pipeline by retaining development and commercialization rights to our product candidates, indications and geographies that we believe we can ultimately commercialize successfully on our own if they are approved. We will seek to collaborate on product candidates that we believe have promising utility in disease areas or patient populations that are better served by the resources or specific expertise of larger biopharmaceutical companies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our SN&#197;P Platform</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our proprietary SN&#197;P platform enables rapid and precise drug design through iterative molecular SN&#197;Pshots that help us design and predict which product candidates will demonstrate the highest potency, selectivity and tolerability in the clinic. Through this approach, we have developed next-generation precision small molecule candidates with novel structures designed to inhibit the target while avoiding off-target toxicities and resistance mutations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our SN&#197;P platform is driven by our ability to generate iterative data rapidly and concurrently from the following three key pillars.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Protein crystallography</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. We have developed proprietary protein crystallography techniques that enable us to determine the co-crystal structures of newly synthesized compounds in target proteins in as little as three days. This enables weekly generation of detailed structural insights on the precise interactions and conformational changes that occur when our potential product candidates bind to a particular target, creating opportunities to further refine the structural design. </span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cell-based assays</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. We assess inhibitor potency directly in in vitro target-specific anti-proliferation assays, in addition to enzymatic assays, to enable us to simultaneously understand target potency and cell penetration as well as target-specific cell killing. Our process allows us to generate data on newly synthesized compounds in as little as two days. </span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In vivo models</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Our direct structural insights and in vitro datasets are complemented by in vivo pharmacologic data generated through in-house animal models that provide us with bioavailability, PK data and anti-tumor activity in as little as five days. </span></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Together, these three pillars of our platform provide a molecular SN&#197;Pshot for our compound candidates. At this time, we are able to generate a molecular SN&#197;Pshot for a compound candidate within one week. We believe that a sharp focus on efficiently generating these three key empirical datasets for compound candidates enables us to balance speed with the robust identification of pivotal insights to rapidly and precisely iterate the design of our novel molecular structures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overcoming First Generation FGFR Inhibitor Liabilities</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have initially leveraged our SN&#197;P approach to develop novel small molecules designed to overcome the toxicity and resistance liabilities of prior generation pan-FGFR inhibitors. Four FGFR targeted therapies have been approved by the U.S. Food and Drug Administration (FDA) for oncology: erdafitinib for bladder cancer that has spread or cannot be removed by surgery, and pemigatinib, infigratinib and futibatinib for ICC with FGFR2-fusions or gene rearrangements (infigratinib was later withdrawn from the market effective March 31, 2023). These inhibitors have demonstrated clinical responses, however, response rates and duration of response are limited and come with toxicities driven by the inhibition of FGFR receptors 1, 2 and 4. FGFR1 is expressed in kidney cells where it regulates phosphate and calcium reabsorption, and consequently, inhibition of FGFR1 results in hyperphosphatemia. Inhibition of FGFR2 can result in toxicities that significantly impact quality of life, such as skin and nail toxicities (e.g., onycholysis and hand-foot syndrome), stomatitis, and ocular toxicities such as keratitis and blurred vision. Inhibition of FGFR4 disrupts bile acid metabolism and can result in diarrhea and elevated liver enzymes (AST and ALT). Hyperphosphatemia was a dose-limiting toxicity (DLT) of erdafitinib and was reported in over 70% of patients in the Phase 3 clinical trial conducted in mUC. Overall, Phase 3 AEs resulted in 72% dose interruptions, 69% dose reductions, and 14% treatment discontinuations. By way of example, we believe the safety and tolerability profile of erdafitinib is a key limitation to its efficacy, as demonstrated by the dosing instructions to start at a daily 8 mg dose, and only increase to 9 mg if hyperphosphatemia is not observed. A similarly high rate of FGFR-related toxicities has been reported in clinical trials of other non-isoform selective FGFR inhibitors including pemigatinib, infigratinib and futibatinib in pivotal studies for ICC. In addition to being limited by toxicity, patients can develop acquired drug resistance, ultimately resulting in disease progression and discontinuation of therapy.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our FGFR3 Program for Urothelial Carcinoma</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Dabogratinib for LG-UTUC and NMIBC</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FGFR3 is a protein receptor expressed on the cell surface that stimulates cellular proliferation upon binding of fibroblast growth factor. Uncontrolled activation of FGFR3 has been implicated in oncogenesis across the spectrum of urothelial carcinoma, and most frequently in the earliest stages of the disease.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dabogratinib was designed to be more selective for FGFR3 over FGFR1, FGFR2, and FGFR4, to minimize side effects resulting from inhibition of these related proteins and achieve greater potency against the FGFR3 driver mutation. Dabogratinib established clinical proof-of-concept in SURF301 in mUC, and is currently being studied in the global Phase 2a/b SURF303 trial in patients with LG-UTUC, as well as the global Phase 2 SURF302 trial in patients with IR NMIBC.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disease background &#8211; urologic cancers</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Urothelial carcinoma (UC) is one of the most common malignancies of the genitourinary system. Urothelial carcinoma is classified anatomically, with tumors originating in the ureters and renal pelvis known as upper tract urothelial carcinoma (UTUC) and tumors originating in the lower tract referred to as bladder cancer. Across urothelial carcinoma, tumors are often characterized by histologic grade (low or high) as well as by invasiveness.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UTUC is estimated to account for 5-10% of urothelial cancer cases and is defined as a rare disease. We estimate that approximately 50% of UTUC tumors are diagnosed at the non-invasive stage and that approximately 40% of non-invasive tumors present with low-grade histology.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lower tract urothelial carcinoma, or bladder cancer, is classified into three broad categories: NMIBC where the cancer is restricted to surface lining of the bladder, muscle invasive bladder cancer (MIBC), which is a cancer that has grown deeper into the bladder wall, and mUC, in which cancer has spread beyond the bladder. NMIBC comprises the largest population of bladder cancer patients, representing 70-75% of cases diagnosed annually in the United States. NMIBC can be categorized as low, intermediate and high risk for recurrence or progression, with a significant proportion categorized as intermediate and high risk.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FGFR3 more commonly drives lower grade and more localized stages of urothelial carcinoma. The</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">incidence of activating FGFR3 mutations is estimated to be between 80-90% in LG-UTUC, 60-80% in IR NMIBC and 10-20% in mUC, making FGFR3 an attractive target for development and particularly in early-stage disease.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2022, there were over 740,000 people living with bladder cancer and an estimated 50,000 people living with UTUC in the United States alone. We estimate that in 2025, approximately 185,000 US patients were seeking therapy for first-time treatment or to address a recurrence across LG-UTUC and bladder cancer. Applying FGFR3 alteration incidence to these estimates, we believe that approximately 80,000 FGFR3+ patients, including approximately 3,000 LG-UTUC patients and approximately 35,000 IR NMIBC patients, are addressable across bladder cancer in the United States alone annually.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img94995564_1.jpg" alt="img94995564_1.jpg" style="width:624px;height:278px;"/></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Potential UTUC and bladder cancer patient populations for our FGFR3 inhibitor</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Current LG-UTUC treatment landscape and unmet need</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Significant unmet need remains in treating patients with LG-UTUC who are at risk of kidney loss and dialysis. The structure of the upper tract, including ureter length, diameter and orientation, and intra-renal anatomy, present challenges with diagnosis and treatment. Repetitive kidney-sparing surgeries are the favored standard of care, but will miss up to 25% of UTUC tumors due to challenging anatomy and frequent multifocality, and comes with the risks of repeat general anesthesia and intra- and post-operative complications. 35&#8211;50% of all low grade UTUC tumors will recur within 3 years, with an even higher rate for large tumors. After one or more recurrences, patients often proceed to radical nephroureterectomy, which can result in chronic dialysis and increased cardiovascular morbidity and mortality.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Jelmyto, a mitomycin hydrogel, is the only non-surgical option approved for renal pelvis tumors 5&#8211;15mm in size, based on a 71-patient pivotal Phase 2 trial. Uptake has been limited due to modest efficacy (58% CR and 56% 12-month duration of response (DoR), high rates of local AEs (including 58% ureteric obstruction, 34% urinary tract infection (UTI) and 25% renal dysfunction), challenging administration (ureteral catheter with fluoroscopy or nephrostomy tube) and burdensome preparation (more than 40 steps over 45&#8211;60 minutes). A few additional locally-administered product candidates are currently in Phase 2 or 3 development for LG-UTUC.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Current NMIBC treatment landscape and unmet need</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NMIBC is one of the most recurrent of all cancers and current standard of care treatment comes with drawbacks. For low grade lesions, Transurethral Resection of Bladder Tumor (TURBT) with or without adjuvant intravesical chemotherapy is the standard of care, whereas high risk lesions should be treated with either adjuvant BCG or radical cystectomy. Repeat TURBT comes with risks and burden to patients, including the need to undergo general anesthesia and potential for AEs such as bladder perforation. Within the first two years of initial standard of care treatment, intermediate risk NMIBC recurrence rates are as high as 40% at two years. Zusduri, an intravesical chemotherapy hydrogel, is the single novel therapy approved for IR NMIBC, with only other intravesical therapies remaining in development.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 2 data for erdafitinib in NMIBC suggest the potential for FGFR inhibitors in this indication. In the final Phase 2 analysis, low dose oral erdafitinib demonstrated an 89% CR rate in IR NMIBC patients and notably, the 12-month DoR for those who remained on study drug was 100%. The safety and tolerability results were generally consistent with that known for erdafitinib, despite using a lower 6 mg daily dose in these studies. TAR-210, an erdafitinib-containing device implanted every three months via the urethra, also demonstrated a 90% CR rate in IR patients and 90% recurrence-free survival (RFS) in high-risk papillary patients as presented at AUA 2024. Johnson &amp; Johnson has initiated a Phase 3 trial for TAR-210 in low grade IR NMIBC patients and has not indicated plans to develop oral erdafitinib further in this setting.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our solution, oral dabogratinib, in LG-UTUC and NMIBC</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe an orally administered, highly specific FGFR3-selective inhibitor, with minimal effects from other FGFR-related toxicities, has the potential to be highly efficacious and tolerable and represents a potentially large future market opportunity for patients with LG-UTUC and IR NMIBC.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designing inhibitors that bind to the ATP-binding site and that can selectively differentiate between FGFR3 and FGFR1 is challenging due to the near-identical amino acid sequence in this site. We utilized the differentiated approach of our SN&#197;P platform to generate compounds, including oral dabogratinib, that capitalize on subtle conformational differences between FGFR3 and FGFR1 to obtain greater than ten-fold selectivity for FGFR3 versus FGFR1. In comparison, other FGFR inhibitors that are approved or in clinical development such as erdafitinib, pemigatinib, futibatinib and infigratinib, have demonstrated low or no selectivity for FGFR3 over FGFR1 and FGFR2.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Oral dabogratinib clinical data from SURF301 Phase 1 proof-of-concept study</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SURF301 was designed as a proof-of-concept clinical study to determine the recommended Phase 2 dose of oral dabogratinib in cancer and skeletal dysplasia conditions. Treatment with oral dabogratinib was evaluated in patients with solid tumors across ten dose levels, ranging from 10 mg-120 mg QD, including 40 mg and 50 mg BID. This study is no longer recruiting new patients.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2024, we reported interim data showing a 50% response rate (5/10) in FGFR3 positive patients who received 90 mg daily of oral dabogratinib, with a 100% disease control rate, and favorable safety results demonstrating infrequent FGFR2 and 1 associated toxicities.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe this data suggests that 90 mg QD is the optimal dose for further evaluation in the mUC setting, however, no further development is planned at this time due to our prioritized focus on what we believe are more attractive market opportunities. We expect to publish final Phase 1 results from SURF301 in a future scientific publication.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img94995564_2.jpg" alt="img94995564_2.jpg" style="width:623px;height:319px;"/></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At 90 mg QD, improved anti-tumor activity and tolerability were observed with oral dabogratinib as compared to erdafitinib</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notably, at dose levels equal to or lower than 60 mg QD, including target dose levels for NMIBC and skeletal conditions, oral dabogratinib exhibited favorable interim safety results as of the data cutoff date. No hyperphosphatemia, ALT or AST increases, discontinuations or dose reductions were reported at doses equal to or below 60 mg QD.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img94995564_3.jpg" alt="img94995564_3.jpg" style="width:624px;height:279px;"/></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FGFR-related toxicities were infrequent at lower doses</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the PK/PD analysis in 50 patients as of the data cutoff of August 15, 2024, oral dabogratinib plasma concentrations indicated adequate FGFR3 IC90 target coverage at &#8805;90 mg QD, the half maximal inhibitory concentration (IC</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) target coverage at 60 mg QD, with 40 mg QD nearly covering IC</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img94995564_4.jpg" alt="img94995564_4.jpg" style="width:624px;height:266px;"/></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exposure at doses &#8805;90 mg and &#8805;60 mg exceeded FGFR3 IC</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">90</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and IC</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> target coverage, respectively</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ctDNA analysis published in 18 FGFR3+ mUC patients with positive ctDNA at baseline show strong target engagement at 90 mg QD and activity at doses of 40 mg and 60 mg QD.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img94995564_5.jpg" alt="img94995564_5.jpg" style="width:624px;height:315px;"/></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ctDNA changes in FGFR3+ mUC patients show activity at &gt;40 mg</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The totality of response, safety, PK/PD and ctDNA data from this study, as well as data from pan-FGFR inhibitors, were leveraged to select lower doses that we believe have the potential to achieve our target product profiles designed to optimize for efficacy and minimal FGFR 1 / 2 / 4 toxicity for in our Phase 2 studies and beyond. These data were presented in a poster at the ASCO Genitourinary Cancer Symposium meeting in February 2026.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future clinical development plans for oral dabogratinib in LG-UTUC and NMIBC</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that the full development potential for oral dabogratinib may cover the entire spectrum of disease in urothelial carcinoma and may represent a large opportunity given the high prevalence of FGFR3 mutations and the potential to treat earlier disease.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2025, we announced that an Investigational New Drug application (IND) was cleared by the FDA to enable SURF303, a global, open-label, multicenter Phase 2a/b clinical study evaluating the efficacy and safety of oral dabogratinib in participants with LG-UTUC. In Part A, up to 25 participants are being randomized initially to treatment with oral dabogratinib at 60 mg QD or treatment with oral dabogratinib at 80 mg QD, respectively. Following a review of available efficacy and safety results within Part A, an additional dosing cohort may be evaluated. The primary endpoint is CR rate within six months in FGFR3+ patients. Secondary endpoints include CR within 6 months in all comers, duration of response, safety and tolerability, and conversion of unresectable to resectable disease. Part B was designed as a potential registrational trial and will recruit up to 100 patients at the recommended Phase 2 dose. The first patient in this study is anticipated to be dosed in 2026.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2025, we announced that the first patient was dosed in SURF302, a global, open-label, multicenter Phase 2 clinical study evaluating the efficacy and safety of oral dabogratinib in participants with FGFR3-altered low-grade, IR NMIBC. Up to 30 participants are being randomized initially to treatment with oral dabogratinib at 50 mg QD or treatment with oral dabogratinib at 60 mg QD, respectively. Following a review of available efficacy and safety results, an additional dosing cohort may be evaluated, if necessary. The primary endpoint is CR rate at three months. Secondary endpoints include time to recurrence, the median duration of response, Recurrence Free Survival (RFS), Progression Free Survival (PFS), safety and tolerability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our FGFR3 Program for Skeletal Conditions</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Dabogratinib for ACH and Skeletal Conditions</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Alterations in FGFR3 are implicated in skeletal conditions due to its role in regulating bone and cartilage formation. We believe that there is a significant opportunity to develop oral dabogratinib to potentially address the long-term complications associated with these skeletal conditions including ACH, hypochondroplasia (HCH), Turner syndrome, Short Stature Homeobox (SHOX) deficiency, other FGFR3-driven genetic syndromes and idiopathic short stature.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disease background</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FGFR3 is expressed in growth plate chondrocytes (cartilage cells) where it functions in signaling pathways to limit growth. The G380R mutation in FGFR3, which causes an estimated 99% of ACH, as well as other activating mutations, increases FGFR3 activity, resulting in excessive limitation of growth in the long bones, vertebral bodies and skull base. In children with ACH, the most common form of dwarfism, these growth differences can result in life-long health complications such as sleep apnea, obesity, recurrent ear infections, and bowed legs. The most serious sequelae include spinal stenosis (narrowing of the spinal canal); up to 20% of infants require surgery to address narrowing at the base of the skull (foramen magnum stenosis), which can be life-threatening; in adults, spinal stenosis of the lower back results in chronic pain, necessitating surgery and long-term pain management.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ACH is an autosomal dominant condition that occurs in approximately 1 in 15,000 to 40,000 newborns worldwide, and it is estimated that there are approximately 3,000 affected individuals under the age of 18 in the United States and approximately 23,000 addressable, affected individuals under the age of 18 worldwide. Approximately 80% of ACH cases arise through a spontaneous mutation of FGFR3, whereas 20% of cases are familial.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FGFR3 is implicated in multiple additional skeletal conditions, including HCH, which is most commonly caused by the N540K mutation (approximately 70-80%) in the FGFR3 gene. SHOX is a transcription factor for FGFR3 and deletion of the SHOX gene in Turner syndrome and SHOX deficiency commonly presents with short stature.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Current treatment landscape and unmet need</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ACH had been managed primarily through surgical and physical therapy intervention until the accelerated approval of Voxzogo (vosoritide) in 2021. Voxzogo is a daily injected C-natriuretic peptide (CNP) analog, which acts downstream of FGFR3. In a pivotal study, children treated with 15 mg/kg of Voxzogo achieved 5.66 cm/year in AHV, a 1.40 cm improvement over 4.26 cm baseline. Children in the Phase 2 trial treated with 15 mg/kg achieved 5.91 cm/year AHV, 1.87 cm improvement over 4.04 cm baseline. Children treated with 30 mg/kg saw a lower change from baseline, suggesting the CNP pathway activity is potentially dose-limited in FGFR3-driven conditions. Yuviwel (TransCon CNP), a prodrug of CNP administered to children with ACH by injection on a weekly basis, showed similar efficacy in Phase 3 and was approved by the FDA in February 2026. BridgeBio is developing infigratinib, a daily oral, low-dose FGFR1/2/3 inhibitor, which achieved 5.96 cm/yr AHV and a 1.74 cm/yr improvement over 4.22 cm/yr baseline in a Phase 3 study. BridgeBio previously published that adult doses above 0.33 mg/kg are limited by hyperphosphatemia and to date they have not exceeded the 0.25 mg/kg dose in clinical studies for pediatric skeletal conditions. BioMarin disclosed that prolonged treatment with Voxzogo could result in a final adult height improvement of 26 cm or more in ACH, potentially 20 cm (approximately 8 inches) less than average height for adult males without ACH, pointing to remaining unmet need. To reach final average male stature, 2.7 cm/yr AHV improvement would be needed over 17 years, and, to our knowledge, no approved or pipeline product candidates have achieved this to-date.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our solution, oral dabogratinib, in ACH</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By engaging FGFR3 selectively at higher, safe doses, oral dabogratinib may have the potential to meaningfully improve height, health and functional outcomes beyond what can be achieved with current therapies in development for children with ACH, HCH, Turner syndrome, SHOX deficiency, other FGFR3-driven genetic syndromes and idiopathic short stature. Based on the population size and potential addressable unmet need, we believe ACH alone represents a large future market opportunity for oral dabogratinib.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the Imagine Institute&#8217;s FGFR3Y367C/+ preclinical model, oral dabogratinib administered daily at a 1.2 mg/kg dose for 15 days, increased body length in mice by 17.9% compared to the vehicle (p&lt;0.0001) and increased the length of the femur (+22.6%), tibia (+33.0%) and L4-L6 (+23.5%) in mice (p&lt;0.0001). 1.2 mg/kg in mice roughly equates to a 0.5 mg/kg dose in children and a 40 mg dose in adults. Oral dabogratinib also demonstrated increases in long bone length in the Imagine Institute&#8217;s HCH mouse model.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Development plans for oral dabogratinib in ACH</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2025, we announced that the first child was dosed in BEACH301, a global, Phase 2, multi-center, open-label clinical trial of oral dabogratinib for children ages 3 to 10 with ACH with open growth plates. The primary objective of the study is to assess safety and tolerability in children with ACH and evaluate change from baseline in annualized growth velocity to determine the dose(s) for further development. Secondary objectives include evaluating change from baseline in height z-score, proportionality and PK.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The study is initially enrolling a safety sentinel cohort of 3 or more children, ages 5 to 10, per dose level (0.125, 0.25, 0.375, 0.50 mg/kg). The study is also enrolling children who are treatment-na&#239;ve (Cohort 1) and those who have received prior growth-accelerating therapy (Cohort 2) ages 3-10 at multiple sites across the globe. Cohorts 1 and 2 are anticipated to initiate treatment after completion of safety sentinel dose escalation and a six-month observation period, with each cohort expecting to enroll up to 10 participants per dose level.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have cleared the first two doses in the safety sentinel cohort and are currently dosing children at the third safety sentinel dose level of 0.375 mg/kg and we expect to report initial data from the safety sentinel cohort of the BEACH301 study in the second half of 2026.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2023 and January 2024, the FDA granted orphan drug designation and rare pediatric disease designation to oral dabogratinib, respectively, for the treatment of ACH.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our FGF19+ Program</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TYRA-430 for Hepatocellular Carcinoma</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FGF19 is a post-prandial enterohepatic hormone that signals through FGFR4 and its associated co-receptor Beta-Klotho (KLB) to exert its normal cellular functions. In a subset of certain cancers, such as HCC, gastric adenocarcinoma, and squamous esophageal carcinoma, FGF19 is aberrantly expressed due to focal chromosomal amplifications or epigenetic mechanisms, promoting tumor cells to become dependent on the FGFR4/KLB/FGF19 oncogenic axis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An experiment run by Tao et al (2022) demonstrated a greater dependence of HCC JHH-7 cells on KLB, the common co-receptor for FGFR3 and FGFR4, than on either receptor alone. This is also consistent with the results of the double knock down of FGFR3 and 4 being more deleterious than knock down of either receptor alone, suggesting the need for dual inhibition of FGFR3 or FGFR4.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TYRA-430 is an investigational FGFR4/3 biased inhibitor for FGF19+/FGFR4-driven cancers that is designed to be agnostic to acquired resistance mechanisms originating from the V550 gatekeeper and the C552 mutations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2025, we commenced our Phase 1 clinical trial of TYRA-430, SURF431, a multi-center, open label study designed to evaluate the safety, tolerability, and PK of TYRA-430 and determine the optimal dose for further development, the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as evaluate preliminary antitumor activity in advanced HCC and other solid tumors with activating FGF/FGFR pathway aberrations. We believe TYRA-430 has the potential to address a significant unmet need in HCC, where there are no approved biomarker-driven, targeted therapies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our FGFR2 Program</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TYRA-200 for ICC</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FGFR2 is a protein receptor present on the cell surface that promotes cellular proliferation and transformation upon binding of fibroblast growth factor. Activating gene alterations of FGFR2 have been implicated in the tumorigenesis of multiple solid tumor types.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TYRA-200 is an investigational, oral, FGFR1/2/3 inhibitor designed to be active against activating FGFR2 gene alterations, as well as clinically important molecular brake and gatekeeper resistance mutations, and selective for FGFR4. We are focusing initial Phase 1 development of TYRA-200 in FGFR2-driven ICC resistant to treatment with prior FGFR inhibitors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, we commenced our Phase 1 clinical trial of TYRA-200, SURF201, a multi-center, open label study designed to evaluate the safety, tolerability, and PK of TYRA-200 and determine the optimal dose for further development, the MTD and RP2D, as well as evaluate preliminary antitumor activity. SURF201 is currently enrolling ICC patients with acquired kinase domain mutations. Positive data in this setting, where other FGFR inhibitors have not succeeded, would potentially provide confidence in our belief that addressing acquired resistance may prolong the duration of responses, and ultimately PFS, in the FGFR-naive setting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Beyond FGFR-resistant and FGFR-naive ICC, there is potential for TYRA-200 to extend into metastatic endometrial carcinoma as well as advanced colorectal, breast, ovarian, gastric, and lung cancer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Discovery Engine</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We continue to leverage the SN&#197;P platform in the discovery and development of additional, undisclosed preclinical programs. These efforts are focused in the field of FGFR biology as well as other targets that are important drivers for opportunities across precision oncology and genetically defined conditions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competition</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition, and a strong emphasis on proprietary products. While we believe that our technology, technical expertise, and drug development experience provide us with competitive advantages, we face increasing competition from many different sources, including pharmaceutical and biotechnology companies, academic institutions, governmental agencies, and public and private research institutions. Product candidates that we successfully develop and commercialize may compete with existing and/or new therapies that may become available in the future.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of our competitors, either alone or with their collaborators, have significantly greater financial resources, established presence in the market, expertise in manufacturing, research and development, pre-clinical activities and clinical trial conduct. Additionally, many of our competitors are commercial-stage entities with experience in obtaining regulatory approvals and reimbursement for marketed approved products. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with larger and/or established companies. Additional mergers and acquisitions may result in even more resources being concentrated in our competitors.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our commercial potential could be reduced or eliminated if our competitors develop and commercialize products that are more effective, have a more favorable safety profile, and are more convenient or less expensive than products that we may develop. Our competitors also may obtain FDA or other foreign regulatory approval(s) for their products more rapidly than us, which could result in our competitors establishing a strong market position before we are able to enter the market or could otherwise make our development more complicated. We believe the key competitive factors affecting the success of all of our programs are likely to be efficacy, including duration of human response and breadth of coverage, safety and patient convenience.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are numerous companies developing or marketing treatments for cancer, including many major pharmaceutical and biotechnology companies. These treatments consist of small molecule drug products, biologics, cellular therapies, and traditional chemotherapy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For oral dabogratinib in LG-UTUC, the only agent commercially available is Urogen&#8217;s Jelmyto, a hydrogel reformulation of mitomycin C, which was approved in April of 2020. Additional agents in Phase 2 or 3 development include Steba Biotech&#8217;s TOOKAD Vascular Photodynamic Therapy, Ferring&#8217;s nadofaragene firadenovec and Sustained Therapeutics&#8217; ST-02.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For oral dabogratinib in IR NMIBC, the only agent commercially available beyond intravesical BCG or chemotherapy is Urogen&#8217;s Zusduri, a hydrogel reformulation of mitomycin C, which was approved in June of 2025. Additional agents in Phase 3 development include Janssen Pharmaceutical&#8217;s TAR-210, CG Oncology&#8217;s crestostimogene grenadenorepvec and Ferring&#8217;s nadofaragene firadenovec.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For oral dabogratinib in ACH, BioMarin&#8217;s Voxzogo and Ascendis&#8217; Yuviwel (TransCon CNP) are approved for children of any age with open growth plates. BridgeBio&#8217;s infigratinib has published topline Phase 3 results. Ascendis published Phase 2 data on TransCon CNP and TransCon Human Growth Hormone and BioMarin is studying BMN-333, a long-acting CNP in Phase 1 development.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For oral dabogratinib in HCH, BioMarin&#8217;s vosoritide is in Phase 3 development, BridgeBio&#8217;s infigratinib has initiated a Phase 2/3 study and Ascendis has disclosed plans to initiate a clinical study. BioMarin has also initiated a Phase 2 basket trial for vosoritide in children with Turner syndrome, SHOX Deficiency and Noonan Syndrome without sufficient response to human growth hormone, in addition to a Phase 2 study for children with idiopathic short stature.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For TYRA-430 in HCC, several multi-kinase inhibitors have been approved for the treatment of HCC, but there are currently no approved targeted therapies, including FGFR4-specific inhibitors. In the late line setting, approved, non-targeted treatment options include Bayer&#8217;s Stivarga, Exelixis&#8217; Cabometyx, Eli Lilly&#8217;s Cyramza,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Merck&#8217;s Keytruda and BMS&#8217; Opdivo combined with Yervoy. There are a number of FGFR4 clinical stage programs, with most of the development focused in China, including CStone Pharmaceuticals and Blueprint Medicine&#8217;s BLU-554 (fisogatinib), Everest Medicine&#8217;s FGF401 and Abbisko Therapeutics&#8217; ABSK-011.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For TYRA-200 in ICC, there are two pan-FGFR inhibitors available in the United States that are indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or other rearrangement: Incyte Corporation&#8217;s Pemazyre and Taiho Oncology&#8217;s Lytgobi. Additional inhibitors in development include Elevar&#8217;s Lirafugratinib, TransThera&#8217;s tinengotinib and Cogent&#8217;s CGT-4859.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intellectual Property</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We strive to protect the intellectual property and proprietary technology that we consider important to our business through a variety of methods, including seeking and maintaining patents intended to cover our product candidates and compositions, their methods of use and processes for their manufacture, and any other inventions that are important to our business. We rely on know-how and continuing technological innovation to develop and maintain our proprietary position. We also rely on trade secrets and know-how that may be important to the development of our business. We seek to obtain domestic and international patent protection and endeavor to promptly file patent applications for new commercially valuable inventions to expand our intellectual property portfolio.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are building a patent portfolio and have substantial confidential know-how relating to our product candidates and SN&#197;P platform. As of March 1, 2026, our intellectual property portfolio consists of three granted U.S. patents, 11 pending U.S. provisional applications, 10 pending U.S. nonprovisional applications, 100 pending foreign patent applications, five granted foreign patents and 15 patent applications pursuant to the Patent Cooperation Treaty (PCT), all of which are solely owned by us. We do not license any material patent rights from any third party. Collectively, our patent rights relate to various aspects of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We continually assess and refine our intellectual property strategy as we develop new product candidates and improvements to our SN&#197;P platform. To that end, we are prepared to file additional patent applications in any appropriate fields if our intellectual property strategy requires such filings, or where we seek to adapt to competition or seize business opportunities. Further, we are prepared to file patent applications, as we consider appropriate under the circumstances, relating to the new technologies that we develop.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot be sure that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications we may own or license in the future, nor can we be sure that any patents we may own or license in the future will be useful in protecting our technology. Please see the section entitled &#8220;Risk Factors&#8212;Risks Related to Our Intellectual Property&#8221; for additional information on the risks associated with our intellectual property strategy and portfolio.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intellectual Property Relating to Our FGFR3 Program</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With regard to our FGFR3 product candidates, as of March 1, 2026, we own three pending U.S. provisional applications, four pending U.S. nonprovisional applications, three granted U.S. patent, 10 pending PCT patent applications, 53 pending foreign applications and four granted foreign patents. These patent rights relate to the FGFR3 product candidates&#8217; compositions of matter, formulations containing them, methods of manufacturing, and methods of treating diseases, using our FGFR3 product candidates. Specifically, we have two granted U.S. patents, four granted foreign patents and 28 pending foreign patent applications directed to the composition matter of our leading candidate in the FGFR3 program. We expect any patents issued from these applications to expire between 2040 and 2046 without accounting for any patent term adjustment or extension that may be available.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intellectual Property Relating to Our FGFR2 Program</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With regard to our FGFR2 program, as of March 1, 2026, we own three pending U.S. provisional applications, two pending U.S. nonprovisional applications, one pending PCT patent application, one granted</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">foreign patent and 16 pending foreign applications. These patent rights relate to the FGFR2 program&#8217;s compositions of matter, formulations containing them, methods of manufacturing, and methods of treating diseases. Specifically, we have one pending U.S. nonprovisional and 15 pending foreign patent applications directed to the composition matter of our leading candidate in the FGFR2 program. We expect any patents issued from these applications to expire between 2040 and 2046 without accounting for any patent term extension that may be available.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intellectual Property Relating to Other Programs</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With regard to our other programs, including the FGFR4 program, as of March 1, 2026, we own five pending U.S. provisional patent applications, four pending U.S. nonprovisional applications, four pending PCT patent applications and 32 pending foreign applications. These patent rights relate to these other programs&#8217; compositions of matter, formulations containing them, methods of manufacturing, and methods of treating diseases. We expect any patents issued from these applications to expire between 2042 and 2046 without accounting for any patent term extension that may be available.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Scope and Duration of Intellectual Property Protection</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The term of individual patents depends upon the laws of the countries in which they are obtained. In most countries in which we file, the patent term is 20 years from the earliest date of filing of a non-provisional patent application. However, the term of United States patents may be extended for delays incurred due to compliance with the FDA requirements or by delays encountered during prosecution that are caused by the USPTO. For example, for drugs that are regulated by the FDA under the Hatch-Waxman Act, the FDA is permitted to extend the term of a patent that covers such drug for up to five years beyond the normal expiration date of the patent, provided that the extended patent term may not exceed fourteen years after the date of approval of the marketing application. In the future, if and when our product candidates receive FDA approval, we expect to apply for patent term extensions on any issued U.S. patents covering those product candidates. We intend to seek patent term extensions for our current and future issued patents in jurisdictions where these are available; however, there is no guarantee that the applicable authorities, including the USPTO and FDA, will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions. Our issued patent and any patents issuing from our pending patent applications are expected to expire on dates ranging from 2040 to 2046, without accounting for potentially available patent term extensions or patent term adjustments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">However, the actual protection afforded by a patent varies on a product-by-product basis, from country-to-country, and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patent.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The patent positions of companies like ours are generally uncertain and involve complex legal and factual questions. No consistent policy regarding the scope of claims allowable in patents in the field of oncology therapy has emerged in the United States. The patent situation outside of the United States is even more uncertain. Changes in the patent laws and rules, either by legislation, judicial decisions, or regulatory interpretation in the United States and other countries may diminish our ability to protect our inventions and enforce our intellectual property rights, and more generally could affect the value of our intellectual property. In particular, our ability to stop third parties from making, using, selling, offering to sell, importing or otherwise commercializing any of our patented inventions, either directly or indirectly, will depend in part on our success in obtaining, defending and enforcing patent claims that cover our technology, inventions, and improvements. We cannot be sure that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications filed by us in the future, nor can we be sure that any of our current or future patents will be commercially useful in protecting our product candidates and the methods used to manufacture them. Moreover, our current or future patents may not guarantee us the right to practice our technology in relation to the commercialization of our product candidates.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The area of patent and other intellectual property rights in biotechnology is an evolving one with many risks and uncertainties, and third parties may have blocking patents that could be used to prevent us from commercializing our product candidates and practicing our proprietary technology. Our current or future patents may be challenged, narrowed, circumvented or invalidated, which could limit our ability to stop competitors from</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">marketing related product candidates or limit the length of the term of patent protection that we may have for our product candidates. In addition, the rights granted under our current or future issued patents may not provide us with protection or competitive advantages against competitors with similar technology. Furthermore, our competitors may independently develop similar technologies. For these and other reasons, we may have competition for our product candidates. Moreover, because of the extensive time required for development, testing and regulatory review of a potential product, it is possible that before any product candidate can be commercialized, any related patent may expire or remain in force for only a short period following commercialization, thereby reducing any protection afforded by the patent. For this and other risks related to our proprietary technology, inventions, improvements, SN&#197;P platform and product candidates, please see the section entitled &#8220;Risk Factors&#8212;Risks Related to Our Intellectual Property.&#8221;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have filed applications for trademark registrations in connection with our product candidates in various jurisdictions, including the United States. We have filed for trademark protection of the TYRA, TYRA BIOSCIENCES and HEALTH BEYOND HEIGHT marks with the United States Patent and Trademark Office and certain foreign patent and trademark organizations. We have registered trademarks in the United States and other jurisdictions.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also rely on trade secret protection for our confidential and proprietary information. Although we take steps to protect our confidential and proprietary information as trade secrets, including through contractual means with our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology. Thus, we may not be able to meaningfully protect our trade secrets. It is our policy to require our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to execute confidentiality agreements under the commencement of employment or consulting relationships with us. These agreements provide that all confidential information concerning our business or financial affairs developed or made known to the individual during the individual&#8217;s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. In the case of employees, the agreements provide that all inventions conceived by the individual, and which are related to our current or planned business or research and development or made during normal working hours, on our premises or using our equipment or proprietary information, are our exclusive property. In many cases our confidentiality and other agreements with consultants, outside scientific collaborators, sponsored researchers and other advisors require them to assign or grant us licenses to inventions they invent as a result of the work or services they render under such agreements or grant us an option to negotiate a license to use such inventions. Despite these efforts, we cannot provide any assurances that all such agreements have been duly executed, and any of these parties may breach the agreements and disclose our proprietary information, and we may not be able to obtain adequate remedies for such breaches.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also seek to preserve the integrity and confidentiality of our proprietary technology and processes by maintaining physical security of our premises and physical and electronic security of our information technology systems. Although we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. To the extent that our employees, contractors, consultants, collaborators and advisors use intellectual property owned by others in their work for us, disputes may arise as to the rights in relation to the resulting know-how or inventions. For more information, please see the section entitled &#8220;Risk Factors&#8212;Risks Related to Our Intellectual Property.&#8221;</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commercialization</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We intend to retain significant development and commercial rights to our product candidates and, if marketing approval is obtained, to commercialize our product candidates on our own, or potentially with a partner, in the United States and other regions. We currently have no sales, marketing or commercial product distribution capabilities. We intend to build the necessary infrastructure and capabilities over time for the United States, and potentially other regions, following further advancement of our product candidates. Clinical data, the size of the addressable patient population, the size of the commercial infrastructure and manufacturing needs may all influence or alter our commercialization plans.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturing</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not have any manufacturing facilities or personnel. We currently rely, and expect to continue to rely, on third parties for the manufacture of our product candidates undergoing preclinical testing, as well as for subsequent clinical testing and commercial manufacture if our product candidates receive marketing approval. We believe this strategy allows us to focus our expertise and resources on the development of our product candidates by eliminating the need for us to invest in our own manufacturing facilities, equipment and personnel.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We plan to put agreements in place with contract manufacturing organizations for the necessary quantities of active pharmaceutical ingredients (API) and drug product for each of our product candidates, on a project-by-project basis, based on our development needs.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As we advance our product candidates through development, we will explore adding backup suppliers for the API and drug product for each of our product candidates to protect against any potential supply disruptions.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Government Regulation</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Government authorities in the United States, at the federal, state and local level, and other countries extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, marketing and export and import of drug products. A new drug must be approved by the FDA through the New Drug Application (NDA) process before it may be legally marketed in the United States. We, along with any third-party contractors, will be required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval of our products and product candidates. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">U.S. Drug Development Process</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States, the FDA regulates drugs under the federal Food, Drug, and Cosmetic Act (the FDCA) and its implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. The process required by the FDA before a drug may be marketed in the United States generally involves the following:</span></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">completion of certain preclinical laboratory tests, animal studies and formulation studies in accordance with FDA&#8217;s Good Laboratory Practice (GLP) requirements and other applicable regulations;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">submission to the FDA of an IND, which must become effective before human clinical trials may begin;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">approval by an independent Institutional Review Board (IRB) or ethics committee at each clinical site before each trial may be initiated;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">performance of adequate and well-controlled human clinical trials in accordance with good clinical practices (GCPs) to establish the safety and efficacy of the proposed drug for its intended use;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">preparation of and submission to the FDA of an NDA after completion of all pivotal trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a determination by the FDA within 60 days of its receipt of an NDA to file the application for review;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">satisfactory completion of an FDA advisory committee review, if applicable;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug is produced to assess compliance with current Good Manufacturing Practice (cGMP) or similar </span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">foreign requirements to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">satisfactory completion of potential FDA audit of select clinical trial sites to assure compliance with GCP; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FDA review and approval of the NDA to permit commercial marketing of the product for particular indications for use in the United States.</span></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to beginning the first clinical trial with a product candidate in the United States, a sponsor must submit an IND to the FDA. An IND is a request for allowance from the FDA to administer an investigational drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s) for clinical studies. The IND also includes results of animal and in vitro studies assessing the toxicology, PK, pharmacology, and PD characteristics of the product; chemistry, manufacturing, and controls information; and any available human data or literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30- day time period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA allowance to begin a clinical trial.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCPs, which include among other things, the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. While the IND is active, progress reports summarizing the results of the clinical trials and nonclinical studies performed since the last progress report, among other information, must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the FDA and investigators for serious and unexpected suspected adverse events, findings from other studies suggesting a significant risk to humans exposed to the same or similar drugs, findings from animal or in vitro testing suggesting a significant risk to humans, and any clinically important increased incidence of a serious suspected adverse reaction compared to that listed in the protocol or investigator brochure.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site and must monitor the study until completed. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. Depending on its charter, this group may determine whether a trial may move forward at designated check points based on access to certain data from the trial. The FDA or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients. There are also requirements governing the reporting of ongoing clinical studies and clinical study results to public registries.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 1: The product candidate is initially introduced into healthy human subjects or patients with the target disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness. </span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 2: The product candidate is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks.</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 3: The product candidate is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product labeling. </span></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In some cases, the FDA may require, or sponsors may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These clinical trials, sometimes referred to as Phase 4 studies, may be used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of an NDA.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP or similar foreign requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final drug. In addition, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">U.S. Review and Approval Process</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, including results from preclinical and other non-clinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the drug, proposed labeling and other relevant information are submitted to the FDA as part of an NDA requesting approval to market the product. Data can come from company-sponsored clinical studies intended to test the safety and effectiveness of the use of the product, or from a number of alternative sources, including studies initiated by independent investigators. The submission of an NDA is subject to the payment of substantial user fees; a waiver of such fees may be obtained under certain limited circumstances. Additionally, no user fees are assessed on NDAs for products designated as orphan drugs, unless the product also includes a non-orphan indication.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA conducts a preliminary review of an NDA within the first 60 days after submission, before accepting it for filing, to determine whether it is sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the NDA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. Once filed, the FDA reviews an NDA to determine, among other things, whether a product is safe and effective for its intended use and whether its manufacturing is cGMP-compliant to assure and preserve the product&#8217;s identity, strength, quality and purity. Under the Prescription Drug User Fee Act guidelines that are currently in effect, the FDA has a goal of ten months from the filing date to complete a standard review of an NDA for a drug that is a new molecular entity. This review typically takes twelve months from the date the NDA is submitted to the FDA because the FDA has approximately two months to make a &#8220;filing&#8221; decision after the application is submitted.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Before approving an NDA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP and adequate to assure consistent production of the product within required</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCPs.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After the FDA evaluates an NDA and conducts any necessary inspections of manufacturing facilities where the investigational product and/or its drug substance will be produced, the FDA may issue an approval letter or a Complete Response Letter (CRL). An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A CRL indicates that the review cycle of the application is complete, and the application will not be approved in its present form. A CRL usually describes all of the deficiencies that the FDA has identified and may require additional clinical data, such as an additional clinical trial or other significant and time-consuming requirements related to clinical trials, nonclinical studies or manufacturing. When the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the CRL without first conducting required inspections and/or reviewing proposed labeling. If a CRL is issued, the sponsor must resubmit the NDA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information are submitted, the FDA may decide that the NDA does not satisfy the criteria for approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the NDA with a Risk Evaluation and Mitigation Strategy (REMS) to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a medicine and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries, and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. The FDA may also require one or more post-market studies and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization, and may limit further marketing of the product based on the results of these post-marketing studies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the Pediatric Research Equity Act (PREA) requires a sponsor to conduct pediatric clinical trials for most drugs, for a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration. Under PREA, original NDAs and supplements must contain a pediatric assessment unless the sponsor has received a deferral or waiver. The required assessment must evaluate the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The sponsor or FDA may request a deferral of pediatric clinical trials for some or all of the pediatric subpopulations. A deferral may be granted for several reasons, including a finding that the drug is ready for approval for use in adults before pediatric clinical trials are complete or that additional safety or effectiveness data needs to be collected before the pediatric clinical trials begin. The FDA must send a non-compliance letter to any sponsor that fails to submit the required assessment, keep a deferral current or fails to submit a request for approval of a pediatric formulation.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expedited Development and Review Programs</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA offers a number of expedited development and review programs for qualifying product candidates. For example, the Fast Track program is intended to expedite or facilitate the process for reviewing new product candidates that are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast Track designation applies to the combination of the product candidate and the specific indication for which it is being studied. The sponsor of a Fast Track product candidate has opportunities for more frequent interactions with the applicable FDA review team during product development and, once an NDA is submitted, the application may be eligible for priority review. An NDA for a Fast Track product candidate may also be eligible for rolling review, where the FDA may consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A product candidate intended to treat a serious or life-threatening disease or condition may also be eligible for Breakthrough Therapy designation to expedite its development and review. A product candidate can receive Breakthrough Therapy designation if preliminary clinical evidence indicates that the product candidate, alone or in combination with one or more other drugs or biologics, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the Fast Track program features, as well as more intensive FDA interaction and guidance beginning as early as Phase 1 and an organizational commitment to expedite the development and review of the product candidate, including involvement of senior managers.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any marketing application for a drug submitted to the FDA for approval, including a product candidate with a Fast Track designation and/or Breakthrough Therapy designation, may be eligible for other types of FDA programs intended to expedite the FDA review and approval process, such as priority review. An NDA is eligible for priority review if the product candidate is designed to treat a serious or life-threatening disease or condition, and if approved, would provide a significant improvement in safety or effectiveness compared to available alternatives for such disease or condition. For new-molecular-entity NDAs, priority review designation means the FDA&#8217;s goal is to take action on the marketing application within six months of the 60-day filing date.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, depending on the design of the applicable clinical trials, product candidates studied for their safety and effectiveness in treating serious or life-threatening diseases or conditions may receive accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of accelerated approval, the FDA will generally require the sponsor to perform adequate and well-controlled confirmatory clinical studies to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit, and may require that such confirmatory studies be underway prior to granting any accelerated approval. Products receiving accelerated approval may be subject to expedited withdrawal procedures if the sponsor fails to conduct the required confirmatory studies in a timely manner or if such studies fail to verify the predicted clinical benefit. In addition, the FDA requires pre-approval of promotional materials as a condition of accelerated approval, which could adversely impact the timing of the commercial launch of the product.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fast Track designation, Breakthrough Therapy designation, priority review, and accelerated approval do not change the standards for approval, but may expedite the development or approval process. Even if a product candidate qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Orphan Drug Designation and Exclusivity</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug intended to treat a rare disease or condition, defined as a disease or condition with a patient population of fewer than 200,000 individuals in the United States, or a patient population greater than 200,000 individuals in the United States and when there is no reasonable expectation that the cost of developing and making available the drug in the United States will be recovered from sales in the United States for that drug. Orphan drug designation must be requested before submitting an NDA. After the FDA grants orphan drug designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a product that has orphan drug designation subsequently receives the first FDA approval for the drug and disease or condition for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, to market the same drug for the approved indication or use within such disease or condition for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity in the relevant indication or if the FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs relating to the approved indication or use of patients with the disease or condition for which the drug was designated. Orphan drug exclusivity does not prevent the FDA from approving a different drug for the same indication or use, or the same drug for a different indication or use. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the NDA application user fee.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the disease or condition for which it received orphan designation. In addition, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or, as noted above, if a second applicant demonstrates that its product is clinically superior to the approved product with orphan exclusivity in the relevant indication or the manufacturer of the approved product is unable to assure sufficient quantities of the product to meet the needs relating to the approved indication or use of patients with the rare disease or condition.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Rare Pediatric Disease Priority Review Voucher Program</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2012, the U.S. Congress authorized the FDA to award priority review vouchers to Sponsors of certain rare pediatric disease product applications. This program is designed to encourage development of new drug and biological products for prevention and treatment of certain rare pediatric diseases. Specifically, under this program, a sponsor who receives an approval for a drug or biologic for a &#8220;rare pediatric disease&#8221; may qualify for a voucher that can be redeemed to receive priority review of a subsequent marketing application for a different product. The Sponsor of a rare pediatric disease drug product receiving a priority review voucher may transfer (including by sale) the voucher to another sponsor. The voucher may be further transferred any number of times before the voucher is used, as long as the Sponsor making the transfer has not yet submitted the application. The FDA may also revoke any priority review voucher if the rare pediatric disease drug for which the voucher was awarded is not marketed in the U.S. within one year following the date of approval.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For purposes of this program, a &#8220;rare pediatric disease&#8221; is a (a) serious or life-threatening disease in which the serious or life-threatening manifestations primarily affect individuals aged from birth to 18 years, including age groups often called neonates, infants, children, and adolescents; and (b) rare diseases or conditions within the meaning of the Orphan Drug Act. Congress has only authorized the Rare Pediatric Disease Priority Review Voucher program until September 30, 2029. Consequently, unless Congress reauthorizes the program, the sponsor of the marketing application for a drug that receives Rare Pediatric Disease Designation will only be eligible to receive a voucher if the FDA grants the designation on or before September 30, 2029.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Post-approval Requirements</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Drug products manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual program fees for any marketed products. Drug manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP, which impose certain procedural and documentation requirements upon NDA holders and product manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</span></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls; </span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fines, warning letters, or untitled letters; </span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical holds on clinical studies; </span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product approvals; </span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product seizure or detention, or refusal to permit the import or export of products; </span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs; </span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">mandated modification of promotional materials and labeling and the issuance of corrective information; </span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other safety information about the product; or </span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties. </span></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA closely regulates the marketing, labeling, advertising and promotion of drug products. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe, in their independent professional medical judgment, legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested by us and approved by the FDA. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject of off-label use of their products. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#8217;s FDA-approved labelling.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Marketing Exclusivity</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Non-patent regulatory exclusivity provisions authorized under the FDCA can delay the submission or the approval of certain marketing applications. The FDCA provides a five-year period of non-patent data exclusivity within the United States to the first applicant to obtain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not approve or even accept for review an abbreviated new drug application (ANDA) or an NDA submitted under Section 505(b)(2) (505(b)(2) NDA) submitted by another company for another drug containing the same active moiety, regardless of whether the drug is intended for the same indication as the original innovative drug or for another indication, where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement to one of the patents listed with the FDA by the innovator NDA holder.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDCA alternatively provides three years of non-patent exclusivity for an NDA, or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the modification for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for drugs containing the active agent for the original indication or condition of use. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to any preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pediatric exclusivity is another type of marketing exclusivity available in the United States. Pediatric exclusivity provides for an additional six months of marketing exclusivity attached to another period of regulatory exclusivity or existing patent term if a sponsor conducts clinical trials in children in response to a written request from the FDA and meets other conditions. The issuance of a written request does not require the sponsor to undertake the described clinical trials. In addition, orphan drug exclusivity, as described above, may offer a seven-year period of marketing exclusivity, except in certain circumstances.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">FDA Regulation of Companion Diagnostics</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If safe and effective use of a drug depends on an in vitro diagnostic, then the FDA may require approval or clearance of that diagnostic, known as a companion diagnostic, at the same time that the FDA approves the therapeutic product. In August 2014, the FDA issued final guidance clarifying the requirements that will apply to approval of therapeutic products and in vitro companion diagnostics. According to the guidance, if FDA determines that a companion diagnostic device is essential to the safe and effective use of a novel therapeutic product or indication, FDA may will not approve the drug or new indication if the companion diagnostic device is not also approved or cleared for that indication. Approval or clearance of the companion diagnostic device will ensure that the device has been adequately evaluated and has adequate performance characteristics in the intended population. The review of in vitro companion diagnostics in conjunction with the review of our product candidates will, therefore, likely involve coordination of review by the FDA&#8217;s Center for Drug Evaluation and Research and the FDA&#8217;s Center for Devices and Radiological Health Office of In Vitro Diagnostics and Radiological Health.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the FDCA, in vitro diagnostics, including companion diagnostics, are regulated as medical devices. In the United States, the FDCA and its implementing regulations, and other federal and state statutes and regulations govern, among other things, medical device design and development, preclinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import, and post-market surveillance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless an exemption applies, each medical device commercially distributed in the United States generally requires either FDA clearance of a 510(k) premarket notification, or approval of a premarket approval (PMA) application. Under the FDCA, medical devices are classified into one of three classes&#8212;Class I, Class II or Class III&#8212;depending on the degree of risk associated with each medical device and the extent of manufacturer and regulatory control needed to ensure its safety and effectiveness. While most Class I devices&#8212;devices that generally pose a low risk to users&#8212;are exempt from the 510(k) premarket notification requirement, manufacturers of most Class II devices are required to submit to the FDA a premarket notification under Section 510(k) of the FDCA requesting permission to commercially distribute the device. The FDA&#8217;s permission to commercially distribute a device subject to a 510(k) premarket notification is generally known as 510(k) clearance. Devices deemed by the FDA to pose the greatest risks, or devices that have a new intended use, or use advanced technology that is not substantially equivalent to that of a legally marketed device, are automatically placed in Class III, requiring approval of a PMA unless down-classified in accordance with the &#8220;de novo&#8221; process, which is a route to market for novel medical devices that are low to moderate risk and are not substantially equivalent to a predicate device.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To obtain 510(k) clearance, a manufacturer must submit to the FDA a premarket notification demonstrating that the proposed device is &#8220;substantially equivalent&#8221; to a predicate device already on the market. A predicate device is a legally marketed device that is not subject to premarket approval, i.e., a device that was legally marketed prior to May 28, 1976 (pre-amendments device) and for which a PMA is not required, a device that has been reclassified from Class III to Class II or I, or a device that was found substantially equivalent through the 510(k) process. If the FDA agrees that the device is substantially equivalent to a predicate device currently on the market, it will grant 510(k) clearance to commercially market the device. If the FDA determines that the device is &#8220;not substantially equivalent&#8221; to a previously cleared device, the device is automatically designated as a Class III device. The device sponsor must then fulfill more rigorous PMA requirements or request down-classification of the device through the &#8220;de novo&#8221; process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The PMA process is more demanding than the 510(k) premarket notification process, and can take several years or longer. It involves a rigorous premarket review during which the applicant must prepare and provide the FDA with reasonable assurance of the device&#8217;s safety and effectiveness and information about the device and its components regarding, among other things, device design, manufacturing and labeling. PMA applications are</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">subject to an application fee. In addition, PMAs for certain devices must generally include the results from extensive preclinical and adequate and well-controlled clinical trials to establish the safety and effectiveness of the device for each indication for which FDA approval is sought. As part of the PMA review, the FDA will typically inspect the manufacturer&#8217;s facilities for compliance with the Quality Management System Regulation (QMSR), which imposes elaborate testing, control, documentation and other quality assurance requirements.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the FDA&#8217;s evaluation of the PMA application is favorable, the FDA typically issues an approvable letter requiring the applicant&#8217;s agreement to specific conditions, such as changes in labeling, or specific additional information, such as submission of final labeling, in order to secure final approval of the PMA. If the FDA&#8217;s evaluation of the PMA or manufacturing facilities is not favorable, the FDA will deny approval of the PMA or issue a not approvable letter. A not approvable letter will outline the deficiencies in the application and, where practical, will identify what is necessary to make the PMA approvable. The FDA may also determine that additional clinical trials are necessary, in which case the PMA approval may be delayed for several months or years while the trials are conducted and then the data submitted in an amendment to the PMA. If the FDA concludes that the applicable criteria have been met, the FDA will issue a PMA for the approved indications, which can be more limited than those originally sought by the applicant. The PMA can include post-approval conditions that the FDA believes necessary to ensure the safety and effectiveness of the device, including, among other things, restrictions on labeling, promotion, sale and distribution. Once granted, PMA approval may be withdrawn by the FDA if compliance with post-approval requirements, conditions of approval or other regulatory standards are not maintained or problems are identified following initial marketing.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After a device is placed on the market, it remains subject to significant regulatory requirements. Medical devices may be marketed only for the uses and indications for which they are cleared or approved. Device manufacturers must also establish registration and device listings with the FDA. A medical device manufacturer&#8217;s manufacturing processes and those of its suppliers are required to comply with the applicable portions of the QMSR, which currently cover the methods and documentation of the design, testing, production, processes, controls, quality assurance, labeling, packaging and shipping of medical devices. Domestic facility records and manufacturing processes are subject to periodic unscheduled inspections by the FDA. The FDA also may inspect foreign facilities that export products to the United States.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other U.S. Healthcare Laws</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pharmaceutical companies like us are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business. Such regulation and enforcement may constrain the financial arrangements and relationships through which we research, develop, and ultimately, sell, market and distribute any products for which we obtain marketing approval. Such laws include, without limitation, federal and state anti-kickback, fraud and abuse, and false claims laws, such as the federal Anti-Kickback Statute and the federal civil False Claims Act, as well as federal and state transparency laws and regulations with respect to drug pricing and payments and other transfers of value made by pharmaceutical manufacturers to physicians and other health care providers, such as the federal Physician Payments Sunshine Act.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Violation of any of such laws or any other governmental regulations that apply may result in significant criminal, civil and administrative penalties including damages, fines, imprisonment, disgorgement, additional reporting requirements and oversight if we become subject to a Corporate Integrity Agreement or similar agreement to resolve allegations of non-compliance with these laws, contractual damages, reputational harm, diminished profits and future earnings, disgorgement, exclusion from participation in government healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">U.S. Coverage and Reimbursement</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Significant uncertainty exists as to the coverage and reimbursement status of any product candidate for which we may seek regulatory approval. Sales in the United States will depend, in part, on the availability of sufficient coverage and adequate reimbursement from third-party payors, which include government health programs such as Medicare, Medicaid, TRICARE and the Veterans Administration, as well as managed care organizations and private health insurers. Prices at which we or our customers seek reimbursement for our product candidates can be subject to challenge, reduction or denial by third-party payors. For products administered under</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The process for determining whether a third-party payor will provide coverage for a product is typically separate from the process for setting the reimbursement rate that the payor will pay for the product. In the United States, there is no uniform policy among payors for coverage or reimbursement. Decisions regarding whether to cover any of a product, the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own coverage and reimbursement policies, but also have their own methods and approval processes. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that can require manufacturers to provide scientific and clinical support for the use of a product to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third-party payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product that receives approval. Third-party payors may not consider our product candidates to be medically necessary or cost-effective compared to other available therapies, or the rebate percentages required to secure favorable coverage may not yield an adequate margin over cost or may not enable us to maintain price levels sufficient to realize an appropriate return on our investment in drug development. Additionally, decreases in third-party reimbursement for any product or a decision by a third-party payor not to cover a product could reduce physician usage and patient demand for the product.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, as a condition of participating in, and having products covered under, certain federal healthcare programs, such as Medicare and Medicaid, if we market a product that is approved, we may become subject to federal laws and regulations that require pharmaceutical manufacturers to calculate and report certain pricing metrics to the government, including the Average Manufacturer Price (AMP) and Best Price under the Medicaid Drug Rebate Program, the Medicare Average Sales Price, the 340B Ceiling Price, and Non-Federal AMP reported to the Department of Veteran Affairs, and with respect to Medicaid, pay statutory rebates on utilization of manufacturers&#8217; products by Medicaid beneficiaries. Compliance with these laws and regulations will require significant resources and may have a material adverse effect on our revenues.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">U.S. Healthcare Reform</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States, there has been, and continues to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate post-approval activities, and affect the profitable sale of product candidates.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Among policy makers and payors in the United States, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. For example, the Affordable Care Act (ACA) was enacted in the United States in 2010. Among the provisions of the ACA of importance to our potential product candidates, the ACA: established an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents; extended manufacturers&#8217; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; expanded the entities eligible for discounts under the 340B drug pricing program; increased the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program; and established a Center for Medicare and Medicaid Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending. Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, other legislative changes have been adopted since the ACA was enacted. The Budget Control Act of 2011, among other things, reduced Medicare payments to providers, which went into effect on April 1, 2013</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and will remain in effect until 2032, unless additional Congressional action is taken. The American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products. This has resulted in several Congressional inquiries and proposed and enacted federal and state regulations designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for pharmaceutical products. The Inflation Reduction Act of 2022 (IRA) was enacted in 2022. The IRA marks the most significant action by Congress with respect to the pharmaceutical industry since adoption of the ACA in 2010. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare, with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); redesigns the Medicare Part D benefit (beginning in 2024); and replaces the Part D coverage gap discount program with a new manufacturer discount program (beginning in 2025). The Centers for Medicare &amp; Medicaid Services has published the negotiated prices for the initial ten drugs, which went into effect in January 2026, and the subsequent 15 drugs, which will first be effective in 2027. The Centers for Medicare &amp; Medicaid Services has also published the next set of 15 drugs that will be subject to negotiation. The IRA permits the Secretary of the Department of Health and Human Services (HHS) to implement many of these provisions through guidance, as opposed to regulation, for the initial years. HHS has and will continue to issue and update guidance as these programs are implemented, although the Medicare drug price negotiation program is currently subject to legal challenges. The impact of the IRA on us and the pharmaceutical industry cannot yet be fully determined but is likely to be significant.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">More recently, the One Big Beautiful Bill Act, which was enacted in July 2025, imposes significant reductions in the funding of the Medicaid program. Such reductions are expected to decrease the number of persons enrolled in Medicaid and reduce the services covered by Medicaid, which could adversely affect our sales of any product candidate that we commercialize.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Trump administration is pursuing a two-fold strategy to reduce drug costs in the United States. While it is unclear whether and how the Trump proposals will be implemented, the Trump policies are likely to have a negative impact on the pharmaceutical industry and on our ability to receive adequate revenues for any product candidate that we commercialize. On the one hand, President Trump has threatened to impose significant tariffs on pharmaceutical manufacturers that do not adopt pricing policies such as most favored nation pricing, which would tie the price for drugs in the United States to the lowest price in a group of other countries. In response, multiple manufacturers have entered into confidential pricing agreements with the federal government. On the other hand, the Trump administration is pursuing traditional regulatory pathways to impose drug pricing policies and published two proposed regulations in December 2025, referred to as Globe and Guard. If finalized, these regulations would implement mandatory payment models under which manufacturers of eligible drugs would be required to pay rebates to the federal government on a portion of the units of their drugs that are reimbursed by Medicare, with the rebate amount based on most favored nation pricing. Imposing a rebate in the United States that is based on drug prices outside the United States would mark a drastic and unprecedented shift in the U.S. pharmaceutical market, and while the impact of the Globe and Guard proposed regulations, if finalized, cannot yet be determined, it is likely to be significant. Even regulatory proposals or executive actions that are ultimately deemed unlawful could negatively impact the U.S. pharmaceutical sector and our business.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Individual states in the United States have also become increasingly active in implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Some states have enacted legislation creating so-called prescription drug affordability boards with the goal of imposing price limits on certain drugs in these states, and at least one state board is imposing an upper payment limit. States are also seeking to implement general, across the board price caps for pharmaceuticals, or are seeking to regulate drug distribution. Some measures are designed to encourage importation from other countries. In addition, regional healthcare authorities and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">individual hospitals are increasingly using bidding procedures to determine which drugs and suppliers will be included in their healthcare programs. Furthermore, there has been increased interest by third party payors and governmental authorities in reference pricing systems and publication of discounts and list prices.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our products once approved or additional pricing pressures. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our product candidates.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Foreign Regulation</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To market any product outside of the United States, we would need to comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy and governing, among other things, clinical trials, marketing authorization (MA), commercial sales and distribution of our products. The foreign regulatory approval process includes all of the risks associated with FDA approval set forth above, as well as additional country-specific regulation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Whether or not we obtain FDA approval for a product, we must obtain approval of a product by the comparable regulatory authorities of foreign countries before we can commence clinical trials or marketing of the product in those countries. Approval by one regulatory authority does not ensure approval by regulatory authorities in other jurisdictions. The approval process varies from country to country, can involve additional testing beyond that required by FDA, and may be longer or shorter than that required for FDA approval. The requirements governing the conduct of clinical trials, product licensing, pricing, promotion, and reimbursement vary greatly from country to country.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Non-clinical Studies and Clinical Trials in the EU</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Similarly to the United States, the various phases of non-clinical and clinical research in the European Union (EU) are subject to significant regulatory controls.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Non-clinical studies are performed to demonstrate the health or environmental safety of new chemical or biological substances. Non-clinical (pharmaco-toxicological) studies must be conducted in compliance with the principles of GLP, as set forth in EU Directive 2004/10/EC (unless otherwise justified for certain particular medicinal products, e.g., radio-pharmaceutical precursors for radio-labeling purposes). In particular, non-clinical studies, both in vitro and in vivo, must be planned, performed, monitored, recorded, reported and archived in accordance with the GLP principles, which define a set of rules and criteria for a quality system for the organizational process and the conditions for non-clinical studies. These GLP standards reflect the Organization for Economic Co-operation and Development requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical trials of medicinal products in the EU must be conducted in accordance with EU and national regulations and the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH), guidelines on Good Clinical Practices (GCP), as well as the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. If the sponsor of the clinical trial is not established within the EU, it must appoint an EU entity to act as its legal representative. The sponsor must take out a clinical trial insurance policy, and in most EU member states, the sponsor is liable to provide &#8216;no fault&#8217; compensation to any study subject injured in the clinical trial.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The regulatory landscape related to clinical trials in the EU has been subject to recent changes. The EU Clinical Trials Regulation (CTR), which was adopted in April 2014 and repeals the EU Clinical Trials Directive, became applicable on January 31, 2022. Unlike directives, the CTR is directly applicable in all EU member states without the need for member states to further implement it into national law. The CTR notably harmonizes the assessment and supervision processes for clinical trials throughout the EU via a Clinical Trials Information System, which contains a centralized EU portal and database.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While the EU Clinical Trials Directive required a separate clinical trial application (CTA) to be submitted in each member state in which the clinical trial takes place, to both the competent national health authority and an independent ethics committee, much like the FDA and IRB respectively, the CTR introduces a centralized process and only requires the submission of a single application for multi-center trials. The CTR allows sponsors to make a single submission to both the competent authority and an ethics committee in each member state, leading to a single decision per member state. The CTA must include, among other things, a copy of the trial protocol and an investigational medicinal product dossier containing information about the manufacture and quality of the medicinal product under investigation. The assessment procedure of the CTA has been harmonized as well, including a joint assessment by all member states concerned, and a separate assessment by each member state with respect to specific requirements related to its own territory, including ethics rules. Each member state&#8217;s decision is communicated to the sponsor via the centralized EU portal. Once the CTA is approved, clinical study development may proceed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CTR transition period ended on January 31, 2025, and all clinical trials (and related applications) are now fully subject to the provisions of the CTR.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Medicines used in clinical trials must be manufactured in accordance with Good Manufacturing Practice (GMP). Other national and EU-wide regulatory requirements may also apply.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Marketing Authorization in the EU</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to market our product candidates in the EU and many other foreign jurisdictions, we must obtain separate regulatory approvals. More concretely, in the EU, medicinal product candidates can only be commercialized after obtaining a MA. To obtain regulatory approval of a product candidate under EU regulatory systems, we must submit a MA application (MAA). The process for doing this depends, among other things, on the nature of the medicinal product. There are two types of MAs:</span></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8220;Centralized MAs&#8221; are issued by the European Commission through the centralized procedure based on the opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) and are valid throughout the EU. The centralized procedure is compulsory for certain types of medicinal products such as (i) medicinal products derived from biotechnological processes, (ii) designated orphan medicinal products, (iii) advanced therapy medicinal products (ATMPs) (such as gene therapy, somatic cell therapy and tissue engineered products) and (iv) medicinal products containing a new active substance indicated for the treatment of certain diseases, such as HIV/AIDS, cancer, diabetes, neurodegenerative diseases or autoimmune diseases and other immune dysfunctions, and viral diseases. The centralized procedure is optional for products containing a new active substance not yet authorized in the EU, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EU.</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8220;National MAs&#8221; are issued by the competent authorities of the EU member states, only cover their respective territory, and are available for product candidates not falling within the mandatory scope of the centralized procedure. Where a product has already been authorized for marketing in an EU member state, this national MA can be recognized in another member state through the mutual recognition procedure. If the product has not received a national MA in any member state at the time of application, it can be approved simultaneously in various member states through the decentralized procedure. Under the decentralized procedure an identical dossier is submitted to the competent authorities of each of the member states in which the MA is sought, one of which is selected by the applicant as the reference member state.</span></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the centralized procedure the maximum timeframe for the evaluation of an MAA by the EMA is 210 days, excluding clock stops. Under the above described procedures, in order to grant the MA, the EMA or the competent authorities of the EU member states make an assessment of the risk benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy. MAs have an initial duration of five years. After these five years, the authorization may be renewed on the basis of a reevaluation of the risk-benefit balance.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Data and Marketing Exclusivity in the EU</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EU, new products authorized for marketing (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">i.e.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, reference products) generally receive eight years of data exclusivity and an additional two years of market exclusivity upon MA. If granted, the data exclusivity period prevents generic and biosimilar applicants from relying on the preclinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar MA in the EU during a period of eight years from the date on which the reference product was first authorized in the EU. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the EU until ten years have elapsed from the initial MA of the reference product in the EU. The overall ten-year market exclusivity period can be extended to a maximum of eleven years if, during the first eight years of those ten years, the MA holder obtains an authorization for one or more new therapeutic indications, which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. However, there is no guarantee that a product will be considered by the EU&#8217;s regulatory authorities to be a new chemical or biological entity, and products may not qualify for data exclusivity.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Orphan Medicinal Products in the EU</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The criteria for designating an &#8220;orphan medicinal product&#8221; in the EU are similar in principle to those in the United States. A medicinal product can be designated as an orphan if its sponsor can establish that: (1) the product is intended for the diagnosis, prevention or treatment of a life threatening or chronically debilitating condition (2) either (a) such condition affects not more than five in 10,000 persons in the EU when the application is made, or (b) the product, without the benefits derived from the orphan status, would not generate sufficient return in the EU to justify the necessary investment; and (3) there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized for marketing in the EU or, if such method exists, the product will be of significant benefit to those affected by that condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Orphan designation must be requested before submitting an MAA. An EU orphan medicinal product designation entitles a party to incentives such as reduction of fees or fee waivers, protocol assistance, and access to the centralized procedure. Upon grant of a MA, orphan medicinal products are entitled to ten years of market exclusivity for the approved indication, which means that the competent authorities cannot accept another MAA, or grant a MA, or accept an application to extend a MA for a similar medicinal product for the same indication for a period of ten years. The period of market exclusivity is extended by two years for orphan medicinal products that have also complied with an agreed pediatric investigation plan (PIP). No extension to any supplementary protection certificate can be granted on the basis of pediatric studies for orphan indications. Orphan medicinal product designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The orphan exclusivity period may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for which it received orphan designation, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity or where the prevalence of the condition has increased above the threshold. Additionally, MA may be granted to a similar product for the same indication at any time if (i) the second applicant can establish that its product, although similar, is safer, more effective or otherwise clinically superior; (ii) the applicant consents to a second orphan medicinal product application; or (iii) the applicant cannot supply enough orphan medicinal product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pediatric Development</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EU, MAAs for new medicinal products have to include the results of studies conducted in the pediatric population, in compliance with a PIP agreed with the EMA&#8217;s Pediatric Committee (PDCO). The PIP sets out the timing and measures proposed to generate data to support a pediatric indication of the product candidate for which MA is being sought. The PDCO can grant a deferral of the obligation to implement some or all of the measures of the PIP until there are sufficient data to demonstrate the efficacy and safety of the product in adults. Further, the obligation to provide pediatric clinical trial data can be waived by the PDCO when these data is not needed or appropriate because the product is likely to be ineffective or unsafe in children, the disease or condition for which the product is intended occurs only in adult populations, or when the product does not represent a significant therapeutic benefit over existing treatments for pediatric patients. Once the MA is obtained in all the EU</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">31</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">member states and study results are included in the product information, even when negative, the product is eligible for six months&#8217; supplementary protection certificate extension (if any is in effect at the time of approval) or, in the case of orphan medicinal products, a two year extension of the orphan market exclusivity is granted.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aforementioned EU rules are generally applicable in the European Economic Area (EEA), which consists of the 27 EU member states plus Norway, Liechtenstein and Iceland.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Failure to comply with EU and member state laws that apply to the conduct of clinical trials, manufacturing approval, MA of medicinal products and marketing of such products, both before and after grant of the MA, manufacturing of pharmaceutical products, statutory health insurance, bribery and anti-corruption or with other applicable regulatory requirements may result in administrative, civil or criminal penalties. These penalties could include delays or refusal to authorize the conduct of clinical trials, or to grant MA, product withdrawals and recalls, product seizures, suspension, withdrawal or variation of the MA, total or partial suspension of production, distribution, manufacturing or clinical trials, operating restrictions, injunctions, suspension of licenses, fines and criminal penalties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Regulation of Companion Diagnostics in the EU</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EU, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> diagnostic medical devices (IVD MDs), were regulated by the EU Directive on </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> diagnostic medical devices (Directive No. 98/79/EC, as amended) (IVDD), which regulated the placing on the market, the European Conformity (CE) marking, the essential requirements, the conformity assessment procedures, the registration obligations for manufacturers and devices as well as the vigilance procedure. IVD MDs had to comply with the requirements provided for in the IVDD, and with further requirements implemented at national level (as the case may be).</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The regulation of companion diagnostics is subject to further requirements since Regulation (EU) No 2017/746 (IVDR) became applicable on May 26, 2022. Following subsequent legislative changes, European institutions adopted a &#8220;progressive&#8221; roll-out of the IVDR to prevent disruption in the supply of in vitro diagnostic medical devices. Therefore, the IVDR applies since May 26, 2022, but there is a tiered system extending the grace period for many devices (depending on their risk classification) before they have to be fully compliant with the regulation. The IVDR introduced a new classification system for companion diagnostics which are now specifically defined as diagnostic tests that support the safe and effective use of a specific medicinal product, by identifying patients that are suitable or unsuitable for treatment. Companion diagnostics will have to undergo a conformity assessment by a notified body. Before it can issue an EU certificate, the notified body must seek a scientific opinion from the EMA on the suitability of the companion diagnostic to the medicinal product concerned if the medicinal product falls exclusively within the scope of the centralized procedure for the authorization of medicines, or the medicinal product is already authorized through the centralized procedure, or a MAA for the medicinal product has been submitted through the centralized procedure. For other substances, the notified body can seek the opinion from national competent authorities or the EMA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aforementioned EU rules are generally applicable in the EEA.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Data Privacy &amp; Security</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Numerous state, federal and foreign laws, regulations and standards govern the collection, use, access to, confidentiality and security of health-related and other personal information, and could apply now or in the future to our operations or the operations of our partners. In the United States, numerous federal and state laws and regulations, including data breach notification laws, health information privacy and security laws and consumer protection laws and regulations govern the collection, use, disclosure, and protection of health-related and other personal information. In addition, certain foreign laws govern the privacy and security of personal data, including health-related data. Privacy and security laws, regulations, and other obligations are constantly evolving, may conflict with each other to complicate compliance efforts, and can result in investigations, proceedings, or actions that lead to significant civil and/or criminal penalties and restrictions on data processing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">32</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Human Capital</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of February 25, 2026, we had 87 full-time employees, including a total of 21 employees with M.D. or Ph.D. degrees. Of these full-time employees, 67 employees are engaged in research and development.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and additional employees. The principal purposes of our equity incentive plans are to attract, retain and motivate selected employees, consultants and directors through the granting of stock-based compensation awards. We value our employees and regularly benchmark total rewards we provide, such as short and long-term compensation, 401(k) plan participation, health, welfare and quality of life benefits, paid time off and personal leave, against our industry peers to ensure we remain competitive and attractive to potential new hires.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Available Information</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our internet address is www.tyra.bio. Our investor relations website is located at https://tyrabio.investorroom.com. We make available free of charge on our investor relations website under &#8220;SEC Filings&#8221; our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, our directors&#8217; and officers&#8217; Section 16 reports and any amendments to those reports as soon as reasonably practicable after filing or furnishing such materials to the SEC. They are also available for free on the SEC&#8217;s website at www.sec.gov.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We use our investor relations website as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should monitor such website, in addition to following our press releases, SEC filings and public conference calls and webcasts. Information relating to our corporate governance is also included on our investor relations website The information in or accessible through the SEC and our website are not incorporated into, and are not considered part of, this filing.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1a_risk_factors"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">em 1A. Risk Factors.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">You should carefully consider the following risk factors, together with the other information contained in this Annual Report, including our financial statements and the related notes and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; before making a decision to purchase or sell shares of our common stock. We cannot assure you that any of the events discussed in the risk factors below will not occur. These risks could have a material and adverse impact on our business, results of operations, financial condition and growth prospects. If that were to happen, the trading price of our common stock could decline. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations or financial condition. In this section, we first provide a summary of the principal risks and uncertainties we face and then provide a full set of risk factors and discuss them in greater detail.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Summary of Risks Related to Our Business</span></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are early in our development efforts, have a limited operating history, have not completed any clinical trials, and have no products approved for commercial sale, which may make it difficult for investors to evaluate our current business and likelihood of success and viability.</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have incurred significant net losses in each period since our inception, and we expect to continue to incur significant net losses for the foreseeable future. </span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to generate revenue and achieve profitability depends significantly on our ability to achieve our objectives relating to discovery, development and commercialization of our product candidates.</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">33</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will require substantial additional capital to achieve our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our development programs, commercialization efforts or other operations.</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are early in our development efforts, with three product candidates in clinical development, and our other development programs in the preclinical or discovery stage. If we are unable to successfully develop, obtain marketing approval and ultimately commercialize product candidates, or experience significant delays in doing so, our business will be materially harmed.</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As an organization, we have never completed any clinical trials or submitted an application for marketing approval and may be unable to do so for any of our product candidates.</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Preclinical and clinical development involves a lengthy and expensive process with an uncertain outcome, and the results of preclinical studies and early clinical trials are not necessarily predictive of future results. Our product candidates may not have favorable results in clinical trials, if any, or receive marketing approval on a timely basis, if at all.</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Use of our product candidates could be associated with side effects, adverse events or other properties or safety risks, which could delay or preclude approval, cause us to suspend or discontinue clinical trials, abandon a product candidate, limit the commercial profile of an approved label or result in other significant negative consequences that could severely harm our business, prospects, operating results and financial condition.</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on third parties for the manufacture of our product candidates for preclinical and clinical development. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on third parties to conduct our clinical trials and some of our preclinical studies. If these third parties do not successfully carry out their contractual duties, comply with applicable regulatory requirements or meet expected deadlines, our development programs and our ability to seek or obtain marketing approval for or commercialize our product candidates may be delayed.</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We face significant competition, and, if our competitors develop technologies or product candidates more rapidly than we do or their technologies are more effective, our business and our ability to develop and successfully commercialize products may be adversely affected.</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to obtain and maintain patent protection for our product candidates and other proprietary technologies we develop, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to successfully commercialize our product candidates and other proprietary technologies we may develop may be adversely affected.</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The trading price of the shares of our common stock could be highly volatile, and purchasers of our common stock could incur substantial losses.</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">34</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Limited Operating History, Financial Position and Capital Requirements</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are early in our development efforts, have a limited operating history, have not completed any clinical trials, and have no products approved for commercial sale, which may make it difficult for investors to evaluate our current business and likelihood of success and viability.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investment in drug development is a highly speculative undertaking and involves a substantial degree of risk. We are a biopharmaceutical company formed in 2018 with a limited operating history upon which you can evaluate our business and prospects. We have three product candidates in clinical development. Our other development programs are either in preclinical development or in the drug discovery stage. To date, we have focused primarily on organizing and staffing our company, business planning, raising capital, research and development activities including development of our proprietary SN&#197;P platform and identifying potential product candidates, establishing our intellectual property portfolio, conducting research and preclinical studies and clinical trials, and providing general and administrative support to these operations. Our approach to the discovery and development of product candidates based on our proprietary SN&#197;P platform is unproven, and we do not know whether we will be able to develop any product candidates that are successful in clinical development or products of commercial value.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As an organization, we have not yet completed any clinical trials, obtained regulatory approvals, manufactured a commercial-scale product, or arranged for a third party to do so on our behalf, or conducted sales and marketing activities necessary for successful product commercialization. Consequently, any predictions made about our future success or viability may not be as accurate as they could be if we had a history of successfully developing and commercializing biopharmaceutical products.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have incurred significant net losses in each period since our inception, and we expect to continue to incur significant net losses for the foreseeable future.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have incurred significant operating losses since our inception. Our net losses were $119.9 million and $86.5 million for the years ended December 31, 2025 and 2024, respectively. As of December 31, 2025, we had an accumulated deficit of $371.3 million. Substantially all of our losses have resulted from expenses incurred in connection with our research and development programs and from general and administrative costs associated with our operations. Dabogratinib (formerly TYRA-300), TYRA-430, TYRA-200 and any of our other product candidates will require substantial additional development time and resources before we are able to apply for, or receive, marketing approval and begin generating revenue from product sales. We expect to continue to incur losses for the foreseeable future, and we anticipate these losses will increase substantially as we continue our development of, and seek marketing approval for, and potentially commercialize any of our product candidates and as we seek to discover, develop and market additional potential product candidates.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our ability to generate revenue and achieve profitability depends significantly on our ability to achieve our objectives relating to discovery, development and commercialization of our product candidates.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To generate revenue and achieve profitability, we must succeed in developing and eventually commercializing product candidates that generate significant revenue. This will require us to be successful in a range of challenging activities, including identifying lead product candidates, completing preclinical studies and clinical trials of our product candidates, discovering additional product candidates, obtaining marketing approval for these product candidates and manufacturing, marketing and selling any products for which we may obtain marketing approval. We are only in the preliminary stages of many of these activities. We may never succeed in these activities and, even if we succeed in commercializing one or more of our product candidates, we may never generate revenues that are significant or large enough to achieve profitability. In addition, we have not yet demonstrated an ability to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">35</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the biopharmaceutical industry.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of the numerous risks and uncertainties associated with biopharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. Even if we obtain marketing approval for one or more of our product candidates and achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable may have an adverse effect on the value of our company and could impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our product candidates or even continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We will require substantial additional capital to achieve our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our development programs, commercialization efforts or other operations.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The development of biopharmaceutical product candidates is capital-intensive. We expect our expenses to increase in connection with our ongoing activities, particularly as we conduct our ongoing and planned clinical trials and preclinical studies for our product candidates and other development programs and seek marketing approval for our current product candidates and any future product candidates we may develop. If we obtain marketing approval for any of our product candidates, we also expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. Because the outcome of any preclinical study or clinical trial is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of our product candidates. Furthermore, we expect to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or any future commercialization efforts.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based upon our current operating plan, we believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operations through at least 2027. We have based these estimates on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. Our operating plans and other demands on our cash resources may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned, through public or private equity or debt financings or other capital sources, including potentially additional collaborations, licenses and other similar arrangements. In addition, we may seek additional capital due to favorable market conditions or liquidity or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. For example, in May 2025, we entered into a Sales Agreement (the Sales Agreement) with TD Securities (USA) LLC (the Agent), pursuant to which we may, from time to time, sell shares of our common stock having an aggregate offering price of up to $150 million in &#8220;at the market&#8221; offerings through or to the Agent, as sales agent or principal. However, there can be no assurance that the Agent will be successful in consummating any future sales based on prevailing market conditions or in the quantities or at the prices that we deem appropriate. In addition, the Sales Agreement may be terminated by us or the Agent at any time upon specified notice to the other party, or by the Agent at any time in certain circumstances, including the occurrence of a material adverse change. Attempting to secure additional financing may divert our management from our day-to-day activities, which may adversely affect our ability to develop our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">36</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our future capital requirements will depend on many factors, including, but not limited to:</span></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the type, number, scope, progress, expansions, results, costs and timing of, discovery, preclinical studies and clinical trials of our product candidates which we are pursuing or may choose to pursue in the future;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs and timing of manufacturing for our product candidates and commercial manufacturing if any product candidate is approved;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs, timing and outcome of regulatory review of our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of obtaining, maintaining and enforcing our patents and other intellectual property rights;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our efforts to enhance operational, compliance, and quality systems and hire additional personnel to satisfy our obligations as a public company, including enhanced internal controls over financial reporting;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs associated with hiring additional personnel and consultants as our preclinical and clinical activities increase;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs and timing of establishing or securing sales and marketing capabilities if any product candidate is approved for commercial sale;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third-party payors and adequate market share and revenue for any approved products;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in laws or regulations applicable to our product candidates, including but not limited to clinical trial requirements for approval;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs associated with any products or technologies that we may in-license or acquire.</span></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because we do not expect to generate commercial revenues, if any, from sales of products that we do not expect to be commercially available for many years, if at all, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all, </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">including as a result of financial and credit market deterioration or instability, market-wide liquidity shortages, geopolitical events or otherwise</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through equity offerings, debt financings, or other capital sources, including potential collaborations, licenses and other similar arrangements. We do not have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Any future debt financing and preferred equity financing, if available, may involve, agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, selling or licensing our assets, making capital expenditures, declaring dividends or encumbering our assets to secure future indebtedness. Such restrictions could adversely impact our ability to conduct our operations and execute our business plan.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">37</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we raise additional funds through future collaborations, licenses and other similar arrangements, we may have to relinquish valuable rights to our future revenue streams, research programs or product candidates, or grant licenses on terms that may not be favorable to us and/or that may reduce the value of our common stock. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed or on terms acceptable to us, we would be required to delay, limit, reduce, or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our </span><span style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">portfolio of investments or bank deposits may be subject to market, interest and credit risk that may reduce their value and adversely affect our business, results of operations and financial condition.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">value of our investments may decline due to increases in interest rates, downgrades of the bonds and other securities included in our commercial money market account portfolio and instability in the global financial markets that reduces the liquidity of securities included in our portfolio. In addition, in the past, the closure of financial institutions and their placement into receivership with the Federal Deposit Insurance Corporation (FDIC) created bank-specific and broader financial institution liquidity risk and concerns. Future adverse developments with respect to specific financial institutions or the broader financial services industry may impair our ability to access capital needed to support near-term working capital needs, whether from our existing investment and deposit accounts and credit facilities or otherwise, and may lead to market-wide liquidity shortages and create additional market and economic uncertainty. Furthermore, from time to time recession and inflation concerns have adversely affected and may in the future adversely affect the financial markets in some or all countries worldwide. Each of these events may cause us to record charges to reduce the carrying value of our investment portfolio or sell investments for less than our acquisition cost. Although we attempt to mitigate these risks through diversification of our investments, the value of our investments may nevertheless decline, and our ability to fund our near-term and long-term working capital needs to support our business and clinical development plans may be adversely affected. In addition, any decline in available funding or access to our cash and liquidity resources could also result in breaches of our financial and/or contractual obligations or result in violations of federal or state wage and hour laws.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to the Discovery, Development and Marketing Approval of Our Product Candidates</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are early in our development efforts, with three product candidates in clinical development, and our other development programs in the preclinical or discovery stage. If we are unable to successfully develop, obtain marketing approval and ultimately commercialize product candidates, or experience significant delays in doing so, our business will be materially harmed.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are in the early stages of our clinical development efforts. All of our development programs are either in clinical development or the preclinical or drug discovery stage. We have invested substantially all of our efforts to date in developing our proprietary SN&#197;P platform, developing dabogratinib, TYRA-430 and TYRA-200, identifying other potential product candidates and conducting preclinical studies and clinical trials. We are relatively early in our clinical trials of  our product candidates and will need to progress our other development programs through additional preclinical studies to enable us to submit INDs with the FDA and receive allowance from the FDA to proceed with initiating their clinical development. Our ability to generate product revenues, which we do not expect will occur for many years, if ever, will depend on the successful development and eventual commercialization of our product candidates. The success of our product candidates will depend on several factors, including the following:</span></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successful identification of appropriate patients eligible to enroll, and enrollment of such patients, in clinical trials and completion of clinical trials with favorable results;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">38</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successful completion of preclinical studies with favorable results, including those compliant with Good Laboratory Practice (GLP) such as toxicology studies, biodistribution studies and minimum effective dose studies in animals;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acceptance by the FDA of INDs or of similar regulatory submissions by comparable foreign regulatory authorities for the conduct of clinical trials of our product candidates and our proposed design of future clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successful identification of new product candidates utilizing our SN&#197;P platform;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">demonstrating safety and efficacy to the satisfaction of applicable regulatory authorities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">making arrangements with our third-party manufacturers for, or establishing, commercial manufacturing capabilities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">receipt of marketing approvals from applicable regulatory authorities, including new drug applications (NDAs), from the FDA and maintaining such approvals;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establishing sales, marketing and distribution capabilities and launching commercial sales of our products, if and when approved, whether alone or in collaboration with others;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establishing and maintaining patent and trade secret protection or regulatory exclusivity for our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintaining an acceptable safety profile of our products following marketing approval, including acceptable results from any post-approval studies or clinical trials agreed to by us or required by the FDA; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintaining and growing an organization of people who can develop and commercialize our product candidates.</span></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to develop, obtain marketing approval for, or, if approved, successfully commercialize our product candidates, we may not be able to generate sufficient revenue to continue our business.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">As an organization, we have never completed any clinical trials or submitted an application for marketing approval and may be unable to do so for any of our product candidates.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are relatively early in our development efforts for our product candidates and we will need to successfully complete our ongoing and planned clinical trials and later-stage and pivotal clinical trials, in order to obtain marketing authorization from the FDA or comparable foreign regulatory authorities to market our product candidates, as well as complete IND-enabling studies for our development programs in the preclinical or discovery stage. Carrying out clinical trials and the submission of a successful NDA is a complicated process. As an organization, while we have commenced clinical trials for certain of our product candidates, we have not previously completed any clinical trials, have limited experience as a company in preparing and submitting marketing applications and have not previously submitted an NDA or other comparable foreign regulatory submission for any product candidate. In addition, we have had limited interactions with the FDA and cannot be certain how many clinical trials of dabogratinib, TYRA-430, TYRA-200 or any other product candidates will be required or how such trials should be designed. Consequently, we may be unable to successfully and efficiently execute and complete necessary clinical trials in a way that leads to regulatory submission and approval of any of our product candidates. We may require more time and incur greater costs than our competitors and may not succeed in obtaining marketing approvals of product candidates that we develop. Failure to commence or complete, or delays in, our ongoing or planned clinical trials, could prevent us from, or delay us in submitting NDAs for, and commercializing our product candidates.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">39</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical and preclinical development involves a lengthy and expensive process with an uncertain outcome, and the results of preclinical studies and early clinical trials are not necessarily predictive of future results. Our product candidates may not have favorable results in clinical trials, if any, or receive marketing approval on a timely basis, if at all.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical and preclinical development is expensive and can take many years to complete, and its outcome is inherently uncertain. We cannot guarantee that any clinical trials or preclinical studies will be conducted as planned or completed on schedule, if at all, and delay or failure can occur at any time during the preclinical study or clinical trial process, including due to factors that are beyond our control. Further, we may not be able to meet expected timeframes for data readouts. Despite promising preclinical or clinical results, any biopharmaceutical company&#8217;s product candidate can unexpectedly fail at any stage of preclinical or clinical development, and regulators, such as the FDA or comparable foreign regulatory authorities, may not accept the results as demonstrating the product candidate&#8217;s safety and efficacy. The historical failure rate for product candidates in our industry is high.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The results from preclinical studies or clinical trials of a product candidate may not predict the results of later clinical trials of the product candidate, and interim, topline, or preliminary results of a clinical trial are not necessarily indicative of final results. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy characteristics despite having progressed through preclinical studies and initial clinical trials. In particular, while we have conducted certain preclinical studies of our product candidates , we do not know whether our current product candidates or other potential product candidates will perform in current or future clinical trials as they have performed in these prior studies. The positive results we have observed for our product candidates in preclinical animal models may not be predictive of our current or future clinical trials in humans. In addition, while we have previously reported interim results from our ongoing clinical trials and may do so in the future, such results are not necessarily indicative of final results or results from future trials. It is not uncommon to observe results in clinical trials that are unexpected based on preclinical studies and early clinical trials, and many product candidates fail in clinical trials despite very promising early results. If unexpected observations or toxicities are observed in our ongoing or planned trials, or in IND-enabling studies for any future product candidates, such results could delay and possibly prevent or limit clinical trials for our product candidates. Moreover, preclinical and clinical data may be susceptible to varying interpretations and analyses. A number of companies in the biopharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even after achieving promising results in earlier studies. Such setbacks have occurred and may occur for many reasons, including, but not limited to: clinical sites and investigators may deviate from clinical trial protocols, whether due to lack of training or otherwise, and we may fail to detect any such deviations in a timely manner; patients may fail to adhere to any required clinical trial procedures, including any requirements for post-treatment follow-up; our product candidates may fail to demonstrate effectiveness or safety in certain patient subpopulations, which has not been observed in earlier trials due to limited sample size, lack of analysis or otherwise; or our clinical trials may not adequately represent the patient populations we intend to treat, whether due to limitations in our trial designs or otherwise, such as where one patient subgroup is overrepresented in the clinical trial. There can be no assurance that we will not suffer similar setbacks despite the data we observed in earlier or ongoing studies. Based upon negative or inconclusive results, we or any future collaborator may decide, or regulators may require us, to conduct additional preclinical studies or clinical trials, which would cause us to incur additional operating expenses and delays and may not be sufficient to support regulatory approval on a timely basis or at all.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the foregoing reasons, we cannot be certain that our ongoing and planned clinical trials and preclinical studies will be successful. In addition, any safety concerns observed in any one of our clinical trials in our targeted indications could impair the development, marketing approval or commercial prospects of our product candidates in those and other targeted indications, such as dabogratinib for oncology and ACH, which could have a material adverse effect on our business, financial condition and results of operations.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">40</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the FDA&#8217;s and other regulatory authorities&#8217; policies with respect to clinical trials may change and additional government regulations may be enacted. For instance, the regulatory landscape related to clinical trials in the European Union (EU) recently evolved. The EU Clinical Trials Regulation (CTR) which was adopted in April 2014 and repeals the EU Clinical Trials Directive, became applicable on January 31, 2022. While the EU Clinical Trials Directive required a separate clinical trial application (CTA) to be submitted in each member state in which the clinical trial takes place, to both the competent national health authority and an independent ethics committee, the CTR introduces a centralized process and only requires the submission of a single application for multi-center trials. The CTR allows sponsors to make a single submission to both the competent authority and an ethics committee in each member state, leading to a single decision per member state. The assessment procedure of the CTA has been harmonized as well, including a joint assessment by all member states concerned, and a separate assessment by each member state with respect to specific requirements related to its own territory, including ethics rules. Each member state&#8217;s decision is communicated to the sponsor via the centralized EU portal. Once the CTA is approved, clinical study development may proceed. The CTR transition period ended on January 31, 2025, and all clinical trials (and related applications) are now fully subject to the provisions of the CTR. Compliance with the CTR requirements by us and our third-party service providers, such as contract research organizations (CROs), may impact our developments plans.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">In oncology, our discovery and preclinical development activities are focused on the development of targeted therapeutics for patients with genomically defined cancers, which is a rapidly evolving area of science, and the approach we are taking to discover and develop drugs based on our SN&#197;P platform is novel and unproven and may never lead to approved products of commercial value.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The discovery and development of targeted therapeutics for patients with genomically defined cancers is an emerging field, and the scientific discoveries that form the basis for our efforts to discover and develop product candidates are relatively new. Although we believe, based on our preclinical work in oncology, that the genomic alterations targeted by our programs are oncogenic drivers, clinical results may not confirm this hypothesis or may only confirm it for certain alterations or certain tumor types. In addition, even if our approach is successful in showing clinical benefit for acquired resistance mutation-driven cancers for our dabogratinib, TYRA-430 or TYRA-200 product candidates, we may never successfully identify additional oncogenic alterations for other receptor tyrosine kinases using our SN&#197;P platform, or succeed in identifying additional product candidates to address such alterations. Any product candidates we do discover and advance based on scientific approach may be later shown to have harmful side effects or may have other characteristics that may necessitate additional clinical testing, or make the product candidates unmarketable or unlikely to receive marketing approval. Therefore, we do not know if our approach of discovering and developing product candidates to treat patients with genomically defined cancers will be successful, and if our approach is unsuccessful, we may be forced to abandon our development efforts for a program or programs, which would have a material adverse effect on our business and could potentially cause us to cease operation.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Any difficulties or delays in the commencement or completion, or termination or suspension, of our clinical trials could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Before we can initiate clinical trials for our product candidates, we must submit the results of preclinical studies to the FDA or comparable foreign regulatory authorities along with other information, including information about product candidate chemistry, manufacturing and controls and our proposed clinical trial protocol, as part of an IND or similar regulatory filing required for regulatory allowance before proceeding with clinical development. The FDA or comparable foreign regulatory authorities may require us to conduct additional preclinical studies for any product candidate before it allows us to initiate clinical trials under any IND or similar regulatory filing, which may lead to delays and increase the costs of our preclinical development programs. Moreover, even if these trials begin, issues may arise that could cause regulatory authorities to suspend or terminate such clinical trials. Any such delays</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">41</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in the commencement or completion of our ongoing or planned clinical trials for dabogratinib, TYRA-430, TYRA-200 or any other product candidate, could significantly affect our product development timelines and development costs.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not know whether our planned trials will begin on time or be completed on schedule, if at all. The commencement, data readouts and completion of clinical trials can be delayed for a number of reasons, including delays related to:</span></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inability to generate sufficient preclinical, toxicology, or other </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or in vitro data to support the initiation or continuation of clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtaining regulatory allowance or authorization to commence a trial or reaching a consensus with regulatory authorities on trial design;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any failure or delay in reaching an agreement with CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to reach an agreement with diagnostic companies for the development and use of liquid biopsy companion diagnostic tests in our clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtaining approval from one or more institutional review boards (IRBs) (or ethics committees);</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IRBs (or ethics committees) refusing to approve, suspending or terminating the trial at an investigational site, precluding enrollment of additional patients, or withdrawing their approval of the trial;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes to clinical trial protocol;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">identifying sufficient appropriately qualified investigators and other professionals to conduct the clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical sites deviating from trial protocol or dropping out of a trial;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">manufacturing sufficient quantities of product candidates for use in clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">patients failing to enroll or remain in our trials at the rate we expect, or failing to return for post-treatment follow-up;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">patients choosing alternative treatments for the indications for which we are developing our product candidates, or participating in competing clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">lack of adequate funding to continue the clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">patients experiencing severe or unexpected drug-related adverse effects;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">occurrence of serious adverse events in clinical trials of the same class of agents conducted by other companies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">selection of clinical endpoints that require prolonged periods of clinical observation or analysis of the resulting data;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a facility manufacturing our product candidates or any of their components suspending or limiting manufacturing due to violations of cGMP, or other applicable requirements, including infections or </span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">42</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cross-contaminations of product candidates in the manufacturing process, or the facility being subject to other enforcement by the FDA or comparable foreign regulatory authorities that result in temporary or permanent manufacturing shut downs or product supply limitations;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any changes to our manufacturing process that may be necessary or desired;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">third-party clinical investigators losing the licenses or permits necessary to perform our clinical trials or being suspended or disqualified by the FDA or comparable foreign regulatory authorities, not performing our clinical trials on our anticipated schedule or consistent with the clinical trial protocol, GCPs, or other regulatory requirements;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">third-party contractors not performing data collection or analysis in a timely or accurate manner; or</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">third-party contractors becoming debarred or suspended or otherwise penalized by the FDA or comparable foreign regulatory authorities for violations of regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to use some or all of the data produced by such contractors in support of our marketing applications.</span></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which our trials are being conducted, by a Data Safety Monitoring Board for our trial or by the FDA or comparable foreign regulatory authorities. These authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols and to make the appropriate required records, inspection of the clinical trial operations or trial site by the FDA or comparable foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a clinical trial drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. In addition, changes in regulatory requirements and policies may occur, and we may need to amend clinical trial protocols to comply with these changes. Amendments may require us to resubmit our clinical trial protocols to IRBs for reexamination, which may impact the costs, timing or successful completion of a clinical trial.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, conducting clinical trials in foreign countries, as we may do for our product candidates, presents additional risks that may delay completion of our clinical trials. These risks include the failure of investigators or enrolled patients in foreign countries to adhere to clinical protocol as a result of differences in healthcare services or cultural customs, managing additional administrative burdens associated with foreign regulatory schemes, as well as political and economic risks, including war, relevant to such foreign countries.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we experience delays in the completion of, or termination of, any clinical trial of our product candidates, the commercial prospects of our product candidates will be harmed, and our ability to generate product revenues from any of these product candidates will be delayed. Moreover, any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our proprietary SN&#197;P platform is innovative and unproven, and we do not know whether we will be able to develop any product candidates that are successful in clinical development or products of commercial value.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The success of our business depends primarily upon our ability to identify, develop and commercialize products based on our proprietary SN&#197;P platform, which is designed to efficiently identify and selectively target vulnerabilities in the mutant proteins that commonly eliminate or reduce the effectiveness of standard-of-care therapies. We have not yet succeeded and may not succeed in demonstrating efficacy and safety for any product candidates in clinical trials or in obtaining marketing approval thereafter. We have not yet completed any clinical trials for any product candidate. Our SN&#197;P platform utilizes the rapid generation of precise molecular SN&#197;Pshots to continually gain deeper insights into the structure of inhibitor binding sites and how commonly occurring resistance</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">43</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">mutations lead to acquired drug resistance to existing therapies, which we believe aids in the prediction of amino acid residues most likely to cause resistance to specific existing therapies. This innovative process may never be successful in identifying additional product candidates with innovative structures that are able to inhibit the target while avoiding those specific residues. Further, because all of our product candidates and discovery programs are based on our SN&#197;P platform, adverse developments with respect to one of our programs may have a significant adverse impact on the actual or perceived likelihood of success and value of our other development programs.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the biotechnology and biopharmaceutical industries are characterized by rapidly advancing technologies. Our future success will depend in part on our ability to maintain a competitive position with our innovative approach to compound identification. If we fail to stay at the forefront of technological innovation in utilizing our SN&#197;P platform, we may be unable to compete effectively.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not be able to complete clinical trials for our product candidates if we are unable to identify and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or comparable foreign regulatory authorities. Patient enrollment for our clinical trials may be affected by many factors, including:</span></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the size and nature of the patient population;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">severity of the disease or condition under evaluation;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the proximity of patients to clinical sites;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the eligibility and exclusion criteria for the trial;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the design of the clinical trial;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the risk that enrolled patients will not complete a clinical trial;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">efforts to facilitate timely enrollment in clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">patient referral practices of physicians;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to recruit clinical trial investigators with the appropriate competencies and experience; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">competing clinical trials and clinicians&#8217; and patients&#8217; perceptions as to the potential advantages and risks of the product candidate being studied in relation to other available therapies, including any new products that may be approved for the indications we are investigating as well as any product candidates under development.</span></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will be required to identify and enroll a sufficient number of patients for each of our clinical trials. The patient populations for our product candidates are limited to those with specific target alterations and may not be completely defined but are substantially smaller than the general treated cancer population, and we will need to screen and identify these patients with targeted alterations. Successful identification of patients is dependent on several factors, including achieving certainty as to how specific alterations respond to our product candidates and the ability to identify such alterations. Furthermore, even if we are successful in identifying patients, we cannot be certain that the resulting patient populations for each mutation will be large enough to allow us to successfully obtain approval for each mutation type and commercialize our product candidates and achieve profitability. We may not be able to initiate or continue clinical trials if we are unable to locate a sufficient number of eligible patients to participate in the clinical trials required by the FDA or comparable foreign regulatory authorities. In addition, the process of finding and diagnosing patients may prove costly.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">44</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The timing of our clinical trials depends, in part, on the speed at which we can recruit patients to participate in our trials, as well as completion of required follow-up periods. The eligibility criteria of our clinical trials, once established, will further limit the pool of available trial participants. If patients are unwilling to participate in our trials for any reason, including the existence of concurrent clinical trials for similar patient populations or the availability of other therapies, or we otherwise have difficulty enrolling a sufficient number of patients, the timeline for recruiting patients, conducting clinical trials and obtaining marketing approval of our product candidates may be delayed. Additionally, because some of our initial clinical trials in oncology will be in patients with relapsed/refractory cancer, these patients are typically in the late stages of their disease and may experience disease progression independent from our product candidates, making them unevaluable for purposes of the clinical trial and requiring additional patient enrollment. Our inability to enroll a sufficient number of patients for any of our clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether. In addition, we expect to rely on CROs and clinical trial sites to ensure proper and timely conduct of our clinical trials and, while we intend to enter into agreements governing their services, we will have limited influence over their actual performance.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot assure you that our assumptions used in determining expected clinical trial timelines are correct or that we will not experience delays in enrollment, which would result in the delay of completion of such trials beyond our expected timelines.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of our product candidates could be associated with side effects, adverse events or other properties or safety risks, which could delay or preclude approval, cause us to suspend or discontinue clinical trials, abandon a product candidate, limit the commercial profile of an approved label or result in other significant negative consequences that could severely harm our business, prospects, operating results and financial condition.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have not completed the evaluation of any of our product candidates in human clinical trials. It is impossible to predict when or if any product candidates we may develop will prove safe in humans. As is the case with biopharmaceuticals generally, and treatments for cancer and rare diseases in particular, it is likely that there may be side effects and adverse events associated with the use of our product candidates. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. Undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of marketing approval by the FDA or comparable foreign regulatory authorities. If adverse events or other side effects are observed in any of our clinical trials, we may have difficulty recruiting patients to our clinical trials, patients may drop out of our trials, or we may be required to abandon the trials or our development efforts of one or more product candidates altogether. Any of these occurrences may harm our business, financial condition and prospects significantly.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, if our product candidates are associated with undesirable side effects in clinical trials or have characteristics that are unexpected, we may elect to abandon their development or limit their development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective, which may limit the commercial expectations for the product candidate if approved. Any such undesirable side effects observed in one of our clinical trials in our targeted indications could impair the development, marketing approval or commercial prospects of our product candidates in those and other indications. We, the FDA or other applicable regulatory authorities, or an IRB, may suspend or terminate future clinical trials of a product candidate at any time for various reasons, including a belief that subjects in such trials are being exposed to unacceptable health risks or adverse side effects. Many compounds that initially showed promise in early-stage testing have later been found to cause side effects that prevented further development of the compound. In addition, regulatory authorities may draw different conclusions or require additional testing to confirm these determinations.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">45</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is possible that as we test our product candidates in larger, longer and more extensive clinical trials, including with different dosing regimens, or as the use of these product candidates becomes more widespread if they receive marketing approval, illnesses, injuries, discomforts and other adverse events that were observed in earlier trials, as well as conditions that did not occur or went undetected in previous trials, may be reported by patients. If such side effects become known later in development or upon approval, if any, such findings may harm our business, financial condition and prospects significantly.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patients treated with our products, if approved, may experience previously unreported adverse reactions, and it is possible that the FDA or comparable foreign regulatory authorities may ask for additional safety data as a condition of, or in connection with, our efforts to obtain approval of our product candidates. Even if the side effects do not preclude the product candidate from obtaining or maintaining marketing approval, undesirable side effects may inhibit market acceptance of the approved product due to its tolerability versus other therapies. If safety problems occur or are identified after our products, if any, are available for commercial sale and use, we may make the decision, or be required by regulatory authorities, to amend the labeling of our product candidates, recall our product candidates or even withdraw approval for an approved product.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such product, a number of potentially significant negative consequences could result, including:</span></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory authorities may withdraw, suspend or limit approvals of such product, or seek an injunction against its manufacture or distribution;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be required to recall a product or change the way such product is administered to patients;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory authorities may require additional warnings on the label, such as a &#8220;black box&#8221; warning or a contraindication;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be required to implement a Risk Evaluation and Mitigation Strategy (REMS) or create a medication guide outlining the risks of such side effects for distribution to patients;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be required to change the way a product is distributed, conduct additional clinical trials or change the labeling of a product or be required to conduct additional post-marketing studies or surveillance;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we could be sued and held liable for harm caused to patients; or</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sales of the product may decrease significantly or the product could become less competitive and our reputation may suffer.</span></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm our business, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our product candidates are subject to extensive regulation and compliance, which is costly and time consuming, and such regulation may cause unanticipated delays or prevent the receipt of the required approvals to commercialize our product candidates.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The clinical development, manufacturing, labeling, packaging, storage, record-keeping, advertising, promotion, import, export, marketing, distribution and adverse event reporting, including the submission of safety and other information, of our product candidates are subject to extensive regulation by the FDA in the United States and by comparable foreign regulatory authorities in foreign markets. In the United States, we are not permitted to market our product candidates until we receive marketing approval from the FDA. The process of obtaining</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">46</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">marketing approval is expensive, often takes many years following the commencement of clinical trials and can vary substantially based upon the type, complexity and novelty of the product candidates involved, as well as the target indications and patient population. Approval policies or regulations may change, and the FDA has substantial discretion in the drug approval process, including the ability to delay, limit or deny approval of a product candidate for many reasons. Despite the time and expense invested in clinical development of product candidates, marketing approval is never guaranteed. Neither we, nor any future collaborator, is permitted to market any of our product candidates in the United States until we receive marketing approval from the FDA.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to obtaining approval to commercialize a product candidate in the United States or abroad, we or our collaborators must demonstrate with substantial evidence from adequate and well-controlled clinical trials, and to the satisfaction of the FDA or comparable foreign regulatory authorities, that such product candidates are safe and effective for their intended uses. Results from preclinical studies and clinical trials can be interpreted in different ways. Even if we believe the preclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authorities, as the case may be, may also require us to conduct additional preclinical studies or clinical trials for our product candidates either prior to or post-approval, or may object to elements of our clinical development program.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA or comparable foreign regulatory authorities can delay, limit or deny approval of a product candidate for many reasons, including:</span></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">such authorities may disagree with the design or implementation of our, or our any of our potential future collaborators&#8217; clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">negative or ambiguous results from our clinical trials or results may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for marketing approval;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">serious and unexpected drug-related side effects may be experienced by participants in our clinical trials or by individuals using drugs similar to our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">such authorities may not accept clinical data from trials which are conducted at clinical facilities or in countries where the standard of care is potentially different from that of the United States;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we, or any of our potential future collaborators may be unable to demonstrate that a product candidate is safe and effective, and that product candidate&#8217;s clinical and other benefits outweigh its safety risks;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">such authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">such authorities may not agree that the data collected from clinical trials of our product candidates are acceptable or sufficient to support the submission of an NDA or other submission or to obtain marketing approval in the United States or elsewhere, and such authorities may impose requirements for additional preclinical studies or clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">such authorities may disagree regarding the formulation, labeling and/or the specifications of our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">such authorities may require additional information, data, qualification, or validation of our manufacturing and testing processes as part of the chemistry, manufacturing, and controls information we submit as part of our application;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">approval may be granted only for indications that are significantly more limited than what we apply for and/or with other significant restrictions on distribution and use;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">47</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">such authorities may find deficiencies in the manufacturing processes, approval policies or facilities of our third-party manufacturers with which we or any of our current or future collaborators contract for clinical and commercial supplies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulations of such authorities may significantly change in a manner rendering our or any of our potential future collaborators&#8217; clinical data insufficient for approval; or</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">such authorities may not accept a submission due to, among other reasons, the content or formatting of the submission.</span></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any delays in the marketing approval of our product candidates may negatively impact our ability to successfully position the product candidate in the market or the product candidate may face additional competition from other products.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With respect to foreign markets, marketing approval procedures vary among countries and, in addition to the foregoing risks, may involve additional product testing, administrative review periods and agreements with pricing authorities. In addition, events raising questions about the safety of certain marketed biopharmaceuticals may result in increased cautiousness by the FDA or comparable foreign regulatory authorities in reviewing new drugs based on safety, efficacy or other regulatory considerations and may result in significant delays in obtaining marketing approvals. Any delay in obtaining, or inability to obtain, applicable marketing approvals would prevent us or any of our potential future collaborators from commercializing our product candidates.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to successfully develop companion diagnostics for biomarkers that enable patient selection, or experience significant delays in doing so, we may not be able to commercialize the product candidate and our ability to generate revenue will be materially impaired.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A key component of our strategy includes the use of companion diagnostics to guide patient selection of our product candidates. We do not have the ability to develop such tests on our own, and so we plan to rely on third parties for the design, development and manufacture of companion diagnostic tests for any of our product candidates that may require such tests. If we enter into such collaborative agreements, we will be dependent on the sustained cooperation and effort of our future collaborators in developing and obtaining approval, certification or clearance for these companion diagnostics. To be successful in developing and commercializing product candidates in combination with these companion diagnostics, we and our future collaborators will need to address a number of scientific, technical, regulatory and logistical challenges.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">According to FDA guidance, if the FDA determines that a companion diagnostic device is essential to the safe and effective use of a novel therapeutic product or indication, the FDA generally will not approve the therapeutic product or new therapeutic product indication if the companion diagnostic is not also approved or cleared at the same time the product candidate is approved. To date, the FDA has generally required premarketing approval for companion diagnostic tests for use with cancer therapies. Various foreign regulatory authorities also regulate in vitro companion diagnostics as medical devices and, under those regulatory frameworks, will likely require the conduct of clinical trials to demonstrate the safety and effectiveness of these companion diagnostics, which we expect will require separate regulatory clearance or approval prior to commercialization.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The approval, certification or clearance of a companion diagnostic as part of the therapeutic product&#8217;s labeling limits the use of the therapeutic product to only those patients who express certain biomarkers or the specific genomic alteration that the companion diagnostic was developed to detect. If the FDA or comparable foreign regulatory authorities require approval or clearance of a companion diagnostic for any of our product candidates, whether before or concurrently with marketing approval of the product candidate, we and/or our collaborators, may encounter difficulties in developing and obtaining approval, certification or clearance for these companion diagnostics. Any delay or failure by us or potential future collaborators to develop or obtain regulatory</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">48</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">approval or clearance of a companion diagnostic could delay or prevent approval, certification or continued marketing of our related product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indeed, approval, certification or clearance of companion diagnostics may be subject to further legislative or regulatory reforms notably in the EU, where it continues to undergo legislative changes. On May 25, 2017, the new In Vitro Medical Devices Regulation (IVDR) entered into force. The IVDR repeals and replaces the EU In Vitro Diagnostic Medical Devices Directive. Unlike directives, which must be implemented into the national laws of the EU member states, regulations are directly applicable, i.e., without the need for adoption of EU member states laws implementing them, in all EU member states and are intended to eliminate current differences in the regulation of medical devices among EU member states. The IVDR, among other things, is intended to establish a uniform, transparent, predictable and sustainable regulatory framework across the EU for medical devices and ensure a high level of safety and health while supporting innovation. The IVDR became applicable on May 26, 2022. Following subsequent legislative changes, European institutions adopted a &#8220;progressive&#8221; roll-out of the IVDR to prevent disruption in the supply of in vitro diagnostic medical devices. Therefore, the IVDR applies since May 26, 2022, but there is a tiered system extending the grace period for many devices (depending on their risk classification) before they have to be fully compliant with the regulation.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The regulation of companion diagnostics is subject to further requirements since the IVDR became applicable as it introduced a new classification system for companion diagnostics which are now specifically defined as diagnostic tests that support the safe and effective use of a specific medicinal product, by identifying patients that are suitable or unsuitable for treatment. Companion diagnostics will have to undergo a conformity assessment by a notified body. Before it can issue an EU certificate, the notified body must seek a scientific opinion from the European Medicine Agency (EMA) on the suitability of the companion diagnostic to the medicinal product concerned if the medicinal product falls exclusively within the scope of the centralized procedure for the authorization of medicines, or the medicinal product is already authorized through the centralized procedure, or a marketing authorization application for the medicinal product has been submitted through the centralized procedure. For other substances, the notified body can seek the opinion from national competent authorities or the EMA. These modifications may make it more difficult and costly for us to obtain regulatory clearances, approvals or certification for our companion diagnostics or to manufacture, market or distribute our products after clearance, approval or certification is obtained.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, in January 2024, the FDA announced its intention to initiate the process to reclassify most in vitro diagnostic tests (IVDs) that are currently Class III into Class II, including companion diagnostic IVDs. If such reclassification efforts occur, any companion diagnostics that are the subject of the down- classification may no longer require premarket approval, but rather may be marketed pursuant to the generally less burdensome 510(k) clearance process. However, there is no assurance that any companion diagnostic required for our pharmaceutical development programs will benefit from any reclassification, or that such reclassification, even if it does occur, will result in a shorter timeline to development or marketing of the companion diagnostic.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may also be required to conduct additional studies to support a broader claim. Also, to the extent other approved diagnostics are able to broaden their labeling claims to include our approved drug products, we may be forced to abandon any partnered companion diagnostic development plans we undertake or we may not be able to compete effectively upon marketing approval, which could adversely impact our ability to generate revenue from the sale of our approved products and our business operations.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, even if data from preclinical studies and early clinical trials appear to support development of a companion diagnostic for a product candidate, data generated in later clinical trials may fail to support the analytical and clinical validation of the companion diagnostic. We and our future collaborators may encounter difficulties in developing, obtaining regulatory approval, certification or clearance for, manufacturing and commercializing companion diagnostics similar to those we face with respect to our product candidates themselves, including issues</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">49</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">with achieving regulatory clearance or approval, production of sufficient quantities at commercial scale and with appropriate quality standards, and in gaining market acceptance. If we are unable to successfully develop companion diagnostics for our product candidates, or experience delays in doing so, the development of our product candidates may be adversely affected, our product candidates may not obtain marketing approval, and we may not realize the full commercial potential of any of our product candidates that obtain marketing approval. As a result, our business, results of operations and financial condition could be materially harmed. In addition, a diagnostic company with whom we contract may decide to discontinue selling or manufacturing the companion diagnostic test that we anticipate using in connection with development and commercialization of product candidates or our relationship with such diagnostic company may otherwise terminate. We may not be able to enter into arrangements with another diagnostic company to obtain supplies of an alternative diagnostic test for use in connection with the development and commercialization of our product candidates or do so on commercially reasonable terms, which could adversely affect and/or delay the development or commercialization of our product candidates.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may expend our limited resources to pursue a particular product candidate and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because we have limited financial and managerial resources, we focus on specific product candidates, development programs and specific indications. As a result, we may forgo or delay pursuit of opportunities with other product candidates that could have had greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable potential commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable product candidates. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaborations, licenses and other similar arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be able to obtain or maintain orphan drug designations for any of our product candidates, and we may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs or biologics for relatively small patient populations as orphan drugs. Under the Orphan Drug Act of 1983, the FDA may designate a product as an orphan product if it is intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the United States, or a patient population of greater than 200,000 individuals in the United States, but for which there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the EU, the European Commission grants orphan designation after receiving the opinion of the EMA&#8217;s Committee for Orphan Medicinal Products. In the EU, a medicinal product can be designated as an orphan if its sponsor can establish that: (1) the product is intended for the diagnosis, prevention or treatment of a life threatening or chronically debilitating condition (2) either (a) such condition affects not more than five in 10,000 persons in the EU when the application is made, or (b) the product, without the benefits derived from the orphan status, would not generate sufficient return in the EU to justify the necessary investment; and (3) there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized for marketing in the EU or, if such method exists, the product will be of significant benefit to those affected by that condition.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have received orphan drug designation from the FDA for dabogratinib for the treatment of ACH, and we may seek additional orphan drug designations in the United States and/or the EU for dabogratinib and our other product candidates in qualified patient populations. There can be no assurance that the FDA or European Commission will grant orphan designation for any indication for which we apply, or that we will be able to maintain such designation.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">50</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States, orphan designation entitles a party to financial incentives such as opportunities for grant funding toward clinical trial costs, tax advantages and user-fee waivers. In addition, if a product candidate that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications, including an NDA, to market the same product for the same approved indication or use within such disease or condition for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity in the relevant indication or use, or where the manufacturer is unable to assure sufficient product quantity. In the EU, orphan designation entitles a party to financial incentives such as reduction of fees, fee waivers, protocol assistance, and access to the centralized marketing authorization procedure. Moreover, upon grant of a marketing authorization and assuming the requirement for orphan designation are also met at the time the marketing authorization is granted, orphan medicinal products are entitled to a ten-year period of market exclusivity for the approved therapeutic indication. The period of market exclusivity is extended by two years for orphan medicinal products that have also complied with an agreed Pediatric Investigation Plan. The European exclusivity period can be reduced to six years, if, at the end of the fifth year a drug no longer meets the criteria for orphan designation (i.e. the prevalence of the condition has increased above the orphan designation threshold or it is judged that the product is sufficiently profitable so as not to justify maintenance of market exclusivity).</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs can be approved for the same indications or uses within the same disease or condition. Even after an orphan drug is approved, the FDA or comparable foreign regulatory</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">authorities can subsequently approve the same drug for the same disease or condition if such regulatory authority concludes that the later drug is clinically superior within the relevant indication because it is shown to be safer, more effective or makes a major contribution to patient care. Orphan drug exclusivity may also be lost if the FDA later determines that the initial request for designation was materially defective. In addition, orphan drug exclusivity does not prevent the FDA from approving competing drugs containing a different active ingredient for the same or similar indication or use within the relevant disease or condition. In addition, if a subsequent drug is approved for marketing for the same or a similar indication or use as any of our product candidates that receive marketing approval, we may face increased competition and lose market share regardless of orphan drug exclusivity. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we successfully develop our product candidates, we may seek Breakthrough Therapy designation or Fast Track designation by the FDA for one or more of our product candidates, but we may not receive such designation, and even if we do, such designation may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may seek Breakthrough Therapy or Fast Track designation for some of our product candidates. A Breakthrough Therapy is defined as a drug or biologic that is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life- threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs or biologics that have been designated as Breakthrough Therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. An NDA for a Breakthrough Therapy-designated product candidate may also be eligible for rolling review, where the FDA may consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">51</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a product candidate is intended for the treatment of a serious or life-threatening condition and clinical or preclinical data demonstrate the potential to address unmet medical needs for this condition, the sponsor may apply for Fast Track Designation. The sponsor of a Fast Track product candidate has opportunities for more frequent interactions with the applicable FDA review team during product development and an NDA for a Fast Track product candidate may also be eligible for rolling review.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Whether to grant Breakthrough Therapy or Fast Track Designation is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for these designations, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of either of these designations for a product candidate may not result in a faster development process, review or approval compared to product candidates considered for approval under non-expedited FDA review procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify for either of these designations, the FDA may later decide that the product candidate no longer meet the conditions for qualification.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have obtained a rare pediatric disease designation for dabogratinib for the treatment of ACH, however, there is no guarantee that any FDA approval of dabogratinib will result in issuance of a priority review voucher.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2012, Congress authorized the FDA to award priority review vouchers to sponsors of certain rare pediatric disease product applications. This program is designed to encourage development of new drug and biological products for prevention and treatment of certain rare pediatric diseases. Specifically, under this program, a sponsor who receives an approval for a drug or biologic for a &#8220;rare pediatric disease&#8221; (RPD) that meets certain criteria may qualify for a voucher that can be redeemed to receive a priority review of a subsequent marketing application for a different product. The sponsor of a RPD drug product receiving a priority review voucher may transfer (including by sale) the voucher to another sponsor.  The voucher may be further transferred any number of times before the voucher is used, as long as the sponsor making the transfer has not yet submitted the application. The FDA may also revoke any priority review voucher if the RPD drug for which the voucher was awarded is not marketed in the U.S. within one year following the date of approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have obtained a RPD designation for dabogratinib for the treatment of ACH, however, there is no guarantee that we will be able to obtain a priority review voucher, even if dabogratinib is approved by the FDA for use in ACH patients. For example, the FDA may determine that an NDA, even if ultimately approved, does not meet the eligibility criteria for a priority review voucher, including for the following reasons:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the product no longer meets the definition of a RPD;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the product contains an active ingredient (including any ester or salt of the active ingredient) that has been previously approved in another marketing application;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the application does not rely on clinical data derived from studies examining a pediatric population and dosages of the drug intended for that population; or</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the application is approved for a different adult indication than the RPD for which the product is designated</span></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, Congress included a sunset provision in the statute authorizing the RPD priority review voucher program. Under the current statutory sunset provisions, provided the eligibility criteria are otherwise met, the FDA may only award a voucher for an approved RPD product application if the sponsor has RPD designation for the product candidate and the product candidate is approved by September 30, 2029. After September 30, 2029, the FDA may not award a voucher, regardless of an existing designation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have conducted, and may continue to conduct, clinical trials for certain of our product candidates outside of the United States. However, the FDA and other foreign equivalents may not accept data from such trials, in which case our development plans will be delayed, which could materially harm our business.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">52</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have conducted, and may continue to conduct, one or more of our clinical trials for our product candidates outside the United States. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of this data is subject to certain conditions imposed by the FDA. Where data from foreign clinical trials are intended to as the sole basis for marketing approval in the United States, the FDA will not approve the application on the basis of foreign data alone unless those data are applicable to the U.S. population and U.S. medical practice; the trials were performed by clinical investigators of recognized competence; and the data are considered valid without the need for an on-site inspection by the FDA or, if the FDA considers such an inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. For trials that are conducted only at sites outside of the United States and not subject to an IND, the FDA requires the clinical trial to have been conducted in accordance with GCP and the FDA must be able to validate the data from the clinical trial through an on-site inspection if it deems such inspection necessary. For such trials not subject to an IND, the FDA generally does not review the clinical protocols for the trials, and therefore there is an additional potential risk that the FDA could determine that the trial design or protocol for a non-U.S. clinical trial was inadequate, which could require us to conduct additional clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, such foreign trials would be subject to the applicable local laws of the foreign regulatory and legal requirements where the trials are conducted. There can be no assurance the FDA will accept data from clinical trials conducted outside of the United States. If the FDA does not accept data from our clinical trials of our product candidates, it would likely result in the need for additional clinical trials, which would be costly and time consuming and delay or permanently halt our development of our product candidates.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interim, topline and preliminary data from our preclinical studies and clinical trials that we may announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may publicly disclose preliminary, interim or topline data from our preclinical studies and clinical trials. These interim updates are based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. For example, we may report responses in certain patients that are unconfirmed at the time and which do not ultimately result in confirmed responses to treatment after follow-up evaluations. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline results that we report may differ from future results of the same studies or trials, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available. In addition, we may report interim analyses of only certain endpoints rather than all endpoints. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse changes between interim data and final data could significantly harm our business and prospects. Further, additional disclosure of interim data by us or by our competitors in the future could result in volatility in the price of our common stock.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the information we choose to publicly disclose regarding a particular study or trial is typically selected from a more extensive amount of available information. Investors may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product candidate or our business. If the interim, topline or preliminary data that we report differ from late, final or actual results, or if others, including regulatory authorities, disagree with the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">53</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">conclusions reached, our ability to obtain approval for, and commercialize, any of our product candidates may be harmed, which could harm our business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may attempt to secure approval from the FDA through the use of the accelerated approval pathway. If we are unable to obtain such approval, we may be required to conduct additional preclinical studies or clinical trials beyond those that we contemplate, which could increase the expense of obtaining, and delay the receipt of, necessary marketing approvals. Even if we receive accelerated approval from the FDA, if our confirmatory trials do not verify clinical benefit, or if we do not comply with rigorous post-marketing requirements, the FDA may seek to withdraw any accelerated approval we have obtained.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may in the future seek accelerated approval for our one or more of our product candidates. Under the accelerated approval program, the FDA may grant accelerated approval to a product candidate designed to treat a serious or life-threatening condition that provides meaningful therapeutic benefit over available therapies upon a determination that the product candidate has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease, such as irreversible morbidity or mortality. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accelerated approval pathway may be used in cases in which the advantage of a new drug over available therapy may not be a direct therapeutic advantage, but is a clinically important improvement from a patient and public health perspective. If granted, accelerated approval is usually contingent on the sponsor&#8217;s agreement to conduct, in a diligent manner, additional confirmatory studies to verify and describe the drug&#8217;s clinical benefit. If such post-approval studies fail to confirm the drug&#8217;s clinical benefit or are not completed in a timely manner, the FDA may withdraw its approval of the drug on an expedited basis. In addition, the Food and Drug Omnibus Reform Act of 2022 provided the FDA further statutory authority to mitigate potential risks to patients from continued marketing of ineffective drugs previously granted accelerated approval. Under these provisions, the FDA may require a sponsor of a product seeking accelerated approval to have a confirmatory trial underway prior to such approval being granted. In December 2024, the FDA further issued draft guidance for industry regarding the accelerated approval of drugs and biologics, which among other things, set forth the FDA&#8217;s current expectations for accelerated approval endpoints and confirmatory trials as well as the process for withdrawing accelerated approval and in January 2025, the FDA issued draft guidance intended to clarify when a confirmatory trial may be considered underway. The FDA may continue to develop guidance or otherwise change its policies with respect to the accelerated approval pathway that may make it more difficult to seek accelerated approval of any of our product candidates.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to seeking accelerated approval for any of our product candidates, we intend to seek feedback from the FDA and will otherwise evaluate our ability to seek and receive accelerated approval. There can be no assurance that after our evaluation of the feedback and other factors we will decide to pursue or submit an NDA for accelerated approval or any other form of expedited development, review or approval. Furthermore, if we decide to submit an application for accelerated approval for our product candidates, there can be no assurance that such application will be accepted or that any expedited development, review or approval will be granted on a timely basis, or at all. The FDA or other comparable foreign regulatory authorities could also require us to conduct further studies prior to considering our application or granting approval of any type. A failure to obtain accelerated approval or any other form of expedited development, review or approval for our product candidate would result in a longer time period to commercialization of such product candidate, if any, could increase the cost of development of such product candidate and could harm our competitive position in the marketplace.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">54</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Disruptions at the FDA and other government agencies caused by funding shortages, staffing limitations or policy changes could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ability of the FDA and comparable foreign regulatory activities to review and approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory and policy changes, the FDA&#8217;s and comparable foreign regulatory activities&#8217; ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s and comparable foreign regulatory activities&#8217; ability to perform routine functions. Average review times at the FDA and comparable foreign regulatory activities have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and comparable foreign regulatory activities may also slow the time necessary for new drugs and biologics or modifications to approved drugs and biologics to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, in recent years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. In addition, the current U.S. Presidential administration has issued certain policies and Executive Orders directed towards reducing the employee headcount and costs associated with U.S. administrative agencies, including the FDA, and it remains unclear the degree to which these efforts may limit or otherwise adversely affect the FDA&#8217;s ability to conduct routine activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a prolonged government shutdown occurs, or if funding shortages, staffing limitations or similar factors hinder or prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, such events could significantly impact the ability of the FDA or other such regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As product candidates progress through preclinical studies and clinical trials to marketing approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize safety, efficacy, yield and manufacturing batch size, minimize costs and achieve consistent quality and results. Similarly, in the future we may introduce an alternative formulation of one or more of our product candidates during the course of our ongoing or planned clinical trials. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause our product candidates to perform differently and affect the results of ongoing, planned or future clinical trials conducted with the altered materials. This could delay initiation or completion of clinical trials, require the conduct of bridging studies or clinical trials or the repetition of one or more studies or clinical trials, increase development costs, delay approval of our product candidates and jeopardize our ability to commercialize our product candidates, if approved, and generate revenue.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Reliance on Third Parties</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We rely on third parties for the manufacture of our product candidates for preclinical and clinical development. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not own or operate manufacturing facilities and have no plans to develop our own clinical or commercial-scale manufacturing capabilities. We rely, and expect to continue to rely, on third parties for the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">55</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">manufacture of our product candidates and related raw materials for preclinical and clinical development, as well as for commercial manufacture if any of our product candidates receive marketing approval. The facilities used by third-party manufacturers to manufacture our product candidates must be approved by the FDA or comparable foreign regulatory authorities for the manufacture of our product candidates pursuant to inspections that will be conducted after we submit an NDA to the FDA or any comparable filing to a foreign regulatory authority. We do not control the manufacturing process of, and are completely dependent on, third-party manufacturers for compliance with cGMP or similar foreign requirements for manufacture of products. If these third-party manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or any comparable foreign regulatory authority, they will not be able to secure and/or maintain marketing approval for their manufacturing facilities. In addition, we have no control over the ability of third-party manufacturers to maintain adequate quality control, quality assurance, qualified personnel, and accurate and complete recordkeeping. If the FDA or comparable foreign regulatory authorities does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain marketing approval for or market our product candidates, if approved. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us or the third-party manufacturers, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our products.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our or a third party&#8217;s failure to execute on our manufacturing requirements on commercially reasonable terms and in compliance with cGMP or similar foreign requirements (where applicable) could adversely affect our business in a number of ways, including:</span></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an inability to initiate clinical trials of our product candidates under development;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delay in submitting regulatory applications, or receiving marketing approvals, for our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">subjecting third-party manufacturing facilities or our manufacturing facilities to additional inspections by regulatory authorities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">requirements to cease development or to recall batches of our product candidates; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in the event of approval to market and commercialize our product candidates, an inability to meet commercial demands for our product candidates or any other future product candidates.</span></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we do not have any long-term commitments or supply agreements with our third party manufacturers. We may be unable to establish any agreements with third-party manufacturers or to do so on acceptable terms, which increases the risk of timely obtaining sufficient quantities of our product candidates or such quantifies at an acceptable cost. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:</span></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure of third-party manufacturers to comply with regulatory requirements and maintain quality assurance;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">breach of the manufacturing agreement by the third party;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to manufacture our product according to our specifications;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to manufacture our product according to our schedule or at all;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">misappropriation of our proprietary information, including our trade secrets and know-how; and</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">56</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us.</span></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product candidates and any products that receive marketing approval may compete with the product candidates and products of other companies for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP and similar foreign regulations and that might be capable of manufacturing for us. This could lead to a delay in the manufacture of our product candidates or any products that receive marketing approval, and negatively impact the supply of such product candidates or products for clinical trials or commercialization.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval, and any related remedial measures may be costly or time consuming to implement. We do not currently have arrangements in place for redundant supply or a second source for all required raw materials used in the manufacture of our product candidates. If our existing or future third-party manufacturers cannot perform as agreed, we may be required to replace such manufacturers and we may be unable to replace them on a timely basis or at all. In particular, any replacement of our manufacturers could require significant effort and expertise because there may be a limited number of qualified replacements. In some cases, the technical skills or technology required to manufacture our product candidates may be unique or proprietary to the original manufacturer and we may have difficulty transferring such skills or technology to another third-party and a feasible alternative may not exist. In addition, certain of our product candidates and our own proprietary methods have never been produced or implemented outside of our company, and we may therefore experience delays to our development programs if and when we attempt to establish new third-party manufacturing arrangements for these product candidates or methods.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we currently and may in the future rely on contract manufacturers in China. Such foreign contract manufacturers may be subject to U.S. legislation, sanctions, tariffs, trade restrictions and other foreign regulatory requirements which could increase the cost or reduce the supply of material available to us, delay the procurement or supply of such material or have an adverse effect on our ability to secure significant commitments from governments to purchase our potential therapies. For example, the U.S. BIOSECURE Act, which was enacted in December 2025, prohibits  federal agencies from procuring or using any biotechnology equipment or services from &#8220;biotechnology companies of concern&#8221;, or entering into, extending, or renewing any contracts with entities that use such biotechnology equipment or services from &#8220;biotechnology companies of concern&#8221;. Congress has interpreted a &#8220;biotechnology company of concern&#8221; as an entity that is under the control of a foreign adversary and that poses a risk to national security based on its research or multiomic data collection (e.g., collection of genomic information). While the U.S. BIOSECURE Act has a grandfathering period of five years for existing contracts, and has carveouts for manufacture of drugs for supply under Medicaid and Medicare Part B, subject to the Secretary of Veteran Affairs&#8217; discretion, the impact of the U.S. BIOSECURE Act on the biotechnology industry is uncertain. This and similar laws could have the potential to materially restrict the ability of U.S. biopharmaceutical companies like us to purchase services or products from, or otherwise collaborate with, certain Chinese biotechnology companies &#8220;of concern&#8221; without losing the ability to contract with, or otherwise receive funding from, the U.S. government.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, changes by the U.S. and foreign governments in trade policies including the imposition of higher tariffs on imports into the United States and other governmental regulations affecting trade between the United States and other countries where we, our contract manufacturers and/or our CROs conduct business, and any retaliatory actions by other governments, could increase costs, impact the supply of materials and adversely impact our business, financial condition and results of operations.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">57</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our current and anticipated future dependence upon others for the manufacture of our product candidates or products may adversely affect our future profit margins and our ability to commercialize any products that receive marketing approval on a timely and competitive basis.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our reliance on third parties requires us to share our confidential information, which increases the possibility that confidential information will be misappropriated or disclosed.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because we currently plan to rely on third parties to manufacture our product candidates and to perform quality testing, we must, at times, share our proprietary technology and confidential information with them. We seek to protect our proprietary technology, in part, by entering into confidentiality agreements, and, if applicable, material transfer agreements, collaborative research agreements, consulting agreements or other similar agreements with our advisors, employees and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information. Despite the contractual provisions employed when working with third parties, the need to share confidential information increases the risk that such trade secrets become known by our competitors, are intentionally or inadvertently incorporated into the technology of others or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and confidential information and despite our efforts to protect our confidential information, a competitor&#8217;s discovery of our proprietary technology and confidential information or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may seek to enter into collaborations, licenses and other similar arrangements and may not be successful in doing so, and even if we are, we may relinquish valuable rights and may not realize the benefits of such relationships.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may seek to enter into collaborations, joint ventures, licenses and other similar arrangements for the development or commercialization of our product candidates, due to capital costs required to develop or commercialize the product candidate or manufacturing constraints. We may not be successful in our efforts to establish such collaborations for our product candidates because our research and development pipeline may be insufficient, our product candidates may be deemed to be at too early of a stage of development for collaborative effort or third parties may not view our product candidates as having the requisite potential to demonstrate safety and efficacy or significant commercial opportunity. In addition, we face significant competition in seeking appropriate strategic partners, and the negotiation process can be time-consuming and complex. We may have to relinquish valuable rights to our future revenue streams, research programs or product candidates, or grant licenses on terms that may not be favorable to us, as part of any such arrangement, and such arrangements may restrict us from entering into additional agreements with other potential collaborators. We cannot be certain that, following a collaboration, license or strategic transaction, we will achieve an economic benefit that justifies such transaction.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we are successful in our efforts to establish such collaborations, the terms that we agree upon may not be favorable to us, and we may not be able to maintain such collaborations if, for example, the development or approval of a product candidate is delayed, the safety of a product candidate is questioned or the sales of an approved product candidate are unsatisfactory.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, any potential future collaborations may be terminable by our strategic partners, and we may not be able to adequately protect our rights under these agreements. Furthermore, strategic partners may negotiate for certain rights to control decisions regarding the development and commercialization of our product candidates, if approved, and may not conduct those activities in the same manner as we do. Any termination of collaborations we enter into in the future, or any delay in entering into collaborations related to our product candidates, could delay the development and commercialization of our product candidates and reduce their competitiveness if they reach the market, which could have a material adverse effect on our business, financial condition and results of operations.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">58</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We rely on third parties to conduct our clinical trials and some of our preclinical studies. If these third parties do not successfully carry out their contractual duties, comply with applicable regulatory requirements or meet expected deadlines, our development programs and our ability to seek or obtain marketing approval for or commercialize our product candidates may be delayed.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are dependent on third parties to conduct our clinical trials and some of our preclinical studies. Specifically, we have used and relied on, or intend to use and rely on, medical institutions, clinical investigators, CROs, contract development and manufacturing organizations, and consultants to conduct some of our preclinical studies and to conduct clinical trials in accordance with our clinical protocols and regulatory requirements. These CROs, investigators and other third parties play a significant role in the conduct and timing of these preclinical studies and clinical trials and subsequent collection and analysis of data. While we have and will have agreements governing the activities of our CROs, investigators and other third-party contractors, we have limited influence over their actual performance. Nevertheless, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards, and our reliance on our CROs and other third parties does not relieve us of our regulatory responsibilities. We and our CROs are required to comply with GLP and GCP requirements, which are regulations and guidelines enforced by the FDA or comparable foreign regulatory authorities for all of our product candidates in preclinical and clinical development. Regulatory authorities enforce these requirements through periodic inspections of trial sponsors, principal investigators, trial sites, and other third parties. If we or any of our CROs, trial sites or other third parties fail to comply with applicable GLP or GCP or other requirements, the clinical data generated in our clinical trials may be deemed unreliable, and the FDA or comparable foreign regulatory authorities may require us to perform additional preclinical studies or clinical trials before approving our marketing applications. In addition, our clinical trials must be conducted with products produced under cGMP regulations or similar foreign requirements. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the marketing approval process.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is no guarantee that any of our CROs, investigators or other third parties will devote adequate time and resources to such trials or perform as contractually required. If any of these third parties fail to meet expected deadlines, adhere to our clinical protocols or meet regulatory requirements, or otherwise performs in a substandard manner, our clinical trials may be extended, delayed or terminated. In addition, many of the third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other development activities that could harm our competitive position. In addition, principal investigators for our clinical trials may also serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or the FDA concludes that the financial relationship may have affected the interpretation of the study, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection by the FDA of any NDA we submit. Any such delay or rejection could prevent us from commercializing our product candidates.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our CROs have the right to terminate their agreements with us in the event of an uncured material breach. In addition, some of our CROs have an ability to terminate their respective agreements with us if we make a general assignment for the benefit of our creditors or if we are liquidated. If any of our relationships with these third parties terminate, we may not be able to enter into arrangements with alternative third parties on commercially reasonable terms or at all. Switching or adding additional CROs, investigators and other third parties involves additional cost and requires our management&#8217;s time and focus. In addition, there is a natural transition period when a new CRO, investigator or other third party contractor commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we carefully manage our relationships with our CROs, investigators and other third parties, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">59</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Commercialization of Our Product Candidates</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if we receive marketing approval for any product candidate, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. Additionally, our product candidates, if approved, could be subject to labeling and other restrictions on marketing or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our product candidates, when and if any of them are approved.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following potential approval of any our product candidates, the FDA may impose significant restrictions on a product&#8217;s indicated uses or marketing or impose ongoing requirements for potentially costly and time consuming post-approval studies, post-market surveillance or clinical trials to monitor the safety and efficacy of the product, may contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, and may include burdensome post-approval study or risk management requirements. For example, the FDA may require a REMS, as a condition of approval of our product candidates, which could include requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or a comparable foreign regulatory authority approves our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export recordkeeping, and other activities relating to our products will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMP (and similar requirements outside the United States) and GCP requirements for any clinical trials that we conduct post- approval. Manufacturers of approved products and their facilities are subject to continual review and periodic, unannounced inspections by the FDA and other regulatory authorities for compliance with cGMP or similar foreign regulations and standards. Later discovery of previously unknown problems with our products, including additional adverse events or adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</span></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on the marketing or manufacturing of our products, withdrawal of the product from the market or product recalls;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on product distribution or use, or requirements to conduct post-marketing studies or clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fines, restitutions, disgorgement of profits or revenues, civil money penalties, warning letters, untitled letters or holds on clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of approvals;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product seizure or detention, or refusal to permit the import or export of our products; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties.</span></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue and could require us to expend significant time and resources in response and could generate negative publicity.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, if any of our product candidates are approved, our product labeling, advertising and promotion will be subject to regulatory requirements and continuing regulatory review. The FDA strictly regulates the promotional claims that may be made about drug products. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product&#8217;s approved labeling. If we receive marketing approval</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">60</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for a product candidate, physicians may nevertheless, in their independent medical judgment, prescribe it to their patients in a manner that is inconsistent with the approved label. The FDA does not regulate the behavior of physicians in their choice of treatments but the FDA does restrict manufacturer&#8217;s communications on the subject of off-label use of their products. If we are found to have promoted such off-label uses, we may become subject to significant liability. The FDA, the Department of Justice, and other governmental authorities actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant sanctions. For example, the federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into corporate integrity agreements, consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA&#8217;s and other regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay marketing approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may be subject to enforcement action and we may not achieve or sustain profitability, which would adversely affect our business, prospects, financial condition and results of operations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The commercial success of our product candidates will depend upon the degree of market acceptance of such product candidates by physicians, patients, healthcare payors and others in the medical community.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product candidates may not be commercially successful. Even if any of our product candidates receive marketing approval, they may not gain market acceptance among physicians, patients, healthcare payors or the medical community. The commercial success of any of our current or future product candidates will depend significantly on the broad adoption and use of the resulting product by physicians and patients for approved indications. The degree of market acceptance of our products will depend on a number of factors, including:</span></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">demonstration of clinical efficacy and safety compared to other more-established products;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the indications for which our product candidates are approved;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the limitation of our targeted patient population and other limitations or warnings contained in any FDA-approved labeling;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acceptance of a new drug for the relevant indication by healthcare providers and their patients;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the pricing and cost-effectiveness of our products, as well as the cost of treatment with our products in relation to alternative treatments and therapies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to obtain and maintain sufficient third-party coverage and adequate reimbursement from government healthcare programs, including Medicare and Medicaid, private health insurers and other third-party payors;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">61</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the willingness of patients to pay all, or a portion of, out-of-pocket costs associated with our products in the absence of sufficient third-party coverage and adequate reimbursement;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any restrictions on the use of our products, and the prevalence and severity of any adverse effects;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential product liability claims;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing of market introduction of our products as well as competitive drugs;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the effectiveness of our or any of our current or potential future collaborators&#8217; sales and marketing strategies; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unfavorable publicity relating to the product.</span></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any product candidate is approved but does not achieve an adequate level of acceptance by physicians, hospitals, healthcare payors or patients, we may not generate sufficient revenue from that product and may not become or remain profitable. Our efforts to educate the medical community and third-party payors regarding the benefits of our products may require significant resources and may never be successful.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We currently have no marketing and sales organization and have no experience as a company in commercializing products, and we may have to invest significant resources to develop these capabilities. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our products, we may not be able to generate product revenue.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have no internal sales, marketing or distribution capabilities, nor have we commercialized a product. If any of our product candidates ultimately receives marketing approval, we must build a marketing and sales organization with technical expertise and supporting distribution capabilities to commercialize each such product in major markets, which will be expensive and time consuming, or collaborate with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. We have no prior experience as a company in the marketing, sale and distribution of biopharmaceutical products and there are significant risks involved in building and managing a sales organization, including our ability to hire, retain and incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. We may not be able to enter into collaborations or hire consultants or external service providers to assist us in sales, marketing and distribution functions on acceptable financial terms, or at all. In addition, our product revenues and our profitability, if any, may be lower if we rely on third parties for these functions than if we were to market, sell and distribute any products that we develop ourselves. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we are not successful in commercializing our products, either on our own or through arrangements with one or more third parties, we may not be able to generate any future product revenue and we would incur significant additional losses.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The successful commercialization of our product candidates, if approved, will depend in part on the extent to which governmental authorities and health insurers establish coverage, adequate reimbursement levels and favorable pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our products could limit our ability to market those products and decrease our ability to generate revenue.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adequate coverage and reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers and other third-party payors are essential for most patients to be able to afford prescription medications such as our product candidates, if approved. Our ability to achieve coverage and acceptable</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">62</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">levels of reimbursement for our products by third-party payors will have an effect on our ability to successfully commercialize those products. Moreover, we are initially developing dabogratinib for the treatment of pediatric ACH, NMIBC and LG-UTUC, TYRA-430 for advanced HCC and other solid tumors with activating FGF/FGFR pathway aberrations, and TYRA-200 for FGFR2-driven ICC resistant to previous FGFR inhibitors. Some of these indications target a small patient population. In order for products that are designed to treat smaller patient populations to be commercially viable, the reimbursement for such products must be higher, on a relative basis, to account for the lack of volume. Accordingly, we will need to implement a coverage and reimbursement strategy for any approved product candidate with a smaller patient population that accounts for the smaller potential market size. Even if we obtain coverage for a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization. We cannot be sure that coverage and reimbursement in the United States, the EU or elsewhere will be available for any product that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Obtaining and maintaining reimbursement status is time consuming, costly and uncertain. The Medicare and Medicaid programs increasingly are used as models for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs. However, no uniform policy for coverage and reimbursement for products exists among third-party payors in the United States. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases at short notice, and we believe that changes in these rules and regulations are likely.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third-party payors increasingly are challenging prices charged for biopharmaceutical products and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drugs when an equivalent generic drug or a less expensive therapy is available. It is possible that a third-party payor may consider our products as substitutable and only offer to reimburse patients for the less expensive product. Even if we are successful in demonstrating improved efficacy or improved convenience of administration with our products, pricing of existing drugs may limit the amount we will be able to charge for our products. These payors may deny or revoke the reimbursement status of a given product or establish prices for new or existing marketed products at levels that are too low to enable us to realize an appropriate return on our investment in product development. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our product candidates and may not be able to obtain a satisfactory financial return on products that we may develop, once approved. In addition, in the event that we or third parties develop companion diagnostic tests for use with our product candidates, if approved, such companion diagnostic tests will require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement applicable to pharmaceutical or biological products will apply to companion diagnostics tests.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe and other countries has and will continue to put pressure on the pricing and usage of our products, once approved. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">63</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the amount that we are able to charge for our products. Accordingly, in markets outside the United States, the reimbursement for our products, once approved, may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, increasing efforts by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our products, once approved. We expect to experience pricing pressures in connection with the sale of any of our products due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We face significant competition, and if our competitors develop technologies or product candidates more rapidly than we do or their technologies are more effective, our business and our ability to develop and successfully commercialize products may be adversely affected.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The biotechnology and biopharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary and novel products and product candidates. Our competitors have developed, are developing or may develop products or product candidates competitive with our product candidates. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. We believe that a significant number of products are currently under development, and may become commercially available in the future, for the treatment of conditions for which we may attempt to develop product candidates. In particular, there is intense competition in the precision oncology field. Our competitors include larger and better-funded pharmaceutical, biopharmaceutical, biotechnological and therapeutics companies. Moreover, we may also compete with universities and other research institutions who may be active in the indications we are targeting and could be in direct competition with us. We also compete with these organizations to recruit management, scientists and clinical development personnel, which could negatively affect our level of expertise and our ability to execute our business plan. We will also face competition in establishing clinical trial sites, enrolling patients for clinical trials and in identifying and in-licensing new product candidates. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect to face competition from existing products and products in development for each of our product candidates. There are three currently marketed pan-FGFR inhibitors: Incyte Corporation&#8217;s Pemazyre (pemigatinib), Taiho&#8217;s Lytgobi (futibatinib) approved in FGFR2 gene rearrangements in cholangiocarcinoma, and Janssen Biotech, Inc.&#8217;s Balversa (erdafitinib), approved in specific FGFR3 gene alterations. There are a number of other isoform-specific FGFR inhibitors such as Elevar Therapeutics&#8217; and Relay Therapeutics, Inc.&#8217;s lirafugratinib (RLY-4008), Cogent Biosciences&#8217; CGT4859, TransThera&#8217;s tinengotinib and Lilly&#8217;s Loxo Oncology&#8217;s isoform-selective FGFR3 inhibitor compound, LOXO-435 (LOX-24350). There are currently no approved FGFR4 inhibitors, but there remain a number of FGFR4 programs in clinical development in China, including Abbisko&#8217;s ABSK011. BioMarin Pharmaceutical&#8217;s Voxzogo, a once daily injectable C-natriuretic peptide (CNP) analog and Ascendis&#8217; CNP pro-drug (TransCon CNP) are approved in the United States for children with ACH. There are a number of other experimental therapies in development for ACH, including QED Therapeutics&#8217; low dose pan-FGFR inhibitor (infigratinib).</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of our competitors have significantly greater financial, technical, manufacturing, marketing, sales and supply resources or experience than we do. If we successfully obtain marketing approval for any product candidate, we will face competition based on many different factors, including the safety and effectiveness of our products, the ease with which our products can be administered and the extent to which patients accept relatively</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">64</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">new routes of administration, the timing and scope of marketing approvals for these products, the availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage and patent position. Competing products could present superior treatment alternatives, including by being more effective, safer, more convenient, less expensive or marketed and sold more effectively than any products we may develop. Competitive products or technological approaches may make any products we develop obsolete or noncompetitive before we recover the expense of developing and commercializing our product candidates. If we are unable to compete effectively, our opportunity to generate revenue from the sale of our products we may develop, if approved, could be adversely affected.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If the market opportunities for our product candidates are smaller than we believe they are, our revenue may be adversely affected, and our business may suffer.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The precise incidence and prevalence for all the diseases or conditions we aim to address with our product candidates are unknown. Our projections of both the number of people who have these diseases or conditions, as well as the subset of people with these diseases or conditions who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including the scientific literature, surveys of clinics, patient foundations or market research, and may prove to be incorrect. Further, new trials may change the estimated incidence or prevalence of these indications. The total addressable market across all of our product candidates will ultimately depend upon, among other things, the diagnosis criteria included in the final label for each of our product candidates which receives marketing approval for these indications, the availability of alternative treatments and the safety, convenience, cost and efficacy of our product candidates relative to such alternative treatments, acceptance by the medical community and patient access, drug pricing and reimbursement. The number of patients in the United States and other major markets and elsewhere may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our product candidates or new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect our results of operations and our business. Further, even if we obtain significant market share for our product candidates, because some of our potential target populations are very small, we may never achieve profitability despite obtaining such significant market share.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our future growth may depend, in part, on our ability to develop and commercialize our product candidates in foreign markets. We are not permitted to market or promote any of our product candidates before we receive marketing approval from applicable regulatory authorities in foreign markets, and we may never receive such marketing approvals for any of our product candidates. To obtain separate marketing approval in many other countries we must comply with numerous and varying regulatory requirements regarding safety and efficacy and governing, among other things, clinical trials, commercial sales, pricing and distribution of our product candidates. If we obtain marketing approval of our product candidates and ultimately commercialize our products in foreign markets, we would be subject to additional risks and uncertainties, including:</span></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">different regulatory requirements for approval of drugs in foreign countries;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reduced protection for intellectual property rights;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the existence of additional third-party patent rights of potential relevance to our business;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unexpected changes in tariffs, trade barriers and regulatory requirements;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">economic weakness, including inflation, political instability or war in particular foreign economies and markets;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">65</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">foreign reimbursement, pricing and insurance regimes;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">workforce uncertainty in countries where labor unrest is common;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters including earthquakes, typhoons, floods and fires.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Business Operations and Industry</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our quarterly and annual operating results may fluctuate significantly, which makes it difficult for us to predict our future operating results. These fluctuations may occur due to a variety of factors, many of which are outside of our control, including, but not limited to:</span></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing and cost of, and level of investment in, research, development, marketing approval and commercialization activities relating to our product candidates, which may change from time to time;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">coverage and reimbursement policies with respect to our product candidates, if approved, and potential future drugs that compete with our products;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of manufacturing our product candidates, which may vary depending on the quantity of production and the terms of our agreements with third-party manufacturers;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expenditures that we may incur to acquire, develop or commercialize additional product candidates and technologies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the level of demand for any approved products, which may vary significantly;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">future accounting pronouncements or changes in our accounting policies; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing and success or failure of preclinical studies or clinical trials for our product candidates or competing product candidates, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners.</span></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">66</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">substantially. Such a stock price decline could occur even when we have met any previously publicly stated revenue or earnings guidance we may provide.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are dependent on the services of our management and other clinical and scientific personnel, and if we are not able to retain these individuals or recruit additional management or clinical and scientific personnel, our business will suffer.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our success depends in part on our continued ability to attract, retain, manage and motivate highly qualified management, clinical and scientific personnel. We are highly dependent upon our senior management, as well as our senior scientists and other members of our management team. The loss of services of any of these individuals could delay or prevent the successful development of our product pipeline, initiation or completion of our preclinical studies and clinical trials or the commercialization of our product candidates. Although we have executed employment agreements or offer letters with each member of our senior management team, these agreements are terminable at will with or without notice and, therefore, we may not be able to retain their services as expected. We do not currently maintain &#8220;key person&#8221; life insurance on the lives of our executives or any of our employees. This lack of insurance means that we may not have adequate compensation for the loss of the services of these individuals.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will need to expand and effectively manage our managerial, operational, financial and other resources in order to successfully pursue our clinical development and commercialization efforts. We may not be successful in maintaining our unique company culture and continuing to attract or retain qualified management and scientific and clinical personnel in the future due to the intense competition for qualified personnel among biopharmaceutical, biotechnology and other businesses, particularly in the San Diego County area. Our industry has experienced a high rate of turnover of management personnel in recent years. If we are not able to attract, integrate, retain and motivate necessary personnel to accomplish our business objectives, we may experience constraints that will significantly impede the achievement of our development objectives, our ability to raise additional capital and our ability to implement our business strategy.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We will need to continue to grow the size and capabilities of our organization, and we may experience difficulties in managing this growth.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of February 25, 2026, we had 87 full-time employees , including 67 employees engaged in research and development. In order to successfully implement our development and commercialization plans and strategies, we expect to need to continue to add significant additional managerial, operational, sales, marketing, financial and other personnel. Future growth will impose significant added responsibilities on members of management, including:</span></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">identifying, recruiting, integrating, maintaining, retaining and motivating our current and additional employees;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">managing our internal development efforts effectively, including the preclinical, clinical, the FDA or comparable foreign regulatory authorities&#8217; review process for product candidates, while complying with any contractual obligations to contractors and other third parties;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">managing increasing operational and managerial complexity; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">improving our operational, financial and management controls, reporting systems and procedures.</span></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our future financial performance and our ability to successfully develop and, if approved, commercialize product candidates will depend, in part, on our ability to effectively manage any future growth, and our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">67</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are not able to effectively expand our organization by hiring new employees and/or engaging additional third-party service providers, we may not be able to successfully implement the tasks necessary to further develop and, if approved, commercialize our product candidates and, accordingly, may not achieve our research, development and commercialization goals.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are subject to various federal, state and foreign healthcare laws and regulations, which could increase compliance costs, and our failure to comply with these laws and regulations could harm our results of operations and financial condition.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors and customers expose us to broadly applicable foreign, federal and state fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute any products for which we obtain marketing approval. Such laws include, without limitation:</span></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the federal Anti-Kickback Statute, which is a criminal law that prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or providing any remuneration (including any kickback, bribe or certain rebates), directly or indirectly, overtly or covertly, in cash or in kind, in return for, either the referral of an individual or the purchase, lease, or order, or arranging for or recommending the purchase, lease, or order of any good, facility, item or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the federal Anti- Kickback Statute or specific intent to violate it in order to have committed a violation;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the federal false claims laws, including the civil False Claims Act, and civil monetary penalties laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, to the federal government, claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making or causing to be made a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA) which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to the Centers for Medicare &amp; Medicaid Services (CMS) information related to payments and other &#8220;transfers of value&#8221; made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain non-physician practitioners (physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, anesthesiology assistants and certified nurse-midwives) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; some state laws require biopharmaceutical and biotechnology companies to comply with the industry&#8217;s voluntary compliance </span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">68</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">guidelines and the relevant compliance guidance promulgated by the federal government and may require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; some state laws that require biopharmaceutical and biotechnology companies to report information on the pricing of certain drug products; and some state and local laws require the registration or pharmaceutical sales representatives.</span></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Efforts to ensure that our current and future business arrangements with third parties will comply with applicable healthcare laws and regulations will involve ongoing substantial costs. It is possible that governmental authorities will conclude that our business practices, including certain arrangements with physicians who receive stock or stock options as compensation for services provided to us, may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings and the curtailment or restructuring of our operations. Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. Further, if any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect our business, results of operations, and financial condition.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We, our future collaborators and our service providers may be subject to a variety of privacy and data security laws and contractual obligations, which could increase compliance costs and our failure to comply with them could subject us to potentially significant fines or penalties and otherwise harm our business. We are subject to laws and regulations governing the privacy and security of sensitive information, including confidential business and health-related information. The global data protection landscape is rapidly evolving, and we may be affected by or subject to new, amended or existing laws and regulations in the future, including as our operations continue to expand or if we operate in foreign jurisdictions. These laws and regulations may be subject to differing interpretations, which adds to the complexity of processing personal information. Guidance on implementation and compliance practices are often updated or otherwise revised.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States, there are numerous federal and state privacy and data security laws and regulations governing the collection, use, disclosure and protection of personal information, including health information privacy laws, security breach notification laws and consumer protection laws. Each of these laws is subject to varying interpretations and constantly evolving. By way of example, HIPAA imposes privacy and security requirements and breach reporting obligations with respect to individually identifiable health information upon &#8220;covered entities&#8221; (health plans, health care clearinghouses and certain health care providers), and their respective business associates, individuals or entities that create, received, maintain or transmit protected health information in connection with providing a service for or on behalf of a covered entity, as well as their covered subcontractors. While we do not believe that we are currently acting as a covered entity or business associate under HIPAA and thus are not directly regulated under HIPAA, any person may be prosecuted under HIPAA&#8217;s criminal provisions either directly or under aiding-and-abetting or conspiracy principles. Consequently, depending on the facts and circumstances, we could be subject to significant penalties if we knowingly receive individually identifiable health information from a HIPAA-covered healthcare provider or research institution that has not satisfied HIPAA&#8217;s requirements for disclosure of individually identifiable health information.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">69</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, certain state laws and regulations govern the privacy, processing and security of health-related and other personal information in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. By way of example, the California Consumer Privacy Act, as amended by the California Privacy Rights Act (collectively, the CCPA) requires covered businesses that process the personal information of California residents to, among other things: (i) provide certain disclosures to California residents regarding the business&#8217;s collection, use, and disclosure of their personal information; (ii) receive and respond to requests from California residents to access, delete, and correct their personal information, or to opt out of certain disclosures of their personal information; and (iii) enter into specific contractual provisions with service providers that process California resident personal information on the business&#8217;s behalf. Additional compliance investment and potential business process changes may be required. Similar laws have passed in other states, reflecting a trend toward more stringent privacy legislation in the United States. The enactment of such laws could have potentially conflicting requirements that would make compliance challenging. In the event that we are subject to or affected by HIPAA, the CCPA or other domestic privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our operations abroad may also be subject to increased scrutiny or attention from data protection authorities. For example, in Europe, we are subject to the European Union General Data Protection Regulation, (EU GDPR) and to the United Kingdom General Data Protection Regulation and Data Protection Act 2018 (collectively, the UK GDPR) (the EU GDPR and UK GDPR together referred to as the GDPR). Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to &#8364;20 million / &#163;17.5 million or 4% of the annual global revenues of the noncompliant company, whichever is greater. Among other requirements, the GDPR regulates transfers of personal data subject to the GDPR to third countries that have not been found to provide adequate protection to such personal data, including the United States, and the efficacy and longevity of current transfer mechanisms between the EEA, and the United States remains uncertain. Case law from the Court of Justice of the European Union (CJEU) states that reliance on the standard contractual clauses - a standard form of contract approved by the European Commission as an adequate personal data transfer mechanism alone may not necessarily be sufficient in all circumstances and that transfers must be assessed on a case-by-case basis. We expect the existing legal complexity and uncertainty regarding international personal data transfers to continue, and international transfers to the United States and to other jurisdictions more generally to continue to be subject to enhanced scrutiny by regulators. As the regulatory guidance and enforcement landscape in relation to data transfers continue to develop, we could suffer additional costs, complaints and/or regulatory investigations or fines, and/or if we are otherwise unable to transfer personal data between and among countries and regions in which we operate, it could affect the manner in which we provide our services, the geographical location or segregation of our relevant systems and operations, and could adversely affect our financial results.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As we continue to expand into other foreign countries and jurisdictions, we may be subject to additional laws and regulations that may affect how we conduct business.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we work to comply with applicable laws, regulations and standards, our contractual obligations and other legal obligations, these requirements are evolving and may be modified, interpreted and applied in an inconsistent manner from one jurisdiction to another, and may conflict with one another or other legal obligations with which we must comply. Any failure or perceived failure by us or our employees, representatives, contractors, consultants, collaborators, or other third parties to comply with such requirements or adequately address privacy and security concerns, even if unfounded, could result in additional cost and liability to us, damage our reputation, and adversely affect our business and results of operations.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">70</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently enacted legislation, future legislation and healthcare reform measures may increase the difficulty and cost for us to obtain marketing approval for and commercialize our product candidates and may affect the prices we may set.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States and some foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system, including cost-containment measures that may reduce or limit coverage and reimbursement for newly approved drugs and affect our ability to profitably sell any product candidates for which we obtain marketing approval. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, the Affordable Care Act (ACA) was enacted in the United States in 2010. Among the provisions of the ACA of importance to our potential product candidates, the ACA: established an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents; extended manufacturers&#8217; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; expanded the entities eligible for discounts under the 340B drug pricing program; increased the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program; and established a Center for Medicare and Medicaid Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending. Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. The Budget Control Act of 2011, among other things, reduced Medicare payments to providers, which went into effect on April 1, 2013 and will remain in effect until 2032, unless additional Congressional action is taken. The American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, there has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs. Such scrutiny has resulted in several recent congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Inflation Reduction Act of 2022 (IRA) was enacted in 2022. The IRA marks the most significant action by Congress with respect to the pharmaceutical industry since adoption of the ACA in 2010. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare, with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); redesigns the Medicare Part D benefit (beginning in 2024); and replaces the Part D coverage gap discount program with a new manufacturer discount program (beginning in 2025). The Centers for Medicare &amp; Medicaid Services has published the negotiated prices for the initial ten drugs, which went into effect in January 2026, and the subsequent 15 drugs, which will first be effective in 2027. The Centers for Medicare &amp; Medicaid Services has also published the next set of 15 drugs that will be subject to negotiation. The IRA permits the Secretary of the Department of Health and Human Services (HHS) to implement many of these provisions through guidance, as opposed to regulation, for the initial years. HHS has and will continue to issue and update guidance as these programs are implemented, although the Medicare drug price negotiation program is currently subject to legal challenges. The impact of the IRA on us and the pharmaceutical industry cannot yet be fully determined but is likely to be significant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">71</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">More recently, the One Big Beautiful Bill Act, which was enacted in July 2025, imposes significant reductions in the funding of the Medicaid program. Such reductions are expected to decrease the number of persons enrolled in Medicaid and reduce the services covered by Medicaid, which could adversely affect our sales of any product candidate that we commercialize.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Trump administration is pursuing a two-fold strategy to reduce drug costs in the United States. While it is unclear whether and how the Trump proposals will be implemented, the Trump policies are likely to have a negative impact on the pharmaceutical industry and on our ability to receive adequate revenues for any product candidate that we commercialize. On the one hand, President Trump has threatened to impose significant tariffs on pharmaceutical manufacturers that do not adopt pricing policies such as most favored nation pricing, which would tie the price for drugs in the United States to the lowest price in a group of other countries. In response, multiple manufacturers have entered into confidential pricing agreements with the federal government. On the other hand, the Trump administration is pursuing traditional regulatory pathways to impose drug pricing policies and published two proposed regulations in December 2025, referred to as Globe and Guard. If finalized, these regulations would implement mandatory payment models under which manufacturers of eligible drugs would be required to pay rebates to the federal government on a portion of the units of their drugs that are reimbursed by Medicare, with the rebate amount based on most favored nation pricing. Imposing a rebate in the United States that is based on drug prices outside the United States would mark a drastic and unprecedented shift in the U.S. pharmaceutical market, and while the impact of the Globe and Guard proposed regulations, if finalized, cannot yet be determined, it is likely to be significant. Even regulatory proposals or executive actions that are ultimately deemed unlawful could negatively impact the U.S. pharmaceutical sector and our business. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access, marketing cost disclosure, drug price reporting and other transparency measures. Some states have enacted legislation creating so-called prescription drug affordability boards with the goal of imposing price limits on certain drugs in these states, and at least one state board is imposing an upper payment limit. States are also seeking to implement general, across the board price caps for pharmaceuticals, or are seeking to regulate drug distribution. Some measures are designed to encourage importation from other countries. These types of initiatives may result in additional reductions in Medicare, Medicaid, and other healthcare funding, and may otherwise affect the prices we may obtain for our product candidates, if approved. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our product candidates, if approved, or put pressure on our product pricing, which could negatively affect our business, results of operations, financial condition and prospects.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect that these new laws and other healthcare reform measures that may be adopted in the future may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare and other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our product candidates, if approved.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We and any of our third-party manufacturers or suppliers may use potent chemical agents and hazardous materials, and any claims relating to improper handling, storage or disposal of these materials could be time consuming or costly.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We and any of our third-party suppliers and potential future collaborators will use biological materials, potent chemical agents and may use hazardous materials, including chemicals and biological agents and compounds</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">72</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that could be dangerous to human health and safety of the environment. Our operations and the operations of our third-party manufacturers and suppliers also produce hazardous waste products. Federal, state and local laws and regulations govern the use, generation, manufacture, storage, handling and disposal of these materials and wastes. Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our product development efforts. In addition, we cannot eliminate the risk of accidental injury or contamination from these materials or wastes. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. In the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or marketing approvals could be suspended.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we maintain workers&#8217; compensation insurance for certain costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials or other work-related injuries, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for toxic tort claims that may be asserted against us in connection with our storage or disposal of biologic, hazardous or radioactive materials.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations, which may become more stringent over time. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions or liabilities, which could materially adversely affect our business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our products.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We face an inherent risk of product liability as a result of the clinical trials of our product candidates and will face an even greater risk if we commercialize our product candidates. For example, we may be sued if our product candidates allegedly cause injury or are found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product candidate, negligence, strict liability and a breach of warranties. Claims may be brought against us by clinical trial participants, patients or others using, administering or selling products that may be approved in the future. Claims could also be asserted under state consumer protection acts.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit or cease the commercialization of our products. Even a successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">decreased demand for our products, if approved;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">injury to our reputation and significant negative media attention;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">withdrawal of clinical trial participants;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs to defend the related litigation;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a diversion of our management&#8217;s time and our resources;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">substantial monetary awards to trial participants or patients;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">73</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significant negative financial impact;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the inability to commercialize our product candidates; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a decline in our stock price.</span></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently hold $10 million of product liability insurance coverage. We may need to increase our insurance coverage as we initiate additional clinical trials or if we commence commercialization of our product candidates, if ever. Insurance coverage is increasingly expensive. Our inability to obtain and retain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of our product candidates. Although we maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies will also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our insurance policies are expensive and only protect us from some business risks, which will leave us exposed to significant uninsured liabilities.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not carry insurance for all categories of risk that our business may encounter, including product liability insurance. Some of the policies we currently maintain include property, general liability, employment benefits liability, business automobile workers&#8217; compensation, directors&#8217; and officers&#8217;, employment practices and fiduciary liability insurance. We do not know, however, if we will be able to maintain insurance with adequate levels of coverage. Any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our financial position and results of operations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We and any of our potential future collaborators will be required to report to regulatory authorities if any of our product candidates or approved products in clinical trials cause or contribute to certain adverse medical events, and any failure to do so would result in sanctions that would materially harm our business.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA or comparable foreign regulatory authorities would require that we and potential future collaborators report certain information about adverse medical events relating to any product that is approved or product candidate in clinical trials. The timing of our obligation to report would be triggered by the date we become aware of the adverse event as well as the nature of the event. We and any of our potential future collaborators or CROs may fail to report adverse events within the prescribed timeframe. If we or any of our potential future collaborators or CROs fail to comply with such reporting obligations, the FDA or a comparable foreign regulatory authority could take action, including criminal prosecution, the imposition of civil monetary penalties, seizure of our products or delay in approval or clearance of future products.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our information technology systems, or those of any of our CROs, other contractors or consultants or potential future collaborators, may fail or suffer security breaches, which could result in a material disruption of our product development programs, harm our reputation, significant fines, penalties and liability and loss of customers or sales.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the ordinary course of business, we collect, store, transmit and otherwise process large amounts of confidential information including, without limitation, intellectual property, proprietary business information, preclinical and clinical trial data, health-related information and personal information (collectively, Confidential</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">74</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information). We face evolving cybersecurity risks that threaten the confidentiality, integrity and availability of our information technology systems and Confidential Information. Despite the implementation of security measures, our information technology systems (including infrastructure) and those of our current and any future CROs and other contractors, consultants and collaborators are vulnerable to attack, damage or interruption from diverse threat actors, such as state-sponsored organizations, opportunistic hackers and hacktivists, as well as through diverse attack vectors, including computer viruses and malware (e.g. ransomware), malicious code, denial-of-service attacks, cyberattacks or cyber-intrusions over the Internet, phishing and other social engineering attacks, misconfigurations, &#8220;bugs&#8221; or other vulnerabilities, fraud, unauthorized access or use, natural disasters, terrorism, war, and telecommunication and electrical failures. Our systems are also subject to compromise from internal threats, such as theft, misuse, unauthorized access or other improper or accidental actions by employees, vendors and other third parties with otherwise legitimate access to our systems. Third parties may also attempt to fraudulently induce our employees and contractors into disclosing sensitive information such as usernames, passwords or other information, or otherwise compromise the security of our electronic systems, networks, and/ or physical facilities in order to gain access to our data.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cyberattacks are expected to accelerate on a global basis in frequency and magnitude as threat actors are becoming increasingly sophisticated in using techniques and tools &#8211; including artificial intelligence &#8211; that circumvent security controls, evade detection and remove forensic evidence. As a result, we may be unable to detect, investigate, remediate or recover from future attacks or incidents, or to avoid a material adverse impact to our information technology systems, Confidential Information or business. Given the unpredictability of the timing, nature and scope of information technology disruptions, there can be no assurance that our or our third-party partners&#8217; and service providers&#8217; cybersecurity risk management programs and processes, including any related policies, controls or procedures, will be fully implemented, complied with or effective in protecting our information technology systems and Confidential Information. The latency of a cyberattack is often measured in months, but could be years, and we may not be able to detect such a compromise in a timely manner. New techniques may not be identified until they are launched against a target, and we may be unable to anticipate these techniques or detect an incident, assess its severity or impact, react or appropriately respond in a timely manner or implement adequate preventative measures, resulting in potential data loss or other damage to our information technology systems.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We and certain of our service providers are from time to time subject to cyberattacks and security incidents.</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While we do not believe that we have experienced any significant system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our or our third party service provider&#8217;s operations or result in the unauthorized disclosure of or access to Confidential Information (violating certain privacy laws such as the GDPR), it could result in a material disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other similar disruptions. Some of the federal, state and foreign government requirements include obligations of companies to notify individuals, governmental authorities, supervisory bodies, the media and other parties of security breaches involving particular personally identifiable information, which could result from breaches experienced by us or by our vendors, contractors, or organizations with which we have formed strategic relationships. Also, due to the continued hybrid working environment, many of our employees are working remotely. As a result, we may have increased cyber security and data security risks, due to increased use of home wi-fi networks and virtual private networks, as well as increased disbursement of physical machines. While we implement information technology controls to reduce the risk of a cyber security or data security breach, there is no guarantee that these measures will be adequate to safeguard all systems, especially with an increased number of employees working remotely. Furthermore, any integration of artificial intelligence in our or any third party&#8217;s operations, products or services is expected to pose new or unknown cybersecurity risks and challenges.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any security breach or other incident, whether real or perceived, could impact our reputation, impact the availability, integrity or confidentiality of our data, result in legal claims or proceedings (such as class actions), harm customer confidence, hurt our expansion into new markets, cause us to incur remediation costs or cause us to lose existing customers. For example, the loss of clinical trial data from clinical trials could result in delays in our</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">75</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">marketing approval efforts and significantly increase our costs to recover or reproduce the data. We also rely on third parties to manufacture our product candidates, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any real or perceived disruption or security breach affects our systems (or those of our third-party collaborators, service providers, contractors or consultants) or were to result in a loss of or accidental, unlawful or unauthorized access to, use of, release of, or other processing of Confidential Information, or damage to, our data or applications, or inappropriate disclosure of Confidential Information, we could incur liability, the further development and commercialization of our product candidates could be delayed, and we could be subject to significant incident response, system restoration or remediation and future compliance costs, as well as significant fines, penalties or liabilities for any noncompliance to certain privacy and security laws. We maintain cyber liability insurance; however, this insurance may not be sufficient to cover the financial, legal, business or reputational losses that may result from an interruption or breach of our systems.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our business could be affected by litigation, government investigations and enforcement actions.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We operate in a highly regulated industry and we could be subject to litigation, government investigation and enforcement actions on a variety of matters in the United States or foreign jurisdictions, including, without limitation, intellectual property, regulatory, product liability, environmental, whistleblower, false claims, privacy, anti-kickback, anti-bribery, securities, commercial, employment and other claims and legal proceedings which may arise from conducting our business. Any determination that our operations or activities are not in compliance with existing laws or regulations could result in the imposition of fines, civil and criminal penalties, product seizure, equitable remedies, including disgorgement, injunctive relief and/or other sanctions against us, and remediation of any such findings could have an adverse effect on our business operations.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Legal proceedings, government investigations and enforcement actions can be expensive and time consuming. An adverse outcome resulting from any such proceeding, investigations or enforcement actions could result in significant damages awards, fines, penalties, exclusion from the federal healthcare programs, healthcare or regulatory debarment, injunctive relief, product recalls, reputational damage and modifications of our business practices, which could have a material adverse effect on our business and results of operations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our employees and independent contractors, including principal investigators, CROs, consultants and vendors, may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are exposed to the risk that our employees and independent contractors, including principal investigators, CROs, consultants and vendors may engage in misconduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violate: (i) the laws and regulations of the FDA and other similar regulatory requirements, including those laws that require the recording and reporting of true, complete and accurate information to such authorities, (ii) manufacturing standards, including cGMP requirements or similar foreign requirements, (iii) federal and state data privacy, security, fraud and abuse and other healthcare laws and regulations in the United States and abroad or (iv) laws that require the true, complete and accurate reporting of financial information or data. Activities subject to these laws also involve the improper use or misrepresentation of information obtained in the course of clinical trials, the creation of fraudulent data in our preclinical studies or clinical trials or illegal misappropriation of drug product, which could result in regulatory consequences or sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. In addition, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">76</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">financial results, including, without limitation, the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, imprisonment, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may engage in strategic transactions that could impact our liquidity, increase our expenses and present significant distractions to our management.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may consider strategic transactions, such as acquisitions of companies, asset purchases and out-licensing or in-licensing of intellectual property, products or technologies. Additional potential transactions that we may consider in the future include a variety of business arrangements, including spin-offs, strategic partnerships, joint ventures, restructurings, divestitures, business combinations and investments. Any future transactions could increase our near and long-term expenditures, result in potentially dilutive issuances of our equity securities, including our common stock, or the incurrence of debt, contingent liabilities, amortization expenses or acquired in-process research and development expenses, any of which could affect our financial condition, liquidity and results of operations. Future acquisitions may also require us to obtain additional financing, which may not be available on favorable terms or at all. These transactions may never be successful and may require significant time and attention of our management. In addition, the integration of any business that we may acquire in the future may disrupt our existing business and may be a complex, risky and costly endeavor for which we may never realize the full benefits of the acquisition. Accordingly, although there can be no assurance that we will undertake or successfully complete any additional transactions of the nature described above, any additional transactions that we do complete could have a material adverse effect on our business, results of operations, financial condition and prospects.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Unstable market and economic conditions and adverse developments with respect to financial institutions and associated liquidity risk may have serious adverse consequences on our business, financial condition and stock price.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, the global credit and financial markets have experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability, including changes related to the U.S. and foreign governments in tariffs and trade policies affecting trade between the United States and other countries. The financial markets and the global economy may also be adversely affected by the current or anticipated impact of military conflict, terrorism or other geopolitical events. Sanctions imposed by the United States and other countries in response to such conflicts may also adversely impact the financial markets and the global economy, and any economic countermeasures by affected countries and others could exacerbate market and economic instability. In addition, in 2023 the closures of financial institutions and their placement into receivership with the FDIC created bank-specific and broader financial institution liquidity risk and concerns. Future adverse developments with respect to specific financial institutions or the broader financial services industry may lead to market-wide liquidity shortages, impair the ability of companies to access near-term working capital needs, and create additional market and economic uncertainty. There can be no assurance that future credit and financial market instability and a deterioration in confidence in economic conditions will not occur. Our general business strategy may be adversely affected by any such economic downturn, liquidity shortages, volatile business environment, changes in tariffs and trade policies or continued unpredictable and unstable market conditions. If the equity and credit markets deteriorate, or if adverse developments are experienced by financial institutions, it may cause short-term liquidity risk and also make any necessary debt or equity financing more difficult, more costly, more onerous with respect to financial and operating covenants and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">77</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">financial performance and stock price and could require us to delay or abandon clinical development plans. In addition, there is a risk that one or more of our current service providers, financial institutions, manufacturers and other partners may be adversely affected by the foregoing risks, which could directly affect our ability to attain our operating goals on schedule and on budget.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in tax law may materially adversely affect our financial condition, results of operations and cash flows.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, or interpreted, changed, modified or applied adversely to us, any of which could adversely affect our business operations and financial performance. The likelihood of specific changes in tax law being enacted or implemented is unclear. We are currently unable to predict whether such changes will occur. If such changes are enacted or implemented, we are currently unable to predict the ultimate impact on our business. We urge our investors to consult with their legal and tax advisors with respect to any changes in tax law and the potential tax consequences of investing in our common stock.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our ability to use net operating loss carryforwards and other tax attributes may be limited.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have incurred substantial losses during our history, do not expect to become profitable in the near future and may never achieve profitability. To the extent that we continue to generate net operating losses (NOLs), such NOLs will carry forward and, subject to limitations, offset future taxable income, if any, until such unused NOL carryforwards expire (if subject to expiration). At December 31, 2025, we had U.S. federal and state NOL carryforwards of approximately $188.7 million and $67.3 million, respectively.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">U.S. federal NOLs generated in periods after December 31, 2017 may be carried forward indefinitely but may only be used to offset 80% of our taxable income in years beginning after December 31, 2020.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our NOL carryforwards and other tax attributes are subject to review and possible adjustment by the U.S. Internal Revenue Service and state tax authorities. Under Section 382 of the U.S. Internal Revenue Code of 1986, as amended (the Code), our U.S. federal NOL carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership of our company. An &#8220;ownership change&#8221; pursuant to Section 382 of the Code generally occurs if one or more stockholders or groups of stockholders who own at least 5% of a company&#8217;s stock increase their ownership by more than 50 percentage points over their lowest ownership percentage within a rolling three-year period. Our ability to utilize our NOL carryforwards and other tax attributes to offset future taxable income or tax liabilities may be limited as a result of ownership changes, including potential changes in connection with our initial public offering (IPO) or any other offerings. Similar rules may apply under state tax laws. We have not yet determined the amount of the cumulative change in our ownership resulting from our IPO or other transactions, or any resulting limitations on our ability to utilize our NOL carryforwards and other tax attributes. If we earn taxable income, such limitations could result in increased future income tax liability to us and our future cash flows could be adversely affected. We have recorded a full valuation allowance related to our NOL carryforwards and other deferred tax assets due to the uncertainty of the ultimate realization of the future benefits of those assets.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Intellectual Property</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to obtain and maintain patent protection for our product candidates and other proprietary technologies we develop, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">78</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">to successfully commercialize our product candidates and other proprietary technologies we may develop may be adversely affected.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our product candidates and other proprietary technologies we may develop as well as our ability to operate without infringing upon the proprietary rights of others. We seek to protect our proprietary position, in part, by filing patent applications in the United States and abroad relating to our product candidates and other proprietary technologies we may develop. If we are unable to obtain or maintain patent protection with respect to our product candidates and other proprietary technologies we may develop, our business, financial condition, results of operations and prospects could be materially harmed.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in either the patent laws or their interpretation in the United States and other countries may diminish our ability to protect our inventions, obtain, maintain and enforce our intellectual property rights and, more generally, could affect the value of our intellectual property or narrow the scope of our protection. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any of our issued patents will provide sufficient protection against competitors or other third parties.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The patent prosecution process is expensive, time-consuming, and complex, and we may not be able to file, prosecute, maintain, enforce, or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output in time to obtain patent protection. Although we enter into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, CROs, consultants, advisors and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. In addition, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our inventions and the prior art allow our inventions to be patentable over the prior art. Furthermore, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in any of our pending patent applications, or that we were the first to file for patent protection of such inventions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The patent position of biopharmaceutical and biotechnology companies generally is highly uncertain, involves complex legal and factual questions and has been the subject of much litigation in recent years. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our patent applications may not result in patents being issued which protect our product candidates and other proprietary technologies we may develop or which effectively prevent others from commercializing competitive technologies and products.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, the claim coverage in a patent application can be significantly reduced before the patent is granted. Even if they issue, our pending patent applications may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us or otherwise provide us with any competitive advantage, and patents issuing from our patent applications may be challenged, narrowed, circumvented or invalidated by third parties. Consequently, we do not know whether our product candidates and other proprietary technology will be protectable or remain protected by valid and enforceable patents. Our competitors or other third parties may be able to circumvent our existing patent or patents issuing from our patent applications by developing similar or alternative technologies or products in a non-infringing manner which could materially adversely affect our business, financial condition, results of operations and prospects. In addition, given the amount of time required for the development, testing and regulatory review of our product candidates, patents protecting the product candidates might expire before or shortly after such product candidates are commercialized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">79</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The issuance of a patent is not conclusive as to its inventorship, scope, validity, or enforceability and our patents may be challenged in the courts or patent offices in the United States and abroad. We may be subject to a third-party pre-issuance submission of prior art to the United States Patent and Trademark Office (USPTO) or become involved in opposition, derivation, revocation, reexamination, post- grant and inter partes review, or other similar proceedings challenging our patent rights. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate or render unenforceable, our patent rights, allow third parties to commercialize our product candidates and other proprietary technologies we may develop and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. Such proceedings also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Substantive examination is just beginning on our pending patent applications, which makes it difficult to forecast the extent of any future patent right.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot be certain that the claims in our U.S. pending patent applications or corresponding international patent applications, or patent applications in certain foreign territories, will be considered patentable by the USPTO. Patent claims are subject to revision during prosecution and pending patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless, and until, patents issue from such applications, and then only to the extent the issued claims cover the third party&#8217;s technology. There can be no assurance that our patent applications will result in patents being issued or that issued patents will afford sufficient protection against competitors with similar technology. For example, examiners at a patent office may uncover prior art of which we were not previously aware, and if this cited prior art encompasses our claimed inventions, it may restrict patentability or prevent allowance of any pending patent claims. Furthermore, the patent prosecution process is expensive, time-consuming, and often a multi-year process. We and any future licensors may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner or in all jurisdictions where protection may be commercially advantageous. Therefore, we cannot be certain that we will own any issued patents or develop a patent portfolio, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be able to protect our intellectual property and proprietary rights throughout the world.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Filing, prosecuting and defending patents on our product candidates and other proprietary technologies we may develop in all countries throughout the world would be prohibitively expensive, and the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection but enforcement is not as strong as that in the United States. These products may compete with our product candidates, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology and pharmaceutical products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our intellectual property and proprietary rights</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">80</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">generally. In India, unlike the United States, there is no link between regulatory approval for a drug and its patent status. In addition, some jurisdictions, such as Europe, Japan and China, may have a higher standard for patentability than in the United States, including, for example, the requirement of claims having literal support in the original patent filing and the limitation on using supporting data that is not in the original patent filing. Under those heightened patentability requirements, we may not be able to obtain sufficient patent protection in certain jurisdictions even though the same or similar patent protection can be secured in U.S. and other jurisdictions.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, geo-political actions in the United States and in foreign countries could increase the uncertainties and costs surrounding the prosecution or maintenance of our patent applications or those of any current or future licensors and the maintenance, enforcement or defense of future issued patents or those of any future licensors. For example, the United States and foreign government actions related to Russia&#8217;s war with Ukraine may limit or prevent filing, prosecution, and maintenance of patent applications in Russia. Government actions may also prevent maintenance of issued patents in Russia. In addition, a decree was adopted by the Russian government in March 2022, allowing Russian companies and individuals to exploit inventions owned by patentees from the United States without consent or compensation. Consequently, we would not be able to prevent third parties from practicing our inventions in Russia or from selling or importing products made using our inventions in and into Russia. Accordingly, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, a Unitary Patent and Unified Patent Court (UPC) system was implemented in Europe on June 1, 2023, which has become a common forum for challenging patents in the pharmaceutical space. This new regime may present uncertainties for our ability to protect and enforce our patent rights against competitors in Europe. Under the UPC, all European patents, including those issued prior to ratification of the European Patent Package, will automatically fall under the jurisdiction of the UPC. The UPC provides our competitors with a new forum to centrally revoke our European patents, and allows for the possibility of a competitor to obtain pan-European injunctions. It will be several years before we will understand the scope of patent rights that will be recognized and the strength of patent remedies that will be provided by the UPC. Under the EU Patent Package, we will have the right to opt our patents out of the UPC over the first seven years of the court&#8217;s existence, but doing so may preclude us from realizing the benefits of the new unified court.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">81</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Periodic maintenance fees, renewal fees, annuity fees, and various other government fees on patents and applications will be due to be paid to the USPTO and various government patent agencies outside of the United States over the lifetime of our patents and applications. The USPTO and various non-U.S. government agencies require compliance with several procedural, documentary, fee payment and other similar provisions during the patent application process. In some cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in a partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market with similar or identical products or technology, which could have a material adverse effect on our business, financial condition, results of operations, and prospects. In addition, there could be delays at the USPTO caused by staffing cuts and other U.S. government actions as a result of the U.S. Department of Government Efficiency or other executive actions to reduce the size of the U.S. government.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. Since March 2013, under the Leahy-Smith America Invents Act (the America Invents Act) enacted in September 2011, the United States transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. A third party that files a patent application in the USPTO after March 2013, but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we were the first to either (i) file any patent application related to our product candidates and other proprietary technologies we may develop or (ii) invent any of the inventions claimed in our patent applications. There remains many subsisting issued patents and some pending patent applications in the U.S. that were filed prior to enactment of the America Invents Act, and are therefore subject to the pre-America Invents Act U.S. patent laws, which may have relevance to our freedom-to-operate or ability to obtain patent issuances.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The America Invents Act also includes a number of significant changes that affect the way patent applications will be prosecuted and also may affect patent litigation. These include allowing third party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, inter partes review and derivation proceedings. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Therefore, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of patents issuing from those patent applications, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">82</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. For example, the scope of patentable subject matter under 35 U.S.C. &#167; 101 has evolved significantly over the past several years as the Court of Appeals for the Federal Circuit and the Supreme Court issued various opinions, and the USPTO modified its guidance for practitioners on multiple occasions. This combination of events has created uncertainty with respect to the validity and enforceability of patents, once obtained. Depending on future actions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our ability to protect and enforce our intellectual property in the future.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Issued patents relating to our product candidates and other proprietary technologies we may develop could be found invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we initiated legal proceedings against a third party to enforce a patent relating to our product candidates and other proprietary technologies we may develop, the defendant could counterclaim that such patent is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Third parties may raise claims challenging the validity or enforceability of a patent before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post-grant review, inter partes review, derivation proceedings, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in the revocation of, cancellation of or amendment to our patents in such a way that they no longer cover our product candidates and other proprietary technologies we may develop. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we or our licensing partners and the patent examiner were unaware during prosecution. If a third party were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates and other proprietary technologies we may develop. Such a loss of patent protection would have a material adverse impact on our business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited, and once the patent life has expired, we may be open to competition from competitive products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we do not obtain patent term extension for our product candidates, our business may be materially harmed.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depending upon the timing, duration and specifics of any FDA marketing approval of any product candidate we may develop, one or more of our patents or patents issuing from our U.S. patent applications may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Action of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">83</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1984 (the Hatch-Waxman Amendments). The Hatch-Waxman Amendments permit a patent extension term (PTE) of up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it or a method for manufacturing it may be extended. Similar patent term restoration provisions to compensate for commercialization delay caused by regulatory review are also available in certain foreign jurisdictions, such as in Europe under Supplemental Protection Certificate (SPC). If we encounter delays in our development efforts, including any clinical trials, the period of time during which we could market any future product candidates under patent protection would be reduced. Additionally, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents, or otherwise fail to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or restoration, or the term of any such extension is less than we request, the period during which we will have the right to exclusively market our product will be shortened and our competitors may obtain approval of competing products following our patent expiration, and our revenue could be reduced.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be subject to claims challenging the inventorship of our patents and other intellectual property.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may be subject to claims that former employees, collaborators or other third parties have an interest in our patent rights, trade secrets, or other intellectual property as an inventor or co-inventor. For example, we may have inventorship disputes arise from conflicting obligations of consultants or others who are involved in developing our product candidates and other proprietary technologies we may develop. Litigation may be necessary to defend against these and other claims challenging inventorship or our patent rights, trade secrets or other intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our product candidates and other proprietary technologies we may develop. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to our management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to seeking patent protection for our product candidates and other proprietary technologies we may develop, we also rely on trade secrets and confidentiality agreements to protect our unpatented know-how, technology, and other proprietary information and to maintain our competitive position. With respect to our development programs, we consider trade secrets and know-how to be one of our important sources of intellectual property, including our extensive knowledge of crystallography structure-based drug design. Trade secrets and know-how can be difficult to protect. In particular, the trade secrets and know-how in connection with our development programs and other proprietary technology we may develop may over time be disseminated within the industry through independent development, the publication of journal articles describing the methodology and the movement of personnel with scientific positions in academic and industry.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We seek to protect these trade secrets and other proprietary technology, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, CROs, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. We cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">84</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third party, our competitive position would be materially and adversely harmed.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may be subject to claims that third parties have an ownership interest in our trade secrets. For example, we may have disputes arise from conflicting obligations of our employees, consultants or others who are involved in developing our product candidate. Litigation may be necessary to defend against these and other claims challenging ownership of our trade secrets. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable trade secret rights, such as exclusive ownership of, or right to use, trade secrets that are important to our product candidates and other proprietary technologies we may develop. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to our management and other employees. We may need to share our proprietary information, including trade secrets, with our current and future business partners, collaborators, contractors and others located in countries at heightened risk of theft of trade secrets, including through direct intrusion by private parties or foreign actors, and those affiliated with or controlled by state actors. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be successful in obtaining necessary rights to any product candidate we may develop through acquisitions and in-licenses.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently solely own intellectual property covering our product candidates. Other pharmaceutical companies and academic institutions may also have filed or are planning to file patent applications potentially relevant to our business. In order to avoid infringing these third-party patents, we may find it necessary or prudent to obtain licenses to such patents from such third-party intellectual property holders. However, we may be unable to secure such licenses or otherwise acquire or in-license any compositions, methods of use, processes or other intellectual property rights from third parties that we identify as necessary for our product candidates and other proprietary technologies we may develop. The licensing or acquisition of third-party intellectual property rights is a competitive area, and several more established companies may pursue strategies to license or acquire third party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program or product candidate, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be subject to claims that our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Some of our employees, consultants and advisors are currently or were previously employed at universities or other biopharmaceutical or biotechnology companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these individuals have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer. Litigation may be necessary to defend against these claims. If we fail in defending any</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">85</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to our management.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Third-party claims of intellectual property infringement, misappropriation or other violations against us or our collaborators may prevent or delay the development and commercialization of our product candidates and other proprietary technologies we may develop.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our commercial success depends in part on our ability to avoid infringing, misappropriating and otherwise violating the patents and other intellectual property rights of third parties. There is a substantial amount of complex litigation involving patents and other intellectual property rights in the biopharmaceutical and biotechnology industries, as well as administrative proceedings for challenging patents, including derivation and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. As discussed above, as a result of the America Invests Act, procedures including inter partes review and post-grant review have been implemented. The America Invents Act adds uncertainty to the possibility of challenge to our patents in the future.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Numerous U.S. and foreign issued patents and pending patent applications owned by third parties exist in the fields in which we are commercializing or plan to commercialize our product candidates and in which we are developing other proprietary technologies. As the biopharmaceutical and biotechnology industries expand and more patents are issued, the risk increases that our product candidates and commercializing activities may give rise to claims of infringement of the patent rights of others. We cannot assure you that our product candidates and other proprietary technologies we may develop will not infringe existing or future patents owned by third parties. We may not be aware of patents that have already been issued and that a third party, for example, a competitor in the fields in which we are developing our product candidates, might assert as infringed by us. It is also possible that patents owned by third parties of which we are aware, but which we do not believe we infringe or that we believe we have valid defenses to any claims of patent infringement, could be found to be infringed by us. It is not unusual that corresponding patents issued in different countries have different scopes of coverage, such that in one country a third-party patent does not pose a material risk, but in another country, the corresponding third-party patent may pose a material risk to our planned products. As such, patents owned by third parties of which we are aware are monitored in the relevant pharmaceutical markets. In addition, because patent applications can take many years to issue and may be confidential for 18 months or more after filing, there may be currently pending patent applications that may later result in issued patents that we may infringe.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event that any third party claims that we infringe their patents or that we are otherwise employing their proprietary technology without authorization and initiates litigation against us, even if we believe such claims are without merit, a court of competent jurisdiction could hold that such patents are valid, enforceable and infringed by us. In this case, the holders of such patents may be able to block our ability to commercialize the infringing products or technologies unless we obtain a license under the applicable patents, or until such patents expire or are finally determined to be held invalid or unenforceable. Such a license may not be available on commercially reasonable terms or at all. Even if we are able to obtain a license, the license would likely obligate us to pay license</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">86</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fees or royalties or both, and the rights granted to us might be nonexclusive, which could result in our competitors gaining access to the same intellectual property. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, we may be unable to commercialize the infringing products or technologies or such commercialization efforts may be significantly delayed, which could in turn significantly harm our business.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we collaborate with third parties in the development of technology in the future, our collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to litigation or potential liability. Further, collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability. In the future, we may agree to indemnify our commercial collaborators against certain intellectual property infringement claims brought by third parties.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Defense of infringement claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of management and other employee resources from our business, and may impact our reputation. In the event of a successful claim of infringement against us, we may be enjoined from further developing or commercializing the infringing products or technologies. In addition, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties and/or redesign our infringing products or technologies, which may be impossible or require substantial time and monetary expenditure. In that event, we would be unable to further develop and commercialize our product candidate or technologies, which could harm our business significantly. Further, we cannot predict whether any required license would be available at all or whether it would be available on commercially reasonable terms. In the event that we could not obtain a license, we may be unable to further develop our product candidate and commercialize our future product, if approved, which could harm our business significantly. Even if we are able to obtain a license, the license would likely obligate us to pay license fees or royalties or both, and the rights granted to us might be nonexclusive, which could result in our competitors gaining access to the same intellectual property. Ultimately, we could be prevented from commercializing a product, or be forced to cease some aspect of our business operations, if, as a result of actual or threatened patent infringement claims, we are unable to enter into licenses on acceptable terms.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Engaging in litigation defending against third parties alleging infringement of patent and other intellectual property rights is very expensive, particularly for a company of our size, and time-consuming. Some of our competitors may be able to sustain the costs of litigation or administrative proceedings more effectively than we can because of greater financial resources. Patent litigation and other proceedings may also absorb significant management time. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could impair our ability to compete in the marketplace. The occurrence of any of the foregoing could have a material adverse effect on our business, financial condition or results of operations.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may in the future pursue invalidity proceedings with respect to third-party patents. The outcome following legal assertions of invalidity is unpredictable. Even if resolved in our favor, these legal proceedings may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such proceedings adequately. Some of these third parties may be able to sustain the costs of such proceedings more effectively than we can because of their greater financial resources. If we do not prevail in the patent proceedings the third parties may assert a claim of patent infringement directed at our product candidates.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">87</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may become involved in lawsuits to protect or enforce our patents and other intellectual property rights, which could be expensive, time consuming and unsuccessful.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third parties, such as a competitor, may infringe, misappropriate, or otherwise violate our current or future issued patents and other intellectual property rights. In a patent infringement proceeding, a court may decide that a patent owned by us is invalid or unenforceable or may refuse to stop the other party from using the invention at issue on the grounds that the patent does not cover the technology in question or that the other party&#8217;s use of our patented technology falls under the safe harbor to patent infringement under 35 U.S.C. &#167; 271(e)(1). In addition, our patent rights may become involved in inventorship, priority or validity disputes. To counter or defend against such claims can be expensive and time consuming. An adverse result in any litigation proceeding could put our patent rights at risk of being invalidated or interpreted narrowly. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to enforce our patent rights depends on our ability to detect infringement. It may be difficult to detect infringers who do not advertise the components or methods that are used in connection with their products and services. Moreover, it may be difficult or impossible to obtain evidence of infringement in a competitor&#8217;s or potential competitor&#8217;s product or service. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded if we were to prevail may not be commercially meaningful.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of the expense and uncertainty of litigation, we may conclude that even if a third party is infringing any patents that may be issued as a result of our pending or future patent applications or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action may be too high or not in the best interest of our company or our stockholders. In addition, the uncertainties associated with litigation could compromise our ability to raise the funds necessary to continue any clinical trials, continue our internal research programs, in-license needed technology or other product candidates, or enter into development partnerships that would help us bring our product candidates to market. In such cases, we may decide that the more prudent course of action is to simply monitor the situation or initiate or seek some other non-litigious action or solution.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented, declared generic or determined to be infringing on other marks. During trademark registration proceedings, we may receive rejections of our applications by the USPTO or in other foreign jurisdictions. Although we are given an</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">88</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, which may not survive such proceedings. Moreover, any name we have proposed to use with our product candidates in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. Similar requirements exist in Europe. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA or an equivalent administrative body in a foreign jurisdiction objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in an effort to identify a suitable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. Furthermore, in many countries, owning and maintaining a trademark registration may not provide an adequate defense against a subsequent infringement claim asserted by the owner of a senior trademark.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade names, domain name or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intellectual property rights do not necessarily address all potential threats.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">others may be able to make products that are similar to our product candidate or utilize similar technology but that are not covered by the claims of the patents that we may license or may own;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we might not have been the first to make the inventions covered by our current or future patents;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we might not have been the first to file patent applications covering our inventions;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">it is possible that our current or future patent applications will not lead to issued patents;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any patents issuing from our current or future patent applications may be held invalid or unenforceable, including as a result of legal challenges by our competitors or other third parties;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our competitors or other third parties might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may not develop additional proprietary technologies that are patentable;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the patents of others may harm our business; and</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">89</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may choose not to file for patent protection in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent application covering such intellectual property.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be successful in obtaining or maintaining necessary rights to product components and processes for our development pipeline through acquisitions and in-licenses.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The growth of our business may depend in part on our ability to acquire, in-license or use third-party proprietary component and process rights. For example, our product candidates may require specific formulations to work effectively and efficiently, we may develop product candidates containing our compounds and pre-existing pharmaceutical compounds, or we may be required by the FDA or comparable foreign regulatory authorities to obtain marketing authorization of companion diagnostic test or tests for use with our product candidates, any of which could require us to obtain rights to use intellectual property held by third parties. For example, we are working with diagnostic companies to develop and utilize companion diagnostic tests to aid in identifying appropriate patients in our SURF302 Phase 2 clinical trial, and we will need to engage additional diagnostic partners across all our oncology programs to identify appropriate patients for study inclusion. In addition, with respect to any patents we may co-own with third parties, we may require licenses to such co-owners interest to such patents. We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary or important to our business operations. In addition, we may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. Were that to happen, we may need to cease use of the compositions or methods covered by those third-party intellectual property rights, and may need to seek to develop alternative approaches that do not infringe on those intellectual property rights, which may entail additional costs and development delays, even if we were able to develop such alternatives, which may not be feasible. Even if we are able to obtain a license, it may be non-exclusive, which means that our competitors may also receive access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, we might sometimes collaborate with academic institutions to accelerate our preclinical research or development under written agreements with these institutions. In certain cases, these institutions provide us with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the collaboration. Even if we hold such an option, we may be unable to negotiate a license from the institution within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to others, potentially blocking our ability to pursue our program.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The licensing and acquisition of third-party intellectual property rights is a competitive area, and companies that may be more established or have greater resources than we do may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. There can be no assurance that we will be able to successfully complete these types of negotiations and ultimately acquire the rights to the intellectual property surrounding the additional product candidates that we may seek to develop or market. If we are unable to successfully obtain rights to required third-party intellectual property or to maintain the existing intellectual property rights we have, we may have to abandon development of certain programs and our business financial condition, results of operations and prospects could suffer.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">90</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The trading price of the shares of our common stock could be highly volatile, and purchasers of our common stock could incur substantial losses.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our stock price is likely to be volatile. The stock market in general and the market for stock of biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, investors may not be able to sell their common stock at or above the price at which they paid. The market price for our common stock may be influenced by those factors discussed in this &#8220;Risk Factors&#8221; section and many others, including:</span></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">results of our preclinical studies and clinical trials, and the results of trials of our competitors or those of other companies in our market sector;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to enroll patients in our future clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">marketing approval of our product candidates, or limitations to specific label indications or patient populations for its use, or changes or delays in the regulatory review process;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory or legal developments in the United States and foreign countries;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in the structure of healthcare payment systems;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the success or failure of our efforts to develop, acquire or license additional product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">innovations, clinical trial results, product approvals and other developments regarding our competitors;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">manufacturing, supply or distribution delays or shortages;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any changes to our relationship with any manufacturers, suppliers, collaborators or other strategic partners;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">achievement of expected product sales and profitability;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">variations in our financial results or those of companies that are perceived to be similar to us, or fluctuations in the valuation of such other companies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">market conditions in the biopharmaceutical sector and issuance of securities analysts&#8217; reports or recommendations;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">trading volume of our common stock;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an inability to obtain additional funding;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sales of our stock by insiders and stockholders;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the impact of any natural disasters or public health emergencies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">general economic, industry, geopolitical and market conditions, events or factors, many of which are beyond our control, including war and terrorism, inflation and interest rate changes and financial institution instability;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expiration of market stand-off or lock-up agreements;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">91</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">additions or departures of key personnel; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">intellectual property, product liability or other litigation against us.</span></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, in the past, stockholders have initiated class action lawsuits against biopharmaceutical companies following periods of volatility in the market prices of these companies&#8217; stock. Such litigation, if instituted against us, could cause us to incur substantial costs and divert our management&#8217;s attention and resources, which could have a material adverse effect on our business, financial condition and results of operations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">An active, liquid trading market for our common stock may not be maintained.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We can provide no assurance that we will be able to maintain an active trading market for our common stock. If an active market for our common stock is not sustained, it may be difficult for you to sell your shares at the time you wish to sell them or at a price that you consider reasonable. An inactive market may also impair our ability to raise capital by selling shares and may impair our ability to acquire other businesses or technologies using our shares as consideration, which, in turn, could materially adversely affect our business.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our executive officers, directors and principal stockholders, if they choose to act together, have the ability to significantly influence all matters submitted to stockholders for approval.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our executive officers, directors and greater than 5% stockholders, in the aggregate, own a significant amount of our outstanding common stock. Furthermore, certain of our current directors were appointed by our principal stockholders. As a result, such persons or their appointees to our board of directors, acting together, have the ability to significantly influence all matters submitted to our board of directors or stockholders for approval, including the appointment of our management, the election and removal of directors and approval of any significant transaction, as well as our management and business affairs. This concentration of ownership may have the effect of delaying, deferring or preventing a change in control, impeding a merger, consolidation, takeover or other business combination involving us, or discouraging a potential acquiror from making a tender offer or otherwise attempting to obtain control of our business, even if such a transaction would benefit other stockholders.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We do not currently intend to pay dividends on our common stock, and, consequently, your ability to achieve a return on your investment will depend on appreciation, if any, in the price of our common stock.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have never declared or paid any cash dividend on our common stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. In addition, any future debt agreements may preclude us from paying dividends. Any return to stockholders will therefore be limited to the appreciation of their stock. There is no guarantee that shares of our common stock will appreciate in value or even maintain the price at which stockholders have purchased their shares.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to fall.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sales of a substantial number of shares of our common stock by our executive officers, directors and principal stockholders in the public market or the perception that these sales might occur could significantly reduce the market price of our common stock and impair our ability to raise adequate capital through the sale of additional equity securities.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, certain of our existing stockholders are entitled to rights with respect to the registration of their shares under the Securities Act. Registration of these shares under the Securities Act would result in the shares</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">92</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">becoming freely tradable without restriction under the Securities Act, except for shares held by affiliates, as defined in Rule 144 under the Securities Act. Also, in connection with the private placement of our common stock in February 2024, we filed a registration statement for the resale by certain holders of our common stock and pre-funded warrants. Any sales of securities by these stockholders could have a material adverse effect on the trading price of our common stock.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are an emerging growth company and a smaller reporting company, and the reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are an emerging growth company, as defined in the JOBS Act, and may remain an emerging growth company until the last day of the fiscal year following the fifth anniversary of the completion of our IPO. However, if certain events occur prior to the end of such five-year period, including if we become a &#8220;large accelerated filer,&#8221; our annual gross revenues exceed $1.235 billion or we issue more than $1.0 billion of non-convertible debt in any three-year period, we will cease to be an emerging growth company prior to the end of such five- year period. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include:</span></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly reduced &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; disclosure;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements, unless the SEC determines the new rules are necessary for protecting the public;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reduced disclosure obligations regarding executive compensation; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.</span></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be reduced or more volatile. In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of these accounting standards until they would otherwise apply to private companies. We have elected to avail ourselves of this exemption and, therefore, we will not be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are also a smaller reporting company as defined in the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as our voting and non-voting common stock held by non-affiliates is less than $250.0 million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0 million during the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates is less than $700.0 million measured on the last business day of our second fiscal quarter.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">93</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General Risk Factors</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We incur significant costs as a result of operating as a public company, and our management is required to devote substantial time to new compliance initiatives.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a public company, we incur significant legal, accounting and other expenses. We are subject to the reporting requirements of the Exchange Act, which requires, among other things, that we file with the SEC annual, quarterly and current reports with respect to our business and financial condition. In addition, the Sarbanes-Oxley Act, as well as rules subsequently adopted by the SEC and Nasdaq to implement provisions of Sarbanes-Oxley, impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. Further, pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, the SEC has adopted additional rules and regulations in these areas, such as mandatory &#8220;say on pay&#8221; voting requirements and &#8220;pay versus performance&#8221; disclosure requirements that will apply to us when we cease to be an emerging growth company. Stockholder activism, changes in the political environment and the level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The rules and regulations applicable to public companies have substantially increased our legal and financial compliance costs and made some activities more time consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business, financial condition and results of operations. The increased costs will decrease our net income or increase our net loss, and may require us to reduce costs in other areas of our business or increase the prices of our products or services. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We could face criminal liability and other serious consequences for violations, which could harm our business.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, and various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Controls and anti-corruption and anti-money laundering laws and regulations, including the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, CROs, contractors and other collaborators and partners from authorizing, promising, offering, providing, soliciting or receiving, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. We may engage third parties for clinical trials outside of the United States, to sell our products abroad once we enter a commercialization phase, and/or to obtain necessary permits, licenses, patent registrations and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, CROs, contractors and other collaborators and partners, even if we do not explicitly authorize or have actual knowledge of such activities. We are also subject to other U.S. laws and regulations governing export controls, as well as economic sanctions and embargoes on certain countries and persons. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">94</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, U.S. export control laws and economic sanctions prohibit the provision of certain products and services to countries, governments, and persons targeted by U.S. sanctions. U.S. sanctions that have been or may be imposed as a result of military conflicts in other countries may impact our ability to continue activities at future clinical trial sites within regions covered by such sanctions. If we fail to comply with export and import regulations and such economic sanctions, penalties could be imposed, including fines and/or denial of certain export privileges. These export and import controls and economic sanctions could also adversely affect our supply chain.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our operations could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or manmade disasters or business interruptions, for which we are predominantly self-insured. We rely on third-party manufacturers to produce our product candidates. Our ability to obtain clinical supplies of our product candidates could be disrupted if the operations of these suppliers were affected by a man-made or natural disaster or other business interruption. In addition, our corporate headquarters is located in Carlsbad, California near major earthquake faults and fire zones, and the ultimate impact on us of being located near major earthquake faults and fire zones and being consolidated in a certain geographical area is unknown. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our business is subject to risks arising from pandemic and epidemic diseases.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future pandemics or other public health epidemics have the potential to present substantial public health and economic challenges and affect our employees, patients, physicians and other healthcare providers, communities and business operations, as well as the U.S. and global economies and financial markets. A pandemic or epidemic poses the risk that we or our employees, contractors, including our CROs, suppliers, collaborators and other partners may be prevented from conducting business activities for an indefinite period of time, including due to spread of the disease within these groups or due to shutdowns that may be requested or mandated by governmental authorities. While it is not possible at this time to estimate the impact on our business of pandemic or epidemic disease outbreaks, such outbreaks could: disrupt the supply chain and the manufacture or shipment of drug substances and finished drug products for our product candidates for use in our research, preclinical studies and clinical trials, delay, limit or prevent our employees and CROs from continuing research and development activities; impede our clinical trial initiation and recruitment and the ability of patients to continue in clinical trials, including the risk that participants enrolled in our clinical trials will contract the pandemic or epidemic disease in question, while the clinical trial is ongoing, which could impact the results of the clinical trial, including by increasing the number of observed adverse events; and impede testing, monitoring, data collection and analysis and other related activities, any of which could delay our preclinical studies and clinical trials and increase our development costs, and have a material adverse effect on our business, financial condition and results of operations. Future pandemics or epidemics could also potentially affect the business of the FDA or comparable foreign regulatory authorities, which could result in delays in meetings related to planned or ongoing clinical trials. Any future pandemic or epidemic disease outbreak may have an adverse impact on global economic conditions which could have an adverse effect on our business and financial condition, including impairing our ability to raise capital when needed. The extent to which any future pandemic or epidemic disease could impact our results will depend on future developments that are highly uncertain and cannot be predicted.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">95</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If securities or industry analysts do not publish research or reports or publish unfavorable research or reports about our business, our stock price and trading volume could decline.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The trading market for our common stock depends in part on the research and reports that securities or industry analysts publish about us, our business, our market or our competitors. If one or more of the analysts who covers us downgrades our stock, our stock price would likely decline. If one or more of these analysts ceases to cover us or fails to regularly publish reports on us, interest in our stock could decrease, which could cause our stock price or trading volume to decline.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate and timely financial statements could be impaired, investors may lose confidence in our financial reporting and the trading price of our common stock may decline.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to Section 404 of the Sarbanes-Oxley Act, our management is required to report upon the effectiveness of our internal control over financial reporting. When we lose our status as an &#8220;emerging growth company&#8221; and reach an accelerated filer threshold, our independent registered public accounting firm will be required to attest to the effectiveness of our internal control over financial reporting. The rules governing the standards that must be met for our management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation. To comply with the requirements of being a reporting company under the Exchange Act, we may need to upgrade our information technology systems; implement additional financial and management controls, reporting systems and procedures; and hire additional accounting and finance staff. If we or, if required, our independent registered public accounting firm are unable to conclude that our internal control over financial reporting is effective, investors may lose confidence in our financial reporting and the trading price of our common stock may decline.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot assure you that there will not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting once that firm begins its Section 404 reviews, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Provisions in our charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could significantly reduce the value of our shares to a potential acquiror or delay or prevent changes in control or changes in our management without the consent of our board of directors. The provisions in our charter documents include the following:</span></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a classified board of directors with three-year staggered terms, which may delay the ability of stockholders to change the membership of a majority of our board of directors;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">96</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the exclusive right of our board of directors, unless the board of directors grants such right to the stockholders, to elect a director to fill a vacancy created by the expansion of the board of directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the required approval of at least 66-2/3% of the shares entitled to vote to remove a director for cause, and the prohibition on removal of directors without cause;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquiror;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability of our board of directors to alter our amended and restated bylaws without obtaining stockholder approval;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the required approval of at least 66-2/3% of the shares entitled to vote to adopt, amend or repeal our amended and restated bylaws or repeal the provisions of our amended and restated certificate of incorporation regarding the election and removal of directors;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an exclusive forum provision providing that the Court of Chancery of the State of Delaware will be the exclusive forum for certain actions and proceedings;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the requirement that a special meeting of stockholders may be called only by the board of directors, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">advance notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders&#8217; meeting, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror&#8217;s own slate of directors or otherwise attempting to obtain control of us.</span></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are also subject to the anti-takeover provisions contained in Section 203 of the Delaware General Corporation Law. Under Section 203, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three years or, among other exceptions, the board of directors has approved the transaction.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders and that the federal district courts shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees or the underwriters or any offering giving rise to such claim.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a breach of fiduciary duty, any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws, or any action asserting a claim against us that is governed by the internal affairs doctrine, our amended and restated certificate of incorporation also provides that unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act, including all causes of action asserted against any</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">97</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">defendant named in such complaint. For the avoidance of doubt, this provision is intended to benefit and may be enforced by us, our officers and directors, the underwriters to any offering giving rise to such complaint, and any other professional entity whose profession gives authority to a statement made by that person or entity and who has prepared or certified any part of the documents underlying the offering. These choice of forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees and result in increased costs for investors to bring a claim. By agreeing to this provision, however, stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder. Furthermore, the enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. If a court were to find the choice of forum provisions in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We could be subject to securities class action litigation.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us, because biopharmaceutical and biotechnology companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of our management&#8217;s attention and resources, which could harm our business.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to the periodic reporting requirements of the Exchange Act. We designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1b_unresolved_staff_comments"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">em 1B. Unresolved Staff Comments.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p><div><ix:nonNumeric id="F_312e8756-458a-47e6-ae77-d3bc771edcd6" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" escape="true" continuedAt="F_312e8756-458a-47e6-ae77-d3bc771edcd6_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1c_cybersecurity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1C. Cybersecurity.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cybersecurity Risk Management and Strategy</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have developed and implemented a cybersecurity risk management program intended to protect the confidentiality, integrity, and availability of our critical systems and information. We implement reasonable administrative, technical and procedural safeguards to manage cybersecurity risks, including enforcing single sign-on or multi-factor authentication where supported or appropriate. We </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9b840dfc-860d-4f3a-b7e5-a632b2a8114d" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">engage</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_26b8bd8b-d6aa-4223-bbc0-f336691c4b19" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">third-party cybersecurity experts</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to assess the security of our network. In addition, we engage a third-party to perform internal audits of our IT General Controls (ITGCs).</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We design and assess our program based on the National Institute of Standards and Technology Cybersecurity Framework (NIST CSF).  This does not imply that we meet any particular technical standards,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">98</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_312e8756-458a-47e6-ae77-d3bc771edcd6_1" continuedAt="F_312e8756-458a-47e6-ae77-d3bc771edcd6_2"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">specifications, or requirements, only that we use the NIST CSF as a guide to help us identify, assess, and manage cybersecurity risks relevant to our business.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bbd429fb-8c4f-430b-93ce-0a6731d39dc8" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" escape="true"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity risk management program is designed to be </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7c3c0945-6097-41c7-8b0a-b5e0f3ee4e82" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">integrated</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> into our overall risk management program, and shares common methodologies, reporting channels and governance processes that apply across the risk management program to other legal, compliance, strategic, operational, and financial risk areas.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Key elements of our cybersecurity risk management program include but are not limited to the following:</span></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">risk assessments designed to help identify material risks from cybersecurity threats to our critical systems and information;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a security team principally responsible for managing (i) our cybersecurity risk assessment processes, (ii) our security controls, and (iii) our response to cybersecurity incidents;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the use of external service providers, where appropriate, to assess, test or otherwise assist with aspects of our security processes;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cybersecurity awareness training of our employees, including incident response personnel and senior management; </span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a cybersecurity incident response plan that includes procedures for responding to cybersecurity incidents; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a third-party risk management process for key service providers, based on our assessment of their criticality to our operations and respective risk profile, suppliers, and vendors that have access to our critical systems and information.</span></div></div></ix:nonNumeric></div><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have not identified risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b2208269-d4fe-46f6-bc27-4d83f593bdf1" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">materially affected</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> us, including our operations, business strategy, results of operations, or financial condition. We face risks from cybersecurity threats that, if realized, are reasonably likely to materially affect us, including our operations, business strategy, results of operations, or financial condition. See &#8220;Risk Factors &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our information technology systems, or those of any of our CROs, other contractors or consultants or potential future collaborators, may fail or suffer security breaches, which could result in a material disruption of our product development programs, harm our reputation, significant fines, penalties and liability and loss of customers or sales.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cybersecurity Governance</span></p><div><ix:nonNumeric id="F_e502b1e8-5454-4186-8707-ff898a57e5f7" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" escape="true" continuedAt="F_e502b1e8-5454-4186-8707-ff898a57e5f7_1"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3fbd007a-93ca-47bc-9f7c-74538023488c" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors considers cybersecurity risk as part of its risk oversight function and has delegated to the audit committee (the Committee) oversight of cybersecurity risks, including oversight of management&#8217;s implementation of our cybersecurity risk management program</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e0d43b1e-eeda-42e2-aea8-0d81fbb427ae" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" escape="true" continuedAt="F_e0d43b1e-eeda-42e2-aea8-0d81fbb427ae_1"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Committee receives quarterly reports from management on our cybersecurity risks. In addition, management updates the Committee where it deems appropriate, regarding any cybersecurity incidents it considers to be significant or potentially significant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:continuation id="F_e0d43b1e-eeda-42e2-aea8-0d81fbb427ae_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Committee reports to the full board of directors regarding its activities, including those related to cybersecurity. The full board of directors may also periodically receive briefings from management on our cyber risk management program</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Board members may receive presentations on cybersecurity topics from our Chief Financial Officer (CFO), internal security staff or external experts as part of the board of director</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s continuing education on topics that impact public companies.</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b70255f8-51b3-4ca7-befc-aa8f42a5f1ed" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" escape="true" continuedAt="F_b70255f8-51b3-4ca7-befc-aa8f42a5f1ed_1"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b0181fc2-9fcf-4bc9-ad5a-fce118b6a852" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Our IT Senior Director, is primarily responsible for assessing and managing our material risks from cybersecurity threats.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IT Senior Director has primary responsibility for our </span></ix:nonNumeric></span><span style=""></span></p></ix:nonNumeric></div></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">99</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_312e8756-458a-47e6-ae77-d3bc771edcd6_2"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_e502b1e8-5454-4186-8707-ff898a57e5f7_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_b70255f8-51b3-4ca7-befc-aa8f42a5f1ed_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">overall </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cybersecurity risk management program and supervises our retained external cybersecurity consultants.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_98c15c0b-f3c2-4009-b1d2-805ab96a1b10" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our IT Senior Director has over 25 years of IT and cybersecurity experience.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div><ix:nonNumeric id="F_7e3469a8-cd96-471a-a890-b0f2590530e3" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" escape="true"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_64412295-2179-45c2-bf2f-6b3223fc4c3a" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our IT Senior Director takes steps to stay informed about and monitor efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which may include briefings from internal security personnel; threat intelligence and other information obtained from governmental, public or private sources, including external consultants engaged by us; and alerts and reports produced by security tools deployed in our information technology environment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div></ix:continuation></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_2_properties"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">em 2. Properties.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our corporate headquarters are located in Carlsbad, California, where we lease approximately 13,065 square feet of laboratory and office space. Our headquarters consist of approximately 4,734 square feet of original space (the Original Space) and 8,331 square feet of space in an adjacent building (the Expansion Space). The lease for the Expansion Space commenced in November 2023. The lease for the Original Space and Expansion Space will end 120 months after the commencement date (November 2023) of the Expansion Space lease, subject to certain renewal options granted to us. We believe that our existing and planned expansion facilities are adequate for our current needs and that suitable additional or alternative space will be available in the future on commercially reasonable terms, if required.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For additional information, see Note 9, Leases, to the financial statements included in this Annual Report.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_3_legal_proceedings"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ite</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">m 3. Legal Proceedings.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are not currently subject to any material legal proceedings. From time to time, we may be involved in legal proceedings or subject to claims incident to the ordinary course of business. Regardless of the outcome, such proceedings or claims can have an adverse impact on us because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_4_mine_safety_disclosures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">em 4. Mine Safety Disclosures.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART II</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_5_market_for_registrants_common"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">em 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Market Information</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our common stock trades on the Nasdaq Global Select Market under the symbol &#8220;TYRA&#8221;.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Holders of Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of February 25, 2026, there were approximately 21 holders of record of our common stock. This number was derived from our shareholder records and does not include beneficial owners of our common stock whose shares are held in the name of various dealers, clearing agencies, banks, brokers and other fiduciaries.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dividend Policy</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have never declared or paid any cash dividends on our capital stock. We intend to retain future earnings, if any, to finance the operation of our business and do not anticipate paying any cash dividends in the foreseeable future. Any future determination related to dividend policy will be made at the discretion of our board of directors after considering our financial condition, results of operations, capital requirements, business prospects and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">100</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">other factors the board of directors deems relevant, and subject to the restrictions contained in any future financing instruments.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities Authorized for Issuance Under Equity Compensation Plans</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See Item 12 of Part III of this Annual Report for information about our equity compensation plans which is incorporated by reference herein.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Performance Graph</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unregistered Sales of Equity Securities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Issuer Repurchases of Equity Securities and Affiliated Purchasers</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_6_selected_financial_data"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">em 6. [Reserved].</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7_managements_discussion"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">em 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and related notes included elsewhere in this Annual Report on Form 10-K. This discussion contains forward-looking statements that involve risks and uncertainties, including those described in the section entitled &#8220;Forward Looking Statements and Market Data.&#8221; Our actual results and the timing of selected events could differ materially from those discussed below. Factors that could cause or contribute to such differences include, but are not limited to, those identified below and those set forth under the section entitled &#8220;Risk Factors&#8221; or in other parts of this Annual Report.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overview</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our in-house precision medicine platform, SN&#197;P, enables rapid and precise drug design through iterative molecular SN&#197;Pshots that help us design and predict which product candidates may demonstrate the highest potency, selectivity and tolerability in the clinic. Through this approach, we have built a wholly-owned pipeline of oral small molecule product candidates focused on targets that have previously been considered difficult-to-drug.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our FGFR3 Programs&#8212;oral dabogratinib (formerly TYRA-300) for Urothelial Cancers and Skeletal Dysplasia</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Alterations in the protein receptor FGFR3 are a validated driver in multiple indications with large market opportunities: urothelial cancers and skeletal dysplasia conditions. In urothelial cancer, uncontrolled activation of FGFR3 on the cell surface stimulates cellular proliferation. In skeletal dysplasia conditions, increased activity of FGFR3 expressed in growth plate chondrocytes (cartilage cells) results in excessive limitation of long bone growth.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our lead program, oral dabogratinib, was designed to be more selective for FGFR3 over FGFR1, FGFR2, and FGFR4 to minimize off-target side effects, providing potential clinical advantages over less selective first-generation compounds and potentially addressing key unmet needs across both urothelial cancers and skeletal dysplasia conditions. To date, oral dabogratinib has been administered to over 100 participants across multiple clinical studies.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">101</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We demonstrated initial clinical proof-of-concept results with oral dabogratinib in the SURF301 study, a Phase 1 proof-of-concept study in metastatic urothelial carcinoma (mUC). Oral dabogratinib demonstrated encouraging anti-tumor activity and was generally well-tolerated, with infrequent FGFR2- and FGFR1-associated toxicities. Response, safety, pharmacokinetics (PK) / pharmacodynamics (PD) and circulating tumor DNA (ctDNA) data from this study were leveraged to select doses that have the potential to achieve our target product profile for efficacy and safety in our Phase 2 trials and beyond.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are currently advancing oral dabogratinib in three Phase 2 trials for three outsized market indications: SURF303, evaluating the treatment of low-grade upper tract urothelial carcinoma (LG-UTUC); SURF302, evaluating the treatment of intermediate risk non-muscle invasive bladder cancer (IR NMIBC); and BEACH301, evaluating the treatment of achondroplasia (ACH) in children. If we are successful with these Phase 2 studies, we expect to advance oral dabogratinib toward three potential registrational trials in LG-UTUC, IR NMIBC and ACH. We are calling this approach our &#8220;dabogratinib 3x3&#8221; strategy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SURF303 for LG-UTUC: This open-label Phase 2a/b clinical trial was designed as a potential registrational trial to evaluate the efficacy and safety of oral dabogratinib at doses of 60 mg and 80 mg once daily (QD) in participants with FGFR3-altered low-grade upper tract urothelial carcinoma, where approximately 85% of tumors are driven by FGFR3. Study startup is ongoing and the first patient in this study is anticipated to be dosed in 2026.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SURF302 for IR NMIBC: This open-label Phase 2 clinical trial is evaluating the efficacy and safety of oral dabogratinib at 50 mg and 60 mg QD in participants with FGFR3-altered low-grade IR NMIBC, where approximately 70% of tumors are driven by FGFR3. We anticipate reporting initial three-month CR data from approximately 10-20 patients per cohort from this study by the end of the first half of 2026.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">BEACH301 for ACH: This study is an open-label, Phase 2 dose-escalation/dose-expansion trial evaluating oral dabogratinib at lower doses (0.125, 0.25, 0.375, 0.50 mg/kg), as compared to the oncology studies, in children ages 3 to 10 with ACH with open growth plates, where approximately 99% of cases are driven by FGFR3. The study is enrolling a safety sentinel cohort of 3 or more participants per dose level in children ages 5 to 10, and a natural history run-in for cohorts 1 and 2 with children ages 3 to 10. Initial results from the safety sentinel cohort, including 6-month average height velocity (AHV) results and interim safety, are on-track and expected to be reported in the second half of 2026.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our Other Programs</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TYRA-430 was designed to be biased for FGFR4 and FGFR3 over the FGFR1 and FGFR2 isoforms specifically to address the FGF19 signaling pathway, while also potentially limiting side effects due to inhibition of FGFR1 and FGFR2, as well as to address acquired resistance mutations that have limited the efficacy of previous FGFR4-specific inhibitors. TYRA-430 is currently being evaluated in SURF431, a global, Phase 1, multicenter, open-label trial, with a focus on achieving clinical proof-of-concept in a cohort of patients with FGF19+ hepatocellular carcinoma (HCC).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TYRA-200 is an FGFR1/2/3 inhibitor designed to be active against nearly all of the clinically identified acquired resistant mutations that arise during treatment with pan-FGFR inhibitors, which we believe is necessary to address the problem of disease progression due to polyclonal resistance. TYRA-200 is currently being evaluated in SURF201, a global, Phase 1, multicenter, open-label trial, with a focus on achieving clinical proof-of-concept in a cohort of FGFR2-driven intrahepatic cholangiocarcinoma (ICC) resistant to previous FGFR inhibitors.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Financial Overview</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since the commencement of our operations in 2018, we have devoted substantially all of our resources to organizing and staffing the company, business planning, raising capital, developing our proprietary SN&#197;P platform, undertaking research and development activities for our development programs, establishing our intellectual property portfolio, and providing general and administrative support for our operations. We have not generated any revenue to date and have funded our operations primarily from our initial public offering (IPO), private placements of our convertible preferred stock and the issuance of common stock and pre-funded common stock warrants</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">102</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">through a private placement. Our net losses for the years ended December 31, 2025 and 2024 were $119.9 million and $86.5 million, respectively. As of December 31, 2025, we had an accumulated deficit of $371.3 million. As of December 31, 2025, we had cash, cash equivalents, and marketable securities of $256.0 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have incurred significant operating losses since inception. Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of our clinical development activities, other research and development activities and capital expenditures. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future if and as we continue to develop and conduct clinical trials for our product candidates, continue our research and development activities for future product candidates, expand our clinical and regulatory capabilities, add operational and management information systems and hire additional personnel, expand and protect our intellectual property, establish marketing, sales, distribution and other commercialization capabilities if we obtain approval for any of our product candidates and incur additional costs associated with operating as a public company.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on our current operating plan, we believe that our cash, cash equivalents and marketable securities as of December 31, 2025 will be sufficient to fund our operating expenses and capital expenditures through at least 2027. We have never generated any revenue and do not expect to generate any revenue from product sales unless and until we successfully complete the development of and obtain regulatory approval for our product candidates, which will not be for several years, if ever. In addition, if we obtain regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. Accordingly, until we can generate significant revenue from sales of our product candidates, if ever, we expect to finance our cash needs through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may not be able to raise additional funds or enter into such other arrangements when needed or on favorable terms, or at all. If we are unable to raise additional capital or enter into such arrangements when needed, we could be forced to delay, limit, reduce or terminate our research and development programs or future commercialization efforts, or grant rights to develop and market our product candidates even if we would otherwise prefer to develop and market such product candidates ourselves.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Components of Results of Operations</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, our research and development expenses consist primarily of external and internal costs related to the development of our SN&#197;P platform and our product candidates and development programs. Our research and development expenses primarily include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.693432091613477%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">external costs, including:</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expenses incurred in connection with conducting clinical trials, including investigator grants and site payments for time and pass-through expenses and expenses incurred under agreements with contract research organizations (CROs), central laboratories and other vendors and service providers engaged to conduct our trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expenses incurred in connection with the discovery and preclinical development of our product candidates, including under agreements with third parties, such as consultants and CROs; </span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs associated with consultants for chemistry, manufacturing and controls (CMC) development, and other services;</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of manufacturing compounds for use in our preclinical studies, including under agreements with third parties, such as consultants and third-party manufacturers; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs related to compliance with drug development regulatory requirements; and</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">103</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.693432091613477%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">internal costs, including: </span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">employee-related expenses, including salaries, related benefits, recruiting costs, travel and share-based compensation expenses for employees engaged in research and development functions; </span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of laboratory supplies and acquiring, developing and manufacturing preclinical study materials; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">facilities, depreciation and other indirect expenses, which include allocated expenses for rent and maintenance of facilities and supplies. </span></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expense research and development expenses in the periods in which they are incurred. External expenses are recognized based on an evaluation of the progress to completion of specific tasks using information provided to us by our service providers or our estimate of the level of service that has been performed at each reporting date. We track external expenses on a development program and other program-specific basis. However, we do not track internal costs, such as personnel-related expenses, stock-based compensation expense, facility-related costs and supplies and certain external consultant costs on a program-specific basis because these costs are deployed across multiple programs under development.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development activities are central to our business model. There are numerous factors associated with the successful development of any of our product candidates, including future trial design and various regulatory requirements, many of which cannot be determined with accuracy at this time based on our stage of development. In addition, future regulatory factors beyond our control may impact our clinical development programs. Product candidates in later stages of development generally have higher development costs than those in earlier stages of development. As a result, we expect that our research and development expenses will increase substantially over the next several years as we advance our product candidates into later phases of clinical trials or through preclinical studies into and through clinical trials, continue to discover and develop additional product candidates and expand our pipeline, maintain, expand, protect and enforce our intellectual property portfolio and hire additional personnel.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our future research and development expenses may vary significantly based on a wide variety of factors, such as:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number and scope, rate of progress, expense and results of our discovery and preclinical development activities and clinical trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number of trials required for approval; </span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number of sites included in each of our trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the countries in which the trials are conducted; </span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the length of time required to enroll eligible patients; </span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number of patients that participate in the trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability to identify appropriate patients eligible for our clinical trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number of doses that patients receive; </span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the drop-out or discontinuation rates of patients; </span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential additional safety monitoring requested by regulatory agencies; </span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the duration of patient participation in the trials and follow-up; </span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the phase of development of the product candidate; </span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">104</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the efficacy and safety profile of the product candidate; </span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing, receipt, and terms of any approvals from applicable regulatory authorities including the FDA and non-U.S. regulators; </span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintaining a continued acceptable safety profile of our product candidates following approval, if any; </span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost and timing of manufacturing our product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significant and changing government regulation and regulatory guidance; </span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability to attract and retain personnel;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the impact of any business interruptions to our operations or to those of the third parties with whom we work;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">geopolitical instability, including war and terrorism;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adverse effects on the financial markets, the global economy, the supply chain and our expenses due to tariffs and trade policies, pandemic or epidemic diseases, geopolitical instability, inflation, interest rates and other factors; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent to which we establish additional strategic collaborations or other arrangements. </span></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A change in the outcome of any of these variables with respect to the development of any of our product candidates could significantly change the costs and timing associated with the development of that product candidate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The process of conducting the necessary preclinical and clinical research to obtain regulatory approval is costly and time-consuming. The actual probability of success for our product candidates or any future candidates may be affected by a variety of factors. We may never succeed in achieving regulatory approval for any of our product candidates or any future candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses consist primarily of personnel-related expenses, including employee salaries, bonuses, benefits, and stock-based compensation charges for personnel in executive, finance and other administrative functions. Other significant general and administrative expenses include legal fees relating to intellectual property and corporate matters, allocated facility-related costs, professional fees for accounting, tax, business development and consulting services and insurance costs. We expect our general and administrative expenses will increase for the foreseeable future to support our increased research and development activities, manufacturing activities, and the increased costs associated with operating as a public company. These increased costs will likely include increased expenses related to hiring additional personnel, audit, legal, regulatory and tax-related services associated with maintaining compliance with exchange listing and the Securities and Exchange Commission (SEC) requirements, director and officer insurance costs, and investor and public relations costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Income</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other income consists primarily of interest income from cash, cash equivalents and marketable securities and accretion income from marketable securities.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">105</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Results of Operations for the Years Ended December 31, 2025 and 2024</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our results of operations for the periods indicated (in thousands):</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:44.118%;box-sizing:content-box;"/>
     <td style="width:1.701%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:14.926%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.701%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:14.926%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.701%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:14.926%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102,928</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80,077</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,851</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,834</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,100</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,734</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">132,762</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104,177</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,585</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(132,762</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(104,177</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(28,585</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest and other income, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,815</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,696</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(4,881</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other income</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,815</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,696</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(4,881</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(119,947</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(86,481</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(33,466</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our research and development expenses by development program for the periods indicated (in thousands):</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:44%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:15%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:15%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:17%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">External research and development expenses by program:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dabogratinib (TYRA-300</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">ACH</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,379</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,718</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,661</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dabogratinib (TYRA-300</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">NMIBC</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,244</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">122</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,122</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dabogratinib (TYRA-300</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">UTUC</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,440</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,440</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dabogratinib (TYRA-300</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">mUC</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,590</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,319</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(4,729</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">TYRA-430</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,055</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,677</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,378</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">TYRA-200</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,308</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,969</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(661</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">FGFR discovery</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,967</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,199</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,768</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other development programs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,623</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,537</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unallocated research and development expenses:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel costs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,218</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,423</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,795</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Facilities and other costs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,104</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,113</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(9</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total research and development expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102,928</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80,077</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,851</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses were $102.9 million and $80.1 million for the years ended December 31, 2025 and 2024, respectively. The increase of $22.8 million was primarily driven by:</span></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.693432091613477%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a $17.0 million increase in external costs, including an $11.5 million increase related to development activities for oral dabogratinib, reflecting ongoing BEACH301 and SURF302 clinical trials and start-up costs for SURF303, as well as a $3.4 million increase in development expenditures for SURF431; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.693432091613477%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an increase of $5.8 million in compensation and other personnel expenses.</span></div></div><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses were $29.8 million and $24.1 million for the years ended December 31, 2025 and 2024, respectively. The increase of $5.7 million was primarily related to higher compensation and other personnel expenses, including an increase in non-cash stock-based compensation costs of $3.7 million, driven by headcount growth.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">106</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Income</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other income was $12.8 million and $17.7 million for the years ended December 31, 2025 and 2024, respectively. The decrease of $4.9 million was due to lower interest rates and reduced balances in cash, cash equivalents and marketable securities.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liquidity and Capital Resources</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sources of Liquidity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 3, 2022, we entered into an ATM Sales Agreement (the 2022 Sales Agreement) with Virtu Americas LLC (the 2022 Sales Agent), under which we could have, from time to time, sold shares of our common stock having an aggregate offering price of up to $150.0 million in &#8220;at the market&#8221; offerings through the 2022 Sales Agent. We did not sell any shares under the 2022 Sales Agreement. In connection with the 2025 Sales Agreement (as defined below), effective May 8, 2025, we terminated the 2022 Sales Agreement.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 8, 2025, we entered into a Sales Agreement (the 2025 Sales Agreement) with TD Securities (USA) LLC (the 2025 Sales Agent), under which we may, from time to time, sell shares of our common stock having an aggregate offering price of up to $150.0 million in &#8220;at the market&#8221; offerings through the 2025 Sales Agent. Sales of the shares of common stock, if any, will be made at prevailing market prices at the time of sale or as otherwise agreed with the 2025 Sales Agent. The 2025 Sales Agent will receive a commission from us of up to 3.0% of the gross proceeds of any shares of common stock sold under the 2025 Sales Agreement. As of December 31, 2025, we had not sold any shares under the 2025 Sales Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash Flows</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth a summary of our cash flows for the periods indicated (in thousands):</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:43.66%;box-sizing:content-box;"/>
     <td style="width:1.72%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:15.06%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.72%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:15.06%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.72%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:15.06%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by (used in):</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Operating activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(95,142</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(69,774</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(25,368</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Investing activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72,463</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(98,403</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">170,866</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Financing activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,100</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">202,137</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(194,037</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net increase (decrease) in cash and cash equivalents</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(14,579</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,960</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(48,539</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating Activities</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The increase of $25.4 million in net cash used in operating activities for the year ended December 31, 2025, compared to the same period in 2024, was primarily due to an increase of $33.5 million in net loss and a decrease in net changes in operating assets and liabilities of $0.9 million, offset by an increase of $5.2 million in non-cash stock-based compensation expense and a decrease of $3.8 million in non-cash net accretion on marketable securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investing Activities</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The increase of $170.9 million in net cash provided by investing activities for the year ended December 31, 2025, compared to the same period in 2024, was driven by a reduction in purchases of marketable securities of $162.4 million, a $8.0 million increase in maturities of marketable securities, and a $0.5 million decrease in capital expenditures for property and equipment.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Financing Activities</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The decrease of $194.0 million in net cash provided by financing activities for the year ended December 31, 2025, compared to the same period in 2024, was primarily due to the $199.6 million in net proceeds</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">107</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">from the 2024 Private Placement received during the year ended December 31, 2024. This decrease was partially offset by an increase of $5.6 million in proceeds from issuances of common stock under benefit plans.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Material Cash Requirements</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our material cash requirements consist of expected operating expenses to conduct our clinical trials and other research and development activities, personnel-related expenses and operating lease obligations.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our primary uses of cash to date have been to fund our research and development activities, including with respect to dabogratinib, TYRA-430, TYRA-200 and other research programs, business planning, establishing and maintaining our intellectual property portfolio, hiring personnel, raising capital, and providing general and administrative support for these operations.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on our current operating plan, we believe that our existing cash, cash equivalents and marketable securities as of December 31, 2025 will be sufficient to meet our anticipated operating expenses and capital expenditures through at least 2027. However, our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially. We have based this estimate on assumptions that may prove to be wrong, and we could deplete our capital resources sooner than we expect. Additionally, the process of conducting preclinical studies and testing product candidates in clinical trials is costly, and the timing of progress and expenses in these studies and trials is uncertain.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our future capital requirements will depend on many factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the initiation, type, number, scope, results, costs and timing of our ongoing and planned preclinical studies and clinical trials of existing product candidates or clinical trials of other potential product candidates we may choose to pursue in the future, including based on feedback received from regulatory authorities; </span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs and timing of manufacturing for current or future product candidates, including commercial scale manufacturing if any product candidate is approved; </span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs, timing and outcome of regulatory review of current or future product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of obtaining, maintaining and enforcing our patents and other intellectual property rights; </span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our efforts to enhance operational systems and hire additional personnel to satisfy our obligations as a public company, including enhanced internal controls over financial reporting; </span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs associated with hiring additional personnel and consultants as our business grows, including additional executive officers and clinical development personnel, as well as retaining personnel; </span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs and timing of establishing or securing sales and marketing capabilities if any current or future product candidate is approved; </span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third-party payors and adequate market share and revenue for any approved products; </span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs associated with any products or technologies that we may in-license or acquire; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays or issues with any of the above, including that the risk of each may be exacerbated by tariffs or trade policies, any future pandemics or epidemic diseases, potential geopolitical instability, war, terrorism, inflation or rising interest rates. </span></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Until such time, if ever, as we can generate substantial product revenues to support our cost structure, we expect to finance our cash needs through equity offerings, debt financings or other capital sources, including</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">108</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through collaborations or other similar arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us and/or may reduce the value of our common stock. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market our product candidates even if we would otherwise prefer to develop and market such product candidates ourselves.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We lease our corporate office and laboratory space in Carlsbad, California. As of December 31, 2025, total future aggregate operating lease commitments were $7.8 million, with approximately $0.9 million due in 2026, and the remaining due in periods from 2027 through 2033. These obligations are further described in Note 9 to our audited financial statements.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we enter into agreements and purchase orders in the normal course of business with vendors for the provision of goods and services. These agreements may include certain provisions for termination, with notice, which typically consist of payments for services provided or expenses incurred through the date of cancellation. We believe that our non-cancelable obligations under these agreements are not material.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Critical Accounting Policies and Estimates</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management&#8217;s discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States (GAAP). The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events, and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Our actual results may differ from these estimates under different assumptions or conditions.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While our significant accounting policies are described in more detail in Note 1 to our financial statements included elsewhere in this filing, we believe the following accounting policies and estimates to be most critical to the preparation of our financial statements.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accrued Research and Development Expenses</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses consist of external and internal costs associated with the Company&#8217;s research and development activities, including its discovery and research efforts and the preclinical and clinical development of its product candidates. Research and development costs are expensed in the period incurred.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has entered into various research and development contracts with clinical research organizations, clinical manufacturing organizations, clinical sites and other vendors and consultants. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and payments made in advance of or after the performance are reflected in the accompanying balance sheets as prepaid expenses or accrued liabilities, respectively. The Company records accruals for estimated costs incurred for ongoing research and development activities. When evaluating the adequacy of the accrued liabilities, the Company analyzes the progress of the services, including the phase or completion of events, invoices received and contracted costs. The Company holds discussions with applicable personnel and outside service providers as to the progress of clinical trials, or the services completed. Significant judgments and estimates may be made in determining the status and timing of services performed, and actual results could differ from the Company&#8217;s</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">109</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">estimates. Nonrefundable advance payments for goods and services, including fees for process development, are deferred and recognized as expenses in the period that the related goods are consumed or services are performed.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Pronouncements</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note 1 to our financial statements appearing elsewhere in this Annual Report on Form 10-K.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Emerging Growth Company and Smaller Reporting Company Status</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, as amended (JOBS Act). We will remain an emerging growth company until the earliest to occur of: (i) the last day of the fiscal year in which we have more than $1.235 billion in annual revenue; (ii) the date we qualify as a &#8220;large accelerated filer,&#8221; with at least $700 million of equity securities held by non-affiliates; (iii) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period; and (iv) December 31, 2026. As a result of this status, we have taken advantage of reduced reporting requirements in this Annual Report on Form 10-K and may elect to take advantage of other reduced reporting requirements in our future filings with the SEC. In particular, in this Annual Report on Form 10-K, we have provided only two years of audited financial statements and have not included all of the executive compensation-related information that would be required if we were not an emerging growth company.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards, delaying the adoption of these accounting standards until they would apply to private companies. We have elected to use the extended transition period to enable us to comply with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date on which we (i) are no longer an emerging growth company and (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are also a &#8220;smaller reporting company&#8221; as defined in the Exchange Act. We may continue to be a smaller reporting company if either (i) the market value of our stock held by non-affiliates is less than $250 million measured on the last business day of our second fiscal quarter or (ii) our annual revenue was less than $100 million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700 million measured on the last business day of our second fiscal quarter. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company, we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form 10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation and other matters.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7a_quantitative_and_qualitative"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ite</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">m 7A. Quantitative and Qualitative Disclosures About Market Risk.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest Rate Risk</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are exposed to market risk based on changes in interest rates. Our cash, cash equivalents and marketable securities were $256.0 million as of December 31, 2025 and consisted of cash, money market funds and securities issued by the U.S. government and its agencies. Due to the short-term nature of these instruments, we believe that we do not have any material exposure to changes in the fair value of our portfolio. However, declines in interest rates would reduce future interest income and cash flow. A hypothetical 10% relative change in interest rates during the periods presented would not have had a material impact on our financial statements.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">110</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Foreign Currency Exchange Risk</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our expenses are generally denominated in U.S. dollars. However, we have entered into a limited number of contracts with vendors for research and development services that are denominated in foreign currencies. We are subject to foreign currency transaction gains or losses on our contracts denominated in foreign currencies. As of December 31, 2025, foreign currency transaction gains and losses have not been material to our financial statements, and we have not had a formal hedging program with respect to foreign currency. A hypothetical 10% increase or decrease in exchange rates during any of the periods presented would not have had a material impact on our financial results.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Effects of Inflation</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inflation generally affects us by increasing our cost of labor and clinical trial costs. We do not believe that inflation has had a material effect on our financial results during the periods presented.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">111</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_8_financial_statements"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ite</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">m 8. Financial Statements and Supplementary Data.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:91%;box-sizing:content-box;"/>
     <td style="width:9%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#report_of_independent_registered_public"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></a><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">&#160;(PCAOB: 42)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">113</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Balance Sheets</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">114</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_of_operations_and_comploss"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Statements of Operations and Comprehensive Loss</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">115</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_of_stockholders_equity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Statements of Stockholders&#8217; Equity</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">116</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_of_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Statements of Cash Flows</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">117</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#note_1"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Notes to Financial Statements</span></a></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">118</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">112</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="report_of_independent_registered_public"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rep</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ort of Independent Registered Public Accounting Firm</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the Stockholders and the Board of Directors of Tyra Biosciences, Inc.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c61f54e7-fba4-400c-a3c5-52d542f69755" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="dei:AuditorOpinionTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Opinion on the Financial Statements</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited the accompanying balance sheets of Tyra Biosciences, Inc. (the Company) as of December 31, 2025 and 2024, the related statements of operations and comprehensive loss, stockholders&#8217; equity and cash flows for each of the two years in the period ended December 31, 2025, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2025, in conformity with U.S. generally accepted accounting principles.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis for Opinion</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_79c7feb4-60c1-4945-926c-bf6c31ecdac1" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="dei:AuditorName"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ernst &amp; Young LLP</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have served as the Company&#8217;s auditor since 2021.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_386f5296-cd93-45bc-92c3-3071055e51e4" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="dei:AuditorLocation"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">San Diego, California</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 2, 2026</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">113</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tyra Biosciences, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="fin189651_2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Balan</span><span id="balance_sheets"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ce Sheets</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands, except share and per share data)</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:63.48%;box-sizing:content-box;"/>
     <td style="width:1.68%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:14.58%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.68%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:14.58%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current assets:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_156f81bf-84a9-4210-90b4-e9f03e068c6d" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">77,387</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a4ade29-616c-4ea8-b8c5-407685145af2" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">91,966</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_be3de640-e2b3-4b2d-978a-54473e5564f5" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">178,616</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5aa68fe3-8b37-4c95-9854-d4a3f0a31651" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">249,475</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6be74b01-ebdd-4dc8-ad1a-98be183223eb" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,447</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_51991d5f-e075-4a60-a41e-da7aaa555964" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,022</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_678b1a46-b63a-46b2-a706-4d77306c30b5" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">265,450</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c306ce48-4916-4369-b2aa-fdbb0dd67ad4" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">347,463</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f57ab50a-f5c4-49d6-92ac-b4ce59d12ad7" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,000</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_11037853-5b16-4535-99a9-87bb6b93a4f2" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,000</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af1bd023-d303-4fef-b077-44d23a033e3f" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,314</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_49aa5d09-6a03-4460-92ec-c204d9c623e8" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,651</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right-of-use assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_498cbd76-8f42-4bfb-9fc2-36f6951f31fd" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="tyra:RightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,573</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4dc06be2-5b1e-4e7c-b6fb-94d4486048fb" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="tyra:RightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,068</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other long-term assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d45293b-da81-4bad-a786-75ddaef36322" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,272</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d75a0eae-3b94-4c0c-9bde-c75c90b15475" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,376</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b7cfa70-8ab4-4c40-b4b0-2821c2237866" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">282,609</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_600727bd-df56-46e1-8aa1-aa90c9884da7" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">363,558</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Liabilities and Stockholders&#8217; Equity</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current liabilities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b665c5e3-f0bb-4563-b16d-08cc20ab075a" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,178</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_be4936f8-9e79-4394-9218-e3733bbebb68" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">590</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liabilities, current</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f86fef8-0da1-4dc7-93c5-bf3b1a304a99" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">472</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d6e39bf-cc79-4c70-bff4-a42fc8ed3b56" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">412</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0fc90133-029c-4a87-86bd-2324ec925652" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,444</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_76bc8e19-8bda-4b98-8cd8-dae11c44ff04" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,592</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_150440c0-c10b-46fc-ac92-17dbb11c7f67" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,094</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6db87db0-20ac-4e82-955f-dfde0d7c0fb7" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,594</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liabilities, noncurrent</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4653a869-11e6-4320-a661-30e216c771b7" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,338</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2c7c0298-e5f9-49d1-b58a-8c0ca656ef57" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,810</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other long-term liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_47557cd9-7001-4100-88e8-db851e1e74b4" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b86d8bd9-b52a-4cc2-b39e-748786db11cb" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70af4668-a02f-454b-a342-9fe5f3c0b28f" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,432</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d78d7e0-027d-45d5-a1f9-ba9c6f5a891b" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,407</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_e3d03354-93a3-4909-bbcb-fa330f37e738;"><span style="-sec-ix-hidden:F_b98141a9-56b2-47e3-96de-3efef16eed5c;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commitments and contingencies (Note 10)</span></span></span></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stockholders&#8217; equity:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Preferred stock, $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5eda8113-16fa-4074-8b6d-0ceaa76f23f6" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_3a15f910-4e68-4f99-800b-6fbfed2e4e5c" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;par value; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1baac7eb-9af4-42fc-a560-12cffdd0c378" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_53c4714b-20d1-446c-8d7d-22d3ca5b4e5b" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">50,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares <br/>&#160;&#160;&#160;authorized at December 31, 2025 and December 31, 2024;  <br/>&#160;&#160;&#160;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_494406fe-6992-48c7-88ef-93fc14597851" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_883036a1-fb68-40b3-ba41-823f8c9c47a0" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_ee9d0a9b-1965-4aca-8d7d-6b5c883cb303" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_858e1e1d-10ef-4e1a-b3d9-1981ed6d29a7" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares issued and outstanding at December 31, 2025 and <br/>&#160;&#160;&#160;December 31, 2024</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df04201d-67e9-4bc4-9cfe-a578d919721c" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a726c260-7c9a-42ea-bd8e-656b08090da2" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock, $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9c50f995-040e-4cc1-b3d4-bb879a959fc8" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_a2a0107e-7778-42bc-a6fe-0b350b61b2db" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;par value; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2da194a3-acc9-4cf9-82aa-67893e050b59" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_15ba0d68-0e42-4b5b-954c-048a0a74ba1a" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">500,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares authorized <br/>&#160;&#160;&#160;at December 31, 2025 and December 31, 2024; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c1309e1a-5d01-489c-bd7e-7549e6756a4c" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">53,706,357</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;and <br/>&#160;&#160;&#160;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aae78993-0b76-425d-af68-bc0cb0961b1a" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">50,754,262</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares issued at December 31, 2025 and <br/>&#160;&#160;&#160;December 31, 2024, respectively, and </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_076446c2-d431-45cb-b324-8d78afaa4e37" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">53,706,357</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;and <br/>&#160;&#160;&#160;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee6d58b8-0273-4860-b45c-9e053ac9c336" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">50,749,945</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares outstanding at December 31, 2025 and <br/>&#160;&#160;&#160;December 31, 2024, respectively</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_58223adf-cd32-4ccf-aa71-1df495ef1799" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef185d8d-ea1e-44d3-b8e9-493223682a72" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additional paid-in capital</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7b3b6fd-5df2-4c33-a1b4-96abad8c8338" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">630,037</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e4ae5d4-2a9f-46c5-bf07-becffc989077" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">593,687</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated other comprehensive income</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9144f3ff-c667-475d-98d0-80ba66b3b6db" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">393</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_20a4b466-b52c-4eee-bfc1-d0333bbd0a5c" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">770</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated deficit</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_198214a5-3045-45b5-ae2b-780cd4195402" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">371,258</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df943fe7-4832-42c9-b3bf-920595b08073" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">251,311</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stockholders&#8217; equity</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e869fc63-41fd-4b6f-9b1c-2a41c0e78925" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">259,177</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bcea6423-2bcf-4e93-baa4-18502ae29e4b" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">343,151</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities and stockholders&#8217; equity</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c0236afe-d7c3-4b34-b917-ae5838a890d1" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">282,609</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_75cc0535-e864-4b0d-83da-28a8877c0023" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">363,558</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">See accompanying notes to financial statements.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">114</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tyra Biosciences, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="fin189651_3"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Statem</span><span id="statements_of_operations_and_comploss"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ents of Operations and Comprehensive Loss</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands, except share and per share data)</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:58.76%;box-sizing:content-box;"/>
     <td style="width:1.9%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:16.72%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.9%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:16.72%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3415dba0-9192-4290-9a0d-81bbba8c3e88" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">102,928</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_630c9340-c7b3-414d-8f6c-cabc7b0310b6" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">80,077</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d70a0975-d478-451c-98d9-13103765d9b0" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,834</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_171451a5-58b0-453a-bc6e-b80276923c50" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,100</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1415eda3-8ad1-4038-9410-f87bebf608ed" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">132,762</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f0c2cc0-5aa8-43b7-b504-2ed60abef01d" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">104,177</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7bd0e25d-6070-45de-9c95-7ec8692ed770" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">132,762</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a076ed0-3d81-4a08-a4b8-28906a684ca0" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">104,177</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest and other income, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_63db744c-ce6c-483d-912e-652cca89934f" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:InterestAndOtherIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,815</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_49a70a6e-f190-431c-87cb-bf224f489525" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="us-gaap:InterestAndOtherIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,696</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other income</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_29f568c6-d95f-47f1-849d-482c39e29155" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,815</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e71a000-4f45-42e8-829f-b6436d913b49" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,696</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1cbac3cd-a9bf-46e4-849f-cd452b3c9ba8" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">119,947</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8fe0ef60-531a-41be-b7e5-b1ce8f8e6bbb" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">86,481</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized gain (loss) on marketable securities <br/>&#160;&#160;&#160;available-for-sale, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d830deb-fd61-484a-9d67-3eb0eb1a5bd2" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">377</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f81d2616-f575-422c-9bea-15c5a4b17769" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">389</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Comprehensive loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9de0b1ae-e709-4094-a9e8-6ac791d2a6ee" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">120,324</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_baf3f0f0-cf7a-4cee-952a-16667890ed17" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">86,092</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_29ced3d9-08b3-4d1e-a2fe-3133c869ad46" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_a5fa0ecb-cd73-44bf-b784-fb33ea8ef671" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">2.01</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a455b135-a198-47bd-a71b-4f11059ab842" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_772ff367-4804-4219-be9b-7a903b45c22d" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.51</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average shares used to compute net <br/>&#160;&#160;&#160;loss per share, basic and diluted</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c9ec98dc-7d7b-41b9-a807-84a945c3aae3" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_9dbea86c-394e-4939-9704-70768a64775e" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">59,602,328</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b49c7f76-ed2a-4f4b-b38e-e7e610024591" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_2bdb5ad8-268d-47a3-9fd0-f37814f780ef" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">57,217,746</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">See accompanying notes to financial statements.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">115</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.7in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tyra Biosciences, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_of_stockholders_equity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">State</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ments of Stockholders&#8217; Equity</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands, except share amounts)</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:32.133%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8.023%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8.043%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8.043%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.044%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8.043%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.663%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common Stock</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Additional Paid-In Capital</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated Other Comprehensive Income</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated<br/>Deficit</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total Stockholders&#8217; Equity</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d475bae9-ea9c-4c5c-88ca-b7dbe29c00d3" contextRef="C_8c23cd18-4f82-4221-821a-3472384eac40" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">43,024,634</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d0dc9223-912a-406a-8c11-06b9c0a68764" contextRef="C_8c23cd18-4f82-4221-821a-3472384eac40" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01415431-3085-4517-83f1-a18a390ca174" contextRef="C_a11e42ed-6bba-4898-af75-300d1ef896ce" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">368,707</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f2013521-4f89-4345-ab7b-6bff7b2b8295" contextRef="C_57adc4c3-e413-40ba-9f2b-b0623d7e6ec7" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">381</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ae07a04-b509-44a5-a4ba-082918db4b0c" contextRef="C_d259c846-1a3b-459d-8db5-38b89ca9f52b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">164,830</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4bf86453-2549-4a45-aea8-5e53001c317e" contextRef="C_90b314f0-e678-446e-845b-a940c76b3ed3" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">204,262</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:14.4pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock under Private Placement, net of issuance costs of $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_612fd17c-d6ea-45b7-9068-bb7c64f0248f" contextRef="C_e25b71f6-c32b-4edc-aafd-1871c1261431" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;million</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_05139a54-42d7-429f-adc2-f5357e4fbb04" contextRef="C_04a08b7e-86bb-4a84-910d-c8256976e1da" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">9,286,023</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e40c67d4-fcda-416c-8d11-cb3a49a45a59" contextRef="C_04a08b7e-86bb-4a84-910d-c8256976e1da" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_14d4eada-53a9-41de-8432-bf4d7c3de622" contextRef="C_6cb8fd5f-1c00-421b-8722-81009515faf7" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">120,557</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f21efb3-5073-49c2-a05d-50e00bcd1b12" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">120,558</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:14.4pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of pre-funded warrants, net of issuance costs of $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2ed62094-4748-41b6-9da0-4116e428c133" contextRef="C_15910e68-42b0-4058-8d01-7cdf352e9ab5" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;million</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ccb53e22-6c75-483a-93d3-45ffed703d35" contextRef="C_80b76e96-2cd7-4fc4-8522-d847b364b8ec" name="tyra:IssuanceOfPreFundedWarrantsUnderPrivatePlacement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">79,022</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df209ee4-309d-4666-adff-ce3cffb12c83" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="tyra:IssuanceOfPreFundedWarrantsUnderPrivatePlacement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">79,022</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:14.4pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock pursuant to pre-funded warrant exercise</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_126f7150-c9b9-40c7-b7b4-25f4d880b728" contextRef="C_8959a728-1257-4d40-89a1-c9a8bdd37f42" name="tyra:IssuanceOfCommonStockPursuantToPreFundedWarrantExercise" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">705,000</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:14.4pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exchange of common stock for pre-funded warrants</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_616b0cfc-9b3c-46a4-a911-0824f4ab4ddb" contextRef="C_01b9476b-1614-4aa1-8247-68243ed0c8dd" name="tyra:ExchangeOfCommonStockForPre-FundedWarrantsShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">3,000,000</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:14.4pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock under benefit plans</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d4f3a348-fb8d-4822-9cfc-d6e98d0e6236" contextRef="C_01b9476b-1614-4aa1-8247-68243ed0c8dd" name="tyra:IssuanceOfCommonStockUnderBenefitPlansShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">664,184</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c0b96f6c-5bf0-4e96-b073-64937e502817" contextRef="C_80b76e96-2cd7-4fc4-8522-d847b364b8ec" name="tyra:IssuanceOfCommonStockUnderBenefitPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,557</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_95d427ab-2f8c-425b-9e41-aa6e2a8f0d74" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="tyra:IssuanceOfCommonStockUnderBenefitPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,557</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:14.4pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vesting of shares of common stock subject to repurchase</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a2c0829b-a9aa-4b02-bc11-1dbe200903a8" contextRef="C_01b9476b-1614-4aa1-8247-68243ed0c8dd" name="tyra:VestingOfSharesOfCommonStockSubjectToRepurchaseShare" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">70,104</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_73be0f3f-ac0b-4ab6-8f7a-e173add797df" contextRef="C_80b76e96-2cd7-4fc4-8522-d847b364b8ec" name="tyra:VestingOfSharesOfCommonStockSubjectToRepurchase" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_81ee16cf-29ca-4ce6-856e-3fef8b742100" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="tyra:VestingOfSharesOfCommonStockSubjectToRepurchase" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:14.4pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d551b186-98f2-4030-8137-74f54f11b17a" contextRef="C_80b76e96-2cd7-4fc4-8522-d847b364b8ec" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,801</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1b09024b-9257-42c3-a9dc-48089eba80e3" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,801</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:14.4pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized gain on marketable securities available-for-sale, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd0ea5cc-60be-453e-a3c8-e489efccf6bb" contextRef="C_2a06acfa-3379-4f4d-8b99-addfb1d70ade" name="tyra:AvailableForSaleDebtSecuritiesNetUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">389</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_08bf543e-2485-4932-89e7-a638e107340b" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="tyra:AvailableForSaleDebtSecuritiesNetUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">389</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:14.4pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_82778317-ec13-4870-9b10-ec86071eda12" contextRef="C_8160c430-5e2d-4be6-9c79-14512c0fe02b" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">86,481</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(86,481</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance at December 31, 2024</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eadfd38d-9239-40de-b7db-484893438c1c" contextRef="C_1faac4fa-e650-47b7-9da8-bf595e935e95" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">50,749,945</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dfa7aa98-bb3b-4f8d-822c-19ebd134e292" contextRef="C_1faac4fa-e650-47b7-9da8-bf595e935e95" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f4675f19-fd46-413d-aa28-bbd94f2c9460" contextRef="C_a190af4b-bf04-4d25-9ef5-ba22a9fc2494" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">593,687</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a9bc6c0-cdbb-43a3-9535-e3f537edce90" contextRef="C_afd54226-bb0b-422e-afb5-a979bf3c3fb7" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">770</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ab94ee3f-a305-45c7-9be4-8e3019a90933" contextRef="C_c487f789-6116-468a-b633-8abf3bf8a878" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">251,311</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9fe9afad-4b36-4fcf-940f-256c6e87c05c" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">343,151</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:14.4pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock pursuant to pre-funded warrant exercise</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a73368f-0a18-41cb-8e05-272a340316ac" contextRef="C_b208f498-8b12-48b2-b2d8-4d1f1322980d" name="tyra:IssuanceOfCommonStockPursuantToPreFundedWarrantExercise" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,000,069</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_009f07eb-855d-4ca7-a929-5a964e853a17" contextRef="C_ab4cdc5b-1496-46f9-9dd9-d01d8da9a387" name="tyra:IssuanceOfCommonStockPursuantToPreFundedWarrantExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:14.4pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock under benefit plans</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_74a8566c-4ce2-4efe-8b94-26c313fa6a42" contextRef="C_68757860-b94a-4127-be6e-9246030381f8" name="tyra:IssuanceOfCommonStockUnderBenefitPlansShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">952,026</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6e0723c-4b90-44fb-bb92-622871c668fe" contextRef="C_1113fea0-b015-450d-8260-f27bbaccdf6f" name="tyra:IssuanceOfCommonStockUnderBenefitPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,341</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_36ab7506-c2f1-4c6e-b4c2-06b7013464a6" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="tyra:IssuanceOfCommonStockUnderBenefitPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,341</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:14.4pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vesting of shares of common stock subject to repurchase</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bdc2d188-29d6-450f-bd1f-093fbbab76aa" contextRef="C_68757860-b94a-4127-be6e-9246030381f8" name="tyra:VestingOfSharesOfCommonStockSubjectToRepurchaseOneShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">4,317</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7aa20d6c-8347-4650-82a1-66ae010c67b1" contextRef="C_1113fea0-b015-450d-8260-f27bbaccdf6f" name="tyra:VestingOfSharesOfCommonStockSubjectToRepurchaseOne" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_75b51620-90c0-4de6-b492-3adce985fe1e" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="tyra:VestingOfSharesOfCommonStockSubjectToRepurchaseOne" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:14.4pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_63a499ca-1793-4ee7-8c3a-649bfc5a97de" contextRef="C_1113fea0-b015-450d-8260-f27bbaccdf6f" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,006</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_09e023f8-56fa-4de6-8052-1ea60f9f35ee" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,006</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:14.4pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized loss on marketable securities available-for-sale, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa184049-9a20-4114-9416-811a4f5a0b9f" contextRef="C_88813698-fe70-4238-9dca-06637a729f85" name="tyra:AvailableForSaleDebtSecuritiesNetUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">377</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c20388d7-f1ce-44b6-b6f6-e728618b4f08" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="tyra:AvailableForSaleDebtSecuritiesNetUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">377</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:14.4pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="text-indent:-2.74%;padding-left:2.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e388d2c9-ce2b-41d5-b5a3-aac8c29c1a2d" contextRef="C_df547fe0-45f9-4a1e-9a51-de2c71f2fc5c" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">119,947</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f47553ae-6905-4029-92eb-0974f37c7c85" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">119,947</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance at December 31, 2025</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6130cb36-4323-41f7-9e4b-c890fbd9ce17" contextRef="C_bf0901d4-ef49-48dc-b81b-94822de4c19d" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">53,706,357</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5400ed7b-0971-441e-afb0-e58d1f8bcba2" contextRef="C_bf0901d4-ef49-48dc-b81b-94822de4c19d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_46602ce8-39d3-4cb5-b3c4-1c8c40afbb68" contextRef="C_7a958c54-6cff-41ea-bb1a-33c200dccaae" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">630,037</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b64cabd-7388-422c-914f-18602ef3567c" contextRef="C_58b2744f-4829-4186-a4c0-62f067475f6f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">393</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f6bab05-b4a5-497a-9d55-51e2f45cf184" contextRef="C_27fab6ea-d588-459f-a85f-6bc9be1ab8c8" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">371,258</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d030e5e-d769-4c61-9348-f2b3fdbc4a66" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">259,177</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">See accompanying notes to financial statements.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.9in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">116</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tyra Biosciences, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="fin189651_5"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">State</span><span id="statements_of_cash_flows"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ments of Cash Flows</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands)</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:66.867%;box-sizing:content-box;"/>
     <td style="width:1.481%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:13.425%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.481%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.745000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from operating activities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b7d1a5ca-9e5d-4ba8-b6b8-b34f0532ef8c" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">119,947</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c748e617-c522-4497-8405-5bc39746fef6" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">86,481</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a6c999d1-4f54-4f54-a16c-9a0eaf9e87e7" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">546</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cf550943-dd78-44a1-9d1b-5959b514179b" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">519</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_859d68e7-8eed-44d4-a9e8-4712fd0fb0e9" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,006</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_18d83882-9451-4824-add6-354454c0f233" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,801</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accretion of marketable securities, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ef30bd4-3c03-413c-86f5-4243774dfc44" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="tyra:AccretionOnMarketableSecuritiesNet" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,119</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_358061fa-00da-4bc0-8226-70de0b89cdec" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="tyra:AccretionOnMarketableSecuritiesNet" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,884</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb212838-51cf-4250-a1ab-04d58b9ca61e" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,080</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9b9aafde-2e05-457a-91e7-adf357944930" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">169</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable, accrued expenses and other liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6063e0e3-ab42-473f-a2f9-95fda053761b" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,369</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_520f66ee-c1c6-4e13-94f4-74a6eed60307" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">744</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right-of-use assets and lease liabilities, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7eb78b7c-45f8-408f-8923-3103f3dc0cd5" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="tyra:IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">83</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_30c9c722-bc65-497c-895e-a5664dc03af8" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="tyra:IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">184</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in operating activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7393c695-da6b-40d4-a01a-3cbf1a206cf1" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">95,142</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3fb9d7ef-fe10-4d92-8a3a-53ef66b17762" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">69,774</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from investing activities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of marketable securities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d33fc03c-ce06-427b-a977-77bc310f972d" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">101,254</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3a4692d5-0823-428d-b81f-60becc86d387" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">263,624</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Maturities of marketable securities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8eea8f3c-d367-495e-b46d-98aa7d127105" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">173,858</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_78e48cd7-25a3-4f26-9547-392dca07fc61" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">165,885</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of property and equipment</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e8fda148-bd6e-4e54-b959-d1b38ae85bcc" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">141</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b241c8e-ea71-420f-94e5-62e36b67879e" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">664</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by (used in) investing activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7648c9f8-fb42-4b51-adac-4f5aa6be686c" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">72,463</ix:nonFraction></span></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ab132f26-740f-4306-9437-dd1e2a0618bc" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">98,403</ix:nonFraction></span></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from financing activities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from issuances of common stock under benefit plans</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34949fea-105c-42d6-8aff-3cc69506d2bb" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="tyra:ProceedsFromIssuanceOfCommonStockUnderBenefitPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,100</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_847c600d-c944-49d5-bf91-e1c9a286eb1a" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="tyra:ProceedsFromIssuanceOfCommonStockUnderBenefitPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,557</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from issuance of common stock and pre-funded warrants from Private Placement</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1cd1269a-e04f-4020-9760-ca33a2d4bf6b" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="tyra:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromPrivatePlacement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ec20e95-8be1-4950-b305-62a36be5702b" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="tyra:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromPrivatePlacement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">200,000</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Payments of issuance costs for common stock and pre-funded warrants from Private Placement</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c6be6fb-b8bd-4cf7-8d42-38777d5ea760" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="tyra:PaymentsOfIssuanceCostsForCommonStockAndPreFundedWarrantsFromPrivatePlacement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bfa96a59-1b4a-482e-a5e2-2d1df29e1c1b" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="tyra:PaymentsOfIssuanceCostsForCommonStockAndPreFundedWarrantsFromPrivatePlacement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">420</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_14a84d68-e22c-42f6-815c-90fa612e7463" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,100</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a54deb6b-fb89-4667-8ea9-605aae8fe2e3" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">202,137</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash increase (decrease) for the period</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_03fd2181-81fd-461a-b91b-633f8feae647" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">14,579</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a5342886-a64b-4bff-aa29-392757ab413c" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,960</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash, cash equivalents and restricted cash at beginning of the period</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f601457c-4064-43e3-9f8e-120aba81dc5c" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">92,966</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c8847f29-6c29-4b4d-bce9-38e336a12e02" contextRef="C_90b314f0-e678-446e-845b-a940c76b3ed3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59,006</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash, cash equivalents and restricted cash at end of the period</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b21045bb-a924-4c09-9905-48e8e4fcfb42" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">78,387</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4400d00-8872-423c-bbf4-61804ee78463" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">92,966</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reconciliation of cash, cash equivalents and restricted cash to the <br/>&#160;&#160;&#160;balance sheet</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ccfc80e5-d74f-4703-88a2-b43a22d6d62f" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">77,387</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce229368-5a20-4343-bf95-601fc5591f24" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">91,966</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df83d26d-e066-488e-b6fd-30ff611043c7" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,000</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f4455c29-6c63-4787-9907-1d6def9594d8" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,000</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash, cash equivalents and restricted cash</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b767acc-dc66-4c40-865f-8d2b7e8ca6d5" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">78,387</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ea4fead5-2f9e-4902-9fa1-83caa299f0cd" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">92,966</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Supplemental disclosure of cash flow information:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-cash investing and financing activities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dba8d4d2-a60a-4afa-a3a4-1d5a5dcc8d8b" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_698430b7-f139-45b7-b74e-620a7d3f38ac" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vesting of options early exercised subject to repurchase</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_58462d26-9f36-4a51-8bb8-b2bc16308717" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="tyra:VestingOfOptionsEarlyExercisedSubjectToRepurchase" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2fa5a4ab-7aa6-411a-921e-3c189265ac89" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="tyra:VestingOfOptionsEarlyExercisedSubjectToRepurchase" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Receivable from exercise of stock options included in prepaid expenses and other current assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_03fce516-f193-4920-9315-466c8787bd16" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="tyra:ReceivableFromExerciseOfStockOptionsIncludedInPrepaidExpensesAndOtherCurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">241</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_042934f5-13dc-40c3-8474-21ee30734aa1" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="tyra:ReceivableFromExerciseOfStockOptionsIncludedInPrepaidExpensesAndOtherCurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">See accompanying notes to financial statements.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">117</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tyra Biosciences, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to the Financial Statements</span></p><div><ix:nonNumeric id="F_a9cce930-c962-4202-a5af-8560e60677a4" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" escape="true" continuedAt="F_a9cce930-c962-4202-a5af-8560e60677a4_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="note_1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. Orga</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nization and Summary of Significant Accounting Policies</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_adcba966-3790-4e02-8731-6f688c7b8fb3" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="tyra:OrganizationPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Organization</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tyra </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Biosciences, Inc. (the Company) was incorporated in the state of Delaware on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_87a306cb-793d-41da-a78a-2c0b3a880653" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="dei:EntityIncorporationDateOfIncorporation" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">August 2, 2018</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The Company&#8217;s in-house precision medicine platform, SN&#197;P, enables rapid and precise drug design through iterative molecular SN&#197;Pshots that help predict which product candidates may demonstrate the highest potency, selectivity and tolerability. The Company&#8217;s focus is on applying its accelerated small molecule drug discovery engine to develop therapies in targeted oncology and genetically defined conditions</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since its inception, the Company has devoted substantially all of its resources to research and development activities, business planning, establishing and maintaining its intellectual property portfolio, hiring personnel, raising capital, and providing general and administrative support for these operations. It has incurred losses and negative cash flows from operations since commencement of its operations. The Company had an accumulated deficit of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_66fb0dfd-a8dc-4494-b14a-e4b6df45ae38" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">371.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and cash, cash equivalents and marketable securities of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b498cea-fde5-4189-8490-e5875b37ba85" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="tyra:CashCashEquivalentsAndMarketableSecurities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">256.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of December 31, 2025. From its inception through December 31, 2025, the Company has financed its operations primarily through the sale of common stock, private placements of its convertible preferred stock, and the issuance of common stock and pre-funded common stock warrants through a private placement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As the Company continues its expansion, it may seek additional financing and/or strategic investments. However, there can be no assurance that any additional financing or strategic investments will be available to the Company on acceptable terms, if at all. If events or circumstances occur such that the Company does not obtain additional funding, it will most likely be required to reduce its plans and/or certain discretionary spending, which could have a material adverse effect on the Company&#8217;s ability to achieve its intended business objectives. Management believes that it has sufficient working capital on hand to fund operations through at least the next twelve months from the date of issuance of these financial statements.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5cbed0d4-f59e-412f-b1e8-58b074239c04" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true" continuedAt="F_5cbed0d4-f59e-412f-b1e8-58b074239c04_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of Presentation</span></p></ix:nonNumeric></div><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:continuation id="F_5cbed0d4-f59e-412f-b1e8-58b074239c04_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying financial statements have been prepared in accordance with generally accepted accounting principles in the United States (GAAP). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) promulgated by the Financial Accounting Standards Board (FASB).</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Summary of Significant Accounting Policies</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ef40ec59-550f-45b2-8d0c-9546ef27dfc4" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:UseOfEstimates" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates and assumptions made in the accompanying financial statements include, but are not limited to, the valuation of share-based awards, the valuation of deferred tax assets and income tax uncertainties, accruals for research and development activities, and incremental borrowing rate (IBR) for right-of-use (ROU) assets. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable. Actual results may differ from those estimates or assumptions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">118</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_a9cce930-c962-4202-a5af-8560e60677a4_1" continuedAt="F_a9cce930-c962-4202-a5af-8560e60677a4_2"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_61ab8795-cd38-4869-a562-92d4729e922c" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments which potentially subject the Company to a significant concentration of credit risk consist of cash, cash equivalents and marketable securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the nature of the instruments held in the depository institutions.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_776765fd-d2ce-4f13-a48c-f73bc80aff70" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents primarily represent funds invested in readily available money market accounts. As of December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had cash and cash equivalents balances deposited at major financial institutions.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ac15e38c-2ff7-40d9-9411-00d0cccf7898" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:MarketableSecuritiesPolicy" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Marketable Securities</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketable securities consist of debt securities of government-sponsored entities. These securities are classified as available-for sale, as the sale of such securities may be required prior to their maturity. Available-for-sale securities are recorded at fair value, with the related unrealized gains and losses included in accumulated other comprehensive income or loss and included as a separate component of stockholders&#8217; equity. The amortized cost of available-for-sale securities reflects amortization of premiums and accretion of discounts to maturity. Premiums and discounts on debt securities are amortized or accreted into interest and other income, net. The Company classifies investments in marketable debt securities as current assets, regardless of the stated maturity date, which may be beyond one year from the current balance sheet date. Short-term classification reflects management&#8217;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s view that the entire portfolio is available, and the Company may use the proceeds from sales of these investments to fund current operations, as necessary.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_65fb84ea-317f-4dca-90a5-712d1a6a2633" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="tyra:AllowanceForCreditLossesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Allowance for Credit Losses</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company regularly reviews its portfolio for declines in fair value. For investments in an unrealized loss position, the Company assesses whether the decline is based on credit losses or other factor. As part of this assessment, the Company considers the cause of the impairment, the creditworthiness of the security issuers, current market conditions, the number of securities in an unrealized loss position, the severity of the losses, whether it will be required or will intend to sell the investment before recovery of its amortized cost basis. If fair value decline is determined to be due to a credit-related factor, the amortized cost basis is written down to fair value through net loss. If fair value decline is not due to credit-related factors, a loss is recorded in other comprehensive income or loss. The Company recognizes an allowance for credit losses up to the amount of the unrealized loss when appropriate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not measure an allowance for credit losses for accrued interest receivables. For the purposes of identifying and measuring an impairment, accrued interest is excluded from both the fair value and amortized costs basis of the investment. Uncollectible accrued interest receivables associated with an impaired marketable security are reversed against interest income in a timely manner upon identification of the impairment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_79f756f5-9253-494e-8786-a7354122c8be" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" escape="true" continuedAt="F_79f756f5-9253-494e-8786-a7354122c8be_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value Measurements</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company measures cash equivalents and available-for-sale debt securities at fair value. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. Therefore, fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability. Fair value is affected by a number of factors, including the type of asset or liability, the characteristics specific to the asset or liability and the state of the marketplace, including the existence and transparency of transactions between market participants. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</span></p></ix:nonNumeric></div></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">119</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_a9cce930-c962-4202-a5af-8560e60677a4_2" continuedAt="F_a9cce930-c962-4202-a5af-8560e60677a4_3"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_79f756f5-9253-494e-8786-a7354122c8be_1"><p style="margin-left:6.667%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Money market funds are highly liquid investments and are classified as Level 1. The pricing information for these assets is readily available and can be independently validated as of the measurement date. Available-for-sale debt securities, including U.S. Treasury securities and U.S. Agency bonds are classified as Level 2. These securities are valued using fair value from third-party pricing services, which may use observable inputs based on real-time trade data for similar assets, broker/dealer quotes, bids and/or offers and other observable inputs. The Company validates valuations obtained from third-party pricing services by understanding the models used and obtaining market values from independent sources.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8e92b2b4-d3dd-40f9-bb70-a56dfbc7abb5" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Cash</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted cash is comprised of cash that is restricted as to its withdrawal or use under the terms of certain contractual agreements. Restricted cash as of December 31, 2025 and 2024 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b3e1459-f6e8-44a2-8332-27413229433d" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_6517cc2b-3839-44ff-86c2-bb810f0357b4" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which consisted of collateral for letters of credit related to the Company&#8217;s operating leases.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d9f289e2-2422-4915-8683-115a7cce2e62" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Property and Equipment</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment is stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets (generally </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_de6e2adb-217c-46f8-87ab-7f9f75f3c64f;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a9176b49-3a99-425e-93c1-016a2f9e9b66" contextRef="C_d58f684d-19a9-4256-8716-4e0a68a997cd" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seven years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or the remaining term of the lease).</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1159cb0e-c347-4fd0-bc89-737a1c911279" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Impairment of Long-Lived Assets</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for the impairment of long-lived assets by reviewing these assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group to be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted-cash-flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f7b2804-83dc-4418-b7d8-a46c34e08733" contextRef="C_4a3a2077-3bda-4557-8dc1-0b3803890cbf" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_8e3e343e-5b92-4894-93d1-99e47e32f5cd" contextRef="C_82407490-dbff-4f2d-ab88-7b2feada5686" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recognize impairment losses for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_ca400e5e-266e-4163-a708-f54743b0e14c" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="tyra:AccruedResearchAndDevelopmentExpensePolicyPolicyTextBlock" escape="true" continuedAt="F_ca400e5e-266e-4163-a708-f54743b0e14c_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accrued Research and Development Expenses</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses consist of external and internal costs associated with the Company&#8217;s research and development activities, including its discovery and research efforts and the preclinical and clinical development of its product candidates. Research and development costs are expensed in the period incurred.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company has entered into various research and development contracts with clinical research organizations, clinical manufacturing organizations, clinical sites and other vendors and consultants. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and payments made in advance of or after the performance are reflected in the accompanying balance sheets as prepaid expenses or accrued liabilities, respectively. The Company records accruals for estimated costs incurred for ongoing research and development activities. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs. The Company holds discussions with applicable personnel and outside service providers as to the progress of clinical trials, or the services completed. Significant judgments and estimates may be made in determining the prepaid or accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. Nonrefundable advance payments for goods and services, including fees for process</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">120</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_a9cce930-c962-4202-a5af-8560e60677a4_3" continuedAt="F_a9cce930-c962-4202-a5af-8560e60677a4_4"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_ca400e5e-266e-4163-a708-f54743b0e14c_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">development, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">are deferred and recognized as expenses in the period that the related goods are consumed or services are performed.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6a0bd7aa-5209-40ef-85fe-c9a09d15712c" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="tyra:PatentCostsPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent Costs</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company expenses all costs as incurred in connection with patent applications (including direct application fees, and the legal and consulting expenses related to making such applications) and such costs are included in general and administrative expenses in the statements of operations and comprehensive loss.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_de3f3620-f899-4151-a81d-c43844170297" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has operating leases for office and lab space. At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, the Company records the associated lease liability and corresponding ROU asset upon commencement of the lease using the implicit rate or a discount rate based on a credit-adjusted secured borrowing rate commensurate with the term of the lease. The Company evaluates leases at their inception to determine if they are to be accounted for as an operating lease or a finance lease.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating lease assets represent a right to use an underlying asset for the lease term and operating lease liabilities represent an obligation to make lease payments arising from the lease. Operating lease liabilities with a term greater than one year and their corresponding ROU assets are recognized on the balance sheet at the commencement date of the lease based on the present value of lease payments over the expected lease term. The Company excludes short-term leases, if any, having initial terms of 12 months or less at lease commencement as an accounting policy election.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain adjustments to the ROU assets may be required for items such as payments made at or before the commencement date, initial direct costs paid or lease incentives received. As the Company&#8217;s leases do not typically provide an implicit rate, the Company utilizes the appropriate IBR, determined as the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term and in a similar economic environment. Lease cost is recognized on a straight-line basis over the lease term and variable lease payments are recognized as operating expenses in the period in which the obligation for those payments is incurred. Variable lease payments primarily include common area maintenance, utilities, real estate taxes, insurance, and other operating costs that are passed on from the lessor in proportion to the space leased by the Company. In measuring the ROU assets and lease liabilities, the Company has elected to combine lease and non-lease components.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating ROU assets are reflected in right-of-use assets in the accompanying balance sheets. Operating lease liabilities are reflected in lease liabilities, current and noncurrent in the accompanying balance sheets.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7df216d2-6fa0-41a6-bdd7-5b038326d3e1" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="tyra:CommonStockWarrantsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Common Stock Warrants</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common stock warrants are classified as either a liability or equity, based on an assessment of specific terms and applicable authoritative guidance in ASC 480, Distinguishing Liabilities from Equity (ASC 480) and ASC 815, Derivatives and Hedging (ASC 815). The Company considers whether the warrants are freestanding financial instruments, whether they meet the definition of a liability pursuant to ASC 480, and whether they meet all of the requirements for equity classification under ASC 815. This assessment is performed at the time of warrant issuance and re-assessed as of each subsequent quarterly balance sheet date, while the warrants are outstanding.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_19d6ac3c-936f-4af6-bc72-af6843f44b74" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true" continuedAt="F_19d6ac3c-936f-4af6-bc72-af6843f44b74_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-Based Compensation</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense represents the cost of the grant date fair value of employee, officer, director and non-employee equity awards, estimated in accordance with the applicable accounting guidance, and, for those awards subject only to service conditions, recognized on a straight-line basis over the vesting period. The vesting period generally approximates the expected service period of the awards. The Company recognizes stock-based compensation expense for awards with performance conditions when it is probable that the condition will be</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">121</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_a9cce930-c962-4202-a5af-8560e60677a4_4" continuedAt="F_a9cce930-c962-4202-a5af-8560e60677a4_5"><div style="font-size:12pt;font-family:Times New Roman;"><ix:continuation id="F_19d6ac3c-936f-4af6-bc72-af6843f44b74_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">met, and the award will vest. If the achievement of performance conditions is no longer deemed probable, previously recognized compensation cost is reversed. For awards with performance and service conditions, the Company begins recording share-based compensation when achieving the performance criteria is probable and recognizes the costs using the accelerated attribution method. The Company recognizes forfeitures as they occur.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of stock options is estimated using a Black-Scholes valuation model on the date of grant. This method requires certain assumptions to be used as inputs, such as the fair value of the underlying common stock, expected term of the option before exercise, expected volatility of the Company&#8217;s common stock, risk-free interest rate and expected dividend. Options granted have a maximum contractual term of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d013e45f-5355-41a7-834a-46468b48d430" contextRef="C_3bfbb795-7b7e-4213-b6a6-ea14b283ed4f" name="tyra:OptionsGrantedContractualTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ten years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company has limited historical stock option activity and therefore estimates the expected term of stock options granted using the simplified method, which represents the arithmetic average of the original contractual term of the stock option and its weighted-average vesting term. The expected volatility of stock options is estimated based on the average historical volatilities of common stock of comparable publicly traded companies and the Company</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s own volatility. The comparable companies are chosen based on their size and stage in the life cycle. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available. The risk-free interest rates used are based on the U.S. Treasury yield in effect at the time of grant for zero-coupon U.S. treasury notes with maturities approximately equal to the expected term of the stock options. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5eaf8aaf-af4f-4477-951f-ffbdfdea54d4" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:DividendPaymentRestrictionsScheduleDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has historically not declared or paid any dividends and does not currently expect to do so in the foreseeable future, and therefore, has estimated the dividend yield to be </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_702db042-5141-4eb7-816f-d2d46cb7ca63" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="tyra:DividendYield" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">zero</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></ix:nonNumeric></span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9eaf7090-76ef-40a1-ac38-69601e041f16" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Commitments and Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes a liability with regard to loss contingencies when it believes it is probable a liability has been incurred, and the amount can be reasonably estimated. If some amount within a range of loss appears at the time to be a better estimate than any other amount within the range, the Company accrues that amount. When no amount within the range is a better estimate than any other amount, the Company accrues the minimum amount in the range.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_c18cdd7a-a6b4-4cac-aaff-effdcd169151" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true" continuedAt="F_c18cdd7a-a6b4-4cac-aaff-effdcd169151_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the statement of operations in the period that includes the enactment date.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025 and 2024, the Company maintained valuation allowances against its deferred tax assets as the Company concluded it had not met the &#8220;more likely than not&#8221; to be realized threshold. Changes in the valuation allowance when they are recognized in the provision for income taxes may result in a change in the estimated annual effective tax rate.</span></p></ix:nonNumeric></div></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">122</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_a9cce930-c962-4202-a5af-8560e60677a4_5" continuedAt="F_a9cce930-c962-4202-a5af-8560e60677a4_6"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_c18cdd7a-a6b4-4cac-aaff-effdcd169151_1"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records uncertain tax positions on the basis of a two-step process whereby (1) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability. As of December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c56df925-b00d-4814-ba8b-f8792f90ec7d" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> accrued interest or penalties.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6c3e2de3-af4f-459b-a7ae-49caef133af6" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comprehensive Loss</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprehensive loss consists of two components: net loss and other comprehensive income or loss. Other comprehensive income (loss) refers to gains or losses that are recorded as an element of stockholders&#8217; equity but are excluded from net loss. The Company&#8217;s other comprehensive income (loss) consists of unrealized gains and losses on marketable securities.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ad8bd3d0-b458-42c1-b723-1873ed2b66b2" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Loss Per Share</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock and common stock equivalents outstanding for the period. Common stock equivalents are only included when their effect is dilutive. Pre-funded warrants are considered outstanding for the purposes of computing basic and diluted net loss per share because shares may be issued for little or no additional consideration and are fully vested and exercisable after the original issuance date of the pre-funded warrant. The Company&#8217;s potentially dilutive securities include unvested common stock upon early exercise of stock options, outstanding stock options under the Company&#8217;s equity incentive plan, and estimated shares purchasable under the employee stock purchase plan, and have been excluded from the computation of diluted net loss per share as their inclusion would be anti-dilutive. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#8217;s net loss position.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2464a8c1-49a9-4486-9381-33f28734202a" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="tyra:RelatedPartiesPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Related Parties</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transactions between related parties are considered to be related party transactions even though they may not be given accounting recognition. FASB ASC 850, Related Party Disclosures (ASC 850) requires that transactions with related parties that would make a difference in decision making shall be disclosed so that users of the financial statements can evaluate their significance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e33e2582-20ff-4937-ac05-7115b366ba12" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="tyra:CapitalizedSoftwareImplementationCostsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Capitalized Software Implementation Costs</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company capitalizes certain implementation costs incurred under a cloud computing arrangement that is a service contract. Costs incurred during the application development stage related to the implementation of the hosting arrangement are capitalized and included within prepaid and other current assets, and other long-term assets on the accompanying balance sheets. Amortization of capitalized implementation costs is recognized on a straight-line basis over the term of the associated hosting arrangement when it is ready for its intended use. Costs related to preliminary project activities and post-implementation activities are expensed as incurred.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1984f704-ac75-4c9b-ae70-d9c2b6ea8625" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures.&#8221; ASU 2023-09 requires disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation as well as information on income taxes paid. ASU 2023-09 is effective for public entities with annual periods beginning after December 15, 2024, with early adoption permitted. The Company adopted this standard prospectively for the period ending December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The adoption impacted the disclosures and did not impact the financial statements. See Note 8, Income Taxes, for disclosures related to the adoption of ASU 2023-09.</span></p></ix:nonNumeric></div></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">123</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_a9cce930-c962-4202-a5af-8560e60677a4_6"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_62265f44-bc56-4069-bc59-d16fe05b5a5c" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="tyra:IssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Issued Accounting Pronouncements Not Yet Adopted</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03, "</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">". In January 2025, the FASB issued ASU 2025-01, "</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">", to clarify the effective date of ASU 2024-03. These amendments are intended to provide more information about certain costs and expenses on an interim and annual basis. The amendments are effective for annual periods beginning after December 15, 2026 and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The new standards are expected to be applied prospectively, but retrospective application is permitted. The Company is currently evaluating the impact on its financial statements and related disclosures.</span></p></ix:nonNumeric></div></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2f558a7e-fb64-45ea-bb4f-c30bdab89006" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. Fair Value Measurements</span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_b57f7558-f74f-4798-93db-5e79b9df9d9b" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock" escape="true"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables show the Company</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;s cash equivalents and marketable securities measured at fair value as of December 31, 2025 and 2024 (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:37.932%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.297%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:14.177000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.297%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.297%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="11" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Quoted prices in active markets for identical assets (Level 1)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant other observable inputs (Level 2)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant unobservable inputs (Level 3)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Money market funds</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2904317-d75d-4ed4-a624-81602dc79fc2" contextRef="C_91ad5ba4-1680-46a4-9791-00d5894e9338" name="us-gaap:FairValueConcentrationOfRiskCashAndCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">54,444</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da9e8cf0-7983-48f6-aa3b-748a8b121e73" contextRef="C_4952b098-3c5d-47e1-a11e-2ad51ec8c584" name="us-gaap:FairValueConcentrationOfRiskCashAndCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">54,444</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd623ff0-912a-47d9-bea2-8e39eae89b5f" contextRef="C_2d692ebc-a844-453a-851e-e2ddc17d2c55" name="us-gaap:FairValueConcentrationOfRiskCashAndCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df481196-ed1a-42e4-b932-b29b3a19de1d" contextRef="C_dfcd0690-10f5-44d8-bca0-e39e09cfb498" name="us-gaap:FairValueConcentrationOfRiskCashAndCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fa2b40e3-5eec-4343-84ea-07fce5eb1e4b" contextRef="C_f0dad730-1497-4f1d-aca3-f9d1d48a1d39" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">133,264</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d31fcfb-3d29-4b15-95ff-bd21e3fc1f0f" contextRef="C_66a3ee93-337d-4531-9b7b-c8623780d836" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ead449d1-bbe9-4935-9e7c-52841c4f95fd" contextRef="C_5a67af1f-955f-4fed-a7a1-8ddc18ed22ab" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">133,264</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4da31ef4-7a36-46a2-ab24-b603ea0abced" contextRef="C_c6068cd1-21e5-450a-9869-2d60615e13b4" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;U.S. government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e89a966b-367c-429b-b274-ca7cd7783a00" contextRef="C_997236c7-47c3-4ba7-822f-0fd00f5213e3" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,352</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9c6ec649-3080-4846-a1c4-254d7e12ff55" contextRef="C_23d8f849-93e2-4c5e-8518-5df9a193ecf2" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_26d935ee-f996-495d-8fcb-818958bae6d0" contextRef="C_371b11b6-fa70-4468-9e81-af92b5ec918f" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,352</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9f54adb-14ec-4337-9aff-f60cd31b7e11" contextRef="C_83e9b223-47dc-4d04-a739-70fa68863bb9" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Total marketable securities</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_69c769cc-50d1-453b-8d9d-9d410615fa89" contextRef="C_69bde7cd-c11f-4704-8be8-b885ee6842e9" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">178,616</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d667129-09d9-410f-984d-76b0985f248b" contextRef="C_6fe01dec-1d26-432c-84d4-861aa02e32d6" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_58b73a24-10ef-4b6f-bee7-b0cebf51a026" contextRef="C_e0df3a23-dd2e-494b-a002-48c55afa2131" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">178,616</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_746b09d2-8501-49c6-ae02-ef7d1cb51f52" contextRef="C_b8c32c5b-98c6-4415-8115-4d928ac1827f" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Total</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5b19074-ab91-454d-aeb9-fbabafb9a6b6" contextRef="C_cdc6cc80-baf4-45fe-8841-dff91027f8b8" name="us-gaap:AssetsFairValueAdjustment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">233,060</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_27dd1143-ff3b-4253-9b15-0d3499d44d45" contextRef="C_93dfdc64-6b4a-406f-b392-50dedb2970c5" name="us-gaap:AssetsFairValueAdjustment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">54,444</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_785f3111-da80-4681-a95f-91e6e233189d" contextRef="C_822f9ef4-d69d-4947-92b4-eae4cf622064" name="us-gaap:AssetsFairValueAdjustment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">178,616</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_49392b3f-4db3-4a3f-a729-2f3750ad5130" contextRef="C_1e213811-870d-4dbf-826c-e35260a70b15" name="us-gaap:AssetsFairValueAdjustment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="text-indent:9.067%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:37.932%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.297%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:14.177000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.297%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.297%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="11" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Quoted prices in active markets for identical assets (Level 1)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant other observable inputs (Level 2)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant unobservable inputs (Level 3)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Money market funds</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6be0a00b-f1bf-487e-815e-2a2d23201ad3" contextRef="C_9dc741f3-157e-4e28-9a5f-c2124c563656" name="us-gaap:FairValueConcentrationOfRiskCashAndCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">69,698</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_36d5827d-cab4-425c-b80e-9537baf44c58" contextRef="C_8b56e0c7-22d7-4f97-bc7f-f3c1c34ac2a5" name="us-gaap:FairValueConcentrationOfRiskCashAndCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">69,698</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7066c364-ea14-44e4-84ad-a4513fba4f87" contextRef="C_859a4837-02fe-4595-8853-de8c56b1c468" name="us-gaap:FairValueConcentrationOfRiskCashAndCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_61e9994e-2ac4-461b-bb18-71b4d81854cc" contextRef="C_4f2fa7fb-50cf-4ab7-a541-88b9de8c16cd" name="us-gaap:FairValueConcentrationOfRiskCashAndCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_524e28de-1b13-4208-8eac-69613871242f" contextRef="C_445d4a10-50d6-4fad-8ed4-556b6ce24ec6" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">122,980</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f8fcf428-09da-4859-a0ce-f64b56d4f25f" contextRef="C_35d9901f-2f43-4932-960b-edaffa307b8e" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_66ebb087-669a-4390-92fd-917c3059e6cc" contextRef="C_da6d61f4-da45-4047-8849-7facd82c9bab" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">122,980</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d746953-9262-4a3e-8cae-75e73d38244f" contextRef="C_1373ea03-27b7-4611-89c2-aedca10e502b" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;U.S. government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f1ab6b2-98a6-4f31-b9a1-330e78b2289c" contextRef="C_7235c0d6-d80c-4a20-a791-afd7ff2647e0" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">126,495</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b8ec27f8-1c07-4e2e-bc13-80a0e1308674" contextRef="C_bab9baa6-70cc-470c-8e11-bb4b93099597" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0465d6f6-ba31-4445-9a06-6cb9d2cf1be1" contextRef="C_cabc47b3-0098-4429-acc8-8b363378e0b6" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">126,495</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9647447-35f7-431b-9f51-07cf4dc09489" contextRef="C_0732721d-acf1-480d-a569-2b3ce25dc4c8" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Total marketable securities</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_40e86e59-4aa7-4ff2-b020-b4b6e2f02550" contextRef="C_31ea1ae9-69e0-48ac-9963-d48f9f1c7a0d" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">249,475</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_076555de-af51-4047-9bd7-5a0f0fce2e5a" contextRef="C_7168fb48-4ee5-4fb1-9a24-58d8fea23470" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2afb7f0b-4758-4bc6-91b3-6ce5e5576ef6" contextRef="C_dea229cd-0197-42d7-b781-d2cf1a9090ed" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">249,475</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_77af5557-4b8f-492f-9039-36e98392e800" contextRef="C_c3062351-4e8a-468c-9ace-a5178560f024" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Total</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_673fbc68-73df-4248-af02-7e4850abacce" contextRef="C_31142ef9-0890-41ac-a5b5-d09b26dfd124" name="us-gaap:AssetsFairValueAdjustment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">319,173</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1405f91a-b1ff-48b9-81a3-61bb35288f34" contextRef="C_b08ce2b8-ac16-4b53-b8cb-6aa4f4c5e677" name="us-gaap:AssetsFairValueAdjustment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">69,698</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_43203c08-affa-4aae-bb26-54347edea474" contextRef="C_e15e6e13-7c17-4e72-95fd-e55ebe7fabb3" name="us-gaap:AssetsFairValueAdjustment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">249,475</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_00e8e035-c57b-49c6-9e7a-a75b53a1fa00" contextRef="C_0f90cf19-a5f9-46f3-880e-0596d855590c" name="us-gaap:AssetsFairValueAdjustment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The carrying amounts of the Company&#8217;s prepaid and other current assets, accounts payable, and accrued and other current liabilities approximate fair value due to their short maturities. None of the Company&#8217;s non-financial assets or liabilities are recorded at fair value on a non-recurring basis. There were no transfers between Levels 1, 2 or 3 for any of the periods presented.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">124</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fc480d08-428f-45c2-b970-cfc06a3bef5f" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3. Marketable Securities</span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_5b33dd3b-459b-4a66-8323-3169e667440f" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:MarketableSecuritiesTextBlock" escape="true" continuedAt="F_5b33dd3b-459b-4a66-8323-3169e667440f_1"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables summarize the Company</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;s marketable securities (see below and Note 2) accounted for as available-for-sale securities (in thousands, except years):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:32.323%;box-sizing:content-box;"/>
         <td style="width:14.141%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.141%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.141%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:10.121%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:11.131%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="12" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Maturity <br/>(in years)</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized cost</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized gains</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized losses</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated fair value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less than one</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d59c4ed-7cc6-4a1f-9956-697a3e139593" contextRef="C_ab8dd7ed-5d07-40f6-9887-243d8544fc7c" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">107,324</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6302e9b-524b-4382-922c-a340960564f9" contextRef="C_9631bb15-a89e-4277-b443-2488946a4125" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">223</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b060e3be-e623-4903-b415-a551c65f420e" contextRef="C_9631bb15-a89e-4277-b443-2488946a4125" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3919c37b-a10d-4329-98be-27e8ab04519f" contextRef="C_ab8dd7ed-5d07-40f6-9887-243d8544fc7c" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">107,547</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less than one</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_632d4099-8b5a-4d2e-beb4-522e420741a1" contextRef="C_9e723f9e-f294-44a4-b7ba-1b0bfe9753cc" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,215</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d8a5e55-149f-4fb3-bf86-95786517df02" contextRef="C_8ffa982e-10e5-4fab-99ed-6f19493d39e3" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">137</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7edab796-34a1-4a28-bf6c-619b5edcabb9" contextRef="C_8ffa982e-10e5-4fab-99ed-6f19493d39e3" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb2ac512-7618-4ded-84a0-ec54ed77a69c" contextRef="C_9e723f9e-f294-44a4-b7ba-1b0bfe9753cc" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,352</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1-2</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d327483b-0425-4d2e-aed4-ac39998cdb07" contextRef="C_6d93fb41-00d4-4bba-9d0f-e71f27a586ce" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,684</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fce96d90-3450-40f1-a77f-528be3b77851" contextRef="C_a3aa4fd7-a874-4bd2-a938-6252e0593cbe" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d8a4184-56d7-476c-a690-9dbfc7af82d8" contextRef="C_a3aa4fd7-a874-4bd2-a938-6252e0593cbe" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1803e64a-6bce-4dad-ab84-92b663cb79bf" contextRef="C_6d93fb41-00d4-4bba-9d0f-e71f27a586ce" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,717</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e8858fdf-0594-4f6c-8c72-3c96b1a9d4ac" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">178,223</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d675d94a-5aac-44ae-ac63-585781d5bbee" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">393</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_53eeb3b2-ba71-41dc-81e2-e36382e09dbd" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b78d5a78-d89f-4be5-961f-9230d14eb6f8" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">178,616</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="text-indent:9.067%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:32%;box-sizing:content-box;"/>
         <td style="width:14%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:10%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="12" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Maturity <br/>(in years)</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized cost</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized gains</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized losses</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated fair value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less than one</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de45c263-967a-4bde-914c-a5beac6643f3" contextRef="C_73360da3-36fa-405b-810f-ac396bf24bee" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">77,990</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d1b915b-60bf-47c7-b037-fd8c899f26b8" contextRef="C_12bd91d1-7116-4439-9d77-a7650dbde2f7" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">210</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2cde5652-dfcd-4152-b338-bab4dcf77ba6" contextRef="C_12bd91d1-7116-4439-9d77-a7650dbde2f7" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c8a14078-b51a-4934-937b-ba7301c15272" contextRef="C_73360da3-36fa-405b-810f-ac396bf24bee" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">78,197</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less than one</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2fc057d-baa3-478a-9457-0b2f7ee32d17" contextRef="C_4b1febba-292b-4542-9c54-ea17a48a4fcd" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">94,153</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_341abb84-51d2-412e-ae10-4776cfe02b4b" contextRef="C_c2661784-8ff1-4a9e-8a82-f75b049f70ad" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">189</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_17b4ebd2-89f2-47fa-b0d0-30e963c1c911" contextRef="C_c2661784-8ff1-4a9e-8a82-f75b049f70ad" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_06fa9f16-3c45-4fea-9db8-90939bc11636" contextRef="C_4b1febba-292b-4542-9c54-ea17a48a4fcd" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">94,333</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1-2</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af18fad1-5f87-4fda-af5a-a337948d40ca" contextRef="C_885b4f15-9028-4e67-83a3-63a20100958e" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,547</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_60d2db30-0334-482e-9a54-6f4288b7baec" contextRef="C_95f923d9-c4c3-4d2a-b6b5-83207327a686" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">239</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0073b45e-f460-4a74-9579-1cc343937804" contextRef="C_95f923d9-c4c3-4d2a-b6b5-83207327a686" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_536e82b0-9b0d-4c34-86cd-6e5a82a1dc69" contextRef="C_885b4f15-9028-4e67-83a3-63a20100958e" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,783</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1-2</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ba887e7-5aed-4c4b-af6c-73670d050ef9" contextRef="C_730568c6-2cf1-41de-a80e-e6d97f16ba8c" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,015</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d82d1a5c-88c1-429f-bc82-5284f33b5d2f" contextRef="C_a968be01-32a6-49ed-80ec-d5190256e424" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">159</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_07551962-587e-4b15-8fb7-d99770d4c983" contextRef="C_a968be01-32a6-49ed-80ec-d5190256e424" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f84546ac-36b8-4722-ac99-4260c85733f2" contextRef="C_730568c6-2cf1-41de-a80e-e6d97f16ba8c" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,162</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_969fe764-20f0-4363-89f1-27c40bf0ea72" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">248,705</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1dc5402f-fcb7-490d-ba99-c77bc846de3a" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">797</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f8f940c9-4688-42ae-a449-6c71dd6123f2" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d748a41f-115b-4270-98c5-41ab02625a9d" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">249,475</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents fair values and gross unrealized losses for those available-for-sale securities that were in an unrealized loss position, aggregated by category and the length of time that the securities have been in a continuous loss position (in thousands):</span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:continuation id="F_5b33dd3b-459b-4a66-8323-3169e667440f_1">
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:23.071%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.836%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.16%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.836%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.16%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.836%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.16%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.836%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.16%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.836%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.279%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.836%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></td>
         <td colspan="22" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Less than 12 months</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">12 months or longer</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized losses</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized losses</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized losses</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e15745b2-4251-40b9-8701-50c66126c584" contextRef="C_54f748e8-97d4-411e-9f01-5dd8ca0908ba" name="tyra:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,033</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a51c43d7-d064-40ec-8610-27210b01844b" contextRef="C_54f748e8-97d4-411e-9f01-5dd8ca0908ba" name="tyra:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ac0dd9d-10cc-44f2-bc47-9cbd58d8d25b" contextRef="C_54f748e8-97d4-411e-9f01-5dd8ca0908ba" name="tyra:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrGreaterFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a3abc9c3-11c3-49f0-bd89-647547b72c2b" contextRef="C_54f748e8-97d4-411e-9f01-5dd8ca0908ba" name="tyra:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5fcc4041-9731-4a80-a6bd-3ab59d73838e" contextRef="C_d60e36b5-9479-436f-8d6e-500af75adcec" name="us-gaap:FairValueOptionCreditRiskGainsLossesOnAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,033</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bcde3a51-d7f2-475f-9495-f0f3b5c03405" contextRef="C_54f748e8-97d4-411e-9f01-5dd8ca0908ba" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e243132-cd31-4205-9196-ecbd4d29980e" contextRef="C_4a9d47d3-2b9a-48d7-83f8-6532afecf992" name="tyra:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,891</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1abd8c9c-0213-4266-a1ff-8b4b9e96c4d3" contextRef="C_4a9d47d3-2b9a-48d7-83f8-6532afecf992" name="tyra:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85bd6e37-82af-41ec-97bd-de8c2b0e829a" contextRef="C_4a9d47d3-2b9a-48d7-83f8-6532afecf992" name="tyra:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrGreaterFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_713d4141-3abf-4736-937c-62613a0fe4c0" contextRef="C_4a9d47d3-2b9a-48d7-83f8-6532afecf992" name="tyra:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_46fe91b4-f321-4393-a210-82118d5b2334" contextRef="C_b90df891-3d95-47b5-b447-6bd47c401d88" name="us-gaap:FairValueOptionCreditRiskGainsLossesOnAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,891</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_42c5dfdd-7a65-4a86-9ee1-e09756a7b0e4" contextRef="C_4a9d47d3-2b9a-48d7-83f8-6532afecf992" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6517aff2-9205-4f52-9b2c-17f0949afd9b" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="tyra:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,924</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee8f6a1a-df86-4bf9-9dd5-6ebe9fdf5077" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="tyra:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_29b6716c-5dd0-4ea7-95b6-081a44d141aa" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="tyra:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrGreaterFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c4869c0-02c8-499c-b8b7-eb12192cd4bd" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="tyra:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d21148d3-7d04-4995-8eee-cb68a3473475" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="us-gaap:FairValueOptionCreditRiskGainsLossesOnAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,924</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9214ca85-3ee3-4eff-8c44-b31e149ef697" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table></ix:continuation></div><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, there were no available-for-sale securities in an unrealized loss position.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The amortized cost and fair value of marketable securities excludes $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70be79e0-c2c2-4ada-8224-f4ff81701eaf" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="tyra:AccruedInterestAvailableForSaleSecurities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ce27c6f-5181-4a67-b270-73aa2f848315" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="tyra:AccruedInterestAvailableForSaleSecurities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of accrued interest receivable as of December 31, 2025 and 2024, respectively. Accrued interest receivable is included in prepaid expenses and other current assets on the Company's balance sheets. The Company has not written off any accrued interest receivables for the years ended December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ae1a8854-0e16-449c-9e57-c9dbd5353e26" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4. Accrued Expenses and Other Current Liabilities</span></p><div style="font-size:11pt;font-family:Times New Roman;"><ix:nonNumeric id="F_94d6d6d7-d9d7-4d94-8780-bfc2a23fc291" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities consisted of the following (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:67.313%;box-sizing:content-box;"/>
         <td style="width:1.5%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.843%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.5%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.843%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued payroll and other employee benefits</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3dfb1692-a18a-4f07-b92f-25adfd390b90" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:AccruedSalariesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,533</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1f74d68b-ff2c-424f-a67b-26f14b82e4f3" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="us-gaap:AccruedSalariesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,451</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued research and development expenses</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87e65705-49ec-49d1-9c48-4695c6db3236" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="tyra:AccruedResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,840</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_726f6e6c-800c-45a4-abd4-a27069d9b856" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="tyra:AccruedResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,612</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued legal and professional fees</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b83ec5df-7253-44e8-b771-19063fde190d" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">316</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_492967d4-764f-46bd-813e-cb81effa5c28" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">296</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued other general and administrative fees</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ac828282-1344-41f1-8af7-4731ae633e5d" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="tyra:AccruedOtherGeneralAndAdministrativeFee" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">755</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b40bd27b-1920-4682-9880-6fbda7cb1f2a" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="tyra:AccruedOtherGeneralAndAdministrativeFee" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">233</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7978d06b-1c19-4b6b-9ae0-76dde9fcd5dc" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,444</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4cad5219-2e50-4e43-9fbb-ceebf0d903a2" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,592</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div></ix:nonNumeric></div><p style="text-indent:9.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">125</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:nonNumeric id="F_b8dff0a0-6875-4842-bcd6-820835acb9b2" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true" continuedAt="F_b8dff0a0-6875-4842-bcd6-820835acb9b2_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5. Stockholders</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Equity</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_34850273-689e-4047-a4f1-9d8af9160c91" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" escape="true"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common stock reserved for future issuance consisted of the following:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:67.313%;box-sizing:content-box;"/>
         <td style="width:1.02%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.323%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.02%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.323%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock options granted and outstanding</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6e952ede-240f-48e0-ba50-f0aa2052bb92" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="tyra:CommonStockOptionsGrantedAndOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">13,617,445</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a509c9c9-3211-4b22-a143-2db14d675714" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="tyra:CommonStockOptionsGrantedAndOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">10,462,129</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares available for future issuance under the 2021<br/>&#160;&#160;&#160;Incentive Award Plan</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e45a8e5-9fe3-47c9-b2bb-9e2cb7a5af29" contextRef="C_3df03dca-0dc7-4c5f-a85f-71adcbb157d4" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,528,992</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a11c53a9-dff1-41a3-90aa-32ac1044d3d2" contextRef="C_c95fc3d9-d94a-493b-a598-ac4bb3b1b07c" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">3,051,588</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares available for future issuance under the <br/>&#160;&#160;&#160;2021 Employee Stock Purchase Plan</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b066953-f440-49e3-a2c5-7cb7dcd4ba87" contextRef="C_af11564f-7c3c-4fbd-944d-2526428166a5" name="tyra:SharesAvailableForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,951,705</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f2896396-f87f-4276-bae3-8192b5d4b4e4" contextRef="C_cc72b396-646c-4763-93d2-cd1c738569ec" name="tyra:SharesAvailableForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,491,195</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pre-funded warrants issued and outstanding</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_84afd8e1-6e70-4da3-8fcd-606ebcbe0e93" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">6,381,950</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7e73e077-738b-4122-837e-8677ddc4ac55" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">8,382,187</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total common stock reserved for future issuance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_758150da-1e93-4b62-a96a-f4607b6e4ee8" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">23,480,092</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_20db3a6a-5552-45eb-8103-934a0b022fc9" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">23,387,099</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 3, 2022, the Company entered into an ATM Sales Agreement (the 2022 Sales Agreement) with Virtu Americas LLC (the 2022 Agent), under which the Company could have, from time to time, sold shares of its common stock having an aggregate offering price of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b3eddb7-3c54-479c-9d25-d4a2a8d1563c" contextRef="C_3ddda0f3-7839-43d8-b02a-428842db25ae" name="tyra:AggregateCommonStockOfferingPrice" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">150.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, in &#8220;at the market&#8221; offerings through the 2022 Sales Agent. The 2022 Agent would have received a commission from the Company of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_52c38274-ecc5-48c4-b5d6-2513f733ddcb" contextRef="C_718b96d9-785c-40ed-a094-d99e0b9a8377" name="tyra:CommissionForAgentOnSales" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the gross proceeds of any shares of common stock sold under the 2022 Sales Agreement. No shares of common stock were issued and sold pursuant to the 2022 Sales Agreement. The Company terminated the 2022 Sales Agreement in May 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 8, 2025, the Company entered into a Sales Agreement (the 2025 Sales Agreement)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> with TD Securities (USA) LLC (the 2025 Sales Agent), under which the Company may, from time to time, sell shares of its common stock having an aggregate offering price of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4bdaea02-7284-4c13-8039-d1d7ef3a41fd" contextRef="C_27b488c8-414a-4614-80fa-db1682dc7f77" name="tyra:AggregateCommonStockOfferingPrice" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">150.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, in &#8220;at the market&#8221; offerings through the 2025 Sales Agent. Sales of the shares of common stock, if any, will be made at prevailing market prices at the time of sale, or as otherwise agreed with the 2025 Sales Agent. The 2025 Sales Agent will receive a commission from the Company of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fdb01282-0224-46bc-881a-e9c36f2ee467" contextRef="C_bc04b846-a20d-4016-ac01-a4c1c095b08c" name="tyra:CommissionForAgentOnSales" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the gross proceeds of any shares of common stock sold under the 2025 Sales Agreement. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025, no shares of common stock had been issued and sold pursuant to the 2025 Sales Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 1, 2024, the Company entered into a securities purchase agreement for a private placement of </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_5dbc52e9-98e2-4d12-9402-ace50585b2c0" contextRef="C_a2ec13b8-8e1d-47c2-8e4f-4c5969096b03" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">9,286,023</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company's common stock at a price of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_7a84f548-329f-4077-86e1-4dc361055e7c" contextRef="C_ab0a8b53-9e09-43e5-aaf1-65d9f9db8341" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">13.01</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share (the 2024 Private Placement). The 2024 Private Placement also included pre-funded warrants (the 2024 Pre-Funded Warrants) to purchase an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_8eaec984-ba59-4c7d-95ce-538d4aa7e9f5" contextRef="C_7fed64a7-b51b-4be1-a469-9f7679712854" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">6,087,230</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock at a purchase price of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_8ac9aeaf-e6d6-4d66-99cf-7e448e4a3a14" contextRef="C_7fed64a7-b51b-4be1-a469-9f7679712854" name="tyra:WarrantsIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">13.009</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per pre-funded warrant. Each pre-funded warrant has an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_2a5a02ea-3295-4504-9021-68eb3b2c51e5" contextRef="C_e120fb96-8ac9-4670-bbd9-1db2900be3f3" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share of common stock, is immediately exercisable on the date of issuance and will not expire. The 2024 Private Placement closed on February 6, 2024 and the Company received gross proceeds of approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_33d1c457-a8e9-4d83-8ad1-4d5afe350de4" contextRef="C_31bd97f3-271f-4ee8-8a62-0213b666d430" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">200.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, before deducting offering expenses of $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_4c00b93b-2b7f-41ea-acab-340bd58f5ced" contextRef="C_31bd97f3-271f-4ee8-8a62-0213b666d430" name="tyra:OfferingExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the 2024 Private Placement, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_7ff43eb6-ad75-4255-b401-13dda245b30f" contextRef="C_e120fb96-8ac9-4670-bbd9-1db2900be3f3" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">4,780,846</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock and pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_1e012b37-9d62-43b8-9128-a2fb0b16db43" contextRef="C_e120fb96-8ac9-4670-bbd9-1db2900be3f3" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,243,737</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock to related parties, resulting in aggregate gross proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_f7d005e3-01fc-4729-aec5-b9ebb64c078c" contextRef="C_31bd97f3-271f-4ee8-8a62-0213b666d430" name="us-gaap:ProceedsFromIssuanceOfWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">91.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 19, 2024, the Company filed a registration statement on Form S-3 with the SEC registering the resale of the shares of common stock issued, or underlying the pre-funded warrants issued, in the 2024 Private Placement. The 2024 Pre-funded Warrants did not meet the characteristics of a liability or a derivative and are classified within stockholders&#8217; equity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 18, 2024, the Company entered into an exchange agreement with certain of the Company&#8217;s stockholders, who were related parties to the Company at the time of the exchange. Pursuant to the exchange agreement, </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_928f221e-2152-49f8-b9ec-aeb841432781" contextRef="C_6b1f5ee9-14ee-4a7c-af93-d46a982aa30b" name="tyra:ExchangeOfCommonStockForPre-FundedWarrantsShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">3,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock were exchanged for pre-funded warrants to acquire an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_e5a2b0af-965c-45d9-bc5e-258ef642c5aa" contextRef="C_f04ad497-713a-4578-b5ab-98ae7619c3da" name="tyra:ExchangeOfCommonStockForPre-FundedWarrantsShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">3,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock (each of such pre-funded warrants an Exchange Warrant and collectively the Exchange Warrants, and such exchanges of common stock for Exchange Warrants collectively the Exchange). Each Exchange Warrant has an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_a34005d8-a9dc-499d-8f7f-6c7dce4cfb9f" contextRef="C_9b41307d-a228-4022-aec0-907dd0345fdf" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share of common stock, is immediately exercisable on the date of issuance and will not expire. No cash was exchanged related to the transaction. The Exchange closed on October 22, 2024. The Exchange Warrants did not meet the characteristics of a liability or a derivative and are classified within stockholders</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217; equity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">126</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_b8dff0a0-6875-4842-bcd6-820835acb9b2_1"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2025, </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_30d18660-1d9d-4e58-b9c7-e62ef2214013" contextRef="C_96648163-51bf-41fb-8618-dc87cf09bd07" name="tyra:ExerciseOfPre-FundedWarrants" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Exchange Warrants and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_76e118ef-4470-403e-b103-d2029fbc720c" contextRef="C_a8ff3708-7767-47f5-93fc-4c5992d13af3" name="tyra:ExerciseOfPre-FundedWarrants" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">237</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the 2024 Pre-Funded Warrants were exercised in cashless transactions, which resulted in an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_57095817-d811-448c-a497-d096f1112dd9" contextRef="C_4892d6b0-f063-48f2-b508-738cf390c782" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,000,069</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock being issued. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c8ca523-7ba9-4a97-8e41-1722cdab5709" contextRef="C_96648163-51bf-41fb-8618-dc87cf09bd07" name="tyra:Pre-FundedWarrantsAvailableForExercise" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">6,381,950</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> pre-funded warrants remained available for exercise, including </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3a70f7ef-3dad-4a8e-852e-453bc5bc00a7" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="tyra:WarrantsAvailableForExercise" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Exchange Warrants and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c71f76a0-8458-4497-8306-22e280a5d6e7" contextRef="C_deb06a64-1ca6-42a0-9e9d-5e5fc523e1b1" name="tyra:Pre-FundedWarrantsAvailableForExercise" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">5,381,950</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 2024 Pre-Funded Warrants.</span></p></ix:continuation></div><div><ix:nonNumeric id="F_fae409ca-a345-4108-bd00-24955de4682d" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" escape="true" continuedAt="F_fae409ca-a345-4108-bd00-24955de4682d_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6. Equity Incentive Plans and Stock-Based Compensation</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2021 Incentive Award Plan</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2021, the Company&#8217;s Board of Directors adopted, and its stockholders approved, the 2021 Incentive Award Plan (the 2021 Plan). Upon the adoption of the 2021 Plan, the Company restricted the grant of future equity awards under the 2020 Equity Incentive Plan (the 2020 Plan).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 2021 Plan provides for the grants of stock options and other equity-based awards to employees, non-employee directors, and consultants of the Company. Shares that expire, terminate or are cancelled under the 2020 Plan are added back to the 2021 Plan share reserve. In addition, the number of shares of the Company&#8217;s common stock available for issuance under the 2021 Plan automatically increases on the first day of each fiscal year, beginning with the Company&#8217;s 2022 fiscal year, in an amount equal to the lesser of (1) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c5e06aa3-d95a-406f-b3f2-0f11e2346ab4" contextRef="C_dfcfe63e-d4f8-4148-85c4-ec750c1d7200" name="tyra:StockholdersEquityIncreaseDecreaseInCommonStockPercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the outstanding shares of the Company&#8217;s common stock on the last day of the immediately preceding fiscal year, or (2) such smaller amount as determined by the Company&#8217;s Board of Directors. The Company issues new shares of common stock upon exercise of options. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_95ee0a0f-c394-42da-b56c-ea46ff91ee7d" contextRef="C_dfcfe63e-d4f8-4148-85c4-ec750c1d7200" name="tyra:SharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,528,992</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares were available for future grant under the 2021 Plan.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2c073389-a3af-49fc-a4d1-e28717515910" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A summary of the Company&#8217;s stock option activity for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 was as follows (in thousands, except share and per share data and years):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:47.94%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:11.2%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.2%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.420000000000002%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.2%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:9.9%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.2%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:8.940000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Options</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-Average<br/>Exercise<br/>Price per Share</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-Average<br/>Remaining<br/>Contractual Term</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Intrinsic Value</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2024</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6a0fba28-ba10-42a9-86f4-c93a7b3b671e" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,462,129</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6e491b42-f574-49a1-b16a-e1021bbbf07b" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">13.43</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_8efcaa31-4f72-4cde-bccf-c2d82da23a97" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.6</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b91db41f-588d-4d00-94b9-03347c8a3375" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,798</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6050649-36cc-4668-916d-2d547a0b3a82" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="tyra:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">5,029,190</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_93bdef09-c044-4f88-982f-38ecfc9259f7" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">12.08</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e98505d9-02a9-44dc-926d-19b84905676f" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">904,993</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_04e8c741-25b9-4a3f-9cf5-f501873e7ea4" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">8.72</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited and expired</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a0608d0f-f0e2-40a6-9811-0227eec9a31c" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">968,881</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f377970-1a8c-4e62-9da9-aafcf96b5029" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">16.31</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2025</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8eae0f86-2c18-4f50-8ca4-37d7acb236be" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">13,617,445</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd95e922-1703-450b-a1a9-8192624553dc" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">12.58</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_32ce05e0-4505-4df7-895c-d72ad2034358" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.0</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_397b66ff-dcef-4ad2-b022-5f3233cb1b9f" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">186,669</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercisable at December 31, 2025</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fa0eef88-272d-44b7-935e-6e66c72cec51" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,300,582</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6263e299-0483-4e8a-9df8-8a2d0d31a546" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">11.39</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_b5833592-7640-4bc5-865f-44fcf826c133" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.8</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e8e0e3c2-9daf-46d7-88af-694bd73efb69" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">93,903</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested and expected to vest as of December 31, 2025</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9b19f224-e4b3-4285-a2c1-bf3812e2a944" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">13,617,445</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5cf9015c-a7e5-4ef0-954d-89eb280d54e4" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">12.58</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_f30f258b-f748-4b40-b818-6fd5b40791b3" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.0</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_86147302-0c10-4f28-a075-0b7afaf229ef" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">186,669</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Employee Stock Purchase Plan</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2021, the Company&#8217;s Board of Directors adopted, and its stockholders approved, the 2021 Employee Stock Purchase Plan (ESPP). </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8fd42bda-4986-48e6-891b-4ebb819a4973" contextRef="C_8d8b0049-b397-46d9-9515-7b644360184f" name="tyra:EmployeeStockPurchasePlanDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ESPP permits eligible employees who elect to participate in an offering under the ESPP to have up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_524c1a88-3759-480a-aa5e-4461bff7c193" contextRef="C_8d8b0049-b397-46d9-9515-7b644360184f" name="tyra:PurchaseOfCommonStockThroughPayrollDeduction" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">15</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of their eligible earnings withheld, subject to certain limitations, to purchase shares of common stock pursuant to the ESPP. The price of common stock purchased under the ESPP is equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_04221690-8a3b-4047-967d-a3b759be57a0" contextRef="C_8d8b0049-b397-46d9-9515-7b644360184f" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">85</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the lower of the fair market value of the common stock at the commencement date of each offering period or the relevant date of purchase. </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8355f13-e139-4673-a429-6ff0d58d236a" contextRef="C_e212c6e1-9c59-4476-81a3-9bdba80a582e" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,951,705</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares available for future purchase under the ESPP.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">127</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_fae409ca-a345-4108-bd00-24955de4682d_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-Based Compensation Expense</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company estimated the fair value of stock options using the Black-Scholes valuation model. The Company accounts for forfeitures of options when they occur. Previously recognized compensation expense for an unvested award is reversed in the period that the award is forfeited.</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3f979ea7-aca8-4386-9927-8fbbefed0b4d" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true" continuedAt="F_3f979ea7-aca8-4386-9927-8fbbefed0b4d_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The fair value of stock options was estimated using the following assumptions: </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_3f979ea7-aca8-4386-9927-8fbbefed0b4d_1">
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:58.14%;box-sizing:content-box;"/>
         <td style="width:1.7%;box-sizing:content-box;"/>
         <td style="width:18.92%;box-sizing:content-box;"/>
         <td style="width:1.7%;box-sizing:content-box;"/>
         <td style="width:18.54%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free rate of interest</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_294322c6-cd91-4a6e-93a5-0bed5a290407" contextRef="C_692e28c5-456f-441d-81a6-b3281646a0af" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d67412ff-1ce6-4a43-bb58-0e79c7f5843c" contextRef="C_3bfbb795-7b7e-4213-b6a6-ea14b283ed4f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_980845c9-6115-4f58-bcfa-6504e03389b3" contextRef="C_a9af0aa2-ccc8-48f7-89f5-e604bc391411" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a2c83ba7-ed89-465d-92ee-b6b2d112af91" contextRef="C_2f77ccfa-5653-4673-b977-01323fe14f9a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="background-color:#ffffff;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_5429a522-f38c-4926-8bcf-75fc73ca2d87" contextRef="C_692e28c5-456f-441d-81a6-b3281646a0af" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.1</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><ix:nonNumeric id="F_49d7c068-05a8-420f-9aa5-411bc885b1ec" contextRef="C_3bfbb795-7b7e-4213-b6a6-ea14b283ed4f" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.1</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_97e14788-abd3-4c68-a276-02b1f27f1c48" contextRef="C_a9af0aa2-ccc8-48f7-89f5-e604bc391411" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.3</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><ix:nonNumeric id="F_e707bb89-7fd9-44f8-9cb2-fe73b3c81cd1" contextRef="C_2f77ccfa-5653-4673-b977-01323fe14f9a" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.1</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected stock price volatility</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3a27cff2-ba5f-4a12-8e4a-9b862a58cc58" contextRef="C_692e28c5-456f-441d-81a6-b3281646a0af" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">84.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a619174-6cf1-46f7-962d-7647665836ec" contextRef="C_3bfbb795-7b7e-4213-b6a6-ea14b283ed4f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">95.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eea9c2e7-bf91-4b72-ab4b-e959636892ba" contextRef="C_a9af0aa2-ccc8-48f7-89f5-e604bc391411" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">87.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1232cf32-7a29-4f0c-92ed-bc81a91de761" contextRef="C_2f77ccfa-5653-4673-b977-01323fe14f9a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">98.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="background-color:#ffffff;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dividend yield</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d968a509-e639-4dbe-8e0a-7e0834bd8749" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_12dafda1-4267-4acf-9759-e45864df2d8a" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_12420d4d-d2c4-4a9b-8fa5-aa2cbd506279" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense recognized for all equity awards, including stock options and ESPP, has been reported in the statements of operations and comprehensive loss as follows (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:56.031%;box-sizing:content-box;"/>
         <td style="width:1.8%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:17.863999999999997%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:2.44%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:17.863999999999997%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_713bc725-34b1-46d0-b5bf-b1b571a4b423" contextRef="C_04b24ac9-453f-4621-9f44-543a1e069772" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,749</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f28325e2-7da7-4117-baef-a26628fd213b" contextRef="C_7f967b5d-c00a-4062-a27e-e4707a82ef23" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,291</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_59ba63f3-de5c-4c66-ba61-c36c7760c400" contextRef="C_8e43d91f-24cf-4fdb-b79e-137f0345b2bb" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,257</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_393b8aaf-054d-48ed-907a-c75dc3edba0c" contextRef="C_c857b1ec-ca11-4482-b531-9da5ac07706d" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,510</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_822c20ae-133f-47e4-8904-6940b2f94b21" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,006</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2fd27fbb-d721-4515-8e56-d43af59d8123" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,801</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted-average grant date fair value of options granted (excluding modified options) for the years ended December 31, 2025 and 2024 were </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_56ffc575-5b8f-4e9f-a16f-c6542f0a268c" contextRef="C_356fc121-7b99-4486-a3fc-2e281fdbe579" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">9.05</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2f7c19e-7948-453b-9ca1-10f9d35e638a" contextRef="C_00649a27-87e2-4280-9938-2abad92658ac" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">15.95</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_35c9d6c9-99e4-4ddd-b54e-1417a8e053f0" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in additional stock-based compensation expense recorded within research and development expenses, in connection with the modification and acceleration of stock options held by a former executive.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the years ended December 31, 2025 and 2024, forfeitures resulting in the reversal of compensation expenses were immaterial.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, the unrecognized compensation cost related to options was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_061e984a-d3b1-4c68-82f0-1dd6344712f4" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">75.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, and is expected to be recognized as expense over a weighted-average period of approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fe84068b-76b2-4038-93f8-aab8465be417" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.6</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, the unrecognized compensation cost related to ESPP was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c4153bf-77d1-4118-812f-3ff828d54803" contextRef="C_aea32a63-e986-417a-9465-dd9fe57915c7" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, and is expected to be recognized as expense over a weighted-average period of approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_470ae42b-8ad5-4468-afcf-97e6c9956488" contextRef="C_6aa70afb-c483-4af1-aab6-5e31327063dc" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.2</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span></p></ix:continuation></div><div><ix:nonNumeric id="F_ee412665-cca5-496c-a688-df15813da750" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:EarningsPerShareTextBlock" escape="true" continuedAt="F_ee412665-cca5-496c-a688-df15813da750_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7. Net Loss Per Share</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ad2e2c55-4eae-4044-a814-2efa2fe54a04" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth the computation of the basic and diluted net loss per share (in thousands, except share and per share amounts):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:67.313%;box-sizing:content-box;"/>
         <td style="width:1.5%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.843%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.5%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.843%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8679b378-db2c-46d8-bae4-05d82099833b" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">119,947</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_53d30aa0-3f53-4f4d-a0b3-1d961d510380" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">86,481</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average common shares outstanding</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ac22948f-ff37-4285-8861-1a2921d8d05d" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:WeightedAverageBasicSharesOutstandingProForma" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">59,602,328</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1a590935-e221-4b55-b2a5-50b108f78173" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="us-gaap:WeightedAverageBasicSharesOutstandingProForma" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">57,250,061</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: weighted-average unvested common stock issued upon early exercise of common stock options</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e472048c-1f41-48e2-b085-2116f9dbbc9a" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="tyra:WeightedAverageUnvestedCommonStockIssuedUponExerciseOfCommonStockOptions" unitRef="U_shares" decimals="INF" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad2da83b-a518-475f-a29a-5b4769eb7bf7" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="tyra:WeightedAverageUnvestedCommonStockIssuedUponExerciseOfCommonStockOptions" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">32,315</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average shares used to compute net loss per common share, basic and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ee7dc32-9512-4541-80d1-0176cbbb53f4" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_c3e256df-c778-4bd8-a732-06de3b13f5af" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">59,602,328</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d225846-8d88-4ed7-ab66-2d0c6fa08075" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_8558f24d-783a-4110-8d86-d2c5d8ff3813" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">57,217,746</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b85f589-c422-4387-aae1-00a587e704aa" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_85bc4366-396b-417b-b425-4b22b75485c8" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">2.01</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c29278ca-3bb0-40fb-9651-43d68019f5ba" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_4f76b772-2b2a-4387-94f0-60fb6f03adef" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.51</ix:nonFraction></ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">128</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_ee412665-cca5-496c-a688-df15813da750_1"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Shares issuable pursuant to the 2024 Pre-Funded Warrants and the Exchange Warrants are included in the calculation of weighted-average shares of common stock outstanding, both basic and diluted, for the years ended December 31, 2025 and 2024. These warrants are exercisable at any time for nominal consideration, and therefore, the shares thereunder are considered outstanding for the purpose of calculating basic and diluted net loss per share.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c1756a2b-4741-40b8-8ac3-9340be512462" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because their inclusion would be anti-dilutive.</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:67.313%;box-sizing:content-box;"/>
         <td style="width:1.02%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.323%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.02%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.323%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options to purchase common stock</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd079344-c0f0-467c-b47d-e64b1cca1e20" contextRef="C_56b4e6c1-43af-48e2-a24b-2a315a435b15" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">13,617,445</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_86ac19cf-acc5-4c51-bcc0-a5161134fd83" contextRef="C_1f9dc1d4-60d0-45af-852c-cdd76bc64f9f" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">10,462,129</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested common stock upon early exercise of stock options</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_115497f7-a916-44b1-964c-bdf9470557d8" contextRef="C_e3b45be7-247c-43d2-afaf-765b16ea5709" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6a4d6939-e081-4a56-b5ac-6ffb5bb36af0" contextRef="C_0982e5f9-320c-4189-b4b7-e92e3372022d" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">4,317</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Estimated shares purchasable under the ESPP</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_81d137e8-3cbc-4db7-b0a7-13d24c5386d7" contextRef="C_f4992ea8-42cd-4f1d-87f7-2a24c1d21969" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">27,761</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4dffebfa-9842-47f4-ae03-a3a1cca77577" contextRef="C_9a95952b-9590-45cc-ba3c-2182f5811f96" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">14,280</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d912abc-1721-4241-a1ff-7810d7e55f17" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">13,645,206</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a45370a0-8b2f-4254-b001-1b838d5e4ae5" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">10,480,726</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_ab3c7e10-1d2a-4494-aef2-84283bfa79a6" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true" continuedAt="F_ab3c7e10-1d2a-4494-aef2-84283bfa79a6_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company's pretax losses for the years ended December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> are from U.S. operations. There was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e54e5a27-4f8d-4e9c-84e5-98fb7c4b1715" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_fa6bbf8e-a0b7-494f-8d14-bc1a61a7fba6" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> provision for or benefit from income taxes for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company adopted ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures prospectively, as disclosed in Note 1. </span><span><ix:nonNumeric id="F_961118a8-b187-4149-a747-490f7f679239" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true" continuedAt="F_961118a8-b187-4149-a747-490f7f679239_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following is a reconciliation between the provision for income taxes and income taxes computed using the U.S. federal statutory corporate tax rate for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025, in accordance with the new disclosure requirements (in thousands):</span></ix:nonNumeric></span></p><div><ix:continuation id="F_961118a8-b187-4149-a747-490f7f679239_1" continuedAt="F_961118a8-b187-4149-a747-490f7f679239_2">
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.94%;box-sizing:content-box;"/>
         <td style="width:1.76%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.860000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.44%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income tax benefit at statutory federal rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b194ad98-d10b-4f66-8221-70adfd51cee2" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">25,189</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_96ed86dc-d027-43ae-a638-d23a1563550f" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">21.00</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State and local taxes, net of federal benefit </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1feeacb7-f63b-4743-b9bf-d02683a62a3e" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,330</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5afad17c-078e-4959-a690-06c22068e3d4" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">1.11</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax credits</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Federal research and development credits</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a37b19cf-c8d7-4309-b38d-a42bdc0d19f4" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,411</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_55e16ef9-5a7b-4d71-843f-37481ad35f9e" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">5.35</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6bc15362-54ad-4762-9f08-bccf0a9002d5" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,683</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3579b54b-9e66-4dcb-b87d-123c88ddfed8" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:num-dot-decimal">19.75</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nontaxable or nondeductible items</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Stock based compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_04200008-408c-403f-a30d-cb69e2a916b0" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,653</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_00765124-f347-4697-84e6-574ec1ea3d05" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:num-dot-decimal">1.38</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Officer compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c3284ef-4929-4f4f-a474-c3b3f3f8b0e6" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="tyra:IncometaxreconciliationOfficersCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,725</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c248505b-df99-4b40-b794-1629967be6f6" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="tyra:IncomeTaxReconciliationOfficersCompensationPercentage" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:num-dot-decimal">3.94</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2f0c62b3-cca8-4346-a76c-a4389ca04d10" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_19ede753-003b-41e1-8c86-033811ad75c7" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:num-dot-decimal">0.04</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in unrecognized tax benefits</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_961a53d7-4487-4d2f-969c-8f5927624df2" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="tyra:IncomeTaxReconciliationChangesInUnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,823</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_125ff552-b43e-44f7-910b-364c4fa92468" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="tyra:IncomeTaxReconciliationChangesInUnrecognizedTaxBenefitsPercentage" unitRef="U_pure" scale="-2" decimals="4" sign="-" format="ixt:num-dot-decimal">2.35</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Provision for income taxes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e774965-6de3-49b7-b5f0-3380a20fc0ff" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_79767db5-ee4b-4e95-9201-34949d675563" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.00</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1)</span><ix:footnote id="FNT_7f5db674-35e9-4226-a24a-70d6bb548e24" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The state that contributes to the majority (greater than 50%) of the tax effect in this category is California for the year ended December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></ix:footnote></p></ix:continuation></div></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">129</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_ab3c7e10-1d2a-4494-aef2-84283bfa79a6_1" continuedAt="F_ab3c7e10-1d2a-4494-aef2-84283bfa79a6_2"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_961118a8-b187-4149-a747-490f7f679239_2"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following is a reconciliation between the provision for income taxes and income taxes computed using the U.S. federal statutory corporate tax rate for the year ended December 31, 2024, in accordance with the guidance prior to the adoption of ASU 2023-09 (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:80%;box-sizing:content-box;"/>
         <td style="width:2.1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:15.9%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected tax benefit at statutory rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9aa896ac-7143-40a9-95bf-c21934f6b500" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">18,161</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State income tax, net of federal benefit</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c2361c3-eca4-4221-8b12-f666f8741f8c" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">134</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock based compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6bd99a88-6123-4a79-a3f0-9c30e70c899e" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">757</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Officer compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd0cb4c3-8153-4c0f-8ef1-db0c51e47fe8" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="tyra:IncometaxreconciliationOfficersCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">977</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Permanent items and other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_702a1b69-024f-471f-9f47-d538acb2b12b" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research credits</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c7c4fbb3-abdc-4a28-b32f-a3b4c3ae7a87" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,363</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b12c4a6b-eb3a-418f-a881-107ae6171019" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,431</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Provision for income taxes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc26ccfd-60a5-4739-8dad-16948ce3d9b2" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:continuation></div><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company did not pay federal or state cash income taxes or have cash income taxes refunded in the year ended December 31, 2025.</span></p><div style="font-size:11pt;font-family:Times New Roman;"><ix:nonNumeric id="F_aadd7691-1008-4983-97ab-51f87879cb1a" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024 are as follows (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.673%;box-sizing:content-box;"/>
         <td style="width:1.74%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.923%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.74%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.923%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f904a04-8839-4031-afb4-48aedc4b4769" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,792</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4bfb4f3b-f9aa-4a71-861d-4db9764e7efc" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,938</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized research and development</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c7e63f39-6784-4fcc-a65f-017aae9a51e8" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="tyra:DeferredTaxAssetsCapitalizedResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,439</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_36134d31-b109-499c-869b-33e5a6193b01" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="tyra:DeferredTaxAssetsCapitalizedResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,105</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax credits</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_42d9d6d7-bdc1-4c8b-937c-0604077549e3" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="tyra:DeferredTaxAssetsTaxCredits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,380</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34f70259-46c0-4ab6-921b-b989068bbcc0" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="tyra:DeferredTaxAssetsTaxCredits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,725</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock based compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_11677f72-c0bc-41eb-8017-c373b2a77903" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,570</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e7c3b4b-c243-4129-923d-580715a4741c" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,771</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe3cc1c6-1607-4de5-b3e9-5b5841179269" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,287</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6dd614f6-6db6-437b-b9a8-ef66de9a4a49" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,267</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a48d6f2d-99a1-4d8e-9e27-56c0c88765b0" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">89,468</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5435fd4e-7f90-489c-982c-ae498d1d2cf6" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64,806</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_47032013-27af-4eeb-8e5c-ef0e00e2d52f" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">88,026</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9ce8fc3-9a66-4a91-b62c-2387db7039e8" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63,267</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets, net of valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d6df9445-0f36-4e9d-9e96-2cec5465c471" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,442</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_99ce9996-4b28-44d7-bd59-9c021b076194" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,539</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7b135514-9f82-4329-8eb7-fe9f7105e256" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">175</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d796c72b-6515-440e-aac3-1a886b6719cd" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">256</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right of use assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_52922c88-683f-4e56-af5c-9591f34bdb6c" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,182</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c91bc242-cd04-4e1e-8bb3-a4b306904b4d" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,283</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_99d09b81-7e06-420d-bfe5-9b0ebf827039" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:DeferredTaxLiabilitiesOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">85</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2ce8030c-dcd5-4d54-82b7-ff4a291d6174" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="us-gaap:DeferredTaxLiabilitiesOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cafb00ac-059a-46a3-a45b-7976e522a4fc" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,442</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0981f15e-341c-470c-a4d8-bb4fd0f95914" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,539</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred tax assets / (liabilities)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fce8928a-33fc-4c57-b366-9fe736240c4b" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fed20822-efd8-4820-b2f5-3471dfc4182f" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has established a valuation allowance against its net deferred tax assets due to the uncertainty surrounding the realization of such assets. The Company periodically evaluates the recoverability of the deferred tax assets. At such time as it is determined that it is more likely than not that deferred assets are realizable, the valuation allowance will be reduced. The Company has recorded a full valuation allowance of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a190ad08-d77d-4259-a8ae-dcd16ee69d1c" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">88.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of December 31, 2025 as management cannot conclude that it is more likely than not that certain deferred tax assets will be realized primarily due to the history of losses from inception. The Company increased its valuation allowance by approximately $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_459f4a38-3a62-4a33-83d8-bc205ec1225e" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">24.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million during the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At December 31, 2025, the Company had federal and state tax loss carry forwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_79770caf-45ac-4e61-9199-c496062e834a" contextRef="C_25ac70f7-9ef0-442b-8bfc-d6387da53e1f" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">188.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b0649506-662f-44f4-9889-f50802819f9e" contextRef="C_81db5fa1-5ce2-4991-960b-fe8f42d5dc85" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">67.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. As a result of the Tax Cuts and Jobs Act of 2017, for U.S. income tax purposes, net operating losses generated after December 31, 2017 can be carried forward indefinitely, but are limited to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_563e337a-4d82-42fa-91d3-782fe6d7cb4a" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="tyra:NetOperatingLossCarryforwardsAvailableForOffsettingAgainstFutureTaxableIncomePercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">80</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% utilization against future taxable income each year. Of the amount of federal and state net operating loss carryforwards, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad2ef762-012c-4b8f-bb84-fc63c77f04d7" contextRef="C_25ac70f7-9ef0-442b-8bfc-d6387da53e1f" name="tyra:NetOperatingLossCarryForwardIndefinitely" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">188.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7acbe39b-1caf-4da3-9676-c6b17e59aee4" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="tyra:NetOperatingLossCarryForwardIndefinitely" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, can be carried forward indefinitely. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_24380db2-6b9a-4678-842f-d8d280b24f6d" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="tyra:OperatingLossCarryforwardsExpirationDates1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless previously utilized, the state net operating losses will begin to expire in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2038</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">130</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_ab3c7e10-1d2a-4494-aef2-84283bfa79a6_2"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At December 31, 2025, the Company has federal and state research and development tax credits of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_26e6b2cd-7fcf-46b7-98c0-f20b1579bb93" contextRef="C_25ac70f7-9ef0-442b-8bfc-d6387da53e1f" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">18.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af9059a6-968f-4c45-a96f-48a83d43e51a" contextRef="C_81db5fa1-5ce2-4991-960b-fe8f42d5dc85" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4e7a5868-0bb1-4664-bb32-c7476b3e9733" contextRef="C_f25354f8-700d-4a8d-907f-0257bf311019" name="tyra:ResearchAndDevelopmentCreditCarryforwardsUnderInternalRevenueCodeDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The federal research and development tax credit carryforwards begin to expire in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2040</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the state research and development tax credit carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_e3bc702f-8716-44ff-8eae-a69dc8caa3f8" contextRef="C_0244e69e-96e4-4497-bf2c-57c743c5abcb" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million will not expire and the state research and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_83ec96fd-5b10-4b5b-bb0b-8ae18097de30" contextRef="C_d576a493-6d1f-4530-ae76-85c14a98774c" name="tyra:ResearchAndDevelopmentCreditCarryforwardsUnderInternalRevenueCodeDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">development tax credit carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_7bb28eab-2004-4abc-b76c-d4a155196108" contextRef="C_2d6333b8-aede-4396-b3d4-df2848f7e547" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million will begin to expire in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2039</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></ix:nonNumeric></span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the IRC Sections 382 and 383, annual use of the Company&#8217;s net operating loss (NOL) and research and development credit carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period. The Company has not completed an ownership change analysis pursuant to IRC Section 382. If ownership changes have occurred or occurs in the future, the amount of remaining tax attribute carryforwards available to offset taxable income and income tax expense in future years may be restricted or eliminated. If eliminated, the related asset would be removed from deferred tax assets with a corresponding reduction in the valuation allowance.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Uncertain tax positions are evaluated based upon the facts and circumstances that exist at each reporting period. Subsequent changes in judgment based upon new information may lead to changes in recognition, derecognition, and measurement. Adjustment may result, for example, upon resolution of an issue with the taxing authorities or expiration of a statute of limitations barring an assessment for an issue.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes a tax benefit from an uncertain tax position when it is more likely than not that the position will be sustained upon examination by tax authorities.</span></p><div style="font-size:11pt;font-family:Times New Roman;"><ix:nonNumeric id="F_260ae749-f9d5-4173-b7f8-007bc6790f05" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" escape="true"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the changes to the Company&#8217;s gross unrecognized tax benefits for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024, respectively (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.883000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.62%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.883000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Beginning balance at January 1</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ecde34a-f9cf-4c8f-b531-bcf11712d770" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,529</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1352b738-a204-4cb5-b9c5-c8d684ae09f2" contextRef="C_90b314f0-e678-446e-845b-a940c76b3ed3" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,006</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additions related to current year positions</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e322fb92-0927-4ca9-b79f-d7d1c731f19e" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,043</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5f127c3-5099-49e8-a566-db5b7d4f5e9a" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,869</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additions related to prior year positions</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_13d88ace-3ec8-4b09-b8d2-f8823679dab0" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,133</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_77976117-c652-4d2a-8e2a-108dd1d4b05e" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">654</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ending balance at December 31</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e524d52f-569b-4cb9-82a8-db87211e6fa2" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,705</ix:nonFraction></span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_94970866-3c39-47c6-8c0f-e9c0dd2776c2" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,529</ix:nonFraction></span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Due to the existence of the valuation allowance, future recognition of previously unrecognized tax benefits will not impact the Company&#8217;s effective tax rate. The Company is subject to taxation in the United States and various state jurisdictions. All of the Company&#8217;s tax years from inception are subject to examination by federal and state tax authorities. The Company&#8217;s practice is to recognize interest and penalties related to income tax matters in income tax expense.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae05abc4-2e90-4833-a8ba-8427bcd6f963" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> accrued interest or penalties related to income tax matters in the Company&#8217;s balance sheet as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and has not recognized interest or penalties in the Company&#8217;s statements of operations and comprehensive loss for the years ended December 31, 2025 and 2024. Further, the Company is not currently under examination by any federal, state or local tax authority.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On July 4, 2025, the U.S. President signed into law H.R.1, the legislation commonly known as the One Big Beautiful Bill (OBBB). This legislation extended, modified, or made permanent many of the tax provisions which were initially enacted as part of the Tax Cuts and Jobs Act of 2017. The OBBB contains a number of tax provisions including, but not limited to, immediate expensing of domestic research and experimental expenditures, modifications to the limitation on business interest, bonus depreciation modifications, as well as international tax provision modifications. The Company has reflected the effect of OBBB within the provision for income taxes and the deferred taxes as of December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">131</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:nonNumeric id="F_e9f11a86-e51b-40b3-8b37-d470c688f68f" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:LesseeOperatingLeasesTextBlock" escape="true" continuedAt="F_e9f11a86-e51b-40b3-8b37-d470c688f68f_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9. Leases</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has operating leases for its office and laboratory space, including its corporate headquarters.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2020, the Company entered into a lease agreement for approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_185c274b-458a-4b68-b213-136acd6d5812" contextRef="C_0639343e-0151-4fb3-a3ca-f73ad2a5550b" name="tyra:AreaOfLease" unitRef="U_sqft" decimals="0" format="ixt:num-dot-decimal">4,734</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet of office and lab space at 2656 State Street in Carlsbad, California, for the Company</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s headquarters (the Original Lease). The Original Lease commenced in May 2021 and had an original term of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_85e63fdb-ae6a-4353-8460-a9b2c23d431e" contextRef="C_3ef83027-7be9-4941-bbec-b03fb69c9691" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">60 </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">months, with an option to extend for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd5b270c-1313-421d-80e7-75adae81a413" contextRef="C_4bfe509f-d4f2-43a9-a149-54a5ecae443d" name="tyra:NumberOfLeaseTermRenewal" unitRef="U_Renewal" decimals="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> additional </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ac253aac-469e-43de-bbe6-66fabebe358a" contextRef="C_3ef83027-7be9-4941-bbec-b03fb69c9691" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">36 </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">month periods.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 2022, the Company entered into a lease agreement for approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_04ef3225-2b29-424d-adaa-9b10304e9074" contextRef="C_28193a65-0be5-40f3-9592-5ab7a4f62e34" name="tyra:AreaOfLease" unitRef="U_sqft" decimals="0" format="ixt:num-dot-decimal">8,331</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet of additional office and laboratory space at 2676 State Street in Carlsbad, California (the Expansion Lease). The Expansion Lease commenced for accounting purposes in May 2023, when the Company gained access to the premises. The Company</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;s obligation for payment of base rent began on the date the landlord delivered possession of the Expansion Lease premises in November 2023. The landlord completed improvements to the Expansion Lease premises, and the Company paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bec94228-1686-45c6-bdb8-776f6ff63363" contextRef="C_e1d47e5f-72ba-41d6-899c-26d974ae34de" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million toward these costs prior to the Expansion Lease commencement. The Company determined that the landlord is the accounting owner of these improvements, and therefore this payment was included in the measurement of the right-of-use asset and corresponding lease liability. The Company was granted rent abatement for delays related to the landlord&#8217;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s delivery of the Expansion Lease premises to the Company. The Expansion Lease has a lease term of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_99b443fb-de38-4a23-a42c-8569ab7775fd" contextRef="C_c949f769-29f9-45f2-a776-8adefcf0977e" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">120 </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">months, commencing on the day the landlord delivered possession of the Expansion Lease premises. The Company has the option to renew the Expansion Lease for two additional </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cc087390-b096-43f7-abe0-845d2a20906d" contextRef="C_55243387-85c0-4527-827d-52fcc91c1646" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">36</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-month periods. The Original Lease was also amended to have the same lease expiration as the Expansion Lease.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company did not include the renewal periods in determining the lease term, as the Company was not reasonably certain to exercise either the amended Original Lease or the Expansion Lease renewal options.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Company&#8217;s lease agreements, the Company paid security deposits of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_383f5035-ea4b-4f20-bcfd-ee02374c3682" contextRef="C_591792f7-6fd3-4548-a3dc-761a47696c50" name="us-gaap:SecurityDeposit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and is required to maintain a letter of credit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d689b8f-a6f5-456b-9529-4d4fa283265f" contextRef="C_591792f7-6fd3-4548-a3dc-761a47696c50" name="us-gaap:LineOfCredit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The letter of credit may be reduced to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2c33911d-7c58-46b0-b9b0-df40e731d4dd" contextRef="C_0cc2e2b1-f863-41ab-8c8e-baf6fe802ceb" name="us-gaap:LineOfCredit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in 2027 and further reduced to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd507251-9c58-4ceb-8d4f-c47b69bae4b9" contextRef="C_a6c7e448-562b-41de-8bae-d10d83c24d49" name="us-gaap:LineOfCredit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in 2028.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash paid for amounts included in the measurement of lease liabilities was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_599cc70d-082e-4267-ad38-1a27dceba6af" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_a7bb331b-a721-4dfd-aeaa-5cdb4b85f7f1" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024, respectively.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of lease expense include operating, short-term, and variable lease costs. Amortization is recorded within research and development and general and administrative expenses in the statements of operations and comprehensive loss. </span><span><ix:nonNumeric id="F_2592f51f-5ca5-4dfa-b37a-a01ef3e2bad7" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:LeaseCostTableTextBlock" escape="true" continuedAt="F_2592f51f-5ca5-4dfa-b37a-a01ef3e2bad7_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Components of lease cost for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024, respectively, were as follows (in thousands):</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_2592f51f-5ca5-4dfa-b37a-a01ef3e2bad7_1">
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:67.313%;box-sizing:content-box;"/>
         <td style="width:1.5%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.843%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.5%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.843%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease cost</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba3b94b8-6649-428e-81fe-e565d2822db6" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">957</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ab293a12-653f-4b26-ab1e-d27b51037b9c" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">957</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term lease cost</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6227bae3-680f-4424-af74-5312d6ce1d28" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:ShortTermLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">90</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_953e3260-2769-4439-9df7-09d24b08a5d7" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="us-gaap:ShortTermLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">90</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Variable lease cost</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_303b6d26-9998-4110-bedd-3087eeac04b1" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">139</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d8d0afb-a432-4767-9584-44687a5e0953" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">127</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease cost</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a823cd70-877a-4555-b3e5-7617c30176d5" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,186</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_48f9fec8-20bf-4dab-85f3-df59a609b4a3" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,174</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:continuation></div></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">132</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_e9f11a86-e51b-40b3-8b37-d470c688f68f_1"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_54f11898-3851-4620-982a-ce7742ce5806" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="tyra:ScheduleOfMaturitiesOfLeaseLiabilitiesWithWeightedAverageRemainingTermAndDiscountRateTableTextBlock" escape="true"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Maturities of lease liabilities, weighted-average remaining term and weighted-average discount rate were as follows (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:75.64%;box-sizing:content-box;"/>
         <td style="width:1.9%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:20.459999999999997%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Year ending December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe4ab782-c0b2-42bc-b54e-9c29f164de36" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">900</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d98eb385-fcde-4d62-913a-131c4753febf" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">927</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1db3ca6a-2f1d-43fe-bb11-e0f71c00940d" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">955</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e4f5dcbf-1521-4f8c-a6ed-0c101d3d367b" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">983</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2030</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4eb3d845-ea66-4740-88bc-8a318c712201" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,013</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_97ff31a7-2dfe-45f4-810f-1edf165e0cb5" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,035</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total minimum lease payments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd6badb6-6afe-4e47-9f00-26246d4253ce" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,813</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: amount representing interest</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_323b8e6f-1303-466c-892a-0a8ac7d9c07b" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,003</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Present value of lease liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e434cb6e-c4aa-4438-949b-0842a4315331" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,810</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: current portion of lease liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f0afd14d-3009-461d-8f7a-72064e3a97b0" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">472</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liabilities, noncurrent</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee44a613-20c4-4d09-b878-44a006f309fd" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,338</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:67.34%;box-sizing:content-box;"/>
         <td style="width:1.021%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.31%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.021%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.31%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average remaining lease term (years) - operating leases</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_8ef4e66a-869d-42a8-81d9-4d7fc85c940a" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.9</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_6af5f3fb-3b68-487b-8d5f-6a4c39278245" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.9</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average incremental borrowing rate - operating leases</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e8309bdb-b613-412a-a2a9-e8c309b3cc1c" contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">8.07</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0472d2ac-aa5c-4b86-b100-dae60b9ba969" contextRef="C_75025707-e814-4796-aefb-117d79769679" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">8.07</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table></ix:nonNumeric></div></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f93183e5-cb6e-46ae-a50b-9b2282718999" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10. Commitments and Contingencies</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Funding Commitments</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, the Company had ongoing clinical and pre-clinical studies for its various programs. The Company enters into contracts in the normal course of business with contract research organizations in preparation for clinical trials, professional consultants for expert advice and other vendors for clinical supply manufacturing or other services. These contracts are generally cancellable, with notice, at the Company's option and do not have significant cancellation penalties.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Litigation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company, from time to time, may be party to litigation arising in the ordinary course of business. The Company was not subject to any material legal proceedings as of December 31, 2025, and no material legal proceedings are currently pending or threatened. I</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">f the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount is reasonably estimable, the Company will accrue a liability for the estimated loss.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a00f4d64-6b02-47e3-b868-18a31bf3e083" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11. Employee Benefits</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company offers a 401(k) plan (401(k) Plan) for all employees who have met certain eligibility requirements. Under the 401(</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">k) Plan, employees may elect to contribute a portion of their eligible compensation, subject to certain limitations. The Company has a program to match </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_56adada0-2d90-4ad9-aa40-b8f4a1decb21" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of employee contributions to the 401(k) Plan up to a maximum of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c5fc6cd8-a6ac-4988-8882-436f180be10d" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of eligible earnings, subject to statutory limitations. Employer contributions for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> were $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_c8223e4f-2c9b-4724-9e34-85363440979d" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">133</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d69e4f07-3e86-41fe-98a3-866c75b80de1" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:SegmentReportingDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12. Segment Information</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company reports segment information based on the management approach, which reflects the way in which the internal reporting is used by the chief operating decision maker (CODM) to analyze performance, make decisions and allocate resources. The CODM is the Company&#8217;s </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_1e6f4a6c-c495-424f-a078-c4745eb638bc;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company manages its operations as a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_1191e240-a690-465b-8ee1-430de97506c1;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">single</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reportable segment, which includes all activities related to the research, development, and potential future commercialization of its small molecule drug development candidates. The CODM assesses performance and decides how to allocate resources based on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ca6ee9a4-6ee1-4117-a745-1b0e73206bde" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">net loss</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (presented in the statements of operations and comprehensive loss). The measure of segment assets is reported on the balance sheets as total assets. All long-lived assets are located in the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_deec4d11-d47c-431c-8736-7b60cd2da636" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" escape="true"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The table below shows a reconciliation of the Company&#8217;s net loss, including the significant expense categories regularly provided to and reviewed by the CODM, to the Company&#8217;s total net loss in the statements of operations and comprehensive loss (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:58.76%;box-sizing:content-box;"/>
         <td style="width:1.9%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:16.72%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.9%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:16.72%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended<br/>December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development expenses:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;External research and development <br/>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;expenses by program:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Dabogratinib (TYRA-300</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">ACH</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad0b7324-a83c-4f94-a1e9-348cac6f22fb" contextRef="C_7ed9a919-4011-4987-b82f-187ecd2ac2c6" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,379</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_188eb986-cf35-4541-9aca-03714d23b767" contextRef="C_87dc3b26-58ec-4bf3-9b29-98e651cdbe8a" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,718</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Dabogratinib (TYRA-300</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">NMIBC</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b8a09384-3c61-4df9-a99c-0a3ccc36ef87" contextRef="C_66a8c0d4-dc01-437f-8643-ae23ca05710c" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,244</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe4b661d-2a56-4774-a802-fc547aae4372" contextRef="C_7060b8eb-7cf2-40dd-abeb-7bbe283f0ab1" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">122</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Dabogratinib (TYRA-300</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">UTUC</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ac05b4ef-5f3a-4f00-a3d6-25d7b1e11bc9" contextRef="C_4210f2e9-05d8-4850-ac3c-f78b3d31289e" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,440</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_498aaf5d-1900-47b1-9e01-b17854987d8f" contextRef="C_5e5587d3-9989-48f5-9e25-23f05bd5b860" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Dabogratinib (TYRA-300</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">mUC</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5ea54e9-2e76-49ed-9e7f-13f7ac76922a" contextRef="C_b5150520-b9f3-4bdf-8a55-8f5cea1cb93e" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,590</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3da43496-ccc0-44de-b697-0865f211cafc" contextRef="C_9622fb4d-a971-4870-b202-86d8c0745065" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,319</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;TYRA-430</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2ace0361-f872-4fab-bce6-ba34c404e80d" contextRef="C_dbea103f-6acc-4340-83b5-1436e3999584" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,055</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c239262-6b0f-41c5-8122-8e3254d82066" contextRef="C_18a4d379-7bc9-4fbe-85e9-2af7258397b9" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,677</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;TYRA-200</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7aa8bf55-281f-4b50-8913-41f1c32955e4" contextRef="C_032ccc29-8b89-4307-90c0-e7071ba56b28" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,308</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d8c94a2-5a7c-42b5-ac23-836dafeb4c44" contextRef="C_4723f99d-c390-41ed-a5c5-1df9fcae7f68" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,969</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;FGFR discovery</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ae4655f-911b-49c9-bdac-bbb0969291fc" contextRef="C_ab4f8aaa-c4e6-4bd1-a17b-592c475ced76" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,967</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_20e41772-f570-461a-a875-c54c058259d2" contextRef="C_8c64e7bc-c688-492a-99e8-86f5cb335e47" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,199</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Other development programs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eb4ccca3-9ed3-4efb-8aa7-3ea1803fbbf2" contextRef="C_d412cb4d-1732-4801-8e1b-648dfb7030c2" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,623</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_19cbfc22-d915-43cf-bf6f-90dd80dcbcf3" contextRef="C_011705ed-dba2-4b57-a549-edfd6d1424ce" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,537</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Unallocated research and development <br/>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;expenses:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Personnel costs</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a4c73223-a8f2-45c0-b939-895fae466da5" contextRef="C_14e460cb-2da4-49f1-a533-de969fc89258" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,218</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_95fed51a-1724-4c4a-bca1-cd4dd667f477" contextRef="C_a412b29c-2a01-4356-b322-11c7037ef382" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,423</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Facilities and other costs</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2ef49d1a-2d11-4c19-9f37-954b86c4a8fb" contextRef="C_cd230b0d-0361-47ec-8672-4de4e7ba7e85" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,104</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f608c29-f15c-4349-8faf-2c8418f2cb3b" contextRef="C_0aaa07cf-e8dc-4ed0-ba3c-1e37ea8486c6" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,113</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total research and development expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7b567cdb-db38-47e0-999e-e5900e983f32" contextRef="C_88fc6773-cb7f-4a2b-917e-b6e8a47d801c" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">102,928</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa360ad2-98cc-464e-9460-43c6885b5bf1" contextRef="C_e214f6fc-28de-40f3-bcc1-08bf1f39a68d" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">80,077</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative expenses</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_54208db0-fdfa-4282-bd8a-f1b532057094" contextRef="C_88fc6773-cb7f-4a2b-917e-b6e8a47d801c" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,834</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_462c7276-b09b-4c39-9995-95a55b303357" contextRef="C_e214f6fc-28de-40f3-bcc1-08bf1f39a68d" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,100</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest and other income, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d4e00aa1-0c2d-4f09-9bcd-258affda2cca" contextRef="C_88fc6773-cb7f-4a2b-917e-b6e8a47d801c" name="us-gaap:InterestAndOtherIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,815</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1aeef8a4-5f3d-43f8-ae83-9891052c2165" contextRef="C_e214f6fc-28de-40f3-bcc1-08bf1f39a68d" name="us-gaap:InterestAndOtherIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,696</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d97620d3-061d-4e2a-88f5-25c5644284f5" contextRef="C_88fc6773-cb7f-4a2b-917e-b6e8a47d801c" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">119,947</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7e027649-0f58-4e83-9d3d-0ea7bb3420a0" contextRef="C_e214f6fc-28de-40f3-bcc1-08bf1f39a68d" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">86,481</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) </span><ix:footnote id="FNT_132f20ce-f34d-4ee8-a541-6bc46878b344" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Personnel costs include $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_f8fdaf44-9964-4c55-91e7-c16594a26234" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_14f57931-fd5b-4bfa-912a-0dad475453ad" contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">14.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of stock-based compensation for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</span></ix:footnote></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2)</span><ix:footnote id="FNT_bba94c94-ee85-4e4d-b64e-20c95d3d3e2a" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Facilities and other costs consist of research consumables, facility-related costs, depreciation and costs not attributed to a specific program.</span></ix:footnote></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(3) </span><ix:footnote id="FNT_a2a8f412-f3ed-40a6-91bc-571db48e95e7" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses consist of personnel-related expenses, including stock-based compensation, legal fees, facility-related costs, depreciation, professional and consulting fees and insurance costs.</span></ix:footnote></p></ix:nonNumeric></div></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">134</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9_changes_in_and_disagreements"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">em 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9a_controls_and_procedures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">tem 9A. Controls and Procedures.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management, with the participation of our chief executive officer and our chief financial officer (our principal executive officer and principal financial and accounting officer, respectively), evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2025. The term "disclosure controls and procedures," as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission (the SEC)&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company's management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of December 31, 2025, our chief executive officer and our chief financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Management&#8217;s Annual Report on Internal Control Over Financial Reporting</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Exchange Act Rules 13a-15(f). Management assessed our internal control over financial reporting as of December 31, 2025, and based its assessment on criteria established in "Internal Control - Integrated Framework (2013)" issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on that assessment, our management concluded that our internal control over financial reporting was effective as of December 31, 2025.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risks that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in Internal Control Over Financial Reporting</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended December 31, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">135</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9b_other_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">em 9B. Other Information.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Director and Officer Trading Arrangements:</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7f72030d-cf11-4653-bc49-83b53e160112" contextRef="C_6f8e39dd-1c81-4d46-8007-0bbb98e5748d" name="ecd:MtrlTermsOfTrdArrTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Rule 10b5-1 Trading Plans</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, our officers (as defined in Rule 16a-1(f) of the Exchange Act) and directors may enter into Rule 10b5-1 or non-Rule 10b5-1 trading arrangements (as each such term is defined in Item 408 of Regulation S-K). During the three months ended December 31, 2025, our officers and directors took the following actions with respect to such trading arrangements:</span></p>
     <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
      <tr style="visibility:collapse;">
       <td style="width:22.825%;box-sizing:content-box;"/>
       <td style="width:1.52%;box-sizing:content-box;"/>
       <td style="width:12.182%;box-sizing:content-box;"/>
       <td style="width:1.52%;box-sizing:content-box;"/>
       <td style="width:10.002%;box-sizing:content-box;"/>
       <td style="width:1.26%;box-sizing:content-box;"/>
       <td style="width:12.322%;box-sizing:content-box;"/>
       <td style="width:1.52%;box-sizing:content-box;"/>
       <td style="width:10.502%;box-sizing:content-box;"/>
       <td style="width:1.52%;box-sizing:content-box;"/>
       <td style="width:1%;box-sizing:content-box;"/>
       <td style="width:10.202%;box-sizing:content-box;"/>
       <td style="width:1%;box-sizing:content-box;"/>
       <td style="width:1.52%;box-sizing:content-box;"/>
       <td style="width:11.102%;box-sizing:content-box;"/>
      </tr>
      <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading Arrangement</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      </tr>
      <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name and Title</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Action</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_321556ab-c7c1-4b9a-b697-06f97459d98a" contextRef="C_6c246792-9518-4437-a499-5e637972016a" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_8d581a29-3591-4446-9773-93bf8c438afa" contextRef="C_68fd01c3-dd3c-414b-9432-cffd7c483daf" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Rule 10b5-1</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">*</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Non-Rule 10b5-1**</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total Shares Authorized to be Sold***</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Expiration Date</span></p></td>
      </tr>
      <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      </tr>
      <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
       <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_6b6fb485-92f5-4998-98dd-768b66400c63" contextRef="C_6c246792-9518-4437-a499-5e637972016a" name="ecd:TrdArrIndName"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Todd Harris</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br/></span><span><ix:nonNumeric id="F_7bcca592-850d-40d4-9b53-34f40be2a33b" contextRef="C_6c246792-9518-4437-a499-5e637972016a" name="ecd:TrdArrIndTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">President, Chief Executive Officer and Director</span></ix:nonNumeric></span></p></td>
       <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Terminate </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
       <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_44bb98cf-92f7-4ab3-ad5c-24fabb0ce38c" contextRef="C_6c246792-9518-4437-a499-5e637972016a" name="ecd:TrdArrTerminationDate"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11/21/2025</span></ix:nonNumeric></span></p></td>
       <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_e299fb40-d822-4869-ae82-ef177b7b53cd" contextRef="C_6c246792-9518-4437-a499-5e637972016a" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></ix:nonNumeric></span></p></td>
       <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_30572f37-19f4-4213-9294-40a0c2ae99b7" contextRef="C_5bd11727-b5f4-41c0-a8a8-fecf149214ac" name="ecd:TrdArrSecuritiesAggAvailAmt" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">315,000</ix:nonFraction></span></p></td>
       <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_89589979-fdb4-4496-8810-12bc3fd03dd6" contextRef="C_6c246792-9518-4437-a499-5e637972016a" name="ecd:TrdArrExpirationDate"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12/31/2026</span></ix:nonNumeric></span></p></td>
      </tr>
      <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
       <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_aafd2c86-64c5-4fff-a5e3-bc6bfcbce02a" contextRef="C_68fd01c3-dd3c-414b-9432-cffd7c483daf" name="ecd:TrdArrIndName"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Alan Fuhrman</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br/></span><span><ix:nonNumeric id="F_eac1015f-d128-40df-bb30-847050b24116" contextRef="C_68fd01c3-dd3c-414b-9432-cffd7c483daf" name="ecd:TrdArrIndTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer</span></ix:nonNumeric></span></p></td>
       <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Terminate </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
       <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_46bb6771-b381-4990-9dee-ffd3bd2db4e5" contextRef="C_68fd01c3-dd3c-414b-9432-cffd7c483daf" name="ecd:TrdArrTerminationDate"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11/21/2025</span></ix:nonNumeric></span></p></td>
       <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_648a6197-e955-4f1d-be99-0c3d1cd14a34" contextRef="C_68fd01c3-dd3c-414b-9432-cffd7c483daf" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></ix:nonNumeric></span></p></td>
       <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_112f0a02-1adc-426b-90ee-2868bf27eca2" contextRef="C_1fbdc9f6-75dd-418c-a9c1-887b681c7dc0" name="ecd:TrdArrSecuritiesAggAvailAmt" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">80,000</ix:nonFraction></span></p></td>
       <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_60364b5c-6a12-4c91-9f40-a51a79ad1a32" contextRef="C_68fd01c3-dd3c-414b-9432-cffd7c483daf" name="ecd:TrdArrExpirationDate"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7/31/2026</span></ix:nonNumeric></span></p></td>
      </tr>
     </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* Intended to satisfy the affirmative defense of Rule 10b5-1(c)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">** Not intended to satisfy the affirmative defense of Rule 10b5-1(c)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">*** Represents the maximum number of shares that may be sold pursuant to the 10b5-1 arrangement. The number of shares sold is dependent on the satisfaction of certain conditions as set forth in the written plan and the satisfaction of applicable vesting conditions of equity awards.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) Trading arrangement was originally adopted on 11/4/2024.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2) Trading arrangement was originally adopted on 11/5/2024.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9c_disclosure_regarding_foreign"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">em 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART III</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_10_directors_executive_officers"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 10. Directors, Execu</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">tive Officers and Corporate Governance.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information required by this item and not set forth below will be contained in our definitive proxy statement to be filed with the SEC in connection with our 2026 Annual Meeting of Stockholders (the Definitive Proxy Statement), which is expected to be filed not later than 120 days after the end of our fiscal year ended December 31, 2025, and is incorporated herein by reference.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Code of Business Conduct and Ethics</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have adopted a Code of Business Conduct and Ethics that applies to our officers, directors and employees, which is available on our website at www.tyra.bio. The Code of Business Conduct and Ethics contains general guidelines for conducting the business of our company consistent with the highest standards of business ethics and is intended to qualify as a &#8220;code of ethics&#8221; within the meaning of Section 406 of the Sarbanes-Oxley Act of 2002 and Item 406 of Regulation S-K. In addition, we intend to promptly disclose (1) the nature of any amendment to our Code of Business Conduct and Ethics that applies to our principal executive officer, principal financial officer, principal accounting officer or controller or persons performing similar functions and (2) the nature</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">136</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of any waiver, including an implicit waiver, from a provision of our code of ethics that is granted to one of these specified officers, the name of such person who is granted the waiver and the date of the waiver on our website in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Insider Trading Policy and Procedures</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a847e001-c9b3-4e4e-9ee1-090aa9d033b5" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted an insider trading policy and procedures</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> governing the purchase, sale, and/or other dispositions of our securities by our directors, officers, employees and other covered persons that are designed to promote compliance with insider trading laws, rules and regulations, and the Nasdaq Stock Market LLC listing rules, as applicable. A copy of our Insider Trading Compliance Policy and Procedures is filed as Exhibit 19.1 to this Annual Report. It is our policy to comply with U.S. insider trading laws and regulations, including with respect to transactions in our own securities.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="toc652748_19"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 11. Exe</span><span id="item_11_executive_compensation"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cutive Compensation.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information required by this item will be contained in our Definitive Proxy Statement and is incorporated herein by reference.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="toc652748_20"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 12. Security Own</span><span id="item_12_security_ownership_of_certain"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information required by this item will be contained in our Definitive Proxy Statement and is incorporated herein by reference.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="toc652748_21"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 13. Certain Relatio</span><span id="item_13_certain_relationships_and_relate"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nships and Related Transactions, and Director Independence.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information required by this item will be contained in our Definitive Proxy Statement and is incorporated herein by reference.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="toc652748_22"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 14. Prin</span><span id="item_14_principal_accounting_fees_servic"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cipal Accounting Fees and Services.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information required by this item will be contained in our Definitive Proxy Statement and is incorporated herein by reference.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART IV</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_15_exhibits_financial_statement"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">em 15. Exhibits and Financial Statement Schedules.</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial Statements.</span></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The financial statements of Tyra Biosciences, Inc., together with the report thereon of Ernst &amp; Young LLP, an independent registered public accounting firm (PCAOB ID No. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c623dab0-c416-4a61-9d1c-20159f4597e0" contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa" name="dei:AuditorFirmId"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">42</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">), are included in this Annual Report contained in Part II, Item 8. Financial Statements and Supplementary Data.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Finance Statement Schedules.</span></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All schedules are omitted because they are not applicable or the required information is shown in the financial statements or notes thereto.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibits.</span></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A list of exhibits is set forth on the Exhibit Index immediately preceding the signature page of this Annual Report and is incorporated herein by reference.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_16_form_10_k_summary"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">em 16. Form 10-K Summary.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">137</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXHIBIT INDEX</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:10.118%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:46.451%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8.058%;box-sizing:content-box;"/>
     <td style="width:1.02%;box-sizing:content-box;"/>
     <td style="width:10.118%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.098%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.138%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:20.15pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:1pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit Description</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:1pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td colspan="5" style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Incorporated by Reference</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:1pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Filed</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Herewith</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Form</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:1pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:1pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:1pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:1pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1863127/000095017023009181/tyra-ex3_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Certificate of Incorporation</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/22/23</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.2</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1863127/000119312524151705/d807421dex31.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certificate of Amendment of Amended and Restated Certificate of Incorporation, dated May 29, 2024</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5/31/24</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.3</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1863127/000119312523264152/d537796dex31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Bylaws, effective as of October 26, 2023</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10/26/23</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1863127/000119312521252729/d189651dex41.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Specimen stock certificate evidencing the shares of common stock</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8/20/21</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1863127/000119312521268272/d189651dex42.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Investors&#8217; Rights Agreement, dated March 5, 2021, by and among the Registrant and certain of its stockholders</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1/A</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9/9/21</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.3</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1863127/000095017022002814/tyra-ex4_3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Description of Registered Securities</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/3/22</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.3</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.4</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1863127/000119312524023367/d620082dex41.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Pre-Funded Warrant</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2/5/24</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.5</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1863127/000119312524239650/d814860dex41.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Exchange Warrant</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10/18/24</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1#</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001863127/000119312521252729/d189651dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Tyra Biosciences, Inc. 2020 Equity Incentive Plan and form of stock option agreement thereunder</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8/20/21</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2#</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1863127/000119312521268272/d189651dex102.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Tyra Biosciences, Inc. 2021 Incentive Award Plan and form of stock option grant notice and stock option agreement thereunder</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1/A</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9/9/21</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3#</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1863127/000119312521268272/d189651dex103.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Tyra Biosciences, Inc. 2021 Employee Stock Purchase Plan</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1/A</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9/9/21</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4#</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1863127/000095017025108899/tyra-ex10_1.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Non-Employee Director Compensation Program, amended and restated effective May 29, 2025</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8/14/2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.5#</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1863127/000095017023009181/tyra-ex10_5.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Tyra Biosciences, Inc. Annual Bonus Plan</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/22/23</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.5</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.6#</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1863127/000119312521252729/d189651dex1012.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Second Amended and Restated Employment Letter Agreement, dated August 18, 2021, by and between Todd Harris and the Registrant</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8/20/21</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.12</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.7#</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1863127/000119312521252729/d189651dex1013.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Second Amended and Restated Employment Letter Agreement, dated August 18, 2021, by and between Daniel Bensen and the Registrant</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8/20/21</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.13</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.8#</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1863127/000095017023009181/tyra-ex10_14.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Letter Agreement, dated December 31, 2022, by and between Alan Fuhrman and the Registrant</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/22/23</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.14</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.9#</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1863127/000095017024123346/tyra-ex10_2.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement, dated September 9, 2024, between the Registrant and Douglas Warner, M.D.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11/7/2024</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.10#</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1863127/000119312521252729/d189651dex1020.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Indemnification Agreement for Directors and Officers</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8/20/21</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.20</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.11</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001863127/000119312521252729/d189651dex1019.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Office Lease, between the Registrant and Fabric 2656 State, LLC, a California limited liability company, dated August 5, 2020</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8/20/21</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.19</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.12</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1863127/000095017022002814/tyra-ex10_14.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">First Amendment to Lease, between the Registrant and Fabric 2656 State, LLC, a California limited liability company, dated March 2, 2022</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/3/22</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.14</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.13</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1863127/000095017023009181/tyra-ex10_19.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Second Amendment to Lease, between the Registrant and Fabric 2656 State, LLC, a California limited liability company, dated December 20, 2022</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/22/23</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.19</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.14</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1863127/000095017022002814/tyra-ex10_15.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Office Lease, between the Registrant and Fabric 2676 State Street, LLC, a California limited liability company, dated March 2, 2022</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/3/22</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.15</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">138</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;">
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:10.118%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:46.451%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8.058%;box-sizing:content-box;"/>
     <td style="width:1.02%;box-sizing:content-box;"/>
     <td style="width:10.118%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.098%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.138%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.15</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1863127/000095017023009181/tyra-ex10_21.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">First Amendment to Lease, between the Registrant and Fabric 2676 State, LLC, a California limited liability company, dated May 16, 2022</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/22/23</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.21</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.16</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1863127/000095017023009181/tyra-ex10_22.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Second Amendment to Lease, between the Registrant and Fabric 2676 State, LLC, a California limited liability company, dated January 6, 2023</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/22/23</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.22</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.17</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1863127/000095017024033461/tyra-ex10_23.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Third Amendment to Lease, between the Registrant and Fabric 2676 State, LLC, a California limited liability company, dated March 18, 2024</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/19/2024</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.23</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.18</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1863127/000119312525116008/d932226dex12.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Sales Agreement, dated May 8, 2025, by and between the Registrant and TD Securities (USA) LLC</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-3</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5/8/25</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.2</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.19#</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="tyra-ex10_19.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement, dated December 1, 2025, between the Registrant and Bhavesh Ashar</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1863127/000095017025046124/tyra-ex19_1.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Insider Trading Compliance Policy and Procedures</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/27/25</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="tyra-ex23_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="tyra-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Chief Executive Officer, as required by Rule 13a-14(a) or Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.2</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="tyra-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Chief Financial Officer, as required by Rule 13a-14(a) or Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.1*</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="tyra-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.2*</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="tyra-ex32_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1863127/000095017024033461/tyra-ex97_1.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Policy for Recovery of Erroneously Awarded Compensation</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/19/2024</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.INS</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Instance Document - the Instance Document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;101.SCH</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL Document)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"># Indicates management contract or compensatory plan.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* This certification is deemed not filed for purpose of Section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">** Certain schedules and annexes have been omitted in accordance with Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule and/or annex will be furnished as a supplement to the U.S. Securities and Exchange Commission upon request.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">139</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="signatures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNATURES</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:44.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"/>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">TYRA BIOSCIENCES, INC.</span></p></td>
    </tr>
    <tr style="height:12.25pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;border-bottom:0.75pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Todd Harris, Ph.D.</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Todd Harris, Ph.D.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">President, Chief Executive Officer, and Director</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Date: March 2, 2026</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:32.98%;box-sizing:content-box;"/>
     <td style="width:1.04%;box-sizing:content-box;"/>
     <td style="width:43.3%;box-sizing:content-box;"/>
     <td style="width:1.04%;box-sizing:content-box;"/>
     <td style="width:21.64%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date</span></p></td>
    </tr>
    <tr style="height:4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Todd Harris, Ph.D.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">President, Chief Executive Officer and Director</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 2, 2026</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Todd Harris, Ph.D.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(principal executive officer)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Alan Fuhrman</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 2, 2026</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Alan Fuhrman</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(principal financial and accounting officer)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Adele M. Gulfo</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Director</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 2, 2026</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Adele M. Gulfo</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Gilla Kaplan, Ph.D.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Director</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 2, 2026</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gilla Kaplan, Ph.D.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Melissa McCracken, Ph.D.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Director</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 2, 2026</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Melissa McCracken, Ph.D.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Susan Moran, M.D., M.S.C.E.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Director</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 2, 2026</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Susan Moran, M.D., M.S.C.E.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Robert More</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Director</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 2, 2026</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Robert More</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ S. Michael Rothenberg, M.D., Ph.D.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Director</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 2, 2026</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">S. Michael Rothenberg, M.D., Ph.D.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Jake Simson, Ph.D</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Director</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 2, 2026</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Jake Simson, Ph.D.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:4pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Rehan Verjee</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Director</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 2, 2026</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Rehan Verjee</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">140</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.19
<SEQUENCE>2
<FILENAME>tyra-ex10_19.htm
<DESCRIPTION>EX-10.19
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-03-02T14:21:18.5190+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-10.19</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 10.19</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TYRA BIOSCIENCES, INC.<br><br></font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EMPLOYMENT AGREEMENT</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Employment Agreement (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) is effective as of December 1, 2025 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), by and between Tyra Biosciences, Inc., a Delaware corporation (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and Bhavesh Ashar (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Executive</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; and, together with the Company, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Parties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).  Capitalized terms used herein and not otherwise defined shall have those meanings set forth in </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Appendix I</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hereto.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company desires to retain the services of Executive by engaging Executive to perform services as an employee of the Company under the terms hereof; and</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WHEREAS</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, Executive desires to provide services to the Company on the terms hereof.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOW, THEREFORE</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, in consideration of the foregoing, and for other good and valuable consideration, including the respective covenants and agreements set forth below, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto agree as follows:</font></p><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">1.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Company shall employ Executive upon the terms and conditions provided herein effective as of the Effective Date.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Position and Duties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Executive shall serve as the Chief Operating Officer of the Company, with responsibilities, duties, and authority usual and customary for such position subject to direction by the Chief Executive Officer (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CEO</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).  During Executive&#x2019;s employment with the Company, Executive shall report directly to the CEO and agrees promptly and faithfully to comply with all present and future policies, requirements, rules and regulations, and reasonable directions and requests, of the Company in connection with the Company&#x2019;s business.  Executive will at all times perform all of the duties and obligations required by Executive under this Agreement in a loyal and conscientious manner and to the best of Executive&#x2019;s ability and experience. </font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Performance of Executive&#x2019;s Duties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  During Executive&#x2019;s employment with the Company, and except for periods of illness, vacation, disability, or excused leaves of absence, Executive shall devote Executive&#x2019;s full time and attention to the business and affairs of the Company pursuant to the general direction of the CEO; provided that nothing herein shall preclude Executive from, subject to prior consent of the CEO: (i) engaging in additional activities in connection with personal investments and community affairs including service on non-profit boards of directors, (ii) serving as a member of the board of directors of for-profit organizations that are not competitors of the Company, and (iii) serving as an advisor, or as a member of an advisory board of organizations that are not competitors of the Company; provided, that such activities do not individually or in the aggregate interfere with the performance of Executive&#x2019;s duties under this Agreement, violate the Company&#x2019;s standards of conduct then in effect or raise a conflict under the Company&#x2019;s conflict of interest policies. Executive&#x2019;s primary work location shall </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be his home office in Chatham, New Jersey, subject to such travel as reasonably required in connection with Executive&#x2019;s duties whenever deemed necessary or requested by the Company from time to time. The Company reserves the right to reasonably require Executive to perform his duties at places other than his primary work location from time to time, and to require reasonable business travel with reimbursement in a manner consistent with the Company&#x2019;s travel reimbursement policies.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">2.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Term</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The period of Executive&#x2019;s employment under this Agreement shall commence on the Effective Date and shall continue until Executive&#x2019;s employment with the Company is terminated.  The phrase &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Term of Employment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; as used in this Agreement shall refer to the entire period of employment of Executive by the Company.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">3.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compensation and Related Matters</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Annual Base Salary</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Executive shall receive a base salary at the rate of $550,000 per annum (as may be increased from time to time, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Annual Base Salary</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), subject to withholdings and deductions, which shall be paid to Executive in accordance with the customary payroll practices and procedures of the Company.  Commencing in 2027, such Annual Base Salary shall be reviewed by the Board of Directors of the Company (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) or its designated committee, not less than annually, and may be increased, but not decreased, in connection with any such review.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Annual Bonus</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Commencing with the 2026 calendar year, </font><font style="color:#231f20;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Executive shall be eligible to receive a discretionary annual bonus (the &#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Annual Bonus</font><font style="color:#231f20;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) based on the Company&#x2019;s and/or Executive&#x2019;s achievement of performance objectives in accordance with the terms set forth by the Board or its designated committee. Executive&#x2019;s target Annual Bonus shall be equal to 40% of Executive&#x2019;s Annual Base Salary (the &#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Target Bonus</font><font style="color:#231f20;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). Except as set forth in Section 6, Executive must be employed by the Company on the date of payment of any Annual Bonus to remain eligible to receive such Annual Bonus. Except as otherwise provided in Section 6, any Annual Bonus earned will be paid at the same time annual bonuses are paid to other executives of the Company generally. For the avoidance of doubt, Executive shall not be entitled to an Annual Bonus with respect to the 2025 calendar year.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Executive shall be entitled to participate in such employee and executive benefit plans and programs as the Company may offer from time to time to provide to its executives, subject to the terms and conditions of such plans.  Notwithstanding the foregoing, nothing herein is intended, or shall be construed, to require the Company to institute or continue any, or any particular, plan, or benefits.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Business Expenses</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Company shall reimburse Executive for all reasonable, documented, out-of-pocket travel and other business expenses incurred by Executive in the performance of Executive&#x2019;s duties to the Company in accordance with the Company&#x2019;s applicable expense reimbursement policies and procedures as are in effect from time to time.  </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	 </font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(e)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vacation; Paid Time Off</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Executive will be entitled to vacation or paid time off in accordance with the Company&#x2019;s policy.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(f)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity Awards</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  </font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.667%;">(i)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to the approval of the Board or its designee, Executive will be granted an option to purchase 300,000 shares of the Company&#x2019;s common stock (with the exercise price based on the price of a share of the Company&#x2019;s common stock on the date of grant) (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">New Hire Option</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). The New Hire Option will be granted pursuant to the Company&#x2019;s 2021 Incentive Award Plan (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and will be subject to the terms and conditions of the Plan and the stock option agreement issued by the Company evidencing the New Hire Option.  Subject to Executive&#x2019;s continued employment or service with the Company on each vesting date, twenty-five percent of the New Hire Option will vest upon the one-year anniversary of the Effective Date and then ratably over the thirty-six months thereafter. </font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.667%;">(ii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Executive shall be eligible to receive additional grants of equity awards in the Company&#x2019;s sole discretion.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(g)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indemnification Agreement; Insurance</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  As an officer of the Company, Executive shall be entitled to enter into the Company&#x2019;s standard indemnification agreement.  Executive will also be covered under a directors and officers liability insurance policy paid for by the Company for so long as Executive serves as an officer of the Company.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">4.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Acceleration of Equity Awards Upon a Change in Control</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Notwithstanding anything herein to the contrary, in the event of a Change in Control, the vesting of Executive&#x2019;s then outstanding options, restricted stock and other equity awards covering shares of the Company&#x2019;s common stock (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity Awards</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) shall accelerate as of immediately prior to such Change in Control with respect to fifty percent of the unvested shares of Company common stock subject to such Equity Awards.  The remaining fifty percent of the unvested shares of Company common stock subject to Executive&#x2019;s Equity Awards shall continue to vest at the same rate as immediately prior to the Change in Control, subject to Executive&#x2019;s continued employment with the Company or its successor through the applicable vesting date.  Any portion of Executive&#x2019;s Equity Awards that remains unvested as of the first anniversary of the Change in Control shall thereupon vest in full, subject to Executive&#x2019;s continued employment with the Company or its successor through such first anniversary.  Notwithstanding the foregoing and for the avoidance of doubt, any shares subject to Equity Awards that do not accelerate immediately prior to the Change in Control in accordance with the foregoing shall be subject to accelerated vesting in accordance with Section 6(d)(iii) below.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">5.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At-Will Employment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Company and Executive acknowledge that Executive&#x2019;s employment is and shall continue to be at-will, as defined under applicable law.  This means that it is not for any specified period of time and can be terminated by Executive or by the </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	 </font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company at any time, with or without advance notice, and for any or no particular reason or cause.  It also means that Executive&#x2019;s job duties, title, and responsibility and reporting level, work schedule, compensation, and benefits, as well as the Company&#x2019;s personnel policies and procedures, may be changed with prospective effect, with or without notice, at any time in the sole discretion of the Company (subject to any ramification such changes may have under Section 6 of this Agreement).  This &#x201c;at-will&#x201d; nature of Executive&#x2019;s employment shall remain unchanged during Executive&#x2019;s tenure as an employee and may not be changed, except in an express writing signed by Executive and an authorized officer of the Company.  If Executive&#x2019;s employment terminates for any lawful reason, Executive shall not be entitled to any payments, benefits, Equity Awards or other compensation other than as provided in this Agreement.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notice of Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  During the Term of Employment, any termination of Executive&#x2019;s employment by the Company or by Executive (other than by reason of death) shall be communicated by written notice (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notice of Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) from one Party hereto to the other Party hereto (i) indicating the specific termination provision in this Agreement relied upon, if any, (ii) setting forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of Executive&#x2019;s employment under the provision so indicated and (iii) specifying the date of the termination of Executive&#x2019;s employment with the Company (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Date of Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).  The failure by the Company to set forth in the Notice of Termination all of the facts and circumstances which contribute to a showing of Cause shall not waive any right of the Company hereunder or preclude the Company from asserting such fact or circumstance in enforcing its rights hereunder.  The failure by Executive to set forth in the Notice of Termination all of the facts and circumstances which contribute to a showing of Good Reason shall not waive any right of Executive hereunder or preclude Executive from asserting such fact or circumstance in enforcing Executive&#x2019;s rights hereunder.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deemed Resignation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Upon termination of Executive&#x2019;s employment with the Company for any reason, Executive shall be deemed to have resigned from all offices and board memberships, if any, then held with the Company or any of its affiliates, and, at the Company&#x2019;s request, Executive shall execute such documents as are necessary or desirable to effectuate such resignations.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">6.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consequences of Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payments upon Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In the event Executive&#x2019;s employment with the Company terminates pursuant to Section 5, then Executive shall be entitled to the applicable payments and benefits set forth below subject to, </font><font style="color:#231f20;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in the case of a termination described in Section 6(c) or 6(d), </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Executive delivering to the Company a waiver and release of claims agreement in standard reasonable form approved by the Company that becomes effective and irrevocable in accordance with Section 7 hereof (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Release</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payments upon Termination by the Company for Cause or by Executive Without Good Reason</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Upon a termination of Executive&#x2019;s employment with the Company at any time for Cause or by Executive without Good Reason, Executive (or Executive&#x2019;s estate or legal </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	 </font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">representative, as applicable) shall be entitled to receive, within thirty days of the Date of Termination (whether such termination of employment is effected by the Company or Executive) (or such earlier date as may be required by applicable law): (i) any portion of Executive&#x2019;s Annual Base Salary earned through Executive&#x2019;s Date of Termination not theretofore paid; (ii) any reimbursement of expenses owed to Executive under Section 3(d) above; and (iii) any accrued but unused vacation or paid time-off owed to Executive ((i)-(iii) defined as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).  In the event Executive is terminated by the Company for Cause, Executive shall forfeit, effective as of the date Executive engages in such conduct giving rise to Executive&#x2019;s termination for Cause, all unexercised, unearned and/or unpaid Equity Awards, including without limitation, Equity Awards earned but not yet paid, all unpaid dividends and dividend equivalents and all interest, if any, accrued on the foregoing.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Severance Payments upon Involuntary Termination Outside a Change in Control Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  If, outside a Change in Control Period, Executive&#x2019;s employment is terminated due to an Involuntary Termination, the Company shall provide the following payments and benefits:</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.667%;">(i)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Accrued Obligations;</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.667%;">(ii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an amount in cash equal to (A) twelve months of Executive&#x2019;s Annual Base Salary plus (B) Executive&#x2019;s target Bonus for the calendar year in which such Involuntary Termination occurs, pro-rated based on the total number of days elapsed in the calendar year as of Executive&#x2019;s Date of Termination;</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.667%;">(iii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fifty percent of the unvested Equity Awards held by the Executive as of the Date of Termination will become fully vested and, if applicable, exercisable, and all restrictions and rights of repurchase thereon shall lapse with respect to all of the shares of the Company&#x2019;s common stock subject thereto; and </font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.667%;">(iv)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">during the period commencing on the Date of Termination and ending on the twelve-month anniversary thereof or, if earlier, the date on which Executive becomes eligible for comparable replacement coverage under a subsequent employer&#x2019;s group health plan, subject to Executive&#x2019;s valid election to continue healthcare coverage under Section 4980B of the Internal Revenue Code of 1986, as amended (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Code</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and the regulations thereunder (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">COBRA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), the Company shall, in its sole discretion, either (A) continue to provide to Executive and Executive&#x2019;s dependents, at the Company&#x2019;s sole expense, or (B) reimburse Executive and Executive&#x2019;s dependents for the cost of, in either case, coverage under its group health plan (if any) at the same coverage levels in effect on the Date of Termination (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Benefits Coverage</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;); </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that if (1) any plan pursuant to which such benefits are provided is not, or ceases prior to the expiration of the continuation coverage period to be, exempt from the application of Section 409A under Treasury Regulation Section 1.409A-1(a)(5), (2) the Company is otherwise unable to continue to cover Executive or Executive&#x2019;s dependents under its group health plans or (3) the Company cannot provide the benefit without violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then, in any such case, the cash amount necessary to maintain the Benefits Coverage shall thereafter be paid to Executive in substantially </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	 </font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">equal taxable monthly installments over the COBRA continuation period (or remaining portion thereof).</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Severance Payments upon Involuntary Termination During a Change in Control Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  If, during a Change in Control Period, Executive&#x2019;s employment is terminated due to an Involuntary Termination, the Company shall provide the following payments and benefits:</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.667%;">(i)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Accrued Obligations;</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.667%;">(ii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an amount in cash equal to (A) eighteen months of Executive&#x2019;s Annual Base Salary plus (B) one hundred percent (100%) of Executive&#x2019;s Target Bonus for the calendar year in which such Involuntary Termination occurs (for the avoidance of doubt, if (x) Executive incurred an Involuntary Termination prior to a Change in Control that qualifies Executive for severance payments under Section 6(c)(ii), and (y) a Change in Control occurs within the three-month period following Executive&#x2019;s Involuntary Termination that qualifies Executive for the increased benefits under this Section 6(d)(ii), then Executive shall be entitled to a lump-sum payment of the amount calculated under this Section 6(d)(ii), less any amount already paid under Section 6(c)(ii));</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.667%;">(iii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">one hundred percent (100%) of all unvested Equity Awards held by Executive as of the Date of Termination, will become fully vested and, if applicable, exercisable, and all restrictions and rights of repurchase thereon shall lapse with respect to all of the shares of the Company&#x2019;s common stock subject thereto effective on the later of (x) the Date of Termination or (y) the date of the Change in Control (for the avoidance of doubt, if Executive&#x2019;s Involuntary Termination occurs prior to a Change in Control, then any unvested portion of Executive&#x2019;s outstanding Equity Awards will remain outstanding for three months following the Date of Termination (or, if earlier, until the occurrence of a Change in Control) so that any vesting acceleration benefits provided under this clause (iii) can be provided if a Change in Control occurs within three months following such termination (provided that in no event will the Equity Awards remain outstanding beyond the Equity Award&#x2019;s maximum term or expiration date)). In such case, if no Change in Control occurs within three months following Executive&#x2019;s termination, any unvested portion of Executive&#x2019;s Equity Awards automatically will be forfeited without having vested; and</font></div></div><div class="item-list-element-wrapper" style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.667%;">(iv)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">during the period commencing on the Date of Termination and ending on the twelve-month anniversary thereof or, if earlier, the date on which Executive becomes eligible for comparable replacement coverage under a subsequent employer&#x2019;s group health plan, subject to Executive&#x2019;s valid election to continue healthcare coverage under COBRA, the Company shall, in its sole discretion, either (A) continue to provide to Executive and Executive&#x2019;s dependents, at the Company&#x2019;s sole expense, or (B) reimburse Executive and Executive&#x2019;s dependents for the cost of, in either case, the Benefits Coverage; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that if (1) any plan pursuant to which such benefits are provided is not, or ceases prior to the expiration of the continuation coverage period to be, exempt from the application of Section 409A under Treasury Regulation Section 1.409A-1(a)(5), (2) the Company is otherwise unable to continue to cover Executive or </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	 </font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Executive&#x2019;s dependents under its group health plans or (3) the Company cannot provide the benefit without violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then, in any such case, the cash amount necessary to maintain the Benefits Coverage shall thereafter be paid to Executive in substantially equal taxable monthly installments over the COBRA continuation period (or remaining portion thereof).</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(e)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Other Severance</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The provisions of this Agreement, including, without limitation, this Section 6, shall supersede in their entirety any severance payment provisions in any severance plan, policy, program, or other arrangement maintained by the Company except for such additional benefits otherwise approved by the Board or Compensation Committee of the Board after the date hereof.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(f)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Requirement to Mitigate; Survival</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Executive shall not be required to mitigate the amount of any payment provided for under this Agreement by seeking other employment or in any other manner.  Notwithstanding anything to the contrary in this Agreement, the termination of Executive&#x2019;s employment shall not impair the rights or obligations of any Party.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">7.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Release and Payment Timing.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></div></div><div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:13.605%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.9014788270327565%;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Release</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </font><font style="color:#231f20;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding anything to the contrary in this Agreement, any payments or other benefits due under this Agreement under Sections 6(c) and 6(d) as a result of Executive&#x2019;s termination of employment (other than the Accrued Obligations) are subject to Executive&#x2019;s execution and delivery of a Release, as follows: (i) the Company shall deliver the Release to Executive within five days following Executive&#x2019;s Date of Termination, and the Company&#x2019;s failure to deliver a Release prior to the expiration of such five day period shall constitute a waiver of any requirement to execute a Release, (ii) if Executive fails to execute the Release on or prior to the Release Expiration Date (as defined below) or timely revokes Executive&#x2019;s acceptance of the Release thereafter, Executive shall not be entitled to any payments or benefits otherwise conditioned on the Release, and (iii) if the Release does not become effective and irrevocable no later than sixty days following the Date of Termination (such deadline, the &#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Release Deadline</font><font style="color:#231f20;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), Executive shall not be entitled to any payments or benefits otherwise conditioned on the Release. For purposes of this Section 7, &#x201c;</font><font style="color:#231f20;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Release Expiration Date</font><font style="color:#231f20;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean the date that is twenty-one days following the date upon which the Company timely delivers the Release to Executive, or, in the event that Executive&#x2019;s termination of employment is &#x201c;in connection with an exit incentive or other employment termination program&#x201d; (as such phrase is defined in the Age Discrimination in Employment Act of 1967), the date that is forty-five days following such delivery date. </font></div></div><p style="margin-left:14.253%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.037%;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:0.935%;text-indent:13.605%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#231f20;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.9014788270327565%;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid #231f20;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payment Timing</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The payments due under Sections 6(c)(ii) and 6(d)(ii) of this Agreement as a result of Executive&#x2019;s termination of employment shall be paid in a lump sum on the date that is sixty days following the Date of Termination; provided, however, that, in the event of Executive&#x2019;s Involuntary Termination during the Change in Control Period but prior to a Change in Control, any additional amount payable to Executive under Section 6(d)(ii) in excess of the amounts payable to such Executive under Section 6(c)(ii) shall be paid in a lump </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	 </font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:0.935%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sum on the date that is sixty days following the later of (i) the Date of Termination, or (ii) the date of the Change in Control.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.037%;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">8.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Continuing Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Proprietary Information Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In connection with Executive&#x2019;s commencement of employment, Executive will be required to sign and agree to abide by the terms of the Company&#x2019;s standard employee proprietary information and inventions agreement (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Proprietary Information Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), which is attached hereto as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Appendix II</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and incorporated herein by reference, and agrees that Executive shall continue to be subject to the terms and conditions of such agreement during the term of this Agreement and that such obligations shall survive the Date of Termination. </font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Non-Solicitation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  For a period of one year following Executive&#x2019;s Date of Termination, Executive shall not, either directly or indirectly (i) solicit for employment through any individual, corporation, firm, or other business, any employees, consultants, independent contractors, or other service providers of the Company or any of its affiliates, or (ii) solicit any employee, consultant or other service provider of the Company or any of its affiliates to leave the employment or consulting of or cease providing services to the Company or any of its affiliates; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that the foregoing clauses (i) and (ii) shall not apply to inbound inquiries or any general advertisement or solicitation (or any hiring pursuant to such advertisement or solicitation) that is not specifically targeted to such employees, consultants or other service providers.  </font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Return of Property</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Upon the Date of Termination, Executive agrees to promptly deliver to the Company, all Company documents (and all copies thereof) and other Company property that Executive had in his possession at any time, including but not limited to Company files, notes, drawings, records, business plans and forecasts, financial information, specification, computer-recorded information, tangible property (including, but not limited to, computers, laptops, pagers, etc.), credit cards, entry cards, identification badges and keys and any materials of any kind which contain or embody any proprietary or confidential information of Company (and all reproductions thereof).  </font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Remedies</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If Executive breaches or threatens to commit a breach of any of the provisions of this Section 8, Executive agrees that such breach or threatened breach would cause irreparable injury to the Company and that money damages would not provide an adequate remedy to the Company.  The Company shall also have any other rights and remedies available to the Company under law or in equity, as well as the right to immediately cease providing the post-termination compensation in Section 6(c) and Section 6(d). </font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(e)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other Protections</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Nothing in this Agreement or the Proprietary Information Agreement shall prevent Executive or any other person from (i) communicating directly with, cooperating with, or providing information to, or receiving financial awards from, any federal, state or local government agency, including without limitation the U.S. Securities and Exchange </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	 </font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commission, the U.S. Commodity Futures Trading Commission, the U.S. Department of Justice, the U.S. Equal Employment Opportunity Commission, or the U.S. National Labor Relations Board, without notifying or seeking permission from the Company, (ii) exercising any rights Executive or any other person may have under Section 7 of the U.S. National Labor Relations Act, such as the right to engage in concerted activity, including collective action or discussion concerning wages or working conditions, or (iii) discussing or disclosing information about unlawful acts in the workplace, such as harassment or discrimination based on a protected characteristic or any other conduct that Executive or any other person has reason to believe is unlawful. In addition, Executive acknowledges receipt of the following notice of immunity rights under the U.S. Defend Trade Secrets Act, which states: &#x201c;(1) An individual shall not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal; and (2) an individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose a trade secret to the attorney of the individual and use the trade secret information in the court proceeding, if the individual (A) files any document containing the trade secret under seal, and (B) does not disclose a trade secret, except pursuant to court order.&#x201d;</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">9.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Golden Parachute Excise Tax</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Best Pay</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Any provision of this Agreement to the contrary notwithstanding, if any payment or benefit Executive would receive from the Company pursuant to this Agreement or otherwise (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) would (i) constitute a &#x201c;parachute payment&#x201d; within the meaning of Section 280G of the Code and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Excise Tax</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), then such Payment will be equal to the Reduced Amount (as defined below).  The &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reduced Amount</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; will be either (i) the largest portion of the Payment that would result in no portion of the Payment (after reduction) being subject to the Excise Tax or (ii) the entire Payment, whichever amount after taking into account all applicable federal, state, and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate, net of the maximum reduction in federal income taxes which could be obtained from a deduction of such state and local taxes), results in Executive&#x2019; s receipt, on an after-tax basis, of the greater economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax.  If a reduction in a Payment is required pursuant to the preceding sentence and the Reduced Amount is determined pursuant to clause (i) of the preceding sentence, the reduction shall occur in the manner (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reduction Method</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) that results in the greatest economic benefit for Executive.  If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pro Rata Reduction Method</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).  Notwithstanding the foregoing, if the Reduction Method or the Pro Rata Reduction Method would result in any portion of the Payment being subject to taxes pursuant to Section 409A (as defined below) that would not otherwise be subject to taxes pursuant to Section 409A, then the Reduction Method and/or the Pro Rata Reduction Method, as the case may be, shall be modified </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	 </font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">so as to avoid the imposition of taxes pursuant to Section 409A as follows: (A) as a first priority, the modification shall preserve to the greatest extent possible, the greatest economic benefit for Executive as determined on an after-tax basis; (B) as a second priority, Payments that are contingent on future events (</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">e.g</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">., being terminated without cause), shall be reduced (or eliminated) before Payments that are not contingent on future events; and (C) as a third priority, Payments that are &#x201c;deferred compensation&#x201d; within the meaning of Section 409A shall be reduced (or eliminated) before Payments that are not deferred compensation within the meaning of Section 409A.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounting Firm</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  All determinations regarding the application of this Section 9 shall be made by an independent accounting firm or consulting group with nationally recognized standing and substantial expertise and experience in performing calculations regarding the applicability of Section 280G of the Code and the Excise Tax retained by the Company prior to the date of the applicable change in ownership or control (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">280G Firm</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). The Company will bear all expenses with respect to the determinations by the 280G Firm required to be made hereunder. The 280G Firm engaged to make the determinations hereunder will provide its calculations, together with detailed supporting documentation, to the Company within thirty days before the consummation of a Change in Control (if requested at that time by the Company) or such other time as requested by the Company. If the 280G Firm determines that no Excise Tax is payable with respect to a Payment, either before or after the application of the Reduced Amount, it will furnish the Company with documentation reasonably acceptable to the Company that no Excise Tax will be imposed with respect to such Payment. Any good faith determinations of the 280G Firm made hereunder will be final, binding and conclusive upon the Company and Executive.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">10.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 409A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The intent of the Parties is that the payments and benefits under this Agreement comply with or be exempt from Section 409A of the Code and the Department of Treasury regulations and other interpretive guidance issued thereunder, including without limitation any such regulations or other guidance that may be issued after the Effective Date, (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 409A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and, accordingly, to the maximum extent permitted, this Agreement shall be interpreted to be in compliance therewith.  If Executive notifies the Company that Executive has received advice of tax counsel of a national reputation with expertise in Section 409A that any provision of this Agreement would cause Executive to incur any additional tax or interest under Section 409A (with specificity as to the reason therefor) or the Company independently makes such determination, the Company and Executive shall take commercially reasonable efforts to reform such provision to try to comply with or be exempt from Section 409A through good faith modifications to the minimum extent reasonably appropriate to conform with Section 409A, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that any such modifications shall not increase the cost or liability to the Company.  To the extent that any provision hereof is modified in order to comply with or be exempt from Section 409A, such modification shall be made in good faith and shall, to the maximum extent reasonably possible, maintain the original intent and economic benefit to Executive and the Company of the applicable provision without violating the provisions of Section 409A.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	 </font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Separation from Service</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Notwithstanding any provision to the contrary in this Agreement: (i) no amount that constitutes &#x201c;deferred compensation&#x201d; under Section 409A shall be payable pursuant to Section 6(c) or Section 6(d) above unless the termination of Executive&#x2019;s employment constitutes a &#x201c;separation from service&#x201d; within the meaning of Section 1.409A-1(h) of the Department of Treasury Regulations (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Separation from Service</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;); (ii) for purposes of Section 409A, Executive&#x2019;s right to receive installment payments shall be treated as a right to receive a series of separate and distinct payments; and (iii) to the extent that any reimbursement of expenses or in-kind benefits constitutes &#x201c;deferred compensation&#x201d; under Section 409A, such reimbursement or benefit shall be provided no later than December 31st of the year following the year in which the expense was incurred.  The amount of expenses reimbursed in one year shall not affect the amount eligible for reimbursement in any subsequent year.  The amount of any in-kind benefits provided in one year shall not affect the amount of in-kind benefits provided in any other year.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Specified Employee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Notwithstanding anything in this Agreement to the contrary, if Executive is deemed by the Company at the time of Executive&#x2019;s Separation from Service to be a &#x201c;specified employee&#x201d; for purposes of Section 409A, to the extent delayed commencement of any portion of the benefits to which Executive is entitled under this Agreement is required in order to avoid a prohibited distribution under Section 409A, such portion of Executive&#x2019;s benefits shall not be provided to Executive prior to the earlier of (i) the expiration of the six-month period measured from the date of Executive&#x2019;s Separation from Service with the Company or (ii) the date of Executive&#x2019;s death.  Upon the first business day following the expiration of the applicable Section 409A period, all payments deferred pursuant to the preceding sentence shall be paid in a lump sum to Executive (or Executive&#x2019;s estate or beneficiaries), and any remaining payments due to Executive under this Agreement shall be paid as otherwise provided herein.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">11.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Withholding</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Company shall be entitled to withhold from any amounts payable under this Agreement any federal, state, local, or foreign withholding or other taxes or charges which the Company is required to withhold.  The Company shall be entitled to rely on an opinion of counsel if any questions as to the amount or requirement of withholding shall arise.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">12.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Miscellaneous Provisions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior Employment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Executive represents and warrants that Executive&#x2019;s acceptance of employment with the Company has not breached, and the performance of Executive&#x2019;s duties hereunder will not breach, any duty owed by Executive to any prior employer or other person.  Executive further represents and warrants to the Company that: (i) the performance of Executive&#x2019;s obligations hereunder will not violate any agreement between Executive and any other person, firm, organization, or other entity; (ii) Executive is not bound by the terms of any agreement with any previous employer or other party to refrain from competing, directly or indirectly, with the business of such previous employer or other party that would be violated by Executive entering into this Agreement and/or providing services to the Company pursuant to the terms of this Agreement; and (iii) Executive&#x2019;s performance of Executive&#x2019;s duties under this Agreement will not require Executive to, and Executive shall not, rely on in the performance of Executive&#x2019;s duties or disclose to the Company or any other person or entity or </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	 </font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">induce the Company in any way to use or rely on any trade secret or other confidential or proprietary information or material belonging to any previous employer of Executive.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assignment and Successors</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Company shall assign its rights and obligations under this Agreement to any successor to all or substantially all of the business or the assets of the Company (by merger or otherwise).  This Agreement shall be binding upon and inure to the benefit of the Company, Executive, and their respective successors, assigns, personnel, and legal representatives, executors, administrators, heirs, distributees, devisees, and legatees, as applicable.  None of Executive&#x2019;s rights or obligations may be assigned or transferred by Executive, other than Executive&#x2019;s rights to payments hereunder, which may be transferred only by will, operation of law, or as otherwise provided herein.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governing Law</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  This Agreement shall be governed, construed, interpreted, and enforced in accordance with its express terms, and otherwise in accordance with the substantive laws of the State of California, without giving effect to any principles of conflicts of law, whether of the State of California or any other jurisdiction, and where applicable, the laws of the United States, that would result in the application of the laws of any other jurisdiction.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Validity</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The invalidity or unenforceability of any provision or provisions of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement, which shall remain in full force and effect.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(e)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amendments; Waivers</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  This Agreement may not be modified, amended, or terminated except by an instrument in writing signed by Executive and a duly authorized representative of the Company.  By an instrument in writing similarly executed, Executive or a duly authorized officer of the Company, as applicable, may waive compliance by the other Party with any specifically identified provision of this Agreement that such other Party was or is obligated to comply with or perform; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that such waiver shall not operate as a waiver of, or estoppel with respect to, any other or subsequent failure.  No failure to exercise and no delay in exercising any right, remedy, or power hereunder shall preclude any other or further exercise of any other right, remedy, or power provided herein or by law or in equity.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(f)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dispute Resolution</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Unless otherwise prohibited by law or specified below, all disputes, claims and causes of action, in law or equity, arising from or relating to this Agreement or its enforcement, performance, breach, or interpretation, including any dispute regarding the existence of Cause or Good Reason for Executive&#x2019;s termination of employment, shall be resolved solely and exclusively by final and binding arbitration held in Los Angeles, California, before a single, mutually-agreed neutral arbitrator, through Judicial Arbitration &amp; Mediation Services (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">JAMS</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) under the then existing JAMS arbitration rules. The rules may be found online at www.jamsadr.com or upon written request to the Company. This Section 12(f) is intended to be the exclusive method for resolving any and all claims by the Parties against each other relating to Executive&#x2019;s employment; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that Executive will retain the right to file administrative charges with or seek relief through any government agency of competent jurisdiction, and to participate in any government investigation, including but not limited to (i) claims for workers&#x2019; </font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	 </font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">compensation, state disability insurance or unemployment insurance; (ii) claims for unpaid wages or waiting time penalties brought before the California Division of Labor Standards Enforcement (</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that any appeal from an award or from denial of an award of wages and/or waiting time penalties shall be arbitrated pursuant to the terms of this paragraph); and (iii) claims for administrative relief from the United States Equal Employment Opportunity Commission and/or the California Department of Fair Employment and Housing (or any similar agency in any applicable jurisdiction other than California); </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">further</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that, except as otherwise provided by law, Executive will not be entitled to obtain any monetary relief through such agencies other than workers&#x2019; compensation benefits or unemployment insurance benefits. Further, nothing in this Section 12(f) is intended to prevent either Party from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration, including without limitation injunctive relief, in any court of competent jurisdiction pursuant to California Code of Civil Procedure &#167;1281.8 or any similar statute of an applicable jurisdiction. Seeking any such relief shall not be deemed to be a waiver of such Party&#x2019;s right to compel arbitration. In resolving any matter submitted to arbitration, the arbitrator will strictly follow the substantive law applicable to the dispute, claim or controversy and the arbitrator&#x2019;s authority and jurisdiction will be limited to determining the dispute in conformity with applicable law as to liability, damages and remedies, to the same extent as if the dispute was determined by a court without a jury. The arbitrator will issue a written decision that contains the essential findings of fact and conclusions of law on which the decision is based, which may be entered as a judgment in any court of competent jurisdiction. The Company shall pay all costs of arbitration, including without limitation, arbitration administrative fees, arbitrator compensation and expenses, and costs of any witnesses called by the arbitrator. Unless otherwise ordered by the arbitrator under applicable law, the Company and Executive shall each bear its or his own expenses, such as attorneys&#x2019; fees, costs and disbursements. The prevailing party in any arbitration or other dispute between the Parties will be entitled to an award of attorneys&#x2019; fees and costs, in addition to any other relief. Each Party warrants that it has had the opportunity to be represented by counsel in the negotiation and execution of this Agreement, including the attorneys&#x2019; fees provision herein. Both Executive and the Company expressly waive his and its right to a jury trial. Executive furthers waives his right to pursue claims against the Company on a class basis; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that Executive does not waive his right, to the extent preserved by law, to pursue representative claims against the Company under the California Private Attorney General Act.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(g)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Enforcement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  If any provision of this Agreement is held to be illegal, invalid, or unenforceable under present or future laws, such provision shall be fully severable; this Agreement shall be construed and enforced as if such illegal, invalid, or unenforceable provision had never comprised a portion of this Agreement; and the remaining provisions of this Agreement shall remain in full force and effect and shall not be affected by the illegal, invalid, or unenforceable provision or by its severance from this Agreement.  Furthermore, in lieu of such illegal, invalid, or unenforceable provision there shall be added automatically as part of this Agreement a provision as similar in terms to such illegal, invalid, or unenforceable provision as may be possible and be legal, valid, and enforceable.</font></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	 </font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(h)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Entire Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The terms of this Agreement and the other agreements referenced herein, including the Proprietary Information Agreement, are intended by the Parties to be the final expression of their agreement with respect to the employment of Executive by the Company and supersede all prior understandings and agreements, whether written or oral, regarding Executive&#x2019;s employment with the Company.  The Parties further intend that this Agreement shall constitute the complete and exclusive statement of their terms and that no extrinsic evidence whatsoever may be introduced in any judicial, administrative, or other legal proceeding to vary the terms of this Agreement.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(i)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Executive Acknowledgement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Executive acknowledges that Executive has read and understands this Agreement, is fully aware of its legal effect, has not acted in reliance upon any representations or promises made by the Company other than those contained in writing herein, and has entered into this Agreement freely based on Executive&#x2019;s own judgment.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(j)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Counterparts</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  This Agreement may be executed in several counterparts, each of which shall be deemed to be an original, but all of which together will constitute one and the same Agreement.  Signatures delivered by facsimile shall be deemed effective for all purposes.</font></div></div><div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(k)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notices</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  All notices required or permitted hereunder shall be in writing and shall be deemed effectively given: (i) upon personal delivery to the party to be notified; (ii) when sent by confirmed electronic mail or facsimile if sent during normal business hours of the recipient, and if not, then on the next business day; (iii) five days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or (iv) one day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt.  All communications shall be sent to the Company at its principal executive offices or to Executive at his most recent address on the Company&#x2019;s payroll records or at such other address(es) as the Company or Executive may designate by ten days advance written notice to the other party hereto.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Signature Page Follows</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">]</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	 </font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN WITNESS WHEREOF, the Parties have duly executed this Agreement as of the date and year set forth below.</font></p><p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TYRA BIOSCIENCES, INC.</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br>By: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ Todd Harris	</font></p><p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Name:	Todd Harris</font></p><p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Title:	Chief Executive Officer and President</font></p><p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXECUTIVE</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br>By: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ Bhavesh Ashar	</font></p><p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Name:	Bhavesh Ashar</font></p><p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Signature Page to Employment Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">]</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">APPENDIX I</font></p><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DEFINITIONS</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All defined terms used in this Appendix I that are not otherwise defined in this Appendix I shall have the meaning ascribed to such terms in the Employment Agreement to which this Appendix I relates.</font></p><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cause</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean the occurrence of any one or more of the following events or conditions:</font></p><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(i)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any material failure on the part of Executive (other than by reason of Disability of Executive) to faithfully and professionally carry out Executive&#x2019;s duties which failure continues for ten (10) days after written notice detailing such failure is delivered to Executive by the Company;</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(ii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Executive&#x2019;s dishonesty or other misconduct, if such dishonesty or other misconduct is intended to or likely to materially injure the business or reputation of the Company;</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(iii)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Executive&#x2019;s conviction or no contest plea to any misdemeanor involving dishonesty, theft, fraud or moral turpitude, or any felony.</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(iv)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Executive&#x2019;s insobriety or illegal use of drugs, chemicals or controlled substances either (A) in the course of performing Executive&#x2019;s duties and responsibilities under this Agreement or (B) otherwise materially affecting the ability of Executive to perform the same;</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(v)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Executive&#x2019;s material breach of any written agreement with the Company or any of its affiliates or material violation of the Company&#x2019;s Code of Conduct or any other material written policy of the Company; or</font></div></div><div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">(vi)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any wanton or willful dereliction of duties by Executive.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Change in Control</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall have the meaning given to such term in the Company&#x2019;s 2021 Incentive Award Plan. Notwithstanding the foregoing, if a Change in Control constitutes a payment event with respect to any amount hereunder that provides for the deferral of compensation that is subject to Section 409A, to the extent required to avoid the imposition of additional taxes under Section 409A, the transaction or event shall only constitute a Change in Control for purposes of the payment timing of such amount if such transaction also constitutes a &#x201c;change in control event,&#x201d; as defined in Treasury Regulation Section 1.409A-3(i)(5).</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Change in Control Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean the period commencing three months prior to a Change in Control and ending on the eighteen-month anniversary of the Change in Control.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean permanent and total disability within the meaning of Section 22(e) of the Code.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Good Reason</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean any one of the following: (i) the material reduction of Executive&#x2019;s Annual Base Salary (other than as part of a reduction in the base salaries of all or substantially all other similarly situated employees of the Company that is in the same proportion as the reduction in Executive&#x2019;s Annual Base Salary); (ii) a material reduction of Executive&#x2019;s duties and</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">responsibilities from those in effect on the Effective Date; (iii) the Company&#x2019;s material breach of this  Agreement (other than a reduction of Executive&#x2019;s Annual Base Salary as part of a reduction in the base salaries of all or substantially all other similarly situated employees of the Company that is in the same proportion as the reduction in Executive&#x2019;s Annual Base Salary); or (iv) the permanent, non-voluntary relocation of Executive&#x2019;s principal place of employment that increases Executive&#x2019;s one-way commute by more than thirty-five miles, provided, that, in each case, Executive will not be deemed to have Good Reason unless (A) Executive first provides the Board with written notice of the condition giving rise to Good Reason within thirty days of its initial occurrence, (B) the Company or the successor company fails to cure such condition within ten days after receiving such written notice (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cure Perio</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">d&#x201d;), and (C) Executive&#x2019;s resignation based on such Good Reason is effective within thirty days after the expiration of the Cure Period.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Involuntary Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean Executive&#x2019;s termination (i) by the Company without Cause, (ii) by the Executive for Good Reason, (iii) due to death or (iv) due to Disability. In no event will Executive&#x2019;s voluntary resignation without Good Reason be considered an Involuntary Termination.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Person</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; shall mean any individual, corporation, limited liability corporation, partnership, or other business entity.</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">APPENDIX II</font></p><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Proprietary Information Agreement</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Attached)</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>tyra-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-03-02T14:21:18.3223+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="z-index:2;min-height:1in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#333333;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 23.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#333333;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We consent to the incorporation by reference in the following Registration Statements:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registration Statements (Form S-3 Nos. 333-278068 and 333-287086) of Tyra Biosciences, Inc.,</font></div></div><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registration Statement (Form S-8 No. 333-259560) pertaining to the Tyra Biosciences, Inc. 2020 Equity Incentive Plan, Tyra Biosciences, Inc. 2021 Incentive Award Plan, and the Tyra Biosciences, Inc. 2021 Employee Stock Purchase Plan of Tyra Biosciences, Inc., and</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registration Statement (Form S-8 No. 333-278069) pertaining to the Tyra Biosciences, Inc. 2021 Incentive Award Plan and Tyra Biosciences, Inc. 2021 Employee Stock Purchase Plan of Tyra Biosciences, Inc.;</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of our report dated March 2, 2026, with respect to the financial statements of Tyra Biosciences, Inc., included in this Annual Report (Form 10-K) of Tyra Biosciences, Inc. for the year ended December 31, 2025.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ Ernst &amp; Young LLP</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">San Diego, California</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 2, 2026</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>tyra-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-03-02T14:21:18.3352+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.1</font></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Todd Harris, certify that:</font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Tyra Biosciences, Inc.;</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:45.46%;box-sizing:content-box;"></td>
     <td style="width:5.04%;box-sizing:content-box;"></td>
     <td style="width:3.04%;box-sizing:content-box;"></td>
     <td style="width:46.46%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 2, 2026</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Todd Harris, Ph.D.</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Todd Harris, Ph.D.</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">President, Chief Executive Officer, and Director</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>tyra-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-03-02T14:21:18.3308+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.2</font></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Alan Fuhrman, certify that:</font></p><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Tyra Biosciences, Inc.;</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(d)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:45.46%;box-sizing:content-box;"></td>
     <td style="width:5.04%;box-sizing:content-box;"></td>
     <td style="width:3.04%;box-sizing:content-box;"></td>
     <td style="width:46.46%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 2, 2026</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Alan Fuhrman</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Alan Fuhrman</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Chief Financial Officer</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>tyra-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-03-02T14:21:18.3287+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 32.1</font></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Annual Report of Tyra Biosciences, Inc. (the &#x201c;Company&#x201d;) on Form 10-K for the period ending December 31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</font></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:45.46%;box-sizing:content-box;"></td>
     <td style="width:5.04%;box-sizing:content-box;"></td>
     <td style="width:3.04%;box-sizing:content-box;"></td>
     <td style="width:46.46%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 2, 2026</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Todd Harris, Ph.D.</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Todd Harris, Ph.D.</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">President, Chief Executive Officer, and Director</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>tyra-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-03-02T14:21:18.4098+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-32.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 32.2</font></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Annual Report of Tyra Biosciences, Inc. (the &#x201c;Company&#x201d;) on Form 10-K for the period ending December 31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</font></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:45.46%;box-sizing:content-box;"></td>
     <td style="width:5.04%;box-sizing:content-box;"></td>
     <td style="width:3.04%;box-sizing:content-box;"></td>
     <td style="width:46.46%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 2, 2026</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Alan Fuhrman</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Alan Fuhrman</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Chief Financial Officer</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>img94995564_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img94995564_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" )P!.4# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MXH:&/AI\3OCW\0?$OQ%D\*I=V6LW?@.VU&RBT_PS8ZE*L5QIEQK%A;01W5_
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M/_GD4?\ "D?!G_08^+?_ (?_ ./'_P \BO7:*/:U?^?E3_P.7^?DON#V=/\
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M:AA\&V$^N:O\'_%_[-GP^^%47B?1=.0W6J6VC^+O ^LRZE9:W]BCF:P^U%+
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MQY/SU0^&'[4?[/WQC^&.H_&3X>?%3PQK7PTT9;MM=\57DUUX;M?#XLE+W/\
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M_P#!?PY_PD.G12!KG2O[=TS7)=0TG[6@,?VZSC>>#.^-217H7Q8_X*'?L;_
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M,4[6NDMNVVWEL>'1_LP?LTQ>%9_ L7[/'P,C\$76IQ:U=>#H_A+X!3PK<ZS
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M7AGQCX7O4CCO/#?BK0=*\0Z!=I"08DNM'U>TO-.G2(@&-9;9PA *@8%0^$/
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M(_BOP_X,\06[$3>+/!FN>%/#][XCNM4U&(B.>UUJ^6QM50+;1DLSCV;]D/\
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M6/\ +'[E_71?<<E_P@/@3_H2O"7_ (3FC_\ R'1_P@/@3_H2O"7_ (3FC_\
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MX$_Z$KPE_P"$YH__ ,AUUM%'//\ FE_X$_\ ,.6/\L?N7]=%]QR7_" ^!/\
MH2O"7_A.:/\ _(='_" ^!/\ H2O"7_A.:/\ _(==;11SS_FE_P"!/_,.6/\
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M*\)?^$YH_P#\AUUM%'//^:7_ ($_\PY8_P L?N7]=%]QR7_" ^!/^A*\)?\
MA.:/_P#(='_" ^!/^A*\)?\ A.:/_P#(==;11SS_ )I?^!/_ ##EC_+'[E_7
M1?<<E_P@/@3_ *$KPE_X3FC_ /R'1_P@/@3_ *$KPE_X3FC_ /R'76T4<\_Y
MI?\ @3_S#EC_ "Q^Y?UT7W')?\(#X$_Z$KPE_P"$YH__ ,AT?\(#X$_Z$KPE
M_P"$YH__ ,AUUM%'//\ FE_X$_\ ,.6/\L?N7]=%]QR7_" ^!/\ H2O"7_A.
M:/\ _(='_" ^!/\ H2O"7_A.:/\ _(==;11SS_FE_P"!/_,.6/\ +'[E_71?
M<<E_P@/@3_H2O"7_ (3FC_\ R'1_P@/@3_H2O"7_ (3FC_\ R'76T4<\_P":
M7_@3_P PY8_RQ^Y?UT7W')?\(#X$_P"A*\)?^$YH_P#\AT?\(#X$_P"A*\)?
M^$YH_P#\AUUM%'//^:7_ ($_\PY8_P L?N7]=%]QR7_" ^!/^A*\)?\ A.:/
M_P#(='_" ^!/^A*\)?\ A.:/_P#(==;11SS_ )I?^!/_ ##EC_+'[E_71?<<
ME_P@/@3_ *$KPE_X3FC_ /R'1_P@/@3_ *$KPE_X3FC_ /R'76T4<\_YI?\
M@3_S#EC_ "Q^Y?UT7W')?\(#X$_Z$KPE_P"$YH__ ,AT?\(#X$_Z$KPE_P"$
MYH__ ,AUUM%'//\ FE_X$_\ ,.6/\L?N7]=%]QY)I/@GP9)XN\86\GA'PP]O
M;VWAEK>!] TIH8&GM=0:8PQ-:%(C,R(92BJ9"JE\E1CKO^$!\"?]"5X2_P#"
M<T?_ .0Z@T;_ )'3QM_UZ^%?_234J[2JE.=U[TOAA]I_RKS$HQM\,=WT7?\
MX"^XY+_A ? G_0E>$O\ PG-'_P#D.C_A ? G_0E>$O\ PG-'_P#D.NMHJ>>?
M\TO_  )_YCY8_P L?N7]=%]QR7_" ^!/^A*\)?\ A.:/_P#(='_" ^!/^A*\
M)?\ A.:/_P#(==;11SS_ )I?^!/_ ##EC_+'[E_71?<<E_P@/@3_ *$KPE_X
M3FC_ /R'1_P@/@3_ *$KPE_X3FC_ /R'76T4<\_YI?\ @3_S#EC_ "Q^Y?UT
M7W')?\(#X$_Z$KPE_P"$YH__ ,AT?\(#X$_Z$KPE_P"$YH__ ,AUUM%'//\
MFE_X$_\ ,.6/\L?N7]=%]QR7_" ^!/\ H2O"7_A.:/\ _(='_" ^!/\ H2O"
M7_A.:/\ _(==;11SS_FE_P"!/_,.6/\ +'[E_71?<<E_P@/@3_H2O"7_ (3F
MC_\ R'1_P@/@3_H2O"7_ (3FC_\ R'76T4<\_P":7_@3_P PY8_RQ^Y?UT7W
M')?\(#X$_P"A*\)?^$YH_P#\AT?\(#X$_P"A*\)?^$YH_P#\AUUM%'//^:7_
M ($_\PY8_P L?N7]=%]QR7_" ^!/^A*\)?\ A.:/_P#(='_" ^!/^A*\)?\
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M!\"?]"5X2_\ "<T?_P"0ZZVBCGG_ #2_\"?^8<L?Y8_<OZZ+[CDO^$!\"?\
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MW')?\(#X$_Z$KPE_X3FC_P#R'1_P@/@3_H2O"7_A.:/_ /(==;14<\_YI?\
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M7Q)X&\$V_AW7YX/!_A:">#1=4FAFA\/Z3'+#+'8SO'+%(EHKQR1NH='1@R,
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M_P 1 ]W_ -&B_P#F=)/_ )S='_$0/=_]&B_^9TD_^<W1_9N-_P"?/_E2E_\
M+ ^OX3_G[_Y3J_\ R!_2)17\W?\ Q$#W?_1HO_F=)/\ YS='_$0/=_\ 1HO_
M )G23_YS=']FXW_GS_Y4I?\ RP/K^$_Y^_\ E.K_ /('](E%?S=_\1 ]W_T:
M+_YG23_YS='_ !$#W?\ T:+_ .9TD_\ G-T?V;C?^?/_ )4I?_+ ^OX3_G[_
M .4ZO_R!_0AXT^YX7_['3P[_ .E$E=I7\T.M?\%\+K5UTM3^R;]F_LW6M.U?
M/_"[I)?/-A(TGV;_ )(_%Y?F[L>;^\V8SY3YP-K_ (B![O\ Z-%_\SI)_P#.
M;JGEV-M%>QVO?]Y2ZO\ Z^$K'X2\G[7>UOW=3HO\!_2)17\W?_$0/=_]&B_^
M9TD_^<W1_P 1 ]W_ -&B_P#F=)/_ )S=3_9N-_Y\_P#E2E_\L*^OX3_G[_Y3
MJ_\ R!_2)17\W?\ Q$#W?_1HO_F=)/\ YS='_$0/=_\ 1HO_ )G23_YS=']F
MXW_GS_Y4I?\ RP/K^$_Y^_\ E.K_ /('](E%?S=_\1 ]W_T:+_YG23_YS='_
M !$#W?\ T:+_ .9TD_\ G-T?V;C?^?/_ )4I?_+ ^OX3_G[_ .4ZO_R!_2)1
M7\W?_$0/=_\ 1HO_ )G23_YS='_$0/=_]&B_^9TD_P#G-T?V;C?^?/\ Y4I?
M_+ ^OX3_ )^_^4ZO_P @?TB45_-W_P 1 ]W_ -&B_P#F=)/_ )S='_$0/=_]
M&B_^9TD_^<W1_9N-_P"?/_E2E_\ + ^OX3_G[_Y3J_\ R!_2)17\W?\ Q$#W
M?_1HO_F=)/\ YS='_$0/=_\ 1HO_ )G23_YS=']FXW_GS_Y4I?\ RP/K^$_Y
M^_\ E.K_ /('](E%?S=_\1 ]W_T:+_YG23_YS='_ !$#W?\ T:+_ .9TD_\
MG-T?V;C?^?/_ )4I?_+ ^OX3_G[_ .4ZO_R!_2)17\W?_$0/=_\ 1HO_ )G2
M3_YS='_$0/=_]&B_^9TD_P#G-T?V;C?^?/\ Y4I?_+ ^OX3_ )^_^4ZO_P @
M?TB45_-W_P 1 ]W_ -&B_P#F=)/_ )S='_$0/=_]&B_^9TD_^<W1_9N-_P"?
M/_E2E_\ + ^OX3_G[_Y3J_\ R!_17XC_ .1>U[_L#:I_Z0STWPS_ ,BYX?\
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M_P"(@>[_ .C1?_,Z2?\ SFZ/^(@>[_Z-%_\ ,Z2?_.;H_LW&_P#/G_RI2_\
ME@?7\)_S]_\ *=7_ .0/Z1**_F[_ .(@>[_Z-%_\SI)_\YNC_B('N_\ HT7_
M ,SI)_\ .;H_LW&_\^?_ "I2_P#E@?7\)_S]_P#*=7_Y _I$HK^;O_B('N_^
MC1?_ #.DG_SFZ/\ B('N_P#HT7_S.DG_ ,YNC^S<;_SY_P#*E+_Y8'U_"?\
M/W_RG5_^0/Z1**_F[_XB![O_ *-%_P#,Z2?_ #FZ/^(@>[_Z-%_\SI)_\YNC
M^S<;_P ^?_*E+_Y8'U_"?\_?_*=7_P"0/Z1**_F[_P"(@>[_ .C1?_,Z2?\
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MAC_V]^9*^*7_ &[^04445)04444 %%%% !1110 4444 %%%% !1110 4444
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MS-NBL3^U;_\ Z%K6?_ CP]_\O:/[5O\ _H6M9_\  CP]_P#+VCE?]W_P*/\
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M\^S-NBL3^U;_ /Z%K6?_  (\/?\ R]H_M6__ .A:UG_P(\/?_+VCE?\ =_\
M H_Y^?Y]F',O[W_@,O\ +S_/LS;HK$_M6_\ ^A:UG_P(\/?_ "]H_M6__P"A
M:UG_ ,"/#W_R]HY7_=_\"C_GY_GV8<R_O?\ @,O\O/\ /LS;HK$_M6__ .A:
MUG_P(\/?_+VC^U;_ /Z%K6?_  (\/?\ R]HY7_=_\"C_ )^?Y]F',O[W_@,O
M\O/\^S-NBL3^U;__ *%K6?\ P(\/?_+VC^U;_P#Z%K6?_ CP]_\ +VCE?]W_
M ,"C_GY_GV8<R_O?^ R_R\_S[,VZ*Q/[5O\ _H6M9_\  CP]_P#+VC^U;_\
MZ%K6?_ CP]_\O:.5_P!W_P "C_GY_GV8<R_O?^ R_P O/\^S-NBL3^U;_P#Z
M%K6?_ CP]_\ +VC^U;__ *%K6?\ P(\/?_+VCE?]W_P*/^?G^?9AS+^]_P"
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M,O[W_@,O\O/\^S-NBL3^U;__ *%K6?\ P(\/?_+VC^U;_P#Z%K6?_ CP]_\
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M?9AS+^]_X#+_ "\_S[,VZ*Q/[5O_ /H6M9_\"/#W_P O:/[5O_\ H6M9_P#
MCP]_\O:.5_W?_ H_Y^?Y]F',O[W_ (#+_+S_ #[,QM&_Y'3QM_UZ^%?_ $DU
M*NTKS/1]2OAXQ\9./#^K,SVWA<-$L^A!X@MKJ(4N6UI8R),DKY<DA 4[PA(!
M['^U;_\ Z%K6?_ CP]_\O:<HNZV^&'VH_P L?/S_ *LQ*2M]K=_9EW]//\^S
M-NBL3^U;_P#Z%K6?_ CP]_\ +VC^U;__ *%K6?\ P(\/?_+VERO^[_X%'_/S
M_/LQ\R_O?^ R_P O/\^S-NBL3^U;_P#Z%K6?_ CP]_\ +VC^U;__ *%K6?\
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M  (\/?\ R]H_M6__ .A:UG_P(\/?_+VCE?\ =_\  H_Y^?Y]F',O[W_@,O\
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M/\^S#F7][_P&7^7G^?9CO$?_ "+VO?\ 8&U3_P!(9Z;X9_Y%SP__ -@32O\
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M_GV8<R_O?^ R_P O/\^S-NBL3^U;_P#Z%K6?_ CP]_\ +VC^U;__ *%K6?\
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M?_ CP]_\O:GE?]W_ ,"C_GY_GV8^9?WO_ 9?Y>?Y]F;=%8G]JW__ $+6L_\
M@1X>_P#E[1_:M_\ ]"UK/_@1X>_^7M'*_P"[_P"!1_S\_P ^S#F7][_P&7^7
MG^?9FW16)_:M_P#]"UK/_@1X>_\ E[1_:M__ -"UK/\ X$>'O_E[1RO^[_X%
M'_/S_/LPYE_>_P# 9?Y>?Y]F;=%8G]JW_P#T+6L_^!'A[_Y>T?VK?_\ 0M:S
M_P"!'A[_ .7M'*_[O_@4?\_/\^S#F7][_P !E_EY_GV9MT5B?VK?_P#0M:S_
M .!'A[_Y>T?VK?\ _0M:S_X$>'O_ )>T<K_N_P#@4?\ /S_/LPYE_>_\!E_E
MY_GV9MT5B?VK?_\ 0M:S_P"!'A[_ .7M']JW_P#T+6L_^!'A[_Y>T<K_ +O_
M (%'_/S_ #[,.9?WO_ 9?Y>?Y]F;=8/BK_D6/$?_ & =8_\ 3?<4_P#M6_\
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MW_(Z>-O^O7PK_P"DFI5VE5+=?X8?^D1$MOG+\V%%%%2,**** "BBB@ HHHH
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M)\4?LQ^';K6M3^(_@O0FUWQ-/%IL:>'-+11;.=.?5)KN.>?4O+O+>0Q6EC/
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M3X=OO"^M^?:6L4N\'3(8S<&/S7DB9&^4/V.OV?/VTO$'[-?P6U_P9_P4 NO
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M_3^[YH7UQ?\ 0-B__!/I_>\_ZNK_ -(=%?S>?\)U_P %[?\ H31_X3_P(_\
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MG]WS0?7%_P! V+_\$^G][S_JZO\ T'^-/N>%_P#L=/#O_I1)7:5_-%K7C?\
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M%_X. L3970O3_8'P+&+0P2"X.8[PR#$.\Y0;_P"[\V*33/''_!>)=-T]=/\
M!X:P6QM!8M_8'P+.;,01BV.9+P2',.PY<!S_ !?-FJ^I/E_WG"?$M?;Z:I65
M^7?5"^N*Z_V;%[?\^==7'IS;?UVO_2C17\WG_"=?\%[?^A-'_A/_  (_^3:/
M^$Z_X+V_]":/_"?^!'_R;4_4G_T%8/\ \'^G]WS0_KB_Z!L7_P""?3^]Y_U=
M7_I#HK^;S_A.O^"]O_0FC_PG_@1_\FT?\)U_P7M_Z$T?^$_\"/\ Y-H^I/\
MZ"L'_P"#_3^[YH/KB_Z!L7_X)]/[WG_5U?\ I#HK^;S_ (3K_@O;_P!":/\
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MPRH8K+,OQ<:63U98'^SI3J5J=5S@YQIO]NZ***_63^40HHHH **** "BBB@
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M^-:_M6<WYOOMNPVO]DV7V;RMWVB??M7D/B=^S(/&'QY^%7[1/@CQL/AUX_\
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MB=.%2RG%2MM=7MW^3ZK9]3XW^+7[#/P6^*47@>?2;WXA?!/Q+\.=&7PUX/\
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M4J[2JENO\,/_ $B(EM\Y?FPHHHJ1A1110 4444 %%%% !1110 4444 %%%%
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M)@:&6XW%XCAG$T<1'-,5@Z&.S=X/"X!8I4J.#2A0IS=7IZ***_3#^; HHHH
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MC_5GY7+O^5_>O\_7^GIMT5B?V3??]#)K?_?GP]_\H:/[)OO^ADUO_OSX>_\
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M\H:++^:/_DW_ ,C_ %9^5R[_ )7]Z_S]?Z>FW16)_9-]_P!#)K?_ 'Y\/?\
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M^5R[_E?WK_/U_IZ;=%8G]DWW_0R:W_WY\/?_ "AH_LF^_P"ADUO_ +\^'O\
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M_NB3?-+W7]GJNWJ;=%8G]DWW_0R:W_WY\/?_ "AH_LF^_P"ADUO_ +\^'O\
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ML_*Y=_RO[U_GZ_T]-NBL3^R;[_H9-;_[\^'O_E#1_9-]_P!#)K?_ 'Y\/?\
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MP"/#?A\%BQ&B:5\S;<G_ $&#KM"C\@*W*4MWZO\ ,J.R]%^04444AA5+4O\
MCPN_^N$G_H)J[5+4O^/"[_ZX2?\ H)H \\HHHH **** "BBB@ HHHH ****
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MQ^M #Z*0D ;B0% R22  /7/3'O2*RNH9&5U/1E(93]""0?PH =1110 4444
M%%%% '%Z-_R.GC;_ *]?"O\ Z2:E7:5Q>C?\CIXV_P"O7PK_ .DFI5VE5+=?
MX8?^D1$MOG+\V%%%%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@#B_&GW/"_\ V.GAW_THDKM*XOQI]SPO_P!CIX=_]*)*[2J?PQ_[>_,E?%+_
M +=_(****DH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#&\1_\
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M^+OL^J[4>=;=5>5C^IM?G%^RSX<^)'Q#_:+^+7[5?BKX/^(?@)X6\:>"- \
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M_#:?['O_ $=1^SM_X>?X=_\ S14?\-I_L>_]'4?L[?\ AY_AW_\ -%7YV_\
M#B#]CW_H?/VB?_"Q^'?_ ,ZBC_AQ!^Q[_P!#Y^T3_P"%C\.__G44<F _Y_XC
M_P %1_S]?Z6ISXW_ )\4?_!C_P C]$O^&T_V/?\ HZC]G;_P\_P[_P#FBH_X
M;3_8]_Z.H_9V_P##S_#O_P":*OSM_P"'$'['O_0^?M$_^%C\._\ YU%'_#B#
M]CW_ *'S]HG_ ,+'X=__ #J*.3 ?\_\ $?\ @J/^?K_2U.?&_P#/BC_X,?\
MD?HE_P -I_L>_P#1U'[.W_AY_AW_ /-%1_PVG^Q[_P!'4?L[?^'G^'?_ ,T5
M?G;_ ,.(/V/?^A\_:)_\+'X=_P#SJ*/^'$'['O\ T/G[1/\ X6/P[_\ G44<
MF _Y_P"(_P#!4?\ /U_I:G/C?^?%'_P8_P#(_1+_ (;3_8]_Z.H_9V_\//\
M#O\ ^:*C_AM/]CW_ *.H_9V_\//\._\ YHJ_.W_AQ!^Q[_T/G[1/_A8_#O\
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MHG_PL?AW_P#.HIN& M']_7MK;]U'757Z_=_5TIXV\OW-&^E_WCTTTZ'Z)?\
M#:?['O\ T=1^SM_X>?X=_P#S14?\-I_L>_\ 1U'[.W_AY_AW_P#-%7YV_P##
MB#]CW_H?/VB?_"Q^'?\ \ZBC_AQ!^Q[_ -#Y^T3_ .%C\.__ )U%+DP'_/\
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M .=11_PX@_8]_P"A\_:)_P#"Q^'?_P ZBCDP'_/_ !'_ (*C_GZ_TM3GQO\
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M  \_P[_^:*C_ (;3_8]_Z.H_9V_\//\ #O\ ^:*OSM_X<0?L>_\ 0^?M$_\
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MBKX-?#3XUZ!^W7H/Q0\+6WBS2=#^+OBK7])M+F]U6P^PZO;:9JAAO89]'O\
M3KK<OEH&B>9[>55"RQ..*^J?^"-%K;V/[//C"RM(A#:VOQ6\3V]O"I9A%##,
M\<<89V9R$10H+,S'&22>:YZ^&H4X8EP]IS4IT4E*W*HU8\UKIWD]]7&-K+>[
M-\/B:]2IAXSY.6I"OS-7YI2I22O:UHKTD[W=TK(_8:BBBO./2"BBB@ HHHH
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M<\+_ /8Z>'?_ $HDKM*I_#'_ +>_,E?%+_MW\@HHHJ2@HHHH **** "BBB@
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MVGB/XVZ%J?B;6KK7=6A\/_$6'2K.:^O+E[N4JL'A\W2QB61O*W7;S1*0$F!
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MQ/#/_(N>'_\ L":5_P"D%O6W1+=^K_,([+T7Y!1112&%4=3(%A=DD >1)R2
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M  K7X=?]"#X*_P#"5T+_ .0*/^%:_#K_ *$'P5_X2NA?_(%%H?S2_P# 5_\
M)A[W:/\ X$__ )'U_IZ8/F1_\]$_[Z7_ !H\R/\ YZ)_WTO^-;W_  K7X=?]
M"#X*_P#"5T+_ .0*/^%:_#K_ *$'P5_X2NA?_(%%H?S2_P# 5_\ )A[W:/\
MX$__ )'U_IZ8/F1_\]$_[Z7_ !H\R/\ YZ)_WTO^-;W_  K7X=?]"#X*_P#"
M5T+_ .0*/^%:_#K_ *$'P5_X2NA?_(%%H?S2_P# 5_\ )A[W:/\ X$__ )'U
M_IZ8/F1_\]$_[Z7_ !H\R/\ YZ)_WTO^-;W_  K7X=?]"#X*_P#"5T+_ .0*
M/^%:_#K_ *$'P5_X2NA?_(%%H?S2_P# 5_\ )A[W:/\ X$__ )'U_IZ8/F1_
M\]$_[Z7_ !H\R/\ YZ)_WTO^-;W_  K7X=?]"#X*_P#"5T+_ .0*/^%:_#K_
M *$'P5_X2NA?_(%%H?S2_P# 5_\ )A[W:/\ X$__ )'U_IZ8/F1_\]$_[Z7_
M !H\R/\ YZ)_WTO^-;W_  K7X=?]"#X*_P#"5T+_ .0*/^%:_#K_ *$'P5_X
M2NA?_(%%H?S2_P# 5_\ )A[W:/\ X$__ )'U_IZ8/F1_\]$_[Z7_ !H\R/\
MYZ)_WTO^-;W_  K7X=?]"#X*_P#"5T+_ .0*/^%:_#K_ *$'P5_X2NA?_(%%
MH?S2_P# 5_\ )A[W:/\ X$__ )'U_IZ8/F1_\]$_[Z7_ !H\R/\ YZ)_WTO^
M-;W_  K7X=?]"#X*_P#"5T+_ .0*/^%:_#K_ *$'P5_X2NA?_(%%H?S2_P#
M5_\ )A[W:/\ X$__ )'U_IZ8/F1_\]$_[Z7_ !H\R/\ YZ)_WTO^-;W_  K7
MX=?]"#X*_P#"5T+_ .0*/^%:_#K_ *$'P5_X2NA?_(%%H?S2_P# 5_\ )A[W
M:/\ X$__ )'U_IZ8/F1_\]$_[Z7_ !H\R/\ YZ)_WTO^-;W_  K7X=?]"#X*
M_P#"5T+_ .0*/^%:_#K_ *$'P5_X2NA?_(%%H?S2_P# 5_\ )A[W:/\ X$__
M )'U_IZ8/F1_\]$_[Z7_ !H\R/\ YZ)_WTO^-;W_  K7X=?]"#X*_P#"5T+_
M .0*/^%:_#K_ *$'P5_X2NA?_(%%H?S2_P# 5_\ )A[W:/\ X$__ )'U_IZ8
M/F1_\]$_[Z7_ !H\R/\ YZ)_WTO^-;W_  K7X=?]"#X*_P#"5T+_ .0*/^%:
M_#K_ *$'P5_X2NA?_(%%H?S2_P# 5_\ )A[W:/\ X$__ )'U_IZ8/F1_\]$_
M[Z7_ !H\R/\ YZ)_WTO^-;W_  K7X=?]"#X*_P#"5T+_ .0*/^%:_#K_ *$'
MP5_X2NA?_(%%H?S2_P# 5_\ )A[W:/\ X$__ )'U_IZ8/F1_\]$_[Z7_ !H\
MR/\ YZ)_WTO^-;W_  K7X=?]"#X*_P#"5T+_ .0*/^%:_#K_ *$'P5_X2NA?
M_(%%H?S2_P# 5_\ )A[W:/\ X$__ )'U_IZ8/F1_\]$_[Z7_ !H\R/\ YZ)_
MWTO^-;W_  K7X=?]"#X*_P#"5T+_ .0*/^%:_#K_ *$'P5_X2NA?_(%%H?S2
M_P# 5_\ )A[W:/\ X$__ )'U_IZ8/F1_\]$_[Z7_ !H\R/\ YZ)_WTO^-;W_
M  K7X=?]"#X*_P#"5T+_ .0*/^%:_#K_ *$'P5_X2NA?_(%%H?S2_P# 5_\
M)A[W:/\ X$__ )'U_IZ8/F1_\]$_[Z7_ !H\R/\ YZ)_WTO^-;W_  K7X=?]
M"#X*_P#"5T+_ .0*/^%:_#K_ *$'P5_X2NA?_(%%H?S2_P# 5_\ )A[W:/\
MX$__ )'U_IZ8/F1_\]$_[Z7_ !H\R/\ YZ)_WTO^-;W_  K7X=?]"#X*_P#"
M5T+_ .0*/^%:_#K_ *$'P5_X2NA?_(%%H?S2_P# 5_\ )A[W:/\ X$__ )'U
M_IZ8/F1_\]$_[Z7_ !H\R/\ YZ)_WTO^-;W_  K7X=?]"#X*_P#"5T+_ .0*
M/^%:_#K_ *$'P5_X2NA?_(%%H?S2_P# 5_\ )A[W:/\ X$__ )'U_IZ8/F1_
M\]$_[Z7_ !H\R/\ YZ)_WTO^-;W_  K7X=?]"#X*_P#"5T+_ .0*/^%:_#K_
M *$'P5_X2NA?_(%%H?S2_P# 5_\ )A[W:/\ X$__ )'U_IZ8/F1_\]$_[Z7_
M !H\R/\ YZ)_WTO^-;W_  K7X=?]"#X*_P#"5T+_ .0*/^%:_#K_ *$'P5_X
M2NA?_(%%H?S2_P# 5_\ )A[W:/\ X$__ )'U_IZ8/F1_\]$_[Z7_ !H\R/\
MYZ)_WTO^-;W_  K7X=?]"#X*_P#"5T+_ .0*/^%:_#K_ *$'P5_X2NA?_(%%
MH?S2_P# 5_\ )A[W:/\ X$__ )'U_IZ8/F1_\]$_[Z7_ !H\R/\ YZ)_WTO^
M-;W_  K7X=?]"#X*_P#"5T+_ .0*/^%:_#K_ *$'P5_X2NA?_(%%H?S2_P#
M5_\ )A[W:/\ X$__ )'U_IZ8/F1_\]$_[Z7_ !H\R/\ YZ)_WTO^-;W_  K7
MX=?]"#X*_P#"5T+_ .0*/^%:_#K_ *$'P5_X2NA?_(%%H?S2_P# 5_\ )A[W
M:/\ X$__ )'U_IZ8/F1_\]$_[Z7_ !H\R/\ YZ)_WTO^-;W_  K7X=?]"#X*
M_P#"5T+_ .0*/^%:_#K_ *$'P5_X2NA?_(%%H?S2_P# 5_\ )A[W:/\ X$__
M )'U_IZ8/F1_\]$_[Z7_ !H\R/\ YZ)_WTO^-;W_  K7X=?]"#X*_P#"5T+_
M .0*/^%:_#K_ *$'P5_X2NA?_(%%H?S2_P# 5_\ )A[W:/\ X$__ )'U_IZ8
M/F1_\]$_[Z7_ !H\R/\ YZ)_WTO^-;W_  K7X=?]"#X*_P#"5T+_ .0*/^%:
M_#K_ *$'P5_X2NA?_(%%H?S2_P# 5_\ )A[W:/\ X$__ )'U_IZ>6Z-(G_"9
M^-3O3!M?"N#N'.+34L]Z[3S(_P#GHG_?2_XUO?\ "M?AU_T(/@K_ ,)70O\
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M?^$KH7_R!1_PK7X=?]"#X*_\)70O_D"BT/YI?^ K_P"3#WNT?_ G_P#(^O\
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M_P#Y'U_IZ8/F1_\ /1/^^E_QH\R/_GHG_?2_XUO?\*U^'7_0@^"O_"5T+_Y
MH_X5K\.O^A!\%?\ A*Z%_P#(%%H?S2_\!7_R8>]VC_X$_P#Y'U_IZ<1XCDC_
M .$>UWYT_P"0-JG\2_\ /E/[TWPU)&/#GA_+I_R!-*_B7_GQ@]Z[G_A6OPZ_
MZ$#P5_X2NA?_ "!1_P *U^'7_0@>"O\ PE="_P#D"G[EK7EO?X5VM_.'O7O:
M.UOB?6W]WR_J^F#YD?\ ST3_ +Z7_&CS(_\ GHG_ 'TO^-;W_"M?AU_T(/@K
M_P )70O_ ) H_P"%:_#K_H0?!7_A*Z%_\@4K0_FE_P" K_Y,/>[1_P# G_\
M(^O]/3!\R/\ YZ)_WTO^-'F1_P#/1/\ OI?\:WO^%:_#K_H0?!7_ (2NA?\
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M$'P5_P"$KH7_ ,@4?\*U^'7_ $(/@K_PE="_^0*+0_FE_P" K_Y,/>[1_P#
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M$'P5_P"$KH7_ ,@4?\*U^'7_ $(/@K_PE="_^0*+0_FE_P" K_Y,/>[1_P#
MG_\ (^O]/3!\R/\ YZ)_WTO^-'F1_P#/1/\ OI?\:WO^%:_#K_H0?!7_ (2N
MA?\ R!1_PK7X=?\ 0@^"O_"5T+_Y HM#^:7_ ("O_DP][M'_ ,"?_P CZ_T]
M,'S(_P#GHG_?2_XT>9'_ ,]$_P"^E_QK>_X5K\.O^A!\%?\ A*Z%_P#(%'_"
MM?AU_P!"#X*_\)70O_D"BT/YI?\ @*_^3#WNT?\ P)__ "/K_3TP?,C_ .>B
M?]]+_C1YD?\ ST3_ +Z7_&M[_A6OPZ_Z$'P5_P"$KH7_ ,@4?\*U^'7_ $(/
M@K_PE="_^0*+0_FE_P" K_Y,/>[1_P# G_\ (^O]/3!\R/\ YZ)_WTO^-'F1
M_P#/1/\ OI?\:WO^%:_#K_H0?!7_ (2NA?\ R!1_PK7X=?\ 0@^"O_"5T+_Y
M HM#^:7_ ("O_DP][M'_ ,"?_P CZ_T],'S(_P#GHG_?2_XT>9'_ ,]$_P"^
ME_QK>_X5K\.O^A!\%?\ A*Z%_P#(%'_"M?AU_P!"#X*_\)70O_D"BT/YI?\
M@*_^3#WNT?\ P)__ "/K_3T\OT-E'BWQPQ8!7D\.;6) #;=(PVTG@X/!QG!X
M-=EYD?\ ST3_ +Z7_&M[_A6OPZ_Z$'P5_P"$KH7_ ,@4?\*U^'7_ $(/@K_P
ME="_^0*<G"3O>6T5\*^S%1_GZVN"YETCNW\3ZN_\OF_N\],'S(_^>B?]]+_C
M1YD?_/1/^^E_QK>_X5K\.O\ H0?!7_A*Z%_\@4?\*U^'7_0@^"O_  E="_\
MD"E:'\TO_ 5_\F'O=H_^!/\ ^1]?Z>F#YD?_ #T3_OI?\:/,C_YZ)_WTO^-;
MW_"M?AU_T(/@K_PE="_^0*/^%:_#K_H0?!7_ (2NA?\ R!1:'\TO_ 5_\F'O
M=H_^!/\ ^1]?Z>F#YD?_ #T3_OI?\:/,C_YZ)_WTO^-;W_"M?AU_T(/@K_PE
M="_^0*/^%:_#K_H0?!7_ (2NA?\ R!1:'\TO_ 5_\F'O=H_^!/\ ^1]?Z>F#
MYD?_ #T3_OI?\:/,C_YZ)_WTO^-;W_"M?AU_T(/@K_PE="_^0*/^%:_#K_H0
M?!7_ (2NA?\ R!1:'\TO_ 5_\F'O=H_^!/\ ^1]?Z>F#YD?_ #T3_OI?\:/,
MC_YZ)_WTO^-;W_"M?AU_T(/@K_PE="_^0*/^%:_#K_H0?!7_ (2NA?\ R!1:
M'\TO_ 5_\F'O=H_^!/\ ^1]?Z>F#YD?_ #T3_OI?\:/,C_YZ)_WTO^-;W_"M
M?AU_T(/@K_PE="_^0*/^%:_#K_H0?!7_ (2NA?\ R!1:'\TO_ 5_\F'O=H_^
M!/\ ^1]?Z>F#YD?_ #T3_OI?\:P?%,D9\,>(P'3/]@ZO_$O_ $#[CWKO/^%:
M_#K_ *$'P5_X2NA?_(%'_"M?AU_T(/@K_P )70O_ ) IKD33O+1W^%?_ "8/
MF::M'56^)_\ R/K_ $]-KPS_ ,BYX?\ ^P)I7_I!;UMU%###;0QV]O#%!!"B
MQPPPQI%#%&@"I''&@5$15 "HJA5    J6I;NV^[N-:)+LD%%%%(84444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ*-XO_\  /P)_P#,56W11S/M'_P"'_R(<D?/_P "EY>?DC$^Q>*/^BC>+_\
MP#\"?_,51]B\4?\ 11O%_P#X!^!/_F*K;HHYGVC_ . 0_P#D0Y(^?_@4O+S\
MD8GV+Q1_T4;Q?_X!^!/_ )BJ/L7BC_HHWB__ , _ G_S%5MT4<S[1_\  (?_
M "(<D?/_ ,"EY>?DC$^Q>*/^BC>+_P#P#\"?_,51]B\4?]%&\7_^ ?@3_P"8
MJMNBCF?:/_@$/_D0Y(^?_@4O+S\D8GV+Q1_T4;Q?_P" ?@3_ .8JC[%XH_Z*
M-XO_ / /P)_\Q5;=%',^T?\ P"'_ ,B')'S_ / I>7GY(Q/L7BC_ **-XO\
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MO/R1B?8O%'_11O%__@'X$_\ F*H^Q>*/^BC>+_\ P#\"?_,56W11S/M'_P
MA_\ (AR1\_\ P*7EY^2,3[%XH_Z*-XO_ / /P)_\Q5'V+Q1_T4;Q?_X!^!/_
M )BJVZ*.9]H_^ 0_^1#DCY_^!2\O/R1B?8O%'_11O%__ (!^!/\ YBJ/L7BC
M_HHWB_\ \ _ G_S%5MT4<S[1_P# (?\ R(<D?/\ \"EY>?DC$^Q>*/\ HHWB
M_P#\ _ G_P Q5'V+Q1_T4;Q?_P" ?@3_ .8JMNBCF?:/_@$/_D0Y(^?_ (%+
MR\_)&)]B\4?]%&\7_P#@'X$_^8JC[%XH_P"BC>+_ /P#\"?_ #%5MT4<S[1_
M\ A_\B')'S_\"EY>?DC$^Q>*/^BC>+__  #\"?\ S%4?8O%'_11O%_\ X!^!
M/_F*K;HHYGVC_P" 0_\ D0Y(^?\ X%+R\_)&)]B\4?\ 11O%_P#X!^!/_F*H
M^Q>*/^BC>+__  #\"?\ S%5MT4<S[1_\ A_\B')'S_\  I>7GY(Q/L7BC_HH
MWB__ , _ G_S%4?8O%'_ $4;Q?\ ^ ?@3_YBJVZ*.9]H_P#@$/\ Y$.2/G_X
M%+R\_)&)]B\4?]%&\7_^ ?@3_P"8JC[%XH_Z*-XO_P# /P)_\Q5;=%',^T?_
M  "'_P B')'S_P# I>7GY(Q/L7BC_HHWB_\ \ _ G_S%4?8O%'_11O%__@'X
M$_\ F*K;HHYGVC_X!#_Y$.2/G_X%+R\_)&)]B\4?]%&\7_\ @'X$_P#F*H^Q
M>*/^BC>+_P#P#\"?_,56W11S/M'_ , A_P#(AR1\_P#P*7EY^2,3[%XH_P"B
MC>+_ /P#\"?_ #%4?8O%'_11O%__ (!^!/\ YBJVZ*.9]H_^ 0_^1#DCY_\
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M#PD6W@QB3>6]\\N8Y/"+V\>#$N#;P0%^3,96",O3?8O%'_11O%__ (!^!/\
MYBJQM&_Y'3QM_P!>OA7_ -)-2KM*J4G?:/PQ^Q#^5?W1**\]W]J71Z=?)?<8
MGV+Q1_T4;Q?_ . ?@3_YBJ/L7BC_ **-XO\ _ /P)_\ ,56W14\S[1_\ A_\
MB/DCY_\ @4O+S\D8GV+Q1_T4;Q?_ . ?@3_YBJ/L7BC_ **-XO\ _ /P)_\
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M?]%&\7_^ ?@3_P"8JMNBCF?:/_@$/_D0Y(^?_@4O+S\D8GV+Q1_T4;Q?_P"
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M;Q?_ . ?@3_YBJVZ*.9]H_\ @$/_ )$.2/G_ .!2\O/R1B?8O%'_ $4;Q?\
M^ ?@3_YBJ/L7BC_HHWB__P  _ G_ ,Q5;=%',^T?_ (?_(AR1\__  *7EY^2
M.#TVX\8WFO>)=,E^(GBD6^D/I"VK)8>!Q*PO[#[5-YS'P<ROB3B/8D>U.&W'
MYJZ'[%XH_P"BC>+_ /P#\"?_ #%5C:%_R-_CK_KIX;_],]=I53DTU91^&#^"
M&[A%O[/5ML2BO/=_:ET>G7R7W&)]B\4?]%&\7_\ @'X$_P#F*H^Q>*/^BC>+
M_P#P#\"?_,56W14\S[1_\ A_\B/DCY_^!2\O/R1B?8O%'_11O%__ (!^!/\
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MO'&G_'?Q;8>*/'G@358(&ETO7O#OBN2WTS4-7LKR<+:7>BFR>."-C(J%V%S
MW12C[U6"J."FJ;4MFN9)RMRJ<HM-1\TFT] 55N7NTY2AS<CFFM[J+?+\3BF[
M2ETLW9I7/OFBBBL#8**** "BBB@ HHHH 0D*"S$  9))   ZDD\ #U-5/[1T
M_P#Y_K/_ ,"8/_BZ\V^.?_)&?BG_ -B%XI_],]W7\WG[.Q_X(N2_!OX;6_QK
MT&ZNOB]+H5M%XWD33?VHY%F\0274Z/B;PJP\-$-&UN-VE$68[$,'KIHT/:PG
M-^V?+*,;4:/M7[UW=_O(66EEO=OI8YZM?V<XP_=+FBY7JU?9K248V7N3N]?(
M_J522.1!)&Z21D9#HRLA ZD,I*D#U!J)+NUD?RX[FW>3_GFDT;/_ -\JQ;]*
M_+OXNZ#90Q?LO?L4?LUZ[KWP;^&?Q,TK6O%>I^(?"NI:NOB33OA/HEJ-=OM'
M\/:SXCN[OQ!IVJ:_<:I$IO+FYEU"S@FEB\N,KMCX'XO_ +&O[ 7P.C$FB?&'
M2/V6_C]<Z<^J^%/B;XA_:&UW0_%^HZC;LF-5UK3_ !?XREL]>TJ\O%0:U%;:
M1##<B22*,PA@E$:,'RJ4YIU+NFHTN=\JDX\U1*=X*\7=151JS>O4E6FN:T(-
M0Y5-RJ<JYFE)QIMP]_1I)RY$VUYH_8:66*%=\TL<29 WRNL:Y/0;F(&3V&>:
M@&H6!( OK,DG  N8223T &_DFOR$_P""C.L^&=>_8;^%VK_$#Q9X=^(?A>[\
M=?"%O&GC+PA<3W_AOQ78PZS96_B#6-&G\.DW,]G?M%=RH-(VS!F:.U1'547Q
M;X0>"O\ @B'\2_B1X1\&_"WP=<:EX_U76+3_ (1>TF@_:LTN.35;:5;FU9K[
MQ#>66C0".6)7SJ%Q';DKMDW*2IJ.&3I>TDZS2E43]E0]I&*I\MW*3J0Y;\SW
M72[ZBEB&JGLU[)/EA)*I6Y)/G>T8J$T[;:2U;5M-3][BRJ"S,%4#)8D  >I)
MX ]S0&5E#*P*D;@P(*E2,@@C@@CG(.,5^<__  4)\-?'[Q'\'?B'!X'\>Z#\
M-?A%H'PZUG6/%U]I46H7OQ,\67=G"63PKIDSQP:7X;\/W,"F/4M82[N]7D#^
M5:V\:EW/.?'OQOXT\ _\$W?!>M^!];N_"^HW'PU^#^B:KXKL&,5YX7\,ZWI^
M@Z=XBU^VN%BF:TETS2Y[BX6\5";8KYH*[=PSC0YE2:G&]6I[.VKY;\MG)]_>
M^%7?S=BY5N5U$X2M3ASWNO>WTCY:;NVO0_3:.XMYF9(IX967[RQRH[+V^8*Q
M(Y]0*FK\,_BM\(OV:/V)O GPG^/O[.OC[4M ^)&L^+? ]F^IV_Q*UCQ3;_M!
MZ5XBU*S@\0)XFT#4]:O]+UF.ZM;J?5Q>Z)::8NF7"K>,X5&S^Y,4@EBCE ($
MD:2 'J ZA@#[C.*56FH*,HRE*$W**<X<DN:'+S>[S25O>5GS7[I--#IU'-RC
M**C**BVHRYURS3<7?EB[Z.Z:Z73:8^BBBL34**** "BBB@ HHHH **** "BB
MB@ HHKYH^,?[87[-_P  ?%7A_P %?%KXHZ-X1\2^)A&^G:;<6FKZ@UO;S/Y<
M-[K=QI.GW]KX<TZ5P5CU'7Y]-L7VL5N"%8BHQE-\L(RG)[1BG)Z;Z)-Z"E*,
M5>4E%;7DTE=[*[LM3Z7IK.B;=[JNXA5W,%W,>BKDC)/8#DUQND?$;P%X@U+3
M='T'QAX<UO4]8T0^)=+L])U>RU&>]\/B1(AK4"6<TQ?3&EDCB2]_X]Y)76-)
M&<A:_+;]I[PY^T!)^T9^R]XP^)'C[0;+X>-^TIX<T7P)\*?!$6H-9-9".>:+
MQ/X[US4(K275?$+"-EMM*LK3^R=-#K-'<3W*;ZNG2YY\DI*&C?O)W=DVDENV
M_.R2NV^^=2HH14DG.[2]UJRNTKR?1:KNWT74_7B6X@@ ,\T4(8X4RR)&">N
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MZEBU_P P]3_P&_Y L7AG_P OJ?S=OSL?L+17Y$?\/L_V)O\ H(?$G_PA;O\
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M "+GA_\ [ FE?^D%O7YRW/\ P5F_8)\06UQH.D_&N[NM5UN"72-,MC\,/BU
M+C4-2C:SLX#/<>!XK>$2W,T<9EGECACW;Y9$0,P+7_@K)^P7X<M;;P]K'QJN
M[35M"@AT;5+4?#'XLW MM1TN-;&^MQ/;>!YK><0W,$L8F@EEADV[XI'1E8OZ
MKB>6WU>M?FO;V<[VMO:VVOY]F'UG#W7[^EL_^7D.O+Y_?VZGZ:T5^:/_  ]]
M_P""?7_1<KS_ ,-7\7__ )@Z/^'OO_!/K_HN5Y_X:OXO_P#S!TOJN)_Z!Z__
M (*G_P#(^?Y]F'UG#_\ /^C_ .#(?Y^?Y]F?I=17YH_\/??^"?7_ $7*\_\
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M*C&3ARW<XQ22?.E=)N+8E2FFU&IRTW+G<5'W[N7,TI\WPMWNG!NS:Y@HHHK
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M/_DZC_AW?^Q+_P!&W?#?_P %]Y_\G5]G44>VK?\ /VK_ .#)?Y^2^X/8T?\
MGU2_\%Q_R\E]Q\+ZW^PC^R!X=72VT3X > --;6M:T[P[JIMK&[4WVB:M(T6I
M:;/NO6W6UY&B),HPQ"C#"MK_ (=W_L2_]&W?#?\ \%]Y_P#)U?37C3[GA?\
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M ."X?_(^2^X_.G_ATS_P3Z_Z-YL__#C_ !?_ /G@T?\ #IG_ ()]?]&\V?\
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MR+'B/_L ZQ_Z;[BMZL'Q5_R+'B/_ + .L?\ ION*<=UZK\Q2V?H_R/4_#/\
MR+GA_P#[ FE?^D%O6W6)X9_Y%SP__P!@32O_ $@MZVZ);OU?YA'9>B_(****
M0PK(US_D'2_[\7_HQ:UZP?$LYM](GE$,\Y5X?W5NGF2MF51\J97..IYZ4;AL
M<;16'_;;?] ?6O\ P"'_ ,=H_MMO^@/K7_@$/_CM5R2[?BO\R>>/?\'_ )&Y
M16'_ &VW_0'UK_P"'_QVC^VV_P"@/K7_ (!#_P".T<DNWXK_ ##GCW_!_P"1
MN45A_P!MM_T!]:_\ A_\=H_MMO\ H#ZU_P" 0_\ CM')+M^*_P PYX]_P?\
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MYX]_P?\ D;E%8?\ ;;?] ?6O_ (?_':/[;;_ * ^M?\ @$/_ ([1R2[?BO\
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MT<DNWXK_ ##GCW_!_P"1N45A_P!MM_T!]:_\ A_\=H_MMO\ H#ZU_P" 0_\
MCM')+M^*_P PYX]_P?\ D;E%8?\ ;;?] ?6O_ (?_':/[;;_ * ^M?\ @$/_
M ([1R2[?BO\ ,.>/?\'_ )&Y16'_ &VW_0'UK_P"'_QVC^VV_P"@/K7_ (!#
M_P".T<DNWXK_ ##GCW_!_P"1N45A_P!MM_T!]:_\ A_\=H_MMO\ H#ZU_P"
M0_\ CM')+M^*_P PYX]_P?\ D;E%8?\ ;;?] ?6O_ (?_':/[;;_ * ^M?\
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M_P! #6/RT[_Y84?VO=?] #6/RT[_ .6%%GY?>O\ ,+KS^Y_Y&Y16'_:]U_T
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M]S_R-RBL/^U[K_H :Q^6G?\ RPH_M>Z_Z &L?EIW_P L*+/R^]?YA=>?W/\
MR-RBL/\ M>Z_Z &L?EIW_P L*/[7NO\ H :Q^6G?_+"BS\OO7^877G]S_P C
M<HK#_M>Z_P"@!K'Y:=_\L*/[7NO^@!K'Y:=_\L*+/R^]?YA=>?W/_(?XC_Y%
M[7O^P-JG_I#/3?#/_(N>'_\ L":5_P"D%O6/X@U:Z;0=;4Z%JZ!M(U)2[?V?
MM4&RG!9MM^3M7J< G X!/%-\.:M=+X>T%1H6KN%T;2U#K_9^U@+& !EW7X.U
MNHR <'D \55GR=/B[KMZBYES+?9_9?=>7D=K16'_ &O=?] #6/RT[_Y84?VO
M=?\ 0 UC\M._^6%39^7WK_,=UY_<_P#(W**P_P"U[K_H :Q^6G?_ "PH_M>Z
M_P"@!K'Y:=_\L*+/R^]?YA=>?W/_ "-RBL/^U[K_ * &L?EIW_RPH_M>Z_Z
M&L?EIW_RPHL_+[U_F%UY_<_\C<HK#_M>Z_Z &L?EIW_RPH_M>Z_Z &L?EIW_
M ,L*+/R^]?YA=>?W/_(W*I3PR/(65<@@<Y4=!CN15#^U[K_H :Q^6G?_ "PH
M_M>Z_P"@!K'Y:=_\L*+/R^]?YA=>?W/_ "+7V>;^Y_X\O_Q5'V>;^Y_X\O\
M\557^U[K_H :Q^6G?_+"C^U[K_H :Q^6G?\ RPHL_+[U_F%UY_<_\BU]GF_N
M?^/+_P#%4?9YO[G_ (\O_P 557^U[K_H :Q^6G?_ "PH_M>Z_P"@!K'Y:=_\
ML*+/R^]?YA=>?W/_ "([ZZAT[[']L<Q?;[Z#3K7"M)YMY<[_ "8OW8?8'\M_
MWDFV-<?,ZY&;WV>7^Y_X\O\ \57">,-4N7/A;.B:K'L\8Z(XW_8/WA476(TV
MWS?.V?EW;5X.6'&>Q_M>Z_Z &L?EIW_RPIN.B>FM_M1Z/U$I:M:Z6Z/JO0M?
M9Y<8V#'IE,?EFD%M(HPL84=< H!D]3@&JW]KW7_0 UC\M._^6%']KW7_ $ -
M8_+3O_EA2MZ?>O\ ,=_7[G_D6OL\N<[!GURF?SS5NW1D5@PP2V1R#QCV)K*_
MM>Z_Z &L?EIW_P L*/[7NO\ H :Q^6G?_+"BS\OO7^877G]S_P C<HK#_M>Z
M_P"@!K'Y:=_\L*/[7NO^@!K'Y:=_\L*+/R^]?YA=>?W/_(W**P_[7NO^@!K'
MY:=_\L*/[7NO^@!K'Y:=_P#+"BS\OO7^877G]S_R-RBL/^U[K_H :Q^6G?\
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MW_(Z>-O^O7PK_P"DFI5VE5+=?X8?^D1$MOG+\V%%%%2,**** "BBB@ HHHH
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MH3P9X4GNM-MK-;G4ISX+N=!U3Q#";*3S(1#''<S7.P20QD,!7Z#5\K?MP?\
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M5DV8N52G3IU.>516CSQDH)MU.6,>5QC"UI-;O9N]VD?0W_#;6K7_ ,#/CO\
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M6PCB57D_$7X2_L^?&KX0_!'X#_MUZ/XQU3XQ_$'P'X4LI-8^&-S9:>?#FF_
MNX@:#4O#_@&UDTZ34;#Q/IUD)=6O-6MI#=:O,#;"VVQ1S5^Z_P *_B?X.^,O
MP_\ #'Q+\!ZI%J_A?Q7ID&IZ==1D"2/S5Q/9W<>28+VRG$EK=P-S'-$X!9"K
MMEB(0IQ_=\LTZDU.HD_=DF[4E%I<L5'7FWJ:V:4;&E"<IM>T<HR5.#C%VM.,
ME&]1M-\S<KJVG(G9J[N>@T445R'4%%%% !1110!Q>C?\CIXV_P"O7PK_ .DF
MI5VE?C5^V-^R+^VS\>/B]J&K? /]IM/AAHNDPJ;[34\??$OX=>9::JD,NB6+
MV_P^TG4[;6GTI;/4LZEJCQ7:B^$,2-$&(^4/^'9?_!5;_H^S_P V&_:._P#F
M6KM6'HSC&4L72A)PA>#C-N/NK1M+YG)*O5C*48X6I-*32DI12>NZN_-_=ZV_
MI$HK^;O_ (=E_P#!5;_H^S_S8;]H[_YEJ/\ AV7_ ,%5O^C[/_-AOVCO_F6I
M_5:'_0=1_P# )B^LU_\ H#J_^!0\O\_P];?TB45_-W_P[+_X*K?]'V?^;#?M
M'?\ S+4?\.R_^"JW_1]G_FPW[1W_ ,RU'U6A_P!!U'_P"8?6:_\ T!U?_ H>
M7^?X>MOZ1**_F[_X=E_\%5O^C[/_ #8;]H[_ .9:C_AV7_P56_Z/L_\ -AOV
MCO\ YEJ/JM#_ *#J/_@$P^LU_P#H#J_^!0\O\_P];?TB45_-W_P[+_X*K?\
M1]G_ )L-^T=_\RU'_#LO_@JM_P!'V?\ FPW[1W_S+4?5:'_0=1_\ F'UFO\
M] =7_P "AY?Y_AZV_I$HK^;O_AV7_P %5O\ H^S_ ,V&_:._^9:C_AV7_P %
M5O\ H^S_ ,V&_:._^9:CZK0_Z#J/_@$P^LU_^@.K_P"!0\O\_P /6W](E%?S
M=_\ #LO_ (*K?]'V?^;#?M'?_,M1_P .R_\ @JM_T?9_YL-^T=_\RU'U6A_T
M'4?_  "8?6:__0'5_P# H>7^?X>MOZ1**_F[_P"'9?\ P56_Z/L_\V&_:._^
M9:C_ (=E_P#!5;_H^S_S8;]H[_YEJ/JM#_H.H_\ @$P^LU_^@.K_ .!0\O\
M/\/6W](E%?S=_P##LO\ X*K?]'V?^;#?M'?_ #+4?\.R_P#@JM_T?9_YL-^T
M=_\ ,M1]5H?]!U'_ , F'UFO_P! =7_P*'E_G^'K;^D2BOYN_P#AV7_P56_Z
M/L_\V&_:._\ F6H_X=E_\%5O^C[/_-AOVCO_ )EJ/JM#_H.H_P#@$P^LU_\
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ME_G^'K;^D2BOYN_^'9?_  56_P"C[/\ S8;]H[_YEJ/^'9?_  56_P"C[/\
MS8;]H[_YEJ/JM#_H.H_^ 3#ZS7_Z ZO_ (%#R_S_  ];?TB45_-W_P .R_\
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MS_#UM_2)17\W?_#LO_@JM_T?9_YL-^T=_P#,M1_P[+_X*K?]'V?^;#?M'?\
MS+4?5:'_ $'4?_ )A]9K_P#0'5_\"AY?Y_AZV_HK\1_\B]KW_8&U3_TAGIOA
MG_D7/#__ &!-*_\ 2"WK^>"Q_P"";W_!4+1;VSUC7?VW?[4T32;JWU/6-,_X
M7]^T+=_VCI5A*EUJ%C]DO/#"6ES]KM(IK?[/=.EM-YGESNL3,0M__P $W_\
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M?$Q=?T/]JCPOX>T/7!XRUW^UM%T.ZO=8CN-(TN^^V?:;+39E1!)96\B6[B-
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M:7_@*_\ DP][M'_P)_\ R/K_ $]*%%7_ /A5_A#_ )Y^(_\ PNO'/_S1T?\
M"K_"'_//Q'_X77CG_P":.BT/YI?^ K_Y,/>[1_\  G_\CZ_T]*%%7_\ A5_A
M#_GGXC_\+KQS_P#-'1_PJ_PA_P \_$?_ (77CG_YHZ+0_FE_X"O_ ),/>[1_
M\"?_ ,CZ_P!/2A15_P#X5?X0_P">?B/_ ,+KQS_\T='_  J_PA_SS\1_^%UX
MY_\ FCHM#^:7_@*_^3#WNT?_  )__(^O]/2A15__ (5?X0_YY^(__"Z\<_\
MS1T?\*O\(?\ //Q'_P"%UXY_^:.BT/YI?^ K_P"3#WNT?_ G_P#(^O\ 3TH4
M5?\ ^%7^$/\ GGXC_P#"Z\<__-'1_P *O\(?\\_$?_A=>.?_ )HZ+0_FE_X"
MO_DP][M'_P "?_R/K_3TH45?_P"%7^$/^>?B/_PNO'/_ ,T='_"K_"'_ #S\
M1_\ A=>.?_FCHM#^:7_@*_\ DP][M'_P)_\ R/K_ $]*%%7_ /A5_A#_ )Y^
M(_\ PNO'/_S1T?\ "K_"'_//Q'_X77CG_P":.BT/YI?^ K_Y,/>[1_\  G_\
MCZ_T]*%%7_\ A5_A#_GGXC_\+KQS_P#-'1_PJ_PA_P \_$?_ (77CG_YHZ+0
M_FE_X"O_ ),/>[1_\"?_ ,CZ_P!/2A15_P#X5?X0_P">?B/_ ,+KQS_\T='_
M  J_PA_SS\1_^%UXY_\ FCHM#^:7_@*_^3#WNT?_  )__(^O]/2A15__ (5?
MX0_YY^(__"Z\<_\ S1T?\*O\(?\ //Q'_P"%UXY_^:.BT/YI?^ K_P"3#WNT
M?_ G_P#(^O\ 3TH45?\ ^%7^$/\ GGXC_P#"Z\<__-'1_P *O\(?\\_$?_A=
M>.?_ )HZ+0_FE_X"O_DP][M'_P "?_R/K_3TH45?_P"%7^$/^>?B/_PNO'/_
M ,T='_"K_"'_ #S\1_\ A=>.?_FCHM#^:7_@*_\ DP][M'_P)_\ R/K_ $]*
M%%7_ /A5_A#_ )Y^(_\ PNO'/_S1T?\ "K_"'_//Q'_X77CG_P":.BT/YI?^
M K_Y,/>[1_\  G_\CZ_T]*%%7_\ A5_A#_GGXC_\+KQS_P#-'1_PJ_PA_P \
M_$?_ (77CG_YHZ+0_FE_X"O_ ),/>[1_\"?_ ,CZ_P!/2A15_P#X5?X0_P">
M?B/_ ,+KQS_\T='_  J_PA_SS\1_^%UXY_\ FCHM#^:7_@*_^3#WNT?_  )_
M_(^O]/3SS1O^1T\;?]>OA7_TDU*NTK"\-^#? &N:CXK2UTOQ+9WNAZX=!U&>
M7QOXS$FH-9VL$]O<K)%XE9WMPEV\<"SE9(RLHV*K#/6?\*O\(?\ //Q'_P"%
MUXY_^:.JDHIV;DGRQTY5_*K/X^JU%%MJZ4;7?VGWUWBMM?N\]*%%7_\ A5_A
M#_GGXC_\+KQS_P#-'1_PJ_PA_P \_$?_ (77CG_YHZFT/YI?^ K_ .3'[W:/
M_@3_ /D?7^GI0HJ__P *O\(?\\_$?_A=>.?_ )HZ/^%7^$/^>?B/_P +KQS_
M /-'1:'\TO\ P%?_ "8>]VC_ .!/_P"1]?Z>E"BK_P#PJ_PA_P \_$?_ (77
MCG_YHZ/^%7^$/^>?B/\ \+KQS_\ -'1:'\TO_ 5_\F'O=H_^!/\ ^1]?Z>E"
MBK__  J_PA_SS\1_^%UXY_\ FCH_X5?X0_YY^(__  NO'/\ \T=%H?S2_P#
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M'_X77CG_ .:.C_A5_A#_ )Y^(_\ PNO'/_S1T6A_-+_P%?\ R8>]VC_X$_\
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MH_X5?X0_YY^(_P#PNO'/_P T=%H?S2_\!7_R8>]VC_X$_P#Y'U_IZ4**O_\
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MO"Z[K^O^'7WEJBJOVZR_Y_+7_P "(O\ XNC[=9?\_EK_ .!$7_Q=%GV?]?\
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MV?\ 7_#K[PNNZ_K_ (=?>6J*J_;K+_G\M?\ P(B_^+H^W67_ #^6O_@1%_\
M%T6?9_U_PZ^\+KNOZ_X=?>6J*J_;K+_G\M?_  (B_P#BZ/MUE_S^6O\ X$1?
M_%T6?9_U_P .OO"Z[K^O^'7WEJBH([JVE;9%<02/@G;'+&[8'4[58G [G'%?
M.7[7'Q6UKX,_ ?QIXX\-E$U^W@M]-TBXEC$T=G?:E(8(KQHF^5S;C<Z*WR^9
MM+ @$'AS''4,KP&-S+%.2P^!PM?%U^2/-/V5"G*K/DC=7DXQ:BFTFVKM+4]G
MAW(\=Q/GV3<.Y8J<LPSS,\%E6"56?LZ/UG'XBGAJ+JU+2Y*49U(RJ249-03:
MC)V3^D&FB0[7EC5O1G53^1(-/R,9R,=<Y&,>N>E?S8_![X+?M)?M1^#O'?Q?
M3XR:G;OX?DNI$AUGQ1XA^UZC=6UI)?S160M?-@TZ)(XBL>TVT0DVI'$D8W#N
M?V<OVE?B_J?PC_:%^&WB;Q?KNIR>&OAYJ.K>&]=N=4NI]=T6\LKF&&YM[?5Y
M'>_-O) YV>9=.\4G$#1QY4_EN"\685JF">.X:S'+L'F^$Q^*R7&3Q.'K0Q\<
M#2J5)0E"$8N@ZCI^S4FZBC.<'9TY<Z_J'.?HIU<)0SB&1^(_#_$6;\*9KD65
M\9910RW'X.KD4L]Q6&PU*K3KUJE2&/5!8AUYTU##N=*C6BI1Q$/8/^A165L[
M65L==I!Q]<$T;TW;=R[O[NX;ORSFOP1_X)C_ !Z\4R_%_7?AYXO\5ZYKEAXL
MTFXETJ'6]6U'5!;:MIK^>'@>_N+CRGN8"T&Q-@<@DY(Q4_PX^(?CR\_X*/:I
MH=UXR\3W&B_\)_JNG_V1-KNIR:7]A2VPEI_9S7)LA;J -L2P!5(RH!R3UX+Q
M2P&-RKAW,J66U[Y[GT<AGA_K--RP-=RC^]J3]FE5BZ=2E4C",8-J;7,G'7Q\
MX^C!GF3<3^('#F)XDP3CP/P)+CNCF']G8B-//<$H3OA:%'ZRWA*D<10Q6&G5
MG4KQC.A=0DI^[ZO^UMXM^('Q>_:I\/\ [-%K\1[CX2^"$TVPO+C5ENI[*+5;
MJ\MY+EWG6"\T_P#M)SL$%C937D5LS;BVV3#UM_L1>./B#X*_:!^(G[-^L?$$
M_%3P=H%M?7&E>(3<SWR6%SIXBDS;W$]U>R6L-S')]GDT_P"U3017",T3DC!\
M&_X*?VO_  EO[0/PY\'Z/#:1:Q-X?M+2>Z2(?:Y9-1O=UK]H=?FE2&)6$2OG
M:NX+@$UT?_!*2>RT;XE?&'PA>6]K+KEIIR*FIF)?M4D>GZO):7-O%*P\Q82Z
M&5HE(&>2.*^!P^/Q+\6'@W7Q'M_]9\52EF[QF)=.IET,K]LN'?[/Y_JL:5.=
MDJR7/[2TN6]F?O6/R' +Z*:S;ZEE[P/_ !#/+,13X463Y:L1AN(:O$L<)+Q
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M+/L_Z_X=?>%UW7]?\.OO+5%5?MUE_P _EK_X$1?_ !='VZR_Y_+7_P "(O\
MXNBS[/\ K_AU]X77=?U_PZ^\M455^W67_/Y:_P#@1%_\71]NLO\ G\M?_ B+
M_P"+HL^S_K_AU]X77=?U_P .OO+5%5?MUE_S^6O_ ($1?_%T?;K+_G\M?_ B
M+_XNBS[/^O\ AU]X77=?U_PZ^\M455^W67_/Y:_^!$7_ ,71]NLO^?RU_P#
MB+_XNBS[/^O^'7WA==U_7_#K[RU157[=9?\ /Y:_^!$7_P 71]NLO^?RU_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2-0U31YXK-054RW,3)<Q6^YV1 +EX1 2[JN)#N(7)KT, * J@!0      !@
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M)+DM/(\:JB AF/!L?V"GA[Q==:):PR"WTKX\_#*SC;8WSK:^'IHI)R0""9)
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/BO-LJP6.CC>(JV1XG#XK"T\5.KC)N%*H\-&C6<I5Z_L*E:%*M2E5G-_E/\
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MRC-MD7(W(V&7(R!FOR?_ &#46/\ ;=_X*PHJ!$7XV? I455"JJ+\(I54*H
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MU1/B5IFDP2Q^*UT?0[7X=:Q)$K^$M/76+]HM9;Y]^%O_  6$\3:9X3_;KO\
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ME4+ ,P498JI.3@<G .!UIDD\$+1)--%$T[^5"LDB(TTA!(CB5F!D? )V("V
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M?&:_^&WAKXF?$KXCS_%'6_[3\/KIUO\ :=:\#:'\/]'O_M%D]S9^+RE^EC9
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M5\7ZU_P0]TCQC^Q_:_MNZ,_[&GB^9_@C=Z-^S_KL5Y/%\+=":'7C8?M)^,_
MGPV8Z,W^E"2XUY-4C(SIUO//A* /ZP+._L=0B,]A>6E] &*&:SN(;F(..JF2
M%W3<,C*YR.XJ ZQI"W@T]M4TY;\L$%B;ZV%X7(R%%L9?.+$<A=F2.0*_F#\
M_&NW_9.\0_\ !5;_ (5A^SQXO_8=\3>#/V=/ /Q5^&7[&TVC_"RS\&VD1AU/
MP[K?Q\\&P_!#Q5\0/@E97]_KE_I=EK^D>$=7GGW:=:WGB"UDD\K;^CO@+_@F
M%^R5\0_V</ &O>(?!^GG]H3Q;X'\&?$#4_VU+$VMQ^U7:_$35M)TOQ'>>.]
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M-(T_X@(/AZTNM6A$WA*""Y4P '[O4444 %%%% !1110 4444 %%%% !1110
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MY]1AL+ZWN_L,,[12QD;U\;_98_;[TCQ-^R-XP^-G[6>M>!OA9X]^ /C7QO\
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MKWBZU?7UBNK;1FU&ZLKN*( \;^-_[ /Q+\?_ !F^.?Q+^$W[35E\&] _:?\
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MPO:V_P 8-1TR\@G\$>']!\176H>'O#7@ZWTN&VL/#WBKQ'\0O$6JS3W-U?\
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MK/XF@?6-0NA&9+K0Y+.Q$D\DDS:V2Q%<AK7_  3H^+&@7'[$WB/X%?M,>"O
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M^$/A[XC?"FYT+2[7Q/<OJ/@J'P]\1K.3PQ;Q06%Y-XAA69Y_ICXI_M]_L_\
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M?P9\*/"?C'Q1=W,]M:7$BO'I)A'E[6E#LJGD_@S^W'\!/CA\2;CX/>'3\6_
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M&+Q3\<?@'\"_V5O#TWQW7XR_#S0/!-O-XN^/&MRR^'? OASPKJ7Q>^&/Q)\
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M2!HOCC1]/TW5-0TB-]9TZP35(X++5["4:EI+7NF2F8QQ7;RQ2H@!\-?\%?\
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M2W&L>&;B]^)>O>(KNRO+*YGC_LF^UOQ?H<;Z>_PYBNK;1=5\.>$(;.'0]/\
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M6?$FL+IUO<'3M#TJ B;4-3NA%9VD?SSS(O-<!HUUXD_8*_:F_:=\8>*?@_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\,^.O#NG^'?'FE:9\/\ XD:$FGV4>E_$OX?6?A;Q]9Q6T<4/B-8@4(!\X?\
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M;9^M$L44\4D$\<<T,T;Q30RHLD4L4BE)(Y(W!1XW0E71@59258$$BO@/5/\
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MH^(&KV7PP%[-"- T"'4[*Q33= -];1Z)I]U'9K.;6TC\V+T3POXS_:[^(O\
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MTFZU.YU31O#&B_#/P=X%AT_Q.;_2M.MTUG[3X;GG(TR?4K1[66"0W2S-)!$
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MUUCX4>)_''P8C^#5SXK\*>-K_P 40_ CXTVOPRU>RU/7?AOXWO[+PGJWB1?
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M%KJ"]M[6]U:\U+3M+M)[I/F#X8?\%A/$/[1VF?LY:'^SQ\(O@Y+\4?COX/\
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M1>$+/Q'J>DQ/:SP6.HR^#=.O+M?*EN-*LB[QQ@'YH_\ !0SXC_M.^#/VS/\
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MCX@Z7#J5DSZ7X<N?''ANXF-Q#;^*I#%&TWQ[I_\ P2T_:?N+7]M:S%G^QO\
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M_P!E[_@H5^U#\'O#/[+G[4%U^Q_8?#.UUGPE<?$#X\_#?QE\7_%?Q5\=:=X
MURSU?2+_ $'X,^+/A-X4\+_#KQ;XH.EV3:MK$GQP\=P>&+N>_GTVT\0+)"D8
M!O?\$ZOB!X\\7_L6?M'>)/%GC;Q=XH\0Z/\ '#]K;3-(U_Q#XDUG6]9TO3=
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M=OC3\1?A3X;U+XN?$[P3=>+=2^*5WJ?PVUKPY)\0M(M+FRAC\,^'_%6H>)_
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MJ\\=O8P_K]^R1K&K>(?V6/V<->U_4]0UO7-:^!OPKU76-8U6\N-0U35=3O\
MP3HEU?:AJ-_=R2W5Y>WES+)<75U<2R33S2/+*[.Q)\8T7]C=O /[ .K_ +&7
M@7Q):7VK3_!KQEX M/%WB,7UEIVH>+/&=KK%UJNOZC#;#6K^PTVZ\0ZU>WGV
M6W74[BSLF2!/M<L9:3Z0^ /P_P!6^$_P,^#OPOUZ[TZ_UOX=_##P+X(U>^TA
M[F72KS4O"_AK3=%O;K39+RVLKN2QGN;*26U>ZL[6X:!D,UO#(6C4 ]<HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@#\O?VS?VK_ -M7]F'4]$UGP?\
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MLW@[]LOXJ^%-9^+^BZI?7,/A#0=6^"WP:T:#XL?#;X>67Q2\11)J%U'JVO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
IHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>img94995564_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img94995564_1.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_X@'824-#7U!23T9)3$4  0$   '(
M  0P  !M;G1R4D="(%A96B 'X  !  $       !A8W-P
M                     0  ]M8  0    #3+0
M                                              ED97-C    \
M "1R6%E:   !%    !1G6%E:   !*    !1B6%E:   !/    !1W='!T   !
M4    !1R5%)#   !9    "AG5%)#   !9    "AB5%)#   !9    "AC<')T
M   !C    #QM;'5C          $    ,96Y54P    @    < ', 4@!' $)8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]865H@        ]M8  0    #3+7!A<F$       0
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M!3-"H;'!T? R-')B\08C)(*BLN'_V@ , P$  A$#$0 _ /\ 5,
M
M
M
M
M
M
M
M
M
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MSJF6EXYD5/EM%!R7'YGBJVR93(BO]VM'>-J\CXK(E%^PR(Q)#.>SI_J+P?\
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MIPM_+DGGO\Q?.)EIXQCWW;TO&ZNIJUT_=N8[>WK=^_I7ZM5  '!]0
M
M
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MDM"R)25$>Y&1^1D/T
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M\=NNWK>T7#*<=K\NQJTQ>U;)<2UB.Q'B,M_56DT[E^LM]R_61#G;LZIR#/\
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MWPFW,^'#O?7ZIXF>_M,Q.  X.P                       QK7.=C-;FN
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M64NN>@.2;TW/#/%LXT1M)XDLO8K;;<O8>Y#[:V_GX-_6Z!_]E0DXQYM5M_\
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M$//E=S;[>A,3IXSC-Q7<  &74
M
M                  5[.BS]6/N%IHN@3=]XC@=X3QQ>[W]??N?6Y;>7F7SB
M*TBT\>TXQ15;96:;.ZLYK]K<STHX%*FO*Y.*(O8DBXI+RZ)+H6^PNP"WM25O
M8  (H
M                                                #-%8WK303Y[6
M*Y716E9.DN26OEXI"Y$,EG_FVU(,R4DO9N>W3R(:6 UCETN.KHQJU<S$Q[32
MK:>X4YA=5*:G6BK.TLY;D^PF&V2.]>7MOQ27YJ2(B(B_;Y;[%:0 29G*;EO3
MT\=+&,,>T   C8
M                        /!:O7C*6SI*Z!+49GWA2IJXY)+V;&EIS?V_-
M_:/> " \;GOU:H/?;WW0/&Y[]6J#WV]]T$^ M\)7* \;GOU:H/?;WW0/&Y[]
M6J#WV]]T$^ 7P5R@/&Y[]6J#WV]]T#QN>_5J@]]O?=!/@%\%<H#QN>_5J@]]
MO?= \;GOU:H/?;WW03X!?!7* \;GOU:H/?;WW0/&Y[]6J#WV]]T$^ 7P5R@/
M&Y[]6J#WV]]T#QN>_5J@]]O?=!/@%\%<H#QN>_5J@]]O?= \;GOU:H/?;WW0
M3X!?!7* \;GOU:H/?;WW0/&Y[]6J#WV]]T$^ 7P5R@/&Y[]6J#WV]]T#QN>_
M5J@]]O?=!/@%\%<H#QN>_5J@]]O?= \;GOU:H/?;WW03X!?!7* \;GOU:H/?
M;WW0/&Y[]6J#WV]]T$^ 7P5R@/&Y[]6J#WV]]T#QN>_5J@]]O?=!/@%\%<H#
MQN>_5J@]]O?= \;GOU:H/?;WW03X!?!7* \;GOU:H/?;WW0/&Y[]6J#WV]]T
M$^ 7P5R@/&Y[]6J#WV]]T#QN>_5J@]]O?=!/@%\%<H#QN>_5J@]]O?= \;GO
MU:H/?;WW03X!?!7* \;GOU:H/?;WW0/&Y[]6J#WV]]T$^ 7P5R@/&Y[]6J#W
MV]]T#QN>_5J@]]O?=!/@%\%<H#QN>_5J@]]O?= \;GOU:H/?;WW03X!?!7*
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M-MF1[[]-O[?F]@!90  (H
M
M
M     /RXXAEM3KJB2A"34I1^1$7F8SD]7;'PIY&C ;%6+$O8[4I".\[OEQ[T
MH_Y_#V[[^746,9R[).41W:0 _#+S4AE#[*R6VXDEH47D:3+<C'[$4
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MTUO12*6XKB0M^&ZXETC;7^:M#B>BT]-MR\C%Z9JSJBZ6<  94
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M5+C-@  PV
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M G.6<&BKX\QW?O)#45"'5[^>ZB+<_P#S&^N)FV.B8BGN0GBA*?F(B'Z !S=
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M;#8KX+"&(\9M+33:"V)"2+8B+^P3*8FZ]5QB8J_1]P !AL
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MCN93'(M^#K>Y\5%[2W,2("3E<4U$5-@  RH
M
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MKJRUL6))QK2=$@(6V2-F5R%DAM3G)1;)Y*21F6Y[J+H8PG-I&18SHGGV%5E
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M(.B*N3JFZAT96NV#]?&>MH;,2:MI*I##+YO-M.&7K)2X:4FLB/IOQ+?YB'I
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M4AG<S/NW"02T[F?11>LK\X[<,S%334;P  "*
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M[(S&?23T?@%EZ:\KI+"4SOD]:UQE.ET4ILUI2KB?GL9=-]MSVW.3 !E0
M                          ?EQM#J%-.H2M"R-*DJ+<C(_,C(?H %'RC2
M;"[/'+.NI<,QN)/E1'6HS_R<TWW3JDF25<DH-2=CV/<NH\\K2:OFZ;0\*9.+
M4S8R(\A,N"R1)3.:2G\MMLGF9F1[F>QF1^PQH #?F9>[S3X31RF9Z>\5^C+'
ML$U0S-Z%6ZDW] 5'!?;D.QZEETG;!39D:2>-PB)"=R(S)'3V;%T,M/>[Y+*S
MC(0ITDGW:5J-*35MT(S(C,BW_48^@"993DWI:&.C<Q,S,^LS<J C3%R?I];X
MS>6#7ROD*G)5C.82:D^)4HE)XDK8S0CBA)$>WJI]FX^U)B&2R,LK\KRMVM:<
MJ*Q5?&8@.K=)U:S+F\M2T(X[DDB)!$K;?\XQ>0%\R6(\)IQ,3[5^M;Q?Z[@
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ME:C_ $UC?]Y?^"'XI6H_TUC?]Y?^"'GZ?N?57C?PY8F VS\4K4?Z:QO^\O\
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MY$?0>G\4K4?Z:QO^\O\ P0\_3CU;U?V7XS+.9C3GNQ,!MGXI6H_TUC?]Y?\
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M,EQ$Q)3+:DDQ())[H6M/'<UI+H2MRZ=!.@ DS,]W3'#'"^F.^X  (T
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M
M                                            @,E_EG%/Z7<_P$L3
MX\<ZL8GR:^4\M9+K9*I31),MC4;+C6ROU<75'[.I$+"2]@  B@
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MU&RXULK]7%U1^SJ1"PDO8  (H                    *7JW_HK!_K/C?\
MWF&+H*7JW_HK!_K/C?\ WF&+CWA)[+H  (H
M
M
M
M                                                       *7JW_
M **P?ZSXW_WF&+H*7JW_ **P?ZSXW_WF&+CWA)[+H  (H
M
M
M
M
M     *7JW_HK!_K/C?\ WF&+H*7JW_HK!_K/C?\ WF&+CWA)[+H  (H
M
M
M
M
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M1JY^T&__ ',#[L%<E\)\! >C5S]H-_\ N8'W8/1JY^T&_P#W,#[L%<E\)\!
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M-7/V@W_[F!]V#T:N?M!O_P!S ^[!7)?"? 0'HU<_:#?_ +F!]V#T:N?M!O\
M]S ^[!7)?"? 0'HU<_:#?_N8'W8/1JY^T&__ ',#[L%<E\)\! >C5S]H-_\
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MMVWW41[$),1Z+$SZ@  B@
M
M           _"W6FU(0XXE*G5<4$9[&I6QGL7SGL1G^PC'[$!DO\LXI_2[G^
M EBQND[)\  10                !^&W6GDFMEQ*TDI23-)[ER29D9?M(R,
MC_60_8@,(_D:3_2]M_CWQ?1/5/@ "*                #\+=:;4A#CB4J=
M5Q01GL:E;&>Q?.>Q&?[",?L0&2_RSBG]+N?X"6)\5   10
M  ?A#K3BEH;<2I32N*R(]S2K8CV/YCV,C_89#]B QK^6<K_I=O\ P$03XLQ2
M1N  "*              _#CK3*26\XE"34E)&H]BY*,B(OVF9D1?K,?L0&;_
M ,C1OZ7J?\>P+$7-).T)\  10                    4O5O_16#_6?&_\
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M_CWQ/B PC^1I/]+VW^/?%]$]4^  (H                (#)?Y9Q3^EW/\
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MOFXK8B,R-*=O))"SECE&[&GH:VEE$X[1-?IOO$^^U1'-SZK@  .#Z@
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M..P&EM<51&5GR[GER/F1&9[&>Q]0U,XS[)X/PN?AIB<M[C?B>^W$W\XOUE9
M !Q?2! 81_(TG^E[;_'OB?$!A'\C2?Z7MO\ 'OB^B>J?  $4
M    $!DO\LXI_2[G^ EB?$!DO\LXI_2[G^ EB?%GT2/4  $4
M    $!C7\LY7_2[?^ B"?$!C7\LY7_2[?^ B"?%R[I   (H
M" S?^1HW]+U/^/8$^(#-_P"1HW]+U/\ CV!<>\)/9/@ "*
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M0
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M_P#(T;^EZG_'L"X]X2>R?  $4                    %+U;_T5@_UGQO\
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M)^&'I# _1[/W9)^&%27"3 1GI# _1[/W9)^&'I# _1[/W9)^&%27"3 1GI#
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M](8'Z/9^[)/PQ[(<QF<V;K*'TI)7'9YA;2M_V+(CV_7Y"4MON
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MY>KR=$G5#7P !EH
M
M      !&VMH[7SZ:(VTE2;.:J*LS\T)*,\[N7Z]VB+]AF D@
M         1N/VCMQ =EO-);4W-F12)/D:69+C1'^TR;(S_68"2
M           1MK:.U\^FB-M)4FSFJBK,_-"2C/.[E^O=HB_89B2
M             $;56CMA/N8CC24IK)J8J#+S6DXS+NY_KW=,OV$0D@[
M              (W(+1VG@-2V6DN*<FPXIDKR)+TEMHS_:1.&9?K((W.R2
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M78\Q(174=5+7(6\M]KNUG*<,B0LD_G)XEY[>6QFK'36]M]5^C9@ !AH
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M:B;E0I"'V5FD]C(EH,TGL9&1]?,A[@
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MRR]Z+CAT55EB\>7"1'?\7(C^/**3Y/&[P;4DUIW1W:R5P4>Z>1$F]$P=<-H
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M +Z.?A]2='+'&KB8B(_*YC;_ /:>)B/1K0  \[[(             #&.U?\
MZM(G]+L?])T;.,8[5_\ JTB?TNQ_TG1UT?WF/YO'^T/^IJ_^,_T<C  #[#^;
M                 #ZR?\X7_AH_Y2'R'UD_YPO_  T?\I!ZND?NY_./[OD
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ME^0?ZF>_)/0^N^Y=>IB^CAJ7U5+ZOA.F=*)QO?O?>_6_U  !AZ0
M$!C7\LY7_2[?^ B"?$!C7\LY7_2[?^ B"?%R[I   (H             " S?
M^1HW]+U/^/8$^(#-_P"1HW]+U/\ CV!<>\)/9/@ "*
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MB7RBIDHBLHFO-O2$MI)UQMLVT+7MZRDI,U&DC/<R+<]OG/S'U !%
M
M                                !E7:,QRYRS#:S'\?A^*GRK=ON6>\
M0CEQ8?6KUEF22V2DSZG[!JH@,E_EG%/Z7<_P$L:PRZ<HRARU].-;3RT\NTQ7
MS<C?BZZR?4[_ (A%^*'XNNLGU._XA%^*.V 'I^F:GM#XGV;\+\67SC_#B?\
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M4-]\V[NV;3225NA2B\T*+;??H-1 8U/$YZF/3+U>#_8VAX+5\W3F9GFO\
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MR=)U?PJT:KWW8D.LN4/2$M&IME:_"\"4K;9)J)*]MSZ[*V\C&3N8E9UE9EF
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M:IADA9I)B<MI)N&VX2$(2F1(2:%>KZJ246W@ DS:Q%   B@
M
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ML:QF/#:[QQ%C7OF6Y%LAJ6TXL^OS)0H_[.@F ")K<G<
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M1GA\E^EJSW>Y\8>F&W9H-?RA,BOD>W'N8RFMOGWW6K?_ .@]0!:@  @
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M<!+4
M
M
M
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M)6A3CZRX(29?G*4A"N?)>9X_IMH+KQV?,GM6VM1;JZRMC'\;<>Y6=\BZ==5
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M^ZHV)\)^OFO5=I66+)-3*R>R9$[&?2DU)YIW(^2%+0I*DJ0I:5)486T
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M<9C$U$MM-L6FY7 )!1;V33QW+!@D;\2;DJ0;B=N2MME%MN?SC[9CIIIQJ*<
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MQ;272K!KNPR7"M,L4Q^WMB44^PJZ6-$DRR4OFKO76T)4YNOUCY&>Y]?,>YK
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MC;B6Q=-BV 6P!Y:NNCU%9$J8?+N(3#<=KD>Y\$)));G[3V(AZ@
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M[(V^\42E&DDW#4O&L\EY]IGVA,5T\M+&?C<*QK+G%%2Z]FS\%8(9-7=.K?\
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MLC<S')X$#(7JF;;RYS<@[)$:<P\T;;Q.2UFT9NH0:6R0I:4J,P&W8UK]A]M
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M(3*R9)M/>$I"242FTI[SB9H5TN
M
M
M                                                         #SO
MU\"5)C394&.](A*4N,ZXTE2V%*2:5&A1ENDS29I,R\R,R'H         >=^O
M@2I,:;*@QWI$)2EQG7&DJ6PI232HT*,MTF:3-)F7F1F0]   \MI5UEY62Z6Z
MKHMA7SV%QI<24REUF0RM)I6VXA1&E:5),R-)D9&1F1CU  C<<QK',.I(N-8C
MC];25$!!HBU]=$;C1F$F9J,D--D24EN9GL1%U,Q)   //$KX$!4A<&#'CJEO
M'(D&TTE!O.F1)-:]B]91DE);GUV27S#T         //$KX$!4A<&#'CJEO'(
MD&TTE!O.F1)-:]B]91DE);GUV27S#T            #SQ*^! 5(7!@QXZI;Q
MR)!M-)0;SID236O8O649)26Y]=DE\P]
M
M
M
M
M
M
M
4                       /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img94995564_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img94995564_2.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" )[!-@# 2(  A$! Q$!_\0
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M\#Z#IGB7]KCQ]XI\/WFH:Y;0Q:UX>DT_3C'J^F?,6O;*412>5+ K^85*H&;
MKV'PMK\/[9/[;_P\^+'@S2+Z\^!'[+W@_P 4?\(]X^U'3-0TZP\7?%+QV@TJ
M\/A>2ZB@^WV&C^'(7AN;@H8S)>*T>X.I72I[3VE7VG/[+ZNK\U^7G]C#DY>;
M3G]KR[:[]+F5+V?LZ;ARJK[;3EMS./M+3YN77EY.;?38_5NBBBO./1"BBB@
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M^*_%5W/XZOI?$UKJ<EE\2]2:+P]KK6_GZ+8?:-#LP+."-T$3W4><7#$?M?\
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M^Y$;,\<;LC1LZ(S1MC=&S*"4;'&Y2=IQQD'%?C[\&OAU8_\ !17Q=\2OCO\
M&W6M3\1_ ;1?&OB_X:?!'X2:-KFJ:3X/U'PYX9U2;1=6\8^+8=.N+.?7-5U^
M]LY46VN7^S64$;) &65BW["U^/'P2^)EG_P3X\=_%;X#?'VVG\*?!;Q'X_\
M%WQ.^ _Q5M-(O)O!$7AGQ1J/]L:SX0\0ZA:13+H^LZ!J5]+-*]XD%M-%=8MF
M>*$,<:'-R5?9_P :T.2WQ\EWS^SZ\]^3X?>Y>:VES6M;FI^TM[*\N:_P\_N^
MSY^G+\6^G-RES]I3]D?0OV3?AOJG[2'[%UI>_"WQ?\%[:;Q=K/P[T_7]6?X<
M_$+P5:S0W/C#1-<T'4[Z[M8+G^S([C4[74[4"]CGM&CA#/<$-]+?M#2_#O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM1\%^#M8L++2M6\)^&M4TS3E5=/T[4="TN^L+!54(JV5G<VLMO:JJ (H@CC
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MU7]BWX]:?I=C>:E?W/A?3TMK&PMIKR\N''B;0W*06UNDDTK!%9RL:,0JLQ&
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M_!A-;U."&SD\$/9VJVB^'F@LHY)]-:Z:18Y)VDD,A8%N,5]]?!KX*6/A_P"
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M@NC^*]%\'6WCGXA>/_B!97FL:)X9L=3G>+1='BT6Q>.>ZOM3C0W ?S!LB8,
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MSG UL1@G@W'&9C&4*5%8ZAC8N4HX/!8>I.=:?+[.I]6J82I.FI<L_G[P=?\
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MKB[\+^']4M/$.H>'_#MQ(SNRR:1I-Q:VAMRV+7R_LXXC%?3?[7O[-UG^T/\
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MF\(ZGX\_9Q^-OA#18VFU?7?AKXKM--@12SW-ZNE7$]M;(HR6>YEA6!  26D
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M3K^'5U_9*U*Q;2Y;.XCU%;T_#B^A%FUB\8N1=&4B(6YB\TR$($W'%>:? ?\
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M /+^C_A1'PM_Z%^^_P#"L\8__+^O7J*/:U?^?E3_ ,#E_GY+[@]G3_Y]P_\
M 8_Y'D/_  HCX6_]"_??^%9XQ_\ E_1_PHCX6_\ 0OWW_A6>,?\ Y?UZ]11[
M6K_S\J?^!R_S\E]P>SI_\^X?^ Q_R/(?^%$?"W_H7[[_ ,*SQC_\OZ/^%$?"
MW_H7[[_PK/&/_P OZ]>HH]K5_P"?E3_P.7^?DON#V=/_ )]P_P# 8_Y'D/\
MPHCX6_\ 0OWW_A6>,?\ Y?T?\*(^%O\ T+]]_P"%9XQ_^7]>O44>UJ_\_*G_
M ('+_/R7W![.G_S[A_X#'_(\A_X41\+?^A?OO_"L\8__ "_H_P"%$?"W_H7[
M[_PK/&/_ ,OZ]>HH]K5_Y^5/_ Y?Y^2^X/9T_P#GW#_P&/\ D>0_\*(^%O\
MT+]]_P"%9XQ_^7]'_"B/A;_T+]]_X5GC'_Y?UZ]11[6K_P _*G_@<O\ /R7W
M![.G_P ^X?\ @,?\CR'_ (41\+?^A?OO_"L\8_\ R_H_X41\+?\ H7[[_P *
MSQC_ /+^O7J*/:U?^?E3_P #E_GY+[@]G3_Y]P_\!C_D>0_\*(^%O_0OWW_A
M6>,?_E_1_P *(^%O_0OWW_A6>,?_ )?UZ]11[6K_ ,_*G_@<O\_)?<'LZ?\
MS[A_X#'_ "/(?^%$?"W_ *%^^_\ "L\8_P#R_H_X41\+?^A?OO\ PK/&/_R_
MKUZBCVM7_GY4_P# Y?Y^2^X/9T_^?</_  &/^1Y#_P *(^%O_0OWW_A6>,?_
M )?T?\*(^%O_ $+]]_X5GC'_ .7]>O44>UJ_\_*G_@<O\_)?<'LZ?_/N'_@,
M?\CR'_A1'PM_Z%^^_P#"L\8__+^C_A1'PM_Z%^^_\*SQC_\ +^O7J*/:U?\
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M $#-3_\ "K\7?_+VO2:*/:U?^?E3_P #E_GY+[@]G#^2'_@*_P O)?<>;?\
M"H_ ?_0,U/\ \*OQ=_\ +VC_ (5'X#_Z!FI_^%7XN_\ E[7I-%'M:O\ S\J?
M^!R_S\E]P>SA_)#_ ,!7^7DON/-O^%1^ _\ H&:G_P"%7XN_^7M'_"H_ ?\
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MSA_)#_P%?Y>2^X\V_P"%1^ _^@9J?_A5^+O_ )>T?\*C\!_] S4__"K\7?\
MR]KTFBCVM7_GY4_\#E_GY+[@]G#^2'_@*_R\E]QYM_PJ/P'_ - S4_\ PJ_%
MW_R]H_X5'X#_ .@9J?\ X5?B[_Y>UZ311[6K_P _*G_@<O\ /R7W![.'\D/_
M  %?Y>2^X\V_X5'X#_Z!FI_^%7XN_P#E[1_PJ/P'_P! S4__  J_%W_R]KTF
MBCVM7_GY4_\  Y?Y^2^X/9P_DA_X"O\ +R7W'FW_  J/P'_T#-3_ /"K\7?_
M "]H_P"%1^ _^@9J?_A5^+O_ )>UZ311[6K_ ,_*G_@<O\_)?<'LX?R0_P#
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M_P"@9J?_ (5?B[_Y>UZ311[6K_S\J?\ @<O\_)?<'LX?R0_\!7^7DON/-O\
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M5'X#_P"@9J?_ (5?B[_Y>T?\*C\!_P#0,U/_ ,*OQ=_\O:])HH]K5_Y^5/\
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M - S4_\ PJ_%W_R]H_X5'X#_ .@9J?\ X5?B[_Y>UZ311[6K_P _*G_@<O\
M/R7W![.'\D/_  %?Y>2^X\V_X5'X#_Z!FI_^%7XN_P#E[1_PJ/P'_P! S4__
M  J_%W_R]KTFBCVM7_GY4_\  Y?Y^2^X/9P_DA_X"O\ +R7W'FW_  J/P'_T
M#-3_ /"K\7?_ "]H_P"%1^ _^@9J?_A5^+O_ )>UZ311[6K_ ,_*G_@<O\_)
M?<'LX?R0_P# 5_EY+[CS;_A4?@/_ *!FI_\ A5^+O_E[1_PJ/P'_ - S4_\
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M^((-1_M73AJ"F/38-)DMO)!FA\HAKR;><MO!4<;>?A3_ (;W^/W_ #\^$/\
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MU?P<\_\ PCOBKPQXHM&O/#OB*TM;D>=ILMY%'(+C3I7:2VD4JW8GF?'6N_\
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M /T'-8_\&=[_ /'Z/J+_ .?B_P# 7_\ )!];7\C_ / O_M?7^GI^H%%?E_\
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M +7U_IZ?J!5:\NH[.#SY S+YUM#A<9W75S#:H>>P>92W^R#7Y#_%3Q1XFMO
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M]M>:O<0QV\^I7,,2I->RP0DQ0R7+AI6BC)1"VU20!7Q3\3OV$_!_BGX@:_\
M%KX4_$GXC?L\?$SQ3;B/Q)K_ ,,-1MH=*\07JDF/6-;\+:A%+I&H:L 522]9
M(Y98XT5SG<S.,X2C.G4:AS2A-3C#W4X)QLXQ2]UJ5[I73UL[Z)PE&4)P3ERQ
ME"492O)J3C*ZE)M.47&UF[-/?1'*_M4?M-_M _LZ>+? NJ/\*_A=K_PA\9_&
M3X:_"?2=?NO%NL0^-K>X\?ZDFG3ZD=&BL)+-/L*QW;HJS[9 L"RLH=L>,?\
M!2BQ\8ZG^T-_P3GL?A]KVE^&/&5S\7OBHF@:]K6E'6]+TV\'@;2V:>\TH2P&
M]B-NLT0B\U,/(CY^3!]W\%?L$6B^*/!WC3X]_'KXM?M*:_X UE_$'A.W\?7&
MEZ5X7TS6U<-9:LWA;0X(["[U'3@J?8;JY>1K>4--$$=VS-^T?^Q3XN_: ^+_
M ,/OBS;?M'^+/A\_PGU*?6_ASX;TGP5X=UBR\-ZWJ.B6^AZWJ*WNH7L-S?-J
ML-OYSPW$8CMWD98B5 -:TYT*<Z;4HIPA64ZG)/EFYTW""Y6I-V;;DW"*=VK:
M*^4H5I0J74GSSI2C#FAS14)1E/WERI7M:-G)II.^NGT7\&/#GQ\\/Q:VOQP^
M)/@WXARW$ELVA2^$_!;>$!IT:*PNH[Q&O;P7AE8JT;@H8\$8-?E7JVB_M!:O
M_P %-OVRW_9Y\=>#?!?B:P^"7P.NKM?&?A-_%-EKK+X4G;2M.@5+RT.G,;R-
MUFN<R;DG7Y1Y9S^V>BV5YIND:;8:AJ<VM7UG96]M>:O<0QV\^I7,42I->RP0
MEHH9+APTK11DHA;:I( KX-^&'[$?C3X>?M+^)/VE;[]ICQ=XMUSQM;:3I7C;
MPW?>!_#>GZ;XB\/>';&]L?#FBO>VM[)<V4>DK=12+=01&:X:U02@"1L9T:D8
MNM*3IIRI<L8NG>$I*=.5N2,7%)J#U:7O-/NUI5IRDJ,8J;4:BE*7/[T5RRC\
M3E=M.71O1/?1/D_^"9L%OXF^'OQ%^,'BW7]2\1?'[Q_X_P!5L?CNVJV5OI<G
MAOQ=X3D;18_".E:3"TC:?X>TFTMXVT9)W:6YM9ENVP9B*Z#XZ?M4_$7Q)\2-
M5_9F_9#\/:?XP^+NFP*OQ$^(.MF4?#[X-6E] ZP3:O<VX<ZIXF#LLMMH4!+I
MY4GVG8P16]F\!_LMV/PR_: ^(?QJ\$>/=>T7P]\52-5\<_"9-.TZ3PKJGC18
M+>U_X3*WOLI?V.H2VT CNK:*-X+@D.S*5 /SUX/_ & /B!\,/&'Q9\5?"C]K
M3QQX(C^,'CW4_B#XDTW_ (5]X4UQAJVHA(_*74KZ^2YFAMX8XXT+HA8AI"H9
MS5<U&56=24HZQBZ<9QGR*6B<)*";<::5DE[LDHK:Z)4:L:<*<8O2352491YY
M17VTY25I3>LFVVM;+9KZ2_97^"GAO]GGP'<?#6W\91^-O']QJ=WXV^)^O7=W
M:-KVM^+?%DSW]_K>H:="YN=/LKR9GCTF.>)5%E#''&\@0FNR_:6_Y-R^/_\
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M-4?M"?\ 15/$GYZ?_P#(-'_#5'[0G_15/$GYZ?\ _(->5_Q4B\,/^B-\1/\
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M9W6BZ1K2W#6:)JEZ!:SFWD\Z'[!&F9 K_+MG?*XY.#GBN1_X9^^'G_/+6/\
MP9M_\9JG\>-?UCPYI>@ZAHE_/IUXU[>6S7%OL\PP210.\?SHXVLT49/&<J.>
MM?,G_"V/B+_T-FI_G;__ !BNRA3KRA>G5Y(\S5KO?2[T3\OZ9RU:E*,VI4^:
M5E=V7;3=]CZG_P"&?OAY_P \M8_\&;?_ !FC_AG[X>?\\M8_\&;?_&:^6/\
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M+_T-FI_G;_\ QBC_ (6Q\1?^ALU/\[?_ .,4>QQ7_/\ 7WR_R\OS[L/:T/\
MGS^"_P SZG_X9^^'G_/+6/\ P9M_\9K.O_@/X!MY=+2.+5@MWJ(MILZD23$;
M*]GPO[GY6\R"/GGY<COFOFG_ (6Q\1?^ALU/\[?_ .,5%)\4OB!,T+2>*=2=
MH)?.A)-OF.7RY(MZX@'/ERR)SD8<\4O88K_G_P#C+_+R_J[#VM#_ )\_@O\
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MYV__ ,8H_P"%L?$7_H;-3_.W_P#C%'L<5_S_ %]\O\O+\^[#VM#_ )\_@O\
M,^I_^&?OAY_SRUC_ ,&;?_&:/^&?OAY_SRUC_P &;?\ QFOEC_A;'Q%_Z&S4
M_P [?_XQ1_PMCXB_]#9J?YV__P 8H]CBO^?Z^^7^7E^?=A[6A_SY_!?YGU/_
M ,,_?#S_ )Y:Q_X,V_\ C-'_  S]\//^>6L?^#-O_C-?+'_"V/B+_P!#9J?Y
MV_\ \8H_X6Q\1?\ H;-3_.W_ /C%'L<5_P _U]\O\O+\^[#VM#_GS^"_S/I:
M_P#@/X!MY=+2.+5@MWJ(MILZD23$;*]GPO[GY6\R"/GGY<COFM'_ (9^^'G_
M #RUC_P9M_\ &:^4Y/BE\0)FA:3Q3J3M!+YT))M\QR^7)%O7$ Y\N61.<C#G
MBI?^%L?$7_H;-3_.W_\ C%+V&*_Y_P#XR_R#VM#_ )\_@O\ ,^I_^&?OAY_S
MRUC_ ,&;?_&:/^&?OAY_SRUC_P &;?\ QFOEC_A;'Q%_Z&S4_P [?_XQ1_PM
MCXB_]#9J?YV__P 8I^QQ7_/]??+_ "\OS[L/:T/^?/X+_,^I_P#AG[X>?\\M
M8_\ !FW_ ,9H_P"&?OAY_P \M8_\&;?_ !FOQDN?VIOV@TN;A%^*?B0*L\JJ
M =/P%61@ /\ 0N@  J#_ (:H_:$_Z*IXD_/3_P#Y!K_.JI^T?\,:52I2?!OB
M&W3G*#:I<.6;A)Q;5\^O9N/5>N[/ZBA]%GBRI"$UGG#"4XQFDYYI=*232=LM
MM>SU/VB_X9^^'G_/+6/_  9M_P#&:/\ AG[X>?\ /+6/_!FW_P 9K\7?^&J/
MVA/^BJ>)/ST__P"0:/\ AJC]H3_HJGB3\]/_ /D&L_\ BI%X8?\ 1&^(G_@K
MAS_Y_>7Y]V5_Q*MQ;_T/.%__  /-/_G:?M%_PS]\//\ GEK'_@S;_P",T?\
M#/WP\_YY:Q_X,V_^,U^+O_#5'[0G_15/$GYZ?_\ (-?7/[%GQM^*WQ#^+M]H
M/C7QMJ_B+2(O!6LZC'87WV7R5O;?4]"AAN!Y-M$_F1Q7,Z+\VW$K9!."/K^
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M*4<#E,HTZ.'A"E2IISP,I-0A",4Y-R:BVVVVWPO_  [@\(?]%,\2?^"32_\
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MW>JZ1J7ACQ)K7B"6+4[E;C5[[0CI=I:6UY?V=REVOER:E-<RPK<(S2+#O^5
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MYXI<F-_Y^1_#_P"0\OZNPY\+_)+\?+^]_6O?7UG_ (9HT;_H:-3_ / &U_\
MCM'_  S1HW_0T:G_ . -K_\ ':\N_P"&@?B'_P ]='_\%B__ !ZC_AH'XA_\
M]='_ /!8O_QZGR8W_GY#_P E_P#D/+\^[#GPO_/N7X^7]_\ JS[Z^H_\,T:-
M_P!#1J?_ ( VO_QVC_AFC1O^AHU/_P  ;7_X[7EW_#0/Q#_YZZ/_ ."Q?_CU
M'_#0/Q#_ .>NC_\ @L7_ ./4<F-_Y^0_\E_^0\OS[L.?"_\ /N7X^7]_^K/O
MKZC_ ,,T:-_T-&I_^ -K_P#':/\ AFC1O^AHU/\ \ ;7_P".UY=_PT#\0_\
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M]XSOA]/W;Z:W=DF[)OWGKHVXZRLFVMSQB7_@G'X1EEDE/Q+\2 R2/(0-$TS
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M1114%GR?KWP,UCQ7XA\0Z];:YIEK#?:[JKI!/#=-*@6[E7#-&I0DXSP:R_\
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MSE%[-/E5FFDT_FFG\_2VL:%*23Y6M[IR=TT[-;]&FCX[_P"&:M?_ .ADT?\
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MG_H5],_\#KK_ .-4?[;VA_Y)_G_5WY6/]E_O?^3$7_#-6O\ _0R:/_X#WO\
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M-1_P\?\ %_\ T3/PW_X.]4_^1J/^)[OH[?\ 19YC_P"(AQ/_ /.K^KORL?\
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MG_((MO\ >G_]'R4 ;E%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,CVE/;GC=.WQ+?\ K^M&>TT5XM_POWX=?\_FI_\ @JN*/^%^_#K_ )_-3_\
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MU*\/?2<G>347&3<F_>D[N[NE0DKO1ZQ?+)W3BE)<K?(K)-II**6BT5E;\_\
M]DWXJ>+O%WQ(^&&K?$#Q3?75QJ?[']EK-S/J5W+:6FKMI/Q#\66DOBB>S=X[
M,WDNEQV,U[J B5_)>)F<1% .:\!>&/B%\5O@!^R_K.G7*?%70K0^-[OQE\*-
M2^)=[X(USQ[;W-XT.C>)M*\3KJ5G<WLWA.1)(WL;N^2QEMM7WL6EBA4?I%XQ
M^ 'P<\??\(O_ ,)5X!T;4#X,M)-/\,FW:^T<Z5IDOV?S=)B.B7>G&?1Y?LL'
MFZ3=FXTV0(0]JP>3=FW_ .S3\#-1\(^&? D_P[TB#PMX,,W_  BNG:;=:OH\
MN@I<;OM,.FZGI&HV.K6]M<ELW%JM_P#9IRL9EB<Q1E#VU/FYE%Q;:=N5-124
MU[MI1;=I)73@U;1W2$J,]$Y*246KMM.3;IN[34E:]/KS)IZKH<5^R5K_ (8U
MOX5:C;^%]-\<^'8_#?B[Q;X8U?PAX^\0'Q1JW@W7M$U2XL]4\-66N[YQ?Z/I
MES&T6F3"[O,VP3_29.M?"'AV?Q+\.O\ @GQX@^,7@R^\3ZK\5?&O]DZ/KWBV
M]\3:G=ZK;:#J7Q%AT&:2QFUB^N='T3^Q-"U.ZMK/5/LL"62".^U":5;8N/UJ
M\%^!/"/P[\.VGA3P5H5EX?T"R\TPZ?9^<X:2=VDN+BYN;F6>\O;NYD9I+F\O
M;BXNKB1FDFF=R6JKH_PW\":#X+/PZTKPMI-KX&:RO-.?PPT!N=*DL;]I6O+6
M6WNVG\V&X::4R+(S9+DC&!B%5BIR:3<95*<[/K&#;:;NV[W6EWW;NE?3V4G&
M*<DG&E.%TMI2Y+22M96Y7M;?1):+\./VC?A1XML/!5N!\-KWX??#'4M&\&W'
MC/1O$G[0EGXXNO%&M)\2? 5KH/C/0M)T[7[C5ENUM-2URTUFY@D726BO+*06
M\-S:PS+[C^UL=3\+ZUXF\'>$/$7B7PKHUE^S#\%;72%T;Q!JT4^D2WG[05OI
M#ZC97$]Y/*=3%@XMS?3O-<30JL-Q)+#E#]_6'[(O[..G66O:=#\+-%N+3Q+I
M$>@:M'JE_K^M.^C0W:W\>FV$^L:O?7&C6JWB1W/EZ-+IX,L,#')@AV=??? +
MX/:G;6]IJ7@72]0AM?#&A^#8?MUQJ=W,/#'AK6T\2:'I$ES/?27,T&G:Y&FI
M0232R7!N5!EFD3*G7ZS']W=2?(VVK64KN#N^:I-MKE:5WM9*RT6+P\O>MRKF
M26^UN;K&G'3WKZ+>[W=SX;FM-6_9\^*?Q=T?X37/B*[M7_8__P"%HV?AC5M;
MUGQ+#>?$;2[WQ=8P:W -7O+^YCO=133+);RVM'BM9WC'EVR$G/*+IUG\-/#G
M[(_Q0\ >,?$M]\0/C'XPL])^(D]YXLU;Q"GQ$TKQ)X,\0:YXEFO]+N;VYTRU
M/A[5;*SN;6?1[+3ETMG-O+E954?J(/ _A(>*?^$U_L*Q/BG_ (1N'PA_;3+(
MUT?#5O=W-_#H[*TA@:T2[O+F<*T1<M,X9RI"CSGPY^SA\%O!FNW_ (J\(^ -
M&T7Q+=PZJD&H)+J5U!IDFL!S?OHNFWM]=:7H(NG;_2!H=EI_F1@1$>6 @A5H
MVU4N:RYFDO?M%QM/79.TD[2;:V3LU?L9;)QM=M:OW;RA+W5;KRM-:*S[71^4
M_P .=+LO"'[+/P3_ &AO#GCOQ9XF^-^H?%GPAH:7]WXYUS5AKT.N^-QX;USX
M>W.@SW\VFW%EI/AR2^D%N+#[?:2:4M[+=L(I"S?VA/&?B"]M/'/QG\(6'B**
M[\(_M$:!X7M/C+XG^(SZ!#I9TSXAZ+X5U/X<>"_AMI.I!+^S@BFU+3S>^(-,
MD34;*VU#4I)4EDM]OWU^S?\ L7?#7X*>&/!3Z[X=\/>(OB5X56]FD\6VCZU_
M9SZC=SSL=4L=#O[PZ5:ZF;:40R:FFEQZ@Y,S&X+32,_I?B+]E#]GCQ9JWB/6
M_$?PNT+5K[Q;+-<^(1=7&L&PU&]N'BDFU,Z1'J::1;:N\D*2?VQ9V-OJBR;Y
M$NU>64OI[>FJC;YY)2E9V7PN2?(DI*\$DU'F;6KO"UK0J%1TTKQBW"*:N])*
M/Q-\K7-=ZV5]%::Z_F!\;_AQX3.H_M\ZQ8PWNF^(-3U']FBW;5[36M7>ZM?^
M$KN_A=?ZI>VMM=7]Q81W#ZC*UW:2FS86<B+%:"&W7R:^B+3X0QZ#\8?B5\"/
M /B3Q7H/AOXB?LHZ5XA2"?Q3KVI2:;\0I-<\2Z'9^+;"]U+4+N\L+UFL--FN
MX[*:"TE-M@6ZAW#?:.J?LY_!/6M6U+7-5^'^E7NJ:SHV@:!J]U+=:L!J>D^%
MKO3KWP];7\":BEM=OI%UI.G265U/#)>1_98X_M!C+HW9ZEX*TJ+6+[QUX?T/
M1!\1H_")\)Z1K>JM?)!_9EK<7>HZ9I&H/:-)*NDQZI=RW$S6\#W86:4QLQVK
M6;KWBHIRVBGS6M>,:,5U>B=-N_GMN4L/9MOE6M_=O>SE-OHM6I^=VO0^)_V0
M?B3XD^/?C&[\?ZG>WD>F_#7X:>$_A=J>E>==+:?\+-=&UGQY//&76WN;RR67
M2=,DE:.22":UN(@Z$N#^@]]_QY7G_7K<?^B7KR3X'?"M/A/X0O-+N1I#^(O$
MWB;Q%XW\7W.A6\MMI-SXG\5:I<:MJATZ.X5+DV$$UP;>R-RJSFVBC\Q5;('K
M=]_QY7G_ %ZW'_HEZRJN,IR<%:*TBO):?B[OYFU*+C!<SO)ZROO=]'Z*R^1Y
M#11169H?F[\2?^1^\8?]C!J?_I2]<37Z=Q>&]%5KF2?3-.NYKF[NKN2:XL+2
M64O=3/,RM(\3,P0OM4L<D 9J7_A'M _Z >C_ /@LLO\ XQ7?'&J,8Q]FWRQ2
MOS+HK=CC>%;;?.M6WL^KOW/R_HK]0/\ A'M _P"@'H__ (+++_XQ1_PCV@?]
M /1__!99?_&*KZ\O^?;_ / E_P#(B^J/^=?<_P#,\Y^*^A7WB/X:?V1I^GR:
MK/<7O@Z1[&*,2M+:VVOZ/<WI:-B T45I%-+*#QY2/D'I5&?PUXDD^)VL:EI#
MR:#;W7PZ\/:5:^(#IL.H6D6HV6LZM--;&TEEACN)8K26,;)'41I,C*> *]K
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MCDW%%;"RS"GE4\9.6#IU5AYUOK678O I1K2A5C#DEB54;=.5U!Q5F[K\=O\
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M " ]9_[!6H_^DDU:$'^HA_ZY1_\ H"U'>6RWEG=V;L42[MI[9G4995GB>)F
M/!*AR0#W%3HH1%0=$55'T4 #^5 #J*** "O3/#G_ ""+;_>G_P#1\E>9UZ9X
M<_Y!%M_O3_\ H^2@#<HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*<HS8..EKQ#2Q&/CQK TWR_LI^%_ADZOY'W/MHUO75TS[0%^43?V>,1;L/\
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M@A<:EJ]_JVBW6G?\343^*))/)WRN;:P@MG2PTC;@M'9&,?O(RS>XVXLE\??
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MU!1Q=%=I_P (UI__ $$_U@_^+H_X1K3_ /H)_K!_\70!Q=%=I_PC6G_]!/\
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M6W0XNBNT_P"$:T__ *"?ZP?_ !='_"-:?_T$_P!8/_BZ0SBZ*[3_ (1K3_\
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M);7=G-;W<'F1L4E6.94E7 D5MJX]8_X1K3_^@G^L'_Q='_"-:?\ ]!/]8/\
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MM!M+_4;40+'<2-<1^8MM+YUNEW##-%!?QP2_/%'>Q7"1G[J@<5UX 4!5 "@
M     #   X  X ' %=K_ ,(UI_\ T$_U@_\ BZ/^$:T__H)_K!_\73;;23;:
M6R;;2]%T^0DDKM))O5M)*[[ON<717:?\(UI__03_ %@_^+H_X1K3_P#H)_K!
M_P#%TAG%T5VG_"-:?_T$_P!8/_BZ/^$:T_\ Z"?ZP?\ Q= '%T5VG_"-:?\
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M]8/_ (NC_A&M/_Z"?ZP?_%TFW)MR;;>[;;;]6]1I)*R226R2LE\D<717:?\
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ML1>%M)D/_,+\/QW:Z98JORK!;J%^4"OFO]L;X=ZCX?T"RTWPK\,+R^^ NO\
MC3Q!\7/VI-2\(7,#^,-1LK*?_A)KVTT_2YY/ME_8ZYJEJU[XHAL&$DVG1-9P
M0F.XF6KA"G*JZ;DW'FM&2<8W2;N_>NFVE[L5\4FE<B4ZBIQFHI-I-Q:E*S=K
M+2UDF_>;V6MKZ'Z+Z'K>D^)='TSQ!H5]!J>BZS8V^I:7J-L6:WO;&[B6:VN8
M2RJQBFB=70LJDJ1D"M6N-^'?B/PKXO\  GA#Q1X&E@G\':[X>TK4_#,EK$(+
M=M%NK.*33Q%" !$J6Y1/+P-A4J1D5V58M6;5FK-JSW7D_/N:IW2=T[I.ZV=^
MJ\NP4444AA12$X!)Z $_E7E?@KXR^!_'_P .M0^*7ARZU";PEI@\3M=7%UIT
MUK>J/"-Q?6VL[+&0^:_ERZ?<B#!_TA0A3[XIV;3:3:32;[-WLOG9V]!72=KJ
M[3=O)6N_175_5'JM%<?X \<Z!\2_!?AKQ]X5EN9_#OBS2;36M'FO+:2SNI+"
M]C$D#SVLN9()"I&Z-_F4\&NPH::;3T:=FNS0)II-.Z:336S3U3^84444AA11
M7!GXC^&!\2C\)S/=_P#"8CP?!XZ-M]CD^P_\(_<ZM?:+%-]NSY/VDWVGW*-:
MX\P1A)/NN*:3=[*]E=^G<3:6[2N[*_5]O4[RBBBD,***XCXC?$+PW\+/"&H^
M-_%TUU;Z#I=SH]I=RV5I)?7*S:[K6G:!IX2VB(=U?4=4M$E8<11,\K?*AII-
MM)*[;226[;T2^8FTDV]$E=OLD=O144,R7$,,\9)CGBCFC)&"4D0.I([':PR.
MQXJ0D $DX !)/H!R32&+17(^!O'/AGXC^&K'Q=X0U%=5\/:F]TMAJ*1O'%=+
M:7,MK++"' 9HC+"_EO@!U 8<&NNH::;35FM&GNGV8DTTFM4U=/NF%%%8]EK(
MO=5UC2AIFLVIT=K-3J%[I[V^E:G]LM8[H-H]\S%+];82?9[PHJ_9[I)(6R4)
MH_0?ZFQ56^_X\KS_ *];C_T2]6JJWW_'E>?]>MQ_Z)>@#R&BBB@ HK#M_$&E
MN;E+B_L+66VO;NT:*:]MXY!]EG>$,R/(K+O";L$#&:L?VYHO_08TO_P86G_Q
MZG9]G]S%==U]Z-2BLO\ MS1?^@QI?_@PM/\ X]1_;FB_]!C2_P#P86G_ ,>H
ML^S^YA==U]Z-2BLO^W-%_P"@QI?_ (,+3_X]1_;FB_\ 08TO_P &%I_\>HL^
MS^YA==U]Z-2BLO\ MS1?^@QI?_@PM/\ X]5RVN[2\5GM+JWND5MC/;31SJKX
M!VLT3, V"#M)!P0<8(HL^S^X+KNOO+%%%%(845Y_XJ^).@>$]2BT:XM=<UC5
MWTV?69=-\.Z3/K%Y9Z3 YC;4+V* K]GMGD62.%F):5H90BG8:ZW1]8T[7]*L
M-:TFY2[TW4K:*[L[E/NRP3*'1L'E3@X93@JP((!%4XR45)Q:B]FUH_ZZ=];;
M$J46W%--K=7U7_#75^U]33HKA;OXD>$;#PQJ_C&^U-;/P[H\M_#/J-RGDQ7;
MZ<\D<HTT.P-\)I(G2U\C/VEAF/*_-4FL^/M#T6PT2]>/5-1E\1J'T72](T^6
M_P!7OX_LZW4DD-A&5D\NW@='N'8JL7F(K'<P!.2>GNRU;BM&M4DVO5)IOLG=
MZ!SP_FCLGNMF[)[[-Z+N]$=M17ENH?&'P5I^BZ/KOVC4;ZTUM+^:U@TW3;B\
MOH;?2%5M8N;ZT3$EI!I&]5U)Y.;9V"E6.<=G:>)M(O\ 4K?2[*=[JYN-)AUL
M-#&SP0Z?<R&.UDN)ONPO=LLOV>)OGD6&5L!5R1PFE=QDEKJTU\+M+?L]'YZ;
M@IQ;LI)O32^OO*Z^]:^FIOT5B:3X@TW6;G5[.S>5;O0M0?3=2MKB)H)H9U19
M8I C\O;7,$D=Q:SKE)H9$=<9(&W2::T::?9Z;ZK[UJ---76J"BBBD,**** "
MBJ5O=^?<ZA;[-OV&>&'=G/F>;:07.[';'G;,?[.>]7: "BBB@ HHHH ****
M"BBB@ HHJE;W?GW.H6^S;]AGAAW9SYGFVD%SNQVQYVS'^SGO0!=HHHH ****
M "BBB@ HHHH **** "BJ2W>[49;'9_JK*WN_,SU\^>YAV8[;?L^[/?=[5=H
M**** .Q\(_ZR^_W+?_T*6NWKB/"/^LOO]RW_ /0I:[>@#R?5O^0G?_\ 7U-_
MZ&:SZT-6_P"0G?\ _7U-_P"AFL^@ HK+O=5MK"[L[>ZE@MXKN*\D^T7$T<,:
MM:FU CW2,JEI!<$@9S\AP/0_MS1?^@QI?_@PM/\ X]3LWLF_D*Z6[2^9J45E
M_P!N:+_T&-+_ /!A:?\ QZC^W-%_Z#&E_P#@PM/_ (]19]G]S"Z[K[T:E%9?
M]N:+_P!!C2__  86G_QZC^W-%_Z#&E_^#"T_^/46?9_<PNNZ^]&I167_ &YH
MO_08TO\ \&%I_P#'J/[<T7_H,:7_ .#"T_\ CU%GV?W,+KNOO1J45E_VYHO_
M $&-+_\ !A:?_'J/[<T7_H,:7_X,+3_X]19]G]S"Z[K[T:E%9?\ ;FB_]!C2
M_P#P86G_ ,>JI<^)-'MY+)%U/39!=78MF(O[7]TOV:YG\UL2GY0T"IS@9D'.
M<46?9_<PNNZ^]&_167_;FB_]!C2__!A:?_'J/[<T7_H,:7_X,+3_ ./46?9_
M<PNNZ^]&I167_;FB_P#08TO_ ,&%I_\ 'J/[<T7_ *#&E_\ @PM/_CU%GV?W
M,+KNOO1J45E_VYHO_08TO_P86G_QZC^W-%_Z#&E_^#"T_P#CU%GV?W,+KNOO
M1J45E_VYHO\ T&-+_P#!A:?_ !ZC^W-%_P"@QI?_ (,+3_X]19]G]S"Z[K[T
M:E%9?]N:+_T&-+_\&%I_\>H_MS1?^@QI?_@PM/\ X]19]G]S"Z[K[T:E%8%U
MXET>WDLD74],D%U=BV8C4+7]TOV:YG\UL2G@- J<X&9!SG -O^W-%_Z#&E_^
M#"T_^/46?9_<PNNZ^]&I167_ &YHO_08TO\ \&%I_P#'J/[<T7_H,:7_ .#"
MT_\ CU%GV?W,+KNOO1J45E_VYHO_ $&-+_\ !A:?_'J/[<T7_H,:7_X,+3_X
M]19]G]S"Z[K[T:E%9?\ ;FB_]!C2_P#P86G_ ,>H_MS1?^@QI?\ X,+3_P"/
M46?9_<PNNZ^]&I167_;FB_\ 08TO_P &%I_\>H_MS1?^@QI?_@PM/_CU%GV?
MW,+KNOO1J45E_P!N:+_T&-+_ /!A:?\ QZJE]XET>TM_.34],F;S[2'8M_:Y
MQ<W<%LS\2DXC64R'C&$.>,T6?9_<PNNZ^]&_167_ &YHO_08TO\ \&%I_P#'
MJ/[<T7_H,:7_ .#"T_\ CU%GV?W,+KNOO1J45E_VYHO_ $&-+_\ !A:?_'J/
M[<T7_H,:7_X,+3_X]19]G]S"Z[K[T:E%9?\ ;FB_]!C2_P#P86G_ ,>IK:]H
M:*SOK.DHB*6=VU&S55502S,QF 55 )))  !).*3]U.4O=C%-RD]$DE=MMZ))
M:MO1(::;23NVTDEJVWHDDM6V]D:U%<U_PF?@_P#Z&SPU_P"#W2__ )*H_P"$
MS\'_ /0V>&O_  >Z7_\ )5>9_;63_P#0VRS_ ,+\+_\ +?-?>=?U#'?] >+_
M /">M_\ (>:^\Z6BL>P\0Z!JLYMM,US1]1N1&TIM[#4[*\G$2E5:0Q6\\D@C
M5G16<KM!902"PSG>)?%2>&OLQDT#Q1K0N5E8MX=T:75EMA#MR;MHY(Q!O#9C
MW9W!7/&VN[#UZ&+@JF%KT<33;<54H5:=6FY+5KGIRE&Z35U>ZOJ<]6G4H/EK
M4YTI))\M2$H2L]GRR2=GT=K,ZFBO(H?C/X6O?"MKXHTZS\0W:ZDVK1Z3HXT:
M==;U$Z,774+B#3B_F-86KJ#->!O)6-T=68.N9;SXT>";+1-(UTS:G=0:NFIR
M):6&F7%UJ-A%H6P:_-J=DN);*'0Y'6+4WE_X]Y&"X8FNGV52]N25[N-N5WNK
MW7X/[GV=L?:T[7YXVLI7NMG:S^=U]Z/6**P;7Q)I-]J<6DV<[75U)I,&MEH8
MV>WAL+N1HK-YYQ\D4EX8YFMHF^>1()GP%4%MZH::W37KH4FGL[]- KTSPY_R
M"+;_ 'I__1\E>9UZ9X<_Y!%M_O3_ /H^2D,W**** "OR$_X*4>,M.^'O[0W_
M  3G\9ZM8:YJFG:!\7OBG>75AX:TFXUW7;F-O VEVXCTW2;3_2+Z</,KF*+Y
MA$LDA^5#7Z]U^0W[<]S\7=9_:C_9+U[P/^SM\7_B#X8_9X\<^)_&7BCQ+X5T
M6UO-(UBR\7^#+'3K>ST*>2[B>>]TZ\5X-021%6-XV"DXS73A/XR;M94ZM[M1
MWI3BE=]6Y)+U,,3?V32O=SI6LFWI5@[V2>R3;Z:'TSH_Q5^#/Q);X@_M*:#\
M+/'.F?$SX-_"?Q9I=EXD\>^ ]>\)Z^_A9;*^\5W.@:)!?R^5J-I>:CIXEF6*
MW>87!1 X#!3YU_P31^&WA5_@!X=^/FHVZ>)?BO\ '5[[X@^-O'>N11WWB6YN
M=9O9I[71S?3HTUG9Z-:^380V-L888Q -T>X5^A5A,OB3P];2ZGI%UI\>MZ4I
MO]$U6-5N[6._MMMSIU_$I9!,B2O!<("RAMR@D<U^6?@+P;^U%^P==^*_ WPW
M^%=]^TM^S==ZOK/BSP+8:#XAL=/^)_@:;6]0GU#4/"36>L2):ZUI\5Q-)+I]
MQ$\*1Q2);I&NQ@"+4Z=2G&7))N#BIS5I0CS)PYY<L5:34TFTG;2[2%).$Z<Y
M+FBE--Q@[QG+DM-Q5V[QBXWLW'1=6>U_&KQ7^Q9<?M'_  <UKXD_%+P_X2^.
MGPC\3SZ=X2TV*]N-)O\ 5]6\?6$6AV7AO7I8M-9-:MKHW4<FEZ9-?>5%?3&<
M*'+8\!_X*4>,M.^'W[0W_!.?QGJUAKFIZ=H'Q>^*EY=6'AK2;C7==N8V\"Z7
M;B/3=)M/](OI]\RL8HOF$:R2'Y4-9WQ$\.?M _MR:U\'].U']EJ__9O\%>#/
MC+X-^+'B_P 9_$N_\./X^OC\.]0>]TO0]*TO1O.GGAUB=W2YN+JZV1P+#*BL
M1@:7[<]S\7=9_:C_ &2]>\#_ +.WQ?\ B#X8_9X\<^)_&7BGQ-X5T6UO-(UB
MS\7^#+'3K:ST*:6[B:XO=.O%D@U!)$58GC8*6K>E%1J4DY7E&E74XNI"48)T
MYJ*C*+LN><W:-VU=-[F4Y.4*C4;*56@XR5.<7)\\')N+NWRQBM;).S/LOX1>
M+_@O\?OB'/\ &/1/AEXUT/XD^!_#,O@6T\6?$/P/KG@[68O"FMWW]K76C:2N
MI3"WO+"?4(A<W+) TB3 #S ORU^=M]^T%X-_9Z_X*>_MB>)?&VB>/=7TJ]^#
M'P)WR>!/!NJ>,)M.ATOPO+=W=WJL&E@R6-HL,FZ.:0%9"DJJ,H:_:W1=0FU;
M2--U.XTV]T>>_LK>[FTK445+_3Y)XED:SO$0LJ7-N6,<RJQ"NK $CFOR*^"5
MQ\6+[_@HA\>?B;XF_9I^,7AOX:?&WP3\._A]IWB/Q'H-G%HVFOX%T+4;35;_
M %YUNY/+TC5'18+%UC<S?:H5=0'.,J+B_;N2;@J*BHNHD[*K2ERQDU;:,I))
M;)KS+K*25&S3DZRDY*#:^"<>:23[N*NWV['J'[!=I=_$GXC?M(_M:Z1H&I^#
MOAC^T'K7AA_AMH=_';6-QK>C>%]*-A<?$"[TFW7?I^H>*+MY9'6[/VR2""!Y
MU$A-?/GQP_9^^''P4_;W_8*UOP;I]Z_B'XF?&[XV^*_&/B/6K^;5M<U:^NOA
M]=/;V<NH7.9ETO2HG^RZ78(5@M8%"JI8LQ^GOV1O!GQ5_9Q^*?Q7_9UU+P%X
MEU'X&7?BC6_B'\%OB3:B&X\+>'M \03)?7W@#5)GN7N[?4K'5;FZDL(?*$/V
M1O+BVI$!7S1^T;XZ^-GQ(_:=_9)^*?A_]D+]HA_#?[/?C7XAZKXI:3PU8";5
M;/Q!X8G\/V$NB@:AB=6N2LY+[?\ 1V#=>*U@W[>IRR7LY4)1C::LXNA*-*,F
MW\6R:>JG>_0SFE["'-%NI&M3;]R3:E[>$JC5D[1M=IK1QTO>Y^VE?EE^W9_R
M=M_P3*_[+/\ %C_U7MA7Z+?#KQ=J'CKPAI/BC4_!WB7P#>ZG'))+X5\7VT5I
MX@TS9(R*FH6\,DL<4DBJ)%4.V%89YK\O?VY[GXNZQ^U)^R7K_@?]G;XO_$'P
MQ^SOXX\4>,?%'B7PKHMK>:1K%GXP\%V.G6UGH4\EW$\][IUXLD&H)(BK')&P
M4G )PPRM6ULK0K)WDDKNE.*U;L[R:2L];]C;$.]+1-WG2M9-O^+![)75DFW?
M;J?5/[?_ ,,?#?Q(_95^+DNL016^M>"/">I?$#P=XBCCB75?#?B?P9'_ ,)#
MI>HZ5>,C26LYN-/6!BA =)B""0N,BR\?ZC\5/^"<>J?$75[>ZM=4\9?LD>*M
M>O[>]&V[CN[[X7ZM).+@ #$K/EGX&2V:\7^-.M_M/?MC^#[WX(>$?@3XQ^ G
MP^\9W>G:9\1OB/\ %*_T[2M;7P>EW;76NZ9X9\.:=+=:@U_J<$,NG1W4Y$(6
M1I"/*<U]-?M&V.I_#O\ 92\7?#[X<?#CQC\1[O4?AMK/PG\.^&O!5E#?ZM;?
MVWX,UC0;#5KN*66!%TNRG^SB_F5MR&XCVH=W%)<L:-.3BY^WY[*49<D;13NT
MVDY-7Y6[KENUJ2WS3J5(J7)['D;<9+GE=M632;LG:Z6M[+9'Y!_#3]K+P'J'
M_!.KX3?LJZ=\-/B1XL^+'Q4^$EI\*O NE:GX#O+'P5X@\3WVF^1]OLO%VI@:
M++::'&YUP788-LLO-MP9%6OW6^ G@35/AA\%?A;\/-<U&?5]8\&>!O#OA[4]
M2N91//>7VFZ;!;W,LLP"B1C*C+O"@,%!  K\L/AY\ OBI\5O^";_ ((^$U_\
M,O&/PF^/_P"SM9>$]2^&TOC6RATRYN_'_@>VM-4M=0T62&Z8R:+JJO=:',99
M$2XE+Q3(8UK]$? /QF^(5]^SY;_$WQE\#OB3I/Q TG3(8-9^%*6%G/XTU35K
M2[MM+O9=%M8KDVUS:W4CRZI:2&90^G(TN 0 :Q/++FC3LKXBHYKG4FY2?N23
MT2C*-]KI-/F>UIP]TXN=W^X@H/E:2C%>_%K5\ZEO>UTU9;GQQ_P27TFPU_\
M8QUS0M5MXKS2]:^*OQUTK4;29%DAN;'4/''B"TN[>6-PR/'-!-)&ZL"K*Q!!
M!Q4G_!/+QHOP=\)?M'_LV>/-0N(9_P!D_P ?>+YK2]U5H8)+KX5ZDU[XF\/:
MS;VZMB#28K#[1:6&/W9@M%V$# I?^"5.F_%7X<_"+6?A'\4O@C\2?AKJ=AXS
M\>>-(=;\6Z9;V6BZE:>+_%VJ:M8Z?831W$TDM_;6EQ&UVA550G@G->2?M_?L
MU?M#Z[^T+HOBG]G+0M8NO#_[2?P_MO@?\?M3T00VT/AK0;#Q'I-T?&6J7+8
MFC\*G4=$L0ZL)4N+^,G?)&1I/EJ8C$TI3C&%2?/&7,N5.+O>][:TW->;LNQ*
M<H4</5C&4I4X*$H*+YG&44FK-75I*#OVOT;/I'_@G#X:O?$?A+XH_M2>);5D
M\4_M/?$;7/&]B]Q)#<SV7P^M+N73O ^EV]U&H8:<-*@2_M[8N4A:[? R23\W
MQ_$KQW\-_P#@J5^UY=^!?@OXK^,USJ?PD^ $%_I_A76-#T>;18;?PP[PW5W)
MK<L4<T=V\LD420;G5H7+@ K7[%^!?"&C^ /!OA?P3X?M(;'1?"NA:9H6FVMO
M&D,,-KIMI%:QJD<:JB B/<0J@98G%?CKX(\=_&SP5^W+^TC^T#>?L@_M$7_@
MKXF^"/A?X/\ #R6'AJPDOC>> M.N--U*\GC:_"BSNY&66R<'+Q,&8 \5G3E[
M26)ERIQ=+EA"4N56]K2<()\T7I"#V?V?,N<>2&'C>2<:B<Y1CS.[IS4I/W6M
M922NUU\C]2/@5!;W?AC5_&5Q\&[CX(^*/'GB;5_$/C+PMJ,^EWFLW^N"<V/_
M  D&KWVCO)97=UJMG;6]PDBMYBP-''* ZFOQX^ W[77PQ_9>^-'_  4>OOB5
MH?Q'O=,?]JGQCK4^K>$? NK>*-$L+1++3[(1ZQJ=@IMM-EDG0+LN>%BDCF?$
M;9K] /@A\=?VD/'OQ4_:!U;QW\#?'O@+X+^%_ O@_5_A!X?\2^%[33/&WB3Q
M/#IVK2^-=*@NHK^==4N+J]L[./2;:1(%A^V6Z&1A(2/EW]C+P=X]\2?$3]M[
MPA\9?V=/BEX'\!_M/?$KQU\0=-U;QKHMK:Z*OAK6]+TW1UT/4)8[J5H]>G$L
MUS:Q(NU?LKR!U9 :<(J*Q'M4G%PI-QA45TG.G/E4I<S<H1W2OJFK]0FW)T/9
MW34JB4ITY6;491YI**BDIR>^GQ72/I'_ ()U_#SQ-X3^%GC_ ,<^(]!N/!D'
MQQ^+/B_XN>&? ,\EF5\&^%?$]PDFAZ<D%@/LME)>6<<>J75I$6$-S>2(3N!%
M=CXW_9-\2ZU^T+K?[1?@?XW:IX&\5:WX,T3P/_9M_P"!/#WC;3]&TG1FFE8>
M'9M6O+.YT?\ M6XG>ZU2.!F6ZN/G<X"J.7_82M?C7\-O">N_LZ?&#P3XF@A^
M#FHWFC^ OBG=B&;POX]\!27]T?"T>FWHN);J74](TE;>RU)+I5D#QK(2=XK[
M[K&K4G&M4E&47S75THSC*F[..CYEK%1O?WN^MS2E",J-.,HOW;-IWC*,TGS;
M6ZMVMI9Z:6/BC0_@/\=?!FM64ME\<-9\9_\ ":_&/3OB#\4O$6HZ=I_AQ['P
MCH/@Z/0H/ _A?0K6YU*WM[+7-5M=/O\ 4&MVA \J]+A7N5<[?CO]E[Q/XUE\
M8Z7%^T7\6M#\"?$"ZU:;Q1X0MI=)NIDL]:54O]'\,>(Y;>/4?#.DRPM<0"VM
MXKITBN76.9-JD?7E%9^UG>_NIZ:J$=;--.UK)JR2LE9)6UNW?LH6:=VGT<I?
M-7O>SU;3;W9SGA#PIH?@7PMX?\&^&K--/\/^&-(L=$T>RCQMMM/TZW2VMH_E
M"@D1H"S!1N8LV,FNCHHK-MMMMW;U;>[?=EI))):)*R79(****!C7^XW^ZW\C
M7X_?L[^"/C3J?[(_C?5?#GQSM/#'A=I?CI)'X3D^%?A_7)([>+6/%'VJV/B"
M[UFVO'-WMDQ.;4/;^8-BOL&?V#(R"#T/!KB?#OPX\#^$_"=UX%\.>&]/TGPE
M>C61=:%:B;[%./$$MS-K(<23/+_Q,);NY>?$HYF;9L& -85.2,E9-RE!ZQC)
M6CS7TDGJ[JSMWU,YPYI1=VDH3CI*47>3@UK%K3W7=/RT/RTT?QS?_ ;]G/\
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MFL7NLMI>H3QW%S8WFHZEJ5Y=ZC;>;%&;>/4);H6:(L5G]GB&RO8[[_CRO/\
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M[+03(Z&LRR\1^+? >M+%$;:T>\M_!>H/H5Y:1W.HZ_9Z[J[^'[;1]/O'F22
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M%?HK_P *G^'7_0IZ9^5Q_P#'Z/\ A4_PZ_Z%/3/RN/\ X_1]>I_R3_\ )?\
M,/JL_P":'X_Y>O\ 3T_.JBOT5_X5/\.O^A3TS\KC_P"/T?\ "I_AU_T*>F?E
M<?\ Q^CZ]3_DG_Y+_F'U6?\ -#\?\O7^GI^=5%?HK_PJ?X=?]"GIGY7'_P ?
MJG=_"3P(TEB;;PMIBHEX'NQF<;[7[+=*4YG^;_2&MVP,'Y<YP#1]>I_R3_\
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M&OC5J.B^'K.VT[1]2^'&BZKJ%C81QV]D-2M]7U.PM[S[+"J11W-Q9PQQRS!
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MBBG=I)\VBOJN;31N*DTE=V2ONF?5@(8!E(96 *L"""",@@C@@CD$<$4M>2?
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MCM"Q*L L@4DJPQD&N&^,&J7VB_##QSJ>F^>+ZV\/7XMWMI!%<1/.@MS/#*Q
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M+C9MJ4;JZL])2@[V;6\6UY-=2Z<W-.ZLTTG9W6L8S5MNDDO5,****@L****
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M G)J:JUZ2+.[()!%M.00<$$1.001R"#R".E '&_\(E<_\_<'_?$E'_")7/\
MS]P?]\25S/VJY_Y^)_\ O])_\51]JN?^?B?_ +_2?_%4 =-_PB5S_P _<'_?
M$E'_  B5S_S]P?\ ?$E<S]JN?^?B?_O])_\ %4?:KG_GXG_[_2?_ !5 '3?\
M(E<_\_<'_?$E'_")7/\ S]P?]\25S/VJY_Y^)_\ O])_\51]JN?^?B?_ +_2
M?_%4 =-_PB5S_P _<'_?$E'_  B5S_S]P?\ ?$E<S]JN?^?B?_O])_\ %4?:
MKG_GXG_[_2?_ !5 '3?\(E<_\_<'_?$E'_")7/\ S]P?]\25S/VJY_Y^)_\
MO])_\51]JN?^?B?_ +_2?_%4 =-_PB5S_P _<'_?$E'_  B5S_S]P?\ ?$E<
MS]JN?^?B?_O])_\ %4?:KG_GXG_[_2?_ !5 '3?\(E<_\_<'_?$E'_")7/\
MS]P?]\25S/VJY_Y^)_\ O])_\51]JN?^?B?_ +_2?_%4 =-_PB5S_P _<'_?
M$E'_  B5S_S]P?\ ?$E<S]JN?^?B?_O])_\ %4?:KG_GXG_[_2?_ !5 '3?\
M(E<_\_<'_?$E'_")7/\ S]P?]\25S/VJY_Y^)_\ O])_\51]JN?^?B?_ +_2
M?_%4 =-_PB5S_P _<'_?$E'_  B5S_S]P?\ ?$E<S]JN?^?B?_O])_\ %4?:
MKG_GXG_[_2?_ !5 '3?\(E<_\_<'_?$E'_")7/\ S]P?]\25S/VJY_Y^)_\
MO])_\51]JN?^?B?_ +_2?_%4 =-_PB5S_P _<'_?$E'_  B5S_S]P?\ ?$E<
MS]JN?^?B?_O])_\ %4?:KG_GXG_[_2?_ !5 '3?\(E<_\_<'_?$E'_")7/\
MS]P?]\25S/VJY_Y^)_\ O])_\51]JN?^?B?_ +_2?_%4 =-_PB5S_P _<'_?
M$E'_  B5S_S]P?\ ?$E<S]JN?^?B?_O])_\ %4?:KG_GXG_[_2?_ !5 '3?\
M(E<_\_<'_?$E'_")7/\ S]P?]\25S/VJY_Y^)_\ O])_\51]JN?^?B?_ +_2
M?_%4 =-_PB5S_P _<'_?$E'_  B5S_S]P?\ ?$E<S]JN?^?B?_O])_\ %4?:
MKG_GXG_[_2?_ !5 '3?\(E<_\_<'_?$E'_")7/\ S]P?]\25S/VJY_Y^)_\
MO])_\51]JN?^?B?_ +_2?_%4 =-_PB5S_P _<'_?$E'_  B5S_S]P?\ ?$E<
MS]JN?^?B?_O])_\ %4?:KG_GXG_[_2?_ !5 '3?\(E<_\_<'_?$E'_")7/\
MS]P?]\25S/VJY_Y^)_\ O])_\51]JN?^?B?_ +_2?_%4 =-_PB5S_P _<'_?
M$E'_  B5S_S]P?\ ?$E<S]JN?^?B?_O])_\ %4?:KG_GXG_[_2?_ !5 '3?\
M(E<_\_<'_?$E'_")7/\ S]P?]\25S/VJY_Y^)_\ O])_\51]JN?^?B?_ +_2
M?_%4 =-_PB5S_P _<'_?$E'_  B5S_S]P?\ ?$E<S]JN?^?B?_O])_\ %4?:
MKG_GXG_[_2?_ !5 '3?\(E<_\_<'_?$E'_")7/\ S]P?]\25S/VJY_Y^)_\
MO])_\51]JN?^?B?_ +_2?_%4 =-_PB5S_P _<'_?$E'_  B5S_S]P?\ ?$E<
MS]JN?^?B?_O])_\ %4?:KG_GXG_[_2?_ !5 '3?\(E<_\_<'_?$E'_")7/\
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M]JN?^?B?_O\ 2?\ Q5 '3?\ ")7/_/W!_P!\24?\(E<_\_<'_?$E<S]JN?\
MGXG_ ._TG_Q5'VJY_P"?B?\ [_2?_%4 =-_PB5S_ ,_<'_?$E'_")7/_ #]P
M?]\25S/VJY_Y^)_^_P!)_P#%4?:KG_GXG_[_ $G_ ,50!TW_  B5S_S]P?\
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M!TW_  B5S_S]P?\ ?$E'_")7/_/W!_WQ)7,_:KG_ )^)_P#O])_\51]JN?\
MGXG_ ._TG_Q5 '3?\(E<_P#/W!_WQ)1_PB5S_P _<'_?$E<S]JN?^?B?_O\
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M7/\ S]P?]\24?\(E<_\ /W!_WQ)7,_:KG_GXG_[_ $G_ ,51]JN?^?B?_O\
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M;IR3DDX24>;9)\R<=4TU=6VN?LA17X)_LQ_M!^.M9_X*!>)/B/KOBP7OP/\
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MYSU,0J<N7E;LD[WMO\F?J#17Y??\)!KW_0;U?_P97O\ \>H_X2#7O^@WJ_\
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MI9MIZ_:9"H24J$KQ3IV51*[4N6$H1DG9/F][6ZU6G17_ "P_:3\$_"?XN?\
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M"A:2:2M**M*U]).VR;^:/^">7_)C?[*O_9$O O\ Z9X*\W_X*NWMG;?\$_\
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M]'_Q+1XC?\_>'/\ PYXG_P"=Q^X%%?A__P -Z_M ?\_OA/\ \)J+_P"2J/\
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M&72/_ 6]_P *Y?\ X: ^(?\ SWTC_P %:?\ QVC_ (: ^(?_ #WTC_P5I_\
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M2IMMJINN9VDKJRC'F3O=*T;.WGK9M'YI?"SX/ZM:2?M?6/C+]G_XP>)?A_\
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MQ[*FTH^TT:F]&DY*3E?5;Q3D[)II-7WO?Y,^"'@1=>^,?@WQEJOA3]K.74_
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M^?32_P#P:0?_ !->Q:A\<](\*:QKN@W.AZE=S6.N:JCSP3VJ12%KR5LJLAW
M#..:K?\ #2V@_P#0M:O_ .!5E_C7HQJ8M1BHTHN*BK/NK*WV^J7XORMQ2CAN
M9WG*]W??>ZO]G^M>VGDW_"@?B+_SZ:7_ .#2#_XFC_A0/Q%_Y]-+_P#!I!_\
M37K/_#2V@_\ 0M:O_P"!5E_C1_PTMH/_ $+6K_\ @59?XU7M,9_SZA_7_;_]
M7?E9<F%_Y^2_'R_N?U=]M/)O^% _$7_GTTO_ ,&D'_Q-'_"@?B+_ ,^FE_\
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MU7M_@5\0+I9'BM=,(BN+BV?=J<*_O;:5H90,CE0Z,%;^(<CK7L/_  TMH/\
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M1?\ GTTO_P &D'_Q-'_"@?B+_P ^FE_^#2#_ .)KUG_AI;0?^A:U?_P*LO\
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M_!?=_P#QFC^P]:_Z ^J?^"^[_P#C-?J)11]>?_/M?^!/_P"1#ZHOYW_X#_\
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M  '_ .V]?Z6O\\WQE\)^*;KX@:M):^&M?N8Q;:6I>#1M1F0,-.MR5+1VS*"
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M:W65;FXN(9'NCGUO4H;Z^^)WPLLI"L^I>&_#'B'5/$=U%]V&/4H=*T^VB<\
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MEZ;<7MM#?ZE'8"%KZ2PLY)5N+Q+);FW-VUO'(ML)X3,4$J;@#0HHHH ****
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MZ:A3G>]]O?M:UTUN[GM5%%%<YT'8^$?]9??[EO\ ^A2UV]<1X1_UE]_N6_\
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MFEZ[H_@'38[&QCTV2333!8V=]K#:[=V%O9VJVLL165I@#Y'\;?&S_@H+X$^
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M .-T>SEWI_\ @VE_\GY_GV8>TCVG_P""ZG_R)V%%<?YWQ=_Z)&O_ (7WAO\
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M[*]KV3GI?2_X[,2E!-M1DF[7:I3N[;7?)K;H=A17'^=\7?\ HD:_^%]X;_\
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M_A?>&_\ XW1[.7>G_P"#:7_R?G^?9A[2/:?_ (+J?_(G845Q_G?%W_HD:_\
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MWR8N:%T^65TVT_93NF]VGR:-]>YV%%<?YWQ=_P"B1K_X7WAO_P"-T>=\7?\
MHD:_^%]X;_\ C=+V<N]/_P &TO\ Y/S_ #[,?M(]I_\ @NI_\B=A17'^=\7?
M^B1K_P"%]X;_ /C='G?%W_HD:_\ A?>&_P#XW1[.7>G_ .#:7_R?G^?9A[2/
M:?\ X+J?_(G845Q_G?%W_HD:_P#A?>&__C='G?%W_HD:_P#A?>&__C='LY=Z
M?_@VE_\ )^?Y]F'M(]I_^"ZG_P B=A17'^=\7?\ HD:_^%]X;_\ C='G?%W_
M *)&O_A?>&__ (W1[.7>G_X-I?\ R?G^?9A[2/:?_@NI_P#(G6RQ13Q20S1I
M+#*CQ2Q2HKQR1NI5XY$8%71U)5E8%64D$$&N2T+P!X/\-SW=SHNA6MI/?0&V
MN7:2YN]UJQ9GM8EO9[E+:U<L?,MK98H) %#QL$0*>=\7?^B1K_X7WAO_ .-T
M>=\7?^B1K_X7WAO_ .-TU&HDTI12=KI5J:3VM=<^MM-]ODQ.4&TW&3:V;I5+
MJ^]GR:7\A_A[P)X1\*75U>^']#M--NKQ%BGGC:XE<0*[.MO ;F:86EL'8L+:
MU$,&[!\OA<=;7'^=\7?^B1K_ .%]X;_^-T>=\7?^B1K_ .%]X;_^-T.$Y.\I
M0;TU=:FWTMJY]-/3Y,%*$591DEV5*HE]R@=A17'^=\7?^B1K_P"%]X;_ /C=
M'G?%W_HD:_\ A?>&_P#XW2]G+O3_ /!M+_Y/S_/LQ^TCVG_X+J?_ ")V%%<?
MYWQ=_P"B1K_X7WAO_P"-T>=\7?\ HD:_^%]X;_\ C='LY=Z?_@VE_P#)^?Y]
MF'M(]I_^"ZG_ ,B=A17'^=\7?^B1K_X7WAO_ .-T>=\7?^B1K_X7WAO_ .-T
M>SEWI_\ @VE_\GY_GV8>TCVG_P""ZG_R)V%%<?YWQ=_Z)&O_ (7WAO\ ^-T>
M=\7?^B1K_P"%]X;_ /C='LY=Z?\ X-I?_)^?Y]F'M(]I_P#@NI_\B0Z5\./!
M&AZP^OZ3X=LK+57DNY1<1-<-'!+?R>;>26=G).]E8O<.29'L[>!B&9<A&93-
MIW@#P=I.MS>(].T"RM=9G-RS7D?G$1O>,'NWM;9Y7M+.2Y8 SR6D$#RY.]F#
M,">=\7?^B1K_ .%]X;_^-T>=\7?^B1K_ .%]X;_^-U355WO.+NDG>M3U71.\
M]4K[/;7LR4Z:M:#5G=6HST?=>YH_,["BN/\ .^+O_1(U_P#"^\-__&Z/.^+O
M_1(U_P#"^\-__&ZGV<N]/_P;2_\ D_/\^S*]I'M/_P %U/\ Y$["O3/#G_((
MMO\ >G_]'R5X'YWQ=_Z)&O\ X7WAO_XW7M7@F379-!@'B+0?^$=U))KE7TX:
MI9ZN!$9G:*7[98@0'S%8'RP-R=&YJ7!Q5VX_*<)/[HR;_ :DF[)2^<)Q7WRB
ME^)UU%%%24%%%>5?'/XL>'O@3\&OBA\9O%4R0Z!\,? OB;QKJ(=UC-RF@:3=
M:A#I\)8C==ZG<PPZ?9Q+EY[NZAAC5G=5(!5\%?'[X,?$7XB?$?X2^!_B/X8\
M3?$GX17%A:_$KP;I=\9M;\'3ZHLC6":O;-&@C%SY4J*\+S(LT,L$C)-%)&OK
M]?R._L;>.?&'[/\ ^TK^Q'\<?B+\(?VCO!/B7]JQ/BC\+_VI/B)\4OA5?>"_
MA]K/C[XP>(M5^,OPGGL/$]SJ5S%J0T[5KCQ3X?T97MH@]M?V<<112B5]I_&3
MXC?M#?";XQ>+/BE\<OBA^U#X<^$TGQS;0OA_\8_V<O&'P^^)W[-WA;P[+\0-
M \)>$? WQ@^ MK9GQ+X>N[VWURW\.>*O$>KZ]\OB,7NIQVD+VT<! /Z#Z\<^
M+7[0/P:^!<W@JV^+/C[1_!EW\1O$47A/P-8W\>H75_XF\02M HT[2[#2[*_O
M)FB-S;FZN6@2SLUGB>[N(4=6/QA^UGXP\<>,?VDOV2_V7M%^,GB[X*^!_C+X
M7^+7CGQ1XW^&]];^&OB+XJU+X=V/A/\ X1_P9X8\27UAJ5GH<&H+XDU#6]6B
MAL[B_N[?3H((46".9Q^4/P@O/B)^T)^VO^P?J7Q'^-WQ7US4/@[X]_;\^$VB
M>+O#WB2QT?3OB3X<^"7CGP3H7A_Q+KMK#I%S:ZEJGBC2GBT[QO?V3V\6O"PM
M_L_V14+. ?TM_$'XC>!OA3X&\1?$SXB^)M,\(> _"6E2:YXD\3ZS*\&F:1I4
M6P/>7;K')*$W21HJ1Q/+))(D<<;2,JFSX$\=^#_B=X.\-_$'X?\ B+2_%W@K
MQAI%GKWACQ+HMRMWI6MZ/J$2SV6H6-PH EM[B)E=&(4X.&4$$#\D_P#@K5\3
MKN_U']E;]E?1/"?Q*^(4?Q>^+MC\3/B]X/\ A#X2F\=^,[CX&?!&XL?$FK0R
M^'+:ZM)6TC7_ !S<^#M.GN)9DADAM+^$B11*H^ O@I^TCX_^"?[!'[5/P0\&
M1_%'X&^,?V3/VK_AGX9\ V'Q!\/?\(7\0='_ &>?C!\<O 6L^"A?Z#J$FH+I
MVD/X$\5WOA1Y6D>+R+>Y5)(G7Y #^I6BOY^?V\OVQ/CE\*/VA_B3X"^&OQ3G
MT'1+K]F_]E>SED1].O['X8ZW\;/VB]6^'?BCXH?961FL_$$?@^ZMH]'O+^3[
M%;WATC43 \41,E?Q;XV^._[//Q+_ ."B/PNT#]K7XH?%K0OA5_P3CT?XV?#5
M?'6N:-XE\=_#;XC:F/BS)>:_>:Y9:59->7>HR:%INK:(E[9+'8:-'IUI'%/!
M"MQ* ?T'5C:_XBT'PII5QKGB;6=-T'1[5[>.XU/5KR"PLH9;RYBL[2)[BY>.
M(2W5W/!:VT>[?/<310Q*TCJI_%GXH?M&_'7_ (2;]A#PU\.OC/H^@^)_BW^Q
MK^T1X^UF7Q7J6CCPIK/CS0O 'PWN? GC/QNLYB0:-I/B35=2GEO?/M-/ GOE
ME<K&PC_)/]NJ_P#BQ;?"W1?@S^T#\9/V]_A%\2?&7BWX1ZY;Z'XH^(7@+XM_
M CXU6NC?%_X-/JFO_#;XK^%-"MK/P8WA>;QBFIQ>&A;W<R7$>EB[NG72E%R
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M'++5]2U*S6U>.::]M+.6SMTF@^T3Q&>$/Y?KW_!0_P#8K\->#/"GC_6/VAO
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M#X L[OPIX=\9>'_%6M?'+6KJU\!#3_%>D>+-"C\.6*'[=J&H/J5DJI+IDOF
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MQ+\+O"_B;XB73:AI2W?Q(O+K]G[PI\;[R70&(2.PGN+'Q$FE.VI*B?VE%-.
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M_$WQ)\/M5LKJ[@MM,\ ^(A\2+#3KCQ3:,=->71;D:C;R1P0 ?TAT4 ?@1?\
M[+OC;X._LE_L.^&/''@[]JE/C/\ !+X0>)?!5K\7OV-[K2?%?COX1^(/%.E^
M'WF\+:IX+OHI9_&G@B[GT;3Q>S1O;V4<OAJVL+NZB35$8?%W@[]G3]L;2?CY
MKW[3W[2OA#]KR]\,_%;X8Z]X \*:G^QEX0\*?##XS1:=X?\ B+XPUS0V^/\
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MVN?$_P"T]X@@TGP[XKM_C!8Z/??'*;XZ:/\ "O3+B<?\(M+IMYXJLM"N-?\
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M\%^*+"'4] \1Z'=+=Z=J5E,,I+#( KHZD&.:WG2*YMIE>&XABF1T7\[?V?\
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M](U!(M&NM3AU"[6W$ME;W$4T#R@'P#\1_P#@F]^U(GAC]JWX9_!3XN_!/2?
M?[9?P@\+^"OB5J_Q \/>,;_Q?X&\6^'?@?I'P3O;_P "6FC*=%U;P]XATCPS
MHMS/'XAFM]1TF6]U66R6:2&S5]?]I#_@G'\;/C?X<@^&[C]D_7?#A\%^%O#&
M@_&/Q%X3\?\ @S]I#X,WVF>!QX&U#5OAOXW^',EE<^(I=)2XU7Q-X6B\6ZW:
MV)U/4(])U?3Y=+L()&^^?C+^W5^R3^SYXO;P%\9/CCX3\"^*X;+3-1OM*U&'
M7+P:/8ZU-Y.EW7B"_P!(TG4=,\.Q7K%9(6UV\T_-L\5XP6TECF;G/BI^WK^S
M'X"O_B#X"B^/'PPTOXL^"_#&N:S>:+XG/B>ZT+PO+IW@!?B/;ZCX\O/#6D7T
MFB^'1X3N+3Q%<79GAFNM(:7^S#<7B&!0#XF^$_\ P3*^,_PXOOAEX9U#XM^!
M/$OPY^#W[=?BO]KSPKK%[8^)W^)/B+2?'OACXMV/B;PQXND>/^PSKL'B'XD6
M]WINJ6$CV]QI]E=B]VW4D(/(?MC?\$L_CE^T9XX_;!N_#WBW]F[4-!_:J\(V
M_AG1?'_QI\$^*O'OQ6^ 6GVWPVT_P?)X9^%6CW"WW@/2M%U+6M+.KW.N646D
M^);9M=U.^$U[J&GZ6H_17Q?^WO\ LG_"W4/#OAGXH_';P+H'BW6= \/:Y-;6
M$/B34M(MK7Q%##+IU_>ZG8Z-?6GA[3;Y94O+63Q-=Z7*FERP:A=+%:2+.W4+
M^VI^RJ_Q9L/@=%\<? \WQ0U2ZM-/L/#5O>75Q'<ZI?Z8-9LM'3Q!!:2>&1K=
MWIC+=V^BOK*ZK+&RJEF9&"$ _.#7O^"8?QNOK;XX>$M,^)OPKA\"_&SQ5^QC
M\2[^XO=-\6OXIT3Q[^S!<_!"R\0V5HL,7]EW/A;Q;H/PCFDTIY674[#5]4A6
MY0V<4C5]$?&S_@GYJ/Q8_;9^!_[2=MXYTG2/A9X1TWP[J/QJ^$TVE7,LWQ5^
M(7PGC\6+\"_%/VV+%I"/!DOCW7[K45O0\]Y/H7@KR3LT8*/<1_P4%_8Q/Q!L
M_A8O[0?@5O'=_P".-2^&D.B(^KND?Q!TC7+_ ,-W_@V^U==+.AZ;XCAUW3+S
M3(]*U'4K6[N;I(EM8YUNK5IOL?KTH _%WP5_P34^(GPE^)/BS3OAUIO['6M?
M!CQA\>M<^-2>-OBM\#+/QK^T9X+T_P 8^*7\=>+O .@ZC=:*_AK6[)O$%SJ>
MG^&?$>MZK'J_A_1-1A>WC>[TFS1_V?C01QI& H$:*@"J$4!5"@*B_*BX'"KP
MHX' I]% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2^#O@3XI_#OQM;:;XN\;^!=<^(7@C7H?B;X?NKKP9JOA/7= TB&2[U6RD/\
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MB+\"?CMK?Q1T;QMX@T'2@T^J_#R6YUZRT[Q?#I<<^L:?X:37M2MK>:>&UC8
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MXIZAX?L+D7&KP^&8%8ZJ9M&@1KJ,%^<^ 7[?/Q^\?_&']O1]5^!&O^+OA?\
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M.%L\D\MS;R^"[F^>]5WLKBUO[40,S)(: /Q1_:Y^%GQS\)>#_P#@K+\'+?\
M9 ^*/[1^J?MO:!:>,O@GXN\%:#IOB#PG?.WP3\)^ H/!OQ UJ]O;=O!FN_#3
MQ)X(NM7\-6%U%-%K"OH)TF2&_P!09U_1[]M?X&_$SXM?L$Z;\._ _AV77/&_
MA6Z_9T\>:A\.Y)H+:?QMIGP=^(WP^^('C#X=YN2;62\\1Z)X6U31K6SN2;>]
MU"2WLI3Y<[&ON+XB_%7X??"O2UU'QSXQ\*>&)+RWU%]"L/$?B;1/#UWXEO=.
MMQ/)I>@QZQ>VC:GJ$C26\*VUFL\HENK=6CS*@;Q7X)?MA?"+XM?LY?!']I'Q
M%XA\.?!SPS\=/!&A>-?#.D_$OQEX8T*[@BUS3K?4ETDZA?7]EI^HW]G#<Q"Y
M_L]Y%&Y7 "NI(!^>_P <-2^)GQRO_@?^T!X+_8B^*N@^'/V;/VF/!'Q&\<^$
M?&WA+1?#?Q=^,6@K\)/&/P\OM=\*_#N&YDU+Q!J/PJU#Q3H<_AQ?$%\[:M9:
M3<2>'3:MIL&/ $_9@^-7Q5^-_A7X_P!Y\!/&'ACX>_$O_@JCX,_:'M?AOXOT
M2TL/$W@?X=>!/V4O$7PN?XG_ !!\,-<31^&-3\1_$71[+6EM#)<7L,VJ:-?7
M!-[/+(O[[>,/BO\ "WX>V^F77C[XE> / ]KK:R/HUSXP\8^'?#-OJZ0K$\S:
M9-K6HV4=^L23P/(UHTH19HF8@2(3G^'OB78ZSJ'Q#-Z?#>F>&/ TVGRP^*X?
M'7AG6++4M%N_#.G^)+G7-6M;"Y,W@ZTLXKV953Q!)$UWI]LFN0/_ &9>6\A
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MULFEZU>SZCHMR]Y/!XQO;>[T@6$GA[P_-/JNV:YOM@MM,O-H!ZS17#7/Q/\
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M6E6=_+_PD^LN-+M=2U3P7:3V$S:IK/A:/5(DMX9?(F:9HE?+US_@HO\ L;>
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MU^S?X \/:]83Z7K>B?"'0]*U;3;I0MS8:C8^%8+:[M)U4L%FMYXWBD 8@,I
M)K^<?]@_P7\2/VC?V4_^"=7P@\$_L\^//A&?@A\2_$OQF\4_'ZZT;3=+^'=]
MX4E\+?$?0(9/!OBVRN!=>(_$7Q/U3QGH^H>)M%@MX;S31I=\=5EGN[6!J /Z
M%_!7[8W[,7Q%^*>I_!3P3\9_!_B+XGZ3+J]O<^%K&>]\V>Y\/SK;ZY:Z3JD]
ME#H>NW6DS,$U"VT/4]1GM,,TT:*CLORI\=_^"MO[(7P7\?\ PS^&5K\1=)\;
M>+_'/QY3X$>(K'P]%KEZGP[URVB\31ZU<^))K/1;FW-QI6L>&VT&?1[>X;4A
M>:A;7A@.G1S7(^)O@7\%?CQJ%I_P3G_9MU/]G'QO\,O$W[$7Q=UOQG\7/C1?
M:/;V?PLUSP_HG@;QSX+:;X;>-A=/<>-K_P"*NI^*M*UK4K0VT,\,%C<W&K/-
M=P0O62/V;/C;\//"/AOQ]'\"O'FKW_A#_@L/\7_VBO$WAGPEH$&I^-?$7PG\
M5WWQC\.:'X_TK2X[J%M8L%L/%'AN[4F=+A=%;S50+;E  ?L-H_[5GPITKX9_
M$+XL_$?XM?"JS\#>!?B5XM\!W_B?PS>:])IFEWNA^)KCP]:^%M7M]3LQJEUX
M]M;F)=.UK2=$L[R)]6CN4TQ)K>/>*\O[=7[(L'PST+XPW'QY\#6OPX\3>*KK
MP+HGB2ZN-0MDO?&EE8:KJ=QX3.F3V$>M6OB-;'1=3N(]&O--M]0N%M2EO;RR
M2P)+^36G?L[?'[PKX T/XG7/P/\ %/BN/X2_\%3?CS^TOK'PF:P2;QGXR^$G
MC/Q!\4=*T#Q7X,\.O<_9/$&LZ9'XSTCQ9H^D7,L<\\-M--:-#>P1$8%S^S'\
M:OBY\:M$^/UQ\ _&7A?X>_$W_@I[\-?CQ:?#;QCH=II_BCPA\/OA[^S9XA^'
M-U\4/'_A9[B>/PU?:_X\TVRU9+9I+F]CDO\ 2KVX+74TCJ ?N=\$/VB/@K^T
MAX;U+Q;\$?B%HOQ!T'1M:NO#NLW6E)J%K<:/KMFD<MQI6K:7J]EIVJZ;>I#-
M#.L-[90-+;S17$/F0R([<;JO[97[+^B?&!/@)JOQH\'V7Q;>^BTK_A$)9KXR
MQZQ/8-J<.ASZO'8OX?M]?FL5,\6A3ZM'J\@Q&EDTI"'Q+]EKX6^.O!'[7/\
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MDUN]C\)V$NC6RWGG@I;P.QCVG)YK2_:7_:W_ &L/@';?$/XAP_ SX?77P1^
M/A_P'J7Q5\2^)-;\2Z-KWQ2U#Q'-I:^*+;]GF"..73[VW\+)J]O:P'QD;:YU
MS7;>YT/3X7NS"7\F_9D_X)X_"_Q3\5?VNOBU^T#\$_$-OXN\7?M??$7QU\/]
M9U3QA\0/#7]K^#)KS3[SPQK=II'AGQAIFC3V<CQ%D>YT]I)S&R7(E4$'1_;]
MT#QM\7=)^)/P.\5?LK_$3X@:S%IQO_V+/BS\)X/$&M^%?"/Q NO#&FKX;\6?
M&2^;6-/T3PEJ'@;XH6-MJL9UW3/$>C-H6D:?K*VINI)5 !L_&_\ X* _&O2-
M9_:&US]G_P"$_@/QI\,/V.? _@WQU^T))XZUGQ'I'C?6H]?\&:=\5/$7ACX6
M6NCP2:/_ &_X2^&&IVFLW<GBF2&SN]6E_LJ !XW8]G\:O^"D>E^ OC)^Q;\(
M_ 'PN\6^.8/VK/%'A*+6?B)-I=_9?#SX=^$/&7@KQUXHT(3^)546VH>.-7N/
M!D\=CX=B5UATR.ZO[V2(2V:R?%'CKX4?M5_![3/V]_A$?@KXY^-OBC]O?X8^
M#+'P=\1_ >EV]YX!T+XG^(/V??#/P!^(C_%'6#<VQ\"Z'H6H:)+XNMKZ6VN8
M=2TJ40VJ+<;EK[ ^.W[.'Q TOP?_ ,$Q/ /@OP[JGB^W_9\_:)^&=_X]U'2X
MUFAT#PMX9^!WQ/\ "M]XDU%I)0R::FM:IIED9E,KF:_MQM(8L #]*?'7CSP=
M\,O"6N^._'_B+3/"?A#PU8R:CKFOZQ<"WL;"TC(7<[ -)+-+(R06UK;QS7=Y
M<R16UK!-<2QQ-^<GQQ_X*\_L;?"CX*>)/C'X:^)6F_$:'PUXS^&_@N_\-Z98
M^)=(UVWNOB1XKTWPY8ZM/I6L^'[/53HVG6MW?ZU-?PV+VMY%H]WIUG<R:FT5
MLWU!^VGX$TKXD?LY^.?"NM?#CQU\5--ENO">M3>%?AAK=CH'Q&BE\+>+]#\3
M6?B3P->ZBDMO/XI\)7ND6WB31M+$<DVKWNF1:9;HTUT@K\./'OPL_;+^*?PE
M_:'TS3/!GQ_^*WPN\,-^SGXF^%\O[2?P:\,>!_VNM1U+P!^TQHWQ.\8_#C2]
M=TZZ_M?XH^%=&\ V-G-X?U361I"W&O17]A;V8G,LS@'[XZ1^U%\!-8\,?$?Q
M?:_$_P -'0O@[X?L/$WQ7OI)+RWC\ Z/J/@ZR\?6U[XBBN;2&YLHI/"&HV>O
M!6A:5;">-WC63,8^7/VS/^"F7[.W[*_P@^)7BFT^)'@3Q#\5O#WP5UKXN> O
MAW?7FLBV\4PQZ#?:SX6MM7U;2-.NK?PY:^)_L833O[6NM.O+V.:%K&&9KBV$
MOYW_ !PT7X_Z+IO_  4[T'PU^RC^T#X]O?V\/@UX>U;X)S^'/"-K_9FE:C<?
MLTZ)\,-8\)_%"_NM3CC\ >*M$USP_?-_9=\EU_:0FTZ"TF$E\A3R7XD_!;]H
M3X6_L^?\%#?@+J?[&OQ5^/WB?]L/X.^"-7^$^N^$- TS7O#:ZGI_P!\'_#R7
MP#\1=8N[V'_A"]<^&OBCP9=:IX=LKF.X@U<'1CI;Q7M\T@ /WY\&?M4_!CQ%
M\,O$?Q'U/X@^%=+L?AO!H5I\7B+V<VWP[\3ZQHNA:R- UCS8!<I<M#XATIK)
M5BE:\BO[-H#*TZ@_1EM<07EO;W=M(LUM=0Q7%O*N=LL$Z++%(N0#M>-E89 .
M#R :_GH^+/P%\?VW[9_[,WP2\/>'OLOPR_:X\%?!_P"*_P"TY8)+Y$^A:Y^Q
M=9:4PN]1M$+*\WC34;SX,^&IB^([FU\#ZE$_GEI,?T-HBQHL:*$1%5$51A55
M0 JJ!P    !T H =1110 4444 %%%% !1110 4444 %%%% 'XY_'_P"-OPT_
M9W_X*E^"?B%\9-=O?!G@C5_V)[KPMI_BB3POXMUO1Y_$4?Q@US4'T8W?AK0M
M92"_%BZ77V>X\IS ZR#*L"?C']JJS\1_M(V7[7/[3_@/PCXPNO@_XO\ &G_!
M/#X/?"F\N/#FM6DWQ4T[X6?M+>%?%_C3XE:3X;O+&+6!X:M[SQE?Z!;:G?6-
MN;G3O"]Q?R11685A_2U7">&OB=X!\8^*O'O@CPQXJTK6O%GPNU32]%^(.A64
MKO?^%-5UO0M/\3:38ZM&T:K%/?Z#JVG:I J/(&M;R%R0Q*@ _F'\ _LM^"1;
M?L^SW7[.GA47/_#ZG]H:ZU>:X^$6D>?_ ,*_6/\ :*?1;C49)/#WF?\ "'+(
MFAOI<URW]B!TTEK1MRV9'$:-\%-1NOB[\6?A[\??CUXX^&_[26I?MP:GXS\(
M:#X2_8\T3XA_&/7?#G_"TK7Q1\+_ !'\,/V@'D74=-^%[_#N'3=+U:SCU+3-
M/\.^#H?$&@W&E3B"19_ZZJ* /Y8O$7[,?C:[_8&_;M\4?#;P)K.F_&#7_P!O
MCXR:UXZ\7V/@.WU3XJZ]\ =*_:ABU/X@:?X<M-2CL=3UWPSJG@71Y-7N_!FG
M:G;:/XMTV"_M8O.EU(RR>2_$;X(^ _B!\&/V@]7^$?QA\8_''P[XMO\ ]B;P
M-XZ\&_#7]DFV_9P^$ EL/VH/ NH7-]';^%8K.75_BAHWA>\N[?Q7J=IIL<UE
MX8CT>:]U.06:/#_7O6?JNJZ9H6F:AK6M:A9:3H^DV5SJ.J:IJ5S#9:?IVGV<
M+W%W>WMW</'!;6MM!&\T\\SI'%&C.[!030!_-#^VE^S_ *]X-^-G[4GAO]GG
MX4ZAX9^'.M?LJ?L2^*_B?X4^%?A:;P_IGCKPMX/_ &HO%MU\:[.UL_#UM86&
MK>+;SX.Z9?6>N0VQ;7-5T)8[.[\]+BW5_5/VH8/@]\8_V'/VF;7_ ()S_#_Q
M%X0M&\:_ ?7/C7KOPT^$6L^&M&\<^#/#6M^#)_B5IGA'PEJL/AJP\:ZUH/PX
MT=K7QIH.F:;IHU^RM+S1KN\OKJ_DD;^@[3M0L=6L+/5-,NH+[3M0MH;RQO+9
MQ+;W5K<(LL%Q!(N5DBEC97C=20RD$<&K,LB0QR32-MCB1Y)&P3M1%+.V "3A
M03@ DXX!- '\N_@CX-?!#QEX-_:?\5Z#^TM\5O%?PZU/X<?!#1O'T_P._8ET
MSX1_";POK'@_XC0>+-,\0:QX&T,Z;;?$/7M$L(H[#XP:8VF20ZA\,6BL=6FU
M*%?LX^R?^"8VNP:I\>/C'IOAOP9\"O'7@C0OA_X9M-,_:N^!/PC\4? &U\97
M4_BWQ?-:_#?XB?"Z]TO0?!T?CGPWX<_L+6;K6?"-A?P2VVMQ6\VJNL<=M!^S
MWA#Q?X=\>^&])\7^$M275_#NNVB7VE:DMM>6:W=K)G9*+;4+>TO(@V#\L]O$
MX[J*S/$GQ(\">$6UV/Q#XHTK3[KPSX5NO&^O:=YS7>K:;X2LS<B?7I](L4N=
M4.G[[*[BAEBM)#=36T\-JLTL3H #^4_2?@QJM_\ &#XM^ OV@?C[X[^'?[2^
MJ_MR:KXW\*:)X6_8]T;XB_&;Q!X??XJ6WBKX9^)OAI^T%+*-3L?AA+\/8M.T
MS6;5-3TZP\/^#H?$.A7&ES^1(L_TU\,O#@TO_@H1;_'R\^&7B>3]AOQ=^T!X
MT\#?"K3+O1M6CM/#O[8;>&M)\.^)_P!HRZ\"KIJQZ5X'^(FH>&O%OACPMKDU
MLD&E>)I-4\4*\</Q!@GA_I TW4;/5]/LM4TZ87-AJ-K!>V=P$EB$UM<QK-!*
M(YDCF0/&ZMLEC1USAE4@@7: /Y5[_P  >%=-\(^)O&'Q+\;W_P $_$'A[]L_
M_@HC<> -6^+7[.5]\=OV=_$ESXP^,UQ?:/8?$+PE>:??QZ?J6K)I-K>>#/%E
MEH][J,?AZ7Q:VAW*M<D3]-_P3'L/"VF?\%"=;^(_C#]F3X9? ?4?C-^S[<:7
M\(O$WPR\ >*K/X??%6^\'?'/XT'6/B#X$N_%.AQZWX&@\:>![CPKXAB\.ZN?
M#[1:'=Z=8V-A'86UK:Q?U!44 ?S\_M<R_LM>&/\ @IE\3?%G[77PLU3QKX&U
MC]@?P#X.\%:KJ/PUU[Q_X/N?$EU\2?C3/K?@ZP33]&U>RM_B)KVGR::OA:<)
M;ZC:*EX;?4-.%R7G^5OB5\)_VB/"OPR_X)5ZA^T[XWUCX=?"OP'\%OB+X;^*
M&O>,_@OIW[2/AOP-\6=;L?"LWPV'Q8^'.M&[M[F]_P"$+L-=\.Z5XGO++56T
M36DOK4I'/JRW"_U7UPGQ%^)W@#X2>'[?Q5\2?%6E>#O#MWXB\+^$K;5]9E>&
MTF\2^-=?T_PMX4T9'CCE8WFN^(=5T[2;!-H62[NX49D5BP /YG?@]^S_ /!K
MPA\<_P!@;Q3XMG\0?&GX+_$%OVY/ GASX@?$C]G.U^'^GZ5=_%3Q#\-K_P "
M^#?"7A.PT[6)?!WPRO8Y/&C_  HEO7TRPLM$O+J&R3389FB;Q"[MOVF/A%X4
MUK]H2P^%GQ$\0?$#_@E+XDTW]C_X<:!;:%KEQ<?%GPSJDGQ(\(W/BCPTC022
M>(/#_B _$7X%:SJFKVB/$I\#7_FR>3:DQ?V%@@@$'((!!]0>0:6@#^*[1_V1
MM0^".J_M ?!7]J7XU:_\-]7\:^"/A2GP;U2T_9%T?]H#Q;XYTC5OAMH-G?R?
M 3QU=%K_ .'_ ,2],^+C>*KZZT_3I="NXO&=U!XEFOYC?J\7VU^U[\-=?\.?
MM9>$=8_:-^-.I^%O@/>?L6^ O OPR\??%C]E;0_VC/#VK^.=#U77V^*VCZOX
M1U :C;?#WXI^([._\+ZI+>VMF]QJUDJ6-MJD T9E?^G>L/6O$WA[PVVDIK^M
MZ7H\FO:K!H6B1ZC>P6DFKZS<Q3SV^EZ;',ZO>W\MO:W-PMK;K)-Y%O/,5$4,
MCJ ?SJ?LK_LB>"M8_:8LM&^*_AOQK\?_  EX3_X)??![PMX3\5_M'?"^'2]5
MU ZC\3?C=.UKKOA#45U;0]-\8:=HHT>WCA\^YUW2+*6-HI[?[?*TWVI^QSX7
MU'7?^"-_P[\$?$B'XJZ?<:A^RAJWA+Q!!X4L-7E^+NF6-QX5U'2&'A?3;B2T
MUF7Q7IUDZMHMJTT-W)=P6\:R*Q##]2_"OC/PUXVMM3O/#&IKJEMHVO:UX8U*
M5;6]M1;:[X>OY]+UBP*WUM:O*;*_MYK<W$"RVLQ0R6T\T15SU% '\3G[1?A7
MP=XN\)VO@_P1\+_@!^UW\./AG>_"WXAZS\>/ /[+GB+X,?&+X)>%O"GQP_9^
MGU[P_P#%3P79>&[;P7X__P"$DT*W^(3PWMA_PD/B;^R] ULW45M'>WRWGW!\
M<?BIX#^&7A/_ (+ >"FT3Q7%=_M7_!+P[XI_9;\.>$_AOXLOXOBGX3U+]C_P
MKX"AD\&6VDZ%]AM5T37?#NLV>JZ5?MI=YI<.F3D6;?N8Y/Z@ZBGFBMH9KB=U
MB@@BDFFE8X6.*)"\CL>RHBEB?0&@#^/G]HC1?A;H/[/?_!2;P#^U1\(/&GC'
MX\_%;X&> -7_ &3YH_AMXD\6^)M<^'EE^SIX*TCPYH7PD\0:=I%^_A1?!?Q#
MT#Q?-\0-!M;[1)Y'BUZ\U"VU&+5FBN/NS]NC0?'_ ,(M=^ OB3X3Z/KJZW^W
M_P# SP7_ ,$__'CZ0)(KKP]XEN6M]:\'?$"Y@PC6UWX1^%NN_'>>\U KYZMH
M/AVT(588]O[T_#GXC^!OBYX)\._$?X:^)M,\9>!O%NG0ZMX;\3:-*\VF:QIM
MQDPWEG+)'$[PR8.TM&I..E<3XE^ W@_QA\8O!'QG\2ZGXLU?6/ASIM];>"_"
M-YK:R?#W0=<U&*\L[KQQ9^&#9_+XW;2-0OM!376OF,.C7=Q9Q6R&:21@#XZ_
MX*"?"[6]$_8(G^'/PR\+^(-=\,> ]5^!">-/!7@=Y;;6=>^!O@7XC^"KWXK:
M!I]K:-'=7]I>?#S2]=74]%LV6XU;2A?:=$'-SY;_ (U_M'^"_ _QKM/VN=<_
M96^'>JV_[)'C&#_@G%X(U+2_!O@77O!G@_Q3\7M#_:FTJ\^)%]X7\)QZ/HT\
M5_H/PTU+PCIWC?Q#8:1;QS-8H;J\FDTR>X7^L">>*V@FN9Y%B@MXI)YI7X6.
M*)#))(QYPJ(K,>.@-<=\.?B/X&^+G@GP[\1_AKXFTSQEX&\6Z=#JWAOQ-HTK
MS:9K&FW&3#>6<LD<3O#)@[2T:DXZ4 ?&W[;'P*\+7O\ P3A_:K^#GPW^%WA9
M+'4/V:?B[%X9^'GAWPEH]MI=UXE?P/K6I:>=-\/65A'8OKEQKJ17MI-%:_;9
M=:,5TDAO666OS9_90^%GP:^*_P"UMH?Q#TCX5:+K7@/PG_P3'^ >E> )]3^&
MTFF^&/#OCG2_B7\9SK\>C:+K6@V=AI?C/1M4L+:0W%M90:SISR_:+66.._\
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MHZUIL$-G'J%JVCO&_P#:+10!_+CX]^&7P[^#'@[]GC6?$7QXU6^\::%^S/\
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M$>]N/$_B'P/HUO8:%XQL+'1M(T:#XI:=.L]UJWP^%W;ZU#>V3QPR?KA^RA\
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M\/?\):FI75[XQU(ZF1'-H?A?2M(U#5]7AM_]+:RMI6AY0U<^,_[;O@GX/?M
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M<^$?#/Q+GT.Z\2V%E%J<*7=HL]Y:W M)(@ ?TWP_$SX;W'@Z3XB0?$#P1/\
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MGPUH&N>&_&7P9N6LOBS%KWCN_#^%8-#\'7K65J-?C#6FL2ZIIJV*?Z2-K_\
M@H[^V=JG[-UA\,OA7X,UBU\"^._CO>ZYIL?QD\2^%/%GB?P1\&O"6BVL)U[Q
MEJ-IX7T76)-4\5EKZVM/!7ANX6&WU+4A/=7LBV&GW&[X0\+VO[/O[.7CO]@W
M]H_X6>+?%'Q(_9M^'FD_M0?#7XT_&RZ\+>,K_5$^*GQ=N? GB>X^)'CG3I=
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MXC^)UWID,VF-INB>*]!TU=/T7PS96NG:9X-L-/BF71]-TZQC29;J-FH ^O\
M]DC]I+PU^UY^SK\+/VC_  =H6L^&O#/Q7\-6_BC1=%\0&+^V;&PNGD6"/4!
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M5H=K/>:UK7A*R>?PQ\3M!L;6UCENKTW7@'Q#K>JQZ=!'(][J.AZ:B1O*D8H
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MM;S3[_[%-%&@!^I?[/WQNT']H;X5^'?BGX?T#Q7X4MM;-]:7_A?QOHEYX?\
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MX<1MJ?@;1KC1[8V7@_6-5LM2?0WBLK#2+2VC6 1V 5;9/W#H **** "BBB@
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MF:=X#NW\4?$>:6SCU&*XT2R2QB-N7?\ 3;]I+]E#4OC1\0/A+\:OAI\7]=^
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MCC^R%3[E\9OVP?VNOA[XQ_9.^"^G?!CX-Z1\9?CM\+/C/X[^)+^*O&7B;6?
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M $$9!R#R".A'K7\O'_!2;5=:_:O_ &G_ -I3X?:!\*OV@_BGX?\ V7OV=(O
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M/;Z5#IOQ''AT>)5U'35C9+^:3_A%]*^Q2O(AM-L^T/YQQ[)10 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?Q,\0_$2]\8Z5H/@?9J=Y9IX3\)V5IX3;^U_%.E_:=7%QK,ZVT);3$#?F=\
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M<U75O#5O<7;#PI9)#9>*9K:QBFN;>ZO7"]IX+_;-_;"\&>%/C^WQND\:^"?
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MKI7C[P]X;\"V(M+6UTG2(M>T33!<"]AU2_FT^U6P%_'"3G\__%_[?'QMT/\
M:9_:2M/CU\//C9\$_!/P]^!'[(FHV/PC\*_$7PCJ%Q#XJ^*_[0FL^$1XO\,>
M/-*TZ;1KZ#4]/N]"T[QE9*ADCLM.U/0,1W@-P?IX_P#!5N:,>-?%47[+7Q)E
M^!OPJ_:+;]FGXD_&.Y\:^#[==$\5/XZLOA[8>(=*\&R)_;WBKPW<:WJFD+J%
M]IKQ/I;WD\5Q&[V,Y(!]1_M ?\$^_P!G;]I?5/&.K_%"P\87-YXZ^&_@/X5:
M^VA>++S0@_A+X<>/I/B3X:BLFM(3-8ZC%XFE:6[U&"59[BTVVP\K:)*Y:S_X
M)J?L\MX6\=>'?%>K?%KXE:I\1+WX<3>(O'_Q&^(5SXE^(0T?X2^)M*\7> ?"
M.F>(VT^U&F^$M"UK2+>XCTBWLA]I$]X;JXFEN7E'C'Q!_P""JEKX0/B'QKX=
M_9J^)'C_ /9[\/?'SPY^S7+\<=#\3>%[6UN_B=K/C[2/AQJ;V_@>\4^(AX*\
M/>(]0N[2[\9/(-.NI;".&UB+:A;,/8?^"F_[0WQI_9G_ &3M8^*WP&\*6OBC
MQS'X^^$7AL0WNKZ-I,.G:-XT^)'ACPUJEP'UH&VGN+VWU0Z):F/]Y87.J1:L
MP>"PE1@#V74OV._@QJL7[3<-W9^(BG[6^A6OASXP>7KTR&[TVS\ VOPUA7P^
M1 ?[#F'ABSAB:6+SBUZ&N\!F*5^1G[8O_!.+XO\ Q)U;XM_"?X._"'6-(^&?
MQ@^&O@?X5WGQ%\&_M.)X \)Z[HNA>'=/\*0Z_P#M#?">_P!(FUWX@>)?!>F6
MJKHMUX+U#3(]7L-+T.RU(3F*[1_M3XA?\%'M4^'TWQ ^R?LW^.?'/AW]G7PK
MX0U[]J_QAH?C+PK!8_!JX\0Z#I_BC4=+TJRNXUN_BAJ7AKPMJ%MXCUZ+PJ(4
MM["0B-GE4I7UG\<?VH/A]\#OV?[C]H;4X=4\3>&KNS\(#P?HN@0I)K?C37_B
M'J6E:)X#\.:5'*1%#>>(=:US2[)KFX/V?389KB^NOW%I+0!-XV_9G\!_%+X
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M>*UTCX4?$O0;+P]XC\#6%H--L+.'1ULK&.;3G-NVH6EY)+.]].ICCCZ[3/\
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M'_9QNI/#0U:3^T?^$=.N_P!DF9(X3;&R7[*>;T7_ (*B?#?Q;\"O!?Q(\">
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M/1+C5?-/B]M6632DC2SN* /UY\(>'$\(>%O#_A:+6->\01^'M(L=(CUOQ1J
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ME%O): _G[^W/_P %#=6\1?L=^.K_ /8BUNZA^-7B3X-?%+XB1>(-8TN6SO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM8X[@1JQ1?TAHH _%GQ+_P $[?VE_C9H=_8?M!?%_P"$E]J7@+]D[XQ_LQ_
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MQ*Z=X9\-W^AWUC90ZH?MTVGR6)?]^L]?K%10!^.O[=WA+]H;7/V^/^"?NO\
M[.MUX7TSQ1X6\#_M2W.H7WQ#T'Q'JGPVO["^MOA+;'PWXKU/PS$^J:"VI'=J
M&E7EDXO)KO1C;)&]K)=LE3QQ_P $T_B9K/[.?A+P)I_Q!^'/BGXJS?M0:_\
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I%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img94995564_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img94995564_3.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" (V!.\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_!Y,9YQ[
M9[<\D9_.LVXNQ'GYAU[GO_3V[]/?#;NY\M6.<=>3]?Z=NG^' :QK2PAQNQ@'
MG/.?_K__ *O8 Z"YU=8SRP[]_P ^/PS[_P \2?Q!$I_U@P,]_P!?T_S@UY'K
M'BH1,RAR3G  ))))P  .23[9)/X9ABT3Q_J\8EL/#FH&.1=\;W3VVG;E.<,H
MU&XM20P&5./F4AERK D ]6;Q-$.D@^IQC\*C/BF,?Q_EBO*7\$?%,@@>&G/<
M?\3G0/?&<ZM47_"#_%7_ *%E_P#P<^'_ /Y;T >M_P#"4Q?W_P!*/^$IB_O_
M *5Y)_P@_P 5?^A9?_P<^'__ );T?\(/\5?^A9?_ ,'/A_\ ^6] 'K?_  E,
M7]_]*/\ A*8O[_Z5Y)_P@_Q5_P"A9?\ \'/A_P#^6]'_  @_Q5_Z%E__  <^
M'_\ Y;T >M_\)3%_?_2C_A*8O[_Z5Y)_P@_Q5_Z%E_\ P<^'_P#Y;T?\(/\
M%7_H67_\'/A__P"6] 'K?_"4Q?W_ -*/^$IB_O\ Z5Y)_P (/\5?^A9?_P '
M/A__ .6]'_"#_%7_ *%E_P#P<^'_ /Y;T >M_P#"4Q?W_P!*/^$IB_O_ *5Y
M)_P@_P 5?^A9?_P<^'__ );T?\(/\5?^A9?_ ,'/A_\ ^6] 'K?_  E,7]_]
M*/\ A*8O[_Z5Y)_P@_Q5_P"A9?\ \'/A_P#^6]'_  @_Q5_Z%E__  <^'_\
MY;T >M_\)3%_?_2C_A*8O[_Z5Y)_P@_Q5_Z%E_\ P<^'_P#Y;T?\(/\ %7_H
M67_\'/A__P"6] 'K?_"4Q?W_ -*/^$IB_O\ Z5Y)_P (/\5?^A9?_P '/A__
M .6]'_"#_%7_ *%E_P#P<^'_ /Y;T >M_P#"4Q?W_P!*/^$IB_O_ *5Y)_P@
M_P 5?^A9?_P<^'__ );T?\(/\5?^A9?_ ,'/A_\ ^6] 'K?_  E,7]_]*/\
MA*8O[_Z5Y)_P@_Q5_P"A9?\ \'/A_P#^6]'_  @_Q5_Z%E__  <^'_\ Y;T
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MH=E<AP#GL/7_ "?S]>_4 Z $$9%+4,;Y'U/ZG'OTJ:@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.TN;RRU/3;C3=>M;"[GB1Y/LCVDT4LGS3^Q/^Q[\9_V:_P!JOXXR>)6GU_\
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M+S7+GP^)I;77=!&GZ-<WMD\-A;WRSSG2_P K_B7^S#\9/@)\ (M2L?!/A?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-1E)VBG)[V2;=N^@FU%7DTEW;27WL^L=-_A_"NHB^X/P_D*^?--^-?@T;?\
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M5ZEI\+_BQ<M9WD./-M+I8? [FWN8LCS()@DJ9&Y!FO:/ ?C[PG\3?"VG>-/
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MP%\1/%?@73]0\.Z)KECX9U/6-(L+=;;5]:LKK7;_ %:\@FU28R78@U&TNI;
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MB/2M)O/-CAN(6D*6[1HS&-G$J.B^C5\;?LH?\C5^U5_V<GX\_E8U[G\:M?\
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M_';1:?H/A^PEFO[B,75[<+#!&\UW)#"'D)G:/:_%W_Q,_:U\-Z4?'OB#X.^
M-7\(D:3//\/?!.L^+=<^+^FVE_/:V]T MOI5UX=U_4+(W)GFL]+CABCBAF+7
M9MXI+U)]A-N5N6*4Y0CSU(1<I1:3C%MQ4FKJ[LHZK57L5[>*46^:3<(SDX0D
MU&,EI*25W%.SLKN5D][-GTOX@^('A#PMXB\'>$]>U?[!X@\?W.JV?A+3_L&I
MW/\ :USHEI%?:G']JL[*XLK'[-:SQ2[]3N;..;?LMVED5D'95\I?$'XE?$3P
MI\>?@SX4N-.^'U]X#^)^H:]:Z4]UH6N-X\\/2:#X7L]1U-I-4DUU='CDN]1N
M5CA^SZ,&2QC\BX#S@3U1^,OQI^+'PJ^*_P /O#6G>&O"'C3PK\49]<TCPMHU
ME'J^E>,K36M&T;2YC-K&NW>K3:!_9$FK:AYMU+;:&+BQT..>=5O+VV6"[:H2
ME[-1<;SI2J*\U9J+G>UTN5I1:<9-ZQD[V:0G7C'VCE>T*L:;M!WCS*%G+5\R
MDY)IQ2=I).-TV_KNBODS3/B[\:O!7Q \)>$OCCX-\!0:%\1M3O=*\)^*OAIJ
M^NWUIHNK16KWEGH'BBW\26MI/<7=W!#.J:IIL=O;23")(K Q_:);?K_BSXV^
M*?A2[GN-#U/X#>#?"MK;Q31^(OBUXLUJTDU6Z8(K:<NGV4>BV>C0M<2+;C5I
MM;U9HV\MDT>Y,VR*?834HQO#WX\T9*<7&23L[-7U3335KZ/2VI7MH<LI6G[K
MM*+BU)-I-73M9--/F;4?.^A]"45\T?"GXR^)_C?\,/$^K^"D\#Z5\0O#?B34
M/"-PUU>:IXM^'S:MI5U9S2WUGJ6D2:)?:QH^J:'=1WNG7%A<JL4]W LDURD$
MHE\@^%/[07[1?QS\!IJ?P\^'WPWT_P 0:9=7^G^(?$WC:^\4:;X'NM2M+Z>)
M+#PMH^E_VEK^HR&PCM[B]NKK5K:PLKJ[6S2YNYK:Z6)_5JGOWY(^SFH3YIQ7
M+S)N+;O9Q=G9IN[V1/UBG[EN:7M(.<.6+?,DTFE;5-75[V2ZL^]JC2:&5I%C
MECD:)BDJHZNT;CJD@4DHP[JV"/2O O@Q\6?$GQ<\!^++B72=%\,_$GP?KOB7
MP-K6FR/J&J>&;'QEHT0-K*TBFQOKS1IC<V%Y<P6MT+A()9K.._-Q&9A\V_LF
MP_&'_A87QY:?4?ALVB1_'GQ>OQ BBT7Q.FJ7>NBVB%S+X.N'U^2TTW23<?96
M@M]:MM5O%A6=)+IG>-XVL.U&NYRC"5'EO%ZWYFEHU=6L]&KW=EI>X.NKT5&,
MI*K>SVM97U4K.]]&G9QU[6/T3HKXDT']H'XT^-]-\0^/_ ?@+P7X@\%^&?%5
M[X8O_AVFI:XOQCDCL-733[C49$>.'0](U(VL@U*/POJ>GI*;$B[;7 K)$_VO
M$[211R-&T3/&CM$^-\;,H8QOC(W(3M;!(R#BLZE*=*RG9-MII23<7&UU)+5/
MWEY/HW9VN%2-2[CS6LFFXM*2=[2BVK-.S\U;5+2\E%4-5&IMIFHKHDEA%K+6
M%X-(EU6*XGTR/4S;R"PDU&"TFMKJ:P2[\IKR*VN(+B2W$B0S12,KK\/^ /V@
M/VA/'^I_$?X=Z'X#^'=_\0?AYXPUOPWJGC"ZN?$_A_X76MMITHM;*9[8R^(/
M$NHZK?W4=XRZ797$2PV5JMS>75F;NVB=TZ4JBE*+BE"W-S24>5-VYFW96OIH
M[WT2;"=6-.48R4KSOR\L7*[6MM+N]M=59*[;2/N^BOG3X&_%OQ?XUUKX@_#W
MXEZ'X?T/XD?#*]TB'75\)7.I7?AK5-.UZR>[TG5M+;5(_M=M'=>1=)]BN+FY
MN(DBCEF:,S+&OL'CO73X7\#^,O$P$A/AWPIXBUT"%4:8G2-(O-0Q$KO&C2'[
M/\BO(B%L!G4$L%.G*$_9NW-[MK.Z:FE*+36ZDI)I]F.-2,X<ZO97O=--.+:D
MFGU333\T<98?'#P!=Z7X\\0WE_<Z!X5^'GB&[\,ZQXL\0P1:7X?O]3T\P0WQ
MT&Z>X>?5+6VOYO[)^T):Q"ZU.&:VL5NMJN_3^!/B1X'^)FF3ZQX&\0V>OV5G
M=O87PACNK2]TV^C57>RU32]1M[/4],O%1T<VM_9VTX1T?R]K GYD^'WPG;QU
M^RQ\(].T/4[/0M?2+P?\5=*U+4=/DUC2YO%4EP/$LTGB'2A=V9U:VU";4+Q;
MM9+GS(+N6'4K=VN[*V<4[V+Q_P##S7?$%@=?T'7_ -H3]H">QMM*C\'^'-0T
MSP=X$\/>&-+CTJ?QKJ=AJ-_K9EBT6*5Y?[1UB47&NZM-I6@()K*R40;NC2?/
M&$W[2,Y149/3E@XIRE:#2CR^TG*7.E'E4>5W3>"JU$J<IQ7)*$9-JU^:2;44
M^9:W<81CR/F;;YE9H^M--\:^'-9USQ)X;T>^DU/6_"0M5U^TM;.]^SV-U>P-
M<VVGMJTUO#HLFIO $EETZ/4FN[.*>VFOHK:&Y@DDH_#WX@:)\2?#P\1:)!J=
MC''J.IZ/J&E:W;166LZ/J^CWLVGZEINIVD%S=PPW5M<P.I\FZN()4*30S212
M(YC^&WP_TKX:>$]/\,:9-<WTD/F7>KZWJ#K-JWB'7+MO.U37=7N51/M.HZE=
M-)<7$I4 LP555%51X9\&KB'1_P!H/]J#P/86D5MIL&L> ?'A:$+$DFK>-O"L
M3ZLQMT0*)))]+6XEN?,9[B29BZ*REGRY(259PNU249J3WE'GC3E=:6O*<9):
MN*T;EJS1SG%T>?E7M)2C)+I)QE.*3N[\JA)-Z)[I+1'U?117F&I_%[PGI.H7
MNF76E?$Z6YT^ZFM)Y--^"?QFUG3WEMY&CD>RU;1_ 5]I6I6S,I,-[IU[=6=S
M'MEMYY8F5SG&,I.T8RD^T4V^W3ST-7*,?BDH^K2_,]/HKR+_ (7=X,_Z _Q;
M_P## ?'C_P"=O1_PN[P9_P! ?XM_^& ^/'_SMZKV57_GW4_\ E_EYK[R?:4_
M^?D/_ H_YGKM%>1?\+N\&?\ 0'^+?_A@/CQ_\[>C_A=W@S_H#_%O_P ,!\>/
M_G;T>RJ_\^ZG_@$O\O-?>'M*?_/R'_@4?\SUVBO(O^%W>#/^@/\ %O\ \,!\
M>/\ YV]'_"[O!G_0'^+?_A@/CQ_\[>CV57_GW4_\ E_EYK[P]I3_ .?D/_ H
M_P"9Z[17D7_"[O!G_0'^+?\ X8#X\?\ SMZ/^%W>#/\ H#_%O_PP'QX_^=O1
M[*K_ ,^ZG_@$O\O-?>'M*?\ S\A_X%'_ #/7:*\B_P"%W>#/^@/\6_\ PP'Q
MX_\ G;T?\+N\&?\ 0'^+?_A@/CQ_\[>CV57_ )]U/_ )?Y>:^\/:4_\ GY#_
M ,"C_F>NT5Y%_P +N\&?] ?XM_\ A@/CQ_\ .WH_X7=X,_Z _P 6_P#PP'QX
M_P#G;T>RJ_\ /NI_X!+_ "\U]X>TI_\ /R'_ (%'_,]=HKR+_A=W@S_H#_%O
M_P ,!\>/_G;T?\+N\&?] ?XM_P#A@/CQ_P#.WH]E5_Y]U/\ P"7^7FOO#VE/
M_GY#_P "C_F>NT5Y%_PN[P9_T!_BW_X8#X\?_.WH_P"%W>#/^@/\6_\ PP'Q
MX_\ G;T>RJ_\^ZG_ (!+_+S7WA[2G_S\A_X%'_,]=HKR+_A=W@S_ * _Q;_\
M,!\>/_G;T?\ "[O!G_0'^+?_ (8#X\?_ #MZ/95?^?=3_P  E_EYK[P]I3_Y
M^0_\"C_F>NT5Y%_PN[P9_P! ?XM_^& ^/'_SMZ/^%W>#/^@/\6__  P'QX_^
M=O1[*K_S[J?^ 2_R\U]X>TI_\_(?^!1_S/7:*\B_X7=X,_Z _P 6_P#PP'QX
M_P#G;T?\+N\&?] ?XM_^& ^/'_SMZ/95?^?=3_P"7^7FOO#VE/\ Y^0_\"C_
M )GKM%>1?\+N\&?] ?XM_P#A@/CQ_P#.WH_X7=X,_P"@/\6__# ?'C_YV]'L
MJO\ S[J?^ 2_R\U]X>TI_P#/R'_@4?\ ,]=HKR+_ (7=X,_Z _Q;_P## ?'C
M_P"=O1_PN[P9_P! ?XM_^& ^/'_SMZ/95?\ GW4_\ E_EYK[P]I3_P"?D/\
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M7.JZUJZV7@,6LTDLM[>:@VEV>ISQWL\0EF^QVUQ]Z1AU1%D<22!%#N%V!W
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M-%%%8&X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU_5]!TK4M;\+_#3XES>'=4O;.&XOM%EU'P=JEM?2:=<2(TEJ]U BQ3-$5+H
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MXU\+3/IWP?TK1+/1]5^&$VFWFKV>G7,NE:JVE^(/#BZMI5]HMM!J%O#8_O\
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MC8A%C5MJA21&OR(K8R$7Y5!VC@5YK_PN3X<?]#$W_@E\0?\ RJH_X7)\./\
MH8F_\$OB#_Y543J2J6YE!6O;DITZ>]KW]G&-]EO?RW80IQA?E<W>U^>I4J;=
MO:2E;?I8^"=6_P""?'Q6\-:MXXT/]G/]M#XB?L^_ WXE^(-9\2^+/A!I7P_\
M)>+YM%U#Q1<2W'B>/X4^/M7O;+7?A;9ZC+/<7%I!H=K<MIM],]Y'+,P2-/8_
M'7["/PVUSX!?"KX(?#WQ'XI^$]_\!]5T;Q1\&OB9X<FMKOQ?X3\::0ETLWB3
M4EN(H++Q(WB:34-2F\8:==1VMIKSZA=$_9#Y+1?2?_"Y/AQ_T,3?^"7Q!_\
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MF3;T]Y7MUQE_&C>]G2J)6O>_-!RM;JU9I+71VV/#_!O[1_QX\<_!2[^,.D>
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M&\9?M%?&*V\/^#6TSP&WA#P[H&G:Q+JX\.>!].NY?$VM:EXEUPBSTR[U.]U
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MT-4]5RO38B@I+ZO&2Y91PJ4UK=:TU!2NDT_=G=->Z^9:[GJU%%%<9UA1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7SW^TI*UUX%T+PB)/
M+C^(?Q$\$>"[P;YHA/I=WJPUC6K-Y8%+K'?:-HFH6<B$I'<1SM:RNL<[5]"5
MX5^T9IFH77PQO-;TFWN+O4O NN^&OB!!;6987EQ;^$M9M=3U>"UVE=\\^A1Z
MI"D+.B7'F&WD=8Y6(UH65:G?^=6>UG?W7\I69E6O[*I;^5W\U]I+S<;I%/\
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MM*_^2Z/^$U\&_P#0V^&?_!]I7_R77F'_  R[^S1_T;U\$/\ PU7@7_Y14?\
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M9)XY\%1(\LOC#PM''&I>223Q!I*(B*,LSNUV%55 )+,0 !DFO,_^&7?V:/\
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M ,KJ/W7>I_X#'_Y+U_IZ'[WM3_\  I?_ "/K_3TZ_P#X2#0?^@WI'_@RLO\
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M/?"7_HF'P]_\(SP[_P#*ZC]UWJ?^ Q_^2]?Z>A^][4__  *7_P CZ_T].O\
M^$@T'_H-Z1_X,K+_ ./4?\)!H/\ T&](_P#!E9?_ !ZN0_X4]\)?^B8?#W_P
MC/#O_P KJ/\ A3WPE_Z)A\/?_",\._\ RNH_==ZG_@,?_DO7^GH?O>U/_P "
ME_\ (^O]/3K_ /A(-!_Z#>D?^#*R_P#CU']OZ .FMZ1SR?\ B967)]?]=7(?
M\*>^$O\ T3#X>_\ A&>'?_E=1_PI[X2_]$P^'O\ X1GAW_Y74?NN]3_P&/\
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M *#>D?\ @RLO_CU'_"0:#_T&](_\&5E_\>KD/^%/?"7_ *)A\/?_  C/#O\
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M (2#0?\ H-Z1_P"#*R_^/4?\)!H/_0;TC_P967_QZN0_X4]\)?\ HF'P]_\
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M::8@>I_3_P"O4M% $/DK_G/^-(81V&?QQ_6IZ* *_E?[/Z__ %Z/*_V?U_\
MKU8HH K^5_L_K_\ 7H\K_9_7_P"O5BB@"OY7^S^O_P!>CRO]G]?_ *]6** *
M_E?[/Z__ %Z/*_V?U_\ KU8HH K^5_L_K_\ 7H\K_9_7_P"O5BB@"OY7^S^O
M_P!>CRO]G]?_ *]6** *_E?[/Z__ %Z/*_V?U_\ KU8HH K^5_L_K_\ 7H\K
M_9_7_P"O5BB@"OY7^S^O_P!>CRO]G]?_ *]6** *_E?[/Z__ %Z/*_V?U_\
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M?%3_ )"OP>_[*S9?^H-X]KUVKE\%/TE_Z4R(_'4]8_\ I*"BBBH+"O(O@?\
M\B#%_P!C'XQ_]2K5Z]=KR+X'_P#(@Q?]C'XQ_P#4JU>M(_PJG^*G_P"WD/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4?C'_P!?G@G_ -1&QKURKJ?$O\%/_P!-Q,Z>TO\ KY4_]+85Y-\:O$VM^&?
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M;O+WFKIV<O>:M?45*+C!*22=Y.RMHG)M)I>ZFD]5'W4]M KR[XU_\DJ\;_\
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ML\B^R?'G_H8/A)_X1WC'_P";NC[)\>?^A@^$G_A'>,?_ )NZ]=HH]H_Y*?\
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MPRZ7XCT:)(L9RKPR-G&'ZUVWV3X\_P#0P?"3_P ([QC_ /-W2^#?^2H_&/\
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MXON'(OYI_P#@;/(OLGQY_P"A@^$G_A'>,?\ YNZ/LGQY_P"A@^$G_A'>,?\
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MB^R?'G_H8/A)_P"$=XQ_^;NC[)\>?^A@^$G_ (1WC'_YNZ]=HH]H_P"2G_X
MO+_+\7W#D7\T_P#P-GD7V3X\_P#0P?"3_P ([QC_ /-W1]D^//\ T,'PD_\
M".\8_P#S=UZ[11[1_P E/_P!>7^7XON'(OYI_P#@;/(OLGQY_P"A@^$G_A'>
M,?\ YNZ/LGQY_P"A@^$G_A'>,?\ YNZ]=HH]H_Y*?_@"\O\ +\7W#D7\T_\
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M&#X2?^$=XQ_^;NO7:*/:/^2G_P" +R_R_%]PY%_-/_P-GD7V3X\_]#!\)/\
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M[-I]WJ$7O7[(GC77OB%^S=\(_%7BBZ&H>(+WPE96FK:HN"FKWNDM)I,VL1L
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MJ>M_"_1O#MIX4MKY&4B>QL-1\<S:_'"QVIK.C:/>!3+9PO'YQXH^'6E^'_\
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MDM\+_P#7&]_].-W7KE>1_ K_ ));X7_ZXWO_ *<;NK7\.7^.G_Z34(?\2/\
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MJ]SK23<](1F[/XVU".UYRUBK)7W:2O=WLD9U?AUE**NO@5Y2[1CHW=NVRO\
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M7P/_ .1!B_[&/QC_ .I5J]>NUY%\#_\ D08O^QC\8_\ J5:O6D?X53_%3_\
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MQ-;^=]H\.W6IZMJEI96^NP?9Y_.TB6=-0B\B;?;KY;[;WAGXI?#+QK::!?\
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M0_1^BJ]I,;BUMKAE*-/;PS%",%3+&KE2.Q4MC&>U6*P-]PKR[XU_\DJ\;_\
M8&?_ -*+>O4:\N^-?_)*O&__ &!G_P#2BWJZ?\2G_CC_ .E(BI_#J?X)?^DL
M]%T[_D'V/_7G:_\ HA*N53T[_D'V/_7G:_\ HA*N5!4=EZ+\@HHHH&%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!CWWA[0=
M3U/1];U+1-)O]9\//>R:!JU[IUI=:EHCZC;BUU!](OIX7N=.>^M5%M>-9RPF
MY@ BF+QC;5C5M(TK7M-O=&US3+#6=(U&![74-+U2SM]0TZ^MI/\ 66]Y97<<
MMM<P/@;XIHW1L<J:T**=WIJ]-M=M;Z=M6WIU=Q66NBUWTWTMKWT26O30\XUO
MX.?"3Q+-9W'B+X7_  ]UZXT[3K71["?6?!OA[4YK+2;$,MEIEI+>Z=,]OI]F
MKN+6SB9+> .XBC0,<W-,^%OPST71-2\-:/\ #WP1I7AW69HKG5]!T[PKH=EH
MVJ7$!B,,^HZ9;V,=G>S0FW@,4ES#(\9AB*$&-,=W13YYV2YY66J7,[)IW32O
MT:3]4+DA>_+&[W?*KN^^MNH@ 4!5 "@      #   X  X ' %8M[X9\.:C>S
MZEJ&@:+?:C=:-<>';J_O-+LKF\N/#]W(9KK0Y[F:!YI=(N929;C39':SFD)>
M2%F)-;=%3=K9V*LGNKF#+X6\,S6&CZ5-X>T.73/#MQIUWH&G2:58O8Z)=:0N
MS2KG2+1H#!IT^F)\EA-9QPR6:_+;M&.*S=9^'O@+Q%K6G^(_$'@KPGKGB'2/
M*_LK7=7\.Z3J.L:;Y$IG@^P:E>6DUY:>3.3-%]GFC\N4F1,,<UV%%-2DMI-;
M[-K??[^HG&+T:36FC2>VWW=.QF6NB:-9:EJ6LV>DZ;::OK*64>KZI;6-M!J.
MJ)IT3P:>FHWL42W-ZMC#))%9K<R2"VC=TA"*Q!YWQ'\-OAYXPO[/5?%O@3P=
MXGU/3@HT_4?$'AK1M9OK$)(LJ"TN]0LKB>W"RJLBB&1 '57'S $=K10I23NF
MT]KIM.VUK^F@.,6K-)K>S2:O>][>NOJ<?XD^'O@'QE'IT7B[P3X3\41Z06.E
M1^(?#ND:RFF%@@8V"ZC:7"VFX11@_9Q'D1H#]T8E3P'X(BT[6=(C\'>%X]*\
M1RF;Q!IB:!I2Z?KDQ@AM3+J]FMH+?4I#;6\%N7O(YF\B"*+/EQHJ]713YI62
MYI66RN[+6^BV6NOKJ+EC=OEC=[NRN]+:O=Z:>FAR_A;P1X,\#VL]EX+\)>&O
M"5G=2B>YM/#6AZ9H=M<3 ;1+/#IEK:QRR!?E#R*S < XK/M?AE\.++Q'+XPL
MO '@NT\63R22S>)[;POHD'B"664*)9)-8BLEU!Y) JAW:X+.% 8D "NXHHYI
M7;YI7DK2=W=KLW?5>H<L;)<L;1=TK*R?==GZ!1114E!1110 5Y'\$_\ D2]1
M_P"RD?&+_P!6SXTKURO(_@G_ ,B7J/\ V4CXQ?\ JV?&E6OX<O\ '3_])J&;
M_BP_Z]U?_2J)ZY1114&@5B^)?#NC^+_#NO>%/$-H;_0/$VC:GX?UNQ%Q<VAO
M=)UBRGT[4;475E-;WEL;BSN)HO/M+B"YAW^9!-'*JNNU11ML&^YRG@3P1X8^
M&O@OPK\/?!>FG1_"/@K0-)\+^&=*-[?ZB=.T/1+*'3M,LC?ZI=7NI7AMK.WA
MA^TW]Y=7<VSS+B>65F<\#\7/ASK?B[4?ACXQ\'7>F67C;X6^.;?Q#IHUB>YM
M-+UKPUK5A=^&?'7A?4;RRLM1N[:'4O#VIRZIILD5E<QKXHT'P[+=1-9Q3X]I
MHIJ33YMV[WOK>]T[^J;OUU$XIKEM9*UDM+6::MVLTK>AX4_[-_PDE\;2^/9-
M%\0'4[CQ!%XNN/#G_"POB(?AC-XNA>&YC\5R_"#_ (2D?"J7Q,FIP0ZZOB%_
M!AU?_A)8T\3?:QKX&HU+\//AEJ^C_$SXL_%GQA+I5QXH\>7ND>&O#\&D7-[>
MVOA_X6^"5OH_"6D/<7UGI[-JVJ:EJWB'Q=X@2WM%MK+4_$+:);WFK6NBVVKW
MWN%%/GDTTY-II1U;=HIIV5WHKQ7W"Y(W322:;>B2NVFKNV[2;M?NWO:Q1114
ME!1110 4444 %%%% !1110 4444 %%%% !7E7QT_Y(O\5O\ LGWBW_TQWM>J
MUY5\=/\ DB_Q6_[)]XM_],=[6E'^+2_Z^0_]*1%3^'4_P2_])9Z=:_\ 'M;_
M /7"'_T6M3U!:_\ 'M;_ /7"'_T6M3UF5'9>B_(****!GD?@W_DJ/QC_ .OS
MP3_ZB-C7KE>1^#?^2H_&/_K\\$_^HC8UZY5U/B7^"G_Z;B9T]I?]?*G_ *6P
MI" P*L 5((((!!!&""#P01P0>"*6BH-#X7B_X)I?L.0?$P?%R/\ 9[\*KXS7
M63X@0G4O%+>%(]8\[[0M[%\/FUX^ (GCN0+F*./PRL,-R!<11I.!(/N=5555
M54*J@*JJ %50,!5 P     !@#@4M%7*I.=N><Y\JM'FDY<J[*[=EY(F,(0OR
M0C#F=WRQ4;ON[)7?FSYTT[X'11^*OC5IFMVVBZ]\(?C#>Z1XRFT"YN;^VUG0
M/'RV5GIGB*334M;6..VL;^;0="\8Z5KEAK%CK^C>,Y=6U&T$<OV"]MMO1/V<
M_A+HF@>*?#AT37?$=KXSAL;;Q'JOC[QYX^^)'BZ^M=)E>YT.UC\<^/\ Q-XD
M\9V%KX<OI)=5\+VVG:]:0>&=9FGUG08].U2:6[?W"BCGG_,U\.B;2O%))V6E
M_=6N]U?<.2/\J>]KI-KF;;2=MM7IYVV/G.Z^!<7@?P#\0-+^"DU];?$/QOI4
M.AKX[^*/Q"^(OQ%\06%M*SZ?%=2^+_'6K>./%]W8^#K'4]8USPMX/34K70)-
M<>6UCDT)=;U+5X_6?AUX$T'X8^!/"7P]\,6YMM \&^']+\/:5$S%W^R:7:16
MD3RR,2\L\HC\V:5R7EE=Y'9F8D]G12<Y-6;;UYFWJV[)*[>KLEIVN^X*$8NZ
M26EE9625[NR7=[][+L%%%%24%%%% !1110!\+_&/_@FS^QG\?OB'KGQ5^+7P
MEOO%GCSQ&M@FKZXWQ-^+6C"XCTO3[;2["*+3- \=:5I%E#;6-G;P)#8V%M$1
M'YC(TKN[>G?L[?L=_L[?LHKXH7X"^ 9O! \9MIC>(Q+XP\<^*_[0.CB\&G%3
MXR\2^(39_9Q?W8(L/LHF\W]_YOEQ[/IJBM'6JN'LW5J.G9+D<Y.%HVLN6_+9
M65E;2RML9JE24N=4Z:G=OG4(J5WN^9*]WUUU/%_B]\.=;\87OPV\6^#[O3;'
MQM\,/'%KXCTHZO-<VNEZQX?U6RNO#OC7PSJ-W96>H7=M;ZGH&I2ZC820V5PJ
M>(]$T"6YC-K%/CMM1\ >$]8\:^%_B+J6E>?XQ\':/XBT+P[JHO\ 4HUT[2_%
MDNCSZ_:_88;J'3;S[=+H&E,+B^L;BYMA:XLY+99[E9>RHJ>9V2[)I-:.TMU?
MMJ]/-]RN57;M>[3=]5>-K.STNK+7R78\.NOV<_A+>>,SXYGT373J#ZW%XGG\
M/1^/?'\'PUN_%,,ZWD7BF_\ A'!XGC^%M_XG34DCUE?$5YX/GUD:]##KOVW^
MUX8KU%\ ?#+5M)^)WQ5^+/C"72KCQ)XVN-(\,>&[?2;F]O+;0/ACX.6\7PSI
M<MQ>V=@QU;5=2U37/%6NQV]H+:RU#7#H\%YJMOI-OJEW[A11SR::<F[KEU;=
MHW3LKO1:+Y*VP<D;I\J33OHK:V:N[;M)M*^UPHHHJ2@KR/X%?\DM\+_]<;W_
M -.-W7KE>1_ K_DEOA?_ *XWO_IQNZM?PY?XZ?\ Z34(?\2/^"I_Z53/7***
M*@L*\CUK_DN'@#_LG/Q+_P#3]\-Z]<KR/6O^2X> /^R<_$O_ -/WPWJZ?Q/_
M  5/_3<B*GPK_'3_ /3D3URBBBH+"OACXQ_\$VOV-/C_ /$/6_BK\6OA-?>+
M/'GB)+"+5M<;XF_%G1A<1:786VF6$,6F>'_'.E:190VUC:6\"0V5A;QGR_,9
M6E=W;[GHJH3G3?-3G*$K6O"3B[73M>+3M=)V[I$SA":M.$9J][3BI*_>S35S
MYD_9V_8Z_9V_91'B<? 7P#-X('C(Z:?$?F^,/'/BO^T#I NQI^W_ (3+Q+XA
M^Q^0+ZZS]A^S>=YG[_S-D>SL_B_\.=;\8W?PX\5^#[O3;'QM\,?&]IXDTEM7
MFN;72]7T'4[.Y\/>,_#6HW=E9ZA=VUOJ>@:C-?V4D-E<*OB'1M!DN(S:QS8]
MHHINI-S<Y2<Y/>4VY.2MRVDVVVN73?;02IP4>2,5".Z4$HI.][I)))WU]3PJ
M;]F_X277C27QY<:+X@.IW.NP>*KSPXGQ#^(B_#*Z\56[Q7$7B:Z^$:>*(_A9
M>>(H]0@BUD:]<^#'U5M?BC\0M=?VVHO@V[_9H^#%]\0/^%EW/A2[?Q$WB&W\
M83:>GBSQC#X%O/&=I:"QM?&VH?#&'7X_AQJ/C:VME1;?QA?>%;CQ)#)'#<1Z
MFMQ#%*GN]%'M)_SSVY?B?P]M]M%IL/DA_)'>_P *W[[;^>YX?X!^&6K:5\4/
MBG\6O&$NDW'B/QI-I/ACPU;Z3<WMY;Z!\,_""W8\.:;-<7MG8,=6U;4M2UOQ
M1KD=O:BVLK_6CI$%YJMMI=OJ=U[A114RDY.[Z))>2BDDODDAI**LN[;\VW=M
M^K?IT22T"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH \B^*G_ "%?@]_V
M5FR_]0;Q[7KM>1?%3_D*_![_ +*S9?\ J#>/:]=JY?!3])?^E,B/QU/6/_I*
M"BBBH+"O(O@?_P B#%_V,?C'_P!2K5Z]=KR+X'_\B#%_V,?C'_U*M7K2/\*I
M_BI_^WD/^)'_  5/_2J9Z[1116992U+3=/UC3[[2=6L;34]+U.SN=/U+3=0M
MX;RQO["\A>WN[.\M+A)(+FUN8))(;B"9'BFB=XY%96(/Q5X*_P"";7[$?P\^
M(EM\5/"7P!\,:=XSL=175]-NKC5?%6KZ-I&IQR^=!?Z+X2UG7]0\):/=6DP$
MUE-IFB6CV,RI+:&!T1A]Q45<:DX*2A.<5)6DHR<5)=I)-77DR90A-IRA&3CK
M%RBFXONFT[?(.G2OC^R_9/\ #FL:;J?@CX@MJ>H^!?#/Q3UKXF_!J[\%_$?X
MD?#GQ;X1G\3)?7=]IMQJ'P_UCPE>VT?A^^US7M*\.R6FNWD3>'KBVAGM;:Y2
M8R_8%%*,Y0ORMJ]M4VFFNJ:U3LVO1M!*,96NKVOH]4T[733T:ND_5)G@B_LU
M?"R3P?JO@;5A\1?%F@ZMJNG:Z9/'GQJ^,WC_ ,0:-K6D/')I>K^$?%_C7Q[K
MWBSP3J>G31+/97_A#6M$NK6X,EQ#*DTLLC\OXO\ V<=*A^$6K_!KX6VUOH&@
M_$+Q%'_PM'7_ !+XG\6^(_%VL^&M7N?M'C>_NO$^O7'B+Q3XR\7>)+"W3PP+
M[Q/XBCEM-,U*:]&J/_9%EI5W]1T4U4G=/FD[-2LVVKJUFTW9M67W(3IP::Y8
MJ\7&Z23Y7ND[7292TW3K32-.L=*L(4M['3K2WL;2",!4AMK6)(88U P $C10
M,>E7:**@L**** "BBB@ KP[X^_LX?!W]I_P9:_#[XW^%;GQCX0L]:M?$,.C0
M>*/%OA:,ZO96]U:VEW/<^#]=T"]NA!#>W*QV]S<RVP:4R>3YBHZ^XT4XRE%J
M49.,D[J46TT^Z:LT_032DFI)23W32:?JGHS\[O!O_!*3]@SX?^+/#GC?PE\$
M;K2_$_A/6=/\0:!J+?%7XR7ZV.K:5<QW=C=&QU+X@WFGW8@N(HY#;WMK<6TN
MW9-#(A*G]!-2TVRU?3;_ $C4K:.[TW5+&ZTV_M)EWPW5E>P26MU;2J>&CG@E
MDB=3U5B#UJ[153JU*C3J5)S:V<YRDUZ.3=OD3&G3@FH0A!/=1C&*?JDE?YGR
MSX6_9PLK[X9^$OAY\5;O4M5N_AE?:CIW@'QUX#\?^/\ X?>.E\*QL]GI#WGB
MWP-J?@SQ3I.HW^B)86WBK2--UVZT+5;RQ@N9?M*V]FEM=\9?L^V.KZ%\,_AC
MX7M-*T7X2^'_ !I:^./'=M>:KKFI>)O$U[X=O4\0:#937=^M_>>(+K7/&+1>
M)O%WB?Q)X@FUB]NM'B6ZCUF;6[V[L?IFBCVD[WN]&Y)-MQ4G?WE&]D[NZ\Q>
MSA:W*MDKV5VE:R;M=JR2:>ZT$ "@*H 50  !@  8  [ #@"EHHJ#0*\N^-?_
M "2KQO\ ]@9__2BWKU&O+OC7_P DJ\;_ /8&?_THMZNG_$I_XX_^E(BI_#J?
MX)?^DL]%T[_D'V/_ %YVO_HA*N53T[_D'V/_ %YVO_HA*N5!4=EZ+\@HHHH&
M%%%% 'E5Y\#OA'J%Y=7][\/_  U<7E]<SW=W<2:?&9)[FYE::>:0\9>65V=C
M@99C5;_A0?P:_P"B<^%__!='_C7KU%7[6I_S\G_X'+R\_)?<B/94_P#GW#_P
M"/\ EY+[CR'_ (4'\&O^B<^%_P#P71_XT?\ "@_@U_T3GPO_ ."Z/_&O7J*?
MM:O_ #\J?^!R_P _)?<+V5+_ )]T_P#P"/\ EY+[CR'_ (4'\&O^B<^%_P#P
M71_XT?\ "@_@U_T3GPO_ ."Z/_&O7J*/:U?^?E3_ ,#E_GY+[@]E2_Y]T_\
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M='_C1_PH/X-?]$Y\+_\ @NC_ ,:]>HH]K5_Y^5/_  .7^?DON#V5+_GW3_\
M (_Y>2^X\A_X4'\&O^B<^%__  71_P"-'_"@_@U_T3GPO_X+H_\ &O7J*/:U
M?^?E3_P.7^?DON#V5+_GW3_\ C_EY+[CR'_A0?P:_P"B<^%__!='_C1_PH/X
M-?\ 1.?"_P#X+H_\:]>HH]K5_P"?E3_P.7^?DON#V5+_ )]T_P#P"/\ EY+[
MCR'_ (4'\&O^B<^%_P#P71_XT?\ "@_@U_T3GPO_ ."Z/_&O7J*/:U?^?E3_
M ,#E_GY+[@]E2_Y]T_\ P"/^7DON/(?^%!_!K_HG/A?_ ,%T?^-'_"@_@U_T
M3GPO_P""Z/\ QKUZBCVM7_GY4_\  Y?Y^2^X/94O^?=/_P  C_EY+[CR'_A0
M?P:_Z)SX7_\ !='_ (T?\*#^#7_1.?"__@NC_P :]>HH]K5_Y^5/_ Y?Y^2^
MX/94O^?=/_P"/^7DON/(?^%!_!K_ *)SX7_\%T?^->D:%H.C>&=*M=$T#3K7
M2=)L1*+33[*)8;:W$\TES-Y<:\+YD\TLKGJTDC,<DFM:BIE.<E:4Y26]I2;5
M]KV;[:%1A".L81B]KQBEIVT7DON"BBBI*"OEKX7?!_X8^)/#VLZSKO@CP_JF
MJ7?Q'^+@N;V[L4DGF%O\4O&%M"'?C(B@ABB08X1%4<"OJ6O(_@G_ ,B7J/\
MV4CXQ?\ JV?&E:QE*-.;C*47ST]8MI[5'T\S*48RJTU**DO9U79I-7YJ6MGU
M&_\ "@_@U_T3GPO_ ."Z/_&C_A0?P:_Z)SX7_P#!='_C7KU%+VM7_GY4_P#
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MXUZ]11[6K_S\J?\ @<O\_)?<'LJ7_/NG_P" 1_R\E]QY#_PH/X-?]$Y\+_\
M@NC_ ,:/^%!_!K_HG/A?_P %T?\ C7KU%'M:O_/RI_X'+_/R7W![*E_S[I_^
M 1_R\E]QY#_PH/X-?]$Y\+_^"Z/_ !H_X4'\&O\ HG/A?_P71_XUZ]11[6K_
M ,_*G_@<O\_)?<'LJ7_/NG_X!'_+R7W'D/\ PH/X-?\ 1.?"_P#X+H_\:/\
MA0?P:_Z)SX7_ /!='_C7KU%'M:O_ #\J?^!R_P _)?<'LJ7_ #[I_P#@$?\
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M_P"%!_!K_HG/A?\ \%T?^-'_  H/X-?]$Y\+_P#@NC_QKUZBCVM7_GY4_P#
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M^#7_ $3GPO\ ^"Z/_&C_ (4'\&O^B<^%_P#P71_XUZ]11[6K_P _*G_@<O\
M/R7W![*E_P ^Z?\ X!'_ "\E]QY#_P *#^#7_1.?"_\ X+H_\:\Z^+?P2^$V
ME?#?Q=J.G> ?#=I>VFE--;7,-@BRPRB> !T;/# $X-?4=>7?&O\ Y)5XW_[
MS_\ I1;U5.K4]I!>TG;GC]N7=>?DON)J4J:IS:IP34)6]R.EEIT\E]R/1--
M&G6  P!96H '0 0( *NU3T[_ )!]C_UYVO\ Z(2KE8FL=EZ+\@HHHH&%%%%
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MFDKV]HKMOG?/!2=*$HP?/[->S:E"+EAHOEBZ<Y03?M9J'([I7]F^5)>QZ/\
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M$<_A/0)_&/AFSTOQ3X7UC7H=6T'P-J6BZ+)XFOKB!YO#MO9:Y\K3^ O&5O\
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MZU_X]K?_ *X0_P#HM:GJ"U_X]K?_ *X0_P#HM:GK,J.R]%^04444#/(_!O\
MR5'XQ_\ 7YX)_P#41L:]<KR/P;_R5'XQ_P#7YX)_]1&QKURKJ?$O\%/_ --Q
M,Z>TO^OE3_TMA6)XFL=9U/PYX@TWPYK,7ASQ#J&BZK9:%XAGTT:Q#H6L75C/
M!INL2Z0;O3QJD>F7LD-Z^GF^LQ>K ;8W4 D,J[=<EX^\4R>!_!'B[QC#H&N^
M*Y_"_AO6=>M_#'A?3;O6/$?B*XTO3Y[RWT/0],L(+F[OM5U6:&.QL;>""5GN
M)X\KM#$2KMJV]U;;?IOI]^A;LD[[6=]]NNVOW:GXE?M0_L*?L]?LS_L]Z_\
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M:C!\UDM6FFM$EO'FMNN:VUDI:***S- KR/X%?\DM\+_]<;W_ -.-W7KE>1_
MK_DEOA?_ *XWO_IQNZM?PY?XZ?\ Z34(?\2/^"I_Z53/7****@L*\CUK_DN'
M@#_LG/Q+_P#3]\-Z]<KR/6O^2X> /^R<_$O_ -/WPWJZ?Q/_  5/_3<B*GPK
M_'3_ /3D3URBBBH+"O@[XW_L'^ /VF/BKJWC;]H[Q;XF^(7PPL-!T;3?A_\
M!6RUWQ;X"\(^#;ZSAG?Q!XIU;4?"GB_3KKQ1KNLW4I>&]E@TA-+TZ./3I8]1
M2*&>+[QK\4/V[/C7\2_%?QLD^ .L_!/]M;4OV7] T?3KKX@:M^S)\$_$?B+5
M/C9K>IV\5[/X+?QZ^I>';;1?A[IUE/'8ZX/#5W=ZEKFH'4]/FN+6""TGBWPR
MJ2J6IS]G+E=YJRDHZ7Y'=-2;M%<KB]6G)1YF8UW34%[2*FG))1?PRETYMURK
M=\R:V=F['M7_  3;#Z7?_M+^#/AYXR\2>/?V7? WQ6B\-_ /7_$NK7OB%+6.
MTTBW'C;PWX3\1ZC<75SKO@CP[KI&G:'J,5Q<V<TL=^T5U/,;AA]X?%+XH0?#
MF/P;86ND_P#"1^+/B#XSTOP7X1\-KJ*Z6=0N[B.YU/6]2NK\V>HO9Z7X;\-:
M;J^N7]RMA<^8UG;:9&JW6I6IKQ#]D#XR>#/B#X3NO!'@#]FG]H']FWPG\,M/
MT32=$T'XV?"$?"JPOK"XCNDAA\)PKK6KC518"S)U61C%+%)=6\DK3/<,PM_&
MJUELOVE/V2O%-])'#X>CNOC%X*\V5F*#Q?XK\+Z#K'AN'9L,227&D^#?%B17
M+NCHRFVCW&\(+J>_7DY1:T;<;IM\E.ZYG'2\^5.?+UD[:DP:C0ARR35XJZ6B
MYZB323VC%2M%/:*5S<T'XP_%_P :_$CQKX=\$_"CX=WWP[^'_CNW\"Z_XW\1
M_&;Q%H'B6ZN[?2=&U/Q'>Z!X%T[X(^)M+U"/1IM5FTRW@OO'VD'4K_3YTFFT
MR-@Z<1K'[6VK:=K>JZ[:_#"UU#X#>&_B[9_!/Q-\4CXZEM?$^G^+KC7K?P9=
M:S9_#E_!<NGWW@32O'=Y:^%]0\07'Q#TW5%8W.K6OARZTR".:X^>/%7PU\!1
M>(_$MA\.OV;-<^'O[65]\=;+Q/I7Q4A^'GCOQO:G1+_XFZ;K_BOQO8?M):WX
M-C\&:%HGBSX<R:_<:M\/(O&=D]A-K&I>!(M!O;V5K>[S-5\)>.8?AKX[_9)_
MX5_\0[GQEXL_:@G\9:-XKM?!WB=OAZ?AAK/QVLOC1=^.KSXGVFG+X"T^?3M#
MBO=+?PI<>)=.\92>((X;&TT9TDBO7M4Z;Y=-^5-2O%J/N\]:ZJ2325W&2M"_
M->+21#J5+.S;:<G=)-.7V:6L(M/=--<^WO)L_1KP+\35\6>+?B)X&U71AX=\
M3_#_ %BU0V0U(:G!K_@_7;<WWA+QIIEP;'39!9:U:I<V=[:-;.ND^(=*UO1H
M[[4XM/34KOU2OCWPY;2:A^VUX[O])CD.F^$OV>?AWX2\5WZ!_L]QXDO_ !;X
MR\0Z/I<C-\GV[3- O(]1D"L\PM/$%GYVQ#;F3["KGFE%JW6$)6[.44W]][KR
M:.B$FT[ZM2E&_>S=MDE=+1VTNG;0****@L**** "BBB@ HHKR_4_@U\.=8U"
M\U34?#[W%]?W$MU=S#6==A$L\SEY'$4&IQ0Q[F8G;'&B#HJ@<4UR_:;7I%2_
M.41/F^RD_63C^49'J%%>0_\ "B/A9_T+4G_@]\1__+:M71/A%\/O#NJ6FLZ/
MH3VFHV+.]K<'5];N!&TD4D+DPW6HS0/F*5UQ)$X&[<,, 134+.TIWZ7@DK^;
M]H[>MGZ$ISOK&%NMIMNWI[-7]+KU/2:***@L**** /(OBI_R%?@]_P!E9LO_
M %!O'M>NUY%\5/\ D*_![_LK-E_Z@WCVO7:N7P4_27_I3(C\=3UC_P"DH***
M*@L*\B^!_P#R(,7_ &,?C'_U*M7KUVO(O@?_ ,B#%_V,?C'_ -2K5ZTC_"J?
MXJ?_ +>0_P")'_!4_P#2J9Z[111699XW^T0/B&?@5\7/^%2W<=A\2A\/_%!\
M%WLEY9Z?]DUX:5<FSN(M0U%XK"QN8F#/:7M[-#:6MT(9[B>&*-Y4_FY^'?B3
M]D.>]_9XNOV4OB'\5V_X*%Z_\1? UE\1-3\0>,?'=Q+KSM?(_P 58/B5?^*=
M5'PI\0Z#)IT.JR16?@.]O;_4I8[0:;'.3D?T(?ME?"_QQ\:/V8?C'\,?AO=V
MMIXU\6^%'LM#%]<O9VFH36^H6.H76B7%Y&\9M8]?L;.ZT0W#2111&_#SRPPB
M25/RW^)_C'QW^TE\%/!W[)G@_P#8 ^-OPK^)ND:EX%LK;QUXQ^'NA^$_@S\%
M+OPUJNF3:EXX^'WQ(M=3\O5;G3+.RNETE-#L;&ZOX+EX56Z5VLKGOPLDJ;5]
M'4]^TXP48<J2E64OXM%MOW$XZQ=Y7<4<.)3<UIM!.%X2FY2YK\M*4?X=6R24
MW?XE[MDV?N]#YHBB$Q4S"-/-*#"F7:/,*CLI?)4=ABOE'5?VE/$E_INM7OPM
M^#VL?$QF^*[?"/P3=6>MW>G>'=:U/21<P^,O%_C'Q!8>%/$:> ?A[X8U+3-9
MTB/Q']A\3W6NZC:64.FZ1C5K9U^H-,L[BSTBPL+BX:ZNK73K6TFNG)W7$\-L
MD,D['&<RR*9"<9R<XS7YD_#_ .*/C7X)?L<^ O#_ (/\,^(/$'Q*M_&OB#X3
MZ_J>B?#?XB?%;3OASX@TCQ)KEKXQ\9>+?"WPVT+6O%NLVFC26-T=/LK>SMO^
M$AUN[TN"ZO['3;B]U&VY:<%*_N\SYH12;:C9\S;;5G]E+T;M[UFNFI)QM[S@
MN64FTDW=."LKW5_>>MFM+O3?W ?M<:S8Z5XA\/>(?A=86'QTT7XL:-\&[/X;
MZ5X_FUGP;KGBGQ+H2>,-!U.S^)DW@;2-0M_"K^"C+XAUG4+SX=PZOI+VEWI<
M.@:E=_8S>Z]A^U)K%IX:\<:AXU^&<'AWQ/\ ![XA:/X0^,WA[2/&K^(].\+>
M&->M+#4;#XD>%]=N?"'AVZ\7>&4TK6]#UF_74O#_ (.N+'26UZXE)N="%GJ/
MS8GA+P[I/@_X2_$'X9:/\<?B%J/PI_:&B^*'QLUWQU\%OBUX-^)GCN?Q7X,\
M5>%_%'C2R\)>-O 7A#7_ !>^D-XBTV6TT'P)HNIIIVB6/]D:)82G3(M..UJ\
M<U]\-_V^_CCKOA;Q3H?A+XP:!-X?\!>'O&&@Z_X4\3^);/1OA9IGPYTF_F\'
M^(++3/$OAVX\5^+B]EHNG:UH6FZ]);OI]S+; 7%O%'M[.G>RA:\HK5R4N9SA
M'D47*Z4H.52*DG*S7O-)F*G5ZS5U%O:#7*H\W-=*S:DN1M-1OT3:9^FL$\-S
M!#<V\BRP7$4<T,J$,DD4J!XY$8<%71@RD=00:EKS[X3:9JVB_##X?:1KKN^L
MZ;X.\.V6IM)@.;VWTNVCN-X!.&$BL&&3@@YYKT&N5Z-J][/?OYG4G=)O=I,*
M***0PHHHH *Y/QU/XUM_"'B&;X<6'AW4_'2Z;./"MEXNO[_3/#$NL/MCM6UV
M]TJSO]2ATR!F-Q=BQM);J:*)H(/+DD65.LHIIV:=D[.]GL_)VL[?,'JGT\UN
M?DI^QIX>^+OAG]M_]K73OC;\2D^)OCV?X:_ S5=2U'3=.?1?"NAKJR^+[^+P
MQX.T:2:>2Q\/:*DPM+62=_MFHO')J5\!>7<P'ZRW-S;V=O/=W<\5M:VL,MS<
MW,\B106]O C2S3S2N52***-6DDD=@B(K,Q !-?"OPK\)>*]/_;Z_:L\7W_AG
MQ#9>$_$'PP^ UAH/BB[T74K;P[K=]I%AXC35;/2-;FMDTW4KO3'GA34+>RN9
MIK)IHEN4B,B _3_QPT#6?%7P7^+GACPZI;Q!XB^&?CO0]#02O"7U?5?"^J6.
MFH)D#/$6O)X5$BJ60D, 2*WKM3J0;<5>G03Y4HI?NH7T5DK=M+&%).%.>[M.
MJUS-MNTY6NW=N_>[N>(P_M(_$3Q;HOP_O_A1\"+SQ?<_$^_\47_A?4O$GBS5
MO!_P_P!+^'OA]D&G>+_'7C?3?AWXTE\+ZMXPCN;"?PMX,M/#>OZA>0S7DMUJ
M%FFFW#&SX1_:F_MSP[X$\1^(/ 4GABSUCXC>(?@[\1F7Q-'J]O\ #?XDZ+J=
MSH-I9I>IH=A!XG\*:WXATZ]T:P\4?\2"Y6[NO#R2>'_-UF>'2O"_$GQO\1:'
M\!/V=/"?POM/'VEV/Q(\#Z=#K_Q>\#_!;XH?&!/AEX9TG1K*WO\ ^R_#_P -
MO!_BR6/Q_K%S/]B\,#7[.+1-':VU#6=3AOWLK/2-2?\ $W3?AS8_L::7X ^$
M>B^.(+;5OB#\-/"WA"W\=^!OB'X#\<:QXV;XH>'M<U#Q-JFD?$CPUX7\6WNI
MNVGZQXKU36KK2EM]32UOKO[2]L\D@KV<?=3@US5.5-.3:CS2BW)WY4UHXJUW
MR-OW79S[26K4[\M-2<;1UDXPDE%)<S3UYG>R4DEJKK])Z*K6<<D5I:Q3'=+'
M;01RM_>D2)5<^G+ FK-<ITA7EWQK_P"25>-_^P,__I1;UZC7EWQK_P"25>-_
M^P,__I1;U=/^)3_QQ_\ 2D14_AU/\$O_ $EGHNG?\@^Q_P"O.U_]$)5RJ>G?
M\@^Q_P"O.U_]$)5RH*CLO1?D%%%% PHHHH **\KO/B)XIM;NZMH?@?\ %34(
MK>YG@BO[/4/@XMI>QPRM&EW:K??%JRO5MKE5$T"WEG:70B=1<6T$H>)*W_"R
M_%O_ $03XN_^#'X)?_/DJ^27>'_@RG_\D1SQ[3_\%U/_ )$]=HKR+_A9?BW_
M *()\7?_  8_!+_Y\E'_  LOQ;_T03XN_P#@Q^"7_P ^2CV<N\/_  93_P#D
M@]I'M/\ \%U/_D3UVBO(O^%E^+?^B"?%W_P8_!+_ .?)1_PLOQ;_ -$$^+O_
M (,?@E_\^2CV<N\/_!E/_P"2#VD>T_\ P74_^1/7:*\B_P"%E^+?^B"?%W_P
M8_!+_P"?)1_PLOQ;_P!$$^+O_@Q^"7_SY*/9R[P_\&4__D@]I'M/_P %U/\
MY$]=HKR+_A9?BW_H@GQ=_P#!C\$O_GR4?\++\6_]$$^+O_@Q^"7_ ,^2CV<N
M\/\ P93_ /D@]I'M/_P74_\ D3UVBO(O^%E^+?\ H@GQ=_\ !C\$O_GR4?\
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M_P"1/7:*\B_X67XM_P"B"?%W_P &/P2_^?)1_P ++\6_]$$^+O\ X,?@E_\
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MHKR+_A9?BW_H@GQ=_P#!C\$O_GR4?\++\6_]$$^+O_@Q^"7_ ,^2CV<N\/\
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M^%E^+?\ H@GQ=_\ !C\$O_GR4?\ "R_%O_1!/B[_ .#'X)?_ #Y*/9R[P_\
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M  74_P#D3UVBO(O^%E^+?^B"?%W_ ,&/P2_^?)1_PLOQ;_T03XN_^#'X)?\
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MY4ZEK?%3WE&/\_632,Y24:D+W^"IM&4NM/I%-GU/17D7_"R_%O\ T03XN_\
M@Q^"7_SY*/\ A9?BW_H@GQ=_\&/P2_\ GR5/LY=X?^#*?_R0_:1[3_\ !=3_
M .1/7:*\B_X67XM_Z()\7?\ P8_!+_Y\E'_"R_%O_1!/B[_X,?@E_P#/DH]G
M+O#_ ,&4_P#Y(/:1[3_\%U/_ )$]=KE="\$^&?#.L^*M>T+33IVH^-=3M]9\
M2M#>7[6>HZM;V%MIBZDNF2W4FFV5[/9V=M'>W-A:6LNH21+<7S7%P6E/&?\
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M%06%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y'\"O^26^%_\
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MBBB@ HHHH **** "O+OC7_R2KQO_ -@9_P#THMZ]1KR[XU_\DJ\;_P#8&?\
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M .OSP3_ZB-C7KE74^)?X*?\ Z;B9T]I?]?*G_I;"OFS]LC5-8T7]D[]I'5=
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MH6AR/#[#^S[\,I/@Y\%_AS\-;F]_M+4/"OAC3K#5]1VE?[0UMX_M.LWP5BS
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M,SQ;I[0R3>6LNSS83YC;X71^-V*VJ**@M;:ZOJ]KA1110 5Y'\"O^26^%_\
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MJ/\ A7'C;_HOWQ3_ /!#\#__ )SU')'_ )^T_NJ__*_ZL_*YSR_Y]5/OI?\
MRS^K/ROZ[17D7_"N/&W_ $7[XI_^"'X'_P#SGJ/^%<>-O^B_?%/_ ,$/P/\
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MGJ/^%<>-O^B_?%/_ ,$/P/\ _G/4<D?^?M/[JO\ \K_JS\KG/+_GU4^^E_\
M+/ZL_*_KM%>1?\*X\;?]%^^*?_@A^!__ ,YZC_A7'C;_ *+]\4__  0_ _\
M^<]1R1_Y^T_NJ_\ RO\ JS\KG/+_ )]5/OI?_+/ZL_*_KM%>1?\ "N/&W_1?
MOBG_ ."'X'__ #GJ]'T+3KW2=*M=/U'7M4\3WEN)1-KFLP:);:E?&2>25#<P
M>'=(T'1D,$;I;1_8]*M T,,;3"6X:6:29125U.,O)*=_7WH17EO>_2VI49-[
MPE'SDX?=[LY/\+:/7:^M1114E!7D?P3_ .1+U'_LI'QB_P#5L^-*]<KY;^%O
M@CQ5JGAW6;ZP^,7Q \-VDWQ(^+GE:-H^C_"BYTZT\OXI>+XG-O-X@^&NN:NY
MN)$>YE^U:G<A9II%@$-N(H(M8I.G.\HQ]^GK+F[5/Y8R?GM^)E)M5:;47+]W
M5T7+?XJ6OO2BK?._D?4E%>1?\*X\;?\ 1?OBG_X(?@?_ /.>H_X5QXV_Z+]\
M4_\ P0_ _P#^<]2Y(_\ /VG]U7_Y7_5GY7?/+_GU4^^E_P#+/ZL_*_KM%>1?
M\*X\;?\ 1?OBG_X(?@?_ /.>H_X5QXV_Z+]\4_\ P0_ _P#^<]1R1_Y^T_NJ
M_P#RO^K/RN<\O^?53[Z7_P L_JS\K^NT5Y%_PKCQM_T7[XI_^"'X'_\ SGJ/
M^%<>-O\ HOWQ3_\ !#\#_P#YSU')'_G[3^ZK_P#*_P"K/RN<\O\ GU4^^E_\
ML_JS\K^NT5Y%_P *X\;?]%^^*?\ X(?@?_\ .>H_X5QXV_Z+]\4__!#\#_\
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M_P#*_P"K/RN<\O\ GU4^^E_\L_JS\K^NT5Y%_P *X\;?]%^^*?\ X(?@?_\
M.>H_X5QXV_Z+]\4__!#\#_\ YSU')'_G[3^ZK_\ *_ZL_*YSR_Y]5/OI?_+/
MZL_*_KM%>1?\*X\;?]%^^*?_ ((?@?\ _.>H_P"%<>-O^B_?%/\ \$/P/_\
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M>1?\*X\;?]%^^*?_ ((?@?\ _.>H_P"%<>-O^B_?%/\ \$/P/_\ G/4<L?\
MGY#[JG_RL.>7_/JI]]+_ .6?U9^5_7:*\B_X5QXV_P"B_?%/_P $/P/_ /G/
M4?\ "N/&W_1?OBG_ ."'X'__ #GJ.6/_ #\A]U3_ .5ASR_Y]5/OI?\ RS^K
M/ROZ[17D7_"N/&W_ $7[XI_^"'X'_P#SGJ/^%<>-O^B_?%/_ ,$/P/\ _G/4
M<L?^?D/NJ?\ RL.>7_/JI]]+_P"6?U9^5_7:*\B_X5QXV_Z+]\4__!#\#_\
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M+_A7'C;_ *+]\4__  0_ _\ ^<]1_P *X\;?]%^^*?\ X(?@?_\ .>HY8_\
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M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y5\=/\
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MB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %!(
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MO(]:_P"2X> /^R<_$O\ ]/WPWKURO(]:_P"2X> /^R<_$O\ ]/WPWJZ?Q/\
MP5/_ $W(BI\*_P =/_TY$]<HHHJ"PKQ_]H7_ )()\;?^R2_$7_U$=8KV"J6I
M:;I^L:??Z1JUC::GI6J6=SIVI:;J%O#>6.H6%["]M>65[:7"2075I=6\DD%Q
M;S1O%-$[QR(R,07%V:?9I_<Q/5-=TSY:_80_Y,S_ &8_^R)_#S_U&M/JM\;#
M<ZE^TK^R1X=O4EF\,+<_&/QE) RR"R?QAX9\,^'M*\,37#?ZF2YM=+\6>*Y;
M*WDRY8S74*YM'9?J/P_X>T'PGHFE>&O"^BZ5X<\.Z%8VVEZ+H.AZ?:Z5H^D:
M;9Q+!::?INFV,4%G8V5K"B16]M;0QPPQJJ1HJ@ <'\4_AG_PL2'P;>V&L_\
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M?HVF7WBO6M6\77<4MUX5\"64B:;?>-]:CEDENY/[-L+2QU76[S3+*7D_B?\
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M=_&WX26-U<V5Y\0_"MO=V=Q-:W4$FJVXDAN+>1HIHG&XX>.1&1ADX(/-5_\
MA>_P;_Z*3X2_\&UO_C7JAAA)),,1)Y),:9)]3Q1Y$'_/&+_OVG^%7>G_ "3_
M /!D?+_IUZ_AVUBU3^:'_@$O_EAY7_PO?X-_]%)\)?\ @VM_\:/^%[_!O_HI
M/A+_ ,&UO_C7JGD0?\\8O^_:?X4>1!_SQB_[]I_A3O2_DJ?^#(__ "KU_I:E
MJG\T/_!<O_EAY7_PO?X-_P#12?"7_@VM_P#&C_A>_P &_P#HI/A+_P &UO\
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M+TOY*G_@R/\ \J]?Z6I:I_-#_P %R_\ EAY7_P +W^#?_12?"7_@VM_\:/\
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M,7_?M/\ "CR(/^>,7_?M/\*+TOY*G_@R/_RKU_I:EJG\T/\ P7+_ .6'E?\
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M/_!D?_E7K_2U+5/YH?\ @N7_ ,L/*_\ A>_P;_Z*3X2_\&UO_C1_PO?X-_\
M12?"7_@VM_\ &O5/(@_YXQ?]^T_PH\B#_GC%_P!^T_PHO2_DJ?\ @R/_ ,J]
M?Z6I:I_-#_P7+_Y8>5_\+W^#?_12?"7_ (-K?_&C_A>_P;_Z*3X2_P#!M;_X
MUZIY$'_/&+_OVG^%'D0?\\8O^_:?X47I?R5/_!D?_E7K_2U+5/YH?^"Y?_+#
MRO\ X7O\&_\ HI/A+_P;6_\ C1_PO?X-_P#12?"7_@VM_P#&O5/(@_YXQ?\
M?M/\*/(@_P">,7_?M/\ "B]+^2I_X,C_ /*O7^EJ6J?S0_\ !<O_ )8>5_\
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M **3X2_\&UO_ (T?\+W^#?\ T4GPE_X-K?\ QKU3R(/^>,7_ '[3_"CR(/\
MGC%_W[3_  HO2_DJ?^#(_P#RKU_I:EJG\T/_  7+_P"6'E?_  O?X-_]%)\)
M?^#:W_QH_P"%[_!O_HI/A+_P;6_^->J>1!_SQB_[]I_A1Y$'_/&+_OVG^%%Z
M7\E3_P &1_\ E7K_ $M2U3^:'_@N7_RP\K_X7O\ !O\ Z*3X2_\ !M;_ .-'
M_"]_@W_T4GPE_P"#:W_QKU3R(/\ GC%_W[3_  H\B#_GC%_W[3_"B]+^2I_X
M,C_\J]?Z6I:I_-#_ ,%R_P#EAY7_ ,+W^#?_ $4GPE_X-K?_ !H_X7O\&_\
MHI/A+_P;6_\ C7JGD0?\\8O^_:?X4>1!_P \8O\ OVG^%%Z7\E3_ ,&1_P#E
M7K_2U+5/YH?^"Y?_ "P\K_X7O\&_^BD^$O\ P;6_^-'_  O?X-_]%)\)?^#:
MW_QKU3R(/^>,7_?M/\*/(@_YXQ?]^T_PHO2_DJ?^#(__ "KU_I:EJG\T/_!<
MO_EAY7_PO?X-_P#12?"7_@VM_P#&C_A>_P &_P#HI/A+_P &UO\ XUZIY$'_
M #QB_P"_:?X4>1!_SQB_[]I_A1>E_)4_\&1_^5>O]+4M4_FA_P""Y?\ RP\K
M_P"%[_!O_HI/A+_P;6_^-5/@!=VU]\)?"-W9SQ7-M/;7CPSPN'CD0ZC=X96'
M!'\CP>:]?\B#_GC%_P!^T_PKRCX% #X6>%@  !#>X X _P")C=TVX>SERQDO
M?A?FDI?9J;6A&W7O^&LI2]I'F<7[D[6BX_:I]Y2O^!ZY11161J%>!>/O%OAK
MP=\8OAYJ7BG6].T&PF\ _$BTBN]2N$MH'N9-:^'DJ0*[G!D>.&5U7N(V/:O?
M:\AUQ$?XW_#\.JL/^%<_$LX90PS_ &[\-^<$&M*=N;5-KDJ72=G;V<MFT[>M
MGZ&=2_+HTGST[-JZ_B1Z)J_WHE_X7O\ !O\ Z*3X2_\ !M;_ .-'_"]_@W_T
M4GPE_P"#:W_QKU3R(/\ GC%_W[3_  H\B#_GC%_W[3_"B]+^2I_X,C_\J]?Z
M6KM4_FA_X+E_\L/*_P#A>_P;_P"BD^$O_!M;_P"-'_"]_@W_ -%)\)?^#:W_
M ,:]4\B#_GC%_P!^T_PH\B#_ )XQ?]^T_P *+TOY*G_@R/\ \J]?Z6I:I_-#
M_P %R_\ EAY7_P +W^#?_12?"7_@VM_\:/\ A>_P;_Z*3X2_\&UO_C7JGD0?
M\\8O^_:?X4>1!_SQB_[]I_A1>E_)4_\ !D?_ )5Z_P!+4M4_FA_X+E_\L/*_
M^%[_  ;_ .BD^$O_  ;6_P#C1_PO?X-_]%)\)?\ @VM_\:]4\B#_ )XQ?]^T
M_P */(@_YXQ?]^T_PHO2_DJ?^#(__*O7^EJ6J?S0_P#!<O\ Y8>5_P#"]_@W
M_P!%)\)?^#:W_P :/^%[_!O_ **3X2_\&UO_ (UZIY$'_/&+_OVG^%'D0?\
M/&+_ +]I_A1>E_)4_P#!D?\ Y5Z_TM2U3^:'_@N7_P L/*_^%[_!O_HI/A+_
M ,&UO_C1_P +W^#?_12?"7_@VM_\:]4\B#_GC%_W[3_"CR(/^>,7_?M/\*+T
MOY*G_@R/_P J]?Z6I:I_-#_P7+_Y8>5_\+W^#?\ T4GPE_X-K?\ QH_X7O\
M!O\ Z*3X2_\ !M;_ .->J>1!_P \8O\ OVG^%'D0?\\8O^_:?X47I?R5/_!D
M?_E7K_2U+5/YH?\ @N7_ ,L/*_\ A>_P;_Z*3X2_\&UO_C1_PO?X-_\ 12?"
M7_@VM_\ &O5/(@_YXQ?]^T_PH\B#_GC%_P!^T_PHO2_DJ?\ @R/_ ,J]?Z6I
M:I_-#_P7+_Y8>5_\+W^#?_12?"7_ (-K?_&C_A>_P;_Z*3X2_P#!M;_XUZIY
M$'_/&+_OVG^%'D0?\\8O^_:?X47I?R5/_!D?_E7K_2U+5/YH?^"Y?_+#RO\
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M8O\ OVG^%'D0?\\8O^_:?X47I?R5/_!D?_E7K_2U+5/YH?\ @N7_ ,L/*_\
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ME_P@*?$3P@WC3[8%W&T_X19=8.N?:@OS&W^P>:%Y*8YKU:OQ#_;"_90_8G^
M7[,L/PH\,_"70O$'[0_CBUMO"OP)U/2-)TF[_:.\<?%(RQRV'BQ_&-A8VOB
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M^$]\"_\ 0Z>$_P#PH]'_ /DRC_A/? O_ $.GA/\ \*/1_P#Y,JN67\LON?\
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M> =6\=>%M)\6:GX8^%'A3P/IYF\8^.(M%U)/#$^N7U_K&K6.@V&B:MXBBO\
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M)NU][7;M>ROZ#C&,;\L8QOORI*]MKV2V"BBBI*"O*OCI_P D7^*W_9/O%O\
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MMQ;>NT(\L4KMOJ[MMWT[!&GRM.]THR2VO><E*6R22NE9+3?06BBBLS0****
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M_P#2J9ZY1114%A7D>M?\EP\ ?]DY^)?_ *?OAO7KE>1ZU_R7#P!_V3GXE_\
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M@?\ \B#%_P!C'XQ_]2K5ZTC_  JG^*G_ .WD/^)'_!4_]*IGKM%%%9EGS_\
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M'4=5U^+3I]#_ +;L[>^@OKBT+\_XOT_Q9H'PC_;#^)/BKPEJ_@\_'2Q@\/>
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M^5CD?_/RI]\?_D?ZN_*WD7]H?';_ *%7X6?^%KXI_P#F(H_M#X[?]"K\+/\
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M^2_J[\K'(_\ GY4^^/\ \C_5WY6\B_M#X[?]"K\+/_"U\4__ #$4?VA\=O\
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MOAO6E)VDW9/W*FCO;^'+LT9U%>-KM>_3U6_\2/J)_:'QV_Z%7X6?^%KXI_\
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MG_YB*\Z^+=]\9W^&_BY=4\-_#:#3VTIA=S6/B_Q)<W<</VB#<UO!/X.MH99
M<822>)3SEQ7U%7EWQK_Y)5XW_P"P,_\ Z46]53FG4@N2"]^.J4K[K^]_5_2T
MU(-4Y_O)OW);N/;_  _U=^5O1--S_9UAG@_8K7('(!\A,XJ[5/3O^0?8_P#7
MG:_^B$JY6)K'9>B_(****!A1110 4444 %%%% !1110 4444 %%%% !1110
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M?J1O;"W^BJ**B3<G=]$DO2*27X+[QQBHII7=VVV]VV[M]%^&P4444B@HHHH
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M6_\ "J3_ .5]>O44>TGW_!>7EY(/9P[?B_+S\D>0_P#"II_^BH?%;_PJD_\
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M*I/_ )7UZ]11[2??\%Y>7D@]G#M^+\O/R1Y#_P *FG_Z*A\5O_"J3_Y7T?\
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MOKUZBCVD^_X+R\O)![.';\7Y>?DCR'_A4T__ $5#XK?^%4G_ ,KZ/^%33_\
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M6_\ "J3_ .5]>O44>TGW_!>7EY(/9P[?B_+S\D>0_P#"II_^BH?%;_PJD_\
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M7Y>?DCR'_A4T_P#T5#XK?^%4G_ROH_X5-/\ ]%0^*W_A5)_\KZ]>HH]I/O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-R:AXF\5>,-=^'MUX@^'/@_6Y?AE\,?"EK)#XHU;Q_P.K_LD?M07?PQ\8_\
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M_9@E\.^%I4TCQ%J#Z[)J,?P_\7LNJ^&%UO0[;^QV%YJ=N;W3A> '[F_7_/\
M.BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P *O$T?BSPM8^,OB!\/[K58],UK2%B\7_"WQOK_ ,./'FC_ &37]-TJ^=M
M\:>%]=T1[V.U?3M0>P-]I-Y?Z9<6E[. >FT5R6I>/?!6D>,/#7P^U/Q3H5CX
MZ\9:9X@UKPKX0N-2MD\1Z]HOA1M+3Q-K.F:.9/MUSI.@2ZYHEOJ^II";&PNM
M9TFUN9X[G4K**?K: "BO"?BW^TI\'?@?XJ^%?@;XAZ_KUOXT^->NW_A_X:>$
M_"/PZ^)/Q.\1^(+G2&TE-=U:XT7X8^$?&&H^'O!_AHZ]HG_"4^//$]OHW@CP
MLNKZ:_B'Q#IJ7MNTGNP.1GUYY!!_$'D?0\T %%%% !17)^-O'G@OX;Z"WBCQ
M]XIT+P?X>74]#T0:QXAU*UTNQDUKQ/K-AX<\-Z-!-=21K<:MX@\0:IINAZ)I
ML'F7NJZM?V>G6,$]W<PQ/SW@CXQ_#?XC^+?BKX%\%^)8];\5?!+Q5I/@GXH:
M2FF:U8MX6\3Z[X-\.?$#2M+DN]3TVRL-6:[\(>+?#VL"[T*ZU2QA745L[BZB
MU&WO+2W /3:*** "BBB@ HHK \5>)=,\&^&M>\6:S%K,VD>&](U#6]3B\.^&
MO$?C+7Y;'3+:2[NDT;PGX/TK7?%7B34VAB=;+1/#FBZKK6IW!CM--T^[NY8H
M' -^BJUG=PW]I:WUN+A8+RWANH5NK2ZL+I8IXUEC%Q8WT-M>V<X1@);6[MX+
MF!]T4\,<BL@LT %%>4_&[XV_#/\ 9S^%WBKXS?&'Q#<>%OASX*ATZ?Q%K=GX
M<\4^+KVU&L:SIWA[2X;+PSX*T7Q'XKUN\U#6M6T[3K2PT/1-2OIKB[C"6Y4.
MR_/?@'_@H;^RU\1/'?ASX:V&N_%_P7XQ\96NNW/@S3_C;^RM^U7^SM8^-)?#
M.DRZ_KFD^#?$/Q]^"OPU\-^+/$MAH%O>Z^_A3P]J^I>)I="TW5M9M])FTW2=
M2NK4 ^VJ*\Z^$GQ9^'WQU^&G@GXP_"GQ"GBSX<?$;P[IOBOP9XDCT[5](36O
M#^KVZ76G:@NF:_I^E:U8K<P.L@MM3TZRNXP=LUO&X*CT6@ HHHH **\\^+7Q
M9^'/P(^&?CGXR?%WQ;I7@3X9?#;PUJ?B[QMXNUIIQI^A:!I%NUS>W<D5I#=7
MU[.5406.F:;:7FJZK?36VFZ797FH75M:R]CHVKZ=X@TC2]=T>Y%YI.LZ?9ZI
MIEVL<T*W5A?V\=U:7 BN(X9XQ-!+'((YHHY4#;9$1@5 !I4444 %%<EXH\>^
M"O!5WX4L/%OBG0O#M_X[\20^#O!=AJ^I6UE?>+/%4^G:CK$?A_P]9S2+<ZOJ
MPT?1]7U>6RL8IYH-*TK4M2G6.RL;J>*7PGXPT?QI8ZAJ&B0^(8;?3-?U_P -
M72^)/!_B[P7=OJ?AK5;K1=3ELM/\9:'H-_J>BR7MG,^C>)=-MKOPYXDTUK;6
M?#FJZKH]Y9W\X!U%%%% !117A'PO_:5^#OQF\=?%/X=_#37]?\3:_P#!CQ%<
M>$/B%J"?#KXE:7X%T[Q787=UI^L>&=$^*&M^$-,^&?C?Q!X=U&RNM-\5:-X&
M\6^)-1\*:E"VG^)+?2[PK P![O17@VH?M/\ P"TZ_P#!&FO\3O#U]<_$;XOZ
M[\ O!S:"-0\2V>K?&'POI'BK6_$O@*34O#MCJFG:5K'A^Q\$>+(]9;6;K3['
M3-3T.]T.\NX=:6/3Y/>: "BBOB3XF_\ !13]D;X0^-/%G@7QM\0O%J:A\/;V
MQTWXF^)?"?P,^/OQ'^%GPFO[ZTL=2-I\7_C5\./A?XK^#WPEN-+T?4].U[Q)
M'\1_'/AAO"GAR_LO$7B<:1H=U!J#@'VW17DFC?';X2^(OB>WP:T'QKI^L?$4
M?"_PW\:4T/3;75+RTN/A?XNUW7O#?AOQ=9^)(+%_"U]8ZMK/AC7+2VMK/6I]
M2"60O)K**QNK.YN/./&/[9_[-?@'PI^T!XV\4?$:6S\.?LN>+]%\ _'.YL/!
M/Q"U^^\%^,?$6C^"=>T/P_;Z'X?\)ZIKOC"_U/2_B-X+GM%\#:;XEBDEUV&R
M\P7UK?VUH ?45%?$7@;_ (*(_LM>/O'7@WX<6>L?&CP5XI^(FI3Z)X$7XV?L
ME_M:_L\^'?%WB"#2[W6_^$:\/^-OCS\#_AOX*U3Q1<Z1INI:EIWAFT\0R:]J
MEEIVH7&FZ==QV5TT6-K/_!2S]E#2/%_COP-;7?[1/C'7?AGXQUKX?>-Y_A9^
MQ!^V[\8?#.B>-/#DXMM=\.GQQ\*?V>/&7@G4=0TN=EBO$TGQ#?QQ,R@R$,"0
M#[VHKX_^(/[>O[*OPK\<Z+\._'_Q(U7PYXEU>P\%:C?O<?"_XNW?A?P!;?$B
M_P#[*\ K\9O'FF^ [WP+\"+SQCJ1CL/#NG?&GQ)X"U#5;R>UM[2UEEN[9);'
MQD_;J_9:^ /CJQ^'/Q5^)-[H/B2YM/"VHZM/I?PY^*?C3PCX#TOQQK;^'/!V
ML?%OXA^!O!/B3X??!?1?$^LQRV>AZS\6O$_@O2]2$,]S:W<MI!-.@!]<45Y/
M\0/CG\)?A9X@^$_A3Q]XYT?PYXD^.GC*;P!\)=$N/M=WJ7CGQ7;>&M9\87>G
M:1:Z=:WD@@LO#F@:EJ5]J]X+71;%4L[:[U&&]U32[:]]8H **Y+Q1X]\%>";
MGPK9>+O%.A>'+WQSXD@\'^#+'5]2MK*]\5>*;G3]0U:+P_X?M)I%N-7U;^R=
M(U;5I+*QBGFATO2]1U&98[.RN9XNMH **\^^+'Q4\ _ [X9^._C%\4_$">%/
MAQ\-/"^L>-/&_B633]6U:/0_#.@6<NH:OJ;Z9H-AJFM7ZV=I#),;72].OKZ8
M+LM[::0JA[73M0L]6T^QU33YA<6&I6EO?65P$DC$]K=PI/;RB.9(Y8_,BD1]
MDL:2+G:Z*P( !<HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.M=5OGTC4)[#[#-_/S>_\%C/VAO!2?&J!_$?[//[1,&@_L!?M3?M8_"[Q_\
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MMG?$/]N'0K'0UC^'\<L&D7WQ/^).M>&M6BOY=1O)? 5GI=A9WMEXABN_$EX
M>;>-?V^OVM?V??'7Q_\ V??BSH/[/_QD^-NAZ5^QE<? #Q=\+_"'Q!^#'PUO
M]8_;3^-?C']GKPYI_P 6_"?C#XK?&CQ'!I?PQ\:>$9?%_B'6O"7C,7?C#PE=
M'1=+T'PWK,":E<^>_M@_M1_MB^'OV8_^"J?[/7B_QQ\(_#G[27[.W[%ME^T;
MX _:!^"W@3XF> _"VN_#'XEZ!\6=-O+32? &I?&_Q5XT^'GQ9\':Q\(/&>EZ
M-XPM_C#XAT<7.N>#O&,?AF1-*UCPI>_H;\<_^">?P._:$\=_&3XA?$#4O'1U
MSXQ?"KX'?#.0Z)K6GZ1_PK[4?V<_B9XX^+_PB^*/P[O[?1O[9T7XD^%?B#XW
M?7[?4[_4]6T263P_H=M+H#69UB#5LS1?^">/P[N/ _[5/AWXO_%+XM_M!>-_
MVQ_ABOP7^-'QC^)4OPYT;QW=_"O3O"?BOPEX5\$^%M'^$_P\^&WPQ\(:3X.A
M\=^--<T9M ^']E>WGB?Q/JVO>(KK6[^9)8P#X^T[]JG]N;0OB??? ;2O$O[&
M=IHO[/O["'P _:H^+'Q7^)_@WXF^!O"OBN[\8>(?C+H6O>#4U&7X\ZC;?!+P
MK<>'/AA9:M>?&'Q)<?%F'X;KIWB+6=2^'_Q#M]7T_2- ROV3O^"EOQB^)W[4
MOA_X"^,_&OP2^./@[X@?LU?&'XU>$?BI\%_V2_VL_P!G#P5;>)O@_P"*/AOH
MUWI_@_Q_\?\ QWX\^'W[37PS\5:?\0C?Z!\3O@GKL6D&'2++4G2;2/%FBW2_
M7"?\$T/AAK'AWXQZ'\3OBW\;/BW?_';]D7P=^QG\0_%7BG4OA_X;\1:A\-_
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M  Q\,:GX,B\7Z99KXY\82^%;W4O$WQ!^UE_P4C_;$\=_LC_M.Z#:_'#]CSX
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MK^S+\=?AU^T-\6OB-\)KRU_9P_9^_:L7P7\.-?T/X5?$;XF^&K'PA^W[XO\
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M%O@7QW!J7A[59]2\+75SI/AWQ+:PZ3=:+J=GXC\-:/>PZFL$=U:77RS\*?\
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MM+'C"7P[J6C'4+NRT;3?$<\.NVX!\6_'+_@H5^U?\*?C+<_LJ0:_\*[GXO\
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M_@*70+'Q9IVER^$]5C\)1>-]$M-/CM_^$MN3<W\EV ?G1<_MF_M<_M7^ ?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
A10 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img94995564_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img94995564_4.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" (,!,T# 2(  A$! Q$!_\0
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M;?7V>^EB974Y<O-[?VE3;F?[KD?+H]''X;6TYNTKG%>+_P!FGQK\'OV;;/\
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M@NI+6*]FTJZ2\M;>]\K!N+(W$<<DULQ"3&- QP*[&BFFTTT[-:IH32:L]4Q
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MGKQ0!M45C&UUH[\:K",Z6MNG^@Q_+J@V[]0/S?-$V&Q:?<7=U.!2_9=8R?\
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MB_O_ /7=?GY-:]% &0-#TT8Q%)\NE_V./](G.+#Y?W?,G^L^1?W_ /KN/O\
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MO-_GA]TA\TMO;:TFYDR-A7 QLT4 8\&@Z;;?8/*BD7^S4NH[3=<3OL6\W_:
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M4ITXRDOO;TZ;=!TFW#7I*<4WU49.*?GHE=]7J%%%%9&@4444 %%%% !1110
M445XE^T=XAUOPI\$?B-XA\.:E<Z1K>E>'+NZT[4K1E6YL[E-NR:%F5E#KV)4
MCVJH1<YP@G9SE&*;V3DTKO[R9248RD]5&+DTM[)7/;:*^(?!_P $OC%K_A+P
MUXH7]JCXH1W^LZ!I6M"RN-/T&?3H[F_L(;S[/*! )I+5))=C<B1HQ_>->C_
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M^B/6J*_/>X\ _P#!1GQ9<S:Q<_'3X(?#"WN4CGLO!N@_#R]\5_V1(5.^TO\
MQ#JEQ&^IA6QF6"-$;YMO&*Z7P7XQ_;(^%NI:=I/QU\*>#_C/X5O9XK:;XD_!
MVUN-$UO1YKFY$44FL^ M1D9I].AC=#<7FF7.Z+#2.A48.KHZ:5:4I:>ZI-/7
MHG*,8R:[1DV^ES/VNJO3J13:7,XJVNUU&3DEYN*MUL?<=%(I#*K#(# $ C!
M(SR.Q]1VI:Q-0HHHH **** "BBB@ HHHH *\=^.G_(@R_P#8>\-_^GBUKV*O
M%?V@([B7X;WL5I.+6ZDUCP^EO<M&)1;S-JUL(Y3$Q"RA&P2A(#="<4 >U45B
MZ!::S8Z9#;Z]JL>M:DC2&74(K*.P252V8U%M$S(A1>"0?FZFMJ@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MGC37?VPOB%X),MUI=M\/K?P1I>K61<V^I:QI<<ESJ+6,D>5N1;H7BDEB+;6
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M6YM#VK;<U&,;64(OG=]VW)QCMLDEW;>PZBBBLC0**** "BBB@ HHHH ****
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MRF^;Y+R3^"+D'^]0!M45AP:X+@VX33M1!FLYKJ0&%";22$9^PW060^5>R?\
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M&E^R?\2O4X_M5C->GS+<+]G,/2TN/G_=W<O_ "SBYW?WA0!M45BPZPTOV/\
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M_AF/5[Z+3M&\7>,_AUXD\,>!-7O+J18K"+3O%6HVZ:?/_:4CHNGOE$N=ZE6
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M!8?/M)6$)>,;'215(?G[STOXM?"[6E#Z5\1/!5\#@ 0>)M'+DG  \MKQ9.I
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?"%SKOB751)XA\7:])%KUG)<W>I:G<I-=/&H#RM##Y5K N=L2JN:^V@
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M+P/>_#OP/8>%M0N[>^NK34-;O'N+972%DU36+W48D"R?-NCCN51R>"ZDCC%
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M\(U\8/\ HIFC_P#A&6/_ ,?H_P"$:^,'_13-'_\ ",L?_C]>O44>UE_+3_\
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M?_PC+'_X_7KU%'M9?RT__!5/R_N^7XON'(N\_P#P.?EY^7XON>0_\(U\8/\
MHIFC_P#A&6/_ ,?H_P"$:^,'_13-'_\ ",L?_C]>O44>UE_+3_\ !5/R_N^7
MXON'(N\__ Y^7GY?B^YY#_PC7Q@_Z*9H_P#X1EC_ /'Z/^$:^,'_ $4S1_\
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M0H94MY=9T35=*BGD5FC@?4+&>T25U3YF2-I@[*O)52!R:^"+[]BKQ3=_L8>
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M-<% -[ISU- 'KOQ*\!7VH+\(+#PGID$>E>"O'_AO4KBUA:.WAT[0-)MYK?\
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M";:A)-K?=:/JKI76FZNO,WZ***S+"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH ^=OC!_P E0_9V_P"QW\0_^HM>5]$U\[?&#_DJ'[.W_8[^(?\
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M5J!Z117CEO\ M!_!:[\(ZYX]M_B-X<E\'^&M0.DZ]X@6YE^P:7J0<QFSN7,
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M]H^T?>\W]Y_J\\XKU+_@G+]K_P"&*O@%]L^U[_\ A$9_L_V[=]I^P?VYJO\
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M5-7S#\!]4NM#\:_&3X0SMOT[P1XBLM=\+$LS-!X=\80S7XT\[B<1V.HPW8@
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M_P "C_\ (^O]+4_>=X?=+_,Y'_A;GPU_Z''1_P#O[+_\:H_X6Y\-?^AQT?\
M[^R__&JZ[_A'M _Z >C_ /@LLO\ XQ1_PCV@?] /1_\ P667_P 8H_==JG_@
M4?\ Y'U_I:G[SO#[I?YG(_\ "W/AK_T..C_]_9?_ (U1_P +<^&O_0XZ/_W]
ME_\ C5==_P (]H'_ $ ]'_\ !99?_&*/^$>T#_H!Z/\ ^"RR_P#C%'[KM4_\
M"C_\CZ_TM3]YWA]TO\SD?^%N?#7_ *''1_\ O[+_ /&J/^%N?#7_ *''1_\
MO[+_ /&JZ[_A'M _Z >C_P#@LLO_ (Q1_P (]H'_ $ ]'_\ !99?_&*/W7:I
M_P"!1_\ D?7^EJ?O.\/NE_F<C_PMSX:_]#CH_P#W]E_^-4?\+<^&O_0XZ/\
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M ,CZ_P!+4_>=X?=+_,Y'_A;GPU_Z''1_^_LO_P :H_X6Y\-?^AQT?_O[+_\
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M7P5T?P%^S_XE34M-\16&C^%=<\2>%=2TVTT*VR+:ULM,MS++)>L%F^U1P2D
M>0NXD9Q^B?PM_9O^%/P_L(-5L_"=C<>,=8\/+IOBKQ5>I.^M^(!J$?G:DNIN
MTY0B>::13&J*8HPD2L @KL?B;X5U;Q+>?#J;2[:"X3P]X^T?7=2,SQH8=.M$
MG6>6(2*=\BEUPBX9L\'BO5::R[+U)36!P:FJE*JI+"T%)5:-)T*-12Y+JI2H
MMT:4T^:G2;IP:AH2^(<_E3E2EGF<2I2H8G"RI/,\:Z<L-C,2L;C,/*#K\KH8
MK&)8O$T6G3KXE*O5C*JE,\3L_P!G#X&Z?X6UOP59?#3PW;^%?$<YN=<T2."X
M%EJ4YE\_S+D&X,A/G 28615#\@5?U;X"?!W71X1&K_#[P_J \!P);>#Q<0SM
M_8$$?W(K'$XVHO99?,'KFO7:\7^+7C?5=,73? ?@G9<_$/QIYEKI:XWQZ!I8
MPFI>)]1 R(K73XF8VX?'VB[\N-,X-0LKRQ14%EV 4%3ITE!8/#J*I4JOMZ5)
M1]G94Z5=NM3A;EA5?M(I3U-7Q1Q+*I*L^(L]=66(Q&*E5>;8]U)8K%X58'%8
MF4WB.9XC$X)+!XBLW[2MA4L/4E*DN0^'OVG_ (/?#;XJ^+;YO"OAK3]*N_#6
MI>'[7XC?$'3A,+R^FNKB"PT_PA:MYIMIKBUMW^T7+! +-51#\Y KZET+]C#]
MF_0] /AP?#32-2T^6.,7J:E-?SB_G0+ONKE%NXXVFE<>8Y" ;CQTS5WQKX"T
MWP'\&[7PSHRO<-#K_AZZU'4)OFO=7U2XUFVFU#5+Z4Y:6YNIR\C%B=B;(U^5
M!7TO5/+<NES<V7X)\WUCFOA:#YOKEOK?->GK]:LOK%[^WLO:\UD1'B3B*')R
M9]G4/9?V>J?+FF.C[-90Y/*E"U=<G]F.4GE_+;ZDY2^K>RN[^$S?LQ?L_P!Q
M_8'G?"?P?(?"Y!T$MIQSIY7IL(E!F ]+GSA[5TNF_!3X4:-XGU+QGI7@/P_I
MWBC5]*?1-2UBSM#!<W6DR0_9WL'6.18%@:$^65CB0E>]>HT4UEV7J2FL#@U-
M5*5526%H*2JT:3H4:BER752E1;HTII\U.DW3@U#0E\0Y_*G*E+/,XE2E0Q.%
ME2>9XUTY8;&8E8W&8>4'7Y70Q6,2Q>)HM.G7Q*5>K&55*9XE:_LX? RR\+ZM
MX+M/AIX;@\*Z[.]UJ^B)!<"SOYY)?.>2<&Y,A+2@2$+(J[@#C@5I:G\!_@_K
M*>#H]4\ :#>I\/HE@\%K/#.P\.PJ<K'I^)QM4'G$GF9[YKUNBH65Y8HJ"R[
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M\JQ>=<2I#&)"I9V ]Z^I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !D_9^^.7P^^*_@WX]?LFV7@G7_$.C_#FS^%/BWX;^/-3N- T?Q1X9T@0_\
M"/W=OKUNDK:?>:08L;?**S(Q YK]%J*U>(G=>[34?>YH*+4)N=N9R5[MNRM9
MKELN6QDJ$$FN:;?NVDY7E!0UBHNVB5W>]^:[YKGPW^RO\"_BUX>\>?%+]H3]
MH:?PNGQ@^*\6C:/_ ,(YX/FEOM!\$^#_  ^K'3O#UKJTP635)/M#O<S7>Q Q
M8#;D5[O^T(SK\,]1:.[2PD75=!*7TJJT5HPU:VQ<2*Y5&2(_,RNRJ0/F(%>V
MUXC^T*T2_#'4FGM7O85U306ELHXA/)=QC5;8M;I"WRS/*/E6,\.3@UE.;G+F
ME;9))*RC&*2C%+HDDDOO=WJ:P@H1Y5=ZMMMW<FW=MOJV]_PT.@G\&^'OB3X$
MF\+_ !!ET7XEZ'J;D:@WV>*+2]06*4/"C0V-QL#0,!G9-DL 6 /%0ZC\$/A/
MJX\%KJ7@;1+Q?AUY9\$":.<CPWY./*_L[;.NS9@8\WS.@KK?!\VG3Z';R:7H
M%SX9M&DFV:1=Z>FF3P,&^=VM(_E02'Y@P^\.3S73UQ5L#@L1.52O@\+7G.%.
MG.=;#T:LYPHU?;4H2E.$G*%*M^]IQ;:A5_>12EJ>MA,[SK 4J=# YOFF"H4:
MN(Q%&CA,?B\/2I5\7AOJ>*K4Z=&K"$*N)PG^RXBI&*G6PW[BI*5+W3SNW^$W
MPXM/&6L_$*V\(Z3#XU\0Z>VE:UXB1)O[0U'3GC,36EPYF,9B,9V$+&IQWK\W
M_!FDG7/B)\>_@1X,_9S\,V7@W4]5T^[U*W\2SZE9^&(Y;!9(UUB^CBD,]Y-J
MSRF\M[>UF&_R^RYQ^LE>/>#<?\+7^+W ^YX([#/_ "![OJ>I_&H>69;+FYLO
MP4N;ZSS7PE!\WURWUOFO3U^M67UF_P#'LO:\UD;1XDXBAR<F?YU#V7]G*ERY
MKCH^S64<SRE0M77)_9;E)Y=RV^I<TOJWLKL^,_BE^R3:Z]<_!>;X@^+'OI-"
M\6Z+X>T'0_#.FQ:1X;\.Z0TOVHV6E0R22W3%9+9 +FY=I2,]*]LU;X0_#?Q-
M^T'976G^$M,&I^']!BU/QWXA59GO=8EF@-AX>T:_D:4Q2+'#YEXZ"-'P 2:]
M,^.>JV>A6W@+6M1E$-AI/CK3;^ZD8@!8;:VNI6 SQN<J$0=V8 <UH_!71[R/
MP[?^,-9C9-?^(&J3^)KX2 B6WL;@[-&L3GE5M=.6(A!@!I6XS3679>I*:P&#
M4U4I55-86@I*K1I.A1JJ7)=5*5!NC2FGS4Z3=.#4-"7Q#G\J<J,L\SATIT,3
MA9TGF>-=.6%QF*6-Q>&E!U^65#%8Q+%XFBTZ=?%)8BK&55*9'8?L\?!;3?!.
ML?#JT^'NA1^"O$%\VI:WX?*7+66IW[2&4W5T#<>8TN\YRLB#@<<5J:C\$/A/
MJZ^"UU+P-HEXOPZ,1\$":.<CPV8<>5_9VV==FS V^;YG05ZI14+*LL45!9;@
M%!4Z=)06#PZBJ5&K[>E24?9V5.E7_?4X)<L*O[R*4]35\4<2RJ.K+B+/75EB
M,1BY57F^8.I+%8O"K XK$N;Q',\1B<$E@\16;]I6PJ6'J2E22@>:_P#"L/A?
MI7B_6/B,WAG0[#QAXAL3I&L^)I7:&]U&PE3R393RRW A,;H=@5$5B#@'->8Z
MQX _9J\'>$-;^',_A+PTOAKQ/?MJFK^"M,AN]0?6M1E?S3<RV-K<2W+3/(=V
MXR1(2<]*N?'WPPOQ"D\$> +;4;S3[_5-:DU*:>SD93:Z3I\.Z\NYT5EWA25C
M@!.!,<CD5ZQX2\ >&/!MG;P:3IEN+N*"**?59T\_4KN2- K33WDQDG+2$%BJ
MR!!G   %4\LRV7-S9?@I<WUGFOA*#YOKEOK?->GK]:LOK-_X]E[7FLB(\2<1
M0Y.3/\ZA[+^SE2Y<UQT?9K*.9Y2H6KKD_LMRD\NY;?4N:7U;V5V?/NH?#&T^
M(2^"DT[X2^'/#6D_#XQ?\(/J_B]+B?4O#R1?ZF71=$MKD>254!H_M\DF#C<,
M#GJ](_9B^&4/BS5OB!XGTP>+_'6OVXMM9U[5=R)=0!/+%NMA ZVR0*ORJA#@
M#'>OHNBFLNR]24U@<&IJI2JJ2PM!256C2]A1J*7)=5*-']S2G?FITOW<&H:$
MOB'/Y4Y499YG#I3H8G"SI/,\:Z<L+C,4L;B\-*#K\LJ&*QB6+Q-%ITZ^*2Q%
M6,JJ4SQNT_9[^"UAX-UKX>V?PZ\/6_@KQ%?'4M;\.117"Z=J5\S^8;FX3[1Y
MADW_ #?)(B@]% K0U'X(?"?5U\%IJ7@;1+Q?AT8SX(6:.<CPV8<>6=."SKMV
M8&/-\SH,YKU2BH6598HJ"R[ *"ITZ*@L'AU%4J57V]*DH^SLJ=*NW6IP2Y85
M?WD4IZFKXHXEE4=67$6>NK+$8C%RJO-\P=26*Q>%6!Q6)<WB.9XC$X)+!XBL
MW[2MA4L/4E*DE \\M_A-\.+3QEK/Q"M_".E1>-?$&GMI6M>(T2;^T=0TYXS$
MUI.YF,9B,9*82-3CO7/VW[/OP7L_!^N> +7X>:!#X,\2W[:IKOAY([D:?J>H
M/(96NKE3<F0RM(2Y*R*N><5['15/+<NES<V7X)\WUCFOA:#YOKEOK?->GK]:
MLOK%[^WLO:\UD1#B3B*GR<F?YU#V2RY4^3-<='V:RAMY2H6KKD65N4GEW+;Z
MDY-X;V5V>5:C\$/A/JZ^"TU+P-HMXGPZ,9\$+,EP1X;,./+.G;;A=NS QYOF
M=!G-:-O\)OAQ:^,]8^(=OX1TJ'QKX@T]M*UGQ&B3C4-1TYXS$UI<,9C&8C&2
MF%C4XZ$5Z)13679>I*:P.#4U4I55)86@I*K1I.A1J*7)=5*5%NC2FGS4Z3=.
M#4-"7Q#G\J<J,L\SATIT,3A94GF>-=.6&QF)6-QF'E!U^5T,7C(QQ>)HM.G7
MQ*5>K&=5*9XY;?L^_!>S\'ZYX M?AYH$/@SQ+?MJFN^'DCN1I^IZ@\AE:ZN5
M-R9#*TA+DK(JYYQ5_4?@A\)]73P7'J7@;1+Q/AV8CX)69+@CPV8<&(Z=BX&P
MI@8\WS.@SG%>J45"RO+%%0678!05.G24%@\.HJE2J^WI4E'V=E3I5VZU.%N6
M%5^TBE/4U?%'$TJCK/B+/75EB*^+E5>;Y@ZCQ6*PJP.*Q+F\1S/$8G!)8.O6
M;]I6PJ6'J2E22@>=V_PF^'%KXSUCXAV_A'2HO&NOZ>VE:SXC1)AJ&H:<\9B:
MTN',QC,1C)3"QJ<=#6!;?L^_!BS\'Z[X M?AYH$/@WQ-?OJFO>'DCN18:GJ#
MN9'NKE#<F0RM(2Q*2*N>W2O8Z*IY;ETN;FR_!/F^L<U\+0?-]<M];YKT]?K5
ME]8O?V]E[7FLB(\2<10Y%#/\Z@J2R]4^7-<='V:RAR>5*%JZY%ECE)Y>HV^I
M.4GAO9-N_E6H_!#X3ZLG@N/4O VB7B?#HQ'P0LT=P1X;,./*.G;;A=FS QYG
MF=!G.*T;?X3?#BU\9ZQ\0[?PCI47C77]/;2M9\1JDW]H:AISQF)K2X8S&,Q&
M,E"%C4[> :]$HIK+LO4E-8'!J:J4JJDL+04E5HTG0HU%+DNJE*BW1I33YJ=)
MNG!J&A+XAS^5.5*6>9Q*E.AB<+*D\SQKIRPV-Q*QN,P\H.ORRH8O&)8O$T6G
M3KXE*O5C.JE,\<MOV??@Q9^#]=\ 6OP\\/P^#?$U^^J:]X>2*Y^P:IJ#R&5[
MJY4W)D,K2$L2DB#)Z5>U'X'_  FU=/!<>I>!=$O(_AV8SX)6:.X(\.&'!B.G
M;9UV[,#'F^;TYKU6BH65Y8HJ"R[ *"ITZ2@L'AU%4J57V]*DH^SLJ=*NW6IP
MMRPJOVD4IZFKXHXF=1UGQ%GKJRQ%?%RJO-\P=26*Q6%6!Q.)<WB.9XC$8)+!
MUZS?M*V%2P]24J2Y#SRW^$WPXM?&>L?$.W\(Z3%XUU_3VTK6?$:I-_:&H:<\
M9B:TN&,QB,31DH0L:MCO7/VW[/OP8L_!^N^ +7X>>'X?!OB:_?5->\/)%<_8
M-4U!Y#*]U<J;DR&5I"6)21!D]*]CHJGEN72YN;+\$^;ZQS7PM!\WURWUOFO3
MU^M67UB]_;V7M>:R(CQ)Q%#D4,_SJ"I++U3Y<UQT?9K*')Y4H6KKD66.4GEZ
MC;ZDY2>&]DV[^5:C\#_A-JZ>"X]2\"Z)>1_#LQGP2LT=P1X<,.#$=.VSKMV8
M&/-\WIS6E;_";X<6OC/6/B';^$=)B\:Z_I[:5K/B-4F_M#4-.>,Q-:7#&8Q&
M)HR4(6-6QWKT.BFLNR]24U@<&IJI2JJ2PM!256C2="C44N2ZJ4J+=&E-/FIT
MFZ<&H:$OB'/Y4Y4I9YG$J4Z&)PLJ3S/&NG+#8W$K&XS#R@Z_+*AB\8EB\31:
M=.OB4J]6,ZJ4SQRV_9]^#%GX/UWP!:_#SP_#X-\37[ZIKWAY(KG[!JFH/(97
MNKE3<F0RM(2Q*2(,GI5[4?@?\)M7C\%Q:EX%T2\C^'9B;P2LT<Y'ALPD&(Z=
MB<;=A (\WS>E>JT5"RO+%%0678!05.G24%@\.HJE2J^WI4E'V=E3I5VZU.%N
M6%5^TBE/4U?%'$SJ.L^(L]=66(KXN55YOF#J2Q6*PJP.)Q+F\1S/$8C!)8.O
M6;]I6PJ6'J2E27(>=V_PF^'%KXSU?XAV_A'28O&VOZ>VE:QXC5)O[0U#3GC,
M3VD[F8QF)HR4(6-3CO6!:_L^_!>R\'Z[X!M?AWX?@\&^)K]]4U[P^D5R+#5-
M0=S(]U<J;@R&5I"6)21!GM7L=%4\MRZ7-S9?@GS?6.:^%H/F^N6^M\UZ>OUJ
MR^L7O[>R]KS61$>).(H<BAG^=05)9>J?+FN.C[-90Y/*E"U=<BRQRD\O4;?4
MG*3PWLFW?QO6?V>_@KX@M_"UKK/PW\-W\'@J-(O"J2VTJG18XN(TM)(IHY"$
MP-OG/*1U'-<P?V8/AG8>*=1\<^%;?4?"?B_5;"33+_6],O9IGN].E0QO97$%
MX\T<MNR,4V$C"?*"*^BZ*:R[+U)36!P:FJE*JI+"T%)5:-)T*-12Y+JI2HMT
M:4T^:G2;IP:AH2^(<_E3E2EGF<2I3H8G"RI/,\:Z<L-C<2L;C,/*#K\LJ&+Q
MB6+Q-%ITZ^)2KU8SJI3/D2V_9LL_#/A#7? 6D>&?A]XF\"^(]0?5-=\+ZKIM
M[I U>^=S(UU=7%G=2*\[.2Q<NB[C]W%7M1\)^!C'X+A\>? 618/AP8CX.O-)
M1M?T_P -&#'E/IHM;F.XC1",CSDE( '6OJVBH6598HJ"RW *"ITZ*@L'AU%4
MJ57V]*DH^SLJ=.O^^IP2Y85?WD4IZFKXHXF=1UGQ%GKJRQ%?%RJO-\P=26*Q
M6%6!Q.)<WB.9XC$8)+!UZS?M*V%2P]24J2Y#Y\T2W_9^N_&VJ^/;*Q\/Z?X_
M\0:>VD:SK&HQW6F:S>V#QF)[*Z%Z\47EF,E"J*#@\-6Y8? 3X(Q^#-<\"Z;X
M"\-_\(3XHOVU37=#MO.DTW5K^1S*UW<%+IG>1G)?*2JN>@Q7INI^'- UI&CU
M;1M,U!7^\;JR@F?\)&0R*?=6!KA9OA%X;AD:?P_>Z[X5N3RK:'JUS%;JV<Y-
MG<-/ P[;0JC'%4\LRV7-S9?@GS_6'*^$H/F>,26+<KT_>^M))8B]_;I+VO-9
M$1XDXBAR*&?YU!4EEZI\N:XZ/LUE#D\J4+5UR++'*3R]1M]2<I/#>R;=TU'X
M'_";5X_!<6I>!=$O(_AT8F\$)-'<%?#9AQY1TX+.NPI@;?-\SH*TK?X3_#FU
M\9ZO\0[?PCI47C;7M/;2M8\1JDW]HZAISQF)K2=S,8S$8R4(6-3CO64-"^*F
MC?\ (+\7:3XDMUY%MXDTTVMTP[+]NT\G<?\ := ,\XH_X3CQII)V^)?AWJ+Q
MK]^_\,7<&L6X49R_V8F.Z [X.3VZTUEV7J2DL!@U*-2E54EA:"DJM"E["C43
MY+JI1H_N:4T^:G2_=P:AH2^(<_E3E2EGF<2I3H8G"RI/,\:Z<L-C<2L;C,/*
M#K\LJ&+QB6+Q-%ITZ^)2KU8SJI3*MK^S[\&++PAKO@&U^'F@0>#?$]^^J:_X
M?2.Y%AJFH2.9'NKI3<F1I6D)8E9%&>U7=1^!_P )M7C\%Q:EX%T2\C^'1B;P
M0DL=P5\-F$@Q'3MLZ[-F!CS?-Z<YJ_I_Q7\#7\@MY=7_ +)NR=OV/7+:XTFX
M#>A%W&D?7CB0_P J[VVO+2]C$MG=6]W$0")+:>.="#T.Z)F7GZU"RK+%%067
M8!05.G145@\/RJE2J^WI4E'V=E3IU_WU."7+"K^\BE/4U?%'$SJ.L^(L]=66
M(KXN55YOF#J2Q6*PJP.)Q+F\1S/$8C!)8.O6;]I6PJ6'J2E27(<+!\)OAQ:^
M,]7^(=OX1TJ+QMKVG-I.L>(U2;^T-0TYXS$UI.QF,1B:,E"%B5L=ZY>W_9Q^
M!EKX9UKP;;_#+PO%X9\0WDNH:UI(M)##J%Y.Y>:>:5IC<JTCDLZQ3QHQ/*XK
MVNBJ>6Y=+FYLOP3YOK'-?"T'S?7+?6^:]/7ZU9?6+W]O9>UYK(B/$G$4.10S
M_.H*DLO5/ES7'1]FLH<GE2A:NN198Y2>7J-OJ3E)X;V3;O\ "?[3Y^%W@?1O
MACX'\,_#O0/%OQFGNQH/[/OA.1;B0>'-0"[7\2SK'/NLO#WAR/\ TZ_N[D/&
MPB6 ,7D KY!_8N\#ZA\-OBY^W9>>.]=G^(OQ \"0:?<7OC#5U8W$]WJ_A"]U
MKQ!:64:,!;Z1->QB"UML,T=G!"@8-NS]P_M!?L+_  5_:4\<:%\1/'VH?$S2
MO%7AS1)_#^EZAX#^(&L>#&ATRYF$]Q"W]E!9&:9U'FL)5$B@*ZD5\=?LE_L"
M67PJ_:._:7\0W\'Q=L_"Q6'PU\--9\5>.=6UG3O%VA^(_#,^GZ_?:JMW/)_P
MDEYI\LOE6=YJ*"6Q;Y(>.G=2R_*%1FU@\&JR="NV\%A^?V^'Y*%"=.IR\RG1
MP[E0IR2YZ=&4HQ?L_=.*KQ#Q+*:@\ZSB5"5/%8/V?]K8YTWA,;6^NXVA4I.K
MR.CC,=%8O$TI-TZ^)A"M5C*K^\//O@1^PW\$?BY^Q?>_&'Q?X8BO/B_X_P##
M?CWQUI7CU;JYCUGPG)<WNL7>EZ9H+K(+>UTZU2UBC:"6WF9U=P[%L&OMO]D'
MPMX+^./[+?[-7CCXA^#-&U?Q)X6\,0?V-=7*2NVDZIHU_=Z5)?6;131J);A[
M 7#EU=3([$*!Q7R;X:OOVS_@3\)/$'[('AK]F?7?'DR-XI\+?#3XW:=K^EP_
M#RQ\(>)+V];3KSQ4L\JZK:7VDVNH3">&VB=2\:[2 0!^G'[-WPD7X%? SX9_
M"?[2MY/X+\,66FW]VC,\=SJDADO-4FC9_F:)[^YN#&QY9-I/)J,1E>5JFX?4
M,M<.:%.A"&%PK4,)2J2KTJ*C&G:%&E7E&M3HV485^:K&,9WD]J/%'$SK>V?$
M&?\ MG.OBJ]66:YBJD\?BL-# XG%2G+$<T\5B,%%X/$8B[J5L)RX>I.5%*"_
M-[QG\?\ XCV_[0?[3<'P/_9/\!^./'?PBCL+?Q;\0=:\4ZCX?35O ]QH;W^I
M6=S(?-%SXA=%=-/TRQA6.6W5I)901BO-;7]IJQA^%O@KQG8?L;>%]'_8R^+_
M (L\,Z+XXU35?$5S;^*)_%_B748]+FU6S\*QROY^B0:X\MK'>W%S')/Y3N(U
MK[5^$WPO\>:)\5?V]];U7PIJ=CIWQ*U72)? >H3PQK%XH@A\"W^G3-ICB0M(
MD=_+';,)!'B5@,=Q\Q^+?@%\9+[_ ()L?!7X3VGP\\0S_$?P_P#$3X?:IK7A
M!((3J^G:?I?Q/N=8U"[N(C.(UBM-,=;V4K*Q$+ @$\5JLLR64HPGE>724Y2A
M4G*A2;DLPI)X^<M+.6(E%*NWI4M:LINUL%Q+Q33473XASZ'LE@W2C#,L9%4_
M[%JO^QX4TJMX1RU3F\O4?]S;<L+[&[;]Z_:F\4:%X/\ %7P,^"_P<_9[\+?&
M+XS?9+S7OAKH/B'5;KP]X5\ >&=!,?VO7=1UB&1YK.!)'C@MD*3,\I!8%0:J
M?LQ?%";XI_M.?&?PU\2/V=_#WPJ^+/@GP#X;/B_7[;5+S6+_ %Z?7)7M+RVL
MK[>MA?>&9(-K:;>Q1)<RCS$F 9*D_:>L_B9\+OVBOA!^T1\+?!2?&#4],\!^
M(/A_XL^$&CZYI.F_$#4M!U*>WO8_$'A.QU*YA^WG3;N$1WR!3''&^^1U Q7F
MG[%'CKXC_$[]M;]J3QK\1_A]+\,M2G^'?PZT^U\'76H6FIZMH.GQ7MQ)867B
M.>Q>2V@UZ2/SI[JSC=A#$8CT85,<JRSV+JQR[ <\8TJZK>PHJM'$T6L/2FHI
M73HX9^RHSY4X4I<D)J+Y1RXEXBE+V$\^SMTYT\3@Y4'F&-="6#QM58_&8>2=
M1Q='&8Y+%XJBVX5\3%5ZL)5(\[_1:U_9]^#%EX0U[P#:_#SP_!X.\47[ZIK_
M (?2*X%AJFH2.9'NKE3<&0RLY+921!GH!5W4?@?\)M7B\%0:EX%T2\B^'31-
MX(CFCG*^&VAP8CIVV=2NS:,>:9>@SFMOQ=X>\6ZO/9W7A?QK+X7>UADCFM&T
MFTU2ROG=U=);A9W21&C"E!Y9P58YYQ7'^3\>M*P5O? 'BI!GY)K?4M#N6 Z?
M-$9;<,W?L*\]97EBBH++L H*G3I*"P>'452I5?;TJ2C[.RITJ[=:G"W+"J_:
M12GJ>@^*.)74=9\19ZZTL17Q<JKS?,'4EBL5A5@<3B7-XCF>(Q&"2P=>LW[2
MMA4L/4E*BN0Z>#X3_#FU\::M\1;?PCI,7C?7=.;2=7\2*DW]HW^G/'Y36D[F
M8Q&(Q_(0L:MMXW5@6O[/WP8LO"&O> ;7X>>'X/!WBB_?5/$'A](K@6&JZ@[F
M1[JZ4W!D,K2'=E)$&>@%5O\ A/?B?I@QK?PDO+L#&^?PSKVGZBF.[);S>5.0
M.?E)SVZTX?''P]:$1^(/#OC;PU)DA_[3\-7K0(!W-S:"X0CWQ5/+,MES<V7X
M)\_UAROA*#YGC$EBW*]/WOK226(O?VZ2]KS61$>).(H<BAGV=05)9<J:CFF.
MC[-90Y/*5"U=<BRMRD\N4;?4G*3PWLFW?4U'X'_";5XO!4&I>!=$O(OATT3>
M"(YHYROAMH<&(Z=MG4KLVC'FF7H,YK2@^$_PYM?&FK?$6W\(Z3%XWUW3FTG5
M_$BI-_:-_ISQ^4UI.YF,9B:/Y"%C5L<;JBT[XO\ PTU1D2U\8Z,LKX_<W<[6
M$JD_PLEZD!5NV#WKN;/5=+U!0UAJ5A>J>C6EY;W(/XPR.*:R[+U)26 P:E&I
M2JJ2PM!256A2]A1J)\EU4HT?W-*:?-3I?NX-0T)?$.?RIRI2SS.)4IT,5A9T
MGF>-=.6&QN)6-QN'E!U^65#%XQ+%XJBTZ>(Q*5>K&=5*9Y9:_L^_!BR\(:]X
M!M/AYX?@\'>*+]]4\0>'TBN!8:KJ#OYCW5TIN#(92_S921!GH!5W4?@?\)=7
MB\%0:EX$T.\A^'31-X(CFCG*^&V@(,1T[;.NS85!'F^;T&<UZK14+*LK45!9
M;@%!4X45!8/#\JI4JOMZ=)1]G94Z=?\ ?0A;EA5_>12G[QJ^*.)74=9\19ZZ
MTL17Q<JKS?,'4EBL5A5@<3B7-XCF>(Q&"2P=>LW[2MA4L/4E*BN0\\@^$_PY
MM?&FK?$6W\(Z3%XWUW3FTG5_$BI-_:-_ISQ^4UI.YF,9B:/Y"%C5L<;JP+7]
MG[X,67A#7_ -I\//#\'@[Q1?OJGB#P_'%<"PU74)'\Q[JZ4W!D,K.=Q*2(,]
M!7L5%-Y9ELN;FR_ OF>(<KX2@^9XQ)8MRO3U>*22Q%[^W22J\UD1'B3B*'(H
M9]G4%267*FHYICH^S64.3RE0M77(LK<I/+E&WU)RD\-[)MW\JU'X'_";5H?!
M4&I>!=#O(?ATT3>"(Y8YROAMH,&(Z<%G7:8RHV^;YO09S6E!\)_AS;>--6^(
ML'A'28O&^NZ<VDZOXD5)O[1O]->/RFM)W,QB,31_(0L:MC^*O0Z*:R[+U)36
M P2FJE*JI+"T%)5:%)T:%12]G=5*-%NE2FGS4Z3=.#4-"7Q#G\J<J4L\SB5*
M=#%86=)YGC73EAL;B5C<;AY0=?EE0Q>,2Q>*HM.GB,2E7JQG52F>.VO[/WP8
MLO"&O^ K3X>>'X/!WBB_?5/$'A](KD6&JZA(YD>ZNE-P9&E9SN)21!GH*NZC
M\#OA+J\/@NWU+P)H=Y#\.FB;P1'-'.5\-M!CRCIP6==A3 V^;YG09S7JM%2L
MJRM14%EN 4%3A14%@\/RJE2J^WITE'V=E3IU_P!]"%N6%7]Y%*?O&KXHXF=2
M59\19ZZTL17Q<JKS?,'4EBL5A5@<3B93^L<SQ&(P26#KUF_:5L*EAZDI44H'
M@?B+X$>$+WXJ>'/BII/AG1+7Q.+B]@\7:\PG74]7T:?3);.&R8^:8G19'4D*
MB$*#\U;5K^S[\&++PCK_ ("M/AYX?@\'^*;]]3\0>'TBN18:KJ#N9'NKI3<&
M1I6<EB4D09[5Z^TB(R*[HK2$JBLP5G8#)" D%B!R0,D#FGU3RS+9<W-E^"ES
M?6'*^$H/F>,26+<KT]?K226(O_'27M>:Q$.).(J:@H9_G4%267*FH9ICHJFL
MH;EE*@E77(LK<I/+E&WU)R;PWLFV>4ZC\#OA+J\/@NWU+P)H=Y#\.FB;P1'-
M'.5\-M"08CIVV==A0@%?-,G05ZM116U'"X;#N<L/AZ%"554U4E1HTZ3J*C!4
MJ2FX1BYJE32IT^:_)!*$;121QXO,\RS"%"GC\PQV-AAGB'AH8O%U\3##O%UI
M8G%.A&M4FJ3Q.(G/$8ATU%UJTI5:G-4DY/COB'HE]XD\">+_  _IBQ/J.L^'
M-7TVQ6:00Q-=7EE-! LDI!$:&1U#.00HR3TK(^#_ (9U7P9\+? 7A/7$ACUC
MP]X7TG2M22WF6X@2\L[5(IEBG4!98PZG:Z@!AR*](HJ'A*3QL<?>?MXX66$2
MNO9^RG5A6;Y>6_/SPC9\UN6ZY;ZFJS7%+)YY&E2^I3S.GFK?)+V_UJEA:N#B
ME4Y^7V7LJLVX<G,YV?.DK/Y$^(?PP^,GA'XA:S\6/V?[WPQ?7?BNSL8/&_P[
M\7O+9:3X@O--5HK'5M/UB'<VF:@L+F&Y=D99H0% !Y/!>&?@U\:_B!\1? _C
MGXH^#?A!\*-/\">(V\2C2? ,$.M:_P")=3\IT1[WQ"MI:F&U9I&:XAD,DDC_
M +S):OOBBO&J\,8&MB?;2Q&/CAGBECI9;'$16 >+5:.(=:,'2EB*7/7@JU2C
M0Q-+#U*G-*=&3G/F^QPOB7G>$R]86&7Y#/,8Y6\DI\1U<OJ//H94\'/+X8.=
M6&*AE^+]C@9RPF&Q>.R[%8_#X=4Z='%P5&C[/P;X*?#_ ,1^!M3^+MUK\5I'
M%XQ^)6I>)]$-K=)<M)I5S8V5O$]PJ &WF,D$@:%LLH )/-'Q(^'_ (C\3?%;
MX)>+M*BM'T;P+J_B&\U]YKI(;B*#4M%FL;4VT# M<LT\BAU0@HN6/ KWFBN]
M91A5@:67IUO84<32Q<'SQ]I[6CCXYC"\N2SA[>*37*FZ=XW3]X\"7%>:2SK$
M9\XX7Z]B<MQ.55$J4_8+#8K(Y\/U7&G[7F558"I*49NHTL1:HXN/[M_+_P 4
MOA+XIMOB+X0^,OP?@L8?&%A>P:1XYT*>]CTG3/&_@^Z<)=+?RE3 VK:2I-SI
MUU(C3':8 V&&,/QY8_M9^%?&NO:K\*1X/^(?A'Q;':R0:%XZUN31;CX?7\4'
MDW!TF:V@*:GITQ(G%HY+><KEG 917UY17/7R'#U)8F>'Q>8Y?/$XJ&,E+ 8F
M-%4\2J4J%:K3ISI5:3^M4I)8F%6G5I3J0A7A"&(3K/T<%QUF&'AEU+'Y3P_G
M]++<MK913AGN7U,9*OELL52QN$PN(KTL5AL4EEF)IN675L-7PV(HT*M7 5:U
M?+Y1PD?#OV?_ (5ZG\)_ DVC^(-6AUOQ3XA\0:UXP\5W]I&8;!M>\03K/=PZ
M="P#1V5LJ100AN3L+<@@UY9\&-(O](M/VB/A#,J+K<'BKQ1KVCB5A$E_H_C[
M3Y)M,NU=@,PQWJ36T\H!6-@H;DC/V)6.?#^B_P!NCQ-_9UN->&G-I/\ :BJR
MW3::TRW!M)&5@LD0F19%$BLR,/D902"WDU&C'*J>$?LZ660KX;EJ2E.53!XF
M@Z->+J/FDZ[J1HXCVDD^>=.49-*HY*8\98O$U.*,1FL5B,5Q'6P69>UHTJ5*
MGALVRW,(8S!U(X>#ITXX)4)XO O#TN54J->G*FG[!0E\HP?L\^)=3_9P^&WP
M_GU6V\+?$_X<P:;J_AS7K60:A::/XHTJ\N+B L\8475A<1R"WNU09>&1PO(S
M7):KI'[;GQ(T]OAYXIT_X9?#WPY?A+'Q#\1O"_B"]U'Q!J&F*P%V=(T4)$='
MO-0B#"*83,;,MWQ7WG17/4X8P<X4J=+&9GA*<<'ALOQ-/"8M48X_"X2G[&C#
M%_NI24U2O3E7PLL+B)4Y.FZO)&$8^CAO$O.*57%5\5E/#6;8BIG&8Y]EV(S;
M*YXNID.9YIB?K>+K93_M5.FZ,L2H5X8',X9E@(5X*LL,ZLZLZGPE9>!];\!>
M,KCQCKFD>&_$WAS3?%^@^%_"]ZOB_P 4W_C*TM8+"QTO3I);.VU >'1.EZ9+
MB^M+^"6]<2>9)EF4U>^'ES-:>+?A1XGM=1OKCQ!\1/$7Q,T_QZDNHW=W%=V>
MBG5VT])K-YWL[(:.UC9)"UM;VY  \TN9"3]0+\+? *^*F\:KX:M%\3-+]H;4
M5GOE1KG9Y?VIM/%T-,:ZV8'VIK,W&0K>9N4$2Z7\,_ FBZ[J_B;2_#5A9:YK
MJSIJ=_";C?.+H*MT8H6G:VLWN0H^T264-N\_)E9B23QTN'L10K4I498:G1IX
MUXE1=24ZD?\ :L-B'B(5(X2BW6J4:$\$J-1S5'#XBI;$U8N5*?K8KQ R_&8/
M$4\7#,<1BZ^31R^=18>G1P]6V5X_+X8"K0J9MBXPP=#%8REG+Q='V<\7F&!P
MSGEN&G&GB:'C'P1LFU[XH_'7XGQ!QI6M:_I/@W1),#RKZV\'6LL5_?Q,.'C;
M4+R2V1AD%K>09XKZAK+T71-)\.Z;;:/H=A;Z9IEH'%O9VJ;(8O-D>:4@$EF>
M261Y)'=F=W9F9B36I7T&6X-X'"1HSE&=657$8FO.-^26(Q>(JXJOR7L^15:T
MHT[I/D4;J]SX#B/-XYWFM3&TJ<Z.%IX7+LNP-*HXNK3P&4Y?A<KP*K.-XNO+
M"X2E.NXMQ]M*IRMQLPHHHKO/#"BBB@ HHHH *\C^*'_(5^%__90M(_\ 09*]
M<KR/XH?\A7X7_P#90M(_]!DK2E_$C\__ $ED5/@?K'_TI'KE%%%9EA1110 4
M44$@ DD  9)/  '4D]@* "BL:S\1^'M1NY=/T_7=&OK^'<9K*SU2QNKN((<.
M9;:"=YH]IX;>@VG@X-3:EK6CZ,D<NL:MIFE12MLBDU*_M;%)'_N1O=2Q*[?[
M*DGVIV=[6=WLK._W"NM[JW>YIT5%#/#<Q1SV\T5Q!,@DBFAD26*5&&5>.1"R
M.C#D,K$$=#4M(84444 %%%% !1110 4444 %%8]QXB\/VE]'I=UKNC6VIRE1
M%IUQJ=E#?2%^$$=I).MPY8_="QG=VS6Q19]A73O9IVW\O4****!A1110 445
M5N;ZRLC +R\M;0W,R6UL+FXB@-Q<2?<@@\UT\V9_X(H]SMV4T 6J**Q[_P 0
MZ!I=Q#9ZGKFCZ==W&#;VM_J=E9W$X8[5,,%Q/'++EOE&Q6R>!S19O97$VENT
MO70V**8\L4<;3221QPHAD>5W58U0#)=G8A50#DL2 !SG%9FFZ_H6LM,FCZUI
M.JO;D"X33=2L[YH"20!,MK-*8B2"!O"Y((H'=;7U>R[VW-:BLG4-?T+2988-
M5UK2=,GN#BWAU#4K.REG). (8[F:-Y23Q\BMSQUK55E90RD,K ,K*0592,@@
MC@@CD$<$<BG9]GKMYBNG>S3MOY>IY)XF_P"2N?#/_L&^+_\ TV&O7*\C\3?\
ME<^&?_8-\7_^FPUJ_$_XA:/\/O"VJ:E>74<FL26DUOX>T.W=9=7UO6;E&ATZ
MPTVP0M<W,LUT\:L8XV2)-TDK(BEAI)-^R2U;@DOG.9$6DZK>B4U_Z;IGEG['
MW_) O#?_ &-WQ@_]7-\0*\#_ &B_V"O$'QW^.F@?'C1OVG/B9\)O$'A/04T+
MPKIGA30/#.I6/A_S#-_:&HZ>^MK<>7J.I"1%GNE@6:-88Q#*G-?77P'\$7WP
M[^$O@SPIJH1-8M;&]U36XHSN2#7/$VKZAXGUJV5QPZVVJ:S=P"0<2"/>.&%>
MN4_:RIU:DZ<DN9S5[1DG&3=U:2:LUY;:;,2IQG2A":;LH.UW%J44K:Q:>C\]
MSXP^!7[,GQC^$_C=?%/CC]L?XR?''11IUY9'P5XYTGPM9Z*UQ<QE(=0,VD6\
M5W]HLV_>0J&V%AAP17O'PT^'WBKP/J/CR]\2?%3Q5\2+?Q;XE;7-"T_Q);:;
M;V_@736C=!X;T)K"-'FTU699!)>%I]R#G!->KT5$JDI7ORZI)VA".B=U91BD
MO56;6CNBHTXQLE?2[5Y2ENK:\TG?3H[I;K4^?OVD?V?](_:0\ V'@+6O$.I>
M&K2P\8^$_&":AI=K:WES)<^%-8MM8M[-HKMEB$%W);+#-(#YB(Q9 6 K+^(W
M[-FC?%3XR?"GXH^,?$^IZEH/PA%]J/AKX9R6%D?#4_BZZA-O:^+M2N&8W5UJ
M.E1DC3K=XS;PLSO@LV1]*T4*I.*23LESVT6G.E&5G:Z;22ONNE@=.#;DXW<N
M6^KUY&W&ZO:R;O;9O>]D?+G@+]E[1/AI^T+\2?CKX-\6:SI&G_%?2;"'QG\,
MHK2T/A6_\3:>Q$?C.*8O]JMM:E@V6UP(HQ%+$'W9:1C7U'112E*4FG)W:25W
MO9*R];+2[U'&,8IJ*LFV[+:[=WZ7>MEH%(<@$@9(!P/4^E+2'&#G@8.3[=ZD
MH_&/X+>%_C-^U!XB^,_BCXB_M>_$?X3ZWX5^*OBGP99?"?P/>:!HUCX6T#1K
MTQ:+>RP7\37TS:S9&.Z6=RT4A+%7)X'Z/? /X4ZG\*M*UZPU+XV>.?C2^J7U
MM=1:CXWU#3;^YT588&B-G8OIT:+'#<$^=(LN6+J"N *_%3Q!\$?!GQE^*WQ;
MU;]EW]E_Q/\ $C3?#OB[5=+\>_$SQ+\<M=\":?XH\5VT\DNK:=X86WD:?5/[
M,G9[4+._EQ2!8HMJK@?HU_P3LE^$TG@+Q];?#_P?XW^'?B_1/&)\._%7P%X\
M\3W_ (HU;PWXJTJV,4<5O>7T\V-.N[5C<VDD&U9XF21P6YKT,1'W).+:24+T
ME3HIPORV4G";J16FG-&[T4G=N_%0D^=*2N_?_>.I5?-:U[*45!OORO3=:'Z(
M4445YYVA1110 4444 %%%% !1110 5XK^T ]S'\-KZ2RA2XO$U?P^UK;RR"&
M.><:M;&.*24@B)'; +D$+G)XKVJO%?V@'N8_AM?/90QW%XFK^'VM8)9/)BFN
M!JUL8XY)<'RT=L!GQ\HYH ]/\/76NWFEPS^(],M='U5FD$UC9WJZA!&H;$;+
M<JJARZ\D8^7I6W7GWAG5/B/>:B8?%7A;1-'TWR'9;O3];_M"<SC[D9M]B_(W
M=\\5Z#0 5\,>"=,_:&7X\_&J6VUOPJNBO+H)ACU:&>> VSVDK:,MM%9@3Q30
MVGFK.TA*MG'4BON>O'O!O_)5_B]_N>!__3/=T ?+_P"T7X!^.OBN3X9Z9?>)
M_"U[H]WX\TB*\T_3[&>PB,_FB:%[LSEGNK>-8I%\L%<D@MUQ7WS:0FWM;:W(
M0&"WAA(C79&#%&J8C0<*@V_(O\*X':O/OB%9W=W=>!&M;::X6U\;:5<W)B0N
M(+>-)]\\N/NQID;F/ R*])H *.G6BO/_ (F^()O#_A*^>QRVKZJ\.AZ+$O+R
M:GJC_98"H'S'R@[S$C[H3- '.^!O^*H\9>+O'4@WV5M+_P (CX;8\K]CTU]^
MJ74.?NBZOB$W*!N6-ADU[%7.>$?#\/A?PWH^@P8(T^RBBFD[S73#S+N=CP6:
M:Y>60D\G=S71T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% &;J&C:3JT9BU33+#4(V!4
MK>6D%P,'C ,J,5X[J0:X&Y^$/@]I#/I,>I>&KKDK/X?U2[L &ZAC!YDEN0#_
M  ^4!VKU"B@#R?\ X1?XDZ/DZ'X[@UB%>5L_%6F)*Y"](_[0LBLXR/E+M'[F
MMOP_K'CJ744T[Q1X5LK.!XI6&M:3JB75COB7*I);3*MW&TY^5,@@'KQ7>T4
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MRJV&/L#4M4-5LWU#2]1L(IC;R7MC=VD=P 28'N;>2%90!@DQLX? .>*%NO\
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MWCTVBBBN [@HHHH S]6U73M#TV^UC5KN&QTW3K:6[O;NX=8X;>W@0O)([L0
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M@3_H=?"7_A1Z/_\ )E'++^67W/\ KJOO#FC_ #1^]?UU7WG6T5R7_"?>!/\
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M1Z/_ /)E'++^67W/^NJ^\.:/\T?O7]=5]YUM%<E_PGW@3_H=?"7_ (4>C_\
MR91_PGW@3_H=?"7_ (4>C_\ R91RR_EE]S_KJOO#FC_-'[U_75?>=;17)?\
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MQ&0"F[FOH']E3]G)_P!GCP=XAMM=\53^//B+\0O%%[XX^)'C*>W%HFL^)-0
M5TL;0$FVTRPB'V6PB<F06ZJ).17D'_#S7]E3^T/L8UKQZUE]\>(E^&GBX^&C
M!U^UC6!IWD&TV_O/M &SR_GSBOLSX>_$CP+\5O"]AXT^'7BC2/%_A?4U8V>L
M:+=)=6LC(=LD3D8>&>)OEE@F2.6-AAD%;U76C!J5%48R:<FJ<H\[6JNY-V75
M1CRQOK8QIJE*=XU75E%.R<U+E3LFTDEOHG)IO7?77MJ***YCH"BBB@ HHHH
M**** "BBB@ KQ7X_PRW'PWO8(;A[2:;6/#\45U&JO);2/JUL%FC5_D9XS\RA
MOE)X/%>U5X[\=/\ D09?^P]X;_\ 3Q:T >D>'],O](TR&QU+6KK7[N-I&?4[
MV&&"XF#ME5:.#]V!&/E!')'6MJBB@ KY\\.?':+4_B-XB\#ZYX?N?#5GI4[V
MVFZYJ+/#:ZA/&X41M)(BP1M.#NM\2 ..,YXKZ#K-U'1M*U:VGL]3TZSO;:Y7
M;/%<01N)!T!)*[@R_P +JP=3RK T :*LK ,I#*P!5E(((/(((X((Y!'!I:^8
MO'?AGXO^$KO0HO@_?2W^@27OF:EHVKW$5PNGQHRL(+6ZNF,Z6,L8*>6Q<Q-@
MJV!BO0!\7--T>)E\=Z1J_@VX@BWSW%_:O<:1(47+M;ZG:B2!E9@?+#A"<@$Y
MH 9\37?7]3\*?#RW9L:_J"ZGKFP\IX>T9UN+A'[!;N=8H,'[W*C.<5Z\B)&B
M1QJ$CC541%&%1$ 554#@!5  '8"O#?A3JMA\0-=\5_$RSN%NK"XN$\->'3T:
M#2M-"R7$IC/,+WMT_F,."50$]:]TH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $958%6 92,%6 ((/4
M$'@CV-<?J_P_\%ZX2^I>'-,EF.<7,5N+2Z!_O"XM##-N!Y!+GGFNQHH \H/P
MN;3OF\+>,O%7A\CE8'OO[7L./NJ;6_#'8.!@2YQT.:0+\8-%QA_"_C&W7CYA
M-H.HE!WR/,LV<CU8 GTKUBB@#R?_ (6A/IOR^*O!/BK0<<-=0V8UFP&.K"YL
M"Q">YCSCJ*Z72/B%X+UPA-/\1::\Q&3;7$XL[E3_ '6@NQ#(&'<!2:[.N9U?
MP;X4UT$:MX?TJ]8\F62SB6<'U%Q$J3@^XD!H Z165U#(RNK#*LI#*1Z@@D$>
MX-.KRAOA/8V+&3POXE\4>%Y,Y6*TU.2]L%]%^Q7_ )RE/]D2*,<"D^P_%W1>
M;36/#?BZW3A8=3LY=&OW7M_I%H9+<MCC+@#/- 'K%%>3GXCZUI7R^*O 'B+3
MD3B2^TA8M>L!ZL&M"LRIU/S1E@.V:W-+^)O@;5W6*W\0V4%RQQ]DU%FTZY5N
MFUHKQ8<,#P0">: .\HJG_:.GY@'V^RS<G%L/M4&;@^D \S,IY'$>[K5R@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ KQCXO:?8:G>?#.SU*RM-0M)?B#I*RVM];0W=M*I63*R07"21.#W#*17L]>
M1_%#_D*_"_\ [*%I'_H,E:4OXD?G^3(J? _6/_I2.L_X5YX _P"A&\'_ /A,
MZ+_\A4?\*\\ ?]"-X/\ _"9T7_Y"KL**GGG_ #2_\"?^8^6/\L?N7]=%]QQ_
M_"O/ '_0C>#_ /PF=%_^0J/^%>> /^A&\'_^$SHO_P A5V%%'//^:7_@3_S#
MEC_+'[E_71?<<?\ \*\\ ?\ 0C>#_P#PF=%_^0J/^%>> /\ H1O!_P#X3.B_
M_(5=A11SS_FE_P"!/_,.6/\ +'[E_71?<<?_ ,*\\ ?]"-X/_P#"9T7_ .0J
M/^%>> /^A&\'_P#A,Z+_ /(5=A11SS_FE_X$_P#,.6/\L?N7]=%]QQ__  KS
MP!_T(W@__P )G1?_ )"H_P"%>> /^A&\'_\ A,Z+_P#(5=A11SS_ )I?^!/_
M ##EC_+'[E_71?<<?_PKSP!_T(W@_P#\)G1?_D*C_A7G@#_H1O!__A,Z+_\
M(5=A11SS_FE_X$_\PY8_RQ^Y?UT7W''_ /"O/ '_ $(W@_\ \)G1?_D*C_A7
MG@#_ *$;P?\ ^$SHO_R%7844<\_YI?\ @3_S#EC_ "Q^Y?UT7W''_P#"O/ '
M_0C>#_\ PF=%_P#D*C_A7G@#_H1O!_\ X3.B_P#R%7844<\_YI?^!/\ S#EC
M_+'[E_71?<<?_P *\\ ?]"-X/_\ "9T7_P"0J/\ A7G@#_H1O!__ (3.B_\
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MNB^']$T>673/%RRR:7I5AI[R*--.%D>TMX6<#)P&) R:]WKR/Q-_R5SX9_\
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MHH **** "L[5](T[7=-O=(U:TBOM.U"![:[M9EW1RQ2##*1V/<$8((!%:-%
M'+>$/!GASP)HZ:%X7TZ/3=-2:6X\A&9RTTQ!DD=W)9F; Y)Z"NIHHH **KW-
MW:V:"6[N8+6,L$$EQ-'"A=CA5#2,JEB>B@Y/85."" P(*D A@0001D$$<$$<
M@C@B@!:*8TL:8WR(F>FYU7/TR15=]0L(R0][:(5^\'N85(^N7&/QH MT5E/K
MNB1C+ZQI:#IEK^T _66J4OB[PM"6$OB'1T*#<P^WVQP ,Y^60YX],T =%17G
MWAGXI>"/%MSJ%IHVM0//ILODSK<E;02'<5#VQF91/&2" R>W'-=^KHZAD974
M\AE8,I'J""0?P- #J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "L/5/#/AW6T9-6T32]0#C#-<V4$DGX2
ME/-4^ZN#[UN44 ?.WB']G/PSJOBCPUXBTG5=6\.P^'[Q+M])LKF>6RNGCE65
M1&)YV-IN*[7\KY60X*U]$T44 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %>1_%#_ )"OPO\ ^RA:1_Z#)7KE>1_%
M#_D*_"__ +*%I'_H,E:4OXD?G_Z2R*GP/UC_ .E(]<HHHK,L**** "BBO"_V
MA]=^)&A_#B_/PM\-:IXE\3ZE<V^F"+1TBDU#3M/NWV7VI6J3ND37%O;E_LYD
M8(LQ5FX%5"+G.,$TG)I7DTDKO=MV22W;9,Y<D92LWRINT5>3\DEJV^QS$_[1
MVGW7QYT#X,^'=+75+6ZBU=/$'B=GE6SL=3TVS-U_9.G,@,-Y=1+M^WY;;;[T
M7[YQ3?'GQH^(1\>:C\./@SX TWQOKOAS3K74_%6H:_K9T/1-+2]+?9-/CN8T
MDDFU*9%:00D!0N,D9!KXVM?&7B'PQ\8?@'86/[/GQ&\/R:#8>)K9=,U2?1Y-
M:\3W.JPQ)J_B)YXIV266&0O?:E)._F,AV19"JH^M_@S<V]C\=?VCM*OV2WU>
M_P!9\+Z[9PSE(YYM$;1VMUEB4D-)!#<!T9URH8\D=NZ=&G22G[.,^6@Y*,I\
MRE)5E!SDJ<KVY9*5DTNEW9G'"M.HW%U'%RKN/,H<O+'V2FH1]I%7?,FKN+;6
MMES1/4/@W\5/^%HZ%JDU_HD_ACQ3X9U>X\/^+/#ES(LSZ9JUL Q,,J_ZZSNH
MSYUI*0"\7)&:]?KY-_9^E@U+XJ?M*ZYIH631KSQSH5E;7L+K);7=[IFB&'46
MA9"48Q2LD4I4\.N#S7UE7)6C&-1J*LFH2Y=?=<X1DXZZ^ZY-:]CIHR<J:<G=
MIRCS:+F49.*EIIJDF[:7VTL%%%%9&H4444 %%%% '(>./'?AGX=Z#<>(_%6H
MII^GP%8HAM>6YO;N3(@L;&VC5I;F[N'PD,,:EF8CH,FO._@7\8W^,7A#7O%]
MSHDGAJUTSQ3KFBV]E=-)]L&GZ4EO)'=ZA'(!]GNY8YF>:W7B$ (?F#5[)?Z7
MINIB#^T;"SO_ +',+JU%Y;0W(M[E 0EQ")D<1S("=DJ@.N<JP-?)W[.T,L_P
MY^-<%N"9YOB?\4(H0HRQEDBB6,*.YW$8'<\5O",)4:CL^>,J:YF]$I2:LHKT
MU;OV26M\)RFJT%=<CA4?*EJW%1=V_GHEYMWTME7/[1_Q9U6WUWQQX&^#]IK_
M ,)/#FH:A:7>MW6O_9/$^KVNCS-#J6HZ!HRHT5U:H8Y3 9)%,@C;VKZR\(>*
M-+\:^&-"\6:+(9=+\0:;;:G9LV ZQ7,8<QR $@2PONBD Z.C"OF+X"Z]H5C^
MRG;R7MU:6T7ASP_XKTSQ"LTL4?V34K6[U5;R&[#,/*FD=U;9)ACY@ '2NZ_9
M2L[FQ_9^^&T-U!);2/H]Q<QP2YWI:W>J7US: YY -M+$RC^Z1CC%76A!1GRT
MU!TJRI)WDW./++65VUS>XI7C96EML11E/FAS5'-5*/M6FHVC*\%:/*E:+YFK
M.[]W?<^AJ***Y3J"BBB@#!\4^(+?PKX=UGQ'=P75U;Z-I]SJ$MM90R7-W<+;
MQLXAMX(E:2264@(BJI))Z8KY%O/VA?CEX:TNU^('C3X):?I/PMGDM)KBZL_$
MANO&6DZ5?NBPZAJ>BM$L,2PI(LMTBONCC.,!@17VC=75O96UQ>7<T=M:VL,E
MQ<7$SA(H88D+R2R.V J(BEF)Z 5\<ZSJ/B;]J&]'AOPY:7?A[X&6NHHWB+Q=
M=(8-0\?"PG#_ -D>'+=P'CT6>6,"ZU)QB>+Y8LJ]=-!0=^>G&4$U[2I.4ERQ
M[0Y6OWCUY5:3?9)-G/7<U;DG)3::A"*B^:5U[TW)/W%M*W+9-ZMM(^P[&]M]
M1L;/4;1_,M+^TM[VVDP1YEO=0I/"^#R-\3JV#R,X-?*6L?&?XY:QJWB.7X7?
M!O3M;\(^%M2O=+N]7\5:]/X?U'6;C3<&]?P_IS0;KF%2'BADEVK-( 48H:^L
M+6V@LK:WL[6-8;:T@AMK>)!A8H((UBBC4=E2-%51Z 5\U_$?XJ>*/$&NZA\)
M_@OIPU7Q:J"U\3^+[D$>&_ 4%TF'DN9^%O=92%_,MM.A8L'*&7:#4T4G-_NX
MS6C;J-J$(W5Y3Y7'R7Q=;)2;2*K-J*]^4'?14TG.<K:1CS*6F[:MMJVDG>6T
M^+_Q$^(7PT\/^-O@QX&T76=9O-3O-,\1^'?&>NOH)T&XTTRP7]N+F&*07%S!
M>(D>P *8I-V=RD5P&A_&_P#:)_X6SX5^&7BSX5> K1]80ZGK=SX=\87FLW.@
M>'H7"3ZG>1B!(H&=B$LXIR/M,F54<9KZ(\ >"](^#OP[M]!M[J:\@T2SU#5M
M6U6[(^TZIJ4WFZAJNI7+<#S;J<R-CHJ!%_AKR']E_2KC7=)\5_&G6B]QKWQ5
MUV^O;*:;EK/PCIMS-9:!I]ODDPP-'$]S)&IVM*P?&36B=)1K25*$H1;C2E+G
MYW*;?)>TTK0C%RUCK:S;N9M57*C%U)QG)*511Y.1*"CS_8;O*3BM&EK)K1%+
M7_CM\4]9\3^+=+^#7POTSQGH/@&\.F^)M=UO7SHXO-2AA%Q=Z?X=AC207US:
MQ_)(LC*/.94XYKW3X6?$73?BGX*TOQAIMK<:?]K:YM-0TJ\V_;-)U:PF:VU#
M3;H*2/-MKA&4D?>4JW>O$/V7;ZRT_0_BYI5_/#;:KHGQ9\;7FMQSO'%-#:WT
MT5Y97=PC,&2"2S ,<C@(50D'FI_V10)O OC75+>+9I>M?%KQ[J>C2*P:*YTZ
M74(HH[JW8$J8)Y8IG1E.TY)!-%6$%&HHP472E349IR;J*<6WS7;C=VYERJ-D
MVM58*4YN5-RFY>UA4DXVBE!PE%)1LE)6NXRYF[M7NMCU#Q-_R5SX9_\ 8-\7
M_P#IL-=AXZ\6Z9X&\(Z_XJU>YCM;31]-N;H,[ --<K$PM+2!"=TUS=W)B@@A
MC#22R.JHI)Q7'^)O^2N?#/\ [!OB_P#]-AI;SX,>%=6\<'QWX@O_ !-XENX9
MXKK2O#^O:W)?>$-!NH8UCCN=(\/"&*UBF4KYRO=-=E)V::/8^",I<O[OF;LJ
M:=EN_?EIY777IV9LKWJ6WYUOT_=PU\[=NIE_LW^%-2\&?!7P/HNL6[VFJSV^
ML^)-1LY1B:RO/&GB/6/&-Q8SJ?N3V4FO-:SI_!+$Z=J]OHHK*3YI2D]Y-O[W
M<N*Y8J*V227R5@HHHI#"BBB@ HHHH *^9?VMM9_9YT;X.:S)^TQ:Z=J'PYNK
MNRM1IEU9W&H:EJ.MO)NTNW\.V5CC4I]=,ZAK :>5N%E (8 \_35?"G[<?P<\
M??$32_@W\0?AOX?M?&_B7X$_%#3_ (B+\/[V[CLX/&.G1VS6>H:?#+.#;'48
M(6^T:<DXV&Z5,,IYK6BHNK#FDXJ_Q1?*TTFU:6T;NRYMHWOT,ZMU3E:*D[;-
M<RM=7O'[5E=VZVL?F/>Z/^Q!K&G:%'\)I/VVOBWX@UNXO]5G^#/ACXD>.]+U
M_P -:=ILRB\?Q1X?UF2VN="TU=P2VL[JX'VJ(A(-PZ?K;^QAXF^ 'B'X/06_
M[//AY_!_AK0=9U'2/$/A+4+"?3_$F@^+()3_ &O:^)X;MI+R75WG#22W5Q+(
M;GF5&VFNG\._"+PGX;\=>,_VG-+\'ZS9_$_Q]\.-&L?$GA036;7,SZ#9OJ5G
MHT"(BP1ZY)<L=.N+D3-#<3A6<A0"/%OV'?AKX[\-7'QZ^*/Q*T.V\#^+/CK\
M2_\ A.Y?AI%J-M>W?@G2DT]=/TFUU>.T;RK;5;^WC-W=QA /,+89QS715J1J
MTI>_4?)R-<]3FYIR:4H<J234%?EJ)+1:ZR2,*<)0J0]V'OJ5W"G91C&*M+FN
M[.4K7@V]]+V;/OBBBBN(ZPHHHH **** "BBD) !)(  )))P !R22>  .IH 6
MBODU/VR/A'J'[2F@?LO^&;YO%7CC4M#U_6];U'1;BWN-$\+#0H$G.FZG=*62
M;4[L.0MI;.TEN%+3A>E0_M$_M;:-\"O$/A?X?Z!\.O'/QH^+'C&SO-4T/X:_
M#RVMI=:DT;3V"7FKWMW?/'8:?9Q.P1'NI$\Y\K'DBM%2J.48J#YIQYXIV5XZ
M^]=M)+1ZMI&;JTU&4N96C+E;5W:6BY=$VW=I65]78^N*\=^.G_(@R_\ 8>\-
M_P#IXM:XC]F_]I[PO^T78>*+>U\,^)_A[X\\!ZG'H_CSX;^-K5+3Q-X7OYXO
M.MQ<"(FWO+6XB^:&]M&>WD(*JQ(KM_CI_P B#+_V'O#?_IXM:F490DXR5I+=
M>JNO)IIIIK1IW6A491G%2B[I[/\ #KJFGHT]4]&>Q4445)04444 %%%% !11
M10!XE\:?#4'C*U\)^&&NKFUN=2\0QF*2V?'EVT$1DO9I$!&\10@%"3A7(.<U
MT5K\*O#MO;V\#7GB&X\B&.$M+KEZ/-$:A<NJ.H ;'W1@ < \9IUN!K7Q*O;G
M&^U\):/'8Q'J@U/5CYT_7I)':IL)'(! [UZ30!Y^OPQ\'C/F65W<#L+C5-1E
M"_[H-R,'M]*G7X:^"% !T"W?!SNEGO)&/^\7N26^C9%=S10!R$?@#P7&24\-
M:5DC!W6X<8^CE@#[@9]ZNQ^$/"T2A8_#VC*HZ?\ $NM6/YM&6_6NBHH X6'X
M9> H/M7D^%M)C-Y,9[@K 59Y222RLK!H^IP(R@'855?X::'$QDTF_P!>T.0'
M*'3M7NA$A[8@N&G0J/[O KT2B@#SG_A&O'%A_P @OQQ]L4=(==TN&YR!_";B
MW9)!GNP3(]*0ZC\2]//^D^']"UN)1\TFEZE)93MC^[#>KMR1T /IR>:]'HH
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M:PZ&@#KJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#_H!_#K_ ,&NN?\ QBO7:*/:+_GW3^Y^7][R_%]PY'_//[U_\B>1?;OCA_T
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M --AKURG5=_9NR7[M:*]OBGW;%!6=17;]]:NU_X=/LD%%%%9&@4444 %%%%
M!1110 5^:?\ P40NM;\0:I^RM\%K;Q!K?A_PI\;/CA;^%O'4OA[4[K1]4O\
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M<]AS7;UFZEHVDZS"8-5TZSOXB"-MS!'*5!Z['8;XS[HRD=0: -!65U#HRNK
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M +!OB_\ ]-AKURO(_$W_ "5SX9_]@WQ?_P"FPUZY6=3:E_U[7_I<S2/Q5/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MKJ^@7$D<$;33ND6K6S,L,2_-+(0,*B\L>!7M=>._'3_D09/^P]X;_P#3Q:T
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MAI_T)^D_]\S_ /Q^C]UWJ?\ @,?_ )+U_IZ'[SM#[Y?Y'9?V_H7_ $&M)_\
M!C9__'J/[?T+_H-:3_X,;/\ ^/5QO_"H/AI_T)^D_P#?,_\ \?H_X5!\-/\
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MQL__ (]7&_\ "H/AI_T)^D_]\S__ !^C_A4'PT_Z$_2?^^9__C]'[KO4_P#
M8_\ R7K_ $]#]YVA]\O\CLO[?T+_ *#6D_\ @QL__CU']OZ%_P!!K2?_  8V
M?_QZN-_X5!\-/^A/TG_OF?\ ^/T?\*@^&G_0GZ3_ -\S_P#Q^C]UWJ?^ Q_^
M2]?Z>A^\[0^^7^1V7]OZ%_T&M)_\&-G_ /'J/[?T+_H-:3_X,;/_ ./5QO\
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MQS[-BA>]2]K\ZV;:_AT^Z04445D:!1110 4444 %%%% !1110 4444 %%%%
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M$RBI1::336SU3[;^9\C?\$Z42/\ 8P^!4<:JB)X9O$1% 541==U5555& %4
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y'\4/^0K\+_\
MLH6D?^@R5ZY7E7Q2T;Q1J2>$+_PKI5KK-[X>\5V&LW%C=:C#IBRVMLKB39<S
M@IO!883&3S@BM*5E4C=I+75M);/=NR7S(J? ]&]8NR3;TDGLM7\CU6BO(?\
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M_@$_+R\_P?8]>HKR'_A)_B]_T3#3?_"STS_XBC_A)_B]_P!$PTW_ ,+/3/\
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M?_@VGY?WO/\ !]@YUVG_ . 3\O+S_!]CUZBO(?\ A)_B]_T3#3?_  L],_\
MB*/^$G^+W_1,--_\+/3/_B*/92_FI_\ @VGY?WO/\'V#G7:?_@$_+R\_P?8]
M>HKR'_A)_B]_T3#3?_"STS_XBC_A)_B]_P!$PTW_ ,+/3/\ XBCV4OYJ?_@V
MGY?WO/\ !]@YUVG_ . 3\O+S_!]CUZBO(?\ A)_B]_T3#3?_  L],_\ B*/^
M$G^+W_1,--_\+/3/_B*/92_FI_\ @VGY?WO/\'V#G7:?_@$_+R\_P?8]>HKR
M'_A)_B]_T3#3?_"STS_XBC_A)_B]_P!$PTW_ ,+/3/\ XBCV4OYJ?_@VGY?W
MO/\ !]@YUVG_ . 3\O+S_!]CUZBO(?\ A)_B]_T3#3?_  L],_\ B*/^$G^+
MW_1,--_\+/3/_B*/92_FI_\ @VGY?WO/\'V#G7:?_@$_+R\_P?8]>HKR'_A)
M_B]_T3#3?_"STS_XBC_A)_B]_P!$PTW_ ,+/3/\ XBCV4OYJ?_@VGY?WO/\
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M/B)_X42__(= 'KE%>1_\*DB_Z'SXB?\ A1+_ /(='_"I(O\ H?/B)_X42_\
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M?_D.C_A4D7_0^?$3_P *)?\ Y#H ]<HKR/\ X5)%_P!#Y\1/_"B7_P"0Z/\
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MM[WQGX\N[>08>"YUR&:)A[I)8D?B,'WH ]:2\M)%B>.ZMY%G_P!2R3QLLO\
MUS(8A_\ @.:LU\TR?LP^%A?Z7>V7C#X@6(TV[>[-O%XCF:*8LA")$&0+:;),
M2YB1@^-A7:37=?\ "I(O^A\^(G_A1+_\AT >N45Y'_PJ2+_H?/B)_P"%$O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %?FY_P4F_:=^+GP%^'_P]\$_LVC1+K]I+
MXV>,+S0/AG8Z_HI\0Z5'I_A70K_Q7XPU34-+6> R6UOI=C#9+*TBK%/J$<BE
MG0*?TCK\KOC/^Q/\3/VF/VW(/C%X[^(GQ*^#WPH^#'PD3PC\#=8^"?Q#TGP]
MXQUSQAXUO3<_$76=>@O= \0?V=9V^F0V^@V<;6T4MW"S3+,$!4@'K'PY_;U^
M&^J?L<_!?]J3QM'K#3_$_3/#>A0>"O!>B77B3Q;KGQ7OI)]'U3P%X4\.6C+=
M:CKA\0Z;JT%GIQDBD\BV)=UV\^W_  *_:8\&?'K_ (2NTTKPE\5?AQXD\$3V
MD?B7P9\9?A[K'PY\5:?;:A UQIVI_P!GZIYMO<Z9?0I(\%U:WLPPC"5(B #^
M6?PZ_80^,?P1^!7QY_9JU#X/Z#^U9\$]._:)_P"%L?!+2?B9\83X;^(7B3PA
MXJ8ZUXEM+7QEHHT!O"/CSPUXFEN9]$U._ETC3+JWN[GYX]P5OI_]@?X"_M$?
M"_2_C)I?Q9O_ (@>%/A3XF.E:9\&?@M\3/BWHOQW\6?"G3K;3KZV\0?9_B+H
MEK!;77A_5KR\CFT71+N[U34=-M[58[V_D<K0!V]A_P %*/V=-6\8CPGI=I\4
MKRQU37/%'A'P-\1%^'6KI\+/BAXZ\)6UU/JG@7X<>.'D73O$_BEY+.ZLK'3X
M$A2_OH)K:VN)'C;'"?\ !+;]IKXR?M>_!SQ?\<_BL_B32K+Q!\0O%&F^"?!.
MO?"2+X<6_A+P[H6N:II%K9Z5KQU;4+WQ^'CL4;5-8N[;3S9:F9]/2%UB\P_+
M_@_]C;]K6YT#]G']EKQCX(\%Z3\(/V9/V@+SXQVO[06F>,M%DF^(7AW1M8\2
M>(?"7AC2?AW:#_A)?#?B.\N_$CV6O:GJ973%BM#+;L_G8K[G_8K^#/Q@_9L_
M8RL/AIK>AZ)=_%OPY_PM75M(T*WUZUGT:_U;7?%?B?Q!X6M)]<0"V@@O%O\
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MN@7WB70/$G@>'6K.V\%^)])@M;&]\3W\.EZE96<GB_2K2WTR[GLI9C"B21Y
M/5_VZ_VN/V@?@#\6_P!E3P!\*?A*M_X!^*_QO^'W@SXJ?&;Q#<Z?_P (_P"'
MM%\4ZI>:<OA#P[HTLR:CJOBO5C MRU] OV71K%&FDWR.$KQ3]J+]MC7/#_[:
M^H_LYZ7^V)X'_9:\+^"_A=X/\0ZS+K/P2@^+NK>)_&WC?6V72M,EN[F[MK7P
MQID6@Q23-=7+QQ&5M\DR*AQ]E?MM_ OX@?'/3?V=K;P!::;=R_#?]J#X4?%3
MQ0-2U.#3!!X1\(WE_-K-Q:-."+R]C2XC\BQCQ+<$D(1@UYO^T-X5_:J7Q?\
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M_M 7GQT^)NL^/D\7V^O7WB;Q9J\VJZGHWE:\GGSVJ>&$L+2W;S%OK*"5H44
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M7)]-HHIMN3;;NWJVQ))))*R2LEY!1112&%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 ><>)_@Y\(O&WB+2O%_C/X5_#CQ=XLT+RO[$\4>)_ _AC7_$6C>1*)X/
M[*UK5=+N]2T_R9@)HOLES#Y<H$B;7 ->CT44 %%%% !1110!5BL;&&ZNKZ&S
MM8;Z]6!+V\BMX8[J[2V4I;+=7"()KA;=&9(%E=Q$K%8PH)%6J** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
#/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img94995564_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img94995564_5.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" (D!#L# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ9IG]L>%O_)"9!_UYQ7_ *G8D****\P_0 HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% 'G7Q1O]=TWPG<76@^!;?XC3+<P+?\
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MGQO_ .21H_\ 8\P?_J)BCY$HHHKZX_DT**** /V6_P""27_(5^+O_8+\/?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MD_\ ;'^,O[1GQ0'@'5KW1_#EHVBZCJQOM/TU+FXW:8+=A"J3.$"SB9A(2<Y
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M$K)/_"00<R*X_P")3:X 48V >9]T_P 0[GG(Q67U&K_/3\]9:;?W/5?([/\
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M@':,D$USULLQ&'=-573BZK:@E*4KN*NT[1=M/OV[V]?*^,<DSB&,G@*M>I'
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M +"NG_\ I5'4S^"7^&7Y,ZL#_ON#_P"PK#_^GH'PA_P5,_Y.#TG_ +$72O\
MTIFK\T:_2[_@J9_R<'I/_8BZ5_Z4S5^:-?195_R+\+_U[?\ Z7(_"?$[_DN^
M(O\ L*H?^H.%"BBBO0/@PK]'/^"8'_)R"?\ 8F^)?_0+*OSCK]'/^"8'_)R"
M?]B;XE_] LJX,T_Y%^+_ .O3_-'VWAQ_R7'#?_8P7_IFJ?C'^WC_ ,G?_M _
M]E(U[_T<E?(]?7'[>/\ R=_^T#_V4C7O_1R5\CT87_=L/_UXH_\ IN)]#Q!_
MR/<X_P"QGCO_ %)J!1116YY 5_3[_P $/_\ DW3]H7_L94_]1(U_,%7]/O\
MP0__ .3=/VA?^QE3_P!1(UY><?[C/_KY2_\ 3B/T#PS_ .2JI?\ 8OS#_P!-
MQ/KJY_US_1/_ $6M05/<_P"N?Z)_Z+6H*\R6[]7^9]3+=^K_ #"BBBD(<GWU
M_P!Y?YBOH^;_ )-[M?\ L,K_ .ELM?."??7_ 'E_F*^CYO\ DWNU_P"PRO\
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MOBU_]*[>OTXK\Q]!_P"0I:?]?%K_ .E=O7Z<5YV.WI^DOSB??\'?[MC/^O\
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M_KXM?_2NWK].*\[';T_27YQ/O^#O]VQG_7^G_P"FV%%%%<!]B%%%% !1110
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M_I#=5V]1-WC3T2TEHK_S/NV_Q-(JSGJW[V[M_)'LDOP"BBBLRPHHHH ****
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M_P!+K'!T445P'KA1110!L:#_ ,A2T_Z^+7_TKMZ_3BOS'T'_ )"EI_U\6O\
MZ5V]?IQ7G8[>GZ2_.)]_P=_NV,_Z_P!/_P!-L*_F%_;$^('CS2_VG/C+I^F>
M-O%VG6%KXOFBM;*Q\2:S:6EM&+&R(C@MK>]CAA0$D[(T5<DG&2:_IZK^5?\
M;2_Y.G^-G_8Y3?\ I!8UZ'#T8RQ5922DOJ[=FDU?VE/74^#\<ZM6CP[E$J56
MI2D\ZBG*G.4&U]1QCLW%IM72=MKI/H>,?\+/^)?_ $4/QS_X5NO_ /RPK^GK
M]CN_OM4_9C^#6H:G>W>HW]UX0AENKV^N9KN[N9#?7H,D]S</)-,Y  WR.S8
M&< 5_*97]5'[%O\ R:Q\$_\ L38?_2^^KNXAC&.&H.,8Q?M^B2_Y=S[(^+\"
M\1B*W$6;QJUZU6*R634:E6<TG]>P:NE*32=M+[VT/J"OS(^*GQ=UGQ=\0/&]
MI=?M,Z=^SGX,\#ZX/"7AR&VCTZ?6/%_B6"WCFU"XU1;R.>2/1XI98H%6.-&)
M+E9"*_3>OS%U67X;? +XF?&27XM_!G6O&"_$CQ#+XA\(^*=*\%R^-X-6L;VT
MCBD\/R%+>Z&AW5O<QX:5EA1Q(KM(2IQX. 47.HW!U*B@O9PC&G.3;G%2Y8UE
M*G=1;NW";4;V6\H_N?%TZT</@$L33P>#GBJBQN(K5L=AZ$$L-5EAXUZN7U*.
M)C3G744HQKT(SJ^RC*<KJE4[:[\:_'7QM8?![X0V?CG0_#/C'QKIGB#7O$?Q
M/\(-9ZTMSX0\.R""RU?P^C![*'4-:+1/-'*'6W8NCKNR*[+X;?$+QA\)?$?Q
M0^''QD\:7?CVP\ ^%-/\?:1XXGT^&'7[[PW>3-;7EOJ=E9!(9KRTN@-CPA%:
M,A1G!-?-/@#1?&?P'M?A?\;M?\ ^*(_!MM>_$73KSP?IEK/J_B+P)X+\8W\>
MH>'B=(MQ),T=JT966SMMS0+,H"C)QV^J7FL?&/3OVD/C5IOA3Q)HWA34_A$G
M@/P7!KNDW>G:YXA-G*]]?:@FC31_;(H3,1!"DD8E9L_+@BNV=*F^:'+2^K2T
M=6$:::Q#Q2BXQFG*2<:;^!2<5"[2<=3YC"YABH.EB95<P6=4TJD,%B:^-J4I
M9-3R)5O;5L/)4:%2E/&Q<I8J=&&)EB;4I3A4?LSZ(L/VS?@%?ZU-HA\3W]@T
M>EMJUMJNIZ'J-CH6J1);+=26FCZM+$+74]1C1PCV5HTDOG9B + UJ^%/VM/@
MGXM\/^,?$EMXAOM&L? D:3>([?Q/H]]H&IVUO,2MK<PZ;?HEU<PWK@1V;Q(3
M<.RK&"37C_BWP=:7&B_L66)\,136NE>)/#$U[:?V0)(=/ \+(\SWD(@*VR_:
M26E,ZHOG\O\ .*\O_:,\"^(]8^-7CC7M \(W?B.R\->'/A;XJU70[6R8)XHT
M_P />(9+C4--@?RQ!?WL%O\ OX[0L[MY84KC .,,-@ZCC%>UAS1E+FE6@U'V
M>(C2:?[N*_>1;:;:4&U?F5V>GB,[XDPE*K7D\!BE1JT:3HTLNQ49U%C,I>/A
M43CC*LN7!5%R3C"G.>*AS)>QJ<L7]-> _P!LGX*_$3Q;HG@?0KGQ9:^)?$4T
M\6DZ?KWA'5M#>ZBMX3.]XC7\<8-BR#$=RNY'<JHZYKU#XW?$B7X5?#O6/%=G
M8KJFL"6RTCP]IKL4BOM?UBY2RTNWF<<I"UQ(K2L,X13ZU\0W7QR\*?&;]HG]
MG)_"G@3Q;HL&AZMK\-[X@\4>%KCPULN'T5U_X1VT^VPQ7%TMN 9RT.;0! 4P
MV,_8W[1/@#6?B-\,=3TCPUY3>)M)U'2/%/AR"X8)!=ZSX=O8]0L[.:0\1I=-
M&T)D_A+@X/2LJN'I4J^$4Z<Z4*BC*K3JU%-Q_>RBTY1A"T6DKZ72;ZG?@,US
M',,ISZ>'QF&S'$X.=6A@,9E^$J8:%9O+\/B(NG0K5L2IUH5:TX0:J2ISE"*M
M>Z/#!\$OVIY['_A,G_:9U6V\;/!_:2^!8_#FE-\.XKLQ^<FC,K+_ &HUNK$6
MSS^;EG!D'R&O.=:^)GQ0^-MO\!O#VC>/=>^#7B/Q#XE\;>%_B!<^$(K&[=-;
M\(63K<Q01:E%)&]I/.JW$(8J463 ) &=3Q;^W'XBT:'1='T?X+>/KSXAV\S6
MGB[P1?\ A;78VBE6V(:?0_$=M;RZ%<Q)<+YX^T3+YMH0$_>\5XKH'C/1/A_I
MO[//Q3UJT\2:I%<^/?B=XC\>V_ASPOK6K:CH'B+Q#:2";2+C2X+8W436)6"V
M9F4(Q D4E7%=E.EB;<]:A1]I>:PW)1H7;]C6LG"$>6<&XP=.4U/FE;E;;9\S
MC,PRB,_J^69IF,L*XX66=2Q&89G:,%FF4J56-?$5E6P^)C3K8FGC*6%G1E2I
MN?MZ4%&DW]#ZW8?'/]FK4O"GBW6/C/K7QG^'FJ>)M*\->,=-\9Z9I=AJVCPZ
MY<K9V6K:-=:8B1M]FNG03Q3 AHV.2,"OOD$$ @Y! ((Z$'D'\:_/7QC\6A^U
M9)X5^&OPP\&^.XO#DGBW1-:\=^+O%GA34?#&G:-HVA7::C]E@35(XIKN\OYH
MHX8A"I49.3FOT*50JJHX"@*!Z # _2O/Q:DHT75A"G7:G[2,80IOD3C[-SA!
M*,9OWU;E4G%1;Z'V7#T\/*KF*RW$8C%91&6$^J5J^(Q.+I_673J?7*>%Q.+G
M4K5:$4L,W^]J4X5Y5H0::G&*T445Q'TX4444 9.M:]HOARR.HZ]JECH]@)$A
M-YJ-S%:VXEDSY<9EF94#O@[5SDX..E?G;:Q_"[XE?&CXK-\6/BC=JEG?V3>
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MQ_Y&&._[#,5_Z?F%%%%6<85_3'^QA_RA^^.W_7+XD?\ H=A7\SE?TQ_L8?\
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M5H5H*I1K0E3J0;:4H33C)7BU)73T<6I)ZIII,^7?AO\ LV7?A3Q?IWCGQ_\
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M]2:@4445N>0%?T^_\$/_ /DW3]H7_L94_P#42-?S!5_3[_P0_P#^3=/VA?\
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MO['_ /R6*7_L3-1_]+TK^4K]J?\ Y.*^,G_90/$O_ISN*G ?[_B_^O-$_/\
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M/_2!J_.ZO*PO^[4/^O4/_24?TK7_ (U7_'+\PHHHK<R"OW"_X(T?\ACXW_\
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ME3_U$C7\P5?T^_\ !#__ )-T_:%_[&5/_42->7G'^XS_ .OE+_TXC] \,_\
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M'_8)+_TZC]Z\-?\ DEL9_P!CBI_ZC88^>:***L^V"BBB@#ZC_8__ .2Q2_\
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M?]CEX7_]/MA4S^"7^&7Y,Z<%_OF$_P"PFA_Z=@?O%_P78_UG[-__ &*.H_\
MHV&OYZ:_H6_X+L?ZS]F__L4=1_\ 1L-?STUY^4?\B^A_W$_].3/KO$7_ )*W
M,O\ !@O_ %"PX4445Z1\0%?I5_P26_Y/=^%O^[K7_IO>OS5K]*O^"2W_ ">[
M\+?]W6O_ $WO7+CO]SQ/_7FI_P"DL^@X4_Y*7(O^QI@__3T#Z/\ ^"H__)WW
MCC_L%>'/_2!J_.ZOT1_X*C_\G?>./^P5X<_](&K\[J\K"_[M0_Z]0_\ 24?T
MK7_C5?\ '+\PHHHK<R"OW"_X(T?\ACXW_P#8IV'_ *62U^'M?N%_P1H_Y#'Q
MO_[%.P_]+):Y,=_NE;TC_P"EQ.G!_P"\TO67_I$C^=SXP?\ )5?B/_V//BS_
M -/^H5YQ7H_Q@_Y*K\1_^QY\6?\ I_U"O.*^@I_PZ?\ @C_Z2C^4LQ_Y&&._
M[#,5_P"GYA1115G&%?TQ_L8?\H?OCM_UR^)'_H=A7\SE?TQ_L8?\H?OCM_UR
M^)'_ *'85YF:_P "C_V%X?\ ]*9^B>&W_(US;_LG\P_]*PY_,\_WV_WF_F:;
M3G^^W^\W\S3:],_.PHHHH <GWU_WE_F*_MJ\*?\ )I'[-W_8EZ+_ .F=*_B5
M3[Z_[R_S%?VU>%/^32/V;O\ L2]%_P#3.E>-FO\ $P/_ %]J?^D(_4?#G_=.
M*O\ L74/_2ZQP=%%%<!ZX4444 ;&@_\ (4M/^OBU_P#2NWK].*_,?0?^0I:?
M]?%K_P"E=O7Z<5YV.WI^DOSB??\ !W^[8S_K_3_]-L*_EX_;)_X)6?M=_&G]
MI_XS_%/P+X>\%W7A'QMXOEUG0;C4/'&E:=>RV+V%C;JUQ8SKYMM)YD$@,;_-
M@ ]"*_J'HK+"8RK@YRJ45!RE#D?.G)6NI:6<=;I=3TN(.',OXEPU#"9C+$QI
M4*_UB#PU2%*?M/9SIVDYTZJ<>6;T23O9WZ/^-_\ X<N?MS_]"M\/_P#PXNB?
M_$U_4/\ L;?"_P 6?!;]F#X,?"OQU;V=KXN\$^$(M&UZWT^]BU&RBODO[ZX9
M+>^@Q%<Q^7/&?,C^4DD=C7TS16N+S'$8R$:=94U&,N=<D7%WLXZMREI9LX>'
M^#,HX:Q5;%Y?/&RJUZ#P\UB:U.K!4W4A5]U0H4FI<U..K;5KJVMPKX,^+?[/
M'[3,_P 2?%?C3]GK]H+2O >B?$FRL+/QMX9\<Z#?^*H-'N+"W>T&L> 7CN/+
MT;4KBWD8RI)&MJ)51]CG)'WG17)3J2I2<HJ+NK-3A&<6KIZQDFM&DT[736A]
M#C<#1Q].-*M*O#DFJD*F'Q%;#5H3490;C5H3A-*4)SA*-^649--;-?G=K?[#
M^N>&O 7PF'P-^)K>$?C/\(KC6K_3_B!XHTUM:T[Q?>>*V:;Q8GC#3+<I+=6F
MKW3FXV0,'B9(U4@+Q9\._L@?$:\\!?'J\^*WQ.T;QM\=/CMX3_X1'4?%=AHU
MUI'@WPYI%I"\>EZ5HNCAI+V/3H97-S/N)G>4D#(Q7Z$45I]:KVUDF^;FYG"'
M/\:J<O/R\W)SI2<+\K?2VAQ+(,L4U.-&I&*I>R5&.(KK#K_9OJ:K?5_:>R^L
M+#/V*KN+J\F\F]3Y-\1?L\:YK5C^RQ:0^(=)A;X :WX?U76WDM[PKK\>C^&D
MT.6+2PJDP/-,IGC-WM41':V'XKYN_;+^!/AR'5/B=\>_'OC;4O"GA^[\+_#S
M1_#.M^%= U+7?$/@3QCX5UY]1TOQ=J%M;1M'+H$$[*-19,F"U,KRX7%?J'5:
M\L[34+6>RO[6VOK.ZC:&YM+R"*YM;B%QM>*>WF5XI8W!(:.1&5@<$$44\1.$
MHRO=1NFE9/E=15))-J2NY+=QDK.S36@\7DN$Q.'KT5!*57DG&51U:E.-:EA'
M@Z,Y0A5I3E&%&R<8U*;;7.I1G:2_!WX.>,_B/\<_VL_V>-1U+]I7P+^TA!X!
ME\3:E?1?"7PAJFA^$?">D#1FMAJ_B?4K^,))XIU"5DMEMD<*Z-(T:9K]JOBI
M\,_#'Q@\ ^)/AUXOMY)]"\36#V5R]N_E7EI+D26U_8SX+6][97"1W%M,F&21
M 01FMSP]X,\'^$5N$\)^%/#7AA+LAKI/#VA:7HJW+*<JUPNFVML)B"209 Q!
M/%=+3KXA5)TY4X^R5**C"W*FFI.?-[D(13YGI:*VNVVS/*<HE@L+BZ&,K+'3
MQU:53$.;KSA*,J%+#>SOBJ^)KS3ITES.=5KWG&,8Q21^1_CS]BG]M/QC#X?\
M&)^UMX>MO G@VX8^$O%2^%M;L?B[960MFM([74=7T^^30]4#6I6TG-Y:3"2%
M?,&R?YZTXOV._P!IO2? 7P!L/A]XX^$/@?XB_ +7/%_V;Q#J^BZ]XDT3QAIW
MB"VE@.O7NFQE+B'6]1:XDGU!)YBJSJSJS;P!^KM%5]=K6BFJ347=+V5-)MQE
M%\RC%*7,I2NI)K5M)-MF/^K&6*=2HI8_GJ0IP<WF&+G.,:-6A6HJE.=64Z3H
MU,/1<)TY1G:$8RE**27YX^'/V7OVC?B'XS\%>)/VLOC=X-\=^'_AWKL/B?P]
MX!^&G@VY\+^'=5\06BL-.U'Q-)J,\MS>'39#Y]K!$/*,H!8 C=7Z'445A4JR
MJ6YN5**M&,(1A&-]7:,4E=O5O=]7L>K@\!0P,:BHNM.=:2G6KXFO5Q.(JRC%
M0ASUJTYS:A!*,(W48J[44Y2;****S.T**** "OR3_:"T?6? 7BOQY-KOA+Q!
MJR^,/C%X \>Z!XKTC1KG6H_^$9T.5&U'0GFLXYKBUETW:98K1PJ3F3$>6S7Z
MV5\V>!OB;XU\??&CXA>'+)M!TKP)\-+F3P[J-A<1RR^)M:UN>"&XM]4MY,K'
M::7 #)$ 487#$;7W(175A:DJ4JDU%2C&"<TY<FBG%Q2E:6KFHJUFGU[KGQ$(
MS4(N34I3M"T>;5QDFVFUHHW=[IIVM>]GR/P!CUOQA\5/BG\9!X<U?PIX.\6Z
M?X<T7P]8ZW:MIVHZQ+HD+I=:_+ISA9;=;K>J*9E64[,/DBOL&OFSX2?$CQEJ
M7Q,^)OPH\;W.C:UJ'@H:;J^F^(-"MVM;>;1]<,K6NFZA;EG6/5+ (([E@P\P
M_-M7.*^DZSKW]IJDER4^51;:Y/9QY-79M\MKW2UOHBJ%O9Z-OWIN3:2?.YRY
MU9722E=))M6V;W"BBBL38**YB3QOX+B=XI?%WAB.2-F22.37]*1T=20R.C78
M964@AE8 @@@C-:*:_H4FG-J\>M:2^DH2KZHFI6;:<C*VQ@UZLQME*N0A!E!#
M':>>*;36Z:OM=,5UW7WFM16%8>*/#.JW M-+\1:%J5TRLXMK#5]/O+@HN-SB
M&WN))"JY&Y@N!D9(K=H::W37KH.Z>SN<1XL_Y"O@G_L8Q_Z0W5=O7$>+/^0K
MX)_[&,?^D-U7;U4O@I^DO_2F3'>?^)?^D1"BBBH*"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#^#?]O'_D[_
M /:!_P"RD:]_Z.2OD>OKC]O'_D[_ /:!_P"RD:]_Z.2OD>OT'"_[MA_^O%'_
M --Q/X^X@_Y'N<?]C/'?^I-0****W/("OZ??^"'_ /R;I^T+_P!C*G_J)&OY
M@J_I]_X(?_\ )NG[0O\ V,J?^HD:\O./]QG_ -?*7_IQ'Z!X9_\ )54O^Q?F
M'_IN)]=7/^N?Z)_Z+6H*GN?]<_T3_P!%K4%>9+=^K_,^IEN_5_F%%%%(0Y/O
MK_O+_,5]'S?\F]VO_897_P!+9:^<$^^O^\O\Q7T?-_R;W:_]AE?_ $MEK"MO
M1_Z^Q_,^AR#;-O\ L58C\X'S>W4_4_SI*5NI^I_G25N?/!1110!-!_K/^V<W
M_HF2OA3_ (+K_P#)/?V:/^NNM?\ IET^ONN#_6?]LYO_ $3)7PI_P77_ .2>
M_LT?]==:_P#3+I]50_W[!_XJO_ILZL5_R2/%/_8/@_\ U*@?S:4445],?AH4
M444 ?=W_  31_P"3VO@)_P!C@O\ Z;-1K^BC]J/_ )+3XL_Z]?#7_IG%?SK_
M /!-'_D]KX"?]C@O_ILU&OZ*/VH_^2T^+/\ KU\-?^F<5XF+_P"1E#_L$E_Z
M=1^]>&O_ "2V,_['%3_U&PQ\\T4459]L%%%% 'U'^Q__ ,EBE_[$S4?_ $O2
MOY2OVI_^3BOC)_V4#Q+_ .G.XK^K7]C_ /Y+%+_V)FH_^EZ5_*5^U/\ \G%?
M&3_LH'B7_P!.=Q4X#_?\7_UYHGY_XG_\B+)_^QE7_P#4>9X#1117M'X>%%%%
M '],'_!-C_E&G^TQ_P!<?'7_ *CLM?S0O]X_A_(5_2]_P38_Y1I_M,?]<?'7
M_J.RU_-"_P!X_A_(5Y6!_P![S+_K_'_TD_0^,/\ DG>!?^Q16_\ =4;1117J
MGYX%/C_UD?\ OK_Z$*93X_\ 61_[Z_\ H0H _IJ_:5_Y0S?"#_L'> O_ $MU
M&OYDJ_IM_:5_Y0S?"#_L'> O_2W4:_F2KRLH_@XG_L-K_E3/T/Q&_P"1CDW_
M &3V7?G6"BBBO5/SP*[3X;_\E"\"?]CEX7_]/MA7%UVGPW_Y*%X$_P"QR\+_
M /I]L*F?P2_PR_)G3@O]\PG_ &$T/_3L#]XO^"['^L_9O_[%'4?_ $;#7\]-
M?T+?\%V/]9^S?_V*.H_^C8:_GIKS\H_Y%]#_ +B?^G)GUWB+_P E;F7^#!?^
MH6'"BBBO2/B K]*O^"2W_)[OPM_W=:_]-[U^:M?I5_P26_Y/=^%O^[K7_IO>
MN7'?[GB?^O-3_P!)9]!PI_R4N1?]C3!_^GH'T?\ \%1_^3OO''_8*\.?^D#5
M^=U?HC_P5'_Y.^\<?]@KPY_Z0-7YW5Y6%_W:A_UZA_Z2C^E:_P#&J_XY?F%%
M%%;F05^X7_!&C_D,?&__ +%.P_\ 2R6OP]K]PO\ @C1_R&/C?_V*=A_Z62UR
M8[_=*WI'_P!+B=.#_P!YI>LO_2)'\[GQ@_Y*K\1_^QY\6?\ I_U"O.*]'^,'
M_)5?B/\ ]CSXL_\ 3_J%><5]!3_AT_\ !'_TE'\I9C_R,,=_V&8K_P!/S"BB
MBK.,*_IC_8P_Y0_?';_KE\2/_0["OYG*_IC_ &,/^4/WQV_ZY?$C_P!#L*\S
M-?X%'_L+P_\ Z4S]$\-O^1KFW_9/YA_Z5AS^9Y_OM_O-_,TVG/\ ?;_>;^9I
MM>F?G84444 .3[Z_[R_S%?VU>%/^32/V;O\ L2]%_P#3.E?Q*I]]?]Y?YBO[
M:O"G_)I'[-W_ &)>B_\ IG2O&S7^)@?^OM3_ -(1^H^'/^Z<5?\ 8NH?^EUC
M@Z***X#UPHHHH V-!_Y"EI_U\6O_ *5V]?IQ7YCZ#_R%+3_KXM?_ $KMZ_3B
MO.QV]/TE^<3[_@[_ ';&?]?Z?_IMA117YV_%3]I?XG>$?B'XL\-://H:Z9H^
MJ/:6:W&D+/.(5AA<>9,9U,C;G;YMHXP,<5ST,//$2<*;BG&/,^9M*UTNB?<^
MLK5H4(J4[V;Y597ULWW71,_1*BORM_X:Z^,'_/SX=_\ !&G_ ,D5^B/PJ\2:
MEXO^'GA3Q+K#0-J>L:6MW>M;1"" S&::,F.(,PC7:B_+N/.3WJZ^$JX>,95'
M"TGRKE;;O:^MTO\ AR*.)IUY.,.:Z7,^9):72[OJ_P ST&BOD5_VM/#.K?''
MP;\'?!6EW7B*UUJ]UW3]?\9F&YMM T[4-&M&GDTG2;MHUBU748Y$9;U8R8;5
M5*ES)@'.^)'[0GQ<_P"%@^(_ 'P#^$>F_$FX\ 6MG<^/M6U_Q%_PCNGV4]]$
M;F#1=%=8Y&U#6C;(TAMV"H"R L,U"PU9RC%Q4'*'M+SE&"4+\J<G)I1O*R2=
MFVUIJ4\12M)J3ERS]F^2,IMRY5)J*BFY6B[MJZ5G=Z'V717Q]J/[6=@WP8\,
M_$3PYX/U36/&GC+7_P#A!]!^'<DJ6^H#QU%<26E]H]_<\I!;:;-$\MY= $+;
M#>N35OX3_'[X@7WC>\^&/Q]^'FD_"WQF^@3>*]!N-(\1)KGA;6M"M95BOC'J
MTRP>1?:>S!KR&4*B*058\D#PU91G)Q2Y').+E%3?([3<87YI1BWK**:6][7#
MV]+FC%2;YU%J2C+E]Y7BG*UHN2V3:?D?6U%8T'B+P_=7<NGVNNZ-<W\%N+N>
MR@U.RFNX;5D$BW,MM'.TT=NR$.)G18RA#!L$&I=,UO1=:BEGT;5]+U:&"0PS
MS:9J%I?Q0RKG=%+):S2I'(N#E'*L,'(K&S6Z:VZ/KM]_0UNNZ^\U**YN/QGX
M/FN'M(?%?AN6[BG6UDM8]=TM[B.Y=_+2W>%;HR).T@*+$RB1G^4*6XJC\0?'
M?A_X9^#M>\<>*+A[?1?#]D]Y=&)#+<3$$)#:VL(^::ZN9F2&"),L\C@ &FHR
M;45%\TFE%6U;=DDN][JWJ)RBDY-I**NW?1)=6=E17P2/V@?VM)K(^.K3]E_3
M7^&AA.IQ6DWC>*+XERZ)L\U;E?#1B^S+=R6^+A+9IPVP[2 _%=;\0OVI;^/X
M,> _BA\&_#.G>+]4^('BK1?">E^'_%.H3Z EEJFIW,EG=V.J7,,<KV=WIUU$
M\,RNFS*[CA6%;/"UKP2Y)<\N2\:M.2C*U^6<HR:@[7?O-;.U[,R^LTK2;YUR
MQYK2ISBY1NES0BXIS5VE[J>Z[H^R:*^"+S]HW]I3X8-8:]\??@'X:T#X>3:E
M9:=JWB?X?>-6\67/AY;^=;:+4M5T]X(773899$^T31DF-"6/2OO"UN8+VVM[
MRUE6>UNX(;FVF0Y2:">-9894/=9(W5U/<$&HJ49TE%RY'&5U&4)PJ1;C;F7-
M!M75U=.SU3+IU85+J/,G&UXSA*$DGL^6:3L[/5::,GHHHK(T"BBB@ K\_=>T
M_P"#?Q ^+WQ'L_B%J,OPH\8^']1M[#3]5\,^.9_#5_XU\.I:Q&'5M62%OL\L
MD,K26T<38FC W."Q)K] J_.GXR^-/@Q8?$'4K2#X%Z1XYN[?QEX<\->._&5[
M'';65CKWBBY2&&S5V?SK_48HB9[E401QKM#$DUU81-SFH^TNX6YJ;2<5S1O?
MFE&+3^&SO=M65[-<V*LHQ<N2RFKQFFU+1[<J<DU\5U:UM=+GU%\%?"GP=\&V
MNK:;\,-7L]<OKR9-0\0ZK+KP\1^(-0E;,<-QJVI/))<2A0ICBW!$&#@%LFO=
M*^</@^?ACI/CWXC^"_"7P_L/ OB;PP^G)J)M(8T&NZ#>H;C2=4A='8_9I&:4
M"*0!T<,3P17T?6-:_M&VYOF497J6YFI133T;5FGI9[670THV]FDE!)-QM3OR
MIQ;32ND[W3O=;Z^85A?\)/X9:].F?\)#H1U$RFW.GC5]/-[YXR#!]D%QY_FC
MG,?E[Q_=K=KQI/V>O@M'XP_X3Y/A[H2^,?[3?6/[? O/MW]IN6+WG_'WY/FL
M6;/[K;S]VE'D][G<UI[O+%.[[2O*-EYJ[\BY<^G(HO77F;5EY63N]]';U/FC
M]H?X*? 3PGH<$6B?"+PQJ/Q&^(^N#P]X8#+J#2?VOJCE[[6YHUO<-%I<+R7T
MQ"A0X3(VY%5_C'\.-&^$G[._@?X1:#H6LZ[INK^,- MO$%GH]E<ZE>:I%]I.
MIZ^S0PYV#4)T6W0%HXT$@.X;,CW77?"?B'Q'^TEX1UZ^TBZ/@OP/X(U*XTW4
MY #82>*M7N_)<1Y)Q=6]C&%/ (1L@\C/9?%_4_BIH6E:1KWPOTNP\22Z5J8G
M\2^%+F-5U#7]$:/;)!HMX[HMKJ,#_O8P0PGR(S@9-=<:T[X>+J.;3]J^>JU'
MGU5./,V^1127;63NTK-<CI0:KR5-0T]DN2FG)P7*YOE27-S.ZZOEBK>?S'\#
MY_@;X?\ B;8:)!^SYK'P/^(%]I]Y_P (Q>>(K:1&U^P"K]L2RNHKZYM4F=$5
MVM9?WQ52R@ <_;>L>*-!\/O#'K&H1V3W",\*O%<R%T4[68>1#*  >/F(-?)V
MG+\3_CE\3?AYXF\0_#/6/A1X1^&-]>ZX1XIFLY/$&NZU=V;64=I9Q64DB1:8
MD;&265G#.X4%>!7V?66(:<X.3DY."YXJK[3D:;2BJCY].6SY;RY6[7-</?ED
MDDHJ?N2]E[/FCRQNW!*.SO%.RNDG9GC^K>,M UWQ)X+T_2+J6^E36_M,DL=G
M=):Q(+.Z0))<3PQ()6/*QC+%>>E>P5Q'BPG^U?!7/_,QC_TANJ[>LIVY:=DT
MK2W=W\3ZV7Y?YFL;WG=IOFZ*WV(]+O\ ,****S+"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#^/?]K_]@K]K
M/Q]^TQ\:/&'A3X+>+M8\.^(/'>LZCH^J6=I%+;7UA/*I@N87,ZDI* 2N0#QS
M7S;_ ,.V_P!M3_H@?CC_ , (?_DBO[FJ*]JGG>)ITX4U2HM4X1@FU.[44DKV
MEV7XORM^:XSPOR/&XO$XRKB\S53%8BMB*D85<,H1E6J.I*,$\-)J*<FHW;=K
M7;:N?PR_\.V_VU/^B!^./_ "'_Y(H_X=M_MJ?]$#\<?^ $/_ ,D5_<U15_V]
MB?\ GU0^Z?\ \G_5WY6Y_P#B$W#_ /T&9K_X-POE_P!0OD_O\C^&7_AVW^VI
M_P!$#\<?^ $/_P D5^^W_!)[X"?%SX"_ KXY:)\6O!&L>"M2UG63J&EVNKQ)
M'->V</AAK>6>)$>0E$F4QGG)8=*_:2D95965E#*P*LK %64C!5@<@@@D$$8(
MX-<^*S:OBJ3HSITHQ<HR;BI7]UII:R:U:['L9%P!E/#^/CF.#Q./J5XT:U!1
MQ$Z$J?+6BHR;5.A3E=6NO>2U/S N+.Y:5B(6(*QD'*]#&OO4/V*Z_P">+?FO
M_P 57Z8'0-")R=$T@D]2=-LR3^/DTG_"/Z#_ - 32/\ P6V7_P 9J'CTVW[)
MZN_Q+_Y$I\&W=_K^[O\ [OZ?]/O7\/,_-#[%=?\ /%OS7_XJC[%=?\\6_-?_
M (JOTO\ ^$?T'_H":1_X+;+_ .,T?\(_H/\ T!-(_P#!;9?_ !FE]>7_ #[?
M_@2_^1#_ %-_ZF'_ );^G_3[U_#S/S22RNMR_N6^\.Z^H_VJ^B+B-T_9]M49
M2&&LK\I'/-Y*1C'4$=".#7U+_P (_H/_ $!-(_\ !;9?_&:K:UX6T+7]'DT'
M4M/B?2I&1S:0 VJ*T;;T:/[/Y?ED-DY7'4U$\7&;IW@XJ,XR;O?1;I*R_,[\
M#PY+ QQG+BE5GBL)5PT5*DZ<8NIRM2;4ZC:36R5[>>A^:3(^3\K=3_"?7Z4F
MQ_[K?]\G_"ONO_A0OPR/70Y?_!C??_'J/^%"_#'_ * 4O_@QOO\ X]6_UVCV
MJ?\ @,?_ )+^K/ROXO\ J?C?^@G"_P#E7_Y#^K/RO\*;'_NM_P!\G_"C8_\
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M:_\ 3.*_G7_X)H_\GM? 3_L<%_\ 39J-?T4?M1_\EI\6?]>OAK_TSBO$Q?\
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M_P"C8:_GIK^A;_@NQ_K/V;_^Q1U'_P!&PU_/37GY1_R+Z'_<3_TY,^N\1?\
MDK<R_P &"_\ 4+#A1117I'Q 5^E7_!);_D]WX6_[NM?^F]Z_-6OTJ_X)+?\
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MEI_U\6O_ *5V]?IQ7G8[>GZ2_.)]_P '?[MC/^O]/_TVPK\;?CY_R6+X@?\
M8>D_])[>OV2KY^\4?LT?#'Q?X@U7Q+K$.N-J>L71N[PVVK-! 9F1$)BA^SOY
M:[47Y=QYSS4X+$4\/4G.IS6E#E7*DW?FB^K6EDSZ;%T9UZ<8PY;J:D^9VTLU
MV?<_)"OV1^ 7_)'/A_\ ]@)/_2JYKS__ (9%^#__ #P\1_\ @\;_ .1:^@?"
M_AO3?"'A_2O#6CK.NF:/;"TLUN9?/G$(=Y!YLQ5?,;<[?-M'&!CBM<=BZ6(I
MPC34TXSYGS)+3E:Z-]6983#5*$Y2GRV<.56;;O>+[+L_F?*_Q=T^PTW]H?\
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MU_\ 2NWK].*_,?0?^0I:?]?%K_Z5V]?IQ7G8[>GZ2_.)]_P=_NV,_P"O]/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[=P?\M?_ , C_P#)^O\ 3T^-_P"(4<2_\_\ *O\ PIQ'_P R'\>U/C_UD?\
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MT;/K/$'"8JKQ7F,Z>&Q%2$H8*TX4:DXNV"PZ=I1BT[/1V>CT/.**]'_X4_\
M%3_HG?C7_P )?6__ )!H_P"%/_%3_HG?C7_PE];_ /D&O1]I3_Y^0_\  H_Y
MGQ7U#'?] >+_ /">M_\ (>:^\\XK]*O^"2W_ ">[\+?]W6O_ $WO7PY_PI_X
MJ?\ 1._&O_A+ZW_\@U^BW_!*WX=>/M _;0^&.HZUX,\4:580KK/FWNH:%J=G
M:Q;K!@/,GN;6*),G@;F&3P,FN;&U(/"8A*<&W1G9*2;?NOI<]_A;!XN'$>1S
MGA<3"$<SPCE*5"K&,4JT&VY.*226K;=DM3US_@J/_P G?>./^P5X<_\ 2!J_
M.ZOU _X*8> /&VO?M9>-=0T;PIXAU.QDTOP^L=Y8Z1?W5M(R6)5PDT%O)&Q5
MN&PQP>*^ ?\ A4WQ,_Z$3Q9_X(-5_P#D2O+PS7U>AJOX4.J_E1_1M:,G6J6B
MW[\NC[_\%?>>>T5Z%_PJ;XF?]")XL_\ !!JO_P B4?\ "IOB9_T(GBS_ ,$&
MJ_\ R)6]UW7WHRY9?RR^Y_UU7WGGM?N%_P $:/\ D,?&_P#[%.P_]+):_'__
M (5-\3/^A$\6?^"#5?\ Y$K]HO\ @D'X1\4>&]8^-)U_P]K.CBX\*6"6[:EI
MMW9+.XNY28XC<PQ"1\<E4R0.3@5R8YKZK6U6T>O]^)TX1-8BDVFE=[I_R/\
MS1_-U\8/^2J_$?\ ['GQ9_Z?]0KSBOHCXL_";XG77Q/^(=Q!\/O&<L,WC;Q5
M)%(GAK6722-]=OW1T=+)E9'4AE8$AE(()!!KS[_A3_Q4_P"B=^-?_"7UO_Y!
MKWJ=2G[.'OP^"/VH]EYG\MYA@<;+'XUQP>*:>,Q+36'JM-.M.S34+-.ZMZH\
MXHKT?_A3_P 5/^B=^-?_  E];_\ D&C_ (4_\5/^B=^-?_"7UO\ ^0:OVE/_
M )^0_P# H_YG']0QW_0'B_\ PGK?_(>:^\\XK^F/]C#_ )0_?';_ *Y?$C_T
M.PK^>/\ X4_\5/\ HG?C7_PE];_^0:_H[_8]\*>)]-_X)*?'#0-0\/:U9:W<
M1_$06^DW6F7L&I7'G/8^48+*2%;F428)0I&=P!*YQ7FYI.#HT4IQ;^MX=V4D
M].9ZZ,_0?#K"XFEFF:NKAZ]-2R#,(Q=2C4@I2<J#44Y12<FM4EJS^7]_OM_O
M-_,TVO26^$'Q3+,1\._&I!8X(\,:W@C)Y'^@]#3?^%/_ !4_Z)WXU_\ "7UO
M_P"0:]+VE/\ Y^0_\"C_ )GY]]0QW_0'B_\ PGK?_(>:^\\XHKT?_A3_ ,5/
M^B=^-?\ PE];_P#D&C_A3_Q4_P"B=^-?_"7UO_Y!H]I3_P"?D/\ P*/^8?4,
M=_T!XO\ \)ZW_P AYK[SSI/OK_O+_,5_;5X4_P"32/V;O^Q+T7_TSI7\;B_"
M#XIAE)^'?C4 ,"2?#&M@  Y/)L:_LO\ #6GWUM^RA^SO:75I<VUS9^#]&ANK
M>>WGCFMY1I*+Y<\)C\V)RPVA713G@@&O'S2474P+4HM*K4O9IV]Q=F?IOA[A
ML12PO%"JT*U-SR^@H*I2J0YGSU=(\T5S/5:*[U7='F]%6?LDW]Q_^_,__P :
MH^RS?W'_ ._-Q_\ &JXKKNOZ_P"'7WGJ^QK?\^JO_@N7^7FOO*U%6?LLW]Q_
M^_-Q_P#&J/LLW38__?FX_GY.*+KNOZ_X=?>'L:W_ #ZJ_P#@N7^7FOO+^@_\
MA2T_Z^+7_P!*[>OTXK\S]"M9AJEF!'(S-<VJJJPSEF8W=N< >5UP">2!@'FO
MTPKSL=O3])?G$^]X0A.&&QBG&46Z]-I2BXW7L]U=(*_CB_;V_P"3P_C_ /\
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M6PTY=8UY9;#1/"VD2,4BU/Q-KMW'IVC6D\B\QP-=3*\SCI&C>M?E7\6/VF/
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@!DD44RE)HXY4)!*2(KJ2.A*L",CMQQ5?[!
M8_\ /E:?^ T/_P 15NB@"I]@L?\ GRM/_ :'_P"(H^P6/_/E:?\ @-#_ /$5
M;HH J?8+'_GRM/\ P&A_^(I186(((L[0$'((MX001T(.S@BK5% $,MO;S[?.
M@AFVY"^;$DFT'J%WJ<9P,XJ+[!8_\^5I_P" T/\ \15NB@"I]@L?^?*T_P#
M:'_XBC[!8_\ /E:?^ T/_P 15NB@"I]@L?\ GRM/_ :'_P"(I\=G:1,'BM;>
M-QG#QP1(PSUPRJ",]\&K%% $+V]O(Q9X(78]6>)&8XZ9)4D_G3?LEI_S[6__
M 'YC_P#B:L44 5_LEI_S[6__ 'YC_P#B:/LEI_S[6_\ WYC_ /B:L44 5_LE
MI_S[6_\ WYC_ /B:D2&&+/EQ11[AAMD:ID>AV@9'UJ2B@"J;&Q))-G:DDDDF
MWA))/)))3))/4TGV"Q_Y\K3_ ,!H?_B*MT4 5/L%C_SY6G_@-#_\11]@L?\
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M#8549;L2!7H59N+C:ZM?5:I_D:)IWMT=OP3_ %"BBBD,**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/^?LO_ 5_F'UZ?\ S[C][/V+LKZSU&W2[L;F&[MI/N3P.'C?']UAP:M5X_\
M LEOAUHQ)).).223][U->P5YE2/).<$[\LFK][,]"#<HQD]Y13T\U<****@H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MKQ[X%?\ ).=&^DG_ *%7L-?.5_XU7_'+\SW:?\.G_@C_ .DH****R+"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=$=+17-?\)EX5_Z&#2O_  ,B_P#BJ/\ A,O"O_0P:5_X&1?_ !59\D_Y9?\
M@+_R*YH_S1^]?UU7WG2T5S7_  F7A7_H8-*_\#(O_BJ5?&'A9V"KK^ELS$*J
MB[B)))P !NY)-')/^67_ ("_\@YH_P T?O7]=5]YTE%-1U=5=&#*P#*PY!!Z
M$'T-.J2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\^T7'_/>;_OZ_P#\57V#??\ )NMO_OC_ -&+7QQ7-AMJW_7^I_[:=.)WI?\
M7J'Y(F^T7'_/>;_OZ_\ \51]HN/^>\W_ ']?_P"*J&BNDYB;[1<?\]YO^_K_
M /Q5:&E7$YU/3P9YB/MEOP9'_P">J_[59-:&D_\ (3T__K\M_P#T:M*6S]'^
M0X[KU7YGZYZ&2='TPDY/V*WY/_7-:U:RM#_Y VF?]>5O_P"BUK5KYF6[]7^9
M[T=EZ+\@HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^K_,]Z.R]%^04444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !117*:EXZ\'Z/=R6&J>(]*L
M+V''FVUS=)'+'N&1N0\C(Y'M3492=HIR>]DFW;OH)M+=I>KM^9U=%<+_ ,+-
M^'__ $-VA_\ @;'1_P +-^'_ /T-VA_^!L=5[.I_S[G_ . R_P B?:0_GA_X
M$O\ /S7WG=45PO\ PLWX?_\ 0W:'_P"!L='_  LWX?\ _0W:'_X&QT>SJ?\
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MM\*O[NRVMLB5""YK0BN;XK12YO\ %IK\SS;P'\'OAC\,&O)/ /@O1/#$M_\
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MK0TG_D)Z?_U^6_\ Z-6E+9^C_(<=UZK\S]<]#_Y VF?]>5O_ .BUK5K*T/\
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MR;K;_P"^/_1BU\<5S8;:M_U_J?E$Z<3O2_Z]0_)!11172<P5H:3_ ,A/3_\
MK\M__1JUGUH:3_R$]/\ ^ORW_P#1JTI;/T?Y#CNO5?F?KGH?_(&TS_KRM_\
MT6M:M96A_P#(&TS_ *\K?_T6M:M?,RW?J_S/>CLO1?D%%%%(84444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 5^9OQ^_Y*AX@_[=O_10K],J_,WX_?\ )4/$'_;M_P"BA7H9=_%G
M_P!>W_Z5$X\;_"7^)'C-%%%>P>6%%%% 'V'^R;_Q^>+?^O:Q_P#1K5]JU\5?
MLF_\?GBW_KVL?_1K5]JUX.-_WFK_ -N?^FX'L87^##Y_F%%%%<IT!1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MD:7KWAXZ9I>G:<9;F<2FQL;:T,@6%MHD-O%&7"Y.-V<9.*[RN4UK_D.^&O\
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MK7S,MWZO\SWH[+T7Y!1112&%%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_-7XK?\ (_>)/^O^7^9KT\%&,I>]%2_=+=)_:\SAQ<I12Y6U^\Z-K[$.P?\
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MMJW_ %_J?E$Z<3O2_P"O4/R04445TG,%:&D_\A/3_P#K\M__ $:M9]:&D_\
M(3T__K\M_P#T:M*6S]'^0X[KU7YGZYZ'_P @;3/^O*W_ /1:UJUE:'_R!M,_
MZ\K?_P!%K6K7S,MWZO\ ,]Z.R]%^04444AA1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7YF_'
M[_DJ'B#_ +=O_10K],J_,WX_?\E0\0?]NW_HH5Z&7?Q9_P#7M_\ I43CQO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<L5%WU^:-)86I*%.-XIP3N[NSYFKVTZ:^I^;%%?I+_PSK\,?^@;?_P#@P?\
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M_P"^Z^\];^"?@?Q%>'4-9BU2^NV4(9I=08OM'09$0X%8_P#PSK\,?^@;?_\
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MJ6Z7O;FE/"U(*HGROGIN"LWHW9W=TM%KZGY9T5^DO_#.OPQ_Z!M__P"#!_\
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M (2KQ)_T'-3_ / N;_XJC_A*O$G_ $'-3_\  N;_ .*K]!O^&=?AC_T#;_\
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MC",/9I1BD^:[NU9:6Z6UU]"O_P -(?#/_G^O_P#P7S_X4?\ #2'PS_Y_K_\
M\%\_^%6/^&=?AC_T#;__ ,&#_P#QNC_AG7X8_P#0-O\ _P &#_\ QNC_ &'_
M *B/OA_EZ_T]"V+[T?NEY?YO[O,K_P##2'PS_P"?Z_\ _!?/_A1_PTA\,_\
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M!_\ XW6O]H4?Y:GW+_Y+U_IZ1]2J_P T/O?EY>;^[S/S:KWO]G+_ )*-9_\
M7M-_Z":^JO\ AG7X8_\ 0-O_ /P8/_\ &ZU]%^"7@;P]>KJ&CPZG97BJ56>+
M4&WA6X(!,1X(ZU%3'49TYQ2FG*+2NE:[777;^O2Z>$J0G";<&HR3:3=W:VFJ
M]?N\SX>^-%Q<+\1->59YE42IA5E< ?+V 8 5Y7]JN?\ GXG_ ._TG_Q5?I=J
MGP*\ :S>S:CJ5KJ5U>7!S+/)J#[G(Z$XCK/_ .&=?AC_ - V_P#_  8/_P#&
MZ*>.HPA"+4[QC&+:2L[))O?KJ_\ A]%/"593E*\%S.]KO2]O+S?W>9^</VJY
M_P"?B?\ [_2?_%4?:KG_ )^)_P#O])_\57Z/?\,Z_#'_ *!M_P#^#!__ (W1
M_P ,Z_#'_H&W_P#X,'_^-U?]H4?Y:GW+_P"2]?Z>D_4JO\T/O?EY>;^[S/SA
M^U7/_/Q/_P!_I/\ XJOL;]ENY98O$<MQ,[1Q"-V:1V?:H!)/)/IVKUC_ (9U
M^&/_ $#;_P#\&#__ !NNCT/X1>$?#D=S#HW]JV,=VNVX6+4#B1<$8;,1.,$U
MC7QE&M2E32FG+EU:6EI)OKU2:_JQI1PM2G4C-N+2OHF^R\N^GRO8;-\9OAU!
M+)#+X@A62)VC=?+D.UT)5AG'8@BH_P#A=?PW_P"AAA_[]R?X5C2_L]?#6:22
M:73]0>25V=V.H/EG8DLQQ'C)))-1_P##.OPQ_P"@;?\ _@P?_P"-URVP?>O]
MT/+_ (/];=/^T]J*^<O+R]?Q[JV[_P +K^&__0PP_P#?N3_"C_A=?PW_ .AA
MA_[]R?X5A?\ #.OPQ_Z!M_\ ^#!__C='_#.OPQ_Z!M__ .#!_P#XW1;!]Z_W
M0\O^#_6R_P!I_P"G/3K+R\O7\>ZMN_\ "Z_AO_T,,/\ W[D_PKL+'QAX<U#1
MCX@M]4M_[(4D->RMY42D<'<6QCGCFO,O^&=?AC_T#;__ ,&#_P#QNNFB^$OA
M2'17\/1G5ET>3.^R&H'RFSSR/*]>?K4R6&LN255.ZOS*+]WK:UM>W3\E4?;Z
M\RI[:6<OBTM>]M-[_P##&I_PLOP%_P!#7HW_ (&1_P"-'_"R_ 7_ $->C?\
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M);)1BDDO1+6[W9,(1IKE@K)N[U;;>UVVVV[)*[;T26R"BBBI+"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&(J/KK]IS]F7Q'\=OBW^Q[\1-$\2:)HFG_LW?&75/B9XAT_5(;^6\\1:=?\
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M)Z!X:T[6;[6M9L-,D-E>7FMVUEI$>N,MF;D113RQ\KX _:1_:0^,_P#P4>^
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MO@U;V]YXZ\;7OC7PW;:CJVN>");.]L)?#TFAV%UJM^UXL<EM&\$X7P_X<_\
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MG'X;_$7X<_$L6EOJL<_B^Q\??"Z'X>RW'A-F@7[+)9RK+?J=5,!*>6H!<,M
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M1:CI/@*\U&YOM(LQ8Q2NFHWRWJ+:23A;9&1O.=00: /AZ;]LOX_>$]#^-O\
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M\?\ AOP@OB.[L;CQ'XEU0W:^)O#=WK5A93_V-9PK%/$FH16^HQWZ*4B,:*Y
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
L* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>14
<FILENAME>tyra-20251231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2026-03-02T14:21:21.1171+00:00 -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://tyra.bio/20251231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:tyra="http://tyra.bio/20251231" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2025" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd" namespace="http://xbrl.sec.gov/ecd/2025"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" namespace="http://fasb.org/us-gaap/2025"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2024-01-31"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" namespace="http://fasb.org/srt/2025"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2025"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd" namespace="http://xbrl.sec.gov/cyd/2025"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" namespace="http://xbrl.sec.gov/dei/2025"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" namespace="https://xbrl.org/2023/calculation-1.1"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://tyra.bio/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>75000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheets" id="Role_StatementBalanceSheets">
        <link:definition>75010 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheetsParenthetical" id="Role_StatementBalanceSheetsParenthetical">
        <link:definition>75020 - Statement - Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" id="StatementStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>75030 - Statement - Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLossParenthetical" id="StatementStatementsOfOperationsAndComprehensiveLossParenthetical">
        <link:definition>75040 - Statement - Statements of Operations and Comprehensive Loss (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity" id="StatementStatementsOfStockholdersEquity">
        <link:definition>75050 - Statement - Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfStockholdersEquityParenthetical" id="StatementStatementsOfStockholdersEquityParenthetical">
        <link:definition>75060 - Statement - Statements of Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows" id="Role_StatementStatementsOfCashFlows">
        <link:definition>75070 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfCashFlowsParenthetical" id="StatementStatementsOfCashFlowsParenthetical">
        <link:definition>75080 - Statement - Statements of Cash Flows (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" id="DisclosureCybersecurityRiskManagementStrategyAndGovernance">
        <link:definition>995457 - Disclosure - Cybersecurity Risk Management, Strategy, and Governance</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies" id="DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies">
        <link:definition>995467 - Disclosure - Organization and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tyra.bio/20251231/taxonomy/role/Role_DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>995477 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecurities" id="DisclosureMarketableSecurities">
        <link:definition>995487 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tyra.bio/20251231/taxonomy/role/Role_DisclosurePropertyAndEquipment" id="Role_DisclosurePropertyAndEquipment">
        <link:definition>995497 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" id="DisclosureAccruedExpensesAndOtherCurrentLiabilities">
        <link:definition>995507 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tyra.bio/20251231/taxonomy/role/Role_DisclosureSimpleAgreementsForFutureEquity" id="Role_DisclosureSimpleAgreementsForFutureEquity">
        <link:definition>995517 - Disclosure - Simple Agreements for Future Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquity1" id="DisclosureStockholdersEquity1">
        <link:definition>995527 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensation" id="DisclosureEquityIncentivePlansAndStockbasedCompensation">
        <link:definition>995537 - Disclosure - Equity Incentive Plans and Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tyra.bio/20251231/taxonomy/role/Role_DisclosureNetLossPerShare" id="Role_DisclosureNetLossPerShare">
        <link:definition>995547 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>995557 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureLeases" id="DisclosureLeases">
        <link:definition>995567 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>995577 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tyra.bio/20251231/taxonomy/role/Role_DisclosureEmployeeBenefits" id="Role_DisclosureEmployeeBenefits">
        <link:definition>995587 - Disclosure - Employee Benefits</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureSegmentInformation" id="DisclosureSegmentInformation">
        <link:definition>995597 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>995607 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
        <link:definition>995617 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecuritiesTables" id="DisclosureMarketableSecuritiesTables">
        <link:definition>995627 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tyra.bio/20251231/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables" id="Role_DisclosurePropertyAndEquipmentTables">
        <link:definition>995637 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" id="DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables">
        <link:definition>995647 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquityTables" id="DisclosureStockholdersEquityTables">
        <link:definition>995657 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationTables" id="DisclosureEquityIncentivePlansAndStockbasedCompensationTables">
        <link:definition>995667 - Disclosure - Equity Incentive Plans and Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tyra.bio/20251231/taxonomy/role/Role_DisclosureNetLossPerShareTables" id="Role_DisclosureNetLossPerShareTables">
        <link:definition>995677 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>995687 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesTables" id="DisclosureLeasesTables">
        <link:definition>995697 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureSegmentInformationTables" id="DisclosureSegmentInformationTables">
        <link:definition>995707 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>995717 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails" id="DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails">
        <link:definition>995727 - Disclosure - Fair Value Measurements - Assets measured at fair value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableforsaleSecuritiesAndGrossUnrealizedLossesDetails" id="DisclosureMarketableSecuritiesSummaryOfAvailableforsaleSecuritiesAndGrossUnrealizedLossesDetails">
        <link:definition>995737 - Disclosure - Marketable Securities - Summary of Available-for-Sale Securities and Gross Unrealized Losses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" id="DisclosureMarketableSecuritiesAdditionalInformationDetails">
        <link:definition>995747 - Disclosure - Marketable Securities (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" id="DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails">
        <link:definition>995757 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tyra.bio/20251231/taxonomy/role/Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails" id="Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails">
        <link:definition>995767 - Disclosure - Property and Equipment - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" id="DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
        <link:definition>995777 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquitySummaryOfReservedSharesOfCommonStockDetails" id="DisclosureStockholdersEquitySummaryOfReservedSharesOfCommonStockDetails">
        <link:definition>995787 - Disclosure - Stockholders' Equity - Summary of Reserved Shares of Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" id="DisclosureStockholdersEquityAdditionalInformationDetails">
        <link:definition>995797 - Disclosure - Stockholders' Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationAdditionalInformationDetails" id="DisclosureEquityIncentivePlansAndStockbasedCompensationAdditionalInformationDetails">
        <link:definition>995807 - Disclosure - Equity Incentive Plans and Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationSummaryOfStockOptionActivityDetails" id="DisclosureEquityIncentivePlansAndStockbasedCompensationSummaryOfStockOptionActivityDetails">
        <link:definition>995817 - Disclosure - Equity Incentive Plans and Stock-Based Compensation - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationSummaryOfFairValueOfStockOptionGrantsDetails" id="DisclosureEquityIncentivePlansAndStockbasedCompensationSummaryOfFairValueOfStockOptionGrantsDetails">
        <link:definition>995827 - Disclosure - Equity Incentive Plans and Stock-Based Compensation - Summary of Fair Value of Stock Option Grants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails" id="DisclosureEquityIncentivePlansAndStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails">
        <link:definition>995837 - Disclosure - Equity Incentive Plans and Stock-Based Compensation - Summary of Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationScheduleOfSharebasedCompensationEmployeeStockPurchasePlanDetails" id="DisclosureEquityIncentivePlansAndStockbasedCompensationScheduleOfSharebasedCompensationEmployeeStockPurchasePlanDetails">
        <link:definition>995847 - Disclosure - Equity Incentive Plans and Stock-Based Compensation - Schedule of Share-Based Compensation, Employee Stock Purchase Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails" id="DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails">
        <link:definition>995857 - Disclosure - Net Loss Per Share - Basic and Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tyra.bio/20251231/taxonomy/role/Role_DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesIncludingAllOutstandingStockOptionsWereExcludedInCalculationOfDilutedSharesOutstandingDetails" id="Role_DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesIncludingAllOutstandingStockOptionsWereExcludedInCalculationOfDilutedSharesOutstandingDetails">
        <link:definition>995867 - Disclosure - Net Loss Per Share - Potentially Dilutive Securities Including All Outstanding Stock Options were excluded in Calculation of Diluted Shares Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" id="Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
        <link:definition>995877 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" id="Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>995887 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>995897 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails" id="Role_DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails">
        <link:definition>995907 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" id="DisclosureLeasesAdditionalInformationDetails">
        <link:definition>995917 - Disclosure - Leases (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails" id="DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails">
        <link:definition>995927 - Disclosure - Leases - Schedule of Components of Lease Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesLeaseLiabilitiesWeightedaverageRemainingTermAndWeightedaverageDiscountRateDetails" id="DisclosureLeasesScheduleOfMaturitiesLeaseLiabilitiesWeightedaverageRemainingTermAndWeightedaverageDiscountRateDetails">
        <link:definition>995937 - Disclosure - Leases - Schedule of Maturities Lease Liabilities Weighted-Average Remaining Term and Weighted-Average Discount Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesLeaseLiabilitiesWeightedaverageRemainingTermAndWeightedaverageDiscountRateParentheticalDetails" id="DisclosureLeasesScheduleOfMaturitiesLeaseLiabilitiesWeightedaverageRemainingTermAndWeightedaverageDiscountRateParentheticalDetails">
        <link:definition>995947 - Disclosure - Leases - Schedule of Maturities Lease Liabilities Weighted-Average Remaining Term and Weighted-Average Discount Rate (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformationDetails" id="DisclosureEmployeeBenefitsAdditionalInformationDetails">
        <link:definition>995957 - Disclosure - Employee Benefits (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails" id="DisclosureSegmentInformationAdditionalInformationDetails">
        <link:definition>995967 - Disclosure - Segment Information (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfTheCompanysNetLossDetails" id="DisclosureSegmentInformationScheduleOfReconciliationOfTheCompanysNetLossDetails">
        <link:definition>995977 - Disclosure - Segment Information - Schedule of reconciliation of the Company's net loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfTheCompanysNetLossParentheticalDetails" id="DisclosureSegmentInformationScheduleOfReconciliationOfTheCompanysNetLossParentheticalDetails">
        <link:definition>995987 - Disclosure - Segment Information - Schedule of reconciliation of the Company's net loss (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" xlink:type="simple"/>
        <link:roleRef roleURI="http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheetsParenthetical" xlink:href="tyra-20251231.xsd#Role_StatementBalanceSheetsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity" xlink:href="tyra-20251231.xsd#StatementStatementsOfStockholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfStockholdersEquityParenthetical" xlink:href="tyra-20251231.xsd#StatementStatementsOfStockholdersEquityParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows" xlink:href="tyra-20251231.xsd#Role_StatementStatementsOfCashFlows" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#IndividualsOnly" xlink:type="simple"/>
        <link:roleRef roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:href="tyra-20251231.xsd#DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:type="simple"/>
        <link:roleRef roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="tyra-20251231.xsd#DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails" xlink:href="tyra-20251231.xsd#DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableforsaleSecuritiesAndGrossUnrealizedLossesDetails" xlink:href="tyra-20251231.xsd#DisclosureMarketableSecuritiesSummaryOfAvailableforsaleSecuritiesAndGrossUnrealizedLossesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" xlink:href="tyra-20251231.xsd#DisclosureMarketableSecuritiesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:href="tyra-20251231.xsd#DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquitySummaryOfReservedSharesOfCommonStockDetails" xlink:href="tyra-20251231.xsd#DisclosureStockholdersEquitySummaryOfReservedSharesOfCommonStockDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:href="tyra-20251231.xsd#DisclosureStockholdersEquityAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationAdditionalInformationDetails" xlink:href="tyra-20251231.xsd#DisclosureEquityIncentivePlansAndStockbasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationSummaryOfFairValueOfStockOptionGrantsDetails" xlink:href="tyra-20251231.xsd#DisclosureEquityIncentivePlansAndStockbasedCompensationSummaryOfFairValueOfStockOptionGrantsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails" xlink:href="tyra-20251231.xsd#DisclosureEquityIncentivePlansAndStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationScheduleOfSharebasedCompensationEmployeeStockPurchasePlanDetails" xlink:href="tyra-20251231.xsd#DisclosureEquityIncentivePlansAndStockbasedCompensationScheduleOfSharebasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://tyra.bio/20251231/taxonomy/role/Role_DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesIncludingAllOutstandingStockOptionsWereExcludedInCalculationOfDilutedSharesOutstandingDetails" xlink:href="tyra-20251231.xsd#Role_DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesIncludingAllOutstandingStockOptionsWereExcludedInCalculationOfDilutedSharesOutstandingDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="tyra-20251231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" xlink:href="tyra-20251231.xsd#DisclosureLeasesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfTheCompanysNetLossDetails" xlink:href="tyra-20251231.xsd#DisclosureSegmentInformationScheduleOfReconciliationOfTheCompanysNetLossDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd#eedm" xlink:type="simple"/>
        <link:roleRef roleURI="http://tyra.bio/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="tyra-20251231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheets" xlink:href="tyra-20251231.xsd#Role_StatementBalanceSheets" xlink:type="simple"/>
        <link:roleRef roleURI="http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" xlink:href="tyra-20251231.xsd#StatementStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
        <link:roleRef roleURI="http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLossParenthetical" xlink:href="tyra-20251231.xsd#StatementStatementsOfOperationsAndComprehensiveLossParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfCashFlowsParenthetical" xlink:href="tyra-20251231.xsd#StatementStatementsOfCashFlowsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements" xlink:type="simple"/>
        <link:roleRef roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="tyra-20251231.xsd#DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://tyra.bio/20251231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:href="tyra-20251231.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple"/>
        <link:roleRef roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecurities" xlink:href="tyra-20251231.xsd#DisclosureMarketableSecurities" xlink:type="simple"/>
        <link:roleRef roleURI="http://tyra.bio/20251231/taxonomy/role/Role_DisclosurePropertyAndEquipment" xlink:href="tyra-20251231.xsd#Role_DisclosurePropertyAndEquipment" xlink:type="simple"/>
        <link:roleRef roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:href="tyra-20251231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple"/>
        <link:roleRef roleURI="http://tyra.bio/20251231/taxonomy/role/Role_DisclosureSimpleAgreementsForFutureEquity" xlink:href="tyra-20251231.xsd#Role_DisclosureSimpleAgreementsForFutureEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquity1" xlink:href="tyra-20251231.xsd#DisclosureStockholdersEquity1" xlink:type="simple"/>
        <link:roleRef roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensation" xlink:href="tyra-20251231.xsd#DisclosureEquityIncentivePlansAndStockbasedCompensation" xlink:type="simple"/>
        <link:roleRef roleURI="http://tyra.bio/20251231/taxonomy/role/Role_DisclosureNetLossPerShare" xlink:href="tyra-20251231.xsd#Role_DisclosureNetLossPerShare" xlink:type="simple"/>
        <link:roleRef roleURI="http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="tyra-20251231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
        <link:roleRef roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureLeases" xlink:href="tyra-20251231.xsd#DisclosureLeases" xlink:type="simple"/>
        <link:roleRef roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:href="tyra-20251231.xsd#DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
        <link:roleRef roleURI="http://tyra.bio/20251231/taxonomy/role/Role_DisclosureEmployeeBenefits" xlink:href="tyra-20251231.xsd#Role_DisclosureEmployeeBenefits" xlink:type="simple"/>
        <link:roleRef roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureSegmentInformation" xlink:href="tyra-20251231.xsd#DisclosureSegmentInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="tyra-20251231.xsd#DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureFairValueMeasurementsTables" xlink:href="tyra-20251231.xsd#DisclosureFairValueMeasurementsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecuritiesTables" xlink:href="tyra-20251231.xsd#DisclosureMarketableSecuritiesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://tyra.bio/20251231/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables" xlink:href="tyra-20251231.xsd#Role_DisclosurePropertyAndEquipmentTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="tyra-20251231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquityTables" xlink:href="tyra-20251231.xsd#DisclosureStockholdersEquityTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationTables" xlink:href="tyra-20251231.xsd#DisclosureEquityIncentivePlansAndStockbasedCompensationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://tyra.bio/20251231/taxonomy/role/Role_DisclosureNetLossPerShareTables" xlink:href="tyra-20251231.xsd#Role_DisclosureNetLossPerShareTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:href="tyra-20251231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesTables" xlink:href="tyra-20251231.xsd#DisclosureLeasesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureSegmentInformationTables" xlink:href="tyra-20251231.xsd#DisclosureSegmentInformationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://tyra.bio/20251231/taxonomy/role/Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:href="tyra-20251231.xsd#Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="tyra-20251231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationSummaryOfStockOptionActivityDetails" xlink:href="tyra-20251231.xsd#DisclosureEquityIncentivePlansAndStockbasedCompensationSummaryOfStockOptionActivityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails" xlink:href="tyra-20251231.xsd#DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="tyra-20251231.xsd#Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="tyra-20251231.xsd#Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails" xlink:href="tyra-20251231.xsd#Role_DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails" xlink:href="tyra-20251231.xsd#DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesLeaseLiabilitiesWeightedaverageRemainingTermAndWeightedaverageDiscountRateDetails" xlink:href="tyra-20251231.xsd#DisclosureLeasesScheduleOfMaturitiesLeaseLiabilitiesWeightedaverageRemainingTermAndWeightedaverageDiscountRateDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesLeaseLiabilitiesWeightedaverageRemainingTermAndWeightedaverageDiscountRateParentheticalDetails" xlink:href="tyra-20251231.xsd#DisclosureLeasesScheduleOfMaturitiesLeaseLiabilitiesWeightedaverageRemainingTermAndWeightedaverageDiscountRateParentheticalDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformationDetails" xlink:href="tyra-20251231.xsd#DisclosureEmployeeBenefitsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails" xlink:href="tyra-20251231.xsd#DisclosureSegmentInformationAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://tyra.bio/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfTheCompanysNetLossParentheticalDetails" xlink:href="tyra-20251231.xsd#DisclosureSegmentInformationScheduleOfReconciliationOfTheCompanysNetLossParentheticalDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="tyra_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsAbstract" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_Pre-FundedWarrantsExercised" xlink:label="tyra_Pre-FundedWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueAdjustment" xlink:label="us-gaap_AssetsFairValueAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_CapitalizedSoftwareImplementationCostsPolicyTextBlock" xlink:label="tyra_CapitalizedSoftwareImplementationCostsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_CommonStockWarrantsPolicyTextBlock" xlink:label="tyra_CommonStockWarrantsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_TYRA-300MUCMember" xlink:label="tyra_TYRA-300MUCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:label="tyra_DeferredTaxAssetsCapitalizedResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesTradingRestricted" xlink:label="us-gaap_DebtSecuritiesTradingRestricted"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_CashCashEquivalentsAndMarketableSecurities" xlink:label="tyra_CashCashEquivalentsAndMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_CaliforniaResearchAndDevelopmentMember" xlink:label="tyra_CaliforniaResearchAndDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" xlink:label="us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_IssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:label="tyra_IssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_AccruedOtherGeneralAndAdministrativeFee" xlink:label="tyra_AccruedOtherGeneralAndAdministrativeFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_AllowanceForCreditLossesPolicyTextBlock" xlink:label="tyra_AllowanceForCreditLossesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_ScheduleOfMaturitiesOfLeaseLiabilitiesWithWeightedAverageRemainingTermAndDiscountRateTableTextBlock" xlink:label="tyra_ScheduleOfMaturitiesOfLeaseLiabilitiesWithWeightedAverageRemainingTermAndDiscountRateTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet" xlink:label="tyra_IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_RestrictedCashMember" xlink:label="tyra_RestrictedCashMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_PurchaseOfCommonStockThroughPayrollDeduction" xlink:label="tyra_PurchaseOfCommonStockThroughPayrollDeduction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_PreFundedWarrantsMember" xlink:label="tyra_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_VestingOfSharesOfCommonStockSubjectToRepurchaseOneShares" xlink:label="tyra_VestingOfSharesOfCommonStockSubjectToRepurchaseOneShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOptionCreditRiskGainsLossesOnAssets" xlink:label="us-gaap_FairValueOptionCreditRiskGainsLossesOnAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtMember" xlink:label="us-gaap_ShortTermDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_StockOptionsToPurchaseCommonStockMember" xlink:label="tyra_StockOptionsToPurchaseCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_OtherDevelopmentProgramsMember" xlink:label="tyra_OtherDevelopmentProgramsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_IssuanceOfCommonStockPursuantToPreFundedWarrantExercised" xlink:label="tyra_IssuanceOfCommonStockPursuantToPreFundedWarrantExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_IncomeTaxReconciliationChangesInUnrecognizedTaxBenefitsPercentage" xlink:label="tyra_IncomeTaxReconciliationChangesInUnrecognizedTaxBenefitsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_FederalMember" xlink:label="tyra_FederalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_DanielBensenMember" xlink:label="tyra_DanielBensenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_PatentCostsPolicyPolicyTextBlock" xlink:label="tyra_PatentCostsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_OtherResearchAndDevelopmentMember" xlink:label="tyra_OtherResearchAndDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_TYRA-200Member" xlink:label="tyra_TYRA-200Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_VestingOfSharesOfCommonStockSubjectToRepurchase" xlink:label="tyra_VestingOfSharesOfCommonStockSubjectToRepurchase"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_IncomeTaxReconciliationChangesInUnrecognizedTaxBenefits" xlink:label="tyra_IncomeTaxReconciliationChangesInUnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageBasicSharesOutstandingProForma" xlink:label="us-gaap_WeightedAverageBasicSharesOutstandingProForma"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_AccruedInterestAvailableForSaleSecurities" xlink:label="tyra_AccruedInterestAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_FGFRDiscoveryMember" xlink:label="tyra_FGFRDiscoveryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_SeriesAConvertiblePreferredStockMember" xlink:label="tyra_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_StateMember" xlink:label="tyra_StateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_SharesAvailableForFutureIssuance" xlink:label="tyra_SharesAvailableForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_EstimatedSharesPurchasableUnderTheEsppMember" xlink:label="tyra_EstimatedSharesPurchasableUnderTheEsppMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_IssuanceOfCommonStockPursuantToPreFundedWarrantExercise" xlink:label="tyra_IssuanceOfCommonStockPursuantToPreFundedWarrantExercise"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionsLessThanTwelveMonthsFairValue" xlink:label="tyra_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionsLessThanTwelveMonthsFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_StockOptionsAbstract" xlink:label="tyra_StockOptionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_ConvertiblePreferredStockTextBlock" xlink:label="tyra_ConvertiblePreferredStockTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_CommonStockOptionsGrantedAndOutstanding" xlink:label="tyra_CommonStockOptionsGrantedAndOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_RelatedPartiesPolicyPolicyTextBlock" xlink:label="tyra_RelatedPartiesPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_TYRA-430Member" xlink:label="tyra_TYRA-430Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_MinimumLeasePaymentsForLeasesNotYetCommenced" xlink:label="tyra_MinimumLeasePaymentsForLeasesNotYetCommenced"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_DividendYield" xlink:label="tyra_DividendYield"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_EmployeeStockPurchasePlanDescription" xlink:label="tyra_EmployeeStockPurchasePlanDescription"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_VestingOfSharesOfCommonStockSubjectToRepurchaseShare" xlink:label="tyra_VestingOfSharesOfCommonStockSubjectToRepurchaseShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_AlanFuhrmanMember" xlink:label="tyra_AlanFuhrmanMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_SimpleAgreementsForFutureEquityTextBlock" xlink:label="tyra_SimpleAgreementsForFutureEquityTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_SimpleAgreementsForFutureEquityAbstract" xlink:label="tyra_SimpleAgreementsForFutureEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_TwoThousandTwentyFourPrivatePlacementMember" xlink:label="tyra_TwoThousandTwentyFourPrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_DeferredTaxAssetsTaxCredits" xlink:label="tyra_DeferredTaxAssetsTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="dei_EntityIncorporationDateOfIncorporation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_IssuanceOfCommonStockUnderBenefitPlans" xlink:label="tyra_IssuanceOfCommonStockUnderBenefitPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_ComputersAndSoftwareMember" xlink:label="tyra_ComputersAndSoftwareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" xlink:label="us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_NetOperatingLossCarryforwardsAvailableForOffsettingAgainstFutureTaxableIncomePercentage" xlink:label="tyra_NetOperatingLossCarryforwardsAvailableForOffsettingAgainstFutureTaxableIncomePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_IssuanceOfPreFundedWarrantsUnderPrivatePlacement" xlink:label="tyra_IssuanceOfPreFundedWarrantsUnderPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_AccruedResearchAndDevelopment" xlink:label="tyra_AccruedResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_IssuanceOfCommonStockUnderBenefitPlansShares" xlink:label="tyra_IssuanceOfCommonStockUnderBenefitPlansShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_PersonnelCostsMember" xlink:label="tyra_PersonnelCostsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="us-gaap_CompensationRelatedCostsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_IncomeTaxReconciliationOfficersCompensationPercentage" xlink:label="tyra_IncomeTaxReconciliationOfficersCompensationPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_WarrantsIssuedPricePerShare" xlink:label="tyra_WarrantsIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_OrganizationPolicyTextBlock" xlink:label="tyra_OrganizationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_ConversionOfConvertiblePreferredStockInConnectionWithInitialPublicOffering" xlink:label="tyra_ConversionOfConvertiblePreferredStockInConnectionWithInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAccumulatedLoss" xlink:label="tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_PaymentsOfIssuanceCostsForCommonStockAndPreFundedWarrantsFromPrivatePlacement" xlink:label="tyra_PaymentsOfIssuanceCostsForCommonStockAndPreFundedWarrantsFromPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_TwentyTwentyOneEquityIncentivePlanMember" xlink:label="tyra_TwentyTwentyOneEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_VestingOfOptionsEarlyExercisedSubjectToRepurchase" xlink:label="tyra_VestingOfOptionsEarlyExercisedSubjectToRepurchase"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_SeriesBConvertiblePreferredStockMember" xlink:label="tyra_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_UnvestedCommonStockExerciseOfStockOptionsMember" xlink:label="tyra_UnvestedCommonStockExerciseOfStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue" xlink:label="tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_AccruedAndOtherRelatedParties" xlink:label="tyra_AccruedAndOtherRelatedParties"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_AccruedResearchAndDevelopmentExpensePolicyPolicyTextBlock" xlink:label="tyra_AccruedResearchAndDevelopmentExpensePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_Rule10B51ArrModifiedFlag" xlink:label="tyra_Rule10B51ArrModifiedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendPaymentRestrictionsScheduleDescription" xlink:label="us-gaap_DividendPaymentRestrictionsScheduleDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="us-gaap_MarketableSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_ExchangeOfCommonStockForPre-FundedWarrantsShares" xlink:label="tyra_ExchangeOfCommonStockForPre-FundedWarrantsShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_FirstAmendmentMember" xlink:label="tyra_FirstAmendmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UsGovernmentAgencyInsuredLoansMember" xlink:label="us-gaap_UsGovernmentAgencyInsuredLoansMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_IssuanceOfConvertiblePreferredStockInExchangeForSimpleAgreementForFutureEquity" xlink:label="tyra_IssuanceOfConvertiblePreferredStockInExchangeForSimpleAgreementForFutureEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_IncomeTaxReconciliationProvisionForIncomeTaxesPercentage" xlink:label="tyra_IncomeTaxReconciliationProvisionForIncomeTaxesPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_SharesReservedForFutureIssuance" xlink:label="tyra_SharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="us-gaap_IncomeTaxContingencyLineItems"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_ExerciseOfPre-FundedWarrants" xlink:label="tyra_ExerciseOfPre-FundedWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_WeightedAverageUnvestedCommonStockIssuedUponExerciseOfCommonStockOptions" xlink:label="tyra_WeightedAverageUnvestedCommonStockIssuedUponExerciseOfCommonStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_AccretionOnMarketableSecuritiesNet" xlink:label="tyra_AccretionOnMarketableSecuritiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_ExpansionLeaseAgreementMember" xlink:label="tyra_ExpansionLeaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_AtmSalesAgreementMember" xlink:label="tyra_AtmSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_ReceivableFromExerciseOfStockOptionsIncludedInPrepaidExpensesAndOtherCurrentAssets" xlink:label="tyra_ReceivableFromExerciseOfStockOptionsIncludedInPrepaidExpensesAndOtherCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_NumberOfLeaseTermRenewal" xlink:label="tyra_NumberOfLeaseTermRenewal"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_FebruaryTwoThousandTwentyFourSecuritiesPurchaseAgreementMember" xlink:label="tyra_FebruaryTwoThousandTwentyFourSecuritiesPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_AccumulatedOtherComprehensiveLossMember" xlink:label="tyra_AccumulatedOtherComprehensiveLossMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_ResearchAndDevelopmentCreditCarryforwardsUnderInternalRevenueCodeDescription" xlink:label="tyra_ResearchAndDevelopmentCreditCarryforwardsUnderInternalRevenueCodeDescription"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_ProceedsFromIssuanceOfCommonStockUnderBenefitPlans" xlink:label="tyra_ProceedsFromIssuanceOfCommonStockUnderBenefitPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="tyra_OrganizationAndSummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_TwoThousandTwentyEightLeaseAgreementMember" xlink:label="tyra_TwoThousandTwentyEightLeaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAccumulatedLoss" xlink:label="tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfPropertiesSubjectToGroundLeases" xlink:label="us-gaap_NumberOfPropertiesSubjectToGroundLeases"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ExtinguishmentOfDebtAxis" xlink:label="us-gaap_ExtinguishmentOfDebtAxis"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_AccountsPayableAccruedExpensesAndOtherLiabilitiesRelatedPartyTransactions" xlink:label="tyra_AccountsPayableAccruedExpensesAndOtherLiabilitiesRelatedPartyTransactions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_TYRA-300NMIBCMember" xlink:label="tyra_TYRA-300NMIBCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_StockholdersEquityIncreaseDecreaseInCommonStockPercent" xlink:label="tyra_StockholdersEquityIncreaseDecreaseInCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDisclosuresAbstract" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:label="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_OperatingLossCarryforwardsExpirationDates1" xlink:label="tyra_OperatingLossCarryforwardsExpirationDates1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="us-gaap_IncomeTaxContingencyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_FacilitiesAndOtherCostsMember" xlink:label="tyra_FacilitiesAndOtherCostsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_Pre-FundedWarrantsAvailableForExercise" xlink:label="tyra_Pre-FundedWarrantsAvailableForExercise"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_TwoThousandsAndTwentyOneIncentiveAwardPlanMember" xlink:label="tyra_TwoThousandsAndTwentyOneIncentiveAwardPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_TYRA-300UTUCMember" xlink:label="tyra_TYRA-300UTUCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_AvailableForSaleDebtSecuritiesNetUnrealizedGain" xlink:label="tyra_AvailableForSaleDebtSecuritiesNetUnrealizedGain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_DenominatorAbstract" xlink:label="tyra_DenominatorAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_TwentyTwentyEquityIncentivePlanMember" xlink:label="tyra_TwentyTwentyEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_OptionsGrantedContractualTerm" xlink:label="tyra_OptionsGrantedContractualTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_TwentyTwentyOneEmployeeStockPurchasePlanMember" xlink:label="tyra_TwentyTwentyOneEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_WarrantsAvailableForExercise" xlink:label="tyra_WarrantsAvailableForExercise"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_TYRA-300ACHMember" xlink:label="tyra_TYRA-300ACHMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherTypesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherSellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherSellingGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_IncometaxreconciliationOfficersCompensation" xlink:label="tyra_IncometaxreconciliationOfficersCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_OfferingExpenses" xlink:label="tyra_OfferingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseAgreementsMember" xlink:label="us-gaap_LeaseAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OfficeBuildingMember" xlink:label="srt_OfficeBuildingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriod" xlink:label="tyra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_TwoThousandTwentySevenLeaseAgreementMember" xlink:label="tyra_TwoThousandTwentySevenLeaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_NetOperatingLossCarryForwardIndefinitely" xlink:label="tyra_NetOperatingLossCarryForwardIndefinitely"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_RightOfUseAsset" xlink:label="tyra_RightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_ChiefOperatingDecisionMakerMember" xlink:label="tyra_ChiefOperatingDecisionMakerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_NonRule10B51ArrModifiedFlag" xlink:label="tyra_NonRule10B51ArrModifiedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_TwoThousandTwentyFourPreFundedWarrantsMember" xlink:label="tyra_TwoThousandTwentyFourPreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_PersonnelStockBasedCompensationMember" xlink:label="tyra_PersonnelStockBasedCompensationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_NumeratorAbstract" xlink:label="tyra_NumeratorAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMember" xlink:label="us-gaap_LongTermDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:label="us-gaap_ExtinguishmentOfDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrGreaterFairValue" xlink:label="tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrGreaterFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="us-gaap_MarketableSecuritiesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_VestingOfSharesOfCommonStockSubjectToRepurchaseOne" xlink:label="tyra_VestingOfSharesOfCommonStockSubjectToRepurchaseOne"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_WeightedAverageUnvestedRestrictedCommonStockSubjectToRepurchase" xlink:label="tyra_WeightedAverageUnvestedRestrictedCommonStockSubjectToRepurchase"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_AreaOfLease" xlink:label="tyra_AreaOfLease"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_AggregateCommonStockOfferingPrice" xlink:label="tyra_AggregateCommonStockOfferingPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromPrivatePlacement" xlink:label="tyra_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_ToddHarrisMember" xlink:label="tyra_ToddHarrisMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_CommissionForAgentOnSales" xlink:label="tyra_CommissionForAgentOnSales"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueConcentrationOfRiskCashAndCashEquivalents" xlink:label="us-gaap_FairValueConcentrationOfRiskCashAndCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Exercise Price, Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Shares Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization and Summary of Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization and Summary of Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization and Summary of Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Benefit Plan, Plan Assets, Contributions by Employer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employer contributions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_Pre-FundedWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-funded warrants exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_Pre-FundedWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-Funded Warrants Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_Pre-FundedWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre-Funded Warrants Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Government Agency Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government Agencies Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred tax assets, net of valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_CapitalizedSoftwareImplementationCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized Software Implementation Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_CapitalizedSoftwareImplementationCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Software Implementation Costs Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_CapitalizedSoftwareImplementationCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Capitalized Software Implementation Costs Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_CommonStockWarrantsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_CommonStockWarrantsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Warrants [PolicyText Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_CommonStockWarrantsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common Stock Warrants [PolicyText Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SEC Schedule, 12-09, Valuation Allowances and Reserves Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_TYRA-300MUCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">TYRA-300mUC</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_TYRA-300MUCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">TYRA-300mUC [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_TYRA-300MUCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">TYRA-300mUC [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_DeferredTaxAssetsCapitalizedResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_DeferredTaxAssetsCapitalizedResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Tax Assets Capitalized Research And Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_DeferredTaxAssetsCapitalizedResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Capitalized Research And Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesTradingRestricted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesTradingRestricted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Trading, Restricted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_CashCashEquivalentsAndMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, cash equivalents and marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_CashCashEquivalentsAndMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash, cash equivalents and marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common Stock Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board of Directors Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_CaliforniaResearchAndDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">California Research and Development [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_CaliforniaResearchAndDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">California Research And Development [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_CaliforniaResearchAndDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">California research and development.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions related to current year positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Greater than 12 months, Fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Held-to-Maturity, Continuous Unrealized Loss Position, 12 Months or Longer, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair market value of the common stock, percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_IssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issued Accounting Pronouncements Not Yet Adopted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_IssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issued Accounting Pronouncements Not Yet Adopted, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_IssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issued Accounting Pronouncements Not Yet Adopted, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_AccruedOtherGeneralAndAdministrativeFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued other general and administrative fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_AccruedOtherGeneralAndAdministrativeFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Other General And Administrative Fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_AccruedOtherGeneralAndAdministrativeFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued Other General And Administrative Fee.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchases of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted- Average Exercise Price, Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_AllowanceForCreditLossesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allowance for Credit Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_AllowanceForCreditLossesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Allowance for Credit Losses Policy Text Block</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_AllowanceForCreditLossesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Allowance for Credit Losses Policy Text Block</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets, valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Valuation Allowance, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax benefit at statutory federal rate Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued, price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share issued, price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Third Party Engaged [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provision for income taxes, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Percent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Jurisdiction [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of reconciliation of the Company's net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Common Stock, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Common Stock, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_ScheduleOfMaturitiesOfLeaseLiabilitiesWithWeightedAverageRemainingTermAndDiscountRateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Lease Liabilities with Weighted Average Remaining Term and Weighted Average Discount Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_ScheduleOfMaturitiesOfLeaseLiabilitiesWithWeightedAverageRemainingTermAndDiscountRateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Maturities of Lease Liabilities with Weighted Average Remaining Term and Discount Rate Table Text Block</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_ScheduleOfMaturitiesOfLeaseLiabilitiesWithWeightedAverageRemainingTermAndDiscountRateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of maturities of lease liabilities along with weighted average remaining term and discount rate.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic and Diluted Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nontaxable or nondeductible items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets and lease liabilities, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Right Of Use Assets And Lease Liabilities Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in right of use assets and lease liabilities net.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Share-Based Compensation, Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_RestrictedCashMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_RestrictedCashMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_RestrictedCashMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted Cash [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_PurchaseOfCommonStockThroughPayrollDeduction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase of common stock through payroll deduction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_PurchaseOfCommonStockThroughPayrollDeduction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Of Common Stock Through Payroll Deduction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_PurchaseOfCommonStockThroughPayrollDeduction_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase of common stock through payroll deduction.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance-based stock options, outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Outstanding Options, Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Outstanding Options, Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-funded Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-funded Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre-funded Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2030</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Domestic Country [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions related to prior year positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_VestingOfSharesOfCommonStockSubjectToRepurchaseOneShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting Of Shares Of Common Stock Subject To Repurchase, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_VestingOfSharesOfCommonStockSubjectToRepurchaseOneShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting Of Shares Of Common Stock Subject To Repurchase One, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_VestingOfSharesOfCommonStockSubjectToRepurchaseOneShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vesting Of Shares Of Common Stock Subject To Repurchase One, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOptionCreditRiskGainsLossesOnAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized losses on fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOptionCreditRiskGainsLossesOnAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Option, Credit Risk, Gains (Losses) on Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' equity:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less than one year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Debt [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_StockOptionsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Options To Purchase Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_StockOptionsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock options to purchase common stock member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_StockOptionsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options to Purchase Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_OtherDevelopmentProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other development programs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_OtherDevelopmentProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Development Programs [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_OtherDevelopmentProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other Development Programs [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected tax benefit at statutory rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants issued to purchase common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Warrants exchanged to acquire common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Pre-funded warrants issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities, Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment reporting, CODM, profit (loss) measure, how used, description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Role of Management [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_IssuanceOfCommonStockPursuantToPreFundedWarrantExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock Pursuant To Pre Funded Warrant Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_IssuanceOfCommonStockPursuantToPreFundedWarrantExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance Of Common Stock Pursuant To Pre Funded Warrant Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_IssuanceOfCommonStockPursuantToPreFundedWarrantExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock pursuant to pre-funded warrant exercise</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforward</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Exercise Price, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: accumulated depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_IncomeTaxReconciliationChangesInUnrecognizedTaxBenefitsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Changes in Unrecognized Tax Benefits Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_IncomeTaxReconciliationChangesInUnrecognizedTaxBenefitsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income Tax Reconciliation Changes in Unrecognized Tax Benefits Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_IncomeTaxReconciliationChangesInUnrecognizedTaxBenefitsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in unrecognized tax benefits Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Liabilities, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_FederalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_FederalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Federal [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_FederalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Federal.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_DanielBensenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Daniel Bensen [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_DanielBensenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Daniel Bensen [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_DanielBensenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Daniel Bensen [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of cash flow information:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_PatentCostsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Patent Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_PatentCostsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Patent Costs Policy Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_PatentCostsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Patent Costs Policy</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_OtherResearchAndDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_OtherResearchAndDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Research and Development [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_OtherResearchAndDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other Research and Development [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_TYRA-200Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">TYRA-200 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_TYRA-200Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">TYRA-200 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_TYRA-200Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">TYRA-200</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Net cash decrease for the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash increase (decrease) for the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive securities excluded from computation of earnings per share, amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_VestingOfSharesOfCommonStockSubjectToRepurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of shares of common stock subject to repurchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_VestingOfSharesOfCommonStockSubjectToRepurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting Of Shares Of Common Stock Subject To Repurchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_VestingOfSharesOfCommonStockSubjectToRepurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vesting of shares of common stock subject to repurchase.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security deposit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds From Issuance Of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted- Average Remaining Contractual Term, Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted- Average Remaining Contractual Term, Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_IncomeTaxReconciliationChangesInUnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Changes in Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_IncomeTaxReconciliationChangesInUnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income Tax Reconciliation Changes in Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_IncomeTaxReconciliationChangesInUnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in unrecognized tax benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_IncomeTaxReconciliationChangesInUnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Changes in unrecognized tax benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized losses less than 12 months</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Held-to-Maturity, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock for stock option exercises (Shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Outstanding Options, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for stock option exercises, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Marketable Securities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageBasicSharesOutstandingProForma_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Basic Shares Outstanding, Pro Forma</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageBasicSharesOutstandingProForma_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average common shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_AccruedInterestAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest available-for-sale securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_AccruedInterestAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Interest Available For Sale Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_AccruedInterestAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued interest available-for-sale securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_FGFRDiscoveryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">FGFR Discovery</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_FGFRDiscoveryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">FGFR Discovery [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_FGFRDiscoveryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">FGFR Discovery [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total common stock reserved for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_SeriesAConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_SeriesAConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_SeriesAConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State income tax, net of federal benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">State income tax, net of federal benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Stock-based Compensation Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses and Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Deferred Tax Assets and Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest and Other Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest and other income, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest and other income, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PerformanceSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance Shares [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PerformanceSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Shares [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_StateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_StateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">State [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Proceeds from maturities of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale and Maturity of Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturities of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized losses greater than 12 months</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Held-to-Maturity, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Assets, Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_SharesAvailableForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares Available For Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_SharesAvailableForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Available For Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_SharesAvailableForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares available for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_EstimatedSharesPurchasableUnderTheEsppMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated shares purchasable under the ESPP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_EstimatedSharesPurchasableUnderTheEsppMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Estimated shares purchasable under the ESPP [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_EstimatedSharesPurchasableUnderTheEsppMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Estimated shares purchasable under the ESPP [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_IssuanceOfCommonStockPursuantToPreFundedWarrantExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock pursuant to pre-funded warrant exercise, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_IssuanceOfCommonStockPursuantToPreFundedWarrantExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock Pursuant To Pre Funded Warrant Exercise</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_IssuanceOfCommonStockPursuantToPreFundedWarrantExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance Of Common Stock Pursuant To Pre Funded Warrant Exercise</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Aggregate Intrinsic Value, Vested and expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">State and Local Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionsLessThanTwelveMonthsFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AvailableForSale Securities, Continuous Unrealized Loss Positions, Less than Twelve Months, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionsLessThanTwelveMonthsFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Available-for-Sale Securities, Continuous Unrealized Loss Positions, Less than Twelve Months, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionsLessThanTwelveMonthsFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available For Sale Securities Continuous Unrealized Loss Positions Less Than Twelve Months Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_StockOptionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock Options Abstract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_StockOptionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Options Abstract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_ConvertiblePreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' Equity and Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_ConvertiblePreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The entire disclosure for Convertible Preferred Stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_ConvertiblePreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_CommonStockOptionsGrantedAndOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock options granted and outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_CommonStockOptionsGrantedAndOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Options Granted And Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_CommonStockOptionsGrantedAndOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock options granted and outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Value, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Value, Issued, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Value, Issued, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.0001 par value; 50,000,000 shares authorized at December 31, 2025 and December 31, 2024; no shares issued and outstanding at December 31, 2025 and December 31, 2024.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_RelatedPartiesPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Related Parties Policy.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_RelatedPartiesPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Parties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_RelatedPartiesPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Parties Policy Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_TYRA-430Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">TYRA-430</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_TYRA-430Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">TYRA-430 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_TYRA-430Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">TYRA-430 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_MinimumLeasePaymentsForLeasesNotYetCommenced_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum Lease Payments for Leases Not Yet Commenced</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_MinimumLeasePaymentsForLeasesNotYetCommenced_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Lease Payments for Leases Not Yet Commenced</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_MinimumLeasePaymentsForLeasesNotYetCommenced_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legally binding minimum lease payments for leases not yet commenced</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of pre-funded warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease renewal term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Renewal Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Subject to or Available for Operating Lease [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 10)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SEC Schedule, 12-09, Valuation Allowances and Reserves</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shareholders' Equity and Share-Based Payments [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Incentive Plans and Stock-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Present value of lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Present value of lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_DividendYield_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_DividendYield_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_DividendYield_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividend Yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expenses, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_EmployeeStockPurchasePlanDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee Stock Purchase Plan Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_EmployeeStockPurchasePlanDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Purchase Plan Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_VestingOfSharesOfCommonStockSubjectToRepurchaseShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting Of Shares Of Common Stock Subject To Repurchase, Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_VestingOfSharesOfCommonStockSubjectToRepurchaseShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vesting Of Shares Of Common Stock Subject To Repurchase, Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_VestingOfSharesOfCommonStockSubjectToRepurchaseShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of shares of common stock subject to repurchase, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred but Not yet Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Penalties and interest accrued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Examination, Penalties and Interest Accrued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination, Penalties and Interest Accrued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_AlanFuhrmanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Alan Fuhrman [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_AlanFuhrmanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Alan Fuhrman [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_AlanFuhrmanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Alan Fuhrman [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_SimpleAgreementsForFutureEquityTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Simple Agreements For Future Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_SimpleAgreementsForFutureEquityTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Simple Agreements For Future Equity [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_SimpleAgreementsForFutureEquityTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Simple Agreements for Future Equity Text Block</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares used to compute net loss per share - basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Aggregate Intrinsic Value, Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Effective Income Tax Rate Reconciliation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right of use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Leasing Arrangements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Right of use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segments [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of private placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock under Private Placement, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Proceeds from issuance of private placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_SimpleAgreementsForFutureEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Simple Agreements For Future Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_SimpleAgreementsForFutureEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Simple Agreements for Future Equity Abstract.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_TwoThousandTwentyFourPrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Four Private Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_TwoThousandTwentyFourPrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Twenty Four Private Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_TwoThousandTwentyFourPrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024 Private Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_DeferredTaxAssetsTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_DeferredTaxAssetsTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_DeferredTaxAssetsTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets tax credits.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, Date of Incorporation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, Date of Incorporation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Expenses and Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash investing and financing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Investing and Financing Items [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_IssuanceOfCommonStockUnderBenefitPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of Common Stock Under Benefit Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_IssuanceOfCommonStockUnderBenefitPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of Common Stock Under Benefit Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_IssuanceOfCommonStockUnderBenefitPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under benefit plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Unrecognized Tax Benefits Roll Forward</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets On Recurring Basis Line Items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_ComputersAndSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computers and Software</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_ComputersAndSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computers And Software [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_ComputersAndSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Computers and software.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Impairment, Long-Lived Asset, Held-for-Use, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment, Long-Lived Asset, Held-for-Use</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairement loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available-for-sale security in gross unrealized loss position for less than 12 months, fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Held-to-Maturity, Continuous Unrealized Loss Position, Less than 12 Months, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unrealized losses less than 12 months, fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_NetOperatingLossCarryforwardsAvailableForOffsettingAgainstFutureTaxableIncomePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of federal net operating losses used to offset of future taxable income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_NetOperatingLossCarryforwardsAvailableForOffsettingAgainstFutureTaxableIncomePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Operating Loss Carryforwards Available For Offsetting Against Future Taxable Income Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_NetOperatingLossCarryforwardsAvailableForOffsettingAgainstFutureTaxableIncomePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net Operating Loss Carryforwards Available For Offsetting Against Future Taxable Income Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-funded warrants issued and outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related and Nonrelated Parties [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_IssuanceOfPreFundedWarrantsUnderPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Pre Funded Warrants Under Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_IssuanceOfPreFundedWarrantsUnderPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance Of Pre Funded Warrants Under Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_IssuanceOfPreFundedWarrantsUnderPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Pre Funded Warrants under Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_AccruedResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_AccruedResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_AccruedResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued research and development expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of reportable segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Reportable Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_IssuanceOfCommonStockUnderBenefitPlansShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock shares under benefit plans.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_IssuanceOfCommonStockUnderBenefitPlansShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of Common Stock Under Benefit Plans Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_IssuanceOfCommonStockUnderBenefitPlansShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under benefit plans, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_PersonnelCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Personnel Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_PersonnelCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Personnel Costs [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_PersonnelCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Personnel Costs [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property plant and equipment, gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Outstanding Options, Vested and expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationRelatedCostsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Compensation Related Costs [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_IncomeTaxReconciliationOfficersCompensationPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Officers Compensation Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_IncomeTaxReconciliationOfficersCompensationPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income Tax Reconciliation Officers Compensation Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_IncomeTaxReconciliationOfficersCompensationPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Officer compensation Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total cash, cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash at beginning of the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash at end of the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_WarrantsIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants issued price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_WarrantsIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Issued Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_WarrantsIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants Issued Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants exercise price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrants issued, price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title and Position [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Outstanding Options, Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_OrganizationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_OrganizationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_OrganizationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">.Organization.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_ConversionOfConvertiblePreferredStockInConnectionWithInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion of convertible preferred stock in connection with initial public offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_ConversionOfConvertiblePreferredStockInConnectionWithInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of convertible preferred stock in connection with initial public offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_ConversionOfConvertiblePreferredStockInConnectionWithInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock in connection with initial public offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Salaries, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued payroll and other employee benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Held to Maturity Securities Continuous Unrealized Loss Position Less Than Twelve Months Accumulated Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Held to Maturity Securities Continuous Unrealized Loss Position Less Than Twelve Months Accumulated Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized losses less than 12 months, unrealized losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of cash, cash equivalents and restricted cash to the balance sheet</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_PaymentsOfIssuanceCostsForCommonStockAndPreFundedWarrantsFromPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of issuance costs for common stock and pre-funded warrants from Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_PaymentsOfIssuanceCostsForCommonStockAndPreFundedWarrantsFromPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments of issuance costs for common stock and pre-funded warrants from Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_PaymentsOfIssuanceCostsForCommonStockAndPreFundedWarrantsFromPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments of issuance costs for common stock and pre-funded warrants from Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_TwentyTwentyOneEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Twenty Twenty One Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_TwentyTwentyOneEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Twenty twenty one equity incentive plan member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_TwentyTwentyOneEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Twenty Twenty One Equity Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_TwentyTwentyOneEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2021 Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_VestingOfOptionsEarlyExercisedSubjectToRepurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of options early exercised subject to repurchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_VestingOfOptionsEarlyExercisedSubjectToRepurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting of options early exercised subject to repurchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_VestingOfOptionsEarlyExercisedSubjectToRepurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vesting of options early exercised subject to repurchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares used to compute net loss per share - diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_SeriesBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_SeriesBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_SeriesBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_UnvestedCommonStockExerciseOfStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unvested Common Stock Exercise Of Stock Options [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_UnvestedCommonStockExerciseOfStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unvested common stock exercise of stock options member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_UnvestedCommonStockExerciseOfStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested common stock upon early exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized losses less than 12 months, fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Held to Maturity Securities Continuous Unrealized Loss Position Less Than 12 Months Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Held to Maturity Securities Continuous Unrealized Loss Position Less Than 12 Months Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Available-for-sale security in gross unrealized loss position for less than 12 months, fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_AccruedAndOtherRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued and other related parties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_AccruedAndOtherRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued and other related parties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_AccruedResearchAndDevelopmentExpensePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Expense Policy Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_AccruedResearchAndDevelopmentExpensePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued Research and Development Expense Policy.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_AccruedResearchAndDevelopmentExpensePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Research and Development Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable, accrued expenses and other liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_Rule10B51ArrModifiedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Rule 10b51 Arr Modified Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_Rule10B51ArrModifiedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Rule 10b5-1 Arrangement Modified Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_Rule10B51ArrModifiedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rule 10b5-1 Arrangement Modified</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">US Treasury Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">General and administrative expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendPaymentRestrictionsScheduleDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend payment description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendPaymentRestrictionsScheduleDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividend Payment Restriction and Statutory Capital and Surplus Requirements, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Outstanding Options, Cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted- Average Exercise Price, Vested and expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, plant and equipment, useful life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Adopted Accounting Pronouncements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_ExchangeOfCommonStockForPre-FundedWarrantsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exchange of Common Stock for Pre-Funded Warrants Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_ExchangeOfCommonStockForPre-FundedWarrantsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Exchange of Common Stock for Pre-Funded Warrants Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_ExchangeOfCommonStockForPre-FundedWarrantsShares_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Exchange of common stock for pre-funded warrants, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_ExchangeOfCommonStockForPre-FundedWarrantsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exchange of common stock for pre-funded warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_FirstAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">First Amendment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_FirstAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">First Amendment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Term of Contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Minimum lease term since date of original lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease term of contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UsGovernmentAgencyInsuredLoansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. government agency securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UsGovernmentAgencyInsuredLoansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government Agency Insured Loans [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: current portion of lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Lease liabilities, current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: current portion of lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets / (liabilities)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_IssuanceOfConvertiblePreferredStockInExchangeForSimpleAgreementForFutureEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of convertible preferred stock in exchange for simple agreement for future equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_IssuanceOfConvertiblePreferredStockInExchangeForSimpleAgreementForFutureEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of convertible preferred stock in exchange for simple agreement for future equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_IssuanceOfConvertiblePreferredStockInExchangeForSimpleAgreementForFutureEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of convertible preferred stock in exchange for simple agreement for future equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total research and development expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total research and development expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Leases [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_IncomeTaxReconciliationProvisionForIncomeTaxesPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Provision for Income Taxes Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_IncomeTaxReconciliationProvisionForIncomeTaxesPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income Tax Reconciliation Provision for Income Taxes Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_IncomeTaxReconciliationProvisionForIncomeTaxesPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provision for Income Taxes Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Options Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock based compensation Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Deferred Tax Liabilities, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Aggregate Intrinsic Value, Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Aggregate Intrinsic Value, Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_SharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares reserved for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_SharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares reserved for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxContingencyLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Contingency [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxContingencyLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Contingency [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_ExerciseOfPre-FundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exercise of Pre-funded Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_ExerciseOfPre-FundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercise of Pre-funded Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liability paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free rate of interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_WeightedAverageUnvestedCommonStockIssuedUponExerciseOfCommonStockOptions_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: weighted average unvested common stock issued upon early exercise of common stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_WeightedAverageUnvestedCommonStockIssuedUponExerciseOfCommonStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted average unvested common stock issued upon exercise of common stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_WeightedAverageUnvestedCommonStockIssuedUponExerciseOfCommonStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average unvested common stock issued upon early exercise of common stock options.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_AccretionOnMarketableSecuritiesNet_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accretion on marketable securities, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_AccretionOnMarketableSecuritiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accretion on marketable securities, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_AccretionOnMarketableSecuritiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion on marketable securities, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_AccretionOnMarketableSecuritiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accretion on marketable securities, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee contribution percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Changes in Fair Value of Plan Assets [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Fair Value of Assets Measured</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_ExpansionLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Expansion Lease Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_ExpansionLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Expansion Lease Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_ExpansionLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expansion Lease Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_AtmSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">ATM Sales Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_AtmSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ATM Sales Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_AtmSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ATM Sales Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Option</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_ReceivableFromExerciseOfStockOptionsIncludedInPrepaidExpensesAndOtherCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Receivable From Exercise of Stock Options Included in Prepaid Expenses and Other Current Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_ReceivableFromExerciseOfStockOptionsIncludedInPrepaidExpensesAndOtherCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Receivable From Exercise of Stock Options Included in Prepaid Expenses and Other Current Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_ReceivableFromExerciseOfStockOptionsIncludedInPrepaidExpensesAndOtherCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Receivable from exercise of stock options included in prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_NumberOfLeaseTermRenewal_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of lease term renewal option</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_NumberOfLeaseTermRenewal_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Lease Term Renewal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_NumberOfLeaseTermRenewal_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of lease term renewal.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term line of credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Line of Credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-term Line of Credit, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_FebruaryTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">February Two Thousand Twenty Four Securities Purchase Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_FebruaryTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">February Two Thousand Twenty Four Securities Purchase Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_FebruaryTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024 Securities Purchase Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_AccumulatedOtherComprehensiveLossMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Loss [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_AccumulatedOtherComprehensiveLossMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accumulated Other Comprehensive Loss [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_AccumulatedOtherComprehensiveLossMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Net cash used in investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_ResearchAndDevelopmentCreditCarryforwardsUnderInternalRevenueCodeDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development credit carryforwards under internal revenue code description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_ResearchAndDevelopmentCreditCarryforwardsUnderInternalRevenueCodeDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Credit Carryforwards Under Internal Revenue Code Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_ResearchAndDevelopmentCreditCarryforwardsUnderInternalRevenueCodeDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development credit carryforwards under internal revenue code description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_ProceedsFromIssuanceOfCommonStockUnderBenefitPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from Issuance of Common Stock Under Benefit Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_ProceedsFromIssuanceOfCommonStockUnderBenefitPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock Under Benefit Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_ProceedsFromIssuanceOfCommonStockUnderBenefitPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuances of common stock under benefit plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Money market funds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related and Nonrelated Parties [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization and Summary of Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization and Summary of Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_TwoThousandTwentyEightLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Eight Lease Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_TwoThousandTwentyEightLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Twenty Eight Lease Agreement member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_TwoThousandTwentyEightLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028 Lease Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Liabilities, Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted- Average Exercise Price, Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted- Average Exercise Price, Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance at January 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance at December 31</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized losses 12 months or greater, unrealized losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Held to Maturity Securities Continuous Unrealized Loss Position Twelve Months Or Longer Accumulated Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Held to Maturity Securities Continuous Unrealized Loss Position Twelve Months Or Longer Accumulated Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfPropertiesSubjectToGroundLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfPropertiesSubjectToGroundLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Properties Subject to Ground Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ExtinguishmentOfDebtAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Extinguishment of Debt [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_AccountsPayableAccruedExpensesAndOtherLiabilitiesRelatedPartyTransactions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounts Payable Accrued Expenses And Other Liabilities Related Party Transactions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_AccountsPayableAccruedExpensesAndOtherLiabilitiesRelatedPartyTransactions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Accrued Expenses And Other Liabilities Related Parties Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_AccountsPayableAccruedExpensesAndOtherLiabilitiesRelatedPartyTransactions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related party transaction, accounts payable, accrued expenses and other liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total minimum lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: amount representing interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: amount representing interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research credits Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_TYRA-300NMIBCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">TYRA-300NMIBC [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_TYRA-300NMIBCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">TYRA-300NMIBC [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_TYRA-300NMIBCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">TYRA-300NMIBC</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_StockholdersEquityIncreaseDecreaseInCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_StockholdersEquityIncreaseDecreaseInCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity, Increase Decrease In Common Stock Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_StockholdersEquityIncreaseDecreaseInCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stockholders' equity increase decrease in common stock percent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPO [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IPO [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Exercise Price, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.0001 par value; 500,000,000 shares authorized at December 31, 2025 and December 31, 2024; 53,706,357 and 50,754,262 shares issued at December 31, 2025 and December 31, 2024, respectively, and 53,706,357 and 50,749,945 shares outstanding at December 31, 2025 and December 31, 2024, respectively.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_OperatingLossCarryforwardsExpirationDates1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards, expire date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_OperatingLossCarryforwardsExpirationDates1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Dates1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_OperatingLossCarryforwardsExpirationDates1_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards expiration dates 1.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxContingencyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Contingency [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxContingencyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Contingency [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_FacilitiesAndOtherCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Facilities and Other Costs [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_FacilitiesAndOtherCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Facilities and Other Costs [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_FacilitiesAndOtherCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Facilities and Other Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain (loss) on marketable securities available-for-sale, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_Pre-FundedWarrantsAvailableForExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-Funded Warrants available for exercise</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_Pre-FundedWarrantsAvailableForExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-Funded Warrants Available for Exercise</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_Pre-FundedWarrantsAvailableForExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre-Funded Warrants Available for Exercise</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State and local taxes, net of federal benefit Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_TwoThousandsAndTwentyOneIncentiveAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_TwoThousandsAndTwentyOneIncentiveAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousands And Twenty One Incentive Award Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_TwoThousandsAndTwentyOneIncentiveAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousands and twenty one incentive award plan member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of pre-funded warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense) [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income :</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_TYRA-300UTUCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">TYRA-300UTUC [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_TYRA-300UTUCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">TYRA-300UTUC [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_TYRA-300UTUCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">TYRA-300UTUC</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected stock price volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_AvailableForSaleDebtSecuritiesNetUnrealizedGain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain on marketable securities available-for-sale, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_AvailableForSaleDebtSecuritiesNetUnrealizedGain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Net Unrealized Gain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_AvailableForSaleDebtSecuritiesNetUnrealizedGain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Available for sale debt securities net unrealized gain.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Debt Securities, Available-for-Sale, Unrealized Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_DenominatorAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denominator:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_DenominatorAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Denominator [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_DenominatorAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Denominator [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-Based Payment Arrangement, Accelerated Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Accelerated Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_TwentyTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2020 Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_TwentyTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_TwentyTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_TwentyTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty equity incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_OptionsGrantedContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options granted contractual term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_OptionsGrantedContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options granted contractual term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_OptionsGrantedContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options Granted Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_TwentyTwentyOneEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Twenty Twenty One Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_TwentyTwentyOneEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Twenty Twenty One Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_TwentyTwentyOneEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2021 Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Provision for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Provision for or benefit from income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_WarrantsAvailableForExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants available for exercise</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_WarrantsAvailableForExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Available for Exercise</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_WarrantsAvailableForExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants Available for Exercise</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds From Issuance Of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_TYRA-300ACHMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">TYRA-300ACH [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_TYRA-300ACHMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">TYRA-300ACH [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_TYRA-300ACHMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">TYRA-300ACH</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherTypesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment, Other Types</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherTypesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Other Types [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchases of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted- Average Remaining Contractual Term, Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Remaining Contractual Term, Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherSellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative including related party amounts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherSellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Selling, General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalent, and Marketable Security [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Number of Shares Issued in Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares exchange under exchange agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Share exchanged for acqisation of share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Subject to or Available for Operating Lease [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_IncometaxreconciliationOfficersCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">IncomeTaxReconciliation Officers Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_IncometaxreconciliationOfficersCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IncomeTaxReconciliation Officers Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_IncometaxreconciliationOfficersCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Officers compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title and Position [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_OfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Offering Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_OfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Offering Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_OfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_OfficeBuildingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Office Building [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_OfficeBuildingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office and Laboratory Facilities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Research credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Granted in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Granted in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Outstanding Options, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining lease term (years) - operating leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Real Estate [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Information [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_TwoThousandTwentySevenLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Seven Lease Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_TwoThousandTwentySevenLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Twenty Seven Lease Agreement member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_TwoThousandTwentySevenLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027 Lease Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum lease termination date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_NetOperatingLossCarryForwardIndefinitely_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Operating Loss Carry Forward Indefinitely</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_NetOperatingLossCarryForwardIndefinitely_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net Operating Loss Carry Forward Indefinitely</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_NetOperatingLossCarryForwardIndefinitely_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Operating Loss Carry Forward Indefinitely</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_RightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_RightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_RightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right Of Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_RightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Right of Use Asset.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_ChiefOperatingDecisionMakerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CODM</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_ChiefOperatingDecisionMakerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Chief Operating Decision Maker [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_ChiefOperatingDecisionMakerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Chief Operating Decision Maker [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_NonRule10B51ArrModifiedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Rule 10b5-1 Arr Modified Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_NonRule10B51ArrModifiedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">NonRule10b51ArrModifiedFlag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_NonRule10B51ArrModifiedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-Rule 10b5-1 Arrangement Modified</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_TwoThousandTwentyFourPreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Four Pre Funded Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_TwoThousandTwentyFourPreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Twenty Four Pre Funded Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_TwoThousandTwentyFourPreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024 pre funded warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Benefits and Share-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Benefits And Share Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments Of Stock Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Stock Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_PersonnelStockBasedCompensationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Personnel Stock Based Compensation [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_PersonnelStockBasedCompensationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Personnel Stock Based Compensation [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_PersonnelStockBasedCompensationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Personnel costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average incremental borrowing rate - operating leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Lease liabilities, noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities, noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Lease, Liability, Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Payments of issuance costs for common stock and pre-funded warrants from Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Components of Lease Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_NumeratorAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Numerator:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_NumeratorAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Numerator [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_NumeratorAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Numerator</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">More than One year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ExtinguishmentOfDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Extinguishment of Debt, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrGreaterFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Held to Maturity Securities Continuous Unrealized Loss Position Twelve Months or Greater Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrGreaterFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Held to Maturity Securities Continuous Unrealized Loss Position Twelve Months or Greater Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrGreaterFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized losses 12 months or greater, fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Available-for-Sale Securities and Gross Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. government agency</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government Corporations and Agencies Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potentially Dilutive Securities Including All Outstanding Stock Options were excluded in Calculation of Diluted Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Jurisdiction [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Real Estate, Type of Property [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Expense Information Used by CODM, Type [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_VestingOfSharesOfCommonStockSubjectToRepurchaseOne_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting Of Shares Of Common Stock Subject To Repurchases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_VestingOfSharesOfCommonStockSubjectToRepurchaseOne_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting Of Shares Of Common Stock Subject To Repurchase One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_VestingOfSharesOfCommonStockSubjectToRepurchaseOne_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vesting Of Shares Of Common Stock Subject To Repurchase One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense, Tax Benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_WeightedAverageUnvestedRestrictedCommonStockSubjectToRepurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average unvested restricted common stock subject to repurchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_WeightedAverageUnvestedRestrictedCommonStockSubjectToRepurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted average unvested restricted common stock subject to repurchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_WeightedAverageUnvestedRestrictedCommonStockSubjectToRepurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: weighted-average unvested restricted common stock subject to repurchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Common Stock Outstanding Roll Forward [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Common Stock Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of available-for-sale security in gross unrealized loss position for less than 12 months</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization and Summary of Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_AreaOfLease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Area of Lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_AreaOfLease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Area of Lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_AreaOfLease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Area of lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_AggregateCommonStockOfferingPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate Common Stock Offering Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_AggregateCommonStockOfferingPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Common Stock Offering Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_AggregateCommonStockOfferingPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate offering price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from issuance of common stock and pre-funded warrants from Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common stock and pre-funded warrants from Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock and pre-funded warrants from Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Gain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation cost related to options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorOpinionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Opinion [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorOpinionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Opinion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_ToddHarrisMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Todd Harris [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_ToddHarrisMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Todd Harris [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_ToddHarrisMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Todd Harris [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_CommissionForAgentOnSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commission For Agent on Sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_CommissionForAgentOnSales_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commission For Agent on Sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tyra_CommissionForAgentOnSales_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commission for agent on sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2029</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash And Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueConcentrationOfRiskCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueConcentrationOfRiskCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Concentration of Risk, Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term of Unrecognized Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued legal and professional fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum employee contributions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock, Class of Stock [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Remaining Contractual Term, Vested and expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted- Average Remaining Contractual Term, Vested and expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Name [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_SegmentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="tyra_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:to="us-gaap_DefinedBenefitPlanContributionsByEmployer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_Pre-FundedWarrantsExercised" xlink:to="tyra_Pre-FundedWarrantsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueAdjustment" xlink:to="us-gaap_AssetsFairValueAdjustment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_CapitalizedSoftwareImplementationCostsPolicyTextBlock" xlink:to="tyra_CapitalizedSoftwareImplementationCostsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_CommonStockWarrantsPolicyTextBlock" xlink:to="tyra_CommonStockWarrantsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_TYRA-300MUCMember" xlink:to="tyra_TYRA-300MUCMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:to="tyra_DeferredTaxAssetsCapitalizedResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesTradingRestricted" xlink:to="us-gaap_DebtSecuritiesTradingRestricted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_CashCashEquivalentsAndMarketableSecurities" xlink:to="tyra_CashCashEquivalentsAndMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_CaliforniaResearchAndDevelopmentMember" xlink:to="tyra_CaliforniaResearchAndDevelopmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" xlink:to="us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_IssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:to="tyra_IssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_AccruedOtherGeneralAndAdministrativeFee" xlink:to="tyra_AccruedOtherGeneralAndAdministrativeFee_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_AllowanceForCreditLossesPolicyTextBlock" xlink:to="tyra_AllowanceForCreditLossesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_ScheduleOfMaturitiesOfLeaseLiabilitiesWithWeightedAverageRemainingTermAndDiscountRateTableTextBlock" xlink:to="tyra_ScheduleOfMaturitiesOfLeaseLiabilitiesWithWeightedAverageRemainingTermAndDiscountRateTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet" xlink:to="tyra_IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_RestrictedCashMember" xlink:to="tyra_RestrictedCashMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_PurchaseOfCommonStockThroughPayrollDeduction" xlink:to="tyra_PurchaseOfCommonStockThroughPayrollDeduction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_PreFundedWarrantsMember" xlink:to="tyra_PreFundedWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_VestingOfSharesOfCommonStockSubjectToRepurchaseOneShares" xlink:to="tyra_VestingOfSharesOfCommonStockSubjectToRepurchaseOneShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOptionCreditRiskGainsLossesOnAssets" xlink:to="us-gaap_FairValueOptionCreditRiskGainsLossesOnAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtMember" xlink:to="us-gaap_ShortTermDebtMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_StockOptionsToPurchaseCommonStockMember" xlink:to="tyra_StockOptionsToPurchaseCommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_OtherDevelopmentProgramsMember" xlink:to="tyra_OtherDevelopmentProgramsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:to="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_IssuanceOfCommonStockPursuantToPreFundedWarrantExercised" xlink:to="tyra_IssuanceOfCommonStockPursuantToPreFundedWarrantExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_IncomeTaxReconciliationChangesInUnrecognizedTaxBenefitsPercentage" xlink:to="tyra_IncomeTaxReconciliationChangesInUnrecognizedTaxBenefitsPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_MarketableSecuritiesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_FederalMember" xlink:to="tyra_FederalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_DanielBensenMember" xlink:to="tyra_DanielBensenMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_PatentCostsPolicyPolicyTextBlock" xlink:to="tyra_PatentCostsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_OtherResearchAndDevelopmentMember" xlink:to="tyra_OtherResearchAndDevelopmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_TYRA-200Member" xlink:to="tyra_TYRA-200Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_VestingOfSharesOfCommonStockSubjectToRepurchase" xlink:to="tyra_VestingOfSharesOfCommonStockSubjectToRepurchase_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_IncomeTaxReconciliationChangesInUnrecognizedTaxBenefits" xlink:to="tyra_IncomeTaxReconciliationChangesInUnrecognizedTaxBenefits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecurities" xlink:to="us-gaap_MarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageBasicSharesOutstandingProForma" xlink:to="us-gaap_WeightedAverageBasicSharesOutstandingProForma_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_AccruedInterestAvailableForSaleSecurities" xlink:to="tyra_AccruedInterestAvailableForSaleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_FGFRDiscoveryMember" xlink:to="tyra_FGFRDiscoveryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_SeriesAConvertiblePreferredStockMember" xlink:to="tyra_SeriesAConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndOtherIncome" xlink:to="us-gaap_InterestAndOtherIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_StateMember" xlink:to="tyra_StateMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_SharesAvailableForFutureIssuance" xlink:to="tyra_SharesAvailableForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_EstimatedSharesPurchasableUnderTheEsppMember" xlink:to="tyra_EstimatedSharesPurchasableUnderTheEsppMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_IssuanceOfCommonStockPursuantToPreFundedWarrantExercise" xlink:to="tyra_IssuanceOfCommonStockPursuantToPreFundedWarrantExercise_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashMember" xlink:to="us-gaap_CashMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionsLessThanTwelveMonthsFairValue" xlink:to="tyra_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionsLessThanTwelveMonthsFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_StockOptionsAbstract" xlink:to="tyra_StockOptionsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_ConvertiblePreferredStockTextBlock" xlink:to="tyra_ConvertiblePreferredStockTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_CommonStockOptionsGrantedAndOutstanding" xlink:to="tyra_CommonStockOptionsGrantedAndOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_RelatedPartiesPolicyPolicyTextBlock" xlink:to="tyra_RelatedPartiesPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_TYRA-430Member" xlink:to="tyra_TYRA-430Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_MinimumLeasePaymentsForLeasesNotYetCommenced" xlink:to="tyra_MinimumLeasePaymentsForLeasesNotYetCommenced_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_DividendYield" xlink:to="tyra_DividendYield_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_EmployeeStockPurchasePlanDescription" xlink:to="tyra_EmployeeStockPurchasePlanDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_VestingOfSharesOfCommonStockSubjectToRepurchaseShare" xlink:to="tyra_VestingOfSharesOfCommonStockSubjectToRepurchaseShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_AlanFuhrmanMember" xlink:to="tyra_AlanFuhrmanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_SimpleAgreementsForFutureEquityTextBlock" xlink:to="tyra_SimpleAgreementsForFutureEquityTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_SimpleAgreementsForFutureEquityAbstract" xlink:to="tyra_SimpleAgreementsForFutureEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_TwoThousandTwentyFourPrivatePlacementMember" xlink:to="tyra_TwoThousandTwentyFourPrivatePlacementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_DeferredTaxAssetsTaxCredits" xlink:to="tyra_DeferredTaxAssetsTaxCredits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationDateOfIncorporation" xlink:to="dei_EntityIncorporationDateOfIncorporation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_IssuanceOfCommonStockUnderBenefitPlans" xlink:to="tyra_IssuanceOfCommonStockUnderBenefitPlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_ComputersAndSoftwareMember" xlink:to="tyra_ComputersAndSoftwareMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" xlink:to="us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_NetOperatingLossCarryforwardsAvailableForOffsettingAgainstFutureTaxableIncomePercentage" xlink:to="tyra_NetOperatingLossCarryforwardsAvailableForOffsettingAgainstFutureTaxableIncomePercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_IssuanceOfPreFundedWarrantsUnderPrivatePlacement" xlink:to="tyra_IssuanceOfPreFundedWarrantsUnderPrivatePlacement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_AccruedResearchAndDevelopment" xlink:to="tyra_AccruedResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_IssuanceOfCommonStockUnderBenefitPlansShares" xlink:to="tyra_IssuanceOfCommonStockUnderBenefitPlansShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_PersonnelCostsMember" xlink:to="tyra_PersonnelCostsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsAbstract" xlink:to="us-gaap_CompensationRelatedCostsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_IncomeTaxReconciliationOfficersCompensationPercentage" xlink:to="tyra_IncomeTaxReconciliationOfficersCompensationPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_WarrantsIssuedPricePerShare" xlink:to="tyra_WarrantsIssuedPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_OrganizationPolicyTextBlock" xlink:to="tyra_OrganizationPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_ConversionOfConvertiblePreferredStockInConnectionWithInitialPublicOffering" xlink:to="tyra_ConversionOfConvertiblePreferredStockInConnectionWithInitialPublicOffering_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAccumulatedLoss" xlink:to="tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAccumulatedLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_PaymentsOfIssuanceCostsForCommonStockAndPreFundedWarrantsFromPrivatePlacement" xlink:to="tyra_PaymentsOfIssuanceCostsForCommonStockAndPreFundedWarrantsFromPrivatePlacement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_TwentyTwentyOneEquityIncentivePlanMember" xlink:to="tyra_TwentyTwentyOneEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_VestingOfOptionsEarlyExercisedSubjectToRepurchase" xlink:to="tyra_VestingOfOptionsEarlyExercisedSubjectToRepurchase_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_SeriesBConvertiblePreferredStockMember" xlink:to="tyra_SeriesBConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_UnvestedCommonStockExerciseOfStockOptionsMember" xlink:to="tyra_UnvestedCommonStockExerciseOfStockOptionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue" xlink:to="tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_AccruedAndOtherRelatedParties" xlink:to="tyra_AccruedAndOtherRelatedParties_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_AccruedResearchAndDevelopmentExpensePolicyPolicyTextBlock" xlink:to="tyra_AccruedResearchAndDevelopmentExpensePolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_Rule10B51ArrModifiedFlag" xlink:to="tyra_Rule10B51ArrModifiedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendPaymentRestrictionsScheduleDescription" xlink:to="us-gaap_DividendPaymentRestrictionsScheduleDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_ExchangeOfCommonStockForPre-FundedWarrantsShares" xlink:to="tyra_ExchangeOfCommonStockForPre-FundedWarrantsShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_FirstAmendmentMember" xlink:to="tyra_FirstAmendmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UsGovernmentAgencyInsuredLoansMember" xlink:to="us-gaap_UsGovernmentAgencyInsuredLoansMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_IssuanceOfConvertiblePreferredStockInExchangeForSimpleAgreementForFutureEquity" xlink:to="tyra_IssuanceOfConvertiblePreferredStockInExchangeForSimpleAgreementForFutureEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_IncomeTaxReconciliationProvisionForIncomeTaxesPercentage" xlink:to="tyra_IncomeTaxReconciliationProvisionForIncomeTaxesPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_SharesReservedForFutureIssuance" xlink:to="tyra_SharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxContingencyLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_ExerciseOfPre-FundedWarrants" xlink:to="tyra_ExerciseOfPre-FundedWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_WeightedAverageUnvestedCommonStockIssuedUponExerciseOfCommonStockOptions" xlink:to="tyra_WeightedAverageUnvestedCommonStockIssuedUponExerciseOfCommonStockOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_AccretionOnMarketableSecuritiesNet" xlink:to="tyra_AccretionOnMarketableSecuritiesNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_ExpansionLeaseAgreementMember" xlink:to="tyra_ExpansionLeaseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_AtmSalesAgreementMember" xlink:to="tyra_AtmSalesAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_ReceivableFromExerciseOfStockOptionsIncludedInPrepaidExpensesAndOtherCurrentAssets" xlink:to="tyra_ReceivableFromExerciseOfStockOptionsIncludedInPrepaidExpensesAndOtherCurrentAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_NumberOfLeaseTermRenewal" xlink:to="tyra_NumberOfLeaseTermRenewal_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_FebruaryTwoThousandTwentyFourSecuritiesPurchaseAgreementMember" xlink:to="tyra_FebruaryTwoThousandTwentyFourSecuritiesPurchaseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_AccumulatedOtherComprehensiveLossMember" xlink:to="tyra_AccumulatedOtherComprehensiveLossMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_ResearchAndDevelopmentCreditCarryforwardsUnderInternalRevenueCodeDescription" xlink:to="tyra_ResearchAndDevelopmentCreditCarryforwardsUnderInternalRevenueCodeDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_ProceedsFromIssuanceOfCommonStockUnderBenefitPlans" xlink:to="tyra_ProceedsFromIssuanceOfCommonStockUnderBenefitPlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="tyra_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_TwoThousandTwentyEightLeaseAgreementMember" xlink:to="tyra_TwoThousandTwentyEightLeaseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAccumulatedLoss" xlink:to="tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAccumulatedLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfPropertiesSubjectToGroundLeases" xlink:to="us-gaap_NumberOfPropertiesSubjectToGroundLeases_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExtinguishmentOfDebtAxis" xlink:to="us-gaap_ExtinguishmentOfDebtAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_AccountsPayableAccruedExpensesAndOtherLiabilitiesRelatedPartyTransactions" xlink:to="tyra_AccountsPayableAccruedExpensesAndOtherLiabilitiesRelatedPartyTransactions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_TYRA-300NMIBCMember" xlink:to="tyra_TYRA-300NMIBCMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_StockholdersEquityIncreaseDecreaseInCommonStockPercent" xlink:to="tyra_StockholdersEquityIncreaseDecreaseInCommonStockPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_ClassOfStockDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:to="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_OperatingLossCarryforwardsExpirationDates1" xlink:to="tyra_OperatingLossCarryforwardsExpirationDates1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxContingencyTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_FacilitiesAndOtherCostsMember" xlink:to="tyra_FacilitiesAndOtherCostsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_Pre-FundedWarrantsAvailableForExercise" xlink:to="tyra_Pre-FundedWarrantsAvailableForExercise_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_TwoThousandsAndTwentyOneIncentiveAwardPlanMember" xlink:to="tyra_TwoThousandsAndTwentyOneIncentiveAwardPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_TYRA-300UTUCMember" xlink:to="tyra_TYRA-300UTUCMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_AvailableForSaleDebtSecuritiesNetUnrealizedGain" xlink:to="tyra_AvailableForSaleDebtSecuritiesNetUnrealizedGain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_DenominatorAbstract" xlink:to="tyra_DenominatorAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_TwentyTwentyEquityIncentivePlanMember" xlink:to="tyra_TwentyTwentyEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_OptionsGrantedContractualTerm" xlink:to="tyra_OptionsGrantedContractualTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_TwentyTwentyOneEmployeeStockPurchasePlanMember" xlink:to="tyra_TwentyTwentyOneEmployeeStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_WarrantsAvailableForExercise" xlink:to="tyra_WarrantsAvailableForExercise_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_TYRA-300ACHMember" xlink:to="tyra_TYRA-300ACHMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherTypesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherSellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherSellingGeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_IncometaxreconciliationOfficersCompensation" xlink:to="tyra_IncometaxreconciliationOfficersCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_OfferingExpenses" xlink:to="tyra_OfferingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAgreementsMember" xlink:to="us-gaap_LeaseAgreementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OfficeBuildingMember" xlink:to="srt_OfficeBuildingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriod" xlink:to="tyra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_TwoThousandTwentySevenLeaseAgreementMember" xlink:to="tyra_TwoThousandTwentySevenLeaseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_NetOperatingLossCarryForwardIndefinitely" xlink:to="tyra_NetOperatingLossCarryForwardIndefinitely_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_RightOfUseAsset" xlink:to="tyra_RightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_ChiefOperatingDecisionMakerMember" xlink:to="tyra_ChiefOperatingDecisionMakerMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_NonRule10B51ArrModifiedFlag" xlink:to="tyra_NonRule10B51ArrModifiedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_TwoThousandTwentyFourPreFundedWarrantsMember" xlink:to="tyra_TwoThousandTwentyFourPreFundedWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_PersonnelStockBasedCompensationMember" xlink:to="tyra_PersonnelStockBasedCompensationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_NumeratorAbstract" xlink:to="tyra_NumeratorAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMember" xlink:to="us-gaap_LongTermDebtMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:to="us-gaap_ExtinguishmentOfDebtTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrGreaterFairValue" xlink:to="tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrGreaterFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTextBlock" xlink:to="us-gaap_MarketableSecuritiesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:to="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration" xlink:to="us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_VestingOfSharesOfCommonStockSubjectToRepurchaseOne" xlink:to="tyra_VestingOfSharesOfCommonStockSubjectToRepurchaseOne_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_WeightedAverageUnvestedRestrictedCommonStockSubjectToRepurchase" xlink:to="tyra_WeightedAverageUnvestedRestrictedCommonStockSubjectToRepurchase_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_AreaOfLease" xlink:to="tyra_AreaOfLease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_AggregateCommonStockOfferingPrice" xlink:to="tyra_AggregateCommonStockOfferingPrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromPrivatePlacement" xlink:to="tyra_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromPrivatePlacement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorOpinionTextBlock" xlink:to="dei_AuditorOpinionTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_ToddHarrisMember" xlink:to="tyra_ToddHarrisMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tyra_CommissionForAgentOnSales" xlink:to="tyra_CommissionForAgentOnSales_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsMember" xlink:to="us-gaap_CashAndCashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueConcentrationOfRiskCashAndCashEquivalents" xlink:to="us-gaap_FairValueConcentrationOfRiskCashAndCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://tyra.bio/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="87.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorOpinionTextBlock" order="88.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_RightOfUseAsset" xlink:label="tyra_RightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="tyra_RightOfUseAsset" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_AccruedAndOtherRelatedParties" xlink:label="tyra_AccruedAndOtherRelatedParties"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tyra_AccruedAndOtherRelatedParties" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestAndOtherIncome" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NetIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLossParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherSellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherSellingGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherSellingGeneralAndAdministrativeExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementLineItems" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_SeriesAConvertiblePreferredStockMember" xlink:label="tyra_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_PreFundedWarrantsMember" xlink:label="tyra_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_SeriesBConvertiblePreferredStockMember" xlink:label="tyra_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_IssuanceOfCommonStockUnderBenefitPlans" xlink:label="tyra_IssuanceOfCommonStockUnderBenefitPlans"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_AccumulatedOtherComprehensiveLossMember" xlink:label="tyra_AccumulatedOtherComprehensiveLossMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_IssuanceOfCommonStockUnderBenefitPlansShares" xlink:label="tyra_IssuanceOfCommonStockUnderBenefitPlansShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_IssuanceOfPreFundedWarrantsUnderPrivatePlacement" xlink:label="tyra_IssuanceOfPreFundedWarrantsUnderPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_IssuanceOfCommonStockPursuantToPreFundedWarrantExercised" xlink:label="tyra_IssuanceOfCommonStockPursuantToPreFundedWarrantExercised"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_IssuanceOfCommonStockPursuantToPreFundedWarrantExercise" xlink:label="tyra_IssuanceOfCommonStockPursuantToPreFundedWarrantExercise"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_ExchangeOfCommonStockForPre-FundedWarrantsShares" xlink:label="tyra_ExchangeOfCommonStockForPre-FundedWarrantsShares"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_VestingOfSharesOfCommonStockSubjectToRepurchase" xlink:label="tyra_VestingOfSharesOfCommonStockSubjectToRepurchase"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_VestingOfSharesOfCommonStockSubjectToRepurchaseShare" xlink:label="tyra_VestingOfSharesOfCommonStockSubjectToRepurchaseShare"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_VestingOfSharesOfCommonStockSubjectToRepurchaseOneShares" xlink:label="tyra_VestingOfSharesOfCommonStockSubjectToRepurchaseOneShares"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_VestingOfSharesOfCommonStockSubjectToRepurchaseOne" xlink:label="tyra_VestingOfSharesOfCommonStockSubjectToRepurchaseOne"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_AvailableForSaleDebtSecuritiesNetUnrealizedGain" xlink:label="tyra_AvailableForSaleDebtSecuritiesNetUnrealizedGain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_18"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_19"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tyra_SeriesAConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="tyra_PreFundedWarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tyra_SeriesBConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tyra_IssuanceOfCommonStockUnderBenefitPlans" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="tyra_AccumulatedOtherComprehensiveLossMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tyra_IssuanceOfCommonStockUnderBenefitPlansShares" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tyra_IssuanceOfPreFundedWarrantsUnderPrivatePlacement" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tyra_IssuanceOfCommonStockPursuantToPreFundedWarrantExercised" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tyra_IssuanceOfCommonStockPursuantToPreFundedWarrantExercise" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tyra_ExchangeOfCommonStockForPre-FundedWarrantsShares" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tyra_VestingOfSharesOfCommonStockSubjectToRepurchase" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tyra_VestingOfSharesOfCommonStockSubjectToRepurchaseShare" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tyra_VestingOfSharesOfCommonStockSubjectToRepurchaseOneShares" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tyra_VestingOfSharesOfCommonStockSubjectToRepurchaseOne" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tyra_AvailableForSaleDebtSecuritiesNetUnrealizedGain" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_18" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_19" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfStockholdersEquityParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_ConversionOfConvertiblePreferredStockInConnectionWithInitialPublicOffering" xlink:label="tyra_ConversionOfConvertiblePreferredStockInConnectionWithInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_ProceedsFromIssuanceOfCommonStockUnderBenefitPlans" xlink:label="tyra_ProceedsFromIssuanceOfCommonStockUnderBenefitPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_SeriesAConvertiblePreferredStockMember" xlink:label="tyra_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromPrivatePlacement" xlink:label="tyra_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_SeriesBConvertiblePreferredStockMember" xlink:label="tyra_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_AccretionOnMarketableSecuritiesNet" xlink:label="tyra_AccretionOnMarketableSecuritiesNet"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_VestingOfOptionsEarlyExercisedSubjectToRepurchase" xlink:label="tyra_VestingOfOptionsEarlyExercisedSubjectToRepurchase"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet" xlink:label="tyra_IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_PaymentsOfIssuanceCostsForCommonStockAndPreFundedWarrantsFromPrivatePlacement" xlink:label="tyra_PaymentsOfIssuanceCostsForCommonStockAndPreFundedWarrantsFromPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_ReceivableFromExerciseOfStockOptionsIncludedInPrepaidExpensesAndOtherCurrentAssets" xlink:label="tyra_ReceivableFromExerciseOfStockOptionsIncludedInPrepaidExpensesAndOtherCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_IssuanceOfConvertiblePreferredStockInExchangeForSimpleAgreementForFutureEquity" xlink:label="tyra_IssuanceOfConvertiblePreferredStockInExchangeForSimpleAgreementForFutureEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="tyra_ConversionOfConvertiblePreferredStockInConnectionWithInitialPublicOffering" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="tyra_ProceedsFromIssuanceOfCommonStockUnderBenefitPlans" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tyra_SeriesAConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="tyra_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromPrivatePlacement" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tyra_SeriesBConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="tyra_AccretionOnMarketableSecuritiesNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="tyra_VestingOfOptionsEarlyExercisedSubjectToRepurchase" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="tyra_IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="tyra_PaymentsOfIssuanceCostsForCommonStockAndPreFundedWarrantsFromPrivatePlacement" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="tyra_ReceivableFromExerciseOfStockOptionsIncludedInPrepaidExpensesAndOtherCurrentAssets" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="tyra_IssuanceOfConvertiblePreferredStockInExchangeForSimpleAgreementForFutureEquity" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfCashFlowsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_AccountsPayableAccruedExpensesAndOtherLiabilitiesRelatedPartyTransactions" xlink:label="tyra_AccountsPayableAccruedExpensesAndOtherLiabilitiesRelatedPartyTransactions"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="tyra_AccountsPayableAccruedExpensesAndOtherLiabilitiesRelatedPartyTransactions" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_ToddHarrisMember" xlink:label="tyra_ToddHarrisMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_DanielBensenMember" xlink:label="tyra_DanielBensenMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_AlanFuhrmanMember" xlink:label="tyra_AlanFuhrmanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_Rule10B51ArrModifiedFlag" xlink:label="tyra_Rule10B51ArrModifiedFlag"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_NonRule10B51ArrModifiedFlag" xlink:label="tyra_NonRule10B51ArrModifiedFlag"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="tyra_ToddHarrisMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="tyra_DanielBensenMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="tyra_AlanFuhrmanMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="tyra_Rule10B51ArrModifiedFlag" order="14.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="tyra_NonRule10B51ArrModifiedFlag" order="15.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://tyra.bio/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://tyra.bio/20251231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://tyra.bio/20251231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecurities" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="us-gaap_MarketableSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://tyra.bio/20251231/taxonomy/role/Role_DisclosurePropertyAndEquipment" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://tyra.bio/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://tyra.bio/20251231/taxonomy/role/Role_DisclosureSimpleAgreementsForFutureEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_SimpleAgreementsForFutureEquityAbstract" xlink:label="tyra_SimpleAgreementsForFutureEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_SimpleAgreementsForFutureEquityTextBlock" xlink:label="tyra_SimpleAgreementsForFutureEquityTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tyra_SimpleAgreementsForFutureEquityAbstract" xlink:to="tyra_SimpleAgreementsForFutureEquityTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquity1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_ConvertiblePreferredStockTextBlock" xlink:label="tyra_ConvertiblePreferredStockTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="tyra_ConvertiblePreferredStockTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://tyra.bio/20251231/taxonomy/role/Role_DisclosureNetLossPerShare" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://tyra.bio/20251231/taxonomy/role/DisclosureLeases" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://tyra.bio/20251231/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://tyra.bio/20251231/taxonomy/role/Role_DisclosureEmployeeBenefits" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="us-gaap_CompensationRelatedCostsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationRelatedCostsAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://tyra.bio/20251231/taxonomy/role/DisclosureSegmentInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://tyra.bio/20251231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_OrganizationPolicyTextBlock" xlink:label="tyra_OrganizationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_AllowanceForCreditLossesPolicyTextBlock" xlink:label="tyra_AllowanceForCreditLossesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_AccruedResearchAndDevelopmentExpensePolicyPolicyTextBlock" xlink:label="tyra_AccruedResearchAndDevelopmentExpensePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_PatentCostsPolicyPolicyTextBlock" xlink:label="tyra_PatentCostsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_CommonStockWarrantsPolicyTextBlock" xlink:label="tyra_CommonStockWarrantsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_RelatedPartiesPolicyPolicyTextBlock" xlink:label="tyra_RelatedPartiesPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_CapitalizedSoftwareImplementationCostsPolicyTextBlock" xlink:label="tyra_CapitalizedSoftwareImplementationCostsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_IssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:label="tyra_IssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="tyra_OrganizationPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_UseOfEstimates" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="tyra_AllowanceForCreditLossesPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="tyra_AccruedResearchAndDevelopmentExpensePolicyPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="tyra_PatentCostsPolicyPolicyTextBlock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="tyra_CommonStockWarrantsPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="tyra_RelatedPartiesPolicyPolicyTextBlock" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="tyra_CapitalizedSoftwareImplementationCostsPolicyTextBlock" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="tyra_IssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://tyra.bio/20251231/taxonomy/role/DisclosureFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecuritiesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="us-gaap_MarketableSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="us-gaap_MarketableSecuritiesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://tyra.bio/20251231/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://tyra.bio/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquityTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_StockOptionsAbstract" xlink:label="tyra_StockOptionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tyra_StockOptionsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tyra_StockOptionsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tyra_StockOptionsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tyra_StockOptionsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://tyra.bio/20251231/taxonomy/role/Role_DisclosureNetLossPerShareTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_ScheduleOfMaturitiesOfLeaseLiabilitiesWithWeightedAverageRemainingTermAndDiscountRateTableTextBlock" xlink:label="tyra_ScheduleOfMaturitiesOfLeaseLiabilitiesWithWeightedAverageRemainingTermAndDiscountRateTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="tyra_ScheduleOfMaturitiesOfLeaseLiabilitiesWithWeightedAverageRemainingTermAndDiscountRateTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://tyra.bio/20251231/taxonomy/role/DisclosureSegmentInformationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://tyra.bio/20251231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="tyra_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="tyra_OrganizationAndSummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherTypesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="dei_EntityIncorporationDateOfIncorporation"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_CashCashEquivalentsAndMarketableSecurities" xlink:label="tyra_CashCashEquivalentsAndMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendPaymentRestrictionsScheduleDescription" xlink:label="us-gaap_DividendPaymentRestrictionsScheduleDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_DividendYield" xlink:label="tyra_DividendYield"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_OptionsGrantedContractualTerm" xlink:label="tyra_OptionsGrantedContractualTerm"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tyra_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="tyra_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherTypesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tyra_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tyra_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tyra_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tyra_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tyra_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="tyra_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tyra_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tyra_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="dei_EntityIncorporationDateOfIncorporation" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tyra_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="tyra_CashCashEquivalentsAndMarketableSecurities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tyra_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCash" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tyra_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DividendPaymentRestrictionsScheduleDescription" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tyra_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="tyra_DividendYield" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tyra_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="tyra_OptionsGrantedContractualTerm" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://tyra.bio/20251231/taxonomy/role/DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueAdjustment" xlink:label="us-gaap_AssetsFairValueAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_RestrictedCashMember" xlink:label="tyra_RestrictedCashMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueConcentrationOfRiskCashAndCashEquivalents" xlink:label="us-gaap_FairValueConcentrationOfRiskCashAndCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesTradingRestricted" xlink:label="us-gaap_DebtSecuritiesTradingRestricted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueAdjustment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="tyra_RestrictedCashMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_USTreasurySecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueConcentrationOfRiskCashAndCashEquivalents" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtSecuritiesTradingRestricted" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CashMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_MarketableSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableforsaleSecuritiesAndGrossUnrealizedLossesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ExtinguishmentOfDebtAxis" xlink:label="us-gaap_ExtinguishmentOfDebtAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="us-gaap_MarketableSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:label="us-gaap_ExtinguishmentOfDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMember" xlink:label="us-gaap_LongTermDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UsGovernmentAgencyInsuredLoansMember" xlink:label="us-gaap_UsGovernmentAgencyInsuredLoansMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtMember" xlink:label="us-gaap_ShortTermDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue" xlink:label="tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAccumulatedLoss" xlink:label="tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrGreaterFairValue" xlink:label="tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrGreaterFairValue"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAccumulatedLoss" xlink:label="tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" xlink:label="us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" xlink:label="us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOptionCreditRiskGainsLossesOnAssets" xlink:label="us-gaap_FairValueOptionCreditRiskGainsLossesOnAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_ExtinguishmentOfDebtAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ExtinguishmentOfDebtAxis" xlink:to="us-gaap_ExtinguishmentOfDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:to="us-gaap_LongTermDebtMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_UsGovernmentAgencyInsuredLoansMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_MarketableSecuritiesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAccumulatedLoss" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrGreaterFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAccumulatedLoss" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_FairValueOptionCreditRiskGainsLossesOnAssets" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="us-gaap_MarketableSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionsLessThanTwelveMonthsFairValue" xlink:label="tyra_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionsLessThanTwelveMonthsFairValue"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue" xlink:label="tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" xlink:label="us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_AccruedInterestAvailableForSaleSecurities" xlink:label="tyra_AccruedInterestAvailableForSaleSecurities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_MarketableSecuritiesLineItems" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="tyra_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionsLessThanTwelveMonthsFairValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="tyra_AccruedInterestAvailableForSaleSecurities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://tyra.bio/20251231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_ComputersAndSoftwareMember" xlink:label="tyra_ComputersAndSoftwareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="tyra_ComputersAndSoftwareMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://tyra.bio/20251231/taxonomy/role/Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://tyra.bio/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_AccruedResearchAndDevelopment" xlink:label="tyra_AccruedResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_AccruedOtherGeneralAndAdministrativeFee" xlink:label="tyra_AccruedOtherGeneralAndAdministrativeFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedSalariesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="tyra_AccruedResearchAndDevelopment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="tyra_AccruedOtherGeneralAndAdministrativeFee" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquitySummaryOfReservedSharesOfCommonStockDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_TwentyTwentyOneEquityIncentivePlanMember" xlink:label="tyra_TwentyTwentyOneEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDisclosuresAbstract" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_CommonStockOptionsGrantedAndOutstanding" xlink:label="tyra_CommonStockOptionsGrantedAndOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_TwentyTwentyOneEmployeeStockPurchasePlanMember" xlink:label="tyra_TwentyTwentyOneEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_SharesAvailableForFutureIssuance" xlink:label="tyra_SharesAvailableForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_TwoThousandTwentyFourPrivatePlacementMember" xlink:label="tyra_TwoThousandTwentyFourPrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="tyra_TwentyTwentyOneEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tyra_CommonStockOptionsGrantedAndOutstanding" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="tyra_TwentyTwentyOneEmployeeStockPurchasePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tyra_SharesAvailableForFutureIssuance" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="tyra_TwoThousandTwentyFourPrivatePlacementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_FebruaryTwoThousandTwentyFourSecuritiesPurchaseAgreementMember" xlink:label="tyra_FebruaryTwoThousandTwentyFourSecuritiesPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_AtmSalesAgreementMember" xlink:label="tyra_AtmSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_SeriesAConvertiblePreferredStockMember" xlink:label="tyra_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_TwoThousandTwentyFourPrivatePlacementMember" xlink:label="tyra_TwoThousandTwentyFourPrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_PreFundedWarrantsMember" xlink:label="tyra_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_SeriesBConvertiblePreferredStockMember" xlink:label="tyra_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_TwoThousandTwentyFourPreFundedWarrantsMember" xlink:label="tyra_TwoThousandTwentyFourPreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_ExchangeOfCommonStockForPre-FundedWarrantsShares" xlink:label="tyra_ExchangeOfCommonStockForPre-FundedWarrantsShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_WarrantsIssuedPricePerShare" xlink:label="tyra_WarrantsIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_Pre-FundedWarrantsExercised" xlink:label="tyra_Pre-FundedWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_Pre-FundedWarrantsAvailableForExercise" xlink:label="tyra_Pre-FundedWarrantsAvailableForExercise"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_OfferingExpenses" xlink:label="tyra_OfferingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_CommissionForAgentOnSales" xlink:label="tyra_CommissionForAgentOnSales"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_AggregateCommonStockOfferingPrice" xlink:label="tyra_AggregateCommonStockOfferingPrice"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_WarrantsAvailableForExercise" xlink:label="tyra_WarrantsAvailableForExercise"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_ExerciseOfPre-FundedWarrants" xlink:label="tyra_ExerciseOfPre-FundedWarrants"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="tyra_FebruaryTwoThousandTwentyFourSecuritiesPurchaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="tyra_AtmSalesAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tyra_SeriesAConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="tyra_TwoThousandTwentyFourPrivatePlacementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="tyra_PreFundedWarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tyra_SeriesBConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="tyra_TwoThousandTwentyFourPreFundedWarrantsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tyra_ExchangeOfCommonStockForPre-FundedWarrantsShares" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tyra_WarrantsIssuedPricePerShare" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tyra_Pre-FundedWarrantsExercised" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tyra_Pre-FundedWarrantsAvailableForExercise" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tyra_OfferingExpenses" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tyra_CommissionForAgentOnSales" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tyra_AggregateCommonStockOfferingPrice" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tyra_WarrantsAvailableForExercise" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tyra_ExerciseOfPre-FundedWarrants" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_TwentyTwentyEquityIncentivePlanMember" xlink:label="tyra_TwentyTwentyEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_TwoThousandsAndTwentyOneIncentiveAwardPlanMember" xlink:label="tyra_TwoThousandsAndTwentyOneIncentiveAwardPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_SharesReservedForFutureIssuance" xlink:label="tyra_SharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_StockholdersEquityIncreaseDecreaseInCommonStockPercent" xlink:label="tyra_StockholdersEquityIncreaseDecreaseInCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_EmployeeStockPurchasePlanDescription" xlink:label="tyra_EmployeeStockPurchasePlanDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_PurchaseOfCommonStockThroughPayrollDeduction" xlink:label="tyra_PurchaseOfCommonStockThroughPayrollDeduction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="tyra_TwentyTwentyEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="tyra_TwoThousandsAndTwentyOneIncentiveAwardPlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tyra_SharesReservedForFutureIssuance" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tyra_StockholdersEquityIncreaseDecreaseInCommonStockPercent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tyra_EmployeeStockPurchasePlanDescription" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tyra_PurchaseOfCommonStockThroughPayrollDeduction" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationSummaryOfStockOptionActivityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriod" xlink:label="tyra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_18"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="tyra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_18" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationSummaryOfFairValueOfStockOptionGrantsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationScheduleOfSharebasedCompensationEmployeeStockPurchasePlanDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://tyra.bio/20251231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_NumeratorAbstract" xlink:label="tyra_NumeratorAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_DenominatorAbstract" xlink:label="tyra_DenominatorAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageBasicSharesOutstandingProForma" xlink:label="us-gaap_WeightedAverageBasicSharesOutstandingProForma"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_WeightedAverageUnvestedRestrictedCommonStockSubjectToRepurchase" xlink:label="tyra_WeightedAverageUnvestedRestrictedCommonStockSubjectToRepurchase"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_WeightedAverageUnvestedCommonStockIssuedUponExerciseOfCommonStockOptions" xlink:label="tyra_WeightedAverageUnvestedCommonStockIssuedUponExerciseOfCommonStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="tyra_NumeratorAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tyra_DenominatorAbstract" xlink:to="us-gaap_WeightedAverageBasicSharesOutstandingProForma" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tyra_NumeratorAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="tyra_DenominatorAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tyra_DenominatorAbstract" xlink:to="tyra_WeightedAverageUnvestedRestrictedCommonStockSubjectToRepurchase" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tyra_DenominatorAbstract" xlink:to="tyra_WeightedAverageUnvestedCommonStockIssuedUponExerciseOfCommonStockOptions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tyra_DenominatorAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tyra_DenominatorAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tyra_DenominatorAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tyra_DenominatorAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://tyra.bio/20251231/taxonomy/role/Role_DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesIncludingAllOutstandingStockOptionsWereExcludedInCalculationOfDilutedSharesOutstandingDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_UnvestedCommonStockExerciseOfStockOptionsMember" xlink:label="tyra_UnvestedCommonStockExerciseOfStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_StockOptionsToPurchaseCommonStockMember" xlink:label="tyra_StockOptionsToPurchaseCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_EstimatedSharesPurchasableUnderTheEsppMember" xlink:label="tyra_EstimatedSharesPurchasableUnderTheEsppMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tyra_UnvestedCommonStockExerciseOfStockOptionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tyra_StockOptionsToPurchaseCommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tyra_EstimatedSharesPurchasableUnderTheEsppMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsAbstract" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_IncometaxreconciliationOfficersCompensation" xlink:label="tyra_IncometaxreconciliationOfficersCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_IncomeTaxReconciliationOfficersCompensationPercentage" xlink:label="tyra_IncomeTaxReconciliationOfficersCompensationPercentage"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_IncomeTaxReconciliationChangesInUnrecognizedTaxBenefits" xlink:label="tyra_IncomeTaxReconciliationChangesInUnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_IncomeTaxReconciliationChangesInUnrecognizedTaxBenefitsPercentage" xlink:label="tyra_IncomeTaxReconciliationChangesInUnrecognizedTaxBenefitsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_IncomeTaxReconciliationProvisionForIncomeTaxesPercentage" xlink:label="tyra_IncomeTaxReconciliationProvisionForIncomeTaxesPercentage"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract" xlink:to="tyra_IncometaxreconciliationOfficersCompensation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="tyra_IncomeTaxReconciliationOfficersCompensationPercentage" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="tyra_IncomeTaxReconciliationChangesInUnrecognizedTaxBenefits" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="tyra_IncomeTaxReconciliationChangesInUnrecognizedTaxBenefitsPercentage" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="tyra_IncomeTaxReconciliationProvisionForIncomeTaxesPercentage" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:label="tyra_DeferredTaxAssetsCapitalizedResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_DeferredTaxAssetsTaxCredits" xlink:label="tyra_DeferredTaxAssetsTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="tyra_DeferredTaxAssetsCapitalizedResearchAndDevelopment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="tyra_DeferredTaxAssetsTaxCredits" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:label="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="us-gaap_IncomeTaxContingencyLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="us-gaap_IncomeTaxContingencyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_FederalMember" xlink:label="tyra_FederalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_StateMember" xlink:label="tyra_StateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_CaliforniaResearchAndDevelopmentMember" xlink:label="tyra_CaliforniaResearchAndDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_NetOperatingLossCarryforwardsAvailableForOffsettingAgainstFutureTaxableIncomePercentage" xlink:label="tyra_NetOperatingLossCarryforwardsAvailableForOffsettingAgainstFutureTaxableIncomePercentage"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_NetOperatingLossCarryForwardIndefinitely" xlink:label="tyra_NetOperatingLossCarryForwardIndefinitely"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_OperatingLossCarryforwardsExpirationDates1" xlink:label="tyra_OperatingLossCarryforwardsExpirationDates1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_ResearchAndDevelopmentCreditCarryforwardsUnderInternalRevenueCodeDescription" xlink:label="tyra_ResearchAndDevelopmentCreditCarryforwardsUnderInternalRevenueCodeDescription"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxContingencyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="tyra_FederalMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="tyra_StateMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="tyra_CaliforniaResearchAndDevelopmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="tyra_NetOperatingLossCarryforwardsAvailableForOffsettingAgainstFutureTaxableIncomePercentage" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxContingencyLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="tyra_NetOperatingLossCarryForwardIndefinitely" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="tyra_OperatingLossCarryforwardsExpirationDates1" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="tyra_ResearchAndDevelopmentCreditCarryforwardsUnderInternalRevenueCodeDescription" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_3"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_FirstAmendmentMember" xlink:label="tyra_FirstAmendmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseAgreementsMember" xlink:label="us-gaap_LeaseAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OfficeBuildingMember" xlink:label="srt_OfficeBuildingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_ExpansionLeaseAgreementMember" xlink:label="tyra_ExpansionLeaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OfficeBuildingMember" xlink:label="srt_OfficeBuildingMember_1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_TwoThousandTwentySevenLeaseAgreementMember" xlink:label="tyra_TwoThousandTwentySevenLeaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_TwoThousandTwentyEightLeaseAgreementMember" xlink:label="tyra_TwoThousandTwentyEightLeaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfPropertiesSubjectToGroundLeases" xlink:label="us-gaap_NumberOfPropertiesSubjectToGroundLeases"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_AreaOfLease" xlink:label="tyra_AreaOfLease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_NumberOfLeaseTermRenewal" xlink:label="tyra_NumberOfLeaseTermRenewal"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="tyra_FirstAmendmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:to="us-gaap_LeaseAgreementsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="srt_OfficeBuildingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_SecurityDeposit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="tyra_ExpansionLeaseAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="srt_OfficeBuildingMember_1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LineOfCredit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="tyra_TwoThousandTwentySevenLeaseAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseCost" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="tyra_TwoThousandTwentyEightLeaseAgreementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_NumberOfPropertiesSubjectToGroundLeases" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="tyra_AreaOfLease" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="tyra_NumberOfLeaseTermRenewal" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_ShortTermLeaseCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_VariableLeaseCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCost" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesLeaseLiabilitiesWeightedaverageRemainingTermAndWeightedaverageDiscountRateDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesLeaseLiabilitiesWeightedaverageRemainingTermAndWeightedaverageDiscountRateParentheticalDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_MinimumLeasePaymentsForLeasesNotYetCommenced" xlink:label="tyra_MinimumLeasePaymentsForLeasesNotYetCommenced"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="tyra_MinimumLeasePaymentsForLeasesNotYetCommenced" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://tyra.bio/20251231/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="us-gaap_CompensationRelatedCostsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationRelatedCostsAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationRelatedCostsAbstract" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationRelatedCostsAbstract" xlink:to="us-gaap_DefinedBenefitPlanContributionsByEmployer" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://tyra.bio/20251231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfReportableSegments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://tyra.bio/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfTheCompanysNetLossDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_TYRA-300ACHMember" xlink:label="tyra_TYRA-300ACHMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_ChiefOperatingDecisionMakerMember" xlink:label="tyra_ChiefOperatingDecisionMakerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_TYRA-300NMIBCMember" xlink:label="tyra_TYRA-300NMIBCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_TYRA-300UTUCMember" xlink:label="tyra_TYRA-300UTUCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_TYRA-300MUCMember" xlink:label="tyra_TYRA-300MUCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_TYRA-430Member" xlink:label="tyra_TYRA-430Member"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_TYRA-200Member" xlink:label="tyra_TYRA-200Member"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_FGFRDiscoveryMember" xlink:label="tyra_FGFRDiscoveryMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_PersonnelCostsMember" xlink:label="tyra_PersonnelCostsMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_OtherDevelopmentProgramsMember" xlink:label="tyra_OtherDevelopmentProgramsMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_OtherResearchAndDevelopmentMember" xlink:label="tyra_OtherResearchAndDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_PersonnelStockBasedCompensationMember" xlink:label="tyra_PersonnelStockBasedCompensationMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_FacilitiesAndOtherCostsMember" xlink:label="tyra_FacilitiesAndOtherCostsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain" xlink:to="tyra_TYRA-300ACHMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_TitleOfIndividualAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="tyra_ChiefOperatingDecisionMakerMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpenseAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain" xlink:to="tyra_TYRA-300NMIBCMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain" xlink:to="tyra_TYRA-300UTUCMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_InterestAndOtherIncome" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_SegmentReportingInformationLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain" xlink:to="tyra_TYRA-300MUCMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_NetIncomeLoss" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain" xlink:to="tyra_TYRA-430Member" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain" xlink:to="tyra_TYRA-200Member" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain" xlink:to="tyra_FGFRDiscoveryMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain" xlink:to="tyra_PersonnelCostsMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain" xlink:to="tyra_OtherDevelopmentProgramsMember" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain" xlink:to="tyra_OtherResearchAndDevelopmentMember" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain" xlink:to="tyra_PersonnelStockBasedCompensationMember" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain" xlink:to="tyra_FacilitiesAndOtherCostsMember" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://tyra.bio/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfTheCompanysNetLossParentheticalDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheetsParenthetical">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_AccruedAndOtherRelatedParties" xlink:label="tyra_AccruedAndOtherRelatedParties"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tyra_AccruedAndOtherRelatedParties" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_SeriesAConvertiblePreferredStockMember" xlink:label="tyra_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_PreFundedWarrantsMember" xlink:label="tyra_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_SeriesBConvertiblePreferredStockMember" xlink:label="tyra_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_IssuanceOfCommonStockUnderBenefitPlans" xlink:label="tyra_IssuanceOfCommonStockUnderBenefitPlans"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_AccumulatedOtherComprehensiveLossMember" xlink:label="tyra_AccumulatedOtherComprehensiveLossMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_IssuanceOfCommonStockUnderBenefitPlansShares" xlink:label="tyra_IssuanceOfCommonStockUnderBenefitPlansShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_IssuanceOfPreFundedWarrantsUnderPrivatePlacement" xlink:label="tyra_IssuanceOfPreFundedWarrantsUnderPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_IssuanceOfCommonStockPursuantToPreFundedWarrantExercised" xlink:label="tyra_IssuanceOfCommonStockPursuantToPreFundedWarrantExercised"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_IssuanceOfCommonStockPursuantToPreFundedWarrantExercise" xlink:label="tyra_IssuanceOfCommonStockPursuantToPreFundedWarrantExercise"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_ExchangeOfCommonStockForPre-FundedWarrantsShares" xlink:label="tyra_ExchangeOfCommonStockForPre-FundedWarrantsShares"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_VestingOfSharesOfCommonStockSubjectToRepurchase" xlink:label="tyra_VestingOfSharesOfCommonStockSubjectToRepurchase"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_VestingOfSharesOfCommonStockSubjectToRepurchaseShare" xlink:label="tyra_VestingOfSharesOfCommonStockSubjectToRepurchaseShare"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_VestingOfSharesOfCommonStockSubjectToRepurchaseOneShares" xlink:label="tyra_VestingOfSharesOfCommonStockSubjectToRepurchaseOneShares"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_VestingOfSharesOfCommonStockSubjectToRepurchaseOne" xlink:label="tyra_VestingOfSharesOfCommonStockSubjectToRepurchaseOne"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_AvailableForSaleDebtSecuritiesNetUnrealizedGain" xlink:label="tyra_AvailableForSaleDebtSecuritiesNetUnrealizedGain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tyra_SeriesAConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="tyra_PreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tyra_SeriesBConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tyra_IssuanceOfCommonStockUnderBenefitPlans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="tyra_AccumulatedOtherComprehensiveLossMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tyra_IssuanceOfCommonStockUnderBenefitPlansShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tyra_IssuanceOfPreFundedWarrantsUnderPrivatePlacement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tyra_IssuanceOfCommonStockPursuantToPreFundedWarrantExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tyra_IssuanceOfCommonStockPursuantToPreFundedWarrantExercise" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tyra_ExchangeOfCommonStockForPre-FundedWarrantsShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tyra_VestingOfSharesOfCommonStockSubjectToRepurchase" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tyra_VestingOfSharesOfCommonStockSubjectToRepurchaseShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tyra_VestingOfSharesOfCommonStockSubjectToRepurchaseOneShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tyra_VestingOfSharesOfCommonStockSubjectToRepurchaseOne" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tyra_AvailableForSaleDebtSecuritiesNetUnrealizedGain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfStockholdersEquityParenthetical">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_ConversionOfConvertiblePreferredStockInConnectionWithInitialPublicOffering" xlink:label="tyra_ConversionOfConvertiblePreferredStockInConnectionWithInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_ProceedsFromIssuanceOfCommonStockUnderBenefitPlans" xlink:label="tyra_ProceedsFromIssuanceOfCommonStockUnderBenefitPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_SeriesAConvertiblePreferredStockMember" xlink:label="tyra_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromPrivatePlacement" xlink:label="tyra_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_SeriesBConvertiblePreferredStockMember" xlink:label="tyra_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_AccretionOnMarketableSecuritiesNet" xlink:label="tyra_AccretionOnMarketableSecuritiesNet"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_VestingOfOptionsEarlyExercisedSubjectToRepurchase" xlink:label="tyra_VestingOfOptionsEarlyExercisedSubjectToRepurchase"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet" xlink:label="tyra_IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_PaymentsOfIssuanceCostsForCommonStockAndPreFundedWarrantsFromPrivatePlacement" xlink:label="tyra_PaymentsOfIssuanceCostsForCommonStockAndPreFundedWarrantsFromPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_ReceivableFromExerciseOfStockOptionsIncludedInPrepaidExpensesAndOtherCurrentAssets" xlink:label="tyra_ReceivableFromExerciseOfStockOptionsIncludedInPrepaidExpensesAndOtherCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_IssuanceOfConvertiblePreferredStockInExchangeForSimpleAgreementForFutureEquity" xlink:label="tyra_IssuanceOfConvertiblePreferredStockInExchangeForSimpleAgreementForFutureEquity"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="tyra_ConversionOfConvertiblePreferredStockInConnectionWithInitialPublicOffering" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="tyra_ProceedsFromIssuanceOfCommonStockUnderBenefitPlans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tyra_SeriesAConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="tyra_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromPrivatePlacement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tyra_SeriesBConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="tyra_AccretionOnMarketableSecuritiesNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="tyra_VestingOfOptionsEarlyExercisedSubjectToRepurchase" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="tyra_IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="tyra_PaymentsOfIssuanceCostsForCommonStockAndPreFundedWarrantsFromPrivatePlacement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="tyra_ReceivableFromExerciseOfStockOptionsIncludedInPrepaidExpensesAndOtherCurrentAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="tyra_IssuanceOfConvertiblePreferredStockInExchangeForSimpleAgreementForFutureEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_ToddHarrisMember" xlink:label="tyra_ToddHarrisMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_DanielBensenMember" xlink:label="tyra_DanielBensenMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_AlanFuhrmanMember" xlink:label="tyra_AlanFuhrmanMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="tyra_ToddHarrisMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="tyra_DanielBensenMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="tyra_AlanFuhrmanMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://tyra.bio/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://tyra.bio/20251231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="tyra_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="tyra_OrganizationAndSummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherTypesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="dei_EntityIncorporationDateOfIncorporation"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_CashCashEquivalentsAndMarketableSecurities" xlink:label="tyra_CashCashEquivalentsAndMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendPaymentRestrictionsScheduleDescription" xlink:label="us-gaap_DividendPaymentRestrictionsScheduleDescription"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_DividendYield" xlink:label="tyra_DividendYield"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_OptionsGrantedContractualTerm" xlink:label="tyra_OptionsGrantedContractualTerm"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tyra_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="tyra_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tyra_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherTypesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tyra_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tyra_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tyra_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tyra_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tyra_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tyra_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="dei_EntityIncorporationDateOfIncorporation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tyra_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="tyra_CashCashEquivalentsAndMarketableSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tyra_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCash" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tyra_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DividendPaymentRestrictionsScheduleDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tyra_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="tyra_DividendYield" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tyra_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="tyra_OptionsGrantedContractualTerm" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://tyra.bio/20251231/taxonomy/role/DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueAdjustment" xlink:label="us-gaap_AssetsFairValueAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_RestrictedCashMember" xlink:label="tyra_RestrictedCashMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueConcentrationOfRiskCashAndCashEquivalents" xlink:label="us-gaap_FairValueConcentrationOfRiskCashAndCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesTradingRestricted" xlink:label="us-gaap_DebtSecuritiesTradingRestricted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueAdjustment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="tyra_RestrictedCashMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueConcentrationOfRiskCashAndCashEquivalents" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtSecuritiesTradingRestricted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CashMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_MarketableSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableforsaleSecuritiesAndGrossUnrealizedLossesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ExtinguishmentOfDebtAxis" xlink:label="us-gaap_ExtinguishmentOfDebtAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:label="us-gaap_ExtinguishmentOfDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:label="us-gaap_ExtinguishmentOfDebtTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMember" xlink:label="us-gaap_LongTermDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UsGovernmentAgencyInsuredLoansMember" xlink:label="us-gaap_UsGovernmentAgencyInsuredLoansMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtMember" xlink:label="us-gaap_ShortTermDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue" xlink:label="tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAccumulatedLoss" xlink:label="tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrGreaterFairValue" xlink:label="tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrGreaterFairValue"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAccumulatedLoss" xlink:label="tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" xlink:label="us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" xlink:label="us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOptionCreditRiskGainsLossesOnAssets" xlink:label="us-gaap_FairValueOptionCreditRiskGainsLossesOnAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_ExtinguishmentOfDebtAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ExtinguishmentOfDebtAxis" xlink:to="us-gaap_ExtinguishmentOfDebtTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ExtinguishmentOfDebtAxis" xlink:to="us-gaap_ExtinguishmentOfDebtTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:to="us-gaap_LongTermDebtMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_UsGovernmentAgencyInsuredLoansMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAccumulatedLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrGreaterFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAccumulatedLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_FairValueOptionCreditRiskGainsLossesOnAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionsLessThanTwelveMonthsFairValue" xlink:label="tyra_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionsLessThanTwelveMonthsFairValue"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue" xlink:label="tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" xlink:label="us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_AccruedInterestAvailableForSaleSecurities" xlink:label="tyra_AccruedInterestAvailableForSaleSecurities"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="tyra_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionsLessThanTwelveMonthsFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="tyra_AccruedInterestAvailableForSaleSecurities" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://tyra.bio/20251231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_ComputersAndSoftwareMember" xlink:label="tyra_ComputersAndSoftwareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="tyra_ComputersAndSoftwareMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquitySummaryOfReservedSharesOfCommonStockDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_TwentyTwentyOneEquityIncentivePlanMember" xlink:label="tyra_TwentyTwentyOneEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_CommonStockOptionsGrantedAndOutstanding" xlink:label="tyra_CommonStockOptionsGrantedAndOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_TwentyTwentyOneEmployeeStockPurchasePlanMember" xlink:label="tyra_TwentyTwentyOneEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_SharesAvailableForFutureIssuance" xlink:label="tyra_SharesAvailableForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_TwoThousandTwentyFourPrivatePlacementMember" xlink:label="tyra_TwoThousandTwentyFourPrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="tyra_TwentyTwentyOneEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tyra_CommonStockOptionsGrantedAndOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="tyra_TwentyTwentyOneEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tyra_SharesAvailableForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="tyra_TwoThousandTwentyFourPrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_FebruaryTwoThousandTwentyFourSecuritiesPurchaseAgreementMember" xlink:label="tyra_FebruaryTwoThousandTwentyFourSecuritiesPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_AtmSalesAgreementMember" xlink:label="tyra_AtmSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_SeriesAConvertiblePreferredStockMember" xlink:label="tyra_SeriesAConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_TwoThousandTwentyFourPrivatePlacementMember" xlink:label="tyra_TwoThousandTwentyFourPrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_PreFundedWarrantsMember" xlink:label="tyra_PreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_SeriesBConvertiblePreferredStockMember" xlink:label="tyra_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_TwoThousandTwentyFourPreFundedWarrantsMember" xlink:label="tyra_TwoThousandTwentyFourPreFundedWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_ExchangeOfCommonStockForPre-FundedWarrantsShares" xlink:label="tyra_ExchangeOfCommonStockForPre-FundedWarrantsShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_WarrantsIssuedPricePerShare" xlink:label="tyra_WarrantsIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_Pre-FundedWarrantsExercised" xlink:label="tyra_Pre-FundedWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_Pre-FundedWarrantsAvailableForExercise" xlink:label="tyra_Pre-FundedWarrantsAvailableForExercise"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_OfferingExpenses" xlink:label="tyra_OfferingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_CommissionForAgentOnSales" xlink:label="tyra_CommissionForAgentOnSales"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_AggregateCommonStockOfferingPrice" xlink:label="tyra_AggregateCommonStockOfferingPrice"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_WarrantsAvailableForExercise" xlink:label="tyra_WarrantsAvailableForExercise"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_ExerciseOfPre-FundedWarrants" xlink:label="tyra_ExerciseOfPre-FundedWarrants"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="tyra_FebruaryTwoThousandTwentyFourSecuritiesPurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="tyra_AtmSalesAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tyra_SeriesAConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="tyra_TwoThousandTwentyFourPrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="tyra_PreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tyra_SeriesBConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="tyra_TwoThousandTwentyFourPreFundedWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tyra_ExchangeOfCommonStockForPre-FundedWarrantsShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tyra_WarrantsIssuedPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tyra_Pre-FundedWarrantsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tyra_Pre-FundedWarrantsAvailableForExercise" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tyra_OfferingExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tyra_CommissionForAgentOnSales" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tyra_AggregateCommonStockOfferingPrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tyra_WarrantsAvailableForExercise" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tyra_ExerciseOfPre-FundedWarrants" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_TwentyTwentyEquityIncentivePlanMember" xlink:label="tyra_TwentyTwentyEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_TwoThousandsAndTwentyOneIncentiveAwardPlanMember" xlink:label="tyra_TwoThousandsAndTwentyOneIncentiveAwardPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_SharesReservedForFutureIssuance" xlink:label="tyra_SharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_StockholdersEquityIncreaseDecreaseInCommonStockPercent" xlink:label="tyra_StockholdersEquityIncreaseDecreaseInCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_EmployeeStockPurchasePlanDescription" xlink:label="tyra_EmployeeStockPurchasePlanDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_PurchaseOfCommonStockThroughPayrollDeduction" xlink:label="tyra_PurchaseOfCommonStockThroughPayrollDeduction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="tyra_TwentyTwentyEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="tyra_TwoThousandsAndTwentyOneIncentiveAwardPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tyra_SharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tyra_StockholdersEquityIncreaseDecreaseInCommonStockPercent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tyra_EmployeeStockPurchasePlanDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tyra_PurchaseOfCommonStockThroughPayrollDeduction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationSummaryOfFairValueOfStockOptionGrantsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationScheduleOfSharebasedCompensationEmployeeStockPurchasePlanDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://tyra.bio/20251231/taxonomy/role/Role_DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesIncludingAllOutstandingStockOptionsWereExcludedInCalculationOfDilutedSharesOutstandingDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_UnvestedCommonStockExerciseOfStockOptionsMember" xlink:label="tyra_UnvestedCommonStockExerciseOfStockOptionsMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_StockOptionsToPurchaseCommonStockMember" xlink:label="tyra_StockOptionsToPurchaseCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_EstimatedSharesPurchasableUnderTheEsppMember" xlink:label="tyra_EstimatedSharesPurchasableUnderTheEsppMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tyra_UnvestedCommonStockExerciseOfStockOptionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tyra_StockOptionsToPurchaseCommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tyra_EstimatedSharesPurchasableUnderTheEsppMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="us-gaap_IncomeTaxContingencyLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="us-gaap_IncomeTaxContingencyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:label="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_FederalMember" xlink:label="tyra_FederalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_StateMember" xlink:label="tyra_StateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_CaliforniaResearchAndDevelopmentMember" xlink:label="tyra_CaliforniaResearchAndDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_NetOperatingLossCarryforwardsAvailableForOffsettingAgainstFutureTaxableIncomePercentage" xlink:label="tyra_NetOperatingLossCarryforwardsAvailableForOffsettingAgainstFutureTaxableIncomePercentage"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_NetOperatingLossCarryForwardIndefinitely" xlink:label="tyra_NetOperatingLossCarryForwardIndefinitely"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_OperatingLossCarryforwardsExpirationDates1" xlink:label="tyra_OperatingLossCarryforwardsExpirationDates1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_ResearchAndDevelopmentCreditCarryforwardsUnderInternalRevenueCodeDescription" xlink:label="tyra_ResearchAndDevelopmentCreditCarryforwardsUnderInternalRevenueCodeDescription"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxContingencyTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="tyra_FederalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="tyra_StateMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="tyra_CaliforniaResearchAndDevelopmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="tyra_NetOperatingLossCarryforwardsAvailableForOffsettingAgainstFutureTaxableIncomePercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="tyra_NetOperatingLossCarryForwardIndefinitely" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="tyra_OperatingLossCarryforwardsExpirationDates1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="tyra_ResearchAndDevelopmentCreditCarryforwardsUnderInternalRevenueCodeDescription" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_FirstAmendmentMember" xlink:label="tyra_FirstAmendmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseAgreementsMember" xlink:label="us-gaap_LeaseAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OfficeBuildingMember" xlink:label="srt_OfficeBuildingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_ExpansionLeaseAgreementMember" xlink:label="tyra_ExpansionLeaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_TwoThousandTwentySevenLeaseAgreementMember" xlink:label="tyra_TwoThousandTwentySevenLeaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_TwoThousandTwentyEightLeaseAgreementMember" xlink:label="tyra_TwoThousandTwentyEightLeaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfPropertiesSubjectToGroundLeases" xlink:label="us-gaap_NumberOfPropertiesSubjectToGroundLeases"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_AreaOfLease" xlink:label="tyra_AreaOfLease"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_NumberOfLeaseTermRenewal" xlink:label="tyra_NumberOfLeaseTermRenewal"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LeaseContractualTermAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="tyra_FirstAmendmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:to="us-gaap_LeaseAgreementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="srt_OfficeBuildingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_SecurityDeposit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="tyra_ExpansionLeaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LineOfCredit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="tyra_TwoThousandTwentySevenLeaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="tyra_TwoThousandTwentyEightLeaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_NumberOfPropertiesSubjectToGroundLeases" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseExpirationDate1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="tyra_AreaOfLease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="tyra_NumberOfLeaseTermRenewal" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://tyra.bio/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfTheCompanysNetLossDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_TYRA-300ACHMember" xlink:label="tyra_TYRA-300ACHMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_ChiefOperatingDecisionMakerMember" xlink:label="tyra_ChiefOperatingDecisionMakerMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_TYRA-300NMIBCMember" xlink:label="tyra_TYRA-300NMIBCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_TYRA-300UTUCMember" xlink:label="tyra_TYRA-300UTUCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_TYRA-300MUCMember" xlink:label="tyra_TYRA-300MUCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_TYRA-430Member" xlink:label="tyra_TYRA-430Member"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_TYRA-200Member" xlink:label="tyra_TYRA-200Member"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_FGFRDiscoveryMember" xlink:label="tyra_FGFRDiscoveryMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_PersonnelCostsMember" xlink:label="tyra_PersonnelCostsMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_OtherDevelopmentProgramsMember" xlink:label="tyra_OtherDevelopmentProgramsMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_OtherResearchAndDevelopmentMember" xlink:label="tyra_OtherResearchAndDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_PersonnelStockBasedCompensationMember" xlink:label="tyra_PersonnelStockBasedCompensationMember"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_FacilitiesAndOtherCostsMember" xlink:label="tyra_FacilitiesAndOtherCostsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="tyra_TYRA-300ACHMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="tyra_ChiefOperatingDecisionMakerMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpenseAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="tyra_TYRA-300NMIBCMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="tyra_TYRA-300UTUCMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_InterestAndOtherIncome" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="tyra_TYRA-300MUCMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="tyra_TYRA-430Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="tyra_TYRA-200Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="tyra_FGFRDiscoveryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="tyra_PersonnelCostsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="tyra_OtherDevelopmentProgramsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="tyra_OtherResearchAndDevelopmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="tyra_PersonnelStockBasedCompensationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="tyra_FacilitiesAndOtherCostsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeDomain" xlink:label="us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_ChiefOperatingDecisionMakerMember" xlink:label="tyra_ChiefOperatingDecisionMakerMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeDomain" xlink:to="tyra_ChiefOperatingDecisionMakerMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheets">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecurities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="tyra_RightOfUseAsset" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_RightOfUseAsset" xlink:label="tyra_RightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestAndOtherIncome" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="tyra_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromPrivatePlacement" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="tyra_PaymentsOfIssuanceCostsForCommonStockAndPreFundedWarrantsFromPrivatePlacement" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="tyra_AccretionOnMarketableSecuritiesNet" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" order="5" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="tyra_IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="tyra_ProceedsFromIssuanceOfCommonStockUnderBenefitPlans" order="7" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromPrivatePlacement" xlink:label="tyra_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_PaymentsOfIssuanceCostsForCommonStockAndPreFundedWarrantsFromPrivatePlacement" xlink:label="tyra_PaymentsOfIssuanceCostsForCommonStockAndPreFundedWarrantsFromPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_AccretionOnMarketableSecuritiesNet" xlink:label="tyra_AccretionOnMarketableSecuritiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet" xlink:label="tyra_IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_ProceedsFromIssuanceOfCommonStockUnderBenefitPlans" xlink:label="tyra_ProceedsFromIssuanceOfCommonStockUnderBenefitPlans"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableforsaleSecuritiesAndGrossUnrealizedLossesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" order="3" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" xlink:label="us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" xlink:label="us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://tyra.bio/20251231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://tyra.bio/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="tyra_AccruedResearchAndDevelopment" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="tyra_AccruedOtherGeneralAndAdministrativeFee" order="3" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_AccruedResearchAndDevelopment" xlink:label="tyra_AccruedResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_AccruedOtherGeneralAndAdministrativeFee" xlink:label="tyra_AccruedOtherGeneralAndAdministrativeFee"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="tyra_IncometaxreconciliationOfficersCompensation" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="tyra_IncomeTaxReconciliationChangesInUnrecognizedTaxBenefits" order="6" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="7" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="8" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_IncometaxreconciliationOfficersCompensation" xlink:label="tyra_IncometaxreconciliationOfficersCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_IncomeTaxReconciliationChangesInUnrecognizedTaxBenefits" xlink:label="tyra_IncomeTaxReconciliationChangesInUnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="tyra_DeferredTaxAssetsCapitalizedResearchAndDevelopment" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="tyra_DeferredTaxAssetsTaxCredits" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="6" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:label="tyra_DeferredTaxAssetsCapitalizedResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="tyra-20251231.xsd#tyra_DeferredTaxAssetsTaxCredits" xlink:label="tyra_DeferredTaxAssetsTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_ShortTermLeaseCost" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesLeaseLiabilitiesWeightedaverageRemainingTermAndWeightedaverageDiscountRateDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="tyra_ReceivableFromExerciseOfStockOptionsIncludedInPrepaidExpensesAndOtherCurrentAssets" name="ReceivableFromExerciseOfStockOptionsIncludedInPrepaidExpensesAndOtherCurrentAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tyra_OrganizationPolicyTextBlock" name="OrganizationPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tyra_SeriesBConvertiblePreferredStockMember" name="SeriesBConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tyra_VestingOfSharesOfCommonStockSubjectToRepurchaseOneShares" name="VestingOfSharesOfCommonStockSubjectToRepurchaseOneShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tyra_IssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" name="IssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tyra_WeightedAverageUnvestedRestrictedCommonStockSubjectToRepurchase" name="WeightedAverageUnvestedRestrictedCommonStockSubjectToRepurchase" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tyra_SharesAvailableForFutureIssuance" name="SharesAvailableForFutureIssuance" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="tyra_PreFundedWarrantsMember" name="PreFundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tyra_UnvestedCommonStockExerciseOfStockOptionsMember" name="UnvestedCommonStockExerciseOfStockOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tyra_StockOptionsAbstract" name="StockOptionsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tyra_AggregateCommonStockOfferingPrice" name="AggregateCommonStockOfferingPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tyra_NetOperatingLossCarryforwardsAvailableForOffsettingAgainstFutureTaxableIncomePercentage" name="NetOperatingLossCarryforwardsAvailableForOffsettingAgainstFutureTaxableIncomePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tyra_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionsLessThanTwelveMonthsFairValue" name="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionsLessThanTwelveMonthsFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tyra_TwoThousandsAndTwentyOneIncentiveAwardPlanMember" name="TwoThousandsAndTwentyOneIncentiveAwardPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tyra_FebruaryTwoThousandTwentyFourSecuritiesPurchaseAgreementMember" name="FebruaryTwoThousandTwentyFourSecuritiesPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tyra_RightOfUseAsset" name="RightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tyra_TYRA-300ACHMember" name="TYRA-300ACHMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tyra_TYRA-300UTUCMember" name="TYRA-300UTUCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tyra_ProceedsFromIssuanceOfCommonStockUnderBenefitPlans" name="ProceedsFromIssuanceOfCommonStockUnderBenefitPlans" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tyra_AccruedAndOtherRelatedParties" name="AccruedAndOtherRelatedParties" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tyra_StockholdersEquityIncreaseDecreaseInCommonStockPercent" name="StockholdersEquityIncreaseDecreaseInCommonStockPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tyra_OtherDevelopmentProgramsMember" name="OtherDevelopmentProgramsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tyra_IssuanceOfCommonStockUnderBenefitPlans" name="IssuanceOfCommonStockUnderBenefitPlans" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tyra_MinimumLeasePaymentsForLeasesNotYetCommenced" name="MinimumLeasePaymentsForLeasesNotYetCommenced" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tyra_StockOptionsToPurchaseCommonStockMember" name="StockOptionsToPurchaseCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tyra_ExchangeOfCommonStockForPre-FundedWarrantsShares" name="ExchangeOfCommonStockForPre-FundedWarrantsShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tyra_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromPrivatePlacement" name="ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromPrivatePlacement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tyra_ConversionOfConvertiblePreferredStockInConnectionWithInitialPublicOffering" name="ConversionOfConvertiblePreferredStockInConnectionWithInitialPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tyra_PersonnelCostsMember" name="PersonnelCostsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tyra_TwoThousandTwentySevenLeaseAgreementMember" name="TwoThousandTwentySevenLeaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tyra_PaymentsOfIssuanceCostsForCommonStockAndPreFundedWarrantsFromPrivatePlacement" name="PaymentsOfIssuanceCostsForCommonStockAndPreFundedWarrantsFromPrivatePlacement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tyra_VestingOfSharesOfCommonStockSubjectToRepurchaseOne" name="VestingOfSharesOfCommonStockSubjectToRepurchaseOne" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tyra_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" name="OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tyra_ExpansionLeaseAgreementMember" name="ExpansionLeaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tyra_NetOperatingLossCarryForwardIndefinitely" name="NetOperatingLossCarryForwardIndefinitely" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tyra_IssuanceOfCommonStockPursuantToPreFundedWarrantExercised" name="IssuanceOfCommonStockPursuantToPreFundedWarrantExercised" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tyra_TYRA-430Member" name="TYRA-430Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAccumulatedLoss" name="HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAccumulatedLoss" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tyra_TwoThousandTwentyFourPrivatePlacementMember" name="TwoThousandTwentyFourPrivatePlacementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tyra_TwentyTwentyOneEquityIncentivePlanMember" name="TwentyTwentyOneEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tyra_AllowanceForCreditLossesPolicyTextBlock" name="AllowanceForCreditLossesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tyra_AccruedResearchAndDevelopment" name="AccruedResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tyra_StateMember" name="StateMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tyra_TwoThousandTwentyEightLeaseAgreementMember" name="TwoThousandTwentyEightLeaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tyra_SimpleAgreementsForFutureEquityTextBlock" name="SimpleAgreementsForFutureEquityTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tyra_CommissionForAgentOnSales" name="CommissionForAgentOnSales" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="tyra_DenominatorAbstract" name="DenominatorAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tyra_IncomeTaxReconciliationProvisionForIncomeTaxesPercentage" name="IncomeTaxReconciliationProvisionForIncomeTaxesPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tyra_PurchaseOfCommonStockThroughPayrollDeduction" name="PurchaseOfCommonStockThroughPayrollDeduction" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tyra_IssuanceOfPreFundedWarrantsUnderPrivatePlacement" name="IssuanceOfPreFundedWarrantsUnderPrivatePlacement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tyra_PersonnelStockBasedCompensationMember" name="PersonnelStockBasedCompensationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tyra_RestrictedCashMember" name="RestrictedCashMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tyra_TwoThousandTwentyFourPreFundedWarrantsMember" name="TwoThousandTwentyFourPreFundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tyra_VestingOfSharesOfCommonStockSubjectToRepurchaseShare" name="VestingOfSharesOfCommonStockSubjectToRepurchaseShare" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tyra_TYRA-300MUCMember" name="TYRA-300MUCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tyra_DeferredTaxAssetsTaxCredits" name="DeferredTaxAssetsTaxCredits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tyra_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" name="OrganizationAndSummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tyra_TwentyTwentyOneEmployeeStockPurchasePlanMember" name="TwentyTwentyOneEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tyra_FacilitiesAndOtherCostsMember" name="FacilitiesAndOtherCostsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tyra_SimpleAgreementsForFutureEquityAbstract" name="SimpleAgreementsForFutureEquityAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tyra_AccretionOnMarketableSecuritiesNet" name="AccretionOnMarketableSecuritiesNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tyra_AreaOfLease" name="AreaOfLease" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="tyra_ToddHarrisMember" name="ToddHarrisMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tyra_RelatedPartiesPolicyPolicyTextBlock" name="RelatedPartiesPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tyra_EstimatedSharesPurchasableUnderTheEsppMember" name="EstimatedSharesPurchasableUnderTheEsppMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tyra_WarrantsAvailableForExercise" name="WarrantsAvailableForExercise" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tyra_CommonStockWarrantsPolicyTextBlock" name="CommonStockWarrantsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tyra_ExerciseOfPre-FundedWarrants" name="ExerciseOfPre-FundedWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tyra_OperatingLossCarryforwardsExpirationDates1" name="OperatingLossCarryforwardsExpirationDates1" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tyra_Pre-FundedWarrantsAvailableForExercise" name="Pre-FundedWarrantsAvailableForExercise" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tyra_ChiefOperatingDecisionMakerMember" name="ChiefOperatingDecisionMakerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tyra_AccruedResearchAndDevelopmentExpensePolicyPolicyTextBlock" name="AccruedResearchAndDevelopmentExpensePolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tyra_IssuanceOfCommonStockPursuantToPreFundedWarrantExercise" name="IssuanceOfCommonStockPursuantToPreFundedWarrantExercise" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tyra_TYRA-200Member" name="TYRA-200Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tyra_CaliforniaResearchAndDevelopmentMember" name="CaliforniaResearchAndDevelopmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tyra_IncomeTaxReconciliationChangesInUnrecognizedTaxBenefits" name="IncomeTaxReconciliationChangesInUnrecognizedTaxBenefits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tyra_NonRule10B51ArrModifiedFlag" name="NonRule10B51ArrModifiedFlag" type="xbrli:booleanItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tyra_IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet" name="IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tyra_DanielBensenMember" name="DanielBensenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tyra_PatentCostsPolicyPolicyTextBlock" name="PatentCostsPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tyra_FederalMember" name="FederalMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tyra_SeriesAConvertiblePreferredStockMember" name="SeriesAConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tyra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tyra_NumeratorAbstract" name="NumeratorAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tyra_DeferredTaxAssetsCapitalizedResearchAndDevelopment" name="DeferredTaxAssetsCapitalizedResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue" name="HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tyra_OtherResearchAndDevelopmentMember" name="OtherResearchAndDevelopmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tyra_OptionsGrantedContractualTerm" name="OptionsGrantedContractualTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tyra_FGFRDiscoveryMember" name="FGFRDiscoveryMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tyra_CapitalizedSoftwareImplementationCostsPolicyTextBlock" name="CapitalizedSoftwareImplementationCostsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tyra_TYRA-300NMIBCMember" name="TYRA-300NMIBCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tyra_SharesReservedForFutureIssuance" name="SharesReservedForFutureIssuance" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tyra_CommonStockOptionsGrantedAndOutstanding" name="CommonStockOptionsGrantedAndOutstanding" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="tyra_AccruedOtherGeneralAndAdministrativeFee" name="AccruedOtherGeneralAndAdministrativeFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tyra_AtmSalesAgreementMember" name="AtmSalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrGreaterFairValue" name="HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrGreaterFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tyra_EmployeeStockPurchasePlanDescription" name="EmployeeStockPurchasePlanDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tyra_ComputersAndSoftwareMember" name="ComputersAndSoftwareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tyra_Rule10B51ArrModifiedFlag" name="Rule10B51ArrModifiedFlag" type="xbrli:booleanItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tyra_ScheduleOfMaturitiesOfLeaseLiabilitiesWithWeightedAverageRemainingTermAndDiscountRateTableTextBlock" name="ScheduleOfMaturitiesOfLeaseLiabilitiesWithWeightedAverageRemainingTermAndDiscountRateTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tyra_ConvertiblePreferredStockTextBlock" name="ConvertiblePreferredStockTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tyra_WeightedAverageUnvestedCommonStockIssuedUponExerciseOfCommonStockOptions" name="WeightedAverageUnvestedCommonStockIssuedUponExerciseOfCommonStockOptions" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tyra_VestingOfSharesOfCommonStockSubjectToRepurchase" name="VestingOfSharesOfCommonStockSubjectToRepurchase" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tyra_IncomeTaxReconciliationOfficersCompensationPercentage" name="IncomeTaxReconciliationOfficersCompensationPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tyra_IssuanceOfCommonStockUnderBenefitPlansShares" name="IssuanceOfCommonStockUnderBenefitPlansShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tyra_AvailableForSaleDebtSecuritiesNetUnrealizedGain" name="AvailableForSaleDebtSecuritiesNetUnrealizedGain" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tyra_IncomeTaxReconciliationChangesInUnrecognizedTaxBenefitsPercentage" name="IncomeTaxReconciliationChangesInUnrecognizedTaxBenefitsPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tyra_IncometaxreconciliationOfficersCompensation" name="IncometaxreconciliationOfficersCompensation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tyra_IssuanceOfConvertiblePreferredStockInExchangeForSimpleAgreementForFutureEquity" name="IssuanceOfConvertiblePreferredStockInExchangeForSimpleAgreementForFutureEquity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tyra_NumberOfLeaseTermRenewal" name="NumberOfLeaseTermRenewal" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tyra_FirstAmendmentMember" name="FirstAmendmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tyra_TwentyTwentyEquityIncentivePlanMember" name="TwentyTwentyEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tyra_CashCashEquivalentsAndMarketableSecurities" name="CashCashEquivalentsAndMarketableSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tyra_AccountsPayableAccruedExpensesAndOtherLiabilitiesRelatedPartyTransactions" name="AccountsPayableAccruedExpensesAndOtherLiabilitiesRelatedPartyTransactions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tyra_AccruedInterestAvailableForSaleSecurities" name="AccruedInterestAvailableForSaleSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tyra_OfferingExpenses" name="OfferingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tyra_DividendYield" name="DividendYield" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tyra_VestingOfOptionsEarlyExercisedSubjectToRepurchase" name="VestingOfOptionsEarlyExercisedSubjectToRepurchase" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tyra_ResearchAndDevelopmentCreditCarryforwardsUnderInternalRevenueCodeDescription" name="ResearchAndDevelopmentCreditCarryforwardsUnderInternalRevenueCodeDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tyra_WarrantsIssuedPricePerShare" name="WarrantsIssuedPricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAccumulatedLoss" name="HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAccumulatedLoss" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tyra_AlanFuhrmanMember" name="AlanFuhrmanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tyra_AccumulatedOtherComprehensiveLossMember" name="AccumulatedOtherComprehensiveLossMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tyra_Pre-FundedWarrantsExercised" name="Pre-FundedWarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Feb. 25, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">TYRA BIOSCIENCES, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">83-1476348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2656 State Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Carlsbad<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">728-4760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,867,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001863127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TYRA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain sections of the registrant&#8217;s definitive proxy statement for the </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2025</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> annual meeting of stockholders to be filed with the Securities and Exchange Commission pursuant to Regulation 14A not later than 120 days after the end of the fiscal year covered by this Form 10-K are incorporated by reference into Part III of this Form 10-K.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 297.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Diego, California<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorOpinionTextBlock', window );">Auditor Opinion</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Opinion on the Financial Statements</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited the accompanying balance sheets of Tyra Biosciences, Inc. (the Company) as of December 31, 2025 and 2024, the related statements of operations and comprehensive loss, stockholders&#8217; equity and cash flows for each of the two years in the period ended December 31, 2025, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2025, in conformity with U.S. generally accepted accounting principles.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorOpinionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X<br> -Number 210<br> -Section 2<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorOpinionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 77,387<span></span>
</td>
<td class="nump">$ 91,966<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">178,616<span></span>
</td>
<td class="nump">249,475<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">9,447<span></span>
</td>
<td class="nump">6,022<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">265,450<span></span>
</td>
<td class="nump">347,463<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,314<span></span>
</td>
<td class="nump">1,651<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_RightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="nump">5,573<span></span>
</td>
<td class="nump">6,068<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">9,272<span></span>
</td>
<td class="nump">7,376<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">282,609<span></span>
</td>
<td class="nump">363,558<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,178<span></span>
</td>
<td class="nump">590<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities, current</a></td>
<td class="nump">472<span></span>
</td>
<td class="nump">412<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">16,444<span></span>
</td>
<td class="nump">13,592<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">18,094<span></span>
</td>
<td class="nump">14,594<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, noncurrent</a></td>
<td class="nump">5,338<span></span>
</td>
<td class="nump">5,810<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">23,432<span></span>
</td>
<td class="nump">20,407<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 10)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 50,000,000 shares authorized at December 31, 2025 and December 31, 2024; no shares issued and outstanding at December 31, 2025 and December 31, 2024.</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 500,000,000 shares authorized at December 31, 2025 and December 31, 2024; 53,706,357 and 50,754,262 shares issued at December 31, 2025 and December 31, 2024, respectively, and 53,706,357 and 50,749,945 shares outstanding at December 31, 2025 and December 31, 2024, respectively.</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">630,037<span></span>
</td>
<td class="nump">593,687<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">393<span></span>
</td>
<td class="nump">770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(371,258)<span></span>
</td>
<td class="num">(251,311)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">259,177<span></span>
</td>
<td class="nump">343,151<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 282,609<span></span>
</td>
<td class="nump">$ 363,558<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_RightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right of Use Asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_RightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">53,706,357<span></span>
</td>
<td class="nump">50,754,262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">53,706,357<span></span>
</td>
<td class="nump">50,749,945<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 102,928<span></span>
</td>
<td class="nump">$ 80,077<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">29,834<span></span>
</td>
<td class="nump">24,100<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">132,762<span></span>
</td>
<td class="nump">104,177<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(132,762)<span></span>
</td>
<td class="num">(104,177)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income :</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest and other income, net</a></td>
<td class="nump">12,815<span></span>
</td>
<td class="nump">17,696<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">12,815<span></span>
</td>
<td class="nump">17,696<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(119,947)<span></span>
</td>
<td class="num">(86,481)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on marketable securities available-for-sale, net</a></td>
<td class="num">(377)<span></span>
</td>
<td class="nump">389<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (120,324)<span></span>
</td>
<td class="num">$ (86,092)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (2.01)<span></span>
</td>
<td class="num">$ (1.51)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (2.01)<span></span>
</td>
<td class="num">$ (1.51)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares used to compute net loss per share - basic</a></td>
<td class="nump">59,602,328<span></span>
</td>
<td class="nump">57,217,746<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares used to compute net loss per share - diluted</a></td>
<td class="nump">59,602,328<span></span>
</td>
<td class="nump">57,217,746<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th">
<div>Private Placement [Member] </div>
<div>Common Stock [Member]</div>
</th>
<th class="th">
<div>Private Placement [Member] </div>
<div>Additional Paid-in Capital [Member]</div>
</th>
<th class="th">
<div>Pre-funded Warrants [Member] </div>
<div>Common Stock [Member]</div>
</th>
<th class="th">
<div>Pre-funded Warrants [Member] </div>
<div>Additional Paid-in Capital [Member]</div>
</th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="nump">$ 204,262<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 368,707<span></span>
</td>
<td class="nump">$ 381<span></span>
</td>
<td class="num">$ (164,830)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,024,634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_IssuanceOfCommonStockUnderBenefitPlans', window );">Issuance of common stock under benefit plans</a></td>
<td class="nump">2,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_IssuanceOfCommonStockUnderBenefitPlansShares', window );">Issuance of common stock under benefit plans, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">664,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,286,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Issuance of common stock under Private Placement, net of issuance costs</a></td>
<td class="nump">120,558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 120,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_IssuanceOfPreFundedWarrantsUnderPrivatePlacement', window );">Issuance of Pre Funded Warrants under Private Placement</a></td>
<td class="nump">79,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_IssuanceOfCommonStockPursuantToPreFundedWarrantExercise', window );">Issuance of common stock pursuant to pre-funded warrant exercise, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">705,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_ExchangeOfCommonStockForPre-FundedWarrantsShares', window );">Exchange of common stock for pre-funded warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_VestingOfSharesOfCommonStockSubjectToRepurchase', window );">Vesting of shares of common stock subject to repurchase</a></td>
<td class="nump">43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_VestingOfSharesOfCommonStockSubjectToRepurchaseShare', window );">Vesting of shares of common stock subject to repurchase, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">22,801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_AvailableForSaleDebtSecuritiesNetUnrealizedGain', window );">Unrealized gain on marketable securities available-for-sale, net</a></td>
<td class="nump">389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(86,481)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(86,481)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2024</a></td>
<td class="nump">343,151<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">593,687<span></span>
</td>
<td class="nump">770<span></span>
</td>
<td class="num">(251,311)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,749,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_IssuanceOfCommonStockUnderBenefitPlans', window );">Issuance of common stock under benefit plans</a></td>
<td class="nump">8,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_IssuanceOfCommonStockUnderBenefitPlansShares', window );">Issuance of common stock under benefit plans, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">952,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_IssuanceOfCommonStockPursuantToPreFundedWarrantExercised', window );">Issuance of common stock pursuant to pre-funded warrant exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_IssuanceOfCommonStockPursuantToPreFundedWarrantExercise', window );">Issuance of common stock pursuant to pre-funded warrant exercise, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_VestingOfSharesOfCommonStockSubjectToRepurchaseOneShares', window );">Vesting Of Shares Of Common Stock Subject To Repurchase, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_VestingOfSharesOfCommonStockSubjectToRepurchaseOne', window );">Vesting Of Shares Of Common Stock Subject To Repurchases</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">28,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_AvailableForSaleDebtSecuritiesNetUnrealizedGain', window );">Unrealized gain on marketable securities available-for-sale, net</a></td>
<td class="num">(377)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(377)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(119,947)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(119,947)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2025</a></td>
<td class="nump">$ 259,177<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 630,037<span></span>
</td>
<td class="nump">$ 393<span></span>
</td>
<td class="num">$ (371,258)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,706,357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_AvailableForSaleDebtSecuritiesNetUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available for sale debt securities net unrealized gain.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_AvailableForSaleDebtSecuritiesNetUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_ExchangeOfCommonStockForPre-FundedWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exchange of Common Stock for Pre-Funded Warrants Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_ExchangeOfCommonStockForPre-FundedWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_IssuanceOfCommonStockPursuantToPreFundedWarrantExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance Of Common Stock Pursuant To Pre Funded Warrant Exercise</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_IssuanceOfCommonStockPursuantToPreFundedWarrantExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_IssuanceOfCommonStockPursuantToPreFundedWarrantExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance Of Common Stock Pursuant To Pre Funded Warrant Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_IssuanceOfCommonStockPursuantToPreFundedWarrantExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_IssuanceOfCommonStockUnderBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of Common Stock Under Benefit Plans</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_IssuanceOfCommonStockUnderBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_IssuanceOfCommonStockUnderBenefitPlansShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock shares under benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_IssuanceOfCommonStockUnderBenefitPlansShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_IssuanceOfPreFundedWarrantsUnderPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance Of Pre Funded Warrants Under Private Placement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_IssuanceOfPreFundedWarrantsUnderPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_VestingOfSharesOfCommonStockSubjectToRepurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vesting of shares of common stock subject to repurchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_VestingOfSharesOfCommonStockSubjectToRepurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_VestingOfSharesOfCommonStockSubjectToRepurchaseOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vesting Of Shares Of Common Stock Subject To Repurchase One</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_VestingOfSharesOfCommonStockSubjectToRepurchaseOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_VestingOfSharesOfCommonStockSubjectToRepurchaseOneShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vesting Of Shares Of Common Stock Subject To Repurchase One, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_VestingOfSharesOfCommonStockSubjectToRepurchaseOneShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_VestingOfSharesOfCommonStockSubjectToRepurchaseShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vesting Of Shares Of Common Stock Subject To Repurchase, Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_VestingOfSharesOfCommonStockSubjectToRepurchaseShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Stockholders' Equity (Parenthetical)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments Of Stock Issuance Costs</a></td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments Of Stock Issuance Costs</a></td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (119,947)<span></span>
</td>
<td class="num">$ (86,481)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation</a></td>
<td class="nump">546<span></span>
</td>
<td class="nump">519<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">28,006<span></span>
</td>
<td class="nump">22,801<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_AccretionOnMarketableSecuritiesNet', window );">Accretion on marketable securities, net</a></td>
<td class="num">(2,119)<span></span>
</td>
<td class="num">(5,884)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther', window );">Prepaid expenses and other assets</a></td>
<td class="num">(5,080)<span></span>
</td>
<td class="num">(169)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable, accrued expenses and other liabilities</a></td>
<td class="nump">3,369<span></span>
</td>
<td class="num">(744)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet', window );">Right-of-use assets and lease liabilities, net</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">184<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(95,142)<span></span>
</td>
<td class="num">(69,774)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(101,254)<span></span>
</td>
<td class="num">(263,624)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Maturities of marketable securities</a></td>
<td class="nump">173,858<span></span>
</td>
<td class="nump">165,885<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(141)<span></span>
</td>
<td class="num">(664)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">72,463<span></span>
</td>
<td class="num">(98,403)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_ProceedsFromIssuanceOfCommonStockUnderBenefitPlans', window );">Proceeds from issuances of common stock under benefit plans</a></td>
<td class="nump">8,100<span></span>
</td>
<td class="nump">2,557<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromPrivatePlacement', window );">Proceeds from issuance of common stock and pre-funded warrants from Private Placement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_PaymentsOfIssuanceCostsForCommonStockAndPreFundedWarrantsFromPrivatePlacement', window );">Payments of issuance costs for common stock and pre-funded warrants from Private Placement</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(420)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">8,100<span></span>
</td>
<td class="nump">202,137<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net cash increase (decrease) for the period</a></td>
<td class="num">(14,579)<span></span>
</td>
<td class="nump">33,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of the period</a></td>
<td class="nump">92,966<span></span>
</td>
<td class="nump">59,006<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of the period</a></td>
<td class="nump">78,387<span></span>
</td>
<td class="nump">92,966<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of cash, cash equivalents and restricted cash to the balance sheet</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">77,387<span></span>
</td>
<td class="nump">91,966<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">78,387<span></span>
</td>
<td class="nump">92,966<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities</a></td>
<td class="nump">68<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_VestingOfOptionsEarlyExercisedSubjectToRepurchase', window );">Vesting of options early exercised subject to repurchase</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_ReceivableFromExerciseOfStockOptionsIncludedInPrepaidExpensesAndOtherCurrentAssets', window );">Receivable from exercise of stock options included in prepaid expenses and other current assets</a></td>
<td class="nump">$ 241<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_AccretionOnMarketableSecuritiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accretion on marketable securities, net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_AccretionOnMarketableSecuritiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in right of use assets and lease liabilities net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_PaymentsOfIssuanceCostsForCommonStockAndPreFundedWarrantsFromPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments of issuance costs for common stock and pre-funded warrants from Private Placement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_PaymentsOfIssuanceCostsForCommonStockAndPreFundedWarrantsFromPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock and pre-funded warrants from Private Placement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_ProceedsFromIssuanceOfCommonStockUnderBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Issuance of Common Stock Under Benefit Plans</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_ProceedsFromIssuanceOfCommonStockUnderBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_ReceivableFromExerciseOfStockOptionsIncludedInPrepaidExpensesAndOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Receivable From Exercise of Stock Options Included in Prepaid Expenses and Other Current Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_ReceivableFromExerciseOfStockOptionsIncludedInPrepaidExpensesAndOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_VestingOfOptionsEarlyExercisedSubjectToRepurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vesting of options early exercised subject to repurchase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_VestingOfOptionsEarlyExercisedSubjectToRepurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpensesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (119,947)<span></span>
</td>
<td class="num">$ (86,481)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Rule 10b5-1 Trading Plans</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, our officers (as defined in Rule 16a-1(f) of the Exchange Act) and directors may enter into Rule 10b5-1 or non-Rule 10b5-1 trading arrangements (as each such term is defined in Item 408 of Regulation S-K). During the three months ended December 31, 2025, our officers and directors took the following actions with respect to such trading arrangements:</span></p>
     <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
      <tr style="visibility:collapse;">
       <td style="width:22.825%;box-sizing:content-box;"></td>
       <td style="width:1.52%;box-sizing:content-box;"></td>
       <td style="width:12.182%;box-sizing:content-box;"></td>
       <td style="width:1.52%;box-sizing:content-box;"></td>
       <td style="width:10.002%;box-sizing:content-box;"></td>
       <td style="width:1.26%;box-sizing:content-box;"></td>
       <td style="width:12.322%;box-sizing:content-box;"></td>
       <td style="width:1.52%;box-sizing:content-box;"></td>
       <td style="width:10.502%;box-sizing:content-box;"></td>
       <td style="width:1.52%;box-sizing:content-box;"></td>
       <td style="width:1%;box-sizing:content-box;"></td>
       <td style="width:10.202%;box-sizing:content-box;"></td>
       <td style="width:1%;box-sizing:content-box;"></td>
       <td style="width:1.52%;box-sizing:content-box;"></td>
       <td style="width:11.102%;box-sizing:content-box;"></td>
      </tr>
      <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading Arrangement</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      </tr>
      <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name and Title</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Action</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Rule 10b5-1</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">*</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Non-Rule 10b5-1**</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total Shares Authorized to be Sold***</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Expiration Date</span></p></td>
      </tr>
      <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      </tr>
      <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
       <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Todd Harris</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br/></span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">President, Chief Executive Officer and Director</span></span></p></td>
       <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Terminate </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
       <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11/21/2025</span></span></p></td>
       <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></span></p></td>
       <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">315,000</span></p></td>
       <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12/31/2026</span></span></p></td>
      </tr>
      <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
       <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Alan Fuhrman</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br/></span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer</span></span></p></td>
       <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Terminate </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
       <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11/21/2025</span></span></p></td>
       <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></span></p></td>
       <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80,000</span></p></td>
       <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7/31/2026</span></span></p></td>
      </tr>
     </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* Intended to satisfy the affirmative defense of Rule 10b5-1(c)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">** Not intended to satisfy the affirmative defense of Rule 10b5-1(c)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">*** Represents the maximum number of shares that may be sold pursuant to the 10b5-1 arrangement. The number of shares sold is dependent on the satisfaction of certain conditions as set forth in the written plan and the satisfaction of applicable vesting conditions of equity awards.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) Trading arrangement was originally adopted on 11/4/2024.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2) Trading arrangement was originally adopted on 11/5/2024.</span></p><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=tyra_ToddHarrisMember', window );">Todd Harris [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Todd Harris<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">President, Chief Executive Officer and Director<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrTerminationDate', window );">Termination Date</a></td>
<td class="text">11/21/2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">12/31/2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">315,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=tyra_AlanFuhrmanMember', window );">Alan Fuhrman [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Alan Fuhrman<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Financial Officer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrTerminationDate', window );">Termination Date</a></td>
<td class="text">11/21/2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">7/31/2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">80,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrSecuritiesAggAvailAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrSecuritiesAggAvailAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrTerminationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrTerminationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=tyra_ToddHarrisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=tyra_ToddHarrisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=tyra_AlanFuhrmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=tyra_AlanFuhrmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management, Strategy, and Governance<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><p id="item_1c_cybersecurity" style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1C. Cybersecurity.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cybersecurity Risk Management and Strategy</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have developed and implemented a cybersecurity risk management program intended to protect the confidentiality, integrity, and availability of our critical systems and information. We implement reasonable administrative, technical and procedural safeguards to manage cybersecurity risks, including enforcing single sign-on or multi-factor authentication where supported or appropriate. We </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">engage</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">third-party cybersecurity experts</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to assess the security of our network. In addition, we engage a third-party to perform internal audits of our IT General Controls (ITGCs).</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We design and assess our program based on the National Institute of Standards and Technology Cybersecurity Framework (NIST CSF).  This does not imply that we meet any particular technical standards,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">specifications, or requirements, only that we use the NIST CSF as a guide to help us identify, assess, and manage cybersecurity risks relevant to our business.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity risk management program is designed to be </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">integrated</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> into our overall risk management program, and shares common methodologies, reporting channels and governance processes that apply across the risk management program to other legal, compliance, strategic, operational, and financial risk areas.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Key elements of our cybersecurity risk management program include but are not limited to the following:</span></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">risk assessments designed to help identify material risks from cybersecurity threats to our critical systems and information;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a security team principally responsible for managing (i) our cybersecurity risk assessment processes, (ii) our security controls, and (iii) our response to cybersecurity incidents;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the use of external service providers, where appropriate, to assess, test or otherwise assist with aspects of our security processes;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cybersecurity awareness training of our employees, including incident response personnel and senior management; </span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a cybersecurity incident response plan that includes procedures for responding to cybersecurity incidents; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a third-party risk management process for key service providers, based on our assessment of their criticality to our operations and respective risk profile, suppliers, and vendors that have access to our critical systems and information.</span></div></div></div><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have not identified risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">materially affected</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> us, including our operations, business strategy, results of operations, or financial condition. We face risks from cybersecurity threats that, if realized, are reasonably likely to materially affect us, including our operations, business strategy, results of operations, or financial condition. See &#8220;Risk Factors &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our information technology systems, or those of any of our CROs, other contractors or consultants or potential future collaborators, may fail or suffer security breaches, which could result in a material disruption of our product development programs, harm our reputation, significant fines, penalties and liability and loss of customers or sales.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cybersecurity Governance</span></p><div><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors considers cybersecurity risk as part of its risk oversight function and has delegated to the audit committee (the Committee) oversight of cybersecurity risks, including oversight of management&#8217;s implementation of our cybersecurity risk management program</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Committee receives quarterly reports from management on our cybersecurity risks. In addition, management updates the Committee where it deems appropriate, regarding any cybersecurity incidents it considers to be significant or potentially significant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Committee reports to the full board of directors regarding its activities, including those related to cybersecurity. The full board of directors may also periodically receive briefings from management on our cyber risk management program</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Board members may receive presentations on cybersecurity topics from our Chief Financial Officer (CFO), internal security staff or external experts as part of the board of director</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s continuing education on topics that impact public companies.</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Our IT Senior Director, is primarily responsible for assessing and managing our material risks from cybersecurity threats.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IT Senior Director has primary responsibility for our </span></span><span style=""></span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">overall </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cybersecurity risk management program and supervises our retained external cybersecurity consultants.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our IT Senior Director has over 25 years of IT and cybersecurity experience.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our IT Senior Director takes steps to stay informed about and monitor efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which may include briefings from internal security personnel; threat intelligence and other information obtained from governmental, public or private sources, including external consultants engaged by us; and alerts and reports produced by security tools deployed in our information technology environment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity risk management program is designed to be </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">integrated</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> into our overall risk management program, and shares common methodologies, reporting channels and governance processes that apply across the risk management program to other legal, compliance, strategic, operational, and financial risk areas.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Key elements of our cybersecurity risk management program include but are not limited to the following:</span></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">risk assessments designed to help identify material risks from cybersecurity threats to our critical systems and information;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a security team principally responsible for managing (i) our cybersecurity risk assessment processes, (ii) our security controls, and (iii) our response to cybersecurity incidents;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the use of external service providers, where appropriate, to assess, test or otherwise assist with aspects of our security processes;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cybersecurity awareness training of our employees, including incident response personnel and senior management; </span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a cybersecurity incident response plan that includes procedures for responding to cybersecurity incidents; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a third-party risk management process for key service providers, based on our assessment of their criticality to our operations and respective risk profile, suppliers, and vendors that have access to our critical systems and information.</span></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors considers cybersecurity risk as part of its risk oversight function and has delegated to the audit committee (the Committee) oversight of cybersecurity risks, including oversight of management&#8217;s implementation of our cybersecurity risk management program</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Committee receives quarterly reports from management on our cybersecurity risks. In addition, management updates the Committee where it deems appropriate, regarding any cybersecurity incidents it considers to be significant or potentially significant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Committee reports to the full board of directors regarding its activities, including those related to cybersecurity. The full board of directors may also periodically receive briefings from management on our cyber risk management program</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Board members may receive presentations on cybersecurity topics from our Chief Financial Officer (CFO), internal security staff or external experts as part of the board of director</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s continuing education on topics that impact public companies.</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Our IT Senior Director, is primarily responsible for assessing and managing our material risks from cybersecurity threats.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IT Senior Director has primary responsibility for our </span></span><span style=""></span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">overall </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cybersecurity risk management program and supervises our retained external cybersecurity consultants.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our IT Senior Director has over 25 years of IT and cybersecurity experience.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our IT Senior Director takes steps to stay informed about and monitor efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which may include briefings from internal security personnel; threat intelligence and other information obtained from governmental, public or private sources, including external consultants engaged by us; and alerts and reports produced by security tools deployed in our information technology environment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors considers cybersecurity risk as part of its risk oversight function and has delegated to the audit committee (the Committee) oversight of cybersecurity risks, including oversight of management&#8217;s implementation of our cybersecurity risk management program</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Committee receives quarterly reports from management on our cybersecurity risks. In addition, management updates the Committee where it deems appropriate, regarding any cybersecurity incidents it considers to be significant or potentially significant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Committee reports to the full board of directors regarding its activities, including those related to cybersecurity. The full board of directors may also periodically receive briefings from management on our cyber risk management program</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Our IT Senior Director, is primarily responsible for assessing and managing our material risks from cybersecurity threats.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IT Senior Director has primary responsibility for our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">overall </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cybersecurity risk management program and supervises our retained external cybersecurity consultants.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our IT Senior Director has over 25 years of IT and cybersecurity experience.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our IT Senior Director takes steps to stay informed about and monitor efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which may include briefings from internal security personnel; threat intelligence and other information obtained from governmental, public or private sources, including external consultants engaged by us; and alerts and reports produced by security tools deployed in our information technology environment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Summary of Significant Accounting Policies</a></td>
<td class="text"><p id="note_1" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. Orga</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nization and Summary of Significant Accounting Policies</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Organization</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tyra </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Biosciences, Inc. (the Company) was incorporated in the state of Delaware on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">August 2, 2018</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The Company&#8217;s in-house precision medicine platform, SN&#197;P, enables rapid and precise drug design through iterative molecular SN&#197;Pshots that help predict which product candidates may demonstrate the highest potency, selectivity and tolerability. The Company&#8217;s focus is on applying its accelerated small molecule drug discovery engine to develop therapies in targeted oncology and genetically defined conditions</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since its inception, the Company has devoted substantially all of its resources to research and development activities, business planning, establishing and maintaining its intellectual property portfolio, hiring personnel, raising capital, and providing general and administrative support for these operations. It has incurred losses and negative cash flows from operations since commencement of its operations. The Company had an accumulated deficit of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">371.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and cash, cash equivalents and marketable securities of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">256.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of December 31, 2025. From its inception through December 31, 2025, the Company has financed its operations primarily through the sale of common stock, private placements of its convertible preferred stock, and the issuance of common stock and pre-funded common stock warrants through a private placement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As the Company continues its expansion, it may seek additional financing and/or strategic investments. However, there can be no assurance that any additional financing or strategic investments will be available to the Company on acceptable terms, if at all. If events or circumstances occur such that the Company does not obtain additional funding, it will most likely be required to reduce its plans and/or certain discretionary spending, which could have a material adverse effect on the Company&#8217;s ability to achieve its intended business objectives. Management believes that it has sufficient working capital on hand to fund operations through at least the next twelve months from the date of issuance of these financial statements.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of Presentation</span></p></div><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying financial statements have been prepared in accordance with generally accepted accounting principles in the United States (GAAP). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) promulgated by the Financial Accounting Standards Board (FASB).</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Summary of Significant Accounting Policies</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates and assumptions made in the accompanying financial statements include, but are not limited to, the valuation of share-based awards, the valuation of deferred tax assets and income tax uncertainties, accruals for research and development activities, and incremental borrowing rate (IBR) for right-of-use (ROU) assets. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable. Actual results may differ from those estimates or assumptions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments which potentially subject the Company to a significant concentration of credit risk consist of cash, cash equivalents and marketable securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the nature of the instruments held in the depository institutions.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents primarily represent funds invested in readily available money market accounts. As of December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had cash and cash equivalents balances deposited at major financial institutions.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Marketable Securities</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketable securities consist of debt securities of government-sponsored entities. These securities are classified as available-for sale, as the sale of such securities may be required prior to their maturity. Available-for-sale securities are recorded at fair value, with the related unrealized gains and losses included in accumulated other comprehensive income or loss and included as a separate component of stockholders&#8217; equity. The amortized cost of available-for-sale securities reflects amortization of premiums and accretion of discounts to maturity. Premiums and discounts on debt securities are amortized or accreted into interest and other income, net. The Company classifies investments in marketable debt securities as current assets, regardless of the stated maturity date, which may be beyond one year from the current balance sheet date. Short-term classification reflects management&#8217;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s view that the entire portfolio is available, and the Company may use the proceeds from sales of these investments to fund current operations, as necessary.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Allowance for Credit Losses</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company regularly reviews its portfolio for declines in fair value. For investments in an unrealized loss position, the Company assesses whether the decline is based on credit losses or other factor. As part of this assessment, the Company considers the cause of the impairment, the creditworthiness of the security issuers, current market conditions, the number of securities in an unrealized loss position, the severity of the losses, whether it will be required or will intend to sell the investment before recovery of its amortized cost basis. If fair value decline is determined to be due to a credit-related factor, the amortized cost basis is written down to fair value through net loss. If fair value decline is not due to credit-related factors, a loss is recorded in other comprehensive income or loss. The Company recognizes an allowance for credit losses up to the amount of the unrealized loss when appropriate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not measure an allowance for credit losses for accrued interest receivables. For the purposes of identifying and measuring an impairment, accrued interest is excluded from both the fair value and amortized costs basis of the investment. Uncollectible accrued interest receivables associated with an impaired marketable security are reversed against interest income in a timely manner upon identification of the impairment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value Measurements</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company measures cash equivalents and available-for-sale debt securities at fair value. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. Therefore, fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability. Fair value is affected by a number of factors, including the type of asset or liability, the characteristics specific to the asset or liability and the state of the marketplace, including the existence and transparency of transactions between market participants. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:6.667%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Money market funds are highly liquid investments and are classified as Level 1. The pricing information for these assets is readily available and can be independently validated as of the measurement date. Available-for-sale debt securities, including U.S. Treasury securities and U.S. Agency bonds are classified as Level 2. These securities are valued using fair value from third-party pricing services, which may use observable inputs based on real-time trade data for similar assets, broker/dealer quotes, bids and/or offers and other observable inputs. The Company validates valuations obtained from third-party pricing services by understanding the models used and obtaining market values from independent sources.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Cash</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted cash is comprised of cash that is restricted as to its withdrawal or use under the terms of certain contractual agreements. Restricted cash as of December 31, 2025 and 2024 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which consisted of collateral for letters of credit related to the Company&#8217;s operating leases.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Property and Equipment</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment is stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets (generally </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_de6e2adb-217c-46f8-87ab-7f9f75f3c64f;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seven years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or the remaining term of the lease).</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Impairment of Long-Lived Assets</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for the impairment of long-lived assets by reviewing these assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group to be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted-cash-flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recognize impairment losses for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></div><div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accrued Research and Development Expenses</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses consist of external and internal costs associated with the Company&#8217;s research and development activities, including its discovery and research efforts and the preclinical and clinical development of its product candidates. Research and development costs are expensed in the period incurred.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company has entered into various research and development contracts with clinical research organizations, clinical manufacturing organizations, clinical sites and other vendors and consultants. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and payments made in advance of or after the performance are reflected in the accompanying balance sheets as prepaid expenses or accrued liabilities, respectively. The Company records accruals for estimated costs incurred for ongoing research and development activities. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs. The Company holds discussions with applicable personnel and outside service providers as to the progress of clinical trials, or the services completed. Significant judgments and estimates may be made in determining the prepaid or accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. Nonrefundable advance payments for goods and services, including fees for process</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">development, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">are deferred and recognized as expenses in the period that the related goods are consumed or services are performed.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent Costs</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company expenses all costs as incurred in connection with patent applications (including direct application fees, and the legal and consulting expenses related to making such applications) and such costs are included in general and administrative expenses in the statements of operations and comprehensive loss.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has operating leases for office and lab space. At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, the Company records the associated lease liability and corresponding ROU asset upon commencement of the lease using the implicit rate or a discount rate based on a credit-adjusted secured borrowing rate commensurate with the term of the lease. The Company evaluates leases at their inception to determine if they are to be accounted for as an operating lease or a finance lease.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating lease assets represent a right to use an underlying asset for the lease term and operating lease liabilities represent an obligation to make lease payments arising from the lease. Operating lease liabilities with a term greater than one year and their corresponding ROU assets are recognized on the balance sheet at the commencement date of the lease based on the present value of lease payments over the expected lease term. The Company excludes short-term leases, if any, having initial terms of 12 months or less at lease commencement as an accounting policy election.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain adjustments to the ROU assets may be required for items such as payments made at or before the commencement date, initial direct costs paid or lease incentives received. As the Company&#8217;s leases do not typically provide an implicit rate, the Company utilizes the appropriate IBR, determined as the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term and in a similar economic environment. Lease cost is recognized on a straight-line basis over the lease term and variable lease payments are recognized as operating expenses in the period in which the obligation for those payments is incurred. Variable lease payments primarily include common area maintenance, utilities, real estate taxes, insurance, and other operating costs that are passed on from the lessor in proportion to the space leased by the Company. In measuring the ROU assets and lease liabilities, the Company has elected to combine lease and non-lease components.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating ROU assets are reflected in right-of-use assets in the accompanying balance sheets. Operating lease liabilities are reflected in lease liabilities, current and noncurrent in the accompanying balance sheets.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Common Stock Warrants</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common stock warrants are classified as either a liability or equity, based on an assessment of specific terms and applicable authoritative guidance in ASC 480, Distinguishing Liabilities from Equity (ASC 480) and ASC 815, Derivatives and Hedging (ASC 815). The Company considers whether the warrants are freestanding financial instruments, whether they meet the definition of a liability pursuant to ASC 480, and whether they meet all of the requirements for equity classification under ASC 815. This assessment is performed at the time of warrant issuance and re-assessed as of each subsequent quarterly balance sheet date, while the warrants are outstanding.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-Based Compensation</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense represents the cost of the grant date fair value of employee, officer, director and non-employee equity awards, estimated in accordance with the applicable accounting guidance, and, for those awards subject only to service conditions, recognized on a straight-line basis over the vesting period. The vesting period generally approximates the expected service period of the awards. The Company recognizes stock-based compensation expense for awards with performance conditions when it is probable that the condition will be</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">met, and the award will vest. If the achievement of performance conditions is no longer deemed probable, previously recognized compensation cost is reversed. For awards with performance and service conditions, the Company begins recording share-based compensation when achieving the performance criteria is probable and recognizes the costs using the accelerated attribution method. The Company recognizes forfeitures as they occur.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of stock options is estimated using a Black-Scholes valuation model on the date of grant. This method requires certain assumptions to be used as inputs, such as the fair value of the underlying common stock, expected term of the option before exercise, expected volatility of the Company&#8217;s common stock, risk-free interest rate and expected dividend. Options granted have a maximum contractual term of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ten years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company has limited historical stock option activity and therefore estimates the expected term of stock options granted using the simplified method, which represents the arithmetic average of the original contractual term of the stock option and its weighted-average vesting term. The expected volatility of stock options is estimated based on the average historical volatilities of common stock of comparable publicly traded companies and the Company</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s own volatility. The comparable companies are chosen based on their size and stage in the life cycle. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available. The risk-free interest rates used are based on the U.S. Treasury yield in effect at the time of grant for zero-coupon U.S. treasury notes with maturities approximately equal to the expected term of the stock options. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has historically not declared or paid any dividends and does not currently expect to do so in the foreseeable future, and therefore, has estimated the dividend yield to be </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">zero</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Commitments and Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes a liability with regard to loss contingencies when it believes it is probable a liability has been incurred, and the amount can be reasonably estimated. If some amount within a range of loss appears at the time to be a better estimate than any other amount within the range, the Company accrues that amount. When no amount within the range is a better estimate than any other amount, the Company accrues the minimum amount in the range.</span></p></div><div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the statement of operations in the period that includes the enactment date.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025 and 2024, the Company maintained valuation allowances against its deferred tax assets as the Company concluded it had not met the &#8220;more likely than not&#8221; to be realized threshold. Changes in the valuation allowance when they are recognized in the provision for income taxes may result in a change in the estimated annual effective tax rate.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records uncertain tax positions on the basis of a two-step process whereby (1) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability. As of December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> accrued interest or penalties.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comprehensive Loss</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprehensive loss consists of two components: net loss and other comprehensive income or loss. Other comprehensive income (loss) refers to gains or losses that are recorded as an element of stockholders&#8217; equity but are excluded from net loss. The Company&#8217;s other comprehensive income (loss) consists of unrealized gains and losses on marketable securities.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Loss Per Share</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock and common stock equivalents outstanding for the period. Common stock equivalents are only included when their effect is dilutive. Pre-funded warrants are considered outstanding for the purposes of computing basic and diluted net loss per share because shares may be issued for little or no additional consideration and are fully vested and exercisable after the original issuance date of the pre-funded warrant. The Company&#8217;s potentially dilutive securities include unvested common stock upon early exercise of stock options, outstanding stock options under the Company&#8217;s equity incentive plan, and estimated shares purchasable under the employee stock purchase plan, and have been excluded from the computation of diluted net loss per share as their inclusion would be anti-dilutive. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#8217;s net loss position.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Related Parties</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transactions between related parties are considered to be related party transactions even though they may not be given accounting recognition. FASB ASC 850, Related Party Disclosures (ASC 850) requires that transactions with related parties that would make a difference in decision making shall be disclosed so that users of the financial statements can evaluate their significance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Capitalized Software Implementation Costs</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company capitalizes certain implementation costs incurred under a cloud computing arrangement that is a service contract. Costs incurred during the application development stage related to the implementation of the hosting arrangement are capitalized and included within prepaid and other current assets, and other long-term assets on the accompanying balance sheets. Amortization of capitalized implementation costs is recognized on a straight-line basis over the term of the associated hosting arrangement when it is ready for its intended use. Costs related to preliminary project activities and post-implementation activities are expensed as incurred.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures.&#8221; ASU 2023-09 requires disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation as well as information on income taxes paid. ASU 2023-09 is effective for public entities with annual periods beginning after December 15, 2024, with early adoption permitted. The Company adopted this standard prospectively for the period ending December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The adoption impacted the disclosures and did not impact the financial statements. See Note 8, Income Taxes, for disclosures related to the adoption of ASU 2023-09.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Issued Accounting Pronouncements Not Yet Adopted</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03, "</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">". In January 2025, the FASB issued ASU 2025-01, "</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">", to clarify the effective date of ASU 2024-03. These amendments are intended to provide more information about certain costs and expenses on an interim and annual basis. The amendments are effective for annual periods beginning after December 15, 2026 and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The new standards are expected to be applied prospectively, but retrospective application is permitted. The Company is currently evaluating the impact on its financial statements and related disclosures.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480922/205-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481034/205-10-S45-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. Fair Value Measurements</span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables show the Company</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;s cash equivalents and marketable securities measured at fair value as of December 31, 2025 and 2024 (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:37.932%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.297%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.177000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.297%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.297%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="11" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Quoted prices in active markets for identical assets (Level 1)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant other observable inputs (Level 2)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant unobservable inputs (Level 3)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Money market funds</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54,444</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54,444</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">133,264</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">133,264</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;U.S. government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,352</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,352</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Total marketable securities</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">178,616</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">178,616</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Total</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">233,060</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54,444</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">178,616</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="text-indent:9.067%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:37.932%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.297%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.177000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.297%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.297%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="11" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Quoted prices in active markets for identical assets (Level 1)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant other observable inputs (Level 2)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant unobservable inputs (Level 3)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Money market funds</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">69,698</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">69,698</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">122,980</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">122,980</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;U.S. government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">126,495</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">126,495</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Total marketable securities</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">249,475</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">249,475</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Total</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">319,173</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">69,698</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">249,475</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The carrying amounts of the Company&#8217;s prepaid and other current assets, accounts payable, and accrued and other current liabilities approximate fair value due to their short maturities. None of the Company&#8217;s non-financial assets or liabilities are recorded at fair value on a non-recurring basis. There were no transfers between Levels 1, 2 or 3 for any of the periods presented.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Marketable Securities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3. Marketable Securities</span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables summarize the Company</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;s marketable securities (see below and Note 2) accounted for as available-for-sale securities (in thousands, except years):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:32.323%;box-sizing:content-box;"></td>
         <td style="width:14.141%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.141%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.141%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.121%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.131%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="12" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Maturity <br/>(in years)</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized cost</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized gains</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized losses</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated fair value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less than one</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107,324</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">223</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107,547</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less than one</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,215</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">137</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,352</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1-2</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,684</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,717</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">178,223</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">393</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">178,616</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="text-indent:9.067%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:32%;box-sizing:content-box;"></td>
         <td style="width:14%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="12" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Maturity <br/>(in years)</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized cost</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized gains</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized losses</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated fair value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less than one</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">77,990</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">210</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">78,197</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less than one</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,153</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">189</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,333</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1-2</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,547</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">239</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,783</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1-2</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,015</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">159</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,162</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">248,705</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">797</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">249,475</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents fair values and gross unrealized losses for those available-for-sale securities that were in an unrealized loss position, aggregated by category and the length of time that the securities have been in a continuous loss position (in thousands):</span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;">
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:23.071%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.836%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.836%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.836%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.836%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.836%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.279%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.836%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></td>
         <td colspan="22" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Less than 12 months</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">12 months or longer</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized losses</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized losses</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized losses</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,033</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,033</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,891</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,891</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,924</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,924</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table></div><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, there were no available-for-sale securities in an unrealized loss position.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The amortized cost and fair value of marketable securities excludes $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of accrued interest receivable as of December 31, 2025 and 2024, respectively. Accrued interest receivable is included in prepaid expenses and other current assets on the Company's balance sheets. The Company has not written off any accrued interest receivables for the years ended December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalent, and debt and equity securities, including realized and unrealized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4. Accrued Expenses and Other Current Liabilities</span></p><div style="font-size:11pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities consisted of the following (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:67.313%;box-sizing:content-box;"></td>
         <td style="width:1.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.843%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.843%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued payroll and other employee benefits</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,533</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,451</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued research and development expenses</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,840</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,612</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued legal and professional fees</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">316</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">296</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued other general and administrative fees</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">755</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">233</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,444</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,592</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5. Stockholders</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Equity</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common stock reserved for future issuance consisted of the following:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:67.313%;box-sizing:content-box;"></td>
         <td style="width:1.02%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.323%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.02%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.323%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock options granted and outstanding</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,617,445</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,462,129</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares available for future issuance under the 2021<br/>&#160;&#160;&#160;Incentive Award Plan</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,528,992</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,051,588</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares available for future issuance under the <br/>&#160;&#160;&#160;2021 Employee Stock Purchase Plan</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,951,705</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,491,195</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pre-funded warrants issued and outstanding</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,381,950</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,382,187</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total common stock reserved for future issuance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,480,092</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,387,099</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 3, 2022, the Company entered into an ATM Sales Agreement (the 2022 Sales Agreement) with Virtu Americas LLC (the 2022 Agent), under which the Company could have, from time to time, sold shares of its common stock having an aggregate offering price of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">150.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, in &#8220;at the market&#8221; offerings through the 2022 Sales Agent. The 2022 Agent would have received a commission from the Company of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the gross proceeds of any shares of common stock sold under the 2022 Sales Agreement. No shares of common stock were issued and sold pursuant to the 2022 Sales Agreement. The Company terminated the 2022 Sales Agreement in May 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 8, 2025, the Company entered into a Sales Agreement (the 2025 Sales Agreement)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> with TD Securities (USA) LLC (the 2025 Sales Agent), under which the Company may, from time to time, sell shares of its common stock having an aggregate offering price of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">150.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, in &#8220;at the market&#8221; offerings through the 2025 Sales Agent. Sales of the shares of common stock, if any, will be made at prevailing market prices at the time of sale, or as otherwise agreed with the 2025 Sales Agent. The 2025 Sales Agent will receive a commission from the Company of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the gross proceeds of any shares of common stock sold under the 2025 Sales Agreement. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025, no shares of common stock had been issued and sold pursuant to the 2025 Sales Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 1, 2024, the Company entered into a securities purchase agreement for a private placement of </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">9,286,023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company's common stock at a price of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">13.01</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share (the 2024 Private Placement). The 2024 Private Placement also included pre-funded warrants (the 2024 Pre-Funded Warrants) to purchase an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">6,087,230</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock at a purchase price of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">13.009</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per pre-funded warrant. Each pre-funded warrant has an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share of common stock, is immediately exercisable on the date of issuance and will not expire. The 2024 Private Placement closed on February 6, 2024 and the Company received gross proceeds of approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">200.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, before deducting offering expenses of $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the 2024 Private Placement, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">4,780,846</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock and pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">2,243,737</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock to related parties, resulting in aggregate gross proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">91.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 19, 2024, the Company filed a registration statement on Form S-3 with the SEC registering the resale of the shares of common stock issued, or underlying the pre-funded warrants issued, in the 2024 Private Placement. The 2024 Pre-funded Warrants did not meet the characteristics of a liability or a derivative and are classified within stockholders&#8217; equity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 18, 2024, the Company entered into an exchange agreement with certain of the Company&#8217;s stockholders, who were related parties to the Company at the time of the exchange. Pursuant to the exchange agreement, </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">3,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock were exchanged for pre-funded warrants to acquire an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">3,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock (each of such pre-funded warrants an Exchange Warrant and collectively the Exchange Warrants, and such exchanges of common stock for Exchange Warrants collectively the Exchange). Each Exchange Warrant has an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share of common stock, is immediately exercisable on the date of issuance and will not expire. No cash was exchanged related to the transaction. The Exchange closed on October 22, 2024. The Exchange Warrants did not meet the characteristics of a liability or a derivative and are classified within stockholders</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217; equity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2025, </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">2,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Exchange Warrants and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">237</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the 2024 Pre-Funded Warrants were exercised in cashless transactions, which resulted in an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">2,000,069</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock being issued. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,381,950</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> pre-funded warrants remained available for exercise, including </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Exchange Warrants and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,381,950</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 2024 Pre-Funded Warrants.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans and Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">Equity Incentive Plans and Stock-Based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6. Equity Incentive Plans and Stock-Based Compensation</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2021 Incentive Award Plan</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2021, the Company&#8217;s Board of Directors adopted, and its stockholders approved, the 2021 Incentive Award Plan (the 2021 Plan). Upon the adoption of the 2021 Plan, the Company restricted the grant of future equity awards under the 2020 Equity Incentive Plan (the 2020 Plan).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 2021 Plan provides for the grants of stock options and other equity-based awards to employees, non-employee directors, and consultants of the Company. Shares that expire, terminate or are cancelled under the 2020 Plan are added back to the 2021 Plan share reserve. In addition, the number of shares of the Company&#8217;s common stock available for issuance under the 2021 Plan automatically increases on the first day of each fiscal year, beginning with the Company&#8217;s 2022 fiscal year, in an amount equal to the lesser of (1) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the outstanding shares of the Company&#8217;s common stock on the last day of the immediately preceding fiscal year, or (2) such smaller amount as determined by the Company&#8217;s Board of Directors. The Company issues new shares of common stock upon exercise of options. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,528,992</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares were available for future grant under the 2021 Plan.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A summary of the Company&#8217;s stock option activity for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 was as follows (in thousands, except share and per share data and years):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:47.94%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.2%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.2%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.420000000000002%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.2%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.9%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.2%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.940000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Options</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-Average<br/>Exercise<br/>Price per Share</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-Average<br/>Remaining<br/>Contractual Term</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Intrinsic Value</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2024</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,462,129</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.43</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.6</span></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,798</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,029,190</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.08</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">904,993</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.72</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited and expired</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">968,881</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16.31</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2025</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,617,445</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.58</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.0</span></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">186,669</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercisable at December 31, 2025</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,300,582</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.39</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.8</span></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93,903</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested and expected to vest as of December 31, 2025</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,617,445</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.58</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.0</span></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">186,669</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Employee Stock Purchase Plan</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2021, the Company&#8217;s Board of Directors adopted, and its stockholders approved, the 2021 Employee Stock Purchase Plan (ESPP). </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ESPP permits eligible employees who elect to participate in an offering under the ESPP to have up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of their eligible earnings withheld, subject to certain limitations, to purchase shares of common stock pursuant to the ESPP. The price of common stock purchased under the ESPP is equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the lower of the fair market value of the common stock at the commencement date of each offering period or the relevant date of purchase. </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,951,705</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares available for future purchase under the ESPP.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-Based Compensation Expense</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company estimated the fair value of stock options using the Black-Scholes valuation model. The Company accounts for forfeitures of options when they occur. Previously recognized compensation expense for an unvested award is reversed in the period that the award is forfeited.</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The fair value of stock options was estimated using the following assumptions: </span></span><span style=""></span></p><div style="font-size:10pt;font-family:Times New Roman;">
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:58.14%;box-sizing:content-box;"></td>
         <td style="width:1.7%;box-sizing:content-box;"></td>
         <td style="width:18.92%;box-sizing:content-box;"></td>
         <td style="width:1.7%;box-sizing:content-box;"></td>
         <td style="width:18.54%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free rate of interest</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.8</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.4</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.5</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.6</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="background-color:#ffffff;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.1</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.1</span></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.3</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.1</span></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected stock price volatility</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84.8</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">95.4</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">87.8</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98.7</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="background-color:#ffffff;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dividend yield</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense recognized for all equity awards, including stock options and ESPP, has been reported in the statements of operations and comprehensive loss as follows (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:56.031%;box-sizing:content-box;"></td>
         <td style="width:1.8%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:17.863999999999997%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2.44%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:17.863999999999997%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,749</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,291</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,257</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,510</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,006</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,801</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The weighted-average grant date fair value of options granted (excluding modified options) for the years ended December 31, 2025 and 2024 were </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.05</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.95</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in additional stock-based compensation expense recorded within research and development expenses, in connection with the modification and acceleration of stock options held by a former executive.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the years ended December 31, 2025 and 2024, forfeitures resulting in the reversal of compensation expenses were immaterial.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, the unrecognized compensation cost related to options was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, and is expected to be recognized as expense over a weighted-average period of approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.6</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, the unrecognized compensation cost related to ESPP was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, and is expected to be recognized as expense over a weighted-average period of approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.2</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7. Net Loss Per Share</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth the computation of the basic and diluted net loss per share (in thousands, except share and per share amounts):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:67.313%;box-sizing:content-box;"></td>
         <td style="width:1.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.843%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.843%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">119,947</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86,481</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average common shares outstanding</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59,602,328</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57,250,061</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: weighted-average unvested common stock issued upon early exercise of common stock options</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,315</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average shares used to compute net loss per common share, basic and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59,602,328</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57,217,746</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.01</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.51</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Shares issuable pursuant to the 2024 Pre-Funded Warrants and the Exchange Warrants are included in the calculation of weighted-average shares of common stock outstanding, both basic and diluted, for the years ended December 31, 2025 and 2024. These warrants are exercisable at any time for nominal consideration, and therefore, the shares thereunder are considered outstanding for the purpose of calculating basic and diluted net loss per share.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because their inclusion would be anti-dilutive.</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:67.313%;box-sizing:content-box;"></td>
         <td style="width:1.02%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.323%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.02%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.323%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options to purchase common stock</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,617,445</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,462,129</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested common stock upon early exercise of stock options</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,317</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Estimated shares purchasable under the ESPP</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,761</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,280</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,645,206</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,480,726</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company's pretax losses for the years ended December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> are from U.S. operations. There was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> provision for or benefit from income taxes for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company adopted ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures prospectively, as disclosed in Note 1. </span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following is a reconciliation between the provision for income taxes and income taxes computed using the U.S. federal statutory corporate tax rate for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025, in accordance with the new disclosure requirements (in thousands):</span></span></p><div>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.94%;box-sizing:content-box;"></td>
         <td style="width:1.76%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.860000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.44%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income tax benefit at statutory federal rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,189</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.00</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State and local taxes, net of federal benefit </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,330</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.11</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax credits</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Federal research and development credits</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,411</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.35</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,683</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.75</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nontaxable or nondeductible items</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Stock based compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,653</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.38</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Officer compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,725</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.94</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.04</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in unrecognized tax benefits</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,823</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.35</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Provision for income taxes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1)</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The state that contributes to the majority (greater than 50%) of the tax effect in this category is California for the year ended December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following is a reconciliation between the provision for income taxes and income taxes computed using the U.S. federal statutory corporate tax rate for the year ended December 31, 2024, in accordance with the guidance prior to the adoption of ASU 2023-09 (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:80%;box-sizing:content-box;"></td>
         <td style="width:2.1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.9%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected tax benefit at statutory rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,161</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State income tax, net of federal benefit</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">134</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock based compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">757</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Officer compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">977</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Permanent items and other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research credits</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,363</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,431</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Provision for income taxes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company did not pay federal or state cash income taxes or have cash income taxes refunded in the year ended December 31, 2025.</span></p><div style="font-size:11pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024 are as follows (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.673%;box-sizing:content-box;"></td>
         <td style="width:1.74%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.923%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.74%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.923%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,792</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,938</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized research and development</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,439</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,105</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax credits</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,380</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,725</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock based compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,570</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,771</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,287</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,267</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89,468</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64,806</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88,026</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,267</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets, net of valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,442</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,539</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">175</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">256</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right of use assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,182</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,283</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,442</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,539</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred tax assets / (liabilities)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has established a valuation allowance against its net deferred tax assets due to the uncertainty surrounding the realization of such assets. The Company periodically evaluates the recoverability of the deferred tax assets. At such time as it is determined that it is more likely than not that deferred assets are realizable, the valuation allowance will be reduced. The Company has recorded a full valuation allowance of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of December 31, 2025 as management cannot conclude that it is more likely than not that certain deferred tax assets will be realized primarily due to the history of losses from inception. The Company increased its valuation allowance by approximately $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">24.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million during the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At December 31, 2025, the Company had federal and state tax loss carry forwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">188.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. As a result of the Tax Cuts and Jobs Act of 2017, for U.S. income tax purposes, net operating losses generated after December 31, 2017 can be carried forward indefinitely, but are limited to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% utilization against future taxable income each year. Of the amount of federal and state net operating loss carryforwards, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">188.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, can be carried forward indefinitely. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless previously utilized, the state net operating losses will begin to expire in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2038</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At December 31, 2025, the Company has federal and state research and development tax credits of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The federal research and development tax credit carryforwards begin to expire in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2040</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the state research and development tax credit carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">4.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million will not expire and the state research and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">development tax credit carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million will begin to expire in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2039</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the IRC Sections 382 and 383, annual use of the Company&#8217;s net operating loss (NOL) and research and development credit carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period. The Company has not completed an ownership change analysis pursuant to IRC Section 382. If ownership changes have occurred or occurs in the future, the amount of remaining tax attribute carryforwards available to offset taxable income and income tax expense in future years may be restricted or eliminated. If eliminated, the related asset would be removed from deferred tax assets with a corresponding reduction in the valuation allowance.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Uncertain tax positions are evaluated based upon the facts and circumstances that exist at each reporting period. Subsequent changes in judgment based upon new information may lead to changes in recognition, derecognition, and measurement. Adjustment may result, for example, upon resolution of an issue with the taxing authorities or expiration of a statute of limitations barring an assessment for an issue.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes a tax benefit from an uncertain tax position when it is more likely than not that the position will be sustained upon examination by tax authorities.</span></p><div style="font-size:11pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the changes to the Company&#8217;s gross unrecognized tax benefits for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024, respectively (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Beginning balance at January 1</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,529</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,006</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additions related to current year positions</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,043</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,869</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additions related to prior year positions</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,133</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">654</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ending balance at December 31</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,705</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,529</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Due to the existence of the valuation allowance, future recognition of previously unrecognized tax benefits will not impact the Company&#8217;s effective tax rate. The Company is subject to taxation in the United States and various state jurisdictions. All of the Company&#8217;s tax years from inception are subject to examination by federal and state tax authorities. The Company&#8217;s practice is to recognize interest and penalties related to income tax matters in income tax expense.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> accrued interest or penalties related to income tax matters in the Company&#8217;s balance sheet as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and has not recognized interest or penalties in the Company&#8217;s statements of operations and comprehensive loss for the years ended December 31, 2025 and 2024. Further, the Company is not currently under examination by any federal, state or local tax authority.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On July 4, 2025, the U.S. President signed into law H.R.1, the legislation commonly known as the One Big Beautiful Bill (OBBB). This legislation extended, modified, or made permanent many of the tax provisions which were initially enacted as part of the Tax Cuts and Jobs Act of 2017. The OBBB contains a number of tax provisions including, but not limited to, immediate expensing of domestic research and experimental expenditures, modifications to the limitation on business interest, bonus depreciation modifications, as well as international tax provision modifications. The Company has reflected the effect of OBBB within the provision for income taxes and the deferred taxes as of December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9. Leases</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has operating leases for its office and laboratory space, including its corporate headquarters.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2020, the Company entered into a lease agreement for approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,734</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet of office and lab space at 2656 State Street in Carlsbad, California, for the Company</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s headquarters (the Original Lease). The Original Lease commenced in May 2021 and had an original term of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">60 </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">months, with an option to extend for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> additional </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">36 </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">month periods.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 2022, the Company entered into a lease agreement for approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,331</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet of additional office and laboratory space at 2676 State Street in Carlsbad, California (the Expansion Lease). The Expansion Lease commenced for accounting purposes in May 2023, when the Company gained access to the premises. The Company</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;s obligation for payment of base rent began on the date the landlord delivered possession of the Expansion Lease premises in November 2023. The landlord completed improvements to the Expansion Lease premises, and the Company paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million toward these costs prior to the Expansion Lease commencement. The Company determined that the landlord is the accounting owner of these improvements, and therefore this payment was included in the measurement of the right-of-use asset and corresponding lease liability. The Company was granted rent abatement for delays related to the landlord&#8217;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s delivery of the Expansion Lease premises to the Company. The Expansion Lease has a lease term of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">120 </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">months, commencing on the day the landlord delivered possession of the Expansion Lease premises. The Company has the option to renew the Expansion Lease for two additional </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">36</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-month periods. The Original Lease was also amended to have the same lease expiration as the Expansion Lease.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company did not include the renewal periods in determining the lease term, as the Company was not reasonably certain to exercise either the amended Original Lease or the Expansion Lease renewal options.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Company&#8217;s lease agreements, the Company paid security deposits of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and is required to maintain a letter of credit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The letter of credit may be reduced to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in 2027 and further reduced to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in 2028.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash paid for amounts included in the measurement of lease liabilities was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024, respectively.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of lease expense include operating, short-term, and variable lease costs. Amortization is recorded within research and development and general and administrative expenses in the statements of operations and comprehensive loss. </span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Components of lease cost for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024, respectively, were as follows (in thousands):</span></span></p><div style="font-size:10pt;font-family:Times New Roman;">
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:67.313%;box-sizing:content-box;"></td>
         <td style="width:1.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.843%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.843%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease cost</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">957</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">957</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term lease cost</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">90</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">90</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Variable lease cost</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">139</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">127</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease cost</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,186</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,174</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Maturities of lease liabilities, weighted-average remaining term and weighted-average discount rate were as follows (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:75.64%;box-sizing:content-box;"></td>
         <td style="width:1.9%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:20.459999999999997%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Year ending December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">900</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">927</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">955</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">983</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2030</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,013</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,035</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total minimum lease payments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,813</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: amount representing interest</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,003</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Present value of lease liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,810</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: current portion of lease liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">472</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liabilities, noncurrent</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,338</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:67.34%;box-sizing:content-box;"></td>
         <td style="width:1.021%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.31%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.021%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.31%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average remaining lease term (years) - operating leases</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.9</span></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.9</span></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average incremental borrowing rate - operating leases</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.07</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.07</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10. Commitments and Contingencies</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Funding Commitments</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, the Company had ongoing clinical and pre-clinical studies for its various programs. The Company enters into contracts in the normal course of business with contract research organizations in preparation for clinical trials, professional consultants for expert advice and other vendors for clinical supply manufacturing or other services. These contracts are generally cancellable, with notice, at the Company's option and do not have significant cancellation penalties.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Litigation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company, from time to time, may be party to litigation arising in the ordinary course of business. The Company was not subject to any material legal proceedings as of December 31, 2025, and no material legal proceedings are currently pending or threatened. I</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">f the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount is reasonably estimable, the Company will accrue a liability for the estimated loss.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsAbstract', window );"><strong>Compensation Related Costs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefits</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11. Employee Benefits</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company offers a 401(k) plan (401(k) Plan) for all employees who have met certain eligibility requirements. Under the 401(</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">k) Plan, employees may elect to contribute a portion of their eligible compensation, subject to certain limitations. The Company has a program to match </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of employee contributions to the 401(k) Plan up to a maximum of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of eligible earnings, subject to statutory limitations. Employer contributions for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> were $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480266/715-60-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480126/715-20-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715/tableOfContent<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12. Segment Information</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company reports segment information based on the management approach, which reflects the way in which the internal reporting is used by the chief operating decision maker (CODM) to analyze performance, make decisions and allocate resources. The CODM is the Company&#8217;s </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_1e6f4a6c-c495-424f-a078-c4745eb638bc;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company manages its operations as a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_1191e240-a690-465b-8ee1-430de97506c1;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">single</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reportable segment, which includes all activities related to the research, development, and potential future commercialization of its small molecule drug development candidates. The CODM assesses performance and decides how to allocate resources based on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">net loss</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (presented in the statements of operations and comprehensive loss). The measure of segment assets is reported on the balance sheets as total assets. All long-lived assets are located in the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The table below shows a reconciliation of the Company&#8217;s net loss, including the significant expense categories regularly provided to and reviewed by the CODM, to the Company&#8217;s total net loss in the statements of operations and comprehensive loss (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:58.76%;box-sizing:content-box;"></td>
         <td style="width:1.9%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:16.72%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.9%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:16.72%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended<br/>December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development expenses:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;External research and development <br/>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;expenses by program:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Dabogratinib (TYRA-300</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">ACH</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,379</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,718</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Dabogratinib (TYRA-300</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">NMIBC</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,244</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">122</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Dabogratinib (TYRA-300</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">UTUC</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,440</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Dabogratinib (TYRA-300</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">mUC</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,590</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,319</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;TYRA-430</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,055</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,677</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;TYRA-200</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,308</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,969</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;FGFR discovery</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,967</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,199</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Other development programs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,623</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,537</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Unallocated research and development <br/>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;expenses:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Personnel costs</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,218</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,423</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Facilities and other costs</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,104</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,113</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total research and development expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102,928</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80,077</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative expenses</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,834</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,100</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest and other income, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,815</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,696</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">119,947</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86,481</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Personnel costs include $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">15.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">14.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of stock-based compensation for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2)</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Facilities and other costs consist of research consumables, facility-related costs, depreciation and costs not attributed to a specific program.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(3) </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses consist of personnel-related expenses, including stock-based compensation, legal fees, facility-related costs, depreciation, professional and consulting fees and insurance costs.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_OrganizationPolicyTextBlock', window );">Organization</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Organization</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tyra </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Biosciences, Inc. (the Company) was incorporated in the state of Delaware on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">August 2, 2018</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The Company&#8217;s in-house precision medicine platform, SN&#197;P, enables rapid and precise drug design through iterative molecular SN&#197;Pshots that help predict which product candidates may demonstrate the highest potency, selectivity and tolerability. The Company&#8217;s focus is on applying its accelerated small molecule drug discovery engine to develop therapies in targeted oncology and genetically defined conditions</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since its inception, the Company has devoted substantially all of its resources to research and development activities, business planning, establishing and maintaining its intellectual property portfolio, hiring personnel, raising capital, and providing general and administrative support for these operations. It has incurred losses and negative cash flows from operations since commencement of its operations. The Company had an accumulated deficit of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">371.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and cash, cash equivalents and marketable securities of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">256.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of December 31, 2025. From its inception through December 31, 2025, the Company has financed its operations primarily through the sale of common stock, private placements of its convertible preferred stock, and the issuance of common stock and pre-funded common stock warrants through a private placement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As the Company continues its expansion, it may seek additional financing and/or strategic investments. However, there can be no assurance that any additional financing or strategic investments will be available to the Company on acceptable terms, if at all. If events or circumstances occur such that the Company does not obtain additional funding, it will most likely be required to reduce its plans and/or certain discretionary spending, which could have a material adverse effect on the Company&#8217;s ability to achieve its intended business objectives. Management believes that it has sufficient working capital on hand to fund operations through at least the next twelve months from the date of issuance of these financial statements.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of Presentation</span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying financial statements have been prepared in accordance with generally accepted accounting principles in the United States (GAAP). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) promulgated by the Financial Accounting Standards Board (FASB).</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates and assumptions made in the accompanying financial statements include, but are not limited to, the valuation of share-based awards, the valuation of deferred tax assets and income tax uncertainties, accruals for research and development activities, and incremental borrowing rate (IBR) for right-of-use (ROU) assets. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable. Actual results may differ from those estimates or assumptions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments which potentially subject the Company to a significant concentration of credit risk consist of cash, cash equivalents and marketable securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the nature of the instruments held in the depository institutions.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents primarily represent funds invested in readily available money market accounts. As of December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had cash and cash equivalents balances deposited at major financial institutions.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Marketable Securities</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketable securities consist of debt securities of government-sponsored entities. These securities are classified as available-for sale, as the sale of such securities may be required prior to their maturity. Available-for-sale securities are recorded at fair value, with the related unrealized gains and losses included in accumulated other comprehensive income or loss and included as a separate component of stockholders&#8217; equity. The amortized cost of available-for-sale securities reflects amortization of premiums and accretion of discounts to maturity. Premiums and discounts on debt securities are amortized or accreted into interest and other income, net. The Company classifies investments in marketable debt securities as current assets, regardless of the stated maturity date, which may be beyond one year from the current balance sheet date. Short-term classification reflects management&#8217;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s view that the entire portfolio is available, and the Company may use the proceeds from sales of these investments to fund current operations, as necessary.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_AllowanceForCreditLossesPolicyTextBlock', window );">Allowance for Credit Losses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Allowance for Credit Losses</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company regularly reviews its portfolio for declines in fair value. For investments in an unrealized loss position, the Company assesses whether the decline is based on credit losses or other factor. As part of this assessment, the Company considers the cause of the impairment, the creditworthiness of the security issuers, current market conditions, the number of securities in an unrealized loss position, the severity of the losses, whether it will be required or will intend to sell the investment before recovery of its amortized cost basis. If fair value decline is determined to be due to a credit-related factor, the amortized cost basis is written down to fair value through net loss. If fair value decline is not due to credit-related factors, a loss is recorded in other comprehensive income or loss. The Company recognizes an allowance for credit losses up to the amount of the unrealized loss when appropriate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not measure an allowance for credit losses for accrued interest receivables. For the purposes of identifying and measuring an impairment, accrued interest is excluded from both the fair value and amortized costs basis of the investment. Uncollectible accrued interest receivables associated with an impaired marketable security are reversed against interest income in a timely manner upon identification of the impairment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value Measurements</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company measures cash equivalents and available-for-sale debt securities at fair value. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. Therefore, fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability. Fair value is affected by a number of factors, including the type of asset or liability, the characteristics specific to the asset or liability and the state of the marketplace, including the existence and transparency of transactions between market participants. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Money market funds are highly liquid investments and are classified as Level 1. The pricing information for these assets is readily available and can be independently validated as of the measurement date. Available-for-sale debt securities, including U.S. Treasury securities and U.S. Agency bonds are classified as Level 2. These securities are valued using fair value from third-party pricing services, which may use observable inputs based on real-time trade data for similar assets, broker/dealer quotes, bids and/or offers and other observable inputs. The Company validates valuations obtained from third-party pricing services by understanding the models used and obtaining market values from independent sources.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Cash</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted cash is comprised of cash that is restricted as to its withdrawal or use under the terms of certain contractual agreements. Restricted cash as of December 31, 2025 and 2024 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which consisted of collateral for letters of credit related to the Company&#8217;s operating leases.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Property and Equipment</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment is stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets (generally </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_de6e2adb-217c-46f8-87ab-7f9f75f3c64f;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seven years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or the remaining term of the lease).</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Impairment of Long-Lived Assets</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for the impairment of long-lived assets by reviewing these assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group to be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted-cash-flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recognize impairment losses for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_AccruedResearchAndDevelopmentExpensePolicyPolicyTextBlock', window );">Accrued Research and Development Expenses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accrued Research and Development Expenses</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses consist of external and internal costs associated with the Company&#8217;s research and development activities, including its discovery and research efforts and the preclinical and clinical development of its product candidates. Research and development costs are expensed in the period incurred.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company has entered into various research and development contracts with clinical research organizations, clinical manufacturing organizations, clinical sites and other vendors and consultants. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and payments made in advance of or after the performance are reflected in the accompanying balance sheets as prepaid expenses or accrued liabilities, respectively. The Company records accruals for estimated costs incurred for ongoing research and development activities. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs. The Company holds discussions with applicable personnel and outside service providers as to the progress of clinical trials, or the services completed. Significant judgments and estimates may be made in determining the prepaid or accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. Nonrefundable advance payments for goods and services, including fees for process</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">development, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">are deferred and recognized as expenses in the period that the related goods are consumed or services are performed.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_PatentCostsPolicyPolicyTextBlock', window );">Patent Costs</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent Costs</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company expenses all costs as incurred in connection with patent applications (including direct application fees, and the legal and consulting expenses related to making such applications) and such costs are included in general and administrative expenses in the statements of operations and comprehensive loss.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has operating leases for office and lab space. At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, the Company records the associated lease liability and corresponding ROU asset upon commencement of the lease using the implicit rate or a discount rate based on a credit-adjusted secured borrowing rate commensurate with the term of the lease. The Company evaluates leases at their inception to determine if they are to be accounted for as an operating lease or a finance lease.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating lease assets represent a right to use an underlying asset for the lease term and operating lease liabilities represent an obligation to make lease payments arising from the lease. Operating lease liabilities with a term greater than one year and their corresponding ROU assets are recognized on the balance sheet at the commencement date of the lease based on the present value of lease payments over the expected lease term. The Company excludes short-term leases, if any, having initial terms of 12 months or less at lease commencement as an accounting policy election.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain adjustments to the ROU assets may be required for items such as payments made at or before the commencement date, initial direct costs paid or lease incentives received. As the Company&#8217;s leases do not typically provide an implicit rate, the Company utilizes the appropriate IBR, determined as the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term and in a similar economic environment. Lease cost is recognized on a straight-line basis over the lease term and variable lease payments are recognized as operating expenses in the period in which the obligation for those payments is incurred. Variable lease payments primarily include common area maintenance, utilities, real estate taxes, insurance, and other operating costs that are passed on from the lessor in proportion to the space leased by the Company. In measuring the ROU assets and lease liabilities, the Company has elected to combine lease and non-lease components.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating ROU assets are reflected in right-of-use assets in the accompanying balance sheets. Operating lease liabilities are reflected in lease liabilities, current and noncurrent in the accompanying balance sheets.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_CommonStockWarrantsPolicyTextBlock', window );">Common Stock Warrants</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Common Stock Warrants</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common stock warrants are classified as either a liability or equity, based on an assessment of specific terms and applicable authoritative guidance in ASC 480, Distinguishing Liabilities from Equity (ASC 480) and ASC 815, Derivatives and Hedging (ASC 815). The Company considers whether the warrants are freestanding financial instruments, whether they meet the definition of a liability pursuant to ASC 480, and whether they meet all of the requirements for equity classification under ASC 815. This assessment is performed at the time of warrant issuance and re-assessed as of each subsequent quarterly balance sheet date, while the warrants are outstanding.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-Based Compensation</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense represents the cost of the grant date fair value of employee, officer, director and non-employee equity awards, estimated in accordance with the applicable accounting guidance, and, for those awards subject only to service conditions, recognized on a straight-line basis over the vesting period. The vesting period generally approximates the expected service period of the awards. The Company recognizes stock-based compensation expense for awards with performance conditions when it is probable that the condition will be</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">met, and the award will vest. If the achievement of performance conditions is no longer deemed probable, previously recognized compensation cost is reversed. For awards with performance and service conditions, the Company begins recording share-based compensation when achieving the performance criteria is probable and recognizes the costs using the accelerated attribution method. The Company recognizes forfeitures as they occur.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of stock options is estimated using a Black-Scholes valuation model on the date of grant. This method requires certain assumptions to be used as inputs, such as the fair value of the underlying common stock, expected term of the option before exercise, expected volatility of the Company&#8217;s common stock, risk-free interest rate and expected dividend. Options granted have a maximum contractual term of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ten years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company has limited historical stock option activity and therefore estimates the expected term of stock options granted using the simplified method, which represents the arithmetic average of the original contractual term of the stock option and its weighted-average vesting term. The expected volatility of stock options is estimated based on the average historical volatilities of common stock of comparable publicly traded companies and the Company</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s own volatility. The comparable companies are chosen based on their size and stage in the life cycle. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available. The risk-free interest rates used are based on the U.S. Treasury yield in effect at the time of grant for zero-coupon U.S. treasury notes with maturities approximately equal to the expected term of the stock options. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has historically not declared or paid any dividends and does not currently expect to do so in the foreseeable future, and therefore, has estimated the dividend yield to be </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">zero</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Commitments and Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes a liability with regard to loss contingencies when it believes it is probable a liability has been incurred, and the amount can be reasonably estimated. If some amount within a range of loss appears at the time to be a better estimate than any other amount within the range, the Company accrues that amount. When no amount within the range is a better estimate than any other amount, the Company accrues the minimum amount in the range.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the statement of operations in the period that includes the enactment date.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company recognizes deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025 and 2024, the Company maintained valuation allowances against its deferred tax assets as the Company concluded it had not met the &#8220;more likely than not&#8221; to be realized threshold. Changes in the valuation allowance when they are recognized in the provision for income taxes may result in a change in the estimated annual effective tax rate.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company records uncertain tax positions on the basis of a two-step process whereby (1) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability. As of December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> accrued interest or penalties.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comprehensive Loss</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprehensive loss consists of two components: net loss and other comprehensive income or loss. Other comprehensive income (loss) refers to gains or losses that are recorded as an element of stockholders&#8217; equity but are excluded from net loss. The Company&#8217;s other comprehensive income (loss) consists of unrealized gains and losses on marketable securities.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Loss Per Share</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock and common stock equivalents outstanding for the period. Common stock equivalents are only included when their effect is dilutive. Pre-funded warrants are considered outstanding for the purposes of computing basic and diluted net loss per share because shares may be issued for little or no additional consideration and are fully vested and exercisable after the original issuance date of the pre-funded warrant. The Company&#8217;s potentially dilutive securities include unvested common stock upon early exercise of stock options, outstanding stock options under the Company&#8217;s equity incentive plan, and estimated shares purchasable under the employee stock purchase plan, and have been excluded from the computation of diluted net loss per share as their inclusion would be anti-dilutive. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#8217;s net loss position.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_RelatedPartiesPolicyPolicyTextBlock', window );">Related Parties</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Related Parties</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transactions between related parties are considered to be related party transactions even though they may not be given accounting recognition. FASB ASC 850, Related Party Disclosures (ASC 850) requires that transactions with related parties that would make a difference in decision making shall be disclosed so that users of the financial statements can evaluate their significance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_CapitalizedSoftwareImplementationCostsPolicyTextBlock', window );">Capitalized Software Implementation Costs</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Capitalized Software Implementation Costs</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company capitalizes certain implementation costs incurred under a cloud computing arrangement that is a service contract. Costs incurred during the application development stage related to the implementation of the hosting arrangement are capitalized and included within prepaid and other current assets, and other long-term assets on the accompanying balance sheets. Amortization of capitalized implementation costs is recognized on a straight-line basis over the term of the associated hosting arrangement when it is ready for its intended use. Costs related to preliminary project activities and post-implementation activities are expensed as incurred.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures.&#8221; ASU 2023-09 requires disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation as well as information on income taxes paid. ASU 2023-09 is effective for public entities with annual periods beginning after December 15, 2024, with early adoption permitted. The Company adopted this standard prospectively for the period ending December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The adoption impacted the disclosures and did not impact the financial statements. See Note 8, Income Taxes, for disclosures related to the adoption of ASU 2023-09.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_IssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock', window );">Issued Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Issued Accounting Pronouncements Not Yet Adopted</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03, "</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">". In January 2025, the FASB issued ASU 2025-01, "</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">", to clarify the effective date of ASU 2024-03. These amendments are intended to provide more information about certain costs and expenses on an interim and annual basis. The amendments are effective for annual periods beginning after December 15, 2026 and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The new standards are expected to be applied prospectively, but retrospective application is permitted. The Company is currently evaluating the impact on its financial statements and related disclosures.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_AccruedResearchAndDevelopmentExpensePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Research and Development Expense Policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_AccruedResearchAndDevelopmentExpensePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_AllowanceForCreditLossesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Allowance for Credit Losses Policy Text Block</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_AllowanceForCreditLossesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_CapitalizedSoftwareImplementationCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capitalized Software Implementation Costs Policy [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_CapitalizedSoftwareImplementationCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_CommonStockWarrantsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Warrants [PolicyText Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_CommonStockWarrantsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_IssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issued Accounting Pronouncements Not Yet Adopted, Policy [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_IssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_OrganizationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>.Organization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_OrganizationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_PatentCostsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Patent Costs Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_PatentCostsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_RelatedPartiesPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Parties Policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_RelatedPartiesPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 450<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477850/954-450-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-4<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock', window );">Schedule of Fair Value of Assets Measured</a></td>
<td class="text"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables show the Company</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;s cash equivalents and marketable securities measured at fair value as of December 31, 2025 and 2024 (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:37.932%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.297%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.177000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.297%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.297%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="11" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Quoted prices in active markets for identical assets (Level 1)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant other observable inputs (Level 2)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant unobservable inputs (Level 3)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Money market funds</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54,444</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54,444</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">133,264</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">133,264</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;U.S. government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,352</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,352</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Total marketable securities</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">178,616</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">178,616</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Total</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">233,060</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54,444</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">178,616</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="text-indent:9.067%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:37.932%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.297%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:14.177000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.297%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.297%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="11" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Quoted prices in active markets for identical assets (Level 1)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant other observable inputs (Level 2)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant unobservable inputs (Level 3)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Money market funds</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">69,698</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">69,698</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities:</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">122,980</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">122,980</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;U.S. government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">126,495</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">126,495</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Total marketable securities</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">249,475</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">249,475</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Total</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">319,173</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">69,698</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">249,475</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of beginning and ending balances of the fair value of plan assets of pension plans and/or other employee benefit plans showing separately, if applicable, the effects during the period attributable to each of the following: actual return on plan assets, foreign currency exchange rate changes, contributions by the employer, contributions by plan participants, benefits paid, business combinations, divestitures, and settlements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -SubTopic 20<br> -Subparagraph (b)<br> -Name Accounting Standards Codification<br> -Paragraph 1<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Summary of Available-for-Sale Securities and Gross Unrealized Losses</a></td>
<td class="text"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables summarize the Company</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;s marketable securities (see below and Note 2) accounted for as available-for-sale securities (in thousands, except years):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:32.323%;box-sizing:content-box;"></td>
         <td style="width:14.141%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.141%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.141%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.121%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.131%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="12" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Maturity <br/>(in years)</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized cost</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized gains</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized losses</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated fair value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less than one</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107,324</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">223</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107,547</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less than one</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,215</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">137</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,352</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1-2</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,684</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,717</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">178,223</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">393</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">178,616</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="text-indent:9.067%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:32%;box-sizing:content-box;"></td>
         <td style="width:14%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="12" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Maturity <br/>(in years)</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized cost</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized gains</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized losses</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated fair value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less than one</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">77,990</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">210</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">78,197</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less than one</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,153</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">189</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,333</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1-2</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,547</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">239</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,783</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1-2</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,015</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">159</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,162</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">248,705</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">797</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">249,475</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:23.071%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.836%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.836%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.836%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.836%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.836%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.279%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.836%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p></td>
         <td colspan="22" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Less than 12 months</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">12 months or longer</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized losses</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized losses</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized losses</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury securities</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,033</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,033</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. government agency securities</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,891</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,891</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,924</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,924</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued expenses and other current liabilities consisted of the following (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:67.313%;box-sizing:content-box;"></td>
         <td style="width:1.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.843%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.843%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued payroll and other employee benefits</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,533</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,451</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued research and development expenses</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,840</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,612</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued legal and professional fees</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">316</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">296</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued other general and administrative fees</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">755</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">233</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,444</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,592</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock', window );">Schedule of Common Stock Reserved for Future Issuance</a></td>
<td class="text"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Common stock reserved for future issuance consisted of the following:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:67.313%;box-sizing:content-box;"></td>
         <td style="width:1.02%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.323%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.02%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.323%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock options granted and outstanding</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,617,445</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,462,129</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares available for future issuance under the 2021<br/>&#160;&#160;&#160;Incentive Award Plan</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,528,992</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,051,588</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares available for future issuance under the <br/>&#160;&#160;&#160;2021 Employee Stock Purchase Plan</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,951,705</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,491,195</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pre-funded warrants issued and outstanding</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,381,950</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,382,187</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total common stock reserved for future issuance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,480,092</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,387,099</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans and Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_StockOptionsAbstract', window );"><strong>Stock Options Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Options Activity</a></td>
<td class="text"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A summary of the Company&#8217;s stock option activity for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 was as follows (in thousands, except share and per share data and years):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:47.94%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.2%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.2%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.420000000000002%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.2%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:9.9%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.2%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.940000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Options</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-Average<br/>Exercise<br/>Price per Share</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-Average<br/>Remaining<br/>Contractual Term</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate<br/>Intrinsic Value</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2024</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,462,129</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.43</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.6</span></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,798</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,029,190</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.08</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">904,993</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.72</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited and expired</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">968,881</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16.31</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at December 31, 2025</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,617,445</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.58</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.0</span></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">186,669</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercisable at December 31, 2025</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,300,582</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.39</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.8</span></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93,903</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested and expected to vest as of December 31, 2025</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,617,445</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.58</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.0</span></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">186,669</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The fair value of stock options was estimated using the following assumptions: </span>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:58.14%;box-sizing:content-box;"></td>
         <td style="width:1.7%;box-sizing:content-box;"></td>
         <td style="width:18.92%;box-sizing:content-box;"></td>
         <td style="width:1.7%;box-sizing:content-box;"></td>
         <td style="width:18.54%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free rate of interest</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.8</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.4</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.5</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.6</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="background-color:#ffffff;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.1</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.1</span></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.3</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.1</span></span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected stock price volatility</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84.8</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">95.4</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">87.8</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;- </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98.7</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="background-color:#ffffff;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dividend yield</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based Compensation Expense</a></td>
<td class="text"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense recognized for all equity awards, including stock options and ESPP, has been reported in the statements of operations and comprehensive loss as follows (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:56.031%;box-sizing:content-box;"></td>
         <td style="width:1.8%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:17.863999999999997%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2.44%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:17.863999999999997%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,749</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,291</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,257</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,510</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,006</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,801</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_StockOptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Options Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_StockOptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and Diluted Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth the computation of the basic and diluted net loss per share (in thousands, except share and per share amounts):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:67.313%;box-sizing:content-box;"></td>
         <td style="width:1.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.843%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.843%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">119,947</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86,481</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average common shares outstanding</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59,602,328</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57,250,061</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: weighted-average unvested common stock issued upon early exercise of common stock options</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,315</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average shares used to compute net loss per common share, basic and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59,602,328</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57,217,746</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.01</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.51</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Potentially Dilutive Securities Including All Outstanding Stock Options were excluded in Calculation of Diluted Shares Outstanding</a></td>
<td class="text"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because their inclusion would be anti-dilutive.</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:67.313%;box-sizing:content-box;"></td>
         <td style="width:1.02%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.323%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.02%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.323%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options to purchase common stock</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,617,445</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,462,129</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unvested common stock upon early exercise of stock options</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,317</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Estimated shares purchasable under the ESPP</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,761</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,280</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,645,206</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,480,726</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following is a reconciliation between the provision for income taxes and income taxes computed using the U.S. federal statutory corporate tax rate for the year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025, in accordance with the new disclosure requirements (in thousands):</span>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.94%;box-sizing:content-box;"></td>
         <td style="width:1.76%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.860000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.44%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income tax benefit at statutory federal rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,189</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.00</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State and local taxes, net of federal benefit </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,330</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.11</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax credits</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Federal research and development credits</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,411</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.35</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,683</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.75</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nontaxable or nondeductible items</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Stock based compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,653</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.38</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Officer compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,725</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.94</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.04</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in unrecognized tax benefits</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,823</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.35</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Provision for income taxes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1)</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The state that contributes to the majority (greater than 50%) of the tax effect in this category is California for the year ended December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following is a reconciliation between the provision for income taxes and income taxes computed using the U.S. federal statutory corporate tax rate for the year ended December 31, 2024, in accordance with the guidance prior to the adoption of ASU 2023-09 (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:80%;box-sizing:content-box;"></td>
         <td style="width:2.1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.9%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected tax benefit at statutory rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,161</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State income tax, net of federal benefit</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">134</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock based compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">757</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Officer compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">977</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Permanent items and other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research credits</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,363</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,431</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Provision for income taxes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024 are as follows (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.673%;box-sizing:content-box;"></td>
         <td style="width:1.74%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.923%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.74%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.923%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As of December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,792</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,938</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized research and development</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,439</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,105</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax credits</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,380</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,725</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock based compensation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,570</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,771</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,287</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,267</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89,468</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64,806</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88,026</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,267</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets, net of valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,442</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,539</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">175</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">256</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right of use assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,182</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,283</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,442</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,539</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred tax assets / (liabilities)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits Roll Forward</a></td>
<td class="text"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the changes to the Company&#8217;s gross unrecognized tax benefits for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024, respectively (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.993%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.62%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Beginning balance at January 1</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,529</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,006</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additions related to current year positions</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,043</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,869</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additions related to prior year positions</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,133</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">654</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ending balance at December 31</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,705</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,529</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Components of Lease Cost</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Components of lease cost for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024, respectively, were as follows (in thousands):</span>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:67.313%;box-sizing:content-box;"></td>
         <td style="width:1.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.843%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.843%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease cost</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">957</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">957</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term lease cost</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">90</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">90</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Variable lease cost</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">139</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">127</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease cost</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,186</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,174</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_ScheduleOfMaturitiesOfLeaseLiabilitiesWithWeightedAverageRemainingTermAndDiscountRateTableTextBlock', window );">Schedule of Lease Liabilities with Weighted Average Remaining Term and Weighted Average Discount Rate</a></td>
<td class="text"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Maturities of lease liabilities, weighted-average remaining term and weighted-average discount rate were as follows (in thousands):</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:75.64%;box-sizing:content-box;"></td>
         <td style="width:1.9%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:20.459999999999997%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Year ending December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">900</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">927</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">955</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">983</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2030</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,013</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,035</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total minimum lease payments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,813</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: amount representing interest</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,003</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Present value of lease liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,810</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: current portion of lease liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">472</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liabilities, noncurrent</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,338</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:67.34%;box-sizing:content-box;"></td>
         <td style="width:1.021%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.31%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.021%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.31%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average remaining lease term (years) - operating leases</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.9</span></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.9</span></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average incremental borrowing rate - operating leases</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.07</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.07</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_ScheduleOfMaturitiesOfLeaseLiabilitiesWithWeightedAverageRemainingTermAndDiscountRateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of maturities of lease liabilities along with weighted average remaining term and discount rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_ScheduleOfMaturitiesOfLeaseLiabilitiesWithWeightedAverageRemainingTermAndDiscountRateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Schedule of reconciliation of the Company's net loss</a></td>
<td class="text"><p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The table below shows a reconciliation of the Company&#8217;s net loss, including the significant expense categories regularly provided to and reviewed by the CODM, to the Company&#8217;s total net loss in the statements of operations and comprehensive loss (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:58.76%;box-sizing:content-box;"></td>
         <td style="width:1.9%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:16.72%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.9%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:16.72%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended<br/>December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development expenses:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;External research and development <br/>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;expenses by program:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Dabogratinib (TYRA-300</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">ACH</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,379</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,718</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Dabogratinib (TYRA-300</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">NMIBC</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,244</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">122</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Dabogratinib (TYRA-300</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">UTUC</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,440</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Dabogratinib (TYRA-300</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">mUC</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,590</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,319</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;TYRA-430</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,055</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,677</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;TYRA-200</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,308</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,969</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;FGFR discovery</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,967</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,199</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Other development programs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,623</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,537</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Unallocated research and development <br/>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;expenses:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Personnel costs</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,218</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,423</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;Facilities and other costs</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,104</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,113</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total research and development expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102,928</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80,077</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative expenses</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(3)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,834</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,100</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest and other income, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,815</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,696</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">119,947</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86,481</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1) </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Personnel costs include $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">15.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">14.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of stock-based compensation for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2)</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Facilities and other costs consist of research consumables, facility-related costs, depreciation and costs not attributed to a specific program.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(3) </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses consist of personnel-related expenses, including stock-based compensation, legal fees, facility-related costs, depreciation, professional and consulting fees and insurance costs.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued', window );">Penalties and interest accrued</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (371,258)<span></span>
</td>
<td class="num">$ (251,311)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Entity Incorporation, Date of Incorporation</a></td>
<td class="text">Aug.  02,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_CashCashEquivalentsAndMarketableSecurities', window );">Cash, cash equivalents and marketable securities</a></td>
<td class="nump">$ 256,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendPaymentRestrictionsScheduleDescription', window );">Dividend payment description</a></td>
<td class="text">The Company has historically not declared or paid any dividends and does not currently expect to do so in the foreseeable future, and therefore, has estimated the dividend yield to be zero.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_DividendYield', window );">Dividend yield</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember', window );">Property, Plant and Equipment, Other Types [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairement loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_OptionsGrantedContractualTerm', window );">Options granted contractual term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationDateOfIncorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when an entity was incorporated</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationDateOfIncorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_CashCashEquivalentsAndMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, cash equivalents and marketable securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_CashCashEquivalentsAndMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_DividendYield">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dividend yield</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_DividendYield</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_OptionsGrantedContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Options granted contractual term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_OptionsGrantedContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization and Summary of Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendPaymentRestrictionsScheduleDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of dividends paid, restrictions on dividend payments, statutory capital and surplus amounts, requirements and future requirements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477908/944-505-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendPaymentRestrictionsScheduleDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Assets measured at fair value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets On Recurring Basis Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">$ 178,616<span></span>
</td>
<td class="nump">$ 249,475<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets On Recurring Basis Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueAdjustment', window );">Fair Value</a></td>
<td class="nump">233,060<span></span>
</td>
<td class="nump">319,173<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">178,616<span></span>
</td>
<td class="nump">249,475<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets On Recurring Basis Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueConcentrationOfRiskCashAndCashEquivalents', window );">Cash and Cash Equivalents</a></td>
<td class="nump">54,444<span></span>
</td>
<td class="nump">69,698<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | US Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets On Recurring Basis Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">133,264<span></span>
</td>
<td class="nump">122,980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | U.S. government agency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets On Recurring Basis Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">45,352<span></span>
</td>
<td class="nump">126,495<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets On Recurring Basis Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueAdjustment', window );">Fair Value</a></td>
<td class="nump">54,444<span></span>
</td>
<td class="nump">69,698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets On Recurring Basis Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueConcentrationOfRiskCashAndCashEquivalents', window );">Cash and Cash Equivalents</a></td>
<td class="nump">54,444<span></span>
</td>
<td class="nump">69,698<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | US Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets On Recurring Basis Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | U.S. government agency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets On Recurring Basis Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets On Recurring Basis Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueAdjustment', window );">Fair Value</a></td>
<td class="nump">178,616<span></span>
</td>
<td class="nump">249,475<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">178,616<span></span>
</td>
<td class="nump">249,475<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets On Recurring Basis Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueConcentrationOfRiskCashAndCashEquivalents', window );">Cash and Cash Equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | US Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets On Recurring Basis Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">133,264<span></span>
</td>
<td class="nump">122,980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | U.S. government agency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets On Recurring Basis Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">45,352<span></span>
</td>
<td class="nump">126,495<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets On Recurring Basis Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueAdjustment', window );">Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets On Recurring Basis Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueConcentrationOfRiskCashAndCashEquivalents', window );">Cash and Cash Equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | US Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets On Recurring Basis Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | U.S. government agency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets On Recurring Basis Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which an asset could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueConcentrationOfRiskCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of cash and cash equivalent subject to concentration of credit or market risk or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-23<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueConcentrationOfRiskCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities - Summary of Available-for-Sale Securities and Gross Unrealized Losses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">$ 178,223<span></span>
</td>
<td class="nump">$ 248,705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Unrealized gains</a></td>
<td class="nump">393<span></span>
</td>
<td class="nump">797<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">178,616<span></span>
</td>
<td class="nump">249,475<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue', window );">Unrealized losses less than 12 months, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,924<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAccumulatedLoss', window );">Unrealized losses less than 12 months, unrealized losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrGreaterFairValue', window );">Unrealized losses 12 months or greater, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAccumulatedLoss', window );">Unrealized losses 12 months or greater, unrealized losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOptionCreditRiskGainsLossesOnAssets', window );">Unrealized losses on fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,924<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Debt Securities, Available-for-Sale, Unrealized Loss</a></td>
<td class="num">(27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue', window );">Unrealized losses less than 12 months, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,033<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAccumulatedLoss', window );">Unrealized losses less than 12 months, unrealized losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrGreaterFairValue', window );">Unrealized losses 12 months or greater, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAccumulatedLoss', window );">Unrealized losses 12 months or greater, unrealized losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOptionCreditRiskGainsLossesOnAssets', window );">Unrealized losses on fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,033<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Debt Securities, Available-for-Sale, Unrealized Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. Government Agency Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue', window );">Unrealized losses less than 12 months, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,891<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAccumulatedLoss', window );">Unrealized losses less than 12 months, unrealized losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrGreaterFairValue', window );">Unrealized losses 12 months or greater, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAccumulatedLoss', window );">Unrealized losses 12 months or greater, unrealized losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOptionCreditRiskGainsLossesOnAssets', window );">Unrealized losses on fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,891<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Debt Securities, Available-for-Sale, Unrealized Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAxis=us-gaap_LongTermDebtMember', window );">More than One year | US Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">25,684<span></span>
</td>
<td class="nump">44,547<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Unrealized gains</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">239<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">25,717<span></span>
</td>
<td class="nump">44,783<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAxis=us-gaap_LongTermDebtMember', window );">More than One year | U.S. Government Agency Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Unrealized gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">159<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Unrealized losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,162<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAxis=us-gaap_ShortTermDebtMember', window );">Less than one year | US Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">107,324<span></span>
</td>
<td class="nump">77,990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Unrealized gains</a></td>
<td class="nump">223<span></span>
</td>
<td class="nump">210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">107,547<span></span>
</td>
<td class="nump">78,197<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAxis=us-gaap_ShortTermDebtMember', window );">Less than one year | U.S. Government Agency Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">45,215<span></span>
</td>
<td class="nump">94,153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Unrealized gains</a></td>
<td class="nump">137<span></span>
</td>
<td class="nump">189<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">$ 45,352<span></span>
</td>
<td class="nump">$ 94,333<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Held to Maturity Securities Continuous Unrealized Loss Position Less Than 12 Months Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Held to Maturity Securities Continuous Unrealized Loss Position Less Than Twelve Months Accumulated Loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrGreaterFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Held to Maturity Securities Continuous Unrealized Loss Position Twelve Months or Greater Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrGreaterFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Held to Maturity Securities Continuous Unrealized Loss Position Twelve Months Or Longer Accumulated Loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOptionCreditRiskGainsLossesOnAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the estimated amount of gains or losses included in earnings during the period attributable to changes in instrument-specific credit risk arising from loans and other receivables held as assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOptionCreditRiskGainsLossesOnAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAxis=us-gaap_LongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAxis=us-gaap_LongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAxis=us-gaap_ShortTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAxis=us-gaap_ShortTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities (Additional Information) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue', window );">Available-for-sale security in gross unrealized loss position for less than 12 months, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,924<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_AccruedInterestAvailableForSaleSecurities', window );">Accrued interest available-for-sale securities</a></td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_AccruedInterestAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued interest available-for-sale securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_AccruedInterestAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Held to Maturity Securities Continuous Unrealized Loss Position Less Than 12 Months Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">$ 1,314<span></span>
</td>
<td class="nump">$ 1,651<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued payroll and other employee benefits</a></td>
<td class="nump">$ 5,533<span></span>
</td>
<td class="nump">$ 6,451<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_AccruedResearchAndDevelopment', window );">Accrued research and development expenses</a></td>
<td class="nump">9,840<span></span>
</td>
<td class="nump">6,612<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued legal and professional fees</a></td>
<td class="nump">316<span></span>
</td>
<td class="nump">296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_AccruedOtherGeneralAndAdministrativeFee', window );">Accrued other general and administrative fees</a></td>
<td class="nump">755<span></span>
</td>
<td class="nump">233<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Total accrued and other current liabilities</a></td>
<td class="nump">$ 16,444<span></span>
</td>
<td class="nump">$ 13,592<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_AccruedOtherGeneralAndAdministrativeFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Other General And Administrative Fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_AccruedOtherGeneralAndAdministrativeFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_AccruedResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_AccruedResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Reserved Shares of Common Stock (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_CommonStockOptionsGrantedAndOutstanding', window );">Common stock options granted and outstanding</a></td>
<td class="nump">13,617,445<span></span>
</td>
<td class="nump">10,462,129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Pre-funded warrants issued and outstanding</a></td>
<td class="nump">6,381,950<span></span>
</td>
<td class="nump">8,382,187<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common stock reserved for future issuance</a></td>
<td class="nump">23,480,092<span></span>
</td>
<td class="nump">23,387,099<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tyra_TwentyTwentyOneEquityIncentivePlanMember', window );">2021 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common stock reserved for future issuance</a></td>
<td class="nump">1,528,992<span></span>
</td>
<td class="nump">3,051,588<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tyra_TwentyTwentyOneEmployeeStockPurchasePlanMember', window );">2021 Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_SharesAvailableForFutureIssuance', window );">Shares available for future issuance</a></td>
<td class="nump">1,951,705<span></span>
</td>
<td class="nump">1,491,195<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_CommonStockOptionsGrantedAndOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock options granted and outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_CommonStockOptionsGrantedAndOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_SharesAvailableForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Available For Future Issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_SharesAvailableForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tyra_TwentyTwentyOneEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=tyra_TwentyTwentyOneEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tyra_TwentyTwentyOneEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=tyra_TwentyTwentyOneEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 08, 2025</div></th>
<th class="th"><div>Oct. 18, 2024</div></th>
<th class="th"><div>Feb. 06, 2024</div></th>
<th class="th"><div>Oct. 03, 2022</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,706,357<span></span>
</td>
<td class="nump">50,754,262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants issued, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,558<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_WarrantsAvailableForExercise', window );">Warrants available for exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Pre-funded warrants issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,381,950<span></span>
</td>
<td class="nump">8,382,187<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=tyra_AtmSalesAgreementMember', window );">ATM Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_CommissionForAgentOnSales', window );">Commission for agent on sales</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_AggregateCommonStockOfferingPrice', window );">Aggregate offering price</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_ExchangeOfCommonStockForPre-FundedWarrantsShares', window );">Exchange of common stock for pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=tyra_PreFundedWarrantsMember', window );">Pre-funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_Pre-FundedWarrantsAvailableForExercise', window );">Pre-Funded Warrants available for exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,381,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,286,023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_Pre-FundedWarrantsAvailableForExercise', window );">Pre-Funded Warrants available for exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,381,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_ExerciseOfPre-FundedWarrants', window );">Exercise of Pre-funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_ExchangeOfCommonStockForPre-FundedWarrantsShares', window );">Exchange of common stock for pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member] | Pre-funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_ExchangeOfCommonStockForPre-FundedWarrantsShares', window );">Exchange of common stock for pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member] | Pre-funded Warrants [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member] | 2024 pre funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_ExerciseOfPre-FundedWarrants', window );">Exercise of Pre-funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tyra_TwoThousandTwentyFourPrivatePlacementMember', window );">2024 Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds From Issuance Of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_OfferingExpenses', window );">Offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tyra_TwoThousandTwentyFourPrivatePlacementMember', window );">2024 Private Placement [Member] | Pre-funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_WarrantsIssuedPricePerShare', window );">Warrants issued price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,087,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tyra_TwoThousandTwentyFourPrivatePlacementMember', window );">2024 Private Placement [Member] | Pre-funded Warrants [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,780,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants issued, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,243,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tyra_TwoThousandTwentyFourPrivatePlacementMember', window );">2024 Private Placement [Member] | Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,286,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share issued, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_AggregateCommonStockOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate Common Stock Offering Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_AggregateCommonStockOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_CommissionForAgentOnSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission For Agent on Sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_CommissionForAgentOnSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_ExchangeOfCommonStockForPre-FundedWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exchange of Common Stock for Pre-Funded Warrants Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_ExchangeOfCommonStockForPre-FundedWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_ExerciseOfPre-FundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise of Pre-funded Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_ExerciseOfPre-FundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_OfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Offering Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_OfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_Pre-FundedWarrantsAvailableForExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pre-Funded Warrants Available for Exercise</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_Pre-FundedWarrantsAvailableForExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_WarrantsAvailableForExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Available for Exercise</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_WarrantsAvailableForExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_WarrantsIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Issued Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_WarrantsIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=tyra_AtmSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=tyra_AtmSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=tyra_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=tyra_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=tyra_TwoThousandTwentyFourPreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=tyra_TwoThousandTwentyFourPreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tyra_TwoThousandTwentyFourPrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=tyra_TwoThousandTwentyFourPrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans and Stock-Based Compensation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost related to options</a></td>
<td class="nump">$ 75.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Term of Unrecognized Expense</a></td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common stock reserved for future issuance</a></td>
<td class="nump">23,480,092<span></span>
</td>
<td class="nump">23,387,099<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost', window );">Share-Based Payment Arrangement, Accelerated Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tyra_TwoThousandsAndTwentyOneIncentiveAwardPlanMember', window );">2021 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_SharesReservedForFutureIssuance', window );">Shares reserved for future issuance</a></td>
<td class="nump">1,528,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_StockholdersEquityIncreaseDecreaseInCommonStockPercent', window );">Increase in common stock</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant fair value</a></td>
<td class="nump">$ 9.05<span></span>
</td>
<td class="nump">$ 15.95<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost related to options</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Term of Unrecognized Expense</a></td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common stock reserved for future issuance</a></td>
<td class="nump">1,951,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_EmployeeStockPurchasePlanDescription', window );">Employee Stock Purchase Plan Description</a></td>
<td class="text">The ESPP permits eligible employees who elect to participate in an offering under the ESPP to have up to 15% of their eligible earnings withheld, subject to certain limitations, to purchase shares of common stock pursuant to the ESPP. The price of common stock purchased under the ESPP is equal to 85% of the lower of the fair market value of the common stock at the commencement date of each offering period or the relevant date of purchase. <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_PurchaseOfCommonStockThroughPayrollDeduction', window );">Purchase of common stock through payroll deduction</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Fair market value of the common stock, percentage</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_EmployeeStockPurchasePlanDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee Stock Purchase Plan Description</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_EmployeeStockPurchasePlanDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_PurchaseOfCommonStockThroughPayrollDeduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase of common stock through payroll deduction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_PurchaseOfCommonStockThroughPayrollDeduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_SharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares reserved for future issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_SharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_StockholdersEquityIncreaseDecreaseInCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stockholders' equity increase decrease in common stock percent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_StockholdersEquityIncreaseDecreaseInCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tyra_TwoThousandsAndTwentyOneIncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=tyra_TwoThousandsAndTwentyOneIncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans and Stock-Based Compensation - Summary of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Outstanding Options, Beginning balance</a></td>
<td class="nump">10,462,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriod', window );">Number of Outstanding Options, Granted</a></td>
<td class="nump">5,029,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Outstanding Options, Exercised</a></td>
<td class="num">(904,993)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of Outstanding Options, Cancelled</a></td>
<td class="num">(968,881)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Outstanding Options, Ending balance</a></td>
<td class="nump">13,617,445<span></span>
</td>
<td class="nump">10,462,129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Outstanding Options, Exercisable</a></td>
<td class="nump">6,300,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Outstanding Options, Vested and expected to vest</a></td>
<td class="nump">13,617,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Beginning balance</a></td>
<td class="nump">$ 13.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Granted</a></td>
<td class="nump">12.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Exercised</a></td>
<td class="nump">8.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Forfeited</a></td>
<td class="nump">16.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Ending balance</a></td>
<td class="nump">12.58<span></span>
</td>
<td class="nump">$ 13.43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Exercisable</a></td>
<td class="nump">11.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Vested and expected to vest</a></td>
<td class="nump">$ 12.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Remaining Contractual Term</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted- Average Remaining Contractual Term, Exercisable</a></td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted- Average Remaining Contractual Term, Vested and expected to vest</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Beginning balance</a></td>
<td class="nump">$ 33,798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Ending balance</a></td>
<td class="nump">186,669<span></span>
</td>
<td class="nump">$ 33,798<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">93,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and expected to vest</a></td>
<td class="nump">$ 186,669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Granted in Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans and Stock-Based Compensation - Summary of Fair Value of Stock Option Grants (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate of interest</a></td>
<td class="nump">3.80%<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">5 years 1 month 6 days<span></span>
</td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">84.80%<span></span>
</td>
<td class="nump">87.80%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate of interest</a></td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">4.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">95.40%<span></span>
</td>
<td class="nump">98.70%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans and Stock-Based Compensation - Summary of Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 28,006<span></span>
</td>
<td class="nump">$ 22,801<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">15,749<span></span>
</td>
<td class="nump">14,291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 12,257<span></span>
</td>
<td class="nump">$ 8,510<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Basic and Diluted Net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_NumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (119,947)<span></span>
</td>
<td class="num">$ (86,481)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_DenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageBasicSharesOutstandingProForma', window );">Weighted average common shares outstanding</a></td>
<td class="nump">59,602,328<span></span>
</td>
<td class="nump">57,250,061<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_WeightedAverageUnvestedCommonStockIssuedUponExerciseOfCommonStockOptions', window );">Less: weighted average unvested common stock issued upon early exercise of common stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(32,315)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares used to compute net loss per share - basic</a></td>
<td class="nump">59,602,328<span></span>
</td>
<td class="nump">57,217,746<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares used to compute net loss per share - diluted</a></td>
<td class="nump">59,602,328<span></span>
</td>
<td class="nump">57,217,746<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (2.01)<span></span>
</td>
<td class="num">$ (1.51)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (2.01)<span></span>
</td>
<td class="num">$ (1.51)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_DenominatorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Denominator [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_DenominatorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_NumeratorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Numerator</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_NumeratorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_WeightedAverageUnvestedCommonStockIssuedUponExerciseOfCommonStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average unvested common stock issued upon early exercise of common stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_WeightedAverageUnvestedCommonStockIssuedUponExerciseOfCommonStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageBasicSharesOutstandingProForma">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average number of shares (units) outstanding in the calculation of pro forma basic earnings per share (earnings per unit), which is commonly presented in initial public offerings based on the terms of the offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageBasicSharesOutstandingProForma</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Potentially Dilutive Securities Including All Outstanding Stock Options were excluded in Calculation of Diluted Shares Outstanding (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">13,645,206<span></span>
</td>
<td class="nump">10,480,726<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tyra_UnvestedCommonStockExerciseOfStockOptionsMember', window );">Unvested common stock upon early exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,317<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tyra_StockOptionsToPurchaseCommonStockMember', window );">Options to Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">13,617,445<span></span>
</td>
<td class="nump">10,462,129<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tyra_EstimatedSharesPurchasableUnderTheEsppMember', window );">Estimated shares purchasable under the ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">27,761<span></span>
</td>
<td class="nump">14,280<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tyra_UnvestedCommonStockExerciseOfStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tyra_UnvestedCommonStockExerciseOfStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tyra_StockOptionsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tyra_StockOptionsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tyra_EstimatedSharesPurchasableUnderTheEsppMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tyra_EstimatedSharesPurchasableUnderTheEsppMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Expected tax benefit at statutory rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (25,189)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (18,161)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax benefit at statutory federal rate Percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income tax, net of federal benefit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (1,330)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(134)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State and local taxes, net of federal benefit Percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1.11%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsAbstract', window );"><strong>Tax credits</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research credits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (6,411)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(4,363)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research credits Percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5.35%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 23,683<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">22,431<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance Percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(19.75%)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract', window );"><strong>Nontaxable or nondeductible items</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,653<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(757)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_IncometaxreconciliationOfficersCompensation', window );">Officers compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,725<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 46<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock based compensation Percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1.38%)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Other Percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(0.04%)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_IncomeTaxReconciliationOfficersCompensationPercentage', window );">Officer compensation Percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3.94%)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_IncomeTaxReconciliationChangesInUnrecognizedTaxBenefits', window );">Changes in unrecognized tax benefits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,823<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_IncomeTaxReconciliationChangesInUnrecognizedTaxBenefitsPercentage', window );">Changes in unrecognized tax benefits Percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2.35%)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Provision for income taxes, Percent</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The state that contributes to the majority (greater than 50%) of the tax effect in this category is California for the year ended December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_IncomeTaxReconciliationChangesInUnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax Reconciliation Changes in Unrecognized Tax Benefits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_IncomeTaxReconciliationChangesInUnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_IncomeTaxReconciliationChangesInUnrecognizedTaxBenefitsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax Reconciliation Changes in Unrecognized Tax Benefits Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_IncomeTaxReconciliationChangesInUnrecognizedTaxBenefitsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_IncomeTaxReconciliationOfficersCompensationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax Reconciliation Officers Compensation Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_IncomeTaxReconciliationOfficersCompensationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_IncometaxreconciliationOfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>IncomeTaxReconciliation Officers Compensation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_IncometaxreconciliationOfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 41,792<span></span>
</td>
<td class="nump">$ 18,938<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_DeferredTaxAssetsCapitalizedResearchAndDevelopment', window );">Capitalized research and development</a></td>
<td class="nump">24,439<span></span>
</td>
<td class="nump">27,105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_DeferredTaxAssetsTaxCredits', window );">Tax credits</a></td>
<td class="nump">16,380<span></span>
</td>
<td class="nump">10,725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock based compensation</a></td>
<td class="nump">4,570<span></span>
</td>
<td class="nump">5,771<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other, net</a></td>
<td class="nump">2,287<span></span>
</td>
<td class="nump">2,267<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">89,468<span></span>
</td>
<td class="nump">64,806<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(88,026)<span></span>
</td>
<td class="num">(63,267)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net of valuation allowance</a></td>
<td class="nump">1,442<span></span>
</td>
<td class="nump">1,539<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="num">(175)<span></span>
</td>
<td class="num">(256)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Right of use assets</a></td>
<td class="num">(1,182)<span></span>
</td>
<td class="num">(1,283)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Deferred Tax Liabilities, Other</a></td>
<td class="num">(85)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(1,442)<span></span>
</td>
<td class="num">(1,539)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets / (liabilities)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_DeferredTaxAssetsCapitalizedResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Capitalized Research And Development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_DeferredTaxAssetsCapitalizedResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_DeferredTaxAssetsTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_DeferredTaxAssetsTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for or benefit from income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred tax assets, valuation allowance</a></td>
<td class="nump">88,026<span></span>
</td>
<td class="nump">$ 63,267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Change in valuation allowance</a></td>
<td class="nump">$ 24,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_NetOperatingLossCarryforwardsAvailableForOffsettingAgainstFutureTaxableIncomePercentage', window );">Percentage of federal net operating losses used to offset of future taxable income</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_NetOperatingLossCarryForwardIndefinitely', window );">Net Operating Loss Carry Forward Indefinitely</a></td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_OperatingLossCarryforwardsExpirationDates1', window );">Net operating loss carryforwards, expire date</a></td>
<td class="text">Unless previously utilized, the state net operating losses will begin to expire in 2038.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued', window );">Penalties and interest accrued</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=tyra_FederalMember', window );">Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=tyra_StateMember', window );">State [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Country [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Tax loss carryforwards</a></td>
<td class="nump">188,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_NetOperatingLossCarryForwardIndefinitely', window );">Net Operating Loss Carry Forward Indefinitely</a></td>
<td class="nump">188,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">$ 18,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_ResearchAndDevelopmentCreditCarryforwardsUnderInternalRevenueCodeDescription', window );">Research and development credit carryforwards under internal revenue code description</a></td>
<td class="text"> The federal research and development tax credit carryforwards begin to expire in 2040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Tax loss carryforwards</a></td>
<td class="nump">$ 67,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_ResearchAndDevelopmentCreditCarryforwardsUnderInternalRevenueCodeDescription', window );">Research and development credit carryforwards under internal revenue code description</a></td>
<td class="text">development tax credit carryforwards of $0.1 million will begin to expire in 2039.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_NetOperatingLossCarryForwardIndefinitely">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Operating Loss Carry Forward Indefinitely</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_NetOperatingLossCarryForwardIndefinitely</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_NetOperatingLossCarryforwardsAvailableForOffsettingAgainstFutureTaxableIncomePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Operating Loss Carryforwards Available For Offsetting Against Future Taxable Income Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_NetOperatingLossCarryforwardsAvailableForOffsettingAgainstFutureTaxableIncomePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_OperatingLossCarryforwardsExpirationDates1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards expiration dates 1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_OperatingLossCarryforwardsExpirationDates1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_ResearchAndDevelopmentCreditCarryforwardsUnderInternalRevenueCodeDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development credit carryforwards under internal revenue code description</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_ResearchAndDevelopmentCreditCarryforwardsUnderInternalRevenueCodeDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=tyra_FederalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=tyra_FederalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=tyra_StateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=tyra_StateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance at January 1</a></td>
<td class="nump">$ 5,529<span></span>
</td>
<td class="nump">$ 3,006<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions related to current year positions</a></td>
<td class="nump">2,043<span></span>
</td>
<td class="nump">1,869<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions related to prior year positions</a></td>
<td class="nump">1,133<span></span>
</td>
<td class="nump">654<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance at December 31</a></td>
<td class="nump">$ 8,705<span></span>
</td>
<td class="nump">$ 5,529<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Additional Information) (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 31, 2021 </div>
<div>Renewal</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 957<span></span>
</td>
<td class="nump">$ 957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Lease liability paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=tyra_FirstAmendmentMember', window );">First Amendment [Member] | Lease Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_AreaOfLease', window );">Area of lease | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,331<span></span>
</td>
<td class="nump">4,734<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=tyra_FirstAmendmentMember', window );">First Amendment [Member] | Office and Laboratory Facilities [Member] | Lease Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term of contract</a></td>
<td class="text">60 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tyra_NumberOfLeaseTermRenewal', window );">Number of lease term renewal option | Renewal</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease renewal term</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=tyra_ExpansionLeaseAgreementMember', window );">Expansion Lease Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">120 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Long-term line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=tyra_TwoThousandTwentySevenLeaseAgreementMember', window );">2027 Lease Agreement [Member] | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Long-term line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=tyra_TwoThousandTwentyEightLeaseAgreementMember', window );">2028 Lease Agreement [Member] | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Long-term line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_AreaOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of Lease</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_AreaOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tyra_NumberOfLeaseTermRenewal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of lease term renewal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tyra_NumberOfLeaseTermRenewal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tyra_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=tyra_FirstAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=tyra_FirstAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=us-gaap_LeaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=us-gaap_LeaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=srt_OfficeBuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=srt_OfficeBuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=tyra_ExpansionLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=tyra_ExpansionLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=tyra_TwoThousandTwentySevenLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=tyra_TwoThousandTwentySevenLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=tyra_TwoThousandTwentyEightLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=tyra_TwoThousandTwentyEightLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Components of Lease Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease, Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 957<span></span>
</td>
<td class="nump">$ 957<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">139<span></span>
</td>
<td class="nump">127<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 1,186<span></span>
</td>
<td class="nump">$ 1,174<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Maturities Lease Liabilities Weighted-Average Remaining Term and Weighted-Average Discount Rate (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2026</a></td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2027</a></td>
<td class="nump">927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2028</a></td>
<td class="nump">955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2029</a></td>
<td class="nump">983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2030</a></td>
<td class="nump">1,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">3,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">7,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: amount representing interest</a></td>
<td class="num">(2,003)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">5,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion of lease liabilities</a></td>
<td class="num">(472)<span></span>
</td>
<td class="num">$ (412)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, noncurrent</a></td>
<td class="nump">$ 5,338<span></span>
</td>
<td class="nump">$ 5,810<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (years) - operating leases</a></td>
<td class="text">7 years 10 months 24 days<span></span>
</td>
<td class="text">8 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average incremental borrowing rate - operating leases</a></td>
<td class="nump">8.07%<span></span>
</td>
<td class="nump">8.07%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits (Additional Information) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsAbstract', window );"><strong>Compensation Related Costs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Employee contribution percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Maximum employee contributions</a></td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Employer contributions</a></td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-18<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Additional Information) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration', window );">Segment Reporting, Expense Information Used by CODM, Type [Extensible Enumeration]</a></td>
<td class="text">Chief Operating Decision Maker [Member]<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription', window );">Segment reporting, CODM, profit (loss) measure, how used, description</a></td>
<td class="text">net loss<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of how chief operating decision maker (CODM) uses reported segment profit (loss) measure to assess performance and allocate resource.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates type of expense information used by chief operating decision maker (CODM) to manage operation when segment expense information by category is not disclosed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Schedule of reconciliation of the Company's net loss (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and Development Expense [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 102,928<span></span>
</td>
<td class="nump">$ 80,077<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">29,834<span></span>
</td>
<td class="nump">24,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest and other income, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(12,815)<span></span>
</td>
<td class="num">(17,696)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(119,947)<span></span>
</td>
<td class="num">(86,481)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=tyra_ChiefOperatingDecisionMakerMember', window );">CODM</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and Development Expense [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">102,928<span></span>
</td>
<td class="nump">80,077<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">29,834<span></span>
</td>
<td class="nump">24,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest and other income, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(12,815)<span></span>
</td>
<td class="num">(17,696)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(119,947)<span></span>
</td>
<td class="num">(86,481)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=tyra_ChiefOperatingDecisionMakerMember', window );">CODM | TYRA-300ACH</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and Development Expense [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,379<span></span>
</td>
<td class="nump">7,718<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=tyra_ChiefOperatingDecisionMakerMember', window );">CODM | TYRA-300NMIBC</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and Development Expense [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,244<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=tyra_ChiefOperatingDecisionMakerMember', window );">CODM | TYRA-300UTUC</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and Development Expense [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,440<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=tyra_ChiefOperatingDecisionMakerMember', window );">CODM | TYRA-300mUC</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and Development Expense [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,590<span></span>
</td>
<td class="nump">14,319<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=tyra_ChiefOperatingDecisionMakerMember', window );">CODM | TYRA-430</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and Development Expense [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,055<span></span>
</td>
<td class="nump">5,677<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=tyra_ChiefOperatingDecisionMakerMember', window );">CODM | TYRA-200</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and Development Expense [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,308<span></span>
</td>
<td class="nump">4,969<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=tyra_ChiefOperatingDecisionMakerMember', window );">CODM | FGFR Discovery</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and Development Expense [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,967<span></span>
</td>
<td class="nump">8,199<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=tyra_ChiefOperatingDecisionMakerMember', window );">CODM | Personnel Costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and Development Expense [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">36,218<span></span>
</td>
<td class="nump">30,423<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=tyra_ChiefOperatingDecisionMakerMember', window );">CODM | Other development programs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and Development Expense [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,623<span></span>
</td>
<td class="nump">2,537<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=tyra_ChiefOperatingDecisionMakerMember', window );">CODM | Facilities and Other Costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and Development Expense [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">$ 6,104<span></span>
</td>
<td class="nump">$ 6,113<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses consist of personnel-related expenses, including stock-based compensation, legal fees, facility-related costs, depreciation, professional and consulting fees and insurance costs.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Personnel costs include $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">15.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">14.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of stock-based compensation for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Facilities and other costs consist of research consumables, facility-related costs, depreciation and costs not attributed to a specific program.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=tyra_ChiefOperatingDecisionMakerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=tyra_ChiefOperatingDecisionMakerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=tyra_TYRA-300ACHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=tyra_TYRA-300ACHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=tyra_TYRA-300NMIBCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=tyra_TYRA-300NMIBCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=tyra_TYRA-300UTUCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=tyra_TYRA-300UTUCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=tyra_TYRA-300MUCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=tyra_TYRA-300MUCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=tyra_TYRA-430Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=tyra_TYRA-430Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=tyra_TYRA-200Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=tyra_TYRA-200Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=tyra_FGFRDiscoveryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=tyra_FGFRDiscoveryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=tyra_PersonnelCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=tyra_PersonnelCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=tyra_OtherDevelopmentProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=tyra_OtherDevelopmentProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=tyra_FacilitiesAndOtherCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=tyra_FacilitiesAndOtherCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Schedule of reconciliation of the Company's net loss (Parenthetical) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Employee Benefits And Share Based Compensation</a></td>
<td class="nump">$ 15.7<span></span>
</td>
<td class="nump">$ 14.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>180</ContextCount>
  <ElementCount>341</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>59</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="tyra-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>75000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tyra.bio/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="tyra-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>75010 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="tyra-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>75020 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="tyra-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>75030 - Statement - Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="tyra-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>75050 - Statement - Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity</Role>
      <ShortName>Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="tyra-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>75060 - Statement - Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfStockholdersEquityParenthetical</Role>
      <ShortName>Statements of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="tyra-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>75070 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="tyra-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="tyra-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="tyra-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="tyra-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995457 - Disclosure - Cybersecurity Risk Management, Strategy, and Governance</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tyra.bio/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance</Role>
      <ShortName>Cybersecurity Risk Management, Strategy, and Governance</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="tyra-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995467 - Disclosure - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tyra.bio/20251231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="tyra-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995477 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tyra.bio/20251231/taxonomy/role/Role_DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="tyra-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995487 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="tyra-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995507 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tyra.bio/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="tyra-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995527 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquity1</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="tyra-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995537 - Disclosure - Equity Incentive Plans and Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensation</Role>
      <ShortName>Equity Incentive Plans and Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="tyra-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995547 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tyra.bio/20251231/taxonomy/role/Role_DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="tyra-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995557 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="tyra-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995567 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tyra.bio/20251231/taxonomy/role/DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="tyra-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995577 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tyra.bio/20251231/taxonomy/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="tyra-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995587 - Disclosure - Employee Benefits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tyra.bio/20251231/taxonomy/role/Role_DisclosureEmployeeBenefits</Role>
      <ShortName>Employee Benefits</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="tyra-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995597 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tyra.bio/20251231/taxonomy/role/DisclosureSegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="tyra-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995607 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tyra.bio/20251231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://tyra.bio/20251231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="tyra-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995617 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tyra.bio/20251231/taxonomy/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tyra.bio/20251231/taxonomy/role/Role_DisclosureFairValueMeasurements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="tyra-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995627 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecurities</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="tyra-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995647 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tyra.bio/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tyra.bio/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="tyra-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995657 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquity1</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="tyra-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995667 - Disclosure - Equity Incentive Plans and Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationTables</Role>
      <ShortName>Equity Incentive Plans and Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensation</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="tyra-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995677 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tyra.bio/20251231/taxonomy/role/Role_DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tyra.bio/20251231/taxonomy/role/Role_DisclosureNetLossPerShare</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="tyra-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995687 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxes</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="tyra-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995697 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tyra.bio/20251231/taxonomy/role/DisclosureLeases</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="tyra-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995707 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tyra.bio/20251231/taxonomy/role/DisclosureSegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tyra.bio/20251231/taxonomy/role/DisclosureSegmentInformation</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="tyra-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995717 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tyra.bio/20251231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="tyra-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995727 - Disclosure - Fair Value Measurements - Assets measured at fair value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tyra.bio/20251231/taxonomy/role/DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Assets measured at fair value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="tyra-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995737 - Disclosure - Marketable Securities - Summary of Available-for-Sale Securities and Gross Unrealized Losses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableforsaleSecuritiesAndGrossUnrealizedLossesDetails</Role>
      <ShortName>Marketable Securities - Summary of Available-for-Sale Securities and Gross Unrealized Losses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="tyra-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995747 - Disclosure - Marketable Securities (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails</Role>
      <ShortName>Marketable Securities (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecuritiesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="tyra-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995757 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tyra.bio/20251231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="tyra-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995777 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tyra.bio/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="tyra-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995787 - Disclosure - Stockholders' Equity - Summary of Reserved Shares of Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquitySummaryOfReservedSharesOfCommonStockDetails</Role>
      <ShortName>Stockholders' Equity - Summary of Reserved Shares of Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="tyra-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995797 - Disclosure - Stockholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Stockholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="tyra-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995807 - Disclosure - Equity Incentive Plans and Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Equity Incentive Plans and Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="tyra-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995817 - Disclosure - Equity Incentive Plans and Stock-Based Compensation - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationSummaryOfStockOptionActivityDetails</Role>
      <ShortName>Equity Incentive Plans and Stock-Based Compensation - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="tyra-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995827 - Disclosure - Equity Incentive Plans and Stock-Based Compensation - Summary of Fair Value of Stock Option Grants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationSummaryOfFairValueOfStockOptionGrantsDetails</Role>
      <ShortName>Equity Incentive Plans and Stock-Based Compensation - Summary of Fair Value of Stock Option Grants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="tyra-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995837 - Disclosure - Equity Incentive Plans and Stock-Based Compensation - Summary of Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails</Role>
      <ShortName>Equity Incentive Plans and Stock-Based Compensation - Summary of Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="tyra-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995857 - Disclosure - Net Loss Per Share - Basic and Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tyra.bio/20251231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Basic and Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="tyra-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995867 - Disclosure - Net Loss Per Share - Potentially Dilutive Securities Including All Outstanding Stock Options were excluded in Calculation of Diluted Shares Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tyra.bio/20251231/taxonomy/role/Role_DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesIncludingAllOutstandingStockOptionsWereExcludedInCalculationOfDilutedSharesOutstandingDetails</Role>
      <ShortName>Net Loss Per Share - Potentially Dilutive Securities Including All Outstanding Stock Options were excluded in Calculation of Diluted Shares Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="tyra-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995877 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="tyra-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995887 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="tyra-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995897 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="tyra-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995907 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails</Role>
      <ShortName>Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="tyra-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>995917 - Disclosure - Leases (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails</Role>
      <ShortName>Leases (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="tyra-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>995927 - Disclosure - Leases - Schedule of Components of Lease Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails</Role>
      <ShortName>Leases - Schedule of Components of Lease Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="tyra-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>995937 - Disclosure - Leases - Schedule of Maturities Lease Liabilities Weighted-Average Remaining Term and Weighted-Average Discount Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesLeaseLiabilitiesWeightedaverageRemainingTermAndWeightedaverageDiscountRateDetails</Role>
      <ShortName>Leases - Schedule of Maturities Lease Liabilities Weighted-Average Remaining Term and Weighted-Average Discount Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="tyra-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>995957 - Disclosure - Employee Benefits (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tyra.bio/20251231/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformationDetails</Role>
      <ShortName>Employee Benefits (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tyra.bio/20251231/taxonomy/role/Role_DisclosureEmployeeBenefits</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="tyra-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>995967 - Disclosure - Segment Information (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tyra.bio/20251231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails</Role>
      <ShortName>Segment Information (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tyra.bio/20251231/taxonomy/role/DisclosureSegmentInformationTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="tyra-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>995977 - Disclosure - Segment Information - Schedule of reconciliation of the Company's net loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tyra.bio/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfTheCompanysNetLossDetails</Role>
      <ShortName>Segment Information - Schedule of reconciliation of the Company's net loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="tyra-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>995987 - Disclosure - Segment Information - Schedule of reconciliation of the Company's net loss (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tyra.bio/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfTheCompanysNetLossParentheticalDetails</Role>
      <ShortName>Segment Information - Schedule of reconciliation of the Company's net loss (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="tyra-20251231.htm">tyra-20251231.htm</File>
    <File>tyra-20251231.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img94995564_0.jpg</File>
    <File>img94995564_1.jpg</File>
    <File>img94995564_2.jpg</File>
    <File>img94995564_3.jpg</File>
    <File>img94995564_4.jpg</File>
    <File>img94995564_5.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="512">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="14">http://xbrl.sec.gov/cyd/2025</BaseTaxonomy>
    <BaseTaxonomy items="41">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="16">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>80
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tyra-20251231.htm": {
   "nsprefix": "tyra",
   "nsuri": "http://tyra.bio/20251231",
   "dts": {
    "inline": {
     "local": [
      "tyra-20251231.htm"
     ]
    },
    "schema": {
     "local": [
      "tyra-20251231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    }
   },
   "keyStandard": 276,
   "keyCustom": 65,
   "axisStandard": 22,
   "axisCustom": 0,
   "memberStandard": 27,
   "memberCustom": 30,
   "hidden": {
    "total": 9,
    "http://fasb.org/us-gaap/2025": 5,
    "http://xbrl.sec.gov/dei/2025": 4
   },
   "contextCount": 180,
   "entityCount": 1,
   "segmentCount": 59,
   "elementCount": 667,
   "unitCount": 7,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 512,
    "http://xbrl.sec.gov/dei/2025": 41,
    "http://xbrl.sec.gov/ecd/2025": 16,
    "http://xbrl.sec.gov/cyd/2025": 14
   },
   "report": {
    "R1": {
     "role": "http://tyra.bio/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "longName": "75000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheets",
     "longName": "75010 - Statement - Balance Sheets",
     "shortName": "Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_b1df5da0-307d-4f91-b407-099a8215e1e5",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b1df5da0-307d-4f91-b407-099a8215e1e5",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheetsParenthetical",
     "longName": "75020 - Statement - Balance Sheets (Parenthetical)",
     "shortName": "Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_b1df5da0-307d-4f91-b407-099a8215e1e5",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b1df5da0-307d-4f91-b407-099a8215e1e5",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss",
     "longName": "75030 - Statement - Statements of Operations and Comprehensive Loss",
     "shortName": "Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:OperatingExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity",
     "longName": "75050 - Statement - Statements of Stockholders' Equity",
     "shortName": "Statements of Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_90b314f0-e678-446e-845b-a940c76b3ed3",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_90b314f0-e678-446e-845b-a940c76b3ed3",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfStockholdersEquityParenthetical",
     "longName": "75060 - Statement - Statements of Stockholders' Equity (Parenthetical)",
     "shortName": "Statements of Stockholders' Equity (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_15910e68-42b0-4058-8d01-7cdf352e9ab5",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_15910e68-42b0-4058-8d01-7cdf352e9ab5",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows",
     "longName": "75070 - Statement - Statements of Cash Flows",
     "shortName": "Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_6f8e39dd-1c81-4d46-8007-0bbb98e5748d",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6f8e39dd-1c81-4d46-8007-0bbb98e5748d",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://tyra.bio/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance",
     "longName": "995457 - Disclosure - Cybersecurity Risk Management, Strategy, and Governance",
     "shortName": "Cybersecurity Risk Management, Strategy, and Governance",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://tyra.bio/20251231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies",
     "longName": "995467 - Disclosure - Organization and Summary of Significant Accounting Policies",
     "shortName": "Organization and Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureFairValueMeasurements",
     "longName": "995477 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecurities",
     "longName": "995487 - Disclosure - Marketable Securities",
     "shortName": "Marketable Securities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://tyra.bio/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities",
     "longName": "995507 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquity1",
     "longName": "995527 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensation",
     "longName": "995537 - Disclosure - Equity Incentive Plans and Stock-Based Compensation",
     "shortName": "Equity Incentive Plans and Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureNetLossPerShare",
     "longName": "995547 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxes",
     "longName": "995557 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://tyra.bio/20251231/taxonomy/role/DisclosureLeases",
     "longName": "995567 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://tyra.bio/20251231/taxonomy/role/DisclosureCommitmentsAndContingencies",
     "longName": "995577 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureEmployeeBenefits",
     "longName": "995587 - Disclosure - Employee Benefits",
     "shortName": "Employee Benefits",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://tyra.bio/20251231/taxonomy/role/DisclosureSegmentInformation",
     "longName": "995597 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://tyra.bio/20251231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "995607 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)",
     "shortName": "Organization and Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "tyra:OrganizationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "tyra:OrganizationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://tyra.bio/20251231/taxonomy/role/DisclosureFairValueMeasurementsTables",
     "longName": "995617 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecuritiesTables",
     "longName": "995627 - Disclosure - Marketable Securities (Tables)",
     "shortName": "Marketable Securities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://tyra.bio/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables",
     "longName": "995647 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquityTables",
     "longName": "995657 - Disclosure - Stockholders' Equity (Tables)",
     "shortName": "Stockholders' Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationTables",
     "longName": "995667 - Disclosure - Equity Incentive Plans and Stock-Based Compensation (Tables)",
     "shortName": "Equity Incentive Plans and Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureNetLossPerShareTables",
     "longName": "995677 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesTables",
     "longName": "995687 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesTables",
     "longName": "995697 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://tyra.bio/20251231/taxonomy/role/DisclosureSegmentInformationTables",
     "longName": "995707 - Disclosure - Segment Information (Tables)",
     "shortName": "Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://tyra.bio/20251231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "longName": "995717 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Details)",
     "shortName": "Organization and Summary of Significant Accounting Policies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_b1df5da0-307d-4f91-b407-099a8215e1e5",
      "name": "us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "dei:EntityIncorporationDateOfIncorporation",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "tyra:OrganizationPolicyTextBlock",
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://tyra.bio/20251231/taxonomy/role/DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails",
     "longName": "995727 - Disclosure - Fair Value Measurements - Assets measured at fair value (Details)",
     "shortName": "Fair Value Measurements - Assets measured at fair value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_b1df5da0-307d-4f91-b407-099a8215e1e5",
      "name": "us-gaap:MarketableSecurities",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_cdc6cc80-baf4-45fe-8841-dff91027f8b8",
      "name": "us-gaap:AssetsFairValueAdjustment",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableforsaleSecuritiesAndGrossUnrealizedLossesDetails",
     "longName": "995737 - Disclosure - Marketable Securities - Summary of Available-for-Sale Securities and Gross Unrealized Losses (Details)",
     "shortName": "Marketable Securities - Summary of Available-for-Sale Securities and Gross Unrealized Losses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_b1df5da0-307d-4f91-b407-099a8215e1e5",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "div",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b1df5da0-307d-4f91-b407-099a8215e1e5",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "div",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails",
     "longName": "995747 - Disclosure - Marketable Securities (Additional Information) (Details)",
     "shortName": "Marketable Securities (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_75025707-e814-4796-aefb-117d79769679",
      "name": "tyra:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b1df5da0-307d-4f91-b407-099a8215e1e5",
      "name": "tyra:AccruedInterestAvailableForSaleSecurities",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://tyra.bio/20251231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
     "longName": "995757 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)",
     "shortName": "Property and Equipment - Schedule of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_b1df5da0-307d-4f91-b407-099a8215e1e5",
      "name": "us-gaap:PropertyPlantAndEquipmentNet",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R39": {
     "role": "http://tyra.bio/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
     "longName": "995777 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)",
     "shortName": "Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_b1df5da0-307d-4f91-b407-099a8215e1e5",
      "name": "us-gaap:AccruedSalariesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b1df5da0-307d-4f91-b407-099a8215e1e5",
      "name": "us-gaap:AccruedSalariesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquitySummaryOfReservedSharesOfCommonStockDetails",
     "longName": "995787 - Disclosure - Stockholders' Equity - Summary of Reserved Shares of Common Stock (Details)",
     "shortName": "Stockholders' Equity - Summary of Reserved Shares of Common Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_b1df5da0-307d-4f91-b407-099a8215e1e5",
      "name": "tyra:CommonStockOptionsGrantedAndOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b1df5da0-307d-4f91-b407-099a8215e1e5",
      "name": "tyra:CommonStockOptionsGrantedAndOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
     "longName": "995797 - Disclosure - Stockholders' Equity - Additional Information (Details)",
     "shortName": "Stockholders' Equity - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_b1df5da0-307d-4f91-b407-099a8215e1e5",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9b41307d-a228-4022-aec0-907dd0345fdf",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationAdditionalInformationDetails",
     "longName": "995807 - Disclosure - Equity Incentive Plans and Stock-Based Compensation - Additional Information (Details)",
     "shortName": "Equity Incentive Plans and Stock-Based Compensation - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_b1df5da0-307d-4f91-b407-099a8215e1e5",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b1df5da0-307d-4f91-b407-099a8215e1e5",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationSummaryOfStockOptionActivityDetails",
     "longName": "995817 - Disclosure - Equity Incentive Plans and Stock-Based Compensation - Summary of Stock Option Activity (Details)",
     "shortName": "Equity Incentive Plans and Stock-Based Compensation - Summary of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_75025707-e814-4796-aefb-117d79769679",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "tyra:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriod",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationSummaryOfFairValueOfStockOptionGrantsDetails",
     "longName": "995827 - Disclosure - Equity Incentive Plans and Stock-Based Compensation - Summary of Fair Value of Stock Option Grants (Details)",
     "shortName": "Equity Incentive Plans and Stock-Based Compensation - Summary of Fair Value of Stock Option Grants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails",
     "longName": "995837 - Disclosure - Equity Incentive Plans and Stock-Based Compensation - Summary of Stock-based Compensation Expense (Details)",
     "shortName": "Equity Incentive Plans and Stock-Based Compensation - Summary of Stock-based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://tyra.bio/20251231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails",
     "longName": "995857 - Disclosure - Net Loss Per Share - Basic and Diluted Net Loss Per Share (Details)",
     "shortName": "Net Loss Per Share - Basic and Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:WeightedAverageBasicSharesOutstandingProForma",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesIncludingAllOutstandingStockOptionsWereExcludedInCalculationOfDilutedSharesOutstandingDetails",
     "longName": "995867 - Disclosure - Net Loss Per Share - Potentially Dilutive Securities Including All Outstanding Stock Options were excluded in Calculation of Diluted Shares Outstanding (Details)",
     "shortName": "Net Loss Per Share - Potentially Dilutive Securities Including All Outstanding Stock Options were excluded in Calculation of Diluted Shares Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails",
     "longName": "995877 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "shortName": "Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails",
     "longName": "995887 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "shortName": "Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_b1df5da0-307d-4f91-b407-099a8215e1e5",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b1df5da0-307d-4f91-b407-099a8215e1e5",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
     "longName": "995897 - Disclosure - Income Taxes - Additional Information (Details)",
     "shortName": "Income Taxes - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails",
     "longName": "995907 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details)",
     "shortName": "Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_75025707-e814-4796-aefb-117d79769679",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_90b314f0-e678-446e-845b-a940c76b3ed3",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
     "longName": "995917 - Disclosure - Leases (Additional Information) (Details)",
     "shortName": "Leases (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails",
     "longName": "995927 - Disclosure - Leases - Schedule of Components of Lease Cost (Details)",
     "shortName": "Leases - Schedule of Components of Lease Cost (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:ShortTermLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesLeaseLiabilitiesWeightedaverageRemainingTermAndWeightedaverageDiscountRateDetails",
     "longName": "995937 - Disclosure - Leases - Schedule of Maturities Lease Liabilities Weighted-Average Remaining Term and Weighted-Average Discount Rate (Details)",
     "shortName": "Leases - Schedule of Maturities Lease Liabilities Weighted-Average Remaining Term and Weighted-Average Discount Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_b1df5da0-307d-4f91-b407-099a8215e1e5",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "tyra:ScheduleOfMaturitiesOfLeaseLiabilitiesWithWeightedAverageRemainingTermAndDiscountRateTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b1df5da0-307d-4f91-b407-099a8215e1e5",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "tyra:ScheduleOfMaturitiesOfLeaseLiabilitiesWithWeightedAverageRemainingTermAndDiscountRateTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://tyra.bio/20251231/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformationDetails",
     "longName": "995957 - Disclosure - Employee Benefits (Additional Information) (Details)",
     "shortName": "Employee Benefits (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://tyra.bio/20251231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails",
     "longName": "995967 - Disclosure - Segment Information (Additional Information) (Details)",
     "shortName": "Segment Information (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://tyra.bio/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfTheCompanysNetLossDetails",
     "longName": "995977 - Disclosure - Segment Information - Schedule of reconciliation of the Company's net loss (Details)",
     "shortName": "Segment Information - Schedule of reconciliation of the Company's net loss (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_88fc6773-cb7f-4a2b-917e-b6e8a47d801c",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://tyra.bio/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfTheCompanysNetLossParentheticalDetails",
     "longName": "995987 - Disclosure - Segment Information - Schedule of reconciliation of the Company's net loss (Parenthetical) (Details)",
     "shortName": "Segment Information - Schedule of reconciliation of the Company's net loss (Parenthetical) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:EmployeeBenefitsAndShareBasedCompensation",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "link:footnote",
       "p",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e9d71edc-f2b4-47d5-ad81-4148af049faa",
      "name": "us-gaap:EmployeeBenefitsAndShareBasedCompensation",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "link:footnote",
       "p",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tyra-20251231.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "tyra_AccountsPayableAccruedExpensesAndOtherLiabilitiesRelatedPartyTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "AccountsPayableAccruedExpensesAndOtherLiabilitiesRelatedPartyTransactions",
     "crdr": "credit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Payable Accrued Expenses And Other Liabilities Related Party Transactions",
        "label": "Accounts Payable Accrued Expenses And Other Liabilities Related Parties Transaction",
        "terseLabel": "Related party transaction, accounts payable, accrued expenses and other liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "Accrued Expenses and Other Current Liabilities",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "totalLabel": "Accounts Payable, Current, Total",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r805"
     ]
    },
    "tyra_AccretionOnMarketableSecuritiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "AccretionOnMarketableSecuritiesNet",
     "crdr": "debit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accretion on marketable securities, net",
        "terseLabel": "Accretion on marketable securities, net",
        "label": "Accretion on marketable securities, net",
        "documentation": "Accretion on marketable securities, net"
       }
      }
     },
     "auth_ref": []
    },
    "tyra_AccruedAndOtherRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "AccruedAndOtherRelatedParties",
     "crdr": "credit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued and other related parties",
        "label": "Accrued and other related parties"
       }
      }
     },
     "auth_ref": []
    },
    "tyra_AccruedInterestAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "AccruedInterestAvailableForSaleSecurities",
     "crdr": "debit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest available-for-sale securities",
        "label": "Accrued Interest Available For Sale Securities",
        "documentation": "Accrued interest available-for-sale securities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tyra_AccruedOtherGeneralAndAdministrativeFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "AccruedOtherGeneralAndAdministrativeFee",
     "crdr": "credit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued other general and administrative fees",
        "label": "Accrued Other General And Administrative Fee",
        "documentation": "Accrued Other General And Administrative Fee."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued legal and professional fees",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "tyra_AccruedResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "AccruedResearchAndDevelopment",
     "crdr": "credit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Research And Development",
        "documentation": "Accrued research and development.",
        "terseLabel": "Accrued research and development expenses"
       }
      }
     },
     "auth_ref": []
    },
    "tyra_AccruedResearchAndDevelopmentExpensePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "AccruedResearchAndDevelopmentExpensePolicyPolicyTextBlock",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Research And Development Expense Policy Policy [Text Block]",
        "documentation": "Accrued Research and Development Expense Policy.",
        "terseLabel": "Accrued Research and Development Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedSalariesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedSalariesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Salaries, Current",
        "terseLabel": "Accrued payroll and other employee benefits",
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r745"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r121",
      "r602"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive income",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r14",
      "r61",
      "r127",
      "r597",
      "r630",
      "r631",
      "r1052"
     ]
    },
    "tyra_AccumulatedOtherComprehensiveLossMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "AccumulatedOtherComprehensiveLossMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Loss [Member]",
        "documentation": "Accumulated Other Comprehensive Loss [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance",
        "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r644",
      "r968",
      "r969",
      "r970",
      "r971",
      "r1053",
      "r1117"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r366"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "tyra_AggregateCommonStockOfferingPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "AggregateCommonStockOfferingPrice",
     "crdr": "debit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate Common Stock Offering Price",
        "label": "Aggregate Common Stock Offering Price",
        "terseLabel": "Aggregate offering price"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r842",
      "r853",
      "r863",
      "r896"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r845",
      "r856",
      "r866",
      "r899"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "tyra_AlanFuhrmanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "AlanFuhrmanMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alan Fuhrman [Member]",
        "documentation": "Alan Fuhrman [Member]",
        "terseLabel": "Alan Fuhrman [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r846",
      "r857",
      "r867",
      "r891",
      "r900",
      "r904",
      "r912"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r396",
      "r400",
      "r409"
     ]
    },
    "tyra_AllowanceForCreditLossesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "AllowanceForCreditLossesPolicyTextBlock",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance for Credit Losses",
        "label": "Allowance for Credit Losses Policy Text Block",
        "documentation": "Allowance for Credit Losses Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesIncludingAllOutstandingStockOptionsWereExcludedInCalculationOfDilutedSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share, amount",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r183"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesIncludingAllOutstandingStockOptionsWereExcludedInCalculationOfDilutedSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r183"
     ]
    },
    "tyra_AreaOfLease": {
     "xbrltype": "areaItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "AreaOfLease",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of Lease",
        "label": "Area of Lease",
        "terseLabel": "Area of lease"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r96",
      "r123",
      "r145",
      "r147",
      "r148",
      "r188",
      "r200",
      "r219",
      "r223",
      "r260",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r458",
      "r460",
      "r514",
      "r585",
      "r586",
      "r592",
      "r679",
      "r763",
      "r764",
      "r774",
      "r805",
      "r809",
      "r810",
      "r820",
      "r1007",
      "r1008",
      "r1070"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r128",
      "r145",
      "r147",
      "r148",
      "r260",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r458",
      "r460",
      "r514",
      "r805",
      "r1007",
      "r1008",
      "r1070"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsFairValueAdjustment",
     "crdr": "debit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "totalLabel": "Total assets",
        "label": "Assets, Fair Value Adjustment",
        "documentation": "Amount of addition (reduction) to the amount at which an asset could be incurred (settled) in a current transaction between willing parties."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsFairValueDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tyra_AtmSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "AtmSalesAgreementMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ATM Sales Agreement [Member]",
        "label": "ATM Sales Agreement [Member]",
        "terseLabel": "ATM Sales Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r825",
      "r826",
      "r849"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLocation",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r825",
      "r826",
      "r849"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorName",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r825",
      "r826",
      "r849"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]",
        "terseLabel": "Auditor Opinion"
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableforsaleSecuritiesAndGrossUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r268",
      "r591"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedGain",
     "crdr": "credit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableforsaleSecuritiesAndGrossUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Unrealized Gain",
        "terseLabel": "Unrealized gains",
        "documentation": "Amount of unrealized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r985"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedLoss",
     "crdr": "debit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableforsaleSecuritiesAndGrossUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unrealized losses",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss",
        "documentation": "Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r986"
     ]
    },
    "tyra_AvailableForSaleDebtSecuritiesNetUnrealizedGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "AvailableForSaleDebtSecuritiesNetUnrealizedGain",
     "crdr": "credit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain on marketable securities available-for-sale, net",
        "label": "Available For Sale Debt Securities Net Unrealized Gain",
        "documentation": "Available for sale debt securities net unrealized gain."
       }
      }
     },
     "auth_ref": []
    },
    "tyra_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionsLessThanTwelveMonthsFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionsLessThanTwelveMonthsFairValue",
     "crdr": "debit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AvailableForSale Securities, Continuous Unrealized Loss Positions, Less than Twelve Months, Fair Value",
        "documentation": "Available-for-Sale Securities, Continuous Unrealized Loss Positions, Less than Twelve Months, Fair Value",
        "terseLabel": "Available For Sale Securities Continuous Unrealized Loss Positions Less Than Twelve Months Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableforsaleSecuritiesAndGrossUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated fair value",
        "label": "Debt Securities, Available-for-Sale",
        "totalLabel": "Debt Securities, Available-for-Sale, Total",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r268",
      "r483",
      "r505",
      "r506",
      "r507",
      "r508",
      "r582",
      "r743",
      "r792",
      "r796",
      "r803",
      "r983",
      "r1057",
      "r1058",
      "r1059"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r907"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r908"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationAdditionalInformationDetails",
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r367",
      "r368",
      "r369",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r905"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "tyra_CaliforniaResearchAndDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "CaliforniaResearchAndDevelopmentMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "California Research and Development [Member]",
        "label": "California Research And Development [Member]",
        "documentation": "California research and development."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r21"
     ]
    },
    "tyra_CapitalizedSoftwareImplementationCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "CapitalizedSoftwareImplementationCostsPolicyTextBlock",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized Software Implementation Costs",
        "label": "Capitalized Software Implementation Costs Policy [Text Block]",
        "documentation": "Capitalized Software Implementation Costs Policy [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      },
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheets",
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalent",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r119",
      "r744"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash And Cash Equivalents",
        "label": "Cash and Cash Equivalents [Member]",
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Cash",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r85"
     ]
    },
    "tyra_CashCashEquivalentsAndMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "CashCashEquivalentsAndMarketableSecurities",
     "crdr": "debit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, cash equivalents and marketable securities",
        "documentation": "Cash, cash equivalents and marketable securities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities",
        "label": "Cash, Cash Equivalent, and Marketable Security [Text Block]",
        "documentation": "The entire disclosure of cash, cash equivalent, and debt and equity securities, including realized and unrealized gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r982"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total cash, cash equivalents and restricted cash",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of the period",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of the period",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r66",
      "r144"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash to the balance sheet",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Net cash decrease for the period",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation",
        "totalLabel": "Net cash increase (decrease) for the period",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r66"
     ]
    },
    "us-gaap_CashMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash [Member]",
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "tyra_ChiefOperatingDecisionMakerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "ChiefOperatingDecisionMakerMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfTheCompanysNetLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CODM",
        "label": "Chief Operating Decision Maker [Member]",
        "documentation": "Chief Operating Decision Maker [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationAdditionalInformationDetails",
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesIncludingAllOutstandingStockOptionsWereExcludedInCalculationOfDilutedSharesOutstandingDetails",
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheetsParenthetical",
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows",
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity",
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r124",
      "r125",
      "r126",
      "r145",
      "r148",
      "r177",
      "r178",
      "r180",
      "r182",
      "r190",
      "r191",
      "r260",
      "r296",
      "r298",
      "r299",
      "r300",
      "r303",
      "r304",
      "r309",
      "r310",
      "r312",
      "r313",
      "r315",
      "r318",
      "r321",
      "r322",
      "r325",
      "r328",
      "r335",
      "r514",
      "r638",
      "r639",
      "r640",
      "r641",
      "r644",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r667",
      "r687",
      "r705",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r936",
      "r957",
      "r959",
      "r972"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationAdditionalInformationDetails",
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationScheduleOfSharebasedCompensationEmployeeStockPurchasePlanDetails",
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationSummaryOfFairValueOfStockOptionGrantsDetails",
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquitySummaryOfReservedSharesOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class Of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r125",
      "r126",
      "r190",
      "r312",
      "r321",
      "r322",
      "r323",
      "r325",
      "r328",
      "r333",
      "r335",
      "r466",
      "r638",
      "r639",
      "r640",
      "r641",
      "r775",
      "r936",
      "r954",
      "r957"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants exercise price",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "verboseLabel": "Warrants issued, price per share",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r150",
      "r336"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of pre-funded warrants",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants issued to purchase common stock",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "negatedTerseLabel": "Warrants exchanged to acquire common stock",
        "verboseLabel": "Pre-funded warrants issued",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquitySummaryOfReservedSharesOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Pre-funded warrants issued and outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "tyra_CommissionForAgentOnSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "CommissionForAgentOnSales",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission For Agent on Sales",
        "label": "Commission For Agent on Sales",
        "terseLabel": "Commission for agent on sales"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 10)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r89",
      "r594",
      "r666"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r290",
      "r291",
      "r729",
      "r1004",
      "r1006"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r730"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationAdditionalInformationDetails",
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquitySummaryOfReservedSharesOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total common stock reserved for future issuance",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationAdditionalInformationDetails",
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity",
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r811",
      "r812",
      "r813",
      "r815",
      "r816",
      "r817",
      "r818",
      "r968",
      "r969",
      "r971",
      "r1053",
      "r1115",
      "r1117"
     ]
    },
    "tyra_CommonStockOptionsGrantedAndOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "CommonStockOptionsGrantedAndOutstanding",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquitySummaryOfReservedSharesOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock options granted and outstanding",
        "label": "Common Stock Options Granted And Outstanding",
        "documentation": "Common stock options granted and outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r667"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued",
        "label": "Common Stock, Shares, Issued",
        "totalLabel": "Common Stock, Shares, Issued, Total",
        "verboseLabel": "Common Stock Shares Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding",
        "label": "Common Stock, Shares, Outstanding",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r55",
      "r667",
      "r685",
      "r1117",
      "r1118"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "totalLabel": "Common Stock, Value, Issued, Total",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "terseLabel": "Common stock, $0.0001 par value; 500,000,000 shares authorized at December 31, 2025 and December 31, 2024; 53,706,357 and 50,754,262 shares issued at December 31, 2025 and December 31, 2024, respectively, and 53,706,357 and 50,749,945 shares outstanding at December 31, 2025 and December 31, 2024, respectively.",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r310",
      "r317",
      "r596",
      "r805"
     ]
    },
    "tyra_CommonStockWarrantsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "CommonStockWarrantsPolicyTextBlock",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock Warrants",
        "label": "Common Stock Warrants [PolicyText Block]",
        "documentation": "Common Stock Warrants [PolicyText Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r888"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "us-gaap_CompensationRelatedCostsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CompensationRelatedCostsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Related Costs [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r130",
      "r132",
      "r137",
      "r583",
      "r607",
      "r608"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive Loss",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "tyra_ComputersAndSoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "ComputersAndSoftwareMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computers and Software",
        "label": "Computers And Software [Member]",
        "documentation": "Computers and software."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of Credit Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r511",
      "r512"
     ]
    },
    "tyra_ConversionOfConvertiblePreferredStockInConnectionWithInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "ConversionOfConvertiblePreferredStockInConnectionWithInitialPublicOffering",
     "crdr": "credit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of convertible preferred stock in connection with initial public offering",
        "label": "Conversion of convertible preferred stock in connection with initial public offering",
        "terseLabel": "Conversion of convertible preferred stock in connection with initial public offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertiblePreferredStockMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible Preferred Stock [Member]",
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r322",
      "r325",
      "r815",
      "r816",
      "r817",
      "r818"
     ]
    },
    "tyra_ConvertiblePreferredStockTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "ConvertiblePreferredStockTextBlock",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity and Convertible Preferred Stock",
        "documentation": "The entire disclosure for Convertible Preferred Stock.",
        "label": "Convertible Preferred Stock [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r834",
      "r923"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r834",
      "r923"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r836",
      "r925"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r836",
      "r925"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r838",
      "r927"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r836",
      "r925"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r829",
      "r918"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r830",
      "r919"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r830",
      "r919"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r828",
      "r917"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r828",
      "r917"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r828",
      "r917"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r831",
      "r920"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r833",
      "r922"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r833",
      "r922"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r834",
      "r923"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r837",
      "r926"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r835",
      "r924"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r832",
      "r921"
     ]
    },
    "tyra_DanielBensenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "DanielBensenMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Daniel Bensen [Member]",
        "documentation": "Daniel Bensen [Member]",
        "terseLabel": "Daniel Bensen [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of available-for-sale security in gross unrealized loss position for less than 12 months",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions",
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r995"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "crdr": "debit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableforsaleSecuritiesAndGrossUnrealizedLossesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableforsaleSecuritiesAndGrossUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss",
        "totalLabel": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss, Total",
        "negatedLabel": "Debt Securities, Available-for-Sale, Unrealized Loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r270"
     ]
    },
    "us-gaap_DebtSecuritiesTradingRestricted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesTradingRestricted",
     "crdr": "debit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Cash",
        "label": "Debt Securities, Trading, Restricted",
        "documentation": "Amount of restricted investment in debt security measured at fair value with change in fair value recognized in net income (trading)."
       }
      }
     },
     "auth_ref": [
      "r561",
      "r727",
      "r728"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "totalLabel": "Deferred Tax Liabilities, Gross, Total",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r52",
      "r87",
      "r433"
     ]
    },
    "tyra_DeferredTaxAssetsCapitalizedResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized research and development",
        "documentation": "Deferred Tax Assets Capitalized Research And Development",
        "label": "Deferred Tax Assets Capitalized Research And Development"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r434"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets / (liabilities)",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1047"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred tax assets, net of valuation allowance",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1047"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsNetOfValuationAllowanceAbstract",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets:",
        "label": "Deferred Tax Assets, Net of Valuation Allowance [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1049"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other, net",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1049"
     ]
    },
    "tyra_DeferredTaxAssetsTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "DeferredTaxAssetsTaxCredits",
     "crdr": "debit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credits",
        "label": "Deferred Tax Assets Tax Credits",
        "documentation": "Deferred tax assets tax credits."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock based compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r1049"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "terseLabel": "Deferred tax assets, valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities:",
        "label": "Deferred Tax Liabilities, Gross [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "crdr": "credit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right of use assets",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedLabel": "Right of use assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements."
       }
      }
     },
     "auth_ref": [
      "r1049"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesOther",
     "crdr": "credit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Other",
        "negatedLabel": "Deferred Tax Liabilities, Other",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other."
       }
      }
     },
     "auth_ref": [
      "r1049"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Depreciation",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r1049"
     ]
    },
    "us-gaap_DefinedBenefitPlanContributionsByEmployer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DefinedBenefitPlanContributionsByEmployer",
     "crdr": "debit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer",
        "terseLabel": "Employer contributions",
        "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r342",
      "r355",
      "r356",
      "r360",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Employee contribution percentage",
        "documentation": "Percentage employer matches of the employee's percentage contribution matched."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Maximum employee contributions",
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "tyra_DenominatorAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "DenominatorAbstract",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Denominator:",
        "label": "Denominator [Abstract]",
        "documentation": "Denominator [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Depreciation",
        "totalLabel": "Depreciation, Total",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r30",
      "r140",
      "r746",
      "r747",
      "r749",
      "r751"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Depreciation, Depletion and Amortization",
        "totalLabel": "Depreciation, Depletion and Amortization, Total",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r141",
      "r188",
      "r205",
      "r223",
      "r746",
      "r763",
      "r764"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DividendPaymentRestrictionsScheduleDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DividendPaymentRestrictionsScheduleDescription",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend payment description",
        "label": "Dividend Payment Restriction and Statutory Capital and Surplus Requirements, Description",
        "documentation": "Description of dividends paid, restrictions on dividend payments, statutory capital and surplus amounts, requirements and future requirements."
       }
      }
     },
     "auth_ref": [
      "r954",
      "r958",
      "r1112"
     ]
    },
    "tyra_DividendYield": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "DividendYield",
     "crdr": "debit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend yield",
        "documentation": "Dividend yield",
        "label": "Dividend Yield"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r825",
      "r826",
      "r849"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r825",
      "r826",
      "r849",
      "r892"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal [Member]",
        "label": "Domestic Tax Jurisdiction [Member]",
        "verboseLabel": "Domestic Country [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails",
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings Per Share, Basic, Total",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share, basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r138",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r175",
      "r177",
      "r180",
      "r181",
      "r182",
      "r187",
      "r308",
      "r399",
      "r452",
      "r457",
      "r480",
      "r481",
      "r584",
      "r609",
      "r755"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails",
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share, diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r138",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r177",
      "r180",
      "r181",
      "r182",
      "r187",
      "r308",
      "r399",
      "r452",
      "r457",
      "r480",
      "r481",
      "r584",
      "r609",
      "r755"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r184"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureNetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r183",
      "r185",
      "r186"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provision for income taxes, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Percent, Total",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r418",
      "r784"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Income tax benefit at statutory federal rate Percentage",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r149",
      "r418",
      "r443",
      "r784"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance Percentage",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r422",
      "r784",
      "r954",
      "r961",
      "r1044"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent",
        "terseLabel": "Other Percentage",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r784",
      "r954",
      "r961",
      "r1044",
      "r1045"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "terseLabel": "Stock based compensation Percentage",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r784",
      "r954",
      "r961",
      "r1044",
      "r1045"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State and local taxes, net of federal benefit Percentage",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r421",
      "r784",
      "r954",
      "r961",
      "r1044"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "terseLabel": "Research credits Percentage",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r784",
      "r954",
      "r961",
      "r1044",
      "r1045"
     ]
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeBenefitsAndShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfTheCompanysNetLossParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefits and Share-Based Compensation",
        "terseLabel": "Employee Benefits And Share Based Compensation",
        "documentation": "Amount of expense for employee benefit and equity-based compensation."
       }
      }
     },
     "auth_ref": [
      "r951"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r1040"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Term of Unrecognized Expense",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r397"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost related to options",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1041"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "crdr": "credit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense, Tax Benefit",
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r396"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationAdditionalInformationDetails",
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationScheduleOfSharebasedCompensationEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Purchase Plan [Member]",
        "label": "Employee Stock [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationAdditionalInformationDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039"
     ]
    },
    "tyra_EmployeeStockPurchasePlanDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "EmployeeStockPurchasePlanDescription",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan Description",
        "label": "Employee Stock Purchase Plan Description"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Securities Act File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationDateOfIncorporation",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, Date of Incorporation",
        "terseLabel": "Entity Incorporation, Date of Incorporation",
        "documentation": "Date when an entity was incorporated"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquipmentMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equipment",
        "label": "Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity",
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r109",
      "r110",
      "r111",
      "r134",
      "r135",
      "r136",
      "r158",
      "r159",
      "r160",
      "r162",
      "r169",
      "r171",
      "r173",
      "r189",
      "r261",
      "r262",
      "r283",
      "r307",
      "r337",
      "r399",
      "r441",
      "r442",
      "r449",
      "r450",
      "r451",
      "r453",
      "r456",
      "r457",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r479",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r527",
      "r542",
      "r605",
      "r626",
      "r627",
      "r628",
      "r644",
      "r705"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r842",
      "r853",
      "r863",
      "r896"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r839",
      "r850",
      "r860",
      "r893"
     ]
    },
    "tyra_EstimatedSharesPurchasableUnderTheEsppMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "EstimatedSharesPurchasableUnderTheEsppMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesIncludingAllOutstandingStockOptionsWereExcludedInCalculationOfDilutedSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated shares purchasable under the ESPP",
        "label": "Estimated shares purchasable under the ESPP [Member]",
        "documentation": "Estimated shares purchasable under the ESPP [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "tyra_ExchangeOfCommonStockForPre-FundedWarrantsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "ExchangeOfCommonStockForPre-FundedWarrantsShares",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange of Common Stock for Pre-Funded Warrants Shares",
        "documentation": "Exchange of Common Stock for Pre-Funded Warrants Shares",
        "negatedLabel": "Exchange of common stock for pre-funded warrants, shares",
        "terseLabel": "Exchange of common stock for pre-funded warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "tyra_ExerciseOfPre-FundedWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "ExerciseOfPre-FundedWarrants",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of Pre-funded Warrants",
        "documentation": "Exercise of Pre-funded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "tyra_ExpansionLeaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "ExpansionLeaseAgreementMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expansion Lease Agreement [Member]",
        "label": "Expansion Lease Agreement [Member]",
        "terseLabel": "Expansion Lease Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ExtinguishmentOfDebtAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ExtinguishmentOfDebtAxis",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableforsaleSecuritiesAndGrossUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extinguishment of Debt [Axis]",
        "documentation": "Information by type of debt extinguished."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_ExtinguishmentOfDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ExtinguishmentOfDebtTypeDomain",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableforsaleSecuritiesAndGrossUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extinguishment of Debt, Type [Domain]",
        "documentation": "Type of debt extinguished."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "tyra_FGFRDiscoveryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "FGFRDiscoveryMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfTheCompanysNetLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FGFR Discovery",
        "label": "FGFR Discovery [Member]",
        "documentation": "FGFR Discovery [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "tyra_FacilitiesAndOtherCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "FacilitiesAndOtherCostsMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfTheCompanysNetLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Facilities and Other Costs [Member]",
        "documentation": "Facilities and Other Costs [Member]",
        "terseLabel": "Facilities and Other Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets On Recurring Basis Line Items",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r483",
      "r484",
      "r497",
      "r792"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r483",
      "r484",
      "r497",
      "r792"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r498",
      "r743",
      "r794",
      "r803"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r498",
      "r743",
      "r794",
      "r803"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r356",
      "r357",
      "r482",
      "r484",
      "r485",
      "r486",
      "r487",
      "r496",
      "r497",
      "r499",
      "r506",
      "r550",
      "r551",
      "r552",
      "r743",
      "r772",
      "r773",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r792",
      "r796",
      "r803"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r483",
      "r484",
      "r485",
      "r487",
      "r792",
      "r1058",
      "r1061"
     ]
    },
    "us-gaap_FairValueConcentrationOfRiskCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueConcentrationOfRiskCashAndCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Fair Value, Concentration of Risk, Cash and Cash Equivalents",
        "documentation": "Fair value of cash and cash equivalent subject to concentration of credit or market risk or both."
       }
      }
     },
     "auth_ref": [
      "r509",
      "r510",
      "r937",
      "r938"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r485",
      "r492",
      "r494",
      "r495",
      "r496",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r581",
      "r792",
      "r797"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r342",
      "r347",
      "r356",
      "r484",
      "r497",
      "r506",
      "r550",
      "r743",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r792",
      "r803"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r342",
      "r347",
      "r356",
      "r358",
      "r484",
      "r485",
      "r497",
      "r506",
      "r551",
      "r743",
      "r772",
      "r773",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r792",
      "r803"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r356",
      "r357",
      "r484",
      "r485",
      "r486",
      "r487",
      "r497",
      "r506",
      "r552",
      "r743",
      "r772",
      "r773",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r792",
      "r796",
      "r803"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r483",
      "r484",
      "r485",
      "r487",
      "r792",
      "r1058",
      "r1061"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair Value Measurements",
        "terseLabel": "Fair Value Option",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r356",
      "r357",
      "r482",
      "r484",
      "r485",
      "r486",
      "r487",
      "r496",
      "r497",
      "r499",
      "r506",
      "r550",
      "r551",
      "r552",
      "r743",
      "r772",
      "r773",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r792",
      "r796",
      "r803"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r792",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1061"
     ]
    },
    "us-gaap_FairValueOptionCreditRiskGainsLossesOnAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueOptionCreditRiskGainsLossesOnAssets",
     "crdr": "credit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableforsaleSecuritiesAndGrossUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized losses on fair value",
        "label": "Fair Value, Option, Credit Risk, Gains (Losses) on Assets",
        "documentation": "This item represents the estimated amount of gains or losses included in earnings during the period attributable to changes in instrument-specific credit risk arising from loans and other receivables held as assets."
       }
      }
     },
     "auth_ref": [
      "r516"
     ]
    },
    "tyra_FebruaryTwoThousandTwentyFourSecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "FebruaryTwoThousandTwentyFourSecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "February Two Thousand Twenty Four Securities Purchase Agreement [Member]",
        "documentation": "February Two Thousand Twenty Four Securities Purchase Agreement [Member]",
        "terseLabel": "2024 Securities Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "tyra_FederalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "FederalMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal [Member]",
        "label": "Federal [Member]",
        "documentation": "Federal."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableforsaleSecuritiesAndGrossUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r269",
      "r271",
      "r272",
      "r306",
      "r333",
      "r466",
      "r477",
      "r504",
      "r513",
      "r517",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r562",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r590",
      "r606",
      "r770",
      "r792",
      "r794",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r806",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r987",
      "r988",
      "r989",
      "r990",
      "r1054",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063"
     ]
    },
    "tyra_FirstAmendmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "FirstAmendmentMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First Amendment [Member]",
        "label": "First Amendment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r846",
      "r857",
      "r867",
      "r900"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r846",
      "r857",
      "r867",
      "r900"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r846",
      "r857",
      "r867",
      "r900"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r846",
      "r857",
      "r867",
      "r900"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r846",
      "r857",
      "r867",
      "r900"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and Fixtures",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfTheCompanysNetLossDetails",
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense",
        "totalLabel": "General and Administrative Expense, Total",
        "terseLabel": "General and administrative",
        "verboseLabel": "General and administrative expenses",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r689"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "HeldToMaturitySecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "crdr": "debit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableforsaleSecuritiesAndGrossUnrealizedLossesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableforsaleSecuritiesAndGrossUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized losses greater than 12 months",
        "label": "Debt Securities, Held-to-Maturity, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity), in continuous loss position for 12 months or longer."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r98"
     ]
    },
    "us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "crdr": "debit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableforsaleSecuritiesAndGrossUnrealizedLossesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableforsaleSecuritiesAndGrossUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unrealized losses less than 12 months",
        "label": "Debt Securities, Held-to-Maturity, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity), in continuous loss position for less than 12 months."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r98"
     ]
    },
    "tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue",
     "crdr": "debit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails",
      "http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableforsaleSecuritiesAndGrossUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized losses less than 12 months, fair value",
        "label": "Held to Maturity Securities Continuous Unrealized Loss Position Less Than 12 Months Fair Value",
        "documentation": "Held to Maturity Securities Continuous Unrealized Loss Position Less Than 12 Months Fair Value",
        "verboseLabel": "Available-for-sale security in gross unrealized loss position for less than 12 months, fair value"
       }
      }
     },
     "auth_ref": []
    },
    "tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAccumulatedLoss",
     "crdr": "debit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableforsaleSecuritiesAndGrossUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Held to Maturity Securities Continuous Unrealized Loss Position Less Than Twelve Months Accumulated Loss",
        "documentation": "Held to Maturity Securities Continuous Unrealized Loss Position Less Than Twelve Months Accumulated Loss",
        "negatedLabel": "Unrealized losses less than 12 months, unrealized losses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue",
     "crdr": "debit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableforsaleSecuritiesAndGrossUnrealizedLossesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails",
      "http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableforsaleSecuritiesAndGrossUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Available-for-sale security in gross unrealized loss position for less than 12 months, fair value",
        "label": "Debt Securities, Held-to-Maturity, Continuous Unrealized Loss Position, Less than 12 Months, Fair Value",
        "verboseLabel": "Unrealized losses less than 12 months, fair value",
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity), in continuous unrealized loss position for less than 12 months."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrGreaterFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrGreaterFairValue",
     "crdr": "debit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableforsaleSecuritiesAndGrossUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Held to Maturity Securities Continuous Unrealized Loss Position Twelve Months or Greater Fair Value",
        "documentation": "Held to Maturity Securities Continuous Unrealized Loss Position Twelve Months or Greater Fair Value",
        "terseLabel": "Unrealized losses 12 months or greater, fair value"
       }
      }
     },
     "auth_ref": []
    },
    "tyra_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAccumulatedLoss",
     "crdr": "debit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableforsaleSecuritiesAndGrossUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized losses 12 months or greater, unrealized losses",
        "label": "Held to Maturity Securities Continuous Unrealized Loss Position Twelve Months Or Longer Accumulated Loss",
        "documentation": "Held to Maturity Securities Continuous Unrealized Loss Position Twelve Months Or Longer Accumulated Loss"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue",
     "crdr": "debit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableforsaleSecuritiesAndGrossUnrealizedLossesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableforsaleSecuritiesAndGrossUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Greater than 12 months, Fair value",
        "label": "Debt Securities, Held-to-Maturity, Continuous Unrealized Loss Position, 12 Months or Longer, Fair Value",
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity), in continuous unrealized loss position for 12 months or longer."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IPOMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationAdditionalInformationDetails",
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IPO [Member]",
        "terseLabel": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r825",
      "r826",
      "r849"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Impairment, Long-Lived Asset, Held-for-Use, Total",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "terseLabel": "Impairement loss",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r29",
      "r72",
      "r139",
      "r747",
      "r793"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of Long-Lived Assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r73"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails",
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r286",
      "r287",
      "r462",
      "r463",
      "r464",
      "r465",
      "r489",
      "r493",
      "r498",
      "r515",
      "r517",
      "r518",
      "r623",
      "r625",
      "r690",
      "r742",
      "r743",
      "r785",
      "r786",
      "r790",
      "r791",
      "r795",
      "r803",
      "r1050",
      "r1051",
      "r1085"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails",
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r286",
      "r287",
      "r462",
      "r463",
      "r464",
      "r465",
      "r489",
      "r493",
      "r498",
      "r515",
      "r517",
      "r518",
      "r623",
      "r625",
      "r690",
      "r742",
      "r743",
      "r785",
      "r786",
      "r790",
      "r791",
      "r795",
      "r803",
      "r1050",
      "r1051",
      "r1085"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority",
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r418",
      "r419",
      "r426",
      "r438",
      "r784",
      "r1048"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority",
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r418",
      "r419",
      "r426",
      "r438",
      "r784",
      "r1048"
     ]
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxContingencyLineItems",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Contingency [Line Items]",
        "label": "Income Tax Contingency [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxContingencyTable",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Contingency [Table]",
        "label": "Income Tax Contingency [Table]",
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months."
       }
      }
     },
     "auth_ref": [
      "r1046"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r149",
      "r413",
      "r418",
      "r423",
      "r424",
      "r425",
      "r430",
      "r437",
      "r444",
      "r446",
      "r447",
      "r448",
      "r589",
      "r633",
      "r643",
      "r784"
     ]
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Penalties and interest accrued",
        "totalLabel": "Income Tax Examination, Penalties and Interest Accrued, Total",
        "label": "Income Tax Examination, Penalties and Interest Accrued",
        "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations."
       }
      }
     },
     "auth_ref": [
      "r1046"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Provision for income taxes",
        "label": "Income Tax Expense (Benefit)",
        "verboseLabel": "Provision for or benefit from income taxes",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r107",
      "r145",
      "r172",
      "r173",
      "r188",
      "r208",
      "r223",
      "r417",
      "r418",
      "r445",
      "r610",
      "r748",
      "r750",
      "r752",
      "r784"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r415",
      "r416",
      "r430",
      "r431",
      "r436",
      "r440",
      "r637"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r422",
      "r784",
      "r1044"
     ]
    },
    "tyra_IncomeTaxReconciliationChangesInUnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "IncomeTaxReconciliationChangesInUnrecognizedTaxBenefits",
     "crdr": "credit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Reconciliation Changes in Unrecognized Tax Benefits",
        "documentation": "Income Tax Reconciliation Changes in Unrecognized Tax Benefits",
        "terseLabel": "Changes in unrecognized tax benefits",
        "negatedLabel": "Changes in unrecognized tax benefits"
       }
      }
     },
     "auth_ref": []
    },
    "tyra_IncomeTaxReconciliationChangesInUnrecognizedTaxBenefitsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "IncomeTaxReconciliationChangesInUnrecognizedTaxBenefitsPercentage",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Reconciliation Changes in Unrecognized Tax Benefits Percentage",
        "documentation": "Income Tax Reconciliation Changes in Unrecognized Tax Benefits Percentage",
        "terseLabel": "Changes in unrecognized tax benefits Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected tax benefit at statutory rate",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r418",
      "r784"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseAbstract",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nontaxable or nondeductible items"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseOther",
     "crdr": "debit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount",
        "verboseLabel": "Other",
        "terseLabel": "Other",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r784",
      "r1044",
      "r1045"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "terseLabel": "Stock based compensation",
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r784",
      "r1044",
      "r1045"
     ]
    },
    "tyra_IncomeTaxReconciliationOfficersCompensationPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "IncomeTaxReconciliationOfficersCompensationPercentage",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Reconciliation Officers Compensation Percentage",
        "documentation": "Income Tax Reconciliation Officers Compensation Percentage",
        "terseLabel": "Officer compensation Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "tyra_IncomeTaxReconciliationProvisionForIncomeTaxesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "IncomeTaxReconciliationProvisionForIncomeTaxesPercentage",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Reconciliation Provision for Income Taxes Percentage",
        "documentation": "Income Tax Reconciliation Provision for Income Taxes Percentage",
        "terseLabel": "Provision for Income Taxes Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State income tax, net of federal benefit",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "negatedLabel": "State income tax, net of federal benefit",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r421",
      "r784",
      "r1044"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationTaxCreditsAbstract",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax credits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "crdr": "credit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Research credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r784",
      "r1044",
      "r1045"
     ]
    },
    "tyra_IncometaxreconciliationOfficersCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "IncometaxreconciliationOfficersCompensation",
     "crdr": "debit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IncomeTaxReconciliation Officers Compensation",
        "label": "IncomeTaxReconciliation Officers Compensation",
        "terseLabel": "Officers compensation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "totalLabel": "Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total",
        "terseLabel": "Accounts payable, accrued expenses and other liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpensesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidExpensesOther",
     "crdr": "credit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other assets",
        "negatedLabel": "Prepaid expenses and other assets",
        "label": "Increase (Decrease) in Prepaid Expenses, Other",
        "documentation": "Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "tyra_IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets and lease liabilities, net",
        "label": "Increase Decrease In Right Of Use Assets And Lease Liabilities Net",
        "documentation": "Increase decrease in right of use assets and lease liabilities net."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r846",
      "r857",
      "r867",
      "r891",
      "r900",
      "r904",
      "r912"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r827",
      "r916"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r827",
      "r916"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r827",
      "r916"
     ]
    },
    "us-gaap_InterestAndOtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestAndOtherIncome",
     "crdr": "credit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfTheCompanysNetLossDetails",
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest and Other Income",
        "terseLabel": "Interest and other income, net",
        "negatedLabel": "Interest and other income, net",
        "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": []
    },
    "tyra_IssuanceOfCommonStockPursuantToPreFundedWarrantExercise": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "IssuanceOfCommonStockPursuantToPreFundedWarrantExercise",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock pursuant to pre-funded warrant exercise, Shares",
        "label": "Issuance Of Common Stock Pursuant To Pre Funded Warrant Exercise",
        "documentation": "Issuance Of Common Stock Pursuant To Pre Funded Warrant Exercise"
       }
      }
     },
     "auth_ref": []
    },
    "tyra_IssuanceOfCommonStockPursuantToPreFundedWarrantExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "IssuanceOfCommonStockPursuantToPreFundedWarrantExercised",
     "crdr": "credit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance Of Common Stock Pursuant To Pre Funded Warrant Exercised",
        "documentation": "Issuance Of Common Stock Pursuant To Pre Funded Warrant Exercised",
        "terseLabel": "Issuance of common stock pursuant to pre-funded warrant exercise"
       }
      }
     },
     "auth_ref": []
    },
    "tyra_IssuanceOfCommonStockUnderBenefitPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "IssuanceOfCommonStockUnderBenefitPlans",
     "crdr": "debit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of Common Stock Under Benefit Plans",
        "label": "Issuance of Common Stock Under Benefit Plans",
        "terseLabel": "Issuance of common stock under benefit plans"
       }
      }
     },
     "auth_ref": []
    },
    "tyra_IssuanceOfCommonStockUnderBenefitPlansShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "IssuanceOfCommonStockUnderBenefitPlansShares",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock shares under benefit plans.",
        "label": "Issuance of Common Stock Under Benefit Plans Shares",
        "terseLabel": "Issuance of common stock under benefit plans, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "tyra_IssuanceOfConvertiblePreferredStockInExchangeForSimpleAgreementForFutureEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "IssuanceOfConvertiblePreferredStockInExchangeForSimpleAgreementForFutureEquity",
     "crdr": "credit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of convertible preferred stock in exchange for simple agreement for future equity",
        "label": "Issuance of convertible preferred stock in exchange for simple agreement for future equity",
        "terseLabel": "Issuance of convertible preferred stock in exchange for simple agreement for future equity"
       }
      }
     },
     "auth_ref": []
    },
    "tyra_IssuanceOfPreFundedWarrantsUnderPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "IssuanceOfPreFundedWarrantsUnderPrivatePlacement",
     "crdr": "credit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance Of Pre Funded Warrants Under Private Placement",
        "documentation": "Issuance Of Pre Funded Warrants Under Private Placement",
        "terseLabel": "Issuance of Pre Funded Warrants under Private Placement"
       }
      }
     },
     "auth_ref": []
    },
    "tyra_IssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "IssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued Accounting Pronouncements Not Yet Adopted",
        "label": "Issued Accounting Pronouncements Not Yet Adopted, Policy [Policy Text Block]",
        "documentation": "Issued Accounting Pronouncements Not Yet Adopted, Policy [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseAgreementsMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Agreements [Member]",
        "terseLabel": "Lease Agreements [Member]",
        "documentation": "Contractual agreement that stipulates the lessee pay the lessor for use of an asset."
       }
      }
     },
     "auth_ref": [
      "r789",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003"
     ]
    },
    "us-gaap_LeaseContractualTermAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseContractualTermAxis",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Contractual Term",
        "label": "Lease Contractual Term [Axis]",
        "documentation": "Information by contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r541",
      "r939"
     ]
    },
    "us-gaap_LeaseContractualTermDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseContractualTermDomain",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Contractual Term",
        "label": "Lease Contractual Term [Domain]",
        "documentation": "Contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r541",
      "r939"
     ]
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease cost",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r532",
      "r804"
     ]
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCostAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Components of Lease Cost",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1067"
     ]
    },
    "us-gaap_LeaseExpirationDate1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseExpirationDate1",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum lease termination date",
        "label": "Lease Expiration Date",
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold Improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r540"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee Lease Description [Line Items]",
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r531",
      "r541"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee Lease Description [Table]",
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r531",
      "r541"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r530"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesLeaseLiabilitiesWeightedaverageRemainingTermAndWeightedaverageDiscountRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesLeaseLiabilitiesWeightedaverageRemainingTermAndWeightedaverageDiscountRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total minimum lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r539",
      "r955",
      "r962",
      "r1080"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesLeaseLiabilitiesWeightedaverageRemainingTermAndWeightedaverageDiscountRateDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesLeaseLiabilitiesWeightedaverageRemainingTermAndWeightedaverageDiscountRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r539",
      "r955",
      "r962",
      "r1080"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesLeaseLiabilitiesWeightedaverageRemainingTermAndWeightedaverageDiscountRateDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesLeaseLiabilitiesWeightedaverageRemainingTermAndWeightedaverageDiscountRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r539",
      "r955",
      "r962",
      "r1080"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesLeaseLiabilitiesWeightedaverageRemainingTermAndWeightedaverageDiscountRateDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesLeaseLiabilitiesWeightedaverageRemainingTermAndWeightedaverageDiscountRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2030",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r539",
      "r955",
      "r962",
      "r1080"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesLeaseLiabilitiesWeightedaverageRemainingTermAndWeightedaverageDiscountRateDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesLeaseLiabilitiesWeightedaverageRemainingTermAndWeightedaverageDiscountRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2029",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r539",
      "r955",
      "r962",
      "r1080"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesLeaseLiabilitiesWeightedaverageRemainingTermAndWeightedaverageDiscountRateDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesLeaseLiabilitiesWeightedaverageRemainingTermAndWeightedaverageDiscountRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r539",
      "r955",
      "r962",
      "r1080"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesLeaseLiabilitiesWeightedaverageRemainingTermAndWeightedaverageDiscountRateDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesLeaseLiabilitiesWeightedaverageRemainingTermAndWeightedaverageDiscountRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r539",
      "r955",
      "r962",
      "r1080"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesLeaseLiabilitiesWeightedaverageRemainingTermAndWeightedaverageDiscountRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less: amount representing interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: amount representing interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r539"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease renewal term",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1066"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Term of Contract",
        "verboseLabel": "Minimum lease term since date of original lease",
        "terseLabel": "Operating lease term of contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1066"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r526"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r45",
      "r46",
      "r47",
      "r48",
      "r49",
      "r50",
      "r53",
      "r145",
      "r147",
      "r148",
      "r260",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r459",
      "r460",
      "r461",
      "r514",
      "r665",
      "r757",
      "r774",
      "r820",
      "r1007",
      "r1070",
      "r1071"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r90",
      "r599",
      "r805",
      "r809",
      "r810",
      "r954",
      "r960",
      "r991",
      "r1064"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities, Convertible Preferred Stock and Stockholders\u2019 Equity (Deficit)",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r118",
      "r145",
      "r147",
      "r148",
      "r260",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r459",
      "r460",
      "r461",
      "r514",
      "r805",
      "r1007",
      "r1070",
      "r1071"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term line of credit",
        "label": "Long-Term Line of Credit",
        "totalLabel": "Long-term Line of Credit, Total",
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r88",
      "r1082"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableforsaleSecuritiesAndGrossUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "More than One year",
        "label": "Long-Term Debt [Member]",
        "documentation": "Debt arrangement having an initial term longer than one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails",
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "label": "Marketable Securities",
        "totalLabel": "Marketable Securities, Total",
        "verboseLabel": "Marketable securities",
        "documentation": "Amount of investment in marketable security."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r949"
     ]
    },
    "us-gaap_MarketableSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesLineItems",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails",
      "http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableforsaleSecuritiesAndGrossUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_MarketableSecuritiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesTable",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails",
      "http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableforsaleSecuritiesAndGrossUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities [Table]",
        "documentation": "Disclosure of information about investment in marketable security."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesTextBlock",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Available-for-Sale Securities and Gross Unrealized Losses",
        "label": "Marketable Securities [Table Text Block]",
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationScheduleOfSharebasedCompensationEmployeeStockPurchasePlanDetails",
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationSummaryOfFairValueOfStockOptionGrantsDetails",
      "http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://tyra.bio/20251231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r195",
      "r292",
      "r293",
      "r294",
      "r295",
      "r364",
      "r392",
      "r393",
      "r394",
      "r410",
      "r487",
      "r579",
      "r622",
      "r624",
      "r632",
      "r657",
      "r658",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r722",
      "r723",
      "r725",
      "r726",
      "r740",
      "r741",
      "r769",
      "r775",
      "r782",
      "r785",
      "r787",
      "r788",
      "r796",
      "r797",
      "r801",
      "r802",
      "r807",
      "r1009",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "tyra_MinimumLeasePaymentsForLeasesNotYetCommenced": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "MinimumLeasePaymentsForLeasesNotYetCommenced",
     "crdr": "credit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesLeaseLiabilitiesWeightedaverageRemainingTermAndWeightedaverageDiscountRateParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum Lease Payments for Leases Not Yet Commenced",
        "label": "Minimum Lease Payments for Leases Not Yet Commenced",
        "terseLabel": "Legally binding minimum lease payments for leases not yet commenced"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationScheduleOfSharebasedCompensationEmployeeStockPurchasePlanDetails",
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationSummaryOfFairValueOfStockOptionGrantsDetails",
      "http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://tyra.bio/20251231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r195",
      "r292",
      "r293",
      "r294",
      "r295",
      "r364",
      "r392",
      "r393",
      "r394",
      "r410",
      "r487",
      "r579",
      "r622",
      "r624",
      "r632",
      "r657",
      "r658",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r722",
      "r723",
      "r725",
      "r726",
      "r740",
      "r741",
      "r769",
      "r775",
      "r782",
      "r785",
      "r787",
      "r788",
      "r796",
      "r797",
      "r801",
      "r807",
      "r1009",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Money market funds",
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r1011",
      "r1012"
     ]
    },
    "srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Real Estate, Type of Property [Axis]"
       }
      }
     },
     "auth_ref": [
      "r722",
      "r724",
      "r725",
      "r726",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739"
     ]
    },
    "srt_MortgageLoansOnRealEstateNamePropertyTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MortgageLoansOnRealEstateNamePropertyTypeDomain",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Real Estate [Domain]"
       }
      }
     },
     "auth_ref": [
      "r722",
      "r724",
      "r725",
      "r726",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "negatedTerseLabel": "Payments of issuance costs for common stock and pre-funded warrants from Private Placement",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Net cash used in investing activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "totalLabel": "Net cash provided by (used in) investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r67",
      "r68"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      },
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails",
      "http://tyra.bio/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfTheCompanysNetLossDetails",
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows",
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss",
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "totalLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r68",
      "r92",
      "r111",
      "r116",
      "r129",
      "r131",
      "r136",
      "r145",
      "r147",
      "r148",
      "r152",
      "r161",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r172",
      "r173",
      "r179",
      "r260",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r308",
      "r311",
      "r314",
      "r319",
      "r399",
      "r452",
      "r457",
      "r481",
      "r514",
      "r604",
      "r686",
      "r703",
      "r704",
      "r748",
      "r750",
      "r752",
      "r819",
      "r1007"
     ]
    },
    "tyra_NetOperatingLossCarryForwardIndefinitely": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "NetOperatingLossCarryForwardIndefinitely",
     "crdr": "debit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Operating Loss Carry Forward Indefinitely",
        "documentation": "Net Operating Loss Carry Forward Indefinitely",
        "terseLabel": "Net Operating Loss Carry Forward Indefinitely"
       }
      }
     },
     "auth_ref": []
    },
    "tyra_NetOperatingLossCarryforwardsAvailableForOffsettingAgainstFutureTaxableIncomePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "NetOperatingLossCarryforwardsAvailableForOffsettingAgainstFutureTaxableIncomePercentage",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of federal net operating losses used to offset of future taxable income",
        "label": "Net Operating Loss Carryforwards Available For Offsetting Against Future Taxable Income Percentage",
        "documentation": "Net Operating Loss Carryforwards Available For Offsetting Against Future Taxable Income Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r846",
      "r857",
      "r867",
      "r891",
      "r900"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "tyra_NonRule10B51ArrModifiedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "NonRule10B51ArrModifiedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Rule 10b5-1 Arr Modified Flag",
        "documentation": "NonRule10b51ArrModifiedFlag",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Modified"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash investing and financing activities:",
        "label": "Noncash Investing and Financing Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "tyra_NumberOfLeaseTermRenewal": {
     "xbrltype": "integerItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "NumberOfLeaseTermRenewal",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of lease term renewal option",
        "label": "Number of Lease Term Renewal",
        "documentation": "Number of lease term renewal."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfPropertiesSubjectToGroundLeases": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfPropertiesSubjectToGroundLeases",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating leases",
        "label": "Number of Properties Subject to Ground Leases",
        "documentation": "Number of separate real estate development properties located on land subject to ground leases."
       }
      }
     },
     "auth_ref": [
      "r1065"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r759",
      "r768",
      "r976"
     ]
    },
    "tyra_NumeratorAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "NumeratorAbstract",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Numerator:",
        "label": "Numerator [Abstract]",
        "documentation": "Numerator"
       }
      }
     },
     "auth_ref": []
    },
    "tyra_OfferingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "OfferingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Expenses",
        "documentation": "Offering Expenses",
        "terseLabel": "Offering expenses"
       }
      }
     },
     "auth_ref": []
    },
    "srt_OfficeBuildingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "OfficeBuildingMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office Building [Member]",
        "terseLabel": "Office and Laboratory Facilities [Member]"
       }
      }
     },
     "auth_ref": [
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r748",
      "r752",
      "r758",
      "r975",
      "r977",
      "r978",
      "r979",
      "r980"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease cost",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r533",
      "r804"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesLeaseLiabilitiesWeightedaverageRemainingTermAndWeightedaverageDiscountRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Present value of lease liabilities",
        "terseLabel": "Operating lease liability",
        "label": "Operating Lease, Liability",
        "verboseLabel": "Present value of lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesLeaseLiabilitiesWeightedaverageRemainingTermAndWeightedaverageDiscountRateDetails",
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: current portion of lease liabilities",
        "label": "Operating Lease, Liability, Current",
        "verboseLabel": "Lease liabilities, current",
        "terseLabel": "Less: current portion of lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesLeaseLiabilitiesWeightedaverageRemainingTermAndWeightedaverageDiscountRateDetails",
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "verboseLabel": "Lease liabilities, noncurrent",
        "terseLabel": "Lease liabilities, noncurrent",
        "totalLabel": "Operating Lease, Liability, Noncurrent, Total",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Payments",
        "terseLabel": "Lease liability paid",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r529",
      "r536"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesLeaseLiabilitiesWeightedaverageRemainingTermAndWeightedaverageDiscountRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average incremental borrowing rate - operating leases",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r538",
      "r804"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesScheduleOfMaturitiesLeaseLiabilitiesWeightedaverageRemainingTermAndWeightedaverageDiscountRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining lease term (years) - operating leases",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r537",
      "r804"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax loss carryforwards",
        "label": "Operating Loss Carryforwards",
        "totalLabel": "Operating Loss Carryforwards, Total",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "tyra_OperatingLossCarryforwardsExpirationDates1": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "OperatingLossCarryforwardsExpirationDates1",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards, expire date",
        "label": "Operating Loss Carryforwards Expiration Dates1",
        "documentation": "Operating loss carryforwards expiration dates 1."
       }
      }
     },
     "auth_ref": []
    },
    "tyra_OptionsGrantedContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "OptionsGrantedContractualTerm",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options granted contractual term",
        "documentation": "Options granted contractual term",
        "label": "Options Granted Contractual Term"
       }
      }
     },
     "auth_ref": []
    },
    "tyra_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Summary of Significant Accounting Policies [Line Items]",
        "documentation": "Organization and Summary of Significant Accounting Policies [Line Items]",
        "terseLabel": "Organization and Summary of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "tyra_OrganizationAndSummaryOfSignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "OrganizationAndSummaryOfSignificantAccountingPoliciesTable",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Summary of Significant Accounting Policies [Table]",
        "documentation": "Organization and Summary of Significant Accounting Policies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization and Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r112",
      "r113",
      "r114",
      "r634",
      "r635"
     ]
    },
    "tyra_OrganizationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "OrganizationPolicyTextBlock",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization",
        "label": "Organization Policy [Text Block]",
        "documentation": ".Organization."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://tyra.bio/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total accrued and other current liabilities",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses and other current liabilities",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term assets",
        "label": "Other Assets, Noncurrent",
        "totalLabel": "Other Assets, Noncurrent, Total",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent, Total",
        "terseLabel": "Unrealized gain (loss) on marketable securities available-for-sale, net",
        "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r7",
      "r84"
     ]
    },
    "tyra_OtherDevelopmentProgramsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "OtherDevelopmentProgramsMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfTheCompanysNetLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other development programs",
        "label": "Other Development Programs [Member]",
        "documentation": "Other Development Programs [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term liabilities",
        "label": "Other Liabilities, Noncurrent",
        "totalLabel": "Other Liabilities, Noncurrent, Total",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income :"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "tyra_OtherResearchAndDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "OtherResearchAndDevelopmentMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfTheCompanysNetLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other research and development",
        "label": "Other Research and Development [Member]",
        "documentation": "Other Research and Development [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherSellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherSellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLossParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative including related party amounts",
        "label": "Other Selling, General and Administrative Expense",
        "documentation": "Amount of selling, general and administrative expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r844",
      "r855",
      "r865",
      "r898"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r847",
      "r858",
      "r868",
      "r901"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r847",
      "r858",
      "r868",
      "r901"
     ]
    },
    "tyra_PatentCostsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "PatentCostsPolicyPolicyTextBlock",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patent Costs",
        "label": "Patent Costs Policy Policy [Text Block]",
        "documentation": "Patent Costs Policy"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "tyra_PaymentsOfIssuanceCostsForCommonStockAndPreFundedWarrantsFromPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "PaymentsOfIssuanceCostsForCommonStockAndPreFundedWarrantsFromPrivatePlacement",
     "crdr": "credit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of issuance costs for common stock and pre-funded warrants from Private Placement",
        "documentation": "Payments of issuance costs for common stock and pre-funded warrants from Private Placement",
        "negatedLabel": "Payments of issuance costs for common stock and pre-funded warrants from Private Placement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments Of Stock Issuance Costs",
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of marketable securities",
        "terseLabel": "Purchases of marketable securities",
        "label": "Payments to Acquire Marketable Securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r984"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchases of property and equipment",
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureEmployeeBenefits"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Employee Benefits",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r340",
      "r341",
      "r347",
      "r348",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r361",
      "r362",
      "r363",
      "r780"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance Shares [Member]",
        "label": "Performance Shares [Member]",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": [
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039"
     ]
    },
    "tyra_PersonnelCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "PersonnelCostsMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfTheCompanysNetLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Personnel Costs",
        "label": "Personnel Costs [Member]",
        "documentation": "Personnel Costs [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "tyra_PersonnelStockBasedCompensationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "PersonnelStockBasedCompensationMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfTheCompanysNetLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Personnel Stock Based Compensation [Member]",
        "documentation": "Personnel Stock Based Compensation [Member]",
        "terseLabel": "Personnel costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationAdditionalInformationDetails",
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquitySummaryOfReservedSharesOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationAdditionalInformationDetails",
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquitySummaryOfReservedSharesOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "tyra_Pre-FundedWarrantsAvailableForExercise": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "Pre-FundedWarrantsAvailableForExercise",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-Funded Warrants available for exercise",
        "label": "Pre-Funded Warrants Available for Exercise",
        "documentation": "Pre-Funded Warrants Available for Exercise"
       }
      }
     },
     "auth_ref": []
    },
    "tyra_Pre-FundedWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "Pre-FundedWarrantsExercised",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-funded warrants exercised",
        "label": "Pre-Funded Warrants Exercised",
        "documentation": "Pre-Funded Warrants Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "tyra_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-funded Warrants [Member]",
        "label": "Pre-funded Warrants [Member]",
        "documentation": "Pre-funded Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r321"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r667"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued",
        "label": "Preferred Stock, Shares Issued",
        "totalLabel": "Preferred Stock, Shares Issued, Total",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r321"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding",
        "label": "Preferred Stock, Shares Outstanding",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r667",
      "r685",
      "r1117",
      "r1118"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Value, Issued",
        "totalLabel": "Preferred Stock, Value, Issued, Total",
        "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance",
        "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance",
        "terseLabel": "Preferred stock, $0.0001 par value; 50,000,000 shares authorized at December 31, 2025 and December 31, 2024; no shares issued and outstanding at December 31, 2025 and December 31, 2024.",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r310",
      "r316",
      "r595",
      "r805"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r950"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity",
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement [Member]",
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds From Issuance Of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "tyra_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromPrivatePlacement",
     "crdr": "debit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of common stock and pre-funded warrants from Private Placement",
        "documentation": "Proceeds from issuance of common stock and pre-funded warrants from Private Placement",
        "terseLabel": "Proceeds from issuance of common stock and pre-funded warrants from Private Placement"
       }
      }
     },
     "auth_ref": []
    },
    "tyra_ProceedsFromIssuanceOfCommonStockUnderBenefitPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "ProceedsFromIssuanceOfCommonStockUnderBenefitPlans",
     "crdr": "debit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Issuance of Common Stock Under Benefit Plans",
        "label": "Proceeds from Issuance of Common Stock Under Benefit Plans",
        "terseLabel": "Proceeds from issuances of common stock under benefit plans"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of private placement",
        "label": "Proceeds from Issuance of Private Placement",
        "verboseLabel": "Issuance of common stock under Private Placement, net of issuance costs",
        "negatedTerseLabel": "Proceeds from issuance of private placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds From Issuance Of Warrants",
        "label": "Proceeds from Issuance of Warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Proceeds from maturities of marketable securities",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Maturities of marketable securities",
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://tyra.bio/20251231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r540"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosurePropertyAndEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r104",
      "r105",
      "r106"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property plant and equipment, gross",
        "label": "Property, Plant and Equipment, Gross",
        "totalLabel": "Property, Plant and Equipment, Gross, Total",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r120",
      "r603"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property Plant And Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r540"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://tyra.bio/20251231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total property and equipment, net",
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r540",
      "r588",
      "r603",
      "r805"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentOtherTypesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentOtherTypesMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Other Types",
        "label": "Property, Plant and Equipment, Other Types [Member]",
        "documentation": "Long-lived, physical assets used to produce goods and services and not intended for resale, classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r104",
      "r105",
      "r601"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://tyra.bio/20251231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r540"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment, useful life",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertySubjectToOrAvailableForOperatingLeaseAxis",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property Subject to or Available for Operating Lease [Axis]",
        "documentation": "Information by property that could be leased or is available for lease."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertySubjectToOrAvailableForOperatingLeaseDomain",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property Subject to or Available for Operating Lease [Domain]",
        "documentation": "A descriptive title of whether the property is subject to or available for operating lease."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "tyra_PurchaseOfCommonStockThroughPayrollDeduction": {
     "xbrltype": "percentItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "PurchaseOfCommonStockThroughPayrollDeduction",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase of common stock through payroll deduction",
        "label": "Purchase Of Common Stock Through Payroll Deduction",
        "documentation": "Purchase of common stock through payroll deduction."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationScheduleOfSharebasedCompensationEmployeeStockPurchasePlanDetails",
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationSummaryOfFairValueOfStockOptionGrantsDetails",
      "http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://tyra.bio/20251231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r195",
      "r292",
      "r293",
      "r294",
      "r295",
      "r340",
      "r364",
      "r392",
      "r393",
      "r394",
      "r398",
      "r410",
      "r487",
      "r553",
      "r563",
      "r579",
      "r622",
      "r624",
      "r632",
      "r657",
      "r658",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r722",
      "r723",
      "r725",
      "r726",
      "r740",
      "r741",
      "r769",
      "r775",
      "r782",
      "r785",
      "r787",
      "r788",
      "r796",
      "r797",
      "r801",
      "r802",
      "r807",
      "r813",
      "r1005",
      "r1009",
      "r1058",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationScheduleOfSharebasedCompensationEmployeeStockPurchasePlanDetails",
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationSummaryOfFairValueOfStockOptionGrantsDetails",
      "http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://tyra.bio/20251231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r195",
      "r292",
      "r293",
      "r294",
      "r295",
      "r340",
      "r364",
      "r392",
      "r393",
      "r394",
      "r398",
      "r410",
      "r487",
      "r553",
      "r563",
      "r579",
      "r622",
      "r624",
      "r632",
      "r657",
      "r658",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r722",
      "r723",
      "r725",
      "r726",
      "r740",
      "r741",
      "r769",
      "r775",
      "r782",
      "r785",
      "r787",
      "r788",
      "r796",
      "r797",
      "r801",
      "r802",
      "r807",
      "r813",
      "r1005",
      "r1009",
      "r1058",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077"
     ]
    },
    "tyra_ReceivableFromExerciseOfStockOptionsIncludedInPrepaidExpensesAndOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "ReceivableFromExerciseOfStockOptionsIncludedInPrepaidExpensesAndOtherCurrentAssets",
     "crdr": "credit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivable From Exercise of Stock Options Included in Prepaid Expenses and Other Current Assets",
        "documentation": "Receivable From Exercise of Stock Options Included in Prepaid Expenses and Other Current Assets",
        "terseLabel": "Receivable from exercise of stock options included in prepaid expenses and other current assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureSegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Schedule of reconciliation of the Company's net loss",
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r839",
      "r850",
      "r860",
      "r893"
     ]
    },
    "tyra_RelatedPartiesPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "RelatedPartiesPolicyPolicyTextBlock",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Parties Policy.",
        "terseLabel": "Related Parties",
        "label": "Related Parties Policy Policy [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r151",
      "r152",
      "r229",
      "r349",
      "r359",
      "r543",
      "r544",
      "r593",
      "r600",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r684",
      "r710",
      "r1116"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Member]",
        "terseLabel": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r151",
      "r152",
      "r543",
      "r544",
      "r545",
      "r546",
      "r593",
      "r600",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r684",
      "r710"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r151",
      "r152",
      "r229",
      "r349",
      "r359",
      "r543",
      "r544",
      "r593",
      "r600",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r684",
      "r710",
      "r1069",
      "r1116"
     ]
    },
    "tyra_ResearchAndDevelopmentCreditCarryforwardsUnderInternalRevenueCodeDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "ResearchAndDevelopmentCreditCarryforwardsUnderInternalRevenueCodeDescription",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development credit carryforwards under internal revenue code description",
        "label": "Research And Development Credit Carryforwards Under Internal Revenue Code Description",
        "documentation": "Research and development credit carryforwards under internal revenue code description"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfTheCompanysNetLossDetails",
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "totalLabel": "Total research and development expenses",
        "verboseLabel": "Total research and development expenses",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r412",
      "r742",
      "r748",
      "r749",
      "r763",
      "r1078"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseAbstract",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfTheCompanysNetLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Expense [Member]",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r840",
      "r851",
      "r861",
      "r894"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r841",
      "r852",
      "r862",
      "r895"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r848",
      "r859",
      "r869",
      "r902"
     ]
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash",
        "totalLabel": "Restricted Cash, Total",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r947",
      "r952",
      "r1079",
      "r1083"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "tyra_RestrictedCashMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "RestrictedCashMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Cash",
        "label": "Restricted Cash [Member]",
        "documentation": "Restricted Cash [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheets",
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash, Noncurrent",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r948",
      "r952"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationAdditionalInformationDetails",
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock [Member]",
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r974",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r78",
      "r598",
      "r629",
      "r631",
      "r642",
      "r668",
      "r805"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r158",
      "r159",
      "r160",
      "r162",
      "r169",
      "r171",
      "r173",
      "r261",
      "r262",
      "r283",
      "r307",
      "r399",
      "r441",
      "r442",
      "r449",
      "r450",
      "r451",
      "r453",
      "r456",
      "r457",
      "r467",
      "r469",
      "r470",
      "r472",
      "r479",
      "r525",
      "r527",
      "r626",
      "r628",
      "r644",
      "r1117"
     ]
    },
    "tyra_RightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "RightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease assets",
        "terseLabel": "Right-of-use asset",
        "label": "Right Of Use Asset",
        "documentation": "Right of Use Asset."
       }
      }
     },
     "auth_ref": []
    },
    "tyra_Rule10B51ArrModifiedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "Rule10B51ArrModifiedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b51 Arr Modified Flag",
        "documentation": "Rule 10b5-1 Arrangement Modified Flag",
        "terseLabel": "Rule 10b5-1 Arrangement Modified"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationAdditionalInformationDetails",
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationScheduleOfSharebasedCompensationEmployeeStockPurchasePlanDetails",
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity",
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Shares exchange under exchange agreement",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesIncludingAllOutstandingStockOptionsWereExcludedInCalculationOfDilutedSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r183"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potentially Dilutive Securities Including All Outstanding Stock Options were excluded in Calculation of Diluted Shares Outstanding",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Changes in Fair Value of Plan Assets [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Assets Measured",
        "documentation": "Tabular disclosure of the reconciliation of beginning and ending balances of the fair value of plan assets of pension plans and/or other employee benefit plans showing separately, if applicable, the effects during the period attributable to each of the following: actual return on plan assets, foreign currency exchange rate changes, contributions by the employer, contributions by plan participants, benefits paid, business combinations, divestitures, and settlements."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Common Stock Outstanding Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Common Stock Reserved for Future Issuance",
        "documentation": "Tabular disclosure of the change in common stock outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1047"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic and Diluted Net Loss Per Share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r973"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r420",
      "r784",
      "r1044"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-based Compensation Expense",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "tyra_ScheduleOfMaturitiesOfLeaseLiabilitiesWithWeightedAverageRemainingTermAndDiscountRateTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "ScheduleOfMaturitiesOfLeaseLiabilitiesWithWeightedAverageRemainingTermAndDiscountRateTableTextBlock",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Lease Liabilities with Weighted Average Remaining Term and Weighted Average Discount Rate",
        "label": "Schedule of Maturities of Lease Liabilities with Weighted Average Remaining Term and Discount Rate Table Text Block",
        "documentation": "Schedule of maturities of lease liabilities along with weighted average remaining term and discount rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r540"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfTheCompanysNetLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r26"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block]",
        "terseLabel": "Schedule of Share-Based Compensation, Employee Stock Purchase Plan",
        "documentation": "Tabular disclosure of employee stock purchase plan activity."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r1043"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Stock Options Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r11",
      "r80"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationAdditionalInformationDetails",
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationScheduleOfSharebasedCompensationEmployeeStockPurchasePlanDetails",
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationSummaryOfFairValueOfStockOptionGrantsDetails",
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquitySummaryOfReservedSharesOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Stock By Class [Table]",
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r36",
      "r37",
      "r38",
      "r39",
      "r76",
      "r77",
      "r78",
      "r124",
      "r125",
      "r126",
      "r190",
      "r321",
      "r322",
      "r323",
      "r325",
      "r328",
      "r333",
      "r335",
      "r466",
      "r638",
      "r639",
      "r640",
      "r641",
      "r775",
      "r936",
      "r954",
      "r957"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Unrecognized Tax Benefits Roll Forward",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r427",
      "r783"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "us-gaap_SecurityDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SecurityDeposit",
     "crdr": "debit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Deposit",
        "terseLabel": "Security deposit",
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease."
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentDomain",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfTheCompanysNetLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r94",
      "r95",
      "r96",
      "r188",
      "r197",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r213",
      "r214",
      "r215",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r223",
      "r224",
      "r225",
      "r228",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r288",
      "r289",
      "r454",
      "r455",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r760",
      "r763",
      "r764",
      "r771",
      "r808",
      "r1084",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1113",
      "r1114"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingCodmProfitLossMeasureHowUsedDescription",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description",
        "terseLabel": "Segment reporting, CODM, profit (loss) measure, how used, description",
        "documentation": "Description of how chief operating decision maker (CODM) uses reported segment profit (loss) measure to assess performance and allocate resource."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r760",
      "r766"
     ]
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureSegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Information",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r188",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r212",
      "r214",
      "r215",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r759",
      "r761",
      "r762",
      "r763",
      "r765",
      "r767",
      "r768"
     ]
    },
    "us-gaap_SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Expense Information Used by CODM, Type [Extensible Enumeration]",
        "documentation": "Indicates type of expense information used by chief operating decision maker (CODM) to manage operation when segment expense information by category is not disclosed."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r215",
      "r223"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfTheCompanysNetLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "tyra_SeriesAConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "SeriesAConvertiblePreferredStockMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows",
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A Convertible Preferred Stock [Member]",
        "label": "Series A Convertible Preferred Stock [Member]",
        "documentation": "Series A convertible preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "tyra_SeriesBConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "SeriesBConvertiblePreferredStockMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows",
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B Convertible Preferred Stock [Member]",
        "label": "Series B Convertible Preferred Stock [Member]",
        "documentation": "Series B convertible preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement, Accelerated Cost",
        "label": "Share-Based Payment Arrangement, Accelerated Cost",
        "documentation": "Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost."
       }
      }
     },
     "auth_ref": [
      "r1040"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationSummaryOfFairValueOfStockOptionGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationSummaryOfFairValueOfStockOptionGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected stock price volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationSummaryOfFairValueOfStockOptionGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free rate of interest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised",
        "terseLabel": "Exercise of pre-funded warrants",
        "documentation": "Number of non-option equity instruments exercised by participants."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of Outstanding Options, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted- Average Exercise Price, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Total",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Number of Outstanding Options, Cancelled",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r1020"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Forfeited",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r1020"
     ]
    },
    "tyra_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriod",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Granted in Period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Granted in Period",
        "terseLabel": "Number of Outstanding Options, Granted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant fair value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Aggregate Intrinsic Value, Beginning balance",
        "periodEndLabel": "Aggregate Intrinsic Value, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance-based stock options, outstanding",
        "periodStartLabel": "Number of Outstanding Options, Beginning balance",
        "periodEndLabel": "Number of Outstanding Options, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r372"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted- Average Exercise Price, Beginning balance",
        "periodEndLabel": "Weighted- Average Exercise Price, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r372"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Aggregate Intrinsic Value, Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of Outstanding Options, Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted- Average Exercise Price, Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationAdditionalInformationDetails",
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r367",
      "r368",
      "r369",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Exercise Price, Exercised",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r376"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Exercise Price, Granted",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r370",
      "r389",
      "r390",
      "r391",
      "r392",
      "r395",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationSummaryOfFairValueOfStockOptionGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term (years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r391"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Aggregate Intrinsic Value, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted- Average Remaining Contractual Term, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- Average Remaining Contractual Term, Exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- Average Remaining Contractual Term",
        "periodStartLabel": "Weighted- Average Remaining Contractual Term, Beginning balance",
        "periodEndLabel": "Weighted- Average Remaining Contractual Term, Ending balance",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Remaining Contractual Term, Vested and expected to vest",
        "periodEndLabel": "Weighted- Average Remaining Contractual Term, Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "documentation": "Number of options vested."
       }
      }
     },
     "auth_ref": [
      "r1042"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Fair market value of the common stock, percentage",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": [
      "r1042"
     ]
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity and Share-Based Payments [Text Block]",
        "terseLabel": "Equity Incentive Plans and Stock-Based Compensation",
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP)."
       }
      }
     },
     "auth_ref": [
      "r1010",
      "r1013"
     ]
    },
    "tyra_SharesAvailableForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "SharesAvailableForFutureIssuance",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquitySummaryOfReservedSharesOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Available For Future Issuance",
        "label": "Shares Available For Future Issuance",
        "terseLabel": "Shares available for future issuance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued, price per share",
        "label": "Shares Issued, Price Per Share",
        "verboseLabel": "Share issued, price per share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "tyra_SharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "SharesReservedForFutureIssuance",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares reserved for future issuance",
        "label": "Shares reserved for future issuance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermDebtMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableforsaleSecuritiesAndGrossUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less than one year",
        "label": "Short-Term Debt [Member]",
        "documentation": "Debt arrangement having an initial term within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Lease, Cost",
        "terseLabel": "Short-term lease cost",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r534",
      "r804"
     ]
    },
    "tyra_SimpleAgreementsForFutureEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "SimpleAgreementsForFutureEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Simple Agreements For Future Equity [Abstract]",
        "documentation": "Simple Agreements for Future Equity Abstract."
       }
      }
     },
     "auth_ref": []
    },
    "tyra_SimpleAgreementsForFutureEquityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "SimpleAgreementsForFutureEquityTextBlock",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureSimpleAgreementsForFutureEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Simple Agreements For Future Equity",
        "label": "Simple Agreements For Future Equity [Text Block]",
        "documentation": "Simple Agreements for Future Equity Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State [Member]",
        "label": "State and Local Jurisdiction [Member]",
        "verboseLabel": "State and Local Jurisdiction [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "tyra_StateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "StateMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State [Member]",
        "documentation": "State [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfTheCompanysNetLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r94",
      "r95",
      "r96",
      "r115",
      "r188",
      "r197",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r213",
      "r214",
      "r215",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r223",
      "r224",
      "r225",
      "r228",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r285",
      "r288",
      "r289",
      "r454",
      "r455",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r760",
      "r763",
      "r764",
      "r771",
      "r808",
      "r1084",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1113",
      "r1114"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationAdditionalInformationDetails",
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesIncludingAllOutstandingStockOptionsWereExcludedInCalculationOfDilutedSharesOutstandingDetails",
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheetsParenthetical",
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows",
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity",
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r124",
      "r125",
      "r126",
      "r145",
      "r148",
      "r177",
      "r178",
      "r180",
      "r182",
      "r190",
      "r191",
      "r260",
      "r296",
      "r298",
      "r299",
      "r300",
      "r303",
      "r304",
      "r309",
      "r310",
      "r312",
      "r313",
      "r315",
      "r318",
      "r321",
      "r322",
      "r325",
      "r328",
      "r335",
      "r514",
      "r638",
      "r639",
      "r640",
      "r641",
      "r644",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r667",
      "r687",
      "r705",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r936",
      "r957",
      "r959",
      "r972"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity",
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r55",
      "r58",
      "r59",
      "r109",
      "r110",
      "r111",
      "r134",
      "r135",
      "r136",
      "r158",
      "r159",
      "r160",
      "r162",
      "r169",
      "r171",
      "r173",
      "r189",
      "r261",
      "r262",
      "r283",
      "r307",
      "r337",
      "r399",
      "r441",
      "r442",
      "r449",
      "r450",
      "r451",
      "r453",
      "r456",
      "r457",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r479",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r527",
      "r542",
      "r605",
      "r626",
      "r627",
      "r628",
      "r644",
      "r705"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheetsParenthetical",
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows",
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLossParenthetical",
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity",
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r159",
      "r160",
      "r189",
      "r309",
      "r310",
      "r312",
      "r315",
      "r527",
      "r580",
      "r636",
      "r645",
      "r656",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r667",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r688",
      "r689",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r705",
      "r750",
      "r752",
      "r814",
      "r1116"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheetsParenthetical",
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows",
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity",
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r159",
      "r160",
      "r189",
      "r229",
      "r309",
      "r310",
      "r312",
      "r315",
      "r527",
      "r580",
      "r636",
      "r645",
      "r656",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r667",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r688",
      "r689",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r705",
      "r750",
      "r752",
      "r814",
      "r1116"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r843",
      "r854",
      "r864",
      "r897"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "negatedTerseLabel": "Share exchanged for acqisation of share",
        "terseLabel": "Issuance of common stock, shares",
        "verboseLabel": "Issuance of common stock",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r54",
      "r55",
      "r78",
      "r638",
      "r705",
      "r717"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock for stock option exercises (Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Number of Outstanding Options, Exercised",
        "terseLabel": "Issuance of common stock for stock option exercises, Shares",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r54",
      "r55",
      "r78",
      "r376"
     ]
    },
    "tyra_StockOptionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "StockOptionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Options Abstract",
        "label": "Stock Options Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "tyra_StockOptionsToPurchaseCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "StockOptionsToPurchaseCommonStockMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesIncludingAllOutstandingStockOptionsWereExcludedInCalculationOfDilutedSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options To Purchase Common Stock [Member]",
        "documentation": "Stock options to purchase common stock member.",
        "terseLabel": "Options to Purchase Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheets",
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "totalLabel": "Total stockholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r58",
      "r59",
      "r69",
      "r669",
      "r685",
      "r706",
      "r707",
      "r805",
      "r820",
      "r954",
      "r959",
      "r960",
      "r991",
      "r1064",
      "r1117"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "auth_ref": []
    },
    "tyra_StockholdersEquityIncreaseDecreaseInCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "StockholdersEquityIncreaseDecreaseInCommonStockPercent",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in common stock",
        "label": "Stockholders' Equity, Increase Decrease In Common Stock Percent",
        "documentation": "Stockholders' equity increase decrease in common stock percent."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r320",
      "r322",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r334",
      "r337",
      "r466",
      "r478",
      "r708",
      "r709",
      "r721"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationAdditionalInformationDetails",
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationScheduleOfSharebasedCompensationEmployeeStockPurchasePlanDetails",
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity",
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of cash flow information:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tyra_TYRA-200Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "TYRA-200Member",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfTheCompanysNetLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "TYRA-200 [Member]",
        "documentation": "TYRA-200 [Member]",
        "terseLabel": "TYRA-200"
       }
      }
     },
     "auth_ref": []
    },
    "tyra_TYRA-300ACHMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "TYRA-300ACHMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfTheCompanysNetLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "TYRA-300ACH [Member]",
        "documentation": "TYRA-300ACH [Member]",
        "terseLabel": "TYRA-300ACH"
       }
      }
     },
     "auth_ref": []
    },
    "tyra_TYRA-300MUCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "TYRA-300MUCMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfTheCompanysNetLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TYRA-300mUC",
        "label": "TYRA-300mUC [Member]",
        "documentation": "TYRA-300mUC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "tyra_TYRA-300NMIBCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "TYRA-300NMIBCMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfTheCompanysNetLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "TYRA-300NMIBC [Member]",
        "documentation": "TYRA-300NMIBC [Member]",
        "terseLabel": "TYRA-300NMIBC"
       }
      }
     },
     "auth_ref": []
    },
    "tyra_TYRA-300UTUCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "TYRA-300UTUCMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfTheCompanysNetLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "TYRA-300UTUC [Member]",
        "documentation": "TYRA-300UTUC [Member]",
        "terseLabel": "TYRA-300UTUC"
       }
      }
     },
     "auth_ref": []
    },
    "tyra_TYRA-430Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "TYRA-430Member",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfTheCompanysNetLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TYRA-430",
        "label": "TYRA-430 [Member]",
        "documentation": "TYRA-430 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforward",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward",
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward, Name",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfTheCompanysNetLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r981",
      "r1068"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureSegmentInformationScheduleOfReconciliationOfTheCompanysNetLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "tyra_ToddHarrisMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "ToddHarrisMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Todd Harris [Member]",
        "documentation": "Todd Harris [Member]",
        "terseLabel": "Todd Harris [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableforsaleSecuritiesAndGrossUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r306",
      "r333",
      "r466",
      "r477",
      "r504",
      "r513",
      "r517",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r562",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r590",
      "r606",
      "r792",
      "r794",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r806",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r987",
      "r988",
      "r989",
      "r990",
      "r1054",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r914"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r914"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "tyra_TwentyTwentyEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "TwentyTwentyEquityIncentivePlanMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2020 Equity Incentive Plan [Member]",
        "terseLabel": "2020 Plan",
        "label": "Two Thousand Twenty Equity Incentive Plan [Member]",
        "documentation": "Two thousand twenty equity incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "tyra_TwentyTwentyOneEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "TwentyTwentyOneEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquitySummaryOfReservedSharesOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Twenty Twenty One Employee Stock Purchase Plan [Member]",
        "documentation": "Twenty Twenty One Employee Stock Purchase Plan [Member]",
        "verboseLabel": "2021 Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "tyra_TwentyTwentyOneEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "TwentyTwentyOneEquityIncentivePlanMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquitySummaryOfReservedSharesOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Twenty Twenty One Equity Incentive Plan [Member]",
        "documentation": "Twenty twenty one equity incentive plan member.",
        "terseLabel": "Twenty Twenty One Equity Incentive Plan",
        "verboseLabel": "2021 Equity Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "tyra_TwoThousandTwentyEightLeaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "TwoThousandTwentyEightLeaseAgreementMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Twenty Eight Lease Agreement [Member]",
        "documentation": "Two Thousand Twenty Eight Lease Agreement member.",
        "terseLabel": "2028 Lease Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "tyra_TwoThousandTwentyFourPreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "TwoThousandTwentyFourPreFundedWarrantsMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Twenty Four Pre Funded Warrants [Member]",
        "documentation": "Two Thousand Twenty Four Pre Funded Warrants [Member]",
        "terseLabel": "2024 pre funded warrants"
       }
      }
     },
     "auth_ref": []
    },
    "tyra_TwoThousandTwentyFourPrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "TwoThousandTwentyFourPrivatePlacementMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquitySummaryOfReservedSharesOfCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Twenty Four Private Placement [Member]",
        "documentation": "Two Thousand Twenty Four Private Placement [Member]",
        "terseLabel": "2024 Private Placement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "tyra_TwoThousandTwentySevenLeaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "TwoThousandTwentySevenLeaseAgreementMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Twenty Seven Lease Agreement [Member]",
        "documentation": "Two Thousand Twenty Seven Lease Agreement member.",
        "terseLabel": "2027 Lease Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "tyra_TwoThousandsAndTwentyOneIncentiveAwardPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "TwoThousandsAndTwentyOneIncentiveAwardPlanMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureEquityIncentivePlansAndStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2021 Plan",
        "label": "Two Thousands And Twenty One Incentive Award Plan [Member]",
        "documentation": "Two thousands and twenty one incentive award plan member."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableforsaleSecuritiesAndGrossUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Government Agency Securities",
        "label": "US Government Agencies Debt Securities [Member]",
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)."
       }
      }
     },
     "auth_ref": [
      "r753",
      "r754",
      "r776",
      "r778",
      "r1081"
     ]
    },
    "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. government agency",
        "label": "US Government Corporations and Agencies Securities [Member]",
        "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac)."
       }
      }
     },
     "auth_ref": [
      "r1081"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureFairValueMeasurementsAssetsMeasuredAtFairValueDetails",
      "http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableforsaleSecuritiesAndGrossUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "US Treasury Securities",
        "label": "US Treasury Securities [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r753",
      "r754",
      "r776",
      "r778",
      "r780",
      "r792",
      "r1081"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits",
        "periodStartLabel": "Beginning balance at January 1",
        "periodEndLabel": "Ending balance at December 31",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r427",
      "r783"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions related to current year positions",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r429",
      "r783"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Additions related to prior year positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r428",
      "r783"
     ]
    },
    "tyra_UnvestedCommonStockExerciseOfStockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "UnvestedCommonStockExerciseOfStockOptionsMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesIncludingAllOutstandingStockOptionsWereExcludedInCalculationOfDilutedSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unvested Common Stock Exercise Of Stock Options [Member]",
        "documentation": "Unvested common stock exercise of stock options member.",
        "terseLabel": "Unvested common stock upon early exercise of stock options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UsGovernmentAgencyInsuredLoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UsGovernmentAgencyInsuredLoansMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfAvailableforsaleSecuritiesAndGrossUnrealizedLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. government agency securities",
        "label": "US Government Agency Insured Loans [Member]",
        "documentation": "Guarantee by US government agencies, including but not limited to, Government National Mortgage Association (GNMA) and Department of Veterans Affairs (VA) for government insured loans."
       }
      }
     },
     "auth_ref": [
      "r992",
      "r993",
      "r994"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r103",
      "r192",
      "r193",
      "r194",
      "r195",
      "r585",
      "r587",
      "r756"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationAllowanceOfDeferredTaxAssetsMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset",
        "label": "SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]",
        "documentation": "Valuation allowance of deferred tax asset attributable to deductible temporary difference and carryforward."
       }
      }
     },
     "auth_ref": [
      "r956",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationAllowancesAndReservesDomain",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "documentation": "Valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "documentation": "Information by valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureLeasesScheduleOfComponentsOfLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r535",
      "r804"
     ]
    },
    "tyra_VestingOfOptionsEarlyExercisedSubjectToRepurchase": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "VestingOfOptionsEarlyExercisedSubjectToRepurchase",
     "crdr": "credit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting of options early exercised subject to repurchase",
        "label": "Vesting of options early exercised subject to repurchase",
        "documentation": "Vesting of options early exercised subject to repurchase"
       }
      }
     },
     "auth_ref": []
    },
    "tyra_VestingOfSharesOfCommonStockSubjectToRepurchase": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "VestingOfSharesOfCommonStockSubjectToRepurchase",
     "crdr": "credit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting of shares of common stock subject to repurchase",
        "label": "Vesting Of Shares Of Common Stock Subject To Repurchase",
        "documentation": "Vesting of shares of common stock subject to repurchase."
       }
      }
     },
     "auth_ref": []
    },
    "tyra_VestingOfSharesOfCommonStockSubjectToRepurchaseOne": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "VestingOfSharesOfCommonStockSubjectToRepurchaseOne",
     "crdr": "credit",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Of Shares Of Common Stock Subject To Repurchases",
        "label": "Vesting Of Shares Of Common Stock Subject To Repurchase One",
        "documentation": "Vesting Of Shares Of Common Stock Subject To Repurchase One"
       }
      }
     },
     "auth_ref": []
    },
    "tyra_VestingOfSharesOfCommonStockSubjectToRepurchaseOneShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "VestingOfSharesOfCommonStockSubjectToRepurchaseOneShares",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Of Shares Of Common Stock Subject To Repurchase, Shares",
        "label": "Vesting Of Shares Of Common Stock Subject To Repurchase One, Shares",
        "documentation": "Vesting Of Shares Of Common Stock Subject To Repurchase One, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "tyra_VestingOfSharesOfCommonStockSubjectToRepurchaseShare": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "VestingOfSharesOfCommonStockSubjectToRepurchaseShare",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Of Shares Of Common Stock Subject To Repurchase, Share",
        "documentation": "Vesting Of Shares Of Common Stock Subject To Repurchase, Share",
        "terseLabel": "Vesting of shares of common stock subject to repurchase, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantMember",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "terseLabel": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r811",
      "r812",
      "r815",
      "r816",
      "r817",
      "r818"
     ]
    },
    "tyra_WarrantsAvailableForExercise": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "WarrantsAvailableForExercise",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants available for exercise",
        "label": "Warrants Available for Exercise",
        "documentation": "Warrants Available for Exercise"
       }
      }
     },
     "auth_ref": []
    },
    "tyra_WarrantsIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "WarrantsIssuedPricePerShare",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants issued price per share",
        "label": "Warrants Issued Price Per Share",
        "documentation": "Warrants Issued Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageBasicSharesOutstandingProForma": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageBasicSharesOutstandingProForma",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Basic Shares Outstanding, Pro Forma",
        "terseLabel": "Weighted average common shares outstanding",
        "documentation": "The weighted average number of shares (units) outstanding in the calculation of pro forma basic earnings per share (earnings per unit), which is commonly presented in initial public offerings based on the terms of the offering."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails",
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average shares used to compute net loss per share - diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r182"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails",
      "http://tyra.bio/20251231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "terseLabel": "Weighted-average shares used to compute net loss per share - basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r182"
     ]
    },
    "tyra_WeightedAverageUnvestedCommonStockIssuedUponExerciseOfCommonStockOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "WeightedAverageUnvestedCommonStockIssuedUponExerciseOfCommonStockOptions",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: weighted average unvested common stock issued upon early exercise of common stock options",
        "label": "Weighted average unvested common stock issued upon exercise of common stock options",
        "documentation": "Weighted average unvested common stock issued upon early exercise of common stock options."
       }
      }
     },
     "auth_ref": []
    },
    "tyra_WeightedAverageUnvestedRestrictedCommonStockSubjectToRepurchase": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://tyra.bio/20251231",
     "localname": "WeightedAverageUnvestedRestrictedCommonStockSubjectToRepurchase",
     "presentation": [
      "http://tyra.bio/20251231/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average unvested restricted common stock subject to repurchase",
        "label": "Weighted average unvested restricted common stock subject to repurchase",
        "terseLabel": "Less: weighted-average unvested restricted common stock subject to repurchase"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "460",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481244/470-50-50-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-5"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-7"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481501/840-20-50-4"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481034/205-10-S45-5"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-3"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-5"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715/tableOfContent"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480126/715-20-S99-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-3"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-3"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-4"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-5"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-4"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478600/954-210-50-2"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "450",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477850/954-450-50-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-18"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-23"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-23"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-5"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718-50/tableOfContent"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477908/944-505-50-1"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>81
<FILENAME>0001193125-26-085490-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-26-085490-xbrl.zip
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M&S\WM[C;P*_?_\(E MK[7Z'_N[BD=G'MV;=O[S[1?^$2V1/UKPND]NT_:7A
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M!*HJ*/1&B&Z]RW3%15FXEI8T?#5W4SGH[O"6>:-6P5_MR=J[R\=0Y!_J:?\
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MS6110VB058M9FM=7GC@WE;/-BBX*IMGC>&9H** <\J8U!5+#-'B^2RPO(B3
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M""55ZM^&ARZ8UT>5_=(F8,80))MVN*@;8,7S$'0A2 DLB6J/8*627#^.T5Q
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MQKT#%,\19='0G2RR@2)F$*O8[%,0K*K"QC]!:[+?,[-R4UC!,YNC8^09+ZI
M?(@THW-Q!#-\ERS^/2OLL)/TX!W=I=\#5@8A\.(!.^>,@/-=8]?\UDDL+9ZV
MG:W)\/W&5??:TMQO97(*8M;N)0L&]TU0E,""ZOPOTO6O?F4SZ(!F,;>0'36'
MBXW TZ*X1.!"%=J<+:LD3RX6?!&"%!TZL(>#:?T[HSE=90_+EBK>(E>P,4'1
M4289"C4SE=:S1@N:62NX(0,Q($H@97 X$**H]#VQ&;835TP+PK+_0M6["&@<
M2 WW:I8!2R+*[8\I;.!RM@6ZKXER"FSN%K Q<:XZ.;DW(L"%&>4]G.9F]\5^
M8RD&$=E_P_XHX)J7$1HY4Y#F]5NO?M<?O-?]?\59I\-MI1,L9Y)J=T&!:M9Z
M% A[2_=>.AN, 2,C.&;/MV#64K-5682(@##Y!,;*>=O'OD'EOTL*[]6*&=R1
M/CU0$SR^'?7(C8"\<=9KM]]V'3=*6EZJ+<J$]'+J\X+<M+K+60LYMY#RR+)S
MHN V7U6(++LDEK$8Z.MCX! O_DIO^^'96=,EXNV41U<63C>E!5TC!5*AG]]\
M<^TL[>SQ^+)DO62AYY69-[9I:TIJ0L[:EJ8]" HNO#UEWT\:*XPH]ZJ_341>
M4+:1$X(.P=HE/C=^[VRX9=F,9[=BS*;6_<::<Z&)IN,UV(;]S4XXQD4;OC;X
M ';0CTD7@(4@')B_H3,12& %"T$#N_M@[H$0!-78/L$-%X*^3T/9QX2@E]\0
M["*THA!T$9>"!; "2^S/3X4"65PL](<A)U0(DA2"NG&"AW(K)*?_7*47#QRG
M#/3$M*TN[7[[@)TS%(+4/E$85P$C02Q8?E?7A" ^:K?\RW_W5@II8T(0/A/*
M/H_%I_%B)W=]#OZ>$/313V#S$MO^DAVP<P"B)P0Q=M6+LUO_% YPAAP6@MYT
M=U+X4"%(%?KKFWOUD VY8A?(&>Q_P2/ZGB $07;[/.[FXTX)07%J<P._#Z.]
MA* .(8@S+P3E6X'_#4BB3P$.Z2[ 7-L=?4& @:U)!C@(8G8[B.!^J5KMSK9-
M&W[S&%"_2R9"T'RW$&29#/UW4/HV6:F.$_G\,B'H21^?GSVM^@7/YR4(]H(W
M+%/^[3S*_GL@6R*3+U0A?OURV56@[%^_##Y<R(/^VI;D'X!^>ZCP;V91Z]\%
M^(@E&^U)^;E!$(@:_-Q W(LVQ_Y< P.'L9\V4K"QJI+D#T\7+R"8%;:AQBY=
M]6 5P3F?J??M*Z=TN=G8HXODQF>U3_1:/I^=^AQ7F*.M=OOR\J:3B[:=VV)&
M<4A#;N1FTP;BOITAKD-.>?U6IF!^8X0;O),F4$ 1N_!D<!+$$O-9 .+H$ZO0
M&([&=MS6+N5B#S1;5"Z;$^-OD<GR]3E'RN;!1[RGZ8'.5Y57MY70&TMKC.9Z
M78D80YX=WW#$F#BI/&_607R&E;QC_+4:HKHR#CG.-NC 'YR:[+XP0X75#EBQ
MN^/OJ'GH:][8F/KZE90FU2Z#\!CR-!\)>SX5F1+KV+2P+>LV8]!;':!D^/RX
M7/6\5H-'& 2Y-D9$XK,H8($JP//82:?X2TK\$(AQ,!5,\!'T14 DFJDB"F?/
MOH^I_.'VR,@+>\=GQ=RG*J.^T;\NDTPA$5J>BE5&XLF6UTV^T>NET5Y8VMDQ
MR E E/L=2.49P>:08F@U!OUK#E=P,FI>6_TE^C*X,\7@R+*2:OW]FY_\E*YM
M*['RFL7\#3O,[T$#?Y3'GVPKF<MK*?0DC90RUXK(*3C]U/ [KP:=X6%D;,"0
M\4Y.\+"#K17]VN^BW^#'V!IPNT$B!#2*#3D%O8DX#H1V^%JP*0E;B#UH18#,
MS/-D3C!5TW4?7(PH0D)EFYW *9MT +8E9C:SG'.!^K._R.=854D\-2.G>8!!
M;&-=A@/=<]J["D29C.(*=EZB?21?A.O0D\W=J4T]?"A/!\Y Z3OP-8:FZ:@4
MJJ_V!\[G5(7< T\._(T/P(>;F=(B2'9/P4NGDD=6TAZ\;I#[?JR38/X"LGK-
M)<,[)S]Y)6>C*2K=4W''V?(=SNSC5.,S67*VT4):\KT)AXA2VNQ:PL\1'DS0
M@S_,U^$Y\WV!7-YE3 ?EN!"$Q"?@Y:M)E*. 3A?X_<(VKMF*23P0S/'0J*YA
MA!Y%@=NQ1]'2@T'.,*49&C+*N5_U>MN>N%[W)855$79"&UY<H(AZP?LH!-4N
M4GA:@?EG.3K!=:I[.0E4HBSJ9U=.=2[RKMXN[1T%*JYR5 E5A,<1L$\/E-O'
M'WTI-FG$&3F^TA=SV2Z6DS,T*K-USC9)>XY-<LDL52\,ONO;?T&.EIH[IKYE
M'*]ZM'19WZM>DWTY9R,*V[SP'>GN'T,*>>V>;+GW+:J=.;[BULHI+JJ[URQE
M$"=01U]A6S5UK2_*-Y+8B.1P<:^EV'O9"N^FO:WQC;9NT+0&[+_+;]?+,T]5
M$HRS>NQL#=)N5Q^]NR85LC;M$KHX]#_,UBY<,O;[@@/_".+[MU;&?\,&!O]V
M1*=_E^VV:%K_;8VY_RL:_R>)AH'HBYL3$+W.$POJN]BV.*TQJ9/-N91$=]-A
M/][[-MV 1J6N_)5.Q$'RA?-;B*-TH)M11RSU#'*F W%SV53!04H+]E2OQY:7
M%^Q^-1"Y/-<=HD[+J2/>N*^KL4Z<_UL7P_*F/P\W &SY.DRP)/$OC3%2RHJ%
M>P.=BPJ]]430<=\LBW@"AFS;M^KG=G]A0?8=Z,-H2+%30^>/7^0@"Z3\5HHO
M/"0@(ES37MOWX"58@&SF[\GB0H> <%9TA8514<'[<"]8K@38MJ;EE;Z!+JE/
M'-8PK^^7OS@[KA7P2CSN09K=BV4?U]YWTR*?JLY\(I?;CS=.U?_E9"5[^%^F
MCW\\].L*]R8GBB^'8"8\;K9E![3][HY=%X)NYRDP8[XGK+'6/=OGNP6G@-@*
M_7KF*SD#9P?6A:L6XMG28B_LOV:U)# )'2H&@H,3\XA8BESKGA7?$VS<ZB^F
M0Y*20\= *O3 %E$9^6BBH]\"SNG_.1F4;\@FJ?[1.+' +GE;C)S(6KT3#F.!
MX1]>..TM]RSTNIJ#H!(3/$/Y<B-,>V(IL-V6I70-6@N.,U:,L!B0#<RBH3T7
MLJEZ[JP<X^QTA$9C<-W?T* 1VL6H Y*YTLQ*S#A=1@ 63&),@(L\=;34^"8T
M)6L;+&=I,A^:*E!GWR;HMS <$O(/L@^4Y,Q\-A](L32NI_GBB<M*57&M>?[%
ML++)&?CYM*^-WB%Q.YIG:LMLX5^N88BV8\X/[CER83ENF.6TL<XU M(B_]&U
M^4/59PPK6(MEYXJ*%@94KU?[>/LFPZYOK%5BGJ'] 4XQ6@FN.NN0@#TF. W$
M4O7N-1K$0XZB32<L0TIG3$HO&[:,_14D.,K^IO:(N=Z).3U8^0ZF_%?B:FLT
M>V4^H2UT2O0RD,O.OLY&I))2=HQ@N"M &1LY;_8T K$?E3]AQ9'VGNI6V7DV
MW'>C(D@I><K[4@X^(:+*Q?ZO?8'K=@YW-_AT'HP?-BK#;0"P/'/4Q#RFF'>6
M#QYK5:8#C.:0XN59.79\!<>!REF&$21%@C 6'-U'3]BLUE?!]+NCT!I6>%7D
M6M#JFY&(6P'W(%X[R<U.[!PHH(WO8LQ))LYJ<[)CMRB331TY-D^;_3E&S*P6
MCMHUX$D4DK/GL\\ 0U(>&/$<(X<>_5%A4K6J%-.:]_#^[;2@WQG<^V(YMLK'
M!GV[7$@98R9NTBGIB.-^MU<S6=%:=<RQJ:%.Y)D!6I="RK-R<^?G:92V&+FI
M1Z3<S'0W6XOI1>P_\;04!G:UB?V3&P]$%*&-@3Z.SK5!:##E^>(4@[ZZRR%-
M/L#+<A2T3=[W9/VP<8N#;[2'GC%6,C"KKNYN%I[V>ZQEBU6'#Z=%5/&F[ JY
M[^<(W0-Q>))F1Q\V20@2;X;+US/</XSJ&GQKK&L8CKBPUVW8ZVY5(0IW=;2P
MGC*X%6+,0C;I #=>GD15R\0T#]D)07_AV?98&I*+ LR$((D(!CX%>A2MS"Y$
M-.Y40$R0XS0"5<(+SDY->$XJ13O$'*QC+U95#@2$,'7HDKV>%JPS[<B4%=.Q
M*E#=*9;M&O0VX@BJ:=ZL#0%H1:6VBB_7"Y38"2R1>9R"$-3^.(]OHI(A-?T5
ML(?+>' P27*_:=4U!(#H _$G?9$?'$">+2KQ>U"SDEBL:%=9K#@2?(T2;3JM
M.="GJ/-@$][O41_8NQUIU#&:X6=OF!&LJ81O2K9S_-;D^?,"O:E\IJM'!V\%
MQ H.1;!-NZE*^7ESV'@AB(3K&C@$A+DV#S7[<1!SQ#:?J&[HH6:5Z!*2FK/2
M1#*SL<;L_G7U+J\R]/D;1-W[G2>4BPR[-<?RC^T40<2 CKG/%)+J$XY,QS96
M3"_<:R;:D?,Z6R*(L.1F?@<269!#<K>5&,^-^><?V8]BODGY6FE?_:Q1A(MJ
MQ]:LL][R3O!-=EZA#[)Y75 I]%ZV0J<0),8W48@5G$!K K%E0:K[.5FIS/Y#
MI_)/1F,/T?M#HHE"T%T$B=9)7GQRH$RU*$)5'5EC:<@/%.P'GG!$N7H[39 S
M:(-!/HQ!B:/(8PR_HJ\#KNPUZ)Y._THD11*M=Y\PNRM$+L/-D$/+$I*=X>3\
MC1&6_/CVX#,D_GWQYPFI;DG) [3[9;;6E=IE7]Q=U;1+ZUKZPKSH]GJ=UMNM
MJ<-$$SF-<ZX/"-H?K#Q&[B>8X%LP7CSB*^VPR#&#%KS@4!D/<AV(IOJ:<@PZ
MUFD.;= CI);3\VYL"G5 B7^4HQ#/%^&8GZN2F"'C=]53>EFF.RBJ+/B#/,T$
MER0:'S"F/VL1;?6R"#Y+8!*G4CI:)7?RC UHH6Z !,_:[#$9>7ML2^7T2+NO
M:'9GJPS[R3"V[@UG(FGS%T2MHV@*L%MK>YM&X\$F=A<G,M%U$VC[JYM-9^7Q
MD()>A!QT+E_U_%"S. ?<AM'BV#QOE9GT#,2+DU2\_AQOCF*D?!L)\72;X&L4
M>\\NYX/)[*1DVPBX_6^Q\"DMW6^-+S9@-X[WKR-(;C5%2PBVK5ZDGLNU$=*D
MB</7J8[&NZ]4=ECDW&7SYT+086/LJ?9.?8W4ZO7;;1M5(=3TGMB:(UK</W8F
M3!3;!J16<U[G_7*.HVW[\?OKRQM'8&]<2W8*7&^8'#I4D'$SNWEM=2MM>!P6
M?>'NZD A1!Y#HX@)C(%>>CM6@H1+@IRNA4C@.G_7XW31DEC-CH$C/9#T@*HV
MA@2"VF>A!C!]3'\KXP ;4HJ/V_47-S[D*^9H?6.0UP$M:$?H(6_30N9 +)9L
M$->J5%U@W  Q0B7,F26'$Q,<?5X)OMQJ>;$TTIT3F;DH=Y"I<ODCMU7E]3M8
MC&?0WH)O_+T<R$LV3G"PGP&60RL,A>/E9E&2<[JJ)VK9]/B2D?5A7M=](/A"
MM.O(W:SA-9H!Z[P)LN<VI>Y#8WV#@]&MS\^JL3K00%P25ER@B6DS7Z<ZR&$F
M*%*MQOQ(((7]\_KH"",A%F. ;3=BX"2#)9$20E 2">XP1^QHRI.!-[+QCUG3
M^J6[5E[7A#=0:UT[$RP=T^#LG"=F7^&=S@TN+^286=2MG\X(49%;U^S-2H*7
M##F3&/8&^99KN>7KLF^1UD/N=QW<N1%W:9T>T*%U0'N"!>-HSHE^3%7V!HR*
MT)?A?M16-;9)9WTG0NP'Y/!$L^*;']L0_<&0ZDV)!_-46GK_;IP-T1=X24KL
MQ';DO#;Z<_5GL.?%:PW*NVY3" J"BNVZWEJSU&88IYOKM5,^#_@S)32]V'@J
MY9!F@N7^$F#*CHT:Q$Q5H :<D(@4>:ZIJFPC+J:XCD  GOKXA'JX;I:>@MS[
M)01Q&^+!JMBVT\TBI8"#TXA)GZ08RH*+Y$ 3#<+[?D2(AT!A;&7 X!K'/4\O
MJ>%:X[">[AI\K"(S2_%48(G4NQ/1=%8Z)X7A0#4 - VZ!V0!':9!K"7L#2IE
M#INXN:/@/(RV*9IIPY9[!\(7EH[^<K_3??UPFM7IM%X3L9+DZT7U'FH1[F)6
M-I+@@'7=:PSM:G^- .OI_@LJN??MQ]\C(Z4S7J] L!&,PG-M&Q]FRF9[JD)O
MY8XOVT+?AU[E2+*TV73NG9U,R#&TQQ!$CA_ <6]K0H@ #]9H(VTYT'BR$"2%
MVOO1$753[U*W!Z=]!6,Z5,5X-T+Z\>8]I6EDR^?!=U;E$V>F*?+E=\&ND7WZ
M!BTR;)QG09U58$-9!SE^;54W2H(A>AQZ.RXV9SVE69(]3G<>J2*[.:BBJN[J
MAB.59\[VKHF.&\\HK?N,AG__R^;"&XQ.+T0/-=66#67;K$NGA,H#M^?Z>*=I
MJ >&1YJ*>V]Q#@'2G5X7_Y']IY>'LUB(8=@CL1,?):+K=]4W9$X' 6AFQVWB
M]IC%%PVM8@,^-F82$DI&[H;HD5?6#Y@65W5BL@YS.LOZ2F<&[L?(??1Z:UST
M^6VJP_N2-POG[)U_4\O0=\U>X'+@)=/D6G+ZHR9:?]GH@^<GSUE%BXT"URJY
M"\F-0U5333X*K@2>.Q\%F!BLIE>@?G;B)2$Z?.0.OE4;=8H-5,_/[<3_%:&G
MR1!4%,!+?5&QWE@IH.GCMN?IUW4]W//%I(9<U_>CZK"'NH4Z.MUL(E\VY2-^
MSQ81T!2"VBC/!6#VO1K<1R);FLZX36%FS3#Q^_E0#CBY^<3$(Y^94?/4K=*L
M$%7QP(@@I17'PX-&&M]>]P(0$4["L\+=QR"U[(D$"CMZ2KMYEOPK@T7O8I!P
M+^KXNLFZW$!084N%=]+$M<;'256;&T_7 A/3SKT2"Q[:J;6T9<RX"PZ*LAO7
M8:.[:5*:MB2%Z:M[1&Y-B$)67LV.--]^IK1]-4=9.T"G]/%A@QLGO)ZH588<
MN[VGKMAA\EI1P?<UOV+;25*Q7&_U>$]/=#W,M; ATX-W]5I&1LRJ4EDMNC8J
MTB':BM>[MK3REAN9+03MUP)$ IA@<5085549H,^M[T.]@*M=8M=W4Q31)SG0
M^-:]*()7RTM=/6.69#>MZ)YRXMKM/;"0X)C34QU1;@,J_75DX[,ZX"$3?W\W
MM\.5>W6T]WM<_>2O=N*IV(G8I^?E@#;>+<$X]+UF)_3KQ@K#K .K L!V%5P.
MHA;DJ\"V>0R1!H*1*EBF35QSJ#I7_A%:J?[QG9R8Z(X)P5%*8M4WI2S\[9#%
MFC2QOJ,-.Z&[IF_%7+1C?<\/WU.MYOA$8X0HRL]V(D+M<.1WQ_%PEG37@$OK
M'U<\M> SJT9?;J3FG./W)]J5FO1XOO83@U\*GRX^]Z%_ABPG7]+RE;8&OS V
MG@!7;+!S"DNU.M9NY^2V\(#R@:7M.PZ/>#^^[E+SKW\[_?COWZQ#%2EW6,K<
MWX "8R:427^&#9W =9C74T,/HZ(O 1&[PO:>?2,A?G- "<B:L";%"J19]G"$
MXSCT74&SQ[[ZG/ H)7QZK0?+\_*9'8<YE$ 7TZNDF8+1%$S2Z^^F<KP8U$?^
M>>1TY&YP;55%'R.Q%RM,IJTM4J+7]R.6S;,3B<3TB-3JY+IAF'%:?%V\;:;C
M;NAMLZ=\FV1A5VO^E<A'A2";0L$A14[.Q-QZ!SY>!BR*EITPP<OSX8.6%Q@#
MBH+!W]=HV>T&<9X=%_6F(><Y5[(BH\Q?Y''EX@IJ*.\:1FX_7;OZBEB0$A/9
MV9CQHR,-OW[FVK/7@8//IO]99A)4CNZIZ)OU_=G:/'7\@5V>W?M%?(/]63O7
M,[V6PP_LV6'O[7N\0LSO/A)M"P6TW%?#>)> DI4VZ$&(Z8]9#8Y/5>;L&^-=
M[XN::(_:'L^2:IY("QP"^CI\P3X/J]ZF?L]1D2(?3-MO]#?_;6NCI(A@&ES[
MG2H$)?YV:'<00;O4<PRH>L@_Q\@I4,GK@%?WH<&EWW)?W@:4P\J7HR"*L3:#
MQ63\GRW@6Q,F$N8;@?.V+-;"4^:L!U:.#$[Q)%(-ICJXG@F[:Y"<\#&49D U
MO\\)TW_%EOQH#LF;&]CGN:PDU]L=H$#]U&S%A-M0HY3BJ,$R'1O!]GIUXA6)
M-U][E>T<V4E _S$D:/<U2VCS]&_!)37#J]"1C3])7]7J6L8L+]YG2F"^S"X_
MO.EPEKDUK!.-*H[9N*%FU2V[S%AR2<Y>5SB;<";,+26]-#>CV/J(DW?9DMB,
M[W#PL)RNE5W:_>T+$Q"D-:O4^G65G-)[V];(S 4=XUSW9H>@,>A<$:)&/I4I
M!!T#I'?5[PF[%BC\Z+:]K:KQCCS<[%'J]3&\:[+48\FS#L]8J0)3<ZI>YQ9\
M&&HVP58L#_4=KS'Y*TW1]8+?O"3+CV>)WL.&)@A.\7T!?"'*H#U?M^Y]$[N_
MGY55CZU CF]S7R*F6C,9J6#8*-H)C>DVCI+I#BVTS$KL9@6)N(D#L<R!%_B:
ML6R^="TTMI&8V*K2Q@G]<U@(>A>*D?,US=V-4Q9_ B,!Q&9WVNQ;1I &1*V^
M->&:2YA9<D#":H68XT3;S3\Z1_@/4[I\579V'<OM==EIP9BOZ@Z.!$=PK['S
M4]D_F?14C!0*S$3$65-";Q3W,Q$2>5Y,2"$!"&@SC]O)]?*NKN#VB5=\JJ)1
MFX=ZIW26,Z;3@BNE,P-;8V((M<]5ECXX9Z2EIS]RJ>B3XY)O7G^U4<]KJ"LS
M^53Y9KFN(:#?5;/O5O6">'WMUQWOUIUZ(2@@-8 ;QMEF*;-7F-D):*<Y[(%
MVK-M\Y:Z5TR+'N,6?[VBD+,=5%6Y!'@]!Y.S[>[KR#-9R_2S^.CK?RO)TY_
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MR1/*#4WDPZJGIW02:5LD [% FJ FE%#Y[.2H?N7;VB.1N:G3[@O9SS811W]
MWP_PI9?[J&ZTZOQAP1#-M/!MD.=TB&I%$>#@TCA!Y!O>>+AXVSUP$YGB<3/-
M^3,;+B7:]U54@_,'L-X.K?_. IL6\B)1.MQ38Y8NA2BH(]N7S '/X=OIBDL0
M"[9&:S[[PHO4^?5DVOC+&T5UZ65)6=\[&OU_QS14RR_#',YJ&$AUC*0[I0^K
MTM;.V+F>#^X2O^Y<I2?3,G9^4C]EUFVE7U.=G%M4=?KUC7ZX[9+VR OBE8;Y
MR-\MX)6$5,C)8+ *1H2.^LZ]#O3/Y4JH>0Q%I%"!S- WTRA:M+*XGBDS^F]C
M"0V3@2-6Q4#9K6MQ_API/.^(C8*"I\3JIZSNIIW<"#TO=T""7>@R$1$#0XR'
MHA6+',J0GIVCV8TE9:C!ER:LG>FBYFWWPX?3/MT3EY8]\[B0.0!H9G?0Q2_/
M$6G[-PUHT?8[A'!<(L:RY3^Q]]Y13:U;WVBLJ(A(D2I$I4FW4)06&R(@(*"4
M(&0K(H08V'200%0$! 04!+8@1*E2(R5!6B*$(B+2B82:()U 0EV2=MGO_8[G
MO&>_[QCGNV-\XW[?O>>/C '/P[/F?.::\S=_O\5:63"A8'+C=M*7$@X"EAW-
ME1XK#L'17"'MGB6<( AX-=;FXQT04@QH[.VU6[=>ABY-4U\3K[#W3XQJ4I<C
MZL]/Q(N%LC*52%+.A)=W?(K,O8W>J>,J4N*7IG&XBNHD7\%OW12G5JO1>$16
MT?/SA>HAGHH9$<]+:$L9K^X84DS/E99E8\O6?A:TVT#]+A8:FYJIV-LA4FT2
M"G7]AP<[ZV20HM8.TGM$K2_\XP>\;[NP+A".;Y-%-*.X495A15,&'"<U)=FW
M&>#'::V7FUPDF.6]:\M"\W'N(4ILN3&UBH9>K(^T^QV6&ONNZL?]HRYRD^!H
M,,-F^1%7:C!<!3Z.MX^$>$J@I.\8U12SP4STXA"#1;WIHM3C_T,7FH=/I"WO
M6C@S;P<=_Y[SNL2HW^;3EQSZGE:Y\%7N@3LE<[*R@#,#?9N\[JQ_N<<?2U&E
M&FX4%L]O#E*\TO*'+I;E= 6AT2%J.OC4[K>::IO";:*>_/J/._TALFAO'FCH
M+ E]@'V/*P'0&<6TQ#AM)+]--TIY0C.2:\3 )M8[T[P/+^@DS5'LT@IF"1(#
M.-6W7AI+KH)^OOC!E\=<%9IDWF[TS=R<?6\3:>F9;#N=LQ^?_,2TW\?O2>7#
M5A_<<D!-NVTRY99?\<ES34?QQ2<I\Q:X/0J2.KUC&AOE_7!8E48\4Y<KJ=I*
M$6R9XTK"T9*#RS815!0/)$BD:F30;N<8IX82^:TF!<M%)J(8]!^V(S)..A#*
MW9&+Y:AQ-9/)+N#D\J(5HXMV$[./C6"R2%*0!/HRM7>YZD=OO5/1'-0RYZQ*
MG*%W2SHD&B>X;]:O^6OVG'98X.>AI;W+[;NE@#H24:#^(B-VE;O_SH2FN%.&
ME?#L5O5S+^V%'=-G'3SUVJ(#++QF+-U.&Y]*;YX'NZ4K/C-+;I$W"=687$4_
M#\ *HL23)\/:%OM8#[D=U9A#./!18+P9?!CMNDS9;*R5?;&9=3(+[F5@G?LI
M8$%?,(9[(NYF_=6X:Q41%ZMZ-:J;U;$XB3_,;QTU5/Y"3DY4_3'5HS_PRC6D
M-=ZBMW;&/,,;+IITXM9\"VS4DC$S/;#-7=YDOIUOA*Z@1C 'R$DV#SA= )%E
MPA8$^"=483'C8N'RP>@F%[Y^HPY.2MFUS8<?!SO75'T\M 3T+^ & IS#"O !
M-?'^".EIG46EMN35 <$H, Z\R&$F4A-RF,G4F1:K@PB8@)9;'3*HQ3[9.=B+
M3**UFX_P0$W&[K109^F;W5+GVOX0<2BO")$[<2VE.PJ2]I ':L'RF3/EN/O)
MK$NH0$;68P::NH<'(FD>@3HY+NBA-TQ(B=$0X0#^D\E-JWOZD24/4)J_;074
M)P'A+)N$,76C+[2QT^= MXFZ+-M@TL9] ,L8WLAF*BU2J6&76S8HZ.<$02!B
MXR60-H%X77^90:3Q15>->O+'!UGVR?766Q3""<<'M+:3AJ2*($M!HDI/U%>
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M5':O:SZOQ244^LDG_;PQ- *O+CS[T7I7N;5+(4L?L")))=(S6 ^!*-:EWN4
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M@[G6EVGZH\+S_/&(QO0]53\R3WQQ7-26<91WJOO(_6JW8^LU+'-<'#(E!Z[
M<)(TGZ-9[K!L[88 \,C'EHMFSYW,BV?>EPT/M.>6C;<KW"O/ZV0-*)_7MBZN
M4S]_;#&I1WZX@C4<]&![5[M^RXX]"?KG#_;%=M\RUZ0LMZ0O/V'O8&DO$*0
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M ^F9B22,R)^W=CXK26M$B[/O0)JP,5#%8KCL9[;51.99DLM9<ZQ(?M[!PRY
M.%+6V7/Z^D69UM?>OLL>#T]M3B-M9Q)K<SFO$&:GO<86%9;&+'OJ+(IG^W ,
MK-?--S^EB2H;27F26H1^6DW#P+)\5>" =F@8F:7!=B03SF_+2%>F??/6$6*T
M]I]W#G@-VPYH=6CBT?=+QWX>2UTP0P"T^C"-M9:-NKT?+RH-35UH>382MD$0
MWXY00#"&)AA'O \^N&!D.("ZC+VHV$"+\P8A".J5J5W-E#:2M(6=@X'@>\0)
MVKFR,J_\GEZ1C>%FEEO_G7LU1G=4B/YV 3;Q9B_M3"U-%0*3; +-MF:KR"[3
MKS)2]'R#D$WJU3G(O.)*A//F'6-1.[?(?[K\]A^7X/3FT>4\T&)*J2<TJK*$
MVX&IS"\MGB>3'V85%\VC=Q.D8//0K#RT09H])>I=6 #UM1?6&^N5ESJ]M#3M
MJ/0QRU0QW>3E4.('P/P3]P#C4)I8] 2,#W!J?*AVH'#O2ZJFX)S1T5[JE1W6
M)_K60LWUKPV([KEU[<(-$&B'\U63]^P62=F<U2.6?DE5>8JI[>U5!(N?FA]3
M) H") I&Y3%C+UN#A[>SA1CST%\/THS>$:Q)VYN,#-A#)Z1->O-[A*OTO6W
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MTMQMX%.O*1E#O6<7D^UVLJ?JGJC'T'Z;IT=4S%XFJ$;WA8NA3O>@3A<"<B:
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M])Y2::@A.6=>5Z*A]^'XS:P&#NH;HL7E ,,[H8H?>R!XO,E%DID8N6QS;ME
MEU;*9\8\]#CPQ8N[YJ5@^ZKZOH)KS_9JIPXU'3[P^/$-X/(GESU &!6H5YH
M[P&L&F6///K:'8QHDCW:P]:F M 9KI&4NK1Q945?SED>J.-NZJ<.=FAQ\=\5
M5IWO*&43-XH=&X9]5<.&JE+(>#P];#$D\:G1/K8X$(;U#%=FB/\I_?8QC7#3
MF:[-X8<9@I$&VEC/UJ SE@&&L*N]#W#\/)#>I7MI='OAGPGF1@[3M; C@'BC
MK &N_ .S*Z)>=5)?YJP-;E!K&'($"+W&/%*&*?[^6:%BX %R/4[_,U);]?Q-
M4T383I, [V."HN\_2<W_2O><=(M1_'AH'8<5K6938:HQ:,?"JWA*!6**'4;A
M#_/BL_+R84[M\- "3[$/+@YCT*^1"OC:JH^FZDOJ4Y=LKMV/G_17<+QV#FO(
MX&N$1$ .:&BK$B.)^[8!3[MV\%(9UF]"<$>P?2-9JBCGY[/:5V,RO?YSFD_:
M5]_7PB\1OYX:(>?_ O=+2,5DN&&O5]= P-YD>%6&DTX*.6?6=\O]*0I"=4*&
MU0M1,?S![C?(9<L!I1?7&H3;3/&#!J9^A\;I\2BXSD:E9Y#?YQ=QPW,4\Y_O
M+ @AOWT$B!-6B^/,3ZAP)H1^FF4;7$P->D8X9DQ=2 2Q3S'(3:J"HL. ?F.X
M0/IZF1=N;PTSJO.^M_#"RWUW![);6IX[.2V2-7:Z+C__6P&JY-A8VYJ-;5G[
M>JY,.>6.%1J*X.><$-EN^]I;ZE@)<XK]WCU5U8B ,)$@'-WM'ZCXDW_DY2"H
M\B^2]G;/?YI8Q3R#\1&$V+>K^^A&JBAUP(^I1[Z6;AZO,DP3?V)P=M(\[ SM
MWDH^QBJZ.?U^GLRKWC96C0+>(>O*3\E8IDO<+ZFI-0+U06I76N0W2/5;*);T
MPI?2:]&*J+D";ANQXNI+M'L1'%9!7IS)]WP8]E4W52H!PS"A9J9PXD?KX]0;
M!C)'JZ-.?,37/+GE>#Q+4M@A]Y:_VV_[-C+/-G*%>@*0H2X];'5JI])MIOEP
M!RT,<;U'JT/ J=D7>N6WJF27?B3R;OW V.#..]5AEQ!142=<GQ<)XWI^*2.+
M+S9 GC(<Z?00GH]%BH\\S9&@2V"OI/U(T.F@=I%&=4G0Q"=KRSN ,Z1&2G/M
M4PKQZ6*]9C840-S*L'_55=3Y?O:&0UO>N'GAUTZ==PJ=)=MU):EQO<RT3-R$
M\YH'<A<4=##/ ] ;X8#"N[GD>1V]9DI@(J/@4[K;4PK^]:F:O@#3!XM5$NH_
M^OU9CY3*"<&=G;F?S+W5O';9X_^NW[12Z,JJ\^L/<94/%^ZLM%"8EE\ZC+,7
MZS3EOAA<9HA/N,=A;J+%4!* %2V(K(TP1$/1A]EZC/"JK=:Z@LL;81#H@+1-
MSY+ENV*'3[O%'L8/I:]0A*9(9Y0ZG*-J)A+W )C+>$97C,%Q*OHPX/7-V2@4
M(HA(WYM<[!%8"1<\FGYSD&+!R6MY*CR79"R:CGKIE#-DX(,KCWEY;6[E[]U>
MW7 FG])@J(^*[) )^[Y B(.YS(@',<C43DY;3-ER_8Z)XF&BU-S@ELGSLC*V
MZKO;MX.K3:LNRY2ET>#Y'T*TZ7H4'0_Z(LZN#A\I4>*CDJ2"-*$N/PH($S1A
M?"N=0._SS))FK&TA!Q]3.28DJ/I2]+M1CSS+1+^<.5T=F^_PY#F%PW.5CDZ-
M"H^-=4J%K!/J?J6S!JM!9V NCRB?EA\QE5"K'M2#(+MLS8?[<0?1E9OT6TQ(
MFYA>&TD:.\1'*R"A%Q<\HILTA_FH<@"6Q#W(W%,GI!MG(%D6;$O:),C5#FA+
M/$L(=?;\^0!Y:^?P5?.SB?<Y+WB@^QS;C0"&?4PIVY%F*-@"/AQ^(KALII5P
MKM] F0JPU2=8AF:T,6ES"_XFZ#&X8B6#&^UVP&%N'!Z0?DU(DCZ!_#+N^.N<
M0_7Z_ <T XRA[/)8W\K::3BB;#FPUQ<Y?[_PXLT PQFE4!>+O#"99+9(+?3]
MD/X_R),C+]]7V?PZSH5_%"Z@?VGB*&?\*4H)35-7;17G2C#6E^/\5?4[(5>8
MQF-Q^2- W-4/_3Z<=ZYY"#\GHX*"H7$D#.\$=;XL,-@SDS-A?]GT5^6+>P?A
MX]H#!<D^_]/TXK^?0+2''T/M!$28[M:5@T;*[". .5/3KH\.;27=!!XS)AO'
MSO0_>)!NI5VRN(PRR?&TUQDLU5R6&I.TD5/Z9ANDO7#^%VVV:!E3+QC5P8P]
M[4VJ-"WK5"1,!X\_1KMK#BU3P_^\<J5)LGH,WDN0 1(7^QS1WH X%?W$0*$T
M+&%R9Z@5W7G7Y;YE0N>Y6R(79W[:(*5[/J@.P<_\79W;!"7[ACKC1U._+ I;
MV\6:!IHJ;![_AWV]^!>1^+^=6"%*H/@!.::@2Q_[UB0/%($YP/:CQ2O<=59M
MSCH%A%(U11"4NXW'4O?TK<<CKC7TJZ5*7D@ZCO212+@@ [J3OF[P2VGETY;%
M^I8RK)8OP;7O)SNGU[*OMAW]O>WHJ=:7QL+R/L92*B9'/=[9G.NY<//*C2-"
M%V[= (% RFN_)(B-Q+^8<__C&^8=TSL;&L:2WSLY7Q3HK-JH-#9L:#;5$KDZ
M?[E-S4;5Y,0IZLO^XD/[3E3-I^;Q0++BZ/4F*\[N;KYH'JAIUX35EG"] @_T
M=#J1!_KLC_[GD8#!GEM=D.DT[FX>Z&N6 P^D%C[%\8?YM/_E+__+M28&/% Z
M#!#A@4Y-):ZT+<'(QIM'T]C'C+8/]TZU"098>O! [&B3OXPX(T7]NGYN^_L8
MLGKHWV;_;?;?9O]M]M]F_VWV_V"SLJ:Y@%)C4G!=J]A*L E)T-L;24VM?KPF
MH/SN<0&N7\KUH(6'C=S9$Y)F*J\/%*)2)!:(U!T,)<Y^%^'M5NUGP@/]T(NX
MR@.][&L=7U^@PCCR_<551:]F I;-J=$4])?ZYAQIU.G1-6<>:$+SXX^_+H;\
M963!HW &LVK. ^U$3QO]GQS;?YO]5\W^R-)@6$6H]Y&BQIN,)!YUTNA[Q[R5
M+O1FKR*GLBZJ"2]6P<Y(7MAY#7-R O3%.&"<\0@0X3[%[D=3S^?P0"LR%R>M
M:JAHEHR!/@^4)VP/OSECY,#J9<'@F^O"ST/REK"5/8'G-8$+J/T\T"7[IT3&
MFQX>Z.>AQ+^,U%)40F;8O3S0)\S/Q%1(![@&[2P^X@O[9X/@?QX(J++^14G/
MN[++66GK/6%MVS';)_@8,FO&2..*I$-XH.,]?QDA.QD?7>7"T1-6;-*_+?XO
MM1@R39R [;[\#F'3,C%^H$4-:IDG;]-&I1^73[A2^?IES^#7,WJG#I;DGOFP
M^_"%?"#T$V%?QH7NJ;3&L2.ICOYA9TS=DDF4R^WRB6Z[#)+T'5.# A5>_Y%Z
M7S[)5+&V2VB[-!JPZ._2-WF@7LDY@N0V*/J1>*"-W;W$M2=CQ5DHC"A!<SJL
MP;A#&ANH;Q27$T]8BO+^EXKFB,'_V$M;!W@J<818%K?T+Z;SR5]0>K2<Z\#I
MV)HE3"9M5S+?)\R:0O#VS/Y., _T8O:O0PNEV0DA/) 6D:'$O?/_4[,&B2UC
M^QEN-0SB$%N.^FP;]<1G!U=_ZNU-$<_T/E:[>BS-+?OGBW9<4/-/$XJN\J<R
M(O<P>">Z.X6JR5;20G,O%W&U%JB:+!E_S:D@YU+;-S]=E\WI807C_6:GI]-J
M"5W&W__=$O\W-_LC7?<)2E(I%N6^.TN(T?S"R93*1/+/2MFV>"GVUK=?$<*]
MNU9/_OEC92"(^'7(@.S\%RSJEQ)GQW/U>*"R+&D>J,\P,,7O55G#'$ITBU!%
M&W>A6<<3)):V-'@@QK\(BC=_^0E60Z="?+FU_S*URLE"=VJRM^OF#]^VGZZ;
MF@O9K 3S?TK:G'_ZO0P?>_YO33'Z_Q,&2V#"P=*-.EP9\DQ$(U?L2;"6LXW'
M_6C2UG5?DEK@V7K?EA-0U39YKW<]/1%RH"\70>2<0<%8X@\')ICS*""1HSMB
M:YM);E G4\(X5R:E(7_">35[SZ9L(37;*MI_IZG\;*VU_)LDB^>2\EFFAIU(
M.Z4H](_;#!Z(\U@+RSE675K[VHL#F[X9Z!*W<N!D]HNF0D\8DQK$ ]V6YX&Z
M+9R+H&GLX.U,(N^'K(E<D WY\YK:[8U*VO@!()!UL<_@(LUYU^7^>MOW\6"2
M7GAY"7P+N?P,YRKR3:OAT. *37(=>:%1-)E?==],S>FK*R&A1Y[-(B8$A_FY
MYNZ+I__C_Q;<[*T!YW/*G<9USJ:CZ$ -6'R)L>DYD]>.! ]U=,.Y%J[@LA$/
MA-5G;K8L/^6!#KS%UP 8ICYUDY2!(*\L+AD$3&H> LRD:R U2(V&]]_EE[E?
MKW?2G;V?:9_-GM4;_% >DV'6BQ,POJNT\VI%5?J/JU82AUP/6)KL):H0W3"/
M8;N,%%#R@SS0@T2*:Y.L)(";A,1JTA*E$%+8YM&]FL]J88_K1?+GMUY)F42R
M3U-+898##]98AN(6'_8DO,[K?#]R?069Y?S#T+9 4NE\S<E6Z]@;9K:O"D*-
MG7.KGF>.KIO*#_=Z6II9/Q6]G2=I6H//D6AIT5G,>-@N7S4_W,TQ96"?&RA,
MEHJ1F\/W,TVBZ^]0%Z;4W<H F&,?CB-+-['#]Z\59Q0K?UJZ^_I1*=+$IJ\J
ME+_3WHY8V;O6J4=QZN"86-<^^=+:VCMZ,'G4>72D/G!CD-%:LM*I%7/4@U\?
MM!_;OOR=10,O"I6$]QK))6] @#R?/.?@F<9J,.,%^]!V-I PS\8$ 708.MNR
MFM2:>C@XN6E+/+K*PNY+BWN%3KJGDXEA_;=C,<YYIL1+1 _TS^,0<?1B%E#,
M UF(WYPQ3RV!XVP,ONG=C'C:FXPO#\-50B&-HO-^?7[U\F2=JNF"O9-E\4%V
MM0^Q+5OAB66S62=Z%@TNOT5(N=2\G4_UF9>Z7YT+H\Q#+7/NG EY,?9]7L>W
MTST(KH8V"#IE(:^!.5-SE)RU )$UX@."2-9 7S-8@BOF$2Z8YE#'6'-1&> >
M"[:U8/Q(YSRM: S+-BD=\^R>PQ8/61WL'H47^WJK3\5>FXZ4E!#4XKP@_NCA
M[D4/*3 VN>F1J$V6$$H;\&-"-A#]_E8QX2"&?;.AV/ DIM5I 2G79G2DN]XI
M;WBL($';H7>%7R"<=*,J=DYH5(QV+O66B=NA78>-+?DIY\_[]A5*$)R<6VH4
MUWLW$C*UQ:O>I&C<.J+R:H2S,*3UEIZ/W\2,).:F;7SEO'!\@J5;L\Y7GCY0
M1)0VDA:[KP0"&9@GF4[L:#<XL)&A*1L,MAY8ZQ*<XYYFX#;J2CW,:?%@XTKF
MWA2_8D^"%%K5_9G_J)YT=1VA>YQ^&#F ?)?:6#];?GY5!)*&J=1<[&&=6T!7
MV=-+<Q"P2AZH41UVC5'0[ T: IS,!HR.!(O<Z$-IPX,FWB\ME?KS2S?L13C+
M4J:7.8HT 3U5C_R/G+787M0 75Q,3 _&%K7Z!+W_V@U> *]%+[;05%4%C)K&
MI/6EI55A0K,,*,61XI3[NQ-T^%+,03%&Z\O+PFH^V=F/M#)5S&R>RYBW)KW_
M61-0+Z>50FQQGWLG5&R;8N8I-7"3+NL]\[LWS!S;S,JP8WI'^LN87^K!=0G/
M2NF4TS+:M7B@@W/0LO*"N:VT9][4QTMNY=V+7DO':P:\:-4)IC_P'V)#DB3&
M["[$?CW!](XW $^HBRTT9YUGVD<;2%*'C^6ONC#MJO,!]-6J@X&%-?WKB SS
MD[MD=Z2ZM4_XP43#!] KON /9$Y*UV$>:%ZRQ/Z/69@ "LQRX X19;W#=>%Z
M)LW@O>&=&$9LL!QUG 01OBA62%55=V_1TT>DD^-PW@=']U<UN-^H?:28^6"K
M7OS&9:FSE^&BA3,&1:>GGD\IYBR.F@XIKKU_FR-*L4>6.E4,#%&^3=F9V3R]
M^Z:F7RZP=S ]PQ>NDV0_I#];-8#M >]$60$(IKDEQ@%P9_(U0@ZO9< C&[X5
M3*"/>(2K]M%GCKT\2$X_LLZIMWFQ7Z@^]L=.GY8@;28WF27.5F6 6[OVH^"
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M1-WJ(CZ-'9/= R2BMD;P5W_<+NQ96]XWNE#KGK:AGQ 0=J81UL$90L[53?!
MWQ<FQ^D-;[F=Z#U5FKNYGUX$;S8&RHI4XGH, L=Q)DU8?IV&_##\=O \,?SS
MM0:4_+15@^(-Z<(L]*A[H/SM4$%Z.XT8,P8&$EG"0,ZG\?UDFF#S'^R08N=&
M1GE]T%O VBO *7'/F"'WY;8X))0BC:+W]>6%W&6%#F>$=BE]C;QU[S92S?#(
M+5OK)/M"["!CM?:)5U=JYGL\O=1"N+82CDO'WNH-.)\3:MLWCYMT/V\,[[19
MM[$8NASD'JH/<05">: ]FIQGX<K!6#.&501!#YXF*S>X)%?96[(^OH]]D1%0
M2A_Y*BQ]+<!; K"ZV&LTH/_A&I+"N?_ZLT//'[0&TF0U_3)#?,.]MVK4=3*H
M&:G4*$9I[CR4C%#/+R]=@&9<O6FNB*$N"\ IK0TA2"]'X\Y10H9"*7YJ=3K1
M=V:E8Y*O!4MQWZAAIB:S)-F7.*GU>UBZ0-SM#%-F,T$%B&-&D\:%"HRD&!LY
MWF&%HZ@S^&Z4TAWOTN"LW=$=NGIBA>]-LV-V4V(=FYON;,5,HB,?*D5CQR?=
M(PABPVQ;8&%B>2?D*5MH;\VD.48P8UA!2+QW$;O^.@!\ (#.W$Q2T(MJ0+Y5
M7YLW*(Z9BA"R"U"V*5!!?4%DZGXN[GE/V0Q1H.<<L3R=X6OODQP;AW3,IMJ5
M3-JF-*YHU8Q*?3!=Z *[*NLEO;*Q4#BY>EZ^]'X@A(^KBU(&6%0)@P!&1.L6
M) %UVJ#4B[SE=-O8,(5RL"&U.&^\T;W88W,^5]]A'J\3=$?RWJE%-]?YE)]^
M+'Y/\=3QHV@XRRI65B29*MZV+.T9+L,D/^,><G3TZ V&F3+BZVWGI'2?L2&T
M9<%YO:C7DS4!Y_-5BQ%8L;A@C?8HB^,[Z]JVXAT&GQ18M^KZ5$&1!;G9>;E)
MUND6506BKY*F395</6W]GKPJR0M,-RW6H@QJ.A#*S@SJ5O9O _CG[O_V3<XE
M=%?;:.->G+I+L-?2G3XU+VP>_D-U:-W"4USD]"E'2MOJB/-UD8[JQ[_W?OG\
M*'X(^\VI"SAYOYC1N^;) U4M+[8QW2?XFC)]GF;Q 7EG&YFJ5L3JU^6N@@D&
MD EG(Q84""B=OYC#$HMXWU;D4I4X]?7.R<7:2Z_F84D&G6&O)K\.STG@\W2G
M1"GS5^8O9=9,=827ZJOC7B55V14[:M5W-80?9YLP-)O0^SW'](%$6KS<GS=M
M'5_%&?I!:YP0UT3?F @?U"+KVN+E\)6XV-"ZPFNQ8_OO_5;0PMT;/D2LU*4K
M&)6[,=QI^)<TNOG%:D2GU=4T<R8X"O>]Y(6( EM*/$X+R6]/Z)ML'=(L42M#
M"GUI[>-SLRWP?L?6X1039()%6HW. SY8"RJP'F<E T":N.>0KJ1-*[_\D6M<
MF<'U90''>;M!\HW1;.,B^)95#'*=_]Z34*?B.(F9XZX &,8$QWM!D,N1X9J<
M;",A$\8NBZH>MA]C82*AADJW(D$.EQHI(_1:,OM/P0EJS/Q([:@\Z@[%UP=@
M<",1(F-DL-7$/^R!EB7IFLW3')LSMK?N2!)C]RN)4F(C+ .D*Z=]?#;@SOG)
M9PIM?'R2IOQ_T-+J="C)]LF9_<IY 6X*2DK9\-GP=VQ#(&_"*C9+/+DU?#<Y
MS9'Q52^U/->\R+Q@/EW/!/W6N<.UN&EC:RHA([#0/6!W.:[QD9/9>[<G\+O'
MOX&;NA*(_ 3M=EHY@]B<!%20&Q\N<J7(N#A#ON; +!EGW_Z707=R@]-L>M6J
M!(7;[Y,Z&I))#U-+][SY&#OMD'M<<)7\ENT+)!:R]Z&CQ++$@9<3V*$($@\D
MPX;GAO?!9-AG92()[V1C:()'83F :U-XV)I4+/R2F!5P'65=,-S%B7,_%_-4
M$68(R1&,#!<%0B<PT5F'&>2F3/VKO5Q9.$4LRT#9^VV(19YIKI57,L5E>.22
M@XOT[ ]QWW&#I,Y0M2X_K0I3N?-%_4=$AWV];).>6&A+M':RKJ:U*<CWBZN:
M%IH'B+T?3+E?DOWJMS?#%N?-S*WN9P B%N<)]R@^"9U9CXU%[95[__;J79^'
MNNR$+)UMZ0H[P /-*>8YYX4?#Q]$,^SNL!2YW6/G 7<$RV#!13\4 3X4EN,T
M4/_[V*[JCTG\YE$B'H,YG[CJ>F5I*J-[$JUU=1[G1WFDCN+%L5D0VK%0XI86
MC/TM";V:43;UJ*7_N?L!^^?O^,2[+)Q]RY+2$=,O/S,_>IC=2'$R.Y.$2,JI
MK)M_2Q[IFA..Y7KQ0/]I?0[W!%\=#Y1CS -]G5/B@<[70BI]B*LS/)"*#0\T
M]62+*\(-W_Y!C\A^S#EA#>L<9U\1#.*!KL;Q0*][K;A^_NCF"YOH-0_BSTQY
M'FA&UV3#2Y>+VEYA!F-_,")NZW4,\:<EE@<ZAK[VRGYU>ZG0KE$>J">;!YKV
M3^:!WHR"F8<-QSE2FEQW4\C/SAY.1OSV&LA/FS0>2$T02X7,+'-MMV7F9W"O
MPA'V]M)_LO<7?^Y/HF>ZN#?S>*".70N U4\6#_1JG@=:X5N+,4;KHO^SM?_"
MG:&/XS]7>: 49?3*IW]O_^_;WQ?<MQ0,X[99'=I.YBLI%/O5RZ7H1I0&+J"W
MG]M.O,_M'*RBPR",NMRT+AUA+<Q]'B@)(IXVO=26P>K\H^O5ST\4'NC9XR4>
M:+8'O:IGR@-]\RJ<^CYL'"J#18_9;/NX0%4%/ZW'X,8&.:.6<>Q_T6.K?PPY
M]G^GB/W_/&'^7]Y^#^P9#_3#A4Q<%"A"SQU<&S^X/5JS+1M9.^&PK8O>L&^6
M>7\^!E+;K[7 $@3N893H>'N[+&^VIJ3\"J%O]XN?&1"J93XG8_/!6$9Y?,>;
MB.O;>HPS"J=X80H2AY2^L03B\S"9/!!_ZS7V>$7C45GW;1\.!&QX#]7=WQQ^
MX_7@'GDC4#=UK,T%P0,)IPYN-X)M/!5>V&P L^L*![!+(>#>^'_A% 5 _B'$
MC1ST?AX(@E[)A'$O<%^>Q$XO_Q7"_S/$LW2E>2 C]$J>)M<!#&M"=XVS"^QY
MH!>07#/5GW5_J<E$X)GL,C=>G <ZFXMA3\]R.UMYH"X,N]"<!TKE(S,PJYL\
MD/+ =FP%_Q]TE,?K;"4VAP?Z$H#^N6OK2C8Q@_A/]O[JT.*(-_OG]I)7Q)^_
MA?VOWGZQ"P_4^"D]-S7(YSNWO=QQK!VIYS@Z@D*DK_ [Y<<,CM$0QH"Q!]GZ
MHK+I/;RX7:N_W;/;EYR^VOZ#G>N0JE/_=YCZ_PS3+*SU^5O@FAB(!VI"O/O]
M&E_>N">]F,TBG.#V060()U$7"<!K&B;6Y5Q&BZY4;GI>Y$!!#"Y.8FWO:KJY
M.4RPT3UHMYYAWI,C4;VJ^R;V/9-8>IDYO+6RG8V.X=WAAIQLM!N2OQDC7.:%
M\Q8+1D '#.2":$[O/V<TIU)LK^(?QO>S;FG@CO.'0..;=DQ?+UK9I:JO3?MP
MY%3_'>MO9TU7VN7)JJE%9""ES[Z'7N!!<KWSK/C<_\7>>T<UM:U[P]EV141%
M0$&(4D6:*$4!R;8  D*D=Z(B0H@!$0(! MFB]*94I44I(C520TV44$0$A% D
M""%!0'HB$ *D?/&.[[[WGKW/?<\9WWB_]M[SQQH99#'G?/KO>=9\ULP9$]5O
M_? BA(1":-GZ&,1J+:SAA1YT<COG#ONR#XT@V(<U=(!<CW(BR0T]3W5/J_G>
M *L]>^E4Z[X59Y_..[1(U@7&[TC%91D&A'U:2IK[(>1\ZQSBMS>]=[3:K_A>
M) 8Y[>&PQE;O$M*2PB&_/= _CSK^I=F%?GZLK9&P5#R)CC?U99P]PW;S*V+%
M @4$;^@%EXF;%Y8X.AB['>PZZSQAWS9BK)BLVW%[PL4]DFC8K'#)FND;_UK@
M9_&9AC>#)=IGWEHU3C\:L4U0/_[2(ONT.&K9(I4KGV7A:W[.Y/Q,EEE-33]P
MQ!+6*-L8T9LB55G853)ZC1G7HZDI8$BH>8+%^-VORHH^W:E_K[($7>NP,@7>
MVWX;X:!G1ZU?JWPT[&$1ZG?3]+> @LA:;;B_"O=+P>$OF[FW3X4WB+!LZ!TN
M]T&L,[BERWLJ+_<Q"R#5$Z\T-8.ZSPV26C^J"6@\L,CQ?EKTZ.CK+L^/>S4W
M<5((M:_G/WWBAL3 U0BPTB:)&NWSG?@!:GZL_ZK(8.>+<2[B]/-$^K6#PU^Z
M![/M:L-^OAI_19A><\YI68+#5+ A<Y7QC-ZS9E:N"Q5EW_D^-OA:)%1C9F8D
MQ*F8\P3J*DWG-NW".<HW%,!$WQU5:!A85])EG3XE*NU0?C_]XL=;QH>(@'L,
M^W[4=?JNC?T>_)+LM.:W% 'DTEV&?((<L=?I]N-3IB2EFY#O1THRQG\N]8FP
MZ4B9#U+"G&R"CX!:)&BGIHN=&7UO/,C#S,B.81<EUC;"E:Z$V_(=*4-LQ-),
M97S\6^7'#+>^/\P40PSO2I]Y>J:/;[S!83V@ZJ)V8!17@95!(QR$3EQDK5,I
ML8UMN?OI2SQ >X_;^VJO1W..SYI(=[8E*_*&)QS-3KPLRC!J$7ZJ*/U.UC+]
M0/:=L\FE^N:.EA'%G3F-%5#%(@M#Q8NZ^( RTD_Q#NO4*7.-5T4]MA<LWV[Z
MF([B/@Y*!-IHF"N.VW.XK&)&YP?(_D,O/2J,L#"\],A1&ESL _=0OS?*@)9C
M/MQC2H$0WXP=,PW5ZCCGNF)!:*BNBK@BJ$^MJ]$70KG1%3HANQR0/ !UIE"U
M\)7+. 3Z,_0-V51W3!!\,Z>\5E)KBVPV83.>T_KBS9$N98-(MW2#TTF]XA[$
M4O014-L")6'B MTN"J_$MOLB]%397T@(F2YHH ]$6EZ,G2.+I@6^[2QT]=HX
M/WZN>5A5#/PN[M:SVL;33U<N0%T563P W;1URRX" 8X@[$:XR%P/5]$V9]Q_
MSG E47LSRLACAN_&QK\A84YT/F:Z>_FU1F_4,<FYQ=ZDC&3=-[: H.4*05)Q
M=_2KV:O&MEEME@DZ\$*$@GSJ [+K6MY&>J771-Z'&5?2H<(_.IQ.''H@>7&2
M(5P:;59XPB+^]K2-9F"P;^:0TH0J#P#O=]U)GZ(9M:./3<1AQ-CJ]*@(U,D'
ML_7ZROUA*E!7]2<]T8J)IZ$>KZ$+TWBGS_7:CT_OG+'*MBO_P3U'+XKVR!V[
MPE!]4N[L=%3UU, Z3&+S-?DAZN-241II;[C#[WMC/]EX=EC3%BQFRAJ*Y6RS
M<VQ@$QAEC'[F-J[JV\#%F_=>1[]]]P)_4S;5US)=O-E6W&S4Z/#TKK=-VW7%
MW2OR.#-)R6,6CB>I!L=N[15[C?Y(F<)NS5$)G LC4&?7"!Y !IU(6"B*Y '6
M^EP*7< QZ' ,-RLZG7(I[,&9O-C'?^](HMVW6:5<@Z0C/,#7O?8\ "FTW<?V
M3SNRB0M#87?3^_JY1L4L#ZY!GQ#_?X5->( !@>"Q,O"?\A G?]- ?KYU+K&[
M/^R*P3'+XS8JIEP]OFP7GF*V]I?6FO)A,TF L$55X(9[[NS[]3A&:=)GS.\#
M^B0BP8/ISWI,OT ]C[HWS#W"MI.Z,-1\BJM'QQ _(-YTOO:R-0'AV Y^DF6Z
MR]YWDSCB?18YU\2TVG>>YZP:N%QJ]+,R-AD9L*LVNUBSZ>Q:W)(9=J_W@*\O
MO+1F1<+E8I>QIO_PG'>FOB3K#J.(^9'1%U]#$4 Y<2)4\,>0.VT3?XY!&)UL
MC1$B$"@H/U[N?J"HM7%/"KQDWC3@N]/YL9N1IT^GQ=A(-\<9TCV64K:!SLBH
M5N ._:-(!2:&)5*"C+-GB(7KJ?@R+IBPKC$DJ$1D^/JZI"EQQ!$7J^S-5JE
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M?71M=^RU>C0SRTSHQ+R431DX*SKMW-R<7>Z=,P;2U=O[BDL&2>J?8PG1@)U
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M &44FP<H55=4"BVGC&:@P?\DE1E*W!7N;N J7YSJJ__2Z7\KCM6;H1MZ:CR
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MQ6)=A;,IMG7]3&]?< \4K9O9J, ^MDW,9,:XT9J$OBXP&2D? IFPXO8I>SR
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M)0R_&DOJ&5\S^Q$:@?#;G5;;/CU8O+N\X.BW;WVG!4Z>NR)AJE'1&7%CRC9
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M"']]M+\Z>-]D!P,!Z59&::0-#<KFQ>!VO()GM;H*.B0^W"VEL-W\/+'JJY;
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MT4<93AYO;IS9>F:XK%LV051FO\C5"X\-3N,?$50F-H\F\:/[EH]@^C?J1=G
M+I_G,RA9REZ<!%+4BH8+U=6 ^8V:CB 8UA6^17YWZ$&-V.N%[G9.R=3R)9;4
MY]&706:TY>X.+1*JM[V!6. 75'5G&+>O?X #N(E2I6GB^+%HN>D^\AZ4ZQMD
M4"-&<+S*4:NNPK#>=HG,,]C^NZ[6[?:W)FE3V5DPD42O 5L[.T/AXEW5[^IJ
MC1>>3K6T#KYJU9%OL-62"K0KOIYD$XMQ/7/(LKY91__\"\\\12;][EAL903J
M;<N<Z2+H&FE2,PW]$:E*A3X 2<,4\AG;&H8.TE]''U&LR I>9FDY%@R!EN!>
MK]N]#EPD-DB<\-%5"W(,_1NO^B@V3$5L*"DQE*V,[@ #=*_I;LE%G6*T4I6=
M!AK(?#X>CGM4#Z+TNO.5$<O*$M=*2=Z!=QWW&(U7%[SKG7$H+RWOF.OS?A>)
MZ<+TKXY(98U,.UZH!6G M=@B.T.\9^6L$BTZ/F OT-L?:7P4P? C%\_=;SV>
MD+">8=C<4YSE%RAZS6CF4LQ#M5,YY\Z=.6_AKM(5-=)Z&NPSG9>TFIX?K045
MOMFF</T0*8J:1KJL%E7^2D^*)">:4=T7*%H_A\TB]'$ ES@ .@? ;DQ-U!FT
MN:EV)Z6_26RR&*/]RJ*&70+*6A,?TS;5_M]Z\,K/BAG:M&-*#!L2&4HTZ2:V
M3O$.T[L#1MIFP7G6EKQE!*6^3%/INM['%]\N'.]R][N]BZ3N9PUX&ZLT8<PL
M8Q6B%'PV+-A?<#P<P(T</4P#0936&.S\!N7)R*3BMWIHKLM%J"LI'TK1J;D-
M2US51F=*ILRR*\$I'OXKMADE21VRU[#K];V/7+2?C/L^0IRI9GU4@6;9#\3+
M5KJU%+^ $2 QUH\TRJJU6@C3@X1PS25M_%>)!K(@4^<.';SBSI@>D0QH @J!
M1+\A,0V]J7)T#59C^MMI-C]]*!Y^S]B1[.A(_F;'P-3#LB<^KJKM?Y*,?%5_
ML:#!L*D,)\(!N,^3Y*C #_@=S&MT_ ?R0_+VI6H1_C"V+,-%+R:1#FP<4J?K
M%1"[EOA$&Q*M;>8IRCI&75><OCE=NR"[W(U=\7>^9BL#$J#B'IQ UP*+;3[@
ML:40$8(VRI8V7@_<KUH#CD@:;P(#:T:J#7_[PC0ZA*-%0^IR.0!GF)8UR3HQ
M;^9I_S<C+X'W\;Q Z/%1EEFCE!ZX8.>L'AU*Q=6;[4-6K*[XL5[-,)5SW7$'
M=$^^F@8I%S%\1LB\MH287K929[&]4IM!G4&O=_-13:U2Z[Y8$W_@4WC[=I_3
M6196"O(M5@H*%@[AJAYBYS6$G)7/=%H\%2ZNN&-3\"GY:H]B8A2LVSQ[7I,5
M%QFOI=#D9)-Q8XX@DESDMXP()F_!N"'ZQZGDD.-,!7HZU;"I_;Z47$FW,LK'
MF3[=0/*+T T<5K:6\$LVH>\,U;67+4U\,[6BY;?EUMP2^-W%QP9C^M:^HIK?
MT*&;-7$H6;/)&Q>1'B.J30A>AF#="88)):4I2)T_''R@>'Z?VY5O[5*Y/K J
MC4QDHFUQ%S45_D[2P%2%)]:Q0"+AEJP'4G"EIYL#@"&B0%MI[3/9E#9+;O2S
MTWL@LMIF1*X1<1 IT9 J2<LKC1<N#O>@F.W"[9<+\9' BS@-J5\J3-[[1MD%
MHFFBDWS.2Z],B<(?Q 'L02N@OW$ )2<9.%H99;[>;8FX R6O;42??ZBK15WJ
M2D(N/[GM/4*5/'7%_M0)?<' Y%8UN.,:Z:1N_C*H0"BI;LA8\>0;8J"IW.D2
MM^XR[XP1CSD=O-=7X^D!V*?OD\3!TC6GO*;\684ADD0%>'8W134"4X:H@^^E
MR#6V[:2*/CC*4!B9)@I,D/D)1VV1Z;4PO'XV3.Y216\QF7]JM>)T3UJ9%M Y
M=86_5.88XDBM*+Y3G-E2Q+"B=5'\F$):%"ON_!["YF'X9+E#MJ"EO[G[IFZG
MH1]0))0VWOLXBI^6(P;5K?OB>'KJS:O"><MVRX3%3$4)/P-VV3568.?*!<V]
MK[.F'3>Z*GT[.8#,Z#=GP!Z?^]1R9&8#5'W%E:9_3XM0VG;[QRW0/[1M:\D]
M$/;NU\3B^5E_#H"OS%6Y+XI(\;3C &IEFN'TH=\K1)G2">!;VYGRX'X7+2<S
M\<1U*+""-32UD65(YY\IV]!!-^$$0"?9'Y(.3(I@!);;)&HJ- ONR-5G4^.:
M1,OH2,3%;L_B]HB^./=2FEOG](Z;UV9G\CP?-/MKAD#2P"X<P XDL98#$,'<
M8IG5$T3H_*%+\\+,6YW+F+WD:3O-5YG]#*PQMI9F;Y3MYJ=52JM[^U6V]IG4
M7,/X ]<=IP[?B5A%D!##[Q@LFDL#D6]V6;:C)(>1IV&VUT--J<K.+*)8YTV)
M&3^Y_="E6+TJ\>CB'3[1'9]<(]X=MGEE7>5H[#VJ^#EIY=!D[U@:]95I<X L
MCX<&GK!L9O)"?:+YO%<4S*O$YDEC1+2KG(+=LO_@8#[AX-"T%103[#//D%N=
M@0Z3MT\20*Q\IE\V(Y2JT4E*\1AI:L#$H.5ICJ/$"$3/S86J,]H,XGD:X0E?
MRB)X1>I%J8V3A:$XU77+SFR4]/MW9:RG:$TDQ(B57J6P<6G"2;1+UPM&P8A-
M@$YT5MW)ATD)5G9XRGUAGAG1"S!Y7VXRZV6F7ZY?^?[)6'G)+K\9_0A5=>[,
M!>,'.B"MZRB&L_H<P'8JHY_NUT"RLQMH&=K'\!B>C^8 >%!&.; .Y>JL\.MT
ME0)4@KBX^ZG#U0IO8&I#$_3/M3=AU[W%B45^'W#AH!T,A0TK#Z<C#!W*?% 9
M1D*V!Z4_W/X0O?-]ET]XE9PS,%C%.\=4C&O6,KZZ%;B+=A8Z'$M)KY'.6&SE
MI1O>WE,1]X9RKT>EY^)I.6VO((<.]@'3%@6#U=%B^(U.WW-2E[VS+4U6[UJZ
M"Q]1[P:/CMPQCZN.'?.TJ9Q#7T.W;V/ORM:J(8=\0<$[QW!49H5DL=-I9]B&
ME5HS=;=*EF%]JI K[3.OJ:<63,9V7_T)+P@4/0C:Q7I,.(2T7Y&B)<8L7<A$
MM]CY1?H$!&7(-M577ZRCS-K4KL?D74?-2LVM4F5"_.<?C?)\2BP00V4_<@M1
M9\FPPJK.4(&[T,WDK4P-:C6_#:TOK!BSC=0_1=I7G>4XJ=WXW+>L[',O*209
MPRN:X+<G)LKY?<B9K86Q[P_WB7%-I&&#W>HLSX;D]#U@2,FLBP&MK!ZSG\Q(
MMNY<2MY@:=7UGF+8L4D2;9XKO;OAQ96V^9*'(P+Z#T<8I;A8JWR00,;<NK!*
M/_3.!U<=-M9CP)V^^S--Y])F=8[%5I?$G__J,W=E+"FM^AM8J>B%A)7>RA3&
M/R"QB)@X,E0!'D[1\@-)<L/IA[=A0"&SV=]T+2EKN@JJ=4BBF[U?X3O'R]^F
M^M"J8,%>"'_9(^>"Q63K"\ 7';=STX\1KX'=\?U]%'+]QURT#+L'K=.W;':?
MS*<KJ$P.0PL@??L:D]"1V0S<*K\?E>6^^.%>)R.NWJ#)I2G=K>)F,$*O\J/K
MAOX'1%$$I)2_MCU,2H N]XCHH=H_<*%'0S6" ^#/G[VEBQG&\7XU\_>B8RG1
MW?2F7"2:&YR\L\8Y]A8C(R&,P(:2L4S>-ROK?D^.I]V8!"FR.XA2A(/(H%J0
M3A<8"@&B[!D\5/(N6[. 5R@-VLV<.QOGD?R-6A)R"URQ3(':=B5>Z;P1S&[6
M*RG%97V;U+ICHM?#I!]\%>MJ8;FBEGEF4.'U5&]43G9 U1<KV8-O\J^F*!@H
MV2@%M,9K[*HCU6;\'C_<#>M\ZO9^&M;RXL9:GK+B,9)U]%*1DP97E=IZ=,%O
M!IB^H12Y\)(\DQ7/KBIXUC6F&*T]$G5UG0,(9\K!>9Y.XDG12I;OR^G08%VP
M#RI;)2Z=43FSGM_MWSMH->JRG@QY 2EL#P7)H"ZPTKCN<0]:D0&F N^GBM"S
M'JKS Q@N-2!UD\!334-R[(_=F&(H/31:5PMZO,/-;WA+UH#=8*L>Y;[2WIQG
M80M@0X_D_5UO27Z>)^ZN/DU*E+D:E]1YUS2@TWHL?L!H4.6%MGNLZ:U1^"%+
M["G8F^(7+M"YIK327/FTB ]?_[T*S!2"#,J$)E<+W.DA!68\H<*U:IT$OKP4
MG+KW.4LZ]^0.'9>0@\Y&GGC/\;O2I86%#ZD+8^>ERQX:'C%+1&FP\C!08"1A
M#Y$1/*P:23C0@U+($':\N;(R!^%W<HN6R>%5RIL@' TR[ET**8_O4+8Q[\J+
M[E)CO3!Z#QTH(?,R NKI7R]0E44O]1WI7-;1@YH%616%K.\UM3>+:ROH=@ZA
MR(0CCH_6EQ;-J)V3/_!;R_ )FJH8NG'SJ/IZ_O *U4:P*%.4ABZ@2Y^K"%EO
MK8_F6XYS&!JH,$+XYT_:P9=30ZD!.7XQI[:S9;HT8,Z[<B3>WE>Z&"!AEU5L
M4>E^9=1]4/KCS(#G:J+V*-M(K)TT>#I 2S()IX9^:SQM-CK:M_9DA%R"GUFC
M95$S.IA6K$RF#]74<N4N(Y B$;E!?*0M619=S#K& =@D71N34NW+K]J=CZDU
MH9Z9F6UIR'1;]PW=OI(_+^W@\- 9F)QZL(<)#M@01Y."*- (G^@+*_#.Y4'Q
MON'Q4!2$2IR=/\"X8%::M 5O#TK)=OB&S*I-VKX:<:QS"2,J$6@N;8B;F<A3
M &=S@P#0&12*(4S?:=I["[T-F3R2^$'/\KR)R3/T;N2]\7J,6)42E3%V.FFC
MKLR.E9=034F>OEM03_))>42Z$;'H!+F4>1C1C@DC[P6IH0)HY%DO^L+("H9.
MK.,#4_%UJKS,T[30VFC+2REL!4:OGIQC:74UW2RB2N+EWDJNJ'L$KIP@G7G?
M;=V/ZO#1O>"M]]15%2ILX=&_:'&;]?V0I=7OWZQD88K1D*1TOU%KV.N,<J4&
MK^9:U93&M)3L]N=9IAN?,[\Y:KBV\KA^[L&IP5;-Z%3P0&3C.G FF.9"U4L,
M!HDB;6K$^>:;@$"W]5S?(25Z6WQF='1^)FV5$B-V,_9K:T5? ]>E73Q2>+^-
M)Z=9\:+H<M$'T!8:ANM.[)S@.IHB0<X4W&[&S5I)+8..XJ_6$A[V;C82R4#=
M/D'09'[^:^C[\O?^<JF&3_JQ-1R ..;&0#H-,KP:283"#W11YIO _0-UZY<+
M:)UU)B6.1\G6X>H;,*8I;;Y>9*K Q,N9ZBLJ,'0!^;GM+9BD0BU_5EC6#]P.
M.NH!%@:)(2&-:%F:7"1:')EL7BB Q-8XJ7_1 .^;UI8J]PCS.7B@ZVJ(0KYW
MLXKPZ\[E@^(!'JUGCGJG9-K&G\@=D=?O],W(E!DFC8US +A8#^JXO8Z=R&WK
MCE9W1?,7U6G51OJGV^1:9WJJ/PX2G(S _H$YV=6SP&M<C^_97VL-@>!TN5D>
M&I "J4>(NI$%">HH189_SN#DD$A%22<30=]62Q#I5H$G#)@;O'_8;M]SRU,V
MV#;>[MK(#=ZSRK$\YS83Y3>D.(".;O1G,L.?+<D!+.I##C%]N/.,-;J-7#S?
M9!8&/H#RPC/MOY2PSO/SF0;R!Z',*:UZ:F-C 1+/1M]K#AVE0</S#_N:7+RJ
M[^''\W;VIOWMN4^H=O:A<YO07]8V-M/H76CS'$"*ON^;WY,BL^T*<3)GGL(:
M,M9<TOSZUF?QTJG*QL9"V<:ZG:.>Z:8YU3UEX-^(E&(.P(6\KHW=_%+"#ZXC
MLMW>;";6L["8B2DP%,'4Y0#V<0!K:7ANW^_LG G@ "Z,SPIR ,%8[KT^0IBZ
M,##W>2#8#<<\CMX<VINLYON;J?58IC!P<9F=D(.3X ! \AS <!/;<"*1J8G;
M!#$TW]#!4,89?AQ FS"01L(4S+,D#6=F.8!0'(7, :A;K7$[M._P9C]0K#0,
MK6#SUL]IV)]UXN[OX'&V--<Q,V2R,)G9[5P?#2>$H7%=8NDE$[:$V8H>!Y#^
MAI5"I"TR=3B L0@L P[^NLJ.25_QY0#JVC?)EJ3(W'SY?G03<0F$[@ SKFW>
M.FYNR#P=M/G\J\65<*XSW[39.>V(,R> BQR  )>#Z6PTL;-[LX9:>P28<9(#
M>+(N^U..&_YLY.C-]_^)@ND_9>NA9_QK'$ 8!U!C_I>%(W>O$<QX Y!YD /X
MR#KP4Z:E_VSP1.[KZX%<>O/CBLW8(N#-.[O-?T;LF$L[F=R9 3/,%0D<?JGD
M#)VX2,6R>3'?T>&8.AB;2RH?8%$96PH3BF%VF/]<T+DOIO)SB1W:3I+C /8"
MN;=.R?^4TL>VL3%4,.TJIKUOW>X%@[Q&-^0&->"%_QHQ38_;PB4C'<A0!(]/
MLY0OHQ!,1CH'$ 1< Z9!?B*05_\\8IMQQ$^E _P3^OY1*;) 6FP4EV U6":V
M0_5GT@C^R9!S%LM^*AG GU#X^P=,.].0O0>[N8QC8OGW2OB-H,PJQ-SPR* -
ME[+>8*"M03LCO96RZ\$'"4"3[P,7=*,UZBMUSPXYG-S*&ULJL(7GV<T*\D\U
MYA.=G[F_;\6@T\9 <^@,Z^6W*="1SN+GS'E1)@A>VM=9<8E^BV$KU?]4?J&_
M+.W%7/2ZS86?"5IRR-8.%BO  S%HZ&BUSB+W=*9J+K#:)"8Q0WKJ7:_^JS1*
MY0?Y1OV2N?\JF?ME^'\9_O^PX0<Q^XBWYOMWP/?:A0!)B2O^"3#O% /Y-.R(
M:EU3K)%,T7.+TQVH\[:#7X.MKM@^N[_E6%P=N=1O)GC'@U<U6K-&&[H-ZMH&
MR4(%1O1$"M5(J*#_;*SA4:VP"]+I6_-SMREMW;7=9OQU'C<V560]ON6==WD=
M*(G^TJ:1B@OP.= \PA\:+18[1+)]?!H2?+%A[V%>X:?Q'WGYCZAC&$<@,\&8
MC$F_1>3T2H@MWGM:HMP:?!"E>ZW7/MGM]6.#/%KVU\/0(]MT3CAL_>2O&K>E
ME7EO98Q+3//JV2D5%+QOSFV& Q@=65@ 7]RL?_2_W-)D_E'W\;]T\9<N_O=R
MPNXBRU::64_RL2&@MHTK[/9$()3N&^USYSOS.B-0+@Z^OV+14[:?NFVT3FJ4
MK$01O/W-0-^'_%,A3J0"&4?P,]&9&&=6<A.XF*L+,&2D::>G[O_CJ#ST4FHH
MHMP(N"EE,0,="I+SAC^)B?PI_[5X>=(WUE?ZV(Z&%43(>V/D0.NJ.B*3 T N
M=5T._:_1K/(_RGG/XO^_1,[:%[]Q%]UD!XK/=B]$=Y&WX.-,"RH('LIRU/;[
MRWH6-+O:10DXV*RX+[.BNAH'C8=[("1:=3\]24MPAN#(?Q9,)54'[ECYT2WS
MZ>XYE/8PB)3R\DK77&,DJ("*W3($,W=/O< *+E&R-POQU;+\&HE3G3TY,&1_
MZ<O\PJA-S2O+UCF\$V%J-5.HPG^2*\19NCZX.7DNZ<$2+/YX77NNB:+37SB!
MWTOM81RA>.!"?"N"ZK9ZD,;PP,AEN/:9E<C1JJ*K7#<VWWG'Q9F,+HV3NUUM
M5:Z%;%N=7O%B+ _/DR 4_D?L$TA)SY<=5:;N8W!MIMQ ,=RZIRK%Y&*56W.(
MT8SG*;&$ R[Q>RYJ)L@3&S&1F.%D<"DN&(6Y,[R+#6">IPNUOM%+P88S=5XZ
M3A'V$,M.K5FO/Z##T]HHLZ"A&TJG\C.S[5IO!0?7&I@7L*#H#\ BW[(-)?:G
M(5Z&+34RQP,GG/<YBVHFF/F4[%94T.NSUCLU;5KZ?A_]6Y-+B;.6P/88FWU7
MU'A\)YHZ:BS3+U_SV^<GDRBSMO8*ZB?[:18*OU4"/SC\ECING9:?V0Q%N\DO
MM&FX2HJ:3.;WD6T@[#VB(UA1U!E6'%N)0?Q 8J=3L(*3VAI529YEF9?@\S,9
ML2L'^V?'S0ERBO6(\_D[SOZ^N_T[?RT'$$4N,:S!B:$;T J]&#<NAB.M??94
MEIT3,OT#X407I0)[T3YG\E9&6=>R6/[RWJR%AWFU$/O\YVI/W;Y'7/P\Q;+D
MLOYE%+L!(FYX:<(Z'>QX?@_3C*%%\<#TDZFJ3,$NJO%T16*##:.,\NQH7!U8
M( .R?X )%JUXM'(=$@HA/&(@[07'[ O*WN^OO(1VD6NAF3]ZUSD6)3-H-VEP
M=41.Q_GITZLD3Q&/%/7>@M(7?6J-QAXB>0J-)[/.E1O<-<9I2L>W/M$Q>QX0
M#8IA\:<170=WKB2Q\MC'T%\>CJRT,NIH9%,&@@XT[UC*4_HM1L^ZTT/PS6"8
M\V_)UEW*>=8D^<Z#(_9&(XI;?#ROLL(W( P.@%H6@H)05+<B]U+EPKS[4<JT
MEL" ^K)2&^"-ZC[/XCJ$A+O6]*TKQ_MNC_E?/1GN9/ U] T#N+*5E1+:R!\#
M+DZ,P#:"(XE\H0_9I[XY8EQ0.G1SVAR6>F%?F9?_"F;_N=%+%8_4P@AMZI=P
M&KFQAD\JI:>(T4,Z1< 2N8:U,5I39)6S)+;.A"OXLF7!Q1,:IUX[F+W. ,.[
M=0>274N+C<QOI%JI701<?W(2 &QE.C=6J9@\JNEL[/Y05:?^@>)JOV?*.>=*
MYB&]2ZY.=E]OY)BE.*=EM@S%W?&U 6>"(OS53TF=:3OE8& >_/E5'5,Y>>QV
MS4UUVM=OQ^0$[84?MIQH0:+JDG>D@&?%NE]/991/&IBCIC27\5%D28+T$$J&
ME?P[#1.I4J7U!F6;;%Q WQFN[!(#MQ(Q#&DQ#'%HI!O+0E,M>=^9G*P5D]Z>
ME$7!'4)=9T#IJB.BM7P>U)OE(VVJA@S_?(]UN;"2'"^1O*PID7O(\@C[@.=0
MPC.00\ZKJ@3A/7F'8(=5(2?T\<WY*'E6G-WW9Z,=;$6GB3RA4(]SDJ\+KO]N
M^%GS0%3]MIA3CY66ME'-FN0U($"4,T,#^$C]*^02 XIW-Z,R\D<"SP_7O/8G
MWDC@*; 6P&FY!]T; ("5;FQ9\]RIE@JS\R?(@3Z=.)VD%#SQ.ZRVU-DN1FFZ
M2@XB&-GJN$=X)"1].?<J-"Q55<#XLK \WM\4URE&YC.GO)"4.M"*%#WR>6'&
M"B)XIWS4_?VER-U1+;VFU%1(XBCJMP+&)Z'%XY 5)WMM_\!#>)Z(3'&&@TE$
MIN)MM[4T#F $VH DNF!Y&$-@2<8#E V&+LX!F%;V!7]E=R2;Q2S)6,>:%7G5
MB(]: 7WI]2%G3T+LV5_\<+0G2/L5;YK><G<TN!X8[@0H[[EY$]"6R?"ZA#G@
M<>K;B-O)M2\DHY.G]:\?C-J";8G$A^!NLN*9$G11MJ"JZ"=5])'!R9%:0?=;
M0P=*%Q#GDRL#3^D<K8R;UWU9<',\IF0]!0/G ':'-G$ ]T&BSW5G3]5@ME==
M&%&B/?(LJZ3K18<&'W?]?%#F;<)B\?&ZAPWWCQ**:G/KU!I'[IB=2)55U%6H
MM7)K)*A=*[$RV8O%.#HM7IT:.>2L6) XCSCXMC#.F)S DBO<=ZBY,"KON]#"
M^'&S")!21T/WA^^T%M=@[SMK!VQ/E9QN%0AI>3IE47<UB]W:>D97X[2!*3@,
M%;#AQG7B=#$45T:R8R\&"A1@#'75#<E)2=)#&Z95']V3RJ.-#=0;0$NUQ#]4
M]SC;3].:50:FB?O,WGX.L^MK=PRNEFXB'B2ZX/IUJ$T/F/!A("_*G"X:S3[&
M.&J/XV4J,H"_:X#W?D-Z7?/IMK?%UMC85%ACTQT=3GO@"F&6). )$W_-N'&1
M]X@D\"U<<*H8*P&]G=&^$L@('.8 PBM"'Z$U&8L7Z681[-/(MN%*!F(8;FC9
M(RE%MNC1U7FIT9!V/M=XH/W&35>>7EN ; GS#"4'O(,[)D.P*V+O)*FA+.RX
M-Z1_VJ"PK'?F64E"SJ%[VN\(Q=??M,'/7%^9F8BY+N\HL)"^BH4:7+&,Q,^P
M4FZF396^K8T_K?%IID>GK7@XM]/&"(:A-ED4)C]*/W=UI5A4+2,N4[O$ :*2
MW6VLH*&9.U $?XU.8HJP2M@\* 0#1@6'K^\K\Z=$J]:L)B9!(XH1D@TNE&K,
M^9Y;>3>J M7F=I?L+EY3E0V1.V$(>_/-\\YH><RE-[.8FP@2E+(Z:T+9RP%(
M,L^4T/GR(U\C@Z[09EJI2CH2.L_S9\2>S"F'X++=$Q;Z/P&0,AOG/U[!JLD/
M1##=61$$/I0ZH^\E>O >?P/_7GMDD=$7M@HC!]()5T'XV/._FUHAW7SC7!T2
MR'7G+E=\(]CM"!\+\+<ZWRH8HS2%8TCKYU5C9Q9']BI=?*192A2N,D,@]B0X
M"YWX1&\Z"+UY5T!(_OBG)C&95(]4@GCPZ>L.>ED:"AU&QM_>:KBT>63YZRW?
MB<XMJ]2JHWIT9X=&K9UQ/T\\93/V--M(B=0;L117/=A9"'9^DQ:QB+WXORW9
M_@^;W\Y*^?_3[;__M6VGZ(^)BC]>L#+Q81_$3 H<&!A7;0L6,K<X\<_VX/QX
M4&^^ZH_I:?]X2^U/027^44V8+"[S]&<#V!](6>S'[:8_;DF$N+"'6#P]]\"?
MCPW^@P%LBZ!G079CODZ_PBA5S'K\X9?[/]Z\K!LT@JT%[F+Z,7RHJL&IVNPN
M#N"12X.U!RP[16I!A\_(Q2C!RL,^&SY'C:Y[R0'8P]4$'E^A&381=Q"'GP,+
M5VO $F[ _=XF_!*,G'JT((!A9R:%Y/KS374+\LZ'*N#!KY,S!G+TJZ/,O^4U
M5)P<>A>ZIVXI)*)7..?\@:P]<5&R:+=&4SGON K'3J-5NUNNVD+0T]TIIXWO
ME!W/%"(5591LZ-E "]:< SF [:FLYW-,*RJ_* F)'?$,SF8DVU7T^;BAP'01
M2<7/'M.MB95/W]90%KT+PF\@E'P&V@X\/O#[6>D9<"@'4-1>1PXAS4>B#+FC
M0#BZ$S0[9]4#?0,]K+7CS%RA6\\=-!(?4OCT.8RW3U30P50IX2;Z#L3 W.%]
MB]"=Q5JKQLX0Q==;<Z=_'[=3O%MGE2)&&;>(N]=X]]693K@[Y5A%:JKM\S$Q
M#=XNOGB7DV)HH':=><U8][L266.Q$)$0E1A0-*]Q)&M4$?E)C_?2]24KV'G[
M!J#D(+H1QX- 2?H,Y^2 ][>_;J-*8 5)3IK%.[+3I_I,"F'JSSO;X'G4&WM>
M*^2IG"JQ??9>Q1NU94.&*<WP@U/#EIZA]+.G0*J=^>IP%TC?<G"W1E'6MT:7
M! F/L-Q9Y9<WM]^$%%3E"UL8(C\8KW^.H$W2$GD[\1<$S8ZV'H'PF7R]\O9=
M\=IDYY44C8.5@4D^<I?5_)XZR^TJ$769R6'D4 WD>*):/>C$ U8?7.@0QT9G
M:-)UQT,&<J2.>N/,BUZSV@QWX2E+ZTSK$OF>[-U7'9J:B]#-Q-WC#.=,IK0/
M_0@M%9MO0I6XY"& @7$ ;F:J*:K)OK<N&>R\4V\$%].G:EUH\[T'KFDU%:3R
M1^IBX'B(B1>5'\# 4-C/7[=N/7YO1^)+?=5$==%L+9+*Z\J*QXYMSX87OD,>
M%^B$9DY %K08T^P*)((#N+1,LLD*:KG[[>W=!,C#.F=9W6/\.Q6N9![4>E1[
MKNJ8)(D#J*Q[&QLMSXJ7@TMB4SXCL\(8,2\4H.6]+DE=6<_'_.N/1-=WXP^.
M/:^:-%-ODI5#Y(Z,GW]*U]#*5KR#L/):2Z4#:S #.28,6WK=BE4E@Y^*#U.@
M:U%C&9%U9.%,>KTH6K1+5QN1\<22I6[*]R96*P9JA%]:#0_*[<4>MD9@&-$;
M>NP.#@! .(UNPTE6\=#2YD?RL'7X1TG0^U4V%#+OM'4%.@?VMO]K8*JE: K?
M:%L][^RSN>%WY66DC#.6Q< A1:5!Y%HIT<=(KGWV:/FL>?<C6#,135^]GO>Q
M)[7:=L%$]35^@Y2'A\Y\_R;Q.KNM.\)I-'->"^T]5PP^3!S&$8OZ&A&A$'X,
M#"*$LJ3=H9F%L;60B?6IA[_H"JIDPC!OKPU )A,[!AK>F.X]KKG8ZG7W7<.A
M6:%,PV1=Z_Z%IM>8FI/H?<R+#&5:0$.J)".9XC&_>UH\M!XO,"WBJQUD_SRK
M*S_K<8UWSO:N+4+W'T;5[P2J>3H(KKOHNU@*:T<4/KU>79S=8CWF0&@^W6"P
M<,^V?]&QTFE5,RLXR[3CSM.!=/%P1[Q_#ZRYI=G#)\W:CFNU'9HN_G]XPK-Y
M]T<1T1N/=SZ1D[FO+36&MU(VO-3E$V!T7 ,.:KU:D(Q(<7U#.A< 4VGD374M
M^72W[ECOEL2[DKE;#DJKW^, ((^EO,8,.0 ]0?8ZA)[^"<N^)\=:(H[8DVEY
M:$G,EZ!A/%/66Y5]-ITMC*_#K^]'"7/-;7XP!_!1V#ITD1M@;8$PGX-6N9[E
ML!D'\&0S6Q%T [/8 9[/Y #$=3]R .-I&+()6Z.: ]C31^EC[0+MX0!J;<YS
M -_W@"EV3&T.X-7.&@C#> +"?*#_BMG) 7RPX0".2?W"_(7Y"_,7YB_,7YB_
M,']A_L+\GX>9:I]^$4=[SNB>OR0!V3,\=XC:9=%^;_8_"F^ZH!70>H,@W"'+
M9)\M3[PX1ZY?K^0 5$V(]MZ$_TR_C;^P89AA)0X@CC^@&$.3X[J]?ZG2 %0#
MKTW@5KECBI;Z&_H0!Q#L09MF/P+R8"A*KS +/, ?O.BT7WB_\/[S>&;*](PP
MRUJ&-YANA_1F4;IF#WCU5IK][24(3&T)PX<#.,__D$B+_T)<VXIE6!/W$2?.
MT6S8!RI$.8##EJAH67\8IK"" QB@&MMX=O2284L<0%D@)NLU_W,@<\EL8Q+3
MB/T/85H4@Y,@#*X^?6^:]\6RMW, :T#(Y&30_\L(4\@.V*;*Y,$L./]"^X7V
MKZ/5(V,VMYA)]:&].8#'FME,$PX 9+G1A=*0<:E+!;9F,1^HXZF0-7K04"7N
M_Y;ALW^58?-_FQ>D_C8OH$?S_!&88-^RQ=#J )*./340SB*K3JW_OO:$ VC_
MC0,@)#+=%J4Y@-1P#B!0E=&[RE2"A$*6#F^>++[;<2^W%_)_TG6E"VM<(W ?
MS[ZD-]?!G1QQ'(#T-$OO!.JO<Y2Z_]_@/0+^//@_*63D+\C_AI"ZE8V7<E$*
M)4%P>FI(6W%0R=G*5LU3P6)B<@^^]4'_IAEY\S_:6_.?^#"()QEX9=45&\@&
MRLAXEJ0], O"K<SCEY9J_DY ._ZCJ'_]UO>,]=^/P+\@_Q<**_&"JY0RO4YD
MBY/9/OCULWQE%^O@<D%!-8VWD1K]_]&7O'@A,^\/%Z;ABX2!X],>#\<<I2LQ
M@E/S3 )B;K%KYU^G L._.B1EQ!]]=,,_V5J%_W8SUO^1:+E H68Q6E/8!^_V
ME7WXS4GZ[ ;VWOR?@K"?,#C_MZZJ8C_&9CS)__QUGJ05X=]<8U/\GP[?$SI1
M!^?U7:$U;-^?UL1[HO')!2&WK1EW&A^8"UP%O'DK?!8 4+1+F!N8F]-(,RD\
MIR]D<?#O%W!^M?]PV_(!9<3(II&'YT,\=5WI)HUL<1I_\*QKQ) CHD&[.A7[
MNV?^04,$C+<OMEY%5>7&41V/B]L3!3_^=L=@[BSX!%.- W@8PVZ B%9QYZ)=
MT(=H7<9UA$#SFX:,:Y-#1]_111]B2DO$Q@(" LSV#2+;#;[<8AHJUS<7DC?V
M49EFA&-A%6T"F-0J+8KIJ9577*QP)K2:D>FA4CV,[1>\0(.$LB50.G391Y8,
M!%L0+W8-5/X&95)6""-U624H@\7UGR9EQO<75P6_+@C0C#CGM9K8A+V/XR7H
M,=7H_'7$,"G1CA)3Q0VC\M!+%4DM,@3:*/-*T60%(3APYY. ##(LT8BOIZ0Q
MQ0=V'+Y_[]$8CU>UT:"+W2LQ=Z-<%<XU&"0E642,WO%,-X<1[^V9:UFI'+?,
ML4RZNB;DHJ!O "LW;>B?RGBJ][VS(B%B/E#O?>';Q)M7'IB(RO#LV6$B(K?E
M[/?8VSO/-/@GUK='8?C9 IOQ%A4:K>$QP91X;0KE&\JB$/<QL$VBN_KZC%RW
M&68@E8SZEI/#K/V%'+[9?S7A>7%NO#+VH+2_Z")^Q9&^VH0/![[CCU1/V=D
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MJLOJ?>]R"L*B%+'/P6/%VC0_0Z3SO&IF<7A"K^W1" NQ+I#YAB#J.-TPG U
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MZAKP!Z"\"OFQP'3NVR]P $_V75SC7K=86%PPD/M71FEX:A;(W IDAMTU;.<
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M\1 =Q(GV2K"+>RDJ%\^&4\-N[R2R(+9SG?ET$Y+G2Y0+S/\F%9GY?O2CH]D
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M7%O[^;%O(3W2JO*,OF&CQNF^'_O(I@.E>D&#0DE)![Y9A7B]),9<&7#K\K'
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MY:Z3";1(Q2!N$O5B%7Z9+-7$]S)-K(H2^G;WKW19(FH_G0?* U>MIR$E-%W
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ML9.B(5"0O_A+>T/)7 GY:OO-G%97WG+&PU!J\Z+%$+_14@'J3]8\S@8:JMC
M/>BVT@HG^Z:#J]G CWD(<9P-E(!W1/P;4$RA"=2J;V"J)@1FPT+V<Z+ 6#8
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MB>7O,S:U%]LEBZ,/_.)Z1G_"+=',TW8G!>5B!Z:%49#80C[>A=I=U+!@IF;
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M?!>])<5"G4WUDL;<ME;\4.7^[81H:!42+-@B!G1OI>\5"-<!CE1OBV$?]&$
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M2>C 5C:/ROH4OL@Q5$&;US4W-23V/M"#]\9&BUH)Z]V%IP,V%&MB>JNA(,H
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M>\&AOTJSWQ5 GJ&B$[1.TJZ/+#?IP$F)3X,L6V*G%R>E[\1T&.7C/\IFU^)
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MOC;G,E2YUDK8%??-65@R0( E_20#E!7*U*UML5N;-CC( !W'MH'7!SI0@'W
M' .4H59\_5<> _080[^%#JY"4228<[O# )D8</V+]\NRSZ;3]V-_7=ANU&.
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M^:SAC*W869>DRY@G[62J?&=DF"]5B+#GTFF6YD%]F6Z<;\^*F9 3I _,[93
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M3''OV-+BHQ+B:.J">4MKGW#*7@M"G*,TY9WW$^4*Q?8=G\X8=G.X**WR@;O
MX4(2(W>'-%2I$A]W5HI\3D_ \"8QBO#=B<<YWJ?=2S&B&5>*/W^+/)"5BNC
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MX!^"%CMDDD3?+3X!-!;5DHO#5F%;J/R%LAR9B6Z'JAO>6D;\YFYT>%9AW"Z
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M/@F51#^=C655O1I'OX V2[?.;5DN'A0($%IGE*"%:P=03V/-P<4>6;.3%Q)
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MN]"I=!.'E<LKMZOY$QA5L?WHU)E&E4"/5\-VF3:!J;)-#Z@63J"L8N@<W)>
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MG*^DT<*GNG?!'P=J^ W>8JA-$18/0*NP%YV1TPLNK!?LW8-VGHVE0!:UV"Y
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M)O* +O%N,T#& :#GX7]8KTG:@!'' >[ME00S\SFT$L3M'+]- 4MX2=4\QM9
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M>E0$Q:)^[9]L2Y8_RNHR?]4R8#@!(8?G"(,%<N<E0%J-?=T,"C0D&\P#[*C
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M.4^BJN(NK>LV!3=;BLA@#-TXH%47E0K'?7"'K/:!B_1%N/.@_SK^ WJV[_:
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M7(L]$^4($>X^.1V%;7HID1PAV.<>K \\T/N!^B(ZN^JO==NZHB"_=5GSD'_
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M'R?R.?P Q(/&@/J"3^+# T]43[^<*]90#LT9_/K]47F8%6N69/<S'\LT0[R
M&OJ*8@+3E1Z'QS*(</*#4R!;()ZPX>5;/:2N@L^4N['N3]B$5<=9184G:Q(U
M_]F]"LAWK3S_M96':X'):<T1V^AI/I'MP9>K'D:]&P3=G5Z)Z28EW(679U).
M07$<;C @"B7^*PZZJWR%359<5MGKIMBUGSJIZVY?(SH1936-++.I[^=&+AQJ
M B?N@VU"M(_6Z)J\S?36[WAKZ(UG('Q*O=UN.D58<L9&G85XRK@91:,YYP6[
MOGQ#M6I27&E[@>/-$$7 B9I,P$:)>A'(5Y"&0E E:U=?)]H2S[('DQ3IV4P#
MQBI 57*P2'"CKLR=DUFTL,&FJ\,.J\!F$&R0C=1F9[GQJR5UQJ*%E3<CX84V
M(Q]Y#ZM](\[J.(YC7\:$M!N<902W&)R)QYQ!1IAENO JOTV]ZCUR"-"N;*JL
M&5?).;;4!LGVR\%31\>]\E-Y9>NL)(G+C=W.N?D&7EQ#=1WIM_ZY.4GKB2;S
M8I@DC^P4V0![$XJ"TW9,L9)G ]Z:Q B+MC^4:_%6[]',!XK]_\S>.Q#?C3'[
M[/7Q]U/U> PH$9_NV12\XWP>:9M@Q:-YR$?]WTWIJM=*B@'S+U:]H4!T8\Z@
M843:(<H,VP!1<GA$M$M:M.<8\_KYYXD9G&7-B5?&D'WOXO&#&M*0N*,'(=9#
M;U,N0XP=#:@OH1Q.$$^[F;>"S$WX31[5(4\I[;_2E6VL9YX=4K!^&:6>I')0
MDH9\Y6S5"?@R<1[U:J'*&L8&@4M6.7+V$"8,&DV'%I#!UMFOJ)$Y%3ZEYK7<
M3*% );7*OV(]3+8/[X;M[]$JQ\V"F5 4'PJDO>\6A.T2Z]=^YAOA):??,4Y4
MT[^V\U;T\UP8D;!A&WL)4)_2GFD,VPRQI[1<9&\_<R$($.Z=U:A_J!OP]H2D
MA_GBA.+BG)C (DE0OMKV$^V]1&^$A4BRM%\9>V!N^U5/-M/5%U8K.)VO3KOC
M,EG6<3PS436]4K&=KT G';WX-,!73<YBV]TN*8AI=6^.M'\ _-. ^FARB%E:
M.;2]F/NVZ'QQ@IFA@&_&7(-0(&(:7_:,7_\E4XG+*5D/ZE&#>OT-?TT_OU A
M$EZ"U/*(Q@P4<HA-\/SWB+.]JYBPDIX556]R+C2HISE9_N: 6-!44Q9MLU^4
M_F]SWY?S7YCSZ!B-!!*A$\R&W<9.E39\7\J\E+$;4!4JG.8&N*T]JW]/G,\C
MTK'"(=YSF?&;@#;^2F^,+!:OJ0:P K>$7B!06%";?BLR%.",Z'ZMRG:)9#9"
ME'[<)=G[M/Y3U/>-X&U2TVXX+71;:U$0@3CY A0J39X^W/[P*57O-> ,3;-3
M(__L=W\3ISTFKI$5"V9C"XHW<2J"WX_W[C<LTJ0I_,_GC:G3T)I)WXOD?IFQ
M#+*<=;,HK;IJG+!JH-E!GD3,9%DRMR)1$/\: Z]8W\&KOX]LADB=^(RP75!D
M^\@F?2LK_#45FMP-"?WO%T"(BWW&FQ]W$U?K+>DI"N>I8B[BGJY)@<BJ[]O4
M-=4#R#PX,UZ=::$?R-.+B<^[5$GPMO8P4TDSZ0KUK.P-3>$IS-1;#H-<"8EE
M!TA[>GE&>A%V"#\8 3V]EY3X<-"CY&&;_G6AM!&;TVRMM6.*^1C>4OTPF65%
M<**_:M5[Z.XSUS/.ZIX3#"9QM3@A+2W,FV>!^/[?]J ,B3N7@_D2@9?E<!OT
M22*?:<,8@O\$1WN>L.0.N8HORM,-+W5OP#%T$LWJ\GC&]&Y_>.PZP9Y^:Y)G
M7=OOC@I1,%VI=.["9.F7@XOA3SK<GI9&0ESY3 <E0^\.8=I?4=T'*WI^3)=+
MTIHW%Q#L"TBF[VL:TE25?[!,66W;^>&XI<C>7H)C%)J<IC$JFBG]U7$8C<7(
MAL<(&<5R7$K8<KBSVO&?F9)-$&M*I\!E7*ULY2P!&6&CH1.7K_+3]*O&$X?B
MGE\BU%:(J(__GKDU#R3*73"9/&L=IWF+-KQ#ZZ?O;1)U[I@SD%4&5[:_HC?[
MPB)%&!=2X%.NCJD"JA@[FT&(9_M.Y##!.KIH7? BE8(Z^ZE>'AC0&1S@4VY#
MSGA2X]ZR=53\ BW:5!OLI0Y!S>N)O]89+:H-XU"Q9@ARXV<@N,?,/NE*!)<(
M^\K3D35H4&L.@1?("U,85Q04&WK*$7!:R;<^?28ZV#.-L):ZO0F;X;[$\<4[
M=S461 H&!J0_ZI24]UK-14KZ=JD16?[P/KA"A7]@Q#5"8\BZL,W_E8$'WM'2
MY7Y9G?<9OKHG8HSUJQC6()LYY/P[LTMW5W<O>XN0WJ4WFM&NHZ..9\4(5=!2
M)3-AJ\%(DEP5KG#[<@_V5(RE/^##Q)L=OT.BW.9=E2"QJRCH+CHRQ8&;1<F_
M7:4(^>D#3"MX^H^@G@Y,QL#JH]<8J,TL_ +C;[CRUNG?H95REV*80QP4,V51
MS88UH%:3H.,RW4.8[WZFAP3"'A7E[A1[! ^J/85<=C#O>2F](9"@Z3HN%G7A
MS*C!"7IV-LL87/X4DMX"L3.O\E4.Y6CO1GB?=$83A5:6+C3YA?+>SS>0*5+2
M.G'VC-6]3^+;X.BV!R][IHGS&29 F?A86O\N=Z<K-_Z>_<CJR'NT?V];C9)0
MNK].?"%IPPW6,TCX=O:RR8:BKIRX"T\9H4J,'>, :DELA7/FXL(5OXYO#Y8(
MN;>86V U>]H$YY>;=/O!YT2"8]Z!GJ$OFL"M[0,!PPW%SQK!!JA=HG2<,U#-
MH\E/A0/^8[HY)HVLWVI3TB#^0+>7D-EA*7N\?"<"Y4#)#DK;]3S9ZDY1L>5_
M1=,UKS.N,4.9PT.50NI3HNR/ID;5?CDF76\)"2D-D:GK0/=#9!<LR="O13:\
MF\9/U<01;WH&<[*]*3)\:G#NPPJ^T%=><;N>._]]<' TR1RSY=@F4:E^D(-E
MKF-X JD6'TJ?T5S0W6,Z,VP&6%3NS1(C$*Z<Y++M?5Z 81EE%6-WWPF!&9@Y
M DZ@8KN4M6@$G\ZOBXBM@E-'/[TNVMO0>WNE;C7(A)2M1"O$ELOP!AR9U 1H
M6T>=7^0=D2 ;%&_6=H>\FP[Q-]PR<HK2X;X,;G!LO'<RSBW.?%<Q]6S)^G\I
M!<R5K#8O_D_$FSPO"+VG&,8.V#/+.U:61'R&H%%Q&Q(#U-I]GH)3*<//./+4
M]"YU)L?\&S^M*>OAPY;'$Z,+GT/Z1T4,UF UW7TFZ;P!@D+AC5_HV9IA<9GN
MF1MA"<-.EX^$0^_UHWQ<$<4,.:DKY[DA'G#[2(LHM;-Z!=,4=<Z',&5/4DS4
M/EKEV]&=N2'CIY4O&\0]5GXCL"23'\U9ADZP4*;G!+^6W4ZZ@;/T)F.FL-#
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M2Y>TSADL8&X>CKE:HP@14:M.3WHR+3='K]U?-.%?%,NI,>]8 ?LOA+O<MQV
M Y<]>K'?]?@&?X<[GHOL/?>>[+D>=/SD]859 /,#VL]GF *OMXU7'D?C%B?L
M='?SZ_!7Q@;(W?B=N-S+Q-J"2D7$RZS94-\3NL(G!,=AYMO@6XE--S=411<E
MJ-L'O[6$'-\ZX74O?V3J*VFUX4=).S>34X>]A>:#^U)3O0.SF[*(L" 0CW:G
MK$"ZD$&Z\OU % R*"!FX9<U$&=%DLL0!^E19$16V"L;>(!@@9_GPJJ;-?S;T
M'HVV7P7U'1]LT_ ](CI*=6PTRK0"8C1N\)/R^W;S2NB57/=OXX/ D Z^"<&.
M<1*P%>HTFUNS[B_"J$%>N?R+<MJ-(7YN,_'GLVF!X>UZ-^@XB#G^OZF$0.>@
M6M'=B2'G5GR*WA94.G=R,, VL(>WCB^XMTV^=G(H]FU59"P-4N[GI1SO19E$
M_A=>W#[+Y%2.#(>TE+W_W##S:\>RR]6_N*W8$];HO>6,P*-Y_).O]W'?K>9_
MVV\X6IYQ*/_LRY6WJI9M^W7/IVO$/S W.+6%MWB;4&U:/6<0F6PHR[TMW]F\
M'_+3W(&Q'1Q#QL;^>A_/MK"E\$=N.VFH3+&8&P&UAKU9\LY]2<(NEQ7B^ 7)
ML?:9E2-^YVN+0PXB[ULLVO7;=$_U:]&//.D$,L.A!;[ 0V'BH#&#"PHK$"SH
M@HO;8ZLF9E^#?-E,[S0N<W0#F&?8)5T*P@7DH=^N,QP342L0=)@/#<9@@]FI
M=0]S1UWX X&^&@]=D0?E6B*N=G$IQ UX!>Q\-%6/NV0O$[B6UG4C,61X_YQ!
MSJ9ZG7%'>*B]!Z3.J$%.5HU.-OEEQ..6CP\-7&=M#"BEC+>/CIP; A9:-V2Y
MKK@,WL9PACI?1E;3>R?>JCM&\;!(2,EDK62N ?EU[TM,-HF_O]PAO=/>&URO
M&@_>=_QMT_;L1,7I^!P'E6=LQ?NA^I'7ORWX2M(;M< .FEF8UDD94@>"'AGW
MACGBW<./9J\8MQE]&*L]PHB"I1G(@G^!<5OB]E$K$""G6.K?,*W?38L6^'E/
M)MAU2+-XN/\E-LZ6^<G?P$;<%F/]4II2;0=<NEC/6[@IC!B%U"@89'?A5JD8
M>V+EG.63-LML5 UWM=Y 2Q;'3O\>7]U]<'J'NRZH5W+B>=IT9*[X:$-C2^.I
M+V=S3^HN<''@(60A=^Z\Y]L67"E4&[8IBN<,TA-G-96RX<SZ6-9A+[>93&3G
M([I?Z#V'GH30[2X"EGR$?%0<[+,?O_9ZG$G'XSU75I&77V,1I2_>LF$+^:)*
MQ-Q":5*IFJ?=S]@+<U7'(KATFA)AK="[(_M!IIR5412/HIB'VNJSGH1ZL07(
M/@YA4NH#%QSM=7]_P8._@$X1#(W>_S5@4\NC:(EG8^V99$\M!EF?IWD.I;5H
MSS""OA^0%Z6R589R59[PWK]?>QO#,PK,3<(JNK. 8\Q;&\W$0C/M5Y@+1Z/)
MK 4)H=AC/?&/0H2%J/W$U-!KR<GG8HIIYH-O&\Q/,Q^,LUYTM0;:'@8F950.
MIJ8F7CJ8>_Y/8!WM(5WQE[?AMB@L<V5DXYW87_SKV^-=)JN7T4L"8R__';E
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M\HYRM,OK:AC9$HVPJH[![G#)XS3R_!V%+5!$E2P1,G7/GX+TRI];2&JF3S9
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MQW ."$5__)SH>V4V2JBI#\Q_1;=PP4@-&]:'@GF=]:2A5KTM9%+F"%8;N);
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MOW#UOXW>T]:1MDIWXLIVTRT679V#X^-EW.OJ)GFK<0M<)<:A,R6!DXU;/$7
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MPK4G^GT8P%D1=A@#YU<6,H, QVZB\ZAZN=DI2=1\'AJ\QMS*?/DIBGH^D=S
M<);..HM)Q:F,&FVR]^>WA[\K#QTP6R>I+E1721;--E8;IB:]MR\<$ZEJ]:%3
M$M[K;!U+/H=Q0_"06TG5;<2;X@"7:@DX^_<@I> <_?<H5_6R6AGJG\+Z@%L7
M$\[[?D,(U;PX"ZT_/J,ZT9SZ%6X3$HH6PV5F]R623%3 M20N,/_%M(&+3X$D
M0S(<;PQAB.2X%6C?VB1T#)02W:#<7QKB3L#XKPLEVC!I5FH,].\]EW7[J@,>
MM5TH: PUE!>?EJHV_+4^(VX. T4:]D S;!1-*Z)%$]1:((P/)4B#.5?*\.+[
M0D_&;$3<0&_L0'.]6T /9<7X?]$*77+2RD;5GV_S763@L2*R]]_",R^RM:+7
MXSJG8HAM*(4+SNOP%OON 533S^C@+ '__3TP6MN7IG9@8"5"[^[IB,B8?7[;
M)^^^\OGH;XS:XO'HF:@O;F6*C;PB1>?WT\(Q<K:HV3*'B&>^)"XR52<WX 7^
MFBD7!-_+W+3S^M/DW@.OFLO;E]$R2LK8$K^2&OW^XH3<J+6_W;YQY].ZK"(O
MM%.^,]4RMWU0\_,ZU2J1KE4V99ND;AI$'$H5% ?S2@96>Z%>3YW&6@)K2K\1
M7F:^;)W%YZ3;G!WKE03E2=V"Q:K9L4 7?X'M6"^#%V$\7L:X?5RT3[#+N KY
M\2DZ$N>0(%,^X*T7?9%(],W6SEP6VB'?0:_:(:ONPQV&6]'1P#?<SAS WZ.:
M53\6[9!1<FF92POWSJXM@YB1D=$/UM?M#3?1QP0R_W#W-U5. 39&O_FS?\@3
M,]"P.,#L."!<"J2 G$Y4\6"<G&@/J2]_G/#'+AMK:^4([+6)0*I_];_RRI\8
M-].?]:7P:9GEM<+6OKBH=3\M&,'UXEETNJK5T @F2+GY7&=D!^AJ($.4:TQ'
M^+0V3XPOY*Y@+GRA4^9?4J*!4>L)D:X3$J"%FJE"P!D*/Y;]7;.PIUEM S.5
M<A=2#BN3E?Y@U*6_)R:"]@D_>1@G4[]V1>/6X^*2:F,(LYODQ+2B45K=;^%R
M"/9:D[U.*1,5E5'$XSR+I!EG-(83#F=J"H 8R->0WV,?8S&'V<N6MEGF V&T
M)"?UD3[^E(<JD\R/1'F)1UP&'!DDDLPOE48"0R(3N0F\-,=95&4VQ1&)UT_E
MQ2UZ!I=KE,OW5<L@O#9#QK$ -L W=/ZT@I24YK>')94;X6/L1FI][9CM>!RN
M[4E6T+A,I!U1\Q,X3%]@N>D><3N0#G(+A.O@!$,E."7GK$("NH%PR(5\56TM
M7,V(E+2-7*D"=L#.J Z=BJ5+[0/NMY46(*DZK UL,2Z+O&9USN]YC"LMZNMM
MZ=CA-4 B.HR59NF(!9R5;#R"[ 33!R4LE?L<1LZTASO1CK]I^AWPTEO7XY;>
M4VWH2A2M%%AK;'"*P$O^';[#^ZC)]<JJ/\0GDZ.R<<.S<+E.--&M)[DS5>HG
MBDFO:EK<2CY([Q M ;X'9]!0M%M_E"-55:NE$8O]&M8F6U@G>[S_MFSD9?JV
MI(C[26UI=4XV#R/)_T4V 0OA>AV9S72'2IITY*74.,=;J,8)$C19:SXPUX@@
MCU]T$=:2P( ! ]&3W^>/6\[X7N?9M[[LW< ,V04 J;.YW(QDB^K[4O8/';B7
M^$EK2*)094QDSL>704(DU*O+R$FCS^/'?@2O.:^WIA<1@\$]51I6SN#\F/=&
M@Q]S]%E8Z:S/<PUG*=MK,K26_\J_POWED$]C#7E3]0UE&YRJHTP\IAO/,/\@
MNJ+=&&_N%P;!)ETR1>=4AYW<I-EI;W@%3QI/PM;A\$*/;$9;:R%Q#74.XR#T
M04YV,]V4-6/J4W1KVD">I*RRJG[EYP\)[851WLI7<?-+VA* LQ"N<TK%UK[E
M%C-72NJ1\Z8V9*OQ('SVOW=S&%EX+95I]6H:MS#NQ(?H<9EV1\HIZ,AC.&[Z
M9&OO9+K-&H'A;D2</S4:?]],,O^!HBM6Q=.P)@N,6VDC5B 9Y=GE;^9?1ZE<
MOX&RWCVK@A/TI1U>[Z@)K_C[ /_;M$]*/==B;(,_%X/R$GLXZHUU,3&S/"9\
MJ/H =AW:OJ&Q.8Q]&N]U9"Q;:RG#K@160X9G4()&E/N9DD^T&/2/71CWZI]!
MYAJJ$W;M2.),BW/JZV\WV"9%IYZP3M[S9TWSL^M[X\^0ML-S&,,#^(X^G/QZ
MH?C2^T+DH(9;7/F%20 X@UA#.?B._9#"."4XR*H:+1TU5350778B7XTQE\*_
MW5.<TKL%[A>&%Z\]R#I_YM&?'K]M)/>0AS\9$B'N) 5TZ=52KOB+EB6Z_"N2
MX7.8.U#@<GJ3U*(*IU8N@BI_T^T\U'^F^W/#V4^3,\<N' HYF?MW3'O7W3<G
M8F1M1__'-;3\WQF$O?K R3JCA[E?O03(T)(7C5*6"3?",3)N,^4*?Y@VG@[7
M5L'NKN_ L\_OQE*#?&IZX'$).>MB=51C [&TEGPW*0-Z4;>EWN',0OW44*N>
M+E-:LCK/S&%H[7BYR-&\AL'64*2DU='(:G#P,G)8]X)V%,1*2*L8F=HTDEWS
M"[+XTO[:3!^.]K3.V@U_I"=ETN]I,IJ=IE)T/\M[OO3^GQ9J,E2:[A$.0J?-
M2^.AU&]A+<26"!=!N X*EL9: .#OHJ#/G$\QB^#Y)4<X8">HP]LSR'MZ^5Y>
MZ#A!WM.<0GE=XVB!X[O']UXDK"[%)ET033BCI@][9"AX;E'F-RXS$DX!91D!
M!X7H.0IE#FDU*4'IF%0KB[PPLE@$L[3-H*'*LEC;!,)EJ]*W;Q 4;O?;Q1M2
MTM?3&+M+<Y]RB^=O=,,6F@-Z"5FW 1(T*#:1]D'.$U'@+0.MNP9R5!:D&6LA
MWF7DXFV&2!JW:<"[F;YDS*E%Y=.6]G;/NU5;XL8/)'_[><OLN16E3P]@MYON
M O$:-XIYZ=$YS!*\PJ@<%LE)-@VL[WD8N%XBM#+=Y(N&_S.KR5#U%-L[.1UG
M#Y=+U(\#^-3[(?[O*O^+1A,#0SC4X/G+M:W[![^[_(F$"D(R=Q40:"H6T<)Y
MUW ."*MAY .K)2#/N(.I)+J;[G@#Z0\!)KRX%H@0@"^+[RB@6Q'P*V^AQYM]
M]+JD-D4^L);K<+;/_YG?4PW[R/-V?H'W.M-BB#>A-\;#EH:>9Z;[<Y@$M8WY
M;ZYMLW>&(1$L[6A(D.!6$?V!(W!H/;6,EXOLHC>&-U)+W:U,%4S_J+&R+.4-
M0Z*V[=:^9Q$CISV['FD_D,"(9)8NX2J)UG#:< ,B92,DJ-[0"25<$<0_('7F
M] '[-,KLH%IQ9F0K?'+$89! O0V3(R%#[=VW36,J4;X_UXH1$'NTQN6<2^RU
M"X_5WRT8O<7J)$QS+$57!'0PTE!GJB8$0H.2D0W=_BQ7( 2N@JIT"CEG(7"T
M)UH;(Y_U+&1B&#P%#8R4&$8\^)D_]Y+%4Y9 4+FXU(;N<^5\O./S7?A!4;.G
MC.P(N,/43)UR$>(_(/1FR+,B0\&I/,*7]R(\RD\'\'CJL%K56.46Z(OC8VPM
M?C$5[SD,D'47TR9#_6*W[4@)_67X6H[9 <KHY,";N H.EG%8TRKCY8N:!CLI
M>4[1[TI)4C4'UT27BHKM  9<I14MC_/N"R+E$FP?('[@<C:X>T:!.]N">D\-
M%^+HC@C=6IZ*FKI+(]6.*F,8XF!I. :Q)L-!RQ#XE&8'P:K^+2-!AY,H7>,0
M ORBCI%#= 1.OB+8UN]BW0=\X=JZ41?GHFD%*"I,OF,,J$OUS 6.>/RP7M0]
M[4===Q+[TT.2IN&2N52#&WX%*[3.8O4*)-%T#=FAG;)G<,24!4)B%Q2N+2V^
M WU#/%M^&_4$NW1E+@O+5V(9;3U':%FT;R!+2=>NVG;9-79Z*OW'3R'C(AL4
M<>^0[/V4!8&5"TSUP@4,FN9WE]:)H09FW\CB^6.DXXRZOP\#)+ WBKL"3E64
MS)9*>'E4+2<_Z$30+[>(I=HN[FI&BN[T>1M1X;VM>WJ!S%K4 ;U)5".;,AS]
M=Y09G>]+$"_C460AZ"PA+T0\8(\1_V["8A 7!;,:E>FG;E.3:> M\0!S,UA3
M1V4]2"HU;VP"65?]-TYGWI]8"_K]%.K#2YWA2D6O,Z+A>JBK(VX;1'RF5<+'
MRB@35,C>\#U469I,O#>RJ:T?227E&<:#W 2S7J-VHP$EL[&]?FVY=V@,'Y?7
M/A7KD]?M6? _B?$ 4T5J29!&X T8.-NRTP)V,Q+G/WB*.LHY5O!P!RIGR*X,
M*$*P^.$XB][3S.*0EC\D6&E)V/G[.)*M_RQ1[YT_D[; \*/KN+4;<Z#[7IL3
M]S8+/(AU92C%)'N6IC(@S@&B%R!;$W13PZ1.]]50;&T>?S(RM 4BY36FM8=^
M3,.MZ*QY.QS:D#BX//_3Z*6;)U[_]5?#^F5';/\3Y;-.X>&-]*(T[.MQ#3D?
MB#=ZA(+K##OA?K!>7B(,?CQH]HJ :+KY[4[7!F]T:B.\CH"^R%=HOTFX#J-E
MJYVH+")7KW:C"C?T;2E_#[YQ?K&!.\QJ54[\"RGU][A-GFPA!B_.G%IE5I*:
ML7G,;5U:=1%Q&Y1W6;!5ET7ZYLES?ND>CLS=&J9#Y*.]^+.9.8GOZ%9O.QSW
MZY8OQJ11P(.X8O4*H87Y9:1+J3CV6\5NF LYZ[ 247;<8LBGBF9CJLT!=D'!
MTI;*U:V0[^NW,;%#<5U5H829DI96<&?1X$%QZZD[;UT17ZBJ@X2"?H&><BUD
M/VJ0OXR3OA EY1,BM,6I)]B&&E,3D*F;6H8PP'=-=6&G]#:>L2:NV0,)[6.N
M'OT*;HEA7P.[X7T:45Z#MCTN/)B%C1TU'&BXE74>LM<$3CH:3P-.\!4PT\ #
M,SJX5V^^.<'(D+*6(N>-1.0LG >)CH,BC@#_(*2!D2G+:*-+<9<I&$WSK5U]
MDR>?756]G,,<=OEY#XUZYM%($X\-4$P5+$T5BQ\I"<<-->E;ZHWN#'OML3OW
MJ>&0KSY!0K$'3D'O95A<HM"YWYL?L9V1JJG--[L 06">)((F"W3)*D\:C"2Y
MF->_AF->ML58XQTV[SZ^<%0);R(5 J%:[&M?0Q64D$T(;6!0I)<"Q:052='.
M!8!OO3JQ[-VMBRY?OZ*,!LE+S]-8I]*N-#GV5T@/W=X1MHJ'!B@Z*9^[ L"C
MMOP<)NOIR^!Q>=QJJ/(.W>B) J5S(M%SX#/+(:XB\P 83<N=DKJD3[<T_)#^
M\[.GL4>Z+KP_&/7.^>PIKX^F0/@]2-\%3X'A.M+\]2PC)T9GL5+ZHC'SLN=]
MR=JK8^-D]J''M./^*QL^8EK;2N3G;5ZWEI[)L,!OJOS*./C)]Z#I)U$*KDB]
M3+B4^1>*%LL;C%M'*1BF/2-;RW_/)FY&_"%T%&R1&+A+J\P>=$J%(T/+M?@"
M\PHXII-DG8(<-?U2@W5,.H:FJ2]]?CHT\6$@0YPHN(S]RO2 =8:5&T29Y!AM
M&;1]D'HRH0K.U ]RS%M;91'682:!*,7;<R_D0N4N]Z<X4 <,91<JC"$J%2/Z
M+\6);YXW/P*O!=D4V=X]KDAIN^1]WV"Z,'P(WHF"O(<IC[B(82^GV#>8'? 3
M_QI#3HS X5*U$]$#V<6F"'O^>?2T9YKLG(3V"!"C*V;)R^2_;?A;/:12L--C
M:4<>%5]S*OU!?$,N.HZDFBH)45"(X;KI)^'6Q$NBO"V$8.-.N$I';-6U!QXI
M/\2.ZF\ 3FN\YC!+1U_!%UQW^GR44R=YC5654+K7Y#:_YLC$]94G'[7BC$>8
M+W'.! K$1JLYQ!@TQEK.D;.NV,(*R0L-AUTZ.Y5'Q"'[8!:T<+]9"6'S^+C5
M,%DLW &1KDS'6/6H([NG&TB=<5M:2]Z]B1H9=?^N1O<5=FD[W*Y3+F%UDEF)
M73O#9.Z;A7"&!O_::P]\P_)R>6S_6?"ARTBISLAFO_U>(2%?2,O,^O$_^=##
MZCY-4_CH;?J7[Q-?JCZIAW@&>I\HA3+4*A'Q(^44#J6YL@(JUY<4/X 'M?_.
M2' <M1-S!<-5D\M.KQNC@<9O0+68DQNW#9R1T)T55<>'1UMG_U7(N#;(-WV$
M72SOZ9K:'U6GV!'9HW.8(:/A)/PL4*Z^CFN>FCP<*'XM7 ^<!"VR0?IW\"DP
M,_+_M??F7TV<X=]_+"HB8A0$!(34%14Q55DJ0J96$3'%N%39A%21-6)J 8D0
M$A$A+$):K:1"(2"R*$L4$J)L@01(+<7(+D'(5C<@9D8A3LTD//'S_0.^OSW/
M\\/SPYR3G#/)F7-?]_V^WJ^Y9ZX+LKW1@8&M%)>O??(,]&@T*D[UM0Y'"JLW
M90&5.^_2W#K\BMU)LQOB_N%:WMB4<>QC90L1 S)G/WVI!JPOZL"09$W,67&=
MX6^#*XPUGSE&=81+(&8O9HV1_$_*&QC*$OSQX0:NBR:K8QGLKR(NHX80ETS&
M)5M13AY?0&7>!A_-XR.Y@_.A#NA&C\K$1?/D;G-TKL!"< [(OOSE%0_G N,_
M W(@GQ4$<Q1Z6X.U_G6KTA4KE-85&IR;!A-+#KUSLSCVA_K]IEOXMFO6PQMO
M?A#*CN8>KE,OH/;0SV$F6K6W0<]92&<R#? (7:[8HS!!=_ =#04'*L@WWD%#
M(?!MB&6PDJV.I05F\B3YN&4C!DQL2-1OU;#J&/\WUWDZFGH*9MP/*2[>R^O#
M;W1;0$7I=X)O9ON4!%.#V%XS.V($U, >HK4WN19Q@ZHSY]%Y&.OY]H0?1Y O
MK_BN?1$GB!_CQ39HO/UJ8NVW3Q<56P#?#U4)^,_=@N*YD[B]H^,A1(GL&OLA
M7<V_C_CHF5\:M$O9O4#3'7B_;L.TTTHHCC(D'\NE;2<!JPU8N$GQJMA/CG<,
M%';L $TS$M&,%J?TU V$FG I+!'S:>OS".E6^.<6+Z\]-VF$RXW1\H4T7<P<
MXVJI[W!&EH) !LX"B81!VE>PO05=%:"]I3L]G5(;_C+V\I0'85QT HZ(O4>0
MI]9.)+<6I )YR>&;PA:5C_X+*KLN+?XE:0&% L@"XV5R+]9B\@WK#!*,J;MQ
MOLWC=E!:%32!1XGNV#N0-FA81%@RDUR*&?/V^U(THG033%9(OHH9>,>_O#NN
MB)&5N( J\)+<. O.]V?.-Z2G7DET&X:Q)XRG'C2,V$BCF'<IV/WZZUST&LH^
M[1]#."".SN7)H?D%E-I4]T-L$:$[C[,NQF .#SSH B_VG0#/Q?P\Y4=>HF9T
MH_-"TMX.)$YZ#1T$Y_9X5$3.B?._;)?+G QNAN? R@YGJJ]Q)I@:(^9WU?"-
M<;6L=J=/V,I7"%:UN>N.(;Y@X:]#6^%D)6:I/UAQF,\\"AW*=Z-90]Y3Z_5W
MD=3*M-P7TUJ:4VQ#Q. %E,=[@;S6R=/) <*H[:J0):#/FUF\ LA-%E@DD7,2
MD%\\Z$X-<_V8;E57BJ;' BV/0/;1+:8QZ#F9Y96'VXJ5>G:>YH+K3LTLLFW[
MO5V$9[11@%^MME*QK[&;FYMT&ZB+!Y$$L$*; GZZ@9BJT'G)@$,2(<N(_#R"
MG92RWSV>=$S/1C;>-8+'EF(E$_[>U3W,Z_W,"8C83<\<PE,4;H?:/Q0E?:1_
MJ2*VD7H S L;1E;+B>/[#&9XR*63+[.=)SI]*24C4)N OQ#L# -3]J XU_OD
M)64_V7>4YM@#1H4!2B#7#=_:UP>LH#3,:)G@3QZ:2-?7Q2;O.DZ]J4>.ZK,$
M\<!B&*_EP<ZZ#3!#2V3*/ZG):4JF#:$>.3?<L0&.Z*$O]HY5<59**:F]>0KZ
M8J/^O,ESPV1/K1VI&)I]STUU/-E;BFH%7V91BL)^V?T'2L?4>L.Y6N)#[.P\
M=%+IE^/N<WR6'L7Y"I[H[7"!EE9<J9VQ%0YU-H=T\.OB6DK+W7NTE72O'I_^
M_I'ACV<FC_[SX?"'O<[* +)A>05$[L18>%OI\,@)/:O-7<$9/ZG:65L3(S!M
MBRY'XHN[!=8V)#UPL@6^5(^$P G&)3/V SAV#<%"2U4!0?%D(W [*T\WE7?5
M!+V<\;)HF/E#+=C?L8(F.4GQT^Z%K^BPU(,=0_/^<X2KG[%=DK5QX0ZE\]R^
M,3Y(#;<=T;CA\V8"//3U]W")H[LGQX-?6G_X9Q3R>"M^I<D#Y'\"S>B>+RWI
MC JX@,HVN.E+$YGC(OFA!TF ";(?C!) VV>4XAX?0&A_^;ZID+D<GE$8:N6.
M@)!M43[XGE,WUC.UZ3EM(Q+ /MT\5!3F*=):3?W.0VF!<8EAN3_4IXS.H9^_
M8G"C_6UP@ ^ $NW8<UZK($.J8=#<SR"^4&\&)R9\'=T*=QL"A+NI>T V8\[<
M(B* _X1]8+AMEXIM=\;?CF<8'7*[4E7H0&,9S/&J/ U#\)!^@^I/@DR[9>9U
M2C@'+!1WX]Q!%I/J#XJ#!JFN-? ;/!>R(ZZCX$- K4"A\T^\LS.BO7UHOMCL
M''^G+(9Y4<%18%^0E5'IY?2N/6ZU@C442R.)G2N_3Q?^=7/J8[>%;0YM')3.
M=/VV@!*N.@_.$9+YQTLN$G57W-8%+TV:Q'V->Z.CT?IIN_6U1@5M95ZG+1YM
MVU-&^H!\#\<J7PU[A^)JXRORT$M@P5%H9<7%R"\WFSZI61Z%OQPX?_<OX:<5
M>=[/#X:<0GUI(T?;:'A&<VJ"4VOH75L74"19+F9MQ[<EH>&$G XT2%0_@=YH
MF\'?@<5TA?E8)/0FV[ QEKZ&AJ7^--!A%P2GK)4/4_>JVG=0_,*:H1671ULN
M/_)N-/?066E1^B= [#ZR":V3C:;' NG:$'(F/0Z3]?$=9H4!ZP?Q@XPIZ>2/
M$"$#V9ZDRY/<,%B-M"VY]ZX#0[:.;>9[?HXJ+T..PCF4'G76(^OK0T<>TOJH
M)\&L<A4[$UCM;5IU)MB([UC0-!=QKIXD<M^=)=,Y%&-*/\Q[W)9*V;G39M E
M[]Y-15ES:63F&?&*@J\P$HG9ETTK-PNTP:RX*HS"[FSLUUGOK!*LGOK_!CY
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M]$6"Z"_;;U?9VLOP$&2K(&3-8_/85FU62<I)O/+V5#4X$0+^RU[%S<,7;XT
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MDJLF)&LR?G+&&X=E]C\H68[Y\J3 8BE<S8$_&FV^16(J1NK2S>8YJR,@6Z5
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M(@HF'WB>*+!HJ"C;PE1A5L<ZK1E(!-#!TXW3@3^_:SGHN:+4+%)W* Y82[]
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M57,/'8BL:&BE1V^>ZVDN#_WQSN^/__/_&O,'<%X";]W"T!VA.'1A5O,T\$G
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M -P;_;N,]Q, 0/L. "!U_5WV]YBX/_=X_H^BR^?G1202 -C, 0!NFP$ ]-T
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M^][]IY+S2@7@!<#%"Y<N7KYX[?K%"^<6G%<"+U[B>DXG?IE>21\>P\#(Q&V
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M%Y.3W5CE:G^0+8%Q.JU_V.P,]B?(MQCWL"2Q6VIVD._"0"V',2N!FH<?Y\\
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M?/\8(A>E3Z%:4(\X8_DO.T*X[YO=*0VA?"W HT1ZU3,]1-^7K"&.?.X%D<\
MY4PAP1L$Z^U[;'_8&S'8^C[XH_1.]V&^/E%L$</1%?&E[-?:L#+OG'BWQR>^
M.:D$-E]UG(<$RR]X%7-Y;4;@_<8\OZN6D3Y5N:7?OAC-X9^\B76P2KKZ@]/'
MDW-VX64I>+'$:\QS:N<JD%[^FP/DYAJHF+G3?N>E.M'1" ]\_LJ5GSC0Y>3E
M^%!9LZ/,NU3O2H);"0MG6;'^UN"J)]4K=+3T\6U^*R43E^.7P((@A*N0<$#V
MPKV3$5*%6V/M06KK,EDG%!VW8(:'YHVZ%KKTO7>_[U,W//L5K9?=00^Z%2X^
MBNC@Q78V(4MGK3L@FZ ^SU7/X]<Y:<??B&> F(VB^*6(4/_L')_&#R,3%K;=
M+ILB?H;&<-8%_BJXP8,9,<\=^888NC. (W.Y%H#HU.3:E.S8J93X)/O 6!G=
M1%>!%N!4-,IT.P/43&.M1V7W4E+DU9>N0D8],G@'B>;:&+2VBC8QKKLHRHQ(
M-Z^F;+C%.^1CX<-C4DAMV=4=V^0JFM*N*,Y,DXM*FW.^MS'N(4)[%__8(#-6
M@CSY<$"#9[B*4WD*W4# NK\2^^W1_>R(I^)CMQ;H*QUXXEB2?-B3^%I%@2W/
M]D6&5E\0NO>T-*HX$WSFV!MNA29>V4$L^K-CD',::($JH8I,7"S/2:B*WPRP
M1CS40%[K4K,\=)D)P3_-+S^2U5K4;2IO8H.;*^D;A[GL(@*(6#Z7H/XUC15Q
MIV9YM:_&)M:OEUSIT:^GS&/X;X@PO/_<[G[HBX)JY&6YVJE5,<W;62%5W4_B
M%0D[T6> >./@K?B/JP$:EHZ?I4GP*54S+^=H6VO!7;XR+C$NOJ^(&"P.)@&,
M6:>T=[688?PI+\+;<_*F ET'C]LU7?)ZKD&['A#),1QUDJ^M*IAQ>SJ=XD<9
M**?CP;WY (&B,?SW/PK1@T[XE)*VHT>3JH7/KY(M"VLBGQUJUB'AN,0(5-?G
MHRO.UJ@%.U:=#)-!-('#'F\6U?ZQ;6]VK$C=&P9=4PV(22#$W(FC?Q$V8C/O
MX&VBYRU&/_#8C,45J-C4J$^L(*6O3=C/XN?[PA6I)O 3]7/8V3E\5%KE*_ Q
MLVP"7BJ#355_4KECVJANR;9)XW>9U)7F_161V7)BH%!;?>_0,4"SL=IDR8I3
M/>T$Z&C&M*NBX^7$V[?6"I4@*"-2-L>G/B>@NEO(C+BYA-.'HTE&EG^4?_5+
M*N4QX-=Z07*B#86J.'\@HP6Z/"&@B':W01%;9GF(K(Z*=E^@*]6C5BLV6[8N
MMOCN%YL8$T=X45*B\XLT%56$U C0U5E_O3W8H+UH^MJ#5=J\"E;L:?S7E?WJ
MFXIW5M]QZQJP7Q.^:&7@&$/V<M3@44J[\C F0&M4(D6JM0R3+3%2-4E(90.]
MIQN[G==#;/LX@I\O0F4]]GF2=*^Q0D_&6:_:HM^Z%F/'W/J8(?X7SOV#89JY
M[4+7>][#+++!U*@21I7:*$)ML"SL"5"W,V2.8V3]FH$?-F NH[_(^,&%]4O$
M5/X6?&F,=P_I,+?0C3D.5T>\G-/^;F#G\[GR;?I^$(NS]KC6O4%9GI&+22'"
MO.KXN"#H.YD<'1@$ZB'6(?D@VL::=\>T$VU8V?$[X-'P?VEFQ+7%-.E+5^TD
MSD*A+-(H =V6V9S&/A6(\U?_ND_8TPL1\0S'GP%.O]N*C=7KC8HUJ=K9V:EK
M=+<TWC87_R"LE-,T'F=6.Y4BKFORN^3F7+TW&7_B,_6\!JE@VL:_:_I(:M+A
M^B<GF"%!W^P>'K;%L]97-^T53(?+XL5EAH61N+E_JBIF0*2E^M74  #NW__-
MJL>DC_3.".$2#^NH!)?".+EOX:(/< B63"HF['!;X7=]-U>!)>79Z7OA0HQ7
M,Z*=O>P/GG!V(16/EA5Y3.9CW!:J:$MYU(L&#O?#79+L9=HR&G@V16D)O#%'
M>M&<Q^^;.#"JQ9AQ0=;WR>I1K6A4-BK\NM*K!JQZ@W+0WH7<%N?E:=TDNW C
M1^X(.VJL:E-7.._ )-!;$N@]3HE?A&!0[,E+#GYKX:*BSL^3:"!2Z#JQW)JP
M@0>1EX.+;?0CAHNGXW74'R3H*OO;M<;B8'%RGO/;[SOX2OW$<I3%N+FYGK&T
MN969-OH" /:?_H?#5]T<(Y<2(= 1A8?[Y:'X'O5WQL)89TR7"AR.;\&J9WE#
MEAQ*F(Z\6'^[2=\;R_1U@[)2VJ<JQEW3?\T4-AYT@X<^]! _'B>S*!+]&;^X
M U7PV5H2,=M%1\[?X_$RG:LQ(YE=S&BRX='BH[R%]SI)?JJUH].,]C2>5-$-
MN7C;SB,<01.& 2:&9[-IO>"!C'?9@,@0"(3C9?R:XD5/O/N+_!FJ;]"FBO[3
M]R;UJ4O<XV> +;;E\"3;=!NA->67GX4.PL*"?K\F_7?N<B5 G^[PU^,0('G]
M#DF)J;'J#)"D< 8XO'4H*A[# XA,:NB/T-Q*'\RV!8Z@^2Q"NR<7[4;&[%VP
MTTX0R!0Q)C($"NM]80Z%ZKO8V5>QW*#Y6<3OFJ3V9%42YELG9Y.:_L9I*G@K
MP(UTXC,K':4/A#>94MM;-5[XC,9J>$MB[7U>8BT=KR+H+*3A%9GD$W7K895)
M"XO![U)T2)>95];Z?L \)=;K9P"KA@QZ/W6@5EP9$$P09@B[(:E"N++V8W_>
MON37>2-"&8IR5>A=OPT-;E8@6SM!5I5HD//$3?-5+T( >^C%O<G-S9PGGP(9
M>0:XT/'EW[V_&ISWPJ/353+2!%1)ZLLNW#>^:49X*Z7?ZLQ+6$B(V>!-4YG*
MC<I_'1SI9.GO<50^JS>N'"1!\ZY5P]!J)=R5=T2/V*BJMDRP;+=E?I4#S&[_
M(4TW0H;GKM'WS#[Z0=JZP[SUL713\?2-(FL?!>/::@(K)9%+I#IP6A5XC_NH
M,H4.(86PL.A=5SEU_7M]R3,*QE$]"_><=6WY^F!&[",OXMISF&GF$LD'=<'#
MBOXB(0(Z2YCN3"ZGCZ16J\"1NC*]71<[IE&U*',]@CB3R=-[)695<K>$FOH=
MG10[I8$EZ_5D6RYTR T^%ZF'?WX)Y6E"@21&;]HH:Y*XQ5;HA<(I.Q8V-L4]
M>X +H7_\:[!A6#7N+-@^ ]#YS!-NU;<6<, S5-_K79\M%&/3@C,M"N2QS+Z!
MX54S1*$[>FCTA>=\'9:)7K$W:OL:Y8FL:EQ^8&3-:G)-^FN0@M""45>LY?R2
M@1V,=WUI+5U_!1$&I>?L">J)+9(X ZA"O*<]A#^01A7XI1Q86FEVQF*87_]R
MIV3=&.\AK7$6!%XS!4PE2$-$ME$,\PH^;9NTWZ.NH0PRJTYJ'M_07N!O?:U.
MCL?#31W>AZ+Y[>KX8_D\9DKPC94QM4,*T/;2^^",&[V!L*91*ZW+15EF,]EA
MRX62&WXWS+#[Y[FSTXX/-V16)?T/W<K<X<6DM?]S"N2F,VRSW2IE302Z2H5/
M^]1R>\H-X N&_3/KMLZ&K_P:V=:S#?+7$\%/A.UZTR7R/2 '[XT \7.]56I5
M20HM96L]D?V.<TP?[>,;E4;5D[Q1,8TR5ZD^A*Z(*_5\(M2:WH"8&*8&V&R:
MM;-6P/*U$A%;SCZ7SHTVES?UO#'@TA0/&[;;OHL&O-.WS@"@JO^+O?>.:BO9
M^@7E;F><B$;$)@@0(# 28(*!!@N!$AB13&Y @,$$DXU);AL;,"()(3+8Y)R1
M" 9LDT3..;6))IN<87SGK5G7?>?=]\V:]:UY[\WZ]G^U3OUV[?KM?>KL.J?J
M5.0FE'>$ML_)\4NSNT2IQEW.B<Z<R0\58BLW$DPRXT5R!^+HWCV9Z8PBL"78
M!S<F!.#Q]9(,(=N:.<</6F8K!) 1\W?=CFP94=LK#SRJ9R1/7CDX,,R5R,G=
M"61H=.??<W4U))9II;V+//G:_U+4AG[L6K/-QU)"BIHDCHO3TOF J2"R^?KD
M]^AR^]Q/^VH+Y:]X%7>HW^!6 Q^;[I9)^\=:OG#BN]913GW$[L_X1LQ85JP7
M4II"3X>LX"PUB$R,VK@)?D(5@YSY%U?#+RZ/9;SPK'1!1"S[8;,\JE;'%2X.
M(B'SLIAV6D"S]*+ B+M1AA@#@6(ZA4=8'748E(ZM&:V)[OI!+/]L^UR^"XU-
ML%XK2]>3QJ99,8+-%0QV/QYR/YPIV.=3W@FBD]UP9D\WK\!4U50XA+:?!9H?
M-,<MZ"O]-JV/O]6:EV4<](:3Z'6YS5@Y91[MEL+("R%4A_R:E.KZ5,\X.,C#
M<4"MX*9\:4(LN"!D 6Z=1;96I1RO41:I93GDF5_<574^]]_WH)7#,%""A('
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MU)^\G_*)MC28C46?W6H*6]#F"/&[1:W:U/)&NS+\QC_OC(7KC !^%?Y/39L
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M7$SD!CA1-1WK63/B/5)03I[^,H'!]%H>&G32%ULYIYL_@J..D-^(!$.N@UQ
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M9GV@*.;RZ$_8G_W#Y9=2]7_ZUO+&.2#!_QQPHWY!_?!FF+XUQU'%P;-I:LM
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M@WW)N"S?D^IK/8#UWYX4B]Z]F[B;*?6F5Z<C(NIAWV_#T(9"_@Y"*TI%O8-
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MUK%<)-TU\?_._W,REJ>/1*X<=?]XYDR9A[S_>S'\.7*U^M],VOXWD^NF!>>
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M)4(50AQS)3[G;FYU_"7 ^0[IEE:0([L-?!466O.&=_ 24/I#==X!G]\OC_%
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MU<1R+?F0G^<L?Q-QJ(;*9V8Q4XG<&9C ,N</*5H(YWCX!)1;6>;ALI[R+L;
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MYO_,@V^(;B#[WDP)(I5NL?O[0=E3YQ?UNUZ(%Y85A:;!VBMNZUJY3\VQB;T
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M5\\\Q!U,!':6V:R>TQD7Q(#CD#RTT).(':]CI(MO^?3@UQ1QZA27J&!8D7\
M664-_N[S,><Y68#E'<4]?_#%+(3H:M];S/4%.$(SX-)\2://Q-X2E4Y_Q,)_
M_(0CL",0__/FKC[Q1<JG ]N^*?BM>YM6_!\R+WA*B!P\EUFRTRM"^.+C;^E]
M(C(8T%GZC%V$/FZ[W>-U?V]&D(!:NY['H6!0K&AK_[K>]XP'@37GQZG-6.\
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MO&TB^IQWT0;4YY\E?Z'*@C/=8)U4^![&65X]E'1^C9/MGYD1'?-!&#;LD8:
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M[U]LA#\<]0+GFM \+9Z\)&:BEL6R5T,X."Z'B-<PU>23W7!>U_;@5,J/GKF
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MZX4&QM!9$0N,51=54\5?!6!F4S^3+N^>_.8MT&[Y((T4"&W0<.!G>NNLM$,
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MW&C]6I$VJ2^AV;+@KC[^,M^EL: Y1P84@<"7:TD5*/:@JMCF35HR%8]LN.$
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M!2+)AJ4PW82=_, \1-4JK2UU?<+2=_0+85*YD *O+3LW*HIG-NF=*I0I$!U
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M0+XDQC<IYWG)7>B+&PTPO$[[7P^9_<PM'IW],/%)8\V>@R< 7;4K?0\L71O
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M/:*Z63>T[/-[^+![8/=)3<<;:*& QP_;04ARL;^DD$7@1_*VM[EZ\1^4E_X
M?+[VV/3%V^TQWB7.UK?V-9B/%Y[7VW_;+!C.L!5O7;_V9EJDW]PS5#6= ,&Y
M,:9FR\3#^-YXFK##) ==A%-G'2*4&O0M#C4J]I,6])_5EZ3Q<")JW:FW,SSK
M_/O7GLRI?$7V$_80[4 N&M-?(S$%YV7[<!"D,QR8+48-,M+_&]SSQ*; @J/,
M;^;36:/GL@1;I%3XDM96(0P+W^SH#E,>KE'\=JE7<>#E'R!R@_O]?D]'6@T)
M*_:A,I6:&:NDLH<8$,]%F7?%$VYO^M0)H!?2/][B_UDT:U**Z'Z8*"-2/1+
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MU,6W7IYA+HD?BX@R=SBCG1V3V^&P'M_O<'?'T0>OE5<CPN29+>/;C*PM\AN
MVSP,%7]Y3TNR'V"?M=5'N?HF%53\Y._Q1&[%W,2H0;)B)9[_'N'[$\1Z4"]'
M!\)6/4H5#H$ J=+?1.7%=S+67XZPN84G$AU[_;L\ODR5/UNK</$Y74J &*P>
M[X2'C=B'0?]#/\$)%5.]KK>7/)IXI]P_WY4=,XEE=<D1+<7N%EOZ"QO-<'C7
MF\:RC^+\4/-^UP/0!/<&F+P3/MZ.'#0K76/EUC4$GQ!NPR_TU)[HM,^597 O
M.2.,JZ988)V86(K)QLSP!5I7Z3=. "-7)_?LZ*,)65-QLI6^&=H!1:=LH2!
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M\-7Y*>W4&H\>!7JS1 :58EZYFK*>RXL+SI@2=0M=0SI) %KK0IT*@M"EE<R
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M0!GJ'O(<:_X ET<+)-0P%27_"*/*L^8D9?GH)4?>  $%-" @E-A]Q*E(:2:
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M%?R36<.MS*:X7G5QRAVC*[Q603)C7XN:@<D_#._.E+]/XY\6U8-WIK*Y/I0
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M?IF2U*Y/U?&-I/\?#!+"N#G*>:)).9-TU."5-,8KCRZ&0#+4II_;.1PCUHD
MP!#$0!@\&'0J)/O@^/_]#.%"YK;;IW;-/&&[(#]AL\]:5?Y$[-T]UGLAFQKM
MW<94WQ3S32P42J"'.XO[(,%315L7<PRUF 2[PWJI;QGMS*&2T383#5IH-()0
M1_&O-?U:6=.TVB6/;GN[4?_BBI,(#Z99-FW0 QD>8$!^6K/P6:)6HB\S-Y]T
MM$Y*DK#GC4^[W,/1U[7IK6#ZHV6Y/*/1F8;8;.:0_Y%6PE7K_%PR'<RY\.X_
MCYLZ2K3PVO/89,G$&Q@87$C[I(8=,NGP5/V'2RO/[8[D[E9<,TZL_!5?.JN$
MLN?KNVV@60Y4KG![X/LB\>DQC*\9EUA2W"U3.2<S_BG0N5F?**.C$ZA:[GGF
M-G;+W^?*<J_M0_U4KV\^*5 9'$GE[WT13EFK-QGR9SAHERTPU_0\0ST63E,%
MR!;GT&D&\23LE_!U=I,R,8QLFR]NO7"U-.8KCL;RP$XZ*ND@,D4FKKT=8U1X
M_Q+76'9$D'E3H"QX42S9GYU.9*?I>?SW0CGP;<O9MC*RNW41UA_R2P]T#Y5(
M.5,J[3BNIOMQ60S#0YI3R+12H&\@TQ%37ESEC -&)MQ;)\;AEMY:^[+1T&=N
MQ].B_+#0_MN4[&^I9AIM3(7C&[;X>FQ;T,D6/;3Y5P9*QC9;?_PX5:;?'RPN
M@69#[] ,,A5C7XX;B6B1>3$BA&QD V[0$[FMR?90.I@W]OC3=Y[!AF6;/0N+
M\XY6XU\"\[RS _&6:%Z84]A<LS@>GBAKKY<%+7JC"C=J9*Y]3/WHQZR6@2.]
MXU/%!E_!.<%I!KB?H7^<TU__[#+11%AA=^U5R2X]DGS_5OE4P3XL^>[,^#VJ
MQ[;L)*ETUIAG:[!\\^)F,!8!8O 8$;^,-Y;;?,!DQ[9C'1!I4/#N3R!M"S4*
M8"%V]4<7O)!K<5[]61 A=@W/SD)91%]_Y:^"ABQ+DV.)IM(_K<7IGJ7R!X-D
M7R.YSC0;]P24*;]^C$J!<;7#B'B#IY:I..XM:'L*;@MDDW#$'WH8Q/P=2,*C
M0@JA,RS (.8H5&Z'I10H=%5CDM]"C^P:=D@,NQZHNXUAFTSV8)1T8HV)N'>*
M;"\,PM#19HJ&VJB]+.+8K*6Y78^5W>>:UQWIYY$A \+>Q_R*7\8A)_<S7:@,
M(T/.EUBLU/NUI'=K)MHW.*F0W.O-974Q5/-]+_.!Q])>!8H20[PH-.%F,\^<
M9XF0@J+XY-C0I!S-SU&\]RZJ7[*]G2!Y%CHISZKI:S 6YF:$WE3JBV8'W*.R
M(\BYE=V[H.&4YQOUZWM2%D^JPM;?\O,%YQC.WE[-#?'IL0MV<AYGZ4A('1SU
MH+G3[CK0^R"&5EJGNDU%Z$#Z&9B>@)WQ@9F%E"+OL'Y_5?\4?=[$N4;\1- 8
M%;@YF+'DA-K&&>0(>EL )$0-/#R0#9D'&F!Y/H2+3(V0BSSB5*45Z525(*A4
M87@SZ]\\)1;-]?"AV;<M_.WH5ZR1[XV@H\W*IA!"Q^72L1I_*5G072OD'#4U
M664S;!%V/Y=?WD-=<_O[H4DC%F:4.D!(I$H9WMLE)D<%\HPZN-]'C)9-=SUH
M&*SA&WRCRE0BJNS.S1&\E,ZY&MV>TC_/F]77Z8! JZ 6TEW7 *)_NEADNJV;
MZF,\(S?;ZH>6:4TC,5541.OJX?1*(X.%Y4B; ,=P4S637W[7G^%7BM/W2GX]
ML^*CJ3B#\AQIJ\I[EZQ(;L1!92%&;QA0W+(?1@_9>\TLD^W<9H[KE]-5 O*T
M.ME:_ 2OZJ"(Y?1@[]1Y0(:B6_G5*G+,GWO/;/J$.BMS+&R'.F:BNKO#!HT[
MFBI;:O&VJ<.D0!93$WY=,THNHW7/*G[N(&<T4A)Q/;&C"6S+-C<V_V_Z7UP6
M;X9\.(RS0PQTH7"H=U9_AI'0 A:Z2UE&3T5*!!8$\!2G)VVT?D9;2QN8:D0M
M6/"Z_?'/SS=I5S.R/VO%.H;^]=HNE&UWHOL=)':#8/;<< ) 1B_5V,,+D0'&
M5DDQ0>A:*QR;2HX@J-X])5H:XW$\1I=MOU!"@%8YO)Y'20M#Y?D,+_5/Z%V_
M6EGA;ML1]2UQ.2OH&(]FLN0-\E'W74G!!/@9E %"^.]Y=9T?PCOYL-R8^3;H
M9-].>;MACH?AT"K4"BI+)B#?3&/M][E#-?*9^/"/'.>\[TH6#GH=I0=?2#ES
MBA]:)$5:\PHNWT\[YH3IIM:"V#/(%8E4/0\/#X._(0T32R^"O0J09Z;/PIZ4
M/[5X\G!&:O+$0\>WC8C:AEZ%)1>/-3B%$$'%ADU&2G-_"JUY[1/3ATP_U<I?
M6+M0N(YS!N)&?PD("4-,1S):K(S0_.SZ_]G$K C@21FCN]T2.MA:W)=MS\4B
M"3?*PVU.YM=@+]R3>[-$=4Z%-C?J(#[V!WJ.^!<Z=P$R>6]#U'279NVX?+C8
M7Y+3"-4\$DS0VFU?3R.]6*#7[$#9B[3F3[\B 9\$#JFM$^KXW<=HM<.2NN^
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MZ?Q(,_;\Y,";2U22<^CX2DB7ES']D"J\D*$7S;UG\6)49?J]"'V7#;EGBF,
MW#^:DQ@=D5">J 6=E%2H=F<<C]%8XE@R^O0N7V_>[O6?MS6%1YL>Y51W.#J[
M>0F/'XZ W?LD9AX8Q0^%Q=W9=*<TZ[MVC8U-8BK.Q)T.5OM(IY19YH.&O=Q7
M!P$PJ:KCUT6C_GW:'3(>6?Z&0A \)T)1HOF6E5H6>&$TIC']3X8"#$J_2@F
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M0$.R>2?P[":^"UU( !#8]GD1>'+C[_]U!?^UT_^__N_HQN_%_P902P,$%
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MV$SH[.KNZ>W[W/]E;'QB<FIZ9G:.3%G^_N/GRJ_5-?KO[3\[C%W@[]Y_<!T
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MP :X[8!3T\DJY]?_ 1#GPG,[\/-=+H!L=_J19^06[0D#,]RJ!,\SVZR!:%R
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MAW'.F)PB+AL?E4>K)7YM>!Q@KXPDF;I,G#A[4W9T0_6;V3_,QHN6)G/)D.O
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M92ZQY9@RV][C7R8?7>Q\P$&EP+Y2."[30M'%.7JZIN$67F=9?\[5 9&U-SN
M_/UOK].WRMX<Z_32+8WPV>UUZ/7!WJ$+GC@MJV+YL;_UC$OL!")7]B5":B$;
MJ]7(>K),O#S=MHE6V:DW.?TRA-CX:U$Y]0YA),:J:GZ=.Y;AOKG'[SD-_T3X
MSWZK[P7$&/PSIKU>ET9:P<P;G"_8TRBW\&6;< :"OI#9%-MJ6KF 7WD1*A.+
MUJV%AW]Z# NNNY"S.3:)T*K5U.R7#^/]V?)9?/[K/N@^:?X0XR$ 80J@AZ:D
M-8 FLKYAL D )O-IWJ(-XE8G4)8$7&.">(9UJEEM2M2LQO;)%^<$3NI1?0\_
MB99D\-%J$EOM*<-<ZJ^EU\1JM$J6<487]<?G.^;4ZZ%!WC4=M,I/+GSOD1+P
M^T./2A:7;SW="K4<O]\<MZ?KO0TZ7], .[.V_3B8LSJT#^IF5"[]G%H<QN;,
M^=>,7/@-X=OX&]$LVO"CJ6.#,TG8_CVWM[C>O&=L)N1Z?$[(W@ST?].$N[Q8
M&@"TW/,;:<WX%(L7$QVA^<US<1$ 7R.T$#YF)H$-![_NH3+LM%Z"#>I:]&L5
M_LW(V?0OR?70:9-Z/A95Q'8>TK4!0FE,\[S !LQ!I*XUP=P5G*?;):'P<FW]
M576]^TR/;%W<W2HQ@8R8R["ZU;%$)7C;/+IZ*=U#ODWK*O8,4J6C_7*<)$84
M '<9J30U^L*0!E;O5MTW+FIZ!YN*E$-#TC3AGCW"5G.7;7E4.;RTT*E4.'F]
MYC@0L'*M?IYA<RJ:%YQK@9_?10^66 5,W8)S9)1Y^AZZ@LU$(P/^A+MO,*N_
MJK9H?%Q19\F05=CGAZ^UTYKB-;34##JG)-06$TKN0'74 JM>:>?G:E?.SHL)
MS)Z[V!FG[>LT=_RHL2L01-ON%IW:*VE;,CX"B\PK*)@+T/M_6'O/H*;:\%\W
M5J0+TJO2.XH4I2H(" B1+EU 2HB ]"@A*+VC5 U-Z0$"" D1"$$(14!$0I-0
M$P2D)R@0)<#F_9\S9\[^N&?VS%I?5YX\^<U]7??,L^YTQO_1,?TWX?GP#;)C
M;BMMZG*=;TV2^!O]FOB'@+/MFC+MV__VHB(._QTP*PU5&8X%MK__LG3_C5@R
MYZTEV_M+Z?IB8B^Y.;@NV#X$G%X P WGJ60H^V(G?S^+[G5*8CS=GA4'3<*:
MO0=I;CY[\O.O;(VCBX*#=M&KX.=JXY8FZFB+D3;^Q/<0'SR,ZZ/+S>YCD>]T
MC<I:'A>].X2GJI'<'@"%%GA8!^I,$H!3_!M@!1=R5'NL1 ^FJ2W.,?<LG#N^
M.$</'Q=T\L5:DXZT+-4=,PI(-*2C,6YLT1"D'% <7/-QT5@HR)1P7>'ED:6A
MS9.<G INU>*/V>'YM>9ZK=DR&%Z^@2[BH*7I^ERV^7/_C_1CN@]MZC  ]N.T
M$NTUO!2]%.TQ<@7*,083'Q))I#*313..>RM ;5ZOVC-<+/V)TY82H"P6H/9A
M?462&I9IY]FE(^@17!?@&]V\LWE .5@TQ8I<;:24)%P=W7N^XU\*GW+J+&)I
M&^YIR1;OF9S"9,WJ32\;6PK&^>,;OH_;3<C_[K*.$S>%Y^LI.!>$-*4ORZK/
M934Y*3Y8&_V975@EEQWT$)MC96E!_YAF9:)1VS$39<$Y1@K$RS/71LZP)[J>
M;^I Y4JCVU&4S,2M>F15<JRQ6D>/Y@LSEH^-+%E&Z[\^<S\V J/:T&A<2_&W
M?2+SD-G;8N8"IVK/3RV?$@SE)6YVR6&M>L6R&H12O@S>?WRW%VCX>":R90L]
M76/R- NW;R*4F7@L"F'N#G89(KF=AQC@5=;/Q--QHI3)]#*3%Z([J9BQ.B3\
MIP:5,35A!]Y>1C/N+A;^A,523@ )VCH?7-8%80MA9;_: MX%17TL&MO*GG:Z
MJ_AM*LO8[78)6*NQRUOZ0VDJ)K)E!]?@Y _;/\W=]G4U=B:(F_VXPIZ_/?[%
MQ:H:T';6(S_'A,PJUW4>%:.NLJQONRM$IU2?])=/?)\8&0$0Y\\YP!OP)8EM
M6W^(Q9A%X,4-@=R^!92?0$/\'W/]?U$I'-H;[>W\]9(_4JK;?_K7G$T#7 BW
ML8R86VMIN /2(42%N406EN/.4;3_Z70F5E%\XJ6^*ZR "\S9W-C6.'WW,6PN
MQ>2%!Y'J33$^( GO/!D>(Y7;"F;JYE<^PQ@H$S-NM) N'!?EZ'?WY$YD*23B
M/J%^?FY:>!%<P'Q+RM?E#7^IDN4[CI2L]QGU*4I;X/;P]I;V(Y)71^[AM% ]
M9O%T7^%KREB3Q1TF6LS^K3B.>3!,A*#F5+UHY_W(BGS\C6R;[/ NSH]T[N;E
M5HFW:& B[LR4!";?D:(7IY;LKUC6A,JVH4RF5IN ?7B@M681[4WO/K2D2@_%
MJ'R4LACG5YL:-9R'=ZA/K*T=*'^Z[3D=,1TXN^Q/9UY,-1?;P>_CV"C(EMAJ
MT^:%7WG'(H1K!&5O:WZ'^C\_-B<'5VRO=]N9?(BX*$.!&?:>FG8_?CA\P0(U
MI7UAL<-[RCA%1K7 W[Z;*%(66(%G^)<4^BM0P3MC4"9Z.2=\B-.8#K#W,>2-
MG%OH6*A:?N\0[M+B%"[O,.VP-MGX:&T_;Y+'[F.=^F3X,T,P.)")%<'%0Q$S
M8/$%, OYUKQ_#) ;YK+B_^(,U:&PSG_"2;=1]&*WH:;OILF"F:R^S>#DUM2B
M-E2>.:PUV)F\Z)7L.:(V]1+PF>_<2X8[.C*E!?[$K7;?^GV7UP[AM\$+YVCR
MEE/^=,MJB%[WU+$D*MT=1>7>2?Q3@ PG<GFL<>,:=,KA<3?*LC:$(IAJ>AH!
MO^WW3JL"+:+WQ5.X1HJJ,&\/_-Z(4#;(\3C?LP[4-, QQY7U:/VZ,[&]I^?M
M=*E"8N[5R0DNE[7:,?_P/YORBJ&..ZOKP0)Z^)TSD CC<:P.Z523(0;ZW]6R
M;TS\T1'%.ZJ_*UNO),_Y*[%55#HXW/6"^J#OM;R=NRN;-\?#.R<0?P7D>I%B
M$?]ACN9SCQ(1CPID74 .NM&B32G'V56_(A"0!"UT.\%?\5ICJU/U0,:R-R9(
MDS,KP3IEW;=TIWUB;GTOZDA_J&G4P1?ETL&NU4G!T*\5,TRA1F*+.4^?6Q>5
MM;YT]_O2F**V%@F<[O'P@Y-UXCU4O!5_H^%7ZIW?*J\.,B[ @B!3^]"CBFC?
M=GFWA&)-F@%%<#^:YE-#Z\3#Q&CM2(C<?G]/L20MWY]4Y*CHCQK670"./<UC
M%@XX)O0&*&$-Q/TX/N>?(2N,KNXEI!"XO<Q;<IP;PF1=4/_4D$7%M>^T="PY
M*ZN>S%BB"VUS''&(M:CP<+]?#2!_[EPDNI")1] ,XO_A(8"9BZ/.LOH< )!T
M$?"YGUOA3;^<ME6IF5"*U?V?MJ&A[@GV1A<<[B\BSG-T<?V3%S=('ST6ANI2
MMJO"D+3HS\6LW]$%JRIN?O_T$E3-;UICP[W#(VL/Y?F4ZH6+YH;,Y;.^?;5X
ME(TC*F5,.B; _]G!_X4C]TDU/W32FZ?]#*PY6>_[\2 Y8JB!/03D^JSQU38'
M"8?8Q,>AOZK"]_PQ\^0F)XE,F<Q%C<\_RDT\:#<HI;<]P[)NB]/"2.>S-/3Y
MA85#GPVN_S?BQ>;EW?/VE=./ID&3U.FU_? 6GM?5C_R?(DEH3++Q&<^8\QD2
M#V^=L3FS9E?]81 8OE ;^/M\UK3DKRPFF=+7W2DR[\_^_VXVL O%)Y9NJ7 %
M4M -$Z!R37Y$V1$VVGCR:X<"K]P(SV!48W9*3% /=LA2J7F4)RZM%GL"8$HE
MZ1U=84\LH1E" D\ N;F_0JU7LHCFT(6]T:CNTWH(0T2[< RNZ9ZG&+W$U'Z
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MFDSI]F0[)J#DF8/KOOW.U Y3;:2G%\)QV+-ZFK@P[5R5'^03&<@]@>Q^HCZ
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MGVL8][S/C4^-'>"4*'U%)'"GX#RX[8DKQ\?1*BKK5%+\>/#:#=^\?62D;G4
M2>7>?A!1W%EU-,]-@8>_U*:FJT(S[.HR!:%O&3BJVM V\\G]MU G3XVVDA9#
MLDW9L"V)JBHO9SGQVR9T5?+2M,9S!]]#86YNZL?3[B >]O]V!]-"HK1BC1.
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MNF,!5-2KJ?;@MG@.]!U4J>*6W"KS,3?ES J0VXV ;4UDON_K3ZI94I'[I)&
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M5+$,JC5%-Z_P@Y=?1K;-^AY?&U-<'4M/J'H6C_1JS150?:U* DAU8/;-QD\
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M-&+P4R=CI5>V&=5?=%NO,ZKBM,3\#9QGS/GYB66+1ZY?=^\M,Y''%SB\+US
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MDB<:^\5*5 ^>XD-NK=%-Z73L[+/Z22L?POAX/$V[(MI4'-&,FRT\NA5I1>0
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MK\NWOD!-_=UQ)0"5;DI+B<O6T'97B4S)?.>E9#R0TE@JWS,C]\[-/TQN.&-
M)WM'E=+187;M7=5XN*?T<X:_J?ZHJM9Z:'UM,^CWA>IT@N<Z1='E\#WK%.VM
M 92Z+'T:8<$$S[1$4'/:6WC,FZ&'"D,=4M)9#J9;S5WVUYV61&IO10!N^J8_
ME*!FOOC)'F["=8#Y$/R,^13@668Q<5*( 7O! E7#*>93@G X,\]R6 O)"X]P
M(FE@O#X?6%1GA7SLAOJ]GGQ[#W=*1@GQ+3'XUZ<(72]U+TEW4GU=4\M0$Z1D
MRTNY@T@Q7C.H<L 6Y%7H.Z,K*</[YY-8F<SCM&JF$JJS\,^I,T #7Y!HU#%P
MWPR,#]*JA@1 P6?6M^ !_C U^;>88,;9_'+W7DCPX%\VJG5';Y_85/CM1&OE
M81[!M\5G)XT9PCC=C8%'74 $,(,JF6E4<BI"^^.,$X:.>K5U /$<VKYU[IJD
M^>W&=',+%Y+"XXADA0TYKV?M;@L]%R>WY#ZHFS;4[TE21FZ@H!7N"M5EJY<O
MN5R?=:M+,PC_\"W=UJ$U5:?:_PDEE-1%WG*<\?D"2BRDW]=(G=0^+$'(>C'J
MINOS@@Z +/>15E%5#Y;<.Q=F6:3"((4!>YP]Y12^M:#^C<8S>C&]K?&-\%_'
M0="H+FF,;F(4""[=J3QSR/,'?:I]/19T+H0#B.4 !();SB^N!]LS%.,G>"<6
M'=4_#3I/N?0='S9[]NC\WI,P94#Y;;LAQ(\<#0U=5?\."T61H91@"-I^92OT
MI$,*A6NTKJYJND..+";=SZ;./;\:7>T=&6$490P_2DM;;:95CPG.Q*]0PQC)
M5#-?+LDVD*1*BW1\4FRK-]W68L8634TLD&)S'-4D?!W!GNF+/8_V9+*O?39_
M0V)ST?0"P0\LRAX"8?B_(M.FSK5*^H'I);^PT5/$U@OTJS]"0 (+D_)QE/6V
M5ITT&_'4'[C:7#$8K? /WY07OV+?DGTG;(@]*E8%>;,H<;2BZD9_3E;IW[BY
M-%?5BAH51H!J>M'<N_*R8?\^WDWPY*+/W,I*VK"?ZD;OSFLF[L#-B?V3 SB#
M])GZDR# EEC<![6#3OL!-4G!_]CD%<2>&,;_1HT\05$#SKNW#A,PZ,XB[6J!
M4Y=J:YW2[UW.]'Q^UXEXX,9R.:P&BK)_2-?Y$ EQ4X+<CJ+$#HL,;E7 ]2AJ
M0=2O)!A+^Q/<Y"M)O+.NPCS\L#P IH9--3:/QV*<OM;&W4VHVXOXRRD<:-1O
MH9<Y:Z\P&R)6-G'8Y>/;C1Z:#8UP"QF<WU71/M69!S'^;E/KUKKS:2,I#)OG
MZ#JV;9G$=*7&@'"B\=Q*)4L$B;!LIT$)A*,:K>+0ILX/M'Y>ICCHE/NB!S#9
MN0X[@%'T'EXKR[T97!,><<D)4;\I:S/=]7*&4*_1T4_II1:N7CC01X"8M@Q%
M*BE^FD"YWJ&W'J/5##K',M!CHZCFA%-,2VZQQ?*B30XLQPZ,U6S6G*/ZC[25
MD73LY.M_??.]:7%;6[E^>J[DW3M_H?$<8HA<T42N:W@%SMGX;("P<-E[VG!X
MM4(Z4C@WP-3=<"H#9+-0_1UYAA5P6,0^RQ[@!@-XA#W@4DCD *1]P1(8@@"!
M.)7@<6I@#:$1 :.!><=236SH:UCJJ'=3BLEA[G*@_\>O-Y/NZP!'[ZB!9D!=
M:1393C#&H?% /:JW%J%+[T\TN# M*=@EI<^,9^B,W1_9.I1@GS?M]75QR**B
M#;H"*[K#?81JW<9+BE0O+\@1:Z,C+@3)PS<:-C<G-I3 .6^;P:81];-SK=G#
M412=@$$;V_N_:N?G(::J'I2.R=W9>AS("+J)VQDX+ +YPEZRKS"M2Q$*=)VW
M_"^TI:59&D.M<BP+AH&U!Z0/!9_OTID4X@!BKK=1?'.5RQA'*=COQ9'E-S<P
MS4$//$T+J%F1BCL09NJ!N5_!#>8'>O'.*[KERQ.E]/W^MJ97+QBN7T5V204\
MS%@H3=]YK@$WY*]]3ETMQ%#DWI$EAR6/&U$#YT4WC[Z80=*M"4D>?(,&@M.P
M(^Y3X&[:1Z 6XARCDF+_*A[M]\R$FLK;M1_ZH6*I7[WP8="1L9_.E'[#+YJ)
MYV]TCPYIF^57M)V]5A[EWL+<Z%/L0SU>K^H/*4TL!_II9GJI1*PU>L%Q\(->
M<\P(:=EG^%"A*7RFOB&=)! 4=%'0L*7QS2/![V_J[IS*8M^+J3U^1Q;Q42+H
M*5]4))Q((ZRZT\/N,YUG-!)1U  T%90 %M22CG=9)\).4[@#_S73V< ^).)$
M:H4O4*;A$MXBY)%LM-6YT6[_8R([;\8GG7OEK.^9#(@@,5U$M7"LJQ7/A!_[
MRHC6>IQX6D?PYT&,Q=WN(&KO3:RK_@T[MUO':I9R.W;2(J"EBQMM.%%_ =_A
M\F-L#Y;.82GKMVH(&8R57E6E\45T< #"6V+:_><0&H<%6S!>>%DGD8K^?&"V
MN"^<FC69J88%2T\XOX%&5/M9)'AGWU-S4$J^WJ3U:Z^Q?$)5W5%D;CS#VGHL
M2[>B(+N67&SO9S)NG6>QE!N:9-J!4]O+SS5369V8<%F-FK%VIAB_U_97-!\Q
MPI->V@Y58G^#/KT6^$3#OZA19//%EUP!C1PE24DGA]2@)\$!_TJ=[P]K6UPW
M35+>=C<F_A$=\=<5:MY]/*XV"=J+VEA%/TJ?NS=HGI<(O"=SVRN+[320EQ39
M68RB6/CXAT7Z0 ,_]M 7Z6[NM\Z0ATPN9-][0GLSLE9Z[T76S MWTE6W/]_G
M,A79IV]2S:TNLB29@=,'RQ5C$F !]@_DJ:URC:U1RMC]SU#TG?OWJBL#!.?B
M-GI@ZG.46ST6YZ5&?KGDI(40SB-L#],,!&?^?,VR8%HSZCI;>1D8,[#W![5J
M8D0W!G9^%/.G%@69& RYLNT:[O@LKN">,_[GA#&]N/^X.FQO+\0_\]*W@OVR
M0S)EN3%F^=EWZ]F!"*W\K8!GIF@,1+]JQV?IT L)\T4@V^?-YJW]+R+;._OS
MW0WZ]IT.=_62PFW6:KAJ*VOCU[<[GIZ;/#.XU<B9J7@I58;P6N+,U"DP*(:M
MQ(QH$T2(_\!+ZR:KJQO((FD6BD1<@1P#ULX;3DUNTWN9[Z**'2I.6E[158.@
MW#[F0A!-!0J,M?*9,3#/N%^HN&0\2Y8#H-_OQFL_:E+(@I4>%EL-5B+"^=#?
M/_IS +\N59B+G3BPR=O=?39G"O2\3?P^D $Q=O5=R\_ YJ9N0>TH80,M3_08
M-H$NV%;*LO]0Z'*Q:54%86G[\<0R13)F:&P*ZF*1U8$1V=6]ZKZD$SKD.N8^
M'ID^2(.7O9524J\B#*!GWSC<K (%26@5JL%!JQ<8)AT>O]4Q_:FPW]3?BJ:R
M-5AW/S,CWR]1AOG#2IFA-[7R7=U'M@^2A1Z+IY#$O=.>7@G>S5:J6O=^H9!U
MZ?Q5UB0SOIKUD&EU<)O]([<K=?L?)UF3MM*BP0 9^AHN9+I755+?;D"[/[5N
M,4<5S;PWX;'X8VIQT$]WP*F7;[CX6WWML'$W^8'RCQ#AO?0FO&W++*13G>)"
MSHE8V*KU++>_1>E;A@#?X-U:7&M;DRA+0[Z'5<?.G92)_NW8Q6A^F>@;,J]N
M24*@FRI#.TG,TA#&=2?Z?!)0A:DXW8E[R) B$X&B3'-N)'47B^!3;<_,3PYB
M\Q5I;M=STF<Z],R!'U#R^3710[:J):TV-Z6:^,\A IFK- O1G3^9S?3-=@^!
M 18__:@+PSL11C^PHW\=K@;*F-)'Y?,Z'<73DA[CHY>)R5'^U:M;\D.5Z[\[
M^2LTJ\[_(1QQ:D*!5I71/&<^"9&/<M7'->&#_5N.CAFME)*M0G=>K8V3'58&
M<QY')8WHHTVL:B+NK<,J5WX1&D2RE4."^)HGW6L-BD@#WL'0Y)="S^Y=BC&(
ME0WCQ8JE?1<Z1+&5_,2GNM(2RBL6]AW;K%YP &<-I!FGI4^@XE;7\;=HW7@K
M>GUOQY"O:*M,[H[BH QV)*#(5YO7U37Q\2N(6FFB9^QCV%5F-ZBKAD;XF=,%
M$L3[4-60;9-RS.Z'- L3HHMB;(YQ ]T2I4CL%_5S<(G*JBA=[>M/7!'OB<B+
M2$;?IO3,>M7%V:4<EH[XW0BEV&1Z!F^-U._=W+,Q(]<YCJ@]R7M^BNR ]U1H
M3&^N=0BZ/S>YTQPZN$8IP8(\?*N["OG8DQZJ9"W"681#/3.>:FA#;/< #F%"
M#_.W^@'+84"%&KIW#>T&2_]$*<\KM>F,50^Y(9D"O@B;6KBHN<C U"W)@6MM
M8#+_/PYP=.&J'R0FOIW /[ZHMY9#)](<4Z*DX>9?7$ OR-8DR]AB9MGWMN5.
M,N[:5*J)W3!+^8/YQREDFS8$.KN,'/W[<>X%A6 [^K8@IM'STRM\[^0SZUEF
M",ET(J)^Q#2ZW39"V? BQO2@W&,?. %49Y@LVO_[M Q8CMT'$MI.2W#I2D0_
M9JY/6Z4T6>:7040UQR"3IYN8D3-IO$NXCQOF/A7,R-("BKN*[S&8__/O.!!$
M])SFDU33?<H!VZ :M$R:X0#NMG@I-9AVK*$'T(,1I@JXI3>5C\NJZIM=4;AW
MKE:_^B_]8Y6@JLN$/.4;(^Z(1$6>P\3$:IFO6]J.^2592B5Y/KY=#>J$99"3
M']2/8/7AMNWB?]U[0&A*DI.&1(G<F+6SWCK2L,Z\QR7U^V>ATLSK+1S S/;$
M1<%,3PW?'$W+\>I/A* WM'3_9X828%&?@$G"T-#VD206@<LXXL$<P/LY+DB^
MU)]B@TQ8<GH<P"&/=AKKPB0'P-A'6B,W&<AI#0X@791$W@"Q>#D [#:[H/"C
MD.-KA,O(=HLT-3-G_P1*/:,"2XY!^V^+#<BG\Z_RA=VKS4\RN_#8,8YV]XWK
M>L75\5-_TTB1L#L,<!)>-HR&E(;NV[6>IN\FRF18^FK@'3T_NB_A=G0#%ZJ/
MIR.+S;(#[Y'6CY4I??L9RO/*R28H33/=I=OE^WI.^KH1; ^>ZTCJ[SEH*C<U
MR6K^N!SB]:UD<!TC;=DU&/+6IW+1)78-A7*:&G,'^P[=@7T:NR,3_D2QX.3:
MA[A9D_U&J4FGV=.6MQO^YKF,3_[2U4?ZAO1C3H^MK(FR5?- =0O)S;T2,80'
M+_UI\SH< 'YQ3A(EG$>/(.;ZQ.*AC'B309L0;'R[E/1?+2/?R#G7Q]V88/-<
M&HTV1YTT]2YPA$@F\F;$VM\7.IMK5OIK_:2QJ7PQ?D8THKE".;0Y$OW)WO4I
MQKY4473=#RU1(8?=;+9P]0_>E31Q'-(JK$7Z3A)]855&^;D][=I]0R9R;6+V
M=ZX3LH1>_2YV.B;]1K\@A!%&[=BI\"IR85:U63C:-$;H\RHD[5RH6O-T#(OC
M!Y*TW@P(3/P9(&PN^ IZ?N\7@3E3_-/=:P6C 1B'ZCWQ =HL/:^O 1:&!;XD
M]@F7%1X+Q*F=MU 2._]N:!#=E<+EJ86.S3X9YLQP?YY8S#W^_1+2MJN2MF28
M[:UTX(_75A"4D<+1NS+Y=FG7:H=E,I[-#18:SL@_'L/8OW-?&X=]PK7\O#@;
M7-S+LC37&H/(_5K_AH::%R_./9?*F"D\":WU&X!(71J"E?S $RL2?&@=ES5/
MR6=-6(L?N]HC#A^EGM"5V"C#E##.)O,5Y'TT+W<U\JJT\O<O&__[VQOW<0_9
M;JC0DQX A*2[\7+US._WPS1?;IQHIKI#J=O8D?S5M;P*%XC4F722>:34Y)Q$
MN8'@AR512EG(HGR*B22;@#00OV-R*OU$39I]UN-QON?^Y,0JA#M]AA:05?43
MTN11,;UZ:>V\O[KK6TR#3]KO.(9.;(2/=H^17M^#/F]OFV*O=K6ZX">-C??3
MFF84E<RL+<KR3!LZ=VIAD]DDAP%HR&5/%XL>33/-I #2<\P[= 2F97A_HKE9
MU?E0U"BH@)_0.()0I4Z8,<PFP+Z4D+XOLCS?LTDZK]\L.:5'80?(^@[^AD/0
M-5W+1>T1Q=U8(>M[__KGIN-. >GAZS+WOU:6)BF?6NA3PSNJ./Z4ZSF+3!#'
M.E'"6#%8[O@_K., ABQ2G_SX+]/ ]@^;3.?Q+^Z<J,U6*E$LUJIGN)6#'V0H
MW63+^(UX0J8VSI,Y@.6=?@[ 0D?KM[K_BUGDXP^#4R/D7_/-F4#Y!F!49:VZ
MMO=(C/@)Q9]IS^N<N!KM;R(7@AY ^0_5ARN\_[G>65_Z) =0R8769U,<P.WL
MYN<T@W]YY[APM'L;MG>*^Q5Y>&K_0N7^CW][Y[API#+'NBO,W_LKOO=C55E*
M6I/(\%CB46G;G9BQ+6V_UM##(ICZ"L;P!%2U(MGT57%PG*OS+.YU\1V!QQJ"
MLL+R=EG?3]V_][?PQG^!M:7BN) /W\N**QQF6TF;[M^?_Q5KZ89'CRI&C"$S
M0/>5JGLY@/_ TRUDVYUJ#N!'D!,'\#5_G2M#T5%%',#\/T^*Y0#D?+:QK#0.
MX @'L!J)1*'^,=/*?9!39[D@>ZO/DP,X$49@1:7]9Z>11AQ /U=E_$E@WP/6
M$]YP -/@P^KJK:W#WXL(7-2E7N(&9>%F)7+Z^RZW/@W\UQX_$O:8!+HH!]#-
M\Y\ /<L!_.>#@_ZSPVWN+T&B;*[9>S+[%+8)!_ "N=/ZSP)1X>9N\F0G@9J(
M;Q2IF7G_^JMAI^MA?O8:L,1Q[K]X% K=7Q960_M]L\9=\C>C9ST1'F_,F_6O
M['WS,D[VAL+_O9EV_UTS_[?J&/!?0R7M"OZ;R]<UV&3R_O.H]];@'.[5ZV4.
M8.LB"43WB>  NA;^:Y?#8!8+S.3:_>OE,G1/FGV<2U/V.0 KJ^'3JAL< /N\
M))+],K>+?68=R3R4_L_^]I,Y@$)N^PW)>AWIC^3JA2^$ S!X<7'_A5$4]T;_
MF5S%_]'?_ZS#_.CJ7T@FUQ_0Y4-#D,6:>G%]Q-VG[9/NO$X],[R7< T-O<BZ
MVHFNB[^2ZL YZ.KE2KMZ;,4UX_%8K&J;_6?'9W.PK/HZ=>.S8BG3N6'_2T>!
M_H];L8[^O_&RQK_9^;\YIHJ7--A1&BRN;S=N_?]M0 F[;"SIWS#8.ZJY1_I!
M#<PG.UZE?)C_')Z).Y A_P)U6 G!<\>^2,D6C+6[K.('QBA"N7S@^TEVBC:U
M-C;WUH2'L^0M3_:D\Q\C$U-GUB5O4-A:#,\S%0_Q)I57QRLO6/)1+SC\EKE]
MYC<Q&7'VC?V[D:H;4\7K8EX795]-X\,$1_H:H'SM@5T/@RJ!SI:I!I:0/*]D
M7A7A6M9CU USE2P?>_L4%[38,T4>Y:AE*O(EG""H:1 0%M__>>_N56>L6Y73
M\Y_B#8UV65>D>$6655ZW_[!.=NHXSB,R5#;;M^X"&I(79GWG)N(7QOSAV4EU
M[J<,9VZR4T#4!_!-=CQ,%$DUK>3&Q3^*&QUAA;]!"\,^TLRL:<)>]S\";,H!
M)-I_(RS4?N$ZN5"  ^B;W^HP0EXGT#\;A', =W#)!'H)";FGD\9TDC+@ #Z,
M=4PQ;: @5IX)RRY/A@,HMGZ'I#E&<S-(D1LN$,T^2&/_RF<0TZ<=N1E^>,T:
M_&V==85?"OECE;;.4M8N9%M4D[@9I3A75PE%\N(?!J']*-G5@:)I53))D3;[
M2VQ?JI3D#[ES76KCM4UW)2?:_;X>;:[7;"\D(\[M^WAY: >R>?^DOSO^U]/#
M)][@MS,DK\3^SZ.Q*H&]3_L%5:SXS*^T?;?\9'G:K/;^\X9>3QK^=[JLQ!<W
MW02:'LLD]EOYCW;JU75><_6*N'<%*K4E99_Z15V4;[5Z-TIK#FA%UH71P&>=
M+'=P%':B5XB(02^TQ:%S$KX+Z&V]@#(5?/::^"PE^N1T4IU.38FK*92OLQQU
M2YMNZR5$)@V8PB_&WO%+4\%^"9712)<.E#F3X2'*"")*23-\$O#2T\@5M;/F
MZR)3_97P//O(RYWN5FP!\)G(5ZX-QS==L3TZI1%!98NM/KEB+MB>#V)B-+QI
M\:(+%K=Z*>R3\UC+_,NML0B-T]UR@8DLD$\Q7-"2K%6^%6ZV/O1S:=,B;,[E
M+XJS,=G[OA#RJ7'FXZ*]DCQ'O^Z%^=,0M,-&9GY!?5JNS^;XI^^:Z=;)=;5A
M$1\;,5L11JIC/AIKR]M!?GK//13>[9*@'TTOY.J?:'P!DXOQT2PM#]0WOOIL
M*=:8WT#\<X:1ZKV:WHNIO'M!*GK-1@HC2/7?2S(C4]#8/_TKT2GGK#KWXV)I
MS8;FYLSDD!*G28EFPDEF-MD#RBP>&82SI HDT[Z02#ZZ*;F=S09A<L3D8Z^6
M(I*S-A^J&UZG@E)7?C4F$T7%0\;#*!BV(L'JO(5AY6MFA?./;;L:AGU[Z,"U
MIMI7%/;<C97BIM\\_C;._AD'.)(OY;1I;.9@M@,U==ETG9I8#8!&D&8M8E2#
MS+.M YL'FI?RS R!([O,4,?F>[O)S9EUV,;FUX*2:#Q9\_A!ATQJZ8/66;L7
MZ[:R//:! UE./E5B1Z[OD;R;.0 90Q_V5Y<T=KJ%RSGDQWAV([=XO5=[$&#^
M#U;E\9;:OW?,%=D"8J>EX[__^]\5  '_7+;X2X,E5-35J5>XRL<!')NO8496
M0Z+$&%G]'>M)B>^A%%)F2(N&!5[JQ. H"C\8\UGB9VI3W[GDOC\,$O;VKB*Y
MK%:# MI19H2M'F4@J;L=R4@*J*.0/X\*+ 7BZ//$YR;1+/U*9SC,=3C8/%+0
M==AAG[TCD4<:>8C;+)!(: ]=E[UR]^,)'-'LZJ?2FTJEIY/6U$T;;3//UZ9@
M\%5KZ,>[HS,>FOFZ8BB%69['@X/74PK056]"ZUHHVQ[E14R-G;?U3"]&D GS
M#>/.UR@]AD/C-$'@)_S$;MLD;T;;-5]*WU3\MH2K(B%M%1>WC<1X8;.<S315
M:O\T/8%W99\*FN'GAW( M?S$*;[%02/^1+:4#GJ:D"!NV_9D6T+Z@N]^Z40K
MUG [Y8/Z0_9@L[,&>JY 2_?JM]J4N+Y(#J!HU /29)SW\.-2$-1Q)]1AAYS;
MTGYMK+_<C7B^A%S[]=2U._*]<5E%*9FWQ^Q>'T?8,O1W!.G(I"@9[DU%6H58
MILS4 P/$'PR+AK3V7 Z R&=,D51M%_UDFN9$8JE]-%)_\]'OB["IAK-LMM.,
M45#^M^_78XKU0L3CM3YHWR!.6)[J_'[-?,+/L<G1RE5_X9W\A=M/+=UJ,N4O
MF&WX66HV9>996@=B\^JL(@5ZV"/2F*G5HP=Z<-R7IF*6*M.]FG6)4=AI%4<X
MM94?M=S1U [4P34PV"6YP?MO!HH^I_<!VVHFFE3ZZW__?*7RPYC4-0[@N%(-
MXQ7JX [RZ\V5*&DH!1QGX!7$B* 5^8KO8$LE8>9#,)X7F'K(NM:'*R=V9 /J
M[E[>M.6_#(SZ0SJ,[K@BX-NJ1 ]+!1JRGC.Q!V90-H $;I<2Q#&V.W-*X> _
M2"-$9[\^JO_9DROJVY(W5"+CEF9_0</O6)PS"?TVA4&NV-+6*4>Y)("XGJS#
MO4X&2H/:(LTB8=3^N*W"X_ PIUKZ).[C0O:^%.XC>NU#!%_?IM_GL;U^OO9'
M^F%OLB_;'749RC\=5#9<].Z2LR5*;L][WJ*--ZM<UWLLXVE2F!]%=5;)(5/%
MW73S>V;Q6=\@H]O6F8>S/5FKOJ/=91FM39&B=$]BH;0!2*2><!$HQ]2E7<2=
M=]6)U8AAB4R>$P_VK50OQANWX$7C'%0&&I0\OXII[SE6^!(P(EPJ<ESGL'9J
M)YQ!?HD0I4'YH\%'JZK(G5&"2*%1:&6K4#X&K7?<O/<.ZAH^E01]U]VH",X,
M]P'5/U?+FLLK@=2+QZ%TL)$^7C#_\(KQ.Y+X_:QOUBH6$5?.92==4+^HA19Z
M7"1"*?E3=7HJ3KI&.A4H%37(ECLLA1$@::)PG!L#6Y]1"A\CADWRT"<+RYC)
MQ$G)FI8:^ES2;CVNUFW4I 0];*,V+'"A2GSDV/M3$A<&RL6:!C/*WI4_ZU3/
MIRHK#V4URHH*Y;X<*5W7.L"6NCQ++Q8KQXHGV>2 6H1[E5B6COXW@V%W=P>
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MZIN3D-N^?"L63^K:+V]F\%\VS:CC&5_A !Z!I;ENOM!Z"O& 67Y@#2?28CB
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MQC8>0";L+/Y[5(4)*]!"&651B%%R5;!JR[=)V(U5NX3T'3J@5&UO+X$JH\G
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MR3MM+]&J/HQPL"^EE]S1%LI$\FNUD20 PU6 I#R"7?S'P54,WT+VK6&'H88
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MU2D?[RG_%9]OJ2.EICXEJPFI6,>$'TL$_3B2$^%B-I#RQ),GOKJ7:5Z!__)
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M]_^%N/<.:T+9^D;CMHN(HHBB@")%NDJ3+B)@0(I($4) 4800DT@/79$B74%
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M2N2PX"1\WXS)%H!GC3;$X;J'LF5J4=9"*,F2[L**;-F!2]H%VG43W@R6_!8
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M[8BHU95A79>.KM50S,F:AS\U&!, J&5,. @/TQR;2RE2;_Y$A7B.K0TR/,O
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MM%R*NK6YA))F,-4HU&.*7'<74A2.>_5&([[D5AQQRC/6*\ZJHISR\FB,#:$
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M05DKA@0C>$8'W.17[N= /5I#B#TBF5:/S@O0=AZ5+9YK6O1._4(]T)CM<M-
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ML+D;'O/PA&_7?QBH_U\UK4(LSM6U9+ED3B8B+WW$M-+"XA[XVI4/ARP :!
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M>6)(!>>C85F!F+,\P0(M)B#SP_LT@"W0U\#3=C1>NNPGC@+S^T?FM<F)1I0
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M[YUMG1OL_8ASU(U(+8^"6:>6.K%^#C^\A%T_N9,\58U$$>C3?82 J1(8H[T
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M7A*NDAGH^RGN\V:.*'YT#6@Q=:QJK,A]!8%]-"60F/:(WF/C0/#>Q&,?HZ%
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M\-D/9N&2.9?^I-80"$1OTGF"JU'N:$(41'$Y2&7VXY\!O>"H?T(5D'K_KWX
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MZ$?VH?M5'UF'GF=:+?SJYINK046(L=#]7B.^[EYBQV$]NM3.U)=AO^^\OLN
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M#^ D^S-D[_2YE4PO?WM[]>Z6C>FQ2^/U38["O62IG!'7%!4S Q?W/B-'/]N
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M/@BG4Y,JE UC7P][O7=+LW#H.5I2!CC2!SCRF>7S)R&/.@8 %<T ;&RC:)8
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MC!M&5^+#%GMDN;',5T,^C#,B7K^.F"EFIX BY_3S2DQ9)&H\*L25;H#$&XQ
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MU*OT#HSB-!QE0O56;BP?4D)Q><B\90#</:IK[FXH?IJUKP+5?5L'FHTJ&"A
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MQCG\1!N#JDES)UA!MA#1QI\9]3"_^[1PIN994KSHI]D.5'5F9;DU].9F(N@
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M,FP;+EJFA/2Y^N!FQ4CIPVKW56+,9)?763,0WQ'I6UU:_21@9/9I"C+,JTD
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M]G DNQ*0'PYM%@0,:-SX@-"M&\%H0/*7A)YB*\;D_"?TRD<*4KCKI=W'1BM
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M\G8N]^O<(CH6E@(G &=^F[3C/^-7T^;PEY89@/,:]F3S5KN9>.65ANXU^[9
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M)+V'UZP)HZY?\1NOV7"?O%]?FB35L0[ /OQXS>!=45RM+_/^56;BX1>T!AE
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M<=/A:N*PZ"NKLU>D[=W[6A;'VXPD034.7,-!BI<FR];3>B!\&0AB8N9YCL!
M9\^G?+9S1!M\YG[Q0 @+K!_+A+ZDPD9P.,;X16 S9]F6FR5&E>SYN 7K<"C4
MS'M?:$1]6@Q$5%:%?:ST811R!?6"FLA*)RKKF2 A&-CG<=DD0B'%I4+%<D&:
M1K?C:&>[8 /Q:]=*IUVH]:VP07LAZ^8.W_N%7%!PM@NJ.0KH$FR%0QLV#Y*X
M8*QZ(QO.52,^6Q>69:S&O)]7 ^VG0#5X(ZKB"Z=U\K6T >]N*8U_R>$(82#J
MX&D/-E*.C$*ELPQYN DQ^UYUN*B7TWQ&#+8$!VB$=IN7]=G7%_*&K/1'0J8^
MBW\%R9QYX+JN^I+[.J$?VWNVOVV6Z4DSF_5*/2DB;XV#NO:Y1Y"5=S"-.SUG
M2:1O.)ZVD?Z17'ZMM>VW2A#5%*Y!1-N$T(ZAN^0.9\SI<)#&&<91^CDBB>"@
M_,BEL3G"!#=.Y*O) -O 6VS';Y6%%>ZGSA2Z^]16)^E,]JU.;V;(TVQT7#9^
M5V>:? !$3=877> K0S>FA$#$GH"$.LSG,MUE!AO$Y/G*MVKBJA<KHAW/*H'G
M9V/0]!^&?4KB5+7Q$>M@?UQ]?_L5C2MZM7B_#Z6PK[Q#FZY:C!<@F)'2<L&[
M:+'2]T6"T1U(O&-;F?^^[QB)JG"=#,#+ZN$A%5_0G 19FQ$)9(.R; L]6$;E
M8O,@<@I.LSIDKP K.0XT=?LP_&@X+^J5Z86%F\^CC]8P!YUTKV:9^<?>X\[%
M^S@R&F%&PPW<:5SJ:G*,7F(X=,0+(HQKJU-+"S3\HO?YDH;N)M0\LJCL75%%
MT7VA]38>0S:)8-/#R[>45!%K&3,?<_6_O8_1Q?UT@00:HQJSAT3$]*;T7K%[
MS-[_W+B-;7LCI,YAEE5G+RCAVCV$'([1Z^J>'BW-2HN>]J@3+NDRUS60#FS?
M$2G)GW7U]44=3^1<#3(G\,Y7YX=\:U:IJ2*40>E:),ZN-C/A*R*:&>PG?Q"U
MALY%2SG2J7$7YMO\!#KP'ZV,/Y-*>U:3 V&<?B-^(TU8X^G]PN1&@N=\EFQ+
M!CJN\=1<_Z3K7V<(T?/^X;Y&41S],2C:*PZ$C5*"8NL,1S..&,*',XKX-9Q*
ME(!?;5,P>#%[9C5Y^=$J5G![Z4;SGN,D=.X.P?*@8PU_YR[TX@]WW++DVG7?
M*Q"5"L_3=E^="@I_A R6](@U1BG(I-*N:XGUH]WE':+[Y^$M$/4OWD3#:OQB
MJ.H+L<<P\:![U=TU.'MMV8GL#J!5F"_5",5WUI/ZP&I!C@M +_=4VR*^E=HM
MKS5VOBWQ$"!<>B8=;< YDJJ7"2G.+'<%B90(=;Y5G!;1ZIMY-H$, 06)$E1+
M;'6/':T)/?MPPE>L(P7.7UD@!&/A=#:$$BM+_%;,.G):\/ZG$=\B7U#Y?*8A
M(:I@]1F0D"%VD:?JYY0]?Q8JMY,W7RW( !<Q7]L^>YKX&,<:5A&B1!?."//'
M=%3/G=R9;[59GE&!7H4IMJ=ED*K?$QR-,ZC?N&7$AR&L6YW@Q6K*C1S$?-DL
M)M.,$UZ*9^ZL")T1PH4TS6_08<^^",3PT'0I<=\8LP6MSP\6UEB Q/8X@<MB
M%1OE;$HAFHUIN> \T7L3_)(=''3G0@9RJ(G!KEA."AP.TAB0YG2\: ,'P:(6
M \N$=^,4NT%HI,?<F!CR^-6GVWF)SRJE*Q\_9DPW?;\_:N:U_ZQ(W1+!SZYI
M9N*7NB'8Q1S,V6 YV5E5,)2 '"QJXC#4,[0:A3+]6L\ 20=OP9-5SL,8?+=B
M0VCQ:248H\D^>Z,O(?1CD =XP4XH/6A,A6M /$CKB=B>V#F-P60C5#V>USY.
MX(+#_BBIT_5J4T.51];Y$]K?[F-Q<,*MS1>V&,58V<8EM**YEDF"S4,?PK%'
MW0,.0/M6\-/OKV?X:_+ KLKM*>7Q40$0KK'2;G/]SX^:%/X>GLC)TC2E:?DS
M,FG!O]ZVN::FK(GQ>'-F9,0\>"P_LVD4!>*OG^GB+YN)^.MZE[>N[:2;!.5Y
M1T9885M]7SJTL"ENL:E8B5;F Y,D?:V7\#3GI:)ORN!S)":Z-L?#W2$*F0&=
MHVB)0_O'(.\A)>%2<#UM7T21?:]3N?O'G:_*Q9K7P5W FU57OUR:SZ!P.EJQ
M]V3  .JO8\(6Z83Q/(XW*+:/0S'1T=6;I67[1P@"6L133\[#-:#[P'\VL.0D
M9\UA,D"6*,03B=Y905!R#=&1!!((QJH,\*5A?3+@:SX%;#[K)TK5A)(!]\8J
MR( 7EH[SVG_(%ANW<W96><9/T"?VAS9>#^%+O] \$IMPJV#D-O2/PGAP[T-N
M4)AM03H9$*JC2LC8RR& (.=(866.9,#I4G1'PA\B*);"RXQ)Z TR8'6KNU.
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M*C]3< "%2E!Z_H4J24/E(SJ+0D!43VHK=E'$AM\3#YY$E,$'>,S)@*_!LV0
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M^9* S.MY?07E&9 )&T%?CYC1PYI-)A/-Q^[,<144558DS>["3Y2LQWK-FY#
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MX^QI[AA]F/H643T^8R&BP:"Q-JHNLTFNQII@0XOO^Q+A7-S-D'14%%#PUL;
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M&3PJ#?/*MK55UN45=EZ]TGLK-LV)=%%.5!UO78D*))K(: 6FT6BF?0>U U3
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MQ8+:;+^P EM+1D*90(0X%%J0.$$5-7.I=O0D\M[H O)%Z- 3\D:(+3K&%EH
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M.;ZO:EV@!#VL%O:T+-(.U9NEH2(1;17!& U2.H,\,1 (D%D- :/<\I'IX /
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M#31DQ2C% ?F^ TUHOJUHK%#4DQQ+'K[Y((CHX^,L^^.CPCZ\_,K!UU]H.QK
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MU.'"_1C41:)'+](BDFR"$E*780@[RC!6;'A+85Q!L)#E0C%B9NK8YH^-5NA
MR,>&0R"9> FS0[H*/-/,&_NC378I")&G'@3)#Q6@X:/'K>;RO-SJE/GJ4!_.
M#?N*-*6_R+=!L:+Q;-).U9MEF#[)DD^8DVWZJ6,-@<K;B@.:640<(!<C4HC^
MH)8? \B_:V>9]4GXT04AJ;;9,GGY>^=^;_/,-Y4G"Y[96M$/+9(_><IL("Z
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M=_X?NS8/'M%#^ )U59T"Q&)S/Z(*C (/(4W#ZR-DO)Z]YSU*,%*/4R5F\A1
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MSCHBYFB1=4#U-#N;J%D"JL$Q8PDB!P-WIQQ^'?CVK6NO"[YLJB8QYH5]76[
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MWCG#R$5IV2?A.PQ'2L)KHFZYE)I#KN73WN1C@.T]21[ZZ C#+L\7W^CW\UC
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MIPJ8W6@]VJB>Q#W/CCB*:RL*8<HO!)-PW4KU]]BM+I$O2,=[NC+$"QG/_L<
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M&K&>S/< IO 9P6GDKF!(T'%@*L22J11P6K[/+\S:]3GS=%7N?I 3L1=&R\]
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MO_Z0MG@KB35CZ$[=Y,H3H^ =<K%Z)S&3LZ7!#[8(?4+> WV7VGBW8C=A]GX
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M)^)DX;=1=@>.CY.=P;66RL3(JG.-S6G\9/C24U+E>/O7OC,%R_63\<O] 9_
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M\KV]TX]=UJ?B.%$H@51L-5L/Q$@<.ZGZ$(U[Z_WR'8P!J4Q2^AB8'^S"[!R
MPZ2]>EQ#+R7#+D3WU=""M/B"_(I3W-#-Y4;9LOZ=9P]+9)V60B+ H,&.DO>F
M/._&8;L>0K6+_3-2U:7^BN']NX=@UTJ"(&KZYJ$9'Y#WS8]KT534'QS4K<6:
MVOBF?<[PH!KJ$?U5X>R4_!+D*3NAR&.A7\"7Z*)3#T2T4:EX.55I3NDMXJD@
M5X,@*&E\'RHN"ZN-:"IU?3?B[=_W-3G2K"%VL';>G"G?>6#GQBK4#N5?= 3%
ME?S#6K6:4!*?1PWCY2HM&A0/E/KP;XIBS%Y(SP.('*&838Y;@=&\VPLL5S!4
M7)6F0@P?!!)R]$YI6TE/P6;66C+93.;P@W_TWP2?6E7K3[WU+<LVU^6D_NN*
M#^+O58VU]I^7--W[\PON&A4,I3^O-S*OJGO#Y(8DJ,2^]H:]=T]I^EI5D/T@
M_Y?0S8G.%:L.3L8*+W66(1U8<+E00>KA%F5D1-L?J4H6V#A-!#8,50[^PBF0
M3 O&G3VN7Q1/O$VVR/VP/ZH5]4CXNFFV5^Y/\A91:+:/P7#ESFND)FE5-RW/
MJ:JM9U4MS50;NI=807*6"#M7U;3AHT!3,IIAGQ320<)>&B [UG1>KOD\.16C
M7U(='-2)=+B1_I]*MLH\H5[$[$GY:6A?CVB^D6(!C2FW)**[%-BS30/7GO')
M[J+/V.L(36A@4++;^6K/:#<@/.OTY;WXCZ!C3P-2<W\XF<V)P%@H!^B;,/ID
M#>B._#2AU!F8KP9H8DX:RUW22^T,,1AIR*/BBGJXVD$?GH]&QA<@!_RF#5N"
M!!\J!5.O@HT>+YW*;].;LS5768PJF>B![JDN2*DF.ANU;2X:\^-DD3Y3[.SJ
MWDW94=\\HM=1?:#?9G^JX$5.3=WQZ?'I]E&;U"["F&<+Z<3]L;.9Z^#OD*/,
M N1GN+B!:!&JBZ.VMFN%^3$(XLLZ1S"'(E:JVK&9S0XI<ENHBKNB$O;%U!S,
M#BA'0M/'3[[Y&_+N,-V:[GR"#V/C$APJ$FH@<D1S6(=/<TGYWH_*0>'F5;5H
M1,XAB-?&IVZF$CP9.R+PC4U<*A(BM JUR*YBQ ;EA\95M?4L#?D9U9>-X'68
M-C='G(M7U?)0>G'8S6-<B==ORND)#]!:6'(JH>-NA%Y2U<J)038&=AV$M41"
M [(W2./B4[]#W3C'@H#X3,H^R'#"J\ O]>JT\!3X\ZV*EUD2O[D3KQX3[1(L
M;VN$[GX>Q[,7KZH)PMO'+155+NYRNT@GKR_?RIZ0MP&H[M.L&^'5D?S2G<.+
M"!2IIHNM/]@P]U.@RX.>&"(Z>9Y8NA0\^]*&.'=BZU_W#=54<>4E19\< Q2F
MK*J):CGJ-BK<1&1C&RC5<F*$?NDAR$JR\$.$$S'3Q8H\!^#:*>M3VCC:]C5C
M8S>!JRW 8$?IYN9AV/YRW/9^PI85C8$KZ:MJY\/Q_0MC>!&Q@Y>#?W6N&%AH
M59H4!H&<M.N<<)QI%&K;/T6:D7!T)=D$R@/D$O5<C,FW?XK]T2[NSTB!/_?7
M79OW:'H_M+OIS>__Q;QFO&6;P9>@)(#A&>S>C3D(5*7O9C4-X8^_ E%9#3A$
M,%2P?*Y)[T/%Y,$99&->];2N70%0QRSB[2F8_A+@\O$.RU=4.)<&Y$CXLU\!
M=]D]$)E)/@+$<+$F+CI/27RN$ZZ#LY,4>KPEV2;F7--0H8=3VI*B@/Y<.,J-
MT7ZGY"5LO^ZK9EW](ZIT5<W8'IU%-V8HU95]IIJ*3/:^28RQHA@;2=M(/@7R
M4LG18ANDRCHH!R.L@0==6 2:*=P".Z=_\_+L,*2UU[EU.ADKC?':>.>HD0"O
MCE(3A[K*-IH:;C1%ZMN)SU/N@%;5$@"]+E,#*!%$*[>4B7@"4[Z8D[/HZ8G0
M(Z'$_#O8,+0.V9::I7)[%;KKN8OS<!U4G=A$F\CHK87(5[TO(OC\C>.\_3GR
M.2E"Y?2:%-.QJ<(0#/10A-@@F"&83_(Q!T!:!ODPL:;<6N\OP17!2%F8R4K'
M@]9_[<O.Z%S->G3'3(\N7LBZZ?3I*;AUG*XU56H V G(KZ"7*!-2N-^;H89
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M^W^>NF6;06'4'96-EXGIH^'25*H:5<3P*<2JPQ>BI73!!A$U184G'\>_M?_
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MEAX<G+<GF#B+&>DL(^.BKK*JB,8#7-/W$J/G5P<O#UTO[3IT_W/PEA8Y1BG
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M.VDKL"C>EMS*AV/<D3>','LE<"0[J]>(_%AXBGFA<<@IT>,\W<?<J/:*YC[
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M>]&43-OI8K-V0&T0 A@N6@\/<4-DA/1&3I5O\=9 C]/@UZ3H4(J[C+$^D+@
M&Z:W[X487GU(A=#7)^+\Z(C_@[/SQ!+,EP/PU\P4FC450WU/L*+8JU!0DS(;
MN@O,M%'M-8]QTL=1O0K:"J*YOWZ'$<E+P\0ZCA?#(2)0TJ9%,D\TL?N=$NT$
M6MOFP9CUEVM?#<88NJ]XYY!%KBG;*&G#9R/8DNG-($'I 1E64H4X4\H>F8':
M4S>$QE"<0I+.-)J);M;KX%MB]JB<U'X ^A9V _D5Y4!T-Z2K+5YA^UX-8@Z6
MB3&6MW,G[QZYOFE@4*JI!M%3GJI=9$%K+:37CEBNWA,C"Z,DRO&96]Z)OP;V
MDZ:UF\AM2M49T#?S]QB-K>]S<$U1!3GMQ]GFPHLNEM5LBR^R>_(-MN>/?-/=
MKK-Z)> N:5,MP%:J44 #G84U)!/;@^!08&29OQ?)+IFR7_ZU[PF(+2PSWF^R
MNQE%_QDW&U IBTV(BPRV;A<A'7NVWD2@:*U.V,WJ(^#B"QOIKG;MO5:3?).8
MWA0"FSEM!N!/@KV9Q:,T,XC1QC?D.9"9;4'FS>"1D2?F0_-I7"=WES?67F=R
MQ)+IN3WN0@^K-V]P^W@8BJ?F$=6$<A"<ZX S".OXX8@U%!0/$E:18V6+KR]_
M[0R"0>4JU!C6A@OEEY#U6R1P+)*RHHY-6 N=F#DMY!ZY+,.;D7-]15=CP-NN
MG75F?YGZ>Q()/!Q<:P'IR0)SFLLH&*#^@<P+;@HUM6O=1=/1G ?!@YA@A?=O
MDP00G[[[</];;VU#U>A(N,7M5-NPKU$;(VO6D==4J)9K_RX0M5<RL@J8K7"C
M0&ABYA)V>Q,WPK.];\PW:,NO7I.Q00;T2XQ6"\LG^:M)__ *!:S([=79OQVW
M.K\4@%&7:SO1$DO<-?Y'#ZW!$3!70&/#.V@68LH?8#+%$8QMK0XY]R)7^@]O
M^8#6B.(+LM*FN&C92B<.KP_C44* + Z<J_%X]JFWHAM;L77H;U*]YT]<&X*!
MLXE>@"UZ"F)P8;Z:)]PHT+,=T8#.YOK)"%FX%3,S[$E6&M6B;I"ZCN(!93%3
M;4SHI^AG@ A)FV[4<%[ ET=148DTY$CI;+MEU8TYX:%R9:^7Y@%UZ1C/##HB
M3;27T=*J*': Q:4Z$-4ZO6IE30?CIO,([N@0!G>U8FS7]0>*EPU],9J04XQI
MDTN;&@;LSJ9FUO[ +M=DXZ[!TYCK8E"WM<LAM&S1,6APZ]"7_'8?^H4\-UW6
M^J.!NNGE>R?[GJ-?!<7K7PZ5'Y@OZJ([9>\BMKS+;>K:FMF"N%-LK*G$.DX2
M7O#5)K@.2U:')FBN"\&VZ+2"KZ;X#6SG"T^Q0*M#^%L22^?J!*]!V46S&F2U
M^F!)J$5\YD>!GGC4W^])C_D"#*D6*?>!G@QU+)"@-?!4;1NG6:AC 'O9UW;:
MQW-R1@?3A,R2I7&NZG(*UAFT$Q!GEHSQ;(#=R?(LE?5QA^A)>]SZ":TM:,XD
M!KM_*=_H>D[/K/GV-]I5)QQDQYJZ+&-9!U".]RT><U[Q@?Q&T)%?O+\_YC"S
MW61XS,9A ,GI=M.$"%R1G1R79-F#F6J*5W5K')S^L\=EZ(N;TG28GQOQS\_B
M79KT!=A5O"4%!24"Q';"<BYR\?'XX=<X 0$NQE>/]4,VA^N8^,NRZH0C@^P9
MX_$SERY^ZB8F+*^ON4-H"_;Z\&W9+__^BC"FM6Z.'BY"*+=!E65!9+E$?F$D
M?]I#%1DP0IX?"%B)"8Q$3!N!!Z^)3OO5B4-.WW'Z%E'T</=4\+9CK'>H#[KJ
M9J;['K2/:*U!+DAKH2&X,>!?E*C!&$0J=J>F*&3P9X^G["W5 F>HW4P>ZN$:
MR)KL-U>0HSIPJSF$)6-B1 ;G,BW>V3Z;=%;;G]0OGQC=H['5,1<<H$DM;C+:
M9I)I\)]P.A.>4R'W)FJ-\?"#SKQ[SGB+"9'X:P;+9V=YT5!$B.\ B_5-^;=Q
M^:O_/'Y\I^1O+9S:N@"K1;3 S2]""NE<"TL?LFH7^^1&/@X5S5\I&.SAI98'
ME7)CQQ^&N995TTK&?%WO!1QR]O8\]KQV( :SG]_TTO'D%9@Z4).._447-8>Q
MJ%'J:YT\&"K%I9,P2+"[TX(!QHNZ"!S]-GM&4BS/$+0I9(V.0 FZ3U,AMPL[
M>9;@UUO.@;CC6=[]I8.S1E?"_$D9$9RF\R_SCB9/H: =,YTD\2&$.$!Y5I./
M7?F1_ 6I+Q>E8']1'P(#10)$%M8(V@S".RP9@E<8V_*Q43C0VXZW#BNHOQN\
MG!UDQP?-FY]\^/")Z%K-J<YH,/[H3SC&CX8\E5::7(H^>):0'60,V<K<X7*/
MB8*A5VL:B+LYVW**JJ&<X]M$SM6F;2+7*JW)>^?$XU]>HEV+,QZ%S57MGC$.
M.<]M]&LV5="FQH%S2L;[:*:1F@C1GD S7N^=+]>,;5<JSO?/>AOZJIR&2(F/
M)^>7:W-988[X,$Q]0S!^H+K_^XBZ\$F!\X73.H[,DK#YTQ]52&T/827/ 6)U
M.I)S%:14WB[U=<BM5&TL5,?)^#EHB3G5Y$@I.>MTG]96?90I^WQ/'$Y;APNI
M1A\68KS!77,GS2-'Q^=)&4[T%UE^HI^5P>.ZJ4!T+,#$AX3^BZ]W:]_BEO&V
MJD]#'Q^IPR$T:"4796E_@5 *U$TMG'(:$CR#CDI:Z2>$F#V@?4?!HB%"]+03
M*VL683QA@^AG?YPE-N\2GDQ:[1<V]\-WRN[F NP*_Z- ECV7%(-;2MD",.D<
M.!UK!B*2U!9Q)*///9UTF60]01Q>[,#)]%)UUS=Q09='E\-B69.NMYJ&9N-^
M]: ]?6>XXJOZH,I8^Z9X)^0G0R0UBEIIJS]1'($5E5'5D(7@ALCU6]ZHT0#+
M\N=(KRR1>&)PBNOQL.N/@M1/)N*P>$YUH?B$0P__XY:T]2TX*[5!#?43;2W6
M4=N)J_/LE.1H]T-GRB>5B/IR]797>AL^:W0EF-].LH10,G0FU=2?LH.P47T,
MJ,E-?"2FG'Z/Q'BX%"H"FMWPJ36LX"%9\9L1SA:D-D=3&$/*I%DYHS+X;%(V
MG\C,P!G-\"RI.F"RUAJ,T_2^B# H>-ND+F%1[$68RX"PS685J)_F'!"04-FK
M"Y#D$_W8S;2V<Q$5VUDQB1C:Y?XGM2][J/<AN-)'4TQ=_TF-;@8LVAB&Y&LJ
MF4V67 )7N_&$,BYZU*I?'1?U)(C<OX-U_?K7QH'=W#-Q#\<MXD=+*[N?AL>G
M#OXGUL*"X7CB>]0\<RI A23B+ H5G15 <%L^TXQP)O :P?2$^'E28HS34+]I
MNR_6ROLXQCY*?ECXH%K8?F[L3V+8W5V2C);_P*A6%%>(H0I37]44TZXR,\6]
MBP9C"[!, KR&=HU)UVZ!&!&JG>I  '%+]X]J^R[J=O!&<QG$D,.SN!958;[B
MQ;XV:WH?"A[URIH1A^C' ORB419>RBSZG2[S<]H!VN+FAR^(ENDJYLT@-^@'
M:"$K9J@VJ#&0Z#%YKI6P#KM>^QIGKMT,9<E7\.73YG.=Q9A:D'>?)0Z/IR5O
M7FPX/4%=__Y,Q.^SJNRC7R\V99.J+O"):J_%EJN:VVJ_AV1;@26_A;GFR&/U
M/D!.]FBM;UQ3)]=12/<3*&AG4$+B4J__V0PY,A 3N*L_S"[O3;=?T\#F%_>^
M3$^;K&AZM?<GP60!=EGR$2=79DEI<&A.FI_JC$3):C(B92R](Z7>U=!BD;5J
M]+KR"IC-*95J @X.%!YB3N5]]WIR::2WG MFI34XUOVM*[FCAJ!D.E#E32X)
M@AQ5AZE]9[7O1G="=BI]LH5<^PC=PDBW6<<%F.V,].+] SR[<>PF*%O.-QWV
MG[#$Y6#7D^-%+?[K?+6(_NWL_L>O^.#2P/#3U9I7^,>X*]8(><R<>FVW-#"_
ME;1^PM6NH]E-N1W(8P%?.Z@V%[-'>F]3G*6%WK$>.:,[;8MW_JX^_C3L;ACZ
MSK)@%V;%IR-6]K6-FA$0KK30W-7N\E/CGNLD*&-9>#W-,'H#QE[JE; O!@'W
M? 2=O<:.X^[P3.,8;9HH-B^:JAXE&4W:G>G;'NGX^K>>F.AK<XPTOA'% (AM
ML3&&_( N@65(,M:&;'A R$5*=2,_!KZVN2];@,'#S%^'E(V[&/=L[=]66E05
MV;KJN,-MV].&EC#M->XBO1Z">B(3Y"RQ6VL09HC%6ZDF0^Y/J3V$.EK*F8B\
M-J&RA:XK6JL*!9:E#](,-D(,/R@+M.\2FS^_]V;R*KQ-=',X.<(6HZL'O=G:
M5<VZM-=.">_#A>-T?X$S4R(9(Y6'[O-MBQ^]7^X'#<L)-_G!N%3LC@$.,\N\
M?VSNN,(;'5CH]4*XFWT^8M=*Y+N*K6<?..M]IAUHI$WYJ7:.8]< ",$T>M&3
M%+5<_0M4@>Y</*/[I]&FLD(9/LMQPG*H$IWS\[\IPX]$A#.@.8=\+?:>L;/Z
M]F:KS<9SEOE3('#N(@<:O%JAW@]H/K.F-UR/P*);G6*/8+<&H%.JN"O?0RG(
M-P_60AZG7KS'?_2N4!FQB<Q?-JS4_]$LQXMU8&J@\J(<USPE:4T;LKEN4:I]
M8_Q54]J-'C*F&"WS;46D^9]B5:BW (R.%2"_BZ!/GCO6/$2)E?9:D!F$IOKF
ME_4#3D7;<?H?>LK"Y@ABGSD2(@"$=S$Y_.QH/+2+T3%"5#*A"H ?I,E16TA)
M5NI=4!10TCYO17'O4T>64]\0UF@=H,J3HNMK[L;SW('MK^2%&27>#I_$'O\$
M3<SYB%+"P^]0^RB'-<FT*[A,[>;WF'.*!=BMXG7@BB99,_P@\(Y)OAZCV;.;
MZR:+H\S QZB;:_LXV6YX\'INJ4F?_P?R,Y%??8#OO9X2XG&;%3\K&1\;I!>&
M\D'&D4(9(VU-KNK A^WY8/XIK[!';.A6N:=4!:>#'R?_$$1:&I+5&\K"M-;'
MIE(?ES&))CO6K$[1JX'P<EW4KU>CH#AYCV^W5@C:):D=:\)M3DRGCTX4N)=^
M?IU-2UTMW']A:J79F'-A2>A\")V=[7BP[_='0G:B99OH9/\44K#2H<KA5R^B
MUT4/QU\R5]H>>^^X1URRM9AXXO_Y@.[?0H*FC!T!5Q8 J*FWO*7@M+)2@5M!
M[NTT41_QWA;!LPYER59RG?^@.&_G1&ZI+Y=['Q6UUXN2.MO,O0R/#054-%S:
M&O:S)\XS"VOV@5PBIPE0F8X3#7D-"[#53HQTUPMI]U>O;2Y[5HQ-%IP>Z8YU
M8[I:"+O2'KI,KMP2'+,CU\ITTT;&5+/*(Y3/L6@SLM.E0+K:_1F9<'*0PS(=
M>S%NV=%3.O)S+Q0<R'M?LSVNBM\G=JNH"B)?H%[)'B1\6=&\5*#0;_/V[:B#
M]+V@4N#K67"P2N0R%[3J.<A/(V$"(B)U^ASQ!U[6G7C*^[<-U;3/7W8Z#.H"
M/N\9!YK6)>2WFAJJ'@6C*5;O5^'(K([YO&RP'H50^PHO0U&)4A;BPZ2O9?5<
M-L4CKNSB$1HZ]6C6ZL;;WE;^@5X5R$<_@J-^.6M$/4VF^>N6+]BMW SFW\*X
MR_CT!9AQ-2U\Y"A^HWHCY*="$>=]7@"V^$&U&8@Z[H=UTO8'V3U/[L+:#:B]
MJJJY!?>S1X9>R)I&CEPA$I]65TU=N:,W_Z^0NI7B-D0Y4P$A/,&9I%F"Y5C&
MUH+>Y)^2=6.QHSOZ;3/N;TO$"Y0-_1-#!E:-3[)CPDQ*]E:N/;;<:0&605C#
MH9E.\ SZN31I-;XS?MV?/=60%Q[T24V0)]KLN.C0/]%HQ%$WUC WGGQ3VSSR
MQ-[JES4'M_!U>"DM]@;@ NU&Z S0U$XSH'A8J-?YMC7:=4RCY+&WMT(D^3Y,
MH*QW0[BOXW$YPU3M =UW+JHI?$HF=<2GN)[G6;\:<*:M#7AIKCC%KCL]^\.W
MA;]Z;)[3-64&"&0B <J4'**400%@8>=\_G1RC03RNBA4!Y)D'C*$=1AS;0PJ
MDV!<)HR8XH8\(@]W^#-2OG'WZTW&<QW?Y(ENN-3?%3^'(?H[RT%[V;=LV4O*
MY0JRHLV%:M[H1:\%EVFW]CWNX^@1B3$)F'AJ^;:)BZ-O\NI]H_X[_6UKI!G[
M^UJ3#1LH^<H_-)4\ ^V Q(AB!7K)\+?9@5X'P:EX]JC5<Z9OOV^[1>18 RYD
MP-S;QNICC?Q5G=&RAOI"2^+Z;Q$]?]_VWD#ZZM5*W=&'\5*YTUI=<,'=?'VH
MRP?J )*55?03D )0G8,BY7YLR1*_#V1'Q>[L/T:=!YR-K+3&_*F(WQ1GTT;;
MOMCW'!*<SOAT[._;2<?Y5ZI#9'-3T[(9:#NIG68"^:MDO;>PR_VT@PA]+79B
M/E: ,[[8(<5G:G>1EG\:NT'=+63CC8J.QCF/87!/D<5\TM6G%S]Q:CM%@C]7
MP;1%SJPLOH$:'8&<2>?9J3'O?Y<V#OP>TC3$)<J:=XNM1K;(K;S]W_G-</9M
MR9GT:GR9-'RF(=;O]QJ[-*O_9!XW]C].M5<CDSLL24G;H?O2E92PJM;E[Q@R
M TJP[(/ZS+/AP #GSYS.PH?8Q\[$L=T.@S4/\X;Z+WZN]REV";T5KPU>@%U#
MI(H]NTCB82DB@QL%9+5;B@2)GLHB7<G["_HN]((84J-#UI9>B+5D84L_Y'D6
M-$]EC?>'31,K/_9$QCT65+8!([7(P6>8^C<@D,?7FT'H,D0GDXZSH;J2AV7T
M+DV \NVK1;\#=^G,A\F#ND(;X@_< :?3F@'^)<@+_%1+".6OD0'>S67Y%6'*
M^;S[EV62U1W58:9A=56_U]ZD'> WY$^_EM$^N+7@5F,WD>MT$B"3NCEL 6;"
M<X;LI'(_\MD?WG5-P)QZ6T5%8!#4==;U@7'/(XAPHM_9B.";)M$@JZI+0^,\
M?'5Z?IAG +FK#E!?,^M^0.<"P>L<E6]XO*8X5VYDKCJ5=0+8SBPE_SG3[AI4
M)P](R%,%]N1G\.LX[F['S6$O&H4U!8>,[3^3('L[@9LD$VNL25<;NMRM)N=[
M#=)^)\#"L*B\[A.-S042@;A< ,^TM&%5AO=]/+(K3-D4 VM .[)]GO=&;O3>
ME7^ :@7Y/E%?@DI E?(R5 W:M_!V/1?QC*F#HU::!Q&D693AA(_))7*4]&LK
M*].\>"=('C'TU$_C,-+]W]46'*WB!6;/WGU^I?AHWB\'<*>B^<-TQ==V5#K!
MBKL90"OM1-@=Y 0IO<,]0;:;H_":84@,N7KF+^2H->G>ZOD;M^2&<3''JO!_
M%9]O,,K_FF/_T[!EGI\QNP!;"='\0&:*50MVUP"[FU@=V\I@A?%VD(PF]CXD
M9N_D'BQY%A;_BD/I4DZ:!<2!C;\L87V9:=$I3/@R;1^B(8+?A1BV5;[0/%![
M5&J')&MGLQ$Z%'.6;(2"VPKX]&]YO5/8;74-_5IS\K,WLYREK$:MT9G^B+^.
MOF1):"F2]3QC*/\$%"<CK%"?: 8Y,^E:Q$$%?!6!G![^M<,&":3>?EW:+<\^
ME(CW[+]2_/F;LOK?EYQ:[H]_3-S_$[;%9,D8SW'1G$C645TTUXZS@5 M-_QO
MST24CY)[.UP1J=.DFN +<<BI;\[=D^NOAV1;^\EOC1[Q\;D*2Z+$"Y6UD-U3
M:G\N]8T/]I?^ZSSDL'IO/\_^=>F19V$1ZW@;AF;=/;R%MK7V\4))^#G:M=ZG
M7E=)>L=7Y#OG/?RWGILZ#&9I5Z&DS3ZXX7Y1)W^CUNX@T*N,&M)%6@!AE=H1
MM,C"7<M&*(NA6'A.-<:KYI+Z$* @1_EDSJ-6DB5^_3/1]H5&X<A](^'BZ$B_
MUL0(Y8K5,Q\29/ D[7+J)]Q29KNN_F^X!'U5K@9H:5IS2B#4 -Q &5 .Z52B
MK#<#L18U\S,[HLHAQ@DH;BXC[_UQ*,G>'>^7-$& =Y4'&%S)67<+ADOD$D&<
MK%QPL>H:E W"6T9A]/-Q)<)K("LK&KZJX^GKZ\;E.9W>L:>?>S7<NI)=%A!E
M>WCK(9G';DI6AX0M2<6@P&$E#;*.*/T$Y2B4*0"_G6\&$3O]=Y>7?8)B\4*M
MU4&95U:)V]'OO,<%;ZGV]1&N\C;/6SYBG[N9KS>P7I.@G?R,GUD2,?$DH'\;
MXRY%+0O]0>V=293QLWAH39$S7DQJYZ^='?$- K<72);Q3"'4N=IF*/;AI.DG
M9.J7RNJ)VO&@S7F)OMYI_="'3F_^;:K@QN@O?=$TR!:=08E[#/6>:H 25"CJ
MX%I(KFH/LAABJWH-NLH_JO?\(B9G"J;JNA^/5)<Q_T3^+];>_"_)[/T?9]K,
M7,B]-*6RLG)A*I<90ZC,S$QIU924*<<%R9A&35*$R34ULW+222?)W#(7<D'*
M%%1$7HWCF"N)"]N4N1#W74GWR.*'WG_"]_']@1_8'G"?<UW/Y3[G7%="K<$)
MZ3B.:/'RT[5#B.$V1AVAW?A![4+)@)Q=6O%!F/JQX=F\QZ_K&YQ<ISV%_OT+
MDP]Q[W)GQL<W1Y=X]_C:[!,'SQI01313-X2A2!T%T!:CP7C>"JS%F&XQWK "
M,[C>SPLW:0;O,"1&J.9Y.U= T+7P-WDV[,V#B,)3(R7ZTO:QA-V3%]I^\VFS
M7&Z1U60$*_,U?WSK2-JU+&9A-E,-H=F>&4L0ABMUO4/:3,:>'6XM5>+^D#<V
M/#&;Z?GTWY"/T[6/3C>S',68+ 1+Q(5GTEL$6;JO?>WBF'Y1"-.[J*M:H)1K
MJGV'Q7#S^1EW$)/W)75/ M$6PQ66T2O])+;8PR#R@5UM!&,%=K4[*F&SZ/3#
MB'VM:U9_<>"NP%H5BY^E>&,REN=)ZZ-G;22@?V@>1E+V)^)U27V\8[3O963T
M4T+1\[>QGE6=$Z,N<:3%?_V_,VG?_MZTZ7G1_IF;#,H)*%X2%W$4^)JCIHD9
MQN3TWCXW8":;0:X[,NQ6L-&U^;]]+CG5L5;*K^U-1:2I/J>M+Y#(CP(DC^;
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MV(6I513;(?G2O3@@5/CIX[RH^]34!X%E4%/LLHUO5>B.H,$KWVFN=DN=$:<
M #R6]_0M4;AC&;=@3:VIP(?.>UZOO>PL?.^8CSG56D3TKTNY->IJM=%_QW['
M=<&1/S(&&!,CV@UYP*0R4Y-#W:T57J<9HRZ)!^PET6JG]4N8K%!E5056J@E4
M])R]Z"O)"T!_&LKZ8R?TP"R&96>^_^YFU.$:@X(_F-\V"@J -HY$,1$MM5^!
M75XHVPP1I/0\#@)U7N4%(<-'%*V=V)X5V"K489DM524I>V!90%W[OK"Z__%
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M9UKFW3U,YH$6OZU.9[!<Q@3F/#0&5$BR%QM D9+1!OCF8RXA#=17H 9Q/]V
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MN]VT6YA-'*(BE[:9N0*SUHZAT9I25]'$2*#FX3N G2X>P'%+X.EN"[3-% _
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M1&[Q"JAA)$VQ!6)PV48/PGOKT=F+FQP+;"0QCF]7!/_N;MCYP'[1WR2IXX<
MD?*1O4?5(]1E[P-VHE9BB.4$-Y'](*#[M*V<3%'.1<U<@!,D,4A>L7$R?W+'
MY\AJVWB"WD1RY'+]BU&;\O\]?=2?[-2.$I@2H)Y.7;PHHH-TX]IL.SK3V:]-
M5XVB[W)[\C![I(&:()LIZ3$D1QP9>/](##_.BB>^!';SJSLLK_B7*:[X['G)
M_!_]+D9MQYH7AR@[B.8:8%=KSX=9"8-'74\>D5VCR6[3C]=#G&1@7[CX5Q^2
M;,!+'/A@^\+9(6Y ,/E98(_NF^U9I8%VRKB/]4:U;I;_=%RGI)&YLB X0AJ(
MS_LKVL\</?"=$XG3B%I"Z+'BJR)#+)OZ&U[A5D\4FY-T _UAO$^Z$9U[<Y=E
M\X//#7;>)5<3@&=UWIVL%%'7M+8(G<P/9Z3MHCA0^E4X.)PHJO84?X-QD*LD
MK2 ;:_1.[.+CY>S667!13*2NGM#9YEENW_CB-KG(HCBIC7^(^)FPGMIV4+6=
M_%.6K;P^S5Y&7H=?3WDOK.]II]\DK 7"*H/@N]QB<\CL?RJ]1O!Q0]&'R:CM
MCV+B10E#S_7*PDAWJX,GU_*B7_.#VF9_-2=-ON.4Q=ZHL!M0+0=6P=WR0W#/
M*7B/4Q=JX[>0[7"6V!;'4P?^O_C##243?BH+J+@F*J:47,*C;&;W.KR.0^M.
M&/6%C+L_^0%E66S3& .<U#&L4_E L>\)F>MIO@4>>NXNP:6IOYB)<WKT ?R@
M@XNG.INTTPUC3693*'J$I'1MA6&YT.KV^KKTP7@-PWLW+X!E]7\D".NZIMW%
M/://9[D>(B&-WH#,8EF+S5; I -P#*0C*2O(5)E]F,A:LSM@&V53(_CDSHIF
MX*^*VGNQ(V_1%K^]?N\%?!*"IRLP5R4<+?)^693R'TPB)/>%&-.C#RD#BW$@
MS&VGZ\T5H5<03829<:8/4*<'62=J>>&2(E-UZ'YCR/[?M\#35\/S1J5$:Z:K
ML<+0[Q#40&_SI-[@:#(H6V".U*H]%R7YS$C#$*$P\6S;]@'[W 2_085+.9EZ
M;!AS=4<MQ,AY_^IQM,RI& 7V!X6<===\\/'MEL&8VF6R)40V)T*X^AV$EFC-
M:(@'H16HC0HO$*,PK6?70$A9^./(0K?9+."@^// '>+5ZOKJ:%MJ1\*E[4V;
M_SZ@6^>A8=F(ZF<;1K)MP:]<ZHIO(2[#GR#TS3F&7E1^R/:1LJ*9=9/-'4:3
M3&;MQZM__??#<X?E%_TCEG^^=%NC^1=7^B7GH:JGL'Q&%\*WC]O![@_AP-9"
M#@US44S:,/$6XR>V02$G1DSR:L(2PD)MVT/&#^37EM%'MYWGV.JXUA]_"!P0
M@CX#8A>;CL*"3OIHG039KAVN?*#:2AD@K*IRP!F1_3K\<$98%/!;OWA(X57^
M2UR?P2"E.D1=U\--)+VI+X&I*?[)/A:KPA$::IKFA\DN@*@9'U&P<2L%.\Q*
M^+\"MU^Y='W6/@DN7;6=I$UF'H)(:5B!,O?I!/]U[:"1!4GYZ#+;JN'VMH^O
M,KI#?,3X#S9B[YR+TF"?3LI^> QB=JCLX8L24FJU%)U+U4?F CYB H+<V9^(
M-R!3VP)2 QSO(C,>#@/0Y21[W[M!'X/:HG\<ZQ.XK5LTGAZ!9CL)9BJ#+BB1
M1]",YZ04&C4].0L7M?(O<"1JP"P(@IQ2'<S6"<[6##?HV.K98XU:"MXGGHVS
M/5G:PKR#<OA8FD-[UZ*CTCD8)D'K*7:,Q"PA+CSPX?9 JA'"(%9K5'$0G@%+
MQ',AN_LQ^I=D(;@1AQF?CKJ J/%5?7&F37&ODK;^]"U,@,(F7SS8KNEOMQ&!
M_03KRG7A"%E2$_B9DT[!40;'[4!26IPUQJ$40,/WH&@A3Z@K[3,9/'NPO$?\
M!H,^O[#;7X#<^2Z<O=7A-=5^';+XU[,U-"ZB4H)QP>6H7)#)0O"NVB5/JQ67
M/=5PWE!97/9*#A2^Z"\#4;*+S7>YKKYWY>XJ_8'G:DB[?^=WKYI:0FTQZ5<9
MU\> $T1J96@JCH)6UQNHFP!?Z&MGT1)BM.L@;"#F&,&$4YP"Z874^"PU&#[%
M;CW;?5DDA-WM7=!<_OLZJUSQG1BCG][)_8'A5B>8 ?^5R/[Z=81)@6]0/L1%
M,M8H$D&M#MMU) /51^$:S@4< M@[U#"+G,P7:GUW8(QRCD'?*['TZ@\'=6E9
M&(O$ZLC"X4=1%1-I[ROX_SHUC@<W[:G0^H;J6$)\V"OB_#J#1@S9&A,A2>#*
MD283A2$YD$\;2D<1H18J"3>P>[[QCQ1H94S/<;+&S5..OS+?7+^$2+W %W(-
M<A*K'<_.;0A[<?7H":F!A*,P*)!=@ID2(GUMM#Z\T)9OOAD<25480Z9M.#U,
M^$4Q:CD0 B;<4/RML!73LE1FC74O:1W7CMP+6Q%P_"_NQ7(OQULIWDW%Q#_6
M7D(9X$0EXWIPDI23(UQ=A=U ?L5;0A@ RZ <,;65H4'V/#X41[2":R M20&W
M&Y]U+>9Y044(M81,/-;'<ER\][ZIDG@,#.@J#3IN>,<_#5!*.((B61.5+Y"Y
MPYX)\EWD C$A%;LMDE-_FF-DC_S59K@UP>391P7Z)<A[0,O$V#)&LRQ&6 YA
M896ZT6]GO;*W2.Q';+<R\S;6%UT7H0*!/]2[DD#IP6U4!%(EU9&*@V"IN14X
MFP:@H+UJ]8@$HN+%> W%.; @^;BU&M2!4Z#"2*T4O*P\:Y-MM_\>VC3PI.BH
MV\#SB,(/*\P7(!O953@*.JTP-=\^,"M*$;EWF!E+"-Q77L8GDNQ&\+^J]XU=
M;N<'A+ANNJ0SME,7U6&2BAO]?M($7_?Z_,JUIF)J!HHYG[O0JK:T</9:Q2ZX
M$GHEX<R@Q,+U,*T5IZL(E/;HGH5K $M1UA_FMI ?C;(]^DJ^:F--0W_YD'WB
MAO#$@W:/XI\&"@)Y?Y==]*"*GIE0,[]CEY/Q8NKT5\B@:PEAQ-XW2=@$;*>8
MXK+43!"%-5,<5!;/!YL>@7/%>%-R@=^Z*-\KPP'IY9=)_U]U7]K61-:U"XV*
M@A@!)0J2M"-.F%896@B)$]"(&!4%!"&-R!@A;0,2I4A4A#":5EMHH2$-R-2
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MF,%7[YU._R?XUW6\ Y="%$;^P<GS*X&E0O@LA)*/=K*RB H3F T]HK+&=MS
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M231!=:HCOYSYGK,+7@S =[I*1@1YE98@U+'I^X"M;.4&8D,_HZ&[<QUA2Y0
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MZ/;B)6+SR;3 HX2?-/UJ&_'(IK7^RX-"D(9 6? %)@O=B0'%VU6P;42!X17
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MHG9-=PE!AJ$P9@A:6_!4")(6@MB?,&B1Z2BSRA(A"+J FY(4@B"ZOZ))(K"
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MA8^D[3*AZKS%&#]Y@BIR[F?)[R<O7]WX'#CG:V_UUU=/_1WWMY%LK[C ?GG
ML@U[?B!?>]Y#94"G[W&KJ:,9TMUB4*/VQJOZO%<616K.IU])WAR_>#-NP?XX
M6]!QE1ZV9C\[.&Q_7UV-5SQ ^NVP,O8B:^MT0HCC[:1:TNT"UFJH;VU'-YQ5
MWV#1,QC'<&*FX:O%EK:Q-//[K-4C'DT)7]*<BA"B4]/1ZSQY/4EO</XNVS S
M[$VET6>5_6<?^%W-X";M 'BM."F,%@%-_;1%Y#*BR$[-B6UV>G+9;[S"]01S
M?S;=]BQU1FR]4#FX:!@C@4<<^:=K]H:'JKD\$_(,+D7$2$RCZ&$VU8 SQZ8K
M/H1GBKG2Z&OV*50_.DC+H"^A_4AXW)K[_0Z70YS)9_O>=1UO''@B=6T2R_6F
M+H@[M6?+ 5+L7;<X25%0Q850E5@FY3 E9DF@N/W.Q:=:)N,':[*/X/-JM*_,
M[*ZF7$&)TM9F1^-60G.6'-Q=,Z4%53OL<R3^%D$N,2!5UZHG_[)Z0(?>._M3
M:F1U$Y6)[)J/A2/O<N;L;MF^?#B3>KFC2T2NYCT6EJGFI-15I+N'@&>"Z6?S
M6.#."4MWMBW'*Q*SAP7;R;].A6SZZG?"#P9I>:SUMG1+XZ7S":- AOL]<]^@
M>'>+R^)944TYO3[I-0P(5RMOGR<J1_=NL5YZT;EH%;QT-3U\:N#'\(>ZVD'6
ML'CC<YL4NYJJ;/I*N/$Y?EICU,CLY*RK_^FK1G:5GQNI!4QEV4N+94,IEDXR
M83X9B((,&TMZGWZC2L&[Y+0L.<127EDXU<JYA+ 0T"P%/&-*G'1'%_>WTBG<
M_/X(C&4A&M;."7]^NU+PA:.8_F.;8LTH''4Q>S+SI$B03B!/O&R@! 2IR"ND
M8LK84BS]=IL8.53GMJ%+!1!2@&9\@A\U<IIRA]UBK\26WP&\;H_HQ!\,JA[>
M+-$H"Q:"'!LC?.WN*W]_;DNJ3_NT[SZZ7"P;,\W\M;R#=PUSC0(DL7E7V>"V
M$D8,[##?BPC<=^0D+/?';DA$IE5OV;-Z.N&5L9BK+%]+QR$_5K-__JA;>QI7
M+S8H+.0!K?J?;M+'M=F,)$T'J+6?SZM?]D,NH@[26JM)LXYL6Q4V4W'T1\&/
M+Q/6GHIW+)VDJ0E$E0Q+UP;OB4$H.Z<Y")#A!'1,7AH6G )VL:RCWWOC)*$R
M"P;&A!BIUG2#5$;4IJ$XMF4U,!QN$6YW*@1U?*JFT=;3N&_XRX6VDU6DAT&Q
MX?UPJ\=64HXVA_H*QH!8$J_B0W^IB3\T1;IDAO(=?CMJ8%HDVNT)#FGI94X7
M9\DXZ[UZ.=_S;ESY 4VC/B0A[W6NTLA\1P'^(5*VTW\N@4ZS="9(#^50Z>8%
M&2L-/LB1A^0R!%1A,$@\Q'U(2R<+;$[*X-D-$0LLPRP-+0,AFNL],V=S"J<>
M?VD_O3?8 69@PEEOSQ:KC;<".&RJ"_O&'4_842.5&J@^X'YNI-HD0PARH)8Y
MN;%S>FA*T^WUQF5YHFC46% YT=A&XU]AZS]M-@9LVFBTT"7!:;9#PAQ?69KK
M 1[YD-[:?)ZG7/:YLIH&[52VNF]9W;1&W),SGF<5X'.JSOE46(P2\>&T6GVZ
M_=C(WR2J*UD:KY%:#S=KBN7&V6*_?D5@I!KE1B;7D&^5)_N@">.K?+'IU?T8
M:W8S?MIFU\*T&_MKB?)&L-R;RB$2\^\MW^VO;T/W%)1YW0T_$<4=9!T9I'=6
M_L8^4KGI<5D^%4CBC#%E6LV71$:B5TW9P]M\?QM$P5>_5;*S[\.LY9PF X]4
M)*[0Y"]JER8<E4$W//_-IO[O/]X0$K&M/D6\"\#18WL<AOC!Q>__.IND"+P&
MB?T% DE8>'T"+PE!,GSX=D%C4-@CFD%G%D=9(.OLYC'K5?&M43:?[K(=UZJ?
MYNVK=6[5[UQY@?3BP4GMTG1$D^V9$7M$9[DR-,3Z.4*)18!,JIE<OE1;)N];
MV%2:5O^P^*L]>\4H+M^[TWJ^MG/C]\R0?4IPJ/*7FHDQ>!Z)"$:KNK%?<69?
ML<K$;K'OC4XL2*(SQNS(X7+RAA(Z\#[_\-E]OAWQ5W5"B@S-E$L_]AZ;/UE1
M?P@.PL !7\[-!8TIB/3\Y*E,\[7#N<B='LZ38]>#%4J)+EUVY,K&</U;"7*^
M^K?CQ*B;)T#9G0LL:2>8,MKP4[U77.-5WCW!5ZZ^DYQTM$H3DR*%L#GF&T3X
M&3)Y>? >38\^WQ]R+ #Q:C'C0EWSMPN^!9.C?<8O,LM651-"W>T@\AAE&HVE
MGZ0+/X2FL:)C-\3UIWZU)NW&&+&_$ID\!9?%99I!$84F&"Y9U)>1'GGD9#>\
MN3]-0;N5;E+P/G#]9'U5BW:@.F_ +J7PM[(%Q+(U3WWH>7H]]=?#WPR=8\>>
M-,TL)9?9#:1K/I'1\3'W>9U[^9JYAX7EG?([:U;=W:;S)912F4ZL'$[&?.HF
M64H_[OT %5Y/U5HB'XRL&,ROY>DV?<TMO(I022<8S[1>O8L(#T,]P?[CUNN)
M,M*KD309<DKAGP9\5=N:=OX@E[G I8#%=AJ1B%[MJ+%M4_C:0'0_]+E"Z<*U
MM'K3]*-6VM>HN0FGJ!L-R# T[>S2!#&>?SL/#6[=$H+B-W]GB\NWA3JL$ N[
MY625>;JOM;3-=E]YKK1^_$B+HME;G9BWLI_G7M_O[[6J\STF!&6XZA]_,(BZ
M20CQ]2CO17>OK5L/#'03?R1R4QJL\CFZ^=P!]XW %Y%[WCQ]+VG^!PC4K90-
MVI5L W+JY(*/"D%(_/'YZDEC-J$U*9*.BEA9^C&TP=@%4-JS3Y.!W#+$EZH^
MPN?TZN!>IN^!7W;5>BEF!)\!H^K$Y3U+'V_V<7TATGPGCFK[ZFANIR(4N%>M
M>&QXB6\\?;/1*1\]9CTT.VP$S08/Z'XWLLQS-B-X(#K'VKGI:>PL%<&&VWQQ
MR9P[8C#648>ZL&ZMWB,=8#\S?:D_V9I[^X<?K:K*R;I/-=!K>8KJHSUX&''I
M4EV'RXK1B#7-R:G>RM YE]YXE)/")+0GP#T&C ZR2FR.>: 1TTE.> O2L,H
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M\!"LB$5(E2#)\)FQ'PY:)KW"E43&1-FF#+([0+RRM/?[^GV= -:22?#739F
MKSQ68-G+/+2/?C4555VY83+NM&1:D._T8:1V=HD]07RKHR-Q!/P%*X>)*20Y
MR!T,<+)^L4M$<FZEQ<$$L#:%T4S(/F3AJ3\1H _]:> ]FS*/V+!=.&M6H4"
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M:@M]*\H#X>S<BK' .N?+_+U-%]+KZB/OU1?>'#1M-Q5Y_1WI]N".S\JG8)\
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M?QKP24N& FH::9\4#'2])>UVJITRB6]5 9_&G1#VM_, 6/B$E>0:6ZKN8Q-
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M4487&J^JY:D6_U.7(EIH1]2KC"R&\0F<L"F5D7:%9,@VTRU)>[R#823*H+X
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M'\O" 8>)D ?Y\8YERYD8M'%UWL;83F5GK[RMGU__NU=T*Q.1*MT#@/A[5S2
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MIAI9@U9W]H0:Z\T-7',:[DAL_(ZE__927/480NWUF;[BA/+3 BK*?']?G,Q
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M'V"8:>:TM19STSIR357PYEA +^ZVAR_"^U3=N-X!G_<L1M_C.K!ZP'<6R;N
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M\H\[T7<[UDBO2,? RCY[2QL+S!ZZ;CKG%A3:40KXL]\ .]6E/="HT)I"<'D
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MV\Y;%?NZ9$>+VW($RYDDKF+6MHM+O\:ZH!;77ESKTP1CH<;P'S_P#13R%O&
M[[50]QZU2P 7(PMA)K<6(XK1QK4C4DL=N]8SE&G,<UBKZH@R//>RE1"U]Z+3
MFX>^^M6%TT.R^Q!;\[^X(UM@918N"BV"0(8Q(&* =[MNL+].2S$U?F=#[;>Z
MQGK[[U("(3NN3?=+WGK^I*C,OE/^XH34R2Q$6P$(NJL&W)HYF=HL30_3.DL1
MV(_ " +I)JS3/F2$S)=*_W)!V>V=*AJJ:G-.+]?FB;EKS.UV2=UQ;P>5_BQ+
M87^BNESVEGJQ]+:9+J*X;RRESM0MWJ[H9R&JW/3>JEUZ4,S'(+M$2U5W4QW-
MZMIOR$A96;*A.<=X-5^LD)7RD27]6QU@(OX:APX/H1&9/;&$ SYAWSF%6!>Q
MN>-CG:KP0V\_]Z;HX=1=17S]Q'EX3DD6 FK=F$:G\7Y4[:O9C^FTZ'8\',%5
MZU@HV^$C.1;CSY035OOV^E9UL'.K9+H8JC02E?LDX>'4FY$HU5\3ALLK;<;3
M$'[;W5?,>IU-S WN7=YM3;AJ_B3->+2DO*OH9T/1XNQT4R;!;31]2L.M:&ZC
MKCU!I2KY/WZU:LZG+T4:(EE'.X@\<28N)0!Z8@7+CJ]9EI7GC3/M6S7J6S^2
MUUVM/$O-00G-VMH-\\2\M=TTI?>?#-]<N=^<=7ZO2]0F_75&(;PT$-5MQDNS
M"%]^:VRI>:T%6UO[(F@GT2)D:A7_]>=YZ-007?2 [_.LU?Q3'"OQ0;HQ6((Y
M%(V^6>5SP'?VN3;"Q'2,"WGQU%OJPR'CPL+WZW7,I56J2E)N_GB=BAZ%4#PS
MII,%G>9[>BRLVNR LZ"4UG,CVK" OP)\O ^QT)8SJVS_-_[5X_NNEBU$H)H7
M^T?B^>@LE5?0'-\DUHZ[YXKLKR.!!WP;1S^L.F*Q*RZ9<ZEEO=Z_8M7<G:S^
M[ A_I%!Q!N-;^Y>VN(U:[:UKS=>BWTC>(SVLVMSOSM@OW!]0RJ!>7N3)I*,K
MX4IC843T?K2BUY82;7V431#Y(YFJU1.4??V'Y;0B\CJ0RHP0DK6B"09;L3Q(
M\S@9E'!-:JRAUWL!Z<2_:..(QX2)9SI&\@^)X]K)GA;C8B>5TL@\BE,,_>2W
M2%2'F_K/UI/ 54PA:H*GB.+03Q!8:CVJ'TQILYK;:P]&N3JTK;,K>GJJ(1C$
M>P!^STI.4JO&,W:H=1RG8W&W#7E,;DMIT3P_Z$,A9=SZV^+N,P:SYZUQ4WWY
M=*YQ$U%4X="UUNRLO_]6W%\!X]H2Z&FV+TAJ:::*2CF.CJ$709U;IU9Y^DQ0
M/%?FPQK[WY.PNJF8 JO*N4,4"KNN4 A%9*FTFO]"8<BS325S6#3W\9S_Q8&+
MJS'*K+"M*:HK&?*T/W]JS06(]O:[E_@>"#9G!99&2?4^"T@]"UV>#!)V\Q&D
MYQ2&!PRO_"*06%#M$J]0?[WJY,>3H%6S%%@!,<8U,=XS<N[D-VS(XIO',1*/
M;;?[U6L<Y%.T'4,4@DXG"%SE$[$4];UE?*NXWU;'<[.+8 L1:$H,#6K)MV^W
M+]!35IC.D-';,E4^A916RB+.JOU<1G]G*<\3$UH54/R?9:5;@*B2ARC<Y[P;
M3&(*G67O<3+D1XN)#?/]N&!R+0K*._^/ J$N<W,>ELI5$-=TG!I+?]%Z$9?,
MDQHNL/H%->D.Y/LS^WMXPK'64:9 LE<!H?O5"YFN:A*;G$]//A_4.$KMV-VZ
M&&SSU=>EN/+6->3'\;1%B';8*^#5/!(P+F8U1V@Q%X:B'ET[U>S@5?60"H1>
M$J2-+<%T$E67_KY+;!6$^<M;GJ?0/%0I>O>.5IFD^(P^G%),L'>6?W,RX,W%
M$T[W)!T=;4__K7#.[ZR@CF.1&S)0PBS([$K*)X!1)57;N!B5F& Y4W[-_;*?
MA9J'34R-7=:;B&]X;+#C**QDCNC=1CK&-:I"Y; 32$"M>-(.)FY/,+_]!<UU
M2W860'"OT@:".Z5(<8\F1L<^U_VB0 #+C@94JMVGN+KF.B@V-,"\)G U>2'Y
M6RY\1U]>,3I^H6(B\$GQ<P>);F$7F$0U6*+;8'9%HOB3J5RYG3U]8MHO/2.G
MM?J +[YW/8ULBPR:?F1\P?'>J__X\W11*YMQ]8!$@5DG^R;BV(]9W5'Z'F]O
MTSZ2/#@XJIRWN+H(.UUD?>NTX:=_OEV6JSW/5Q@>A>C/C*(G:IWS=3E1[$E#
M^ UUA.Y_49/-K8$N#] %W/6M].751WU6*GP&4 //E1(4>:-UYP84@L]X/4PZ
MOP+;98<69]84EPX2=?6&30)A?[QJMT)>BTUX<K:B2^'>F==E,T7";949Y)1]
MN]5TEV#+E9\E5>S'(S@EHD4UZ"D6WEL:49ZGRKQ.>]K$C&KC;\/F)_[8$E,7
MG]S-DLK-CW["_+:ZES'J,==?WJ,7Q[V]5[S376PT,$/$P/".SH["SUNA?W&1
MK\"_ )4=V9 +ZUP;EH@)2^]UJSHQ7G/G@$]P!7RL@8G/:B3&5Q6,(;?PL];
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MB=(MO<UN+M&B)7,4Z0H+D]L1'7 '^MN#P)*RUQM8LDEYPG #A#':$AN-WQ.
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M!7>"I !E:*)5ZQL-[-+]*%O[K"7S5R8SF<S=C3]WP?PLH?4VSF_JP1H%W(L
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MMJ'>Y>6V/;E0)=JU:_(YI-"'I!J>9_WM998/;_=@:4V;AM6/1 JL_.&[//N
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MTJ8C-8U:"IOW+$53AS(*:6]M[COQ>J80FTI.HFK6 ZYIRS)M&'[$C200Z&6
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MI*':)\.<5'N1&L*W)PFI<7&&+=F92(VL[6QR@RZ_A:! '(GU,H9>@<TJ?&-
M-XK.&PJ+N?LSZTW-N^>&O U6>GL2GUL"7LC9U+LR=&B=E/JRL?&\.1: 9IF?
M9X>*;YFB[IC2*L+]?:]"^>;R0A&IJ:>E7G^2S4CV#+F=^>P _%1+JUE\G.D3
MRP@3YJ\1$FE425)&1N^2*3)?[3NI-#*BKWUDAZR/_T/8^<\[5V_0)A;,/ IC
MQG+RZ#QGRM\4W:9_J#"K>?ZHPC^&OK_*"3/_$Q'H&_]W#J'_#-+_:U$8!.A\
MV!-?[#+FEV;RC0>ZM3QO%_L'Q5JE,F&,.[0F* ,^SC7,$Z9]H!17T6=CZU\
M/>*BNGG10%%\KX%S1(-$]%?I8U&%2H_AK<J3%]I2$.^R@^[.>B>O^N)K>W1E
M+**<%.]J6XQ49_?"M@+1Q[<#A0^+G[B^?^_AJ_O%KN]_?%V46\&<\$PX\!D
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M,MHX/4GZ$4YEK==:YU&<VXQO@+(!QLW=Z;^C2P2O50A,C KCC(L8SE\7 M3
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MH*U,.9PIW[H>W"*QDOK1C3]4F"\^5C,^6MTSL<]DG5\88N4DAO:M<W=R\H]
MO6N!Q6FO&[V.*1[,(2'K5RK"'Q6/+#JNXYN#+M%B@PLS^G'V5,QQE)5)NNE^
M(=9YHG+7\0[X.Y_#]VOZEXKNQ9GA+T9+.,M].S7U7A-&4:5M,B4[J>CCE2]9
MWT%HBK3P8$J UH92PX'1C1_5K*Z=2Q[\T W,A2]<>&F!+16!J;3BZ[38QGH%
M(MB9L6[,-[:6/(@Y6:^$$?H_[+UY.)MKVS>:M3I756ML*=JB6DK:FEI35@<4
M)451E*Q6E4@C55,0R:I6S;04JU%2,S6DAE!34F)HJ2I!*DHDJ)G$$'>)9.OS
MO>^SGV<][][?NX_]Q_Z^8S\YDC^N^SCNW+G/Z\SO_/VN^SK/<Q8KV<<_6P34
M.%9^*2$K F;LW1SR\X B..->RGTZGAZEG48'O]8-')"1<496#@]G[NKE'V-#
M!NM;0ZSSN);-#,WG>0*:(PV M:R-[(-P2@+2AUP,0DNUK.@-*E(E>.A3_N&R
MO!9Z-+Q(HRSY]WDO98FSEL$K:.7L]%>+\Y(>&[7:H^.]+V[8!550U#&,^E:G
MI/*'#P.?G!Z=D.N+P72<01J0!JS<.O3AJO[8"@#5*I#@IKS ISTQA+*84M,]
MUP9ZF0#*F1;0>7+A@+JAN"L\2.^Z<D=)28_VH[YS2:\/WKA//@KLLN&*MC^I
M^MF^\)(0U!J8B6(T:'FP7:5G6W1'?G-(GY<]+5/A??V'VI3'LD9:Y[X\SB'/
M91@K*(HDJB8$C:E&&*JS".%^_-_ZR+N!2,?>!L\-\*Q,D)M,L+\VGFE&(R6*
M_M;UVAG(#KM\ S\&[2N]7T+:\T(E_?*Y/QD0L2^C&1C1T6!M403OZ!>=6.3E
M9K\I9R$HLHRLK)AXBKU[55W+N^;M-.,>D3V4X;8.I%NY#<R:-/8.>OZI\V90
M6>S0VU.U98%)#VQZ]!;5EXT=-OM6'"QLS:NS^__DQIN*/=?]\8J$8,$?EMTM
MU; +>5><%Q1*_!:B=K[FA\V/=$RWAF%7?<P6N"-/2\4L?-8[>=_]J(*:Q?+G
MT?^H*Z J!!UWVY+-'DIC,H)2@JQCV7^U;JSVG]N!+^OQ;^+H=91U^[]MYGW\
M&S&1@D Q-IJ9E6)/5<-IO]&-E3&P 8P66Q[W'K>7KU'@QIQQ+LU\Y--="*2W
MI%6_;2R(:-CSFCS(O\PVLD:+R]U<$&]6[ZPZ4_!5APVK^EFCM?D/8-%WO)7W
MF./)OG$"IX$9$P<,;@5$?8P7.#<D-.DA]\W]UBGN0P ;!H]U*WB@F:GKJW ]
MGVDG4C9\QL3:Q_RAN:FY;OJM@6JB92F2M)#<7U"N.L?B*KD 5,ZNT?96E+C3
M= @NRE@)<X[C&*]3+"JN_DX[U,BN)5/Q;3^QM.H#:E%'[FO)[7=U208W%XB+
MFM)2%S4^?98U746ZN_1@# H^%J,?._:N:&@>+M7XWD>*W;#2@L:$75H2-6[>
M P9[A(]<(*(62DN02O!MWT9N743N;:"9QB]#YW2$H!.(#0TA:' [8"\$%;HE
M.A&.:.;1*5[=@Y=9I<LRG,:)R594K&Q*%,.];U4(BL#K/=TBSKLO8N)RK3SR
M9]P@A)8'+=9; &$E#9S"=^PY7B Y\QFR[\8; \WGD=HE#7-;;XOD&UFJQ=YX
M>DG^F.3(ID=@Z,Z"C=\P.WLPOC)4#<\Q5+.1*OO:6ATV?1=U'LJ&/KYOZ*N;
M4]R^G6'_Q$VB;B";GMO8QZHCI4%)ECLS>09_*C N.'AUAA@GETWA^7J.LM+E
M>0@'GGYF0383FCLCC7^A&_(Y-E0WO02N9SO8=<YE)L0Z!^E[N^CKM8\!MT.W
M#]38F!A"904!T[+TUNY'Y7Q;@!4T!GX$.X ]A*;Q_OS36R#-V1798,DF'.F&
MLQ>CL$< E2R7(?Z6!SX1@BPYGU/8J&V7\*(UT7PE,%7C]O$^C%[IU!ZVG$OQ
MU\4JHB\'.9YY:+.<K(%6MSQHQEI4Q"@ 0=Q8F[=/#O(@1TR(0 Z+1RR&*K#?
MFK,A^P&_YFHAZ.B-.@(U*$AN1SLC_]W#W"0?37YY?5"=7VSX*V0'?F*2/(\L
M7?20+24%(#ZJ.W>9FK\S&"[ .A":UP=5B'1)&Y,[]_^I:X+C!T+5$4)-$KK@
MJF(%B3*7!@ZGO+VC/XO!IK'YV),*JAMA0M K[>><%9P'[C;.0PBZ=RB>N8X;
MZN(MKOBBW/9,XIKN0B8[!7N*M_0&I&H1<.C)^Y3,JW+')F7@^S7LJT8$:>=2
MW!SHE6_F!\[481,FITE2/UY4XIK<US1GP<")ZF_Q0SXX>->0W^=O<9Z'V]#=
MSIO@Z@VSP=$-SV0>Y02X:C,=-RCH*<<L*G5M3B9_]UGB=Q/NZ6$&BUY=T%BD
M92QR+/$#U>OJ;NO!!5\+H9F"\3$$QG>B<;&ZC%=-+L3'G"SIW+M$3" LF0C4
M<8/&7)3@ST5$/Z*#K(_[* .4"D%W-UHIZ^Z-I2>%(.FT34RDX$54$5^?,)HF
M2.JV)@E!B0C<.DM,$.N<^?J?1I5_?]K>K<1!\5-^5O[X,4K8O'(?05?_KS(7
MZPCB0M .R*:>A'ZHI8#\L_['5UMQ26E5T*_F*Z"[A([46D7%X2F>PG9NZ5H4
M2</,E+-)>-)@%E"&D#7*ZQ*4YGEQO-:29D)2TSP\"V;H02$1\4E= 1Y(1)ZW
MH\2WUB,/OKI=[40IYP6F!?EL@;7M4 6J@H)JS_J!X'2.I?&EMO&>?"$I1F_]
MB"JQKRZ6 /0-NKV- ?VCO76W #((# A!5.QAKAN1-21O=R.1JO\T+_L:XTG(
M[=JG"VU>R$6E@-J8WH$+#I*;]VF4*DCE'(44\6>_\4?49K;VXOFO(HNGC/MY
M/_EN;EA:-Y.'@ZR1'9A:DUU8$32%=VKS$49K0V%8T"L$[2&?PUPB]3?L&A5A
M'N0?W\PK -K'=O-M\F9E/4C]]*?\"T@6K[;'4"NO.[18DC/!?(PTW),U^\4\
M*"#/#%'@/<2 ?%T<[&XUUN12WD,?8\]P-W.KC76Y$"IT)R)3O2KSZV#7?DK1
ME+1,2+:EEZT64I4Q\:)!P3GXVK50&9]=#L<NYJG!3<\6Z2/UW3K,\Z23,4N3
M%<[562KJ(^HOC_0=Z7OEK7=*WQ?OG5VTL\HJKU/!I=%V+=G%_.M*V.763*E>
M'Y*<O&/+B"(-Y1^_%RKI/1#RM++ :1B>>3AZ(2>MQ3F^L>O3PT$OFX\>P4?P
MC1TF!3D,5_5;.\.O_XD]!!1QJ&TC4HU<YF-C)4"L=60WS?0U(S&NX2Q;"!)#
M"*3>NA[73;=', ],.\>///?6_O \KV_?VO/8D_V9DQWVRAA?#M4:".9"K#;S
M#<VY=8L6^J@X"#P#QBIMGB4?3Z8ZN[:]Y*2WA00](A\"3LA-!8B>6K@?X(HR
M"9\#7!=.D+B:C6Q7Y^89JIVK]\S [,LO5:A=3'[@9HZAXH8%G"S*L6]O:90;
M58PJ-3SU&EC@\R_0^6?S$.N)CQMV,FKBRN:,Y;WK)EL4Q8$AZGP.PDVJ@=.?
M_[S0Z]0H<S?#:NP0KJKA4__)C8XE'\/20=4P>-')?%JR]<.@'A4I7.(P!0[V
MS5-PJDX9<E5F#Y&2,,56+M\# 5?!^!=C,%^%"XM(3,!H<,U8]&A#<1W+L -
M^V_<FJ>D1!%1[T4;4J^&_V.VO(%=;:]ID5\Q[.MT(&_GXKR?MUYJM4T+7>]
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M<KOJ%*U38V+%&/Q:K%I7^Q@<T:"E\S0QSXHUO]]5BUHC&S#RJ, \[V9C0G1
MKF:7VN35*J]]LO[K=S"I$D[M^U(12T-5[C%= U@%0*3%>8# AAQ JS>'3$;Y
M)ZIOJ+OV\PUR9_3;TL<M/!_/R:9,Y-)3,Z^-=\D,?D_L?/%28I^?:X1D7VYU
MLLL<@XFC%+ZZLP+7R8]7K68&6;=YE$7G.'D[IU9ZYDY7X\D5J38SZWFD^"K9
MA$*\/W1G)CY^SD:C:^8K5?FY4^FG)!&OX=X#,2T*02TX4;("NEG0;<]%/3*4
M9X=!K?=J;YJU*,CVD-)G#VR)&0W-51'UZ/GFCN+C47=_D[=O__2+?*GD*7.#
M?!ICNFJ>1)Q^?;ZU6!L_TG6"&#HR4K?^"A=MK #L:K.9[D'7-QE+<*^$7'3/
M,V,K[I^6[8!'A._4%2EDW-+(9TG^OOG*[+GLMC53%>@OP'$- Z=>)4Y0Q%AO
M@]FI]!;9.UZRMM/KXVV[D=?J&O$,D3"+RTC4CMK0#]]1QW=G=Z?)JJWZVWU/
M2?J>DMJQT.DR5>T\.UM8ZQ[XPSVHOJ*^E]$X@@_Q>BB0YI@]-A1#&*6%\U58
MQ#U.PQ:JM56<@<A\KT"ZQ"]5EH;Z'J4E#S_(3(@=K_SE_?F2#=A3V/[3#6;@
MN-,-OXS60Z6ARDE=[%"4R-0S=+B3QUZ5)*L[ZBI]"N:_%@8APC]+[E0&J;_+
M3H"[DN%N%KU!08C*H/Z0R-/WTTXC9?Q+2@@!@^L[)&ULK_]<P?PO<WOHZA\$
M>X2@#VF%0M#@5:!5""KV;$M!  __5GWI1%:ZX#1D=ABVJ18]^\+&Y.)K!W T
MQB 'H%#KUB(,+WNA5L0DO!B$R-7Z@[Y^7BC_C#L=808V)!D'.Y<1%[E8@^CL
MY7G-H[61N)?;>SK>S)),Y.[++3S,W,XQ>VHL"X";*6(8F?P,Q6;CO5^T"2*
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M]E;SX,B@-ECE? (Q"Z,%N+-"K=1- $N6$"3K#(RU!]+Q9;5%Z/06.EF^$7K
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MQ[#V9T+07SS9ZZ]^2B?:F/TSSN_ZMQ'^=S#",BR.LATK <?MP:IX.^/^P%R
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MI/<=")L>W\%S2\A=7U&%FM'S;$Y+:)G'T71SB)A[P<DR<CQVPS63VUJ _"X
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M ]\TF;8A 6A#\UO-#P7";KW%Y;^Y#_M$.:F]<;;,0JZ8O,?-]L'F3-%2#%P
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MZ!W+?*W[MY>E$Q1SMA2G+[TJU)W)KY)AZQ/? /<M]'+6Y^&0KJ ;6K)H>ON
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M(*^.J?[F)$ZD"0J&E>5T%@:]_.Q9X$$,WIO&[E"QZBF:^:%;6_W$HGD*7W9
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M+Q8FUG37@JSF^F5A.B*G?B?2%I]=#N>MI=0.<P@"D,(_A!4(.%-)#+ 3_G^
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ME7_>H@DLO#%[\-*0>%PE++)NV('8?IR@8Y@4=:PHY@(ESD'X;-:(V(8*3%P
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M0=]*I#KZP&23O'EM3:*S-MM-8; B($$,KZ?%.CO[1'UYH\E[\HOZRU*MJ.)
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MPA4E5L:DN$]G!.'/F?! W3/=4ZJ!1%68X8AA&$NB14V)[KDLPC^1>I[75[[
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M\:5)Y&@K?>LI22V\4RH\DV5T+:Z-A>)NM4U<!B(*EA27ND;0KH^FA(W:J$^
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M#R7R0.<VN6F%95A-,-.%_.W.#);9Q!7F@?K-F.E<X4H>J",1<..!]O- \P6
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M=/<32Q)C'8B*/1!R%&,2VCF9<_+&UQ#O1V_=,Q24=@9.+QIC+KF!6>;*% =
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M.^VLR^2L_0N'YN:)B,43O4YEH^5ST[/Y3TI=[>_3D"5NK+HZYXK^>JY/^'$
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M-\YC!_,4@.W!D)U?\^2&R4<P(4"L4BO&$-";*(R#[D7GV]QHI;VMBSR(@.X
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MOTSPG>!M5ZLS7;I&")*%5J+9 6EH2 M.7+"7YPXL<<#M"KZQ$H\;5N\MB^P
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M6<V.6BE),!@[]KD?70# )B5YLHW<JVSB7,>&+08-.)6CN[H$ZH 86_(*\*F
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M&+UAG<J&[Z8XVPNB&"EW*/(X7[[Z=[I$77)/";$5\D"@P?'K .^V*7;OK'6
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MXNB0LXC^E#T\0X:299>]YNXT/N5:58#4*D1F4X&*"#E1 *Y"=2FIM-E[88X
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M_YJWC3/ZAIWI*=8!WD\,B7)$4RX!N-*NLA%!%<8 *"GDV>*99GFY^>CXTXT
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M!$PK^"3J)F@..'N'#4?U4PZ9;3D:M;)-<Y7T= M?!P_VROA.4&B\0?*ZY<B
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MI^L9O ;CR@]B;W2DA54SS'S!/%7^?L"%_Q-_3&AC_9U?YR.C95M]@1<R9H+
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M:*_M#Z75$S=\Q'MTS-63_\<M3JL=TO6GO(ADAC2Q?XXZN*VV (Z%KU7L[B-
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M*:-U=&LH%*1HIEE$A5O]>XFFL>Z<*1+_3[3E4)"_/IV 5,>@O970.=0Y.UG
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M1%0''Z 'F2O$ZU%K?6PGJWA4TJ +83KRE+L$:[9BZZNG1 '?\JA#E4!X/R[
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MJV/8Q,T_>LM>EGJZA+45VT(4RF3H*^"H2:=JX:Y9L(5FN$GPX;AKV2G.*FZ
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MIOKYDK.LB2!SF+A/[V*1P>E"3SVR\4=RM# ;LA=KPY3>03P;NDOK_;9VEK4
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MYY-XL>ZL/51@KP[HB-EW>T8(T#CUX+Z#[?R'Z@@[W17FK](H(3+)#(^,UAZ
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M;Y^6/CY!.WNBKT1TT1= /?5*O";R2B.\/ 1P'C- T#<-$I;8>8IN,*6<T27
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M83_18KSD<FL21[Z\4(7EZ969GS"P?R\8467@H+?_Y0[B@A->8$$?EVM<1"&
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M68\EEDHY?,%1<MV\?',#+VKQ]CBZH_RRQ@II853XG4T;X4]I]4V@ F?SP<7
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MN^R&MZ :X[.V$^(.S2>$13%:T6PD%OQ(]_QU!?KSLE,>V?J8-+ 84'U2[%^
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MY-68<)2S)%^SY3$ES5=H3JD#[OB_R@WY5,@Z-U/HUJW&)D,1UDQ*[BO&)(]
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M$\X 9&&XIB5' \JS_*9S8#WY+W5NQ!<2[UU\Y]T;_S.T,P >E52;L<M&NDK
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M9K2FWEQW_%AU'%Z]-&K=X'B@C$P!S;"K2"_[F2XCPB\X_;KA-1[-9QI0Q%$
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ME1<H69FPJJD3YJQF$/&M-+52M\'BV-)C8T:S+>QQ*5E;%9+?4G4HBU:RI:C
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M2.",90[UOF [,.PJ=DBS8+VE&H%AZ71C,*;YVQG*XS MJC*RR,CV#5H*8J[
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M]Z]U/=8[8J>;$4D,:.'!J$O APPRF!JVH%OP(Z@ZN0U.O ZG)FA@5_\N5XN
M/D/*_MCY\>& 001U*J5+@#Y6$7DPQ']1G]^D)GKK<4R%'=-]1D)5*4$-OXES
M/>K!NR^PT,'8ZO!L$.LS<8*G+T.KY ["NH@@)SIB2]DAPD*5']\RW#9V*'?3
MVSQ73ZJO[M<?Z^LM0^?%!#;LC<66-.R5%M?#+[MBD[M_;S[=1-ULX<"#M*.
MY J^A?*0/W:_I]O&)VJ2L4_UP(4\<FS7.,=YM?T&_NX??A=&B_^Z.(A7;9'<
MM&2$VY;LWE.DC90VQCTZ(L()9,QO:MNH,T!DA^D.(EE47[>9)E:QSCPQ2);F
M]]#KKT02MRY^?X;8P60!';70/B\U) RS-$5+>I<- A*][;K1 VG+Q+T9+<ZC
MF'2VIHU+P)O5)^W%[A5(GCZ!SC,Z#)8N9!Y7%RH6K"G\O6[ C),3 :K("G'.
M,= N.:M*.H]&81Y< H(AMI;V9X)_0!A#@OR5XQ8,3-6>F0[B:(\&I\3VCZ*K
M?7?%CC,V]@=X1U'SWU!_JV1X\+>.!I&[5W]6@E>=-WJB_5K/ZXLO 3:.<_N0
M,V#L\NJ%\78W'2):!#ZI=P2=.(@.:6'#VFPGXH"M\"J!K(62S=TPRSO20J53
M\+;KIUU%T/?C;L>C^362*Y%V1>9$E&B[_\7>>T8UV;5;HU%!I$OOH!3I( )2
M)0H"TCNA1T!J!*1)@$ 4I#=I0:E20B_2.PBA" @H54!*0E%Z @(! AQ\]KOW
M?K]G?^>,]SWC_#EC?#_X<:^Q,JY[K,Q[7G/.W*R%#Q6_9>@'6K^3@ ,N\:/$
MR0F2V(:L92 %%(Y*GTK]L\$"Y9;.>$% 8181J5M1O^UIWA=.*>8D3Z9W<YF9
M21#YF3X#(:]4Q?%KLE.IBF"9J6*!OCB+9-18CF2)BW*%O[S4AFJ3;H&)[* 1
MK,P5)MQ[L[QX MVVQ^ \TG!EW-]4;@):?I^5>4N'2J]LOZ^!C0@A5D^J:H(,
M3YL24I9RDSD&E<#()CN=$Q+ C3\X!?#U."/4 AW>H\PY(.<-06%ID66C@[.A
M#O=,B:)EXKFOW$IMSDA2]P]+AB!N'LI45#/"P0DP'>::SM7C)GRH?Y8-=^<
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M%*[\%*QZ.92HHIH?8C5F8! ? ]?-+V)1(Q,BHUYH_?FSUI4PO->?U2P3U![
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M_I)]O<FRDU3XT5U6AD$B<FG$3)<YO=HK%L71EHY4*(P1;ZIH7P9[R$GR]0*
MEIRV93SIC(2]U\V%W]!YS6\O$?LJ1T"8M4%BE&&0 W(85W_\#*N'RM(6NQ((
MI'6]KZ8,CS+=X;XIKDS-ST(/[P["%8['7 !"8GSCR5V4),<<2#P6GR;W581O
MTB8W8:FE_BT5&?O_H"*7_TE%.ID(IK\-'N4BVK[D'R@5=00G1T+7.=]$>'4E
M/LBVZ?1Z44F$B^KV(%OH[7=/OG0EJ0*R4Q_\_,05"MI$&[?A_=&;8=C'."N\
MOB*=O4K3&X%H2]':6$5;>L'D+WW?ULW@V":8 XE\Q*?1R!>W5A<&ZMJUA0YO
M/9)G>GZ@RL+A3]^)[?29<Y>&1W32UQ6RRV2@R3-2J<\^'8X_(>V7N\:\F_YO
MJ- [J>KF.,: 32T:,(-0E<P7#@V[:C.3U[UV5@L\[S$2LKP??3=EMH5M#5$3
M*25\U\J!Q!T,C3'U"9R-KW_?QX5W/A>5SH*A!#LGW$+":*PD,H8<R "#?16?
M?D9_;CC+5B*=A6K98/D:40E4*#0UO2N/*>[ZJ[<_@B),)D+K0O;6=;H2"ZF^
M?"K_ ^LO"8=O\4Z9-EH8-Y&?1!LV]-.B(<N["%N76^1<ZG+=I]$3H8<A> 59
M%MS(>_=^(-^*?%@&H'UT5F09P(7FC9NO_9>=C8#3\00#7UHIK+E27FG8@4I/
M2+_>]W--OZ!BN]JBH5<R*O#._$K'6<XYA:M*]R8<NXN:YNDRM!Q&&_#2<6UI
MN#VT]*OE?J&B3$]T[_A=KTMG5T)8$K31'#>.YWD,9X*&CYX"+:?3670.D0YU
MXC,[9L.K-4^O[/U9%6G7<<PBBGR[TP'W,ZS@1^XK-[L1;A5V:H2+_:V5UW6O
M4$T,8UV83O+YFZ)M&A^L:!]>I;3734D* -"BX_5L)\;_?3&;]4]B%O,/,6NN
M_W<X9WM"_I!0#38G4I'2!;N,^@A5[[5X-0E3_5 @<[7?=$)%,J:U7N:Z6HJ"
MY-4: 2*LD+7*(1PO649-3JF.7HRH[ ^QF&P37NN2.^^!W(XQ<GR\% K  *4&
MH@^*W2O< 7>MNN[*=84[KY!P>%9GR.[&9VT$_'LHM;#ZRRN!>@?+AO=)+CVX
MZ:4'ETV3B5R#QJJ1BG $#)]J?C?^>, GI/5V7P8O@^W08X38R,&)G:LPBS0N
M/S6GI:>BC0)+7'J5,[22'/?213]0B+B^N$YI9_'G2=[ZLU7WM1F"+':[\PT!
M%'2&Q(B2R;H3(ZJ"V@N89%S=*>)NO70D?O:0= E4^^W_4Z01 HW^0&V3IQME
MC/=#;WY;2JT'D_ECM>'5C)]IG$5PLK<>DM(<=SA*+M0G=(V&_>P-F(YGZ[(0
MAM;V6-A^JV_W00FV3]35A$@Z>&GWW7GS@3PL3A>P]O%<%A:,!Y\JX'6!S##]
M:;#F^,ZN_;A4!CF;<)RE]72]QB/GNF%RM1I0V\1N 2 U9)ZTG_>U%=/6V:D=
MC.X,*>X[S(8^O%P&A9X%CL;X4U-L1#Q,HA0JV6MZ\FR$)\*$5:R:'73/I6;@
MW7*+OGX3#X!B*D:H:VZN7ZQ[5EIP\K",5'V^3#GG8[Z!CE%+%JOX]_$_^.QT
M8F+N,!+T%(..HX: PYE.?^B6Q?%=/XNM9],?ND7J_%'0T%YVFSLQ-I<^6(O&
M5+(T961G]- 7?[L(#^[A)*O!NZ&'/,CPI;O;"]S?>$*6S%VG@VW31EN-7CQS
MVB?UK'D,R"8VF_RS.5(HZU=LZ48G%>$!3)$*@8-JZQ$-GT5P%*K6F-MYAD4
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M^%=Z)AT5+T8(EOG^T)?Z6<VJ7K)4O_I,>6ZS@Q!C93,C2/ /<9CQW\$N##3
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M[O7X"IZ8/B!MO3C=K_"I=3$+':&UOL$%_B9CP-R79R$/OS:8/R3*=L8G8B\
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M0G1X'H6^'2XM\B60"C*J1$RP3UYF"CW89?KQRQ#OM:B%TVW.F_NNZP!9MBU
MMB5:+2H/LK+-Y+]K:_A,C7A9*+/#X)KY@T.5:8 Q;W5L]UE+X\)THZ6U#<<3
MP5*_HUFOU:W4RD6WR:I.E1^_JJ(/Q&>YEJ5>!O0G_*X*F1J'<7^MW&7<-)BH
MGY':9;5Q"7!#S2VX3K%2X-19ZMWBI)O>)V;3))'R *WQ?E8U.*77^= 8';'G
MTL/WADQJ]YF>ARR<+"A$(E3/61B>D2W77KTB]5/39\Q+<WA.0\TT2:-I*+7#
MG/?P9> AO5!WOJOHO/ FBQK.K=*YF>]+92/(TN^^<U[TEZ\">6W]F+1>.#F,
M_ZLE"$<TKN/_(OE.3*Z9"M]41:5-+]T3T>>BMTV3E 'S(@4WT EB6X#26 <Y
M@5XYC5;>1OBTS9"IH(:JG$8!HJ(]<7T"% N[CV]DBE6B7.]D)#RR9XK8KO3)
M IEU5L>;OG\N6K<Y])W"T?RNC8?0)&PDYJ>D$*&IBE1OUA(S7)GH@),QQRM
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MA7#@38/J*F^Q>9[F'I+GTC4R3!UQ3<S$;6H WX@5&7S/QFF!L$@F/CH&I%X
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M8W_M9D2@>_>PYPUXVB1BJ+$I?74<<JVXZ3.RO6+PJ2  5CT#K6AZ1DOV>S8
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M^E;HS0W1;S /28G8'RLEX_M,R-'.UR=\6*@HCU25IK/>"[YZ#HT*/P8PD41
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M+A]5!IH)%#;Q#PJZ^@ENJSEQ:*Z/M'T=?50@>-6.EOM36O%L0YMHS[Q52]'
M_'Q=YBPLG?V0- EC(\F1D&KL.)=-?DQ*E!H%0;ST ;(D"C/R;5[&: )TUY#*
ML*PDAAE#NJ#'0V-W0"?_NB;.:SDW/)F>P4XO!)^PUU9#.(.3W)N>5E.U[;E0
MB94\0P!:$O@+O@1#["BF$/J@[D$TQZ:>67L&ATGC]%9)=,B!DPY?W>WU5 D
M?,(00/K4C(H@^AV:$=ZN=EO?6V[8I(26+#R8>FH]7TCBM@%2S7^AS<[I/VPI
M#JHZWYEC>X8Q RC%A+$^!GR]A6ESV),A>!Y*:6!3Z-3A8(X>$B->$!6',IS(
MT6Z/Z,I7R.DQG;5!7COT\)V;'1#G"Y*.NRYQ#!!T9__6](JYU/>:46).$?-1
M3F&&9Y 72MHBN%]N"U'EN&:VG^VO6&FNMY_6H( PR,^=&J,UMQ9"!(XT'.H3
MX%B%[I04'JH.)U0D#R.\G>H6!G3!'<8(\</SJ+]%=.#UZY,*YFZYN!2  T2_
MI7VZMK550N,C^Z%KP"0&L%)]#'!2#<'N)1R:$\$$47P"IFVU^XCE'9!6A1R*
M%K\=HNRI6+4X 7=.W% JBD+87VU5#XC%N_G>XJW/<?1FOR;4F#)[8M-P65TI
M<<> \VI\KB@._J,\DK0KNT1'$<$/HY"HPE%*2$%?J$3W=_.;XSJ2O"K,HMH^
M[HH%*MUK)]M5P@T\2?)!X?0'H6R$OKW'1T5J,ALH1JW>4-'N;/)PHAKL,F*8
M[A[![SURJ\%5;#HK._#)UVT&P?0NY!TJSH<#ZCQ*5NKR#Z\N@^[Z(BZ'IBWD
MK/J'(KP%C3N';GQ)RW&]YULNM0NLT!3O'T:ZNU:9T3G"1,,S,]-;()GM#9,V
M>U3&^ L1!8/4[/4-A6M^MOPZ9-;)!2Y. J,%9"YQ7LZQ'\JZ12^3G;VI,C:[
M\8-I06VPTE5!45!KYCN'XMMWCD^6/\Y<\=6R-3>,4Z$Z*3VJB/:KN(7TJD$7
MSE3K_C=(+1_!5M^GCMKWHI<L?F<+3]T%!#]VCX;M00C*\MHXM1RO;H?0O-XB
MY\%/OL4+>]<K22-L^W"53=4X 9W+LEYIUY:DKSOQ3S )\+P;WWB_?)0;QIX6
MUMM^=>P)/U4QN,&V0<,VM,>\Y1F9<)I46M"0#.DR<X[G,> */!9Z&5'/"<_
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MT;]R5*!R(<9S*P>;)U4;+DEDJ]"*YH$X7RWF:5D-(C]'%G[RL;[ +T?LQ1*
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M]'YKKD=:Z18DSMF&3AKX&?QH8.$H;)8,1JZC]+SW U(/[Y$^-A\#NA75+C]
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MZZ Q]22),4%\541)?7D%V$?PZ;I26'[J"^LMC R]1I3#^7XKUL5'%53>*<>
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MG7Z\*@*W=&9_W?1\#89U(8<&2@,:QNHJ%8SRC/P#XL=67,\F?[U[9L-<#L1
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M=?!)_/9I$J-< 1L_CI4CQK)T6E_3[OL(9A+ICN/H_C5QTH1)B$R7*8<PK\1
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M5/>N?:P[SFDG-?55L<:2%9_E\LZ%;=JS7(ZAH.BC^_A^PNL:Q^> \D+)*RI
MZ5DMC1#YRP%TM/-_;@=];'>(]&BG#EGV[4X3&MC;]RU(ZK8ZF>,N^V>,F#J/
M$0+.TD5_8@3_[QC1P"_7](\802C_G2.,(LXW[O(_-B[M]\9U1JYV.E@6W<EW
MRUS>8QIR4L+FH(<:XL3=(M_[GH\S?FV=^5 X1O7,A[KM(1,&()JSGVU$Q8)N
MDC#7*T:WD4=#A ?'4R:)+A65Z945O*^E336CS6*FHVW+FM 2,R_4<MK5+YB3
M$B>[!E7)&7A;"I+[PJ/E*6IB.OIG$LH293+K>CX)M5-AB#V7O['BR+\GH;*0
M(T4H8PTVO&,!"([(/HOZ\[?.HGXW.X=&E6IX>8G&7X?9R?0+YOPP"VSE8V71
MPG"*X,U]D8N./J\(,HZ9G51#K$M0B:^V S+/3)&/'Y"UN[WY4R 5_T&!..@9
M_H^JQ:O_J^^_NGE=+>*7^)@%]5 1F(#O<TQ1,CJ+&MF-P1Q0,$ ^\UF"C4>*
MQW@^A/<G9-AXFK)I7H]4#MDUFH"?#[P&NV1. 2\J%=A]813$^*+C_;.N%<AY
MEGFJWFT]^5TC:JEO_\PUUC<YN3A;\FI#RX"WC;R)N&]PT]_PN-=/E!'X+S=;
M'@_@M2C>+%*;- #'D.<1M ,W:H7,Z%8YDZ.,X/"@+"4]4X^BW S;O-+?)/IK
MQA8Q0(_DP127_3\D>C^=_YLM?77>4)"/E2]8B_5_-2[75751)PE'- U21.0J
M&QJ*ZQDXCA6L"=S^@P%W3A4K'5ONX*8.=:%-[(OYO"O81<N_N$OJ+<'H$.GK
M:(/SPMU&M%HZV;CKA$(,,LXIX,-4D9[CELZCJ69O)[B_X[<C_7D.H^2NG:D8
MQ6H,S9K,<(1XH$2/_2L5&DLK4^U+)-P%5,Q,;"K2EV[URP.YSJQ)N)?U%:@0
MEB%TOSM<WA8QSS#J6:DIM&P>2;WS98+SC4W6/5-;\F)(R84(SC;.Z(C0 EQU
MWSQL7LKT,77S 6S Z[%INY7Y[FZ7!'1RJ7FIO:A<O$<PVX_9H+U0[DNV,XJ[
MK6.R]+'S B95!V9MMU$VU.CQ7'IJMZ#BY#X^ HM8Y N%W80HTBLZ'*%(K2WQ
M55]Z*5@(LKB 0;L"?/"NME%TG]'8?J2/Q)L20>''3=YJIKD7[A$G=_HZ+"![
M.R(YJ* 4BSG1"F1X)6P^&,L7.=.=KXDEI5PW.P5$>2GRC[ ?=@.=G!^?@\ Q
M3*1)&J> UG[G(TPTK@S;>Z6>;P9$E1#/A$F3,7WJ3F5"'&.8'^F53ZQE$FVQ
MOU!ND*]" Z+0*Q8K5M-YOGS$*A+E-T\C8F)B]Y-TEW')C;NXV\OC5X)"N 'V
M^2 Z),O$)C<=<QQ_Q:/K<;7O1@M= @(](>/I_LS \4CQ"I[_-]C[ROB)\!P$
M9Z;.$ OC<;;B&R&K'+6HS3 <BDMM!3\KN=#PNO_2R]RG-2^NR8W@N-"G@$B"
M-LY\(3VFMJ220PTK#,>P# 4N-VNX<H;HC=A7UTE\O2WD,207S?8P."9-[OIA
M!K#-CM'P96%ZL?DWW>[1GL[=OND ,RG\\NW6)D'T)B;9HK39)V[L,.&BA7$&
M2*;;X8N4-=S&8U;'4%= _X"$+/K3"F+?PNG(RL[PD8"6;F;):+=9?DS"%FKP
M%$#;3HTOFL&(A"K<(7 $]W(PFEAU%OBN*&<?R/,]P'6$;+WE&44-&'R<KD\J
MF%U%ZG$]\'Y-]#C\-L'/]L@4;]S;?%".+?!5Q'"$0LW9*EXY6LE,?A]Q5>"P
M[B%.?N;YIO(=_V\6.'T\R&]@Z>V5WRSP_3\L\(B>96DH3JK$ED?P"J^8H9Q6
MH0!=V5BQC*&38J5>DLEKPV*CE#5E.O15&YJ*8U8&-GM&7[OQZI]@BI6]FMGZ
M>ET=IBUK?2:!GT^K#:H;'PASM@D:L="FF485+:4;(8P1-K>^EAM?,*J#MNMV
MJ2,Z'$X!8?XY74$7M?/Q(481YCAP)%2ITA?1XW.0^/HIBQ7NTKK\K(RG()&Z
MW=-26LKP[QM"GVX@TZ",HR)[,>!I+C3I0$QE)P9."YF62@W5#,K''X&37.YL
M6K[X+#I?,#DV<,'DVRU7C>%OJ?%0Q;Q3P!\8>-S?,/":.8F,,:'.VL34X'[*
M-_2JU, [MW\R*=UH2-;-9RW+ICJ2,7T"1#<Y:^FG/F#G#<FW$LY?3JY:4XOG
MFM94\!M+>3):\KU(SBZF>QP3JP:AB^QQ9WM*;[?I.%JHE<TB,?C\JNUM+ZZ(
MD&(=*1YEWU82Q.B200FR6,#IZ/(U:#[QQB[&$GSP#.^"/0DTFNE"T9RP=A:M
MG; B*Y\PAQ4E8.($=C"8B\.,NEZ/W5F#YS<?VJ$3NW;N6J25%\!F<JC%#O!^
MF"Q%=#H"16X=6HVCZ'8CP0<?ZN*NY!8!+WA[QM%RJZNWCG.2<KY^T/NY 6H\
M[VDLK\/8^86V=+37WE?+O1-=0]"6XQ72C5<D"2W><$0P')5J:NNUG</ 22)3
MI65<X=R/&7])N5'O1ANZ&^),P63VWZ+?]-KFV'V+G0%F"Q>IO%E^G5.)6;=3
MW#18;;[376(<3GPWW.Y%F*_ (.G:EXHU*(_=0J#;1ZL[C;CXI@)?M^YYUC&H
M]3N\===A^9ENTJ+P Z.3)"1L(CI)YK(N]WP]==*+0#'K(#Q/FSO?&U[3E(GM
MB/2[9KX-:/6H32^6]01*Z'T<0_>08E^I<+Z/#]U<=K27]]@H1#)K8^,O'+CY
MS"O +NC--<6'(ETH #PZL[<<7:Z*NPLZ"!\W"EA2:YI:.BZMQ7F*]39/O3PH
M^B#)='W>?ND2J)!P%\L;4[5VPCM*$']L5P4IEW'VP6;&[<:\*_>T"2N&0"2;
MKBN,\*1(;"OR&MEHRGDV!E IU_'KIC%G,?LBHW2]>&02SXH*8</.2<<5FC?G
MG.((OE0R_MS@&3XZK7LB)I7_US<XY1V"/045F(&TCRH&GJPNDJ4:4:Q.831E
MI2@2?K'R^IMZX=N=7WML^1U$&-2GAAE>/WKVQ<^5V;TXZO\=%MS[-Q:<U7QJ
MNNB3S>X3O\(;U*;9FD_\N'WL?;SM[;DG"P.OF(?XLG([?M'-,C7LMH%\D?R>
MQL4061X-[P]04#6JS==955!E*9_%DW,-+68MUXG6EGZ)I\]F$!Y\+U8FU5R+
M9=*Q#AO "GR(PZP/DH06RFP)]<UH%0/=/UR_E=<R3'HK+QIPOH"?3FX%?3)&
M!QVG"'&= I22VCQ:$S 1A# 8PRE@2GE4<8\)J&7=G3!\"M!\8H#GJ C:*_!?
MHM4U3?OS%H72C8N:@ M)8,"%\>1OUP&W*B"*5/@ W99T\-C^'/.O$[9>"%!>
MKW=MZT8$N5U]L$^&?''X?(C3PL+X=%I=_H]^UN;>RB(G7:T9SF2]CKIJ38ZC
MQ+;Q:F##D8#F0;%#@.G<1L7VX?7U@'*?IF)555+L; _KP:ZJ^Z5/W-&.3S1M
M4AGMK*0I:V1N?[]3?<E37.CF/W#G?R^Z!'>,",6TM7KA'*19O+Z87Y<^R[UT
M2B7P)HQ2W8E[_=E2PAP)T]R,>+5JSF-+V:EB%T*;<O2M=X]5:1]>4*4S6OXU
M\.FCB(B0"]GG?I>GPJZ<+V8M- ]OA QY[MH'+43+?YE+^7JY[%9%P/ESF\R6
MW1+^V4WYJT@?1HF#AE]9J5G=Z/B)VYWN<AZ#:3_5>IYF$XN9MJ5V3YO7MGE*
MW"J2JU9GT>9.[+M^,W')QS#N(6FZ@PW=0W(0-8!UA>Y-T?HO^IHQWH1*)YGR
MF5?"--KC%=L99_O]H/Z#E@UW\!5LTXUH8J^Z_0#A@]G)O!HOLB#E4;MP,F.S
M4<_^+7(A]+@X4);?@7OAJFU3AF1*<M^GRF$VB*&IJ0H_:041D/^RJ<:G&_%7
MN5ZI7_+@GSKPWUP&%@>(;7:DEW[/YCT%)#5AAT\ZVT5. 6./X19PKG]'$3L3
MP/BP?(("MKZTU,I2G;>:IV#RA/WKYIS=Q'Z;_1(SFPQ"^[TR4O+.D">NG''Q
M292D)I"3_W%!,JQ?R#P8M"*=2)]<-A^E';3:[) &^V^/P7\\!3AV? -V<["=
MR#ARL(NY33_'.'2Y4?J"E;1)NIH=PL0H2->,%#AV25'3S/'9OZ9G_?SC"[A5
MLU<?F>:;V%(.O$4BK2\0J *QVVB1$#G^LE!MF\G>0X-)3.R6AO@PC?.OB*C]
M<CMW1&5]:<7<1VY6#:YYJ<=63>#I@2RSY&+NIK<3FTQ\3))>3KP5R+3II]VE
MO9ZYUXHVWFWZT!?25E:8^2O*#\<J7(9]SF$\H<'/0?47$V8X%OGZV&B=D&GJ
MG5;2HU AA[RZGL]V-\=)IU5;C8,</[C-*^?6TS,^4PWH0X CY@6P"OF+@RAJ
MJ '.N#LFB!Z?6C=$ L;QU&>ZN2U8BN=[LK-\S>@2\ZN=L#>]E!Y6/!OREL8*
MKGJ_3,NX0[B4SU%9AL_+CK&@S3#33#8O7T>TQGATTTHO;6UZ5Q.E$[_J6J<
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MJ!)G&8MH,.Y679-))UN'3X+S?O,MHIX@M,ZL"06^Z(0;?PJX3\1BDVZ88-(
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M$B04V/"02@+S^ F;TV3S<D2I[V O\\1Q[+1;<JYECP\?@3/17%9;=DX;8/(
MS703&DL)+$&ZG/!"Z?#EBVZ,>!5T>S5.I8N#VJ4VLWR0@GS>3*G2<9YKM'+H
M=8:CFYE4#KBQ'MBL:K-FS,C'N)E2<) 1YZ.CQ=&A[SS!7[MH.(!['B&CNU*7
M7!.=&J_1PPN_IA5=2BPRV[BVV@_1YB[(%38>^C0WW>)Z+=/Z@Y8%WM8*/X0M
M%:[:(LACCWKI06C;0"^>[P?^:FW%F?MC1J8@S8, ?MW\>C7;I9XP5N-)NMWT
MC9\+"?0_RA=1[+X'76P</1TT!*V,_?D(LK[IH&JQ&5E=AX+5W0$%%1^V=K,?
MO(9V-N\2^W])-*[7KO479;_2@Q@LY]))9(S,.^L<NSVO"G9.,<RPVHWV.>NA
MC47992-.YD5S9]58H:W\=UGF-9(_>JNVSAK.=,E#\GI"=;TL^T!EN,+'\3H5
MPP^!*J#QIYRO9_H#;'V<V#Y>>LV^/*]A]/#*-=$/$1^E,6'-IX (@LQ+/++,
M.8>X]I@$8U?<K4B&SSES]2PW<48=[)DXE@<GX^-BY;*EVS&.2:;XKJFS8[P'
MLI2VHFNJ3Z%ZJCM1/02K(]Q-,(I!;P<O(KUN><4]AHH7D*GK-[P1OMG6?,2J
MIIF$N=,OQ;WPI2 J\DX0'50?O8(?QBZBEPX_-N")O!8UH]=E["+B*EQK<Q>.
MS<CT,,L:7FZ4//U'#YLOK@0BM[X_TC60,$YX#R/S%7F(]\,B.K/))JIZ#@IS
M';_.6.M46=WTV-%T%Z2\2ZW=5O[ Y9UT9S0/L!?8P2!^"RA. '4&:(POQX2]
MS4NKM?6$:V]][WB%[NKIU5F%SQ6*S#5#:_3P=KR51F8=@9[6\_(2T;>JB!K/
MITS#$W66LBIC;G5Q9ELL;)(Z]6E;!UOHR7,$G_*.QE8W@$[ID _@ =D-P(3G
M8^"1, D\#P[TL+EMM)7*!P=1'H5>0/M07&L;4_D\AH<;104G*Q3@;HW=?/SZ
MZ>[-GX5FQP#<X4M/D2@%ZDDY!HRN_S1OD]N!^?[8UGSO9NXL8X6Q:+F8WXV+
MRF_C@0NH:%1U1,1&E0*STH(//K_"E()EU>CD)HWOHM$XC0H6H[8N?_PZVY#Y
M:=I'3E6OI^U/@#N]C9B6V_$I=G[]O6X9_(U%*=)L&[-Y*9GK5=&#F+%DZK)^
M'L92)2E9?G$^12<6RUL#.*UM]78X^L,Q%SSX1 HJA%=::+&FPQ]BTJ(PP]%6
M?+C _5U'R;0,^UP_Q; 'WJH53VN'-YIBS7A2<V,UIF,C00.DL2TOZ/8O#\=P
M8L'1"FQ0T8:O7FUJ@]:C\(T- DAH0Y)R]12 C7=:Y50JD]L\F&D9;#') -<*
MO/H<OU._W(D;<L!8;Q(ON#AT^U\IQ/J? C"%<9O'X_,4.,E0[K&]8QDRX1\V
M2#!.J'"\2Z/P@VV-'YKTD,KMU8MG HX"K[+0W,E:1@>)A?R=VI6\6_E.:CO:
M1:-3>>526A(IKF/N'1]23;I<^=<ONT)ZK38J(6UC7W^B>MG%&T>#'. OVJEP
MDC'B9,8/<%7U8BC:-2OF]L8)\<'-ZXA-'QS>>?2 U-)B+;DWK=E@\=I=MK49
M#=YZ!09SJ/@(["Z>5UX$G9 0Y,#FCY']L3>GJ!_/5$L1-9GP%+WIQ0<JQ80\
MO'KI8)COE_7KC;(76UQYX*E=C$04MJ/+_R3G<;XE00<+[SX&8:9]57F)5.]
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MR?*SI!E0K735)H&F>Q/5UAXE)*#DJ*7K)T,\]D WO2IH /$<&%U XT^=_[8
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MU-]?5.O,\P7$0]>:"!)M=H+<*%-7E]F=VIN%-!!F(0B9BQ%'1>4_L3RR81*
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M=BK8:@Q\QE7&J^\9/;!H'Y;0CS+0]S!.?KW&S,?,6U55E:%K-+7KD/(0=!@
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M1G6$NXU6P]VZ)F 311Y2FQMV-042N1/TQ8GTT0FED9$P2,D =F+J,%8!(PN
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M*[%F^_'_"'__9R)" LX/]]A=LNF8D4X"YRAGB L2;>)U05NWN RW]T:11?,
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MU#TW\= OMUO:-?GO./@FOR/H EYB).L.'* ,CH*\3M:JN"<@W2%U18_?LAC
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MC/>76H!;J315)62ZK/>KAT3^ZY:;_T<2UA_7;$:!3\7C=V'!.P&/]2)5TX)
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MWK2O5\H=3KU*=BC^#]!$^C\@0;EC_PU02P,$%     @ 88-B7&.\B)8O,P$
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M7RG&YGZZ&9&.+[Q>O>!77_8[5O%X';7&9F=>]#"2,YB%H+D BQR%,05;X:A
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M/#Z]LPBN,6$RJ!%D"&*Z#V&WNG-B \60S0).Y/Z+4 >Y&$7\'5A<UF><@W^
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M5="<77G?3W? XN>;66V7<@GMA2WG3Z0%[>A97>5V0GB0^ZR39+-@^D]#[Z(
MLPID=^Z.MK]J3&O.9/M\J@HX!GZ/45.4G$AQ\424:=R39<)<N-6Q/U2-(@I
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MSHO%;Q 1UTC=H'8>BB+]#;'Q4[^P\/^4-U[MILW11, (L^<U;:X,U&S [?)
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M]BZ(A9PTN*46\X\BO "X(CUI%,<(13)A.K:X9(Z_&_XHX:8)UK6NJX:='5&
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M)O:NGDIGG?K)!!>;E;YBBU>QO#@A735]FTJQ')'][;/;AA8_NQ;S9\++L=^
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M(<ET5&[(U_X5>,S@0U4:FA+PHVOHI==DNL4+N-ZOEZ@.R>G?KM=F*)EF)U
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M3R@ L!V5\:!W%,CUX,,#8'UF"06 R_21(H<X49WI&3X*@ O\UQ7+'MY<U*(
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MX@]BB"!<5S-7: 31KD@C]WFJ(PBB=$:@_]LZNY*_A:>*7??W$M>K-X,V@GP
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MGK[V)%<>3>71VF'M460JW#$K/PL703_>;CK9\_,3!6 [32#B74@G7;T\C,;
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MEF+<ZQ;QR.*R*7D$]43_6,^U"<3/I,H(.H$G[=L@JULZQ1\2CR3#^2G%X@^
MXIG'EYBT^VF@'RL.Z\I*IU>QRS)I:+<-0$2J>(Q<\4?OA9;#UL]1+?2(%N/;
M%MWA&V8?'*N=$,+""&_[L$[@J/\0418,-4^@-U"XLI-"V#M"6*4>6IJ#"0_$
M;Y[@1/73'E]3WWBQ06_/M1EV];9W$6G^DD4G+T[.:4PMCS^OF@!)3+PM)#=;
MT'0AC+=EA$9WKWE.O#V)#QO8Q"<@?E(\*(]3M[WM^-&!15X!((.Y?EQ7/%C?
MR.#%\^Y*ZS1,PGER#&;.VU>#FK%GQ2BP!3F832/UA))A3KA>@0@_42 )XMDN
M+-7Z*!'H!"$($OYQZIX.\D'XVDF:Q/[*%9XL:Y?VZ=M[>2JBH06J,2-LL7W-
M#@3G4P--/H@G^O5Z>&JI8'TL2Y7MV:5%E/5*%0%5,WB[F80ZB@CO2!63$"50
M]BKWG19G;<3DVK87YU+DL >95O@L+UT]S,7N(?OH(-VA>H?RTTDI*?EUXV\U
M=PIA^P5*0$T7R_]#E(Y@70O7$.O 1$9A55[AV@QE\;6 & G^""DUCZ0FG&(Z
MA.(.>I(U.BM5AO(WG&=.XVL)FT#G&OOK7K(ZAOJA=8LZ#G<V>UY$Z%<MK5O4
M:0! 9=]IT:%\.#N&J?. Y\P]X-D-WX93(80[^3<2MV(TZ@)FIK=G&<M4O,3$
M]]%E,G)WAR+BLFI)G9IJW@8:MP$)4G]\K*0*.71_=#7LH.$^02>R.#28; "A
MNAG/;(BO0.^I0]Z#;ZP4Y1[T,I0$_>'1 A6,OW-A,6NA]2'<5-M?7CLYRSBS
MO[\IEUS(*$/XN;9D.]5?NJ+2G:(YB;J B1"LMWN#/0SZ<:_T@S/T^-A7O!/\
MYR3QE;U8'::+_,^,&Z+U*5L8Y.170$U&YX7*<I(L:[NO7==0.\GZG3'&6YE4
MYC'@*1%R70B3I0RF((L=ZJ("V0G:;DA0ZQ*=2+U%%YU:H/M*\-]IR*>@:\A(
M</LMNK7NC/$IS81WG5A5(M5#YX+85#>5E#?G/-(;VW)E'D^5%:PC9F-]^/E"
MV!4B=;TXW#- X[ZAM*?AMK?@)).!5FN*'9(2PL2&*[MP,I^V[D(?2-W6LZ#7
M5X&?7HE7J90/,"Y[27VY#5\'ATQNPQ:611UM-5D:=&9[M?."F&BZ]?W*NZQZ
MG#[V4B48])H2J>]+_U9IYLFDT .-KFBQ"_/[>F4MHBZYEKYM0V3&#ZA%Q %'
M5/N!HL9I&SI U6$[,GNF#093-IRKZM":6>TE4/%=ZSGK-"'_M;O20'H^H#0D
M3_41JA"%VG[6BF#=\5,I>:KGJH5G_/%M%:%U0AA<"!M,$>SO%,(\K<-HQ:'5
MUJ&T0DI=B_.0;XC^T71PIA8@M=964*2JZ90M&#T+;X5C+/?[?E5J-:G[.R45
MHI!-ENZU#F?&.4&?V8P1O9=SNEE4>WC1%S+4V]5)7%TO0Q5FPB-]&P8R)%69
MJ3433MX,;K$&+]$M-SBQU","+ZCGT.%K/&+X"<:%'3Z^.M3&54];]:^'O=[<
MJK8/A@L"-PC6HUFWSO,SR#*"+VX'F:53P^)A2 _KT.7U7&>9'29,<>@V)#"E
M];2-?I2UWQJ!K#$D'.$][]Y67.;[JNR! ITN9NI0_JXB?$+)Y]/CEBDDT[05
M+OA*V4*Y+*;3@"HV*:0C-X,)YUB+=<;M),JF"8%2%VE#OV%K/;7J62Y1FY+I
M6=AGX6E01NK8T=[M;)-I[-.^Y+#F5.-GFB@P^)Q6G'"/K(%K)$BX=R(OBX=2
M1:>*=!X7NZ)K**+ZLHR4W9-#,K$,_(8^C*\=Q!K09;N M\RJ?,.B-A&NE'P:
MUS+8Y[IXJZ5@Z_9+Q*^$;W#V'3"'J\93Z!1LY)GV\$0846I&K)G(!7PH9R98
M]/'.3G7>7D8*3@BKVWR<P45X?>JF]KB]2^)/NWC,#9RWE$+O>7YT'\S0M0.
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MOM\HL9,O?S?NCZ:I,)1N7[*G&@M-JH*)WUZ4#\Y]RJ@E#XN-%FAZ]33M+F(
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MQ8[(DF;P-5:\JA_:0%R>U_Q&R$<2\#"*&,\?.S2$)UN/_DIL,[0_8A-;*CQ
M7[<9_"M;RK6@=+NK0T^OP#9T@08]ULYSW6"\;/#%"NQ2)&%N24XPT Y'K^6
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M:H?$%IQMY%<( [(9:0L41N<B*'%1_LH;("._,TVV K.(3.#H#]/YZ<+#+.F
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M=3V/^K0#A9&2[<._[^^0F-*=W;\\5$OJJMD^Q(6<#_[=Q!:GA9VIT=*K[A$
M^[[L>)YHX5E").4Y$2[-2(X!\S16G#)*):A47U5G[PS':%;4)X%P^3=.-Y>G
M]V_EY/C056/\9F7X,L] > <SM@I+1U>M]6$5T.3\WD:Y/TB2YRQ.90[N>D:)
MX'%.I#6*T#2-,Y5QZ?OKO7\A!!6F]XXQL_%L!!?:0-#QHLJ=X*-.W6]EO6ZR
MOB%O+/<FS;*8&)V!-Z:X)I)ECN@4# ,0^)RRWL6)^PO4&QI#">0T XQF/,G
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M0!=K-O-%&@Q#K7ZAYLMAL(.3LFKN&0=[FJHDJ8Z9\)2X- -.(E)'<D %HJ0
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M>/%@7-F]JEM?N?1!FF2 M6:2$XGG'PAPA8@24@(4I'$F,TY9VKLDBHT$X/I
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M$WFN6:LKA7W\@BU]RCT\.!_#'<\?-<XQS-9AMJY#E]]W2:G!!+DS<X*G:D=
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MO%C^G,'LKA8S3E"Q=*;(@:JT@L>2#V<C=QZ*6SQG2?1IZV!K=RO*>(H'D+S
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M(R ^8#E1R)T67X4 A..P@(#N?M4^,P1G+JX+=52NOB7"T,'\QO:%R"QND]W
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MBH0HI$V :,AX5IO )$]58#UZ!'8$7MS:ANCYN_WH_>_O?L6WH ;]NK>S^Q?
MCKM?I3J^U1F2YW#/"Q0?Z/0(C!02/8\N8IO7$[*6_6RT6,2I+T3<&87@4+:)
M3V%RA%%R-XQ14V(>1#<<%Q.J<L=% *%VW:T;.&A1)\.7T;R?H9?0WI"MU::E
MCD9M)Y<<W##!NC2@2^^/S^)Y)M!\#\# %/LY][OY&*9OIP;;;3)S.743,E+:
MC>9ZJ%[I*WLE+G/(D-ISM[JAWG9SIH7[FZ!['A"YI%-J;B[@VY1&XS;W/P^_
MH9V&JS';^/E_O0F3[!+;"E,J$%D8@9:9W1]B0NI2Y5JM/PMYH_">//FWL"2+
M%K#-T@B>Z00SB<*;MJ*#8/S"RMQLBME#RWM20D8&TEIH*1CG2;-((>G81GUY
M0TR@YRB X-9QRM/!@%U18AZ4> YAMVKQ516&BZZ@^-?H9+)0Q58I_^O-5VG?
M!>3.U>R*GF7TBWKVM^6]4UU^ '9E3I2#&2! 0*$9N_M+%.WRFQ@EG,ZUL<:L
M?_!]3C#7X"J?ZS9PN(F=I[JUFGRB1AX_N:2=?="/:,B%>-*Y$/&0"S'D0GQE
M+L0/:0CGCDFPA/!K9P27*,6207RYL(C(*XBKP28&LO:J_?L,.A26]5H[N60D
M;[2$H[#(VW*TYW2+\>1E1+?:?^,L_ C&\M4?QR_"KN>P;EU=I,DM5I@7[LZ2
MLQ2%X&",US+:FE3H7Q?B@2Y=BG37-W,V*8,M-6TNXDVF%/<M+(3E)AC:#X1M
MS@)JI+83-YI;1GA:C*EX(6YZR>A/.UF$N,?H>D^2MB=M&%5%H4@2"+7=Q7T>
M53-$K2X;&5]51RQ<RMLNWR@67#DH.NK=1L ZR^UN:?_R'O"T8PBJ#=-$+;)%
MF$=@,"KU?.<O_WVQ1A!V*:#]*,:+6%*[W8<@D_ZCW6L87-4%>VV9R<6^B]IA
M;/5FUC"L2X)K_2$D=\[7)0>ZO]@=@,NO(J8WK6#H(BR+S5<NQ"(HVJUAH.*%
M&.GB"PYSO<2EW; KRQ2^RVL)$9:PF#"_B<DH[.L/F !$^23DW4._,3L8MR<O
M+T2$A;.P"V5I&23";;PA@S_4V5Y:+%QJS\OE/.FE5BC3;=V!OXIV%TPTGLWW
MP%U$4<.;VZUU%ZX,O&:>(- *ALP[.V\,[M^*%J+%O3"+>&"7]-SY[6$"H\LE
M8H9Q\^-1J=7"FL!'856CI9<OEQVP8$>ZZ+5JDQEPB;0-\N(;;@_IAWST"]!=
M>"ESWXK)_PV(!1^7BT75I1CA7W9W7_37(1DF,SB>M*,G82Z\XJ_B"[6\.L55
MNRBHCK$2 "[NA=T'F#O3>:-S-8)/N]W)15@IOS)]FJNS1U4A&6E6A4# (I0;
M= PD1;!M2[/EY<4FB/G^4=RUUVU]OP8@4\Q\<^-0R@3>H]JMB,?='MLY,DS+
MT;D9A8#9Q33OYF4GI2_.2TXW-2_;A:B.5@$_J%28E  RYJ0<J<EQ42Y-RW<P
M+9=&H]W3> %1R\ T\((E7O"QRQS;2 VP8@PFK3(_/X-?I) R25)Q1+?^,3U^
M!G.PN?'SN:<9^I-R,3U[W3G.,33R#/WN(33S-$,S8@C-#*&9'FU3Z>O>!H#M
M@VXIM-=[4P9F>FG,YKM*B^")%>-0@@PS'$PY[C9.+'R141'(4AN?:1,'OKQ7
M8K'"[LZ<F;71M39S9?YJW>WLZ+Y:RLW #;;S)/*0V#(K1K:-5V'R7V!NW=X0
M%4K5M[1JOK<B^EN;:5 L5^K#AQZ7[;)8J$E2U 8=Y_.7EXJ=M17W+NJ_+3)$
M;]]N<CF]O5[P]R6V?I'FNTAO+ULBCLGSZ$=78;MOR..X2/J](,0C94+E!V7=
M/]LEYHN$C+8*RK!J>N%Y87Q@=%%!$H=^K@C+R5=!0X).A&(*Y?:R")>L VX.
M)",@\Z1[:FC[=,E 7.)J5[G2C;PL$(;7078$GU]O8]D@U/AK4K[H9KP5Q_&_
M]4?L77N6#H'XP[G_G[UW;V[;V+)'OPKJ_NI,R364HH?M."=5MTJ6\_#)RV,[
M9^[\_@-)4,0Q"?  A&3FT]^]]J-[-PC*=N(D\@15,R>R1 *-1O?N_5A[K0T-
M;16\5W6#>&+NF(C_Y_\]"PO8N4+I5>[+^KHT?)(#(Z<=+8.P9 4O;<J;>MLG
MZMRS.)I*_KGBC!?KU.E'A?[&^%*+ID$@J4UMOP;]&YTC.$;ZO^/J_V-7__FG
MN?HY0Z6]FS&7XH_NP+K!A[IZSP*HPM:1CA?ARD)VA@QQ;OD6.\\9FC@NTC]_
MD5Y\.HOT6^G339MTL<Q"IV5HY63D'DK"\]3QO-/G2UN,DQ;BA@NPF@CMMW"5
M5;*T][H\U*H+(AR;H0W8WJ+=GF1#V^!7.GN_(8USGYR]2TF/,R%PV\*UELY4
MM*RH8\\)9.WIY1X$E&S9*($ZZCW<?^%_BHS5ND0XQ!'^*N'8?2NM0EAT2%T7
M@2W(UA2%/')G^/+O?5\TVQRBCW;K2V(R.!R;95GL<T#>%LQKBERYX@92HNL(
MU8ZLE.!J+KGXL)..1>6JYD=GJJRV*-X(:?9J1>X.MQWS5MEK\NV/1YM[:XH'
M,1T4(UH'LNT>W0 A%*6MLNE6:64#U]N"P @<:9&$F;8+C5_I]$)%$(7[9EL*
M[SIW4S;8BMH4PH3AS(2)V++\)-B\[E\T]\>DG((9?Z%F? Q__?R %9""@BW*
M=0-'WOUA+& ;\D=2%L0SX7TS.NEPM\NLJH%\HO'2LT !+JGC:FU/NF;D'%<@
MQ4TM;:*NDS3VL!GI[A[^X1.P07_973:PLT"6'\!W/5T)76N%VU",6>==N-J9
MVD?,^@64VX(.U_I68/QH?4('\(9V3M[<X_7Q0>&9KQ[I&OHD([;?X?2[.'GT
M^=GIDX=G3\X?/KQX=/K%_<^X_?Y:84JJ,6MV]#BT.=CK_4T5J(\]Q$@('X\<
M?RQOAA\A8P*L\M^=><QR5N-<91T<='DBE. CKS[6;_O3B /76PA4["JT6W++
M:B06"-Q7-@+^58XRSW:[8L)0,3+S?&>*)>8OW)*S3Q=VAR;K%U%$ Z80&P-3
MG[82N]1&@B+N!4>R^2P&+#1?@3X4KC?3GNJ3"QGZ[;*P[)$UX WX$=-2@K!<
MT<KLI*B,0 9.$:E )2Q@]/%%UW#$W7#]2M"[\2GD7!^.ND?K=K^MV^^84?W=
MK=L5:!%$1H(6&&W#>V?7D&II6P=E5%<]$QC3BKUR^C_RV)M:]V$$YC(Y1,(-
MI,\IQ-_*H,R)N>J7W9IQ=O8!_J6SB"U8A\AG+H0AC-F_X4//@Y73D4GQA/SZ
M#>K6X;81D-P;)'_V3<F-$L+:3".>,5X9SEBK]P].';MR=,EWV-[4T-[6:F9'
M$_/IF9C?,1_^^S/)8F_>U!3DSHO5/;,OV&MB1P9="FG14=."7<=97R9SH(TF
MVT,2@:4^I)&^D(]%&YLWJFW;><QRQ!1Q2?&_SHQX(L+QQ":',P#3LE82=@[N
M)MF+[U1!#4U/ ]0W_8V_D.#OT,[_:X?6K^MKEE29F-J"T'U(O!MRZA9QV[O)
M#V6G0M[>[+#S&T^RRZUDBD2D1EE+^'SQQOWNB^<#E[9R#SCEX#;SL6FI;\E=
M9RVMRTW$I7-/2RFAO[G8TKD?)@&!?['>E$T0 ^3%+^UT>T\7_'8YJJ;YBG-+
M=,09JS^GRNLI6;G043 +CKTA%<+.HVOX7(4Z]3CLMT5(WFGV3U^3Y,KBY,4X
MY?XF+D:T]B>'UGXTHK5'M/:(UGX?)GHZ)W"J?,W,)M_$3 [C$IZ'@.[[4IR;
MLA@;=,/\649/&6@ S WL?RFZ)%").?%JK1OUX,*^>%3+^Y&#5(M#NWYI:!7?
MC'2_EO2Z?!UKOZ/O)/NZ5C[H2'PO*MFX2D1,6'W?RN@_G[S"=VLI$CY#<?!2
M>4#U;D=?/[M\D*!@_IX5S3Q?E$*@@+_T6.>THQ=MR0W@DS7_1=40FV)M V@[
M%.AW0B6P*=:L,,=0RK):E)&B052MRVD>[_C\ZBK2$YT?+SH5L).)@A)2PXAK
MP0@?)==#\S7(%D3?;-[DMU6LQ"CUG[0]PXG_@>7?T3!\?GI^\< D,N/<6P[8
M$64&J%RCO)50%JAO"]9CM-]E3<!\SKN8;0U_AI]J'=$*'RG4J8M5Q5B+PN#W
MN[,#*W6+/LISOM##$VW<+MN4<_E-.:_(_V169>6A*+<F]$XWVRSKED*MK:!L
MZ/EF9;?&7$_;NMF( J+F?%LA^%SM)H,MXXZQ>;G;%$VX\KK,3\Q(N6^<,[)%
MQ1>1X(XSP(L-.XQ=6_:MR_4&G&@LFR@,6$A$38*(;_NFE.IU12&>O]91<7)]
M,J&%OD/7YZXMY?4LZ7^.%S6MWW8'7L1U\8 N1H:,7MJV5!WL6E/2\6IVNS>\
M<;=ZL>FJ8^T]T5P<>MB'P,<TW0;ZPUQ8GI5S9G"E<Z-LUSKY?CKF)2WW92'A
M:4$FBU?AB@G'.<.&9[M\]5K8$;]_3:OXV_ZT\[;(A5$E4  $$W7TC+Z% ?JM
M;WROGA^#N0J4^RLTF&@%7_IY+_H\9H J=Z9KNO[YZB3#,49&=!*^<?E5JX\K
MG_K\_&]"4L+U!LR5T(L__D)_3S/<!25Q&N;9P[^YE@KN#6%!9A-1?,I:A/R
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M:95UB6F?,>YVWM37$--3PFS.WZ$:@4W$[TN8IR-F7#*LKBBGR\O6X=FC-;
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M7KU<#.(YW__O4[\65B7N4-+@[_OYI=03&_XG _0JVD!#+W3XB6)38YB<\T_
M;MPK(_'GN _]#>)6%$<L.+RLI5-\P;/]MD]V[T?+'* #.E])6W"NK>;IS(79
ME@AICX^>O'\H2M$$SD-D)['<8M^XL4&(T+T[-2HIS@F9,,U5]:^&X1=0W;*&
M\]17X%49.K.T_QP281@>2+Q6:%+)Y9S@=41!P_KZ^.P<_\G^ZYDWU _Y=UQ<
MY)^>/G^F1/DR,4R?0F:HNF9J^5G3"5U.1:_'AC76GSWX\Z?9MI[29"'8FXA
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M<4\'&5C60-L&D28K]T\TRSD)X=1<MV\$ 6T#&"/A7(\?&!!)FTBN*BJZ;0U
MYC-64I9R%1_&G^W!88W)'H4C$R+7!FE5!.HIOZ&N!80?=P98'SLS%BA"ET=[
MEGV6G=/_/XS22PO!UN%&AKDQI1MNB&(^5Y,EXPG@QXPX>RXH@4H"2!SIZKA\
M=?43M $=H_>50'5>[=:PF=TZ6Q>%,69_74R;#A^BZ/3QB%[XM'-Z9Z=C4F],
MZHT-W!]:_Y"*_"#$6?J(F UL" 4Y=KR\'T)$#Z=%M^I-;]*#N#_%ZUP39R(:
M1!]M4N$A0_?1NQB4C.!C.-_%WA4TZ'&[BF]0N6:I34Z8HC67/GJ3KXQ M<^:
MFBO'>N(T<#>PJAHUHXS14!;]1WJ/:T6*/F*D*)1C.YIE$U&HLN?5#;@NKZTW
M K=BZ=I\$_BQLJ/G/SY[P*CAV:I@Z(.J*W[][))1$!47UE78!]Q((M8SH7=>
MD+'/IVB=9E8O.=R]'% /*&W8).U 3]P[K=@?0D@+IVU)D]_K>N)6C!=0?+R<
M!':R]./ (HE^44-WJM>,7(K2Q;;@[D)5NXPT4Y6^Q^>?A RV3U6 JV"U,O0N
M;8V27@JH$&[R<L4S/30KH;%6NNOM<?/*LQ&I'.:L7M)6Y'TZ+2(47#IW-PWY
MT.2@DE.RJ4O!>UDKJUZ\+=]:-VP,V@):.WM5 )7AKV&"E 6NI!=Y["[!+ _U
MND!D,<0[-3G43QQ4<M%ZHU_JJH9I''BJP)D6_Q4D2GAZG@X!^8.1:8KK0"T5
M!%99IU4IX !5U^5T=NIK4]L[$?XRR\)\8%1>H7_*,/% +&%M1J+H>:W2PGN!
MPU_>T&G-[Y"9V^Y--[]VFT]5$OL L_6[VBSI0F5Z8NG/$L6:26S;S'[F-7=Q
M^GN8L$<?:,(>?WP3]F%&:P)9WJJ8@0ZYV;W;A/&"B.W\=ULK8:"N7:^^E'F9
M>Z0Z8*I>1A:2KW&C5TEC_T146572MO>!%_R! [9N[+N[CSG,8;7=5X9/O KX
MQ$]DPOX$L=W+JV]YL;_OI/TES[G+0%@?G2ZV^:EV[  PUH#Y$$QO:D; PKEA
MZFVRJU/AA&<RV"U9YVM.K*Z-K&D_JL0]VY[^DP_N^B0@R9$! +]C,C V?Q$2
M1#ZK:-8I.Z]O_#("8-"Z##QH!!#3DIH LUO/EO3GIM8VR:-OK[XE _NZ:RHZ
MSML=_K0FD_V*CQ:PY",Q\2W]KI[6;[.C5]_^]/\]8*D[= ] 9SYV<5\<LT)3
MQ9WJ= R'RRG)[KRLR=]8X@]\]5:N/O*=O*\BZ;CW]S2MHX U,Q.PVC1($XI,
MU_EL!]JSH[B5(6+=/E#5/8I7C$FW%7;A:W*PE.E\B4PS]B<3!NO5Q9_ZYN+)
MZ<N0D0GF)U).=R(,Z11%OOB"B;1Y'[JJDFP?)Y$3TCR3"*(WXZ8UOXG32(94
MS5OX>BA$\T"# Z;3$51)U;31A8&0**8P1=,Z%'O:-\B-33D:!%/#LER1*:K$
MQ/"P^U*NS$R!%-AMWBS*=CU12Z0W]K02*0DWQ,./>4#+@AS[9<^^&:M#NRJ*
M399OJ@)2BU,*2^79C?*PR)O(E-Q*Y#NM;Q$E%-=*-<_C;8N&&668GF.5%\&=
M;3?<,P6>+2:#/ZKRIA$O7=&4^HD9X $/OK1DB9"BT[TYT  \G=."S!"_\Z(L
M\7H:=V%^P[5YQH] !$A!!3GRUU6W#H-YX G,IX5,&CQU6D[8(5]RGF N 4+_
M0?0.4GN$!0GI$,>!OLG+:J*A J^;P'(OOG8\?_!)&E^E"(8QVHY>"+EJG)[(
M4*]J:^DOI$_G3+RI)[&X"O6,5JZD=U(E($::B+X-K1U5+:J*VVG=H#FF;E9S
MNK<VC9?;GFQ6]$(";4I/7B=G@B8VDG.R(/,N7[7"8<FK!&:1%LS9DP,B.7M:
M/.=ZV2BZ,WG_>X3'80FB1#K(+*0)ZT(Q%,%IW5VSON8&-::JP%8.MM?RXY$\
M5'>G70,Z#?22005__^/%O^0>"J=YZKESH@GR6R[U,=CF%KW<;W%,!:%;=U8!
M_HQ#.63J?WST\/2[N(J.T@7^.2O-/;#]( .$6WN2P0,6=W\+IMQ94XJ2P8).
M9[04!Z8@ECW!:'65XD+\95P'5^XYW1+QX0/1O8ZC#\1GPDART($>01.?'FCB
M; 1-C*")$33Q*UGO1ZFO#_-6ERS47I@_/]?B +B,S-4**CU,9K[<>6KNG?2+
MWR!C10=;1_]9B8<WH]"Z:"*C(1+X=.[]LW[[2WU=9T<WY!Z# V->/-"RW=E)
M^"N?J,*H5%;_$D_RZKC*MTT)7F%$*\4&W\V.KGY\\8#AVO6U'?8YZ$?G]2TX
MDXI\'9Q"CF3S( RDH,X0VB94\F>/LO7U9V^N_9@5B3G/'M$*R6;KSW82<V:7
MW_X3];&SDX>G]&LC5A!53A;#.3G'YP,B_"2[LINJ3Y&(%!T8B;O]%V?A]GSO
MLY,GGQ^X\^G# W=.;G)QJC=I\]O &2W(8T&YV@4FQJIBY3R:?TN/1!@R@/,N
MC8EBXK$)+5EZQ/*#GIOM?[J;\K:@*)AU!ZYH1>'U3H1!CFFTZ77@CHE>$(NF
M]?(3\.QDZ;##A?=^6Q1O:##T)& '!VX::FTT*FA[A8);T!82GPVUT, ]Z7 =
M>UC5[&E3SJ^+IR6O7LWP*E^7XYBT98W4+U.4'S/[ 7-(?G;^F=-VC*LYOG99
M=?S2)1"C-__Y0_WET+([U[^%7@2&Z-H#\@[P(P?2"+D1N)BA\4' ,$@M*&XY
MG]+EL].3BPM;F4T1=+2FNWTR"*W5,5T$9G G4&=09(=V*DSLZ<FY+78C*4]J
MR4A.,7DO:QM .6L@ J#G*>L?H-+'9!,K+F3S,]#T,)/>O%^ZM0T^8U6)F)G*
ME45''E[<GW2:%YGL;-.I@S% U.%7_SD;A5Y,@>AZMBS:!]"T:(7J(]?F3;T1
MGE3NO,Y7JD\!20V]05G)'C3&>99(#*?<2?8:?P"/K#Z#7AS7LEAADIV??.Z6
ME'^T6U/8J.3]\(HZ^]S4_.B-3HS."$3TJV*.GB)0WSJFUDVYD64W(.G%2R L
M;N%)JH^9462L ?QJSG-:'*.#8Q/V=">-5F70M?;$SV011(92( 5BW(8ZXH&I
M&.[-6!<Y1@$<Z<YVCV[?B66SF=I1RPKP@;JMR,U(.X70?FE2-^P&MDJ6V(XB
M**GT"1N(@<0\ISWV:WAI+N%CE.JRIR:\*!-C<L4LR]B3OO&2W-%*)?KA7.=F
M">Z$V?U]V-SWWMF8D_8(,+R>YVOL _HO><7EMML6K,_X^9=:3OJ?B\>?7WWV
MG_  PI$++<S5T(9(O"_Q9^ BD#-R[H]OO!GR7N?YSI6O4)29[U3%EQ-[D!0A
MK^'L\Y,O_I;0AV'8-P6M.UHS1YO_6&V_/#VAN3M[T)-IY=J&7$\S:XMB3;;R
MZ#_/ST\>_XW\QRVY5#G]^^+B!(D\?/W[A\??/\9'+DX>26Z/!Y+<Y\0]D7V
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MGUO7E79F23-'&U MR'H_5 AUTD0UJX\1MFV WWQ:;//C[U8UA779T7??/WW
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M<_P-+C=RXD:4!2@.&=_UCH+G[,H,=<(Y61I05?J-3Q.7A0?41L[*<^R?B\3
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MADDXR:Z6:.H*@]*+<@3!X-1N542*5]K#*Y!WKK1B]J\.G85@OU#9 0%N.F9
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M"8@ZE*CRF_(ZE[I30/4X7VX2/;6>AQ;R7RF?@N1*KGDA2LTZ /,@<#[3L_0
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M?6W]\ EU$;B[HV?$?6IM'%U+K]$7#KB)H7\G]5F8V$M=%NN]?\_;1NI >Y4
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M !&LB*H>I[L:WS%IS7@70,/3+K)?MLK+-7N,\53&Z!GSHPB5^"#D!4:D>YP
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M_5NN?T*A]">A6N"VZV=I3)5]]99B,HK::=F.)B!0](2^=3]UE[X!'1N"S\#
M?I%FPS0J'DK+-<PF/ABP 31=":E&/IRB,W7,?7)'VKV+XM9\P//3TPE-&J?#
M*-CK1-"-A]\3T.00?N!ZU^Q'?^#EC'6 _R3Z*E4=?<PB$RF+GD<] XB*QJ]V
MS< ZVM0;H\P(4!FZM8%[T2I\PXR8W'K?DA]Y8+ +@WH("]=/D<<DC3H#N01#
M-R((17,>L1.)G,RD38972$*0DIX8^!Q[F*C9*JF"G<Q;1_:77UM^BQLS0@%:
M+\QT#[*H9BN&?8I !X0I@^#D>,1[$'D\&7D!+/.#;\E)T*U"W-BZ4B072SU(
M*BQ3)?O?W\5)47Z9:X_[WM)P>#->&RLQ)#I0^VL13;CYA98G<2TXII 9^[!W
M&B"XM$@[Z1$UL4@;/XL]F.L2FKNC'$O0<BJ'4C\!CE9E.PI8P5+PEBO+AUB*
M7/\/#OI;=6AC -6QL\ ^EW$H^98K_T;=+)DQ<#Q7_E$TNN#\)?W%S2.$4 4M
M@W\=NOHRUQZ3)7#R$F=+Q*YH\OW@=>'(=3R-XL"=\'X*?3L",Y'"F(BAO>,-
M>7+1 ,UXQPH-J_DV]\1/J;GTSQ^:;!#$%U5<@D*U%9LWZ<[ (>$CR1+C1;<W
M^$GF_QR^X*^R]QVRQXR3YTGDQ>X;(@YM>-;JR=]F,\1Z6SDFC$TKB%>Q;^_H
MN (BPI,;*)9AA"9\XM"$\Q&:,$(31FC"^T 3'#6@MZ]1H%OR[@>/YH7B%,,I
M)D9>.+$D93UMZGQND<E[G&!EN.U\(%KKY>V&!N:+2+R(#\03FLE<(9QQ7H0E
M3O9A<AX,[D\@'+66$^1N:V-Z@U:GN!>($J<UE(Y+D:O%D]OI@Q,U0A-:<T):
M[U%ZP('Z47L>Q) W]?Z.E%3?'(MR+ REER^!GY4(+[;<W>40!=_]HSM#!X/S
M,;]T<-._Q)S%3JMG.GLOS#57./X_:W+FT:\DV<4Q''5=:^>G9^<2\S$]]%5=
MB99X()J8!VN"+<(:L/U"^8W,+U="7IF. L(E<UWSI%?'%GD@UW!AH/(;.JB^
M!R04U:SN&G2N];I)N87- E^#2D7^#B.1Y:@@5/*\\L'=0Z5AO;+.5"Y =YJG
MBT.=N!Z^VV4=PW5/_N%0*P[2I;]6)L7A$1BS(@R]MD#HUW3RD^HLA0]%L98Y
MLW.O_])$:SR*W-^)LPF!CM>JL'<MESKPDOEA[4V[>MRA1<1/2(='U8( \2@B
M=Z8[3J@]X.48'AK=4TK!(8.1D?F+T7P$81B]+O=1@2HF-*&(OH9#P-L5<$*T
MS'3?<IF!>0O=LVNJD/-F-FJ+PW?%UJ.3ECV2B=?+O>;FF_J-)$@.S8X>[G=-
M=AI VQ=QL//NQ8DDPS-F@.!2P !H*@75&:1*Z&JKE>0_V-_)M1^T3U8QVE*
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MJ0?%U$#D$%R EXX*:C2>-D?/G)>0$KIRM=YX3KB^U+2=LH;[^D=KC$P&Y:'
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MK(D)@HWBLU:".(N5TD2:IS7A"BQY33*XXLY^V0F-$5W"3L%EHW$'C#O@(^^
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MX[*?G^N'!E0Z 87GTZQLWX!IHYY)K8_/S:&)MD.+UHTRM2:\SLX(":.-4..
MD=D88]F5@+T[F!S-_IM"X4(8LO09;%["D\@LL4<2WR;3 N79JKZ5!T( VQ:-
M?0MS*NLIAM!WOEWOT/:IA/#D;H#/DS?G\]&2NO9:R/FAV_4JIC*TT%1V=6EA
M.^<8X.)*-EWP64/KWWEK 6H3?(WWNT)N;][1:;UC4\!%C2\EA"SZG;"]3H*+
M,U@(XI?)_CT39])4,^_+1)J/W/O78JIXTNH_FDH(ZR'-;W(F_-H6LV4%?V@7
MH#NLSA)5U.' TIMCP5%]9?E6MK5!P0+GF8Q!SG_D< $*$A+US2H7?K&X XVO
M3M$2SER0:3">RCE-U'&RZ0>A@DI<.@?B[*8VIM*-B5$'5$&>-36O@:#CL^ 2
M+L*7OKD)(#;L'7RAGK-2H1H&951[UVSE*HJ)+^JJ&P_8>WG O@YXF?ZN!#5N
M8M*9,^T#C%BL?TE:(*I#;EB0+(:QNI /K2A;V8,+B^)?,@OS7<J. T#/WB=Y
M*QS8OGU#$/D2^X<X10(GQ<DDVD/);X"%NG_I((W[ T7_YT\FV=D7GS_.CECV
ME8Z2N>1'Y#(/>'/%&K(8A#))RL[[=PV!-_SS8"[X3 L6!_?WSL!SU??KCWY1
M=X@E#NYJE3E-SDK5%GT>P5'<4^?D+.+4?YB]R&9=TS![;_IB)X"KB PS2RWV
M5^W>">:4R^S\<\,=4N#86Y=W6;O^VC1$F"5A['!(+YP>$TX?A1-Z\=7Y$]M.
M7Z,WQV[D1.*B6RTP(2S8VI37=0.Z::R>) W'<"Y+]KOS)2)]W!C]V[[SF!GM
M^CVUZ_3BL 2,!Y06':\/,LJYN/Y!*N=N%RZX$QSWXRLH C'_(+D-"D!J5.B7
M]M;6$F6MP"UD-<:+:[IL+AC%B)>)$ ]>V?2%#3M4$N[?B"BPJ; S7V$0$&5Y
M&)_'E$4<_-M#\85FF8>:Q%R0@P@%&1^:;6$8!J;P(!MQDDCIY3:23LT3?CT)
M%00][[W=32,VY=/#ICP:L2DC-N4#L2G_^T]&G[Y(T=*0Y4SQ"V2B4ZU/"Y/Y
MC(JI#66#U0(3VM^4JIJS8ZVH_*0I] _"%2)?9B3HH2XY>*2E;AQ#8I&\<Y7%
M&&(D_-WPT.'R(72B\SH7DI:MNA%R:D_<$0Q4^FZC'JPRJ*N?/M"H1;\ 4O@0
M=SJ^]U_*HOU#7N4**G^U:[?%VD,4CO[KAU<O'Z0TZVU&"WDJY!ZA'J&3.>F1
MK<<"BI%V1^<A(0\?/4F'>>@7)XM8R'1KQ&^E$J_\AMX)^6=QU;@% Q2!E^""
M'R?MGRY!EOB%X>Z!MH63JJK^Y>!.42S!5!4@)AVJ2@Q'UR\Y/)CS ^,%/%)Y
MH9B'>"6H,35S$;MJBQG2V?*1/DR=9L='G>^8QSU67[=Y-!\P,+>\(VEE[H;N
MSH@$3#G#%K;[DXY\R> ?5*NFV\(54-,B(HS<<&S$^.[5L[* ]+YL4-K'&Y_(
M943/?K&C/VNRQ>.EUX8NT\6D QF0XPI1NZ8KXUOL&TY.5MI-)E&8:9:W>_=:
M6;L,(]450&&!CD$%K6_FEBL3C)Z)=XH]#UH=J6+G3NS!*1D8%!) EDOK+1)<
MC \5EYG0:<;;F34E\[](TIMS0&MD1Y+E8*\<#WF'6'O(%:M('0>*IKZN86+=
MQL8 R(/R4;'7S2'O"K>;,?9)3L5-HK/C%*022)+V+?<614"<O.^9]QYZ,2FE
M=MS/O;+R7E7Y)/L)YP0GGI"+&UH[1K3M)6R&Q G2.4D9]]T,.44WSUT?ZFI1
MQ\#2\JF009 :P)]U^W&*,(C'T7YAP%, 5XY'7SCZ5*K')>ZTHK.?DD1^ PUT
MSKN,8BI)2VZJ4?)#K_ZBRRBDD+G5R/9N9Y0X7OHG:3O::;U8DH^A) T9%JFQ
M#>F@L$V-_N4>4D,?7P$;J0 /#HY>97C0 3R@2*&&LA9,'1>#.R[O#Z@"]:@G
MO#5D_1='F0$O,1BUD$CF[BUY<07=<V[=5=Y!#+9$\C<.WV*2+Q.OIZ%N)OVT
MYT]Z) NMU3?YM:6 VF6YV2A=_QY&Z%F]+AAWIZ?^3G6L9+ 'I_&@S%$+ 'NW
M.BASY/A$L RP_LR;!_P-<"#G?[#%5FQ- &OJ 98B\D?4]2&K(KHBK.GIJ+"^
MSV]'H'7L%EGFY(S/&%;+/H.1<P",R6PHZ8)W+J!C:72"<NPU""D..UVZ 0Q&
M)Q@Y_@L+%0>!RJWS<EL!#6F=CK?&OV@CMG/S)KSNYR[T'VZ9<F3:M:6 6EXA
MN+AC:-B",ZF<ZHT1552H9]%C-[FV7!O03V%^9%/:4+:14=QR,H(QIA/#\TD>
MOUMMRS7C=,G5*8!WM2*G=WE,\-81W80+:]$XH7[09G1^/B8="B(YL-E(K;-3
M:>VZ>PA&E->.WY2S-U,RE_2!)N_$D\ZG#./@B2<K%7B9<),8K/GW>8E+?:>7
M8I/4;2-FR3XE#$)?\R6OY)*7D$VABR$C@__NCY+%A%&; ,O3(+>2UB<T)5(;
MY11%389?S'?Q#:IWJA+%?(0A+,0Y2KXSK<1-NA?2 QS&/G+LQ.O)+LB,K)19
M]@[,5> /RE[8N%YU6% 47T&]=;1*9I7^6=:Q58:I/A8RH[P,5 M1YC\:%';O
MX^*0B)4;(5)E+>\N&J'5Q)%<Y7/ZE3IF0B8N5%<.F#S/UVARGV0JOU"N:=6U
M=26P-=K7UW5SK2 V9S&']?-D,:'?G7NF*8:Y1:!)IK@' ;L*U+K/ [7N9<C1
M((:FAUFA2]PG;NC!&4X/=6)K=E<B@X'L8%OH9C?92$A1AL>E!^C$K,#^TV[!
MP_)L+463<E'J\RPZ[)NL4,K(_J3TB'^1!17)-<YI5?Z8&" #CMM+O'HM7\H_
M2A%=E#Z+#MGDE<T/1Z2=TW!"9T*]*1HETAE=J8/P8#A15W@ID+V6IHIR/>V:
MEE_H:+ELHEXYXP+14ZYF;'?2J=KRB5!K"Y";S,9/IC08M&;Z]CIG4O^ 2=2*
MXHV/?)V+P*C]04BVYC$!4.9\'?;@Q +NA'2$C>]"DI';=."AN)(^@8)]RV9^
MC,N"ZFY7-Q$JJ?FJO5T>=OC>!I^XW?WZY?.KRY=?A5W^3V0I<2I?.LO->L'1
MO5ASL6,NYS39(7)R?W','V2^;_ 8.HR2DV'0?GW1",1XZSRRANW&C")Z,M'D
M&NCT)Q.@'QIH>]+<G[/LLR5L,VN_4@2N>J>,N:W@BK('W9_*D^SK*"#7AC.K
M:(P&:@0XC "'CP9P>#P"'$: PPAP&.!@;SMR'X7M49N1+,B;:.@NC8SO/C,U
M(2VN,)WD#7>%X-A%W$+Q0!Z95;,E+25P9,CI5"_ ,-%O)N(CE-FHQL@R@6L:
M5'.AHCJH< I&4G@+\_WS5KPEPT>&URD\EW;(@\XL%-Y;P"K96[/&)W_;MM@&
M1NAT&0BZ(F#XW<WS6)_PY '#C:Z-MJV3,U"BWIYM:O+X=UJH$Q]"$2+Z+!P?
MN9&@D#%3&M. Q8S<CK5F^34Z=^+::;-:NO37=5<I+9A_:&&AT^F5SA=.RB!I
MAU(0K:O=,?XK?&[,'==SB'03-.@@[S;TQ1 :AA'8%,3$D,N3L9?L7DO9,'7D
M'6XZ7X[[(Z>=UG:X1AR_[*L?H;H8:@E<$+#>]SONL_".'M/&"G^URV.@="5Q
M]$[Z(/@'!ACEFOF8I%&'K?L$>\S4RF)+F,H"^Z;MUI9-F]7M5J@1^<.\2(6'
M7$@U]A-FNE]:CAP$".*;FE&"0H'#E=V2M<1U::"JY+EL2R&9RA:NJAVJ2(;S
M'H:6=]-4RUH("0*%]&H7.>QB)ZLPWU)(L$T:F$=;.K )N?I=S8 9IZ^C%*BQ
M3:2_-[@W&"0C0:*5YP238!S_6'''>Q@$^VQ"8M+B&)YQ,BX""S78+ILA-0':
M'O-Z$R5_I*M9RHSQ[NH R1%-CT6+6S'ZN?NVM(08X.&F",8!HTEK%]+H:\15
MR0WC]6?,L[CH_G_VWJW+;2/)%OXK?)ASEK065)9DN]W=>BI+<EMS6K8^V9Y>
MYVD62()5:)$ &R"KS/[U7\2.B,Q((%$ER26-=(27F;:*N.4E,BX[]NY@;&&E
MM -_D!7 JE?VR]X%_IFY,1IBK'=&4TT$J&*,=9!I"B-,!,>%GQ&I%VG96"42
M G_8 80M,)"ZO[MJJ;0D'/R )C3IVU5HEV&NXFZV5S_5U78M_&*ZM66K('V*
M=Q-0E_RZDJZ%8R^@)X%KZ$1ON4K3^[P&4J6TR?Y=!;0<_53,!YFTA@\C'C'A
M#=T)5:\Q$04*!UY4EN]E.P5=-"CLP)K$21G;>#^MVC@FYR^J9!F?A+\QGL-Q
M*K%VD$FHHCM*PV!V474'M$5EY%3,!BXPX=.N;H4:5?B?'#&K2UD#W%,H_<Z5
MX@7TN.;++253!'3S#4)WM^:VI3Y@9<34$-1]P*$4EAP<5Q+LZ=F:FAH4.=%O
MJXC1/ZY$CT)N@]/</M(*<>0%=<R/8^11(>GGJ5[X+^>ZVU_Z9E@DX!;WSE^^
MDL;-[[FO3OXQ,NK;Z C]SVLQ,Z]D1 OWBRX^1#*CN)'\XNMO'GZ_>%K5T K1
M?^<',M__#U;M?/E*OU(L%E_WC+T2L0>T+#07N3C?;,JZTY-B6*>,D\E.O?#)
M"&)I"0O,Q 0'>I%_AQI8,O**]8FKC.Q#&($E'9-LTEA/I#\#SUR^Q).IIFX#
M0&Z J>K)\!DS$J\I)0 P:;P@-2,'@UG*CKD%CS-$Y;:ZB@.GO.9P8#=;X(")
MOR&^M9YL[9ALF<;I:/Y+$0#%6T;927YJ1):BL'7M?91N>?O'&/,BX1+GJ)=F
M"8TW^*S=8Z4?)&?/Y-MCM(97CHZ^EI/=:0/<=(CC!7<X\#'J=\HFTR.;Q@M>
M#H"TV8?,!WK$F4KV0_( #(/O>DL'L(><JY.Y;(JWB<Q[PG.'RIG F=F;CWT0
MHP7CX)S MZSI)&0\.W(D@2S>7<;NK&(+A'4^(!^;]5>B\*P=QBPDTM](>S8X
MR&G>C[3N3HY0T"4>R2-<'0WB*5:=3KP^\ OB@C3[(&M2&&5VY3^Y3]EM.X$^
M\__4NI6J!\B[G?/MUUC$3W%"T^J]=_[T_#[8$LB)7TW22M$_/G[XZ"$YW9A8
MW1(#63>Z%3"O8"<SZ@+$/D'A++<S]=*_1L!N):%'TQP9,$(+;2W5.@C&5)*M
M:DXF9 /[X,YMX%;D)7IKC.$!(V\!_(NBFR81I6@( ""G=((B'= _D<P:7Y!U
M"8(;H*$6'?U:Q+5 @:D2<'>NJ55-+XX,XYROZO61%^3U98LXOFJT2:YNXGVG
MZZA/=$%62E?%HU"C9ZR^")HZ]- 5IP![Y[S!\4J@6^H+/[%4@MXR.DJ<.-@=
M=\%ARA&HL&OU=A[B$TD+^&GVM)!9/YSVFNC3\*0?%D]?_@)_4"Q"4*ZQ-*-+
M4/ )07_BCVC7E;0<;MOK:NHYO3*(G2U^J7GM,L &>T(\:#L*K3?EG^1."X"1
M;O*4-D47Q/9"F5E<=_722WBE?K-P]\7B/X]-M7CT74'[Z_$CV0SP57XY,L,
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M1XS%@<\&,3?Z["^X_! *D4UUT2(Y$FK#$?(L#>Q=Y(M5[+!=4ZW3!I$5;=;
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M""E4JC5$U]!/RTCM]9$O*Q(:XK?05FA% U8Q,\P^597KK3)-3M0T0L;7X0U
MW\C^R61B5C2*!PG9"5NB22=UW^<M/6_I#["E =I.F,BL6UVQ9,B(*.@=?V L
MI6Z(Q:%:73;T\A=U<O8EJYA;$>@+ZC5+OK X$QVRM*_EX*^[]!Z<,DJU?0?5
MALRNLY>!H4DL1:[L$?;5' '/6^QC97S2:IX>#U)8J $[X92/GBY&T(BC(G\R
M.*9&*)I6$&5+-A)OLE G[(RL.6%?'C\R"GWV>NXZK?)EUY;K8F0*S&N->W!B
MVR&=;*]X"FKB_'*@55D)RH'NWQ?9PW5Z:_^A86)S8*\_FX;9-'Q45NA1>QEV
MZ61+7DR97=87E[0^KUH&I&V-WE6;^[J;+E8(N(,;"?Q[QK#^/X)A_6;&L,X8
MUIFZ\U:=MUP?Y=^UB>WGD"W_T9K88B_V*QU*V%SE_J0;Q83"%]"U^IX=_'-3
MX6U-A?\OTSZ\I9 @#ZZB6!;K[GB1(EL8TZ+>#]>VCJH7!5Z:@U(>@'4Q(&"\
MKR-DL=:*#HH#\"<MEG4[$'D589P3S_A.: T>/WST9TTJ3J_,Q7'?-KJ$F"^!
MF>*3-9*L#4=#8$V [PH^%=C,#<!3[+A:^2Z2_.N@GJ (51GS(2[UUW8A)4[#
MVVW:U;&'UDV]$W!/&Z!Y-@MT+6T<9<S0 2WB"#!;H]!F=F4-PB*%JA>3E+P>
MXN#4%_R'A.I,B/E^^8E.T[]\]^05/_' $RIKQ(M"!1[&'#Z65B1%[TK(U2K'
M&OACCW(%5Z)/"^8)V;3;6I0P($,K!=?X*5,0JJS=$A(%OH=*Q"@AAA?_C0I9
MK>;0'9(>2P/&CMM&E3HL3NUP;*-\KE]W0O2I[76W#&O-#%&PK;$55;/X3'3!
M+0C"PU(%X'# 5(8<PBGW%DZLRQ(!4SLB+<-MO($'+>EL;=\.4$N3=JIN/6!#
MULB55ZS@D6AX0S\NSL6#GNX2#)TTGW0=J_[)L5RZ8M I@FZ-_Z6Z++>;0JHI
MV&K<-EUNJZ$(N+,7L2-F(\596T=1W6Q04&71-X5='+:G0M>F0!B98V57,IQD
M"9%!Y@02/*,=\:Q@;2=\ #$NA:Z-&7!*H6Z#.E^([.N-L:27X4B);D/2 F!6
MUK\V_]OX++/=\"40JKR_:_II]^#/1NNMIBHZ9#JDF1F2<]$-.ZB?_N/1H[^<
M_65!+[>UZ.X__ORGLV_#O]CDG.@X9[PF]]$](YNR6]*)]O4CB!Q\B^OH?WP#
M'V8O5:SMZ6PAH@BCWP=1!$&&''>J'<S*F*L:9_)_?/W=H[.O[37.%K]$AY9S
MU-NM^3SZ-1@<@7FQ+64-04%^B\\D8P9FZJ;1U'^@?9STNY+"-^YY@T_"N)9^
MA.M+9;K.%L_(<@HS>KU<W(.?S7'AK__W]?F#KQ\^O%_(__SFZX?ZOQX_?!CX
M5O630X)_Z"^\37>E_SY0?JO.DE+"*Y&:%G#,3Q$I,OJ+1Y<74ZTCR^J"::V$
MW$"\0:$WP!#:>^/@0@APD\VXU48$R\.?"@+T2GU"6^<\*(9^\J/"ZPCED/#4
M$=YH4Z@.5_5F MJ@3JMYTJ,ZS8V],C*Q> >1P8SD#$527Y)G^VF\R7>?3[PO
MBX#CBS\<?WV7F<3A(SK"[%_*L3#P+@%$/(ZVLY2M\F%:> %_,.O+*#@S,<]'
M$T])8[MR@7! B<2WW,F4>O2>D],'\Y#8R\7Q&LK(N[]5(#Z]YHJP=O%2SASE
M&FR7JA RA0H3,SUA%F,,58M^8;@%#+)TC;BX6<X(R4%IB7L2DQ9R8&TC.5EM
M4MY"A-#R/QB'7:3]Y!:2, W* '_2%DRWE(:_%$01+P2-<]QOAXL+&C^=P(%N
MF(1K_^CARO=I ^\CTED*8OJJ$:+F-K\]!J*7P\!X7>U87K(KK9LT6+Y/EDU]
M+NA^?@7=;^>"[ES0_>P+NG<]G$E"C$]A[EKV1]0D5_&FLX1>;,4T33BN4$AI
M 7I,B <5O&KZP8M-76W74(IBF2E5L]*#<YQZ,X6HV44-4_=])7UW.D]!=7MJ
MPH9YA,G\9LK),@)>6M(U]J$+QS=[.E!=*7>\&OB]+$9>Q\P)/"HN:P!/6>1*
M&!-.Q//H[]S2&O V+L]MWKS+,P?ZF%Y:^[L8^Z<!'=H9HX1.&\1VT!4OZ3)'
M,[6LL-DD6P*1,[O=5EY RO=-[-T$CM+D:%0;;N.K@AKQ :$6&YY<+,D5PBK6
M!VE:#"0:^QT#G/;&3%8 &9#9I;<C3^6&=B[XJDE2Q&>PSHWXW?9_]M-4PIYY
MVV7A@T>_Y:1,)>F[SA0^^$\&,$@42.?TQ<R@]AX,:E_\6<,HVT&)>_KX\&"+
MWB;] =?ZP9KB$[2BY*E'@V1HQ;!.Y-7;YJ(=)B\2!R*D7T,G7;B$DZJ,E*C&
MV8DI2,%;=0],IO=OR/$F,*>IPXE1,U(*S27F$\R]$9[=?##>F#F6DYZM:TR>
MCXMLF0UDT]=%$*#=?2KC4K@:\YKK'?7R*!4E<VH@+B,<.M+P?QI-$ [8="9Y
MO2FJ*?@^^"X58'&R<70R@-@-3]+&1W%<O,7*=$R@B"\(D#^0:5W\<.QX];"3
M4J153AET;WOS9:!0H8-N61#VPF%)9^IJ1>$B_7E[BDX6VUQGGB=L_>;82"XP
MOP?U&(>SYP[Q7(].XFVD9K^#Y7<BKF+YL7FUA@^COW8F/]IZS:NIK;^]VJ:+
M7[?36W1\?_$6_WNX[4#A>5L55QW;4LS7DB:C N*N-(.NTLRKLK\L\'^AMDQF
MJ#)Y)S$%6"=]13>7O"86:27+1PY[7HL#?S$(P]'C6.;NP 7@[R+R3X!6DC.U
M70ZE2I9?VNWM'N4!!A0H*\V;7W<MVR:M_LDZ--W L=0U:U%",$NZ,:/4D&QE
M!10FXY4>&S0AZ][J/1BE>'-^M=4E\O;8WDIN8NEC$_^)#STV3@(I?(/D=&43
MX3@:;//T*_1X+,((JU$!$$RDKU4UF]E=JN7!F$]873 X4#92^BF^NN"+FHF!
MVT)BWD2GZ)ERI,31LD8WQ3:IMOPPK\R?._Q,>YVUU( C\9E60 -E"SYA6],'
MKO43)2E](7J)D$?3%>A2[[;Z+:OMN"YD@(>G?1L 3H.U<<92JK1X2CYB(//X
MDCXG@!LJ3;"PPB$MB%]P@)XS#A>F[AYD$M-_O"]&^]=GK+AJ>^S>;[^<WU_\
M_>]/Y9+S"_YAP5U//5-L\!CYDD<A)7;4]1GY6#.IW2V:9SP2XG(MR@MZF0L8
M:@I>NZ1+Z[CG._['HV\?!FP(?;1*O)4'I33A20KZM7J/: /8[Q<\)CX$8O/J
M6UP$#*/*;ITM?FRO*U3">4W!*^!MW[2BS :6$QB&<+^0FQC )5GLG;7$K&)D
MD#4\.2 ]F7ZD%#':[&+3:-=SHB#P4;&P0%&$-M1J)\X<_8&&<[#V,Y-O;9@A
M+$)NSN31[/M4A0[3"V//6!MR]D1UCR=*AU<1(HPB1'RV/$W<A8='21!7=;<Z
M[MC%&-@!W' E.T+6@E>KTVR'F#_R9 Z'BLVV5+IQ6E2)'3,;) XQ9R/D'-H%
ME4!9PP@+RQ,=TP_H_R4Q1.Q5&':M3O7)WU)!_Q2.\+ED]9F7K/XTEZSFDM4[
MEJR^R&#EYX@:CWZZHR;"*2YP*SZ7O0OMCB5NJ3D@ZV]M28?VKQ]%"W*F*O@2
MJ I0)3OMR7]NC@Q>+H1)I) T!4HOJ,?T$@4IPV1A^1]F_M :VZ;PB+\_C,&*
M#C^G;Q ):"E/PM"6*RPB>]P?0Y%&-MR3F=-CWB@?8*-D%GV:3KXM.>_:U=+K
M:DLG#RY#4ZQV-,^K>E[5'VQ5%[:DI?0>BAP)L>)538^8M-CS^IS7YX>SNKSL
M#&D=X2 !R=YP8<9:N(7_S*=J\TW=B,+F=3NOVSM?MR@Y*8J#F42:2Z&KMH(1
M&.JY;@L::RF-_(O6)B?T^E//TR_T)G6:5Z3K>RY_ O32TZUZA3BU2YI]K01D
M:J\^T:DO@ZP]?8LPQ!^ZEKUQ1MI'YOBN8OH!NF;>(O,6^8 .]0!%0(M^V'<3
MEKUXT0U'H25,?#^BGD["S)13!#B>>3'/B_EC18<INTRGN (66\SP6:S*O11U
ML%K?(B+,<5S-JWM>W1_"F\GT_CI8@75N"VH6+@TR@>6%MJBNJW\=I7NOWBV/
M7>]*H."">2!<,/ORQ!"2Y!*]-TK["DS7/GM%4(7M8#V2\QZ8]\!=[P&I_*-]
M:%M>]T(0@=R(^-Q1BT*HKK-HUNB$CZLZ0]AH4BS"4E?8[+RZY]7]0<I C':]
MR7_QM/;P5]X/(O>$_SZOX7D-W[6%S@:3"7=".Q E,20;EQ1Y,<D"!N)M!>N;
MI4[_LG$-U@T1Z1]CFT @:7!!B?$U1.5>>'T2 $5:2@<K'-YUZ>_'(#@&, HW
M$LK!-,/@[7(2O^/V L^Y9&I76<#>H)LL,)I&EINSQ;GYII.0/^O3#*\*#/2M
MG64W0/4>?_UH\_AC3G1T5@9H[Y@@1*J%^VU#!+"N&#&I9X+@2?O8Q"H_XJ=5
M#M7<7[8=F$@*6D#MON4(F/V@@2PHJ]M^2E#&N8%SFH%=.7\SD'>@-V! UO46
M#5;F, .F?4EO676"-"$_V/KE8J,%_&[/+<1\-@W] [<JH)YC][M=PFINK0DS
M]AM9QZVH6@J<GDRIP-*U>[%L'/>3Z]&R48UF/FD<$UM1Q782ML<1*F^M&X:A
M+X8M',6[]7"\?]O&/\+!HQWNPHE5'PY@"M!*B3Q;!.Z;=0_N;/:=^0?<IZ!'
MF/28Y5J5];LA!E.*<'!L7Z'I8*!XS6<#QB&V(172/MY>TQ20-[Z7X@WMD= -
M@.W$C3+PX(,_'TB=7$N3N#NBF"QF.)AK(UVL:$*<(/$(@8ZWT?V&X\'W6L@F
MIF,R=B&DTVK-K?00;A_1$0A_EH/<CLY"WQ>L[_1YUDR@KV8?POFF!C4!Q-2:
M<#4S8J5AE\8ZL * MA:L4"C BL$>*(U.<V#%^#.*P,N%WAQ>7^'N?5\=P%;P
MIHZ4Y]*.2O>@@< *IR '-R9ODKG-UD)'0,]C!%YZ+]=>H"/)EFE)$\U."1.&
MKB[C1[*!5$J",&',N3!N&4BZD:-U12W]=WK>D-&>NX'.9NS^YXW=_V[&[L_8
M_1F[_[;:CJ-37)HG[0P/C=OOY7&$WE!1!DG\6&B*0-8X<6CU@5;^()M?@4 D
MM)K[UO(L566WH+\WA_B.['W#30B]QQJXQI94"5SI+E^A24]_IFWO.6*<X ;<
MU'\_.:IOT<SKAS'3P*]Y3!=F2_LQ9P2LC5]#"-_(GW"W%&/RE@P1E>N;O9'$
M108]3F:&\WB*;S6\= B!U6^:N ^+;%:LCC-'IS=VYOR11,O_P"L'^1EA,#,.
M*:RN9=F\X48B-N-! YE"M']J""8KHX@1@\O:,"];;E/7G6YKJ<1FVD\C-9?V
MA, "I)YD3!2%'N,YY YSROQ%GU*^+['C?HT)IX^0H:T#:SVP5*B'AH75*7DR
M1:ED\M:519^+9<LFWAV(,1;5\&UMFG&^18+>]N2@!6#PBSM!M,!"=M%:@"ZV
M[3*F8Y%QXANH/94E#F46SZNPN>F5PB,'#>[&J%SV!^EV7VW;_B@$?_'Q_(H4
M^L5=(=N+ J%5I5IH./TA-B"Q/0H7?,,?JC5T&)[)[J;'&R7 T[;;6Y;UW@_/
M7CR]SUM:.NK)'CR(<2TK%;# <X+L="_EA@'60!%V*UHRH 0Z2&N[]+^[PZ^7
MUU0E#,2I]LR)C]<F__';]%5W!68!8]24B#]+%EB* (^%UGKR@Q-)Q+(:\H4>
M\-%-!V>7A.%(/15!J"KTWP=NF+CHE;5'1EV77N\-YZ9<&5++YZ<+/8M/0E0>
MK.]DRMON.2@FV*+G<)PFH]W1J$;FS-. JFG$AH'EU/>F=5(W&\$IA(G5)-=(
M#3N\?M)/-SX!\+?1#F/Z)O2-=. ^Q*AUX-!IN^V:A^!L\9P5=D)22E/\,2EL
M.5TFBF*VA>ZBTG\)_N:*_#]PP4\8+&<B@+B#+D:T9EPSVO(2 KT,5A?7^E3X
MDXN(9XOS[>$2WBA[KT+U@+FDWUQ$Y0TA-37'U2@GZU7"L^4>78S=Y:&9!=<Y
M_0HOJ#8WJYD>.(CB<N=?;5L.LB<7O]\G(\'"K-Z:, 1-JZ>G%I&SIHXVTQ7J
ME+X+E55L8(UID!/&FT<K% B''+NF5I_HIIQO6%U&DI>D&O659%'!X,6M'AX6
M+]E O<M5W1ITAZVUVEGPZ_ $7QMP[1+B.^7U%^%/OY^Z+B_J9['S]]F @>YE
MP+>>&^\?C3C[X*\TYGD:8IXO8(P_M+RN^@[O)C0:3<P-])%10"+<@J/TH9IH
M+N;/2=P5-Q!#@BAZ*S1I(ZVAB<P&)]GIL&'GR)-#(KK'RZ]!N=FW16KZK'YB
M7#];3LFP+NP<J@Q7GZX 6811/ 1V/'=X&(,AG:=!R.PM=&RGA#]SJR\K:!M5
MY/AT916Y*5DUUZ,EX/I$(^=V5=3"_WSM1,^BP!D6LVF<%8F8C1;;;M"X,F_<
M!&??DE8A*+]82I<9 +WIR- PW-2WGB!IC!GB-GL1*!&]?L[X]=$>Y]@5::YV
M'.K\]*QW@="S<X5^(TSB*6RO$0@IA%Q^(F\'V1E<2H^B@3THO5>=7Z8JI9N1
MR\K4MHV4(@4I87Q 'I:#)$D=?<#W@@IP)' ;\K::--.[$;C^>NDD2J>9-=(W
MZ?G].&(>D<^H%AV/-9N(F79FQFK>T8'BJ0O%(+JPR5$*<BMWC>B(9OJB5G>B
M:KJ6T7+2^<W_VPC 4;RW:XKD,'&TVJ85)H\;_@*6(]8_-+V91=W/1?#/KPC^
MY[D(/A?!WZX(/A]R\R%W-X=<>N+DW.#\J9,Z8TQY9JP1![GB;VV[7OQ=\ =,
MTO,*W/7D%]_[V]]?W0]@MD/[>\W#<'&R!Q8LEN%U#I)X@B6?=\>=JONPQ[WF
MA]M/.+='/Z#3<FY&F_?-7>^;V$5LC,X<V]&^04S(Y99-@-0X?BH$CBAZ]$'Q
MK;,V$3I:&_]C.KHO6ZWWF>IVP$2.?<*;);LL3]#V4'?G])- A 4:DMYKWC'S
MCOFHX12K'686+AE]D^.EY3M.;<WK=%ZG=[U.HZRR<*!LJH/( U;,)%&N3E9/
M$FHKP>1K2L#:Z_-&?%ZM\VJ]Z]6J71PIW-04ISQK2>1RK3JX$U*0<KWSQ6*2
M^M6S_LRK>%[%=[V*43+9JTS3L-+:2_WD5O/JXU#V)U!WTZL$17'OIV?G_?TB
MK<<,&2,D'+5GSZM]7NUWO=H3PA)P#!1^V0^T'5/*-<"0RF.SNA1VDX17;1@#
M&I_!6CH0C(,JP@O+K6H^0YO)]8CH&<(_FK? O 4^[!886F"A1A8<,D.T&??<
M2?_)044UVR2K4OU.=K]G#LW3#>SV\SJ>U_'=N]^>X]LW=&G@"&7Z;34TS!&Q
MD'%XO"/C[F@]+.(-,6502VLUX-$L[ST2]^VE'1VXF*!D%YK+8O9RYKR:]\B'
MWR/KQ44G"Y^1[=U%V3C,T+YJ][32KR];D'GXWL$47WF+BN#,A)5V":=(U[<
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MA8-RC,#7-F7_30KK8LG1 AS*KC ^C4B+THOT4WJVS:=\A=B/E(1V:GEA71K
M+ZSX+8\_+>_V> %T3<EZ(]I$&M^*$=E+ >T$&=71+0^G?95I.+AA\&168&II
M2^HP @&?@1[03CK4V@L0&G9'C9,9K,&V74FW\1^!%XR>],<A!B/8EH$5N6-=
MX?$"[H-\<@**X?'!:8$FK@'>:,:C?WYX]&]F//J,1W]'//H7Z:VQ!V4$!%DG
MRWKE"L.@%H9#IF.>'8U#!*G3>12"XAOL?R1'2?J^T^[Y<" $S2XCDQ>WS]<(
M0U4P_PG\QBNZ@K;YDJ+F2VXLQH&]$1]"_$&-95J PUW@(20/]@7T18#&AL^3
MPY%OI^P7DQ\;FLNX99@/J>A/H>CY.WCH1"2")D@T(X;9!;E+3R_,G60YYT2C
M'?T"&2 >%WRI"Z-:M*I&^";PYP$]>G+8T5O<=#EMD0^F?:?L%U@$J<=U T$#
MVKQOZNB;QNMKM!?:N<]#S\'V%#'_PKZT42!TC6@UPQ)!HRX@;_/GL.:]@\V6
M8]]7ZZ\8 @W'^*0^?#%TR-$X>=KS([BC4S8-B\XPF/JBLLBX[@+6QZ(,WZ&O
M?P).7_1N.9 -?CIZWJ<:\'?E&UU=.]:_ 6Q(7:G%_M@Q 5"?KVY*_(XM.&SD
M&"$Y!;Q>-\YO?X?X3OOULRWV@!M'RE_?&J%]^FV786LIE_3V;$4:>+<<(HQ7
MW/;07J!A>^ Y!E5!R?"QJ]XLGK[^V>=)PBA)NR4^N#^*\ 6W;2*2D?J(L2%-
M?"+]LM!.EFM>;8=*0B2X6M+U6=*\*Q>.4/7402G>F#J*$"]B$UMX6S>;[5$L
MRI7L?5:7E^X1)0WDE3NCM'WN0H-"<BQX0D_M48)"I'[IWW::_CKVUMTL'!GH
M;3:!J<$J,=.HK2%MQ\&"V&D^/:M8U\U2<\2=%OK!!AM#L K,0".4 .X81>"L
MBVU9G5KETPBO&MYM;K&87!6_]=4-!U!HBAC2W:2D70.YIT B*R9#-'D[ZXA7
MKAME(L0#='X[]).#-L@.QT+[^BS+  8[Y=B=BNR+8"3+\3<5SB%*^5LV;*C8
M/6IB>I6<C$H%6VT]RI=Y<]U4%])ZQ'R[9*R%=TCI"?CS1*AM>P+S2T+64$3B
MF,+8VJ21G9XF5IG">VZJXC/=H+*S4?-&+3 @1/8#N)P!2"R3>KIAF3-'U)$>
M/$["OCB *H59[OI:DT3:FLJD*& 4K#=3*76CX%*&#9A"2<7P7@B/988VI"BQ
M*$O+V8X:\7K+L++WAW,XU5W5?"O<&\BLBG_56W13@Z*!?'-\E+7.:EJP"]UJ
M?F]+[BW=WD-;P&]]O,F,G"U>ZX*>\!16:O.O*O;.%I=D!963IEQQ40:.70"1
MHWK3\?P&V3G_QJD>8FQ6[.G[Z55^:T ]+[?TU\'0B.3<3<8PV*.VFTC720:2
M'MD=]X<B&K=+\LOR!:K!D5>*6T?_0#]"EV T1.XXY&)-HS15F;#B_9.-FTF#
MGBX-;B.!WIFX"]/>;NB%',9AF5C*DNBC6R0)S36=+/2SX'N&8+AS;9>^1&-'
M0L#5!AI.WP]H<""^JW.P<SEIYV.?>UJN*(AHK<\CFY\QZ;JHC43,'2]3#:)?
MI+F/?&;U=)-[-W97CE.;/L_!@V4ZL!RQ;S]:E["N06(T6&9U-R2W"I['X$_<
MZ<S+K"F[#A45]9>.2Y_["/R[L+=3'Q2VZO#U41ODDH&93C)-^.\H(XN7<!97
M..?@L#TP^E7R481T]JKRS)]9ITJ&R=65\K5R/C_5X9*]!+]^^@N=R7%\ [F,
M!QL&*QKZ"KD87&8>J,VBAMDHLBF:[EW)_A"YM)KWD!EQ;\"%J\*;YXQ07EX5
M ED%IF(M,.[.(PZ,SM9KGY%<S3C$G.1DR\W!DI")EZ+A*IF\M#0J5!T;V0NJ
MA*1,WC$4BZ30M #:7NQO<I0+(:=A*/)4P&>+ER"QTA9^W7^:W^+J\V5[7<%F
M[CC#Q[%DV6U/#Y!_HL$0O@_)&90'L'E4S"QZE"2$IL[\PL(#]N 7Y 5C"=1D
M$V\"F23?:)!>F7 'Y+PJKP,MZ0$I4.GZ4#]"4CPN%64?( 1:FYH.$3E?+"@?
MDJ//Q;S/LICW[5S,FXMY<S'O+;A $+3&.!S>&$)L-I4W',. K9#'"-5FB8[A
MZ-!GLBK 529_Y'B8V7N,=GLMV HR]/0=C1['O8^ )[EYH0H"VJJ.XWMR;FB\
MRC5[/W0-0B&F.\IX'_0^VRU'#@(0_.=1*+Z1 =M)O!*=C$'DIEG80:3&)V5=
M310J-2+1:^GUD5Q!6"/A%8T#.V<'"; YMT!G)EP&NU^(OUC=0V)JB]X07L);
M2,Y>&1V0S39Z7B,!G?C/X#%UHX*\2Z'4V(*"F6.N.]]XKT)@KK"^P+IDT-3"
MN_#%L,IGJX.):)NP)&R=TCU%>$$R6G5FE[^74@6_1-F_D3)<=*LT!PUU&I#&
MQ]6@M.!@QVX:U=7@;Q7^(-<I-,2WW9#X>J[@/:'@< M>V95#PCL?&DD%-!2/
M41$42JQ\+;F8#IN@SZ!,<W*AA7J:1 LX_BMQJ_$JJI!2X\.WQLI[6O#D<0XL
M+;S+YI8AICO0.^SZ:#D 2E:()J\ =D\RZXBW-&+X %/8I.$7DX)+>K"O0@0>
M)%/6S$@+=QSB? GX;BJH"OH:4L7F("=B1G+%9YHU,.U-:JH#M,F+!XY_@H3T
M]06]>+8V\9CW 56=IN&FHVT]//OLEE#,L479O9TOAK^=W#(Q(XPC1I];)'I!
MH4& 0]);BT(^TSN3/<V],!]@ ]UP'IH]*GS:2#)WMEOZ4%</JYTSD57UANT6
M.Y^-'(PE4WF3WUWC:#'IWTI+L^0(+H\SB<^\PC_$"L\7>/1(CAG.ME,!+)SJ
MUV5JQ=G--&F?2F]A,<J\:.=%^Q'-<B;[>UWBEKW!D>&3:J2+L 6?__#)$E)U
MR_9W_/>C)W8AW&U5VXQEAWE=S^OZXQCCFI$XPK"[>,VD+\\C&H?=\9>U-*;2
M?_X"@<>+T^+>Z^<O?[D/LXU$ \,@*ENZBXLC>^;M\;"M#20:>W#'^:3-P ^9
MS?N\#3[^-ACX'Z5W/L+JY)29(:G=$9"!);C;^21%XO(,WV!\XWU+*SO&R=*C
MKH"#[JJJMUO.",V;9-XD'V"3!$!Q?U15K<MJRQ(/(=&'W+UF7KS1I@4Z+\EY
M2=XU,S$$)@<T'H+95?7+I"QD",R0@M3EC.(5T%1>I\($/KMJ;XWO@MGA<N+,
MKC&:C 1'J05,&6%%Y3#L5D!I@:,A6Q+)5#8B_CG7$Y#4KR(D-YW[3%6Q<[CF
M?4*H$>J*<^_);3JE.0"G8LM$.LKJ]%' W;@C]G1PT"0[T4GA. A=:DB_'[D%
M6.85D8*[#^]'170W3&PBO:UKUX)G2T^8,U95O0\PL.!HQ>RIB=C>0FDQ%WS"
M(OC5]V<.<)B65L;TF<O+2/#5&^AT%_3R;5=>5*C(\?G%)Y=,-M>7#W4O%Y#-
M:+6DM.,"= %H8N?!GD4:+X[Z'A3-@%^FS<VT5G>U=*^VH?SI89]H1I3'WZ#-
M]1:KWD'ZM3/NMP;=D+\< E'*\O0.57*GM2X#(5PCHSL71I6"FC7C#P_*,:0&
M=^*CCK2EMGSM-+I%#+I^EK(>17*34/N>%3UGT.6=@2[_-(,N9]#EK.@Y5/0<
MVV9RJ!C)A8.(#R_ZY>)0OD'A@ISU4U5VO9*8V&D(]X=\,L/+9QO>Z&.O6#\\
M)903#4J@_-"F==I7A79U_FZ-?PWYZ-NH)).%?%ZU6W'D(ZS1:6OZ1A!'!.EX
M1LX6YS8 ^W9;KS0]%@]BJ=M(.JX(W&Y\+%_2L]Q' :395:89"'P2BZ.& =:C
M;NA2.+H)>*+6M2P]?Z<$>I;KZ=@@+ IT+'2J/ZOZ?7VH IU)8&9M>J.*%#!G
M5B</4M\Y#H[<BA'QU(LCN2"TM+BIYZ>JABMT3:/5*"^&-:G0XBG)FK%O4@#[
ME_$N;NW>';M"[^QYS!YY 'QV-:<Y6@<\C.KSP_@FM_JR$\+3ONS:4IKF3!_/
MS3YM*O)R:-GM:,&B**14 VX[4<R_!JA4L@!K"L!0*0+":[O%1ZBPP)@4H%D;
MJVM/N[C?E$%>^'T0IH4U03E,P="=YR9O[#-3^[0NN+I3/I0**$;7(8T/ RK4
MQ(@T/S]F:.EA1Y="K=+1-;J#(UR=G9"(075*RZJP'.[7>GU,QL;>0C(J75<2
M@?$ X!I'Q.BH<4#;L.?0Z0Y:DW]]KXDJ76>]5&D$I$Q#V [H=7+UDLQDM.-^
MPQM&3*W?/NRK3HHP$:*H5#]M#/^V2HLS[&[,Z!O/IBM))KPS5)QWT9V<LC.B
M<ZY1?(@:!5 _PX;2N@=Y5J3@,$&G+J(O OT)F9#"SESO3 5V\XPW%IC19^&3
M>8E_X"4>T/+L)>Z6]<51.M"=3Y3K\0_$3'UP/G95);GZ+1^42,CR-N@/JNQH
M!9U5VAGR7CU&8O^'8<6\/^;]<?<"NL+)(*1(@=R(<PD/D*VJUN-NKV7EVO"T
M"3,RO1I!1F9/+4](DE"L=>1_.:+GE9_5!W+62:;[>?7/J_^C.$ @LD29?QBZ
M(JNC+*LH"PLS)0([(74.%ZCFFX9T:/T\-@?NKV9VMTX"9<X^K,MNC6PFFAC[
MI.TKQMN:4"I#A3A)@<Q;8]X:=P^I4TJ@M_3I[6"(DA<^WR:D"KF,7I])9EGF
M&ZPY@RLT=NCC5HL%<:62ZAG-#=0)FL@\.^B\4^:=\C\010N!NN920^P<#Y6W
MRP3.BW=>O!_/ \+J#3096*ML\"4^P*K-T,#=Q)P86=K0$9#+XX]!3S1"/WDB
M._]75TK*%@PGBD75MJ_@@SG@WG $P,L; OE(A/O.V?MYS\Y[]N,>.%UU02&%
MU?L9(1@T\D)O#ZW[KQ1P;K)SIH,RM8?GA3POY(^RD#--RPG0E4^B8O&O(TVD
M+5M$*F3R>:7&ND0*\Y600KDO%1Q309"5<U>!?_.RVC%8]S0""0LN'"" WK\0
M%[]Q*!W\O5 .$<[5N3]ZWCP?8O,$/T<#[PN HB@4;K8G^"H>CA8HIM/&$Y ?
M!5U75EN]5G$57KPG997"62%QS$BB(E#)X_!HQE#W8Y_O^)S1S9\?NOF[&=T\
MHYO?#MT\'V[SX7;7GB$SL4(YG/,&JSH"=%-'+SAWA4-#.[2U+\VHQL=E36/,
MOMO)4XYUJEX8E#H'PGLJ-<FWS"7$A22'@JB-3PNDVM3(?&SK.;R:-]$'8X:R
MN#Z[IU)_4'E 1"FH;,C>DX-'9A[[JE6RU?=&>2&'6#<N]0?_TM M,P_#O D^
M?HF_]"EE(26F<V/7\H)'M!,@N-*#A/O"YB,#<%"JG#1S/5,P9"D8HCJGG-KO
M*%AL6+XM\O-\LB+-$CN::*[YY-\<&3QA;NF4-I!_B1'[1O@9_ X:G81 R9@X
MZ.:"(#1-2I!-SZCY,.G_$/'GWI2!!RWAV3XON&]K.DUZZ>23O1CA,Q#_K2.9
ML[7>\+TO6H@HB ZH\)*C92^MV\@<:RZP"&2=G0!%F52>/E5ETZ5=/XH)PR'<
M=W1^\3LGXG:>7UHY1KH2O2R+?QWY8>@+7+*VG+0* 9; T)^J<S4L!M2-]1DE
M,VHZ?G4C'#(0#3PP@(]90]X;;EHW^M7\K@U]O$#RI&N21EA>M6" !KW-ZA3+
M<>Z&S(=1KQ.JDO2E,T+4C!2\0<"\%]4N427TOU4^?;?UY4^%%[K*W$\U@!WI
MRSM!7*3JZ;K4S"UZ6QZ.3V_'_P^0L[S8&.=#Q HEEMM43;& &YS+=7G1M"(W
MQSXC;1#,;J>9S4IN9 VW/53SK##@%"/R2W -J]&W@?)?>\WLY=*^Q/PY88Q,
M;DF*I.H!%J5B-6&HM"[Y$2R>)_KV4(JKUO.9$1V%Q9M*U=D:[1#F@>V-S5,Z
MH:I$&R>_4G@.0.XY6A<W"6O\HS()#4B\C9JF96V*+!U9=62]$1I=-PHH:'D=
MD2O<"'LTDWLUDF,0G'05-0NEM:9(FN_$<CKB\_SWZ=,W PLV=IVP0WQE+;X[
M9#7H99&#9H12*W^,9@]L8^'X*X+N^I+?G9G>,46-^K\]DH2<X BD58;L:V-A
M+&M;HRB/%>O&3<(%CLI0]A.X1<7=X*O0 -M7^=5PMOBUE092LS291PYM>[XG
MG'ZU5)F\T"0U]5CAMU'CD/UPD;&O5$QVO>[X)/="$#UB9?YJBD&JU26"Z503
MD.Z_;2^L%X6B^.VVHD ^GD*?PL9>S#8NV+@5<TK5HL+([AK;*>$;JV/3N DR
MVAXN\W: UG"] I*6LY[BOH1V]%&?N%K,4O@N5&$';J8G>XVUPR@F&B3"=<FV
MUG>MW _Y.[$[F?M3?()]<O;CF/6!'\0-U4'<QO:]8.[E0W?*/C$1[?5."98,
M@9#S>6Z-^'6A>XO60([;P5SK:7M\-*%UU4UW,D;_I1JHMWCDVD".OR%6O:H/
M73MQSM';"Y_U5M>"!DDL/].I6*Q[SJ:CP;IN.XZ1,).JUV['@^8Y9 +'-"LC
M9'?EF<G"0FN49^MFVVB9=6D\DM<)QU3%X<LA>?=H[EWF,/:_>_LMA"NSS?$=
M[&]UD,(Z9%?X "R3V=8!G1^@9D 7#(4,LQ:!HSC&+LB"#:+LUY?,6;?'L6B1
MLO/_!S VWL?MCM]U>S /)(!8LQ]U35^E;H"<P2) "-?HO:+I &#R&L]O,;JW
M>G*\7RIM=-BT(HG#>K]2A]J*#,]$6BUK%LTY^2I'FJ)R>PTR+ZQ67'/T3[&\
M9@P^L+<6 W^4[.HM>T[+D\;LMP3JSE'G3Q.(<)RN3]8KFD$QGQ\HYL\S*&8&
MQ<R4?U/HQ+<\_(06.QA\R]#>=);0L^J&R?[CB:='IS6NWY"6_13&: Z(8TZ8
MOA?$BF_IH.8#(47".K+CS;&#P[2M+NI^&YA G.?6L2NU0Y1)SMW)ZH+/?RNT
M4;L^A*4&QP)1U46;W%)P$^2U_-PL7M)+//ZV6#Q^^.@["3$Y!'[1+/X+(=Q+
MC=2>::3V.I(PWWOQ7\]>WY=D' C7I&*VJH2>C/_*7-&5D5W2_]Z6*\V$/O\M
M/N-9W%?#QST3]^&*[OE;PX'?8FW_$N(QL.4Q^YNQ_=C+X&-*K:-MR^N@;T /
MWU7(5_4'T[&-V!-.]<M3MB=7H"D6]5EU5L!KM:(8\F#2:-7N+5,[O+L\.KR=
MMKKLI"I( >3H]ZCA=55DQ@,/&@4F#8>7AN.R;OM5!)8YAFQZCU&0C<KD\&EQ
MLE(<P>&27K0'$V7R'CVON[J_),MX;&I>C+1J:*'3MN/78HYQ?JYTSDG#&M*L
M^.]<6+\H5UW;AU4!+IEQ>H"66<^.<[FXY$;I2&H38_E+6FD"?V/]6FG1X\&N
MFX;VJ/"9AH6YK%:<@W'UMU;WPI]X+SQ^?+;X(="Y,O,BI&L/N6U4+)X?.XK&
MH M*J_APU'7$:X)S/B92!YHZB@OI6I.I8X[&![R:=&7BW5CM10\4\I:[X][3
MI@*!AZ@KI%G<N308.7PP3(:FCW#_4C!\B[YF\^0_NE@L964+N4.YH.B)]W9_
MZ@_53KC80Z_61<=  RD\1PHXF[-[DF_',=<HU2-7NL4U":;RO@6'](N3EC"0
M^);:FDD;'"*]5USD<[8DR9:DNS]_Y-1][KA)^D9E51RF-TK90YV>>XO(7<$"
MYR,CG5=;,E/I1T])TK37L:]/*JH;U&4XU3%,6"K9J&O O2%I'-(LV!>UPU,4
M(/=1Y6O43BR!$WM/CG7H_STVX;^0"F!A/AZNL\73_,=Q9M!6LQW!$*)DBPD.
M9X;\]JB@+4_(;ZL<_+)=G\X6W\NNJ.$-TK3U1_Y(-I#1T] ]G5PIIZ'H%+M2
MS((S'P$ !%-K-NNE#$VU.+^@P^2TN/?\Y?G]6"/CKY9R8GM#WEM/V]$P(^%#
M"YB/Y,W$3S8TYTROO=H>>X%+\5XW<[>BMPR/KABBS&7M=<3=A.*D)K7^G1Z
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MQF++26>3_GJ65 ,UPI]C,-%OA")U.,PY.3W-+,-("HE7>'Z"$'(P\P%U^DJ
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MS%OAO.4A)='N+]C9D]6+Z8M6?5ZAQ\;DT D\N:X6&PVQ%M.>(E#/K)Y!QR/
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M;(V7'OX=':TTD\-BP\>PARV2(9?.;-C'ASN@)[HE!-\SN[ ]E:%[#E\?'Q0
MA2$E/I1EKSF''WXI*;<[[,U47U]<",[(ZDW5L4WPD+BDS?LUKY'#2&:YS.*/
M"^^5]B@=U+2,N/.Q_\M'NW)<6BG>?W]55_WQ*K"<")[AX#)+/FDFJRM+_ [7
MUF22%\G'+[&*KNB6_5^NXXE'Z<?1>DMO\-F3SS[[[#\^G@7XV9,O_OCLZ9\^
M?_:GYY]__MD73__\'U_>Q:"74Z9_>1O"(3YF;:,CZ54,TH5!H01@//C_8!E
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M1S^JV3/GB>7A]%R8DF*0!7$,P=H5S<5!V@I1N)I(GHE!5MVLBSAFKE)_4>T
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M%!%?)0B+1C/T$Y+;!ME#G\')O8TGJQ^B^TV'0:%>?PRT12]1PAFDB&+\N*,
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M=ZE(^I0_=Q8MSMFK90<C:,]ZX0N:<'>FU@Y&K LDYUD\^$9QS6+C"MV _@>
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MF;'VA)=O5Y;8R*Y!,XMO&#*]R+1BK!/ 85[T8=@(9]-:68\G*O.Y)LVBQC:
M@%]7K<T-UR['^?PX+J=>(ERN!W2DIM:A%RZ>1SKQC/KA#ILTW84N?6]TO(T1
M;J0=Y!PXG1J.U/% 'VK:VS H*4SIL/TX,%[N*6.C(>>&X3F&>)+4O5J577[:
MO#T'R(6L(O<437Q?G;W,<+U%YT8L.1.ZI]S/TM;&-,MC$R<]_68>$I#7_.D@
MS IH9;8U)!&2+'>2.GL9B>(2V87S!7'GS.V;>8QB&FAF@E">Z%_2R-3RLF=M
MK<'$Y9)\N>HW-\Q!;'5LAJ;>'=8"J&G6O!2V5:@W8[OB5KG 8IF<J+D.\;FZ
MJRV-RV:02"W&RZG(UAP66.(0QF?ZE$(:(/@P"M"1\]9Q:BK:Y5(KA4HJ]J'L
MUH"QHPR%4;V[:6USQ-ZK8^"A<!*8,"(N%;HI701W7[LU_5#RHW!3U/@9N3([
M<B+C5;I3=10WB8U)*N2]2L=KA=PWY5E+H$)[^.&:L"NE-=!ID)DWFO?(#DX8
M5L4+^4ETJ$M&!7'FFUX+9^G AJSDA)R[/G#<,JFP7R$@"TW7@KDP+_;E'^ZE
MR7)5;0 2..O84VJ@6E/J-_["^3V9X;\1A!S5N>#$Q:?:!9>/-/.!2RP Q"FW
M -)#F3^HC5ZNVY!0JJ.V+Q:1'3;N)GM>3E_GEJ5P9&14K(RKV_[4\==SR3>M
MB2WF'2K*LP?43]8]'"<T^%T]%43+YFJ FOU+W%/7Y[@V7HJH;GQ"TW!]%?;E
MO\[QBH\.85_M&$7\N%C]5%8WK7WJ[^?CKKVN5H_B[E]=RX>\CA8#>A&-4*;
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MO)Z$4W%'W[>H,9!SQ005<2S3H;Z77"9_GN,S/H;@*/(ST)NZ0X\6M.5U310
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ML<FTJ[J]"W/WZ05C2=5IE+F/?2H3C[? G^/&;WV +^.BZ%0:P4J_$KAJ&R\
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M\Z60N10R/_E>T_<O9%\>TV&[(0P^G&>JPP#Y<Y.@0'VY#:F[(32W5==J'GY
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MG :DE\(EEH:1>O0PPCEI_4VHF6&CSA^.^/Z#84@W;'_\M$R=(E65^(8A,'(
M=!RBRI;&<AVM'B]SM)D;-\ Z-[T_H3%LD529H=\QY0GBX7$-DIGD9+)+FE/C
M@;:V7MX34HXUNM5QJC:"AB0S$1:8C&A&D@9FJ;+]H2%X[*RGF)^>U$DB\=6I
M)DE)=WM2Y:4;$0NFQFU1XDNAAZ[$*M\(;(SR<3BVO\1MX4ARM1)B9GFEOH_C
M1!T8)O@W)=H!I,ETZ*DKMW##091JY:9J2T;SVN@LUCW=SY<9Y$@&%GS%'5I?
M<X:B>TZU8L+[F#KH"JMSDTFL46+):8_19$:I!*V;C._\D!-4E3F*[ Q-[2]D
M;G:B?CO+(3PGJP6G)T_S^;$4'K^D3&)+U70=F3?!5E>>-%<K!O7313' B3SY
M3$[](>GSCV\M_!O2<M]OS?]*C@A9P:D21K0IY=+9=>4FV3.H>0"'\F>DU&I&
ME#CJV%JVM'\&)C4&Q1RU+U(57US>\>1!;TE6JL1$(Z]I>XGZAGM'Y(9@61/&
M8+XI$W4^)#4^8+3V[(IT=,\_1%V'72#1PC61VSI??B@;[:E"R6)9L92UA?7"
M1#; 91@+I>1']1M;1GMR582IAD>C*D>\6#W<<#QF"B-)$'C-A\K@3NXO7%4G
M$IO_P]Z[-KEM)%G#?X4?=B+L"'2O+O;8,_ZDE>U9;^RL'9;]SF>0++)AD0 '
M(+K%^?5/Y<E+90$@NR6UQM)K1&SL6$T2EZJLJKR</,=1N=^5;<W,TA3F=FF2
M*RWN#(:(*D;;:*8!W2M<3O860%E755XCJ0UHD+-;\S*]QZ0J,56O<W-)\M0
MA@B,).WR'9>&"\.UL=XB:%!W.S<3 P=):U)9Y<T>4)"Y0K-NWA3#QSBJGE+#
M*^>=8["[IY@YZ5<#'D7RU;0"XRR!Z4?=X3.F_\!-GR.]\7Z/P$$!W?=O_HP
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M]L*03<;1+'<")W&KP_A/X^^V6W47Z4#"E>^"=I61RVJ'E;X%QRV(_<C)9N[
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M'"E]?1-.K#-8]O7JQO$%EJ3)MS59KHDE1P50:K=B=YC.DW1/Y(\9\53;TBK
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MUR(S!S.A@X4]S+=Q>AX #9R&=<N2YE&8:Q_G=\H\Q?,AQ#M316T#9+\&4\V
MAY5"BYR,E^,$<-JRU)>$Q"V+&RR;M=N]1]PT0LH[9VALKC>^*V0MW"$9GZL
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MFKBU("E9J0@X)B]+I"_)%XO?)3Y4 J3M0_SR6EBWD3!'Y2;[(&G2R1<&-R9
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MI S:3XX!'B&%?0;A%";2_N&OEV:=3N[W?;.SF&A+7#AH'7/?J,3'G-%XVS+
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MI+Y=AT2%X^.>FO[>YWH[!0IPD] =],%2#8S2F,*"H\2#DY:3@&C2& ,2;"<
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MO#R0"CC(@_C#W<@ ,1'ZQ@ >EETC2!W@@1R69Y#.'K;.ZHU$5$WN*K(6U6O
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M*L7G.N6@][(YUA,V;L\J\%3)GXEW_$]0B#.AGFQ^][ZXWV:6W(PNV6)<C"%
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M#0&M3 O8D&:S( P7] UML[.==R2EK*C2<GJ\;9'58@:=)F$@*,E])B'CDDQ
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M/%H&8,L<@WL!V))]Q[ U(CI?\?)"P@1A49N R,(TII:YM+L<@9CDO(:(4U7
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M\XMQA=?">'0TQ/!H.#6(H=..T*@2]K_6;WD1862)YVAFR]WNQJ965PO8+-7
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MHA%N+CL2$BX*\]4ZL=VV)*S-6H!,4KE&I#<IB:EVB-&C,7J_N44N4UN-HHM
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MLVWJ.VB7%$?)_IBR,<QHF/&.S"C&M]@B)+:2.$($MJ[*MU6YB9PHSK =(2;
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M5SE'J]JJBCQ++*6]!\.CMS;;;K01:&UM,;8>EJ>OV0TAS-Q@./MQW#+#\XY
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M:R2[$1%&1 R$TO<N(FZ%[&E$Q!&(",\[W*Y3(R$>2$*\.F?+,VYDQ, <Q._
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M#(PX-]QLQ/EM4Q+>/+1=(\\'E+<PE58'$5!#G)5V-N93-4+LF1K_10.LUB>
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ME^#>@V':+%9B:?3L!;NB4T;O *]T619XPO&!P OB(0E?Y1Q_CXPC"=\1HRJ
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MUC*'E(@EXI0S*;F/CF\=^?4U0?'\NC$OUKCX>O;?:U1\NP;%7\-\W_L#Z(1
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MP_-SY]*@S=OBRESG%=9)89QK%F%GP+ZQ5G,$' )B9XS6!;$S6+&S6XH(+%C
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M$D9S$8#D."+.L$":,XF\)X$:+(BR6UR\Q]Y!C^+B>[;>4Q..@91/+-&QJBZ
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MR4&7!GG>%E?FVN0D=WYK^F.S2*^'CU=AEJ^5_UC/+T)3+ OYBFEE;#7M=.0
MUI9.E&A.?(/@,:^&#IAUGF/_C#7*<T^1$=@@;J)!AAF.B"]-Z9U37MG]G*A]
M5<W-].>,8[Z:+YK0ONIKD?T/B_FO]?S_AOD;4_D]+6H*-;P%S:%.7JC+ 98Y
M"NL"RQPKRPBM.,-6HDB81KQ,/UG) Q(4&^E99,KLZ?CKIV296'T,'OTG-'6>
MJHH2^A)89N@%,7MNC C!\I/ QC^6*R0I5*ZO\D1JBV":Z74*?$/CJC:%P.W"
M_C.X>6ZAW82K97!]!,@.6F2,U@4M<JQ:I%1<4$\%TI&)%/&6!"EK%;+4.B(8
M5I)L=8SXFHAW?MV8%TL\>QU?]VCV<P:SGU=8]K:'LM_KW]9 MJ>XEX$@@; 7
MJ&94U@6J.5:JH=&4AAN+I#&):@@Q2%,2$'-$:2I*XY1^3-A[4*KAP#6##WYA
MI?@8@M_?@@O5^V[--S;UY3KFS=%P.Z_=O]8Q\>9Z<?JB*U-]=FG8M&V LP5
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MY! ;NI^O;-O-Z&KMIA/?3HX,G>)@9WWK_@'0C(FI.M ;TY* SA]F@QULMW9
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MJ9/C&O$8!:"R(\A8RI'00:=H*>/J <.<U8IYIJ>]@FL%U^<%KM0FIQ)V"!1
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MM'MWF<S@_>=K.!(!5.7XT4>PS:ZC72R_'\X1W9@MW3H.,W>*].UD829/?C^
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M&JE=Q 0Q:B7B!E ;L->C( A8CD)&3OE8PA9$C#1L4:%W/ 2OT%NA]UF&1Y0
M2): YJ!?(^Z(0#HYA8(Q"E1K[HT^:.WYX.!^PO (H17;:PRE@GP%^1& _'$(
M3IH++JU'3#J-N*(466\,:-H2>RT48^E(>Z;[.S<>. [#Z 61%7W'BP)/6ZU1
MWK(;K0WD?_*(0;<+[9,N#?UV9X5X?_+V681W7L]7=GK7 U<WZ*E&_3X)"-)+
MFE$PS-=YY/O85:%S;TAY"MH_;ZW(2).BDAQ1G##B3+)<PT\059YCEW"T1YI6
M"C _%58H:L)!DS(2V9@<(D0%990T4IF1A'PHUQ<*GT7,9X\[OQX%:30DKV!<
MP?A)P9@$+SBF"27O%.(&Y]9^8*)ZI9S77(;(#LKYN+ !?ID0M@#!7&D \,0#
M,CA*SP-E,H>-QA$"4F/M(UR1>%PDKTA<D?B91X223H9C;Q"76B-.;426<X.D
M5R0$2>@1=^2#8_T)(T*T0OV(D&>,,:&*^17SQZ1]!Y5[:Y&$2)XRQZG"R&@O
M4&XHBZFDPIKP$*Z0!PX046XNN*HND#$KWCLQ(O@A<\=_]#OVM_6[N)AX^#E,
MW@]><NB7EY=2JF\_X9PG%'Z^_:N7KY\HAK)=SZ>>_P7AEK<1.'XZG7^ KS:%
M5@T\<0F_70[FW"\;.PO-FZS@P$'J-9QF"C_#[^#(-*NW\V5L;'\<$7R&EG#"
M!H4Y>7K$JOD0%[&9S."&^W=JKN;+23Y.%XU]\V81W]@5_,9=-Q[^\6:^N"Z+
M6,&*IW'V9O6VF:=F!6_>WC=_/GC66_L^-B[&67E609K);#U?+W<?U7P'OX:U
MKY=P[^7W+X9<!1QRY R0/=K_X16\@EM,_G !MUBB);!7ZF"Q>Z@=%C ZQD)@
MN1.A@3^LE+E"FR%&I(G =ISC]'_)-B3YIW9+CL23['HU[X]\YI2\U7#("O&G
M]GJ^[K[2[CK!<-*_[;\/W#:U5\OX8AFO[ *HVW-L"PKENF^.QEG?3Y83-YE.
M5M<O^IO<%$!M'TS9)58D/_EC)F!>9<=]<#P^_O#-'S]U\5VO,Y>:R4=^)KDD
MC_W(^IKU->MKWNHUJ3+/[CT_EPRC/YD+<TS%.)X@<ZBZW%:]/7&JQ>-HI;UZ
M>525!R)F!>%_?D/I-P_RXG?,/!QU(?&'EA_=?!H&6JSN%:E;*:H_1A_?N;AH
M&+EH**;\KB;7$V3@'=\<_:![\[ Y/^<//>\F(4SC?:&'/-$>?LKV.&T$:P-X
M\CYX=S.U3XIW#WND[@QW7SA?D=#F'7S\]LZ=+!YD-[XVB!L#OIP]_2IZ/!)Z
M;#"CF2^:Z7SV)BXJ>CPU]U?TJ.AQ%NAQKZ*+BA?5H*H&U9>#VKT<2!74/KL9
M?]E$+RNR/;4DKYI0!8VS (U_["<W5.QX:MZOV%&QXRRPHRH<XV'Z"AH5-,X"
M-*K",3K>K]A1L>,LL*,J'.-A^@H:%33. C2JPC$FWJ_#A\ZJ.UT9/O0:2+U<
M+TX]<^C93NHZ]VK?S]'U>5?R1B(4%XXB3@5!'#N#M,($">RE)%1ZH0^&D0J>
M%-=1(Z,"1YR0B$S*UX2@O<4&:V?[2M[5]<*^^%]Q&E[/_VI7^3Q=;\MV7\W[
MLKW=O@J_=>5[.6GR]5L[(_2O)?LI:\3_E17B4[7BEA>8U<%\H^^@<^M3_H7*
M]NW(><X*2.78*J#.14 ]57LA*XCG+"@4L 1QEN=&:$DPHHH2[##1G+LG%X&O
M/\3I^]B*P9?>K]^MI[E^_H1=B&25@V?37NAYHTH5B6-EWBH2QV"S<>MQ""8@
M@KU'G">*G.<*&>^"T$$'*IY.8 T%U:^+_X2OP$[<TW!+DX\QH'_'Q3R?;DT)
M_:$*JV=CM)WE,:\RJLJHLV7>QS"JF'7>>(8(@3\XR!KD@C9(<B6X<HIZ.A89
M]4NIISR)454%5154(SOK55!5076VS/L(@DHD[SGF!(0.(XA;C9&5+B"07\($
MQ333<5]0!8DCDTX@PY7)DX 2TD%&)#"V20D;?#R8=;@Q@7Z]RD]_M8@!Y,MD
M^:\\-&+Y2\G5^'7V$OY:G6S2; UO50'TY&>X"J J@,Z6>9]%@,OY/ U)$!14
MH@@,L 2"RPB4<&).>,PX%O>QQ7H1MS>H;J]W^W%3K,:RSAA ;HYE/>TDWYKX
M>)?$QS=SH,CL'7S2V#=QYD>7 7G_L>U5JWQD@C\7T7V#[1@I9X11Y$.V'2D&
MBY 8B:)W@0=JC,8'MB.W)G 5&*+.6,1U4$BSI)$4C-H4?3*&GD7RI+G0AHQ3
MSMZY J%"Q3/4X9^/ 5H%8!6 7YGM2JP#@]-XA"EA(&*E1):DA+3CSD239SFR
M)Q>Q#Y^<2:ND/0.KMXK<*G)'P]Y5Y)ZYR#TN$+5P048&(@UD&>(D>F24"R J
MM*<.1TW-X>#[QQ*(7W7RYSG+PC,%BQ%#016!E:NK"'P0$:@("YQPDG-T0 0J
M)I%ARB-))6$6I\@]'HD(_!IS2ZL<K'*PRL'*U54./G0=H$S1$,=18I0@S@Q#
MEA(,EB$A.@A'&3OHW>(,#DD;D)W!")"=3B#'N4+2@7CT').@]0A25VMPL0)!
M%6]CX>LJWJIX>X[!14Z]""D$I*P4N?8##,D8"8K8*"&M<C@>"- O,23'EQA;
MXXCG$$=\VK:AY74GLP"K? '[\-C"_& ;N^UHGW1IZ+<[*^PH?F8)M_<:R?B
M)X]>TGSTPGP-^#1ZP7_NA2^GH/UST0&.2V@IB+(I461R<BU/ O[EJ$=$)6RX
ML2F8@S8"2F J%%8H:L+!Q#42V9@<(D0%990T4IFSR+"EXL)0?@X">X]U1R^R
MS]1B&"LYGZL17*5AE89?ET4<HT[2$HM" F.8NV20"4$@&5TT*22!E7IR>?L(
MZ;:J2MWQ -2Y)-Q6\5O%;Q6_ST'\'A>.U#BIB/2Y"0)&/%J%C' 284TLYX%P
M8@]2;Q]-.-;4V[.5B]4:K>*PBL,J#L],'!+/M30>(TR]1MP8CYQV(.D<H<10
M'[@+(Q&'-0VWRL0J$ZM,K#+QR6G_O&5BH(1P'1A2 ?,L$P72,4;DG=26<07_
M.VBUQX4-SNN$L 5)R)5F2"<>D,$QMS>@3-(T@I3<&HVLLJ[*NO&P=95U5=8]
M\VBDH81[JP5B,3+$8^[[XSE'CI%(N(E)FH-HI",AB6 Q8E@%Q),AR'$P.+$Q
M%JPU$4D4(\[/K8''$6'1+3-TX8?,+O]1MLZWC@G;[5V8O!^\[S!Q55Y*J;[]
M1/8JH?#S$R2P;A?SJ8??GHHOE\T\-3]&']^YN&@8N6@H!FVR6;V-B]A\R'_,
MYHWMCQV"$X*6<'@&_6>;R:R!-UEOCF(SA4/77'6'\?(^ '7J]VV&7/-U;_WK
MM[&Q[^8 ,GG+_'RY@ET,30+KI7F?S9?,&? N_XKE! TW/'[TTW6 ?_R/8WO[
M!:M]C(8$V$5E(D:>>HJX#19I2CE*/"5-%";1IOO(J>()!8&S6,?P<U8IXG*U
M+Z6V\NM&421W1)'XW/202W.C+!H#;S5P_33O0>:H,V 2XB-57B8DB,Z#9J1"
MCBJ,%+.6)LTU(P>N@2]VES\VD]!+?!Y, CAC6]J *&F)TRQ )$W>%^"QQV54
MX2WX![^ +R^O(KS@^SB]OFQ>?N)>DRRM"GCEWS?P@E=V$@#0KN)L">^1[SG/
MLJ^!S5B4=NO%3]/ ,N'CYM7\'5#N^@_+QMFIG7F Q;<1?G_9O-[^MGD+2Y[-
M5\T'V$]X65@^O"%\_HFW7.:]+(^XCG8!$#O+2[SYI<>TD9<[JEC+<7];OXN+
MB>^U+/CC#B=_<UR[N_7S"R.Q6@N.<"02<6X\,E$HY$UP03#!(I7[IS6:H$@,
M'B7J\FD- MF0SSKAVB;,3;(',S. D>;KV6KYF[W.6]3QU2\3ZR;3UAJ9A5\S
MLPP^^G&R]*#^K!?Q5<M KV$-?Y[._;^^:2(<XZN,!G";VVG:3Z5K?&AKV=Q\
M&AZ&9?CVF/XT/'N%G$U'NF9 UR&+'6<F<C=F,CQ(^*]" 3@$\6 XTDICY)*G
MEC+XTY!3,-/O_FT,ZVG\-1WRT>O,7K=@E(?44\O71ZJJ]JSR"9B>;JF9-VLY
M68+QG^5&AM0TGT[G'^ QS7>3C./S]1+NL/S^Q8"K-@9CI^T>UC?:]6K>&]OY
MK?.RX<05LVAJK^?K[BOM&Q ,-O:W_?>!<E-[M8POEB!P%G85>^JWYGBY[INC
M9:7O)\M)>;/K%_U-;JH7;1\LU24C+#_Y8]Z(O,J.DK#5'W_XYH^?NIA<BKM>
M>=?KZ*7F=UYN?<W;5R;K3X[U.7:8CU<K'X+$Y]U>@Y#$O8,9D]E-?BKR_"(7
ME7"W(!RP<O[U__R&?G-Z(GYQ*Y ;R:Q/1.5MZ.(DNMVMMF%HB?S)+?[X']D:
M>61VOD,CBB?:B^<,%J>B7,6*KPDK>,6*)\&*IVI7<]>@_^TF/8XQ='G/?>QM
MW"M[O0 [;V#BQG=7T_EUC(V+LP@7W6'@XX,G&(UC0YY.[#[D*-IQT/81<X8>
MF5N?2R;0\= 6"\D1:2BR1%O$$U;(&9H0%3:DP QVYJ A^UWR=#K\^MU.[2+7
M@+1^N1.EWH@+P=@)LF^^BI/ZZ(!7Q4D5)U6<?!WBA"3%@]0.I40]XI0G9*5R
MB,I$N-,T\G0P\_%+,B4>19S("RY.T6SUJSBI3VV*]@&*:HH^MBFZB,MH%_YM
ML45#?!^G\ZMW.=C:QV%'C\55<WA^M'UVZNWS5ABTBA*$OT#<1% 83"#(>*X1
MET9X&1RC["!9ZZ[YMW_O .OE+/RXA:O3C3WA-R=4UD/ZO ]IE23/C[;/CDF?
MMR118&/**#W2&(,D$98CZP+\0166)ABGQ8$DN6N2_H-*$GDA":V2Y#S,SQH)
M?2KS<QK?V#8.>K68I[A<PBF!#U*LAF=5%\X9B<;"I,];77":Q3Q"#"DJ&.(\
M:N24(H@8+%D*$?X^:(%WC\#G;P.,^DL\M<>:$5D5AJ_TF%99\OQH^^R8]'G+
M$FXH6(I@:RK)$^+2!:0)RZWC-(DI6>&I/F'4\V%E";Q*E27G87S6V.=3&9]M
MZNV;.(N+S@BU :Z9+%<+FQL-5#/T*U =[E+.,0+JGZ-R<4]2/V_UPWI-\W\1
M81Q4"9((TC8I4"H8L5$R%L6]3-FAY[MT8/C/%O=>SL++'=0#9>1$2H@28H1*
MR-VJANJ1KY*K2JZOE8VKY/J4$Y9C%Z@"J]=0#(8SR#"C-48RN6"5=R31^X_E
M>ES)14=9B5(E5XWOGHF)_7J^RB;U%_5T&@/0CW)GGJ6^<JN.[N.@_UG7,=V;
MZL];>0%E0P<L0?/PQ"#NX%_&1HR4#"&:Y(,(_A01Y**X''8%/*W7G\@+SD\Q
M(N91C_Y7HKM4*5:E6)5B58H]2.S:VR H"# :19Z,S1DRR3GD8W0)!X.9I:>(
M73^.%&,7PHPQ=[I*L4\-7CEL"'[\TZ.=CLTE_G2GXT<21:?N:GR$FID(0,!A
MA^M_%S)\?$%_2-/X$87)(A:>S]V U^]F/X3)\FIJKU_DWQXPYJ4 %LO/[WT@
M\.,_U\O5)%WW"RD7HC@+/_0#6UXLXK3XS(9-9S?\_?&6+/I90GV^4=JP^3+>
M;9B,[PJDI]Y$LM<%L]_!MQOW4[?NR6PZF<&:5G;1]7O>_07L0/OQE7T36T\4
ML@G(\,)./]CK9=?J=\@:.X!6MGK++'N;?MJ]O=^!^Y)M'<UI]%.[7.;-A,O[
M!LSY;_@Y+K[9/ZSB",&_*8WKCS>A=SJ ? "K46HE$-><(N>#1)IBS83USK@#
M&7VG)O2KN?_7V_D4MGOYTW^O)ZOKO\U7<3NSX*8>]$TW.2N&EZO;KO?_DB=7
M9)]PP(&X;(;$'M.XCC(97?UPGR4]./F:ECL_/_7ACB-$&->@XBH&#&PBXI@K
M9'DBR 0X.P:0P)]ZZL.K^;MW\UGAB5_7*Q #LXS=?Y]/IW^9+S[81:A#(#[-
M$BT!815 G=*:9/$^AC(U)ZU7@%W-9+E<EY$\-\]_J ,?#B<A8/K8HQ#8):./
M/_'A.;[GF$<^M!-&3^:H;&_WP"K%J+JYGR,!1]K4_;ZD_.(<GT\1^[FU=K_#
M&(@'W(]/#SQ^?@W>QP ?SWPD1$6/<0V&J.AQ]DES+3T?,&]NI//M[[F;.S;P
M_"H[&)?-FX6=96.W)-!M70MW/5</FV\PFGUY4JG\D)6SHZ'P4Q#S$1CV>6<+
MR&@$C2$BRG%"7$>,G!48)6PMQ8(Z9PXB$5]<:C;TA;8@]I\MAN6!REL$V\D9
M6+ZUBSP:?9LL@#^?*R")NN#\%)5F]=R>^[FM@J8R[%DQ[/,6-"!4C(?_(D8)
M0=S1/*&(,T2#(SQ()13A]ZX,>R1!@R^XI!>$FBIHGC[Q[!&[JU0K]DZ \'LY
M88U];R?3$GL]%L2%?8J+$KVEF)+B+6JY8/CGS[,,DKD=R\L<0F]^F]K9F:![
M54<JK%5U9#3JB(Y<6!T%,BDR4"U ,7%@["(3J7?*"INHV5='6$B8!6\1#EXA
M[D5"5L,?BMC@G2-"!;Z?$#302%[9J\G*3ELT_'N7T/*7^>(O!0E_[H#POKK)
MA:#ZPIPD9[Z>X7,_PU7H5(8]*X9]WD+'$N(%LP:%E'(>J67(8&O!)+:>8,X#
M"P?.5F]$\BS -89;Q USR JCD?7<.>:(P\H_M=!A%UB X-&Z"IUSLH=K5/<L
M[.$;;.%L)C<_O;N:SJ]C;(L/FM_6"__6+F,UC*N.\O04KCK*&>HHV&$IC6 H
M<8[S$$>&+/4"*3"+@P_<6:WV=12;"!&Y4[KRS".>7$ &M!E$!96<:B*EW0T(
MMPCXL@? TQO!!O01A6L@N)[7*F JPYX9PSYO 9.H-I(9B9)6"7&J)'(6I(PF
MACH! H;'@T"P]XJZ?(WD$@2,DF X@ZV,?"!>,2VDB?YQ!0PWY(*8*F#.RN"M
M >"G,7A_@TM2-FA#\\$N<D;&LABZ-8GYJU4I[E@C,X(].%.EX_X$?]YJB>8V
M!1T)DE&!W1LL:"3)!R2QC,Z[B*-AIVC^^2HWEODU_9\6!W]=_#V_[^ERT^0%
MT]G\Q>/43.Y<BE4/?I5E5995EJZR[#:-K*-B$2N%P#9VB!-*D68J(BV5"L%S
MZX4X10O0!Y9E&F09O2!:55DVVH-?0\]G98FWLSC\;5MKC03OQ[HUSU6%N55/
M[='LPK-08NY&\F>NQ@A-! X6$;"]\SP.BJR1%B4NL7(R\A@/IG#?R21_Y'0Y
MRBZXQA=XK$G:=^IM7N&@RK@JXRI35QGW13*.XN"8!:$FA*"(B^B0)CB'M[G%
M#E.:_$$=TIU,]<>7<4PKD'$CK9&N,N[0?/_,"(]'Z4A],G/XU.VH?YTUO_K5
MO'2SN\@URO2B9&?#P8+573<%I<"*GLQ6\P:6^_+U7YO?[12>]O+-(L9W><#E
M=UUY,]W_S??-A\GJ;?-?D\5JW;PL5+?+YI=?7@TN>?DF?_&B2PR'%_=O=Q;@
MY^MI:-[:]_&B28OYNV8%[]K 8O+?%]DS!8>KS3R?IV:R6NZZ >!"H$%>N7T#
MRWIC5Q&^EV I\.D5+"C_V*RO\ATW8Z .>/)V5'^,OD:.Q1"<0LR+@I$>F4 %
M"MQ2JP,1DAW,\F,A@.60&%*:&<19T @0V").M>8T."ILW!U$W%-JV'>BH]EO
MF60W3D&2.U.0Q.?2C01 SXTX.H;3T<#U4UC4!?!_DP<.4/R#717^A//]K[@J
MGY$?-BRUA-\MYNLW;YN#,P%WO&Q>[[!]\V'#W,TB^CC)_BI;&'BR7.9=;SE^
M<!PVS#I^7A74,TT51]'[/%W#<^1$D(@*PI)BP);>'>@ 1#LC@P%>%1YQ' .R
MV' 4C(G8@:W+E#IHC=+2"D1](>JOLT+Q'1Z] @U@PZ2(#KGT<Z.ZV,A9]-M^
M.L";Q7RY!$B;^QA# </,+UMHW('% IL[O2D.P/NR^=O\ILL_Q,Z;VJ4ZE=L!
MD;..M2K@?.--7P^8&40+O);-71]ONB ?O+_:Z_P[<3DFNC=#Y>.KUR'R%NFB
M/XA/Z0\WJ@[B0'48U5X7->;UC\WOT:\791Y@\]T_?G_Y_8XN(X90_PF-YIV]
M/J[*Q.GT*U)EN LV6DR1HAI4&4\8TA@4E$""BHE93E+8%P]4.:ZUUWE8#2@P
M$NQ$C9-%P1&I:? J[8F'JLJ<3I41NZI,^T,G?([+"7A6D4(7<(" MUU^5(@-
M/!;>-2>Q9\YMG]XR\++IEE1.!MQM"0^Y:.:+!NR&>9[,^6&RA!MDE CMJ3R^
MN-='/FT7T>E9ST?-2L%A0C5%(#WA'$GGD=;$HF@\DXG&R.5!99OSF#O-);(4
M!U"S"/S+8X(L'$./C7!8^ZIF/82:=2#H+IN7Y;HQO>RPP7TGTV<WZH)O;8"3
M'6>WT0</WWY,KUU5NJ%*]Y?H%FN[N&Y:'N"?U.N66\7HJB_6MQLM+Z=@V(SP
M[[/.<C6%]9?/;V#[+WBC>R'J+G%O-&.#\X)&@XR.%/% *#(<U!9XI,!""T<]
M/J@<IA'T&:>1CB3D-EP4_L53;JYEI,%&.LR.#K7\N9RA']=%/P$Q/ ^M/QO>
MN/QJ>4__M;F@6EY@RD8-M@.H&?#<'_;T85 5[%;O'=/Z[ZM]/P)7*ZMY$EPC
M1@WP9<ZJU#(2X&_0&@@6(JH#1Z)UV&HG&#(19T=B%,C:1) 4P203G&:<''!U
MV<F6K8O"#5Q=/MM5O.&?,?R^ GA8_IHZ3_&/>6S@8ME]N],J\)#;Z6=;IU]B
M,FY.OP(I6[A]8T;RYK<.*'_K@?+[C4)[Y)<-D&(...RGZUR)=G6D*&UXZXC^
MTOZV2V]=?I_E\Q:T=ZW+,\!G'6WT!DQ(9P5PI5<!&>$C$DP';JV*)AUF!:<8
M)+<*.4$<XBYFU5<"Q"<EE5&@3HO#EH?'LH+_MLYZTJ]IZQAX9:?3&/Y\W9.W
M^^)]@1M 6ZL+RL:M)=^D([90W?-8Q>P[<KKUQD:;4)1! E)+B8SQ":G(.:@7
MEMDCO<:_@-.+I=?S[0-!]N?LP S9^.;@^A@XI6#V(<Q>-C]9__;(+\!"6F9<
MC1_CPD^&_'\&/$>ML)C&W,S/",0%YLA@"C)?1\= ]14E\7!OPC2A.#DC4698
MQ*7"R+E@$ F.&HQ=9.E ^SV*KC]U%"M<N/GE!E+)8S D!GX\&QWBT/^V;";O
MWL4P :I,KWL6+-W9X$M9+0B=H-]T:,OV>_&4S>8KN.!JLHB?5#_\=+[,,ZH'
M%J-L+<9RJZ'1N(EQ'G&B7,%/'X'D99UC(N\9'%+& O%<*&0UV*D\: 9'+V1E
M7M@4F<#AL/<((W D56*(*@(&0(Q@K%J9O8A@N$HI V=X_Y#^UFW87Q;S=WU"
MU:^I8XD-1YS(I4[Q^;C47817@;,4PQJ6.7NSC<O  8JS9:L2G0$G<0_XG)NQ
M4I>[V!  ?NNM0XQC%X1.H%@?!&6^A).*BM$'8'[J:',BAL&7_"S8Y7)4\/;S
M+&_G++9<, RI' '[71]@Y_ =/U>KE#B+3B(;%"@Q5(A</4$082%8RH5C.)U$
MB=D&&8=^CWN:?OQ":7RAN1PW=]]D^LV.^R2&3H?Q<Q")F%#'%#(!D(UGUZX!
MVPE9FAQV1 ;'#]IHG$P-?C0G [V@G%TH=G-E\I@Y#3AJ$:<EF^C*+C*9+G(5
MZ'I:)/)DZ-CZG/YY!I(ZJ8"QB QADG+O.&J0C1Z S43G),AQI0\S04^F\_6,
M=R+1;4B5W7=-O (,;8@Y%J-+DVG))P6FGRQ7"UNX9YD-Y#;Z!A8;;$KS.V);
MN?_[3Z^Z[[?Z:_X,#I&=QD^G>G3*0,G5* 'OZ75_^3'T[[\]F7U"V]@Q.S?W
MZ%FO"9-0;-1W,;9)(R!,,N_ PI>KB6^/=3.=6#>93E;7)8L$F+(\I62 @&3*
M1K//F#M)DRZC9-*]T=OY%+Z\S&DQ1/W0Q/]>PTUJO'JT\>J^C('HS\>KLS,.
MN&7V9ABE+F? Q\7* @OLAAX[)ECN<,9%\^'MO$V%W9,[?<9#__"]I*;\[_[Y
ME[FY_4Z:Q.'*+LY 03)4)TI)1)3D@B^3=)9$'F22TYQP1I4F^^)(.I)$C* 1
M@2A"W"KX>C(,!2ZMT=1:AMV.X?A31YI?TT#3!@S;1K5Z</B]TWWN._\#X_S_
M<8NFH\'R#<<>YFWW#-:VQKA!-[<>\&YQCO' *"QUV"9D9"XA$*!Q.R^ ,86.
M27+JA;7[G)@PMX$;A11A%JY1P+W".F2TC4H2XUFPE1/OJIA_%W-@)&=SKH\&
M2$ITI*=H+]^+>(8WF6;/Q/NLE&?NWO\6@'#)-\LW[OGZ< &9SP^NO/GFWW>A
MG(,EG7,@QS(.]D( D]4$.!;&!*232DAZ%7SD'BS5 Q^(<9R4AA.6@JW+<1YN
M'#U&!CX+F'&10JJ!G+,*Y/QMWGB[? M';SD0!+W^TJD@8"O,EBV!6AU\<Q*V
MP9Y>W<H%HUG=VOOB(VOI8]K&<[$8CI=#ES__GZ;Y$_S=+_??Q9[X^(+^D*;Q
M(PK 284Y7L![K-_-?@B3Y=747K_(OSVH2K\4DUE94-\Z#7[\YQKV/EWW*RL7
MHCC[_]E[U^<VCB0/\/O]%1VZ\9T=@8+K_9#F-H*6[3UMS-D*2]Z-_3113Q$S
M(,!! Y(X?_UE=0,D0(#B"R2ZP9J8D F@GUF9^<M7988WY]-ZU%RYX4A8_S=N
M^C63(;_:Y>;VKW?<G'XKY;[AW2S[,RR/:'?BKSXM]\UWQ?DA5&ZLZVH%3R^[
MUBV?>S09CR;P3'-P4U[;Q7SZ9O,'6('VZW/[*;8-[, B!S*\MN,O]J)^\^K'
MZZRQV= @+_45LUQ;]/VN[>,:#]QG69]3<VQU-5B7QD8%YL6$TY<G-?^%SW'V
MZKJPBAT$AS=;6[M[O$-K5>2;C28+NV96.!U2PA8CJ7-J17,*UG:02%.LF;#>
M&4?_3EZ]]/A$6]'=X-]%M+,J-O;OCGT6W3<D&0Y$2XD1"6!#\BBRI^\5BI+&
M' +@F&RE0HR47!/)D" NIY630UH2C8+7RB=L7,#JFG_5&HRYNN"Z1_7H)$<O
M?*FE.[]M4&6#J/N[TI2,A(##C3C/?><Q SS)#8 "L+E)SBN*M^O+=4I,88V4
MD@IQE00R+"<WO#"&!G#-KQ)F3\XE74^"+?GCIJKN5:BG)5".>S9V_SC6];IY
MWP0Q\P;E-E'6'MB_F(]0V A-% J:$& Y[9'-X9R C4R$$!K"5KLIKH&GI,,H
M85!,7"= +I&9CVF?F,%>:?H\"?ZE1I(=+WN](;KC8I->;0C1B\V,77JX 3B[
M\Z9Y\>/E[#FF:'KMK: ,*6<-XA9$3$=.$%&4^F!=EL-'8_^V+E\?>+;2^4\^
M4*0+[+$S6#J+V0/(F=V-2<LK73]8[@7*4ME]CF)6X:3 3F#!@C5I=41:T(BX
M8,X+YS&V6[O7HPF*Q.!1HBXWP0H"65#\N2F$M@ESDZS=N:?A"?B(],.:[*L9
MZ15)2H)[J3GX&3QCNF98(DHCU=B*(.,6>X3HL+22(^*M1)S"V098!HDHD@?E
M%8DCSZ]P1#\4SDWVY/!ZY' ]%K"*'3;_;$055\5*-G)LO$66<0%R"F86J'V,
M*#="A,AS\Y;'2/G&;M-E2/B7)OQZ,FEW4/]DP0I^;R]R/KW^"'?Y:0S&RZLJ
MUMZ>9T:8+6+[!/!2,9S,[_K8F\&-[D4ROK0!. =$>1J6D<.J)77U;I*#ICEH
M_WX,'D:C8AI;&374;U+3$3R/S#([2U>.BWK-K5[GGK0C?P]Z@@22-5*> .Z'
MAJ"EVF>M9OU#/)^W9GVFUV!GZ<-/TTPZ,*Q_;A(6TQFP9)C">:'-&N<.6^M)
MI+8(]'/^>>E:[UZ(R_W4I/GXP[#Z\WR9A&NNG^'KRCUO#QI<VPA5ST$[KAK?
M?6JRRW#*<DY)FSFJ;+YCO=D_!N\6MLM'PLM'ZA2H%,Z]'%2SSA.Y /GS*,"E
MLOU^R0B-!]WZUBTSM9JT:7^U9 WD&H6Z9)#YM(IGY^/I1<PESW!_M/I8A17G
M#Y;U%),<YEG=9(TEAU4;T(#O["I;/+AJT-BD97,6-F>6<^WY=:YLWB<?84,V
M&_)HI+6^/\OW;7/;R\D\0V#A?'23HFC%8](4NC>O?_>:IDTOZ#+[O?%\R_OG
MW!98:+F3]O@BNTFS:)N]6:WPIM&LGE?!-NV_FIJ5-,J5!DW(/F_R @[+2WQ5
M+7O]P9H.EALG+<-I9],%2#@L'ORP)$L.Q;4O^SWYH0^FN(A@5EN&@A$6<2P3
M<BQ1A!,AD3(NK=O:9!B23U&RB )/3=,^#=Z=SQUAE<">!$7QYM:P#VOJN%5T
M[Y:K]'-L__MNLA:$>P^F^?4=A]]H0G9;OY";YYYW07=<MB!;&RQ]'T%9<OG8
M7C%Y_KQ>5G*>=^@VU]U@8I"K[^D/;955?9;WGLQ6+&UKH&^K)K+87]P1B#?[
MP#;!P[J: %%N"#(N,L!>UEW!KTO-V(N XZ.S>L\@W4;$B"U.R#,#WA8-%CDA
M/8J6RY0,B5%M>6CWE^XGG<U !H+J@?G&^*$N<,>*PYO\S"9V+:V_UAK<@5\;
M/OAC\OA;_CGU6#&F#3BZ-N7J[9P_"01%JA51@@A#MGJ</<@_]Z<Q+,;Q]W3E
ME*][A6U_UE:T3W)I)@# QTR?FSSV9[(GF\,[:E*>@%X^.\MM%[ZU9V&I,"N[
MI.JER;E6CM E,=E2HDW%HLVF\G@\_5)7WS=;AZ:+&H 0K-OXU<<\J+2Q,)L]
MIY>UE,'.;?-5?M7ZA]=K4G0Y(J29$'*M6JHI#FK*H9;%2?F]\X.#=Y$/1V-[
M 5#<'M*^ \D]"[Y;'9\+C.UY'5_7\=S. &$W"XV:\U[MG#+Z>52/VGK(UZN+
MW#0^M+TQ5T/#OULOJ%H5"#4553]^ZUSRW.>1(7WN6S[['<V04[SVOY?PQN;H
MWU&#E*VOZM.*SFU#B/7.&<3ME*?=JGKW8.)M8+M]=M7::+]'#P4<36ZH^=1[
M*OF\FK5VM[K.)YU(URO*'6AT(K!R_KGQV/=.PV\,.%^:.=W@SP?G*.ZV8[:U
MLI^9?Q\P7+YHAZ(=BG9X9NWP/\U9,: 3()S]%/_J9C_^QZH2HOG0;.5KO*S&
ME2]ZI.B1HD>*'KF+'OFC*6"$<YM/;^'@'*C-J;&/<796-$G1)$63%$UR/<R]
MVI'2*(UWH#-&DWKDJ_^VXT6Q/@ZC,VX+4#7Y@.T(E0<")7]#,.J.P:>=+W;;
MBL+)=U-2'9B%OM><[^]K%0-VOK7OE#](?AZT!/>!B@ZLPN$P=_W.D^DQTO;9
MR?C43'JE@I^2E,VMGU1;W#!ZWN+D+-7(68+SM@J#M$P<><.L<LQ)1>+6]!&!
MJ5!8H:A),ZY>(AN30X2HH(R21BJSLX9_JS+@)&]#^-2TP_OI8JNBOZG-748T
MUW1=VSCWEK*2=[_]>EMA"1YP20>$WKQ!LXCV<8MVP9_CH^VFSKP[4?_2>6X]
M<B"*W!#'*4I" :@82Y CTJ)(,"7.N825ZQ@0K<)@RRC81CN\9QJ$R&\>^5GT
M0@&O E[]HNW1,>D!,&MW+;2.R5O+".))4<1]B,AYGY"G0=-@*;-F:\LY%S8X
MKQ/"%D"%JSR *_& #([2\T"9I%N-4AMU[FZ'%W=O>+G,KZRE5G)F91,E4!W]
MZ["8Y:K8IP1Q-;SJ3GB]XV01[9<@V@5_CH^VQ7GJI_/D# F.DX2$U@'QW,W"
M<&<09HPKKRUC:GM:]F&=I\M<7Y/JNW'B$-N8.'1;-W#&!LKHXA(],R0],&.X
MJFDO&</GRAC^9]Z$&$/GM76Q+8Z/MD=G !^W2>$E%EAR@YCT'G$I\VQ,&1 -
M@BN+';.YD>HC6_@]UIY8ZK-WD_?@>DX?V[%5## U V)N;N961/JX1;K@SO'1
MMOBT_00@PUR("1OD,0<P21H 2-.$F(X^>4.%28_J(7MGG[:^"PC5*PPZ>%*0
M#G'Q@ N '1V W:$:_X4HWVY8"X7 /2=PT16%E8^$E8^6P&4O3D\BZRL[O\36
M2XRC^#%]5NA[50O?/Z;[XB.")]%H@44P".<=/9P'CPR5 1'C-#=82"6WYH(_
M*'B2NU"VX]+:89AM$*1M";O>]_-2/SXR1F\P'QA3JIZ?./CY0^<U1(&QXZ-M
M"=5W'<]N&"#(H_:*$T2%RP,$64+&)X&2P$0K%E6T6T,$#A*J7Z%09Z+U>JAN
M;FQ>M,-Q&[E'#&$E -<M>Z$0N.<$+KJBL/*1L/+1$KB4P?<D6/_K=)9BMN>;
M 2+M6+P2N#_RB,=#&BYV@/I]5/^/)/6Q!$L.%?RW6&(=<$()1XHXMA(930C"
ME*H8O;&,^&<)Q]P2C5FJX<4LUB>3\$M6P\T5ZCW5\QNI!UJ3#L97'M9JM /:
MJ.03"KKVA[8EG]!UB+PAGY"84D9A1*SVB$=)D0G6(&N33T8Z@:GI!8 =.KU
MY)!U$?\ZJ2WZ:&EWDI E9G@T(:VNL'(A<-$515<45G[1!"Z; 7J27[AE,(?H
MO @=,1H\?WB/#FF.[X7I(D^C+\F&)TTV/(#8QQU+T=%&G+1$U!.->!(8:6\Y
M8BHHZQUETFT-^' D)!$L1@RK .<8@AS'"F%CK*9$1!)%#P9\L($D:L"YZ& $
MY)M<V^T<0!^51"<)>21HUTG:EM!_/^'*!R.BH101A1GB CMD21Y*10R5E O!
MPE;N^L!P]?1!_MS41Y2F/@6?"CX="VV/CDD[,^F#41^QB#B#AT \)(6T$1X%
M16V@F'$F]-Z2QR]@TH<>XC+IXT6+=L&?XZ-M\8_ZZ1\QHYR4*:'@8T(<$ TY
M#.Z22(PRYAUQ9JNQQX']HR>9]$&T'$A91O<^-R:5/4X]R4$NPQ V!Y1+#O+E
M61TE!UERD%TQ6I+%,>8&[E11,$"X4\@P$9&,4GH%_KH7I M&RYK.W%,.4@X8
MQ@.AN]CDI:0@"]@="=AUDK;%Q>XG6DDJ6:3&(,PU0SQJBTQ(&FE+ PZ,6,%E
MQ]#JX/N,R) 57[R 5P&O8Z'MT3%I9_*33FC&A*%(28X1=UX@+44"MRCYI*GT
MA+$NY"=OAI>;\I/D(/E).=0E/_FB1;O@S_'1MCA/_72>HHXX,M\T; !,DT$A
M#1"%I.$N*!:3DUNM&Q[L/.T'W3;SDV1/"4K#!@:7.04]R4^6/9+/G9_\[UBO
M-6",/G^83ZO/\'5EZVJ:2LKRI1DB)6594I9=L6.,(R91RE'DCB%.-7C<U(-A
MDI@F-%)K^-9(BT,$@5LUVG:?:I3HQVG^JNRF+*G, H)]!,%.TK9XX_U$,>&3
MP41X9%44B,>$D1$\(&VBHQH'P6-/4.S@&<ZR [-@6L&T(Z+MT3%I9S*<B>%$
MA78H*:X1!_1 3A.-9 HB0XDAKA,9SGNC3K<2GV5CYDN7^ )+QT?;XFKUT]72
MDG#%,$78$PQN$]7(8B40=LHFFR@UL1,;,V\'O9-/GV;Q$_A/9>/FX=7!TR1&
MX4/.?.\P',+H\YU>DE#X?(#<XI<VC>NFX_#FVM-]ZVG:0_.M7H_F\!3^/CLI
MS\['TXL8JP_SJ?]G]7XQ\Z<@7-7[L9VLD_N2:LVKCB8!3G\MAU*J[ZX_:@<(
M>0^ZW8E*[R;5AW@^;S.V%%,RJ.:GL<I*RDXN_J__$_29>E-7/TU!%379W=$,
MU,]T5E<V3.&\,&ARP:-Y#6\"=#Z%%8[YU_/SV?1S_CE?+E^X^M:"5-__\N']
M^Q^&U:[96_=X\5>[71N= J<N6,2-EHCK*)$&=P;QZ,#%,98;M>7:Z* =!@\&
M.694+HDQR @BD'*2<R8QT3RMM/S\8F9?K]ZO>;W5V^67^SG6?C9J]'A'5OTC
MK$DF>'4.;E!>NPB,.<IIE[A\B;KZ<CJ%KV&Q<W[_W&9M/#H'>*E&$UARX(4$
M!)Y\ GB!!6]6N;DB''QJ/\=J<9[_?.1R/D>LE7)/K-:(*6& -;!%UHJ(.)?$
MI:0\,8]GC14W_)Y L,ZFDX9%/I[.IHM/IP#VL^EX_',,B^:Y-@#[?+$6^43T
M7J'/FS-^76#![[(V :X9S=:8SS8G N^-YJ>G<0S:HUZX?RQYT(-% 'Y\-1X!
MR[8#>P8-;ZX429L?S=?U#95;C91_KQ=VTEQCQ:;#*HO >0Y#[SJ^N5ZXSMHC
MD)-_+>RX'XR-.:5$&HRT9:#I,%?(2+!7X1-PNHM"6?P8QGYT..=21>95V)",
M]W&6O8Y]28+NAR14X^D78+?EAV1!,L"(^&><5Y^S(;_Z88-7[?SRNSCQ#;FK
MD)4T'!RM/[U2T^?-9*MJVO+S##3[9[MV\(KIKQ#XAN!4%RAVT@AYEYYHJ^BM
ML7MFL?J2_^F^L@B:"9$(0Y$P0$&I&+*<&B13PD'H0)FT6[%?2JB7D2#C,W)R
M!485L0P9%YP%'!6:QNO*8DW(W]KS;-,WNJ'^(]9Q!N;BK]/9KXL\F>U=G77V
MM23A_6>)D@'HKX'"W=8 *^2RG^UHW+1^@9>J4D.(*WC;1*-AIUZ@VG!@=WJG
MS;_@R?X5_KMZWG\W_M;7U_1-&L>O*#3.!:S.:WB1Q=GD31C5YV-[\3K_NN7[
M#P7X^OF)5C7"\/$?BWH^2A>K1VM.1'$2WIQ/ZU%S9=!\ %"?XQLW_9KID-_M
ML@[IZQUC!;>2[AO>WS*>MCRBC7>L/BUC&%UQ#@E5&^NZ6L'3R_+LY7./)N/1
M!)YI#F[":[N83]]L_@ KT'Y];C_%ME(;V01D>&W'7^Q%_>;5C]=98R-FU"SU
M%;-<6_3]KNWCXD#W6=;G6\@=0:9U:?1C6]=Y,>'TY4G-?^%S+D&\)JQB!\'A
MS1HA!\G/)XXF"[O12"9R;#QX5HP+Q G6R 6,$>5&B!"YU#3\G=Q1]%Y.!*N!
M2=1$A*MUV[K*,>!)'4L4:SV>L0Q951$0  R"O"]A949?VL^MT3QM0^K5HLZ&
M<3[JI[$%2G_PI],Q/$$^O"7TV33$<>LKKBYOO9\N)O.ZA>BK2;+Y\JL+?SF-
MDWS=BVKJ_6(VK-[/XN?1=%&/+\#R]M-/$WC_/.%N;4UCNZ;-98&@B\GGY4Z+
M["IEUQ,N$6>9%4;-M5<&_?QTZ0-<'KA\J!AVF@B/#Z:Q9)2)5B'KK4:<:8F,
MH0KIY%Q,,6#'PU[J!/QI#(LQN(:[,R.->*S2(ZLE.P&[\:S][F.VI#[",_PT
MA@-? 6-X>YXE9+98CLX!-17#R?RN+]6HJ"ZP>\.0W^+L+[9>DX,K/D_3,3B9
M^9.]HM/K^[A\KS8R/FMX?6^^VH$3=UV$RWQ(DPZY9HLTT-L8&TOHSRN220K:
M*Q^.P*"<+I:'M-0E& _Q=ZOC?:XZ/*_CZSJ>VQE0<!/&F_->[=RL]GE4C]QH
M/)I?O%Y=Y*9=:.V-A1X2_MVZN;*"W\9>^?%;YY*A>NB9>FCH(>XJ'ORN=SKO
MMDV$^IL]3G=)[^Z-A=L@>'O6<XC)6J[RT5G.]G*[+2:])WOV*O'?@2*2'M+O
M0"4XEW-SV>ZYN8^EY.:F'7#-SN=5/1V/PDW[SP['JP^V[>^T&/\;[:SZ!2SM
M\%<W^W$C!/C\_/V-5;EI(]6QZI " [U?PF.B7X<J,8OJWY/J?UA;@R/5\87!
MCY+!>:?(7XR8'0UQ]F^LW-ABYP'K?+<>.=]:P/ZTQ?EC5/\3I5F,U6Q94#'*
M/!/K^9VD:)]DWXOQ<R3[4(Z7KH\#A4=4BE##&:5>(A\,0=S*B RS><-$#,)2
M@SE6UZ/_TM!(M1>("YD[II*0*T4D<HQJ(KFTV.XN*WO(AHE?[6C6['Q82P5D
M\?P5I//=4BC_ "&]:W79;3LCV/#F#>9/MC:M#*!'U4 ]IEQ(*DYH2HCX*($)
M.$/."8UP5,:K)#1G6^.>F4O.*9.+"55$G!(X1P(31$NXHYK%<$-M81^8@ _Y
M\S/!=R]<!Q9L.3)L,1IK+KQ!DA  "] CR/EDD1281\R8-ML[T*VQ"5M+D?=>
M(ZZ;N<%)H"@Q=YX9P@GIK5IAP_T6+O8!6RSUFCFK4 PZEZ**@,!\B  6C@9"
MJ$UF:^H434KYS"E""M:6KSJC%,*$498BX<GL;D/0!R;@0]D?;%F&T?L>M.VL
MR]_MQ,5+<OE_N6Q_&V=GU?>Y;4C]0Z<S&D=B>/6>?)O*97>1G>#46$$I2DQ[
MQ V52(,MA)1(7C%O:=#[<[,?LGMK%PI>]B8X6',=,21/L'_IP6;3[K7E)BB/
M);C+(I>Y49R0L3871A/GM1:.Q/UYS\>SMO+6M3UNM5&T[I-K7:/ 5U!:(^L"
M^!$>9-12)1&FCB2J$O%<[\T!/1[)%$/6?:T;%5;.@4NI4LC;%9-&QCL V*B8
M8UX3'_;G5Q[/VO94ZQZ](UAROYUS!)?M(YJF$I^G>6=<W@KPPH/))4A_9$%Z
M!A81$)$B9_/X2TLHTI%;9)R6U KMO=BRD0Z> %[)Z']?BN4^([2:O\ <L+"2
M&*(XDCX1L(U2[B]#0YZ/JJ04FLD]>K']X ,C2AJX(,RQT/5@"!.C-9Y&A5QN
MK<J=HN"/<X>B$48RJ0UU6\UH#IX&?F*$42\080AEU"=&D;(4//:$?<X$@X,#
MSKHU)$0ENY<)?F*$T4/5'X0IR>"2#.X$E#UY#.#GT>=1B)-078SB.'0Z,G8D
M=E?OR7<P\RH8J:W !FRCW.LON @./+9(1:P9=T$KOC7K^\%S7O8-JRM!NP^H
M7NL/FD9?P8CX=YQ-,\-I2NB;/;2U[R,+%@GNIP03&FP*%L2/2H6X]0F9W+TZ
M<J$E#XD&O>4@<6$#&,X)89L<2+!F2"<>D,%1>IX;?-+G";T4"3XBRW1C(L5Z
M1Z=5U\_'=(C:2N$2RBD.P+2!>D A:QSPL 4HLM2[(+"D:C_(==EY[+*G?YQ]
M'OEX@T",QU/?_/5[^N.RO=O[IC_;VVD]KV]J0O;2V_:U#0Z;1/CN9GAKS?*:
MOGCC<>[ #CYUV^VN'E2CB1\OLMA5FQW0\E"*W"9W4)W:NG(Q3N!BY]/9_*J!
M7IV'C6:5M>S=%V?VZMS\.+-X"D\Q^IP[<]?P=;WLGU97WS>7F"YJ.+3^X?6:
MK!Q/:S(YQ.QN?;=V=0G33]KI:\=Y:JC!G+WZWX/;E#WP/#KD3]O=[.#O7/KJ
M]!Z[CXE^AVZO)DM[M=)>K70F*3#0OR4\)OH=&@9H@8'2:JTHBZ(LBK+HA+(H
M;>NZ;!S>4+:P+)G;;0C>W?![T%CT^Y0I=&"R]'[;UL4:O"Q_VH0\0_P<Q]/S
M9H9@W)XP<Q]9>MKY])U9BX,"[U,.4>\,A3>Y_>ZD_4M/./=*1S\E99N['R!/
MK0AS7E&!&'=YBT# R F7D"-.*&*YXW2KGQ/FCG+K#>*")3B'$F02YTAP9DG$
MTBA%K^?KE@FX&';GYY;CLC:2S7]^^/DRU\S64\WHMA),(@:*F[WEFU^$&!]"
M)Q;<*;A3<.=%XDZBFE$1*5+!JMQ612%G8T*62DEU"A1PZ3KNJ&2D<@)<$HPM
MXEC2W/HAHL@55E;3F#)6'1)W^( :4G#G(+CSR'+\XM<^KU_[GW$29W;<N+4V
MP%&C>CYK)M46S_:%61@/C(UV8 UZ:C0_GN#';9P(XZQDB0&R"Y][3$DP3B1!
MGDFOE,2>8WS=.-&1LV!(0I1[<(I3<,@I$Q%A*F'&A:/.'=8XH0,J;MZ9V%4-
M\.WP?-$!!=8*K!66+K!VE[9 ACEM;4)8\("XCGEKD;+(*Q$\B\%9O-4.QFNA
M<K-3Y"TAB'--D1.,(!.LL!XKA64X**SI@2"XH%IG54!)-_?*+?\XG=MQ1_1Y
M5PE^K"8*'=*LHL)TD?=%==U(Z7O\?Q^T/VY[15/J*;;9A\YY9A4YT@9S) W'
MCB;#'=UJ+O20O:3/:J]0/<#XYFDQW54'+\=D*2A74*XKJU!0[MA1CJ9 57(.
M!44!IP012$<A4>#,)F$ O+8KL![2*>1Y48X.-.YH)KR@W+9COM$D9&. 0-,B
MY&7WP/AX&JMVLT,,R *?V4^Q^C2S$V";/$H\V=&L^IQ[Z;1=*MH6%<T!,53?
MQZ^K_A=GTS!*(_AN><P/3<N,W.BB&4U6Q;R5MEK?1EOEO55-CCSOFX"GF,5'
MM?K<-VG^LNMA[G&GYTCFR92\4 ()!PJ31Y.0)3(A+P6G"5LJ]783;#C)$U#'
MRID\B$1+9%GR*+=()RFX*'(7FSUU8OJ]98;_S/Q2OYNT36G^9\EO)RV[-3_^
M#,QVV;9I4U'#GZ#8<[>4^O=TTLBN_3DW$9G5S4TOU3C^1L^F[5:F0[S?X:;[
M9K]&,KKT0#V0AT"3\L1$I S7N83;(>,M000G$YB(DFUW)@./E1M+%=(J4L2I
MQL@8IA&US@9#I=#6OP!Y(&)H.BX0YX ;=7[#036+=6[G-OH<QQ?#3CWDNDWR
MLDV+GQ>S;!BL3( ;+ #>I=4;-$^;9=I.+M;;?_5 ]S'A39#>@/:*'/$0 G*"
M1T0X459'+%C:*NQYUJZ,)]['<>YRMGEF;E%WHV<F-SPS<9MG-KPY6]H%]JK@
M_'&S8I,JNV#Y >VXJN_2AVZ6A>?+:'XZRJWDOKUOLFE,EY=Z$EL.R><UK-U:
MZ6VWP+8\=;4H^0NP\#?;V)W&<:C<164;NH/0QJ_1+[+:'18]MUK57^_EYPPR
M*5,<S1>PBGDE%^-Y5I/+KH S6,U9#4P!:[&+%^K63QJ=@10 \MMQ68C+A3AI
M.BEND;Y5ZHO)FCK?H*P'!01T']MFFO;TDOF_V+K8W_?#("Q)-)I;%%C><9D'
MF&KP0Q$)03+.%:&)7\<@1T(2P6+$L J(YYDKCF.%L#%64R(BB>(Z!MVI+^IO
MT\GG6&>[NFG6V63_KP//;]/Y_\;Y5=?4IB7HTDC?$R@IL>?9*4^%2H-&1XWJ
M1M7XI3"XC2ZHMK[$I"GH*<"%K=C1>>/29$&TY^>SZ==15E3CBYV2=(_7N:$E
M;XJ:8ZD=4M*!\X;!;S,L:62MTUP*%\'XV4<:]<D8KO4  4*67^7C]CYI==\<
M0X?R"0;N[IVO&T N^+AO?,Q]C1MP[ $@"<^)8"XAI4*6< * !""$6$J:ZB"X
MQEL)*!LMHU8R!% F4?:>D %=@D(P*0='B?"JSX"$AS>7:'2!3?N,1UQA&SEU
M2%N %<[S!/?4S$< A]H8(;G>GDYJK6K\;\_!_^8VD0Q?$HG("*,*2Q:V I %
MC]8YA@QI/_'H&V,+;I@B#P8-E:",O+? 7T9Z9*76*"0B-&'!*K$5Y'F0O6.;
M%ZJ!'1K>NFF$0+5\>N"Q^5V?[^_D;JGE0\'N5N^W?3."&L)I\^ION:L_$+AJ
M*+S.%GN=6F$#C=0+6(UH(YC(G".K"4<T)DL!T+C%6S[9(Z=67&,>4$PC?S()
M/X_&"]!&'W,VOLRDN#D?WXYY:&+G[12'.,^S'V;+&%XVSA;SRXA=_LIE"K?1
MP);&U008K!D;<9DTV9P:,0#@]#%OVFA^RZ=>'6G/IHO)_$@G2T@U!%Q]\&0)
M\=Q3%NA0\P<_;GG-TCG\&H[TN;]GH5\9(;%/:I<1$J5+< &"'BYAH5_I"]\?
M("A#)+K [D>B+LH0B4/S:ADB<=3*XI%=/>YN'^[/'GS)73V::+>=PP4[HOX[
M0. CP(,.;YP])ENE4+2(?Q'_PJQ'3-'2/+U?]MPR<]V1)A]=I?FQMK#I4R_9
MXVI@\Y*;RG[_F$+!Q[2!D\HXIC0*COH\HDSG43$<81$TQ<9HMCTJYB'%6:!4
MWTW\]"SFHK.[]\&I@?KPUVU;QXD9&%[:KW=&O_S0$?W25;H6[#S\&A3L+-CY
MR+T]+#!L\\;1)!CBN6^!Q8XA$HPD01#,]%X:'CPI=FHYX+H7S>1>.G26M%"O
MP@@_Q\D4?BN)H1(9/I(X9HD,'PU%B_@79NT-LQXM10^;&%K?WMC<Z:"9HO6-
M?&2H!?MNXP'Q-[9>=M<&_)_KS0# BSL#_['9Y5A7T\6\GMM))E1'@@HO&#>>
MR:?M*H4/0<QG8-ACB7'MCD!93ZGA.J&4F,JM@P726A)$+#64!!VP"/O(WEQK
M$-SLIV]VUM>_7ZFP][/IKSG2M!&A:C7=>FCJW6^_WA*2$F8@,1TP>G/;LB+"
M+T>$"^84ANT5PQXWYA K##9,H$CS2!TG!'+4"B2P(U@GI8G:RTB=9\8<-: "
M#[#L:"KDZ$7XL*-LUUU-VBE?F T55L?@"_\MUO7K[?9XBV6+N$O7N.G_/:KK
M!7RW.,^-I^UL?)$;?\_\J([+OM17ARZ[)?<$&XHQ\W(K3GIJ[I1"DV\;1)$K
MBKGVB"0.!I&.%#D,GC@E1"83G/-F:^;/?9SP^<7,7K>&_EQJS;>-)FQZM+YK
M5.:?YWG:8*LJ?T]K/^]JX7H'0RF-OH*R_G><33-7:DKHFVX:2'VN%>FI8N@J
M.0O6'7X->LK2!>L.751I PU6,X>L(!J0421DJ;%(.*ZDB4ZYM#50X3[AA8.B
MZ5;8@=$!(S=/O>NJ\ND\HG:F^O*0FSC[A]Q/FWQ?9MT7==O)OVUC'#<[%:\G
MZ ?;;8T[ E-=7;]CM;RNS3$OMM?3VUX/(_FQ6%^[;2,9HPJ>460$H8@+3I#&
M@2!,E/3..<&VIYOM(=W_VR)WC?T];65?FIS,+380OL4"VOVFGD4J9$C(*P56
MH L:604OCF6(S!&6A$U/^*;+00%;+_S(=_UF84/W3<!K(MEY(["G>K"KY"S@
MWH55Z"E3%W"_#=QYH%1H+I$.&B O!H6LDQ+1@+U,%FNLQ!/451P W+40.E%X
M3'A>FV?BX?S.$@7J1= I,4V>HH+DJ<%=#2A1 \5W#;<KX-Y9/7C8PI,78CL\
M28.NJX%1)5+S<HVYKE*X[_U%7HHU=K#.6TZ+)+1!GE.*.--@[]E($,96:!45
MYO9192,W3=)<FC^;?43@SSSJU\[!(DHGS?1&^W.>9C>KFY,NNXS@=9.(WK7)
MR$UVH/.<@8G+C'1YSK%#CE.!N*/4*<&U\%NS:O=!@6W+]JG?GX+T],0J/#9U
M6EJ1%4.@GYQ;#(&780AX:JC2WB+F'$8<)X>,% !I+$B-B4G";1D"#PF''!X&
M;PA\)26=4A111VUK"!F>,)) "9DPLR%NY7KV\?Z',(3(4!1#H&N&P$8$"#[D
M@=%= N)]C_C>@=D;<]OA<QA]OO';_"]0:WU(_+^;K4E?7],W:1R_HC":Q8:3
M\T3LQ=GD31C5YV-[\3K_NL5K0P&,E9]U%7"#C_]8U/-1NE@]=',BBI/PYGQ:
MCYHKS^+8SD>?X_K@Y<N(YM<[,N:M1+U],M3Z7BV\^K24F8?"U;X7G.2$\]IJ
MKU;P]#+6N7SNT60\FL SS>UL.?-\\P=8@?;K<_LIMF%/9!.0X;4=?[$7]7+<
M]3IK;*JIO-17S')MT?>[MH\3SOLLZT$E=UT:_=C6=5Y,.'TUA#S_%S['V:OK
MPBIV$!S>;&WM[O$.+;CGFXTF"[N^.R9R0J44R'L+KKV1'EFI-0J)"$U8L$K@
MOY/U)5W?ZBB'4JKOOK'?D="'2_!C M7[7MDV&]7L>\SP4YTO9O#79)X+%>>G
ML<I#^:KW\ B_+O(\Y^I_[&P&/]=-R#L?\,M7?VHGG^+:+[-8C29^O,C'CR;-
M40#\?C%NUV>:MG=CKAH37=]C>94E&U1 RM/M>/L@&S[-/2XB&$M5;!YS?>1T
M?@?1G))?9EA]/(UUK+ZL/^YRDV=# 3N'8R^J.9"TN73;37.<#<%Z%/+$-7B)
MP>K]9Q&.B8/F 98OT7R;J35KKKTZ#YYJ[74NGQH(#N+0;B]=$0E^WGK/S7+1
MYE;#=8%\C/A<@>W*-2!*2$NSA9NWEF&GD;:>(</@[R@(Y9+N(T+VP9_&L!A'
M,'E!@)LW!6WP(?K%#!1$K(&Y&C;Z=38]>]N4S3;4_SU=MZD_PG/\- :6>55%
M,)3/LSC/%O&YQ+LYO*,2#NP.S#8>3[]DOFJ,S*J.P/C @2!0F0?7^?)\FL\;
MV?'XHEHM"!R_6A$X'@3D%.2V<C%.0'*6@IY@B7:)^LWL"Q?P=@&L#V>-9JW*
MJ/-97Z:+<8!?@?WG([1ZB'5NOS2:EZ^SO7V]L1:6V)VIG,D$2C@?CL BA#=N
M#VDI1C#X&=^MCO?9[SJOX^LZGEN0][B)P\UYKW:F;C^/ZI$;C4?SB]>KB]R4
MDVUO+-60$?;=NL&Q M#&XOCQ6R>3(:8//?6AY[$AHP]^WO*>/]X]_Z^_N:_C
M[EVUM]7244Z'+M.U>TJ_R[ZYLLS7?M+YVB>-?;UN&9=IVP=D_J+_>[^$A7X]
MZ)M>]/]R,7(8I&C\0[-[41=%7?1%7?"B+CIL('9P@\!+GKNU;,V2$R?GBYD_
MM77<2&;TI*JJU ,>:P%+3W=POI0RP!N*] )6AG&./$X8<:D\<EP%%"5WQ'M+
M(MV:]2FDXU'Z7,EG4]L8TE+N$+6,",N9<$1<S\0],O]V<@80-'_D3D;"!I*H
M ><=;4Q5!+L@44&BPK O$XFTM)X8GY#U7B#N!4'.>YS[)4I"&$]!;^V>)\D$
M3P)'$@= +P%PI 7UR(>@I/.2)[-5+MT)),(#+NF 4%.0J$^;XP_9]? E^[Y_
M[ARF<,,4A3(^H=@BW:%PL45Z:(L0(KA122%KB$0<7&%D) ?7."3#%19"A>T=
MW,QQX:)"E(,3S5D KSB!0:(D^,,R6J&PZ8 MTIO!!T6@"P(5!"H,^S(12%H>
MI&$&19SW.%@AD1/6(YF2$\XQ:=-67!8;3:-(!C&* 8&(-LAQIU T-#*F**8T
M= "!MKQA/F!$%1#JDR-<DL"'<81_J><@,]D37FX&6Z:"FVTJ[9ZP9M/<A_?O
M>Z+&B]U1ABGUS#(IPY1NB>230)B*&C'OP X)8((X;!4BX!-S+YB686O44>(&
MK!2K$:<^()Y(0#H[X-3"*2108F07O.?M#FAJH+HZ6[G/@XYZJAJZ2LZ"=H=?
M@YZR=$&[V_K;IQ1=LLAH3A%7B2,;,4.6V5Q I9106VAGK!%&4(?@/SEO[3UR
MEGE$B:9):$*2D5U$.\('5.."=IU5#26OW2MWONJ(CN\JL8_5;"FC><IHG@Z8
M+CH80BWXZ$11 IXW)\B2E)#2! <5A4ADRW1Y2!NF3I@N;""Y&%"\:XQ-UQ7$
MRS%@"NX5W.O**O24J0ONW89[E@NFL,5(.YH ]P1'#F."B--,!Q&YC7L92=<)
MW,,#KO% T8)[7581NWMUW]R_>KTC[>K[[J!4>^_;>EP^AGC-"^]J+6H=\RH2
MC$C(7?>YR>&X1)'F5#.7K#)6[L.F?3?QT[/XT7[]>53[\;1>W-PDM%HN5@PG
M\[L^XF;KX([%-K8:/NR[IZ@>7D9&.OE\[>)7L/JQ[O2#;@282JO:TUAEQ+63
MB_^[KN!><_NU:1H;ZWMV>7[,HN]]C7.OVZ8][I_##\-J>K[L(5TWK:AGN15U
MO5.<[O$TSV"41<&CL%0AGG1 /!H/"C$*9'1RRG-'%-DRRAZEN'_Y>AXG=?PI
M3B(\W^:XE \_7PY$8>O6%F(;YA:JH\\F5XZ3UW%RTZLE*YU+.B*+';R?X0GI
M0,#H],1*8E5RVYCT$'OS25]M,KW[@)=.B,7Y;)K[)<,J9-F&_[N6'*VLC%H5
M/L\J?*?P=^E=OM%N_O$*_CXF1$^T>V7#]#Q729Y\^#.3B2%L!M4Z:E???YR>
M@]&H./[A=?7N+#-+/(NY8?]\NG9D=67>9<28UN=Y LSG.+X85*!60_MK.XC@
MM^D\5F33=-EMI!I)"-%6(T>TRMK*(*MX5@TXJ225H<SLM__]+RFU#WZI(_ZP
M\_A'A'OXT7C4 ,;'['3<U8B]RRLT1FQ76..J1_VHKFPUVWAUT WS+[G??#,R
M84-Q;"B*+'8;7_C&@8?U7]3YTOGT!H53S*,<QO#B=KZ83V<7<.3L?)J[O><S
MJ^:/=;73!ZTSR%QN/;Q)L!,/AL5HV>!_ E</EX("M/W78C1;BM/WS8B.Z:(&
MVM4_O+[45]==VVW?;L?4E3MRW8.8E5XENOO?]U\.#7]P.WPEG[L=/AUJB=?^
M]^ +]>4\-N0/7I_2_G]7-/"EI6D*^4KS_^YT<_W?;,+\DDV8O[K9C]NF0^GT
M^LW%*:, BC(K6% Z>Q\%%K1YZZ+Q#ZCQ#T'CKC%Y42G'HU*^ZQ2GOS1MTL,F
M$?VK^=QKBO7=98SZ,NMEYVO!Z%5X.D<A.U*VV-5U.9Y:W*Y2>)/S[T[:O_2$
M<X^EF/;[QR2G'E$9XHCA-AB- L$.\20ETI02I+ -*0CB8]S+M/"KU.A&;O"&
MJHJ3^:^M$OVPTJH;J=6[%UW4L'KPUVV-)L2 Z-(N^ED4RP]%L=RF6 HJ]J:T
MO/#L\T&5D3%H"; 3<*YD9#8B*QD@%V66",F$P&D?4'67<I[[ -3Y8A8O$0K1
M=8CBMP$3&>*.MH3HJF@_%)=NCH+TL.]#WY?MD?HC"V5LZLG&4R!*6TXVJ"9Q
MGF<8K/SSE?-^N^6=WQ;QH=1F_7\"R'%+P9@<*CCH?%J/LN"^GL6QS8KE/GX!
MZ8O!5&((QZI2B[74:6OI4*$#DF*TWBF4),N[*#A#SKB4S3.IF974LOB$H8-&
MR9],PM^RBK\\)F_@W6]P@ P8*S98B0UT@*X%Z@K4O6BHVPU$PB8;B/((*QT1
M-\(@*PU&6'I*L=21!?Y<@8$[H=(C(@)D2#K:$;FK(MV9@, J95]J/I\]() W
M&_I9#*/Y@X<6]I^B1U"S]8)(6<A7R%<$^0A(6<CW@AIN]]T\WLN"KO_[ZZH8
M,M;1SOQIDY4)\7,<3\_S'O;'FF4O9)5*Y*=$?EYTY.=020[+E"/&)^1UR$4G
MV"#'=$"64Q<\#L2DO<26;DARP!=O6P7YQU*!/JCAU'8<20YX"225K$87Z%JP
MK6#;B\:V&[(:(A(9DT'"*H<X0 K2G"7$%-?$!B:2V4MZ_6[=R[X)0X_(9X@A
M$P6&>IW/*'[VL_O9;T_MY!,\S6A2?;;C91<WFWOPY=YQ/5'?Q=XX5A55[(T>
MVAO2>2*8I$AP&\!V@+],PAHY[Q.V!F,:]MLC>M/$:%7:N\G/,<49V!IPP$E=
MQWG]WRL%=[+2;WMR@2D;2,V*\5$DNT!18=A^,>RQ0!$Z4%B7"66<X Z9*"4X
MU]XAIU5 A#*O=0@I!OU<SO5#D>_;7O<=B]O-4!7_NY_^=^DA>3#_^S?XRWYM
M^IA/9Q4<&F)8@.SD+^#"9Z7*L!0G]8*4A7R%?$60CX"4A7RE 6-OC.:]5QE^
MF$_]/RMG\["H/#4H3NK&<>J)-U_"3\?J+);P4Z?#3[N#0YC3?'&-.-8>_F$)
M689!\SMI(K6&2(>?,!/RV[H[N>R+V,PL_RGKM[=KZNWMM'[8 ,I=70ZD*+F0
M(ML%C K#]HQACP6,#I4+P5A)02A'B>6QC=*H/!Q:(J%X]"1:%O!>$O]WR84\
M OOVD@X9,EU L-?9D.*/=\ ?_SVED8^SXHL7\Z<[%"[F3Z?-GQNJ$CVC8(TD
MQ TUB"<.OCA7''GF6&)).QSE8XR3^<7,+AWQN?VZ.;A\J<7J=;-C3^XV'RA:
MZBZ*^!:\*0S;,X8]%KPYE+OM*=<""X=",H!HCF/DE.&(2&J,5"[*M"]$VPHM
M[T*T]W&6E]1^VG]U(1L:7D"NE^YT26]WR9V>G\993^"AV#/'JIN*/=-I>V:W
MM4$3]I(ZAKRW&G'&);)*>G"BF3;>8A[(<^>R&VVV+S]:%ONBR' !G<*P_6+8
M8P&=0SG1Q,00E6 (XSQ[AD2"M-<28<8T(38HX=4A<];;&+</?QKXJ/C3_?2G
M2WJZ"\UR%I.<X?DT@1<(>2K@:@9@:3_[4NP<!_(69Y??#,7YO*JGXU&H5MS6
MU37HJ27T>((?BZUTTU1C8@7+O66YAG\"3<A(XY%.PE E*0^)/E4Z8*D9WTW^
M7-.+<-1/2ZVX[U%Z=*!I1XO,O\&F+71C5C1# ;L"=H6E"]AU.3! 14I"4.0X
MBX"I22%#L$-,<L^3-93+1S7V>0R</F&FG7:VC6Z?@;4ST8.2C3]8].#];/IY
M5&<% P)8C1K)SZ&#6&(&+].,HD.:=5B8+G*WIZX;4@]587_I"'?O@_;'8E/=
M$$"(2G$C!9(A,L2-4\B)A!%C&EL*L(%3VFN&?YGB6%HU#TODI]'7&-"_XVR:
M)5U30M_TP7RYQG^=-V!ZZD9U6* +JA6^+F#V9&"FC)(J.(%BY [Q: 0R%!/$
MN.$F2"6$9$^7UW\+UQU-%O#LOY_'6>/3U_L:= ,KB0O$=<? O:./#A]RF]>]
MOQ>A<.[C_=AKBUPO@&_?7#VA'"JXS;>>ZNX$^YY<#K(#+D[3Z7PRG<=6;G_[
M^'>51'!2<<1$-(A3*I&EW"*%@W1.<!TIB,C7L_'KL9U\^G]>Q0GZ\T.G7[AZ
M3 CSBD'V\S ?3R,\ NBH:GYJYXT&G(W<8@Z7FT_ANUB=V7],9Z/Y1?7]IUF$
M V?YR$DE\'<_5-/4')(K'F*C^7(QQ/QT5%<>COPTG5U4\/=;H"GHL,G(-K&.
M?,9%M+,JYOJFZN?HXYF#RS(RJ"C.VU>[0Y[AI32O\>92MN$;WRIVNU2Z8?3Y
M/U:Z^+?%69R-_.6W^5\0_K_"?U<O]6\T @I\?4W?I''\BL)H%AOU#9<=+\XF
M;\*H/A_;B]?YURT%.Q2@)_-CKR)\\/$?BWH^2A>KYV].1$#E-^?3>M1<>1;'
M-L,3*.>OF5B9 )=Z^NL=]>RM]/V&JEV:&<LC6E!9?5I"P$/-@WVO/:%F0Y>O
M5O#T,KBZ?.[19#R:P#/-[6S^VB[FTS>;/\ *M%^?VT^QC;,BFX ,K^WXB[VH
MW[SZ\3IK;&)S7NHK9KFVZ/M=V\=AZ'V6]?D6<H>MOBZ-?FSK.B\FG+X\J?DO
M?,ZUEM>$5>P@.+Q9(^37-,)JU*]C7D6"$0G4(@X6)[(Q4:0YU<PEJXR5?R>M
M]0FGQG RO_-IM+WU#>OZ+?*]NNEQC22$:*N1([EPA'"#K,H-G Q.*DEE*#/-
M?2^YJ>&"3!U0.7(HI?KN^CJN*P]Z+^6Q)WOFR; S3?,,#3@T YVM-AL]5"[.
MO\0X:2#O_,: ?S.[?N.+W-\&,#A4BSI?.I_^Y_##L$K+J?<9L4&A +SZZ>Q\
M.FOP&T"X^>,.&,L'&:BMA[-#GO]1?1G-3YN3/BU&[3?GLU&^3FL#V# ];UX(
M /_DPY_Y$@QA4WW?P/UT4<,;U#^\7A.Q2SNW,7.O*<Q&/S0:<:F?\FIE<H-&
MR8<C0+WI8GE(2WF"P37X;G4\K/C8GM?Q=1W/;7[I35W3G/=J9SXL+X&#]9E?
MO%Y=Y*9$5WMCW=SU4J&N%$2C47_\UHET2!YXYH//$T/SI+>\+<NHRSR1?J>W
M"ODZ,%W@@<4^NXFM]T3KJ_#@0Y#W2ZL?W'0<[K$8_YL![)<,8']ULQ__8PO$
MGI_+'UQT<HC%*>,->E_KL-?(>,ZO^OGF!I7*SM>,R6Q)=22ET=45.9X\75<I
MW/?*DI>2:/O^0)6XQEIMI/5($<X0Q]8@(UQ"GA+#>)).X*W.$US8X+Q."-OD
M$%>:(9UX0 9'Z7F@3-)TQ\X3-Y2KG,Q_;7WS#RMMNI$!W/>.%Z('1))NYOV.
M3;'\L&\;J.S9/9@-]*%)=5W%V@;5),YS5&L565O:13W!DF(%':NRZFDE4C%^
MGM;X$1YL%>(9BM[R7 U!D':$HB2E3%IQDK1_0N.G49\GD_"W*3##Y3%Q[QMZ
M"2O]2/IIVY3XS@%MFS*LLM@R':1PL66*+;-K!(<+QEBMD224(6Z5098EC(QG
M."KLM3'Q"6V9IQJ'>3<+1PE5+)Q>6C@E>G,P"Z>,_RK63><H7*R;3ELWNVT/
M%[!WW(/U0 38'AXGI&,B*#CL!8E<I;C5SN4^ML>!QG\95:R*PPAO"9?TS9AX
M'T&0)O!W!9<Y:XNPIV4@2K$H#D[A8E'TT*)0F%KBI$&8\@36 4G()*Y0$$Q;
M[Z@CU#US-&.? U&*7=$KNZ($*0YF5_P1ZVAG_K3RLQA*"_AB3AR:PL6<Z+0Y
M<:CTBU>>)^<8LBYXQ"W5R#&:D&4Y,&*CLGIKU,T>#1;XXFVK(%<*<V\CT)GL
M:#/XKFJ(SN162CCDP--L\K;PSW:\; A@\][VO!N\)Y!0;)C2V;]G5D[I[']+
MHH90SZUT*#IF$2=@>UBM"2)8V2B)(IB8)[126JWX;O)S3'$V:[KNG]1UG-?_
MO5*2)RL=N2?SA=(!9QW=V=/GGOLE(M,G1"VM]KNP"L=JU_2K*7'?-T27[L2W
M&3G!4^E]"DAB*\!@80;I8 ,BTG#M(PO&;<WJ>Y214UKM]Z8/\=/8+9?MAV_J
M8OHLS?WV9@8\16>_7)YE)Q=5 /-V,IU7Y_;B<I?P-!M]>2>QM_7I9NL^^.G4
M?M[URRRF1=.-;S2YM0?N<'T9=S=X)'=J\'C5B7;5C1+X7$F3/2BL$3>@-XRR
M#@F2M-+*>$?L/CJA?_"G,2S&\?>TY3OE#80CVW3A&\7Z8V;$CW"SG\93_\]7
M503E<YX9;[:(I<MDRXM7#9;KIN=R/,M-'V>9.>';603WLVX;.'\: >_-1G7,
MK1OS5H11 B4Y ?:=SIJ^\ZN>S6&Y*LVU;;,N30G4QO?CJV6"8_*I76K.O"4U
MS0ODSF"5G<7\P&UWSOHE]*F4(!.*/;3]XU#QYVY628>&/OAYRWN6MIP[$?$H
M7>%"OONTY92E+>>3MN4\:0R!=? MC3B_N1R';<19M'\OU%<A7VG*W ?MOSZA
MI^C[ ^C[+FB+?=&O*(M#\^J3*XO2I;W+QN$M=9AWMP[W9PW"H7W*D>\U/?CS
M=E#V=4> H .D/@)DZ'">^YBLED+1(OY%_ NS'C%%#UN&NIZ,;^[TH)JQ?9EZ
MZ^E:,M2"?;?Q@/@;A0+=M05_RXWIVW'QDT_5>%KGH<JSV46:SK[862BUJP='
MB[)KL-=UJ1V&CF>H.67)8&XQ1UHS@SAF!-F4J[NTC<%SQY7<VECC2$@B6(P8
M5@'Q9 AR'"N$<Q]72D0D45RO ]NJ_OI]I=/^!BKM[;I&V]<&8#)0AG:S%K6K
MLMS3W7-=)6<!GP(^!7QN!A_N &H2<R@9:W/K;X*T)  IP1DE>50Q;8TQ40)3
MH0!MHB:Y"-E(9&-RB! 5%)QEI#*'!Q^B!X;I CZ'W^+P[%TGBD_\]$TJ[/EH
M#O?Z=PS5;-5GJZU:_QS'T_,S.*PG"KZ8)D6=]<J6/FZ+Q*LH60)/6"H-UD7R
M'EDI$L)$61N-%62[(?A]W.&F(?B6.;*FSU9=L$XFX><K9;:OIA)\P)DI5DD1
MXX([A6'[Q;#'C3M,$L8# ^0@V"!NC =/V#C$6!16$L,<)H_QA ^,.VI L"BX
MTR=ON&2(^^(-@SB7)M/%^.@$A8OQT4/C@]-@@@P*N> )XEX[9)CR"$L,?JP2
MW$2V?Z?WJO/SOF+N<L T+E9&D=<",(5A^\6PQPTPC"<%OBHXMM)CQ*V3R%#B
MD#/:8*F=\Q[OW[O=/\#@@:+%C>V5&UN2NGUQ8S_,I_Z?E<M3U\MDYV)R=(?"
MQ>3HH<E!B%0J*8H\=AYQ$AW2F"CDF6*.6J4,?I1/>V-I&?RQ^F[97G=]P//)
M)"R[[=8?3NTL_I35W?H!;Z?UOJ+N? #V4[%6BJ@7;"H,VR^&/6YLXE%YYKA#
MGG(&V$0-N,,L(*&Q(L)RQ<G3E#UW!YO$0*F.3K<Y>E$O">$C]Z2;@=^#:A)+
M$?1+L4_*P+XRL*]3-DZ*S'OB)8(U4XB'*)!CT2#AA.9@M!CZ5/N*L_+;5]W:
M@&K532NES. K*%90K#-KT%.6+BCV;123(4C"DT0R.(DX4SEG;36*2<H0C>66
M;Z'8?C8H[Q?%9$&Q[HK\83/;!W6_^^A=?YS.[7C7W*R.Z/2N+L+QF"E=I7!/
MC9"7;6)8KH-,-"!P<@DXRCHB$ZE"0GKLM592N*W:N+TXRO\YF];[JHS39L!E
M:7=2I+7 2V'8GC'L<<.+X$RDP"-2R6#$M?'(:.K!)>5&!Q*H3_))/-A]PHOD
M XUE@9<^N:=[2A<7]_2>:N"_[;@=X5[9//383GSLB2(NED.)G_?,MBCQ\]6R
M?/^8B?"/J:53F%%,&*+*)L1CKO..PJ.8<,0XTB!H>A+W^5+/GJS4[+Y\:3W
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M.##IB!OXYV0<0??#33Z/IHL:_+86<6)HG<&;T")>AJS V<WV3LSOE\&H4Q$
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M_X!#)XOX=AKBS['VLU&39>\(6#2Y_A46W $!-@-\W??<..Z!L[3N)=]_#?8
MR<]0<1&9 WBE"6E%9,Z%P5_11F2E ?7IK65)7Q=03#F/TD30MI%G@T\AEZA'
M0H%8,R^L\^X0>I?W0N^VL95<.+04SLQ1-S#:TRAES:('; U(.+#:N1,.E#+@
MIK:1:&Q4B Q?7_,@E+3<,"0#R3EUAL'(5Q)IX0FW1BO%_;$KY2,2>^4<!3EW
MB.+<Y!XD%CDEP:KFE@A!C"1X2^PIF-R,.0T+'R+BS$CDP#1#(5'-=5)1</7\
M8H_[8HCW)*1JNO0\MX542ZG7^\6L7MBLD-HJTG=_O*T^M*'9NF*:-C#"-!O
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M@*ER0\(=*4C@4^[J'7["LV^:JM.&/N]J\FP,B'4\_-,",8U.4HTG_C5-R]I
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MB#X92H-]N>LP,$5^0"(O!*/D^F' /64#JMX$:'XV\\4ZFK]%\_5X8(TYWMT
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M+/!);$<Q<843Z4"N1R*/>U[LV([CK12F/P9>;\G4N .JSX-$4],?@(TIXMT
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MQU]"QNS7HIE*?9?YDKXVKVJ"$"/%\U9'-KK4M7W]T2A:7L8<7DL^7V5J9IT
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MZ8?,UR'B(8KMROJ <G /"\5B[<@S@]>VK[!'[3",HK:O,+6_=WS7[:]%3N8
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M"0AX,6TNJ0=/;7MH_]1>#]R?\7&ECBLUYH"_U3)9S7TO5H)Z%VF5UECXN'W
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M_$S5/A7A"9#AF&>7?%:]?G$$#_[Y*"[D[+_^[>>C\\DH^Z__'U!+ P04
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MZ]_T["')VS97FX<G@.;<._XA$DZ'SF>A#]&6(U(VX%8=D?Q;$^:MM?0W]%U
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M((2IT>.VRU#D/U!=/0GQWX(78$)1V?OZ9/AH*!V.7LZKBP^+ MZ^&':!Z,
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M\]JA"\3F,;YA9\+K)<79#H S45?$F??":.:+_-5%&:@_OQ%3RI)_> JQ49@
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MLT/ZX]\\'#KA^NEP ^DF0U,\,C0AE!)F\OK'Y=_GR1UI9VSDY \F-8HPX_E
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M;QGJL!^/DG4J!T-R3JQN7CHKQ*<%_KU26Y1-S5R:\CG/ PSAC-T'FYC>PQJ
MGE.J'+9;T)T)(Z3(PU+AP4SXBSYF"M)W?F,B07IT._;U;D\O$NX4@AP&EL+
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M-@@B=)09,DJ*/%;6K.7TT8T!'C_B%^&RHT>+3LNG/W)\@DAG_ <=!F7CH/Q
MBS3<0_S7H 5O;/X+$%J4+CF@I1OLV?=;MR*C@XH.PU"\Z8LQE/,4ZP*@O#$'
M/&1KW4C')=L4ERRPMF3,&4@G]@3O($ 7IS'X5 .YI:]A'KEED-5"#@/LYE(P
M("0R&RLK\C2N(<((ZP7'[U>U!)6:I[H"N2P,6($*6)Z%2+.;YQ)496@<N0!C
M7Y:7FPV@@#_CK-(RW:X\CN3' *:4K%EJF##I#]%VTS&16G4:<)?RXRY0;N3,
M42.T?%&6^8M:HI(QPV#QZ0M,#^":,S3(AZ'0F?*<R;RFJUJH53HC&X_9%7GE
MA5&\I$^9"\^9EF1$1A*E-,WD6^K@0QP;T_-O@F!YP.&.59X88K>KQ9P!ZEQD
MX?3GQV'>H?S!\[U=LD.$Q0;'P%T$^'#(A3<( (=";^OY #N*+2$*#6,W]XBD
MNZFPR\N#&-G,3Q''GV6FP"WVUX=K'V)OW)O T9+4^_W]]VB;#H$<-H9,R3(1
MJS<"@^*+_'2/,MJ($T>".F+DC=TZBF2L%5;C7)&!I;"/@HSVG/@B.9;N.4N<
M:LXX/">>N'OB/G;"^*8C>PMTANGU"?8,=,;!Y.?'<>:0Z<#O)7>@&F*V!GWM
MV.R!2OT<WJ*?TU0!%C#)#53\\3"8"Z*)RT)5O08X/4,)('KYR@LV-\5-6LBM
MG!=7Z@,QG1.IZEST9X*9[]-WESN8U+]FJS;KXJ5"G88(/4&<1]XJY.?(8KT*
M7L_GR.IY2_F)VS!8@WX17?LQWD)9B"&96(UU)U Z%LH&0[_!<*-66I;%QEDB
M!D-9X*'^@[Y%6< \(RH2&>; ";'%1&UPE)*X^A$?OS/*9T>[(U>&2\7.9Y'/
MB-Z@;Y6WX+N9<9C>G15Q8!_'"V9C-C%9OJ&Q=*GT6UP%X;VWHW?=<AMB]MG3
MWUPE$*K(P=D'6@7E9#I4,,72E0*NDXA-BFK_8E;LEQLV+U$"X M>0W%Z7M>N
MQ]JIM_[\%K D?TL@CIYJX$.I\E*0JDRFDFWZ\U*G[(V-3J)MYN7"5^:7OPPU
M(;2X@6'!E0 ;@K3!Z.!&X)R!:-X9-HZ;D9X50Z2"EPJ<GUGQ5/ZHPIJM,O:-
M:>4O;P.:"(=53JUH:(!JC8<R,II.KI>SO*G+,5&D=A30;)M8V2-QEG=3688"
MSV*/<G%'MV'P[$7T!RH%ITUPE,4,]8<22P.S\C6%TQ&9D)NUPY&!2"6C2U'4
M3%^7I)@"8H_K4N5@JCPZT=,5"5Z&IJ^E)%G("Q1[9E1-)K")9'N1)E[*MU)1
MT9<0F4@5S ?(M].#9Y+L=DYXR*!H)""^'.K+8U_N?%4"6)8C)M/ %NE*4+F#
MI3D:E#ZX43"%,LZP;(9J9\+8F&$ZY^!ZC)W]OL&VU4<%*M+:"E)N/4T3#U_6
MMZ*YVX5=*0PD@Y7,29,Q3;X9= I/ 7'IM+C-\&,08]VH4,H@?Q!U2V?+F/PD
M>/55D\I6,3E+R]Z "XFCV\MDJ]FP(7>B(EW,X*XHSB_%FJ<- "%G(32"@J"#
MH<IX*DM\'1\4,/1$]HD,,)I!'//G#[[[H>YGJ.@P=:0%)3Z1+GGH^9&W[E7\
MHAP NMQN0W;(44J92XQJX.>CF5C(B2U3%C7:L$@B6O1K6Z$*)6LH&D<N"+>P
MSN,6YF-1P&#%#Y^QFWJ@I?]X:$4^'@4?"O*J-]D3(\R).W7C[7!5':4Z5)4I
M9M:L@_$!>(9S0(J3%Y'0YP9FGVJ@O'03RV>YT0%3H:CH"FFCJ!-:>2M;X4VS
M)1+C92'&<BI\;Q2(K,3B;9;N_LO(Z>[:V2DA.UAA:_ CGQH2E_0*WO%W50);
M2:16,!=I@;0]>)A,%WIQK*70)_<HMEEECHL,B2Q=:9BGV:=(3'5XK)9XCB2]
M>7!1\N*G>2D'!/58S'@%^KH <H!/HU:'T3/?G,MB#L"255<+F$BN0HS!($+'
MC8?>LD#O9$,)HE!DL7N"\E>W+./?N,R^!=-$<IZC7KE,>BD@8U;4S08%#;N?
M]H&?23K*GX7:K"-!]$6"6SH"W#*I+*WML0G55=C.-1VYT+:=%<R?QU]Z+-K7
MN%P%T;K/LG4Z:^/7Z60)@2N_"F/YF!RAR@\QI8_H_^TRR.4,^&)4&&S=/-84
M'?WR."1?,G,5A7,M,JFF5%YYT=HAO]*;X8K^9I" GZ95<IH(B")&=0:,$%L\
M*)XX"*ICT8,N=L\.GZC<=>U?LTN=ZF$BMFH #'TN;A?B]S8L?H_!KGIR&.2D
MX_P\?Y:)PJT<!D3;;V$DRO1W*!TL#5X#CPD@TLK*;,S "$^H4(GI)VM.M?K_
MV7O7YL9Q)%'TKS#FWH@[&^&:J:J>WMDY]YX/\JO&NR[+8;NFH\]^Z*!%2.(T
M16I)RE6:7W^1>) @"9#@$Y#HB-T>EXA7)H!$OK-4\7: O!'E&K>G 4%06OPC
M+] [47:2@?9!,)@K09FHYDUMJ$W_P("F2*G)@A]&@#.P#,1KM/9#$$# TOMZ
M(![N>*R;W3Z(CBC^ZJ:K+:9FA>_4JW"Y)A^[.R?!O(XX,*D)<.'PN1T^>:%1
MYN,)(@AI<78H*N0VIK,@FEN0(VH_G6-GYCA^16*SD[LP4S$MUX 'JC(<QEF<
M34:B!.AT$!<N:(S %(3G=+B><G)?\6GP4?!Z%9!2Q 1#PE=2@WB\RE+,SK>'
M?"=12%3Q6:* 0;+69F-30X63C3Y-&-B@H&4FV?,!J9AJW2A<BW0')9V38<_?
MXN6K0X8]47 X@WOB8!0DC2HL8U/VC(PS>DJ<>H>HA%.,)1=(N##1Z"J"T: 3
M=TV ;3E) =G1H KJ-LM$V29RT:".DO\&G 54W,GM Z)E@"H@0!?R&".PD_.\
M*5B((?[Q//,(81XZBR]\(;18D>BJ4PQPY,LA=4+I@K+4,43XH049>,Z2<4WE
MEB"Q]/R\([,/,LMUQA@FB692M%85S%08@3DF]PR32,1D1##)4Z2ZDWAP2")0
M^VHOI:&G4_IW@.G23\D3A[<[][CT43)8G*TP!]F[PBS3AMR22\$+DF=5!YY0
MB+Z[0:_XNJR\L%!R(*;CLE-]$C %97"H'$'*8; A3P*.$@VOVY[1;.)UV7.R
M=-'<_>[Z@!XPF_+R'05OZ"N^(=NNC[^RIHF0^#N-G%?D/&*R>D'M8,O02,V/
M,= @7LO/'S__^^AP^2&HFV+D^?VR?D?AY@,YF 'XNH,'!QG3YO4'PM()C;AG
M2[^R?NFBP29'?7']$]EK=&_&8HW72,S@_ELOQ\D7S#PA%T8["] Z$CZ" .8&
M@&<=W4Z1,3K$8RSSS7Q"@4M\S!)6;/%5<!KMG=FG/B/'5"S7+7J-#VY\?/D>
MO6RC0X+90$SBP_1XB[OD[C>/N/]V,"4OG]3!LSI\6H?.Z\#$8JE:/O74RKEI
M,5.N1_>.H0;NX2^&,9#9M0ZOB>_Y& V@=F4"_.*'WXL[@J$R+<;)0!!(%H_I
M&!YI9#7Z"M^= Z'55"V":7B,MIB,X\<#<BSTLP[DHW,UD3@^3=XRC;E@'#BK
M?I+G#6_),:L66!;T.A4QT7?.&R"E.F0/68&3WH'ZY4G]$4\0XE'=$$\7'^7$
M,63K]R)B#APQ)@["8^R_X1/Z&+BK@9@$-J*3#3G9-1X&EL 4&.#AS9BKXZ?/
MKR]^&O03:F$ X @^??[CZ[]QOFVT#'1#+#\PLG))TE&T@2VGA9)(UIMU%.\(
M);H\LH_$8VH QS$VG)--Y@BS79#@1-:">H]-E\7B+#-N+G;@BGR6.-3)L3FR
M=57F?TQ5AU=N'!_QN8:@VN0;1D-,PF9#-WC"3?%K?Q5YZ!HEJ]C?]ZVB^*2J
M?$ 5R/@-%M;B0)J.F$9*AZ1L ED.QIJ'<.=L06>+N:"$M$7)Q9NNPBDLPR'K
M</A"'+82!Y;B7,\ :16?B%,[<20=(_(2\(,0JV]ED;L$:9<H1&L_!3_AOFXC
M?$+JZB"6V1*K*[.#Q>8ESM/C>H2,CX>,H9PI_*6" 0(2>,ZWI!*>36_(*\/"
M?DPL\"?[:Q2B(XV!A;10';4<1>=),B:+>G4@']2)0%$)GR1N*O 'Y']^<X,I
M7$"' 240=X*.YI#A)HS*(HJN1S=.C]?1SO6[O]!48P:;@3G)F/T3!@9M_'_3
MP:>3#P9.ERZ6#SDE&(+R\@LN7%/YVB[CC1NR<M.8(6(5/+ HZV]"?^VOW#!E
M89A8Q"1^P/C,])%AQ0G)D12+AN23.OFL#I]V;$EV8H24&!W;$5.Q&]Y <I4!
M@XEDQE,RAYD@G/'@+6V\/MP[,MVXR6?& [MD$OZ/R;<U2]P'IB.QZ'84KOIG
M#: &J4#P/LLF.!V  A&60M&!?,S3@48THM2"-)&#&G[K8SCSUXC^[UV8^5A=
MN7L?KV"0Q"5Y2'%> IB5N@<2(QS,T?.7C <Q.ZD+[Y^'A#C%@T\:5YLBJ'S/
M=<'X]QJS8N[E5C KDM4Z?^3K!BN;T)2M?<(  [QX/'MZ!%$ZQ7P)"%1$531X
M\#6?B9R5;)K3@R_7GY"!+XA2)"U"92*R?KBB"J4L>SPLZ3'VVV?:K];JX*-_
M<-CX><06F>&T2W8,C[N\@$<SYDZVCL>0:.-&S;&J>F39'^6[8$!7T/.M4Z@*
M)GN#Q*2[B 2Z">P43\^Q#)_ [AZ#]TOH$7T3^R?>.K^7ZB"/\KMPLDERM1;_
M82)[]S>8,L)R^;](\2^FZNZJYA='(SO,QSL1,*KO1^5U<-S4^4\W)([2GTX*
MK)RT%PDW0(0Y1"*U.C^-#M/"\WP@=&X @1=W(>-"^_G+9F.2:(X/F,W-F-N)
MQ/%!P2JXBYJ#C:A2_HX"[R7ZZJ;$#2EW@*>!NX?HD, I=0,XH^ @^Q@E9+UB
MU-XRAJ J% NNKYWJT EHR2<EY>BPI/CIL[,CLSE1[&SP5]S\PCF4V\T%6>QJ
MP(I >.1K$D,8\E4Y CII95"V,(>NS*%+<Y:Q0Q?GB%[,]R/6 [0-K26UYZFC
MMRXYRVV,_N< !9=Z&>Z$ 9ULQ,GL=3R$G G0>%N>#Z__1*OT)?H21P?\)()B
MI!<ERL/)HV)!M/$=V<<!+BC#E8_OL G@R-,IJ/Y[(ILEYLQ2<I+NHQ45_WH&
M/3%A)!O7X0.?$#Q< LU@P#O&X.+#7CB7C-<;-S0*W*!?8A>XR^?C[C7JE46#
M#>30D:Q=<C#E:AL5C0.[)5BF1AW.8:%>H3JQ#T-6)?T'/!X'/]GN2$+::_2:
M]J (Q>& +," $T5'BEFTH0S" 55220EZ%]%-"-^D,($@H/ZE4\JYMQVVDCP1
MUR)+Q"6LQGD2O(N.CKB@\T0;%Z,'0!?\6UC*>>*KZ&]/@=^3LY+FHUXX;BD%
M/_F%(%22OFQ"2[LBX._6#S&/,'H)BC6?QH(2% ."' C0RHVTV61VEJ#(TXW4
M&UA>RP:6NL*AD ?H4\\DQK2V)W%'^>,1N7'R;_-!Q7#FI<;BJ; ^$VJ&)+."
M]$OP(K6K3!&W>H-O;7J\^4%>%)^5%/ CKRO;1H;#^^+D SIT1%L2-/5Q82(^
M2L[.#_W=8<<R\.TG*G8[%GQLY]KEG#(*[+?0@_<&<R? ,*UP4QH;VJ_P+Y3&
M=,DX3HSV>'V(NOA.58EU$I!;;+8XI4/GG"@&=UQ,U%1&-;G]60!U'H&,UU>,
M0L8_TB#)A(<MCAZM#1]X"D$^:589YSQP(@U IN&?"8=TQ (XU.?[UZ?%AY\^
M?GSX>G=YU<^'7QQI(C_]_HLO.^2?)! %!; XW.@L/U>?@Q8P/0*3'84DYV)/
M$P,=S\D'/"E( @40(VL1,[$]"C.C&B5@3+O3U:8EC,?I]A_9D*-+E8,!4V6G
MJ0K))X..>L5)5/0V"CQ\PNFAJ#K'"_'3C/3W--%1-W8_+(1)GP&8F>4NG^S_
M<>AT@OL^GQ'_4HR6'YF#F! 1I:>KB!!$:8_/\>$A^8'@A?9&3^%>HJO=O"/J
MGHB3 $#Q,DSFV9&IDBZ/Q)/W*G"3/D\<&<0AHTSTN)&Y6.[3X:J(4 BR7*AF
M*HG QE"=:1!$WVE:C6NT1G%,'%FIZW5_#O'YYLKA43\7SJ?/'S[^[<+)YG:R
MR2\</CD1QLCT)XR"H#_TDRA&>9'U11@>(/<0Y'CKL]U9T78Z(,L:9SL$@8G%
M9WY&C\M>9PSWG\R%NO-:"^SB! M.\"'XZOX !7;_!;.!K%UK4%CF)+A] I-6
M[WSFP$TFJ;_"=TVP-EFY[J!VR1.Q(XT!=DE#A!V/3$ONF %LR#@[<6LU0A/9
MOT<WLMB--'ZN-*S'B6YT8K9@4MB0+-EXE*(@@1*1H$=M.BY=7W!;,N2%&_\<
M]85 5 G5@#%1BHB^T%3C\&IARH/T+J>)11X&OCP@KQ8Z%JUW(J 5/+\$[<R%
M\W]__-/'CQ\_@:.<\P9#_[_.SQ\_7GRD_^\D0'L2QSVDVR@FD3+%N,0+Y_/'
MSS\3A[GRKW_!(_UT\=>/_W[QT\]_)2U^_GCQUY__<O'YWS_S<7V"S19C7CBX
MVY[:SH+C!1VV.LM?_G;QM[_\S&>)\M#MSE.-FQDI-PE'25)(%'OS8^]3I[-K
M-T5)+Z\M2%PB1,- R%,A"^P%>$#Z,7(\/-6)PLL>#<'^#V 6,P7G<SATDA.%
MM9SEK69KZ<Y2F&%W$^?3Z!K9S+:=5Y,]=HK1EZ=D%(K4'B=/1-\7I, &:++0
MBO[R\F11*#W7')26.YD:I:)D5).%,4G\"8/)-785K6E2</>JD/L3!EF4'UK#
M/;)4L3IZOUT=7^'LT5HH3W[R^U<W=*GD2M)J0V3_;13#:I,$[.L>^)ZMCS2!
M"VF,_WS90EJ I&_P6&$Q#JS&R9?C9.MQ,'Z<;$68H<_71-E)OBR'K6O28+/,
MZ4O<RKY*M]S5K7!"3@:6H!:,*4+G;MT5BP+B\4ND%FQ/UW@^)CEVO.A<DDY4
M5&]0F,I52\\)-O$JJ0$;G?7<[5T_)B&H\;6?[*/$#99K2$QQCP54C[X()&OS
M<9C<Y]E\8+8FY;?)1.SM.0=P@RJDL<,GDT)]0?-B8PZ=_>^$3T.U\B65'A9O
MKA^ O(#I(5XWRG.=Y E,,5NX7&/Z^0CUO*)PD::Q_WI(H==+].CV3N<KK97Y
M1^!)_NW"R1;X :_P RD**^1CR1=Y03*K8K3CA0*B8ZH-%]8*<1ITM3-#=C7;
M\.08GTA);1OBY<FM-JX?.G\$\>K?'(PQ6DZ%X"O)\>P6=@$6?>&$X[FXL-HY
MZ /4$D'>+RZ8D=(D0QQFQ+G]IU_R"3Z#PZ?((27,-6*SG""@@1K&10'&F].%
ML5($RS2L;8)BB!L]9 >-5FZ0M>N<34D_7(A,3'@^,K70'M*]6Q0V-!2&REX;
M%/B  )]2J$/Z>*R1AV+\*Z^--55D45Y- KA\6E%B&0)N0*)_0\1&#HED!JDI
M\8GDI#EIB+@<+10%H<E#6&40/)63S45=# C0DQ=%&05Z26F4-,,"G.V48B$*
MP8F=8\$E6(!R;V.72,F*C&7,1,[CW/L8#RG:=:5S^9@B(_C?,*Q#QC7OQZ3R
MR'F(0NKEP@,=DC0F^Y@YZ70-Z1\@?0->W >Z.A8AX@CKL\GA:4+L%O.$,(<C
M_$Q@CO[#FC(:WQFC,8DPH0SPZNG23^6PVMBU"7W[QP&U6H2(1K,YHZ4&*H2L
M?GOY-DS,, PT;;1M]Z4K(H9/"019O#",-GZ^E\?#:^"O;H/([7766;87.II#
MAK-Z[<'DR^[]\M0E9?I'%.!A("D&R#>#)*IBP8C@]^J\9<//$#O#,3^-N:OR
MA1*9>OP$I<Q$3OPDR<*31>:XV%/GQ8SOS&NRXA9Y6K %9;"8CRL=UUF,#A9-
M%"DHLT!'#7E0<^GD :6YPO5+SUC>LNK6*IWMR'A@FYWK]/ T#K$)D,2S@CP(
MQ@ !4S#9*0->3CM;4&K"UCH>($#8?5!H'8I'971QOPAT&27R"@K#%*$H;;_,
M;'2AK)%P,7DQ! .(*OI?#8JMB<QI4R)-FG^L"]I&5Z/O]D%T1(B\>@/XOK+A
M> (0//,6,F%,HCH=$*9 "LYTN3J?T,8'-468/KB[?EP_E8/R 1T8T78( A.+
M)P_Q-0JCG1^Z:10/H2D2AAM73S3 NH/*DB=0V@VU^!*',RT0O65<_,Z@ +25
MQ9[@3=?+6"F36//5D*>8STM<]^: ((G4;Q0W.<W\1Q0<\ F.C[<^GKA?4C]*
M.;,1'3JD]3 $1I;/C*Y@\Z3_S3*)4=-G=TOK&XI?(]%V_C&WCG&[ZI1VY1%
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M-1]<*:"4#O:_[%YS4%KN!!GLAEEXV8#.QYL@Q\E]M.JCG.5Y3O@PH]_5*-Q
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MYGP29XW&9R.'!2XHPB6.ZL"P%Q.&G4(Y(G#YB?W7 YP_J#;XU?T!->8787B
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M2X.W4E.U603+:O)62J?V0;%C*VO5BEFH-SW/XE!IT_$&*_<LD*5-TYMM[;/
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MFVVZ7&.A99$D*$WP[/?P12#$BCO7>:RAZ7KF*UEPD[R-XJ%H^Z 3G.8-II'
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MWQ*H0VEM$/._@K //SBDJ*V(W6XT"\!?8,'0@\5A\3 W/MW\6 4'?,!N,4F
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MVX2[T0EG;6SKH&@]4_N*\L;7*1[>C^T0I'28.S%=D+R1(#39!<_"^A9OKA_
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MF32#;<F/XP;)3$8W9B35"0)"F&:+/;KBV%&UQ'9FN?%B"T&9;I<934]N.VV
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M=:>O"?VO"?VO"?UE<'<_H;^05N<%^Z%BY5?!W=-UDGE1^_?;),U>DNQWD*V
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M]0.J+U2R2D'-732S]XG*"]I@?KQK+M8IM3PZSZNB:]EQA-FY.,==YS:_LM5
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MZ<9\QV/Z%!GK.JX!3L7JO96N JT0O5/-VQ7PD]@/H["J(;K>X1J1Z)EZ3%]
MAL.#38?S5;-?@0-Z2:#%:)$Q6,.!4Z= 5W..J<TB,.9Y<ZQ^9 7\C1G)H#]N
M,0MF0$NWC6KGP=]7BQ]^^?''Q>VO#!_!02-C@)&CC*O4G(OWE!7I)M;73M+&
MD&2X\@N>R4V>(MZ2IM4>3ADQ>NP^[IQ034[^'+_T=9AAEO<8!^%'&* '(B4N
M@]S.[%1_"[/="D0%8TYWX6&=W,<9K>KBF!'F39ZNZ,7;70@VC=AW!_P0ZV^>
MO3\ 9%3JX7;2=(&]/#_>W/*OL'8S8SSE"Y*>(3IZ<; (]DC>Q3</+FO/YO6\
M7IJ _;K^*H!KJY7!VBM5_I4X6&8[G&,$YR^AH$EIK G$9Q$,G\U#B)XY)1#X
ML4-!KMM&!V!_^>5'#EJG%CJ^__./O.^?6J@.&?_RL,*/U>0#4(H[4ILIGLDK
M@&D2QR#"9@9R #&]G>KR5_B$M@3<5YALH;=GS(K30\?\9(O:\3OI6M&W+/'_
MN/%2$&#U!KH\"LE"8(F9'56?! ]K8JK46@56G(W([N!L*(J,RJ?C53-&HV*U
MZQ9?NTE\K)T,8T-=A^/T2FE#VIN#HVNP&A:AV LA#437":VS=1Q!@!5!<1X$
M;L1!\'U@F8J1VB]'^LWN""8T%U<=H+BQ880]4LXP2% !=#J2Y@S=UBGK.5^E
MY"@ZYTIK@C>YHUZQ<O)91Y7G.,6C)32NCM!F8*;BLH*BCN/NLV*GIJVG=9S@
MT8>&I@%VW/E3; ,\ZUW_">D=O?X]];7CWJT"R][2E#ONP"I ;$LM[[A+*IM8
MH@W <>=3-L5D6X/C/J=LDGDF#<?]3 6(G[[PU4_6J*(%33%:0+#FO<>Q\%C@
M5CPPH1>$ Q#L_WR/^Z4A>I#<Q_D>P.J)C^9OC7-P)3"U7E)?T7+?'&^38$]-
M:WOF8,[Z(%FO29);3?4J-Z&#YGN1GT>>_$GC.?"OT/^TGOE>A(MIONT ()ZW
MUC2(JTE8K;2]7&@2OS1KE>;[$N\?0O1U\F(]A=[[B9<53'V71&C+I/?_FR-H
M28^55I_V_OH.<+A>H8OA<GR3=-[F$+8,W6W*%KZ/*X2EK]X1:VR:EHX0*;9\
MK[ JY5HTQY5>@3,4EC6K&2MXZZ58+L/_#R/PX46%-JTLY(7XB%OD=DX:\R"Z
MME7+A22>P>X2.T+/&#Y*:G729[M"+N,P=D/OZC['_MK:3JS8:J)GT#Z)"3S5
M=O*X//79@W^ #%^(5<*C]L5O.W4<%DK9HB])[#NV2^D<=072#(9^!HIKT4'2
MQ [@J8SEJQ<&C_&M=P@S+VJ=R[9)R&J"N4<2R7 '1&1M6:BT$.2KTPUBR526
MV5)>T:,)F\;PVA>ZMA?@#GEC) .\9\.L- 0C8;:I8MMFO+^X0S=+1"CV;5EW
MF"'.VDZLV+*N<!!^#()[#\9H05-$=[['\P3!'=B$?N@.P;QK%2]KJPWATK&=
MPB%;*JM%XRDO-U\1U\4-G"%'\ X][<A*K[T_0+##"N,/<+)0(_Z[W*R]S[9Q
MV6KJZ7=,Z^(D;%))NJ:JD25VHPSJ9G&ZV4 0?^Y63+-WH]%G6S<T-FF:2I,X
M<4IC@^D8!/>V3;N9J%\ESIK4TMQ&(;TY^ONCT\;85 65O$02Q/H:7@4F_+:4
MLQOJ\XB3YG0RMXD&^CKR?NDW,S9ALAJ..&EB4]NV35O<DMDYK7XF4QY15&I$
M2JC-S?$9 649F0?Q.YJ\>?E:,=I-S.UID"R6&HQ"#Z.+499+56M1N2^MASE^
MQM%9D9D9NY-!3L;725%X&K>CV16BJ)_HJT/NH-@Q;* _ZLR'V,3DVU%.&T1[
M5$J-8OA<#U1!C./<;SOT.NOYE4WF=M9XG#7_D2YK;[HD+IEI:QF*L!,+]'2$
MO='?70/E':%/DU-_D\#4:TO!B^!?>9I5-V$Q[BOV4D3T94A">\\+H7F=O'I.
M>9\TDG(EP,A'ZCI#*C'1%]&BWV[F"''$N3-(/"WWD, ?K*10\H#W5ML1?P6A
MX\B-DW:$6.Z!1/=CTMW7SI%(IV!(+BV4=QRMDSW,>*=R^#"C]C KP.D4!^BB
MH,:OFM?;]=D834_7M+NF(G<IHZFZC<*=,*GE-9NQH@W#NZ7ZFX?:?BZ)D V_
MP;NA7^V'.+8"/$3)=RO>W(B)X/F\PN0C#'!@'@[/>XR;H[KPT?:F>GJ1)73;
M'UJ8X)X)N&NC09NJ^X=6RU< PP0AY,.R&E'Y_]&_HSPH;D%_APNIKM!ZWV\V
M@)KQ0QCU2P"5Z 8[JV NRHH_QA\($^XY0]U\ (+T 8WYAH! N#Q[65%^>KEA
M1F@XBHL@_[D#2.[VR\)7Z+\C4$P<7<Y[+%+_N_B[,P]-:]D2<9-> J@41:K;
M\31G<J*J].@Z6?@(* A$X\/LU$A2P'@(8R_VJ6"4R5!://DQ37,<VH^$NY,K
M!-I9KQ \Y%B$_ U=6AZ"#3=^A6A_9> U\GRPG\'.$>35;SL/@D'.&&<B>:SE
MSL2]Z@BHBGD1U?&%!,C\&%(%QW)3LZ,B,=%# L]A2JXBQN%*9:U@'QU$//PR
M)EUC+PY%^)S'FX><J>L3EQ8ZEG:"Q3GN"3H:O= (_,(8.'.U,S+.<*L4!V:(
M3,]="?N6=!QV>\?HO]S$1HD\^!7Q7'@#8K ),WQ#I6-1F<P$(;E-AO8)T0&N
M=A:QN)?I!5!" ,V$DW 3;!W87>.MIF-QC.>'&(LC#6 R@$!6=TRD57X<8R2+
MJ86)5 IUO48>C=Z,8NI#\@84ZFL;,V&(CF+,A#2 ZA*;ZE29'<H4#VXN$IVB
MNB0N(Z6Q/4>.H243.W?T 53O2[4:+<+>5/H!Q=2+:*>&) GT,NCA(Z9FHGC\
M"'6VB#@QK9$@L4*#*=Z!X]4]PWTY>JRI[SJ"FF;$I38<Q1[7-%RE)4K2G"Q!
MO6$U&40R/<.%.0Z^P"1-O\9H*:/PWV@3HG^!] Y'A496^+7=@?>L->&:%,39
M\=NE._'7)"U3Z)]B%6GA#+^"*%@G];OG]($R.#E/\I0\]!-(T_7.BW_Z^1FU
MW*6#3SGBKF,IK.OO(/H );0/7@C=RL%K&:AM,)?P*8FW  Y!M=VT;!FH]<&O
M :4Q $D[XU3Z%&58#M0MYX]L#!9MEP$1*EU?<Q8^"M/7 A[Y6\Y!QV'M2J%C
M?\LYZ+@,7"EXO*_9^)BHU4)MC="I4C+I5XO>"R)IEH2RDQ</(V?D>5FR.WE^
M^)82OD.>K(?P->F6&D*J;2I'2MG)AHQ$9VX^(MG*AK>1.5?*PEI7VI2N+ V"
M+97;B6,+=[&(C8ME9^MQ--P8/3<\Z& I+7&"&^L :DF.>G=&83)ZE=&9W2")
MOJ#D 0Q7VW:EQKC5+GK1(M<1#'8K'V:5<)'&;6@7$JFQ!C,C@R60+8ST#J:A
MI1YQ%L2T3GJ@YI]'*NC<KO;('D4"A), 4KK0KKW/MHA1NGDV27/0K]CY<P7\
M),9%MBOYRQKIHIEE)1-5]CU*#$%%4(<8R@B+[ $$>$UQGH@<;:=C!Q!GI)'S
M 2H296!+,#I646O/.".;"$!0V\-1.W1D8(?^Y683^@"F3L9(GK_\+PGF-SGB
M";A$?3D*V:$*.^HX4X%(#S#4H"Q7,6@=C $ MT5L0/H88X6IGVQCK#)%K:IA
MB.%7=@:GG;\9T!]N(0C"(H"@$,)(H41SI;[<"8](,"CKYZ &I0,1MBR4E$11
M\AV[Y#2P_,W&EPT'BJ%+&+&U^>FK$7'81"OYAFU0T84=&3"HHZCW!A276(8O
M&)GNMBV4K%@BLWR28[L #<>-5VX8+;MXA'A!V]'R0]FVA"1Q0F;M"/UM(U%*
M9I"A769@MW0S XKP%6.ET6<P4XKQ>M#.+5M]/?UFM3AEF%ODMEKR3?*NX-!?
M1H$%/Q650SV*(.1- K][,'!O%S0TD4,OF#"T,W(X1Z\HD8S7H/5IZ=0<]:Y^
MR';%Z1D;FPS392TV#IW"0<(X/G%;IIIV1F_,Y^B%O#UH5I6?Q/(UQZ-AK@B<
M1&]G,I6=<7VC_ZC_5CT1V\]CM/3U$TO 9&"[NOP<*:?#]R73D4T544*_U0<A
M(H2F]DR<Y4A):6Q\\JR;AD("L8MQ0H2?-KSE$1K%!G+Y[QBQG<@8P1XRF5'E
MHKWL(4=8UR2I3++A[+%4OJP>EI%!E*(EB"+U5ZS 'B,%#W77(T;134=;EA68
M<*NY#9M(H80JQA-4?,H>X 3Y1[NQ/>KTDR:]2&#24J)CQ).X3#%4_(9AMTAU
MWLR)]+#XIP=#'(W=:N2(TI!)UDGT&=!ENXZ,2=?;+H'9&L#]D"Y)]<<T/&!
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MH_YL)<.K]UIKAY$O[BZ1TMVL)+X]T475J]F8Q-\ZFQ$=SGAKF(3%=@O!ULM
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M3/$ 3D95T>:VW(E\Q<4BVQ?>S107=^K/5IY(-0%47U"3#$!ELA-O=%LV"U>
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M1GMFWZ='4+\F[,:@BD4'A4R>KL,!A%_2UTP&\JPX@LA:>3ZO,U*N(@$?B93
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MS2%"]QCK+?)%831%#"^S25[,.6+H(J6]VEU(EM7.P'6$08771UN:21^['34
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M[U>%R4H31QJS#<22!A^5.<5IQ*DWF+=&'E_7B?IWJ?,<M1*30:,7YJA<('J
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MPS'3H.T/M;;?#=KA..PO4$L#!!0    ( &&#8ES,YOM>Y D  -!"   /
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M!9!>"@'KAC-.GY";,8NEFIJ*>QJN$>,:\V_&Z6:A-VI96Z"0J919T7;'HB?
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MUB+55%#)NE#+UO) 1H8+14)%"@R;M/!J6^I5>K;(-0;(9O8KJJ#28E3/PV:
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M2P$"% ,4    " !A@V)<C4.Z68*[ @"N=P, $0              @ $
M:6UG.30Y.34U-C1?,"YJ<&=02P$"% ,4    " !A@V)<UM8Q8G9Y 0!6K0$
M$0              @ &QNP( :6UG.30Y.34U-C1?,2YJ<&=02P$"% ,4
M" !A@V)<&8TK&HKR P#C7P0 $0              @ %6-00 :6UG.30Y.34U
M-C1?,BYJ<&=02P$"% ,4    " !A@V)<$LS1]5:5 @#B.P, $0
M    @ $/* @ :6UG.30Y.34U-C1?,RYJ<&=02P$"% ,4    " !A@V)<L+#2
M"T\- @"\4P( $0              @ &4O0H :6UG.30Y.34U-C1?-"YJ<&=0
M2P$"% ,4    " !A@V)<8[R(EB\S 0"(=0$ $0              @ $2RPP
M:6UG.30Y.34U-C1?-2YJ<&=02P$"% ,4    " !A@V)<=**E[#,&!  T^RP
M$0              @ %P_@T ='ER82TR,#(U,3(S,2YH=&U02P$"% ,4
M" !A@V)<KK'I")1+ 0"MAQ, $0              @ '2!!( ='ER82TR,#(U
M,3(S,2YX<V102P$"% ,4    " !A@V)<1QW]YY)+  #(U ( $
M    @ &54!, ='ER82UE>#$P7S$Y+FAT;5!+ 0(4 Q0    ( &&#8ES"8P?U
MG 0  /$;   /              "  56<$P!T>7)A+65X,C-?,2YH=&U02P$"
M% ,4    " !A@V)<S.;[7N0)  #00@  #P              @ $>H1, ='ER
M82UE>#,Q7S$N:'1M4$L! A0#%     @ 88-B7.L'QJ'/"0  E4,   \
M         ( !+ZL3 '1Y<F$M97@S,5\R+FAT;5!+ 0(4 Q0    ( &&#8EQ/
M(L\G6 8  -HD   /              "  2NU$P!T>7)A+65X,S)?,2YH=&U0
M2P$"% ,4    " !A@V)<% 6Q=CT&  "U)   #P              @ &PNQ,
E='ER82UE>#,R7S(N:'1M4$L%!@     .  X 9P,  !K"$P    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>tyra-20251231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:tyra="http://tyra.bio/20251231"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="tyra-20251231.xsd" xlink:type="simple"/>
    <context id="C_80b76e96-2cd7-4fc4-8522-d847b364b8ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_8160c430-5e2d-4be6-9c79-14512c0fe02b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_81cdd1a9-196d-4908-8af2-c3bceb99e972">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
        </entity>
        <period>
            <instant>2026-02-25</instant>
        </period>
    </context>
    <context id="C_81db5fa1-5ce2-4991-960b-fe8f42d5dc85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_822f9ef4-d69d-4947-92b4-eae4cf622064">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_82407490-dbff-4f2d-ab88-7b2feada5686">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_83e9b223-47dc-4d04-a739-70fa68863bb9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_859a4837-02fe-4595-8853-de8c56b1c468">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_87dc3b26-58ec-4bf3-9b29-98e651cdbe8a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tyra:ChiefOperatingDecisionMakerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">tyra:TYRA-300ACHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_885b4f15-9028-4e67-83a3-63a20100958e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_88813698-fe70-4238-9dca-06637a729f85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tyra:AccumulatedOtherComprehensiveLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_88fc6773-cb7f-4a2b-917e-b6e8a47d801c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tyra:ChiefOperatingDecisionMakerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_8959a728-1257-4d40-89a1-c9a8bdd37f42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tyra:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_8b56e0c7-22d7-4f97-bc7f-f3c1c34ac2a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_8c23cd18-4f82-4221-821a-3472384eac40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8c64e7bc-c688-492a-99e8-86f5cb335e47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tyra:ChiefOperatingDecisionMakerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">tyra:FGFRDiscoveryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_8d8b0049-b397-46d9-9515-7b644360184f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_8e43d91f-24cf-4fdb-b79e-137f0345b2bb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_8ffa982e-10e5-4fab-99ed-6f19493d39e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_90b314f0-e678-446e-845b-a940c76b3ed3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_91ad5ba4-1680-46a4-9791-00d5894e9338">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_93dfdc64-6b4a-406f-b392-50dedb2970c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_95f923d9-c4c3-4d2a-b6b5-83207327a686">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_9622fb4d-a971-4870-b202-86d8c0745065">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tyra:ChiefOperatingDecisionMakerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">tyra:TYRA-300MUCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_9631bb15-a89e-4277-b443-2488946a4125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_96648163-51bf-41fb-8618-dc87cf09bd07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_997236c7-47c3-4ba7-822f-0fd00f5213e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_9a95952b-9590-45cc-ba3c-2182f5811f96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tyra:EstimatedSharesPurchasableUnderTheEsppMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_9b41307d-a228-4022-aec0-907dd0345fdf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
        </entity>
        <period>
            <instant>2024-10-18</instant>
        </period>
    </context>
    <context id="C_9dc741f3-157e-4e28-9a5f-c2124c563656">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_9e723f9e-f294-44a4-b7ba-1b0bfe9753cc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_a11e42ed-6bba-4898-af75-300d1ef896ce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a190af4b-bf04-4d25-9ef5-ba22a9fc2494">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a2ec13b8-8e1d-47c2-8e4f-4c5969096b03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tyra:TwoThousandTwentyFourPrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-02-06</endDate>
        </period>
    </context>
    <context id="C_a3aa4fd7-a874-4bd2-a938-6252e0593cbe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_a412b29c-2a01-4356-b322-11c7037ef382">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tyra:ChiefOperatingDecisionMakerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">tyra:PersonnelCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_a6c7e448-562b-41de-8bae-d10d83c24d49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">tyra:TwoThousandTwentyEightLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_a8ff3708-7767-47f5-93fc-4c5992d13af3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tyra:TwoThousandTwentyFourPreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_a968be01-32a6-49ed-80ec-d5190256e424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_a9af0aa2-ccc8-48f7-89f5-e604bc391411">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_ab0a8b53-9e09-43e5-aaf1-65d9f9db8341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tyra:TwoThousandTwentyFourPrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-06</instant>
        </period>
    </context>
    <context id="C_ab4cdc5b-1496-46f9-9dd9-d01d8da9a387">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tyra:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_ab4f8aaa-c4e6-4bd1-a17b-592c475ced76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tyra:ChiefOperatingDecisionMakerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">tyra:FGFRDiscoveryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_ab8dd7ed-5d07-40f6-9887-243d8544fc7c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_aba7e5f4-1031-43f5-85fd-1ca0501bbfac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_aea32a63-e986-417a-9465-dd9fe57915c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_af11564f-7c3c-4fbd-944d-2526428166a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tyra:TwentyTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_afd54226-bb0b-422e-afb5-a979bf3c3fb7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tyra:AccumulatedOtherComprehensiveLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b08ce2b8-ac16-4b53-b8cb-6aa4f4c5e677">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_b1df5da0-307d-4f91-b407-099a8215e1e5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_b208f498-8b12-48b2-b2d8-4d1f1322980d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tyra:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_b5150520-b9f3-4bdf-8a55-8f5cea1cb93e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tyra:ChiefOperatingDecisionMakerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">tyra:TYRA-300MUCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_b8c32c5b-98c6-4415-8115-4d928ac1827f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_b90df891-3d95-47b5-b447-6bd47c401d88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_bab9baa6-70cc-470c-8e11-bb4b93099597">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_bc04b846-a20d-4016-ac01-a4c1c095b08c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">tyra:AtmSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-08</instant>
        </period>
    </context>
    <context id="C_bf0901d4-ef49-48dc-b81b-94822de4c19d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_c2661784-8ff1-4a9e-8a82-f75b049f70ad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_c3062351-4e8a-468c-9ace-a5178560f024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_c487f789-6116-468a-b633-8abf3bf8a878">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_c6068cd1-21e5-450a-9869-2d60615e13b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_c857b1ec-ca11-4482-b531-9da5ac07706d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_c949f769-29f9-45f2-a776-8adefcf0977e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">tyra:ExpansionLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_c95fc3d9-d94a-493b-a598-ac4bb3b1b07c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tyra:TwentyTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_cabc47b3-0098-4429-acc8-8b363378e0b6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_cc72b396-646c-4763-93d2-cd1c738569ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tyra:TwentyTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_cd230b0d-0361-47ec-8672-4de4e7ba7e85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tyra:ChiefOperatingDecisionMakerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">tyra:FacilitiesAndOtherCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_cdc6cc80-baf4-45fe-8841-dff91027f8b8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_d259c846-1a3b-459d-8db5-38b89ca9f52b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d412cb4d-1732-4801-8e1b-648dfb7030c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tyra:ChiefOperatingDecisionMakerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">tyra:OtherDevelopmentProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_d576a493-6d1f-4530-ae76-85c14a98774c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_d58f684d-19a9-4256-8716-4e0a68a997cd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_d60e36b5-9479-436f-8d6e-500af75adcec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_da6d61f4-da45-4047-8849-7facd82c9bab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_dbea103f-6acc-4340-83b5-1436e3999584">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tyra:ChiefOperatingDecisionMakerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">tyra:TYRA-430Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_dea229cd-0197-42d7-b781-d2cf1a9090ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_deb06a64-1ca6-42a0-9e9d-5e5fc523e1b1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tyra:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_df547fe0-45f9-4a1e-9a51-de2c71f2fc5c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_dfcd0690-10f5-44d8-bca0-e39e09cfb498">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_dfcfe63e-d4f8-4148-85c4-ec750c1d7200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tyra:TwoThousandsAndTwentyOneIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_e0df3a23-dd2e-494b-a002-48c55afa2131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_e120fb96-8ac9-4670-bbd9-1db2900be3f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tyra:TwoThousandTwentyFourPrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tyra:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-06</instant>
        </period>
    </context>
    <context id="C_e15e6e13-7c17-4e72-95fd-e55ebe7fabb3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e1d47e5f-72ba-41d6-899c-26d974ae34de">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">tyra:ExpansionLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_e212c6e1-9c59-4476-81a3-9bdba80a582e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_e214f6fc-28de-40f3-bcc1-08bf1f39a68d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tyra:ChiefOperatingDecisionMakerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e25b71f6-c32b-4edc-aafd-1871c1261431">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e3b45be7-247c-43d2-afaf-765b16ea5709">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tyra:UnvestedCommonStockExerciseOfStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_e9d71edc-f2b4-47d5-ad81-4148af049faa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_f04ad497-713a-4578-b5ab-98ae7619c3da">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-18</startDate>
            <endDate>2024-10-18</endDate>
        </period>
    </context>
    <context id="C_f0dad730-1497-4f1d-aca3-f9d1d48a1d39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_f25354f8-700d-4a8d-907f-0257bf311019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_f4992ea8-42cd-4f1d-87f7-2a24c1d21969">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tyra:EstimatedSharesPurchasableUnderTheEsppMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_00649a27-87e2-4280-9938-2abad92658ac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_011705ed-dba2-4b57-a549-edfd6d1424ce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tyra:ChiefOperatingDecisionMakerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">tyra:OtherDevelopmentProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_01b9476b-1614-4aa1-8247-68243ed0c8dd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_0244e69e-96e4-4497-bf2c-57c743c5abcb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">tyra:StateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_032ccc29-8b89-4307-90c0-e7071ba56b28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tyra:ChiefOperatingDecisionMakerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">tyra:TYRA-200Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_04a08b7e-86bb-4a84-910d-c8256976e1da">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_04b24ac9-453f-4621-9f44-543a1e069772">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_0639343e-0151-4fb3-a3ca-f73ad2a5550b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">tyra:FirstAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="C_0732721d-acf1-480d-a569-2b3ce25dc4c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_0982e5f9-320c-4189-b4b7-e92e3372022d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tyra:UnvestedCommonStockExerciseOfStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_0aaa07cf-e8dc-4ed0-ba3c-1e37ea8486c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tyra:ChiefOperatingDecisionMakerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">tyra:FacilitiesAndOtherCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_0cc2e2b1-f863-41ab-8c8e-baf6fe802ceb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">tyra:TwoThousandTwentySevenLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_0f90cf19-a5f9-46f3-880e-0596d855590c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_1113fea0-b015-450d-8260-f27bbaccdf6f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_12bd91d1-7116-4439-9d77-a7650dbde2f7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_1373ea03-27b7-4611-89c2-aedca10e502b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_14e460cb-2da4-49f1-a533-de969fc89258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tyra:ChiefOperatingDecisionMakerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">tyra:PersonnelCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_15910e68-42b0-4058-8d01-7cdf352e9ab5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_18a4d379-7bc9-4fbe-85e9-2af7258397b9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tyra:ChiefOperatingDecisionMakerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">tyra:TYRA-430Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_1e213811-870d-4dbf-826c-e35260a70b15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_1f9dc1d4-60d0-45af-852c-cdd76bc64f9f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tyra:StockOptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_1faac4fa-e650-47b7-9da8-bf595e935e95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_1fbdc9f6-75dd-418c-a9c1-887b681c7dc0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">tyra:AlanFuhrmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_23d8f849-93e2-4c5e-8518-5df9a193ecf2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_25ac70f7-9ef0-442b-8bfc-d6387da53e1f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_27b488c8-414a-4614-80fa-db1682dc7f77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">tyra:AtmSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-08</startDate>
            <endDate>2025-05-08</endDate>
        </period>
    </context>
    <context id="C_27fab6ea-d588-459f-a85f-6bc9be1ab8c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_28193a65-0be5-40f3-9592-5ab7a4f62e34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">tyra:FirstAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_2a06acfa-3379-4f4d-8b99-addfb1d70ade">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tyra:AccumulatedOtherComprehensiveLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_2d6333b8-aede-4396-b3d4-df2848f7e547">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">tyra:FederalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_2d692ebc-a844-453a-851e-e2ddc17d2c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_2f77ccfa-5653-4673-b977-01323fe14f9a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_31142ef9-0890-41ac-a5b5-d09b26dfd124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_31bd97f3-271f-4ee8-8a62-0213b666d430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tyra:TwoThousandTwentyFourPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-02-06</endDate>
        </period>
    </context>
    <context id="C_31ea1ae9-69e0-48ac-9963-d48f9f1c7a0d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_356fc121-7b99-4486-a3fc-2e281fdbe579">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_35d9901f-2f43-4932-960b-edaffa307b8e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_371b11b6-fa70-4468-9e81-af92b5ec918f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_3bfbb795-7b7e-4213-b6a6-ea14b283ed4f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_3ddda0f3-7839-43d8-b02a-428842db25ae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">tyra:AtmSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-03</startDate>
            <endDate>2022-10-03</endDate>
        </period>
    </context>
    <context id="C_3df03dca-0dc7-4c5f-a85f-71adcbb157d4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tyra:TwentyTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_3e3448c5-6e20-4fa9-a323-78badf09db26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_3ef83027-7be9-4941-bbec-b03fb69c9691">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">srt:OfficeBuildingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">tyra:FirstAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="C_4210f2e9-05d8-4850-ac3c-f78b3d31289e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tyra:ChiefOperatingDecisionMakerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">tyra:TYRA-300UTUCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_445d4a10-50d6-4fad-8ed4-556b6ce24ec6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_4723f99d-c390-41ed-a5c5-1df9fcae7f68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tyra:ChiefOperatingDecisionMakerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">tyra:TYRA-200Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_4892d6b0-f063-48f2-b508-738cf390c782">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tyra:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_4952b098-3c5d-47e1-a11e-2ad51ec8c584">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_4a3a2077-3bda-4557-8dc1-0b3803890cbf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_4a9d47d3-2b9a-48d7-83f8-6532afecf992">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_4b1febba-292b-4542-9c54-ea17a48a4fcd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_4bfe509f-d4f2-43a9-a149-54a5ecae443d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">srt:OfficeBuildingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">tyra:FirstAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="C_4f2fa7fb-50cf-4ab7-a541-88b9de8c16cd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_54f748e8-97d4-411e-9f01-5dd8ca0908ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_55243387-85c0-4527-827d-52fcc91c1646">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">srt:OfficeBuildingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">tyra:FirstAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_56b4e6c1-43af-48e2-a24b-2a315a435b15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tyra:StockOptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_57adc4c3-e413-40ba-9f2b-b0623d7e6ec7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tyra:AccumulatedOtherComprehensiveLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_58b2744f-4829-4186-a4c0-62f067475f6f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tyra:AccumulatedOtherComprehensiveLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_591792f7-6fd3-4548-a3dc-761a47696c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">tyra:ExpansionLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_5a67af1f-955f-4fed-a7a1-8ddc18ed22ab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_5bd11727-b5f4-41c0-a8a8-fecf149214ac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">tyra:ToddHarrisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_5e5587d3-9989-48f5-9e25-23f05bd5b860">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tyra:ChiefOperatingDecisionMakerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">tyra:TYRA-300UTUCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_66a3ee93-337d-4531-9b7b-c8623780d836">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_66a8c0d4-dc01-437f-8643-ae23ca05710c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tyra:ChiefOperatingDecisionMakerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">tyra:TYRA-300NMIBCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_68757860-b94a-4127-be6e-9246030381f8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_68fd01c3-dd3c-414b-9432-cffd7c483daf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">tyra:AlanFuhrmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_692e28c5-456f-441d-81a6-b3281646a0af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_69bde7cd-c11f-4704-8be8-b885ee6842e9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_6aa70afb-c483-4af1-aab6-5e31327063dc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_6b1f5ee9-14ee-4a7c-af93-d46a982aa30b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tyra:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-18</startDate>
            <endDate>2024-10-18</endDate>
        </period>
    </context>
    <context id="C_6c246792-9518-4437-a499-5e637972016a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">tyra:ToddHarrisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_6cb8fd5f-1c00-421b-8722-81009515faf7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_6d93fb41-00d4-4bba-9d0f-e71f27a586ce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_6f8e39dd-1c81-4d46-8007-0bbb98e5748d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_6fe01dec-1d26-432c-84d4-861aa02e32d6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_7060b8eb-7cf2-40dd-abeb-7bbe283f0ab1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tyra:ChiefOperatingDecisionMakerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">tyra:TYRA-300NMIBCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_7168fb48-4ee5-4fb1-9a24-58d8fea23470">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_718b96d9-785c-40ed-a094-d99e0b9a8377">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">tyra:AtmSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-03</instant>
        </period>
    </context>
    <context id="C_7235c0d6-d80c-4a20-a791-afd7ff2647e0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_730568c6-2cf1-41de-a80e-e6d97f16ba8c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_73360da3-36fa-405b-810f-ac396bf24bee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_75025707-e814-4796-aefb-117d79769679">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_7a958c54-6cff-41ea-bb1a-33c200dccaae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_7ed9a919-4011-4987-b82f-187ecd2ac2c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tyra:ChiefOperatingDecisionMakerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">tyra:TYRA-300ACHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_7f967b5d-c00a-4062-a27e-e4707a82ef23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_7fed64a7-b51b-4be1-a469-9f7679712854">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001863127</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tyra:TwoThousandTwentyFourPrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tyra:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-06</instant>
        </period>
    </context>
    <unit id="U_Renewal">
        <measure>tyra:Renewal</measure>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_Segment">
        <measure>tyra:Segment</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_781c05a3-e565-4acb-b9ef-62ffed817c1f">0001863127</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_cd841b59-2d85-4050-a1da-37179de8e753">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_7c3df980-d0d2-4a79-80d2-cb65d24ba954">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_5fdff729-926c-4404-a28d-2bbd12c5440b">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      id="F_e3d03354-93a3-4909-bbcb-fa330f37e738"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      id="F_b98141a9-56b2-47e3-96de-3efef16eed5c"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_3e3448c5-6e20-4fa9-a323-78badf09db26"
      id="F_de6e2adb-217c-46f8-87ab-7f9f75f3c64f">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_1e6f4a6c-c495-424f-a078-c4745eb638bc">http://tyra.bio/20251231#ChiefOperatingDecisionMakerMember</us-gaap:SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration>
    <us-gaap:NumberOfReportableSegments
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="0"
      id="F_1191e240-a690-465b-8ee1-430de97506c1"
      unitRef="U_Segment">1</us-gaap:NumberOfReportableSegments>
    <dei:DocumentType
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_0f445a4c-9bf0-45c7-a554-f714e89fc49d">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_4271b133-44c3-4de9-ac25-12813b1e99c6">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_feef0434-2f04-43b1-875c-5510a7a6ecd4">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_3d9d9b21-ab38-45cc-bdd3-018291f7829f">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_4300de0b-3ca3-46c6-af9f-c3659a1101e4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_0212adb5-3a43-4143-9a76-b76f15b6b5a4">001-40800</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_7225a411-c5f0-4646-8f18-37c9f82823f0">TYRA BIOSCIENCES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_760cc7f2-3e9c-4d1a-96d4-930f1846d12c">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_a0361ea2-18f4-418e-b069-61ca4383014b">83-1476348</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_7b21606e-43f9-4362-b2bd-dd69e3f9142e">2656 State Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_71e47d4d-617e-4b5b-862d-57f207d5de25">Carlsbad</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_fd81a011-86e5-42b4-ae97-fc5fd8c348fc">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_6933ce35-f85a-4e81-9020-9c5f30cc0cf2">92008</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_c152718a-fb82-497b-b6aa-29825125e7b4">619</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_c93075e9-93fa-412f-b29d-fc83e2af0736">728-4760</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_19e9ece8-db0f-4839-8791-93a1a089f5c9">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_4fbd6af9-ec02-4ac4-9ccd-26887e6b0808">TYRA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_7067e5c3-f525-42f0-aae8-cdf9df36a2ba">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_4c9d72c4-9f6f-4fc7-bc1a-b118c958313d">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_9a3bcf9d-40fa-4b57-9829-be0d91d86d86">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_cd9e583c-4493-41e8-b66b-ad5a7dca3750">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_c208c57a-9953-4d0b-96ba-03be3db541bc">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_0b83660c-4bd3-4070-9394-88a0c0ce0f9c">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_c9fdc0d8-6f89-42e4-957f-cb7f807cf018">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_f1466b56-7d8e-452b-a022-a0341f1941f1">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_004c5ff8-be27-4c99-b650-9d5738fe50f0">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_48a7b236-df65-405a-8fc4-c53bed9df404">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_aa28a7bd-ef55-4bf9-ab47-4a4a25b9c353">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_4708947a-e6fe-416a-95a1-6447c8e639ed">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_aba7e5f4-1031-43f5-85fd-1ca0501bbfac"
      decimals="-5"
      id="F_89a2b968-a7a6-45f3-843c-9640e9c48a89"
      unitRef="U_USD">297300000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_81cdd1a9-196d-4908-8af2-c3bceb99e972"
      decimals="INF"
      id="F_8369cd8b-6338-46d0-9671-214393569528"
      unitRef="U_shares">53867115</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_12181c91-2c7d-4306-8b62-23ee606d0412">&lt;p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Certain sections of the registrant&#x2019;s definitive proxy statement for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; annual meeting of stockholders to be filed with the Securities and Exchange Commission pursuant to Regulation 14A not later than 120 days after the end of the fiscal year covered by this Form 10-K are incorporated by reference into Part III of this Form 10-K.&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_312e8756-458a-47e6-ae77-d3bc771edcd6">&lt;p id="item_1c_cybersecurity" style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Item 1C. Cybersecurity.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cybersecurity Risk Management and Strategy&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have developed and implemented a cybersecurity risk management program intended to protect the confidentiality, integrity, and availability of our critical systems and information. We implement reasonable administrative, technical and procedural safeguards to manage cybersecurity risks, including enforcing single sign-on or multi-factor authentication where supported or appropriate. We &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;engage&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;third-party cybersecurity experts&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to assess the security of our network. In addition, we engage a third-party to perform internal audits of our IT General Controls (ITGCs).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We design and assess our program based on the National Institute of Standards and Technology Cybersecurity Framework (NIST CSF).  This does not imply that we meet any particular technical standards,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;specifications, or requirements, only that we use the NIST CSF as a guide to help us identify, assess, and manage cybersecurity risks relevant to our business.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our cybersecurity risk management program is designed to be &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;integrated&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; into our overall risk management program, and shares common methodologies, reporting channels and governance processes that apply across the risk management program to other legal, compliance, strategic, operational, and financial risk areas.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Key elements of our cybersecurity risk management program include but are not limited to the following:&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;risk assessments designed to help identify material risks from cybersecurity threats to our critical systems and information;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;a security team principally responsible for managing (i) our cybersecurity risk assessment processes, (ii) our security controls, and (iii) our response to cybersecurity incidents;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the use of external service providers, where appropriate, to assess, test or otherwise assist with aspects of our security processes;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;cybersecurity awareness training of our employees, including incident response personnel and senior management; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;a cybersecurity incident response plan that includes procedures for responding to cybersecurity incidents; and&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;a third-party risk management process for key service providers, based on our assessment of their criticality to our operations and respective risk profile, suppliers, and vendors that have access to our critical systems and information.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have not identified risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;materially affected&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; us, including our operations, business strategy, results of operations, or financial condition. We face risks from cybersecurity threats that, if realized, are reasonably likely to materially affect us, including our operations, business strategy, results of operations, or financial condition. See &#x201c;Risk Factors &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Our information technology systems, or those of any of our CROs, other contractors or consultants or potential future collaborators, may fail or suffer security breaches, which could result in a material disruption of our product development programs, harm our reputation, significant fines, penalties and liability and loss of customers or sales.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x201d;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cybersecurity Governance&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our board of directors considers cybersecurity risk as part of its risk oversight function and has delegated to the audit committee (the Committee) oversight of cybersecurity risks, including oversight of management&#x2019;s implementation of our cybersecurity risk management program&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Committee receives quarterly reports from management on our cybersecurity risks. In addition, management updates the Committee where it deems appropriate, regarding any cybersecurity incidents it considers to be significant or potentially significant.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Committee reports to the full board of directors regarding its activities, including those related to cybersecurity. The full board of directors may also periodically receive briefings from management on our cyber risk management program&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Board members may receive presentations on cybersecurity topics from our Chief Financial Officer (CFO), internal security staff or external experts as part of the board of director&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;s continuing education on topics that impact public companies.&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Our IT Senior Director, is primarily responsible for assessing and managing our material risks from cybersecurity threats.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Our &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;IT Senior Director has primary responsibility for our &lt;/span&gt;&lt;/span&gt;&lt;span style=""&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;overall &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;cybersecurity risk management program and supervises our retained external cybersecurity consultants.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our IT Senior Director has over 25 years of IT and cybersecurity experience.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our IT Senior Director takes steps to stay informed about and monitor efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, which may include briefings from internal security personnel; threat intelligence and other information obtained from governmental, public or private sources, including external consultants engaged by us; and alerts and reports produced by security tools deployed in our information technology environment.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_9b840dfc-860d-4f3a-b7e5-a632b2a8114d">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_26b8bd8b-d6aa-4223-bbc0-f336691c4b19">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_bbd429fb-8c4f-430b-93ce-0a6731d39dc8">&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our cybersecurity risk management program is designed to be &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;integrated&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; into our overall risk management program, and shares common methodologies, reporting channels and governance processes that apply across the risk management program to other legal, compliance, strategic, operational, and financial risk areas.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Key elements of our cybersecurity risk management program include but are not limited to the following:&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;risk assessments designed to help identify material risks from cybersecurity threats to our critical systems and information;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;a security team principally responsible for managing (i) our cybersecurity risk assessment processes, (ii) our security controls, and (iii) our response to cybersecurity incidents;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the use of external service providers, where appropriate, to assess, test or otherwise assist with aspects of our security processes;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;cybersecurity awareness training of our employees, including incident response personnel and senior management; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;a cybersecurity incident response plan that includes procedures for responding to cybersecurity incidents; and&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;a third-party risk management process for key service providers, based on our assessment of their criticality to our operations and respective risk profile, suppliers, and vendors that have access to our critical systems and information.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_7c3c0945-6097-41c7-8b0a-b5e0f3ee4e82">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_b2208269-d4fe-46f6-bc27-4d83f593bdf1">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_e502b1e8-5454-4186-8707-ff898a57e5f7">&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our board of directors considers cybersecurity risk as part of its risk oversight function and has delegated to the audit committee (the Committee) oversight of cybersecurity risks, including oversight of management&#x2019;s implementation of our cybersecurity risk management program&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Committee receives quarterly reports from management on our cybersecurity risks. In addition, management updates the Committee where it deems appropriate, regarding any cybersecurity incidents it considers to be significant or potentially significant.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Committee reports to the full board of directors regarding its activities, including those related to cybersecurity. The full board of directors may also periodically receive briefings from management on our cyber risk management program&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Board members may receive presentations on cybersecurity topics from our Chief Financial Officer (CFO), internal security staff or external experts as part of the board of director&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;s continuing education on topics that impact public companies.&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Our IT Senior Director, is primarily responsible for assessing and managing our material risks from cybersecurity threats.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Our &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;IT Senior Director has primary responsibility for our &lt;/span&gt;&lt;/span&gt;&lt;span style=""&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;overall &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;cybersecurity risk management program and supervises our retained external cybersecurity consultants.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our IT Senior Director has over 25 years of IT and cybersecurity experience.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our IT Senior Director takes steps to stay informed about and monitor efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, which may include briefings from internal security personnel; threat intelligence and other information obtained from governmental, public or private sources, including external consultants engaged by us; and alerts and reports produced by security tools deployed in our information technology environment.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_3fbd007a-93ca-47bc-9f7c-74538023488c">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our board of directors considers cybersecurity risk as part of its risk oversight function and has delegated to the audit committee (the Committee) oversight of cybersecurity risks, including oversight of management&#x2019;s implementation of our cybersecurity risk management program&lt;/span&gt;</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_e0d43b1e-eeda-42e2-aea8-0d81fbb427ae">&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Committee receives quarterly reports from management on our cybersecurity risks. In addition, management updates the Committee where it deems appropriate, regarding any cybersecurity incidents it considers to be significant or potentially significant.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Committee reports to the full board of directors regarding its activities, including those related to cybersecurity. The full board of directors may also periodically receive briefings from management on our cyber risk management program&lt;/span&gt;</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_b70255f8-51b3-4ca7-befc-aa8f42a5f1ed">&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Our IT Senior Director, is primarily responsible for assessing and managing our material risks from cybersecurity threats.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Our &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;IT Senior Director has primary responsibility for our &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;overall &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;cybersecurity risk management program and supervises our retained external cybersecurity consultants.&lt;/span&gt;</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_b0181fc2-9fcf-4bc9-ad5a-fce118b6a852">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_98c15c0b-f3c2-4009-b1d2-805ab96a1b10">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our IT Senior Director has over 25 years of IT and cybersecurity experience.&lt;/span&gt;</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_7e3469a8-cd96-471a-a890-b0f2590530e3">&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our IT Senior Director takes steps to stay informed about and monitor efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, which may include briefings from internal security personnel; threat intelligence and other information obtained from governmental, public or private sources, including external consultants engaged by us; and alerts and reports produced by security tools deployed in our information technology environment.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_64412295-2179-45c2-bf2f-6b3223fc4c3a">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <dei:AuditorOpinionTextBlock
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_c61f54e7-fba4-400c-a3c5-52d542f69755">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Opinion on the Financial Statements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have audited the accompanying balance sheets of Tyra Biosciences, Inc. (the Company) as of December 31, 2025 and 2024, the related statements of operations and comprehensive loss, stockholders&#x2019; equity and cash flows for each of the two years in the period ended December 31, 2025, and the related notes (collectively referred to as the &#x201c;financial statements&#x201d;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2025, in conformity with U.S. generally accepted accounting principles.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</dei:AuditorOpinionTextBlock>
    <dei:AuditorName
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_79c7feb4-60c1-4945-926c-bf6c31ecdac1">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_386f5296-cd93-45bc-92c3-3071055e51e4">San Diego, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_156f81bf-84a9-4210-90b4-e9f03e068c6d"
      unitRef="U_USD">77387000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="-3"
      id="F_4a4ade29-616c-4ea8-b8c5-407685145af2"
      unitRef="U_USD">91966000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecurities
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_be3de640-e2b3-4b2d-978a-54473e5564f5"
      unitRef="U_USD">178616000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="-3"
      id="F_5aa68fe3-8b37-4c95-9854-d4a3f0a31651"
      unitRef="U_USD">249475000</us-gaap:MarketableSecurities>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_6be74b01-ebdd-4dc8-ad1a-98be183223eb"
      unitRef="U_USD">9447000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="-3"
      id="F_51991d5f-e075-4a60-a41e-da7aaa555964"
      unitRef="U_USD">6022000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_678b1a46-b63a-46b2-a706-4d77306c30b5"
      unitRef="U_USD">265450000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="-3"
      id="F_c306ce48-4916-4369-b2aa-fdbb0dd67ad4"
      unitRef="U_USD">347463000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_f57ab50a-f5c4-49d6-92ac-b4ce59d12ad7"
      unitRef="U_USD">1000000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="-3"
      id="F_11037853-5b16-4535-99a9-87bb6b93a4f2"
      unitRef="U_USD">1000000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_af1bd023-d303-4fef-b077-44d23a033e3f"
      unitRef="U_USD">1314000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="-3"
      id="F_49aa5d09-6a03-4460-92ec-c204d9c623e8"
      unitRef="U_USD">1651000</us-gaap:PropertyPlantAndEquipmentNet>
    <tyra:RightOfUseAsset
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_498cbd76-8f42-4bfb-9fc2-36f6951f31fd"
      unitRef="U_USD">5573000</tyra:RightOfUseAsset>
    <tyra:RightOfUseAsset
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="-3"
      id="F_4dc06be2-5b1e-4e7c-b6fb-94d4486048fb"
      unitRef="U_USD">6068000</tyra:RightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_6d45293b-da81-4bad-a786-75ddaef36322"
      unitRef="U_USD">9272000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="-3"
      id="F_d75a0eae-3b94-4c0c-9bde-c75c90b15475"
      unitRef="U_USD">7376000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_8b7cfa70-8ab4-4c40-b4b0-2821c2237866"
      unitRef="U_USD">282609000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="-3"
      id="F_600727bd-df56-46e1-8aa1-aa90c9884da7"
      unitRef="U_USD">363558000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_b665c5e3-f0bb-4563-b16d-08cc20ab075a"
      unitRef="U_USD">1178000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="-3"
      id="F_be4936f8-9e79-4394-9218-e3733bbebb68"
      unitRef="U_USD">590000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_9f86fef8-0da1-4dc7-93c5-bf3b1a304a99"
      unitRef="U_USD">472000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="-3"
      id="F_2d6e39bf-cc79-4c70-bff4-a42fc8ed3b56"
      unitRef="U_USD">412000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_0fc90133-029c-4a87-86bd-2324ec925652"
      unitRef="U_USD">16444000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="-3"
      id="F_76bc8e19-8bda-4b98-8cd8-dae11c44ff04"
      unitRef="U_USD">13592000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_150440c0-c10b-46fc-ac92-17dbb11c7f67"
      unitRef="U_USD">18094000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="-3"
      id="F_6db87db0-20ac-4e82-955f-dfde0d7c0fb7"
      unitRef="U_USD">14594000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_4653a869-11e6-4320-a661-30e216c771b7"
      unitRef="U_USD">5338000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="-3"
      id="F_2c7c0298-e5f9-49d1-b58a-8c0ca656ef57"
      unitRef="U_USD">5810000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_47557cd9-7001-4100-88e8-db851e1e74b4"
      unitRef="U_USD">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="-3"
      id="F_b86d8bd9-b52a-4cc2-b39e-748786db11cb"
      unitRef="U_USD">3000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_70af4668-a02f-454b-a342-9fe5f3c0b28f"
      unitRef="U_USD">23432000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="-3"
      id="F_4d78d7e0-027d-45d5-a1f9-ba9c6f5a891b"
      unitRef="U_USD">20407000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="INF"
      id="F_5eda8113-16fa-4074-8b6d-0ceaa76f23f6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="INF"
      id="F_3a15f910-4e68-4f99-800b-6fbfed2e4e5c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="INF"
      id="F_1baac7eb-9af4-42fc-a560-12cffdd0c378"
      unitRef="U_shares">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="INF"
      id="F_53c4714b-20d1-446c-8d7d-22d3ca5b4e5b"
      unitRef="U_shares">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="INF"
      id="F_494406fe-6992-48c7-88ef-93fc14597851"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="INF"
      id="F_883036a1-fb68-40b3-ba41-823f8c9c47a0"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="INF"
      id="F_ee9d0a9b-1965-4aca-8d7d-6b5c883cb303"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="INF"
      id="F_858e1e1d-10ef-4e1a-b3d9-1981ed6d29a7"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_df04201d-67e9-4bc4-9cfe-a578d919721c"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="-3"
      id="F_a726c260-7c9a-42ea-bd8e-656b08090da2"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="INF"
      id="F_9c50f995-040e-4cc1-b3d4-bb879a959fc8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="INF"
      id="F_a2a0107e-7778-42bc-a6fe-0b350b61b2db"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="INF"
      id="F_2da194a3-acc9-4cf9-82aa-67893e050b59"
      unitRef="U_shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="INF"
      id="F_15ba0d68-0e42-4b5b-954c-048a0a74ba1a"
      unitRef="U_shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="INF"
      id="F_c1309e1a-5d01-489c-bd7e-7549e6756a4c"
      unitRef="U_shares">53706357</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="INF"
      id="F_aae78993-0b76-425d-af68-bc0cb0961b1a"
      unitRef="U_shares">50754262</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="INF"
      id="F_076446c2-d431-45cb-b324-8d78afaa4e37"
      unitRef="U_shares">53706357</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="INF"
      id="F_ee6d58b8-0273-4860-b45c-9e053ac9c336"
      unitRef="U_shares">50749945</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_58223adf-cd32-4ccf-aa71-1df495ef1799"
      unitRef="U_USD">5000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="-3"
      id="F_ef185d8d-ea1e-44d3-b8e9-493223682a72"
      unitRef="U_USD">5000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_d7b3b6fd-5df2-4c33-a1b4-96abad8c8338"
      unitRef="U_USD">630037000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="-3"
      id="F_8e4ae5d4-2a9f-46c5-bf07-becffc989077"
      unitRef="U_USD">593687000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_9144f3ff-c667-475d-98d0-80ba66b3b6db"
      unitRef="U_USD">393000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="-3"
      id="F_20a4b466-b52c-4eee-bfc1-d0333bbd0a5c"
      unitRef="U_USD">770000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_198214a5-3045-45b5-ae2b-780cd4195402"
      unitRef="U_USD">-371258000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="-3"
      id="F_df943fe7-4832-42c9-b3bf-920595b08073"
      unitRef="U_USD">-251311000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_e869fc63-41fd-4b6f-9b1c-2a41c0e78925"
      unitRef="U_USD">259177000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="-3"
      id="F_bcea6423-2bcf-4e93-baa4-18502ae29e4b"
      unitRef="U_USD">343151000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_c0236afe-d7c3-4b34-b917-ae5838a890d1"
      unitRef="U_USD">282609000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="-3"
      id="F_75cc0535-e864-4b0d-83da-28a8877c0023"
      unitRef="U_USD">363558000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="-3"
      id="F_3415dba0-9192-4290-9a0d-81bbba8c3e88"
      unitRef="U_USD">102928000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="-3"
      id="F_630c9340-c7b3-414d-8f6c-cabc7b0310b6"
      unitRef="U_USD">80077000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="-3"
      id="F_d70a0975-d478-451c-98d9-13103765d9b0"
      unitRef="U_USD">29834000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="-3"
      id="F_171451a5-58b0-453a-bc6e-b80276923c50"
      unitRef="U_USD">24100000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="-3"
      id="F_1415eda3-8ad1-4038-9410-f87bebf608ed"
      unitRef="U_USD">132762000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="-3"
      id="F_9f0c2cc0-5aa8-43b7-b504-2ed60abef01d"
      unitRef="U_USD">104177000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="-3"
      id="F_7bd0e25d-6070-45de-9c95-7ec8692ed770"
      unitRef="U_USD">-132762000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="-3"
      id="F_5a076ed0-3d81-4a08-a4b8-28906a684ca0"
      unitRef="U_USD">-104177000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestAndOtherIncome
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="-3"
      id="F_63db744c-ce6c-483d-912e-652cca89934f"
      unitRef="U_USD">12815000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="-3"
      id="F_49a70a6e-f190-431c-87cb-bf224f489525"
      unitRef="U_USD">17696000</us-gaap:InterestAndOtherIncome>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="-3"
      id="F_29f568c6-d95f-47f1-849d-482c39e29155"
      unitRef="U_USD">12815000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="-3"
      id="F_1e71a000-4f45-42e8-829f-b6436d913b49"
      unitRef="U_USD">17696000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="-3"
      id="F_1cbac3cd-a9bf-46e4-849f-cd452b3c9ba8"
      unitRef="U_USD">-119947000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="-3"
      id="F_8fe0ef60-531a-41be-b7e5-b1ce8f8e6bbb"
      unitRef="U_USD">-86481000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="-3"
      id="F_0d830deb-fd61-484a-9d67-3eb0eb1a5bd2"
      unitRef="U_USD">-377000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="-3"
      id="F_f81d2616-f575-422c-9bea-15c5a4b17769"
      unitRef="U_USD">389000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="-3"
      id="F_9de0b1ae-e709-4094-a9e8-6ac791d2a6ee"
      unitRef="U_USD">-120324000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="-3"
      id="F_baf3f0f0-cf7a-4cee-952a-16667890ed17"
      unitRef="U_USD">-86092000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="2"
      id="F_29ced3d9-08b3-4d1e-a2fe-3133c869ad46"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="2"
      id="F_a5fa0ecb-cd73-44bf-b784-fb33ea8ef671"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="2"
      id="F_a455b135-a198-47bd-a71b-4f11059ab842"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.51</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="2"
      id="F_772ff367-4804-4219-be9b-7a903b45c22d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.51</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="0"
      id="F_c9ec98dc-7d7b-41b9-a807-84a945c3aae3"
      unitRef="U_shares">59602328</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="0"
      id="F_9dbea86c-394e-4939-9704-70768a64775e"
      unitRef="U_shares">59602328</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="0"
      id="F_b49c7f76-ed2a-4f4b-b38e-e7e610024591"
      unitRef="U_shares">57217746</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="0"
      id="F_2bdb5ad8-268d-47a3-9fd0-f37814f780ef"
      unitRef="U_shares">57217746</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="C_8c23cd18-4f82-4221-821a-3472384eac40"
      decimals="0"
      id="F_d475bae9-ea9c-4c5c-88ca-b7dbe29c00d3"
      unitRef="U_shares">43024634</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_8c23cd18-4f82-4221-821a-3472384eac40"
      decimals="-3"
      id="F_d0dc9223-912a-406a-8c11-06b9c0a68764"
      unitRef="U_USD">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a11e42ed-6bba-4898-af75-300d1ef896ce"
      decimals="-3"
      id="F_01415431-3085-4517-83f1-a18a390ca174"
      unitRef="U_USD">368707000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_57adc4c3-e413-40ba-9f2b-b0623d7e6ec7"
      decimals="-3"
      id="F_f2013521-4f89-4345-ab7b-6bff7b2b8295"
      unitRef="U_USD">381000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_d259c846-1a3b-459d-8db5-38b89ca9f52b"
      decimals="-3"
      id="F_4ae07a04-b509-44a5-a4ba-082918db4b0c"
      unitRef="U_USD">-164830000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_90b314f0-e678-446e-845b-a940c76b3ed3"
      decimals="-3"
      id="F_4bf86453-2549-4a45-aea8-5e53001c317e"
      unitRef="U_USD">204262000</us-gaap:StockholdersEquity>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_e25b71f6-c32b-4edc-aafd-1871c1261431"
      decimals="-5"
      id="F_612fd17c-d6ea-45b7-9068-bb7c64f0248f"
      unitRef="U_USD">200000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_04a08b7e-86bb-4a84-910d-c8256976e1da"
      decimals="0"
      id="F_05139a54-42d7-429f-adc2-f5357e4fbb04"
      unitRef="U_shares">9286023</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_04a08b7e-86bb-4a84-910d-c8256976e1da"
      decimals="-3"
      id="F_e40c67d4-fcda-416c-8d11-cb3a49a45a59"
      unitRef="U_USD">1000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_6cb8fd5f-1c00-421b-8722-81009515faf7"
      decimals="-3"
      id="F_14d4eada-53a9-41de-8432-bf4d7c3de622"
      unitRef="U_USD">120557000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="-3"
      id="F_3f21efb3-5073-49c2-a05d-50e00bcd1b12"
      unitRef="U_USD">120558000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_15910e68-42b0-4058-8d01-7cdf352e9ab5"
      decimals="-5"
      id="F_2ed62094-4748-41b6-9da0-4116e428c133"
      unitRef="U_USD">200000</us-gaap:PaymentsOfStockIssuanceCosts>
    <tyra:IssuanceOfPreFundedWarrantsUnderPrivatePlacement
      contextRef="C_80b76e96-2cd7-4fc4-8522-d847b364b8ec"
      decimals="-3"
      id="F_ccb53e22-6c75-483a-93d3-45ffed703d35"
      unitRef="U_USD">79022000</tyra:IssuanceOfPreFundedWarrantsUnderPrivatePlacement>
    <tyra:IssuanceOfPreFundedWarrantsUnderPrivatePlacement
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="-3"
      id="F_df209ee4-309d-4666-adff-ce3cffb12c83"
      unitRef="U_USD">79022000</tyra:IssuanceOfPreFundedWarrantsUnderPrivatePlacement>
    <tyra:IssuanceOfCommonStockPursuantToPreFundedWarrantExercise
      contextRef="C_8959a728-1257-4d40-89a1-c9a8bdd37f42"
      decimals="0"
      id="F_126f7150-c9b9-40c7-b7b4-25f4d880b728"
      unitRef="U_shares">705000</tyra:IssuanceOfCommonStockPursuantToPreFundedWarrantExercise>
    <tyra:ExchangeOfCommonStockForPre-FundedWarrantsShares
      contextRef="C_01b9476b-1614-4aa1-8247-68243ed0c8dd"
      decimals="0"
      id="F_616b0cfc-9b3c-46a4-a911-0824f4ab4ddb"
      unitRef="U_shares">3000000</tyra:ExchangeOfCommonStockForPre-FundedWarrantsShares>
    <tyra:IssuanceOfCommonStockUnderBenefitPlansShares
      contextRef="C_01b9476b-1614-4aa1-8247-68243ed0c8dd"
      decimals="0"
      id="F_d4f3a348-fb8d-4822-9cfc-d6e98d0e6236"
      unitRef="U_shares">664184</tyra:IssuanceOfCommonStockUnderBenefitPlansShares>
    <tyra:IssuanceOfCommonStockUnderBenefitPlans
      contextRef="C_80b76e96-2cd7-4fc4-8522-d847b364b8ec"
      decimals="-3"
      id="F_c0b96f6c-5bf0-4e96-b073-64937e502817"
      unitRef="U_USD">2557000</tyra:IssuanceOfCommonStockUnderBenefitPlans>
    <tyra:IssuanceOfCommonStockUnderBenefitPlans
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="-3"
      id="F_95d427ab-2f8c-425b-9e41-aa6e2a8f0d74"
      unitRef="U_USD">2557000</tyra:IssuanceOfCommonStockUnderBenefitPlans>
    <tyra:VestingOfSharesOfCommonStockSubjectToRepurchaseShare
      contextRef="C_01b9476b-1614-4aa1-8247-68243ed0c8dd"
      decimals="0"
      id="F_a2c0829b-a9aa-4b02-bc11-1dbe200903a8"
      unitRef="U_shares">70104</tyra:VestingOfSharesOfCommonStockSubjectToRepurchaseShare>
    <tyra:VestingOfSharesOfCommonStockSubjectToRepurchase
      contextRef="C_80b76e96-2cd7-4fc4-8522-d847b364b8ec"
      decimals="-3"
      id="F_73be0f3f-ac0b-4ab6-8f7a-e173add797df"
      unitRef="U_USD">43000</tyra:VestingOfSharesOfCommonStockSubjectToRepurchase>
    <tyra:VestingOfSharesOfCommonStockSubjectToRepurchase
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="-3"
      id="F_81ee16cf-29ca-4ce6-856e-3fef8b742100"
      unitRef="U_USD">43000</tyra:VestingOfSharesOfCommonStockSubjectToRepurchase>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_80b76e96-2cd7-4fc4-8522-d847b364b8ec"
      decimals="-3"
      id="F_d551b186-98f2-4030-8137-74f54f11b17a"
      unitRef="U_USD">22801000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="-3"
      id="F_1b09024b-9257-42c3-a9dc-48089eba80e3"
      unitRef="U_USD">22801000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <tyra:AvailableForSaleDebtSecuritiesNetUnrealizedGain
      contextRef="C_2a06acfa-3379-4f4d-8b99-addfb1d70ade"
      decimals="-3"
      id="F_dd0ea5cc-60be-453e-a3c8-e489efccf6bb"
      unitRef="U_USD">389000</tyra:AvailableForSaleDebtSecuritiesNetUnrealizedGain>
    <tyra:AvailableForSaleDebtSecuritiesNetUnrealizedGain
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="-3"
      id="F_08bf543e-2485-4932-89e7-a638e107340b"
      unitRef="U_USD">389000</tyra:AvailableForSaleDebtSecuritiesNetUnrealizedGain>
    <us-gaap:NetIncomeLoss
      contextRef="C_8160c430-5e2d-4be6-9c79-14512c0fe02b"
      decimals="-3"
      id="F_82778317-ec13-4870-9b10-ec86071eda12"
      unitRef="U_USD">-86481000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_1faac4fa-e650-47b7-9da8-bf595e935e95"
      decimals="0"
      id="F_eadfd38d-9239-40de-b7db-484893438c1c"
      unitRef="U_shares">50749945</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_1faac4fa-e650-47b7-9da8-bf595e935e95"
      decimals="-3"
      id="F_dfa7aa98-bb3b-4f8d-822c-19ebd134e292"
      unitRef="U_USD">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a190af4b-bf04-4d25-9ef5-ba22a9fc2494"
      decimals="-3"
      id="F_f4675f19-fd46-413d-aa28-bbd94f2c9460"
      unitRef="U_USD">593687000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_afd54226-bb0b-422e-afb5-a979bf3c3fb7"
      decimals="-3"
      id="F_9a9bc6c0-cdbb-43a3-9535-e3f537edce90"
      unitRef="U_USD">770000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_c487f789-6116-468a-b633-8abf3bf8a878"
      decimals="-3"
      id="F_ab94ee3f-a305-45c7-9be4-8e3019a90933"
      unitRef="U_USD">-251311000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="-3"
      id="F_9fe9afad-4b36-4fcf-940f-256c6e87c05c"
      unitRef="U_USD">343151000</us-gaap:StockholdersEquity>
    <tyra:IssuanceOfCommonStockPursuantToPreFundedWarrantExercise
      contextRef="C_b208f498-8b12-48b2-b2d8-4d1f1322980d"
      decimals="0"
      id="F_0a73368f-0a18-41cb-8e05-272a340316ac"
      unitRef="U_shares">2000069</tyra:IssuanceOfCommonStockPursuantToPreFundedWarrantExercise>
    <tyra:IssuanceOfCommonStockPursuantToPreFundedWarrantExercised
      contextRef="C_ab4cdc5b-1496-46f9-9dd9-d01d8da9a387"
      decimals="-3"
      id="F_009f07eb-855d-4ca7-a929-5a964e853a17"
      unitRef="U_USD">0</tyra:IssuanceOfCommonStockPursuantToPreFundedWarrantExercised>
    <tyra:IssuanceOfCommonStockUnderBenefitPlansShares
      contextRef="C_68757860-b94a-4127-be6e-9246030381f8"
      decimals="0"
      id="F_74a8566c-4ce2-4efe-8b94-26c313fa6a42"
      unitRef="U_shares">952026</tyra:IssuanceOfCommonStockUnderBenefitPlansShares>
    <tyra:IssuanceOfCommonStockUnderBenefitPlans
      contextRef="C_1113fea0-b015-450d-8260-f27bbaccdf6f"
      decimals="-3"
      id="F_c6e0723c-4b90-44fb-bb92-622871c668fe"
      unitRef="U_USD">8341000</tyra:IssuanceOfCommonStockUnderBenefitPlans>
    <tyra:IssuanceOfCommonStockUnderBenefitPlans
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="-3"
      id="F_36ab7506-c2f1-4c6e-b4c2-06b7013464a6"
      unitRef="U_USD">8341000</tyra:IssuanceOfCommonStockUnderBenefitPlans>
    <tyra:VestingOfSharesOfCommonStockSubjectToRepurchaseOneShares
      contextRef="C_68757860-b94a-4127-be6e-9246030381f8"
      decimals="0"
      id="F_bdc2d188-29d6-450f-bd1f-093fbbab76aa"
      unitRef="U_shares">4317</tyra:VestingOfSharesOfCommonStockSubjectToRepurchaseOneShares>
    <tyra:VestingOfSharesOfCommonStockSubjectToRepurchaseOne
      contextRef="C_1113fea0-b015-450d-8260-f27bbaccdf6f"
      decimals="-3"
      id="F_7aa20d6c-8347-4650-82a1-66ae010c67b1"
      unitRef="U_USD">3000</tyra:VestingOfSharesOfCommonStockSubjectToRepurchaseOne>
    <tyra:VestingOfSharesOfCommonStockSubjectToRepurchaseOne
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="-3"
      id="F_75b51620-90c0-4de6-b492-3adce985fe1e"
      unitRef="U_USD">3000</tyra:VestingOfSharesOfCommonStockSubjectToRepurchaseOne>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_1113fea0-b015-450d-8260-f27bbaccdf6f"
      decimals="-3"
      id="F_63a499ca-1793-4ee7-8c3a-649bfc5a97de"
      unitRef="U_USD">28006000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="-3"
      id="F_09e023f8-56fa-4de6-8052-1ea60f9f35ee"
      unitRef="U_USD">28006000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <tyra:AvailableForSaleDebtSecuritiesNetUnrealizedGain
      contextRef="C_88813698-fe70-4238-9dca-06637a729f85"
      decimals="-3"
      id="F_aa184049-9a20-4114-9416-811a4f5a0b9f"
      unitRef="U_USD">-377000</tyra:AvailableForSaleDebtSecuritiesNetUnrealizedGain>
    <tyra:AvailableForSaleDebtSecuritiesNetUnrealizedGain
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="-3"
      id="F_c20388d7-f1ce-44b6-b6f6-e728618b4f08"
      unitRef="U_USD">-377000</tyra:AvailableForSaleDebtSecuritiesNetUnrealizedGain>
    <us-gaap:NetIncomeLoss
      contextRef="C_df547fe0-45f9-4a1e-9a51-de2c71f2fc5c"
      decimals="-3"
      id="F_e388d2c9-ce2b-41d5-b5a3-aac8c29c1a2d"
      unitRef="U_USD">-119947000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="-3"
      id="F_f47553ae-6905-4029-92eb-0974f37c7c85"
      unitRef="U_USD">-119947000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_bf0901d4-ef49-48dc-b81b-94822de4c19d"
      decimals="0"
      id="F_6130cb36-4323-41f7-9e4b-c890fbd9ce17"
      unitRef="U_shares">53706357</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_bf0901d4-ef49-48dc-b81b-94822de4c19d"
      decimals="-3"
      id="F_5400ed7b-0971-441e-afb0-e58d1f8bcba2"
      unitRef="U_USD">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_7a958c54-6cff-41ea-bb1a-33c200dccaae"
      decimals="-3"
      id="F_46602ce8-39d3-4cb5-b3c4-1c8c40afbb68"
      unitRef="U_USD">630037000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_58b2744f-4829-4186-a4c0-62f067475f6f"
      decimals="-3"
      id="F_4b64cabd-7388-422c-914f-18602ef3567c"
      unitRef="U_USD">393000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_27fab6ea-d588-459f-a85f-6bc9be1ab8c8"
      decimals="-3"
      id="F_0f6bab05-b4a5-497a-9d55-51e2f45cf184"
      unitRef="U_USD">-371258000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_9d030e5e-d769-4c61-9348-f2b3fdbc4a66"
      unitRef="U_USD">259177000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="-3"
      id="F_b7d1a5ca-9e5d-4ba8-b6b8-b34f0532ef8c"
      unitRef="U_USD">-119947000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="-3"
      id="F_c748e617-c522-4497-8405-5bc39746fef6"
      unitRef="U_USD">-86481000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="-3"
      id="F_a6c999d1-4f54-4f54-a16c-9a0eaf9e87e7"
      unitRef="U_USD">546000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="-3"
      id="F_cf550943-dd78-44a1-9d1b-5959b514179b"
      unitRef="U_USD">519000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="-3"
      id="F_859d68e7-8eed-44d4-a9e8-4712fd0fb0e9"
      unitRef="U_USD">28006000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="-3"
      id="F_18d83882-9451-4824-add6-354454c0f233"
      unitRef="U_USD">22801000</us-gaap:ShareBasedCompensation>
    <tyra:AccretionOnMarketableSecuritiesNet
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="-3"
      id="F_0ef30bd4-3c03-413c-86f5-4243774dfc44"
      unitRef="U_USD">-2119000</tyra:AccretionOnMarketableSecuritiesNet>
    <tyra:AccretionOnMarketableSecuritiesNet
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="-3"
      id="F_358061fa-00da-4bc0-8226-70de0b89cdec"
      unitRef="U_USD">-5884000</tyra:AccretionOnMarketableSecuritiesNet>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="-3"
      id="F_fb212838-51cf-4250-a1ab-04d58b9ca61e"
      unitRef="U_USD">5080000</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="-3"
      id="F_9b9aafde-2e05-457a-91e7-adf357944930"
      unitRef="U_USD">169000</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="-3"
      id="F_6063e0e3-ab42-473f-a2f9-95fda053761b"
      unitRef="U_USD">3369000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="-3"
      id="F_520f66ee-c1c6-4e13-94f4-74a6eed60307"
      unitRef="U_USD">-744000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <tyra:IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="-3"
      id="F_7eb78b7c-45f8-408f-8923-3103f3dc0cd5"
      unitRef="U_USD">83000</tyra:IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet>
    <tyra:IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="-3"
      id="F_30c9c722-bc65-497c-895e-a5664dc03af8"
      unitRef="U_USD">184000</tyra:IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="-3"
      id="F_7393c695-da6b-40d4-a01a-3cbf1a206cf1"
      unitRef="U_USD">-95142000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="-3"
      id="F_3fb9d7ef-fe10-4d92-8a3a-53ef66b17762"
      unitRef="U_USD">-69774000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="-3"
      id="F_d33fc03c-ce06-427b-a977-77bc310f972d"
      unitRef="U_USD">101254000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="-3"
      id="F_3a4692d5-0823-428d-b81f-60becc86d387"
      unitRef="U_USD">263624000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="-3"
      id="F_8eea8f3c-d367-495e-b46d-98aa7d127105"
      unitRef="U_USD">173858000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="-3"
      id="F_78e48cd7-25a3-4f26-9547-392dca07fc61"
      unitRef="U_USD">165885000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="-3"
      id="F_e8fda148-bd6e-4e54-b959-d1b38ae85bcc"
      unitRef="U_USD">141000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="-3"
      id="F_8b241c8e-ea71-420f-94e5-62e36b67879e"
      unitRef="U_USD">664000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="-3"
      id="F_7648c9f8-fb42-4b51-adac-4f5aa6be686c"
      unitRef="U_USD">72463000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="-3"
      id="F_ab132f26-740f-4306-9437-dd1e2a0618bc"
      unitRef="U_USD">-98403000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <tyra:ProceedsFromIssuanceOfCommonStockUnderBenefitPlans
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="-3"
      id="F_34949fea-105c-42d6-8aff-3cc69506d2bb"
      unitRef="U_USD">8100000</tyra:ProceedsFromIssuanceOfCommonStockUnderBenefitPlans>
    <tyra:ProceedsFromIssuanceOfCommonStockUnderBenefitPlans
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="-3"
      id="F_847c600d-c944-49d5-bf91-e1c9a286eb1a"
      unitRef="U_USD">2557000</tyra:ProceedsFromIssuanceOfCommonStockUnderBenefitPlans>
    <tyra:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromPrivatePlacement
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="-3"
      id="F_1cd1269a-e04f-4020-9760-ca33a2d4bf6b"
      unitRef="U_USD">0</tyra:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromPrivatePlacement>
    <tyra:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromPrivatePlacement
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="-3"
      id="F_3ec20e95-8be1-4950-b305-62a36be5702b"
      unitRef="U_USD">200000000</tyra:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromPrivatePlacement>
    <tyra:PaymentsOfIssuanceCostsForCommonStockAndPreFundedWarrantsFromPrivatePlacement
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="-3"
      id="F_7c6be6fb-b8bd-4cf7-8d42-38777d5ea760"
      unitRef="U_USD">0</tyra:PaymentsOfIssuanceCostsForCommonStockAndPreFundedWarrantsFromPrivatePlacement>
    <tyra:PaymentsOfIssuanceCostsForCommonStockAndPreFundedWarrantsFromPrivatePlacement
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="-3"
      id="F_bfa96a59-1b4a-482e-a5e2-2d1df29e1c1b"
      unitRef="U_USD">420000</tyra:PaymentsOfIssuanceCostsForCommonStockAndPreFundedWarrantsFromPrivatePlacement>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="-3"
      id="F_14a84d68-e22c-42f6-815c-90fa612e7463"
      unitRef="U_USD">8100000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="-3"
      id="F_a54deb6b-fb89-4667-8ea9-605aae8fe2e3"
      unitRef="U_USD">202137000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="-3"
      id="F_03fd2181-81fd-461a-b91b-633f8feae647"
      unitRef="U_USD">-14579000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="-3"
      id="F_a5342886-a64b-4bff-aa29-392757ab413c"
      unitRef="U_USD">33960000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="-3"
      id="F_f601457c-4064-43e3-9f8e-120aba81dc5c"
      unitRef="U_USD">92966000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_90b314f0-e678-446e-845b-a940c76b3ed3"
      decimals="-3"
      id="F_c8847f29-6c29-4b4d-bce9-38e336a12e02"
      unitRef="U_USD">59006000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_b21045bb-a924-4c09-9905-48e8e4fcfb42"
      unitRef="U_USD">78387000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="-3"
      id="F_b4400d00-8872-423c-bbf4-61804ee78463"
      unitRef="U_USD">92966000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_ccfc80e5-d74f-4703-88a2-b43a22d6d62f"
      unitRef="U_USD">77387000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="-3"
      id="F_ce229368-5a20-4343-bf95-601fc5591f24"
      unitRef="U_USD">91966000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_df83d26d-e066-488e-b6fd-30ff611043c7"
      unitRef="U_USD">1000000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="-3"
      id="F_f4455c29-6c63-4787-9907-1d6def9594d8"
      unitRef="U_USD">1000000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_6b767acc-dc66-4c40-865f-8d2b7e8ca6d5"
      unitRef="U_USD">78387000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="-3"
      id="F_ea4fead5-2f9e-4902-9fa1-83caa299f0cd"
      unitRef="U_USD">92966000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="-3"
      id="F_dba8d4d2-a60a-4afa-a3a4-1d5a5dcc8d8b"
      unitRef="U_USD">68000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="-3"
      id="F_698430b7-f139-45b7-b74e-620a7d3f38ac"
      unitRef="U_USD">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <tyra:VestingOfOptionsEarlyExercisedSubjectToRepurchase
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="-3"
      id="F_58462d26-9f36-4a51-8bb8-b2bc16308717"
      unitRef="U_USD">3000</tyra:VestingOfOptionsEarlyExercisedSubjectToRepurchase>
    <tyra:VestingOfOptionsEarlyExercisedSubjectToRepurchase
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="-3"
      id="F_2fa5a4ab-7aa6-411a-921e-3c189265ac89"
      unitRef="U_USD">43000</tyra:VestingOfOptionsEarlyExercisedSubjectToRepurchase>
    <tyra:ReceivableFromExerciseOfStockOptionsIncludedInPrepaidExpensesAndOtherCurrentAssets
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="-3"
      id="F_03fce516-f193-4920-9315-466c8787bd16"
      unitRef="U_USD">241000</tyra:ReceivableFromExerciseOfStockOptionsIncludedInPrepaidExpensesAndOtherCurrentAssets>
    <tyra:ReceivableFromExerciseOfStockOptionsIncludedInPrepaidExpensesAndOtherCurrentAssets
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="-3"
      id="F_042934f5-13dc-40c3-8474-21ee30734aa1"
      unitRef="U_USD">0</tyra:ReceivableFromExerciseOfStockOptionsIncludedInPrepaidExpensesAndOtherCurrentAssets>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_a9cce930-c962-4202-a5af-8560e60677a4">&lt;p id="note_1" style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;1. Orga&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;nization and Summary of Significant Accounting Policies&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Organization&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Tyra &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Biosciences, Inc. (the Company) was incorporated in the state of Delaware on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;August 2, 2018&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The Company is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The Company&#x2019;s in-house precision medicine platform, SN&#xc5;P, enables rapid and precise drug design through iterative molecular SN&#xc5;Pshots that help predict which product candidates may demonstrate the highest potency, selectivity and tolerability. The Company&#x2019;s focus is on applying its accelerated small molecule drug discovery engine to develop therapies in targeted oncology and genetically defined conditions&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Since its inception, the Company has devoted substantially all of its resources to research and development activities, business planning, establishing and maintaining its intellectual property portfolio, hiring personnel, raising capital, and providing general and administrative support for these operations. It has incurred losses and negative cash flows from operations since commencement of its operations. The Company had an accumulated deficit of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;371.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and cash, cash equivalents and marketable securities of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;256.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as of December 31, 2025. From its inception through December 31, 2025, the Company has financed its operations primarily through the sale of common stock, private placements of its convertible preferred stock, and the issuance of common stock and pre-funded common stock warrants through a private placement.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As the Company continues its expansion, it may seek additional financing and/or strategic investments. However, there can be no assurance that any additional financing or strategic investments will be available to the Company on acceptable terms, if at all. If events or circumstances occur such that the Company does not obtain additional funding, it will most likely be required to reduce its plans and/or certain discretionary spending, which could have a material adverse effect on the Company&#x2019;s ability to achieve its intended business objectives. Management believes that it has sufficient working capital on hand to fund operations through at least the next twelve months from the date of issuance of these financial statements.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accompanying financial statements have been prepared in accordance with generally accepted accounting principles in the United States (GAAP). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) promulgated by the Financial Accounting Standards Board (FASB).&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates and assumptions made in the accompanying financial statements include, but are not limited to, the valuation of share-based awards, the valuation of deferred tax assets and income tax uncertainties, accruals for research and development activities, and incremental borrowing rate (IBR) for right-of-use (ROU) assets. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable. Actual results may differ from those estimates or assumptions.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Financial instruments which potentially subject the Company to a significant concentration of credit risk consist of cash, cash equivalents and marketable securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the nature of the instruments held in the depository institutions.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents primarily represent funds invested in readily available money market accounts. As of December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company had cash and cash equivalents balances deposited at major financial institutions.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Marketable securities consist of debt securities of government-sponsored entities. These securities are classified as available-for sale, as the sale of such securities may be required prior to their maturity. Available-for-sale securities are recorded at fair value, with the related unrealized gains and losses included in accumulated other comprehensive income or loss and included as a separate component of stockholders&#x2019; equity. The amortized cost of available-for-sale securities reflects amortization of premiums and accretion of discounts to maturity. Premiums and discounts on debt securities are amortized or accreted into interest and other income, net. The Company classifies investments in marketable debt securities as current assets, regardless of the stated maturity date, which may be beyond one year from the current balance sheet date. Short-term classification reflects management&#x2019;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;s view that the entire portfolio is available, and the Company may use the proceeds from sales of these investments to fund current operations, as necessary.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Allowance for Credit Losses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company regularly reviews its portfolio for declines in fair value. For investments in an unrealized loss position, the Company assesses whether the decline is based on credit losses or other factor. As part of this assessment, the Company considers the cause of the impairment, the creditworthiness of the security issuers, current market conditions, the number of securities in an unrealized loss position, the severity of the losses, whether it will be required or will intend to sell the investment before recovery of its amortized cost basis. If fair value decline is determined to be due to a credit-related factor, the amortized cost basis is written down to fair value through net loss. If fair value decline is not due to credit-related factors, a loss is recorded in other comprehensive income or loss. The Company recognizes an allowance for credit losses up to the amount of the unrealized loss when appropriate.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We do not measure an allowance for credit losses for accrued interest receivables. For the purposes of identifying and measuring an impairment, accrued interest is excluded from both the fair value and amortized costs basis of the investment. Uncollectible accrued interest receivables associated with an impaired marketable security are reversed against interest income in a timely manner upon identification of the impairment.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company measures cash equivalents and available-for-sale debt securities at fair value. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. Therefore, fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability. Fair value is affected by a number of factors, including the type of asset or liability, the characteristics specific to the asset or liability and the state of the marketplace, including the existence and transparency of transactions between market participants. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Money market funds are highly liquid investments and are classified as Level 1. The pricing information for these assets is readily available and can be independently validated as of the measurement date. Available-for-sale debt securities, including U.S. Treasury securities and U.S. Agency bonds are classified as Level 2. These securities are valued using fair value from third-party pricing services, which may use observable inputs based on real-time trade data for similar assets, broker/dealer quotes, bids and/or offers and other observable inputs. The Company validates valuations obtained from third-party pricing services by understanding the models used and obtaining market values from independent sources.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Restricted Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Restricted cash is comprised of cash that is restricted as to its withdrawal or use under the terms of certain contractual agreements. Restricted cash as of December 31, 2025 and 2024 was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, which consisted of collateral for letters of credit related to the Company&#x2019;s operating leases.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment is stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets (generally &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_de6e2adb-217c-46f8-87ab-7f9f75f3c64f;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;seven years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, or the remaining term of the lease).&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for the impairment of long-lived assets by reviewing these assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group to be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted-cash-flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. The Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t recognize impairment losses for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 and 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Accrued Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and development expenses consist of external and internal costs associated with the Company&#x2019;s research and development activities, including its discovery and research efforts and the preclinical and clinical development of its product candidates. Research and development costs are expensed in the period incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Company has entered into various research and development contracts with clinical research organizations, clinical manufacturing organizations, clinical sites and other vendors and consultants. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and payments made in advance of or after the performance are reflected in the accompanying balance sheets as prepaid expenses or accrued liabilities, respectively. The Company records accruals for estimated costs incurred for ongoing research and development activities. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs. The Company holds discussions with applicable personnel and outside service providers as to the progress of clinical trials, or the services completed. Significant judgments and estimates may be made in determining the prepaid or accrued balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s estimates. Nonrefundable advance payments for goods and services, including fees for process&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;development, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;are deferred and recognized as expenses in the period that the related goods are consumed or services are performed.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Patent Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company expenses all costs as incurred in connection with patent applications (including direct application fees, and the legal and consulting expenses related to making such applications) and such costs are included in general and administrative expenses in the statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has operating leases for office and lab space. At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, the Company records the associated lease liability and corresponding ROU asset upon commencement of the lease using the implicit rate or a discount rate based on a credit-adjusted secured borrowing rate commensurate with the term of the lease. The Company evaluates leases at their inception to determine if they are to be accounted for as an operating lease or a finance lease.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operating lease assets represent a right to use an underlying asset for the lease term and operating lease liabilities represent an obligation to make lease payments arising from the lease. Operating lease liabilities with a term greater than one year and their corresponding ROU assets are recognized on the balance sheet at the commencement date of the lease based on the present value of lease payments over the expected lease term. The Company excludes short-term leases, if any, having initial terms of 12 months or less at lease commencement as an accounting policy election.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Certain adjustments to the ROU assets may be required for items such as payments made at or before the commencement date, initial direct costs paid or lease incentives received. As the Company&#x2019;s leases do not typically provide an implicit rate, the Company utilizes the appropriate IBR, determined as the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term and in a similar economic environment. Lease cost is recognized on a straight-line basis over the lease term and variable lease payments are recognized as operating expenses in the period in which the obligation for those payments is incurred. Variable lease payments primarily include common area maintenance, utilities, real estate taxes, insurance, and other operating costs that are passed on from the lessor in proportion to the space leased by the Company. In measuring the ROU assets and lease liabilities, the Company has elected to combine lease and non-lease components.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operating ROU assets are reflected in right-of-use assets in the accompanying balance sheets. Operating lease liabilities are reflected in lease liabilities, current and noncurrent in the accompanying balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Common Stock Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Common stock warrants are classified as either a liability or equity, based on an assessment of specific terms and applicable authoritative guidance in ASC 480, Distinguishing Liabilities from Equity (ASC 480) and ASC 815, Derivatives and Hedging (ASC 815). The Company considers whether the warrants are freestanding financial instruments, whether they meet the definition of a liability pursuant to ASC 480, and whether they meet all of the requirements for equity classification under ASC 815. This assessment is performed at the time of warrant issuance and re-assessed as of each subsequent quarterly balance sheet date, while the warrants are outstanding.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation expense represents the cost of the grant date fair value of employee, officer, director and non-employee equity awards, estimated in accordance with the applicable accounting guidance, and, for those awards subject only to service conditions, recognized on a straight-line basis over the vesting period. The vesting period generally approximates the expected service period of the awards. The Company recognizes stock-based compensation expense for awards with performance conditions when it is probable that the condition will be&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;met, and the award will vest. If the achievement of performance conditions is no longer deemed probable, previously recognized compensation cost is reversed. For awards with performance and service conditions, the Company begins recording share-based compensation when achieving the performance criteria is probable and recognizes the costs using the accelerated attribution method. The Company recognizes forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair value of stock options is estimated using a Black-Scholes valuation model on the date of grant. This method requires certain assumptions to be used as inputs, such as the fair value of the underlying common stock, expected term of the option before exercise, expected volatility of the Company&#x2019;s common stock, risk-free interest rate and expected dividend. Options granted have a maximum contractual term of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The Company has limited historical stock option activity and therefore estimates the expected term of stock options granted using the simplified method, which represents the arithmetic average of the original contractual term of the stock option and its weighted-average vesting term. The expected volatility of stock options is estimated based on the average historical volatilities of common stock of comparable publicly traded companies and the Company&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;s own volatility. The comparable companies are chosen based on their size and stage in the life cycle. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available. The risk-free interest rates used are based on the U.S. Treasury yield in effect at the time of grant for zero-coupon U.S. treasury notes with maturities approximately equal to the expected term of the stock options. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has historically not declared or paid any dividends and does not currently expect to do so in the foreseeable future, and therefore, has estimated the dividend yield to be &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;zero&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Commitments and Contingencies&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognizes a liability with regard to loss contingencies when it believes it is probable a liability has been incurred, and the amount can be reasonably estimated. If some amount within a range of loss appears at the time to be a better estimate than any other amount within the range, the Company accrues that amount. When no amount within the range is a better estimate than any other amount, the Company accrues the minimum amount in the range.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the statement of operations in the period that includes the enactment date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognizes deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025 and 2024, the Company maintained valuation allowances against its deferred tax assets as the Company concluded it had not met the &#x201c;more likely than not&#x201d; to be realized threshold. Changes in the valuation allowance when they are recognized in the provision for income taxes may result in a change in the estimated annual effective tax rate.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company records uncertain tax positions on the basis of a two-step process whereby (1) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability. As of December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company had &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; accrued interest or penalties.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Comprehensive loss consists of two components: net loss and other comprehensive income or loss. Other comprehensive income (loss) refers to gains or losses that are recorded as an element of stockholders&#x2019; equity but are excluded from net loss. The Company&#x2019;s other comprehensive income (loss) consists of unrealized gains and losses on marketable securities.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock and common stock equivalents outstanding for the period. Common stock equivalents are only included when their effect is dilutive. Pre-funded warrants are considered outstanding for the purposes of computing basic and diluted net loss per share because shares may be issued for little or no additional consideration and are fully vested and exercisable after the original issuance date of the pre-funded warrant. The Company&#x2019;s potentially dilutive securities include unvested common stock upon early exercise of stock options, outstanding stock options under the Company&#x2019;s equity incentive plan, and estimated shares purchasable under the employee stock purchase plan, and have been excluded from the computation of diluted net loss per share as their inclusion would be anti-dilutive. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#x2019;s net loss position.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Related Parties&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Transactions between related parties are considered to be related party transactions even though they may not be given accounting recognition. FASB ASC 850, Related Party Disclosures (ASC 850) requires that transactions with related parties that would make a difference in decision making shall be disclosed so that users of the financial statements can evaluate their significance.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Capitalized Software Implementation Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company capitalizes certain implementation costs incurred under a cloud computing arrangement that is a service contract. Costs incurred during the application development stage related to the implementation of the hosting arrangement are capitalized and included within prepaid and other current assets, and other long-term assets on the accompanying balance sheets. Amortization of capitalized implementation costs is recognized on a straight-line basis over the term of the associated hosting arrangement when it is ready for its intended use. Costs related to preliminary project activities and post-implementation activities are expensed as incurred.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU 2023-09, &#x201c;Income Taxes (Topic 740): Improvements to Income Tax Disclosures.&#x201d; ASU 2023-09 requires disaggregated information about a reporting entity&#x2019;s effective tax rate reconciliation as well as information on income taxes paid. ASU 2023-09 is effective for public entities with annual periods beginning after December 15, 2024, with early adoption permitted. The Company adopted this standard prospectively for the period ending December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The adoption impacted the disclosures and did not impact the financial statements. See Note 8, Income Taxes, for disclosures related to the adoption of ASU 2023-09.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Issued Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the FASB issued ASU 2024-03, "&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;". In January 2025, the FASB issued ASU 2025-01, "&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;", to clarify the effective date of ASU 2024-03. These amendments are intended to provide more information about certain costs and expenses on an interim and annual basis. The amendments are effective for annual periods beginning after December 15, 2026 and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The new standards are expected to be applied prospectively, but retrospective application is permitted. The Company is currently evaluating the impact on its financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <tyra:OrganizationPolicyTextBlock
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_adcba966-3790-4e02-8731-6f688c7b8fb3">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Organization&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Tyra &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Biosciences, Inc. (the Company) was incorporated in the state of Delaware on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;August 2, 2018&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The Company is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The Company&#x2019;s in-house precision medicine platform, SN&#xc5;P, enables rapid and precise drug design through iterative molecular SN&#xc5;Pshots that help predict which product candidates may demonstrate the highest potency, selectivity and tolerability. The Company&#x2019;s focus is on applying its accelerated small molecule drug discovery engine to develop therapies in targeted oncology and genetically defined conditions&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Since its inception, the Company has devoted substantially all of its resources to research and development activities, business planning, establishing and maintaining its intellectual property portfolio, hiring personnel, raising capital, and providing general and administrative support for these operations. It has incurred losses and negative cash flows from operations since commencement of its operations. The Company had an accumulated deficit of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;371.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and cash, cash equivalents and marketable securities of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;256.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as of December 31, 2025. From its inception through December 31, 2025, the Company has financed its operations primarily through the sale of common stock, private placements of its convertible preferred stock, and the issuance of common stock and pre-funded common stock warrants through a private placement.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As the Company continues its expansion, it may seek additional financing and/or strategic investments. However, there can be no assurance that any additional financing or strategic investments will be available to the Company on acceptable terms, if at all. If events or circumstances occur such that the Company does not obtain additional funding, it will most likely be required to reduce its plans and/or certain discretionary spending, which could have a material adverse effect on the Company&#x2019;s ability to achieve its intended business objectives. Management believes that it has sufficient working capital on hand to fund operations through at least the next twelve months from the date of issuance of these financial statements.&lt;/span&gt;&lt;/p&gt;</tyra:OrganizationPolicyTextBlock>
    <dei:EntityIncorporationDateOfIncorporation
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_87a306cb-793d-41da-a78a-2c0b3a880653">2018-08-02</dei:EntityIncorporationDateOfIncorporation>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-5"
      id="F_66fb0dfd-a8dc-4494-b14a-e4b6df45ae38"
      unitRef="U_USD">-371300000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <tyra:CashCashEquivalentsAndMarketableSecurities
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-5"
      id="F_3b498cea-fde5-4189-8490-e5875b37ba85"
      unitRef="U_USD">256000000</tyra:CashCashEquivalentsAndMarketableSecurities>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_5cbed0d4-f59e-412f-b1e8-58b074239c04">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accompanying financial statements have been prepared in accordance with generally accepted accounting principles in the United States (GAAP). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) promulgated by the Financial Accounting Standards Board (FASB).&lt;/span&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_ef40ec59-550f-45b2-8d0c-9546ef27dfc4">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates and assumptions made in the accompanying financial statements include, but are not limited to, the valuation of share-based awards, the valuation of deferred tax assets and income tax uncertainties, accruals for research and development activities, and incremental borrowing rate (IBR) for right-of-use (ROU) assets. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable. Actual results may differ from those estimates or assumptions.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_61ab8795-cd38-4869-a562-92d4729e922c">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Financial instruments which potentially subject the Company to a significant concentration of credit risk consist of cash, cash equivalents and marketable securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the nature of the instruments held in the depository institutions.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_776765fd-d2ce-4f13-a48c-f73bc80aff70">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents primarily represent funds invested in readily available money market accounts. As of December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company had cash and cash equivalents balances deposited at major financial institutions.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_ac15e38c-2ff7-40d9-9411-00d0cccf7898">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Marketable securities consist of debt securities of government-sponsored entities. These securities are classified as available-for sale, as the sale of such securities may be required prior to their maturity. Available-for-sale securities are recorded at fair value, with the related unrealized gains and losses included in accumulated other comprehensive income or loss and included as a separate component of stockholders&#x2019; equity. The amortized cost of available-for-sale securities reflects amortization of premiums and accretion of discounts to maturity. Premiums and discounts on debt securities are amortized or accreted into interest and other income, net. The Company classifies investments in marketable debt securities as current assets, regardless of the stated maturity date, which may be beyond one year from the current balance sheet date. Short-term classification reflects management&#x2019;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;s view that the entire portfolio is available, and the Company may use the proceeds from sales of these investments to fund current operations, as necessary.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <tyra:AllowanceForCreditLossesPolicyTextBlock
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_65fb84ea-317f-4dca-90a5-712d1a6a2633">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Allowance for Credit Losses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company regularly reviews its portfolio for declines in fair value. For investments in an unrealized loss position, the Company assesses whether the decline is based on credit losses or other factor. As part of this assessment, the Company considers the cause of the impairment, the creditworthiness of the security issuers, current market conditions, the number of securities in an unrealized loss position, the severity of the losses, whether it will be required or will intend to sell the investment before recovery of its amortized cost basis. If fair value decline is determined to be due to a credit-related factor, the amortized cost basis is written down to fair value through net loss. If fair value decline is not due to credit-related factors, a loss is recorded in other comprehensive income or loss. The Company recognizes an allowance for credit losses up to the amount of the unrealized loss when appropriate.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We do not measure an allowance for credit losses for accrued interest receivables. For the purposes of identifying and measuring an impairment, accrued interest is excluded from both the fair value and amortized costs basis of the investment. Uncollectible accrued interest receivables associated with an impaired marketable security are reversed against interest income in a timely manner upon identification of the impairment.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</tyra:AllowanceForCreditLossesPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_79f756f5-9253-494e-8786-a7354122c8be">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company measures cash equivalents and available-for-sale debt securities at fair value. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. Therefore, fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability. Fair value is affected by a number of factors, including the type of asset or liability, the characteristics specific to the asset or liability and the state of the marketplace, including the existence and transparency of transactions between market participants. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Money market funds are highly liquid investments and are classified as Level 1. The pricing information for these assets is readily available and can be independently validated as of the measurement date. Available-for-sale debt securities, including U.S. Treasury securities and U.S. Agency bonds are classified as Level 2. These securities are valued using fair value from third-party pricing services, which may use observable inputs based on real-time trade data for similar assets, broker/dealer quotes, bids and/or offers and other observable inputs. The Company validates valuations obtained from third-party pricing services by understanding the models used and obtaining market values from independent sources.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_8e92b2b4-d3dd-40f9-bb70-a56dfbc7abb5">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Restricted Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Restricted cash is comprised of cash that is restricted as to its withdrawal or use under the terms of certain contractual agreements. Restricted cash as of December 31, 2025 and 2024 was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, which consisted of collateral for letters of credit related to the Company&#x2019;s operating leases.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedCash
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="-5"
      id="F_5b3e1459-f6e8-44a2-8332-27413229433d"
      unitRef="U_USD">1000000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-5"
      id="F_6517cc2b-3839-44ff-86c2-bb810f0357b4"
      unitRef="U_USD">1000000</us-gaap:RestrictedCash>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_d9f289e2-2422-4915-8683-115a7cce2e62">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment is stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets (generally &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_de6e2adb-217c-46f8-87ab-7f9f75f3c64f;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;seven years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, or the remaining term of the lease).&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_d58f684d-19a9-4256-8716-4e0a68a997cd"
      id="F_a9176b49-3a99-425e-93c1-016a2f9e9b66">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_1159cb0e-c347-4fd0-bc89-737a1c911279">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for the impairment of long-lived assets by reviewing these assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group to be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted-cash-flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. The Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t recognize impairment losses for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 and 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_4a3a2077-3bda-4557-8dc1-0b3803890cbf"
      decimals="-3"
      id="F_5f7b2804-83dc-4418-b7d8-a46c34e08733"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_82407490-dbff-4f2d-ab88-7b2feada5686"
      decimals="-3"
      id="F_8e3e343e-5b92-4894-93d1-99e47e32f5cd"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <tyra:AccruedResearchAndDevelopmentExpensePolicyPolicyTextBlock
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_ca400e5e-266e-4163-a708-f54743b0e14c">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Accrued Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and development expenses consist of external and internal costs associated with the Company&#x2019;s research and development activities, including its discovery and research efforts and the preclinical and clinical development of its product candidates. Research and development costs are expensed in the period incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Company has entered into various research and development contracts with clinical research organizations, clinical manufacturing organizations, clinical sites and other vendors and consultants. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and payments made in advance of or after the performance are reflected in the accompanying balance sheets as prepaid expenses or accrued liabilities, respectively. The Company records accruals for estimated costs incurred for ongoing research and development activities. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs. The Company holds discussions with applicable personnel and outside service providers as to the progress of clinical trials, or the services completed. Significant judgments and estimates may be made in determining the prepaid or accrued balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s estimates. Nonrefundable advance payments for goods and services, including fees for process&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;development, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;are deferred and recognized as expenses in the period that the related goods are consumed or services are performed.&lt;/span&gt;&lt;/p&gt;</tyra:AccruedResearchAndDevelopmentExpensePolicyPolicyTextBlock>
    <tyra:PatentCostsPolicyPolicyTextBlock
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_6a0bd7aa-5209-40ef-85fe-c9a09d15712c">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Patent Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company expenses all costs as incurred in connection with patent applications (including direct application fees, and the legal and consulting expenses related to making such applications) and such costs are included in general and administrative expenses in the statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;</tyra:PatentCostsPolicyPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_de3f3620-f899-4151-a81d-c43844170297">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has operating leases for office and lab space. At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, the Company records the associated lease liability and corresponding ROU asset upon commencement of the lease using the implicit rate or a discount rate based on a credit-adjusted secured borrowing rate commensurate with the term of the lease. The Company evaluates leases at their inception to determine if they are to be accounted for as an operating lease or a finance lease.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operating lease assets represent a right to use an underlying asset for the lease term and operating lease liabilities represent an obligation to make lease payments arising from the lease. Operating lease liabilities with a term greater than one year and their corresponding ROU assets are recognized on the balance sheet at the commencement date of the lease based on the present value of lease payments over the expected lease term. The Company excludes short-term leases, if any, having initial terms of 12 months or less at lease commencement as an accounting policy election.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Certain adjustments to the ROU assets may be required for items such as payments made at or before the commencement date, initial direct costs paid or lease incentives received. As the Company&#x2019;s leases do not typically provide an implicit rate, the Company utilizes the appropriate IBR, determined as the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term and in a similar economic environment. Lease cost is recognized on a straight-line basis over the lease term and variable lease payments are recognized as operating expenses in the period in which the obligation for those payments is incurred. Variable lease payments primarily include common area maintenance, utilities, real estate taxes, insurance, and other operating costs that are passed on from the lessor in proportion to the space leased by the Company. In measuring the ROU assets and lease liabilities, the Company has elected to combine lease and non-lease components.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operating ROU assets are reflected in right-of-use assets in the accompanying balance sheets. Operating lease liabilities are reflected in lease liabilities, current and noncurrent in the accompanying balance sheets.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <tyra:CommonStockWarrantsPolicyTextBlock
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_7df216d2-6fa0-41a6-bdd7-5b038326d3e1">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Common Stock Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Common stock warrants are classified as either a liability or equity, based on an assessment of specific terms and applicable authoritative guidance in ASC 480, Distinguishing Liabilities from Equity (ASC 480) and ASC 815, Derivatives and Hedging (ASC 815). The Company considers whether the warrants are freestanding financial instruments, whether they meet the definition of a liability pursuant to ASC 480, and whether they meet all of the requirements for equity classification under ASC 815. This assessment is performed at the time of warrant issuance and re-assessed as of each subsequent quarterly balance sheet date, while the warrants are outstanding.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</tyra:CommonStockWarrantsPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_19d6ac3c-936f-4af6-bc72-af6843f44b74">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation expense represents the cost of the grant date fair value of employee, officer, director and non-employee equity awards, estimated in accordance with the applicable accounting guidance, and, for those awards subject only to service conditions, recognized on a straight-line basis over the vesting period. The vesting period generally approximates the expected service period of the awards. The Company recognizes stock-based compensation expense for awards with performance conditions when it is probable that the condition will be&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;met, and the award will vest. If the achievement of performance conditions is no longer deemed probable, previously recognized compensation cost is reversed. For awards with performance and service conditions, the Company begins recording share-based compensation when achieving the performance criteria is probable and recognizes the costs using the accelerated attribution method. The Company recognizes forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair value of stock options is estimated using a Black-Scholes valuation model on the date of grant. This method requires certain assumptions to be used as inputs, such as the fair value of the underlying common stock, expected term of the option before exercise, expected volatility of the Company&#x2019;s common stock, risk-free interest rate and expected dividend. Options granted have a maximum contractual term of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The Company has limited historical stock option activity and therefore estimates the expected term of stock options granted using the simplified method, which represents the arithmetic average of the original contractual term of the stock option and its weighted-average vesting term. The expected volatility of stock options is estimated based on the average historical volatilities of common stock of comparable publicly traded companies and the Company&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;s own volatility. The comparable companies are chosen based on their size and stage in the life cycle. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available. The risk-free interest rates used are based on the U.S. Treasury yield in effect at the time of grant for zero-coupon U.S. treasury notes with maturities approximately equal to the expected term of the stock options. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has historically not declared or paid any dividends and does not currently expect to do so in the foreseeable future, and therefore, has estimated the dividend yield to be &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;zero&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <tyra:OptionsGrantedContractualTerm
      contextRef="C_3bfbb795-7b7e-4213-b6a6-ea14b283ed4f"
      id="F_d013e45f-5355-41a7-834a-46468b48d430">P10Y</tyra:OptionsGrantedContractualTerm>
    <us-gaap:DividendPaymentRestrictionsScheduleDescription
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_5eaf8aaf-af4f-4477-951f-ffbdfdea54d4">The Company has historically not declared or paid any dividends and does not currently expect to do so in the foreseeable future, and therefore, has estimated the dividend yield to be zero.</us-gaap:DividendPaymentRestrictionsScheduleDescription>
    <tyra:DividendYield
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="-3"
      id="F_702db042-5141-4eb7-816f-d2d46cb7ca63"
      unitRef="U_USD">0</tyra:DividendYield>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_9eaf7090-76ef-40a1-ac38-69601e041f16">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Commitments and Contingencies&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognizes a liability with regard to loss contingencies when it believes it is probable a liability has been incurred, and the amount can be reasonably estimated. If some amount within a range of loss appears at the time to be a better estimate than any other amount within the range, the Company accrues that amount. When no amount within the range is a better estimate than any other amount, the Company accrues the minimum amount in the range.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_c18cdd7a-a6b4-4cac-aaff-effdcd169151">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the statement of operations in the period that includes the enactment date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognizes deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025 and 2024, the Company maintained valuation allowances against its deferred tax assets as the Company concluded it had not met the &#x201c;more likely than not&#x201d; to be realized threshold. Changes in the valuation allowance when they are recognized in the provision for income taxes may result in a change in the estimated annual effective tax rate.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company records uncertain tax positions on the basis of a two-step process whereby (1) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability. As of December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company had &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; accrued interest or penalties.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_c56df925-b00d-4814-ba8b-f8792f90ec7d"
      unitRef="U_USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_6c3e2de3-af4f-459b-a7ae-49caef133af6">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Comprehensive loss consists of two components: net loss and other comprehensive income or loss. Other comprehensive income (loss) refers to gains or losses that are recorded as an element of stockholders&#x2019; equity but are excluded from net loss. The Company&#x2019;s other comprehensive income (loss) consists of unrealized gains and losses on marketable securities.&lt;/span&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_ad8bd3d0-b458-42c1-b723-1873ed2b66b2">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock and common stock equivalents outstanding for the period. Common stock equivalents are only included when their effect is dilutive. Pre-funded warrants are considered outstanding for the purposes of computing basic and diluted net loss per share because shares may be issued for little or no additional consideration and are fully vested and exercisable after the original issuance date of the pre-funded warrant. The Company&#x2019;s potentially dilutive securities include unvested common stock upon early exercise of stock options, outstanding stock options under the Company&#x2019;s equity incentive plan, and estimated shares purchasable under the employee stock purchase plan, and have been excluded from the computation of diluted net loss per share as their inclusion would be anti-dilutive. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#x2019;s net loss position.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <tyra:RelatedPartiesPolicyPolicyTextBlock
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_2464a8c1-49a9-4486-9381-33f28734202a">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Related Parties&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Transactions between related parties are considered to be related party transactions even though they may not be given accounting recognition. FASB ASC 850, Related Party Disclosures (ASC 850) requires that transactions with related parties that would make a difference in decision making shall be disclosed so that users of the financial statements can evaluate their significance.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</tyra:RelatedPartiesPolicyPolicyTextBlock>
    <tyra:CapitalizedSoftwareImplementationCostsPolicyTextBlock
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_e33e2582-20ff-4937-ac05-7115b366ba12">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Capitalized Software Implementation Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company capitalizes certain implementation costs incurred under a cloud computing arrangement that is a service contract. Costs incurred during the application development stage related to the implementation of the hosting arrangement are capitalized and included within prepaid and other current assets, and other long-term assets on the accompanying balance sheets. Amortization of capitalized implementation costs is recognized on a straight-line basis over the term of the associated hosting arrangement when it is ready for its intended use. Costs related to preliminary project activities and post-implementation activities are expensed as incurred.&lt;/span&gt;&lt;/p&gt;</tyra:CapitalizedSoftwareImplementationCostsPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_1984f704-ac75-4c9b-ae70-d9c2b6ea8625">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU 2023-09, &#x201c;Income Taxes (Topic 740): Improvements to Income Tax Disclosures.&#x201d; ASU 2023-09 requires disaggregated information about a reporting entity&#x2019;s effective tax rate reconciliation as well as information on income taxes paid. ASU 2023-09 is effective for public entities with annual periods beginning after December 15, 2024, with early adoption permitted. The Company adopted this standard prospectively for the period ending December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The adoption impacted the disclosures and did not impact the financial statements. See Note 8, Income Taxes, for disclosures related to the adoption of ASU 2023-09.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <tyra:IssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_62265f44-bc56-4069-bc59-d16fe05b5a5c">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Issued Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the FASB issued ASU 2024-03, "&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;". In January 2025, the FASB issued ASU 2025-01, "&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;", to clarify the effective date of ASU 2024-03. These amendments are intended to provide more information about certain costs and expenses on an interim and annual basis. The amendments are effective for annual periods beginning after December 15, 2026 and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The new standards are expected to be applied prospectively, but retrospective application is permitted. The Company is currently evaluating the impact on its financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;</tyra:IssuedAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_2f558a7e-fb64-45ea-bb4f-c30bdab89006">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2. Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following tables show the Company&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2019;s cash equivalents and marketable securities measured at fair value as of December 31, 2025 and 2024 (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:37.932%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.297%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.177000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.297%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.297%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="11" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Quoted prices in active markets for identical assets (Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant other observable inputs (Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant unobservable inputs (Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;54,444&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;54,444&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;133,264&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;133,264&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45,352&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45,352&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Total marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;178,616&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;178,616&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;233,060&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;54,444&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;178,616&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:37.932%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.297%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.177000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.297%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.297%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="11" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Quoted prices in active markets for identical assets (Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant other observable inputs (Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant unobservable inputs (Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;69,698&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;69,698&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;122,980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;122,980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;126,495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;126,495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Total marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;249,475&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;249,475&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;319,173&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;69,698&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;249,475&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The carrying amounts of the Company&#x2019;s prepaid and other current assets, accounts payable, and accrued and other current liabilities approximate fair value due to their short maturities. None of the Company&#x2019;s non-financial assets or liabilities are recorded at fair value on a non-recurring basis. There were no transfers between Levels 1, 2 or 3 for any of the periods presented.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_b57f7558-f74f-4798-93db-5e79b9df9d9b">&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following tables show the Company&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2019;s cash equivalents and marketable securities measured at fair value as of December 31, 2025 and 2024 (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:37.932%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.297%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.177000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.297%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.297%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="11" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Quoted prices in active markets for identical assets (Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant other observable inputs (Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant unobservable inputs (Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;54,444&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;54,444&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;133,264&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;133,264&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45,352&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45,352&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Total marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;178,616&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;178,616&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;233,060&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;54,444&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;178,616&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:37.932%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.297%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.177000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.297%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.297%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="11" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Quoted prices in active markets for identical assets (Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant other observable inputs (Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant unobservable inputs (Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;69,698&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;69,698&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;122,980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;122,980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;126,495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;126,495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Total marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;249,475&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;249,475&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;319,173&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;69,698&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;249,475&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock>
    <us-gaap:FairValueConcentrationOfRiskCashAndCashEquivalents
      contextRef="C_91ad5ba4-1680-46a4-9791-00d5894e9338"
      decimals="-3"
      id="F_d2904317-d75d-4ed4-a624-81602dc79fc2"
      unitRef="U_USD">54444000</us-gaap:FairValueConcentrationOfRiskCashAndCashEquivalents>
    <us-gaap:FairValueConcentrationOfRiskCashAndCashEquivalents
      contextRef="C_4952b098-3c5d-47e1-a11e-2ad51ec8c584"
      decimals="-3"
      id="F_da9e8cf0-7983-48f6-aa3b-748a8b121e73"
      unitRef="U_USD">54444000</us-gaap:FairValueConcentrationOfRiskCashAndCashEquivalents>
    <us-gaap:FairValueConcentrationOfRiskCashAndCashEquivalents
      contextRef="C_2d692ebc-a844-453a-851e-e2ddc17d2c55"
      decimals="-3"
      id="F_cd623ff0-912a-47d9-bea2-8e39eae89b5f"
      unitRef="U_USD">0</us-gaap:FairValueConcentrationOfRiskCashAndCashEquivalents>
    <us-gaap:FairValueConcentrationOfRiskCashAndCashEquivalents
      contextRef="C_dfcd0690-10f5-44d8-bca0-e39e09cfb498"
      decimals="-3"
      id="F_df481196-ed1a-42e4-b932-b29b3a19de1d"
      unitRef="U_USD">0</us-gaap:FairValueConcentrationOfRiskCashAndCashEquivalents>
    <us-gaap:MarketableSecurities
      contextRef="C_f0dad730-1497-4f1d-aca3-f9d1d48a1d39"
      decimals="-3"
      id="F_fa2b40e3-5eec-4343-84ea-07fce5eb1e4b"
      unitRef="U_USD">133264000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_66a3ee93-337d-4531-9b7b-c8623780d836"
      decimals="-3"
      id="F_7d31fcfb-3d29-4b15-95ff-bd21e3fc1f0f"
      unitRef="U_USD">0</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_5a67af1f-955f-4fed-a7a1-8ddc18ed22ab"
      decimals="-3"
      id="F_ead449d1-bbe9-4935-9e7c-52841c4f95fd"
      unitRef="U_USD">133264000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_c6068cd1-21e5-450a-9869-2d60615e13b4"
      decimals="-3"
      id="F_4da31ef4-7a36-46a2-ab24-b603ea0abced"
      unitRef="U_USD">0</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_997236c7-47c3-4ba7-822f-0fd00f5213e3"
      decimals="-3"
      id="F_e89a966b-367c-429b-b274-ca7cd7783a00"
      unitRef="U_USD">45352000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_23d8f849-93e2-4c5e-8518-5df9a193ecf2"
      decimals="-3"
      id="F_9c6ec649-3080-4846-a1c4-254d7e12ff55"
      unitRef="U_USD">0</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_371b11b6-fa70-4468-9e81-af92b5ec918f"
      decimals="-3"
      id="F_26d935ee-f996-495d-8fcb-818958bae6d0"
      unitRef="U_USD">45352000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_83e9b223-47dc-4d04-a739-70fa68863bb9"
      decimals="-3"
      id="F_a9f54adb-14ec-4337-9aff-f60cd31b7e11"
      unitRef="U_USD">0</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_69bde7cd-c11f-4704-8be8-b885ee6842e9"
      decimals="-3"
      id="F_69c769cc-50d1-453b-8d9d-9d410615fa89"
      unitRef="U_USD">178616000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_6fe01dec-1d26-432c-84d4-861aa02e32d6"
      decimals="-3"
      id="F_4d667129-09d9-410f-984d-76b0985f248b"
      unitRef="U_USD">0</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_e0df3a23-dd2e-494b-a002-48c55afa2131"
      decimals="-3"
      id="F_58b73a24-10ef-4b6f-bee7-b0cebf51a026"
      unitRef="U_USD">178616000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_b8c32c5b-98c6-4415-8115-4d928ac1827f"
      decimals="-3"
      id="F_746b09d2-8501-49c6-ae02-ef7d1cb51f52"
      unitRef="U_USD">0</us-gaap:MarketableSecurities>
    <us-gaap:AssetsFairValueAdjustment
      contextRef="C_cdc6cc80-baf4-45fe-8841-dff91027f8b8"
      decimals="-3"
      id="F_d5b19074-ab91-454d-aeb9-fbabafb9a6b6"
      unitRef="U_USD">233060000</us-gaap:AssetsFairValueAdjustment>
    <us-gaap:AssetsFairValueAdjustment
      contextRef="C_93dfdc64-6b4a-406f-b392-50dedb2970c5"
      decimals="-3"
      id="F_27dd1143-ff3b-4253-9b15-0d3499d44d45"
      unitRef="U_USD">54444000</us-gaap:AssetsFairValueAdjustment>
    <us-gaap:AssetsFairValueAdjustment
      contextRef="C_822f9ef4-d69d-4947-92b4-eae4cf622064"
      decimals="-3"
      id="F_785f3111-da80-4681-a95f-91e6e233189d"
      unitRef="U_USD">178616000</us-gaap:AssetsFairValueAdjustment>
    <us-gaap:AssetsFairValueAdjustment
      contextRef="C_1e213811-870d-4dbf-826c-e35260a70b15"
      decimals="-3"
      id="F_49392b3f-4db3-4a3f-a729-2f3750ad5130"
      unitRef="U_USD">0</us-gaap:AssetsFairValueAdjustment>
    <us-gaap:FairValueConcentrationOfRiskCashAndCashEquivalents
      contextRef="C_9dc741f3-157e-4e28-9a5f-c2124c563656"
      decimals="-3"
      id="F_6be0a00b-f1bf-487e-815e-2a2d23201ad3"
      unitRef="U_USD">69698000</us-gaap:FairValueConcentrationOfRiskCashAndCashEquivalents>
    <us-gaap:FairValueConcentrationOfRiskCashAndCashEquivalents
      contextRef="C_8b56e0c7-22d7-4f97-bc7f-f3c1c34ac2a5"
      decimals="-3"
      id="F_36d5827d-cab4-425c-b80e-9537baf44c58"
      unitRef="U_USD">69698000</us-gaap:FairValueConcentrationOfRiskCashAndCashEquivalents>
    <us-gaap:FairValueConcentrationOfRiskCashAndCashEquivalents
      contextRef="C_859a4837-02fe-4595-8853-de8c56b1c468"
      decimals="-3"
      id="F_7066c364-ea14-44e4-84ad-a4513fba4f87"
      unitRef="U_USD">0</us-gaap:FairValueConcentrationOfRiskCashAndCashEquivalents>
    <us-gaap:FairValueConcentrationOfRiskCashAndCashEquivalents
      contextRef="C_4f2fa7fb-50cf-4ab7-a541-88b9de8c16cd"
      decimals="-3"
      id="F_61e9994e-2ac4-461b-bb18-71b4d81854cc"
      unitRef="U_USD">0</us-gaap:FairValueConcentrationOfRiskCashAndCashEquivalents>
    <us-gaap:MarketableSecurities
      contextRef="C_445d4a10-50d6-4fad-8ed4-556b6ce24ec6"
      decimals="-3"
      id="F_524e28de-1b13-4208-8eac-69613871242f"
      unitRef="U_USD">122980000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_35d9901f-2f43-4932-960b-edaffa307b8e"
      decimals="-3"
      id="F_f8fcf428-09da-4859-a0ce-f64b56d4f25f"
      unitRef="U_USD">0</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_da6d61f4-da45-4047-8849-7facd82c9bab"
      decimals="-3"
      id="F_66ebb087-669a-4390-92fd-917c3059e6cc"
      unitRef="U_USD">122980000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_1373ea03-27b7-4611-89c2-aedca10e502b"
      decimals="-3"
      id="F_2d746953-9262-4a3e-8cae-75e73d38244f"
      unitRef="U_USD">0</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_7235c0d6-d80c-4a20-a791-afd7ff2647e0"
      decimals="-3"
      id="F_8f1ab6b2-98a6-4f31-b9a1-330e78b2289c"
      unitRef="U_USD">126495000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_bab9baa6-70cc-470c-8e11-bb4b93099597"
      decimals="-3"
      id="F_b8ec27f8-1c07-4e2e-bc13-80a0e1308674"
      unitRef="U_USD">0</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_cabc47b3-0098-4429-acc8-8b363378e0b6"
      decimals="-3"
      id="F_0465d6f6-ba31-4445-9a06-6cb9d2cf1be1"
      unitRef="U_USD">126495000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_0732721d-acf1-480d-a569-2b3ce25dc4c8"
      decimals="-3"
      id="F_a9647447-35f7-431b-9f51-07cf4dc09489"
      unitRef="U_USD">0</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_31ea1ae9-69e0-48ac-9963-d48f9f1c7a0d"
      decimals="-3"
      id="F_40e86e59-4aa7-4ff2-b020-b4b6e2f02550"
      unitRef="U_USD">249475000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_7168fb48-4ee5-4fb1-9a24-58d8fea23470"
      decimals="-3"
      id="F_076555de-af51-4047-9bd7-5a0f0fce2e5a"
      unitRef="U_USD">0</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_dea229cd-0197-42d7-b781-d2cf1a9090ed"
      decimals="-3"
      id="F_2afb7f0b-4758-4bc6-91b3-6ce5e5576ef6"
      unitRef="U_USD">249475000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_c3062351-4e8a-468c-9ace-a5178560f024"
      decimals="-3"
      id="F_77af5557-4b8f-492f-9039-36e98392e800"
      unitRef="U_USD">0</us-gaap:MarketableSecurities>
    <us-gaap:AssetsFairValueAdjustment
      contextRef="C_31142ef9-0890-41ac-a5b5-d09b26dfd124"
      decimals="-3"
      id="F_673fbc68-73df-4248-af02-7e4850abacce"
      unitRef="U_USD">319173000</us-gaap:AssetsFairValueAdjustment>
    <us-gaap:AssetsFairValueAdjustment
      contextRef="C_b08ce2b8-ac16-4b53-b8cb-6aa4f4c5e677"
      decimals="-3"
      id="F_1405f91a-b1ff-48b9-81a3-61bb35288f34"
      unitRef="U_USD">69698000</us-gaap:AssetsFairValueAdjustment>
    <us-gaap:AssetsFairValueAdjustment
      contextRef="C_e15e6e13-7c17-4e72-95fd-e55ebe7fabb3"
      decimals="-3"
      id="F_43203c08-affa-4aae-bb26-54347edea474"
      unitRef="U_USD">249475000</us-gaap:AssetsFairValueAdjustment>
    <us-gaap:AssetsFairValueAdjustment
      contextRef="C_0f90cf19-a5f9-46f3-880e-0596d855590c"
      decimals="-3"
      id="F_00e8e035-c57b-49c6-9e7a-a75b53a1fa00"
      unitRef="U_USD">0</us-gaap:AssetsFairValueAdjustment>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_fc480d08-428f-45c2-b970-cfc06a3bef5f">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;3. Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following tables summarize the Company&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2019;s marketable securities (see below and Note 2) accounted for as available-for-sale securities (in thousands, except years):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:32.323%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.141%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.141%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.141%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.121%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.131%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="12" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Maturity &lt;br/&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less than one&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;107,324&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;223&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;107,547&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less than one&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45,215&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;137&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45,352&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1-2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,684&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,717&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;178,223&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;393&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;178,616&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:32%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="12" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Maturity &lt;br/&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less than one&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;77,990&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;78,197&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less than one&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,153&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;189&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1-2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44,547&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44,783&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1-2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,015&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;159&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,162&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;248,705&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;797&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;249,475&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents fair values and gross unrealized losses for those available-for-sale securities that were in an unrealized loss position, aggregated by category and the length of time that the securities have been in a continuous loss position (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:23.071%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.836%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.836%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.836%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.836%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.836%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.279%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.836%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="22" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Less than 12 months&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;12 months or longer&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,033&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,033&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,891&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,891&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,924&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,924&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025, there were no available-for-sale securities in an unrealized loss position.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The amortized cost and fair value of marketable securities excludes $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of accrued interest receivable as of December 31, 2025 and 2024, respectively. Accrued interest receivable is included in prepaid expenses and other current assets on the Company's balance sheets. The Company has not written off any accrued interest receivables for the years ended December 31, 2025 and 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:MarketableSecuritiesTextBlock
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_5b33dd3b-459b-4a66-8323-3169e667440f">&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following tables summarize the Company&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2019;s marketable securities (see below and Note 2) accounted for as available-for-sale securities (in thousands, except years):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:32.323%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.141%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.141%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.141%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.121%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.131%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="12" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Maturity &lt;br/&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less than one&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;107,324&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;223&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;107,547&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less than one&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45,215&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;137&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45,352&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1-2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,684&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,717&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;178,223&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;393&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;178,616&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="text-indent:9.067%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:32%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="12" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Maturity &lt;br/&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less than one&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;77,990&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;78,197&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less than one&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,153&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;189&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1-2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44,547&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44,783&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1-2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,015&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;159&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,162&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;248,705&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;797&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;249,475&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:23.071%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.836%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.836%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.836%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.836%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.836%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.279%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.836%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="22" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Less than 12 months&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;12 months or longer&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,033&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,033&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,891&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,891&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,924&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,924&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_ab8dd7ed-5d07-40f6-9887-243d8544fc7c"
      decimals="-3"
      id="F_9d59c4ed-7cc6-4a1f-9956-697a3e139593"
      unitRef="U_USD">107324000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_9631bb15-a89e-4277-b443-2488946a4125"
      decimals="-3"
      id="F_c6302e9b-524b-4382-922c-a340960564f9"
      unitRef="U_USD">223000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_9631bb15-a89e-4277-b443-2488946a4125"
      decimals="-3"
      id="F_b060e3be-e623-4903-b415-a551c65f420e"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_ab8dd7ed-5d07-40f6-9887-243d8544fc7c"
      decimals="-3"
      id="F_3919c37b-a10d-4329-98be-27e8ab04519f"
      unitRef="U_USD">107547000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_9e723f9e-f294-44a4-b7ba-1b0bfe9753cc"
      decimals="-3"
      id="F_632d4099-8b5a-4d2e-beb4-522e420741a1"
      unitRef="U_USD">45215000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_8ffa982e-10e5-4fab-99ed-6f19493d39e3"
      decimals="-3"
      id="F_9d8a5e55-149f-4fb3-bf86-95786517df02"
      unitRef="U_USD">137000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_8ffa982e-10e5-4fab-99ed-6f19493d39e3"
      decimals="-3"
      id="F_7edab796-34a1-4a28-bf6c-619b5edcabb9"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_9e723f9e-f294-44a4-b7ba-1b0bfe9753cc"
      decimals="-3"
      id="F_cb2ac512-7618-4ded-84a0-ec54ed77a69c"
      unitRef="U_USD">45352000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_6d93fb41-00d4-4bba-9d0f-e71f27a586ce"
      decimals="-3"
      id="F_d327483b-0425-4d2e-aed4-ac39998cdb07"
      unitRef="U_USD">25684000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_a3aa4fd7-a874-4bd2-a938-6252e0593cbe"
      decimals="-3"
      id="F_fce96d90-3450-40f1-a77f-528be3b77851"
      unitRef="U_USD">33000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_a3aa4fd7-a874-4bd2-a938-6252e0593cbe"
      decimals="-3"
      id="F_6d8a4184-56d7-476c-a690-9dbfc7af82d8"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_6d93fb41-00d4-4bba-9d0f-e71f27a586ce"
      decimals="-3"
      id="F_1803e64a-6bce-4dad-ab84-92b663cb79bf"
      unitRef="U_USD">25717000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_e8858fdf-0594-4f6c-8c72-3c96b1a9d4ac"
      unitRef="U_USD">178223000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="-3"
      id="F_d675d94a-5aac-44ae-ac63-585781d5bbee"
      unitRef="U_USD">393000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="-3"
      id="F_53eeb3b2-ba71-41dc-81e2-e36382e09dbd"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_b78d5a78-d89f-4be5-961f-9230d14eb6f8"
      unitRef="U_USD">178616000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_73360da3-36fa-405b-810f-ac396bf24bee"
      decimals="-3"
      id="F_de45c263-967a-4bde-914c-a5beac6643f3"
      unitRef="U_USD">77990000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_12bd91d1-7116-4439-9d77-a7650dbde2f7"
      decimals="-3"
      id="F_2d1b915b-60bf-47c7-b037-fd8c899f26b8"
      unitRef="U_USD">210000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_12bd91d1-7116-4439-9d77-a7650dbde2f7"
      decimals="-3"
      id="F_2cde5652-dfcd-4152-b338-bab4dcf77ba6"
      unitRef="U_USD">3000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_73360da3-36fa-405b-810f-ac396bf24bee"
      decimals="-3"
      id="F_c8a14078-b51a-4934-937b-ba7301c15272"
      unitRef="U_USD">78197000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_4b1febba-292b-4542-9c54-ea17a48a4fcd"
      decimals="-3"
      id="F_d2fc057d-baa3-478a-9457-0b2f7ee32d17"
      unitRef="U_USD">94153000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_c2661784-8ff1-4a9e-8a82-f75b049f70ad"
      decimals="-3"
      id="F_341abb84-51d2-412e-ae10-4776cfe02b4b"
      unitRef="U_USD">189000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_c2661784-8ff1-4a9e-8a82-f75b049f70ad"
      decimals="-3"
      id="F_17b4ebd2-89f2-47fa-b0d0-30e963c1c911"
      unitRef="U_USD">9000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_4b1febba-292b-4542-9c54-ea17a48a4fcd"
      decimals="-3"
      id="F_06fa9f16-3c45-4fea-9db8-90939bc11636"
      unitRef="U_USD">94333000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_885b4f15-9028-4e67-83a3-63a20100958e"
      decimals="-3"
      id="F_af18fad1-5f87-4fda-af5a-a337948d40ca"
      unitRef="U_USD">44547000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_95f923d9-c4c3-4d2a-b6b5-83207327a686"
      decimals="-3"
      id="F_60d2db30-0334-482e-9a54-6f4288b7baec"
      unitRef="U_USD">239000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_95f923d9-c4c3-4d2a-b6b5-83207327a686"
      decimals="-3"
      id="F_0073b45e-f460-4a74-9579-1cc343937804"
      unitRef="U_USD">3000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_885b4f15-9028-4e67-83a3-63a20100958e"
      decimals="-3"
      id="F_536e82b0-9b0d-4c34-86cd-6e5a82a1dc69"
      unitRef="U_USD">44783000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_730568c6-2cf1-41de-a80e-e6d97f16ba8c"
      decimals="-3"
      id="F_7ba887e7-5aed-4c4b-af6c-73670d050ef9"
      unitRef="U_USD">32015000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_a968be01-32a6-49ed-80ec-d5190256e424"
      decimals="-3"
      id="F_d82d1a5c-88c1-429f-bc82-5284f33b5d2f"
      unitRef="U_USD">159000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_a968be01-32a6-49ed-80ec-d5190256e424"
      decimals="-3"
      id="F_07551962-587e-4b15-8fb7-d99770d4c983"
      unitRef="U_USD">12000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_730568c6-2cf1-41de-a80e-e6d97f16ba8c"
      decimals="-3"
      id="F_f84546ac-36b8-4722-ac99-4260c85733f2"
      unitRef="U_USD">32162000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="-3"
      id="F_969fe764-20f0-4363-89f1-27c40bf0ea72"
      unitRef="U_USD">248705000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="-3"
      id="F_1dc5402f-fcb7-490d-ba99-c77bc846de3a"
      unitRef="U_USD">797000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="-3"
      id="F_f8f940c9-4688-42ae-a449-6c71dd6123f2"
      unitRef="U_USD">27000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="-3"
      id="F_d748a41f-115b-4270-98c5-41ab02625a9d"
      unitRef="U_USD">249475000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <tyra:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue
      contextRef="C_54f748e8-97d4-411e-9f01-5dd8ca0908ba"
      decimals="-3"
      id="F_e15745b2-4251-40b9-8701-50c66126c584"
      unitRef="U_USD">16033000</tyra:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue>
    <tyra:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAccumulatedLoss
      contextRef="C_54f748e8-97d4-411e-9f01-5dd8ca0908ba"
      decimals="-3"
      id="F_a51c43d7-d064-40ec-8610-27210b01844b"
      unitRef="U_USD">6000</tyra:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAccumulatedLoss>
    <tyra:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrGreaterFairValue
      contextRef="C_54f748e8-97d4-411e-9f01-5dd8ca0908ba"
      decimals="-3"
      id="F_4ac0dd9d-10cc-44f2-bc47-9cbd58d8d25b"
      unitRef="U_USD">0</tyra:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrGreaterFairValue>
    <tyra:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAccumulatedLoss
      contextRef="C_54f748e8-97d4-411e-9f01-5dd8ca0908ba"
      decimals="-3"
      id="F_a3abc9c3-11c3-49f0-bd89-647547b72c2b"
      unitRef="U_USD">0</tyra:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAccumulatedLoss>
    <us-gaap:FairValueOptionCreditRiskGainsLossesOnAssets
      contextRef="C_d60e36b5-9479-436f-8d6e-500af75adcec"
      decimals="-3"
      id="F_5fcc4041-9731-4a80-a6bd-3ab59d73838e"
      unitRef="U_USD">16033000</us-gaap:FairValueOptionCreditRiskGainsLossesOnAssets>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_54f748e8-97d4-411e-9f01-5dd8ca0908ba"
      decimals="-3"
      id="F_bcde3a51-d7f2-475f-9495-f0f3b5c03405"
      unitRef="U_USD">6000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <tyra:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue
      contextRef="C_4a9d47d3-2b9a-48d7-83f8-6532afecf992"
      decimals="-3"
      id="F_5e243132-cd31-4205-9196-ecbd4d29980e"
      unitRef="U_USD">9891000</tyra:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue>
    <tyra:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAccumulatedLoss
      contextRef="C_4a9d47d3-2b9a-48d7-83f8-6532afecf992"
      decimals="-3"
      id="F_1abd8c9c-0213-4266-a1ff-8b4b9e96c4d3"
      unitRef="U_USD">21000</tyra:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAccumulatedLoss>
    <tyra:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrGreaterFairValue
      contextRef="C_4a9d47d3-2b9a-48d7-83f8-6532afecf992"
      decimals="-3"
      id="F_85bd6e37-82af-41ec-97bd-de8c2b0e829a"
      unitRef="U_USD">0</tyra:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrGreaterFairValue>
    <tyra:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAccumulatedLoss
      contextRef="C_4a9d47d3-2b9a-48d7-83f8-6532afecf992"
      decimals="-3"
      id="F_713d4141-3abf-4736-937c-62613a0fe4c0"
      unitRef="U_USD">0</tyra:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAccumulatedLoss>
    <us-gaap:FairValueOptionCreditRiskGainsLossesOnAssets
      contextRef="C_b90df891-3d95-47b5-b447-6bd47c401d88"
      decimals="-3"
      id="F_46fe91b4-f321-4393-a210-82118d5b2334"
      unitRef="U_USD">9891000</us-gaap:FairValueOptionCreditRiskGainsLossesOnAssets>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_4a9d47d3-2b9a-48d7-83f8-6532afecf992"
      decimals="-3"
      id="F_42c5dfdd-7a65-4a86-9ee1-e09756a7b0e4"
      unitRef="U_USD">21000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <tyra:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="-3"
      id="F_6517aff2-9205-4f52-9b2c-17f0949afd9b"
      unitRef="U_USD">25924000</tyra:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsFairValue>
    <tyra:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAccumulatedLoss
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="-3"
      id="F_ee8f6a1a-df86-4bf9-9dd5-6ebe9fdf5077"
      unitRef="U_USD">27000</tyra:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsAccumulatedLoss>
    <tyra:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrGreaterFairValue
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="-3"
      id="F_29b6716c-5dd0-4ea7-95b6-081a44d141aa"
      unitRef="U_USD">0</tyra:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrGreaterFairValue>
    <tyra:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAccumulatedLoss
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="-3"
      id="F_1c4869c0-02c8-499c-b8b7-eb12192cd4bd"
      unitRef="U_USD">0</tyra:HeldToMaturitySecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerAccumulatedLoss>
    <us-gaap:FairValueOptionCreditRiskGainsLossesOnAssets
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="-3"
      id="F_d21148d3-7d04-4995-8eee-cb68a3473475"
      unitRef="U_USD">25924000</us-gaap:FairValueOptionCreditRiskGainsLossesOnAssets>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_9214ca85-3ee3-4eff-8c44-b31e149ef697"
      unitRef="U_USD">27000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <tyra:AccruedInterestAvailableForSaleSecurities
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-5"
      id="F_70be79e0-c2c2-4ada-8224-f4ff81701eaf"
      unitRef="U_USD">1900000</tyra:AccruedInterestAvailableForSaleSecurities>
    <tyra:AccruedInterestAvailableForSaleSecurities
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="-5"
      id="F_1ce27c6f-5181-4a67-b270-73aa2f848315"
      unitRef="U_USD">2000000</tyra:AccruedInterestAvailableForSaleSecurities>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_ae1a8854-0e16-449c-9e57-c9dbd5353e26">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;4. Accrued Expenses and Other Current Liabilities&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued expenses and other current liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:67.313%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued payroll and other employee benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,533&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,451&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,840&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,612&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued legal and professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;316&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued other general and administrative fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;755&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;233&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,444&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,592&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_94d6d6d7-d9d7-4d94-8780-bfc2a23fc291">&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued expenses and other current liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:67.313%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued payroll and other employee benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,533&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,451&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,840&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,612&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued legal and professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;316&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued other general and administrative fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;755&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;233&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,444&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,592&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedSalariesCurrent
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_3dfb1692-a18a-4f07-b92f-25adfd390b90"
      unitRef="U_USD">5533000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="-3"
      id="F_1f74d68b-ff2c-424f-a67b-26f14b82e4f3"
      unitRef="U_USD">6451000</us-gaap:AccruedSalariesCurrent>
    <tyra:AccruedResearchAndDevelopment
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_87e65705-49ec-49d1-9c48-4695c6db3236"
      unitRef="U_USD">9840000</tyra:AccruedResearchAndDevelopment>
    <tyra:AccruedResearchAndDevelopment
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="-3"
      id="F_726f6e6c-800c-45a4-abd4-a27069d9b856"
      unitRef="U_USD">6612000</tyra:AccruedResearchAndDevelopment>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_b83ec5df-7253-44e8-b771-19063fde190d"
      unitRef="U_USD">316000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="-3"
      id="F_492967d4-764f-46bd-813e-cb81effa5c28"
      unitRef="U_USD">296000</us-gaap:AccruedProfessionalFeesCurrent>
    <tyra:AccruedOtherGeneralAndAdministrativeFee
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_ac828282-1344-41f1-8af7-4731ae633e5d"
      unitRef="U_USD">755000</tyra:AccruedOtherGeneralAndAdministrativeFee>
    <tyra:AccruedOtherGeneralAndAdministrativeFee
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="-3"
      id="F_b40bd27b-1920-4682-9880-6fbda7cb1f2a"
      unitRef="U_USD">233000</tyra:AccruedOtherGeneralAndAdministrativeFee>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_7978d06b-1c19-4b6b-9ae0-76dde9fcd5dc"
      unitRef="U_USD">16444000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="-3"
      id="F_4cad5219-2e50-4e43-9fbb-ceebf0d903a2"
      unitRef="U_USD">13592000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_b8dff0a0-6875-4842-bcd6-820835acb9b2">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;5. Stockholders&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Equity&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Common stock reserved for future issuance consisted of the following:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:67.313%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.323%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.323%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Common stock options granted and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,617,445&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,462,129&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shares available for future issuance under the 2021&lt;br/&gt;&#160;&#160;&#160;Incentive Award Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,528,992&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,051,588&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shares available for future issuance under the &lt;br/&gt;&#160;&#160;&#160;2021 Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,951,705&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,491,195&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Pre-funded warrants issued and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,381,950&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,382,187&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total common stock reserved for future issuance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,480,092&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,387,099&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On October 3, 2022, the Company entered into an ATM Sales Agreement (the 2022 Sales Agreement) with Virtu Americas LLC (the 2022 Agent), under which the Company could have, from time to time, sold shares of its common stock having an aggregate offering price of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;150.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, in &#x201c;at the market&#x201d; offerings through the 2022 Sales Agent. The 2022 Agent would have received a commission from the Company of up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the gross proceeds of any shares of common stock sold under the 2022 Sales Agreement. No shares of common stock were issued and sold pursuant to the 2022 Sales Agreement. The Company terminated the 2022 Sales Agreement in May 2025.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On May 8, 2025, the Company entered into a Sales Agreement (the 2025 Sales Agreement)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; with TD Securities (USA) LLC (the 2025 Sales Agent), under which the Company may, from time to time, sell shares of its common stock having an aggregate offering price of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;150.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, in &#x201c;at the market&#x201d; offerings through the 2025 Sales Agent. Sales of the shares of common stock, if any, will be made at prevailing market prices at the time of sale, or as otherwise agreed with the 2025 Sales Agent. The 2025 Sales Agent will receive a commission from the Company of up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the gross proceeds of any shares of common stock sold under the 2025 Sales Agreement. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025, no shares of common stock had been issued and sold pursuant to the 2025 Sales Agreement.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On February 1, 2024, the Company entered into a securities purchase agreement for a private placement of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;9,286,023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Company's common stock at a price of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;13.01&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share (the 2024 Private Placement). The 2024 Private Placement also included pre-funded warrants (the 2024 Pre-Funded Warrants) to purchase an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;6,087,230&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock at a purchase price of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;13.009&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per pre-funded warrant. Each pre-funded warrant has an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share of common stock, is immediately exercisable on the date of issuance and will not expire. The 2024 Private Placement closed on February 6, 2024 and the Company received gross proceeds of approximately &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;200.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, before deducting offering expenses of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In connection with the 2024 Private Placement, the Company issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;4,780,846&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock and pre-funded warrants to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;2,243,737&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock to related parties, resulting in aggregate gross proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;91.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On March 19, 2024, the Company filed a registration statement on Form S-3 with the SEC registering the resale of the shares of common stock issued, or underlying the pre-funded warrants issued, in the 2024 Private Placement. The 2024 Pre-funded Warrants did not meet the characteristics of a liability or a derivative and are classified within stockholders&#x2019; equity.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On October 18, 2024, the Company entered into an exchange agreement with certain of the Company&#x2019;s stockholders, who were related parties to the Company at the time of the exchange. Pursuant to the exchange agreement, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;3,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock were exchanged for pre-funded warrants to acquire an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;3,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock (each of such pre-funded warrants an Exchange Warrant and collectively the Exchange Warrants, and such exchanges of common stock for Exchange Warrants collectively the Exchange). Each Exchange Warrant has an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share of common stock, is immediately exercisable on the date of issuance and will not expire. No cash was exchanged related to the transaction. The Exchange closed on October 22, 2024. The Exchange Warrants did not meet the characteristics of a liability or a derivative and are classified within stockholders&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2019; equity.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the year ended December 31, 2025, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;2,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of the Exchange Warrants and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;237&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of the 2024 Pre-Funded Warrants were exercised in cashless transactions, which resulted in an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;2,000,069&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock being issued. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, a total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,381,950&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; pre-funded warrants remained available for exercise, including &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Exchange Warrants and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,381,950&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; 2024 Pre-Funded Warrants.&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_34850273-689e-4047-a4f1-9d8af9160c91">&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Common stock reserved for future issuance consisted of the following:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:67.313%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.323%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.323%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Common stock options granted and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,617,445&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,462,129&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shares available for future issuance under the 2021&lt;br/&gt;&#160;&#160;&#160;Incentive Award Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,528,992&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,051,588&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shares available for future issuance under the &lt;br/&gt;&#160;&#160;&#160;2021 Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,951,705&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,491,195&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Pre-funded warrants issued and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,381,950&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,382,187&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total common stock reserved for future issuance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,480,092&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,387,099&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock>
    <tyra:CommonStockOptionsGrantedAndOutstanding
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="0"
      id="F_6e952ede-240f-48e0-ba50-f0aa2052bb92"
      unitRef="U_shares">13617445</tyra:CommonStockOptionsGrantedAndOutstanding>
    <tyra:CommonStockOptionsGrantedAndOutstanding
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="0"
      id="F_a509c9c9-3211-4b22-a143-2db14d675714"
      unitRef="U_shares">10462129</tyra:CommonStockOptionsGrantedAndOutstanding>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_3df03dca-0dc7-4c5f-a85f-71adcbb157d4"
      decimals="0"
      id="F_8e45a8e5-9fe3-47c9-b2bb-9e2cb7a5af29"
      unitRef="U_shares">1528992</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_c95fc3d9-d94a-493b-a598-ac4bb3b1b07c"
      decimals="0"
      id="F_a11c53a9-dff1-41a3-90aa-32ac1044d3d2"
      unitRef="U_shares">3051588</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <tyra:SharesAvailableForFutureIssuance
      contextRef="C_af11564f-7c3c-4fbd-944d-2526428166a5"
      decimals="0"
      id="F_0b066953-f440-49e3-a2c5-7cb7dcd4ba87"
      unitRef="U_shares">1951705</tyra:SharesAvailableForFutureIssuance>
    <tyra:SharesAvailableForFutureIssuance
      contextRef="C_cc72b396-646c-4763-93d2-cd1c738569ec"
      decimals="0"
      id="F_f2896396-f87f-4276-bae3-8192b5d4b4e4"
      unitRef="U_shares">1491195</tyra:SharesAvailableForFutureIssuance>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="0"
      id="F_84afd8e1-6e70-4da3-8fcd-606ebcbe0e93"
      unitRef="U_shares">6381950</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="0"
      id="F_7e73e077-738b-4122-837e-8677ddc4ac55"
      unitRef="U_shares">8382187</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="0"
      id="F_758150da-1e93-4b62-a96a-f4607b6e4ee8"
      unitRef="U_shares">23480092</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="0"
      id="F_20db3a6a-5552-45eb-8103-934a0b022fc9"
      unitRef="U_shares">23387099</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <tyra:AggregateCommonStockOfferingPrice
      contextRef="C_3ddda0f3-7839-43d8-b02a-428842db25ae"
      decimals="-5"
      id="F_6b3eddb7-3c54-479c-9d25-d4a2a8d1563c"
      unitRef="U_USD">150000000</tyra:AggregateCommonStockOfferingPrice>
    <tyra:CommissionForAgentOnSales
      contextRef="C_718b96d9-785c-40ed-a094-d99e0b9a8377"
      decimals="3"
      id="F_52c38274-ecc5-48c4-b5d6-2513f733ddcb"
      unitRef="U_pure">0.03</tyra:CommissionForAgentOnSales>
    <tyra:AggregateCommonStockOfferingPrice
      contextRef="C_27b488c8-414a-4614-80fa-db1682dc7f77"
      decimals="-5"
      id="F_4bdaea02-7284-4c13-8039-d1d7ef3a41fd"
      unitRef="U_USD">150000000</tyra:AggregateCommonStockOfferingPrice>
    <tyra:CommissionForAgentOnSales
      contextRef="C_bc04b846-a20d-4016-ac01-a4c1c095b08c"
      decimals="3"
      id="F_fdb01282-0224-46bc-881a-e9c36f2ee467"
      unitRef="U_pure">0.03</tyra:CommissionForAgentOnSales>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_a2ec13b8-8e1d-47c2-8e4f-4c5969096b03"
      decimals="0"
      id="F_5dbc52e9-98e2-4d12-9402-ace50585b2c0"
      unitRef="U_shares">9286023</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_ab0a8b53-9e09-43e5-aaf1-65d9f9db8341"
      decimals="2"
      id="F_7a84f548-329f-4077-86e1-4dc361055e7c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">13.01</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_7fed64a7-b51b-4be1-a469-9f7679712854"
      decimals="0"
      id="F_8eaec984-ba59-4c7d-95ce-538d4aa7e9f5"
      unitRef="U_shares">6087230</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <tyra:WarrantsIssuedPricePerShare
      contextRef="C_7fed64a7-b51b-4be1-a469-9f7679712854"
      decimals="3"
      id="F_8ac9aeaf-e6d6-4d66-99cf-7e448e4a3a14"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">13.009</tyra:WarrantsIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_e120fb96-8ac9-4670-bbd9-1db2900be3f3"
      decimals="3"
      id="F_2a5a02ea-3295-4504-9021-68eb3b2c51e5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_31bd97f3-271f-4ee8-8a62-0213b666d430"
      decimals="-5"
      id="F_33d1c457-a8e9-4d83-8ad1-4d5afe350de4"
      unitRef="U_USD">200000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <tyra:OfferingExpenses
      contextRef="C_31bd97f3-271f-4ee8-8a62-0213b666d430"
      decimals="-5"
      id="F_4c00b93b-2b7f-41ea-acab-340bd58f5ced"
      unitRef="U_USD">400000</tyra:OfferingExpenses>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_e120fb96-8ac9-4670-bbd9-1db2900be3f3"
      decimals="0"
      id="F_7ff43eb6-ad75-4255-b401-13dda245b30f"
      unitRef="U_shares">4780846</us-gaap:CommonStockSharesIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_e120fb96-8ac9-4670-bbd9-1db2900be3f3"
      decimals="0"
      id="F_1e012b37-9d62-43b8-9128-a2fb0b16db43"
      unitRef="U_shares">2243737</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="C_31bd97f3-271f-4ee8-8a62-0213b666d430"
      decimals="-5"
      id="F_f7d005e3-01fc-4729-aec5-b9ebb64c078c"
      unitRef="U_USD">91400000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <tyra:ExchangeOfCommonStockForPre-FundedWarrantsShares
      contextRef="C_6b1f5ee9-14ee-4a7c-af93-d46a982aa30b"
      decimals="0"
      id="F_928f221e-2152-49f8-b9ec-aeb841432781"
      unitRef="U_shares">3000000</tyra:ExchangeOfCommonStockForPre-FundedWarrantsShares>
    <tyra:ExchangeOfCommonStockForPre-FundedWarrantsShares
      contextRef="C_f04ad497-713a-4578-b5ab-98ae7619c3da"
      decimals="0"
      id="F_e5a2b0af-965c-45d9-bc5e-258ef642c5aa"
      unitRef="U_shares">3000000</tyra:ExchangeOfCommonStockForPre-FundedWarrantsShares>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_9b41307d-a228-4022-aec0-907dd0345fdf"
      decimals="3"
      id="F_a34005d8-a9dc-499d-8f7f-6c7dce4cfb9f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <tyra:ExerciseOfPre-FundedWarrants
      contextRef="C_96648163-51bf-41fb-8618-dc87cf09bd07"
      decimals="0"
      id="F_30d18660-1d9d-4e58-b9c7-e62ef2214013"
      unitRef="U_shares">2000000</tyra:ExerciseOfPre-FundedWarrants>
    <tyra:ExerciseOfPre-FundedWarrants
      contextRef="C_a8ff3708-7767-47f5-93fc-4c5992d13af3"
      decimals="0"
      id="F_76e118ef-4470-403e-b103-d2029fbc720c"
      unitRef="U_shares">237</tyra:ExerciseOfPre-FundedWarrants>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_4892d6b0-f063-48f2-b508-738cf390c782"
      decimals="0"
      id="F_57095817-d811-448c-a497-d096f1112dd9"
      unitRef="U_shares">2000069</us-gaap:CommonStockSharesIssued>
    <tyra:Pre-FundedWarrantsAvailableForExercise
      contextRef="C_96648163-51bf-41fb-8618-dc87cf09bd07"
      decimals="0"
      id="F_0c8ca523-7ba9-4a97-8e41-1722cdab5709"
      unitRef="U_shares">6381950</tyra:Pre-FundedWarrantsAvailableForExercise>
    <tyra:WarrantsAvailableForExercise
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="0"
      id="F_3a70f7ef-3dad-4a8e-852e-453bc5bc00a7"
      unitRef="U_shares">1000000</tyra:WarrantsAvailableForExercise>
    <tyra:Pre-FundedWarrantsAvailableForExercise
      contextRef="C_deb06a64-1ca6-42a0-9e9d-5e5fc523e1b1"
      decimals="0"
      id="F_c71f76a0-8458-4497-8306-22e280a5d6e7"
      unitRef="U_shares">5381950</tyra:Pre-FundedWarrantsAvailableForExercise>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_fae409ca-a345-4108-bd00-24955de4682d">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;6. Equity Incentive Plans and Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;2021 Incentive Award Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In September 2021, the Company&#x2019;s Board of Directors adopted, and its stockholders approved, the 2021 Incentive Award Plan (the 2021 Plan). Upon the adoption of the 2021 Plan, the Company restricted the grant of future equity awards under the 2020 Equity Incentive Plan (the 2020 Plan).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The 2021 Plan provides for the grants of stock options and other equity-based awards to employees, non-employee directors, and consultants of the Company. Shares that expire, terminate or are cancelled under the 2020 Plan are added back to the 2021 Plan share reserve. In addition, the number of shares of the Company&#x2019;s common stock available for issuance under the 2021 Plan automatically increases on the first day of each fiscal year, beginning with the Company&#x2019;s 2022 fiscal year, in an amount equal to the lesser of (1) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the outstanding shares of the Company&#x2019;s common stock on the last day of the immediately preceding fiscal year, or (2) such smaller amount as determined by the Company&#x2019;s Board of Directors. The Company issues new shares of common stock upon exercise of options. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,528,992&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares were available for future grant under the 2021 Plan.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A summary of the Company&#x2019;s stock option activity for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 was as follows (in thousands, except share and per share data and years):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:47.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.420000000000002%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.9%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.940000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-Average&lt;br/&gt;Exercise&lt;br/&gt;Price per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,462,129&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,798&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,029,190&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.08&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;904,993&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.72&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited and expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;968,881&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16.31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,617,445&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.58&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;186,669&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercisable at December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,300,582&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.8&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93,903&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested and expected to vest as of December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,617,445&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.58&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;186,669&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In September 2021, the Company&#x2019;s Board of Directors adopted, and its stockholders approved, the 2021 Employee Stock Purchase Plan (ESPP). &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The ESPP permits eligible employees who elect to participate in an offering under the ESPP to have up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of their eligible earnings withheld, subject to certain limitations, to purchase shares of common stock pursuant to the ESPP. The price of common stock purchased under the ESPP is equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the lower of the fair market value of the common stock at the commencement date of each offering period or the relevant date of purchase. &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,951,705&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares available for future purchase under the ESPP.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company estimated the fair value of stock options using the Black-Scholes valuation model. The Company accounts for forfeitures of options when they occur. Previously recognized compensation expense for an unvested award is reversed in the period that the award is forfeited.&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The fair value of stock options was estimated using the following assumptions: &lt;/span&gt;&lt;/span&gt;&lt;span style=""&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:58.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.7%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:18.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.7%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:18.54%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free rate of interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#ffffff;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.1&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected stock price volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;95.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;87.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#ffffff;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation expense recognized for all equity awards, including stock options and ESPP, has been reported in the statements of operations and comprehensive loss as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:56.031%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.863999999999997%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.44%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.863999999999997%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,749&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,291&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,257&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,510&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,006&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,801&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The weighted-average grant date fair value of options granted (excluding modified options) for the years ended December 31, 2025 and 2024 were &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.05&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.95&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the year ended December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in additional stock-based compensation expense recorded within research and development expenses, in connection with the modification and acceleration of stock options held by a former executive.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the years ended December 31, 2025 and 2024, forfeitures resulting in the reversal of compensation expenses were immaterial.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025, the unrecognized compensation cost related to options was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, and is expected to be recognized as expense over a weighted-average period of approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.6&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025, the unrecognized compensation cost related to ESPP was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, and is expected to be recognized as expense over a weighted-average period of approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <tyra:StockholdersEquityIncreaseDecreaseInCommonStockPercent
      contextRef="C_dfcfe63e-d4f8-4148-85c4-ec750c1d7200"
      decimals="2"
      id="F_c5e06aa3-d95a-406f-b3f2-0f11e2346ab4"
      unitRef="U_pure">0.05</tyra:StockholdersEquityIncreaseDecreaseInCommonStockPercent>
    <tyra:SharesReservedForFutureIssuance
      contextRef="C_dfcfe63e-d4f8-4148-85c4-ec750c1d7200"
      decimals="0"
      id="F_95ee0a0f-c394-42da-b56c-ea46ff91ee7d"
      unitRef="U_shares">1528992</tyra:SharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_2c073389-a3af-49fc-a4d1-e28717515910">&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A summary of the Company&#x2019;s stock option activity for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 was as follows (in thousands, except share and per share data and years):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:47.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.420000000000002%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:9.9%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.940000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-Average&lt;br/&gt;Exercise&lt;br/&gt;Price per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,462,129&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,798&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,029,190&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.08&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;904,993&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.72&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited and expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;968,881&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16.31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,617,445&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.58&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;186,669&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercisable at December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,300,582&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.8&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93,903&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested and expected to vest as of December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,617,445&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.58&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;186,669&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="INF"
      id="F_6a0fba28-ba10-42a9-86f4-c93a7b3b671e"
      unitRef="U_shares">10462129</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="2"
      id="F_6e491b42-f574-49a1-b16a-e1021bbbf07b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">13.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      id="F_8efcaa31-4f72-4cde-bccf-c2d82da23a97">P7Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="-3"
      id="F_b91db41f-588d-4d00-94b9-03347c8a3375"
      unitRef="U_USD">33798000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <tyra:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriod
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="0"
      id="F_c6050649-36cc-4668-916d-2d547a0b3a82"
      unitRef="U_shares">5029190</tyra:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="2"
      id="F_93bdef09-c044-4f88-982f-38ecfc9259f7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.08</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="0"
      id="F_e98505d9-02a9-44dc-926d-19b84905676f"
      unitRef="U_shares">904993</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="2"
      id="F_04e8c741-25b9-4a3f-9cf5-f501873e7ea4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.72</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="0"
      id="F_a0608d0f-f0e2-40a6-9811-0227eec9a31c"
      unitRef="U_shares">968881</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="2"
      id="F_0f377970-1a8c-4e62-9da9-aafcf96b5029"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">16.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="INF"
      id="F_8eae0f86-2c18-4f50-8ca4-37d7acb236be"
      unitRef="U_shares">13617445</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="2"
      id="F_cd95e922-1703-450b-a1a9-8192624553dc"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_32ce05e0-4505-4df7-895c-d72ad2034358">P8Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_397b66ff-dcef-4ad2-b022-5f3233cb1b9f"
      unitRef="U_USD">186669000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="INF"
      id="F_fa0eef88-272d-44b7-935e-6e66c72cec51"
      unitRef="U_shares">6300582</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="2"
      id="F_6263e299-0483-4e8a-9df8-8a2d0d31a546"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_b5833592-7640-4bc5-865f-44fcf826c133">P6Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_e8e0e3c2-9daf-46d7-88af-694bd73efb69"
      unitRef="U_USD">93903000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="INF"
      id="F_9b19f224-e4b3-4285-a2c1-bf3812e2a944"
      unitRef="U_shares">13617445</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="2"
      id="F_5cf9015c-a7e5-4ef0-954d-89eb280d54e4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_f30f258b-f748-4b40-b818-6fd5b40791b3">P8Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_86147302-0c10-4f28-a075-0b7afaf229ef"
      unitRef="U_USD">186669000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <tyra:EmployeeStockPurchasePlanDescription
      contextRef="C_8d8b0049-b397-46d9-9515-7b644360184f"
      id="F_8fd42bda-4986-48e6-891b-4ebb819a4973">The ESPP permits eligible employees who elect to participate in an offering under the ESPP to have up to 15% of their eligible earnings withheld, subject to certain limitations, to purchase shares of common stock pursuant to the ESPP. The price of common stock purchased under the ESPP is equal to 85% of the lower of the fair market value of the common stock at the commencement date of each offering period or the relevant date of purchase. </tyra:EmployeeStockPurchasePlanDescription>
    <tyra:PurchaseOfCommonStockThroughPayrollDeduction
      contextRef="C_8d8b0049-b397-46d9-9515-7b644360184f"
      decimals="2"
      id="F_524c1a88-3759-480a-aa5e-4461bff7c193"
      unitRef="U_pure">0.15</tyra:PurchaseOfCommonStockThroughPayrollDeduction>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_8d8b0049-b397-46d9-9515-7b644360184f"
      decimals="2"
      id="F_04221690-8a3b-4047-967d-a3b759be57a0"
      unitRef="U_pure">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_e212c6e1-9c59-4476-81a3-9bdba80a582e"
      decimals="0"
      id="F_d8355f13-e139-4673-a429-6ff0d58d236a"
      unitRef="U_shares">1951705</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_3f979ea7-aca8-4386-9927-8fbbefed0b4d">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The fair value of stock options was estimated using the following assumptions: &lt;/span&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:58.14%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.7%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:18.92%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.7%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:18.54%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free rate of interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#ffffff;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.1&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected stock price volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;95.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#cff0fc;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;87.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="background-color:#ffffff;padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_692e28c5-456f-441d-81a6-b3281646a0af"
      decimals="3"
      id="F_294322c6-cd91-4a6e-93a5-0bed5a290407"
      unitRef="U_pure">0.038</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_3bfbb795-7b7e-4213-b6a6-ea14b283ed4f"
      decimals="3"
      id="F_d67412ff-1ce6-4a43-bb58-0e79c7f5843c"
      unitRef="U_pure">0.044</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_a9af0aa2-ccc8-48f7-89f5-e604bc391411"
      decimals="3"
      id="F_980845c9-6115-4f58-bcfa-6504e03389b3"
      unitRef="U_pure">0.035</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_2f77ccfa-5653-4673-b977-01323fe14f9a"
      decimals="3"
      id="F_a2c83ba7-ed89-465d-92ee-b6b2d112af91"
      unitRef="U_pure">0.046</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_692e28c5-456f-441d-81a6-b3281646a0af"
      id="F_5429a522-f38c-4926-8bcf-75fc73ca2d87">P5Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_3bfbb795-7b7e-4213-b6a6-ea14b283ed4f"
      id="F_49d7c068-05a8-420f-9aa5-411bc885b1ec">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_a9af0aa2-ccc8-48f7-89f5-e604bc391411"
      id="F_97e14788-abd3-4c68-a276-02b1f27f1c48">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_2f77ccfa-5653-4673-b977-01323fe14f9a"
      id="F_e707bb89-7fd9-44f8-9cb2-fe73b3c81cd1">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_692e28c5-456f-441d-81a6-b3281646a0af"
      decimals="3"
      id="F_3a27cff2-ba5f-4a12-8e4a-9b862a58cc58"
      unitRef="U_pure">0.848</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_3bfbb795-7b7e-4213-b6a6-ea14b283ed4f"
      decimals="3"
      id="F_5a619174-6cf1-46f7-962d-7647665836ec"
      unitRef="U_pure">0.954</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_a9af0aa2-ccc8-48f7-89f5-e604bc391411"
      decimals="3"
      id="F_eea9c2e7-bf91-4b72-ab4b-e959636892ba"
      unitRef="U_pure">0.878</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_2f77ccfa-5653-4673-b977-01323fe14f9a"
      decimals="3"
      id="F_1232cf32-7a29-4f0c-92ed-bc81a91de761"
      unitRef="U_pure">0.987</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="2"
      id="F_d968a509-e639-4dbe-8e0a-7e0834bd8749"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="2"
      id="F_12dafda1-4267-4acf-9759-e45864df2d8a"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_12420d4d-d2c4-4a9b-8fa5-aa2cbd506279">&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation expense recognized for all equity awards, including stock options and ESPP, has been reported in the statements of operations and comprehensive loss as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:56.031%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.863999999999997%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.44%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:17.863999999999997%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,749&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,291&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,257&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,510&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,006&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,801&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_04b24ac9-453f-4621-9f44-543a1e069772"
      decimals="-3"
      id="F_713bc725-34b1-46d0-b5bf-b1b571a4b423"
      unitRef="U_USD">15749000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_7f967b5d-c00a-4062-a27e-e4707a82ef23"
      decimals="-3"
      id="F_f28325e2-7da7-4117-baef-a26628fd213b"
      unitRef="U_USD">14291000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_8e43d91f-24cf-4fdb-b79e-137f0345b2bb"
      decimals="-3"
      id="F_59ba63f3-de5c-4c66-ba61-c36c7760c400"
      unitRef="U_USD">12257000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_c857b1ec-ca11-4482-b531-9da5ac07706d"
      decimals="-3"
      id="F_393b8aaf-054d-48ed-907a-c75dc3edba0c"
      unitRef="U_USD">8510000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="-3"
      id="F_822c20ae-133f-47e4-8904-6940b2f94b21"
      unitRef="U_USD">28006000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="-3"
      id="F_2fd27fbb-d721-4515-8e56-d43af59d8123"
      unitRef="U_USD">22801000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_356fc121-7b99-4486-a3fc-2e281fdbe579"
      decimals="2"
      id="F_56ffc575-5b8f-4e9f-a16f-c6542f0a268c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_00649a27-87e2-4280-9938-2abad92658ac"
      decimals="2"
      id="F_d2f7c19e-7948-453b-9ca1-10f9d35e638a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="-5"
      id="F_35c9d6c9-99e4-4ddd-b54e-1417a8e053f0"
      unitRef="U_USD">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-5"
      id="F_061e984a-d3b1-4c68-82f0-1dd6344712f4"
      unitRef="U_USD">75800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_fe84068b-76b2-4038-93f8-aab8465be417">P2Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_aea32a63-e986-417a-9465-dd9fe57915c7"
      decimals="-5"
      id="F_5c4153bf-77d1-4118-812f-3ff828d54803"
      unitRef="U_USD">600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_6aa70afb-c483-4af1-aab6-5e31327063dc"
      id="F_470ae42b-8ad5-4468-afcf-97e6c9956488">P1Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_ee412665-cca5-496c-a688-df15813da750">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;7. Net Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table sets forth the computation of the basic and diluted net loss per share (in thousands, except share and per share amounts):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:67.313%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;119,947&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;86,481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average common shares outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59,602,328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57,250,061&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: weighted-average unvested common stock issued upon early exercise of common stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,315&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average shares used to compute net loss per common share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59,602,328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57,217,746&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.01&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Shares issuable pursuant to the 2024 Pre-Funded Warrants and the Exchange Warrants are included in the calculation of weighted-average shares of common stock outstanding, both basic and diluted, for the years ended December 31, 2025 and 2024. These warrants are exercisable at any time for nominal consideration, and therefore, the shares thereunder are considered outstanding for the purpose of calculating basic and diluted net loss per share.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because their inclusion would be anti-dilutive.&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:67.313%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.323%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.323%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,617,445&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,462,129&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unvested common stock upon early exercise of stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,317&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Estimated shares purchasable under the ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,761&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,280&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,645,206&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,480,726&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_ad2e2c55-4eae-4044-a814-2efa2fe54a04">&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table sets forth the computation of the basic and diluted net loss per share (in thousands, except share and per share amounts):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:67.313%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;119,947&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;86,481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average common shares outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59,602,328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57,250,061&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: weighted-average unvested common stock issued upon early exercise of common stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,315&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average shares used to compute net loss per common share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59,602,328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57,217,746&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.01&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="-3"
      id="F_8679b378-db2c-46d8-bae4-05d82099833b"
      unitRef="U_USD">-119947000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="-3"
      id="F_53d30aa0-3f53-4f4d-a0b3-1d961d510380"
      unitRef="U_USD">-86481000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageBasicSharesOutstandingProForma
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="INF"
      id="F_ac22948f-ff37-4285-8861-1a2921d8d05d"
      unitRef="U_shares">59602328</us-gaap:WeightedAverageBasicSharesOutstandingProForma>
    <us-gaap:WeightedAverageBasicSharesOutstandingProForma
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="INF"
      id="F_1a590935-e221-4b55-b2a5-50b108f78173"
      unitRef="U_shares">57250061</us-gaap:WeightedAverageBasicSharesOutstandingProForma>
    <tyra:WeightedAverageUnvestedCommonStockIssuedUponExerciseOfCommonStockOptions
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="INF"
      id="F_e472048c-1f41-48e2-b085-2116f9dbbc9a"
      unitRef="U_shares">0</tyra:WeightedAverageUnvestedCommonStockIssuedUponExerciseOfCommonStockOptions>
    <tyra:WeightedAverageUnvestedCommonStockIssuedUponExerciseOfCommonStockOptions
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="INF"
      id="F_ad2da83b-a518-475f-a29a-5b4769eb7bf7"
      unitRef="U_shares">32315</tyra:WeightedAverageUnvestedCommonStockIssuedUponExerciseOfCommonStockOptions>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="0"
      id="F_6ee7dc32-9512-4541-80d1-0176cbbb53f4"
      unitRef="U_shares">59602328</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="0"
      id="F_c3e256df-c778-4bd8-a732-06de3b13f5af"
      unitRef="U_shares">59602328</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="0"
      id="F_4d225846-8d88-4ed7-ab66-2d0c6fa08075"
      unitRef="U_shares">57217746</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="0"
      id="F_8558f24d-783a-4110-8d86-d2c5d8ff3813"
      unitRef="U_shares">57217746</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="2"
      id="F_8b85f589-c422-4387-aae1-00a587e704aa"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="2"
      id="F_85bc4366-396b-417b-b425-4b22b75485c8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="2"
      id="F_c29278ca-3bb0-40fb-9651-43d68019f5ba"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.51</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="2"
      id="F_4f76b772-2b2a-4387-94f0-60fb6f03adef"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.51</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_c1756a2b-4741-40b8-8ac3-9340be512462">&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because their inclusion would be anti-dilutive.&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:67.313%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.323%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.323%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,617,445&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,462,129&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unvested common stock upon early exercise of stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,317&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Estimated shares purchasable under the ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,761&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,280&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,645,206&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,480,726&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_56b4e6c1-43af-48e2-a24b-2a315a435b15"
      decimals="0"
      id="F_cd079344-c0f0-467c-b47d-e64b1cca1e20"
      unitRef="U_shares">13617445</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_1f9dc1d4-60d0-45af-852c-cdd76bc64f9f"
      decimals="0"
      id="F_86ac19cf-acc5-4c51-bcc0-a5161134fd83"
      unitRef="U_shares">10462129</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_e3b45be7-247c-43d2-afaf-765b16ea5709"
      decimals="0"
      id="F_115497f7-a916-44b1-964c-bdf9470557d8"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0982e5f9-320c-4189-b4b7-e92e3372022d"
      decimals="0"
      id="F_6a4d6939-e081-4a56-b5ac-6ffb5bb36af0"
      unitRef="U_shares">4317</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_f4992ea8-42cd-4f1d-87f7-2a24c1d21969"
      decimals="0"
      id="F_81d137e8-3cbc-4db7-b0a7-13d24c5386d7"
      unitRef="U_shares">27761</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_9a95952b-9590-45cc-ba3c-2182f5811f96"
      decimals="0"
      id="F_4dffebfa-9842-47f4-ae03-a3a1cca77577"
      unitRef="U_shares">14280</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="0"
      id="F_8d912abc-1721-4241-a1ff-7810d7e55f17"
      unitRef="U_shares">13645206</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="0"
      id="F_a45370a0-8b2f-4254-b001-1b838d5e4ae5"
      unitRef="U_shares">10480726</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_ab3c7e10-1d2a-4494-aef2-84283bfa79a6">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;8. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company's pretax losses for the years ended December 31, 2025 and 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; are from U.S. operations. There was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; provision for or benefit from income taxes for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 and 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company adopted ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures prospectively, as disclosed in Note 1. &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following is a reconciliation between the provision for income taxes and income taxes computed using the U.S. federal statutory corporate tax rate for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025, in accordance with the new disclosure requirements (in thousands):&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.76%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.860000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.44%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Income tax benefit at statutory federal rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,189&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State and local taxes, net of federal benefit &lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,330&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;Federal research and development credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,411&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Changes in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,683&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Nontaxable or nondeductible items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;Stock based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,653&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.38&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;Officer compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,725&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Changes in unrecognized tax benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,823&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The state that contributes to the majority (greater than 50%) of the tax effect in this category is California for the year ended December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following is a reconciliation between the provision for income taxes and income taxes computed using the U.S. federal statutory corporate tax rate for the year ended December 31, 2024, in accordance with the guidance prior to the adoption of ASU 2023-09 (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:80%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.9%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected tax benefit at statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,161&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State income tax, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;134&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;757&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Officer compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;977&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Permanent items and other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,363&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,431&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company did not pay federal or state cash income taxes or have cash income taxes refunded in the year ended December 31, 2025.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 and 2024 are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.673%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.923%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.923%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41,792&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,938&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Capitalized research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,439&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,380&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,725&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,570&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,287&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,267&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;89,468&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;64,806&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;88,026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,267&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets, net of valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,442&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,539&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;175&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;256&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Right of use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,182&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,283&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,442&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,539&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net deferred tax assets / (liabilities)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has established a valuation allowance against its net deferred tax assets due to the uncertainty surrounding the realization of such assets. The Company periodically evaluates the recoverability of the deferred tax assets. At such time as it is determined that it is more likely than not that deferred assets are realizable, the valuation allowance will be reduced. The Company has recorded a full valuation allowance of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;88.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as of December 31, 2025 as management cannot conclude that it is more likely than not that certain deferred tax assets will be realized primarily due to the history of losses from inception. The Company increased its valuation allowance by approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;24.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million during the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At December 31, 2025, the Company had federal and state tax loss carry forwards of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;188.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively. As a result of the Tax Cuts and Jobs Act of 2017, for U.S. income tax purposes, net operating losses generated after December 31, 2017 can be carried forward indefinitely, but are limited to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% utilization against future taxable income each year. Of the amount of federal and state net operating loss carryforwards, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;188.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively, can be carried forward indefinitely. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Unless previously utilized, the state net operating losses will begin to expire in &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2038&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At December 31, 2025, the Company has federal and state research and development tax credits of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The federal research and development tax credit carryforwards begin to expire in &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2040&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the state research and development tax credit carryforwards of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;4.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million will not expire and the state research and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;development tax credit carryforwards of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million will begin to expire in &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2039&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Pursuant to the IRC Sections 382 and 383, annual use of the Company&#x2019;s net operating loss (NOL) and research and development credit carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period. The Company has not completed an ownership change analysis pursuant to IRC Section 382. If ownership changes have occurred or occurs in the future, the amount of remaining tax attribute carryforwards available to offset taxable income and income tax expense in future years may be restricted or eliminated. If eliminated, the related asset would be removed from deferred tax assets with a corresponding reduction in the valuation allowance.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Uncertain tax positions are evaluated based upon the facts and circumstances that exist at each reporting period. Subsequent changes in judgment based upon new information may lead to changes in recognition, derecognition, and measurement. Adjustment may result, for example, upon resolution of an issue with the taxing authorities or expiration of a statute of limitations barring an assessment for an issue.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company recognizes a tax benefit from an uncertain tax position when it is more likely than not that the position will be sustained upon examination by tax authorities.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the changes to the Company&#x2019;s gross unrecognized tax benefits for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 and 2024, respectively (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Beginning balance at January 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,529&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,006&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Additions related to current year positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,043&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,869&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Additions related to prior year positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,133&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;654&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Ending balance at December 31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,705&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,529&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Due to the existence of the valuation allowance, future recognition of previously unrecognized tax benefits will not impact the Company&#x2019;s effective tax rate. The Company is subject to taxation in the United States and various state jurisdictions. All of the Company&#x2019;s tax years from inception are subject to examination by federal and state tax authorities. The Company&#x2019;s practice is to recognize interest and penalties related to income tax matters in income tax expense.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company had &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; accrued interest or penalties related to income tax matters in the Company&#x2019;s balance sheet as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 and has not recognized interest or penalties in the Company&#x2019;s statements of operations and comprehensive loss for the years ended December 31, 2025 and 2024. Further, the Company is not currently under examination by any federal, state or local tax authority.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On July 4, 2025, the U.S. President signed into law H.R.1, the legislation commonly known as the One Big Beautiful Bill (OBBB). This legislation extended, modified, or made permanent many of the tax provisions which were initially enacted as part of the Tax Cuts and Jobs Act of 2017. The OBBB contains a number of tax provisions including, but not limited to, immediate expensing of domestic research and experimental expenditures, modifications to the limitation on business interest, bonus depreciation modifications, as well as international tax provision modifications. The Company has reflected the effect of OBBB within the provision for income taxes and the deferred taxes as of December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="-3"
      id="F_e54e5a27-4f8d-4e9c-84e5-98fb7c4b1715"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="-3"
      id="F_fa6bbf8e-a0b7-494f-8d14-bc1a61a7fba6"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_961118a8-b187-4149-a747-490f7f679239">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following is a reconciliation between the provision for income taxes and income taxes computed using the U.S. federal statutory corporate tax rate for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025, in accordance with the new disclosure requirements (in thousands):&lt;/span&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.76%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.860000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.44%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Income tax benefit at statutory federal rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,189&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State and local taxes, net of federal benefit &lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,330&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;Federal research and development credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,411&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Changes in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,683&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Nontaxable or nondeductible items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;Stock based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,653&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.38&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;Officer compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,725&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Changes in unrecognized tax benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,823&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The state that contributes to the majority (greater than 50%) of the tax effect in this category is California for the year ended December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following is a reconciliation between the provision for income taxes and income taxes computed using the U.S. federal statutory corporate tax rate for the year ended December 31, 2024, in accordance with the guidance prior to the adoption of ASU 2023-09 (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:80%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.9%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected tax benefit at statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,161&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State income tax, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;134&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;757&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Officer compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;977&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Permanent items and other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,363&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,431&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="-3"
      id="F_b194ad98-d10b-4f66-8221-70adfd51cee2"
      unitRef="U_USD">-25189000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="4"
      id="F_96ed86dc-d027-43ae-a638-d23a1563550f"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="-3"
      id="F_1feeacb7-f63b-4743-b9bf-d02683a62a3e"
      unitRef="U_USD">-1330000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="4"
      id="F_5afad17c-078e-4959-a690-06c22068e3d4"
      unitRef="U_pure">0.0111</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="-3"
      id="F_a37b19cf-c8d7-4309-b38d-a42bdc0d19f4"
      unitRef="U_USD">6411000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="4"
      id="F_55e16ef9-5a7b-4d71-843f-37481ad35f9e"
      unitRef="U_pure">0.0535</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="-3"
      id="F_6bc15362-54ad-4762-9f08-bccf0a9002d5"
      unitRef="U_USD">23683000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="4"
      id="F_3579b54b-9e66-4dcb-b87d-123c88ddfed8"
      unitRef="U_pure">-0.1975</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="-3"
      id="F_04200008-408c-403f-a30d-cb69e2a916b0"
      unitRef="U_USD">1653000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="4"
      id="F_00765124-f347-4697-84e6-574ec1ea3d05"
      unitRef="U_pure">-0.0138</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <tyra:IncometaxreconciliationOfficersCompensation
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="-3"
      id="F_6c3284ef-4929-4f4f-a474-c3b3f3f8b0e6"
      unitRef="U_USD">4725000</tyra:IncometaxreconciliationOfficersCompensation>
    <tyra:IncomeTaxReconciliationOfficersCompensationPercentage
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="4"
      id="F_c248505b-df99-4b40-b794-1629967be6f6"
      unitRef="U_pure">-0.0394</tyra:IncomeTaxReconciliationOfficersCompensationPercentage>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="-3"
      id="F_2f0c62b3-cca8-4346-a76c-a4389ca04d10"
      unitRef="U_USD">46000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="4"
      id="F_19ede753-003b-41e1-8c86-033811ad75c7"
      unitRef="U_pure">-0.0004</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <tyra:IncomeTaxReconciliationChangesInUnrecognizedTaxBenefits
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="-3"
      id="F_961a53d7-4487-4d2f-969c-8f5927624df2"
      unitRef="U_USD">-2823000</tyra:IncomeTaxReconciliationChangesInUnrecognizedTaxBenefits>
    <tyra:IncomeTaxReconciliationChangesInUnrecognizedTaxBenefitsPercentage
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="4"
      id="F_125ff552-b43e-44f7-910b-364c4fa92468"
      unitRef="U_pure">-0.0235</tyra:IncomeTaxReconciliationChangesInUnrecognizedTaxBenefitsPercentage>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="-3"
      id="F_9e774965-6de3-49b7-b5f0-3380a20fc0ff"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="4"
      id="F_79767db5-ee4b-4e95-9201-34949d675563"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="-3"
      id="F_9aa896ac-7143-40a9-95bf-c21934f6b500"
      unitRef="U_USD">-18161000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="-3"
      id="F_5c2361c3-eca4-4221-8b12-f666f8741f8c"
      unitRef="U_USD">-134000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="-3"
      id="F_6bd99a88-6123-4a79-a3f0-9c30e70c899e"
      unitRef="U_USD">-757000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <tyra:IncometaxreconciliationOfficersCompensation
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="-3"
      id="F_bd0cb4c3-8153-4c0f-8ef1-db0c51e47fe8"
      unitRef="U_USD">977000</tyra:IncometaxreconciliationOfficersCompensation>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="-3"
      id="F_702a1b69-024f-471f-9f47-d538acb2b12b"
      unitRef="U_USD">7000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="-3"
      id="F_c7c4fbb3-abdc-4a28-b32f-a3b4c3ae7a87"
      unitRef="U_USD">4363000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="-3"
      id="F_b12c4a6b-eb3a-418f-a881-107ae6171019"
      unitRef="U_USD">22431000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="-3"
      id="F_dc26ccfd-60a5-4739-8dad-16948ce3d9b2"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_aadd7691-1008-4983-97ab-51f87879cb1a">&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 and 2024 are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.673%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.923%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.74%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.923%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41,792&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,938&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Capitalized research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,439&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,380&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,725&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,570&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,287&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,267&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;89,468&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;64,806&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;88,026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,267&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets, net of valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,442&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,539&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;175&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;256&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Right of use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,182&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,283&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,442&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,539&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net deferred tax assets / (liabilities)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_3f904a04-8839-4031-afb4-48aedc4b4769"
      unitRef="U_USD">41792000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="-3"
      id="F_4bfb4f3b-f9aa-4a71-861d-4db9764e7efc"
      unitRef="U_USD">18938000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <tyra:DeferredTaxAssetsCapitalizedResearchAndDevelopment
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_c7e63f39-6784-4fcc-a65f-017aae9a51e8"
      unitRef="U_USD">24439000</tyra:DeferredTaxAssetsCapitalizedResearchAndDevelopment>
    <tyra:DeferredTaxAssetsCapitalizedResearchAndDevelopment
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="-3"
      id="F_36134d31-b109-499c-869b-33e5a6193b01"
      unitRef="U_USD">27105000</tyra:DeferredTaxAssetsCapitalizedResearchAndDevelopment>
    <tyra:DeferredTaxAssetsTaxCredits
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_42d9d6d7-bdc1-4c8b-937c-0604077549e3"
      unitRef="U_USD">16380000</tyra:DeferredTaxAssetsTaxCredits>
    <tyra:DeferredTaxAssetsTaxCredits
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="-3"
      id="F_34f70259-46c0-4ab6-921b-b989068bbcc0"
      unitRef="U_USD">10725000</tyra:DeferredTaxAssetsTaxCredits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_11677f72-c0bc-41eb-8017-c373b2a77903"
      unitRef="U_USD">4570000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="-3"
      id="F_4e7c3b4b-c243-4129-923d-580715a4741c"
      unitRef="U_USD">5771000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_fe3cc1c6-1607-4de5-b3e9-5b5841179269"
      unitRef="U_USD">2287000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="-3"
      id="F_6dd614f6-6db6-437b-b9a8-ef66de9a4a49"
      unitRef="U_USD">2267000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_a48d6f2d-99a1-4d8e-9e27-56c0c88765b0"
      unitRef="U_USD">89468000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="-3"
      id="F_5435fd4e-7f90-489c-982c-ae498d1d2cf6"
      unitRef="U_USD">64806000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_47032013-27af-4eeb-8e5c-ef0e00e2d52f"
      unitRef="U_USD">88026000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="-3"
      id="F_a9ce8fc3-9a66-4a91-b62c-2387db7039e8"
      unitRef="U_USD">63267000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_d6df9445-0f36-4e9d-9e96-2cec5465c471"
      unitRef="U_USD">1442000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="-3"
      id="F_99ce9996-4b28-44d7-bd59-9c021b076194"
      unitRef="U_USD">1539000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_7b135514-9f82-4329-8eb7-fe9f7105e256"
      unitRef="U_USD">175000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="-3"
      id="F_d796c72b-6515-440e-aac3-1a886b6719cd"
      unitRef="U_USD">256000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_52922c88-683f-4e56-af5c-9591f34bdb6c"
      unitRef="U_USD">1182000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="-3"
      id="F_c91bc242-cd04-4e1e-8bb3-a4b306904b4d"
      unitRef="U_USD">1283000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_99d09b81-7e06-420d-bfe5-9b0ebf827039"
      unitRef="U_USD">85000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="-3"
      id="F_2ce8030c-dcd5-4d54-82b7-ff4a291d6174"
      unitRef="U_USD">0</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_cafb00ac-059a-46a3-a45b-7976e522a4fc"
      unitRef="U_USD">1442000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="-3"
      id="F_0981f15e-341c-470c-a4d8-bb4fd0f95914"
      unitRef="U_USD">1539000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_fce8928a-33fc-4c57-b366-9fe736240c4b"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="-3"
      id="F_fed20822-efd8-4820-b2f5-3471dfc4182f"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-5"
      id="F_a190ad08-d77d-4259-a8ae-dcd16ee69d1c"
      unitRef="U_USD">88000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="-5"
      id="F_459f4a38-3a62-4a33-83d8-bc205ec1225e"
      unitRef="U_USD">24800000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_25ac70f7-9ef0-442b-8bfc-d6387da53e1f"
      decimals="-5"
      id="F_79770caf-45ac-4e61-9199-c496062e834a"
      unitRef="U_USD">188700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_81db5fa1-5ce2-4991-960b-fe8f42d5dc85"
      decimals="-5"
      id="F_b0649506-662f-44f4-9889-f50802819f9e"
      unitRef="U_USD">67300000</us-gaap:OperatingLossCarryforwards>
    <tyra:NetOperatingLossCarryforwardsAvailableForOffsettingAgainstFutureTaxableIncomePercentage
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="2"
      id="F_563e337a-4d82-42fa-91d3-782fe6d7cb4a"
      unitRef="U_pure">0.80</tyra:NetOperatingLossCarryforwardsAvailableForOffsettingAgainstFutureTaxableIncomePercentage>
    <tyra:NetOperatingLossCarryForwardIndefinitely
      contextRef="C_25ac70f7-9ef0-442b-8bfc-d6387da53e1f"
      decimals="-5"
      id="F_ad2ef762-012c-4b8f-bb84-fc63c77f04d7"
      unitRef="U_USD">188700000</tyra:NetOperatingLossCarryForwardIndefinitely>
    <tyra:NetOperatingLossCarryForwardIndefinitely
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-5"
      id="F_7acbe39b-1caf-4da3-9676-c6b17e59aee4"
      unitRef="U_USD">1700000</tyra:NetOperatingLossCarryForwardIndefinitely>
    <tyra:OperatingLossCarryforwardsExpirationDates1
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_24380db2-6b9a-4678-842f-d8d280b24f6d">Unless previously utilized, the state net operating losses will begin to expire in 2038.</tyra:OperatingLossCarryforwardsExpirationDates1>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_25ac70f7-9ef0-442b-8bfc-d6387da53e1f"
      decimals="-5"
      id="F_26e6b2cd-7fcf-46b7-98c0-f20b1579bb93"
      unitRef="U_USD">18100000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_81db5fa1-5ce2-4991-960b-fe8f42d5dc85"
      decimals="-5"
      id="F_af9059a6-968f-4c45-a96f-48a83d43e51a"
      unitRef="U_USD">4500000</us-gaap:TaxCreditCarryforwardAmount>
    <tyra:ResearchAndDevelopmentCreditCarryforwardsUnderInternalRevenueCodeDescription
      contextRef="C_f25354f8-700d-4a8d-907f-0257bf311019"
      id="F_4e7a5868-0bb1-4664-bb32-c7476b3e9733"> The federal research and development tax credit carryforwards begin to expire in 2040</tyra:ResearchAndDevelopmentCreditCarryforwardsUnderInternalRevenueCodeDescription>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_0244e69e-96e4-4497-bf2c-57c743c5abcb"
      decimals="-5"
      id="F_e3bc702f-8716-44ff-8eae-a69dc8caa3f8"
      unitRef="U_USD">4400000</us-gaap:TaxCreditCarryforwardAmount>
    <tyra:ResearchAndDevelopmentCreditCarryforwardsUnderInternalRevenueCodeDescription
      contextRef="C_d576a493-6d1f-4530-ae76-85c14a98774c"
      id="F_83ec96fd-5b10-4b5b-bb0b-8ae18097de30">development tax credit carryforwards of $0.1 million will begin to expire in 2039.</tyra:ResearchAndDevelopmentCreditCarryforwardsUnderInternalRevenueCodeDescription>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_2d6333b8-aede-4396-b3d4-df2848f7e547"
      decimals="-5"
      id="F_7bb28eab-2004-4abc-b76c-d4a155196108"
      unitRef="U_USD">100000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_260ae749-f9d5-4173-b7f8-007bc6790f05">&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the changes to the Company&#x2019;s gross unrecognized tax benefits for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 and 2024, respectively (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Beginning balance at January 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,529&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,006&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Additions related to current year positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,043&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,869&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Additions related to prior year positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,133&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;654&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Ending balance at December 31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,705&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,529&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="-3"
      id="F_3ecde34a-f9cf-4c8f-b531-bcf11712d770"
      unitRef="U_USD">5529000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_90b314f0-e678-446e-845b-a940c76b3ed3"
      decimals="-3"
      id="F_1352b738-a204-4cb5-b9c5-c8d684ae09f2"
      unitRef="U_USD">3006000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="-3"
      id="F_e322fb92-0927-4ca9-b79f-d7d1c731f19e"
      unitRef="U_USD">2043000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="-3"
      id="F_e5f127c3-5099-49e8-a566-db5b7d4f5e9a"
      unitRef="U_USD">1869000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="-3"
      id="F_13d88ace-3ec8-4b09-b8d2-f8823679dab0"
      unitRef="U_USD">1133000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="-3"
      id="F_77976117-c652-4d2a-8e2a-108dd1d4b05e"
      unitRef="U_USD">654000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_e524d52f-569b-4cb9-82a8-db87211e6fa2"
      unitRef="U_USD">8705000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="-3"
      id="F_94970866-3c39-47c6-8c0f-e9c0dd2776c2"
      unitRef="U_USD">5529000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-6"
      id="F_ae05abc4-2e90-4833-a8ba-8427bcd6f963"
      unitRef="U_USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_e9f11a86-e51b-40b3-8b37-d470c688f68f">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;9. Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has operating leases for its office and laboratory space, including its corporate headquarters.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In August 2020, the Company entered into a lease agreement for approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,734&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; square feet of office and lab space at 2656 State Street in Carlsbad, California, for the Company&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;s headquarters (the Original Lease). The Original Lease commenced in May 2021 and had an original term of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;60 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;months, with an option to extend for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; additional &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;36 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;month periods.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 2022, the Company entered into a lease agreement for approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,331&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; square feet of additional office and laboratory space at 2676 State Street in Carlsbad, California (the Expansion Lease). The Expansion Lease commenced for accounting purposes in May 2023, when the Company gained access to the premises. The Company&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2019;s obligation for payment of base rent began on the date the landlord delivered possession of the Expansion Lease premises in November 2023. The landlord completed improvements to the Expansion Lease premises, and the Company paid $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million toward these costs prior to the Expansion Lease commencement. The Company determined that the landlord is the accounting owner of these improvements, and therefore this payment was included in the measurement of the right-of-use asset and corresponding lease liability. The Company was granted rent abatement for delays related to the landlord&#x2019;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;s delivery of the Expansion Lease premises to the Company. The Expansion Lease has a lease term of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;120 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;months, commencing on the day the landlord delivered possession of the Expansion Lease premises. The Company has the option to renew the Expansion Lease for two additional &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;36&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;-month periods. The Original Lease was also amended to have the same lease expiration as the Expansion Lease.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company did not include the renewal periods in determining the lease term, as the Company was not reasonably certain to exercise either the amended Original Lease or the Expansion Lease renewal options.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In connection with the Company&#x2019;s lease agreements, the Company paid security deposits of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and is required to maintain a letter of credit of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. The letter of credit may be reduced to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in 2027 and further reduced to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in 2028.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash paid for amounts included in the measurement of lease liabilities was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 and 2024, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The components of lease expense include operating, short-term, and variable lease costs. Amortization is recorded within research and development and general and administrative expenses in the statements of operations and comprehensive loss. &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Components of lease cost for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 and 2024, respectively, were as follows (in thousands):&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:67.313%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;957&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;957&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Short-term lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Variable lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;139&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,174&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Maturities of lease liabilities, weighted-average remaining term and weighted-average discount rate were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:75.64%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.9%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:20.459999999999997%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Year ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;927&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;955&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;983&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,013&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,035&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total minimum lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,813&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: amount representing interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,003&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,810&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: current portion of lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;472&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lease liabilities, noncurrent&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,338&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:67.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.021%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.31%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.021%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.31%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average remaining lease term (years) - operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average incremental borrowing rate - operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <tyra:AreaOfLease
      contextRef="C_0639343e-0151-4fb3-a3ca-f73ad2a5550b"
      decimals="0"
      id="F_185c274b-458a-4b68-b213-136acd6d5812"
      unitRef="U_sqft">4734</tyra:AreaOfLease>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_3ef83027-7be9-4941-bbec-b03fb69c9691"
      id="F_85e63fdb-ae6a-4353-8460-a9b2c23d431e">P60M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <tyra:NumberOfLeaseTermRenewal
      contextRef="C_4bfe509f-d4f2-43a9-a149-54a5ecae443d"
      decimals="0"
      id="F_cd5b270c-1313-421d-80e7-75adae81a413"
      unitRef="U_Renewal">2</tyra:NumberOfLeaseTermRenewal>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_3ef83027-7be9-4941-bbec-b03fb69c9691"
      id="F_ac253aac-469e-43de-bbe6-66fabebe358a">P36M</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <tyra:AreaOfLease
      contextRef="C_28193a65-0be5-40f3-9592-5ab7a4f62e34"
      decimals="0"
      id="F_04ef3225-2b29-424d-adaa-9b10304e9074"
      unitRef="U_sqft">8331</tyra:AreaOfLease>
    <us-gaap:OperatingLeaseCost
      contextRef="C_e1d47e5f-72ba-41d6-899c-26d974ae34de"
      decimals="-5"
      id="F_bec94228-1686-45c6-bdb8-776f6ff63363"
      unitRef="U_USD">500000</us-gaap:OperatingLeaseCost>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_c949f769-29f9-45f2-a776-8adefcf0977e"
      id="F_99b443fb-de38-4a23-a42c-8569ab7775fd">P120M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_55243387-85c0-4527-827d-52fcc91c1646"
      id="F_cc087390-b096-43f7-abe0-845d2a20906d">P36M</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:SecurityDeposit
      contextRef="C_591792f7-6fd3-4548-a3dc-761a47696c50"
      decimals="-5"
      id="F_383f5035-ea4b-4f20-bcfd-ee02374c3682"
      unitRef="U_USD">100000</us-gaap:SecurityDeposit>
    <us-gaap:LineOfCredit
      contextRef="C_591792f7-6fd3-4548-a3dc-761a47696c50"
      decimals="-5"
      id="F_3d689b8f-a6f5-456b-9529-4d4fa283265f"
      unitRef="U_USD">1000000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="C_0cc2e2b1-f863-41ab-8c8e-baf6fe802ceb"
      decimals="-5"
      id="F_2c33911d-7c58-46b0-b9b0-df40e731d4dd"
      unitRef="U_USD">900000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="C_a6c7e448-562b-41de-8bae-d10d83c24d49"
      decimals="-5"
      id="F_fd507251-9c58-4ceb-8d4f-c47b69bae4b9"
      unitRef="U_USD">500000</us-gaap:LineOfCredit>
    <us-gaap:OperatingLeasePayments
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="-5"
      id="F_599cc70d-082e-4267-ad38-1a27dceba6af"
      unitRef="U_USD">900000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="-5"
      id="F_a7bb331b-a721-4dfd-aeaa-5cdb4b85f7f1"
      unitRef="U_USD">800000</us-gaap:OperatingLeasePayments>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_2592f51f-5ca5-4dfa-b37a-a01ef3e2bad7">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Components of lease cost for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 and 2024, respectively, were as follows (in thousands):&lt;/span&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:67.313%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;957&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;957&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Short-term lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Variable lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;139&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,174&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="-3"
      id="F_ba3b94b8-6649-428e-81fe-e565d2822db6"
      unitRef="U_USD">957000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="-3"
      id="F_ab293a12-653f-4b26-ab1e-d27b51037b9c"
      unitRef="U_USD">957000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="-3"
      id="F_6227bae3-680f-4424-af74-5312d6ce1d28"
      unitRef="U_USD">90000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="-3"
      id="F_953e3260-2769-4439-9df7-09d24b08a5d7"
      unitRef="U_USD">90000</us-gaap:ShortTermLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="-3"
      id="F_303b6d26-9998-4110-bedd-3087eeac04b1"
      unitRef="U_USD">139000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="-3"
      id="F_1d8d0afb-a432-4767-9584-44687a5e0953"
      unitRef="U_USD">127000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="-3"
      id="F_a823cd70-877a-4555-b3e5-7617c30176d5"
      unitRef="U_USD">1186000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="-3"
      id="F_48f9fec8-20bf-4dab-85f3-df59a609b4a3"
      unitRef="U_USD">1174000</us-gaap:LeaseCost>
    <tyra:ScheduleOfMaturitiesOfLeaseLiabilitiesWithWeightedAverageRemainingTermAndDiscountRateTableTextBlock
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_54f11898-3851-4620-982a-ce7742ce5806">&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Maturities of lease liabilities, weighted-average remaining term and weighted-average discount rate were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:75.64%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.9%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:20.459999999999997%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Year ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;927&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;955&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;983&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,013&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,035&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total minimum lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,813&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: amount representing interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,003&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,810&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: current portion of lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;472&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lease liabilities, noncurrent&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,338&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:67.34%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.021%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.31%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.021%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.31%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average remaining lease term (years) - operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average incremental borrowing rate - operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</tyra:ScheduleOfMaturitiesOfLeaseLiabilitiesWithWeightedAverageRemainingTermAndDiscountRateTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_fe4ab782-c0b2-42bc-b54e-9c29f164de36"
      unitRef="U_USD">900000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_d98eb385-fcde-4d62-913a-131c4753febf"
      unitRef="U_USD">927000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_1db3ca6a-2f1d-43fe-bb11-e0f71c00940d"
      unitRef="U_USD">955000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_e4f5dcbf-1521-4f8c-a6ed-0c101d3d367b"
      unitRef="U_USD">983000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_4eb3d845-ea66-4740-88bc-8a318c712201"
      unitRef="U_USD">1013000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_97ff31a7-2dfe-45f4-810f-1edf165e0cb5"
      unitRef="U_USD">3035000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_dd6badb6-6afe-4e47-9f00-26246d4253ce"
      unitRef="U_USD">7813000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_323b8e6f-1303-466c-892a-0a8ac7d9c07b"
      unitRef="U_USD">2003000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_e434cb6e-c4aa-4438-949b-0842a4315331"
      unitRef="U_USD">5810000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_f0afd14d-3009-461d-8f7a-72064e3a97b0"
      unitRef="U_USD">472000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="-3"
      id="F_ee44a613-20c4-4d09-b878-44a006f309fd"
      unitRef="U_USD">5338000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      id="F_8ef4e66a-869d-42a8-81d9-4d7fc85c940a">P7Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      id="F_6af5f3fb-3b68-487b-8d5f-6a4c39278245">P8Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_b1df5da0-307d-4f91-b407-099a8215e1e5"
      decimals="4"
      id="F_e8309bdb-b613-412a-a2a9-e8c309b3cc1c"
      unitRef="U_pure">0.0807</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_75025707-e814-4796-aefb-117d79769679"
      decimals="4"
      id="F_0472d2ac-aa5c-4b86-b100-dae60b9ba969"
      unitRef="U_pure">0.0807</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_f93183e5-cb6e-46ae-a50b-9b2282718999">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;10. Commitments and Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Other Funding Commitments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025, the Company had ongoing clinical and pre-clinical studies for its various programs. The Company enters into contracts in the normal course of business with contract research organizations in preparation for clinical trials, professional consultants for expert advice and other vendors for clinical supply manufacturing or other services. These contracts are generally cancellable, with notice, at the Company's option and do not have significant cancellation penalties.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Litigation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company, from time to time, may be party to litigation arising in the ordinary course of business. The Company was not subject to any material legal proceedings as of December 31, 2025, and no material legal proceedings are currently pending or threatened. I&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;f the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount is reasonably estimable, the Company will accrue a liability for the estimated loss.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_a00f4d64-6b02-47e3-b868-18a31bf3e083">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;11. Employee Benefits&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company offers a 401(k) plan (401(k) Plan) for all employees who have met certain eligibility requirements. Under the 401(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;k) Plan, employees may elect to contribute a portion of their eligible compensation, subject to certain limitations. The Company has a program to match &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of employee contributions to the 401(k) Plan up to a maximum of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of eligible earnings, subject to statutory limitations. Employer contributions for the year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="2"
      id="F_56adada0-2d90-4ad9-aa40-b8f4a1decb21"
      unitRef="U_pure">1</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="2"
      id="F_c5fc6cd8-a6ac-4988-8882-436f180be10d"
      unitRef="U_pure">0.04</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="-5"
      id="F_c8223e4f-2c9b-4724-9e34-85363440979d"
      unitRef="U_USD">600000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_d69e4f07-3e86-41fe-98a3-866c75b80de1">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;12. Segment Information&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company reports segment information based on the management approach, which reflects the way in which the internal reporting is used by the chief operating decision maker (CODM) to analyze performance, make decisions and allocate resources. The CODM is the Company&#x2019;s &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_1e6f4a6c-c495-424f-a078-c4745eb638bc;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Chief Executive Officer&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company manages its operations as a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_1191e240-a690-465b-8ee1-430de97506c1;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;single&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; reportable segment, which includes all activities related to the research, development, and potential future commercialization of its small molecule drug development candidates. The CODM assesses performance and decides how to allocate resources based on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;net loss&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (presented in the statements of operations and comprehensive loss). The measure of segment assets is reported on the balance sheets as total assets. All long-lived assets are located in the United States.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The table below shows a reconciliation of the Company&#x2019;s net loss, including the significant expense categories regularly provided to and reviewed by the CODM, to the Company&#x2019;s total net loss in the statements of operations and comprehensive loss (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:58.76%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.9%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:16.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.9%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:16.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development expenses:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;External research and development &lt;br/&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;expenses by program:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Dabogratinib (TYRA-300&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;ACH&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,379&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,718&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Dabogratinib (TYRA-300&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;NMIBC&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,244&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Dabogratinib (TYRA-300&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;UTUC&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,440&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Dabogratinib (TYRA-300&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;mUC&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,590&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,319&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;TYRA-430&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,055&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,677&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;TYRA-200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,308&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;FGFR discovery&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,967&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,199&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Other development programs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,623&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Unallocated research and development &lt;br/&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;expenses:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Personnel costs&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,218&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,423&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Facilities and other costs&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,113&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;102,928&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80,077&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative expenses&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,834&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest and other income, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,815&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,696&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;119,947&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;86,481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Personnel costs include $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;15.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;14.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of stock-based compensation for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 and 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Facilities and other costs consist of research consumables, facility-related costs, depreciation and costs not attributed to a specific program.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;General and administrative expenses consist of personnel-related expenses, including stock-based compensation, legal fees, facility-related costs, depreciation, professional and consulting fees and insurance costs.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_ca6ee9a4-6ee1-4117-a745-1b0e73206bde">net loss</us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_deec4d11-d47c-431c-8736-7b60cd2da636">&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The table below shows a reconciliation of the Company&#x2019;s net loss, including the significant expense categories regularly provided to and reviewed by the CODM, to the Company&#x2019;s total net loss in the statements of operations and comprehensive loss (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:58.76%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.9%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:16.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.9%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:16.72%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development expenses:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;External research and development &lt;br/&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;expenses by program:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Dabogratinib (TYRA-300&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;ACH&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,379&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,718&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Dabogratinib (TYRA-300&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;NMIBC&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,244&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Dabogratinib (TYRA-300&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;UTUC&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,440&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Dabogratinib (TYRA-300&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;mUC&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,590&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,319&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;TYRA-430&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,055&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,677&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;TYRA-200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,308&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;FGFR discovery&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,967&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,199&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Other development programs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,623&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Unallocated research and development &lt;br/&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;expenses:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Personnel costs&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,218&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,423&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Facilities and other costs&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,113&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;102,928&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80,077&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative expenses&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,834&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest and other income, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,815&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,696&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;119,947&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;86,481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Personnel costs include $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;15.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;14.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of stock-based compensation for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 and 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Facilities and other costs consist of research consumables, facility-related costs, depreciation and costs not attributed to a specific program.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;General and administrative expenses consist of personnel-related expenses, including stock-based compensation, legal fees, facility-related costs, depreciation, professional and consulting fees and insurance costs.&lt;/span&gt;&lt;/p&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_7ed9a919-4011-4987-b82f-187ecd2ac2c6"
      decimals="-3"
      id="F_ad0b7324-a83c-4f94-a1e9-348cac6f22fb"
      unitRef="U_USD">13379000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_87dc3b26-58ec-4bf3-9b29-98e651cdbe8a"
      decimals="-3"
      id="F_188eb986-cf35-4541-9aca-03714d23b767"
      unitRef="U_USD">7718000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_66a8c0d4-dc01-437f-8643-ae23ca05710c"
      decimals="-3"
      id="F_b8a09384-3c61-4df9-a99c-0a3ccc36ef87"
      unitRef="U_USD">8244000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_7060b8eb-7cf2-40dd-abeb-7bbe283f0ab1"
      decimals="-3"
      id="F_fe4b661d-2a56-4774-a802-fc547aae4372"
      unitRef="U_USD">122000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_4210f2e9-05d8-4850-ac3c-f78b3d31289e"
      decimals="-3"
      id="F_ac05b4ef-5f3a-4f00-a3d6-25d7b1e11bc9"
      unitRef="U_USD">2440000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_5e5587d3-9989-48f5-9e25-23f05bd5b860"
      decimals="-3"
      id="F_498aaf5d-1900-47b1-9e01-b17854987d8f"
      unitRef="U_USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_b5150520-b9f3-4bdf-8a55-8f5cea1cb93e"
      decimals="-3"
      id="F_e5ea54e9-2e76-49ed-9e7f-13f7ac76922a"
      unitRef="U_USD">9590000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_9622fb4d-a971-4870-b202-86d8c0745065"
      decimals="-3"
      id="F_3da43496-ccc0-44de-b697-0865f211cafc"
      unitRef="U_USD">14319000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_dbea103f-6acc-4340-83b5-1436e3999584"
      decimals="-3"
      id="F_2ace0361-f872-4fab-bce6-ba34c404e80d"
      unitRef="U_USD">9055000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_18a4d379-7bc9-4fbe-85e9-2af7258397b9"
      decimals="-3"
      id="F_7c239262-6b0f-41c5-8122-8e3254d82066"
      unitRef="U_USD">5677000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_032ccc29-8b89-4307-90c0-e7071ba56b28"
      decimals="-3"
      id="F_7aa8bf55-281f-4b50-8913-41f1c32955e4"
      unitRef="U_USD">4308000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_4723f99d-c390-41ed-a5c5-1df9fcae7f68"
      decimals="-3"
      id="F_4d8c94a2-5a7c-42b5-ac23-836dafeb4c44"
      unitRef="U_USD">4969000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_ab4f8aaa-c4e6-4bd1-a17b-592c475ced76"
      decimals="-3"
      id="F_1ae4655f-911b-49c9-bdac-bbb0969291fc"
      unitRef="U_USD">10967000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_8c64e7bc-c688-492a-99e8-86f5cb335e47"
      decimals="-3"
      id="F_20e41772-f570-461a-a875-c54c058259d2"
      unitRef="U_USD">8199000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_d412cb4d-1732-4801-8e1b-648dfb7030c2"
      decimals="-3"
      id="F_eb4ccca3-9ed3-4efb-8aa7-3ea1803fbbf2"
      unitRef="U_USD">2623000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_011705ed-dba2-4b57-a549-edfd6d1424ce"
      decimals="-3"
      id="F_19cbfc22-d915-43cf-bf6f-90dd80dcbcf3"
      unitRef="U_USD">2537000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_14e460cb-2da4-49f1-a533-de969fc89258"
      decimals="-3"
      id="F_a4c73223-a8f2-45c0-b939-895fae466da5"
      unitRef="U_USD">36218000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_a412b29c-2a01-4356-b322-11c7037ef382"
      decimals="-3"
      id="F_95fed51a-1724-4c4a-bca1-cd4dd667f477"
      unitRef="U_USD">30423000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_cd230b0d-0361-47ec-8672-4de4e7ba7e85"
      decimals="-3"
      id="F_2ef49d1a-2d11-4c19-9f37-954b86c4a8fb"
      unitRef="U_USD">6104000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0aaa07cf-e8dc-4ed0-ba3c-1e37ea8486c6"
      decimals="-3"
      id="F_3f608c29-f15c-4349-8faf-2c8418f2cb3b"
      unitRef="U_USD">6113000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_88fc6773-cb7f-4a2b-917e-b6e8a47d801c"
      decimals="-3"
      id="F_7b567cdb-db38-47e0-999e-e5900e983f32"
      unitRef="U_USD">102928000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_e214f6fc-28de-40f3-bcc1-08bf1f39a68d"
      decimals="-3"
      id="F_aa360ad2-98cc-464e-9460-43c6885b5bf1"
      unitRef="U_USD">80077000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_88fc6773-cb7f-4a2b-917e-b6e8a47d801c"
      decimals="-3"
      id="F_54208db0-fdfa-4282-bd8a-f1b532057094"
      unitRef="U_USD">29834000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_e214f6fc-28de-40f3-bcc1-08bf1f39a68d"
      decimals="-3"
      id="F_462c7276-b09b-4c39-9995-95a55b303357"
      unitRef="U_USD">24100000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:InterestAndOtherIncome
      contextRef="C_88fc6773-cb7f-4a2b-917e-b6e8a47d801c"
      decimals="-3"
      id="F_d4e00aa1-0c2d-4f09-9bcd-258affda2cca"
      unitRef="U_USD">12815000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="C_e214f6fc-28de-40f3-bcc1-08bf1f39a68d"
      decimals="-3"
      id="F_1aeef8a4-5f3d-43f8-ae83-9891052c2165"
      unitRef="U_USD">17696000</us-gaap:InterestAndOtherIncome>
    <us-gaap:NetIncomeLoss
      contextRef="C_88fc6773-cb7f-4a2b-917e-b6e8a47d801c"
      decimals="-3"
      id="F_d97620d3-061d-4e2a-88f5-25c5644284f5"
      unitRef="U_USD">-119947000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_e214f6fc-28de-40f3-bcc1-08bf1f39a68d"
      decimals="-3"
      id="F_7e027649-0f58-4e83-9d3d-0ea7bb3420a0"
      unitRef="U_USD">-86481000</us-gaap:NetIncomeLoss>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      decimals="-5"
      id="F_f8fdaf44-9964-4c55-91e7-c16594a26234"
      unitRef="U_USD">15700000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="C_45adbc8f-0afb-4783-8f4d-90e6c4d2362f"
      decimals="-5"
      id="F_14f57931-fd5b-4bfa-912a-0dad475453ad"
      unitRef="U_USD">14300000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <ecd:MtrlTermsOfTrdArrTextBlock
      contextRef="C_6f8e39dd-1c81-4d46-8007-0bbb98e5748d"
      id="F_7f72030d-cf11-4653-bc49-83b53e160112">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Rule 10b5-1 Trading Plans&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;From time to time, our officers (as defined in Rule 16a-1(f) of the Exchange Act) and directors may enter into Rule 10b5-1 or non-Rule 10b5-1 trading arrangements (as each such term is defined in Item 408 of Regulation S-K). During the three months ended December 31, 2025, our officers and directors took the following actions with respect to such trading arrangements:&lt;/span&gt;&lt;/p&gt;
     &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
      &lt;tr style="visibility:collapse;"&gt;
       &lt;td style="width:22.825%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;td style="width:1.52%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;td style="width:12.182%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;td style="width:1.52%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;td style="width:10.002%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;td style="width:1.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;td style="width:12.322%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;td style="width:1.52%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;td style="width:10.502%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;td style="width:1.52%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;td style="width:10.202%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;td style="width:1.52%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;td style="width:11.102%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
       &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Trading Arrangement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
       &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Name and Title&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Action&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Rule 10b5-1&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Non-Rule 10b5-1**&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total Shares Authorized to be Sold***&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Expiration Date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
       &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
       &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Todd Harris&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;President, Chief Executive Officer and Director&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Terminate &lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11/21/2025&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;X&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;315,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12/31/2026&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;/tr&gt;
      &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
       &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Alan Fuhrman&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Chief Financial Officer&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Terminate &lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11/21/2025&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;X&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7/31/2026&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;/tr&gt;
     &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;* Intended to satisfy the affirmative defense of Rule 10b5-1(c)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;** Not intended to satisfy the affirmative defense of Rule 10b5-1(c)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;*** Represents the maximum number of shares that may be sold pursuant to the 10b5-1 arrangement. The number of shares sold is dependent on the satisfaction of certain conditions as set forth in the written plan and the satisfaction of applicable vesting conditions of equity awards.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(1) Trading arrangement was originally adopted on 11/4/2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(2) Trading arrangement was originally adopted on 11/5/2024.&lt;/span&gt;&lt;/p&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_6c246792-9518-4437-a499-5e637972016a"
      id="F_321556ab-c7c1-4b9a-b697-06f97459d98a">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_68fd01c3-dd3c-414b-9432-cffd7c483daf"
      id="F_8d581a29-3591-4446-9773-93bf8c438afa">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrIndName
      contextRef="C_6c246792-9518-4437-a499-5e637972016a"
      id="F_6b6fb485-92f5-4998-98dd-768b66400c63">Todd Harris</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle
      contextRef="C_6c246792-9518-4437-a499-5e637972016a"
      id="F_7bcca592-850d-40d4-9b53-34f40be2a33b">President, Chief Executive Officer and Director</ecd:TrdArrIndTitle>
    <ecd:TrdArrTerminationDate
      contextRef="C_6c246792-9518-4437-a499-5e637972016a"
      id="F_44bb98cf-92f7-4ab3-ad5c-24fabb0ce38c">11/21/2025</ecd:TrdArrTerminationDate>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_6c246792-9518-4437-a499-5e637972016a"
      id="F_e299fb40-d822-4869-ae82-ef177b7b53cd">true</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="C_5bd11727-b5f4-41c0-a8a8-fecf149214ac"
      decimals="0"
      id="F_30572f37-19f4-4213-9294-40a0c2ae99b7"
      unitRef="U_shares">315000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrExpirationDate
      contextRef="C_6c246792-9518-4437-a499-5e637972016a"
      id="F_89589979-fdb4-4496-8810-12bc3fd03dd6">12/31/2026</ecd:TrdArrExpirationDate>
    <ecd:TrdArrIndName
      contextRef="C_68fd01c3-dd3c-414b-9432-cffd7c483daf"
      id="F_aafd2c86-64c5-4fff-a5e3-bc6bfcbce02a">Alan Fuhrman</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle
      contextRef="C_68fd01c3-dd3c-414b-9432-cffd7c483daf"
      id="F_eac1015f-d128-40df-bb30-847050b24116">Chief Financial Officer</ecd:TrdArrIndTitle>
    <ecd:TrdArrTerminationDate
      contextRef="C_68fd01c3-dd3c-414b-9432-cffd7c483daf"
      id="F_46bb6771-b381-4990-9dee-ffd3bd2db4e5">11/21/2025</ecd:TrdArrTerminationDate>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_68fd01c3-dd3c-414b-9432-cffd7c483daf"
      id="F_648a6197-e955-4f1d-be99-0c3d1cd14a34">true</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="C_1fbdc9f6-75dd-418c-a9c1-887b681c7dc0"
      decimals="0"
      id="F_112f0a02-1adc-426b-90ee-2868bf27eca2"
      unitRef="U_shares">80000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrExpirationDate
      contextRef="C_68fd01c3-dd3c-414b-9432-cffd7c483daf"
      id="F_60364b5c-6a12-4c91-9f40-a51a79ad1a32">7/31/2026</ecd:TrdArrExpirationDate>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_a847e001-c9b3-4e4e-9ee1-090aa9d033b5">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <dei:AuditorFirmId
      contextRef="C_e9d71edc-f2b4-47d5-ad81-4148af049faa"
      id="F_c623dab0-c416-4a61-9d1c-20159f4597e0">42</dei:AuditorFirmId>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#F_5afad17c-078e-4959-a690-06c22068e3d4"
          xlink:label="F_5afad17c-078e-4959-a690-06c22068e3d4"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_1feeacb7-f63b-4743-b9bf-d02683a62a3e"
          xlink:label="F_1feeacb7-f63b-4743-b9bf-d02683a62a3e"
          xlink:type="locator"/>
        <link:footnote id="FNT_7f5db674-35e9-4226-a24a-70d6bb548e24" xlink:label="FNT_7f5db674-35e9-4226-a24a-70d6bb548e24" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The state that contributes to the majority (greater than 50%) of the tax effect in this category is California for the year ended December 31, 2025</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_5afad17c-078e-4959-a690-06c22068e3d4"
          xlink:to="FNT_7f5db674-35e9-4226-a24a-70d6bb548e24"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_1feeacb7-f63b-4743-b9bf-d02683a62a3e"
          xlink:to="FNT_7f5db674-35e9-4226-a24a-70d6bb548e24"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_a4c73223-a8f2-45c0-b939-895fae466da5"
          xlink:label="F_a4c73223-a8f2-45c0-b939-895fae466da5"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_95fed51a-1724-4c4a-bca1-cd4dd667f477"
          xlink:label="F_95fed51a-1724-4c4a-bca1-cd4dd667f477"
          xlink:type="locator"/>
        <link:footnote id="FNT_132f20ce-f34d-4ee8-a541-6bc46878b344" xlink:label="FNT_132f20ce-f34d-4ee8-a541-6bc46878b344" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Personnel costs include $</xhtml:span><xhtml:span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">15.7</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</xhtml:span><xhtml:span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">14.3</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of stock-based compensation for the years ended </xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_a4c73223-a8f2-45c0-b939-895fae466da5"
          xlink:to="FNT_132f20ce-f34d-4ee8-a541-6bc46878b344"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_95fed51a-1724-4c4a-bca1-cd4dd667f477"
          xlink:to="FNT_132f20ce-f34d-4ee8-a541-6bc46878b344"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_3f608c29-f15c-4349-8faf-2c8418f2cb3b"
          xlink:label="F_3f608c29-f15c-4349-8faf-2c8418f2cb3b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_2ef49d1a-2d11-4c19-9f37-954b86c4a8fb"
          xlink:label="F_2ef49d1a-2d11-4c19-9f37-954b86c4a8fb"
          xlink:type="locator"/>
        <link:footnote id="FNT_bba94c94-ee85-4e4d-b64e-20c95d3d3e2a" xlink:label="FNT_bba94c94-ee85-4e4d-b64e-20c95d3d3e2a" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Facilities and other costs consist of research consumables, facility-related costs, depreciation and costs not attributed to a specific program.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_3f608c29-f15c-4349-8faf-2c8418f2cb3b"
          xlink:to="FNT_bba94c94-ee85-4e4d-b64e-20c95d3d3e2a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_2ef49d1a-2d11-4c19-9f37-954b86c4a8fb"
          xlink:to="FNT_bba94c94-ee85-4e4d-b64e-20c95d3d3e2a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_462c7276-b09b-4c39-9995-95a55b303357"
          xlink:label="F_462c7276-b09b-4c39-9995-95a55b303357"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_54208db0-fdfa-4282-bd8a-f1b532057094"
          xlink:label="F_54208db0-fdfa-4282-bd8a-f1b532057094"
          xlink:type="locator"/>
        <link:footnote id="FNT_a2a8f412-f3ed-40a6-91bc-571db48e95e7" xlink:label="FNT_a2a8f412-f3ed-40a6-91bc-571db48e95e7" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses consist of personnel-related expenses, including stock-based compensation, legal fees, facility-related costs, depreciation, professional and consulting fees and insurance costs.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_462c7276-b09b-4c39-9995-95a55b303357"
          xlink:to="FNT_a2a8f412-f3ed-40a6-91bc-571db48e95e7"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_54208db0-fdfa-4282-bd8a-f1b532057094"
          xlink:to="FNT_a2a8f412-f3ed-40a6-91bc-571db48e95e7"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
